PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	McDermott, BM; Rux, AH; Eisenberg, RJ; Cohen, GH; Racaniello, VR				McDermott, BM; Rux, AH; Eisenberg, RJ; Cohen, GH; Racaniello, VR			Two distinct binding affinities of poliovirus for its cellular receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE-1 ICAM-1; SURFACE-PLASMON RESONANCE; CONFORMATIONAL-CHANGES; KINETIC-ANALYSIS; VIRUS BINDING; RHINOVIRUS; CELLS; SITE; NEUTRALIZATION; RESIDUES	To study the kinetics and equilibrium of poliovirus binding to the poliovirus receptor, we used surface plasmon resonance to examine the interaction of a soluble form of the receptor with Poliovirus. Soluble receptor purified from mammalian cells is able to bind poliovirus, neutralize viral infectivity, and induce structural changes in the virus particle, Binding studies revealed that there are two binding sites for the receptor on the poliovirus type 1 capsid, with affinity constants at 20 degrees C of K-D1 = 0.67 mu M and K-D2, = 0.11 mu M. The relative abundance of the two binding sites varies with temperature. At 20 circle C, the K-D2 site constitutes approximately 46% of the total binding sites on the sensor chip, and its relative abundance decreased with decreasing temperature such that at 5 degrees C, the relative abundance of the K-D2 site is only 12% of the total binding sites. Absolute levels of the K-D1 site remained relatively constant at all temperatures tested. The two binding sites may correspond to docking sites for domain 1 of the receptor on the viral capsid, as predicted by a model of the poliovirus-receptor complex. Alternatively, the binding sites may be a consequence of structural breathing, or could result from receptor-induced conformational changes in the virus.	Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA; Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA; Univ Penn, Ctr Oral Hlth Res, Sch Dent Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA	Columbia University; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Racaniello, VR (corresponding author), Columbia Univ Coll Phys & Surg, Dept Microbiol, 701 W 168th St, New York, NY 10032 USA.				NIAID NIH HHS [AI20017] Funding Source: Medline; NINDS NIH HHS [NS-30606, NS-36731] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020017, R01AI020017] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS030606, R01NS036731] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arita M, 1998, J VIROL, V72, P3578, DOI 10.1128/JVI.72.5.3578-3586.1998; Belnap DM, 2000, J VIROL, V74, P1342, DOI 10.1128/JVI.74.3.1342-1354.2000; Belnap DM, 2000, P NATL ACAD SCI USA, V97, P73, DOI 10.1073/pnas.97.1.73; BERNHARDT G, 1994, VIROLOGY, V203, P344, DOI 10.1006/viro.1994.1493; BIBB JA, 1994, VIROLOGY, V201, P107, DOI 10.1006/viro.1994.1270; BIBB JA, 1994, J GEN VIROL, V75, P1875, DOI 10.1099/0022-1317-75-8-1875; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P856; Canziani G, 1999, METHODS, V19, P253, DOI 10.1006/meth.1999.0855; CASASNOVAS JM, 1994, J VIROL, V68, P5882, DOI 10.1128/JVI.68.9.5882-5889.1994; CASASNOVAS JM, 1995, J BIOL CHEM, V270, P13216, DOI 10.1074/jbc.270.22.13216; Casasnovas JM, 1998, J VIROL, V72, P6244, DOI 10.1128/JVI.72.7.6244-6246.1998; Casasnovas Jose M., 1994, Methods (Orlando), V6, P157, DOI 10.1006/meth.1994.1018; Chiu CY, 1999, J VIROL, V73, P6759, DOI 10.1128/JVI.73.8.6759-6768.1999; COLSTON E, 1994, EMBO J, V13, P5855, DOI 10.1002/j.1460-2075.1994.tb06930.x; COLSTON E, 1995, THESIS COLUMBIA U NE; Curry S, 1996, J VIROL, V70, P7125, DOI 10.1128/JVI.70.10.7125-7131.1996; DESENA J, 1976, VIROLOGY, V70, P470, DOI 10.1016/0042-6822(76)90288-9; Dove AW, 2000, J VIROL, V74, P3929, DOI 10.1128/JVI.74.8.3929-3931.2000; Dove AW, 1997, J VIROL, V71, P4728, DOI 10.1128/JVI.71.6.4728-4735.1997; FRICKS CE, 1990, J VIROL, V64, P1934, DOI 10.1128/JVI.64.5.1934-1945.1990; GUTTMAN N, 1977, VIROLOGY, V82, P25, DOI 10.1016/0042-6822(77)90029-0; Harber J, 1995, VIROLOGY, V214, P559, DOI 10.1006/viro.1995.0067; He YN, 2000, P NATL ACAD SCI USA, V97, P79, DOI 10.1073/pnas.97.1.79; Hoffman TL, 1999, P NATL ACAD SCI USA, V96, P6359, DOI 10.1073/pnas.96.11.6359; HOGLE JM, 1985, SCIENCE, V229, P1358, DOI 10.1126/science.2994218; HOOVERLITTY H, 1993, J VIROL, V67, P390, DOI 10.1128/JVI.67.1.390-397.1993; KAPLAN G, 1990, J VIROL, V64, P4697, DOI 10.1128/JVI.64.10.4697-4702.1990; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; KOIKE S, 1991, P NATL ACAD SCI USA, V88, P4104, DOI 10.1073/pnas.88.10.4104; Kolatkar PR, 1999, EMBO J, V18, P6249, DOI 10.1093/emboj/18.22.6249; Krummenacher C, 1999, J VIROL, V73, P8127, DOI 10.1128/JVI.73.10.8127-8137.1999; LAMONICA N, 1986, J VIROL, V57, P515, DOI 10.1128/JVI.57.2.515-525.1986; Lea SM, 1998, J BIOL CHEM, V273, P30443, DOI 10.1074/jbc.273.46.30443; Lewis JK, 1998, P NATL ACAD SCI USA, V95, P6774, DOI 10.1073/pnas.95.12.6774; LI QH, 1994, J VIROL, V68, P3965, DOI 10.1128/JVI.68.6.3965-3970.1994; LONBERGHOLM K, 1975, J GEN VIROL, V27, P329, DOI 10.1099/0022-1317-27-3-329; MANDEL B, 1967, VIROLOGY, V31, P702, DOI 10.1016/0042-6822(67)90198-5; MARTIN S, 1993, J VIROL, V67, P3561, DOI 10.1128/JVI.67.6.3561-3568.1993; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; Powell RM, 1997, J VIROL, V71, P9306, DOI 10.1128/JVI.71.12.9306-9312.1997; Racaniello VR, 1996, STRUCTURE, V4, P769, DOI 10.1016/S0969-2126(96)00083-4; Rueckert R R, 1981, Methods Enzymol, V78, P315; Rux AH, 1998, J VIROL, V72, P7091, DOI 10.1128/JVI.72.9.7091-7098.1998; SAUTER NK, 1989, BIOCHEMISTRY-US, V28, P8388, DOI 10.1021/bi00447a018; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SELINKA HC, 1992, J VIROL, V66, P2523, DOI 10.1128/JVI.66.4.2523-2526.1992; SELINKA HC, 1991, P NATL ACAD SCI USA, V88, P3598, DOI 10.1073/pnas.88.9.3598; Tsang SK, 2000, J MOL BIOL, V296, P335, DOI 10.1006/jmbi.1999.3483; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; Zhang WT, 1999, BIOCHEMISTRY-US, V38, P9405, DOI 10.1021/bi990654o	51	55	55	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23089	23096		10.1074/jbc.M002146200	http://dx.doi.org/10.1074/jbc.M002146200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10770940	hybrid			2022-12-27	WOS:000088419400066
J	Perreault-Micale, C; Shushan, AD; Coluccio, LM				Perreault-Micale, C; Shushan, AD; Coluccio, LM			Truncation of a mammalian myosin I results in loss of Ca2+-sensitive motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-FILAMENTS; RAT-LIVER; MOTOR; CALMODULIN; IDENTIFICATION; 130-KDA; INVITRO; COMPLEX; EXPRESSION; ISOFORMS	MYR-1, a mammalian class I myosin, consisting of a heavy chain and 4-6 associated calmodulins, is represented by the 130-kDa myosin I (or MI130) from rat liver. MI130 translocates actin filaments in vitro in a Ca2+- regulated manner. A decrease in motility observed at higher Ca2+ concentrations has been attributed to calmodulin dissociation. To investigate mammalian myosin I regulation, we have coexpressed in baculovirus calmodulin and an epitope-tagged 85-kDa fragment representing the amino-terminal catalytic "motor" domain and the first calmodulin-binding IQ domain of rat myr-1; we refer to this truncated molecule here as MI1IQ. Association of calmodulin to MI1IQ is Ca2+-insensitive. MI1IQ translocates actin filaments in vitro at a rate resembling MI130, but unlike MI130, does not exhibit sensitivity to 0.1-100 mu M Ca2+. In addition to demonstrating successful expression of a functional truncated mammalian myosin I in vitro, these results indicate that: 1) Ca2+-induced calmodulin dissociation from MI130 in the presence of actin is not from the first IQ domain, 2) velocity is not affected by the length of the IQ region, and 3) the Ca2+ sensitivity of actin translocation exhibited by MI130 involves 1 or more of the other 5 IQ domains and/or the carboxyl tail.	Boston Biomed Res Inst, Watertown, MA 02472 USA	Boston Biomedical Research Institute	Coluccio, LM (corresponding author), Boston Biomed Res Inst, 64 Grove St, Watertown, MA 02472 USA.				NIGMS NIH HHS [GM56130] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056130] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHLEY CC, 1977, J PHYSIOL-LONDON, V270, P627, DOI 10.1113/jphysiol.1977.sp011972; Balish MF, 1999, ARCH BIOCHEM BIOPHYS, V370, P285, DOI 10.1006/abbi.1999.1409; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; COLUCCIO LM, 1987, J CELL BIOL, V105, P325, DOI 10.1083/jcb.105.1.325; COLUCCIO LM, 1989, J CELL BIOL, V108, P495, DOI 10.1083/jcb.108.2.495; COLUCCIO LM, 1993, CELL MOTIL CYTOSKEL, V24, P189, DOI 10.1002/cm.970240306; Coluccio LM, 1997, AM J PHYSIOL-CELL PH, V273, pC347, DOI 10.1152/ajpcell.1997.273.2.C347; Coluccio LR, 1999, J BIOL CHEM, V274, P21575, DOI 10.1074/jbc.274.31.21575; GARCIA A, 1989, J CELL BIOL, V109, P2895, DOI 10.1083/jcb.109.6.2895; Geeves MA, 2000, J BIOL CHEM, V275, P21624, DOI 10.1074/jbc.M000342200; HOLMES KC, 1997, CURR BIOL, V7, P112; HOSHIMARU M, 1987, J BIOL CHEM, V262, P14625; MABUCHI K, 1991, J STRUCT BIOL, V107, P22, DOI 10.1016/1047-8477(91)90027-T; MATSUDAIRA PT, 1979, J CELL BIOL, V83, P667, DOI 10.1083/jcb.83.3.667; MOISESCU DG, 1978, J PHYSIOL-LONDON, V275, P241, DOI 10.1113/jphysiol.1978.sp012188; Pato MD, 1996, J BIOL CHEM, V271, P2689, DOI 10.1074/jbc.271.5.2689; POLLARD TD, 1982, METHOD CELL BIOL, V24, P333; RUPPERT C, 1993, J CELL BIOL, V120, P1393, DOI 10.1083/jcb.120.6.1393; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Tan RY, 1996, J BIOL CHEM, V271, P7479, DOI 10.1074/jbc.271.13.7479; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; TRYBUS KM, 1994, J CELL BIOL, V124, P963, DOI 10.1083/jcb.124.6.963; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; Veigel C, 1999, NATURE, V398, P530, DOI 10.1038/19104; Warshaw DM, 1996, NEWS PHYSIOL SCI, V11, P1; WAWRZYNCZAK EJ, 1984, BIOCHEM INT, V9, P177; WILLIAMS R, 1994, CELL MOTIL CYTOSKEL, V27, P41, DOI 10.1002/cm.970270105; Zhu T, 1998, J BIOL CHEM, V273, P20481, DOI 10.1074/jbc.273.32.20481; Zhu T, 1996, BIOCHEMISTRY-US, V35, P513, DOI 10.1021/bi952053c	31	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21618	21623		10.1074/jbc.M000363200	http://dx.doi.org/10.1074/jbc.M000363200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10777479	hybrid			2022-12-27	WOS:000088230600087
J	Bigard, X; Sanchez, H; Zoll, J; Mateo, P; Rousseau, V; Veksler, V; Ventura-Clapier, R				Bigard, X; Sanchez, H; Zoll, J; Mateo, P; Rousseau, V; Veksler, V; Ventura-Clapier, R			Calcineurin co-regulates contractile and metabolic components of slow muscle phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT TRANSCRIPTIONAL PATHWAY; MITOCHONDRIAL CREATINE-KINASE; CALCIUM-PUMP GENE; SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; SOLEUS MUSCLE; FIBER-TYPE; HYPERTROPHY; EXPRESSION; COMPARTMENTATION	Activation of the transcription factor nuclear factor of activated T cells by the calcium-sensitive serine/threonine phosphatase calcineurin has been proposed as one of the molecular mechanisms by which motor nerve activity establishes the slow muscle phenotype. To investigate whether the calcineurin pathway can regulate the large spectrum of slow muscle characteristics in vivo, we treated rats for three weeks with cyclosporin A (an inhibitor of calcineurin). In soleus (slow muscle), but not in plantaris (fast muscle), the proportion of slow myosin heavy chain (MHC-1) and slow sarcoplasmic reticulum ATPase (SERCA2a) was decreased, whereas that of fast MHC (MHC-2A) and fast SERCA1 increased, indicating a slow to fast contractile phenotype transition. Cytosolic isoforms of creatine kinase and lactate dehydrogenase (most abundant in fast fibers), as well as mitochondrial creatine kinase and citrate synthase activities (elevated in fast/oxidative fibers) were dose dependently increased by cyclosporin A treatment in soleus muscle, with no change in plantaris. Calcineurin catalytic subunit was more abundant in soleus muscle fibers compared with plantaris. Taken together these results suggest that the calcineurin pathway co-regulates a set of multigenic protein families involved in the transition between slow oxidative (type I) to fast oxidative (type IIa) phenotype in soleus muscle.	Univ Paris Sud, INSERM, U446, F-92296 Chatenay Malabry, France; Serv Sante Armees, Ctr Rech, Unite Bioenerget & Environm, F-38702 La Tronche, France; Hop Univ Strasbourg, Serv Physiol Clin & Explorat Fonct, F-67091 Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Ventura-Clapier, R (corresponding author), Univ Paris Sud, INSERM, U446, 5 Rue JB Clement, F-92296 Chatenay Malabry, France.	Renee.Ventura@cep.u-psud.fr		Ventura-Clapier, Renee/0000-0002-7488-4123				Bigard AX, 1998, J MOL CELL CARDIOL, V30, P2391, DOI 10.1006/jmcc.1998.0798; Biring MS, 1998, J APPL PHYSIOL, V84, P1967, DOI 10.1152/jappl.1998.84.6.1967; BOOTH FW, 1982, J APPL PHYSIOL, V52, P1113; BRIGGS FN, 1977, J PHYSIOL-LONDON, V266, P587, DOI 10.1113/jphysiol.1977.sp011783; BULLER AJ, 1960, J PHYSIOL-LONDON, V150, P417, DOI 10.1113/jphysiol.1960.sp006395; Buonanno A, 1996, DEV GENET, V19, P95, DOI 10.1002/(SICI)1520-6408(1996)19:2<95::AID-DVG1>3.0.CO;2-V; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; DESPLANCHES D, 1991, J APPL PHYSIOL, V71, P2419, DOI 10.1152/jappl.1991.71.6.2419; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; DUBOWITZ V, 1985, MUSCLE BIOPSY PRACTI, P28; Dunn SE, 1999, J BIOL CHEM, V274, P21908, DOI 10.1074/jbc.274.31.21908; Ho IC, 1998, P NATL ACAD SCI USA, V95, P15537, DOI 10.1073/pnas.95.26.15537; HOPPELER H, 1988, NEWS PHYSIOL SCI, V3, P113; HUDLICKA O, 1992, PHYSIOL REV, V72, P369, DOI 10.1152/physrev.1992.72.2.369; KANDARIAN SC, 1994, AM J PHYSIOL, V266, pC1190, DOI 10.1152/ajpcell.1994.266.5.C1190; KAO AC, 1994, CIRCULATION, V89, P2605, DOI 10.1161/01.CIR.89.6.2605; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; Mende U, 1998, P NATL ACAD SCI USA, V95, P13893, DOI 10.1073/pnas.95.23.13893; Mettauer B, 1996, INT J SPORTS MED, V17, P277, DOI 10.1055/s-2007-972847; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Nakayama M, 1996, MOL CELL BIOL, V16, P2408; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; Park KS, 1999, AM J PHYSIOL-HEART C, V276, pH865, DOI 10.1152/ajpheart.1999.276.3.H865; PAYNE RM, 1994, MOL CELL BIOCHEM, V133, P235, DOI 10.1007/BF01267957; Pette D, 1999, MUSCLE NERVE, V22, P666, DOI 10.1002/(SICI)1097-4598(199906)22:6<666::AID-MUS3>3.0.CO;2-Z; Qin WN, 1999, HISTOCHEM J, V31, P357, DOI 10.1023/A:1003748108062; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; SAKS VA, 1994, MOL CELL BIOCHEM, V133, P155, DOI 10.1007/BF01267954; Sanchez H, 2000, J MOL CELL CARDIOL, V32, P323, DOI 10.1006/jmcc.1999.1078; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; SCHULTE LM, 1993, AM J PHYSIOL, V264, pC1308, DOI 10.1152/ajpcell.1993.264.5.C1308; SILLAU AH, 1977, PFLUG ARCH EUR J PHY, V369, P269, DOI 10.1007/BF00582194; Skorjanc D, 1998, AM J PHYSIOL-CELL PH, V274, pC810, DOI 10.1152/ajpcell.1998.274.3.C810; SMITH D, 1988, AM J PHYSIOL, V254, pC661, DOI 10.1152/ajpcell.1988.254.5.C661; TALMADGE RJ, 1993, J APPL PHYSIOL, V75, P2337, DOI 10.1152/jappl.1993.75.5.2337; THOMASON DB, 1990, J APPL PHYSIOL, V68, P1, DOI 10.1152/jappl.1990.68.1.1; Ventura-Clapier R, 1998, MOL CELL BIOCHEM, V184, P231, DOI 10.1023/A:1006840508139; Watchko JF, 1996, PEDIATR RES, V40, P53, DOI 10.1203/00006450-199607000-00010; WEGMANN G, 1992, J MUSCLE RES CELL M, V13, P420, DOI 10.1007/BF01738037; WU KD, 1995, AM J PHYSIOL-CELL PH, V269, pC775, DOI 10.1152/ajpcell.1995.269.3.C775; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473	43	123	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19653	19660		10.1074/jbc.M000430200	http://dx.doi.org/10.1074/jbc.M000430200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10777482	hybrid			2022-12-27	WOS:000087941300030
J	Rust, C; Karnitz, LM; Paya, CV; Moscat, J; Simari, RD; Gores, GJ				Rust, C; Karnitz, LM; Paya, CV; Moscat, J; Simari, RD; Gores, GJ			The bile acid taurochenodexoycholate activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NF-KAPPA-B; INDUCED APOPTOSIS; ENDOTHELIAL-CELLS; PHOSPHOINOSITIDE 3-KINASE; HEPATOCYTE APOPTOSIS; RAT HEPATOCYTES; PATHWAY; ZETA; LIVER	Liver injury during cholestasis reflects a balance between the effects of toxic and nontoxic bile acids. However, the critical distinction between a toxic and nontoxic bile acid remains subtle and unclear. For example, the glycine conjugate of chenodeoxycholate (GCDC) induces hepatocyte apoptosis, whereas the taurine conjugate (TCDC) does not. We hypothesized that the dissimilar cellular responses may reflect differential activation of a phosphatidylinositol 3-kinase (PI3K)-dependent signaling pathway. In the bile acid-transporting McNtcp.24 rat hepatoma cell line, TCDC, but not GCDC, stimulated PI3K activity. Consistent with this observation, inhibition of PI3K rendered TCDC cytotoxic, and constitutive activation of PI3K rendered GCDC nontoxic. Both Akt and the atypical protein kinase C isoform zeta (PKC zeta) have been implicated in PI3K-dependent survival signaling. However, TCDC activated PKC zeta, but not Akt, Moreover, inhibition of PKC zeta converted TCDC into a cytotoxic agent, whereas overexpression of wild-type PKC zeta blocked GCDC-induced apoptosis, We also demonstrate that TCDC activated nuclear factor kappa B (NF-kappa B) in a PI3K- and PKC zeta-dependent manner. Moreover, inhibition of NF-kappa B by an I kappa B super-repressor rendered TCDC cytotoxic, suggesting that NF-kappa B is also necessary to prevent the cytotoxic effects of TCDC, Collectively, these data suggest that some hydrophobic bile acids such as TCDC activate PI3K-dependent survival pathways, which prevent their otherwise inherent toxicity.	Mayo Clin & Mayo Fdn, Mayo Med Sch, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Oncol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Infect Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Internal Med & Cardiovasc Dis, Rochester, MN 55905 USA; Univ Autonoma Madrid, CSIC, Ctr Biol Mol, E-28049 Madrid, Spain	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Gores, GJ (corresponding author), Mayo Clin & Mayo Fdn, Mayo Med Sch, Div Gastroenterol & Hepatol, 200 1st St SW, Rochester, MN 55905 USA.	gores.gregor@mayo.edu	Moscat, Jorge/A-7011-2009		NATIONAL CANCER INSTITUTE [R29CA073622] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041876, R29DK041876, R37DK041876] Funding Source: NIH RePORTER; NCI NIH HHS [CA73622] Funding Source: Medline; NIAID NIH HHS [AI36079] Funding Source: Medline; NIDDK NIH HHS [DK41876] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Bouscarel B, 1999, GASTROENTEROLOGY, V117, P433, DOI 10.1053/gast.1999.0029900433; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; Faubion WA, 1999, J CLIN INVEST, V103, P137, DOI 10.1172/JCI4765; Folgueira L, 1996, J VIROL, V70, P223, DOI 10.1128/JVI.70.1.223-231.1996; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GREIM H, 1972, GASTROENTEROLOGY, V63, P846; Hedin KE, 1999, J BIOL CHEM, V274, P19992, DOI 10.1074/jbc.274.28.19992; HOFMANN AF, 1984, HEPATOLOGY, V4, pS4, DOI 10.1002/hep.1840040803; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; JAVITT NB, 1966, NATURE, V210, P1262, DOI 10.1038/2101262a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Koh JS, 1998, J CLIN INVEST, V102, P716, DOI 10.1172/JCI1002; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Misra S, 1998, J BIOL CHEM, V273, P26638, DOI 10.1074/jbc.273.41.26638; Miyoshi H, 1999, GASTROENTEROLOGY, V117, P669, DOI 10.1016/S0016-5085(99)70461-0; Ozes ON, 1999, NATURE, V401, P82; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Patel T, 1998, SEMIN LIVER DIS, V18, P105, DOI 10.1055/s-2007-1007147; PATEL T, 1994, J CLIN INVEST, V94, P2183, DOI 10.1172/JCI117579; PATEL T, 1995, HEPATOLOGY, V21, P1725, DOI 10.1002/hep.1840210635; Que FG, 1997, AM J PHYSIOL-GASTR L, V272, pG106, DOI 10.1152/ajpgi.1997.272.1.G106; Roberts LR, 1997, GASTROENTEROLOGY, V113, P1714, DOI 10.1053/gast.1997.v113.pm9352877; Shimoke K, 1998, FEBS LETT, V437, P221, DOI 10.1016/S0014-5793(98)01235-6; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; Sutor SL, 1999, J BIOL CHEM, V274, P7002, DOI 10.1074/jbc.274.11.7002; Torchia EC, 1996, HEPATOLOGY, V24, P206, DOI 10.1053/jhep.1996.v24.pm0008707263; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	44	166	171	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					20210	20216		10.1074/jbc.M909992199	http://dx.doi.org/10.1074/jbc.M909992199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10770953	hybrid			2022-12-27	WOS:000087941300103
J	Yokogawa, T; Shimada, N; Takeuchi, N; Benkowski, L; Suzuki, T; Omori, A; Ueda, T; Nishikawa, K; Spremulli, LL; Watanabe, K				Yokogawa, T; Shimada, N; Takeuchi, N; Benkowski, L; Suzuki, T; Omori, A; Ueda, T; Nishikawa, K; Spremulli, LL; Watanabe, K			Characterization and tRNA recognition of mammalian mitochondrial seryl-tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; NON-SYNDROMIC DEAFNESS; ELONGATION-FACTOR TU; ESCHERICHIA-COLI; TRANSFER RNA(SER); AMINOACYLATION SPECIFICITY; BOVINE MITOCHONDRIA; CRYSTAL-STRUCTURE; NUCLEAR GENES; ACTIVE-SITE	Animal mitochondrial protein synthesis systems contain two serine tRNAs (tRNAs(Ser)) corresponding to the codons AGY and UCN, each possessing an unusual secondary structure; the former lacks the entire D arm, and the latter has a slightly different cloverleaf structure. To elucidate whether these two tRNAs(Ser) can be recognized by the single animal mitochondrial seryl-tRNA synthetase (mt SerRS), we purified mt SerRS from bovine liver 2400-fold and showed that it can aminoacylate both of them. Specific interaction between mt SerRS and either of the tRNAs(Ser) was also observed in a gel retardation assay. cDNA cloning of bovine mt SerRS revealed that the deduced amino acid sequence of the enzyme contains 518 amino acid residues. The cDNAs of human and mouse mt SerRS were obtained by reverse transcription-polymerase chain reaction and expressed sequence tag data base searches. Elaborate inspection of primary sequences of mammalian mt SerRSs revealed diversity in the N-terminal domain responsible for tRNA recognition, indicating that the recognition mechanism of mammalian mt SerRS differs considerably from that of its prokaryotic counterpart. In addition, the human mt SerRS gene was found to be located on chromosome 19q13.1, to which the autosomal deafness locus DFNA4 is mapped.	Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan; Gifu Univ, Fac Engn, Dept Biomol Sci, Gifu 5011193, Japan; Ecole Polytech, Biochim Lab, F-91128 Palaiseau, France; Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA; Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Tokyo 1138656, Japan; Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 194, Japan	University of Tokyo; Gifu University; Institut Polytechnique de Paris; University of North Carolina; University of North Carolina Chapel Hill; University of Tokyo	Watanabe, K (corresponding author), Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.	kw@kwl.t.u-tokyo.ac.jp	Suzuki, Tsutomu/J-1776-2015; Ueda, Takuya/K-5217-2014	Suzuki, Tsutomu/0000-0002-9731-1731; Ueda, Takuya/0000-0002-7760-8271				ACHSEL T, 1993, EMBO J, V12, P3333, DOI 10.1002/j.1460-2075.1993.tb06003.x; ALKSNE LE, 1993, P NATL ACAD SCI USA, V90, P9538, DOI 10.1073/pnas.90.20.9538; ASAHARA H, 1994, J MOL BIOL, V236, P738, DOI 10.1006/jmbi.1994.1186; ASAHARA H, 1991, CHEM LETT, P363, DOI 10.1246/cl.1991.363; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; CHEN AH, 1995, HUM MOL GENET, V4, P1073, DOI 10.1093/hmg/4.6.1073; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; Cusack S, 1996, EMBO J, V15, P2834, DOI 10.1002/j.1460-2075.1996.tb00644.x; DOCKBREGEON AC, 1990, EUR J BIOCHEM, V188, P283, DOI 10.1111/j.1432-1033.1990.tb15401.x; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; HARTLEIN M, 1995, J MOL EVOL, V40, P519; HIMENO H, 1990, NUCLEIC ACIDS RES, V18, P6815, DOI 10.1093/nar/18.23.6815; Himeno H, 1997, J MOL BIOL, V268, P704, DOI 10.1006/jmbi.1997.0991; Hornung V, 1998, BIOCHEMISTRY-US, V37, P7260, DOI 10.1021/bi972969e; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; Johnson DF, 1998, GENOMICS, V52, P363, DOI 10.1006/geno.1998.5448; KISSELEV LL, 1985, PROG NUCLEIC ACID RE, V32, P237, DOI 10.1016/S0079-6603(08)60350-5; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; KUMAZAWA Y, 1991, J BIOCHEM, V109, P421, DOI 10.1093/oxfordjournals.jbchem.a123397; KUMAZAWA Y, 1988, THESIS U TOKYO TOKYO; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lenhard B, 1999, NUCLEIC ACIDS RES, V27, P721, DOI 10.1093/nar/27.3.721; Lenhard B, 1997, J BIOL CHEM, V272, P1136, DOI 10.1074/jbc.272.2.1136; MCCLAIN WH, 1988, SCIENCE, V240, P793, DOI 10.1126/science.2452483; NAKAYAMA H, 1996, BAIO JIKKEN IRASUTOR, V3, P85; NISHIMURA S, 1964, BIOCHIM BIOPHYS ACTA, V80, P574, DOI 10.1016/0926-6550(64)90302-0; NORMANLY J, 1989, ANNU REV BIOCHEM, V58, P1029, DOI 10.1146/annurev.bi.58.070189.005121; OMORI A, 1994, J PROTEIN CHEM, V13, P471; PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289; PRICE S, 1993, FEBS LETT, V324, P167, DOI 10.1016/0014-5793(93)81386-E; RICH A, 1978, SCI AM, V238, P52, DOI 10.1038/scientificamerican0178-52; SAKS ME, 1994, SCIENCE, V263, P191, DOI 10.1126/science.7506844; SAMPSON JR, 1993, NUCLEIC ACIDS RES, V21, P4467, DOI 10.1093/nar/21.19.4467; SCHATZ D, 1991, P NATL ACAD SCI USA, V88, P6132, DOI 10.1073/pnas.88.14.6132; SCHULMAN LH, 1991, PROG NUCLEIC ACID RE, V41, P23; Schwartzbach C J, 1996, Methods Enzymol, V264, P248, DOI 10.1016/S0076-6879(96)64025-7; SCHWARTZBACH CJ, 1989, J BIOL CHEM, V264, P19125; Shah ZH, 1998, GENOMICS, V48, P384, DOI 10.1006/geno.1997.5166; Shah ZH, 1997, GENE, V204, P55, DOI 10.1016/S0378-1119(97)00521-0; SHIMIZU M, 1992, J MOL EVOL, V35, P436; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; STEINBERG S, 1994, J MOL BIOL, V236, P982, DOI 10.1016/0022-2836(94)90004-3; Takeuchi N, 1998, J BIOL CHEM, V273, P15085, DOI 10.1074/jbc.273.24.15085; UEDA T, 1992, NUCLEIC ACIDS RES, V20, P2217, DOI 10.1093/nar/20.9.2217; WAKITA K, 1994, NUCLEIC ACIDS RES, V22, P347, DOI 10.1093/nar/22.3.347; WeygandDurasevic I, 1996, J BIOL CHEM, V271, P2455, DOI 10.1074/jbc.271.5.2455; WU XQ, 1993, NUCLEIC ACIDS RES, V21, P5589, DOI 10.1093/nar/21.24.5589; YOKOGAWA T, 1991, NUCLEIC ACIDS RES, V19, P6101, DOI 10.1093/nar/19.22.6101; YOKOGAWA T, 1989, NUCLEIC ACIDS RES, V17, P2623, DOI 10.1093/nar/17.7.2623	49	38	41	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19913	19920		10.1074/jbc.M908473199	http://dx.doi.org/10.1074/jbc.M908473199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10764807	Green Published, hybrid			2022-12-27	WOS:000087941300066
J	Hillas, PJ; del Alba, FS; Oyarzabal, J; Wilks, A; de Montellano, PRO				Hillas, PJ; del Alba, FS; Oyarzabal, J; Wilks, A; de Montellano, PRO			The AhpC and AhpD antioxidant defense system of Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYL HYDROPEROXIDE REDUCTASE; CYSTEINE-SULFENIC ACID; SALMONELLA-TYPHIMURIUM; THIOREDOXIN REDUCTASE; ISONIAZID RESISTANCE; PEROXIDE REDUCTION; GENE; SENSITIVITY; PROTEIN; KATG	The peroxiredoxin AhpC from Mycobacterium tuberculosis has been expressed, purified, and characterized. It differs from other well characterized AhpC proteins in that it has three rather than one or two cysteine residues. Mutagenesis studies show that all three cysteine residues are important for catalytic activity. Analysis of the M, tuberculosis genome identified a second protein, AhpD, which has no sequence identity with AhpC but is under the control of the same promoter. This protein has also been cloned, expressed, purified, and characterized. AhpD, which has only been identified in the genomes of mycobacteria and Streptomyces viridosporus, is shown here to also be an alkylhydroperoxidase, The endogenous electron donor for catalytic turnover of the two proteins is not known, but both can be turned over with AhpF from Salmonella typhimurium or, particularly in the case of AhpC, with dithiothreitol, AhpC and AhpD reduce alkylhydroperoxides more effectively than H2O2 but do not appear to interact with each other. These two proteins appear to be critical elements of the antioxidant defense system of M. tuberculosis and may be suitable targets for the development of novel anti-tuberculosis strategies.	Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	de Montellano, PRO (corresponding author), Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.		Oyarzabal, Julen/K-7393-2017	Oyarzabal, Julen/0000-0003-1941-7255	NIGMS NIH HHS [GM56531] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM056531] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barry CE, 1998, DRUG RESIST UPDATE, V1, P128, DOI 10.1016/S1368-7646(98)80028-9; BECKWITH ALJ, 1989, J CHEM SOC PERK T 2, P815, DOI 10.1039/p29890000815; BENERJEE A, 1994, SCIENCE, V263, P227; CAPDEVIELLE P, 1980, TETRAHEDRON LETT, V21, P2417, DOI 10.1016/S0040-4039(00)93164-2; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAN J, 1994, IMMUNE MECHANISMS PR; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Deretic V, 1996, NAT BIOTECHNOL, V14, P1557, DOI 10.1038/nbt1196-1557; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P15013, DOI 10.1021/bi972191x; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P13349, DOI 10.1021/bi9713658; ELLIS HR, 1997, BIOCHEMISTRY-US, V36, P13357; Evans J, 1998, CHEM BRIT, V34, P38; Fenton MJ, 1996, INFECT IMMUN, V64, P683, DOI 10.1128/IAI.64.3.683-690.1996; HEYM B, 1995, MOL MICROBIOL, V15, P235, DOI 10.1111/j.1365-2958.1995.tb02238.x; HEYM B, 1993, J BACTERIOL, V175, P4255, DOI 10.1128/JB.175.13.4255-4259.1993; Hirotsu S, 1999, P NATL ACAD SCI USA, V96, P12333, DOI 10.1073/pnas.96.22.12333; IYER KS, 1973, J BIOL CHEM, V248, P707; JOHNSSON K, 1995, J AM CHEM SOC, V116, P7425; Kitano K, 1999, J BIOCHEM, V126, P313, DOI 10.1093/oxfordjournals.jbchem.a022451; Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607; MDLULI K, 1996, J INFECT DIS, V174, P10895; MIDDLEBROOK G, 1954, AM REV TUBERC PULM, V70, P852; NICKON A, 1961, J AM CHEM SOC, V83, P1498, DOI 10.1021/ja01467a049; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Poole LB, 1996, BIOCHEMISTRY-US, V35, P56, DOI 10.1021/bi951887s; Poole LB, 1996, BIOCHEMISTRY-US, V35, P65, DOI 10.1021/bi951888k; PORTER NA, 1987, J ORG CHEM, V52, P5085, DOI 10.1021/jo00232a004; Prein M, 1996, ANGEW CHEM INT EDIT, V35, P477, DOI 10.1002/anie.199604771; RAMACHANDRAN S, 1999, 127576 AF GENB; SCHENCK GO, 1953, LIEBIGS ANN CHEM, V584, P177; SHERMAN DR, 1995, P NATL ACAD SCI USA, V92, P6625, DOI 10.1073/pnas.92.14.6625; Sherman DR, 1996, SCIENCE, V272, P1641, DOI 10.1126/science.272.5268.1641; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; WASSERMAN HH, 1981, TETRAHEDRON, V37, P1825, DOI 10.1016/S0040-4020(01)97932-3; WIELES B, 1995, J BIOL CHEM, V270, P25604, DOI 10.1074/jbc.270.43.25604; WIELES B, 1995, INFECT IMMUN, V63, P4946, DOI 10.1128/IAI.63.12.4946-4948.1995; Yeh JI, 1996, BIOCHEMISTRY-US, V35, P9951, DOI 10.1021/bi961037s; Zhang Y, 1996, P NATL ACAD SCI USA, V93, P13212, DOI 10.1073/pnas.93.23.13212; ZHANG Y, 1993, MOL MICROBIOL, V8, P521, DOI 10.1111/j.1365-2958.1993.tb01596.x; Zhang ZP, 1999, ARCH BIOCHEM BIOPHYS, V363, P19, DOI 10.1006/abbi.1998.1056; Zumla A, 1998, BRIT MED J, V316, P1962, DOI 10.1136/bmj.316.7149.1962	42	109	118	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18801	18809		10.1074/jbc.M001001200	http://dx.doi.org/10.1074/jbc.M001001200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10766746	hybrid			2022-12-27	WOS:000087815900027
J	Johnson, RC; Penzes, P; Eipper, BA; Mains, RE				Johnson, RC; Penzes, P; Eipper, BA; Mains, RE			Isoforms of kalirin, a neuronal Dbl family member, generated through use of different 5 '- and 3 '-ends along with an internal translational initiation site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-PROCESSING ENZYME; CYTOSOLIC ROUTING DETERMINANTS; ALPHA-AMIDATING MONOOXYGENASE; PLECKSTRIN HOMOLOGY DOMAIN; EXCHANGE FACTOR DOMAINS; CRYSTAL-STRUCTURE; PROTEIN-KINASE; SPECTRIN; TRIO; ACTIVATION	Kalirin is a neuron-specific GDP/GTP exchange factor for Rho subfamily GTP-binding proteins. The major Kalirin transcripts in adult rat brain were identified. Most include a Sec14p-like putative lipid-binding motif followed bat nine spectrin-like repeats and a Dbl homology/ pleckstrin homology (DH-PH) domain. Kalirin proteins with four different NH, termini are generated through the use of five different 5'-ends; three of the proteins differ only at the extreme NH2 terminus, and one is truncated because translation is initiated at a methionine in the 5th spectrin repeat. Four different 3'-ends yield Kalirin proteins with additional functional do mains. Kalirin-1 (7-kilobase pair mRNA) terminates with a PDZ-binding motif, which in Kalirin-8 is replaced by an SH3 domain. Kalirin-9 contains another pair of DH-PH and SH3 domains. Kalirin-12 additionally encodes a putative Ser/Thr protein kinase, Antisera specific for different COOH termini established Kalirin-7 as the most abundant in cortex, with significant amounts of Kalirin-9 and Kalirin-12; Kalirin-7 was less prevalent in cerebellum and olfactory bulb. Kalirin proteins lacking the Sec14p-like domain and first four spectrin-like repeats were much less prevalent. Form-specific antisera demonstrated that different forms of Kalirin were localized to distinct subcellular regions of cultured neurons. Members of the family of Kalirin proteins may subserve different functions at these different locations.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University	Mains, RE (corresponding author), Univ Connecticut, Ctr Hlth, Dept Neurosci, MC3401,263 Farmington Ave, Farmington, CT 06030 USA.	mains@nso.uchc.edu	Penzes, Peter/L-3987-2016	Penzes, Peter/0000-0001-5449-1640	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK032948, R37DK032948, R01DK032948] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-32948] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alam MR, 1997, J BIOL CHEM, V272, P12667, DOI 10.1074/jbc.272.19.12667; Alam MR, 1996, J BIOL CHEM, V271, P28636, DOI 10.1074/jbc.271.45.28636; Aravind L, 1999, CURR BIOL, V9, pR195, DOI 10.1016/S0960-9822(99)80127-4; Bellanger Jean-Michel, 1998, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V192, P367; Bellanger JM, 1998, ONCOGENE, V16, P147, DOI 10.1038/sj.onc.1201532; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; Caldwell BD, 1999, J BIOL CHEM, V274, P34646, DOI 10.1074/jbc.274.49.34646; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Colomer V, 1997, HUM MOL GENET, V6, P1519, DOI 10.1093/hmg/6.9.1519; De Matteis MA, 1998, CURR OPIN CELL BIOL, V10, P542, DOI 10.1016/S0955-0674(98)80071-9; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; GRAZIANI G, 1989, ONCOGENE, V4, P823; Gregorio CC, 1999, CURR OPIN CELL BIOL, V11, P18, DOI 10.1016/S0955-0674(99)80003-9; Hanks SK, 1998, SEL METH EN, P39; Holleran EA, 1998, TRENDS CELL BIOL, V8, P26, DOI 10.1016/S0962-8924(97)01195-1; JOHNSON RC, 1994, ENDOCRINOLOGY, V135, P1178, DOI 10.1210/en.135.3.1178; Kawai T, 1999, GENE, V227, P249, DOI 10.1016/S0378-1119(98)00605-2; Kenny PA, 1999, GENE, V232, P11, DOI 10.1016/S0378-1119(99)00122-5; Kins S, 2000, NAT NEUROSCI, V3, P22, DOI 10.1038/71096; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Lorenzi MV, 1999, ONCOGENE, V18, P4742, DOI 10.1038/sj.onc.1202851; Mains RE, 1999, J BIOL CHEM, V274, P2929, DOI 10.1074/jbc.274.5.2929; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Nishida K, 1999, FEBS LETT, V459, P186, DOI 10.1016/S0014-5793(99)01244-2; Penzes P, 2000, J BIOL CHEM, V275, P6395, DOI 10.1074/jbc.275.9.6395; Ratovitski EA, 1999, J BIOL CHEM, V274, P993, DOI 10.1074/jbc.274.2.993; Seipel K, 1999, J CELL SCI, V112, P1825; Sha BD, 1998, NATURE, V391, P506, DOI 10.1038/35179; Stankewich MC, 1998, P NATL ACAD SCI USA, V95, P14158, DOI 10.1073/pnas.95.24.14158; Steven R, 1998, CELL, V92, P785, DOI 10.1016/S0092-8674(00)81406-3; Stull JT, 1998, ACTA PHYSIOL SCAND, V164, P471, DOI 10.1111/j.1365-201X.1998.tb10699.x; Suetsugu S, 1998, EMBO J, V17, P6516, DOI 10.1093/emboj/17.22.6516; TAYLOR SS, 1994, CYCLIC AMP DEPENDENT, P1; Wang DS, 1997, BIOCHEM BIOPH RES CO, V234, P183, DOI 10.1006/bbrc.1997.6589; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097; ZHENG JH, 1992, ACTA CRYSTALLOGR B, V48, P241, DOI 10.1107/S0108768192000909; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	44	79	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19324	19333		10.1074/jbc.M000676200	http://dx.doi.org/10.1074/jbc.M000676200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10777487	hybrid			2022-12-27	WOS:000087815900092
J	Mukai, J; Hachiya, T; Shoji-Hoshino, S; Kimura, MT; Nadano, D; Suvanto, P; Hanaoka, T; Li, Y; Irie, S; Greene, LA; Sato, TA				Mukai, J; Hachiya, T; Shoji-Hoshino, S; Kimura, MT; Nadano, D; Suvanto, P; Hanaoka, T; Li, Y; Irie, S; Greene, LA; Sato, TA			NADE, a p75NTR-associated cell death executor, is involved in signal transduction mediated by the common neurotrophin receptor p75NTR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; ZINC-FINGER PROTEIN; NGF RECEPTOR; LOW-AFFINITY; APOPTOSIS; INDUCTION; ACTIVATION; INTERACTS; P75(NTR); PATHWAY	The low affinity neurotrophin receptor p75NTR can mediate cell survival as well as cell death of neural cells by NGF and other neurotrophins. To elucidate p75NTR-mediated signal transduction, we screened p75NTR-associated proteins by a yeast two-hybrid system. We identified one positive clone and named NADE (p75NTR-associated cell death executor). Mouse NADE has marked homology to the human HGR74 protein. NADE specifically binds to the cell-death domain of p75NTR, Go-expression of NADE and p75NTR induced caspase-2 and caspase-3 activities and the fragmentation of nuclear DNA in 293T cells. However, in the absence of p75NTR, NADE failed to induce apoptosis, suggesting that NADE expression is necessary but insufficient for p75NTR-mediated apoptosis, Furthermore, p75NTR/ NADE-induced cell death was dependent on NGF but not BDNF, NT-3, or NT-4/5, and the recruitment of NADE to p75NTR (intracellular domain) was dose-dependent. We obtained similar results from PC12 cells, nnr5 cells, and oligodendrocytes. Taken together, NADE is the first signaling adaptor molecule identified in the involvement of p75NTR-mediated apoptosis induced by NGF, and it may play an important role in the pathogenesis of neurogenetic diseases.	Columbia Univ Coll Phys & Surg, Dept Otolaryngol Head & Neck Surg & Pathol, Div Mol Oncol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; RIKEN, Tsukuba Life Sci Ctr, Oncol Mol Lab, Tsukuba, Ibaraki 3050074, Japan; Med & Biol Labs Co Ltd, Ina Lab, Nagano 3960002, Japan; ZAIYA Inc, Kyoto 6008815, Japan; Tottori Univ, Sch Life Sci, Dept Mol & Cell Genet, Tottori 683, Japan	Columbia University; Columbia University; RIKEN; Tottori University	Sato, TA (corresponding author), Columbia Univ Coll Phys & Surg, Dept Otolaryngol Head & Neck Surg & Pathol, Div Mol Oncol, 630 W 168th St,P&S 11-451, New York, NY 10032 USA.		Shoji, Shisako/C-3690-2017; Shoji, Shisako/AAJ-2654-2020	Shoji, Shisako/0000-0001-8787-2159; Shoji, Shisako/0000-0001-8787-2159; Mukai, Jun/0000-0003-2065-4784	NIGMS NIH HHS [R01 GM55147] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055147] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRETT GL, 1994, P NATL ACAD SCI USA, V91, P6501, DOI 10.1073/pnas.91.14.6501; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Bunone G, 1997, ONCOGENE, V14, P1463, DOI 10.1038/sj.onc.1200972; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Casademunt E, 1999, EMBO J, V18, P6050, DOI 10.1093/emboj/18.21.6050; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; Chittka A, 1999, P NATL ACAD SCI USA, V96, P10705, DOI 10.1073/pnas.96.19.10705; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; FERRARI G, 1995, J BIOL CHEM, V270, P3074, DOI 10.1074/jbc.270.7.3074; Frade JM, 1996, NATURE, V383, P166; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Gu CH, 1999, J NEUROSCI, V19, P3043; Irie S, 1999, FEBS LETT, V460, P191, DOI 10.1016/S0014-5793(99)01324-1; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; NAKIELNY S, 1997, CURR OPIN CELL BIOL, V17, P7151; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RAPP G, 1990, DNA CELL BIOL, V9, P479, DOI 10.1089/dna.1990.9.479; Soilu-Hanninen M, 1999, J NEUROSCI, V19, P4828; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202	26	156	171	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17566	17570		10.1074/jbc.C000140200	http://dx.doi.org/10.1074/jbc.C000140200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10764727	hybrid			2022-12-27	WOS:000087485000051
J	Charlier, HA; Plapp, BV				Charlier, HA; Plapp, BV			Kinetic cooperativity of human liver alcohol dehydrogenase gamma(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE-REDUCTASE; ESCHERICHIA-COLI; RATE CONSTANTS; MECHANISM; ISOENZYMES; ISOZYMES; SUBUNITS; BINDING; FAMILY; SITES	Previous studies showed that natural human liver alcohol dehydrogenase gamma exhibits negative cooperativity (substrate activation) with ethanol. Studies with the recombinant gamma(2) isoenzyme now confirm that observation and show that the saturation kinetics with other alcohols are also nonhyperbolic, whereas the kinetics for reactions with NAD(+), NADH, and acetaldehyde are hyperbolic. The substrate activation with ethanol and 1-butanol are explained by an ordered mechanism with an abortive enzyme-NADH-alcohol complex that releases NADH more rapidly than does the enzyme-NADH complex, In contrast, high concentrations of cyclohexanol produce noncompetitive substrate inhibition against varied concentrations of NAD+ and decrease the maximum velocity to 25% of the value that is observed at optimal concentrations of cyclohexanol. Transient kinetics experiments show that cyclohexanol inhibition is due to a slower rate of dissociation of NADH from the abortive enzyme-NADH-cyclohexanol complex than from the enzyme-NADH complex. Fluorescence quenching experiments confirm that the alcohols bind to the enzyme-NADH complex. The nonhyperbolic saturation kinetics for oxidation of ethanol, cyclohexanol, and 1-butanol are quantitatively explained with the abortive complex mechanism. Physiologically relevant concentrations of ethanol would be oxidized predominantly by the abortive complex pathway.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa	Plapp, BV (corresponding author), Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA.		Plapp, Bryce V/F-6353-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007344] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07344] Funding Source: Medline; NIAAA NIH HHS [AA00279, F32 AA05330] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AINSLIE GR, 1972, J BIOL CHEM, V247, P946; BERNHARD SA, 1970, BIOCHEMISTRY-US, V9, P185, DOI 10.1021/bi00803a024; BOSRON WF, 1983, BIOCHEMISTRY-US, V22, P1852, DOI 10.1021/bi00277a017; Chen CC, 1999, AM J HUM GENET, V65, P795, DOI 10.1086/302540; Cleland W W, 1979, Methods Enzymol, V63, P103; CLELAND WW, 1969, MECHANISM ACTION DEH, P103; CORNISHBOWDEN A, 1987, J THEOR BIOL, V124, P1, DOI 10.1016/S0022-5193(87)80248-5; DALZIEL K, 1966, BIOCHEM J, V100, P34, DOI 10.1042/bj1000034; DALZIEL K, 1966, BIOCHEM J, V100, P491, DOI 10.1042/bj1000491; DICKINSON FM, 1987, ENZYMOLOGY MOL BIOL, P25; DUBIED A, 1977, J BIOL CHEM, V252, P1464; Duester G, 1999, BIOCHEM PHARMACOL, V58, P389, DOI 10.1016/S0006-2952(99)00065-9; DUNN MF, 1979, BIOCHEMISTRY-US, V18, P2346, DOI 10.1021/bi00578a033; DWORSCHACK RT, 1977, BIOCHEMISTRY-US, V16, P111, DOI 10.1021/bi00620a018; EDENBERG HJ, 1997, COMPREHENSIVE TOXICO, V3, P119; EKLUND H, 1987, EUR J BIOCHEM, V167, P185, DOI 10.1111/j.1432-1033.1987.tb13322.x; FIERKE CA, 1987, BIOCHEMISTRY-US, V26, P4085, DOI 10.1021/bi00387a052; FRIEDEN C, 1994, METHOD ENZYMOL, V240, P311; HADORN M, 1975, EUR J BIOCHEM, V54, P65, DOI 10.1111/j.1432-1033.1975.tb04114.x; HOOG JO, 1986, EUR J BIOCHEM, V159, P215, DOI 10.1111/j.1432-1033.1986.tb09855.x; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; KAMLAY MT, 1983, ARCH BIOCHEM BIOPHYS, V156, P112; KVASSMAN J, 1976, EUR J BIOCHEM, V69, P279, DOI 10.1111/j.1432-1033.1976.tb10884.x; LEE KM, 1988, BIOCHEMISTRY-US, V27, P3528, DOI 10.1021/bi00409a060; MCEVILY AJ, 1988, BIOCHEMISTRY-US, V27, P4284, DOI 10.1021/bi00412a013; NEET KE, 1995, METHOD ENZYMOL, V249, P519; Osier M, 1999, AM J HUM GENET, V64, P1147, DOI 10.1086/302317; PENNER MH, 1987, J BIOL CHEM, V262, P15908; PETTERSSON G, 1986, EUR J BIOCHEM, V154, P167, DOI 10.1111/j.1432-1033.1986.tb09374.x; Plapp B V, 1975, Adv Exp Med Biol, V56, P77; PLAPP BV, 1970, J BIOL CHEM, V245, P1727; PLAPP BV, 1994, MOL BASIS ALCOHOL US, P311; Schindler JF, 1998, J MED CHEM, V41, P1696, DOI 10.1021/jm9707380; SEKHAR VC, 1990, BIOCHEMISTRY-US, V29, P4289, DOI 10.1021/bi00470a005; SEKHAR VC, 1988, BIOCHEMISTRY-US, V27, P5082, DOI 10.1021/bi00414a020; SHEARER GL, 1993, BIOCHEMISTRY-US, V32, P11186, DOI 10.1021/bi00092a031; SHERMAN DIN, 1994, MOL BASIS ALCOHOL US, P291; SHORE JD, 1970, BIOCHEMISTRY-US, V9, P4655, DOI 10.1021/bi00826a006; STONE CL, 1993, J BIOL CHEM, V268, P892; SUN HW, 1992, J MOL EVOL, V34, P522, DOI 10.1007/BF00160465; Sund H., 1963, ENZYMES, V7, P25; Svensson S, 1996, FEBS LETT, V394, P217, DOI 10.1016/0014-5793(96)00954-4; THEORELL H, 1961, ACTA CHEM SCAND, V15, P1811, DOI 10.3891/acta.chem.scand.15-1811; THEORELL H, 1963, BIOCHEM Z, V338, P537; WAGNER FW, 1983, BIOCHEMISTRY-US, V22, P1857, DOI 10.1021/bi00277a018; Whitfield JB, 1998, ALCOHOL CLIN EXP RES, V22, P1463	46	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11569	11575		10.1074/jbc.275.16.11569	http://dx.doi.org/10.1074/jbc.275.16.11569			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766771	hybrid			2022-12-27	WOS:000086695500006
J	Yoshizumi, M; Abe, J; Haendeler, J; Huang, QH; Berk, BC				Yoshizumi, M; Abe, J; Haendeler, J; Huang, QH; Berk, BC			Src and Cas mediate JNK activation but not ERK1/2 and p38 kinases by reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; FOCAL ADHESION KINASE; EXCHANGE PROTEIN C3G; TYROSINE KINASE; OXIDATIVE STRESS; C-SRC; PROTEIN-KINASE-1 BMK1; SIGNAL-TRANSDUCTION; COMPLEX-FORMATION; FREE-RADICALS	c-Jun NH2-terminal kinase (JNK) is activated by a number of cellular stimuli such as inflammatory cytokines and environmental stresses. Reactive oxygen species also cause activation of JNK; however, the signaling cascade that leads to JNK activation remains to be elucidated. Because recent reports showed that expression of Cas, a putative Src substrate, stimulates JNK activation, we hypothesized that the Src kinase family and Cas would be involved in JNK activation by reactive oxygen species. An essential role for both Src and Cas was demonstrated, First, the specific Src family tyrosine kinase inhibitor, PP2, inhibited JNK activation by H2O2 in a concentration-dependent manner but had no effect on extracellular signal-regulated kinases 1 and 2 and p38 activation. Second, JNK activation in response to H2O2 was completely inhibited in cells derived from transgenic mice deficient in Src but not Fyn. Third, expression of a dominant negative mutant of Cas prevented H2O2-mediated JNK activation but had no effect on extracellular signal-regulated kinases 1 and 2 and p38 activation. Finally, the importance of Src was further supported by the inhibition of both H2O2-mediated Cas tyrosine phosphorylation and Cas.Crk complex formation in Src-/- but not Fyn-/- cells. These results demonstrate an essential role for Src and Cas in H2O2-mediated activation of JNK and suggest a new redox-sensitive pathway for JNK activation mediated by Src.	Univ Rochester, Cardiovasc Res Ctr, Rochester, NY 14642 USA	University of Rochester	Berk, BC (corresponding author), Univ Rochester, Sch Med & Dent, Cardiol Unit, 601 Elmwood Ave,Box 679, Rochester, NY 14642 USA.			Haendeler, Judith/0000-0001-8507-4540; Berk, Bradford/0000-0002-2767-4115	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044721, R01HL049192] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44721, HL49192] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe J, 1998, TRENDS CARDIOVAS MED, V8, P59, DOI 10.1016/S1050-1738(97)00133-3; Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Abe J, 1999, J BIOL CHEM, V274, P21003, DOI 10.1074/jbc.274.30.21003; BAAS AS, 1995, CIRC RES, V77, P29, DOI 10.1161/01.RES.77.1.29; Burnham MR, 1996, ONCOGENE, V12, P2467; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Clerk A, 1998, BIOCHEM J, V333, P581, DOI 10.1042/bj3330581; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; DUFF JL, 1993, J BIOL CHEM, V268, P26037; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HALLIWELL B, 1989, BRIT J EXP PATHOL, V70, P737; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Ishida T, 1999, J CLIN INVEST, V103, P789, DOI 10.1172/JCI4189; Kiyokawa E, 1997, CRIT REV ONCOGENESIS, V8, P329, DOI 10.1615/CritRevOncog.v8.i4.30; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Mendelson KG, 1996, P NATL ACAD SCI USA, V93, P12908, DOI 10.1073/pnas.93.23.12908; Nakamura I, 1998, J BIOL CHEM, V273, P11144, DOI 10.1074/jbc.273.18.11144; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Posern G, 1998, ONCOGENE, V16, P1903, DOI 10.1038/sj.onc.1201714; Rao GN, 1996, ONCOGENE, V13, P713; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Tanaka S, 1998, J BIOL CHEM, V273, P1281, DOI 10.1074/jbc.273.3.1281; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Tateno M, 2000, SCIENCE, V287, P324, DOI 10.1126/science.287.5451.324; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Vuori K, 1996, MOL CELL BIOL, V16, P2606	39	217	222	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11706	11712		10.1074/jbc.275.16.11706	http://dx.doi.org/10.1074/jbc.275.16.11706			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766791	hybrid			2022-12-27	WOS:000086695500026
J	Zhou, YL; Snead, ML				Zhou, YL; Snead, ML			Identification of CCAAT/enhancer-binding protein alpha as a transactivator of the mouse amelogenin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C/EBP-ALPHA; TOOTH DEVELOPMENT; TRANSCRIPTIONAL ACTIVATION; ADIPOCYTE DIFFERENTIATION; CELL-PROLIFERATION; MOLAR DEVELOPMENT; IMPERFECTA AIH1; DNA COMPLEX; IN-VITRO; CBF-B	Amelogenin expression is ameloblast-specific and developmentally regulated at the temporal and spatial levels, In a previous transgenic mouse analysis, the expression pattern of the endogenous amelogenin gene was recapitulated by a reporter gene driven by a 2.2-kilobase mouse amelogenin proximal promoter. To understand the molecular mechanisms underlying the spatiotemporal expression of the amelogenin gene during odontogenesis, the mouse amelogenin promoter was systematically analyzed in mouse ameloblast-like LS8 cells. Deletion analysis identified a minimal promoter (-70/+52) containing a CCAAT/enhancer-binding protein (C/EBP)-binding site upstream of the TATA box. In transient transfection assays, C/EBP alpha up-regulated the promoter activity in a dose-dependent manner. The C/EBP-binding site was necessary for both C/EBP alpha-mediated transactivation and basal promoter activity. Electrophoresis mobility shift assays demonstrated that C/EBP alpha bound to its cognate site in the amelogenin promoter and that the binding was specific. Endogenous C/EBPa was detected in LS8 cells, and overexpression of exogenous C/EBPa in LS8 cells was able to increase the expression level of the endogenous amelogenin protein. The activity of the amelogenin promoter in rat parotid Pa-4 cells and Madin-Darby canine kidney cells was minimal, ranging from 20 to 30% of the activity in ameloblast-like cells. Transient transfection experiments showed that C/EBPa transactivated the mouse amelogenin reporter gene in Pa-4 cells, but not in Madin-Darby canine kidney cells. Taken together, these data indicate that C/EBP alpha is a bona fide transcriptional activator of the mouse amelogenin gene in a cell type-specific manner.	Univ So Calif, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA	University of Southern California	Snead, ML (corresponding author), Univ So Calif, Ctr Craniofacial Mol Biol, 2250 Alcazar St,CSA142, Los Angeles, CA 90033 USA.				NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE006988] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE06988] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALDRED MJ, 1992, HUM GENET, V90, P413; ANTONSON P, 1995, BIOCHEM BIOPH RES CO, V215, P106, DOI 10.1006/bbrc.1995.2439; Bi WM, 1997, J BIOL CHEM, V272, P26562, DOI 10.1074/jbc.272.42.26562; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; Brockes JP, 1997, SCIENCE, V276, P81, DOI 10.1126/science.276.5309.81; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; Chen E, 1998, GENE, V216, P131, DOI 10.1016/S0378-1119(98)00300-X; CHEN EH, 1994, DEV DYNAM, V199, P189, DOI 10.1002/aja.1001990304; Constance CM, 1996, MOL CELL BIOL, V16, P3878; COUWENHOVEN RI, 1993, J CRAN GENET DEV BIO, V13, P259; COUWENHOVEN RI, 1994, DEV BIOL, V164, P290, DOI 10.1006/dbio.1994.1199; Croniger C, 1998, J BIOL CHEM, V273, P31629, DOI 10.1074/jbc.273.48.31629; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; Diehl AM, 1998, J BIOL CHEM, V273, P30843, DOI 10.1074/jbc.273.47.30843; DIEKWISCH T, 1993, DEVELOPMENT, V117, P471; Diekwisch TGH, 1997, J HISTOCHEM CYTOCHEM, V45, P859, DOI 10.1177/002215549704500610; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; Kim IS, 1996, MOL CELL BIOL, V16, P4003; LAGERSTROM M, 1991, GENOMICS, V10, P971, DOI 10.1016/0888-7543(91)90187-J; LAGERSTROMFERMER M, 1995, GENOMICS, V26, P159, DOI 10.1016/0888-7543(95)80097-6; Lane MD, 1996, INT J OBESITY, V20, pS91; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LI F, 1995, AM J PHYSIOL-LUNG C, V269, pL241, DOI 10.1152/ajplung.1995.269.2.L241; Lin HH, 1996, J BIOL CHEM, V271, P27637, DOI 10.1074/jbc.271.44.27637; LYNGSTADAAS SP, 1995, EMBO J, V14, P5224, DOI 10.1002/j.1460-2075.1995.tb00207.x; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P34; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Maytin EV, 1998, J INVEST DERMATOL, V110, P238, DOI 10.1046/j.1523-1747.1998.00123.x; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; PIONTKEWITZ Y, 1993, ENDOCRINOLOGY, V133, P2327, DOI 10.1210/en.133.5.2327; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Quissell DO, 1998, IN VITRO CELL DEV-AN, V34, P58; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; SNEAD ML, 1988, DEVELOPMENT, V104, P77; Snead ML, 1996, CONNECT TISSUE RES, V35, P41, DOI 10.3109/03008209609029173; SNEAD ML, 1984, DEV BIOL, V104, P255, DOI 10.1016/0012-1606(84)90053-8; SNEAD ML, 1987, MOL APPROACHES DEV B, P641; Stocum DL, 1997, SCIENCE, V276, P15, DOI 10.1126/science.276.5309.15; Swart GWM, 1997, BIOL CHEM, V378, P373, DOI 10.1515/bchm.1997.378.5.373; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; ZeichnerDavid M, 1997, INT J DEV BIOL, V41, P27	48	67	68	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12273	12280		10.1074/jbc.275.16.12273	http://dx.doi.org/10.1074/jbc.275.16.12273			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766866	hybrid			2022-12-27	WOS:000086695500101
J	Force, WR; Glass, AA; Benedict, CA; Cheung, TC; Lama, J; Ware, CF				Force, WR; Glass, AA; Benedict, CA; Cheung, TC; Lama, J; Ware, CF			Discrete signaling regions in the lymphotoxin-beta receptor for tumor necrosis factor receptor-associated factor binding, subcellular localization, and activation of cell death and NF-kappa B pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPESVIRUS ENTRY MEDIATOR; LYMPHOID-TISSUES; IMMUNE-RESPONSES; ALPHA; FAMILY; GROWTH; EXPRESSION; PROTEINS; MEMBER; MICE	Lymphotoxin-beta receptor (LT beta R), a member of the tumor necrosis factor receptor superfamily, is essential for the development and organization of secondary lymphoid tissue, Wild type and mutant LT beta R containing successive truncations of the cytoplasmic domain were investigated by retrovirus-mediated gene transfer into HT29.14s and in 293T cells by transfection, Wild type receptors accumulated in perinuclear compartments and enhanced responsiveness to ligand-induced cell death and Ligand-independent activation of NF kappa B p50 dimers. Coimmunoprecipitation and confocal microscopy mapped the TRAF3 binding site to amino acids PEEGDPG at position 389, However, LT beta R truncated at position Pro(379) acted as a dominant positive mutant that down-modulated surface expression and recruited TRAF3 to endogenous LT beta R. This mutant exhibited ligand-independent cell death and activated NF-kappa B p50 dimers. By contrast, truncation at Gly(359) created a dominant-negative mutant that inhibited ligand-induced cell death and activation of NF-kappa B p50/p65 heterodimers. This mutant also blocked accumulation of wild type receptor into perinuclear compartments, suggesting subcellular localization may be crucial for signal transduction. A cryptic TRAF-independent NF-kappa B activating region was identified. These mutants define discrete subregions of a novel proline-rich domain that is required for subcellular localization and signal transduction by the LT beta R.	La Jolla Inst Allergy & Immunol, Div Mol Immunol, San Diego, CA 92121 USA	La Jolla Institute for Immunology	Ware, CF (corresponding author), La Jolla Inst Allergy & Immunol, Div Mol Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.	carl_ware@liai.org			NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007469] Funding Source: NIH RePORTER; NCI NIH HHS [CA69381] Funding Source: Medline; NIAID NIH HHS [T32AI07469, AI03368] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexopoulou L, 1998, J EXP MED, V188, P745, DOI 10.1084/jem.188.4.745; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; BROWNING J, 1989, J IMMUNOL, V143, P1859; Browning JL, 1996, J BIOL CHEM, V271, P8618, DOI 10.1074/jbc.271.15.8618; Browning JL, 1996, J EXP MED, V183, P867, DOI 10.1084/jem.183.3.867; BROWNING JL, 1995, J IMMUNOL, V154, P33; CROWE PD, 1994, SCIENCE, V264, P707, DOI 10.1126/science.8171323; DegliEsposti MA, 1997, J IMMUNOL, V158, P1756; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; Force WR, 1997, J BIOL CHEM, V272, P30835, DOI 10.1074/jbc.272.49.30835; FORCE WR, 1994, J BIOL CHEM, V269, P8863; Fu YX, 1999, ANNU REV IMMUNOL, V17, P399, DOI 10.1146/annurev.immunol.17.1.399; Fu YX, 1997, P NATL ACAD SCI USA, V94, P5739, DOI 10.1073/pnas.94.11.5739; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GREEN LM, 1984, J IMMUNOL METHODS, V70, P257, DOI 10.1016/0022-1759(84)90190-X; Hochman PS, 1996, J INFLAMM, V46, P220; Iizuka K, 1999, P NATL ACAD SCI USA, V96, P6336, DOI 10.1073/pnas.96.11.6336; ITOI D, 1999, IMMUNOLOGY, V163, P2809; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Koni PA, 1998, J EXP MED, V187, P1977, DOI 10.1084/jem.187.12.1977; Krajewska M, 1998, AM J PATHOL, V152, P1549; Mackay F, 1996, J BIOL CHEM, V271, P24934, DOI 10.1074/jbc.271.40.24934; Marsters SA, 1997, J BIOL CHEM, V272, P14029, DOI 10.1074/jbc.272.22.14029; Matsumoto M, 1999, J IMMUNOL, V163, P1584; Matsumoto M, 1997, J VIROL, V71, P1301, DOI 10.1128/JVI.71.2.1301-1309.1997; Mauri DN, 1998, IMMUNITY, V8, P21, DOI 10.1016/S1074-7613(00)80455-0; McWhirter SM, 1999, P NATL ACAD SCI USA, V96, P8408, DOI 10.1073/pnas.96.15.8408; Miller WE, 1998, MOL CELL BIOL, V18, P2835, DOI 10.1128/MCB.18.5.2835; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; Murphy M, 1998, CELL DEATH DIFFER, V5, P497, DOI 10.1038/sj.cdd.4400374; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; Nakano H, 1999, P NATL ACAD SCI USA, V96, P9803, DOI 10.1073/pnas.96.17.9803; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Neumann B, 1996, J EXP MED, V184, P259, DOI 10.1084/jem.184.1.259; Park YC, 1999, NATURE, V398, P533, DOI 10.1038/19110; Pullen SS, 1999, J BIOL CHEM, V274, P14246, DOI 10.1074/jbc.274.20.14246; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Smyth MJ, 1999, J IMMUNOL, V163, P1350; STULTZ CM, 1997, PROTEIN STRUCTURAL B; Tschopp J, 1999, CURR BIOL, V9, pR381, DOI 10.1016/S0960-9822(99)80233-4; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VanArsdale TL, 1997, P NATL ACAD SCI USA, V94, P2460, DOI 10.1073/pnas.94.6.2460; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; WARE CF, 1995, PATHWAYS CYTOLYSIS; WilliamsAbbott L, 1997, J BIOL CHEM, V272, P19451, DOI 10.1074/jbc.272.31.19451; Wu MY, 1999, J BIOL CHEM, V274, P11868, DOI 10.1074/jbc.274.17.11868; Xu Y, 1996, IMMUNITY, V5, P407, DOI 10.1016/S1074-7613(00)80497-5; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	49	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11121	11129		10.1074/jbc.275.15.11121	http://dx.doi.org/10.1074/jbc.275.15.11121			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753918	hybrid			2022-12-27	WOS:000086466600060
J	Harris, VK; Coticchia, CM; Kagan, BL; Ahmad, S; Wellstein, A; Riegel, AT				Harris, VK; Coticchia, CM; Kagan, BL; Ahmad, S; Wellstein, A; Riegel, AT			Induction of the angiogenic modulator fibroblast growth factor-binding protein by epidermal growth factor is mediated through both MEK/ERK and p38 signal transduction pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE CONDITIONS; TUMOR-NECROSIS-FACTOR; MAP KINASE; GENE-EXPRESSION; DIFFERENTIAL EXPRESSION; SKIN CARCINOGENESIS; CELLULAR STRESSES; ACTIVATION DOMAIN; CARCINOMA-CELLS; C/EBP ISOFORMS	Fibroblast growth factor-binding protein (FGF-BP) is a secreted protein that binds and activates fibroblast growth factors (FGF-1 and FGF-2) and induces angiogenesis in some human cancers, FGF-BP is expressed at high levels in squamous cell carcinoma (SCC) cell lines and tumor samples and has been shown to be rate-limiting for the growth of SCC tumors in vivo. In this study, we examine the regulation of FGF-BP by epidermal growth factor (EGF) and the signal transduction mechanisms that mediate this effect. We found that EGF treatment of the ME-180 SCC cell line caused a rapid induction of FGF-BP gene expression. This induction was mediated transcriptionally through the AP-1 (c-Fos/JunD) and CCAAT/enhancer-binding protein elements as well as through an E-box repressor site in the proximal regulatory region of the FGF-BP promoter. Pharmacological inhibition of protein kinase C and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 (MEK1/2) completely blocked EGF induction of FGF-BP mRNA, whereas inhibition of phosphatidylinositol 3-kinase had no effect. Additionally, both EGF- and anisomycin-induced FGF-BP mRNA was abrogated by inhibition of p38 mitogen-activated protein kinase, demonstrating a role for p38 in the regulation of FGF-BP. Co-transfection of the FGF-BP promoter with dominant negative forms of MEK2, extracellular signal-regulated kinase 2, and p38 significantly decreased the level of EGF induction, whereas expression of a dominant negative c-Jun N-terminal kinase mutant or expression of c-Jun N-terminal kinase inhibitory protein had no effect, Similarly, activation of the p38 pathway by overexpression of wild-type p38 or MKK6 enhanced FGF-BP transcription. These results demonstrate that EGF induction of FGF-BP occurs selectively through dual activation of the stress-activated p38 and the MEK/extracellular signal-regulated kinase mitogen-activated protein kinase pathways, which ultimately leads to activation of the promoter through AP-1 and CCAAT/enhancer-binding protein sites.	Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Washington, DC 20007 USA; Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Dept Pharmacol, Washington, DC 20007 USA	Georgetown University; Georgetown University	Riegel, AT (corresponding author), Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Res Bldg,Rm E307,3970 Reservoir Rd NW, Washington, DC 20007 USA.			Wellstein, Anton/0000-0002-0570-4950	NCI NIH HHS [CA71508] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071508] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbott DW, 1999, J BIOL CHEM, V274, P2732, DOI 10.1074/jbc.274.5.2732; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM T, 1992, J BIOL CHEM, V267, P5021; Alroy I, 1999, MOL CELL BIOL, V19, P1961; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Baldassare JJ, 1999, J IMMUNOL, V162, P5367; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Czubayko F, 1997, NAT MED, V3, P1137, DOI 10.1038/nm1097-1137; CZUBAYKO F, 1994, J BIOL CHEM, V269, P28243; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Diehl AM, 1998, J BIOL CHEM, V273, P30843, DOI 10.1074/jbc.273.47.30843; DONATO NJ, 1993, CELL GROWTH DIFFER, V4, P411; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Harris VK, 1998, J BIOL CHEM, V273, P19130, DOI 10.1074/jbc.273.30.19130; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; JUAN TSC, 1993, P NATL ACAD SCI USA, V90, P2584, DOI 10.1073/pnas.90.7.2584; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Kurtz A, 1997, ONCOGENE, V14, P2671, DOI 10.1038/sj.onc.1201117; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LiaudetCoopman EDE, 1996, J BIOL CHEM, V271, P21303, DOI 10.1074/jbc.271.35.21303; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rak J, 1997, NAT MED, V3, P1083, DOI 10.1038/nm1097-1083; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; RAY BK, 1994, EUR J BIOCHEM, V222, P891, DOI 10.1111/j.1432-1033.1994.tb18937.x; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SANTON JB, 1986, CANCER RES, V46, P4701; Souttou B, 1997, J BIOL CHEM, V272, P19588, DOI 10.1074/jbc.272.31.19588; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WU DQ, 1991, J BIOL CHEM, V266, P16778; Yin M, 1996, J BIOL CHEM, V271, P17974, DOI 10.1074/jbc.271.30.17974; YUSPA SH, 1994, CANCER RES, V54, P1178; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	65	76	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10802	10811		10.1074/jbc.275.15.10802	http://dx.doi.org/10.1074/jbc.275.15.10802			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753873	hybrid			2022-12-27	WOS:000086466600015
J	Herbert, TP; Kilhams, GR; Batty, IH; Proud, CG				Herbert, TP; Kilhams, GR; Batty, IH; Proud, CG			Distinct signalling pathways mediate insulin and phorbol ester-stimulated eukaryotic initiation factor 4F assembly and protein synthesis in HEK 293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA TRANSLATION; CAP-BINDING-PROTEIN; KINASE IN-VITRO; P70 S6 KINASE; PHAS-I; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAY; GLUCOSE-TRANSPORT; FACTOR 4E; ORNITHINE DECARBOXYLASE	Stimulation of serum-starved human, embryonic kidney (HEK) 293 cells with either the phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA), or insulin resulted in increases in the phosphorylation of 4E-BP1 and p70 S6 kinase, eIF4F assembly, and protein synthesis. All these effects were blocked by rapamycin, a specific inhibitor of mTOR. Phosphatidylinositol 3-kinase and protein kinase B were activated by insulin but not by TPA. Therefore TPA can induce eIF4F assembly, protein synthesis, and the phosphorylation of p70 Se kinase and 4E-BP1 independently of both phosphatidylinositol 3-kinase and protein kinase B. Using two structurally unrelated inhibitors of MEK (PD098059 and U0126), we provide evidence that Erk activation is important in TPA stimulation of eIF4F assembly and the phosphorylation of p70 S6 kinase and 4E-BP1 and that basal MEK activity is important for basal, insulin, and TPA-stimulated protein synthesis. Transient transfection of constitutively active mitogen-activated protein kinase interacting kinase 1 (the eIF4E kinase) indicated that inhibition of protein synthesis and eIF4F assembly by PD098059 is not through inhibition of eIF4E phosphorylation but of other signals emanating from MEK. This report also provides evidence that increased eIF4E phosphorylation alone does not affect the assembly of the eIF4F complex or general protein synthesis.	Univ Dundee, Inst Med Sci, Dept Anat & Physiol, Dundee DD1 5EH, Scotland; Univ Dundee, Inst Med Sci, Dept Biochem, Dundee DD1 5EH, Scotland	University of Dundee; University of Dundee	Herbert, TP (corresponding author), Univ Dundee, Inst Med Sci, Dept Anat & Physiol, Dow St, Dundee DD1 5EH, Scotland.	t.p.herbert@dundee.ac.uk		Herbert, Terence/0000-0001-5402-0814; Proud, Christopher/0000-0003-0704-6442				Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BROSTROM MA, 1987, J BIOL CHEM, V262, P16515; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Dufner A, 1999, MOL CELL BIOL, V19, P4525; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Flynn A, 1996, EUR J BIOCHEM, V236, P40, DOI 10.1111/j.1432-1033.1996.00040.x; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; Huang CS, 1998, CELL SIGNAL, V10, P185, DOI 10.1016/S0898-6568(97)00098-3; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kleijn M, 1998, EUR J BIOCHEM, V253, P531, DOI 10.1046/j.1432-1327.1998.2530531.x; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; Lin TA, 1996, J BIOL CHEM, V271, P30199, DOI 10.1074/jbc.271.47.30199; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; Mendez R, 1996, MOL CELL BIOL, V16, P2857; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; MORLEY SJ, 1993, BIOCHIMIE, V75, P985, DOI 10.1016/0300-9084(93)90149-M; MORLEY SJ, 1989, J BIOL CHEM, V264, P2401; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; MORRIS DR, 1993, BIOCHEMISTRY-US, V32, P2931, DOI 10.1021/bi00063a001; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; Nave BT, 1996, BIOCHEM J, V318, P203, DOI 10.1042/bj3180203; NISSLEY SP, 1985, J CELL SCI, P39; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PETRITSCH C, 1995, EUR J BIOCHEM, V230, P431, DOI 10.1111/j.1432-1033.1995.0431h.x; Polakiewicz RD, 1998, J BIOL CHEM, V273, P23534, DOI 10.1074/jbc.273.36.23534; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; Proud CG, 1997, BIOCHEM J, V328, P329; Ptushkina M, 1999, EMBO J, V18, P4068, DOI 10.1093/emboj/18.14.4068; Pyronnet S, 1998, ONCOGENE, V16, P2219, DOI 10.1038/sj.onc.1201748; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Rao GN, 1999, J BIOL CHEM, V274, P12925, DOI 10.1074/jbc.274.18.12925; RASMUSSEN H, 1995, ENDOCR REV, V16, P649, DOI 10.1210/er.16.5.649; Rau M, 1996, J BIOL CHEM, V271, P8983, DOI 10.1074/jbc.271.15.8983; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Scott PH, 1997, FEBS LETT, V409, P171, DOI 10.1016/S0014-5793(97)00500-0; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; Vries RGJ, 1997, J BIOL CHEM, V272, P32779, DOI 10.1074/jbc.272.52.32779; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909	64	99	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11249	11256		10.1074/jbc.275.15.11249	http://dx.doi.org/10.1074/jbc.275.15.11249			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753934	hybrid, Green Accepted			2022-12-27	WOS:000086466600076
J	Schwientek, T; Yeh, JC; Levery, SB; Keck, B; Merkx, G; van Kessel, AG; Fukuda, M; Clausen, H				Schwientek, T; Yeh, JC; Levery, SB; Keck, B; Merkx, G; van Kessel, AG; Fukuda, M; Clausen, H			Control of O-glycan branch formation - Molecular cloning and characterization of a novel thymus-associated core 2 beta 1,6-N-acetylglucosaminyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; OLIGOSACCHARIDE BIOSYNTHESIS; LINKED OLIGOSACCHARIDES; EXPRESSION CLONING; MUCIN SYNTHESIS; UDP-GALACTOSE; GENE FAMILY; CELL-LINES; CHO CELLS; GALNAC	Core 2 O-glycan branching catalyzed by UDP-N-acetyl-alpha-D-glucosamine: acceptor beta 1,6-N-acetylglucosaminyltransferases (beta 6GlcNAc-Ts) is an important step in mucin-type biosynthesis. Core 2 complex-type O-glycans are involved in selectin-mediated adhesion events, and O-glycan branching appears to be highly regulated. Two homologous beta 6GlcNAc-Ts functioning in O-glycan branching have previously been characterized, and here we report a third homologous beta 6GlcNAc-T designated C2GnT3, C2GnT3 was identified by BLAST analysis of human genome survey sequences. The catalytic activity of C2GnT3 was evaluated by in vitro analysis of a secreted form of the protein expressed in insect cells. The results revealed exclusive core 2 beta 6GlcNAc-T activity. The product formed with core 1-para-nitrophenyl was confirmed by H-1 NMR to be core 2-para-nitrophenyl, In vivo analysis of the function of C2GnT3 by coexpression of leukosialin (CD43) and a full coding construct of C2GnT3 in Chinese hamster ovary cells confirmed the core 2 activity and failed to reveal I activity. The C2GnT3 gene was located to 5q12, and the coding region was contained in a single exon, Northern analysis revealed selectively high levels of a 5.5-kilobase C2GnT3 transcript in thymus with only low levels in other organs. The unique expression pattern of C2GnT3 suggests that this enzyme serves a specific function different from other members of the beta GlcNAc-T gene family.	Univ Copenhagen, Sch Dent, DK-2200 Copenhagen N, Denmark; Burnham Inst, Canc Res Ctr, Glycobiol Program, La Jolla, CA 92037 USA; Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Univ Nijmegen Hosp, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands	University of Copenhagen; Sanford Burnham Prebys Medical Discovery Institute; University System of Georgia; University of Georgia; Radboud University Nijmegen	Schwientek, T (corresponding author), Univ Copenhagen, Sch Dent, Norre Alle 20, DK-2200 Copenhagen N, Denmark.		van Kessel, Ad Geurts/A-2810-2010; clausen, henrik/AAD-8016-2021		NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR005351] Funding Source: NIH RePORTER; NCRR NIH HHS [5 P41 RR05351] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; BAUM LG, 1995, J EXP MED, V181, P877, DOI 10.1084/jem.181.3.877; Bennett EP, 1998, J BIOL CHEM, V273, P30472, DOI 10.1074/jbc.273.46.30472; BIERHUIZEN MFA, 1995, GLYCOCONJUGATE J, V12, P857, DOI 10.1007/BF00731248; BIERHUIZEN MFA, 1995, GLYCOBIOLOGY, V5, P417, DOI 10.1093/glycob/5.4.417; BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BIERHUIZEN MFA, 1994, J BIOL CHEM, V269, P4473; BROCKHAUSEN I, 1985, BIOCHEMISTRY-US, V24, P1866, DOI 10.1021/bi00329a010; BROCKHAUSEN I, 1991, CANCER RES, V51, P1257; Brockhausen I., 1997, GLYCOSCIENCES STATUS, P79; Clausen H, 1996, GLYCOBIOLOGY, V6, P635, DOI 10.1093/glycob/6.6.635; Ellies LG, 1998, IMMUNITY, V9, P881, DOI 10.1016/S1074-7613(00)80653-6; FOX RI, 1983, J IMMUNOL, V131, P762; Fukuda M, 1996, CANCER RES, V56, P2237; Granovsky M, 1995, GLYCOBIOLOGY, V5, P797, DOI 10.1093/glycob/5.8.797; HIGGINS EA, 1991, J BIOL CHEM, V266, P6280; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KUHNS W, 1993, GLYCOCONJUGATE J, V10, P381, DOI 10.1007/BF00731043; Kumar R, 1996, BLOOD, V88, P3872, DOI 10.1182/blood.V88.10.3872.bloodjournal88103872; Martensson S, 1998, EUR J BIOCHEM, V258, P603, DOI 10.1046/j.1432-1327.1998.2580603.x; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; Nakamura M, 1998, J BIOL CHEM, V273, P26779, DOI 10.1074/jbc.273.41.26779; PILLER F, 1988, J BIOL CHEM, V263, P15146; POLLEXKRUGER A, 1993, GLYCOCONJUGATE J, V10, P365, DOI 10.1007/BF00731042; ROPP PA, 1991, J BIOL CHEM, V266, P23863; SAITOH O, 1991, BLOOD, V77, P1491; Sasaki K, 1997, P NATL ACAD SCI USA, V94, P14294, DOI 10.1073/pnas.94.26.14294; Schwientek T, 1998, J BIOL CHEM, V273, P29331, DOI 10.1074/jbc.273.45.29331; Schwientek T, 1999, J BIOL CHEM, V274, P4504, DOI 10.1074/jbc.274.8.4504; SEKINE M, 1994, J BIOL CHEM, V269, P31143; Shimodaira K, 1997, CANCER RES, V57, P5201; SPIRO RG, 1974, J BIOL CHEM, V249, P5704; Toki D, 1997, BIOCHEM J, V325, P63, DOI 10.1042/bj3250063; Tsuboi S, 1997, EMBO J, V16, P6364, DOI 10.1093/emboj/16.21.6364; Ujita M, 1998, J BIOL CHEM, V273, P34843, DOI 10.1074/jbc.273.52.34843; VanderElst IE, 1998, GLYCOBIOLOGY, V8, P731, DOI 10.1093/glycob/8.7.731; Wandall HH, 1997, J BIOL CHEM, V272, P23503, DOI 10.1074/jbc.272.38.23503; Warren CE, 1999, GLYCOBIOLOGY, V9, P1111; WILLIAMS D, 1980, J BIOL CHEM, V255, P1247; YANG JM, 1994, GLYCOBIOLOGY, V4, P873, DOI 10.1093/glycob/4.6.873; Yeh JC, 1999, J BIOL CHEM, V274, P3215, DOI 10.1074/jbc.274.5.3215; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772; Zeng S, 1997, BIOCHEM BIOPH RES CO, V237, P653, DOI 10.1006/bbrc.1997.7209; Zhou DP, 1999, GLYCOBIOLOGY, V9, P1123; Zhou DP, 1999, P NATL ACAD SCI USA, V96, P406, DOI 10.1073/pnas.96.2.406	46	84	88	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11106	11113		10.1074/jbc.275.15.11106	http://dx.doi.org/10.1074/jbc.275.15.11106			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753916	hybrid			2022-12-27	WOS:000086466600058
J	Mirzadegan, T; Diehl, F; Ebi, B; Bhakta, S; Polsky, I; McCarley, D; Mulkins, M; Weatherhead, GS; Lapierre, JM; Dankwardt, J; Morgans, D; Wilhelm, R; Jarnagin, K				Mirzadegan, T; Diehl, F; Ebi, B; Bhakta, S; Polsky, I; McCarley, D; Mulkins, M; Weatherhead, GS; Lapierre, JM; Dankwardt, J; Morgans, D; Wilhelm, R; Jarnagin, K			Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists - Binding to a common chemokine receptor motif within the helical bundle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; DOMINANT RETINITIS-PIGMENTOSA; BRONCHOALVEOLAR LAVAGE FLUID; X-RAY STRUCTURE; COUPLED RECEPTORS; CHEMOTACTIC PROTEIN-1; NMR ASSIGNMENTS; CCR2(-/-) MICE; MCP-1 RECEPTOR; BACTERIORHODOPSIN	Monocyte chemoattracant-1 (MCP-1) stimulates leukocyte chemotaxis to inflammatory sites, such as rheumatoid arthritis, atherosclerosis, and asthma, by use of the MCP-1 receptor, CCR2, a member of the G-protein-coupled seven-transmembrane receptor superfamily, These studies identified a family of antagonists, spiropiperidines. One of the more potent compounds blocks MCP-1 binding to CCR2 with a K-d of 60 nM, but it is unable to block binding to CXCR1, CCR1, or CCR3, These compounds were effective inhibitors of chemotaxis toward MCP-1 but were very poor inhibitors of CCR1-mediated chemotaxis, The compounds are effective blockers of MCP-1-driven inhibition of adenylate cyclase and MCP-1- and MCP-3-driven cytosolic calcium influx; the compounds are not agonists for these pathways. We showed that glutamate 291 (Glu(291)) of CCR2 is a critical residue for high affinity binding and that this residue contributes little to MCP-1 binding to CCR2, The basic nitrogen present in the spiropiperidine compounds may be the interaction partner for Glu(291), be cause the basicity of this nitrogen was essential for affinity; furthermore, a different class of antagonists, a class that does not have a basic nitrogen (2-carboxypyrroles), were not affected by mutations of Glu(291). In addition to the CCR2 receptor, spiropiperidine compounds have affinity for several biogenic amine receptors, Receptor models indicate that the acidic residue, Glu(291), from transmembrane-7 of CCR2 is in a position similar to the acidic residue contributed from transmembrane-3 of biogenic amine receptors, which may account for the shared affinity of spiropiperidines for these two receptor classes. The models suggest that the acid-base pair, Glu(291) to piperidine nitrogen, anchors the spiropiperidine compound within the transmembrane ovoid bundle. This binding site may overlap with the space required by MCP-1 during binding and signaling thus the small molecule ligands act as antagonists. An acidic residue in transmembrane region 7 is found in most chemokine receptors and is rare in other serpentine receptors. The model of the binding site may suggest ways to make new small molecule chemokine receptor antagonists, and it may rationalize the design of more potent and selective antagonists.	Roche Biosci, Palo Alto, CA 94304 USA	Roche Holding	Mirzadegan, T (corresponding author), Roche Biosci, Palo Alto, CA 94304 USA.			BHAKTA, SUNIL/0000-0002-1554-7098				Alam R, 1996, AM J RESP CRIT CARE, V153, P1398, DOI 10.1164/ajrccm.153.4.8616572; BHAT TN, 1990, NATURE, V347, P483, DOI 10.1038/347483a0; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Campbell EM, 1999, J IMMUNOL, V163, P2160; CLARK RD, 1983, J MED CHEM, V26, P657, DOI 10.1021/jm00359a007; FLORY CM, 1993, LAB INVEST, V69, P396; FUENTES ME, 1995, J IMMUNOL, V155, P5769; Gong JH, 1997, J EXP MED, V186, P131, DOI 10.1084/jem.186.1.131; Gosling J, 1999, J CLIN INVEST, V103, P773, DOI 10.1172/JCI5624; Grewal IS, 1997, J IMMUNOL, V159, P401; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; Gunn MD, 1997, J IMMUNOL, V158, P376; Handel TM, 1996, BIOCHEMISTRY-US, V35, P6569, DOI 10.1021/bi9602270; Hemmerich S, 1999, BIOCHEMISTRY-US, V38, P13013, DOI 10.1021/bi991029m; Hesselgesser J, 1998, J BIOL CHEM, V273, P15687, DOI 10.1074/jbc.273.25.15687; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; Horn F, 1998, NUCLEIC ACIDS RES, V26, P275, DOI 10.1093/nar/26.1.275; Howard OMZ, 1996, TRENDS BIOTECHNOL, V14, P46, DOI 10.1016/0167-7799(96)80920-6; Hsieh KH, 1996, J ALLERGY CLIN IMMUN, V98, P580, DOI 10.1016/S0091-6749(96)70092-1; Jarnagin K, 1999, BIOCHEMISTRY-US, V38, P16167, DOI 10.1021/bi9912239; Jarnagin K, 1996, J BIOL CHEM, V271, P28277, DOI 10.1074/jbc.271.45.28277; KOCH AE, 1992, J CLIN INVEST, V90, P772, DOI 10.1172/JCI115950; Kunkel SL, 1996, J LEUKOCYTE BIOL, V59, P6, DOI 10.1002/jlb.59.1.6; Kurashima K, 1996, J LEUKOCYTE BIOL, V59, P313, DOI 10.1002/jlb.59.3.313; LOETSCHER P, 1994, CYTOKINE, V6, P162, DOI 10.1016/1043-4666(94)90038-8; Lubkowski J, 1997, NAT STRUCT BIOL, V4, P64, DOI 10.1038/nsb0197-64; MIRZADEGAN T, 1992, PHOTOCHEM PHOTOBIOL, V56, P883, DOI 10.1111/j.1751-1097.1992.tb09709.x; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; Monteclaro FS, 1997, J BIOL CHEM, V272, P23186, DOI 10.1074/jbc.272.37.23186; NAKAMURA K, 1995, J INVEST DERMATOL, V105, P635, DOI 10.1111/1523-1747.ep12324061; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; Ng HP, 1999, J MED CHEM, V42, P4680, DOI 10.1021/jm990316l; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; Rand ML, 1996, AM J PATHOL, V148, P855; Rollins BJ, 1996, MOL MED TODAY, V2, P198, DOI 10.1016/1357-4310(96)88772-7; SEHERTLER GFX, 1993, NATURE, V362, P770; SKELTON NJ, 1995, BIOCHEMISTRY-US, V34, P5329, DOI 10.1021/bi00016a004; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SUGIYAMA Y, 1995, EUR RESPIR J, V8, P1084, DOI 10.1183/09031936.95.08071084; SUNG CH, 1993, J BIOL CHEM, V268, P26645; SUNG CH, 1994, J NEUROSCI, V14, P5818; SURYANARAYANA S, 1992, J BIOL CHEM, V267, P21991; VON ZM, 1993, J BIOL CHEM, V268, P763; White JR, 1998, J BIOL CHEM, V273, P10095, DOI 10.1074/jbc.273.17.10095; Wong LM, 1997, J BIOL CHEM, V272, P1038, DOI 10.1074/jbc.272.2.1038; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252; Zisman DA, 1997, J CLIN INVEST, V99, P2832, DOI 10.1172/JCI119475	51	221	245	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25562	25571		10.1074/jbc.M000692200	http://dx.doi.org/10.1074/jbc.M000692200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10770925	hybrid			2022-12-27	WOS:000088849400069
J	Laporte, SA; Oakley, RH; Holt, JA; Barak, LS; Caron, MG				Laporte, SA; Oakley, RH; Holt, JA; Barak, LS; Caron, MG			The interaction of beta-arrestin with the AP-2 adaptor is required for the clustering of beta(2)-adrenergic receptor into clathrin-coated pits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SORTING SIGNALS; MEDIATED ENDOCYTOSIS; VESICLE FORMATION; SEQUESTRATION; INTERNALIZATION; RESENSITIZATION; DISTINCT; BINDING; DYNAMIN	beta-Arrestins are cytosolic proteins that regulate the signaling and the internalization of G protein-coupled receptors (GPCRs), Although termination of receptor coupling requires beta-arrestin binding to agonist-activated receptors, GPCR endocytosis involves the coordinate interactions between receptor-beta-arrestin complexes and other endocytic proteins such as adaptor protein 2 (AP-2) and clathrin, Clathrin interacts with a conserved motif in the beta-arrestin C-terminal tail; however, the specific molecular determinants in beta-arrestin that bind AP-2 have not been identified. Moreover, the respective contributions of the interactions of beta-arrestin with AP-2 and clathrin toward the targeting of GPCRs to clathrin coated vesicles have not been established. Here, we identify specific arginine residues (Arg(394) and Arg(396)) in the beta-arrestin 2 C terminus that mediate beta-arrestin binding to AP-2 and show, in vitro, that these domains in beta-arrestin 1 and 2 interact equally well with AP-2 independently of clathrin binding. We demonstrate in HEK 293 cells by fluorescence microscopy that beta(2)-adrenergic receptor-beta-arrestin complexes lacking the beta-arrestin-clathrin binding motif are still targeted to clathrin-coated pits. In marked contrast, receptor-a-arrestin complexes lacking the beta-arrestin/AP-2 interactions are not effectively compartmentalized in punctated areas of the plasma membrane. These results reveal that the binding of a receptor-beta-arrestin complex to AP-2, not to clathrin, is necessary for the initial targeting of beta(2)-adrenergic receptor to clathrin-coated pits.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Labs, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University	Caron, MG (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Labs, Box 3287, Durham, NC 27710 USA.		Laporte, Stephane/ABC-4228-2021; Laporte, Stephane A/F-3282-2012	Laporte, Stephane/0000-0002-0633-543X; 	NHLBI NIH HHS [HL 61365] Funding Source: Medline; NINDS NIH HHS [NS 19576] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BARAK LS, 1994, J BIOL CHEM, V269, P2790; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Bremnes T, 1998, J BIOL CHEM, V273, P8638, DOI 10.1074/jbc.273.15.8638; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Gaidarov I, 1999, NAT CELL BIOL, V1, P1, DOI 10.1038/8971; Gaidarov I, 1999, EMBO J, V18, P871, DOI 10.1093/emboj/18.4.871; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; Hao WH, 1999, J BIOL CHEM, V274, P22785, DOI 10.1074/jbc.274.32.22785; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; Hofmann MW, 1999, J BIOL CHEM, V274, P36153, DOI 10.1074/jbc.274.51.36153; Ishii I, 1998, J BIOL CHEM, V273, P9878, DOI 10.1074/jbc.273.16.9878; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Li JG, 1999, J BIOL CHEM, V274, P12087, DOI 10.1074/jbc.274.17.12087; MANFREDI JJ, 1987, J BIOL CHEM, V262, P12182; Nesterov A, 1999, EMBO J, V18, P2489, DOI 10.1093/emboj/18.9.2489; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Owen DJ, 1998, EMBO J, V17, P5273, DOI 10.1093/emboj/17.18.5273; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; ter Haar E, 2000, P NATL ACAD SCI USA, V97, P1096, DOI 10.1073/pnas.97.3.1096; Troispoux C, 1999, MOL ENDOCRINOL, V13, P1599, DOI 10.1210/me.13.9.1599; Vogler O, 1998, J BIOL CHEM, V273, P12155, DOI 10.1074/jbc.273.20.12155; Vrecl M, 1998, MOL ENDOCRINOL, V12, P1818, DOI 10.1210/me.12.12.1818; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	40	283	292	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23120	23126		10.1074/jbc.M002581200	http://dx.doi.org/10.1074/jbc.M002581200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10770944	hybrid			2022-12-27	WOS:000088419400070
J	Conway, S; Drew, JE; Mowat, ES; Barrett, P; Delagrange, P; Morgan, PJ				Conway, S; Drew, JE; Mowat, ES; Barrett, P; Delagrange, P; Morgan, PJ			Chimeric melatonin mt(1) and melatonin-related receptors - Identification of domains and residues participating in ligand binding and receptor activation of the melatonin mt(1) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; PROTEIN-COUPLED RECEPTORS; GENE SYNTHESIS; BETA-2-ADRENERGIC RECEPTORS; MOLECULAR-CLONING; ADENYLATE-CYCLASE; EXPRESSION; RHODOPSIN; INHIBITION; CONSTRUCTION	Melatonin receptors bind and become activated by melatonin. The melatonin-related receptor, despite sharing considerable amino acid sequence identity with melatonin receptors, does not bind melatonin and is currently an orphan G protein-coupled receptor. To investigate the structure and function of both receptors, we engineered a series of 14 chimeric receptor constructs, allowing us to determine the relative contribution of each transmembrane domain to Ligand binding and receptor function. Results identified that when sequences encoding transmembrane domains 1, 2, 3, 5, or 7 of the melatonin mt, receptor were replaced by the corresponding domains of the melatonin-related receptor, the resultant chimeric receptors all displayed specific 2-[I-125]iodomelatonin binding, Replacement of sequences incorporating transmembrane domains 4 or 6, however, resulted in chimeric receptors that displayed no detectable 2-[I-125]iodomelatonin binding. The subsequent testing of a "reverse" chimeric receptor in which sequences encoding transmembrane domains 4 and 6 of the melatonin-related receptor were replaced by the corresponding melatonin mt, receptor sequences identified specific 2-[I-125]iodomelatonin binding and melatonin-mediated modulation of cyclic AMP levels. To further investigate these findings, site-directed mutagenesis was performed on residues within transmembrane domain 6 of the melatonin mt, receptor. This identified Gly(258) (Gly(6.55)) as a critical residue required for high affinity ligand binding and receptor function.	Rowett Res Inst, Div Appetite & Energy Balance, Mol Neuroendocrinol Grp, Bucksburn AB21 9SB, Aberdeen, Scotland; Inst Rech Int Servier, F-92415 Courbevoie, France	University of Aberdeen; Servier; Institut de Recherches Internationales Servier	Conway, S (corresponding author), Rowett Res Inst, Div Appetite & Energy Balance, Mol Neuroendocrinol Grp, Greenburn Rd, Bucksburn AB21 9SB, Aberdeen, Scotland.			Barrett, Perry/0000-0003-3604-2950; Morgan, Peter/0000-0002-5071-6512				ALEXANDER SPH, 1999, TRENDS PHARM SCI S, V20, P57; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Conway S, 2000, EUR J PHARMACOL, V390, P15, DOI 10.1016/S0014-2999(99)00914-0; Conway S, 1997, BIOCHEM BIOPH RES CO, V239, P418, DOI 10.1006/bbrc.1997.7482; Conway S, 1997, FEBS LETT, V407, P121, DOI 10.1016/S0014-5793(97)00315-3; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DILLON PJ, 1990, BIOTECHNIQUES, V9, P298; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; DONNELLY D, 1994, RECEPTOR CHANNEL, V2, P61; Drew JE, 1998, J NEUROENDOCRINOL, V10, P651, DOI 10.1046/j.1365-2826.1998.00229.x; EBISAWA T, 1994, P NATL ACAD SCI USA, V91, P6133, DOI 10.1073/pnas.91.13.6133; FRIELLE T, 1988, P NATL ACAD SCI USA, V85, P9494, DOI 10.1073/pnas.85.24.9494; HARRIS BA, 1985, SCIENCE, V229, P1274, DOI 10.1126/science.3839937; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; Kokkola T, 1998, BIOCHEM BIOPH RES CO, V249, P531, DOI 10.1006/bbrc.1998.9182; Komatsuzaki K, 1997, FEBS LETT, V406, P165, DOI 10.1016/S0014-5793(97)00257-3; MICHEL T, 1986, P NATL ACAD SCI USA, V83, P7663, DOI 10.1073/pnas.83.20.7663; MORGAN PJ, 1990, J NEUROENDOCRINOL, V2, P773, DOI 10.1111/j.1365-2826.1990.tb00639.x; Navajas C, 1996, EUR J PHARMACOL, V304, P173, DOI 10.1016/0014-2999(96)00114-8; PRODROMOU C, 1992, PROTEIN ENG, V5, P827, DOI 10.1093/protein/5.8.827; Prytulla S, 1996, FEBS LETT, V399, P283, DOI 10.1016/S0014-5793(96)01278-1; RANDS E, 1990, J BIOL CHEM, V265, P10759; Reppert SM, 1996, TRENDS PHARMACOL SCI, V17, P100, DOI 10.1016/0165-6147(96)10005-5; REPPERT SM, 1994, NEURON, V13, P1177, DOI 10.1016/0896-6273(94)90055-8; Reppert SM, 1996, FEBS LETT, V386, P219, DOI 10.1016/0014-5793(96)00437-1; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, J BIOL CHEM, V264, P13572; WONG YH, 1994, METHOD ENZYMOL, V238, P81; YE QZ, 1992, BIOCHEM BIOPH RES CO, V186, P143, DOI 10.1016/S0006-291X(05)80786-7; ZHOU W, 1994, MOL PHARMACOL, V45, P165	36	38	41	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20602	20609		10.1074/jbc.M002358200	http://dx.doi.org/10.1074/jbc.M002358200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10770942	hybrid			2022-12-27	WOS:000088084500055
J	Yang, Y; Hwang, CK; D'Souza, UM; Lee, SH; Junn, E; Mouradian, MM				Yang, Y; Hwang, CK; D'Souza, UM; Lee, SH; Junn, E; Mouradian, MM			Three-amino acid extension loop homeodomain proteins Meis2 and TGIF differentially regulate transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SPECIFICITY; DOPAMINE-RECEPTOR GENE; HOMEOBOX GENE; RETINOIC ACID; MOLECULAR-CLONING; THYROID-HORMONE; EXPRESSION; PROMOTER; EXTRADENTICLE; REGION	Three-amino acid extension loop (TALE) homeobox proteins are highly conserved transcription regulators. me report that two members of this family, Meis2 and TGIF, which frequently have overlapping consensus binding sites on complementary DNA strands in opposite orientations, can function competitively. For example, in the D-1A gene, which encodes the predominant dopamine receptor in the striatum, Meis2 and TGIF bind to the activator sequence ACT (-1174 to -1154) and regulate transcription differentially in a cell type-specific manner. Among the five cloned splice variants of Meis2, isoforms Meis2a-d activate the D-1A promoter in most cell types tested, whereas TGIF competes with Meis2 binding to DNA and represses Meis2-induced transcription activation, Consequently, Meis2 cannot activate the D-1A promoter in a cell that has abundant TGIF expression. The Meis2 message is highly co-localized with the D-1A message in adult striatal neurons, whereas TGIF is barely detectable in the adult brain. Our observations provide in vitro and in vivo evidence that Meis2 and TGIF differentially regulate their target genes. Thus, the delicate ratio between Meis2 and TGIF expression in a given cell type determines the cell-specific expression of the D-1A gene. We also found that splice variant Meis2e, which has a truncated homeodomain, cannot bind to the D-1A ACT sequence or activate transcription. However, Meis2e is an effective dominant negative regulator by blocking Meis2d-induced transcription activation. Thus, truncated homeoproteins with no DNA binding domains can have important regulatory functions.	NINDS, NIH, Expt Therapeut Branch, Genet Pharmacol Unit, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Mouradian, MM (corresponding author), NINDS, NIH, Expt Therapeut Branch, Genet Pharmacol Unit, 10 Ctr Dr,MSC 1406, Bethesda, MD 20892 USA.			Mouradian, M. Maral/0000-0002-9937-412X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002826] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; Bertolino E, 1995, J BIOL CHEM, V270, P31178, DOI 10.1074/jbc.270.52.31178; Bischof LJ, 1998, J BIOL CHEM, V273, P7941, DOI 10.1074/jbc.273.14.7941; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Burglin TR, 1997, NUCLEIC ACIDS RES, V25, P4173, DOI 10.1093/nar/25.21.4173; Cecconi F, 1997, DEV DYNAM, V210, P184, DOI 10.1002/(SICI)1097-0177(199710)210:2<184::AID-AJA10>3.0.CO;2-E; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; CONDIE BG, 1990, MOL CELL BIOL, V10, P3376, DOI 10.1128/MCB.10.7.3376; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; EKKER SC, 1992, EMBO J, V11, P4059, DOI 10.1002/j.1460-2075.1992.tb05499.x; FLINK IL, 1990, J BIOL CHEM, V265, P11233; GINGRICH JA, 1993, ANNU REV NEUROSCI, V16, P299, DOI 10.1146/annurev.ne.16.030193.001503; HORNYKIEWICZ O, 1966, PHARMACOL REV, V18, P925; Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134; Jung AB, 1996, DEV BRAIN RES, V94, P121, DOI 10.1016/0165-3806(96)00034-X; Knoepfler PS, 1997, P NATL ACAD SCI USA, V94, P14553, DOI 10.1073/pnas.94.26.14553; Lee SH, 1999, NEUROSCI RES, V34, P225, DOI 10.1016/S0168-0102(99)00055-3; LEE T, 1978, NATURE, V274, P897, DOI 10.1038/274897a0; LIU YH, 1991, J BIOL CHEM, V266, P21880; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; MINOWA MT, 1993, J BIOL CHEM, V268, P23544; MINOWA MT, 1992, P NATL ACAD SCI USA, V89, P3045, DOI 10.1073/pnas.89.7.3045; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; MOURADIAN MM, 1988, ANN NEUROL, V24, P372, DOI 10.1002/ana.410240304; MUNOZCANOVES P, 1990, J BIOL CHEM, V265, P20065; Nakamura T, 1996, ONCOGENE, V13, P2235; NAKSHATRI H, 1994, J BIOL CHEM, V269, P890; NASH SR, 1993, MOL PHARMACOL, V44, P918; Okazawa H, 1996, P NATL ACAD SCI USA, V93, P11933, DOI 10.1073/pnas.93.21.11933; OuladAbdelghani M, 1997, DEV DYNAM, V210, P173, DOI 10.1002/(SICI)1097-0177(199710)210:2<173::AID-AJA9>3.0.CO;2-D; RAUSKOLB C, 1994, EMBO J, V13, P3561, DOI 10.1002/j.1460-2075.1994.tb06663.x; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; Shiojima I, 1996, CIRC RES, V79, P920, DOI 10.1161/01.RES.79.5.920; Toresson H, 1999, DEVELOPMENT, V126, P1317; TREISMAN J, 1989, CELL, V59, P553; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO; Wotton D, 1999, J BIOL CHEM, V274, P37105, DOI 10.1074/jbc.274.52.37105; WRIGHT CVE, 1987, EMBO J, V6, P4083, DOI 10.1002/j.1460-2075.1987.tb02754.x; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0	41	72	80	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20734	20741		10.1074/jbc.M908382199	http://dx.doi.org/10.1074/jbc.M908382199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10764806	hybrid			2022-12-27	WOS:000088084500072
J	Jackson, VN; Cameron, JM; Fraser, F; Zammit, VA; Price, NT				Jackson, VN; Cameron, JM; Fraser, F; Zammit, VA; Price, NT			Use of six chimeric proteins to investigate the role of intramolecular interactions in determining the kinetics of carnitine palmitoyltransferase I isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL OUTER-MEMBRANE; MALONYL-COA SENSITIVITY; RAT-LIVER; PICHIA-PASTORIS; EXPRESSION; TOPOLOGY; HEART; KETOGENESIS; INHIBITION; OXIDATION	The two isoforms of carnitine palmitoyltransferase I (CPT I; muscle (M)- and liver (L)-type) of the mitochondrial outer membrane have distinct kinetic characteristics with respect to their affinity for one of the substrates (L-carnitine) and the inhibitor malonyl-CoA. Moreover, they differ markedly in their hysteretic behavior with respect to malonyl-CoA and in their response to changes in the in vivo metabolic state. However, the two proteins are 62% identical and have the same overall structure. Using liver mitochondria, we have previously shown that the protein is polytopic within the outer membrane, comprising a 46-residue cytosolic N-terminal sequence, two transmembrane segments (TM1 and TM2) separated by a 27-residue loop, and a large catalytic domain (also cytosolic) (Fraser, F., Corstorphine, C. G., and Zammit, V. A. (1997) Biochem. J. 323, 711-718). We have now conducted a systematic study on six chimeric proteins constructed from combinations of three linear segments of rat L- and M-CPT I and on the two parental proteins to elucidate the effects of altered intramolecular interactions on the kinetics of CPT activity. The three segments were (i) the cytosolic N-terminal domain plus TM1, (ii) the loop plus TM2, and (iii) the cytosolic catalytic C-terminal domain. The kinetic properties of the chimeric proteins expressed in Pichia pastoris were studied. We found that alterations in the combinations of the N-terminal plus TM1 and C-terminal domains as well as in the N terminus plus TM1/TM2 pairings resulted in changes in the K-m values for carnitine and palmitoyl-CoA and the sensitivity to malonyl-CoA of the L-type catalytic domain. The changes in affinity for malonyl-CoA and palmitoyl-CoA occurred independently of changes in the affinity for carnitine, The kinetic characteristics of the M-type catalytic domain and, in particular, its malonyl-CoA sensitivity were much less susceptible to influence by exchange of the other two segments of the protein. The marked difference in the response of the two catalytic domains to changes in the N-terminal domain and TM combinations explains the previously observed differences in the response of L- and M-CPT I to altered physiological state in intact mitochondria and to modulation of altered lipid molecular order of the mitochondrial outer membrane in vivo and in vitro.	Hannah Res Inst, Ayr KA6 5HL, Scotland		Zammit, VA (corresponding author), Hannah Res Inst, Ayr KA6 5HL, Scotland.							Drynan L, 1996, BIOCHEM J, V317, P791, DOI 10.1042/bj3170791; ESSER V, 1993, J BIOL CHEM, V268, P5817; FOLEY JE, 1992, DIABETES CARE, V15, P773, DOI 10.2337/diacare.15.6.773; Fraser F, 1997, BIOCHEM J, V323, P711, DOI 10.1042/bj3230711; Fraser Fiona, 1996, Biochemical Society Transactions, V24, p184S; GRANTHAM BD, 1988, BIOCHEM J, V249, P409, DOI 10.1042/bj2490409; GRANTHAM BD, 1986, BIOCHEM J, V239, P485, DOI 10.1042/bj2390485; Jackson VN, 1999, BIOCHEM J, V341, P483, DOI 10.1042/0264-6021:3410483; KOLODZIEJ MP, 1990, BIOCHEM J, V272, P421, DOI 10.1042/bj2720421; LLOYD AC, 1986, BIOCHEM J, V237, P289, DOI 10.1042/bj2370289; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; McGarry JD, 1998, AM J CLIN NUTR, V67, p500S, DOI 10.1093/ajcn/67.3.500S; MYNATT RL, 1992, BIOCHIM BIOPHYS ACTA, V1128, P105, DOI 10.1016/0005-2760(92)90263-U; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; SAGGERSON ED, 1982, BIOCHEM J, V202, P397, DOI 10.1042/bj2020397; SCORER CA, 1993, GENE, V136, P111, DOI 10.1016/0378-1119(93)90454-B; Shi JY, 2000, BIOCHEMISTRY-US, V39, P712, DOI 10.1021/bi9918700; Shi JY, 1999, J BIOL CHEM, V274, P9421, DOI 10.1074/jbc.274.14.9421; Shi JY, 1998, BIOCHEMISTRY-US, V37, P11033, DOI 10.1021/bi9803426; Swanson ST, 1998, BIOCHEM J, V335, P513, DOI 10.1042/bj3350513; Waterham HR, 1997, GENE, V186, P37, DOI 10.1016/S0378-1119(96)00675-0; YAMAZAKI N, 1995, FEBS LETT, V363, P41, DOI 10.1016/0014-5793(95)00277-G; Zammit VA, 1999, PROG LIPID RES, V38, P199, DOI 10.1016/S0163-7827(99)00002-8; Zammit VA, 1998, LIPIDS, V33, P371, DOI 10.1007/s11745-998-0217-7; Zammit VA, 1999, BIOCHEM J, V343, P505, DOI 10.1042/0264-6021:3430505; Zammit VA, 1998, DIABETES NUTR METAB, V11, P200; Zammit VA, 1997, ADV ENZYME REGUL, V37, P295, DOI 10.1016/S0065-2571(96)00015-5; Zhu HF, 1997, ARCH BIOCHEM BIOPHYS, V347, P53, DOI 10.1006/abbi.1997.0314	28	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19560	19566		10.1074/jbc.M002177200	http://dx.doi.org/10.1074/jbc.M002177200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10766754	hybrid			2022-12-27	WOS:000087941300019
J	Caraco, C; Aloj, L; Chen, LY; Chou, JY; Eckelman, WC				Caraco, C; Aloj, L; Chen, LY; Chou, JY; Eckelman, WC			Cellular release of [F-18]2-fluoro-2-deoxyglucose as a function of the glucose-6-phosphatase enzyme system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STORAGE-DISEASE TYPE-1A; RECOMBINANT ADENOVIRUSES IMPROVES; CEREBRAL GLUCOSE-UTILIZATION; METABOLIC-RATE; LIVER; GENE; ESTABLISHMENT; INACTIVATION; TRANSPORTER; PHOSPHATE	[F-18]-2-Fluoro-2-deoxyglucose (FDG) is a glucose analog currently utilized for positron emission tomography imaging studies in humans. FDG taken up by the liver is rapidly released. This property is attributed to elevated glucose-6-phosphatase (Glc-6-Pase) activity. To characterize this issue we studied the relationship between Glc-6-Pase activity and FDG; release kinetics in a cell culture system. We overexpressed the Glc-6-Pase catalytic unit in a Glc-6-Pase deficient mouse hepatocyte (Ho-15) and in A431 tumor cell lines. Glc-6-Pase enzyme activity and FDG release rates were determined in cells transfected with the Glc-6-Pase gene (Ho-15-D3 and A431-AC3), in mock-transfected cells of both cell lines, and in wild-type mouse hepatocytes (WT10) as control. Although the highest level of Glc-6-Pase activity was measured in A431-AC3, Ho-15-D3 cells showed much faster FDG release rates. The faster FDG release correlated with the level of glucose 6-phosphate transporter (Glc-6-PT) mRNA, which was found to be expressed at higher levels in Ho-15 compared with A431 cells. Overexpression of Glc-6-PT in A431-AC3 produced a dramatic increase in FDG release compared with control cells. This study gives the first direct evidence that activity of the Glc-6-Pase complex can be quantified in vivo by measuring FDG release. Adequate levels of Glc-6-Pase catalytic unit and Glc-6-PT are required for this function. FDG-positron emission tomography may be utilized to evaluate functional status of the Glc-6-Pase complex.	NICHD, Positron Emiss Tomog Dept, Warren G Magnuson Clin Ctr, NIH, Bethesda, MD 20892 USA; NICHD, Dept Nucl Med, Ctr Clin, NIH, Bethesda, MD 20892 USA; NICHD, Dept Nucl Med, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Eckelman, WC (corresponding author), NICHD, Positron Emiss Tomog Dept, Warren G Magnuson Clin Ctr, NIH, Bldg 10,Rm 1C495,10 Ctr Dr,MSC 1180, Bethesda, MD 20892 USA.		Aloj, Luigi/AAK-5104-2020	Aloj, Luigi/0000-0002-7452-4961	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000912] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000912] Funding Source: NIH RePORTER; CLINICAL CENTER [Z01CL000500] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); CLINICAL CENTER		ADAMS HR, 1995, CHEMISTS' VIEWS OF IMAGING CENTERS, P175; ARION WJ, 1980, J BIOL CHEM, V255, P396; Banhegyi G, 1997, J BIOL CHEM, V272, P13584, DOI 10.1074/jbc.272.21.13584; BURCHELL A, 1994, MOL MEMBR BIOL, V11, P217, DOI 10.3109/09687689409160431; Chen Y-T, 1995, METABOLIC MOL BASES, P935; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI Y, 1994, J NUCL MED, V35, P818; CHOU JY, 1985, METHOD ENZYMOL, V109, P385; Conti PS, 1996, NUCL MED BIOL, V23, P717, DOI 10.1016/0969-8051(96)00074-1; ENGELHARDT JF, 1994, P NATL ACAD SCI USA, V91, P6196, DOI 10.1073/pnas.91.13.6196; FULCERI R, 1991, BIOCHEM J, V275, P805, DOI 10.1042/bj2750805; GALLAGHER BM, 1978, J NUCL MED, V19, P1154; Gerin I, 1997, FEBS LETT, V419, P235, DOI 10.1016/S0014-5793(97)01463-4; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; GJEDDE A, 1995, PRINCIPLES NUCL MED, P54; Hiraiwa H, 1999, J BIOL CHEM, V274, P5532, DOI 10.1074/jbc.274.9.5532; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; Lei KJ, 1996, NAT GENET, V13, P203, DOI 10.1038/ng0696-203; Lin BC, 1998, J BIOL CHEM, V273, P31656, DOI 10.1074/jbc.273.48.31656; Pan CJ, 1999, J BIOL CHEM, V274, P13865, DOI 10.1074/jbc.274.20.13865; PHELPS ME, 1979, ANN NEUROL, V6, P371, DOI 10.1002/ana.410060502; REIVICH M, 1979, CIRC RES, V44, P127, DOI 10.1161/01.RES.44.1.127; REIVICH M, 1985, J CEREBR BLOOD F MET, V5, P179, DOI 10.1038/jcbfm.1985.24; Sambrook J., 2002, MOL CLONING LAB MANU; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; YANG YP, 1994, NAT GENET, V7, P362, DOI 10.1038/ng0794-362	27	49	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18489	18494		10.1074/jbc.M908096199	http://dx.doi.org/10.1074/jbc.M908096199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10764804	hybrid			2022-12-27	WOS:000087659400079
J	McLaurin, J; Golomb, R; Jurewicz, A; Antel, JP; Fraser, PE				McLaurin, J; Golomb, R; Jurewicz, A; Antel, JP; Fraser, PE			Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit A beta-induced toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRIL FORMATION; IN-VITRO; HIPPOCAMPAL-NEURONS; CORTICAL-NEURONS; DOWNS-SYNDROME; PC12 CELLS; PROTEIN; DISEASE; NEUROTOXICITY; BRAIN	Inositol has 8 stereoisomers, four of which are physiologically active, myo-Inositol is the most abundant isomer in the brain and more recently shown that epi- and scyllo-inositol are also present. myo-Inositol complexes with A beta 42 in vitro to form a small stable micelle. The ability of inositol stereoisomers to interact with and stabilize small A beta complexes was addressed. Circular dichroism spectroscopy demonstrated that epi- and scyllo- but not chiro-inositol were able to induce a structural transition from random to beta-structure in A beta 42. Alternatively, none of the stereoisomers were able to induce a structural transition in A beta 40. Electron microscopy demonstrated that inositol stabilizes small aggregates of A beta 42. We demonstrate that inositol-A beta interactions result in a complex that is non-toxic to nerve growth factor-differentiated PC-12 cells and primary human neuronal cultures. The attenuation of toxicity is the result of A beta-inositol interaction, as inositol uptake inhibitors had no effect on neuronal survival. The use of inositol stereoisomers allowed us to elucidate an important structure-activity relationship between A beta and inositol. Inositol stereoisomers are naturally occurring molecules that readily cross the blood-brain barrier and may represent a viable treatment for AD through the complexation of A beta and attenuation of A beta neurotoxic effects.	Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 3H2, Canada; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada	University of Toronto; University of Toronto; University of Toronto; McGill University	McLaurin, J (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, Tanz Neurosci Bldg,6 Queens Pk Crescent W, Toronto, ON M5S 3H2, Canada.	j.mclaurin@utoronto.ca	Jurewicz, Anna Magdalena/S-9918-2016; Jurewicz, Anna/AAX-7161-2020	Jurewicz, Anna Magdalena/0000-0003-4214-1963; Jurewicz, Anna/0000-0003-4214-1963; antel, jack/0000-0002-5148-0636				Acevedo LD, 1997, J MASS SPECTROM, V32, P395, DOI 10.1002/(SICI)1096-9888(199704)32:4<395::AID-JMS487>3.0.CO;2-#; Ard MD, 1996, J NEUROSCI RES, V43, P190, DOI 10.1002/(SICI)1097-4547(19960115)43:2<190::AID-JNR7>3.0.CO;2-B; BEHL C, 1994, BRAIN RES, V645, P253, DOI 10.1016/0006-8993(94)91659-4; Boggs LN, 1996, J NEUROCHEM, V67, P1324; Bouillot C, 1996, J BIOL CHEM, V271, P7640, DOI 10.1074/jbc.271.13.7640; Castano EM, 1996, J BIOL CHEM, V271, P32185, DOI 10.1074/jbc.271.50.32185; Castillo GM, 1997, J NEUROCHEM, V69, P2452; ChooSmith LP, 1997, FEBS LETT, V402, P95, DOI 10.1016/S0014-5793(96)01504-9; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Du YS, 1998, J NEUROCHEM, V70, P1182; ElKhoury J, 1996, NATURE, V382, P716; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FRUEN BR, 1990, BIOCHEM J, V270, P119, DOI 10.1042/bj2700119; Giulian D, 1996, J NEUROSCI, V16, P6021; Giulian D, 1998, J BIOL CHEM, V273, P29719, DOI 10.1074/jbc.273.45.29719; Goodman Y, 1996, J NEUROCHEM, V66, P869, DOI 10.1046/j.1471-4159.1996.66020869.x; Goodman YD, 1996, J NEUROCHEM, V66, P1836; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; GUPTABANSAL R, 1995, J BIOL CHEM, V270, P18666, DOI 10.1074/jbc.270.31.18666; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; IVERSEN LL, 1995, BIOCHEM J, V311, P1; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; KISILEVSKY R, 1995, NAT MED, V1, P143, DOI 10.1038/nm0295-143; Klegeris A, 1997, J NEUROSCI RES, V49, P229, DOI 10.1002/(SICI)1097-4547(19970715)49:2<229::AID-JNR11>3.0.CO;2-W; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; LANSBURY PT, 1995, NAT STRUCT BIOL, V2, P990, DOI 10.1038/nsb1195-990; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Mann DMA, 1996, ANN NEUROL, V40, P149, DOI 10.1002/ana.410400205; Matsuoka T, 1998, J NEUROCHEM, V70, P772; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; McLaurin J, 1998, J BIOL CHEM, V273, P4506, DOI 10.1074/jbc.273.8.4506; McLaurin J, 1996, J BIOL CHEM, V271, P26482, DOI 10.1074/jbc.271.43.26482; McLaurin J, 1999, EUR J BIOCHEM, V266, P1101, DOI 10.1046/j.1432-1327.1999.00957.x; McLaurin J, 1998, J MOL BIOL, V278, P183, DOI 10.1006/jmbi.1998.1677; MCLAURIN J, 1995, INT J DEV NEUROSCI, V13, P369, DOI 10.1016/0736-5748(95)00012-6; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MICHAELIS T, 1993, NMR BIOMED, V6, P105, DOI 10.1002/nbm.1940060116; ODA T, 1995, EXP NEUROL, V136, P22, DOI 10.1006/exnr.1995.1080; Paradis E, 1996, J NEUROSCI, V16, P7533; PIKE CJ, 1993, J NEUROSCI, V13, P1676; POLLACK SJ, 1995, NEUROSCI LETT, V184, P113, DOI 10.1016/0304-3940(94)11182-I; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; Schulz JG, 1998, EUR J NEUROSCI, V10, P2085, DOI 10.1046/j.1460-9568.1998.00220.x; SHAFFER LM, 1995, NEUROBIOL AGING, V16, P737, DOI 10.1016/0197-4580(95)00055-J; SHONK T, 1995, MAGN RESON MED, V33, P858, DOI 10.1002/mrm.1910330619; SIMMONS SL, 1994, MARINE ENV MANAGEMEN, V1, P45; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SPECTOR R, 1988, NEUROCHEM RES, V13, P785, DOI 10.1007/BF00971603; SPECTOR R, 1978, J NEUROCHEM, V31, P1113, DOI 10.1111/j.1471-4159.1978.tb00157.x; STOKES CE, 1987, J NEUROCHEM, V48, P1018, DOI 10.1111/j.1471-4159.1987.tb05619.x; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Teller JK, 1996, NAT MED, V2, P93, DOI 10.1038/nm0196-93; Tomiyama T, 1996, J BIOL CHEM, V271, P6839, DOI 10.1074/jbc.271.12.6839; UEDA K, 1994, BRAIN RES, V639, P240, DOI 10.1016/0006-8993(94)91736-1; Wang AJ, 1997, BIOCHEMISTRY-US, V36, P9101, DOI 10.1021/bi970247h; WEISS JH, 1994, J NEUROCHEM, V62, P372; WIESINGER H, 1978, J NEUROCHEM, V31, P1113; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Yang DS, 1999, J BIOL CHEM, V274, P32970, DOI 10.1074/jbc.274.46.32970	60	223	248	1	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18495	18502		10.1074/jbc.M906994199	http://dx.doi.org/10.1074/jbc.M906994199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10764800	hybrid			2022-12-27	WOS:000087659400080
J	Pu, WT; Wickman, K; Clapham, DE				Pu, WT; Wickman, K; Clapham, DE			ICln is essential for cellular and early embryonic viability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY POSTIMPLANTATION LETHALITY; TARGETED DISRUPTION; CHLORIDE CHANNEL; GENE LEADS; XENOPUS-OOCYTES; FISSION YEAST; MICE; PROTEIN; MOUSE; EXPRESSION	pICln is a 26-kDa protein that is ubiquitously expressed and highly conserved from Xenopus laevis to Homo sapiens. The physiological functions of pICln remain to be established. To address this question, we disrupted the ICln gene in embryonic stem cells. We found that murine embryos lacking ICln die early in gestation (between stages E3.5 and E7.5). Furthermore, we found that ICln is essential for embryonic stem cell viability. Previously, we showed that pICln interacts directly with a homolog of a yeast protein that binds a PAK-like kinase and participates in the regulation of cell morphology and cell cycling. pICln also forms a complex with several core spliceosomal proteins, and this interaction may play a role in the regulation of spliceosomal biogenesis. Collectively, these data strongly suggest that pICln participates in critical cellular pathways, including regulation of the cell cycle find RNA processing.	Harvard Univ, Sch Med, Childrens Hosp, Howard Hughes Med Inst,Cardiovasc Div, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute	Clapham, DE (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Howard Hughes Med Inst,Cardiovasc Div, 1309 Enders,320 Longwood Ave, Boston, MA 02115 USA.	clapham@rascal.med.harvard.edu	Clapham, David/S-1123-2019; Clapham, David/R-5974-2019; Pu, William/AAJ-8301-2020	Clapham, David/0000-0002-4459-9428; Pu, William/0000-0002-4551-8079; Wickman, Kevin/0000-0002-5179-9540	NHLBI NIH HHS [T32 HL007572] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABE T, 1993, BIOCHIM BIOPHYS ACTA, V1173, P353, DOI 10.1016/0167-4781(93)90138-4; ACKERMAN MJ, 1994, J GEN PHYSIOL, V103, P153, DOI 10.1085/jgp.103.2.153; Arman E, 1998, P NATL ACAD SCI USA, V95, P5082, DOI 10.1073/pnas.95.9.5082; Buyse G, 1997, J BIOL CHEM, V272, P3615, DOI 10.1074/jbc.272.6.3615; Dealy MJ, 1999, NAT GENET, V23, P245, DOI 10.1038/13886; DEGREGORI J, 1994, GENE DEV, V8, P265, DOI 10.1101/gad.8.3.265; DENG JM, 1995, TRANSGENIC RES, V4, P264, DOI 10.1007/BF01969120; Emma F, 1998, AM J PHYSIOL-CELL PH, V274, pC1545, DOI 10.1152/ajpcell.1998.274.6.C1545; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; Gallicano GI, 1998, J CELL BIOL, V143, P2009, DOI 10.1083/jcb.143.7.2009; Gilbreth M, 1998, P NATL ACAD SCI USA, V95, P14781, DOI 10.1073/pnas.95.25.14781; Gilbreth M, 1996, P NATL ACAD SCI USA, V93, P13802, DOI 10.1073/pnas.93.24.13802; Gorman JR, 1996, IMMUNITY, V5, P241, DOI 10.1016/S1074-7613(00)80319-2; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; ISHIBASHI K, 1993, BIOCHEM BIOPH RES CO, V192, P561, DOI 10.1006/bbrc.1993.1452; Kalitsis P, 1998, P NATL ACAD SCI USA, V95, P1136, DOI 10.1073/pnas.95.3.1136; Koutsourakis M, 1999, DEVELOPMENT, V126, P723; Krapivinsky G, 1998, J BIOL CHEM, V273, P10811, DOI 10.1074/jbc.273.18.10811; KRAPIVINSKY GB, 1994, CELL, V76, P439, DOI 10.1016/0092-8674(94)90109-0; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; MICHAUD EJ, 1993, GENE DEV, V7, P1203, DOI 10.1101/gad.7.7a.1203; MILLER MW, 1994, EMBO J, V13, P1806, DOI 10.1002/j.1460-2075.1994.tb06449.x; Murphy M, 1997, NAT GENET, V15, P83, DOI 10.1038/ng0197-83; Musch MW, 1998, PFLUG ARCH EUR J PHY, V436, P415, DOI 10.1007/s004240050651; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; Pravtcheva DD, 1996, GENETICS, V144, P1747; Pu WT, 1999, MOL CELL BIOL, V19, P4113; Rassoulzadegan M, 1998, EMBO J, V17, P4647, DOI 10.1093/emboj/17.16.4647; Schrank B, 1997, P NATL ACAD SCI USA, V94, P9920, DOI 10.1073/pnas.94.18.9920; Smyth N, 1999, J CELL BIOL, V144, P151, DOI 10.1083/jcb.144.1.151; SPICER AP, 1995, J BIOL CHEM, V270, P30093; SPYROPOULOS DD, 1994, GENE DEV, V8, P1949, DOI 10.1101/gad.8.16.1949; STEPHENS LE, 1995, GENE DEV, V9, P1883, DOI 10.1101/gad.9.15.1883; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Tudor M, 1999, GENE DEV, V13, P2365, DOI 10.1101/gad.13.18.2365; Wang S, 1998, FEBS LETT, V441, P261, DOI 10.1016/S0014-5793(98)01518-X; Wickman K, 1997, GENOMICS, V40, P402, DOI 10.1006/geno.1996.4600; Wickman K, 1998, NEURON, V20, P103, DOI 10.1016/S0896-6273(00)80438-9; Xanthoudakis S, 1996, P NATL ACAD SCI USA, V93, P8919, DOI 10.1073/pnas.93.17.8919; Zizioli D, 1999, J BIOL CHEM, V274, P5385, DOI 10.1074/jbc.274.9.5385	43	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12363	12366		10.1074/jbc.275.17.12363	http://dx.doi.org/10.1074/jbc.275.17.12363			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777517	hybrid			2022-12-27	WOS:000086762300001
J	Germain, D; Russell, A; Thompson, A; Hendley, J				Germain, D; Russell, A; Thompson, A; Hendley, J			Ubiquitination of free cyclin D1 is independent of phosphorylation on threonine 286	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; ESTROGEN-RECEPTOR; BREAST-CANCER; F-BOX; DEPENDENT PROTEOLYSIS; GENE-EXPRESSION; DEGRADATION; PATHWAY; PROTEIN; COMPLEX	Cyclin D1 binds and regulates the activity of cyclin-dependent kinases (CDKs) 4 and 6. Phosphorylation of the retinoblastoma protein by cyclin D1-CDK4/6 complexes during the G(1) phase of the cell cycle promotes entry into S phase. Cyclin D1 protein is ubiquitinated and degraded by the 26 S proteasome, Previous studies have demonstrated that cyclin D1 ubiquitination is dependent on its phosphorylation by glycogen synthase kinase 3 beta (GSK-3 beta) on threonine 286 and that this phosphorylation event is greatly enhanced by binding to CDK4 (Diehl, J. A., Cheng, M. G., Roussel, M. F., and Sherr, C. J. (1998) Genes Dev. 12, 3499-3511). We now report an additional pathway for the ubiquitination of free cyclin D1 (unbound to CDKs). We show that, when unbound to CDK4, a cyclin D1-T286A mutant is ubiquitinated. Further, we show that a mutant of cyclin D1 that cannot bind to CDK4 (cyclin D1-KE) is also ubiquitinated in vivo. Our results demonstrate that free cyclin D1 is ubiquitinated independently of its phosphorylation on threonine 286 by GSK-3 beta, suggesting that, as has been shown for cyclin E, distinct pathways of ubiquitination lead to the degradation of free and CDK-bound cyclin D1. The pathway responsible for ubiquitination of free cyclin D1 may be important in limiting the effects of cyclin DI overexpression in a variety of cancers.	Peter MacCallum Canc Inst, E Melbourne, Vic 3002, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Melbourne, Vic 3002, Australia	Peter Maccallum Cancer Center; University of Melbourne	Germain, D (corresponding author), Peter MacCallum Canc Inst, St Andrews Pl, E Melbourne, Vic 3002, Australia.							Adnane J, 1999, ONCOGENE, V18, P239, DOI 10.1038/sj.onc.1202297; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BARRAL Y, 1995, GENE DEV, V9, P399, DOI 10.1101/gad.9.4.399; BATES S, 1994, ONCOGENE, V9, P1633; Craig KL, 1999, PROG BIOPHYS MOL BIO, V72, P299, DOI 10.1016/S0079-6107(99)00010-3; Dealy MJ, 1999, NAT GENET, V23, P245, DOI 10.1038/13886; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Ganter B, 1998, EMBO J, V17, P255, DOI 10.1093/emboj/17.1.255; GILLETT C, 1994, CANCER RES, V54, P1812; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; Kishi T, 1998, J CELL SCI, V111, P3655; Knudsen KE, 1999, CANCER RES, V59, P2297; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; Li FN, 1997, EMBO J, V16, P5629, DOI 10.1093/emboj/16.18.5629; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Mastrandrea LD, 1999, J BIOL CHEM, V274, P27299, DOI 10.1074/jbc.274.38.27299; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Russell A, 1999, ONCOGENE, V18, P1983, DOI 10.1038/sj.onc.1202511; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wang YS, 1999, CURR BIOL, V9, P1191, DOI 10.1016/S0960-9822(00)80024-X; Welcker M, 1996, ONCOGENE, V13, P419; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; ZHONGKANG Y, 1998, P NATL ACAD SCI USA, V95, P11324; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	31	79	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12074	12079		10.1074/jbc.275.16.12074	http://dx.doi.org/10.1074/jbc.275.16.12074			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766840	hybrid			2022-12-27	WOS:000086695500075
J	Grosse, R; Roelle, S; Herrlich, A; Hohn, J; Gudermann, T				Grosse, R; Roelle, S; Herrlich, A; Hohn, J; Gudermann, T			Epidermal growth factor receptor tyrosine kinase mediates Ras activation by gonadotropin-releasing hormone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SIGNAL-REGULATED KINASE; BETA-GAMMA-SUBUNITS; EGF-RECEPTOR; CELL-LINES; DEPENDENT PHOSPHORYLATION; INTERNALIZATION KINETICS; BINDING DOMAIN; ANGIOTENSIN-II; ION-CHANNEL	Gonadotropin releasing hormone (GnRH) contributes to the maintenance of gonadotrope function by increasing extracellular signal-regulated kinase (ERK) activity subsequent to binding to its cognate G-protein-coupled receptor. As the GnRH receptor exclusively interacts with G(q/11) proteins and as receptor expression is regulated in a beta-arrestin-independent fashion, it represents a good model to systematically dissect underlying signaling pathways. In alpha T3-1 gonadotropes endogenously expressing the GnRH receptor, GnRH challenge resulted in a rapid increase in ERK activity which was attenuated by the epidermal growth factor receptor (EGFR)-specific tyrosine kinase inhibitor AG1478, In COS-7 cells transiently expressing the human GnRH receptor, agonist-induced ERK activation was independent of free G beta gamma subunits but could be mimicked by shortterm phorbol ester treatment. Most notably, G(q/11)-induced ERR activation was sensitive to N17-Ras and to expression of the C-terminal Src kinase but also to other dominant negative mutants of signaling components localized upstream of Ras, like Shc and the EGFR. GnRH as well as phorbol esters led to Ras activation in COS-7 and alpha T3-1 cells, which was dependent on Src and EGFR tyrosine kinases, indicating that both tyrosine kinases act downstream of protein kinase C (PHC) and upstream of Ras, However, Src did not contribute to Shc tyrosine phosphorylation, GnRH or phorbol ester challenge resulted in PKC-dependent EGFR autophosphorylation, Furthermore, a 5-min phorbol ester treatment was sufficient to trigger tyrosine phosphorylation of the platelet-derived growth factor-beta receptor in L cells, Thus, in several cell systems PKC is able to stimulate Ras via activation of receptor tyrosine kinases.	Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pharmakol, D-14195 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Gudermann, T (corresponding author), Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pharmakol, Thielallee 67-73, D-14195 Berlin, Germany.			Grosse, Robert/0000-0002-3380-5273				Berts A, 1999, MOL PHARMACOL, V55, P296, DOI 10.1124/mol.55.2.296; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; Call GB, 1999, BIOL REPROD, V61, P715, DOI 10.1095/biolreprod61.3.715; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Dhanasekaran N, 1998, ONCOGENE, V17, P1383, DOI 10.1038/sj.onc.1202242; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Emkey R, 1997, J BIOL CHEM, V272, P31172, DOI 10.1074/jbc.272.49.31172; Grosse R, 1997, MOL ENDOCRINOL, V11, P1305, DOI 10.1210/me.11.9.1305; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Heding A, 1998, J BIOL CHEM, V273, P11472, DOI 10.1074/jbc.273.19.11472; Herrlich A, 1996, J BIOL CHEM, V271, P16764, DOI 10.1074/jbc.271.28.16764; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HORN F, 1991, MOL ENDOCRINOL, V5, P347, DOI 10.1210/mend-5-3-347; Kaiser UB, 1997, ENDOCR REV, V18, P46, DOI 10.1210/er.18.1.46; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mochly-Rosen D, 1998, ADV PHARMACOL, V44, P91, DOI 10.1016/S1054-3589(08)60126-X; Mulvaney JM, 1999, J BIOL CHEM, V274, P29796, DOI 10.1074/jbc.274.42.29796; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; Palomero T, 1998, MOL PHARMACOL, V53, P613, DOI 10.1124/mol.53.4.613; Reiss N, 1997, ENDOCRINOLOGY, V138, P1673, DOI 10.1210/en.138.4.1673; ROBERSON MS, 1995, MOL CELL BIOL, V15, P3531; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Soltoff SP, 1998, J BIOL CHEM, V273, P23110, DOI 10.1074/jbc.273.36.23110; STRAWN LM, 1994, J BIOL CHEM, V269, P21215; Sundaresan S, 1996, ENDOCRINOLOGY, V137, P304, DOI 10.1210/en.137.1.304; Swanson KD, 1998, J BIOL CHEM, V273, P19965, DOI 10.1074/jbc.273.32.19965; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Vrecl M, 1998, MOL ENDOCRINOL, V12, P1818, DOI 10.1210/me.12.12.1818; White BR, 1999, MOL ENDOCRINOL, V13, P566, DOI 10.1210/me.13.4.566; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Willars GB, 1999, J BIOL CHEM, V274, P30146, DOI 10.1074/jbc.274.42.30146; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	57	58	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12251	12260		10.1074/jbc.275.16.12251	http://dx.doi.org/10.1074/jbc.275.16.12251			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766863	hybrid			2022-12-27	WOS:000086695500098
J	Liu, Y; Zhong, XH; Li, WH; Brattain, MG; Banerji, SS				Liu, Y; Zhong, XH; Li, WH; Brattain, MG; Banerji, SS			The role of Sp1 in the differential expression of transforming growth factor-beta receptor type II in human breast adenocarcinoma MCF-7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; COLON-CARCINOMA-CELLS; CANCER CELLS; TRANSCRIPTIONAL ACTIVATION; FUNCTIONAL INTERACTIONS; EPITHELIAL-CELLS; O-GLYCOSYLATION; PROTEIN-KINASE; FAMILY MEMBERS; PROMOTER	Progression of MCF-7 cells from early passage (MCF-7E, <200 passage) to late passage (MCF-7L, >500 passage) correlates with a loss of sensitivity to exogenous TGF beta 1, We have previously shown that loss of TGF beta sensitivity is due to decreased expression of the transforming growth factor receptor type II (T beta RII) and is associated with increased tumorigenicity in nude mice. Reduced T beta RII expression in MCF-7L cells is caused by decreased T beta RII promoter activity in this cell line. Our previous studies using 5' deletion constructs of this promoter revealed that MCF-7L cells were unable to support transcription of the minimal promoter (-47 to +2) to the same levels as the MCF-7E cells. This region of the promoter contains an Sp1 element at position -25 from the major transcription start site. In this study, we investigated the role of Sp1 in T beta RII transcription. Mutation of the Sp1 site resulted in decreased transcription of T beta RII in MCF-7E and MCF-7L cells, indicating that this site played a role in transcription of this promoter. Gel shift assays using the proximal Spl site from the T beta RII promoter showed enhanced DNA:protein complex formation with nuclear proteins isolated from MCF-7E cells compared with MCF-7L cells. Supershift analysis identified this binding activity as Sp1, Western blot analysis of Sp1 levels demonstrated that MCF-7E cells contain increased Sp1 protein compared with MCF-7L cells, paralleling the increased binding activity. Differential Sp1 activity was also demonstrated by higher levels of transcription of an Sp1-dependent insulin-like growth factor II promoter construct in MCF-7E cells compared with MCF-7L cells. Co-transfection of an Sp1 expression vector with a T beta RII promoter construct in MCF-7L cells induced the expression from the promoter-CAT constructs and resulted in an increase of endogenous T beta RII protein levels. These results demonstrate that the transcriptional repression of T beta RII in MCF-7L cells is caused, in part, by lower Sp1 levels.	Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43614 USA; Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Banerji, SS (corresponding author), Med Coll Ohio, Dept Biochem & Mol Biol, 3035 Arlington Ave,BHS 413, Toledo, OH 43614 USA.				NATIONAL CANCER INSTITUTE [R01CA072001, R29CA079840] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA79840, R01 CA72001-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ammanamanchi S, 1998, J BIOL CHEM, V273, P16527, DOI 10.1074/jbc.273.26.16527; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; BASSING CH, 1994, J BIOL CHEM, V269, P14861; Block KL, 1996, BLOOD, V88, P2071, DOI 10.1182/blood.V88.6.2071.bloodjournal8862071; Brattain Michael G., 1996, Current Opinion in Oncology, V8, P49, DOI 10.1097/00001622-199601000-00009; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRAZEN P, 1993, CELL, V75, P681; GEISER AG, 1993, GENE, V129, P223, DOI 10.1016/0378-1119(93)90272-5; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Hartsough MT, 1997, PHARMACOL THERAPEUT, V75, P21, DOI 10.1016/S0163-7258(97)00020-X; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Ji CH, 1997, J BIOL CHEM, V272, P21260, DOI 10.1074/jbc.272.34.21260; Jiang W, 1997, BIOCHEMISTRY-US, V36, P14786, DOI 10.1021/bi9717892; KADIN ME, 1994, P NATL ACAD SCI USA, V91, P6002, DOI 10.1073/pnas.91.13.6002; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; Kelly D, 1998, J BIOL CHEM, V273, P21115, DOI 10.1074/jbc.273.33.21115; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; Ko Y, 1998, J CELL PHYSIOL, V176, P424, DOI 10.1002/(SICI)1097-4652(199808)176:2<424::AID-JCP21>3.3.CO;2-N; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Menke A, 1999, BBA-MOL CELL RES, V1449, P178, DOI 10.1016/S0167-4889(99)00011-7; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; MULDER KM, 1989, MOL ENDOCRINOL, V3, P1215, DOI 10.1210/mend-3-8-1215; Nuchprayoon I, 1999, J BIOL CHEM, V274, P1085, DOI 10.1074/jbc.274.2.1085; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11579; PARK K, 1994, P NATL ACAD SCI USA, V81, P8772; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SHEN WJ, 1995, J BIOL CHEM, V270, P20525, DOI 10.1074/jbc.270.35.20525; Smith LM, 1997, CANCER RES, V57, P3046; SPORN MB, 1990, ANN NY ACAD SCI, V593, P1, DOI 10.1111/j.1749-6632.1990.tb16095.x; Sun GL, 1998, MOL ENDOCRINOL, V12, P882, DOI 10.1210/me.12.6.882; SUN LZ, 1994, J BIOL CHEM, V269, P26449; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Xie W, 1999, ENDOCRINOLOGY, V140, P219, DOI 10.1210/en.140.1.219; YINGLING JM, 1995, BBA-REV CANCER, V1242, P115, DOI 10.1016/0304-419X(95)00007-2	44	29	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12231	12236		10.1074/jbc.275.16.12231	http://dx.doi.org/10.1074/jbc.275.16.12231			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766860	hybrid			2022-12-27	WOS:000086695500095
J	Streeper, RS; Svitek, CA; Goldman, JK; O'Brien, RM				Streeper, RS; Svitek, CA; Goldman, JK; O'Brien, RM			Differential role of hepatocyte nuclear factor-1 in the regulation of glucose-6-phosphatase catalytic subunit gene transcription by cAMP in liver- and kidney-derived cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-STORAGE-DISEASE; MULTIPLE PROMOTER ELEMENTS; INSULIN-RESPONSE SEQUENCE; RENAL GLUCOSE-PRODUCTION; MESSENGER-RNA LEVEL; PHOSPHOENOLPYRUVATE CARBOXYKINASE; IN-VIVO; CYCLIC-AMP; RAT-LIVER; ACTIVATE TRANSCRIPTION	In liver and kidney, the terminal step in gluconeogenesis is catalyzed by glucose-6-phosphatase. To examine the effect of the cAMP signal transduction pathway on transcription of the gene encoding the catalytic subunit of glucose 6-phosphatase (G6Pase), G6Pase-chloramphenicol acetyltransferase (CAT) fusion genes mere transiently transfected into either the liver-derived HepG2 or kidney-derived LLC-PK cell line. Co-transfection of an expression vector encoding the catalytic subunit of cAMP-dependent protein kinase (PHA) markedly stimulated G6Pase-CAT fusion gene expression, and mutational analysis of the G6Pase promoter revealed that multiple regions are required for this PKA response in both the HepG2 and LLC-PK cell lines. A sequence in the G6Pase promoter that resembles a cAMP response element is required for the full PKA response in both HepG2 and LLC-PK cells. However, in LLC-PK cells, but not in HepG2 cells, a hepatocyte nuclear factor-1 (HNF-1) binding site was critical for the full induction of G6Pase-CAT expression by PKA. Changing this HNF-1 motif to that for the yeast transcription factor GAL4 reduces the PKA response in LLC-PK cells to the same degree as deleting the HNF-1 site. However, co-transfection of this mutated construct with chimeric proteins comprising the GAL4-DNA binding domain ligated to the coding sequence for HNF-1 alpha, HNF-1 beta, HNF-3, or HNF-4 completely restored the PKA response. Thus, we hypothesize that, in LLC-PK cells, HNF-1 is acting as an accessory factor to enhance PKA signaling through the cAMP response element by altering G6Pase promoter conformation or accessibility rather than specifically affecting some component of the PKA signal transduction pathway.	Vanderbilt Univ, Dept Physiol & Mol Biophys, Sch Med, Nashville, TN 37232 USA	Vanderbilt University	O'Brien, RM (corresponding author), Vanderbilt Univ, Dept Physiol & Mol Biophys, Sch Med, 761 MRB 2, Nashville, TN 37232 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056374, P60DK020593] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56374, P60 DK20593] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Argaud D, 1996, DIABETES, V45, P1563, DOI 10.2337/diabetes.45.11.1563; Argaud D, 1997, J BIOL CHEM, V272, P12854, DOI 10.1074/jbc.272.19.12854; Ayala JE, 1999, DIABETES, V48, P1885, DOI 10.2337/diabetes.48.9.1885; Bianchi L., 1993, EUR J PEDIATR S, V152, pS63; BURCHELL A, 1994, MOL MEMBR BIOL, V11, P217, DOI 10.3109/09687689409160431; Cersosimo E, 1999, AM J PHYSIOL-ENDOC M, V276, pE78, DOI 10.1152/ajpendo.1999.276.1.E78; Cersosimo E, 1999, DIABETES, V48, P261, DOI 10.2337/diabetes.48.2.261; Chapman SC, 1999, J BIOL CHEM, V274, P18625, DOI 10.1074/jbc.274.26.18625; Chatelain F, 1998, DIABETES, V47, P882, DOI 10.2337/diabetes.47.6.882; CHEN YT, 1991, PEDIATR NEPHROL, V5, P71, DOI 10.1007/BF00852851; Chou JY, 1999, TRENDS ENDOCRIN MET, V10, P104; Chouard T, 1997, BIOCHIMIE, V79, P707, DOI 10.1016/S0300-9084(97)86928-3; CONSOLI A, 1992, DIABETES CARE, V15, P430, DOI 10.2337/diacare.15.3.430; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; DELAVAL E, 1981, PEDIATR RES, V15, P138, DOI 10.1203/00006450-198102000-00011; Ebert DH, 1999, DIABETES, V48, P543, DOI 10.2337/diabetes.48.3.543; Ekberg K, 1999, DIABETES, V48, P292, DOI 10.2337/diabetes.48.2.292; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; Foster JD, 1997, P SOC EXP BIOL MED, V215, P314; Galli L, 1999, FEBS LETT, V459, P255, DOI 10.1016/S0014-5793(99)01248-X; Gerin I, 1997, FEBS LETT, V419, P235, DOI 10.1016/S0014-5793(97)01463-4; GRANNER DK, 1992, DIABETES CARE, V15, P369, DOI 10.2337/diacare.15.3.369; GSTRAUNTHALER G, 1987, AM J PHYSIOL, V252, pC232, DOI 10.1152/ajpcell.1987.252.2.C232; HABER BA, 1995, J CLIN INVEST, V95, P832, DOI 10.1172/JCI117733; HAENDLER B, 1990, EUR J BIOCHEM, V190, P477, DOI 10.1111/j.1432-1033.1990.tb15598.x; Hanson R W, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P203; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hiraiwa H, 1999, J BIOL CHEM, V274, P5532, DOI 10.1074/jbc.274.9.5532; KUO CJ, 1990, P NATL ACAD SCI USA, V87, P9838, DOI 10.1073/pnas.87.24.9838; LANGE AJ, 1994, BIOCHEM BIOPH RES CO, V201, P302, DOI 10.1006/bbrc.1994.1702; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; Lin BC, 1999, HUM GENET, V105, P515, DOI 10.1007/s004390051140; Lin BC, 1997, BIOCHEMISTRY-US, V36, P14096, DOI 10.1021/bi9703249; LIU JS, 1991, J BIOL CHEM, V266, P19095; Liu XD, 1996, AM J PHYSIOL-RENAL, V271, pF347, DOI 10.1152/ajprenal.1996.271.2.F347; LIU ZQ, 1994, BIOCHEM BIOPH RES CO, V205, P680, DOI 10.1006/bbrc.1994.2719; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; MARKSITZER R, 1995, J BIOL CHEM, V270, P21833, DOI 10.1074/jbc.270.37.21833; Massillon D, 1997, DIABETES, V46, P153, DOI 10.2337/diabetes.46.1.153; Massillon D, 1998, J BIOL CHEM, V273, P228, DOI 10.1074/jbc.273.1.228; Massillon D, 1996, J BIOL CHEM, V271, P9871, DOI 10.1074/jbc.271.17.9871; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; Metzger S, 1997, AM J PHYSIOL-ENDOC M, V273, pE262, DOI 10.1152/ajpendo.1997.273.2.E262; Metzger S, 1997, METABOLISM, V46, P579, DOI 10.1016/S0026-0495(97)90197-9; Minassian C, 1996, MOL CELL BIOCHEM, V155, P37, DOI 10.1007/BF00714331; Mithieux G, 1996, DIABETES, V45, P891, DOI 10.2337/diabetes.45.7.891; Mithieux G, 1997, EUR J ENDOCRINOL, V136, P137, DOI 10.1530/eje.0.1360137; Nordlie RC, 1999, ANNU REV NUTR, V19, P379, DOI 10.1146/annurev.nutr.19.1.379; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; PARYS JB, 1986, BIOCHIM BIOPHYS ACTA, V888, P70, DOI 10.1016/0167-4889(86)90072-8; Peterson RS, 1997, CELL GROWTH DIFFER, V8, P69; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; REITSMABIERENS WCC, 1992, PEDIATR NEPHROL, V6, P236, DOI 10.1007/BF00878355; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sambrook J., 2002, MOL CLONING LAB MANU; Schmoll D, 1999, BIOCHEM J, V338, P457, DOI 10.1042/0264-6021:3380457; Schmoll D, 1996, FEBS LETT, V383, P63, DOI 10.1016/0014-5793(96)00224-4; SELAWRY H, 1973, BIOCHEM BIOPH RES CO, V51, P198, DOI 10.1016/0006-291X(73)90528-7; SEPULVEDA FV, 1982, J CELL PHYSIOL, V112, P182, DOI 10.1002/jcp.1041120205; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; Soubt MK, 1998, MOL CELL BIOL, V18, P4698, DOI 10.1128/MCB.18.8.4698; Streeper RS, 1998, P NATL ACAD SCI USA, V95, P9208, DOI 10.1073/pnas.95.16.9208; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; Stumvoll M, 1997, DIABETOLOGIA, V40, P749, DOI 10.1007/s001250050745; Suh DS, 1997, MOL ENDOCRINOL, V11, P1822, DOI 10.1210/me.11.12.1822; Trinh KY, 1998, J BIOL CHEM, V273, P31615, DOI 10.1074/jbc.273.47.31615; Veiga-da-Cunha M, 1998, AM J HUM GENET, V63, P976, DOI 10.1086/302068; Voice MW, 1997, HORM METAB RES, V29, P97, DOI 10.1055/s-2007-978998; Wang JC, 1999, MOL ENDOCRINOL, V13, P604, DOI 10.1210/me.13.4.604; Wintero AK, 1996, MAMM GENOME, V7, P509, DOI 10.1007/s003359900153; XIAO Q, 1993, MOL CELL BIOCHEM, V122, P17, DOI 10.1007/BF00925733	75	40	41	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12108	12118		10.1074/jbc.275.16.12108	http://dx.doi.org/10.1074/jbc.275.16.12108			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766845	hybrid			2022-12-27	WOS:000086695500080
J	Yasuhira, S; Yasui, A				Yasuhira, S; Yasui, A			Alternative excision repair pathway of UV-damaged DNA in Schizosaccharomyces pombe operates both in nucleus and in mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FISSION YEAST; PYRIMIDINE DIMERS; ULTRAVIOLET-LIGHT; GENE; TRANSCRIPTION; ENDONUCLEASE; CELLS; SITES; REPLICATION; RECOGNITION	The fission yeast, Schizosaccharomyces pombe, possesses a UV-damaged DNA endonuclease-dependent excision repair (UVER) pathway in addition to nucleotide excision repair pathway for W-induced DNA damage. We examined cyclobutane pyrimidine dimer removal from the myo2 locus on the nuclear genome and the coI locus on the mitochondrial genome by the two repair pathways. While nucleotide excision repair repairs damage only on the nuclear genome, UVER efficiently removes cyclobutane pyrimidine dimers on both nuclear and mitochondrial genomes. The ectopically expressed mild type UV-damaged DNA endonuclease was localized to both nucleus and mitochondria, while modifications of N-terminal methionine codons restricted its localization to either of two organelles, suggesting an alternative usage of multiple translation initiation sites for targeting the protein to different organelles. By introducing the same mutations into the chromosomal copy of the uvde(+) gene, we selectively inactivated UVER in either the nucleus or the mitochondria. The results of UV survival experiments indicate that although UVER efficiently removes damage on the mitochondrial genome, UVER in the mitochondria hardly contributes to UV resistance of S. pombe cells. We suggest a possible UVER function in mitochondria as a backup system for other UV damage tolerance mechanisms.	Tohoku Univ, Inst Dev Aging & Canc, Aoba Ku, Sendai, Miyagi 9808575, Japan	Tohoku University	Yasuhira, S (corresponding author), Kyoto Univ, Inst Res Reactor, Div Radiat Life Sci, 1010 Ooaza Noda, Kumatori, Osaka 5900494, Japan.	shinji@rri.kyoto-u.ac.jp						BERGER CA, 1986, MOL CELL BIOL, V6, P3443, DOI 10.1128/MCB.6.10.3443; BOSTOCK CJ, 1969, BIOCHIM BIOPHYS ACTA, V195, P579, DOI 10.1016/0005-2787(69)90667-4; CARR AM, 1993, NUCLEIC ACIDS RES, V21, P1345, DOI 10.1093/nar/21.6.1345; DANPURE CJ, 1995, TRENDS CELL BIOL, V5, P230, DOI 10.1016/S0962-8924(00)89016-9; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; FORSBURG SL, 1993, NUCLEIC ACIDS RES, V21, P2955, DOI 10.1093/nar/21.12.2955; FREYER GA, 1995, MOL CELL BIOL, V15, P4572; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Guzder SN, 1998, J BIOL CHEM, V273, P6292, DOI 10.1074/jbc.273.11.6292; HAFFTER P, 1992, GENETICS, V131, P255; Kanno S, 1999, NUCLEIC ACIDS RES, V27, P3096, DOI 10.1093/nar/27.15.3096; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Kitayama C, 1997, J CELL BIOL, V137, P1309, DOI 10.1083/jcb.137.6.1309; KLOCKER H, 1986, EUR J CELL BIOL, V39, P346; Konat Gregory W., 1994, P37; LING F, 1995, EMBO J, V14, P4090, DOI 10.1002/j.1460-2075.1995.tb00081.x; MASSARDO DR, 1994, CURR GENET, V25, P80, DOI 10.1007/BF00712972; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; NICOLAS P, 1980, MOL GEN GENET, V178, P567, DOI 10.1007/BF00337862; Pinz KG, 1998, MOL CELL BIOL, V18, P1257, DOI 10.1128/MCB.18.3.1257; PRAKASH L, 1975, J MOL BIOL, V98, P781, DOI 10.1016/S0022-2836(75)80010-6; Robinow C, 1989, MOL BIOL FISSION YEA, P273; SLUPPHAUG G, 1993, NUCLEIC ACIDS RES, V21, P2579, DOI 10.1093/nar/21.11.2579; STACKS PC, 1983, MOL CELL BIOL, V3, P1403, DOI 10.1128/MCB.3.8.1403; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; Takao M, 1998, NUCLEIC ACIDS RES, V26, P2917, DOI 10.1093/nar/26.12.2917; Takao M, 1996, NUCLEIC ACIDS RES, V24, P1267, DOI 10.1093/nar/24.7.1267; Todo T, 1996, SCIENCE, V272, P109, DOI 10.1126/science.272.5258.109; TODO T, 1993, NATURE, V361, P371, DOI 10.1038/361371a0; ULERY TL, 1994, MOL CELL BIOL, V14, P1160, DOI 10.1128/MCB.14.2.1160; WATERS R, 1974, BIOCHIM BIOPHYS ACTA, V366, P241, DOI 10.1016/0005-2787(74)90282-2; Yaffe MP, 1996, P NATL ACAD SCI USA, V93, P11664, DOI 10.1073/pnas.93.21.11664; YAJIMA H, 1995, EMBO J, V14, P2393, DOI 10.1002/j.1460-2075.1995.tb07234.x; Yasuhira S, 1999, J BIOL CHEM, V274, P26822, DOI 10.1074/jbc.274.38.26822; YASUHIRA S, 1991, PHOTOCHEM PHOTOBIOL, V53, P211, DOI 10.1111/j.1751-1097.1991.tb03925.x; YASUI A, 1994, EMBO J, V13, P6143, DOI 10.1002/j.1460-2075.1994.tb06961.x; YASUI A, 1992, MUTAT RES, V273, P231, DOI 10.1016/0921-8777(92)90084-G; YASUI A, 1989, MUTAT RES, V217, P3, DOI 10.1016/0921-8777(89)90029-3; Yonemasu R, 1997, NUCLEIC ACIDS RES, V25, P1553, DOI 10.1093/nar/25.8.1553; ZHANG MQ, 1994, NUCLEIC ACIDS RES, V22, P1750, DOI 10.1093/nar/22.9.1750	41	23	23	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11824	11828		10.1074/jbc.275.16.11824	http://dx.doi.org/10.1074/jbc.275.16.11824			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766807	hybrid			2022-12-27	WOS:000086695500042
J	Yoon, YM; Oh, CD; Kim, DY; Lee, YS; Park, JW; Huh, TL; Kang, SS; Chun, JS				Yoon, YM; Oh, CD; Kim, DY; Lee, YS; Park, JW; Huh, TL; Kang, SS; Chun, JS			Epidermal growth factor negatively regulates chondrogenesis of mesenchymal cells by modulating the protein kinase C-alpha, Erk-1, and p38 MAPK signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK LIMB-BUD; APICAL ECTODERMAL RIDGE; IN-VITRO; N-CADHERIN; CARTILAGE DIFFERENTIATION; EXPRESSION; ACTIVATION; BONE; CONDENSATIONS; PRECARTILAGE	During limb development, epithelial cells in the apical ectodermal ridge keep the underlying mesenchymal cells in a proliferative state preventing differentiation by secreting signaling molecules such as epidermal growth factor (EGF). We investigated the molecular mechanism of the EGF effect on the regulation of micromass culture-induced chondrogenesis of chick limb bud mesenchymal cells as a model system. We found that expression and tyrosine phosphorylation of the EGF receptor was increased transiently during chondrogenesis, Exogenous EGF inhibited chondrogenic differentiation of mesenchymal cells, and this effect was reversed by the EGF receptor inhibitor AG1478, EGF treatment also inhibited the expression and activation of protein kinase C-alpha, whereas it activated Erk-1 and inhibited p38 mitogen-activated protein kinase, all of which appeared to be involved in the EGF-induced inhibition of chondrogenesis. Stimulation of the EGF receptor blocked precartilage condensation and altered the expression of cell adhesion molecules such as N-cadherin and integrins alpha(5) and beta(1), All these EGF effects were reversible by AG1478, The data indicate that EGF negatively regulate chondrogenesis of chick limb bud mesenchymal cells by inhibiting precartilage condensation and by modulating signaling pathways including those of protein kinase C-alpha, Erk-1, and p38 mitogen-activated protein kinase.	Kyungpook Natl Univ, Dept Biol, Taegu 702701, South Korea; Kyungpook Natl Univ, Dept Biochem, Taegu 702701, South Korea; Kyungpook Natl Univ, Dept Genet Engn, Taegu 702701, South Korea	Kyungpook National University; Kyungpook National University; Kyungpook National University	Chun, JS (corresponding author), Kyungpook Natl Univ, Dept Biol, Pook Gu, Taegu 702701, South Korea.	jschun@kyungpook.ac.kr		Oh, Chundo/0000-0002-5419-8011				AHRENS PB, 1977, DEV BIOL, V60, P69, DOI 10.1016/0012-1606(77)90110-5; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; AULTHOUSE AL, 1987, DEV BIOL, V120, P377, DOI 10.1016/0012-1606(87)90240-5; Chang SH, 1998, J BIOL CHEM, V273, P19213, DOI 10.1074/jbc.273.30.19213; CHOI B, 1995, BIOCHEM BIOPH RES CO, V216, P1034, DOI 10.1006/bbrc.1995.2724; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dealy CN, 1998, DEV BIOL, V202, P43, DOI 10.1006/dbio.1998.8988; Duprez DM, 1996, DEV BIOL, V174, P448, DOI 10.1006/dbio.1996.0087; FRENZ DA, 1989, DEV BIOL, V136, P97, DOI 10.1016/0012-1606(89)90133-4; Kim JY, 1999, BIOCHEM J, V337, P275, DOI 10.1042/0264-6021:3370275; KOSHER RA, 1979, J EMBRYOL EXP MORPH, V50, P75; KRABBENHOFT KM, 1989, DEV BIOL, V131, P373, DOI 10.1016/S0012-1606(89)80011-9; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; MAINI PK, 1991, INT REV CYTOL, V129, P91; Maleski MP, 1996, EXP CELL RES, V225, P55, DOI 10.1006/excr.1996.0156; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; OBERLENDER SA, 1994, DEVELOPMENT, V120, P177; Oh CD, 2000, J BIOL CHEM, V275, P5613, DOI 10.1074/jbc.275.8.5613; Ohuchi H, 1997, DEVELOPMENT, V124, P2235; PACIFICI M, 1993, DEV DYNAM, V198, P123, DOI 10.1002/aja.1001980206; Quarto R, 1997, ENDOCRINOLOGY, V138, P4966, DOI 10.1210/en.138.11.4966; REDDI AH, 1994, CURR OPIN GENET DEV, V4, P737, DOI 10.1016/0959-437X(94)90141-O; ROARK EF, 1994, DEV DYNAM, V200, P103, DOI 10.1002/aja.1002000203; RYVES WJ, 1991, FEBS LETT, V288, P5, DOI 10.1016/0014-5793(91)80989-G; Sandell L., 1999, FRONT BIOSCI-LANDMRK, V4, P731; SAVAGE MP, 1995, DEV DYNAM, V202, P343, DOI 10.1002/aja.1002020404; Shakibaei M, 1998, EXP CELL RES, V240, P95, DOI 10.1006/excr.1998.3933; Stott NS, 1999, J CELL PHYSIOL, V180, P314, DOI 10.1002/(SICI)1097-4652(199909)180:3<314::AID-JCP2>3.3.CO;2-P; Tavella S, 1997, J CELL SCI, V110, P2261; TSONIS PA, 1994, EXP CELL RES, V213, P433, DOI 10.1006/excr.1994.1220; WIDELITZ RB, 1993, J CELL PHYSIOL, V156, P399, DOI 10.1002/jcp.1041560224; Woodward WA, 1999, DEV GENET, V24, P178, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<178::AID-DVG16>3.0.CO;2-M	35	88	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12353	12359		10.1074/jbc.275.16.12353	http://dx.doi.org/10.1074/jbc.275.16.12353			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766877	hybrid			2022-12-27	WOS:000086695500112
J	Gu, MF; Lynch, J; Brecher, P				Gu, MF; Lynch, J; Brecher, P			Nitric oxide increases p21(Waf1/Cip1) expression by a cGMP-dependent pathway that includes activation of extracellular signal-regulated kinase and p70(S6k)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; PROTEIN-KINASES; GROWTH-FACTOR; ANGIOTENSIN-II; CYCLE ARREST; P53; INHIBITION; PHOSPHORYLATION; PROLIFERATION; FIBROBLASTS	Nitric oxide (NO) regulates the expression of p21(Waf1)/ Cip1 in several cell types. The present study examined the role of both the extracellular signal-regulated kinase (ERK) and p70 S6 kinase (p70(S6k)) in the NO-induced increase in p21 expression that occurred in adventitial fibroblasts during the cell cycle. Both ERK and p70(S6k) were phosphorylated in response to the NO donor S-nitroso-N-acetylpenicillamine (SNAP) and the activation was rapid, transient, and preceded increased p21 expresion under defined conditions where serum was present. Addition of a selective inhibitor of ERK phosphorylation (PD98059) prevented the subsequent phosphorylation of p70(S6k) and the increase in pal protein. Both cGMP and cAMP activated both ERK and p70(S6k), whereas only selective inhibitors of protein kinase G prevented the activation of the kinases by SNAP. A complex between ERK and p70(S6k) was documented by immunoprecipitation procedures. Rapamycin blocked p70(S6k) phosphorylation induced by NO and also inhibited p53 phosphorylation and pal expression whereas PD98059 only prevented the NO-induced increase ill p21 protein without influencing either p53 activation or p21 mRNA expression. The studies show a unique relationship between NO, ERK, and p70(S6k) and also provide evidence for a novel role of p70(S6k) in the activation of p53.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Brecher, P (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	pbrecher@bu.edu		Brecher, Peter/0000-0002-9347-6643	NHLBI NIH HHS [HL53471, HL55001] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053471] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bornfeldt KE, 1997, J CLIN INVEST, V100, P875, DOI 10.1172/JCI119603; Callsen D, 1998, J IMMUNOL, V161, P4852; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CORNWELL TL, 1994, AM J PHYSIOL-CELL PH, V267, pC1405, DOI 10.1152/ajpcell.1994.267.5.C1405; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; Gu MF, 2000, ARTERIOSCL THROM VAS, V20, P27, DOI 10.1161/01.ATV.20.1.27; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hood J, 1998, J BIOL CHEM, V273, P23504, DOI 10.1074/jbc.273.36.23504; Ishida A, 1997, J BIOL CHEM, V272, P10050; Kato H, 1996, HYPERTENSION, V28, P153, DOI 10.1161/01.HYP.28.2.153; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; LOSCALZO J, 1995, PROG CARDIOVASC DIS, V38, P87, DOI 10.1016/S0033-0620(05)80001-5; LOWENSTEIN CJ, 1994, ANN INTERN MED, V120, P227, DOI 10.7326/0003-4819-120-3-199402010-00009; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MILNE DM, 1994, J BIOL CHEM, V269, P9253; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Scott NA, 1996, CIRCULATION, V93, P2178, DOI 10.1161/01.CIR.93.12.2178; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shi Y, 1999, ARTERIOSCL THROM VAS, V19, P1150, DOI 10.1161/01.ATV.19.5.1150; Shi Y, 1996, CIRCULATION, V93, P340, DOI 10.1161/01.CIR.93.2.340; Song XD, 1999, J BIOL CHEM, V274, P1677, DOI 10.1074/jbc.274.3.1677; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Vaandrager AB, 1996, MOL CELL BIOCHEM, V157, P23, DOI 10.1007/BF00227877; VENANCE SL, 1993, J HYPERTENS, V11, P483, DOI 10.1097/00004872-199305000-00003; Wang DM, 1998, J BIOL CHEM, V273, P33027, DOI 10.1074/jbc.273.49.33027; Wang DM, 1999, J BIOL CHEM, V274, P24342, DOI 10.1074/jbc.274.34.24342; Wilcox JN, 1996, INT J CARDIOL, V54, pS21, DOI 10.1016/S0167-5273(96)02811-2	40	71	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11389	11396		10.1074/jbc.275.15.11389	http://dx.doi.org/10.1074/jbc.275.15.11389			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753954	hybrid			2022-12-27	WOS:000086466600096
J	Hosono, S; Gross, I; English, MA; Hajra, KM; Fearon, ER; Licht, JD				Hosono, S; Gross, I; English, MA; Hajra, KM; Fearon, ER; Licht, JD			E-cadherin is a WT1 target gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILMS-TUMOR GENE; ADHESION MOLECULE UVOMORULIN; CANCER CELL-LINES; I RECEPTOR GENE; KIDNEY DEVELOPMENT; SUPPRESSOR GENE; BREAST-CANCER; DNA-BINDING; TRANSCRIPTION FACTOR; CYTOPLASMIC DOMAIN	The WT1 tumor suppressor gene encodes a transcription factor that can activate and repress gene expression. Transcriptional targets relevant for the growth suppression functions of WT1 are poorly understood. We found that mesenchymal NIH 3T3 fibroblasts stably expressing WT1 exhibit growth suppression and features of epithelial differentiation including up-regulation of E-cadherin mRNA. Acute expression of WT1 in NIH 3T3 fibroblasts after retroviral infection induced murine E-cadherin expression. In transient transfection experiments, the human and murine E-cadherin promoters were activated by co-expression of WT1. E-cadherin promoter activity was increased in cells overexpressing WT1 and was blocked by a dominant negative form of WT1. WT1 activated the murine E-cadherin promoter through a conserved GC-rich sequence similar to an EGR-1 binding site as well as through a CAAT box sequence. WT1 produced in vitro or derived from nuclear extracts bound to the WT1-response element within the murine E-cadherin promoter, but not the CAAT box. E-cadherin, a gene important in epithelial differentiation and neoplastic transformation, represents a downstream target gene that links the roles of the WT1 in differentiation and growth control.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA; Univ Michigan, Med Ctr, Dept Internal Med, Div Med & Mol Genet, Ann Arbor, MI 48109 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Michigan System; University of Michigan	Licht, JD (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, Box 1130,1 Gustave L Levy Pl, New York, NY 10029 USA.	jonathan.licht@mssm.edu	Gross, Isabelle/P-9859-2019; Gross, Isabelle/I-4972-2016; Licht, Jonathan/L-4239-2019	Gross, Isabelle/0000-0002-2783-8773; Gross, Isabelle/0000-0002-2783-8773; Licht, Jonathan/0000-0002-3942-1369				Ausubel FM, 1988, MOL REPROD DEV; Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; Becker K F, 1999, Hum Mutat, V13, P171, DOI 10.1002/(SICI)1098-1004(1999)13:2<171::AID-HUMU14>3.0.CO;2-Z; BECKER KF, 1994, CANCER RES, V54, P3845; BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BIRCHMEIER W, 1995, CANCER SURV, V24, P129; Birchmeier W, 1991, CURR OPIN CELL BIOL, V3, P832, DOI 10.1016/0955-0674(91)90057-6; BUSSEMAKERS MJG, 1994, BIOCHEM BIOPH RES CO, V203, P1284, DOI 10.1006/bbrc.1994.2321; Cook DM, 1996, ONCOGENE, V13, P1789; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; EKBLOM P, 1986, ANNU REV CELL BIOL, V2, P27, DOI 10.1146/annurev.cb.02.110186.000331; EKBLOM P, 1981, J CELL BIOL, V91, P1, DOI 10.1083/jcb.91.1.1; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; Englert C, 1998, TRENDS BIOCHEM SCI, V23, P389, DOI 10.1016/S0968-0004(98)01277-8; English MA, 1999, J BIOL CHEM, V274, P13258, DOI 10.1074/jbc.274.19.13258; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; Gluer S, 1998, PATHOL RES PRACT, V194, P773, DOI 10.1016/S0344-0338(98)80067-8; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; HABER DA, 1992, P NATL ACAD SCI USA, V89, P6010, DOI 10.1073/pnas.89.13.6010; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HAMILTON TB, 1995, NUCLEIC ACIDS RES, V23, P277, DOI 10.1093/nar/23.2.277; Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595; HENNIG G, 1995, ONCOGENE, V11, P475; Hiraguri S, 1998, CANCER RES, V58, P1972; Hosono S, 1999, ONCOGENE, V18, P417, DOI 10.1038/sj.onc.1202311; Jankowski JA, 1997, PROG NUCLEIC ACID RE, V57, P187, DOI 10.1016/S0079-6603(08)60281-0; Ji XD, 1997, CELL GROWTH DIFFER, V8, P773; Kim J, 1999, MOL CELL BIOL, V19, P2289; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KLEIN G, 1988, DEVELOPMENT, V102, P749; Koesters R, 1999, CANCER RES, V59, P3880; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; LUO XN, 1995, ONCOGENE, V11, P743; Maheswaran S, 1998, GENE DEV, V12, P1108, DOI 10.1101/gad.12.8.1108; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MAW MA, 1992, CANCER RES, V52, P3094; MCCANN S, 1995, J BIOL CHEM, V270, P23785, DOI 10.1074/jbc.270.40.23785; Menke AL, 1996, ONCOGENE, V12, P537; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; NICHOLS KE, 1995, CANCER RES, V55, P4540; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; Piepenhagen PA, 1998, MOL BIOL CELL, V9, P3161, DOI 10.1091/mbc.9.11.3161; PIERCEALL WE, 1995, ONCOGENE, V11, P1319; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REDDY JC, 1995, J BIOL CHEM, V270, P10878, DOI 10.1074/jbc.270.18.10878; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; RIETHMACHER D, 1995, P NATL ACAD SCI USA, V92, P855, DOI 10.1073/pnas.92.3.855; RINGWALD M, 1991, NUCLEIC ACIDS RES, V19, P6533, DOI 10.1093/nar/19.23.6533; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; RYAN G, 1995, DEVELOPMENT, V121, P867; SATO T, 1990, CANCER RES, V50, P7184; Scharnhorst V, 1997, CELL GROWTH DIFFER, V8, P133; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Thate C, 1998, ONCOGENE, V17, P1287, DOI 10.1038/sj.onc.1202055; TSUDA H, 1990, P NATL ACAD SCI USA, V87, P6791, DOI 10.1073/pnas.87.17.6791; VESTWEBER D, 1985, DEV BIOL, V112, P213, DOI 10.1016/0012-1606(85)90135-6; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1995, ONCOGENE, V10, P415; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WERNER H, 1995, MOL CELL BIOL, V15, P3516; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768	77	104	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10943	10953		10.1074/jbc.275.15.10943	http://dx.doi.org/10.1074/jbc.275.15.10943			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753894	hybrid			2022-12-27	WOS:000086466600036
J	Scott, MT; Morrice, N; Ball, KL				Scott, MT; Morrice, N; Ball, KL			Reversible phosphorylation at the C-terminal regulatory domain of p21(Waf1/Cip1) modulates proliferating cell nuclear antigen binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; DNA-REPLICATION; P21; PCNA; CDK; APOPTOSIS; PROTEIN; INHIBITION; P53; P21(CIP1/WAF1)	The p53-inducible gene product p21(WAF1/CIP1) plays a critical role in regulating the rate of tumor incidence, and identifying mechanisms of its post-translational regulation will define key pathways that link growth control to p21-dependent tumor suppression. A eukaryotic cell model system has been developed to determine whether protein kinase signaling pathways that phosphorylate human pal exist in vivo and whether such pathways regulate the binding of p21 to one of its key target proteins, proliferating cell nuclear antigen (PCNA). Although human p21 expressed in Sf9 cells is able to form a complex with human PCNA, the inclusion of cell-permeable phosphatase inhibitors renders p21 protein inactive for PCNA binding. The treatment of this inactive isoform of p21 with alkaline phosphatase restores its binding to PCNA, suggesting that p21 expressed in Sf9 cells is subject to reversible phosphorylation at a key regulatory site(s), A biochemical approach was subsequently used to map the phosphorylation sites within p21, whose modification in vitro can inhibit p21-PCNA complex formation, to the C-terminal domain at residues Thr(145) Or Ser(146), A phospho-specific antibody was developed that only bound to full-length p21 protein after phosphorylation in vitro at Ser146, and this reagent was further used to demonstrate that the inactive isoform of p21 recovered from Sf9 cells treated with phosphatase inhibitors had been phosphorylated in vivo at Ser(146), These data identify the first phosphorylation site within the C-terminal regulatory domain of p21 whose modification in vivo modulates p21-PCNA interactions and define a eukaryotic cell model that can be used to study post-translational signaling pathways that regulate p21.	Univ Dundee, Sch Med, Canc Res Campaign Labs, Dundee DD1 9SY, Scotland; Univ Dundee, Dept Biochem, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland	University of Dundee; University of Dundee	Ball, KL (corresponding author), Univ Dundee, Sch Med, Canc Res Campaign Labs, Dundee DD1 9SY, Scotland.	k.l.ball@dundee.ac.uk		Scott, Mary/0000-0002-7177-6960				Adams PD, 1996, MOL CELL BIOL, V16, P6623; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Ball K L, 1997, Prog Cell Cycle Res, V3, P125; Ball KL, 1996, EUR J BIOCHEM, V237, P854, DOI 10.1111/j.1432-1033.1996.0854p.x; Ball KL, 1997, CURR BIOL, V7, P71, DOI 10.1016/S0960-9822(06)00029-7; Bond JA, 1999, ONCOGENE, V18, P3788, DOI 10.1038/sj.onc.1202733; Cai K, 1998, P NATL ACAD SCI USA, V95, P12254, DOI 10.1073/pnas.95.21.12254; Cayrol C, 1998, ONCOGENE, V17, P2437, DOI 10.1038/sj.onc.1202189; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Craig AL, 1999, ONCOGENE, V18, P6305, DOI 10.1038/sj.onc.1203085; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erhardt JA, 1998, J BIOL CHEM, V273, P23517, DOI 10.1074/jbc.273.36.23517; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Harlow E., 1988, ANTIBODIES LAB MANUA; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; Hengst L, 1998, GENE DEV, V12, P3882, DOI 10.1101/gad.12.24.3882; HOSS A, 1990, J VIROL, V64, P4799; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; Jones JM, 1999, CELL GROWTH DIFFER, V10, P213; Kriwacki RW, 1997, J CHROMATOGR A, V777, P23, DOI 10.1016/S0021-9673(97)00527-X; Kriwacki RW, 1996, P NATL ACAD SCI USA, V93, P11504, DOI 10.1073/pnas.93.21.11504; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; Lin JY, 1996, MOL CELL BIOL, V16, P1786; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; McDonald E, 1996, CANCER RES, V56, P2250; Midgley CA, 1998, CULT SP CEL, P27; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Park JA, 1998, EUR J BIOCHEM, V257, P242, DOI 10.1046/j.1432-1327.1998.2570242.x; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; Rigberg DA, 1999, J SURG RES, V81, P6, DOI 10.1006/jsre.1998.5483; Rousseau D, 1999, ONCOGENE, V18, P3290, DOI 10.1038/sj.onc.1202681; Savio M, 1996, ONCOGENE, V13, P1591; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shivji MKK, 1998, ONCOGENE, V17, P2827, DOI 10.1038/sj.onc.1202352; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; Waga S, 1998, MOL CELL BIOL, V18, P4177, DOI 10.1128/MCB.18.7.4177; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Wouters BG, 1997, CANCER RES, V57, P4703; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426	59	90	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11529	11537		10.1074/jbc.275.15.11529	http://dx.doi.org/10.1074/jbc.275.15.11529			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753973	hybrid			2022-12-27	WOS:000086466600115
J	Vigano, C; Margolles, A; van Veen, HW; Konings, WN; Ruysschaert, JM				Vigano, C; Margolles, A; van Veen, HW; Konings, WN; Ruysschaert, JM			Secondary and tertiary structure changes of reconstituted LmrA induced by nucleotide binding or hydrolysis - A Fourier transform attenuated total reflection infrared spectroscopy and tryptophan fluorescence quenching analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-GLYCOPROTEIN GENE; MULTIDRUG-RESISTANCE; CONFORMATIONAL-CHANGES; PROTEINS; BIOCHEMISTRY; TRANSPORTER; PEPTIDES; EFFLUX; ATPASE; CELLS	LmrA, a membrane protein of Lactococcus lactis, extrudes amphiphilic compounds from the inner leaflet of the cytoplasmic membrane, using energy derived from ATP hydrolysis. A combination of total reflection Fourier transform infrared spectroscopy, H-2/H exchange, and fluorescence quenching experiments was used to investigate the effect of nucleotide binding and/or hydrolysis on the structure of LmrA reconstituted into proteoliposomes. These measurements allowed us to describe secondary structure changes of LmrA during the catalytic cycle. The structure of LmrA is enriched in beta-sheet after ATP binding, and the protein recovers its initial secondary structure after ATP hydrolysis, when P-i has been released. H-2/H exchange and fluorescence quenching studies indicate that the protein undergoes two distinct tertiary structure changes during the hydrolysis process. Indeed, the protein alone is poorly accessible to the aqueous medium but adopts a more accessible conformation when ATP hydrolysis takes place. After ATP hydrolysis, but when P-i is still associated with the protein, the accessibility is intermediate between these two states.	Free Univ Brussels, Chim Phys Macromol Interfaces Lab, B-1050 Brussels, Belgium; Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Microbiol, NL-9751 NN Haren, Netherlands	Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Groningen	Vigano, C (corresponding author), Free Univ Brussels, Chim Phys Macromol Interfaces Lab, CP 206-2,Bd Triomphe, B-1050 Brussels, Belgium.		Margolles, Abelardo/H-3871-2012; van Veen, Hendrik W./A-4162-2008; Konings, Wilhelmus N./C-7063-2013	Margolles, Abelardo/0000-0003-2278-1816; van Veen, Hendrik W./0000-0002-9658-8077; 				BOLHUIS H, 1994, J BACTERIOL, V176, P6957, DOI 10.1128/JB.176.22.6957-6964.1994; CHALLOU N, 1994, BIOCHEMISTRY-US, V33, P6902, DOI 10.1021/bi00188a020; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHIN KV, 1993, ADV CANCER RES, V60, P157; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FRINGELI UP, 1981, MEMBRANE SPECTROSCOP, P270; GOORMAGHTIGH E, 1994, SPECTROCHIM ACTA A, V50, P2137; Goormaghtigh E, 1999, BBA-REV BIOMEMBRANES, V1422, P105, DOI 10.1016/S0304-4157(99)00004-0; GOORMAGHTIGH E, 1990, EUR J BIOCHEM, V193, P409, DOI 10.1111/j.1432-1033.1990.tb19354.x; Goormaghtigh E, 1994, Subcell Biochem, V23, P329; GOTTESMAN MM, 1993, CANCER RES, V53, P747; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; KAUPPINEN JK, 1981, APPL OPTICS, V20, P1866, DOI 10.1364/AO.20.001866; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; Loo TW, 1999, J BIOL CHEM, V274, P24759, DOI 10.1074/jbc.274.35.24759; Margolles A, 1999, BIOCHEMISTRY-US, V38, P16298, DOI 10.1021/bi990855s; Mechetner EB, 1997, P NATL ACAD SCI USA, V94, P12908, DOI 10.1073/pnas.94.24.12908; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; PASTAN I, 1991, ANNU REV MED, V42, P277, DOI 10.1146/annurev.med.42.1.277; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; Sonveaux N, 1996, J BIOL CHEM, V271, P24617, DOI 10.1074/jbc.271.40.24617; Sonveaux N, 1999, J BIOL CHEM, V274, P17649, DOI 10.1074/jbc.274.25.17649; SUSI H, 1986, BIOPOLYMERS, V25, P459; van Veen HW, 1998, NATURE, V391, P291, DOI 10.1038/34669; vanVeen HW, 1997, BIOL CHEM, V378, P769; VanVeen HW, 1996, P NATL ACAD SCI USA, V93, P10668, DOI 10.1073/pnas.93.20.10668; VIGNERON L, 1995, J BIOL CHEM, V270, P17685, DOI 10.1074/jbc.270.30.17685; Wang GC, 1997, BIOCHEM J, V328, P897, DOI 10.1042/bj3280897; Wang GC, 1998, EUR J BIOCHEM, V255, P383, DOI 10.1046/j.1432-1327.1998.2550383.x	34	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10962	10967		10.1074/jbc.275.15.10962	http://dx.doi.org/10.1074/jbc.275.15.10962			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753896	hybrid			2022-12-27	WOS:000086466600038
J	von Gersdorff, G; Susztak, K; Rezvani, F; Bitzer, M; Liang, D; Bottinger, EP				von Gersdorff, G; Susztak, K; Rezvani, F; Bitzer, M; Liang, D; Bottinger, EP			Smad3 and Smad4 mediate transcriptional activation of the human Smad7 promoter by transforming growth factor beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAD-RELATED PROTEIN; RECEPTOR; IDENTIFICATION; ANTAGONIST; ELEMENTS; BINDING; GENE	Smad7 is an inducible intracellular inhibitor of transforming growth factor-beta (TGF-beta) signaling that is regulated by diverse stimuli including members of the TGF-beta superfamily, To define the molecular mechanisms of negative control of TGF-beta signaling, we have isolated the human SMAD7 gene and characterized its promoter region. A -303 to +672 SMAD7 region contained a palindromic GTCTAGAC Smad binding element (SEE) between nucleotides -179 and -172 that was necessary for the induction of a Smad7 promoter luciferase reporter gene by TGF-beta, Electrophoretic mobility shift assays using oligonucleotide probes demonstrated that TGF-beta rapidly induced the binding of an endogenous SBE-binding complex (SBC) containing Smad2, Smad3, and Smad4. Transfection assays in mouse embryonic fibroblasts (MEFs), with targeted deletions of either Smad2 or Smad3, and the Smad4-deficient cell line MD-MBA-468 revealed that both Smad3 and Smad4, but not Smad2, were absolutely required for induction of the Smad7 promoter reporter gene by TGF-beta. Furthermore, the TGF-beta-inducible SEE-binding complex was diminished in Smad2-deficient MEFs when compared with wild type MEFs and not detectable in Smad3-deficient MEFs and MD-MBA-468 cells. Taken together, our data demonstrate that TGF-beta induces transcription of the human SMAD7 gene through activation of Smad3 and Smad4 transcription factor binding to its proximal promoter.	Albert Einstein Coll Med, Dept Med, Div Nephrol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Bottinger, EP (corresponding author), Albert Einstein Coll Med, Dept Med, Div Nephrol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Susztak, Katalin/ABE-7474-2021	Susztak, Katalin/0000-0002-1005-3726; Bitzer, Markus/0000-0002-3711-2984	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056077] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-56077-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1997, BBA-REV CANCER, V1333, pF105, DOI 10.1016/S0304-419X(97)00017-6; Ghiglione C, 1999, CELL, V96, P847, DOI 10.1016/S0092-8674(00)80594-2; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Heyer J, 1999, P NATL ACAD SCI USA, V96, P12595, DOI 10.1073/pnas.96.22.12595; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, J BIOL CHEM, V272, P2896, DOI 10.1074/jbc.272.5.2896; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Wong C, 1999, MOL CELL BIOL, V19, P1821; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	28	146	151	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11320	11326		10.1074/jbc.275.15.11320	http://dx.doi.org/10.1074/jbc.275.15.11320			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753944	hybrid			2022-12-27	WOS:000086466600086
J	Hoover, DM; Mizoue, LS; Handel, TM; Lubkowski, J				Hoover, DM; Mizoue, LS; Handel, TM; Lubkowski, J			The crystal structure of the chemokine domain of fractalkine shows a novel quaternary arrangement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSAMINOGLYCAN-BINDING; FUNCTIONAL EXPRESSION; CHEMOTACTIC RECEPTOR; CELL-ADHESION; IDENTIFICATION; CX(3)CR1; ACTIVATION; RANTES; FLOW; AGGREGATION	Fractalkine, or neurotactin, is a chemokine that is present in endothelial cells from several tissues, including brain, liver, and kidney. It is the only member of the CX3C class of chemokines. Fractalkine contains a chemokine domain (CDF) attached to a membrane-spanning domain via a mucin-like stalk. However, fractalkine can also be proteolytically cleaved from its membrane-spanning domain to release a freely diffusible form. Fractalkine attracts and immobilizes leukocytes by binding to its receptor, CX(3)CR1. The x-ray crystal structure of CDF has been solved and refined to 2.0 Angstrom resolution. The CDF monomers form a dimer through an intermolecular beta-sheet, This interaction is somewhat similar to that seen in other dimeric CC chemokine crystal structures. However, the displacement of the first disulfide in CDF causes the dimer to assume a more compact quaternary structure relative to CC chemokines, which is unique to CX3C chemokines, Although fractalkine can bind to heparin in vitro, as shown by comparison of electrostatic surface plots with other chemokines and by heparin chromatography, the role of this property in vivo is not well understood.	NCI, Frederick Canc Res & Dev Ctr, Program Struct Biol, Macromol Crystallog Lab, Frederick, MD 21702 USA; Univ Calif Berkeley, Dept Cell & Mol Biol, Berkeley, CA 94720 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of California System; University of California Berkeley	Lubkowski, J (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Program Struct Biol, Macromol Crystallog Lab, Frederick, MD 21702 USA.							Appay V, 1999, J BIOL CHEM, V274, P27505, DOI 10.1074/jbc.274.39.27505; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; BARGATZE RF, 1993, J EXP MED, V178, P367, DOI 10.1084/jem.178.1.367; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Boddeke EWGH, 1999, EUR J PHARMACOL, V374, P309, DOI 10.1016/S0014-2999(99)00307-6; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chakravarty L, 1998, J BIOL CHEM, V273, P29641, DOI 10.1074/jbc.273.45.29641; CLORE GM, 1995, FASEB J, V9, P57, DOI 10.1096/fasebj.9.1.7821760; Cohen GH, 1997, J APPL CRYSTALLOGR, V30, P1160, DOI 10.1107/S0021889897006729; Combadiere C, 1998, BIOCHEM BIOPH RES CO, V253, P728, DOI 10.1006/bbrc.1998.9849; Combadiere C, 1998, J BIOL CHEM, V273, P23799, DOI 10.1074/jbc.273.37.23799; Coulin F, 1997, EUR J BIOCHEM, V248, P507, DOI 10.1111/j.1432-1033.1997.00507.x; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Czaplewski LG, 1999, J BIOL CHEM, V274, P16077, DOI 10.1074/jbc.274.23.16077; Dealwis C, 1998, P NATL ACAD SCI USA, V95, P6941, DOI 10.1073/pnas.95.12.6941; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; Graham GJ, 1996, EMBO J, V15, P6506, DOI 10.1002/j.1460-2075.1996.tb01041.x; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; Haskell CA, 1999, J BIOL CHEM, V274, P10053, DOI 10.1074/jbc.274.15.10053; HONDA S, 1994, J IMMUNOL, V152, P4026; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; HOOVER DM, 2000, IN PRESS PROT PEPT L; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; Koopmann W, 1997, J BIOL CHEM, V272, P10103; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuschert GSV, 1998, BIOCHEMISTRY-US, V37, P11193, DOI 10.1021/bi972867o; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; Lubkowski J, 1997, NAT STRUCT BIOL, V4, P64, DOI 10.1038/nsb0197-64; Mizoue LS, 1999, BIOCHEMISTRY-US, V38, P1402, DOI 10.1021/bi9820614; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Pan Y, 1997, NATURE, V387, P611, DOI 10.1038/42491; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; Proudfoot AEI, 1998, EUR J DERMATOL, V8, P147; Shao WP, 1998, FEBS LETT, V441, P77, DOI 10.1016/S0014-5793(98)01520-8; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9	43	49	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23187	23193		10.1074/jbc.M002584200	http://dx.doi.org/10.1074/jbc.M002584200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10770945	hybrid			2022-12-27	WOS:000088419400080
J	Hosoya, M; Kawamata, Y; Fukusumi, S; Fujii, R; Habata, Y; Hinuma, S; Kitada, C; Honda, S; Kurokawa, T; Onda, H; Nishimura, O; Fujino, M				Hosoya, M; Kawamata, Y; Fukusumi, S; Fujii, R; Habata, Y; Hinuma, S; Kitada, C; Honda, S; Kurokawa, T; Onda, H; Nishimura, O; Fujino, M			Molecular and functional characteristics of APJ - Tissue distribution of mRNA and interaction with the endogenous ligand apelin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; RECEPTOR APJ; PEPTIDE; IDENTIFICATION; BRAIN	We have recently identified apelin as the endogenous ligand for human APJ. In rats, the highest expression of APJ mRNA was detected in the lung, suggesting that APJ and its ligand play an important role in the pulmonary system. When apelin-36 and its pyroglutamylated C-terminal peptide, [<Glu(65)]apelin-13, were compared in microphysiometric analyses, the elevation of extracellular acidification induced in cells expressing APJ by [<Glu(65)]apelin-13 was transient, whereas that by apelin-36 was sustained. These responses were almost completely inhibited by a specific inhibitor for G(i) or that for Na+/H+ exchanger. I-125 -Labeled [<Glu(65)]apelin-13 analogue specifically bound to APJ with a high affinity, and [<Glu(65)]apelin-13 was more potent than apelin-36 in competitive inhibition assays. Because pretreatment with apelin-36 but not [<Glu(65)]apelin-13 drastically reduced the binding of the labeled apelin to APJ, the different patterns of acidification induced by these two peptides appeared to reflect their dissociation rather than association with APJ. Apelin elicited the migration of APJ-expressing cells, and [<Glu(65)]apelin-13 was more potent than apelin-36 in this activity. Heterogeneous molecular forms of apelin corresponding to apelin-36 and [<Glu(65)]apelin-13 were produced in bovine colostrum. Apelin-36 and [<Glu(65)]apelin-13 might have different functions in vivo and in vitro.	Takeda Chem Ind Ltd, Div Discovery Res, Tsukuba, Ibaraki 3004293, Japan	Takeda Chemical Industries	Hinuma, S (corresponding author), Takeda Chem Ind Ltd, Div Discovery Res, Wadai 10, Tsukuba, Ibaraki 3004293, Japan.			Kawamata, Yuji/0000-0001-5652-4899				BOHLEN P, 1980, BIOCHEM BIOPH RES CO, V96, P725, DOI 10.1016/0006-291X(80)91415-1; Choe H, 1998, J VIROL, V72, P6113, DOI 10.1128/JVI.72.7.6113-6118.1998; Edinger AL, 1998, J VIROL, V72, P7934, DOI 10.1128/JVI.72.10.7934-7940.1998; Fukusumi S, 1997, BIOCHEM BIOPH RES CO, V232, P157, DOI 10.1006/bbrc.1997.6252; Habata Y, 1999, BBA-MOL CELL RES, V1452, P25, DOI 10.1016/S0167-4889(99)00114-7; Hinuma S, 1999, J MOL MED, V77, P495, DOI 10.1007/s001090050403; Hinuma S, 1998, NATURE, V393, P272, DOI 10.1038/30515; Hoffman TL, 1998, P NATL ACAD SCI USA, V95, P11360, DOI 10.1073/pnas.95.19.11360; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; NEVE KA, 1995, METH NEUROSCI, V25, P225; ODOWD BF, 1993, GENE, V136, P355, DOI 10.1016/0378-1119(93)90495-O; OHTAKI T, 1990, BIOCHEM BIOPH RES CO, V171, P838, DOI 10.1016/0006-291X(90)91222-E; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489	15	395	440	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21061	21067		10.1074/jbc.M908417199	http://dx.doi.org/10.1074/jbc.M908417199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10777510	hybrid			2022-12-27	WOS:000088230600015
J	Stabach, PR; Morrow, JS				Stabach, PR; Morrow, JS			Identification and characterization of beta V spectrin, a mammalian ortholog of Drosophila beta(H) spectrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AVIAN BRUSH-BORDER; PLASMA-MEMBRANE; BINDING-SITE; ANKYRIN; PROTEINS; SEGMENTS; FODRIN; BETA(HEAVY)-SPECTRIN; TRANSPORT; SKELETON	Four mammalian beta-spectrin genes are currently recognized, all encode proteins of approximate to 240-280,000 M-r and display 17 triple helical homologous approximate to 106-residue repeat units. In Drosophila and Caenorhabditis elegans, a variant beta spectrin with unusual properties has been recognized. Termed beta heavy (beta(H)), this spectrin contains 30 spectrin repeats, has a molecular weight in excess of 400,000, and associates with the apical domain of polarized epithelia, We have cloned and characterized from a human retina cDNA library a mammalian ortholog of Drosophila beta(H) spectrin, and in accord with standard spectrin naming conventions we term this new mammalian spectrin beta 5 (beta V) The gene for human beta V spectrin (HUBSPECV) is on chromosome 15q21. The 11,722-nucleotide cDNA of beta V spectrin is generated from 68 exons and is predicted to encode a protein with a molecular weight of 416,960. Like its fly counterpart, the derived amino acid sequence of this unusual mammalian spectrin displays 30 spectrin repeats, a modestly conserved actin-binding domain, a conserved membrane association domain 1, a conserved self-association domain, and a pleckstrin homology domain near its COOH terminus. Its putative ankyrin-binding domain is poorly conserved and may be inactive. These structural features suggest that beta V spectrin is likely to form heterodimers and oligomers with alpha spectrin and to interact directly with cellular membranes. Unlike its Drosophila ortholog, beta V spectrin does not contain an SH3 domain but displays in repeat 5 a 45-residue insertion that displays 42% identity to amino acids 85-115 of the E4 protein of type 75 human papilloma virus. Human beta V spectrin is expressed at low levels in many tissues. By indirect immunofluorescence, it is detected prominently in the outer segments of photoreceptor rods and cones and in the basolateral membrane and cytosol of gastric epithelial cells. Unlike its Drosophila ortholog, a distinct apical distribution of beta V spectrin is inapparent in the epithelial cell populations examined, although it is confined to the outer segments of photoreceptor cells. The complete cDNA sequence of human beta V spectrin is available from GenBank(TM) as accession number AF233523.	Yale Univ, Dept Pathol, New Haven, CT 06510 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06510 USA	Yale University; Yale University	Morrow, JS (corresponding author), Yale Univ, Dept Pathol, 310 Cedar St, New Haven, CT 06510 USA.	jon.morrow@yale.edu						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Campbell DA, 1997, J MED GENET, V34, P1015, DOI 10.1136/jmg.34.12.1015; CARBONI JM, 1987, AM J PATHOL, V129, P589; De Matteis MA, 1998, CURR OPIN CELL BIOL, V10, P542, DOI 10.1016/S0955-0674(98)80071-9; De Matteis MA, 2000, J CELL SCI, V113, P2331; Devarajan P, 1997, P NATL ACAD SCI USA, V94, P10711, DOI 10.1073/pnas.94.20.10711; Devarajan P, 1996, J CELL BIOL, V133, P819, DOI 10.1083/jcb.133.4.819; Dillon DA, 1998, AM J PATHOL, V152, P75; DRENCKHAHN D, 1987, EUR J CELL BIOL, V43, P479; DUBREUIL RR, 1990, J CELL BIOL, V111, P1849, DOI 10.1083/jcb.111.5.1849; GLENNEY JR, 1983, CELL MOTIL CYTOSKEL, V3, P671, DOI 10.1002/cm.970030531; Grum VL, 1999, CELL, V98, P523, DOI 10.1016/S0092-8674(00)81980-7; HARRIS AS, 1988, J BIOL CHEM, V263, P15754; HARTWIG JH, 1994, PROTEIN PROFILE, V1, P711; Hentati A, 1998, NEUROGENETICS, V2, P55, DOI 10.1007/s100480050052; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOWE CL, 1985, J CELL BIOL, V101, P1379, DOI 10.1083/jcb.101.4.1379; ISAYAMA T, 1991, J NEUROSCI, V11, P3531; Jamieson CR, 1999, AM J HUM GENET, V65, P1465, DOI 10.1086/302640; KENNEDY SP, 1991, J CELL BIOL, V115, P267, DOI 10.1083/jcb.115.1.267; KENNEDY SP, 1994, J BIOL CHEM, V269, P11400; KHATI C, 1993, NEUROLOGY, V43, P1131, DOI 10.1212/WNL.43.6.1131; LOMBARDO CR, 1994, J BIOL CHEM, V269, P29212; Lue AJC, 1999, HEARING RES, V135, P163, DOI 10.1016/S0378-5955(99)00102-1; MACDONALD RI, 1994, P NATL ACAD SCI USA, V91, P1299, DOI 10.1073/pnas.91.4.1299; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; McKeown C, 1998, DEVELOPMENT, V125, P2087; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; Pascual J, 1997, BIOESSAYS, V19, P811, DOI 10.1002/bies.950190911; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHMITZ B, 1993, HISTOCHEMISTRY, V100, P473, DOI 10.1007/BF00267828; SPEICHER DW, 1992, J BIOL CHEM, V267, P14775; SPENCER M, 1991, INVEST OPHTH VIS SCI, V32, P1; THOMAS GH, 1994, DEVELOPMENT, V120, P2039; Thomas GH, 1998, DEVELOPMENT, V125, P2125; Thomas GH, 1997, MOL BIOL EVOL, V14, P1285, DOI 10.1093/oxfordjournals.molbev.a025738; VIEL A, 1994, P NATL ACAD SCI USA, V91, P10839, DOI 10.1073/pnas.91.23.10839; Villamar M, 1999, AM J HUM GENET, V64, P1238, DOI 10.1086/302321; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; WINKELMANN JC, 1993, BLOOD, V81, P3173; Worth PF, 1999, AM J HUM GENET, V65, P420, DOI 10.1086/302495; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097; Zhou DX, 1998, J CELL BIOL, V143, P1295, DOI 10.1083/jcb.143.5.1295; 1994, PIERCE CATALOG HDB, pT116	46	62	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21385	21395		10.1074/jbc.C000159200	http://dx.doi.org/10.1074/jbc.C000159200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10764729	hybrid			2022-12-27	WOS:000088230600058
J	Han, MK; Cho, YS; Kim, YS; Yim, CY; Kim, UH				Han, MK; Cho, YS; Kim, YS; Yim, CY; Kim, UH			Interaction of two classes of ADP-ribose transfer reactions in immune signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE ADENINE-DINUCLEOTIDE; NAD(+) GLYCOHYDROLASE ACTIVITY; RIBOSYLTRANSFERASE ACTIVITY; T-LYMPHOCYTES; HUMAN CD38; SURFACE; PURIFICATION; ERYTHROCYTES; CYSTEINE; ACID	CD38 is a bifunctional ectoenzyme predominantly expressed on hematopoietic cells where its expression correlates with differentiation and proliferation. The two enzyme activities displayed by CD38 are an ADP-ribosyl cyclase and a cyclic adenosine diphosphate ribose (cADPR) hydrolase that catalyzes the synthesis and hydrolysis of cADPR, T lymphocytes can be induced to express CD38 when activated with antibodies against specific antigen receptors, If the activated T cells are then exposed with NAD, cell death by apoptosis occurs. During the exposure of activated T cells to NAD, the CD38 is modified by ecto-mono-ADP-ribosyltransferases (ecto-mono-ADPRTs) specific for cysteine and arginine residues. Arginine-ADP-ribosylation results in inactivation of both cyclase and hydrolase activities of CD38, whereas cysteine-ADP-ribosylation results only in the inhibition of the hydrolase activity. The arginine-ADP-ribosylation causes a decrease in intracellular cADPR and a subsequent decrease in Ca2+ influx, resulting in apoptosis of the activated T cells. Our results suggest that the interaction of two classes of ecto-ADP-ribose transfer enzymes plays an important role in immune regulation by the selective induction of apoptosis in activated T cells and that cADPR mediated signaling is essential for the survival of activated T cells.	Chonbuk Natl Univ, Sch Med, Dept Biochem, Chonju 561182, Chonbuk, South Korea; Chonbuk Natl Univ, Sch Med, Dept Internal Med, Chonju 561182, Chonbuk, South Korea; Chonbuk Natl Univ, Sch Med, Inst Med Sci, Chonju 561182, Chonbuk, South Korea	Jeonbuk National University; Jeonbuk National University; Jeonbuk National University	Kim, UH (corresponding author), Chonbuk Natl Univ, Sch Med, Dept Biochem, Chonju 561182, Chonbuk, South Korea.			/0000-0002-6224-6685; Han, Myung-Kwan/0000-0003-1931-8898; Kim, Uh-Hyun/0000-0003-3304-7190				Ebihara S, 1997, J BIOL CHEM, V272, P16023, DOI 10.1074/jbc.272.25.16023; FURANO A, 1995, FUND CLIN IMMUNOL, V3, P101; GRAEFF RM, 1994, J BIOL CHEM, V269, P30260; GREEN S, 1971, BIOCHEMISTRY-US, V10, P2496, DOI 10.1021/bi00789a011; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guse AH, 1999, NATURE, V398, P70, DOI 10.1038/18024; Han MK, 1996, BIOCHEM J, V318, P903, DOI 10.1042/bj3180903; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; JACKSON DG, 1990, J IMMUNOL, V144, P2811; KIM H, 1993, SCIENCE, V261, P1330, DOI 10.1126/science.8395705; KIM UH, 1993, ARCH BIOCHEM BIOPHYS, V305, P147, DOI 10.1006/abbi.1993.1404; Klebl BM, 1996, ANAL BIOCHEM, V239, P145, DOI 10.1006/abio.1996.0309; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; LEE HC, 1989, J BIOL CHEM, V264, P1608; LIBERMAN I, 1957, J BIOL CHEM, V225, P883; LUND F, 1995, IMMUNOL TODAY, V16, P469, DOI 10.1016/0167-5699(95)80029-8; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mehta K, 1996, FASEB J, V10, P1408, DOI 10.1096/fasebj.10.12.8903511; Moss J, 1997, J BIOL CHEM, V272, P4342, DOI 10.1074/jbc.272.7.4342; Okamoto S, 1998, J IMMUNOL, V160, P4190; SANTOSARGUMEDO L, 1993, J IMMUNOL, V151, P3119; SAXTY BA, 1995, BIOCHEM J, V310, P931, DOI 10.1042/bj3100931; TAKAHASHI K, 1995, FEBS LETT, V371, P204, DOI 10.1016/0014-5793(95)00914-U; TOHGO A, 1994, J BIOL CHEM, V269, P28555; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; VOLWERK JJ, 1989, J CELL BIOCHEM, V39, P315, DOI 10.1002/jcb.240390311; WANG J, 1994, J IMMUNOL, V153, P4048; Wu Y, 1997, SCIENCE, V278, P2126, DOI 10.1126/science.278.5346.2126; YIM CY, 1994, J IMMUNOL, V152, P5796; Zocchi E, 1999, FASEB J, V13, P273, DOI 10.1096/fasebj.13.2.273; Zocchi E, 1996, FEBS LETT, V396, P327, DOI 10.1016/0014-5793(96)01125-8; ZOCCHI E, 1993, BIOCHEM BIOPH RES CO, V196, P1459, DOI 10.1006/bbrc.1993.2416; ZOLKIEWSKA A, 1992, P NATL ACAD SCI USA, V89, P11352, DOI 10.1073/pnas.89.23.11352	33	50	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20799	20805		10.1074/jbc.M001189200	http://dx.doi.org/10.1074/jbc.M001189200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10777496	hybrid			2022-12-27	WOS:000088084500082
J	Nieto, N; Greenwel, P; Friedman, SL; Zhang, F; Dannenberg, AJ; Cederbaum, AI				Nieto, N; Greenwel, P; Friedman, SL; Zhang, F; Dannenberg, AJ; Cederbaum, AI			Ethanol and arachidonic acid increase alpha 2(I) collagen expression in rat hepatic stellate cells overexpressing cytochrome P450 2E1 - Role of H2O2 and cyclooxygenase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; ALCOHOLIC LIVER-INJURY; NECROSIS-FACTOR-ALPHA; LIPID-PEROXIDATION; GENE-TRANSCRIPTION; HYDROGEN-PEROXIDE; MESSENGER-RNA; DEPENDENT PRODUCTION; INDUCTION; FIBROSIS	The ability of ethanol and arachidonic acid (AA), as inducers of oxidative stress and key factors in alcoholic liver disease, to up-regulate alpha 2 collagen type I (COL1A2) gene expression was studied in a hepatic stellate cell line overexpressing the ethanol-inducible cytochrome P450 2E1 (CYP2E1) (E5 cells). A time- and dose-dependent induction in COL1A2 mRNA by ethanol or AA was observed that was prevented by diallylsulfide, a CYP2E1 inhibitor, Nuclear run-on experiments showed transcriptional activation of the COL1A2 gene by ethanol and Ak Catalase abrogated the increase in COL1A2 mRNA suggesting an H2O2-dependent mechanism. Cyclooxygenase-2 (COX-2) levels and production of prostaglandin E-2 upon addition of AA were elevated in the E5 cells. Incubation with NS-398, a COX-2 inhibitor, blocked the effect of AA, but not of ethanol, on COL1A2 expression suggesting that CYP2E1 activates COX-2 expression, and the oxidation of AA by COX-2 is responsible for the increase in COL1A2. Activity of a reporter construct driven by -378 base pairs of the proximal promoter region of the COL1A2 gene increased in E5 but not control cells and was further increased by ethanol or AA. These experiments link CYP2E1-dependent oxidative stress to induction of COX-2 and the actions of ethanol and AA on activation of collagen gene expression in hepatic stellate cells.	Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Med & Liver Dis, New York, NY 10029 USA; Cornell Univ, Weill Med Coll, Dept Cardiothorac Surg, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Med, New York, NY 10021 USA; Strang Canc Prevent Ctr, New York, NY 10021 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Cornell University; Cornell University	Cederbaum, AI (corresponding author), Mt Sinai Sch Med, Dept Biochem & Mol Biol, 1 Gustave L Levy Pl, New York, NY 10029 USA.	Arthur.Cederbaum@mssm.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037340] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA006610, R56AA003312, R01AA006610, R01AA003312] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA03312, AA06610] Funding Source: Medline; NIDDK NIH HHS [DK37340] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adderley SR, 1999, J BIOL CHEM, V274, P5038, DOI 10.1074/jbc.274.8.5038; Albano E, 1996, HEPATOLOGY, V23, P155, DOI 10.1002/hep.510230121; Albano Emanuele, 1999, Frontiers in Bioscience, V4, pd533, DOI 10.2741/Albano; BEDOSSA P, 1994, HEPATOLOGY, V19, P1262, DOI 10.1016/0270-9139(94)90876-1; BOAST S, 1990, J BIOL CHEM, V265, P13351; Boigk G, 1997, HEPATOLOGY, V26, P643, DOI 10.1053/jhep.1997.v26.pm0009303494; BRADY JF, 1991, CHEM RES TOXICOL, V4, P642, DOI 10.1021/tx00024a008; BRENNER DA, 1987, J BIOL CHEM, V262, P17690; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; Casini A, 1997, HEPATOLOGY, V25, P361; Casini A, 1998, J HEPATOL, V28, P40, DOI 10.1016/S0168-8278(98)80200-6; CASTILLO T, 1992, HEPATOLOGY, V16, P992, DOI 10.1002/hep.1840160423; Chen Q, 1997, J BIOL CHEM, V272, P14532, DOI 10.1074/jbc.272.23.14532; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; EKSTROM G, 1989, BIOCHEM PHARMACOL, V38, P1313, DOI 10.1016/0006-2952(89)90338-9; FENG L, 1995, J CLIN INVEST, V95, P1669, DOI 10.1172/JCI117842; FRENCH SW, 1997, J NUTR, V127, P907; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; Garcia-Trevijano ER, 1999, HEPATOLOGY, V29, P960, DOI 10.1002/hep.510290346; GORSKY LD, 1984, J BIOL CHEM, V259, P6812; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; Greenwel P, 2000, HEPATOLOGY, V31, P109, DOI 10.1002/hep.510310118; HURST JS, 1989, BIOCHEM PHARMACOL, V38, P3357, DOI 10.1016/0006-2952(89)90634-5; INAGAKI Y, 1995, J BIOL CHEM, V270, P3353, DOI 10.1074/jbc.270.7.3353; INAGAKI Y, 1995, HEPATOLOGY, V22, P573, DOI 10.1016/0270-9139(95)90582-0; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; Kawada N, 1997, HISTOL HISTOPATHOL, V12, P1069; Kawada N, 1998, HEPATOLOGY, V27, P1265, DOI 10.1002/hep.510270512; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; KOOP DR, 1990, BIOESSAYS, V12, P429, DOI 10.1002/bies.950120906; Kotake Y, 1998, BBA-MOL CELL RES, V1448, P77, DOI 10.1016/S0167-4889(98)00126-8; KUYPERS FA, 1987, BIOCHIM BIOPHYS ACTA, V921, P266, DOI 10.1016/0005-2760(87)90027-0; Li D, 1999, J GASTROEN HEPATOL, V14, P618, DOI 10.1046/j.1440-1746.1999.01928.x; Lieber CS, 1999, ALCOHOL CLIN EXP RES, V23, P991, DOI 10.1111/j.1530-0277.1999.tb04217.x; Lieber CS, 1997, PHYSIOL REV, V77, P517, DOI 10.1152/physrev.1997.77.2.517; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAIORINO M, 1988, BIOCHEM PHARMACOL, V37, P2267, DOI 10.1016/0006-2952(88)90591-6; Matsuura H, 1999, J BIOL CHEM, V274, P29138, DOI 10.1074/jbc.274.41.29138; MORIMOTO M, 1995, HEPATOLOGY, V21, P1610, DOI 10.1016/0270-9139(95)90466-2; MULLER A, 1984, BIOCHEM PHARMACOL, V33, P3235, DOI 10.1016/0006-2952(84)90083-2; MYERS JC, 1983, J BIOL CHEM, V258, P128; NANJI AA, 1994, ALCOHOL CLIN EXP RES, V18, P1280, DOI 10.1111/j.1530-0277.1994.tb00119.x; NANJI AA, 1995, J LIPID RES, V36, P736; Nanji AA, 1997, HEPATOLOGY, V26, P1538, DOI 10.1002/hep.510260622; NANJI AA, 1989, LIFE SCI, V44, P223, DOI 10.1016/0024-3205(89)90599-7; Niemela O, 1998, ALCOHOL CLIN EXP RES, V22, P2118, DOI 10.1111/j.1530-0277.1998.tb05925.x; Nieto N, 1999, HEPATOLOGY, V30, P987, DOI 10.1002/hep.510300433; NORDMANN R, 1992, FREE RADICAL BIO MED, V12, P219, DOI 10.1016/0891-5849(92)90030-K; Oinonen T, 1998, BIOCHEM PHARMACOL, V56, P1075, DOI 10.1016/S0006-2952(98)00062-8; PARES A, 1994, HEPATOLOGY, V19, P498, DOI 10.1016/0270-9139(94)90030-2; PIETRANGELO A, 1995, J CLIN INVEST, V95, P1824, DOI 10.1172/JCI117861; Pratico D, 1998, J INVEST MED, V46, P51; RASHBASTEP J, 1993, ARCH BIOCHEM BIOPHYS, V300, P401, DOI 10.1006/abbi.1993.1054; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; SONG BJ, 1986, J BIOL CHEM, V261, P6689; Thomas CE, 1996, J BIOL CHEM, V271, P3097, DOI 10.1074/jbc.271.6.3097; THURMAN RG, 1973, MOL PHARMACOL, V9, P670; Tsugawa K, 1999, J GASTROEN HEPATOL, V14, P642, DOI 10.1046/j.1440-1746.1999.01930.x; TSUKAMOTO H, 1990, SEMIN LIVER DIS, V10, P56, DOI 10.1055/s-2008-1040457; Yamada T, 1997, LIFE SCI, V61, P171, DOI 10.1016/S0024-3205(97)00372-X; Zhang F, 1998, J BIOL CHEM, V273, P2424, DOI 10.1074/jbc.273.4.2424	62	104	112	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					20136	20145		10.1074/jbc.M001422200	http://dx.doi.org/10.1074/jbc.M001422200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10770928	hybrid			2022-12-27	WOS:000087941300095
J	Watanabe, YH; Motohashi, K; Taguchi, H; Yoshida, M				Watanabe, YH; Motohashi, K; Taguchi, H; Yoshida, M			Heat-inactivated proteins managed by DnaKJ-GrpE-ClpB chaperones are released as a chaperonin-recognizable non-native form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMUS-THERMOPHILUS; ESCHERICHIA-COLI; GROEL-GROES; CRYSTAL-STRUCTURE; FUNCTIONAL CYCLE; ATPASE ACTIVITY; HSP104; SYSTEM; HSP70; MECHANISM	Chaperones of Thermus thermophilus cooperate in reactivation of heat-inactivated proteins. The protein, inactivated at a high temperature in a TDnaKJ-GrpE set, recovered its activity during subsequent incubation with TClpB at moderate temperature (Motohashi, K., Watanabe, Y., Yohda, M., and Yoshida, M. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 7184-7189). Here, we report that the addition of chaperonin (Tcpn) at moderate temperature improves the yield of the TDnaKJ-GrpE-ClpB-dependent reactivation. The trap-Tcpn, which binds substrate protein but does not release it, inhibits reactivation severely. Maximum recovery is gained at substoichiometric amounts of each component of TDnaKJ, TGrpE, and TClpB relative to the substrate monomer, These observations indicate that, driven by ATP hydrolysis, TDnaRJ-GrpE-ClpB chaperones catalytically cooperate and release heat-inactivated protein as a non-native, chaperonin-recognizable folding intermediate.	Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan	Tokyo Institute of Technology	Yoshida, M (corresponding author), Tokyo Inst Technol, Chem Resources Lab, R-1,Nagatsuta 4259, Yokohama, Kanagawa 2268503, Japan.	myoshida@res.titech.ac.jp	Motohashi, Ken/I-4970-2019; Taguchi, Hideki/B-6946-2009; taguchi, hideki/AAM-2663-2021	Motohashi, Ken/0000-0002-8414-2836; Taguchi, Hideki/0000-0002-6612-9339; taguchi, hideki/0000-0002-6612-9339				AMADA K, 1995, J BIOCHEM-TOKYO, V118, P347, DOI 10.1093/oxfordjournals.jbchem.a124913; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Buchberger A, 1996, J MOL BIOL, V261, P328, DOI 10.1006/jmbi.1996.0465; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Diamant S, 1998, BIOCHEMISTRY-US, V37, P9688, DOI 10.1021/bi980338u; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; GOTTESMAN S, 1990, P NATL ACAD SCI USA, V87, P3513, DOI 10.1073/pnas.87.9.3513; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; Klostermeier D, 1998, J MOL BIOL, V279, P841, DOI 10.1006/jmbi.1998.1816; Klostermeier D, 1999, J MOL BIOL, V287, P511, DOI 10.1006/jmbi.1999.2636; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; MOTOHASHI K, 1994, J BIOL CHEM, V269, P27074; Motohashi K, 1996, J BIOL CHEM, V271, P17343, DOI 10.1074/jbc.271.29.17343; Motohashi K, 1997, FEBS LETT, V412, P633, DOI 10.1016/S0014-5793(97)00847-8; OKUNO H, 1985, Journal of Applied Biochemistry, V7, P192; Packschies L, 1997, BIOCHEMISTRY-US, V36, P3417, DOI 10.1021/bi962835l; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; Rye HS, 1999, CELL, V97, P325, DOI 10.1016/S0092-8674(00)80742-4; Sakikawa C, 1999, J BIOL CHEM, V274, P21251, DOI 10.1074/jbc.274.30.21251; SANCHEZ Y, 1993, J BACTERIOL, V175, P6484, DOI 10.1128/jb.175.20.6484-6491.1993; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Taguchi H, 1998, METHOD ENZYMOL, V290, P169, DOI 10.1016/S0076-6879(98)90017-9; TAGUCHI H, 1991, J BIOL CHEM, V266, P22411; TAGUCHI H, 1993, J BIOL CHEM, V268, P5371; Veinger L, 1998, J BIOL CHEM, V273, P11032, DOI 10.1074/jbc.273.18.11032; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; WOO KM, 1992, J BIOL CHEM, V267, P20429; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083; Zolkiewski M, 1999, PROTEIN SCI, V8, P1899, DOI 10.1110/ps.8.9.1899	39	19	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12388	12392		10.1074/jbc.275.17.12388	http://dx.doi.org/10.1074/jbc.275.17.12388			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777521	hybrid			2022-12-27	WOS:000086762300005
J	Douki, T; Court, M; Sauvaigo, S; Odin, F; Cadet, J				Douki, T; Court, M; Sauvaigo, S; Odin, F; Cadet, J			Formation of the main UV-induced thymine dimeric lesions within isolated and cellular DNA as measured by high performance liquid chromatography-tandem mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOBUTANE PYRIMIDINE DIMERS; ULTRAVIOLET-LIGHT; IRRADIATED DNA; CIS-SYN; 6-4 PHOTOPRODUCTS; PYRIMIDINE(6-4)PYRIMIDONE PHOTOPRODUCTS; BIOLOGICAL ROLE; DETECTION ASSAY; QUANTUM YIELDS; ACTION SPECTRA	UVB radiation-induced formation of dimeric photoproducts at bipyrimidine sites within DNA has been unambiguously associated with the lethal and mutagenic properties of sunlight. The main lesions include the cyclobutane pyrimidine dimers and the pyrimidine (6-4) pyrimidone adducts. The latter compounds have been shown in model systems to be converted into their Dewar valence isomers upon exposure to UVB Light. A new direct assay, based on the use of liquid chromatography coupled to tandem mass spectrometry, is now available to simultaneously detect each of the thymine photoproducts. It was applied to the determination of the yields of formation of the thymine lesions within both isolated and cellular DNA exposed to either UVC or UVB radiation. The cis-syn cyclobutane thymine dimer was found to be the major photoproduct within cellular DNA, whereas the related (6-4) adduct was produced in an approximately 8-fold lower yield. Interestingly, the corresponding Dewar valence isomer could not be detected upon exposure of human cells to biologically relevant doses of UVB radiation.	CEA, DRFMC, Serv Chim Inorgan & Biol, Lab Les Acides Nucl, F-38054 Grenoble 9, France	CEA	Cadet, J (corresponding author), CEA, DRFMC, Serv Chim Inorgan & Biol, Lab Les Acides Nucl, 17 Ave Martyrs, F-38054 Grenoble 9, France.		Cadet, Jean/M-2971-2018; Thierry, Douki/H-2108-2018	Cadet, Jean/0000-0003-2594-9485; Thierry, Douki/0000-0002-5022-071X				BENHUR E, 1968, BIOCHIM BIOPHYS ACTA, V166, P9, DOI 10.1016/0005-2787(68)90485-1; BERG RJW, 1993, CARCINOGENESIS, V14, P103, DOI 10.1093/carcin/14.1.103; BEUKERS R, 1960, BIOCHIM BIOPHYS ACTA, V41, P550, DOI 10.1016/0006-3002(60)90063-9; Black HS, 1997, J PHOTOCH PHOTOBIO B, V40, P29, DOI 10.1016/S1011-1344(97)00021-3; BLACK HS, 1997, J PHOTOCH PHOTOBIO B, V46, P1043; BRAGGAAR H, 1985, MUTAT RES, V142, P75, DOI 10.1016/0165-7992(85)90043-0; BYKOV VJ, 1995, CARCINOGENESIS, V16, P113, DOI 10.1093/carcin/16.1.113; CADET J, 1983, J CHROMATOGR, V280, P99, DOI 10.1016/S0021-9673(00)91543-7; CADET J, 1990, BIOORGANIC PHOTOCHEM, V1, P1; CHADWICK CA, 1995, J PHOTOCH PHOTOBIO B, V28, P163, DOI 10.1016/1011-1344(94)07096-7; CLINGEN PH, 1995, CANCER RES, V55, P2245; COOHILL TP, 1987, PHOTOCHEM PHOTOBIOL, V46, P1043, DOI 10.1111/j.1751-1097.1987.tb04891.x; DARDALHON M, 1994, PHOTOCHEM PHOTOBIOL, V59, P423, DOI 10.1111/j.1751-1097.1994.tb05059.x; Douki T, 1999, PHOTOCHEM PHOTOBIOL, V70, P184, DOI 10.1111/j.1751-1097.1999.tb07988.x; DOUKI T, 1995, CHEM RES TOXICOL, V8, P244, DOI 10.1021/tx00044a010; DOUKI T, 1992, J PHOTOCH PHOTOBIO B, V15, P199, DOI 10.1016/1011-1344(92)85124-D; Douki T, 1997, PHOTOCHEM PHOTOBIOL, V66, P171, DOI 10.1111/j.1751-1097.1997.tb08639.x; DOUKI T, 1995, INTERFACE CHEM BIOCH, P173; DOUKI T, 2000, IN PRESS J PHOTOCH B; Drouin R, 1997, PHOTOCHEM PHOTOBIOL, V66, P719, DOI 10.1111/j.1751-1097.1997.tb03213.x; DUMAZ N, 1993, P NATL ACAD SCI USA, V90, P10529, DOI 10.1073/pnas.90.22.10529; GARCES F, 1982, PHOTOCHEM PHOTOBIOL, V35, P9, DOI 10.1111/j.1751-1097.1982.tb03804.x; Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288; Jen J, 1997, PHOTOCHEM PHOTOBIOL, V65, P323, DOI 10.1111/j.1751-1097.1997.tb08565.x; Jing YQ, 1998, NUCLEIC ACIDS RES, V26, P3845, DOI 10.1093/nar/26.16.3845; KAN LS, 1988, BIOCHEMISTRY-US, V27, P5796, DOI 10.1021/bi00415a060; KIM JK, 1995, PHOTOCHEM PHOTOBIOL, V62, P44, DOI 10.1111/j.1751-1097.1995.tb05236.x; KUBITSCHEK HE, 1986, PHOTOCHEM PHOTOBIOL, V43, P443, DOI 10.1111/j.1751-1097.1986.tb05627.x; LECLERC JE, 1984, J MOL BIOL, V180, P217, DOI 10.1016/S0022-2836(84)80001-7; Lee JH, 1999, P NATL ACAD SCI USA, V96, P6632, DOI 10.1073/pnas.96.12.6632; LEMAIRE DGE, 1993, PHOTOCHEM PHOTOBIOL, V57, P755, DOI 10.1111/j.1751-1097.1993.tb09207.x; LIUZZI M, 1989, J BIOL CHEM, V264, P6355; Mamer OA, 1996, J CHROMATOGR B, V682, P182, DOI 10.1016/0378-4347(96)00055-2; MATSUNAGA T, 1993, PHOTOCHEM PHOTOBIOL, V57, P934, DOI 10.1111/j.1751-1097.1993.tb02952.x; MILLER JH, 1985, J MOL BIOL, V182, P45, DOI 10.1016/0022-2836(85)90026-9; MITCHELL DL, 1988, PHOTOCHEM PHOTOBIOL, V48, P51; MITCHELL DL, 1987, PHOTOCHEM PHOTOBIOL, V45, P781, DOI 10.1111/j.1751-1097.1987.tb07882.x; MITCHELL DL, 1990, RADIAT RES, V123, P299, DOI 10.2307/3577736; MITCHELL DL, 1991, PHOTOCHEM PHOTOBIOL, V54, P741, DOI 10.1111/j.1751-1097.1991.tb02084.x; MITCHELL DL, 1984, PHOTOCHEM PHOTOBIOL, V40, P743; MORI T, 1991, PHOTOCHEM PHOTOBIOL, V54, P225, DOI 10.1111/j.1751-1097.1991.tb02010.x; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; NIGGLI HJ, 1983, BIOCHEMISTRY-US, V22, P1390, DOI 10.1021/bi00275a011; PATRICK MH, 1976, PHOTOCHEM PHOTOBIOL, V24, P507, DOI 10.1111/j.1751-1097.1976.tb06867.x; PATRICK MH, 1977, PHOTOCHEM PHOTOBIOL, V25, P357, DOI 10.1111/j.1751-1097.1977.tb07355.x; PFEIFER GP, 1993, MUTAT RES, V288, P39, DOI 10.1016/0027-5107(93)90206-U; PFEIFER GP, 1991, P NATL ACAD SCI USA, V88, P1374, DOI 10.1073/pnas.88.4.1374; Podmore ID, 1996, PHOTOCHEM PHOTOBIOL, V64, P310, DOI 10.1111/j.1751-1097.1996.tb02463.x; POTAMAN VN, 1993, J CHROMATOGR, V648, P151, DOI 10.1016/0021-9673(93)83296-5; Pouget JP, 1999, INT J RADIAT BIOL, V75, P51, DOI 10.1080/095530099140807; RAHN OR, 1979, PHOTOCHEM PHOTOBIOL, V30, P317; Ravanat JL, 1998, J CHROMATOGR B, V715, P349, DOI 10.1016/S0378-4347(98)00259-X; Sauvaigo S, 1998, ANAL BIOCHEM, V259, P1, DOI 10.1006/abio.1998.2628; SEAWELL PC, 1980, J VIROL, V35, P790, DOI 10.1128/JVI.35.3.790-796.1980; Serrano J, 1996, RAPID COMMUN MASS SP, V10, P1789, DOI 10.1002/(SICI)1097-0231(199611)10:14<1789::AID-RCM752>3.0.CO;2-6; SIUZDAK G, 1994, P NATL ACAD SCI USA, V91, P11290, DOI 10.1073/pnas.91.24.11290; SWINTON DC, 1973, PHOTOCHEM PHOTOBIOL, V17, P361, DOI 10.1111/j.1751-1097.1973.tb06370.x; TAYLOR JS, 1990, PHOTOCHEM PHOTOBIOL, V51, P161, DOI 10.1111/j.1751-1097.1990.tb01698.x; TAYLOR JS, 1990, BIOCHEMISTRY-US, V29, P8858, DOI 10.1021/bi00489a049; TAYLOR JS, 1987, J AM CHEM SOC, V109, P2834, DOI 10.1021/ja00243a052; THOMAS DC, 1989, J BIOL CHEM, V264, P18005; Tung BS, 1996, MUTAT RES-DNA REPAIR, V362, P65, DOI 10.1016/0921-8777(95)00034-8; Wang YS, 1999, CHEM RES TOXICOL, V12, P1077, DOI 10.1021/tx9900831; WANI AA, 1984, PHOTOCHEM PHOTOBIOL, V40, P465, DOI 10.1111/j.1751-1097.1984.tb04619.x; WOOD RD, 1984, J MOL BIOL, V173, P273, DOI 10.1016/0022-2836(84)90121-9	65	184	187	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11678	11685		10.1074/jbc.275.16.11678	http://dx.doi.org/10.1074/jbc.275.16.11678			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766787	hybrid			2022-12-27	WOS:000086695500022
J	Frank, S; Lustig, A; Schulthess, T; Engel, J; Kammerer, RA				Frank, S; Lustig, A; Schulthess, T; Engel, J; Kammerer, RA			A distinct seven-residue trigger sequence is indispensable for proper coiled-coil formation of the human macrophage scavenger receptor oligomerization domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERHELICAL SALT BRIDGES; ALPHA-HELICAL PROTEIN; GCN4 LEUCINE-ZIPPER; CRYSTAL-STRUCTURE; CHAIN-LENGTH; STABILITY; DIMERIZATION; PH; RECOGNITION; SPECIFICITY	We have recently identified a distinct 13-residue sequence pattern that occurs with limited sequence variations in many two-stranded coiled coils but not in trimers, tetramers, or pentamers. This coiled-coil trigger pattern was demonstrated to be indispensable for the assembly of the oligomerization domain of the actin-bundling protein cortexillin I from Dictyostelium discoideum and the leucine zipper domain of the yeast transcriptional activator GCN4. With the aim to extend our knowledge on trigger sequences we have investigated the human macrophage scavenger receptor type A oligomerization domain as a representative of three-stranded coiled coils. We prepared a variety of recombinant N- and C-terminal deletion mutants from the full-length oligomerization domain by heterologous gene expression in Escherichia coli and assessed their ability to form trimeric coiled-coil structures by circular dichroism spectroscopy and analytical ultracentrifugation. Deletion mapping identified a distinct seven-residue sequence that was absolutely required for proper coiled-coil formation, supporting our previous results that heptad repeats alone are not sufficient for oligomerization. The finding that all fragments containing this particular sequence exhibited similar thermal stabilities indicates primarily a stabilizing function of the coiled-coil trigger. Based on sequence similarity, we suggest that functionally related sites are present in other three-stranded coiled-coil proteins.	Univ Basel, Biozentrum, Dept Biophys Chem, CH-4056 Basel, Switzerland	University of Basel	Engel, J (corresponding author), Univ Basel, Biozentrum, Dept Biophys Chem, Klingelbergstr 70, CH-4056 Basel, Switzerland.			Kammerer, Richard/0000-0003-4570-5197				Brandenberger R, 1996, J CELL BIOL, V135, P1583, DOI 10.1083/jcb.135.6.1583; Brown JH, 1996, PROTEINS, V26, P134; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; Dames SA, 1999, FEBS LETT, V446, P75, DOI 10.1016/S0014-5793(99)00186-6; DOI T, 1994, J BIOL CHEM, V269, P25598; DOI T, 1993, J BIOL CHEM, V268, P2126; Eckert DM, 1998, J MOL BIOL, V284, P859, DOI 10.1006/jmbi.1998.2214; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EMI M, 1993, J BIOL CHEM, V268, P2120; FAIRMAN R, 1995, PROTEIN SCI, V4, P1457, DOI 10.1002/pro.5560040803; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Kammerer RA, 1997, MATRIX BIOL, V15, P555, DOI 10.1016/S0945-053X(97)90031-7; Kammerer RA, 1998, P NATL ACAD SCI USA, V95, P13419, DOI 10.1073/pnas.95.23.13419; KAMMERER RA, 1995, J MOL BIOL, V250, P64, DOI 10.1006/jmbi.1995.0358; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; Kohn WD, 1997, J BIOL CHEM, V272, P2583, DOI 10.1074/jbc.272.5.2583; Krylov D, 1998, J MOL BIOL, V279, P959, DOI 10.1006/jmbi.1998.1762; Lavigne P, 1996, SCIENCE, V271, P1136, DOI 10.1126/science.271.5252.1136; Lumb KJ, 1996, SCIENCE, V271, P1137, DOI 10.1126/science.271.5252.1137; LUMB KJ, 1994, BIOCHEMISTRY-US, V33, P7361, DOI 10.1021/bi00189a042; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MUNOZ V, 1995, J MOL BIOL, V245, P275, DOI 10.1006/jmbi.1994.0023; Myers JK, 1999, J MOL BIOL, V289, P205, DOI 10.1006/jmbi.1999.2747; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SODEK J, 1972, P NATL ACAD SCI USA, V69, P3800, DOI 10.1073/pnas.69.12.3800; Spek EJ, 1998, PROTEIN SCI, V7, P2431, DOI 10.1002/pro.5560071121; Steinmetz MO, 1998, EMBO J, V17, P1883, DOI 10.1093/emboj/17.7.1883; SU JY, 1994, BIOCHEMISTRY-US, V33, P15501, DOI 10.1021/bi00255a032; Suzuki K, 1997, BIOCHEMISTRY-US, V36, P15140, DOI 10.1021/bi971655o; Suzuki K, 1998, PROTEIN ENG, V11, P1051, DOI 10.1093/protein/11.11.1051; Trybus KM, 1997, P NATL ACAD SCI USA, V94, P48, DOI 10.1073/pnas.94.1.48; Van Holde K. E., 1985, PHYSICAL BIOCH, P93; Yamada Y, 1998, CELL MOL LIFE SCI, V54, P628, DOI 10.1007/s000180050191	39	45	50	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11672	11677		10.1074/jbc.275.16.11672	http://dx.doi.org/10.1074/jbc.275.16.11672			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766786	hybrid			2022-12-27	WOS:000086695500021
J	Kenan, Y; Murata, T; Shakur, Y; Degerman, E; Manganiello, VC				Kenan, Y; Murata, T; Shakur, Y; Degerman, E; Manganiello, VC			Functions of the N-terminal region of cyclic nucleotide phosphodiesterase 3 (PDE 3) isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITED CAMP-PHOSPHODIESTERASE; INSULIN-SENSITIVE PHOSPHODIESTERASE; CATALYTIC DOMAIN; HUMAN-PLATELETS; GUINEA-PIG; AMP PHOSPHODIESTERASE; MOLECULAR-CLONING; FAT-CELLS; EXPRESSION; LOCALIZATION	The N-terminal portion of phosphodiesterase (PDE) 3 was arbitrarily divided into region 1 (amino acids 1-300), which contains a large hydrophobic domain with six predicted transmembrane helices, and region 2 (amino acids 301-500), with a smaller hydrophobic domain (similar to 50 residues). To analyze these regions, full-length human (H)PDE3A and mouse (M)PDE3B and a series of N-terminal truncated mutants were synthesized in Sf9 cells. Activities of HPDE3A, H3A-Delta 189, MPDE3B, and M3B-Delta 196, which retained all or part of the hydrophobic domain in region 1, were recovered almost entirely in particulate fractions. H3A-Delta 321 and M3B-Delta 302, containing region 2, were recovered essentially equally in particulate and cytosolic fractions. H3A-Delta 397 and H3A-Delta 457, lacking both hydrophobic domains, were predominantly cytosolic. H3A-Delta 510 and M3B-Delta 604, lacking both regions 1 and 2, were virtually completely cytosolic. M3B-Delta 196 eluted as a large aggregated complex during gel filtration. With removal of greater amounts of N-terminal sequence, aggregation of PDE3 decreased, and H3A-Delta 607, H3A-Delta 721, and M3B-Delta 604 eluted as dimers. Truncated HPDE3A proteins were more sensitive than full-length HPDE3A to inhibition by lixazinone. These results suggest that the hydrophobic domains in regions 1 and 2 contain structural determinants important for association of PDE3 with intracellular membranes, as well for self-association or aggregation during gel filtration and sensitivity to a specific inhibitor.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA; Lund Univ, Dept Cell & Mol Biol, Sect Mol Signalling, S-22100 Lund, Sweden	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Lund University	Manganiello, VC (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, Rm 5N-307,Bldg 10, Bethesda, MD 20892 USA.	manganiv@nhlbi.nih.gov			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002540, Z01HL000654, ZIAHL002540] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD F, 2000, IN PRESS J IMMUNOL; BARNETTE MS, 1995, J PHARMACOL EXP THER, V273, P674; Bolger GB, 1996, J BIOL CHEM, V271, P1065, DOI 10.1074/jbc.271.2.1065; Cheung PP, 1996, BLOOD, V88, P1321, DOI 10.1182/blood.V88.4.1321.bloodjournal8841321; DEGERMAN E, 1994, BBA-PROTEIN STRUCT M, V1205, P189, DOI 10.1016/0167-4838(94)90233-X; DEGERMAN E, 1987, J BIOL CHEM, V262, P5797; Degerman E, 1997, J BIOL CHEM, V272, P6823, DOI 10.1074/jbc.272.11.6823; Fisher DA, 1998, J BIOL CHEM, V273, P15559, DOI 10.1074/jbc.273.25.15559; Fujishige K, 1999, J BIOL CHEM, V274, P18438, DOI 10.1074/jbc.274.26.18438; GRANT PG, 1984, BIOCHEMISTRY-US, V23, P1801, DOI 10.1021/bi00303a034; HARRIS AL, 1989, J PHARMACOL EXP THER, V251, P199; He Rui, 1998, Cell Biochemistry and Biophysics, V29, P89, DOI 10.1007/BF02737830; JIN SLC, 1992, J BIOL CHEM, V267, P18929; JONES GH, 1987, J MED CHEM, V30, P295, DOI 10.1021/jm00385a011; KAUFFMAN RF, 1986, MOL PHARMACOL, V30, P609; KINCAID RL, 1988, METHOD ENZYMOL, V159, P457; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; KOMAS N, 1996, HDB PHARM PHOSPHODIE, P9; KONO T, 1975, J BIOL CHEM, V250, P7826; Kovala T, 1997, BIOCHEMISTRY-US, V36, P2968, DOI 10.1021/bi9613483; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Leroy MJ, 1996, BIOCHEMISTRY-US, V35, P10194, DOI 10.1021/bi952711t; Liu H, 1998, BRIT J PHARMACOL, V125, P1501, DOI 10.1038/sj.bjp.0702227; MACPHEE CH, 1988, J BIOL CHEM, V263, P10353; MAKINO H, 1980, J BIOL CHEM, V255, P7850; MANGANIELLO V, 1973, J BIOL CHEM, V248, P7164; MEACCI E, 1992, P NATL ACAD SCI USA, V89, P3721, DOI 10.1073/pnas.89.9.3721; MULLER B, 1992, EUR J PHARM-MOLEC PH, V225, P263, DOI 10.1016/0922-4106(92)90028-T; Nagaoka Tadasu, 1998, Cell Biochemistry and Biophysics, V29, P49, DOI 10.1007/BF02737828; PILLAI R, 1994, J BIOL CHEM, V269, P30676; Rahn T, 1996, J BIOL CHEM, V271, P11575, DOI 10.1074/jbc.271.19.11575; REINHARDT RR, 1995, J CLIN INVEST, V95, P1528, DOI 10.1172/JCI117825; Rocque WJ, 1997, PROTEIN EXPRES PURIF, V9, P191, DOI 10.1006/prep.1996.0683; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SHAKUR Y, 1995, BIOCHEM J, V306, P801, DOI 10.1042/bj3060801; SMITH CJ, 1993, BIOCHEM BIOPH RES CO, V190, P516, DOI 10.1006/bbrc.1993.1078; Soderling SH, 1998, J BIOL CHEM, V273, P15553, DOI 10.1074/jbc.273.25.15553; Souness JE, 1997, CELL SIGNAL, V9, P227, DOI 10.1016/S0898-6568(96)00173-8; TAIRA M, 1993, J BIOL CHEM, V268, P18573; Tang KM, 1997, BIOCHEM J, V323, P217; TANG KM, 1993, BIOCHEM J, V294, P329, DOI 10.1042/bj2940329; VENUTI MC, 1988, J MED CHEM, V31, P2132, DOI 10.1021/jm00119a013; Zhao AZ, 1998, J CLIN INVEST, V102, P869, DOI 10.1172/JCI3920	43	52	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12331	12338		10.1074/jbc.275.16.12331	http://dx.doi.org/10.1074/jbc.275.16.12331			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766874	hybrid			2022-12-27	WOS:000086695500109
J	Mreyen, M; Champion, A; Srinivasan, S; Karuso, P; Williams, KL; Packer, NH				Mreyen, M; Champion, A; Srinivasan, S; Karuso, P; Williams, KL; Packer, NH			Multiple O-glycoforms on the spore coat protein SP96 in Dictyostelium discoideum - Fuc(alpha 1-3)GlcNAc-alpha-1-P-Ser is the major modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED OLIGOSACCHARIDES; STRUCTURAL CHARACTERIZATION; GLYCOPROTEIN COMPLEX; CYSTEINE PROTEINASE; NMR-SPECTROSCOPY; ACID-ANALYSIS; PRESPORE; GENE; FUCOSYLATION; SENSITIVITY	A decreased level of fucosylation on certain spore coat proteins of Dictyostelium discoideum alters the permeability of the spore coat. Here the post-translational modifications of a major spore coat protein, SP96, are studied in a wild type strain (X22) and a fucosylation-defective mutant ((HU2470). A novel phosphoglycan structure on SP96 of the wild type strain, consisting of Fuc(alpha 1-3)GlcNAc-alpha-1-P-Ser was identified by electrospray ionization mass spectrometry and NMR, It was shown using monosaccharide and gas chromatography mass spectrometry analysis that SP96 in the mutant HU2470 contained approximately 20% of wild type levels of fucose, as a result of a missing terminal fucose on the novel glycan structure. The results support previous predictions, based on inhibition studies on different fucose deficient strains, about the nature of monoclonal antibody epitopes identified by monoclonal antibodies MUD62 and MUD166, which are known to identify O-linked glycans (Champion, A., Griffiths, K., Cooley, A. A., Gonzalez, B. Y., Gritzali, M., West, C. M., and Williams, K. L. (1995) Microbiology 141, 785-797). Quantitative studies on wild type SP96 indicated that there were approximately 60 sites with phosphodiester-linked acetylglucosamine-fucose disaccharide units and a further approximately 20 sites with fucose directly linked to the protein. Over 70% of the serine sites are modified, with less than 1% of these sites as phosphoserine. Threonine and tyrosine residues were not found to be modified.	Macquarie Univ, Ctr Analyt Biotechnol, Dept Biol Sci, Sydney, NSW 2109, Australia; Macquarie Univ, Dept Chem, Sydney, NSW 2109, Australia	Macquarie University; Macquarie University	Packer, NH (corresponding author), Proteome Syst Ltd, Locked Bag 3073, Sydney, NSW 1670, Australia.		Packer, Nicolle/Q-8929-2019; Karuso, Peter/D-6442-2013	Karuso, Peter/0000-0002-0217-6021; Packer, Nicolle/0000-0002-7532-4021				AKALEHIYWOT T, 1983, CAN J BIOCHEM CELL B, V61, P996, DOI 10.1139/o83-126; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; BOCK K, 1983, ADV CARBOHYD CHEM BI, V41, P27, DOI 10.1016/S0065-2318(08)60055-4; BROWN DM, 1963, ADV ORG CHEM, V3, P75; BUNDLE DR, 1973, CAN J CHEM, V51, P3812, DOI 10.1139/v73-571; CHAMPION A, 1995, MICROBIOL-UK, V141, P785, DOI 10.1099/13500872-141-4-785; COFFMAN DS, 1981, J SUPRAMOL STR CELL, V15, P369, DOI 10.1002/jsscb.1981.380150407; DELANEY SJ, 1983, BIOCHEM J, V212, P699, DOI 10.1042/bj2120699; DEVINE KM, 1982, P NATL ACAD SCI-BIOL, V79, P7361, DOI 10.1073/pnas.79.23.7361; DEVINE KM, 1983, DEV BIOL, V99, P437, DOI 10.1016/0012-1606(83)90293-2; DOUBET S, 1989, TRENDS BIOCHEM SCI, V14, P475, DOI 10.1016/0968-0004(89)90175-8; FOSNAUGH KL, 1989, NUCLEIC ACIDS RES, V17, P9489, DOI 10.1093/nar/17.22.9489; GONZALEZYANES B, 1989, DEV BIOL, V133, P576, DOI 10.1016/0012-1606(89)90060-2; Gooley AA, 1997, NATURE, V385, P557, DOI 10.1038/385557a0; GOOLEY AA, 1992, THESIS MACQUARIE U S; GRIFFITHS KR, 1996, THESIS MACQUARIE U S; Hansen JE, 1996, NUCLEIC ACIDS RES, V24, P248, DOI 10.1093/nar/24.1.248; Haynes PA, 1996, GLYCOBIOLOGY, V6, P869, DOI 10.1093/glycob/6.8.869; HAYNES PA, 1993, EUR J BIOCHEM, V216, P729, DOI 10.1111/j.1432-1033.1993.tb18192.x; Ilg T, 1996, J BIOL CHEM, V271, P21583, DOI 10.1074/jbc.271.35.21583; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KHYSEANDERSON J, 1984, J BIOCHEM BIOPH METH, V10, P203; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEMIEUX RU, 1980, CAN J CHEM, V58, P631, DOI 10.1139/v80-098; LIS H, 1993, EUR J BIOCHEM, V218, P1, DOI 10.1111/j.1432-1033.1993.tb18347.x; McGuire V, 1996, J BIOL CHEM, V271, P14596, DOI 10.1074/jbc.271.24.14596; Mehta DP, 1996, J BIOL CHEM, V271, P10897, DOI 10.1074/jbc.271.18.10897; Ord T, 1997, ARCH BIOCHEM BIOPHYS, V339, P64, DOI 10.1006/abbi.1996.9870; OZAKI T, 1993, DEVELOPMENT, V117, P1299; Packer NH, 1998, GLYCOCONJUGATE J, V15, P737, DOI 10.1023/A:1006983125913; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RILEY GR, 1993, GLYCOBIOLOGY, V3, P165, DOI 10.1093/glycob/3.2.165; SCHLEUCHER J, 1994, J BIOMOL NMR, V4, P301; Sharon N., 1975, COMPLEX CARBOHYDRATE; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; Srikrishna G, 1998, GLYCOBIOLOGY, V8, P799, DOI 10.1093/glycob/8.8.799; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; VOET L, 1985, J CELL SCI, V75, P423; WATSON N, 1993, J BIOL CHEM, V268, P22634; WATSON N, 1994, J CELL SCI, V107, P2567; West CM, 1996, MICROBIOL-UK, V142, P2227, DOI 10.1099/13500872-142-8-2227; WEST CM, 1990, DEV GENET, V11, P492, DOI 10.1002/dvg.1020110526; WEST CM, 1986, MOL CELL BIOCHEM, V72, P121; WIESE M, 1995, EMBO J, V14, P1067, DOI 10.1002/j.1460-2075.1995.tb07089.x; Yan JX, 1996, J CHROMATOGR A, V736, P291, DOI 10.1016/0021-9673(95)01285-0; Yan JX, 1997, J CHROMATOGR A, V764, P201, DOI 10.1016/S0021-9673(96)00931-4; Zachara NE, 1996, EUR J BIOCHEM, V238, P511, DOI 10.1111/j.1432-1033.1996.0511z.x; Zhang YY, 1998, BIOCHEMISTRY-US, V37, P10766, DOI 10.1021/bi9808013	51	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12164	12174		10.1074/jbc.275.16.12164	http://dx.doi.org/10.1074/jbc.275.16.12164			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766852	hybrid			2022-12-27	WOS:000086695500087
J	Ostrom, RS; Gregorian, C; Insel, PA				Ostrom, RS; Gregorian, C; Insel, PA			Cellular release of and response to ATP as key determinants of the set-point of signal transduction pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; EPITHELIAL-CELLS; CYSTIC-FIBROSIS; MDCK-CELLS; RECEPTORS; MECHANISM; ACTIVATION; FORSKOLIN; TRANSPORT; CLONING	The determinants of "basal" activity of signaling pathways regulating cellular responses are poorly defined. One possibility is that cells release factors to establish the set-point of such pathways. Here we show that treatment of Madin-Darby canine kidney cells with the nucleotidase apyrase decreases basal arachidonic acid release and cAMP production 30-40% and that inhibitors of P2Y receptor action also affect basal and forskolin-stimulated cAMP accumulation. Changing medium prominently increases extracellular levels of ATP in Madin-Darby canine kidney, COS-7, and HEK-293 cells. Mechanical stimulation of ATP release likely occurs in virtually every experimental protocol with cultured cells, implicating such release and P2Y receptor activation as critical in establishing the set-point for signal transduction pathways.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Ostrom, RS (corresponding author), Univ Calif San Diego, Dept Pharmacol, 0636, La Jolla, CA 92093 USA.	rostrom@ucsd.edu		Ostrom, Rennolds/0000-0002-7204-0357				BARNARD EA, 1994, TRENDS PHARMACOL SCI, V15, P67, DOI 10.1016/0165-6147(94)90280-1; Beigi R, 1999, AM J PHYSIOL-CELL PH, V276, pC267, DOI 10.1152/ajpcell.1999.276.1.C267; Buell G, 1996, EUR J NEUROSCI, V8, P2221, DOI 10.1111/j.1460-9568.1996.tb00745.x; Caldwell CC, 1999, ARCH BIOCHEM BIOPHYS, V362, P46, DOI 10.1006/abbi.1998.1008; Clarke LL, 1997, AM J PHYSIOL-LUNG C, V272, pL1084, DOI 10.1152/ajplung.1997.272.6.L1084; Coleman RA, 1990, COMPREHENSIVE MED CH, P643; Communi D, 1997, J BIOL CHEM, V272, P31969, DOI 10.1074/jbc.272.51.31969; Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735; Cotrina ML, 1998, J NEUROSCI, V18, P8794; DALY JW, 1984, ADV CYCLIC NUCL PROT, V17, P81; Dessauer CW, 1996, J BIOL CHEM, V271, P16967, DOI 10.1074/jbc.271.28.16967; Firestein BL, 1996, AM J PHYSIOL-RENAL, V271, pF610, DOI 10.1152/ajprenal.1996.271.3.F610; Grygorczyk R, 1997, AM J PHYSIOL-CELL PH, V272, pC1058; HARDEN TK, 1998, IUPHAR COMPENDIUM RE, P209; HUMPHREY PPA, 1998, IUPHAR COMPENDIUM RE, P195; Jorgensen NR, 1997, J CELL BIOL, V139, P497, DOI 10.1083/jcb.139.2.497; KNOWLES MR, 1995, AM J RESP CRIT CARE, V151, pS65, DOI 10.1164/ajrccm/151.3_Pt_2.S65; Lazarowski ER, 1999, BRIT J PHARMACOL, V127, P1272, DOI 10.1038/sj.bjp.0702654; Lazarowski ER, 1997, J BIOL CHEM, V272, P24348, DOI 10.1074/jbc.272.39.24348; Liu P S, 1996, Chin J Physiol, V39, P189; Mitchell CH, 1998, P NATL ACAD SCI USA, V95, P7174, DOI 10.1073/pnas.95.12.7174; OSIPCHUK Y, 1992, NATURE, V359, P241, DOI 10.1038/359241a0; Ostrom RS, 1997, J PHARMACOL EXP THER, V280, P189; PAULMICHL M, 1991, J CELL PHYSIOL, V147, P68, DOI 10.1002/jcp.1041470110; PLESNER L, 1995, INT REV CYTOL, V158, P141; Post SR, 1998, J BIOL CHEM, V273, P23093, DOI 10.1074/jbc.273.36.23093; Post SR, 1996, J BIOL CHEM, V271, P2029, DOI 10.1074/jbc.271.4.2029; Ralevic V, 1998, PHARMACOL REV, V50, P413; Sala-Newby GB, 1999, J BIOL CHEM, V274, P17789, DOI 10.1074/jbc.274.25.17789; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Schwiebert EM, 1999, AM J PHYSIOL-CELL PH, V276, pC1, DOI 10.1152/ajpcell.1999.276.1.C1; SUTKOWSKI EM, 1994, BIOCHEMISTRY-US, V33, P12852, DOI 10.1021/bi00209a017; Taylor AL, 1998, AM J PHYSIOL-CELL PH, V275, pC1391, DOI 10.1152/ajpcell.1998.275.5.C1391; Watt WC, 1998, J BIOL CHEM, V273, P14053, DOI 10.1074/jbc.273.22.14053; Wilson PD, 1999, J AM SOC NEPHROL, V10, P218; Xing MB, 1996, J CLIN INVEST, V97, P1302, DOI 10.1172/JCI118546; Xing MZ, 1997, AM J PHYSIOL-CELL PH, V272, pC1380, DOI 10.1152/ajpcell.1997.272.4.C1380; Xing MZ, 1997, J CLIN INVEST, V99, P805, DOI 10.1172/JCI119227; YANG SM, 1994, CIRC RES, V74, P401, DOI 10.1161/01.RES.74.3.401; ZEGARRAMORAN O, 1995, BRIT J PHARMACOL, V114, P1052, DOI 10.1111/j.1476-5381.1995.tb13312.x	40	152	154	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11735	11739		10.1074/jbc.275.16.11735	http://dx.doi.org/10.1074/jbc.275.16.11735			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766795	hybrid, Green Published			2022-12-27	WOS:000086695500030
J	Abadjieva, A; Hilven, P; Pauwels, K; Crabeel, M				Abadjieva, A; Hilven, P; Pauwels, K; Crabeel, M			The yeast ARG7 gene product is autoproteolyzed to two subunit peptides, yielding active ornithine acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ARGININE; BIOSYNTHESIS; METABOLISM; MECHANISMS	Yeast ornithine acetyltransferase has been purified from total yeast extracts as a heterodimer of two sub-peptides (Liu, Y,, Van Heeswijck, R,, Hoj, P,, and Hoogenraad, N, (1995) fur. J, Biochem, 228, 291-296), confirmed to derive from a single ARG7-encoded precursor (Crabeel, RI., Abadjieva, A, Hilven, P., Desimpelaere, J,, and Soetens, O. (1997) fur. J, Biochem, 250, 232-241), By Western immunoblotting, we show that Arg7p is also present as two subpeptides in isolated mitochondria, but that processing occurs before targeting to the mitochondria: deletion of the N-terminal leader peptide results in cytosolic accumulation of N-Arg7p, whereas C-Arg7p partially reaches the organelle by itself. When artificially co-expressed from separate genes, the two subpeptides can complement an arg7 mutation; ornithine acetyltransferase activity is measurable. Maturation of Arg7p occurs at threonine 215 (N-side), in the region most conserved among the 17 ornithine acetyltransferases characterized. Changing this conserved residue to alanine completely abolishes maturation. Furthermore, Arg7p is both processed and active in Escherichia coli, a heterologous background, and is also cleaved in vitro when produced by coupled transcription/translation in a reticulocyte lysate, Together, these data suggest classic autoproteolysis initiated by threonine 215. Most importantly, maturation is required for the enzyme to be functional, since the T215A substitution mutant is catalytically inactive and incapable of genetic complementation, despite its correct targeting to the mitochondria.	Free Univ Brussels, Dept Microbiol, CERIA COOVI, B-1070 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel	Crabeel, M (corresponding author), Free Univ Brussels, Dept Microbiol, CERIA COOVI, E Grysonlane 1, B-1070 Brussels, Belgium.	mcrabeel@vub.ac.be						Crabeel M, 1997, EUR J BIOCHEM, V250, P232, DOI 10.1111/j.1432-1033.1997.0232a.x; Crabeel M, 1996, J BIOL CHEM, V271, P25011, DOI 10.1074/jbc.271.40.25011; CULLIN C, 1994, YEAST, V10, P105, DOI 10.1002/yea.320100110; CUNIN R, 1986, MICROBIOL REV, V50, P314, DOI 10.1128/MMBR.50.3.314-352.1986; DAVIS RH, 1986, MICROBIOL REV, V50, P280, DOI 10.1128/MMBR.50.3.280-313.1986; HEIMBERG H, 1990, GENE, V90, P69, DOI 10.1016/0378-1119(90)90440-3; HUYGEN R, 1987, EUR J BIOCHEM, V166, P371, DOI 10.1111/j.1432-1033.1987.tb13525.x; JAUNIAUX JC, 1978, J BACTERIOL, V133, P1096, DOI 10.1128/JB.133.3.1096-1107.1978; LIU YS, 1995, EUR J BIOCHEM, V228, P291, DOI 10.1111/j.1432-1033.1995.tb20262.x; MESSENGUY F, 1976, J BACTERIOL, V22, P277; Perler FB, 1997, CURR OPIN CHEM BIOL, V1, P292, DOI 10.1016/S1367-5931(97)80065-8; Perler FB, 1998, NAT STRUCT BIOL, V5, P249, DOI 10.1038/nsb0498-249; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627	13	17	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11361	11367		10.1074/jbc.275.15.11361	http://dx.doi.org/10.1074/jbc.275.15.11361			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753950	hybrid			2022-12-27	WOS:000086466600092
J	Fu, SL; Wang, HJ; Davies, M; Dean, R				Fu, SL; Wang, HJ; Davies, M; Dean, R			Reactions of hypochlorous acid with tyrosine and peptidyl-tyrosyl residues give dichlorinated and aldehydic products in addition to 3-chlorotyrosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HUMAN NEUTROPHILS EMPLOY; STIMULATED HUMAN-NEUTROPHILS; NITROGEN-CENTERED RADICALS; PEROXIDE-CHLORIDE SYSTEM; SMALL MODEL PEPTIDES; ALPHA-AMINO-ACIDS; HYDROGEN-PEROXIDE; LYSINE RESIDUES; P-HYDROXYPHENYLACETALDEHYDE	The toxicity of hypochlorous acid (HOCl) generated from activated neutrophils has been associated with several pathological processes such as atherosclerosis. Formation of 3-chlorotyrosine (Cl-Tyr) has been used as a marker for assessing the involvement of HOCl in such processes. In this study, we aimed to investigate the formation of Cl-Tyr from reaction of HOCl with tyrosine (both free and peptide-bound) and the fate of Cl-Tyr under such conditions. Tyrosine, N-acetyltyrosine, bovine serum albumin, and human low density lipoproteins were incubated with a range of reagent hypochlorite concentrations for varying periods in 10 mM phosphate buffer (pH 7.4) at 22 degrees C. The reaction products, and several biological samples, were hydrolyzed (in the case of proteins), isolated, and purified by high pressure liquid chromatography and characterized or quantitated by mass spectrometry and NMR, A significant amount of 3,5-dichlorotyrosine (diCl-Tyr) was obtained from the bovine serum albumin, low density lipoprotein, and some biological samples, in addition to CI-Tyr, indicating that Cl-Tyr competes effectively for HOCl even when tyrosine is present in great excess. Cl-Tyr and diCl-Tyr were also formed from free tyrosine but then reacted further with HOCl. This finding differs from a claim in the literature that Cl-Tyr was not formed in such a system. The further reaction products of Cl-Tyr and diCl-Tyr with HOCl were elucidated as their corresponding mono- and dichlorinated 4-hydroxyphenylacetaldehydes. These results indicate the importance of assessing other products of HOCl action in addition to Cl-Tyr.	Heart Res Inst, Cell Biol Grp, Sydney, NSW 2050, Australia; Heart Res Inst, EPR Grp, Sydney, NSW 2050, Australia	University of Sydney; Heart Research Institute; University of Sydney; Heart Research Institute	Dean, R (corresponding author), Heart Res Inst, Cell Biol Grp, 145 Missenden Rd, Camperdown, NSW 2050, Australia.		Davies, Michael J/H-4939-2011; Davies, Michael/AGX-9184-2022; Fu, Shanlin/D-8286-2013; Davies, Michael/GWV-2527-2022	Davies, Michael J/0000-0002-5196-6919; Davies, Michael/0000-0002-5196-6919; Fu, Shanlin/0000-0002-6238-3612; Dean, Roger Thornton/0000-0002-8859-8902				AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; AMICONI G, 1985, J BIOCHEM BIOPH METH, V11, P241, DOI 10.1016/0165-022X(85)90006-5; Anderson MM, 1997, J CLIN INVEST, V99, P424, DOI 10.1172/JCI119176; ARNHOLD J, 1990, BIOMED BIOCHIM ACTA, V49, P991; BECKSPEIER I, 1988, FEBS LETT, V227, P1, DOI 10.1016/0014-5793(88)81401-7; Carr AC, 1997, BIOCHEM J, V327, P275, DOI 10.1042/bj3270275; Carr AC, 1996, ARCH BIOCHEM BIOPHYS, V332, P63, DOI 10.1006/abbi.1996.0317; CHUNG BH, 1986, METHOD ENZYMOL, V128, P181; CLARK RA, 1986, BIOCHEM BIOPH RES CO, V135, P451, DOI 10.1016/0006-291X(86)90015-X; DAKIN ND, 1917, BIOCHEM J, V11, P79; DEAN RT, 1996, FREE RADICALS PRACTI, P171; DOMIGAN NM, 1995, J BIOL CHEM, V270, P16542, DOI 10.1074/jbc.270.28.16542; Fu S, 1998, BIOCHEM J, V333, P519, DOI 10.1042/bj3330519; Fu SL, 1998, J BIOL CHEM, V273, P28603, DOI 10.1074/jbc.273.44.28603; GARRISON WARREN M., 1968, CURR TOP RADIAT RES, VVol. 4-4, P43; GARRISON WM, 1987, CHEM REV, V87, P381, DOI 10.1021/cr00078a006; GRISHAM MB, 1984, J BIOL CHEM, V259, P404; HAND VC, 1983, J AM CHEM SOC, V105, P4022, DOI 10.1021/ja00350a046; Hawkins CL, 1998, BIOCHEM J, V332, P617, DOI 10.1042/bj3320617; Hawkins CL, 1998, J CHEM SOC PERK T 2, P1937, DOI 10.1039/a802949k; HAZELL LJ, 1993, BIOCHEM J, V290, P165, DOI 10.1042/bj2900165; Hazell LJ, 1999, BIOCHEM J, V339, P489, DOI 10.1042/0264-6021:3390489; HAZELL LJ, 1994, BIOCHEM J, V302, P297, DOI 10.1042/bj3020297; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; Hazen SL, 1997, J BIOL CHEM, V272, P16990, DOI 10.1074/jbc.272.27.16990; Hazen SL, 1997, FREE RADICAL BIO MED, V23, P909, DOI 10.1016/S0891-5849(97)00084-1; Hazen SL, 1998, J BIOL CHEM, V273, P4997, DOI 10.1074/jbc.273.9.4997; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; Hazen SL, 1996, J BIOL CHEM, V271, P1861, DOI 10.1074/jbc.271.4.1861; HEINECKE JW, 1994, CORONARY ARTERY DIS, V5, P205, DOI 10.1097/00019501-199403000-00004; Heinecke JW, 1997, BIOFACTORS, V6, P145, DOI 10.1002/biof.5520060208; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; Hensley K, 1997, ANAL BIOCHEM, V251, P187, DOI 10.1006/abio.1997.2281; Jesaitis A. J., 1992, MOL BASIS OXIDATIVE; KETTLE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1052, P379, DOI 10.1016/0167-4889(90)90146-5; Kettle AJ, 1996, FEBS LETT, V379, P103, DOI 10.1016/0014-5793(95)01494-2; Kettle AJ, 1997, REDOX REP, V3, P3, DOI 10.1080/13510002.1997.11747085; KETTLE AJ, 1993, BIOCHEM PHARMACOL, V45, P2003, DOI 10.1016/0006-2952(93)90010-T; Kocher M, 1996, INFECT IMMUN, V64, P1342, DOI 10.1128/IAI.64.4.1342-1350.1996; LAMPERT MB, 1983, BLOOD, V62, P645; LI SH, 1993, PHARMACEUT RES, V10, P1572, DOI 10.1023/A:1018960300769; LI SH, 1995, PHARM RES-DORDR, V12, P348, DOI 10.1023/A:1016240115675; MCKENNA SM, 1988, BIOCHEM J, V254, P685, DOI 10.1042/bj2540685; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; Olszowski S, 1996, ACTA BIOCHIM POL, V43, P661; PEREIRA WE, 1973, BIOCHIM BIOPHYS ACTA, V313, P170, DOI 10.1016/0304-4165(73)90198-0; Prutz WA, 1996, J BIOCHEM BIOPH METH, V32, P125, DOI 10.1016/0165-022X(96)00006-1; Prutz WA, 1996, ARCH BIOCHEM BIOPHYS, V332, P110, DOI 10.1006/abbi.1996.0322; Prutz WA, 1998, ARCH BIOCHEM BIOPHYS, V349, P183, DOI 10.1006/abbi.1997.0440; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STELMASZYNSKA T, 1978, EUR J BIOCHEM, V92, P301, DOI 10.1111/j.1432-1033.1978.tb12748.x; SWAIN CG, 1972, J AM CHEM SOC, V94, P3195, DOI 10.1021/ja00764a050; THOMAS EL, 1979, INFECT IMMUN, V23, P522, DOI 10.1128/IAI.23.2.522-531.1979; VAN TAMELEN EE, 1968, TETRAHEDRON, V24, P687, DOI 10.1016/0040-4020(68)88018-4; VANREYK DM, 1995, FREE RADICAL RES, V23, P533, DOI 10.3109/10715769509065274; VISSERS MCM, 1995, BIOCHEM J, V307, P57, DOI 10.1042/bj3070057; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEISS SJ, 1983, SCIENCE, V222, P625, DOI 10.1126/science.6635660; WINTERBOURN CC, 1992, ARCH BIOCHEM BIOPHYS, V296, P547, DOI 10.1016/0003-9861(92)90609-Z; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; Wright NC, 1936, BIOCHEM J, V30, P1661, DOI 10.1042/bj0301661; Wu WJ, 1999, BIOCHEMISTRY-US, V38, P3538, DOI 10.1021/bi982401l; ZGLICZYNSKI JM, 1968, EUR J BIOCHEM, V4, P540, DOI 10.1111/j.1432-1033.1968.tb00246.x; ZGLICZYNSKI JM, 1971, BIOCHIM BIOPHYS ACTA, V235, P419, DOI 10.1016/0005-2744(71)90281-6	66	83	83	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10851	10858		10.1074/jbc.275.15.10851	http://dx.doi.org/10.1074/jbc.275.15.10851			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753880	hybrid			2022-12-27	WOS:000086466600022
J	Uittenbogaard, A; Shaul, PW; Yuhanna, IS; Blair, A; Smart, EJ				Uittenbogaard, A; Shaul, PW; Yuhanna, IS; Blair, A; Smart, EJ			High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SR-BI; PLASMA-MEMBRANE; SCAVENGER RECEPTOR; CHOLESTEROL; DISEASE; CELLS; 5-METHYLTETRAHYDROFOLATE; ATHEROSCLEROSIS; DYSFUNCTION; METABOLISM	Oxidized LDL (oxLDL) depletes caveolae of cholesterol, resulting in the displacement of endothelial nitric-oxide synthase (eNOS) from caveolae and impaired eNOS activation. In the present study, we determined if the class B scavenger receptors, CD36 and SR-BI, are involved in regulating nitric-oxide synthase localization and function, We demonstrate that CD36 and SRBI are expressed in endothelial cells, co-fractionate with caveolae, and co-immunoprecipitate with caveolin-1, Go-incubation of cells with 10 mu g/ml high density lipoprotein (HDL) prevented oxLDL-induced translocation of eNOS from caveolae and restored acetylcholine-induced nitric-oxide synthase stimulation. Acetylcholine caused eNOS activation in cells incubated with 10 mu g/ml oxLDL (10-15 thiobarbituric acid-reactive substances) and blocking antibodies to CD36, whereas cells treated with only oxLDL were unresponsive. Furthermore, CD36-blocking antibodies prevented oxLDL-induced redistribution of eNOS, SR-BI-blocking antibodies were used to demonstrate that the effects of HDL are mediate by SR-BI. HDL binding to SR-BI maintained the concentration of caveola-associated cholesterol by promoting the uptake of cholesterol esters, thereby preventing oxLDL-induced depletion of caveola cholesterol, we conclude that CD36 mediates the effects of oxLDL on caveola composition and eNOS activation. Furthermore, HDL prevents oxLDL from decreasing the capacity for eNOS activation by preserving the cholesterol concentration in caveolae and, thereby maintaining the subcellular location of eNOS.	Univ Kentucky, Sch Med, Dept Physiol, Lexington, KY 40536 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75235 USA	University of Kentucky; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Smart, EJ (corresponding author), Univ Kentucky, Sch Med, Dept Physiol, 800 Rose St,MS 508 C, Lexington, KY 40536 USA.				NHLBI NIH HHS [HL58888, HL62844, HL58475] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058475, R01HL058888, R01HL062844, R29HL058475] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACTON SL, 1994, J BIOL CHEM, V269, P21003; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; Blair A, 1999, J BIOL CHEM, V274, P32512, DOI 10.1074/jbc.274.45.32512; Buege J A, 1978, Methods Enzymol, V52, P302; CARR TP, 1993, CLIN BIOCHEM, V26, P39, DOI 10.1016/0009-9120(93)90015-X; CAYATTE AJ, 1994, ARTERIOSCLER THROMB, V14, P753, DOI 10.1161/01.ATV.14.5.753; COHEN RA, 1995, PROG CARDIOVASC DIS, V38, P105, DOI 10.1016/S0033-0620(05)80002-7; DAVDA RK, 1993, HYPERTENSION, V21, P939, DOI 10.1161/01.HYP.21.6.939; Dorahy DJ, 1996, BIOCHEM J, V319, P67, DOI 10.1042/bj3190067; Feron O, 1998, BIOCHEMISTRY-US, V37, P193, DOI 10.1021/bi972307p; FISHER WR, 1986, METHOD ENZYMOL, V128, P247; FLAVAHAN NA, 1992, CIRCULATION, V85, P1927, DOI 10.1161/01.CIR.85.5.1927; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Graf GA, 1999, J BIOL CHEM, V274, P12043, DOI 10.1074/jbc.274.17.12043; GRUNDY SM, 1986, JAMA-J AM MED ASSOC, V256, P2849, DOI 10.1001/jama.256.20.2849; HARRISON DG, 1994, BASIC RES CARDIOL, V89, P87; KELLEY JL, 1986, METHOD ENZYMOL, V128, P170; KRIEGER M, 1979, J BIOL CHEM, V254, P3845; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; PLANE F, 1993, ATHEROSCLEROSIS, V103, P73, DOI 10.1016/0021-9150(93)90041-R; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1996, J CELL BIOL, V134, P1169, DOI 10.1083/jcb.134.5.1169; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Stan RV, 1997, MOL BIOL CELL, V8, P595, DOI 10.1091/mbc.8.4.595; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; VANE JR, 1990, NEW ENGL J MED, V323, P27; Waugh MG, 1999, BIOCHEM J, V337, P591, DOI 10.1042/0264-6021:3370591	38	254	261	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11278	11283		10.1074/jbc.275.15.11278	http://dx.doi.org/10.1074/jbc.275.15.11278			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753938	hybrid			2022-12-27	WOS:000086466600080
J	Yao, XQ; Liu, WM; Tian, SL; Rafi, H; Segal, AS; Desir, GV				Yao, XQ; Liu, WM; Tian, SL; Rafi, H; Segal, AS; Desir, GV			Close association of the N terminus of Kv1.3 with the pore region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHAKER POTASSIUM CHANNEL; K+ CHANNEL; FUNCTIONAL EXPRESSION; ION CHANNELS; LYMPHOCYTES; BINDING; RESIDUES; CHARYBDOTOXIN; INACTIVATION; MUTATION	The Shaker superfamily encodes voltage-gated potassium (Kv) channels. The N termini of Shaker proteins are located intracellularly and contain several domains shown to regulate important aspects of channel function, such as speed of inactivation, channel assembly (T1 domain), and steady state protein level (T0 domain, amino acids 3-39 in rabbit). Mutations and/or deletion of certain amino acids in the T0 domain lead to a 13-fold amplification of Ky current as compared with wild type channels, primarily by increasing the absolute number of channel proteins present in the membrane (Segal, A. S., Yao, X., and Desir, G. V. (1999) Biochem. Biophys. Res. Commun. 254, 54-64). Although T0 mutants have kinetic properties virtually indistinguishable from wild type, they were noted to have a slightly larger single channel conductance, suggesting that the T0 domain might also interact with the pore region. In the present study we show that although T0 does not affect pore selectivity, it does modulate the binding affinity of the pore blocker, charybdotoxin. These results suggest that the N terminus of Kv1.3 is closely associated with the pore region.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; Chinese Univ Hong Kong, Dept Physiol, Shatin, Hong Kong, Peoples R China; Univ Vermont, Dept Med, Burlington, VT 05446 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; W Haven Vet Adm Med Ctr, New Haven, CT 06510 USA	Yale University; Chinese University of Hong Kong; University of Vermont; Yale University	Desir, GV (corresponding author), Yale Univ, Sch Med, Dept Internal Med, 2073 LMP,333 Cedar St, New Haven, CT 06510 USA.		Yao, Xiaoqiang/I-5413-2016	Yao, Xiaoqiang/0000-0002-0687-8186	NIDDK NIH HHS [DK48105B] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048105] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEZANILLA F, 1991, SCIENCE, V254, P679, DOI 10.1126/science.1948047; Bixby KA, 1999, NAT STRUCT BIOL, V6, P38; CAI YC, 1992, DNA CELL BIOL, V11, P163, DOI 10.1089/dna.1992.11.163; Dauplais M, 1997, J BIOL CHEM, V272, P4302, DOI 10.1074/jbc.272.7.4302; GOLDSTEIN SAN, 1992, BIOPHYS J, V62, P5, DOI 10.1016/S0006-3495(92)81760-5; GRISSMER S, 1990, P NATL ACAD SCI USA, V87, P9411, DOI 10.1073/pnas.87.23.9411; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HONORE E, 1992, EMBO J, V11, P2465, DOI 10.1002/j.1460-2075.1992.tb05311.x; HOPKINS WF, 1994, J NEUROSCI, V14, P1385, DOI 10.1523/JNEUROSCI.14-03-01385.1994; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Kobertz WR, 1999, NAT STRUCT BIOL, V6, P1122; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; LEE SC, 1992, J GEN PHYSIOL, V99, P771, DOI 10.1085/jgp.99.5.771; LEE TE, 1994, BIOPHYS J, V66, P667, DOI 10.1016/S0006-3495(94)80840-9; LEWIS RS, 1988, SCIENCE, V239, P771, DOI 10.1126/science.2448877; LEWIS RS, 1990, ANNU REV PHYSIOL, V52, P415; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; LINSE S, 1988, NATURE, V335, P651, DOI 10.1038/335651a0; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MCCORMACK K, 1991, P NATL ACAD SCI USA, V88, P2931, DOI 10.1073/pnas.88.7.2931; PANTOLIANO MW, 1988, BIOCHEMISTRY-US, V27, P8311, DOI 10.1021/bi00422a004; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PONGS O, 1992, TRENDS PHARMACOL SCI, V13, P359, DOI 10.1016/0165-6147(92)90109-J; Roux B, 1999, SCIENCE, V285, P100, DOI 10.1126/science.285.5424.100; SANGER F, 1977, P NATL ACAD SCI USA, V74, P560; Segal AS, 1999, BIOCHEM BIOPH RES CO, V254, P54, DOI 10.1006/bbrc.1998.9801; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; SLESINGER PA, 1993, NEURON, V11, P739, DOI 10.1016/0896-6273(93)90083-4; Yao XQ, 1998, BIOCHEM BIOPH RES CO, V249, P492, DOI 10.1006/bbrc.1998.9122; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	33	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10859	10863		10.1074/jbc.275.15.10859	http://dx.doi.org/10.1074/jbc.275.15.10859			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753881	hybrid			2022-12-27	WOS:000086466600023
J	Jedrzejas, MJ; Chander, M; Setlow, P; Krishnasamy, G				Jedrzejas, MJ; Chander, M; Setlow, P; Krishnasamy, G			Mechanism of catalysis of the cofactor-independent phosphoglycerate mutase from Bacillus stearothermophilus - Crystal structure of the complex with 2-phosphoglycerate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKALINE-PHOSPHATASE; ESCHERICHIA-COLI; PH; MEGATERIUM; METALLOENZYMES; GERMINATION; SPORULATION; MODELS	The structure of the complex between the 2,3-diphosphoglycerate-independent phosphoglycerate mutase (iPGM) hom Bacillus stearothennophilus and its 3-phosphoglycerate substrate has recently been solved, and analysis of this structure allowed formulation of a mechanism for iPGM catalysis. In order to obtain further evidence for this mechanism, we have solved the structure of this iPGM complexed with 2-phoshoglycerate and two Mn2+ ions at 1.7-Angstrom resolution. The structure consists of two different domains connected by two loops and interacting through a network of hydrogen bonds. This structure is consistent with the proposed mechanism for iPGM catalysis, with the two main steps in catalysis being a phosphatase reaction removing the phosphate from 2- or 3-phosphoglycerate, generating an enzyme-bound phosphoserine intermediate, followed by a phosphotransferase reaction as the phosphate is transferred from the enzyme back to the glycerate moiety, The structure also allowed the assignment of the function of the two domains of the enzyme, one of which participates in the phosphatase reaction and formation of the phosphoserine enzyme intermediate, with the other involved in the phosphotransferase reaction regenerating phosphoglycerate. Significant structural similarity has also been found between the active site of the iPGM domain catalyzing the phosphatase reaction and Escherichia coli alkaline phosphatase.	Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA; Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06030 USA	University of Alabama System; University of Alabama Birmingham; University of Connecticut	Jedrzejas, MJ (corresponding author), Univ Alabama Birmingham, Dept Microbiol, 933 19th St S,CHSB 19,Rm 545, Birmingham, AL 35294 USA.	jedrzejas@uab.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019698, R01GM019698] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19698] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOTHA FC, 1986, ARCH BIOCHEM BIOPHYS, V245, P96, DOI 10.1016/0003-9861(86)90193-1; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNNETT B, 1993, SURVEYS MATH IND, V3, P1; CARRERAS J, 1982, COMP BIOCHEM PHYS B, V71, P591, DOI 10.1016/0305-0491(82)90467-9; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Chander M, 1999, J STRUCT BIOL, V126, P156, DOI 10.1006/jsbi.1999.4112; Chander M, 1998, CAN J MICROBIOL, V44, P759, DOI 10.1139/cjm-44-8-759; Christianson DW, 1999, ANNU REV BIOCHEM, V68, P33, DOI 10.1146/annurev.biochem.68.1.33; Christianson DW, 1997, PROG BIOPHYS MOL BIO, V67, P217, DOI 10.1016/S0079-6107(97)88477-5; COLEMAN JE, 1992, ANNU REV BIOPH BIOM, V21, P441, DOI 10.1146/annurev.biophys.21.1.441; FOTHERGILLGILMORE LA, 1989, ADV ENZYMOL RAMB, V62, P227; Fraser HI, 1999, FEBS LETT, V455, P344, DOI 10.1016/S0014-5793(99)00910-2; Galperin MY, 1998, PROTEIN SCI, V7, P1829, DOI 10.1002/pro.5560070819; GATEHOUSE JA, 1977, BIOCHEMISTRY-US, V16, P3045, DOI 10.1021/bi00633a001; Harding MM, 1999, ACTA CRYSTALLOGR D, V55, P1432, DOI 10.1107/S0907444999007374; HOLM L, 1994, PROTEINS, V19, P165, DOI 10.1002/prot.340190302; Jedrzejas MJ, 2000, EMBO J, V19, P1419, DOI 10.1093/emboj/19.7.1419; JOHNSON CM, 1988, BIOCHEM J, V252, P111, DOI 10.1042/bj2520111; JONES SR, 1978, NATURE, V275, P564, DOI 10.1038/275564a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KUHN NJ, 1995, ARCH BIOCHEM BIOPHYS, V320, P35, DOI 10.1006/abbi.1995.1339; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MAGILL NG, 1994, J BACTERIOL, V176, P2252, DOI 10.1128/JB.176.8.2252-2258.1994; Magill NG, 1996, J BACTERIOL, V178, P2204, DOI 10.1128/jb.178.8.2204-2210.1996; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McPherson A., 1999, CRYSTALLIZATION BIOL; *MOL SIM INC, 1997, MOL SIM QUANTA; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEARSON RG, 1963, J AM CHEM SOC, V85, P3533, DOI 10.1021/ja00905a001; Rigden DJ, 1998, J MOL BIOL, V276, P449, DOI 10.1006/jmbi.1997.1554; SETLOW P, 1970, J BIOL CHEM, V245, P3637; SINGH RP, 1979, J BACTERIOL, V137, P1024, DOI 10.1128/JB.137.2.1024-1027.1979; SMITH GC, 1988, BIOCHEM BIOPH RES CO, V136, P336; SOWADSKI JM, 1985, J MOL BIOL, V186, P417, DOI 10.1016/0022-2836(85)90115-9; Stec B, 1998, J MOL BIOL, V277, P647, DOI 10.1006/jmbi.1998.1635; STERNBERG MJE, 1981, PHILOS T ROY SOC B, V293, P177, DOI 10.1098/rstb.1981.0071; SWERDLOW BM, 1981, J BACTERIOL, V148, P20, DOI 10.1128/JB.148.1.20-29.1981; VOET D, 1990, BIOCHEMISTRY-US, P451; WATABE K, 1979, J BACTERIOL, V137, P773, DOI 10.1128/JB.137.2.773-778.1979	40	40	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23146	23153		10.1074/jbc.M002544200	http://dx.doi.org/10.1074/jbc.M002544200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10764795	hybrid			2022-12-27	WOS:000088419400074
J	Berjukow, S; Marksteiner, R; Gapp, F; Sinnegger, MJ; Hering, S				Berjukow, S; Marksteiner, R; Gapp, F; Sinnegger, MJ; Hering, S			Molecular mechanism of calcium channel block by isradipine - Role of a drug-induced inactivated channel conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ CHANNELS; 1,4-DIHYDROPYRIDINE SENSITIVITY; DIHYDROPYRIDINE SENSITIVITY; DETERMINANTS; VOLTAGE; SUBUNIT; ALPHA(1C); RECEPTOR; BINDING; RESIDUES	The role of the inactivated channel conformation in the molecular mechanism of Ca2+ channel block by the 1,4-dihydropyridine (DHP) (+)-isradipine was analyzed in L-type channel constructs (alpha(1LC); Berjukow, S., Gapp, F., Aczel, S., Sinnegger, M. J., Mitterdorfer, J., Glossmann, H., and Hering, S. (1999) J. Biol. Chem. 274, 6154-6160) and a DHP-sensitive class A Ca2+ channel mutant (alpha(1A-DHP); Sinnegger, M. J,, Wang, Z,, Grabner, RI., Hering, S., Striessnig, J., Glossmann, H., and Mitterdorfer, J. (1997) J. Biol Chem. 272, 27686-27693) carrying the high affinity determinants of the DHP receptor site but inactivating at different rates. Ca2+ channel inactivation was modulated by coexpressing the alpha(1A-DHP)- or alpha(1LC)-subunits in Xenopus oocytes with either the beta(2a)- or the beta(1a)-subunit and amino acid substitutions in L-type segment IVS6 (I1497A, I1498A, and V1504A). Contrary to a modulated receptor mechanism assuming high affinity DHP binding to the inactivated state we observed no clear correlation between steady state inactivation and Ca2+ channel block by (+)-isradipine: (i) a 3-fold larger fraction of alpha(1A-DHP/beta 1a), channels in steady state inactivation at -80 mV (compared with alpha(1A-DHP)/beta(2a)) did not enhance the block by (+)-isradipine; (ii) different steady state inactivation of alpha(1Lc) mutants at -30 mV did not correlate with voltage-dependent channel block; and (iii) the midpoint-voltages of the inactivation curves of slowly inactivating L-type constructs and more rapidly inactivating alpha(1Lc)/beta(1a) channels were shifted to a comparable extent to more hyperpolarized voltages. A kinetic analysis of (+)-isradipine interaction with different L-type channel constructs revealed a drug-induced inactivated state. Entry and recovery from drug-induced inactivation are modulated by intrinsic inactivation determinants, suggesting a synergism between intrinsic inactivation and DHP block.	Inst Biochem Pharmakol, A-6020 Innsbruck, Austria		Hering, S (corresponding author), Inst Biochem Pharmakol, Peter Mayr Str 1, A-6020 Innsbruck, Austria.			Brauns, Martina/0000-0002-0547-2731				BEAN BP, 1984, P NATL ACAD SCI-BIOL, V81, P6388, DOI 10.1073/pnas.81.20.6388; Berjukow S, 1999, J BIOL CHEM, V274, P6154, DOI 10.1074/jbc.274.10.6154; Bodi I, 1997, J BIOL CHEM, V272, P24952, DOI 10.1074/jbc.272.40.24952; CATTERALL WA, 1994, CURR OPIN CELL BIOL, V6, P607, DOI 10.1016/0955-0674(94)90083-3; Cens T, 1999, J BIOL CHEM, V274, P5483, DOI 10.1074/jbc.274.9.5483; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; Hering S, 1998, TRENDS PHARMACOL SCI, V19, P439, DOI 10.1016/S0165-6147(98)01258-9; HILLE B, 1977, J GEN PHYSIOL, V69, P497, DOI 10.1085/jgp.69.4.497; HILLE B, 1978, BIOPHYSICAL ASPECTS, P55; Hockerman GH, 1997, ANNU REV PHARMACOL, V37, P361, DOI 10.1146/annurev.pharmtox.37.1.361; Hu H, 1998, MOL PHARMACOL, V53, P902; Ito H, 1997, MOL PHARMACOL, V52, P735, DOI 10.1124/mol.52.4.735; Lacinova L, 1998, RECEPTOR CHANNEL, V6, P153; Lacinova L, 1999, FEBS LETT, V451, P152, DOI 10.1016/S0014-5793(99)00573-6; Liu HY, 1996, J NEUROSCI, V16, P7557; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Peterson BZ, 1997, J BIOL CHEM, V272, P18752, DOI 10.1074/jbc.272.30.18752; Peterson BZ, 1996, J BIOL CHEM, V271, P5293, DOI 10.1074/jbc.271.10.5293; Pichler M, 1997, J BIOL CHEM, V272, P13877, DOI 10.1074/jbc.272.21.13877; SANGUINETTI MC, 1984, CIRC RES, V55, P336, DOI 10.1161/01.RES.55.3.336; Sinnegger MJ, 1997, J BIOL CHEM, V272, P27686, DOI 10.1074/jbc.272.44.27686; Striessnig J, 1998, TRENDS PHARMACOL SCI, V19, P108, DOI 10.1016/S0165-6147(98)01171-7; TANG SQ, 1993, NEURON, V11, P1013, DOI 10.1016/0896-6273(93)90215-D; Walker D, 1998, TRENDS NEUROSCI, V21, P148, DOI 10.1016/S0166-2236(97)01200-9; Welling A, 1997, CIRC RES, V81, P526, DOI 10.1161/01.RES.81.4.526; Zuhlke RD, 1998, FEBS LETT, V427, P220, DOI 10.1016/S0014-5793(98)00425-6	26	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22114	22120		10.1074/jbc.M908836199	http://dx.doi.org/10.1074/jbc.M908836199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10766758	hybrid			2022-12-27	WOS:000088363800052
J	Bingle, CD; Craig, RW; Swales, BM; Singleton, V; Zhou, P; Whyte, MKB				Bingle, CD; Craig, RW; Swales, BM; Singleton, V; Zhou, P; Whyte, MKB			Exon skipping in Mcl-1 results in a Bcl-2 homology domain 3 only gene product that promotes cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; FAMILY MEMBER; IMMUNOHISTOCHEMICAL ANALYSIS; BCL-2-RELATED GENE; SIGNALING PATHWAY; HUMAN NEUTROPHILS; OUTER-MEMBRANE; B-LYMPHOCYTES; X ISOFORM; IN-VITRO	Mcl-1 is a member of the Bcl-2 family that is regulated transcriptionally and post-transcriptionally, with expression of the full-length Mcl-1-encoded gene product resulting in enhanced cell survival. As reported here, the human Mcl-1 gene can also undergo differential splicing, which yields an internally deleted, death-inducing gene product, Mcl-1(s/Delta TM) . Whereas full-length Mcl-1 derives from three coding exons (instead of the two present in Bcl-2 and other anti-apoptotic members of this family), the Mcl-1(s/Delta TM) splice variant results from the joining of the first and third exons with skipping of the central exon. Because of the skipped exon and a shift in the reading frame downstream, the Bcl-2 homology domain (BH3) remains intact, whereas the BH1-, BH2-, and transmembrane-encoding domains do not. Mcl-1(s/Delta TM) thus has features similar to BH3 only, pro-apoptotic Bcl-2 family members and, accordingly, was found to promote cell death. In addition to a variety of other types of regulation, the Mcl-1 gene appears ideally designed for the generation of either a Bcl-2-like viability promoting or, as reported here, a BH3 only death-inducing gene product.	Univ Sheffield, Sch Med, Div Mol & Genet Med, Resp Cell & Mol Biol Lab, Sheffield S10 2RX, S Yorkshire, England; Dartmouth Med Sch, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA	University of Sheffield; Dartmouth College	Bingle, CD (corresponding author), Univ Sheffield, Sch Med, Royal Hallamshire Hosp, Div Mol & Genet Med, M128,Glossop Rd, Sheffield S10 2RX, S Yorkshire, England.	c.d.bingle@sheffield.ac.uk	Whyte, Moira/E-6210-2010	Bingle, Colin/0000-0002-5405-6988	NCI NIH HHS [CA57359] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057359] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altmeyer A, 1997, IMMUNITY, V7, P667, DOI 10.1016/S1074-7613(00)80387-8; Ban J, 1998, BIOCHEM BIOPH RES CO, V248, P147, DOI 10.1006/bbrc.1998.8907; Bieszczad C. K., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P134; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; Choi SS, 1997, MAMM GENOME, V8, P781, DOI 10.1007/s003359900567; Chuang PI, 1998, BIOCHEM BIOPH RES CO, V249, P361, DOI 10.1006/bbrc.1998.9155; Druilhe A, 1998, AM J RESP CELL MOL, V18, P315, DOI 10.1165/ajrcmb.18.3.3019; Evans DL, 1995, J MOL EVOL, V41, P775; FANG W, 1994, J IMMUNOL, V153, P4388; Gibson L, 1996, ONCOGENE, V13, P665; Grillot DAM, 1997, J IMMUNOL, V158, P4750; GROSS A, 1999, GENE DEV, V13, P632; HASLETT C, 1985, AM J PATHOL, V119, P101; Hatakeyama S, 1998, INT IMMUNOL, V10, P631, DOI 10.1093/intimm/10.5.631; Herberg JA, 1998, GENE, V211, P87, DOI 10.1016/S0378-1119(98)00101-2; Hsu SY, 1998, J BIOL CHEM, V273, P30139, DOI 10.1074/jbc.273.46.30139; Hsu SY, 1997, P NATL ACAD SCI USA, V94, P12401, DOI 10.1073/pnas.94.23.12401; Inohara N, 1998, J BIOL CHEM, V273, P8705, DOI 10.1074/jbc.273.15.8705; Jiang ZH, 1999, P SOC EXP BIOL MED, V220, P64, DOI 10.1046/j.1525-1373.1999.d01-11.x; KELEKER A, 1998, TRENDS CELL BIOL, P324; Klampfer L, 1999, CYTOKINE, V11, P849, DOI 10.1006/cyto.1999.0514; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KRAJEWSKI S, 1994, AM J PATHOL, V145, P515; KRAJEWSKI S, 1995, AM J PATHOL, V146, P1309; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liston DR, 1999, MOL CELL BIOL, V19, P2380; Lomo J, 1997, BLOOD, V89, P4415; Moriishi K, 1999, P NATL ACAD SCI USA, V96, P9683, DOI 10.1073/pnas.96.17.9683; Moulding DA, 1998, BLOOD, V92, P2495, DOI 10.1182/blood.V92.7.2495.2495_2495_2502; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NAKAI M, 1993, BIOCHEM BIOPH RES CO, V196, P233, DOI 10.1006/bbrc.1993.2239; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Reynolds JE, 1996, EXP CELL RES, V225, P430, DOI 10.1006/excr.1996.0194; REYNOLDS JE, 1994, CANCER RES, V54, P6348; Rinkenberger JL, 2000, GENE DEV, V14, P23; Rudin CM, 1997, ANNU REV MED, V48, P267; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Shiraiwa N, 1996, J BIOL CHEM, V271, P13258, DOI 10.1074/jbc.271.22.13258; TANAKA S, 1993, J BIOL CHEM, V268, P10920; Taylor JK, 1999, NAT BIOTECHNOL, V17, P1097, DOI 10.1038/15079; Townsend KJ, 1998, ONCOGENE, V17, P1223, DOI 10.1038/sj.onc.1202035; Townsend KJ, 1999, J BIOL CHEM, V274, P1801, DOI 10.1074/jbc.274.3.1801; Ulrich E, 1997, GENOMICS, V44, P195, DOI 10.1006/geno.1997.4858; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Wang K, 1998, GENOMICS, V53, P235, DOI 10.1006/geno.1998.5489; Whyte M, 1999, BIOCHEM SOC T, V27, P802, DOI 10.1042/bst0270802; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1993, BRIT J CANCER, V67, P205, DOI 10.1038/bjc.1993.40; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Yang XF, 1997, IMMUNITY, V7, P629, DOI 10.1016/S1074-7613(00)80384-2; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630; Zhou P, 1998, BLOOD, V92, P3226, DOI 10.1182/blood.V92.9.3226.421k49_3226_3239	64	150	160	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22136	22146		10.1074/jbc.M909572199	http://dx.doi.org/10.1074/jbc.M909572199			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10766760	hybrid			2022-12-27	WOS:000088363800055
J	Jones, G; Jones, D; Zhou, L; Steller, H; Chu, YX				Jones, G; Jones, D; Zhou, L; Steller, H; Chu, YX			Deterin, a new inhibitor of apoptosis from Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; BACULOVIRUS INHIBITOR; CHROMOSOME SEGREGATION; MAMMALIAN-CELLS; GENE; IAP; PROTEINS; CASPASES; FAMILY; SURVIVIN	Deterin, a new apoptosis inhibitor from Drosophila melanogaster, possesses an unusual structure of only a single baculovirus inhibitor of apoptosis (LAP)-type repeat and no RING finger motif. The biochemical actions of deterin are demonstrated in SF9 and S2 cell transfection assays, in which the expressed protein acts in the cytoplasm to inhibit or deter cells from apoptosis otherwise induced by the caspase-dependent apoptosis activator reaper or by cytotoxicants, A loss of function phenotype for deterin of cell death was indicated by transfections with either a dominant negative deterin mutant or with inhibitory RNA (RNAi) for deterin, The dominant negative C-terminal fragment that antagonized antiapoptotic activity of deterin did not affect antiapoptotic activity of DIAP1 or p35. Both the baculovirus IAP-type repeat (BIR) domain and the alpha-helical C-terminal domain are necessary in both SF9 and 52 cells for deterin to manifest its activity to prevent cell death. The approximately 650-base deterin transcript is present in embryos, third instar larvae, acid late stage nurse cells of adult females. The deterin transcript is distributed throughout early stage embryos, whereas in later stage embryos it becomes progressively restricted to the central nervous system and gonads. Whereas the nematode survivin-type ZAP has thus far been implicated only as a mitotic regulator, Drosophila deterin constitutes the first invertebrate member of the sunvivin-type IAP group to exhibit apoptosis-inhibitory activity.	Univ Kentucky, Sch Biol Sci, Mol & Cellular Sect, Lexington, KY 40506 USA; Univ Kentucky, Chandler Med Ctr, Grad Ctr Toxicol, Lexington, KY 40536 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	University of Kentucky; University of Kentucky; Massachusetts Institute of Technology (MIT)	Jones, G (corresponding author), Univ Kentucky, Sch Biol Sci, Mol & Cellular Sect, Lexington, KY 40506 USA.				NIDDK NIH HHS [DK39197] Funding Source: Medline; NIGMS NIH HHS [GM 33995, GM 60121] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060121] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; ANDRES AJ, 1994, METHOD CELL BIOL, V44, P565, DOI 10.1016/S0091-679X(08)60932-2; Aramaki Y, 1999, FEBS LETT, V460, P472, DOI 10.1016/S0014-5793(99)01386-1; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Claveria C, 1998, EMBO J, V17, P7199, DOI 10.1093/emboj/17.24.7199; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Dorstyn L, 1999, J BIOL CHEM, V274, P30778, DOI 10.1074/jbc.274.43.30778; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Ebert O, 1997, GENE THER, V4, P296, DOI 10.1038/sj.gt.3300394; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Foley K, 1998, DEVELOPMENT, V125, P1075; Fraser AG, 1997, EMBO J, V16, P6192, DOI 10.1093/emboj/16.20.6192; Fraser AG, 1999, CURR BIOL, V9, P292, DOI 10.1016/S0960-9822(99)80137-7; Green D R, 1998, Results Probl Cell Differ, V24, P45; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; Harvey AJ, 1997, CELL DEATH DIFFER, V4, P733, DOI 10.1038/sj.cdd.4400294; Hauser HP, 1998, J CELL BIOL, V141, P1415, DOI 10.1083/jcb.141.6.1415; Hawkins CJ, 1999, P NATL ACAD SCI USA, V96, P2885, DOI 10.1073/pnas.96.6.2885; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hunter CP, 1999, CURR BIOL, V9, pR440, DOI 10.1016/S0960-9822(99)80276-0; Imamura C, 1997, BIOL PHARM BULL, V20, P1119; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jiang CG, 1997, DEVELOPMENT, V124, P4673; Jones G, 1996, GENE, V173, P209, DOI 10.1016/0378-1119(96)00100-X; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; LOCKSHIN RICHARD A., 1965, J INSECT PHYSIOL, V11, P831, DOI 10.1016/0022-1910(65)90186-1; Long AR, 1998, MECH DEVELOP, V76, P33, DOI 10.1016/S0925-4773(98)00110-5; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Neilan JG, 1997, VIROLOGY, V230, P252, DOI 10.1006/viro.1997.8481; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; PARDUE ML, 1994, METHODS CELL BIOL DR, P334; Rajagopalan S, 1999, FEBS LETT, V460, P187, DOI 10.1016/S0014-5793(99)01329-0; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Tamm I, 1998, CANCER RES, V58, P5315; Uren AG, 1998, TRENDS BIOCHEM SCI, V23, P159, DOI 10.1016/S0968-0004(98)01198-0; Uren AG, 1999, P NATL ACAD SCI USA, V96, P10170, DOI 10.1073/pnas.96.18.10170; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Vucic D, 1998, J BIOL CHEM, V273, P33915, DOI 10.1074/jbc.273.51.33915; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yoon HJ, 1999, P NATL ACAD SCI USA, V96, P13208, DOI 10.1073/pnas.96.23.13208; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	58	75	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22157	22165		10.1074/jbc.M000369200	http://dx.doi.org/10.1074/jbc.M000369200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10764741	hybrid			2022-12-27	WOS:000088363800057
J	Leguy, R; Melki, R; Pantaloni, D; Carlier, MF				Leguy, R; Melki, R; Pantaloni, D; Carlier, MF			Monomeric gamma-tubulin nucleates microtubules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINDLE POLE BODY; POLYACRYLAMIDE-GEL-ELECTROPHORESIS; SACCHAROMYCES-CEREVISIAE; ASPERGILLUS-NIDULANS; MAMMALIAN BRAIN; IN-VITRO; CENTROSOME; PROTEIN; BINDING; END	gamma-Tubulin is required for nucleation and polarized organization of microtubules in vivo. The mechanism of microtubule nucleation by gamma-tubulin and the role of associated proteins is not understood. Here we show that in vitro translated monomeric gamma-tubulin nucleates microtubules by lowering the size of the nucleus from seven to three tubulin subunits, In capping the minus end with high affinity (10(10) M-1) and a binding stoichiometry of one molecule of gamma-tubulin/microtubule, gamma-tubulin establishes the critical concentration of the plus end in the medium and prevents minus end growth. gamma-Tubulin interacts strongly with beta-tubulin. A structural model accounts for these results.	CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Carlier, MF (corresponding author), CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France.	carlier@lebs.cnrs-gif.fr						BERGEN LG, 1980, J CELL BIOL, V84, P141, DOI 10.1083/jcb.84.1.141; BEST D, 1981, ANAL BIOCHEM, V114, P281, DOI 10.1016/0003-2697(81)90481-4; BRYAN J, 1971, P NATL ACAD SCI USA, V68, P1762, DOI 10.1073/pnas.68.8.1762; CARLIER MF, 1984, P NATL ACAD SCI-BIOL, V81, P771, DOI 10.1073/pnas.81.3.771; Carlier MF, 1997, BIOPHYS J, V73, P418, DOI 10.1016/S0006-3495(97)78081-0; CLAYTON L, 1980, FEBS LETT, V115, P301, DOI 10.1016/0014-5793(80)81192-6; Detraves C, 1997, CELL MOTIL CYTOSKEL, V36, P179, DOI 10.1002/(SICI)1097-0169(1997)36:2<179::AID-CM7>3.0.CO;2-4; Erickson HP, 1996, J CELL BIOL, V135, P5, DOI 10.1083/jcb.135.1.5; ERICKSON HP, 1981, BIOPHYS J, V34, P293, DOI 10.1016/S0006-3495(81)84850-3; FARRELL KW, 1987, J CELL BIOL, V104, P1035, DOI 10.1083/jcb.104.4.1035; FELIX MA, 1994, J CELL BIOL, V124, P19, DOI 10.1083/jcb.124.1.19; Flyvbjerg H, 1996, P NATL ACAD SCI USA, V93, P5975, DOI 10.1073/pnas.93.12.5975; FYGENSON DK, 1995, PHYS REV E, V51, P5058, DOI 10.1103/PhysRevE.51.5058; HORIO T, 1991, J CELL SCI, V99, P693; HORIO T, 1986, NATURE, V321, P605, DOI 10.1038/321605a0; HOWARD WD, 1986, BIOCHEMISTRY-US, V25, P8292, DOI 10.1021/bi00373a025; Jeng R, 1999, TRENDS CELL BIOL, V9, P339, DOI 10.1016/S0962-8924(99)01621-9; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; JOSHI HC, 1994, CURR OPIN CELL BIOL, V6, P55, DOI 10.1016/0955-0674(94)90116-3; KEATES RAB, 1988, SCIENCE, V241, P1642, DOI 10.1126/science.3420415; KELLOGG DR, 1994, ANNU REV BIOCHEM, V63, P639, DOI 10.1146/annurev.bi.63.070194.003231; Knop M, 1997, EMBO J, V16, P1550, DOI 10.1093/emboj/16.7.1550; Knop M, 1997, EMBO J, V16, P6985, DOI 10.1093/emboj/16.23.6985; LI QQ, 1995, J CELL BIOL, V131, P207, DOI 10.1083/jcb.131.1.207; Llanos R, 1999, BIOCHEMISTRY-US, V38, P15712, DOI 10.1021/bi990895w; MARGOLIS RL, 1978, CELL, V13, P1, DOI 10.1016/0092-8674(78)90132-0; MEADS T, 1995, CELL MOTIL CYTOSKEL, V32, P273, DOI 10.1002/cm.970320404; MELKI R, 1993, J CELL BIOL, V122, P1301, DOI 10.1083/jcb.122.6.1301; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; MITCHISON TJ, 1993, SCIENCE, V261, P1044, DOI 10.1126/science.8102497; Moritz M, 1998, J CELL BIOL, V142, P775, DOI 10.1083/jcb.142.3.775; MORITZ M, 1995, NATURE, V378, P638, DOI 10.1038/378638a0; Murphy SM, 1998, J CELL BIOL, V141, P663, DOI 10.1083/jcb.141.3.663; OAKLEY BR, 1990, CELL, V61, P1289, DOI 10.1016/0092-8674(90)90693-9; OAKLEY CE, 1989, NATURE, V338, P662, DOI 10.1038/338662a0; Oegema K, 1999, J CELL BIOL, V144, P721, DOI 10.1083/jcb.144.4.721; OOSAWA F, 1975, THERMODYNAMICS POLYM, P41; Rodionov VI, 1997, SCIENCE, V275, P215, DOI 10.1126/science.275.5297.215; Ruiz F, 1999, CURR BIOL, V9, P43, DOI 10.1016/S0960-9822(99)80045-1; Sobel SG, 1995, J CELL BIOL, V131, P1775, DOI 10.1083/jcb.131.6.1775; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; SUNKEL CE, 1995, EMBO J, V14, P28, DOI 10.1002/j.1460-2075.1995.tb06972.x; VASSILEV A, 1995, J CELL SCI, V108, P1083; VOTER WA, 1984, J BIOL CHEM, V259, P430; WILLIAMS RC, 1989, J BIOL CHEM, V264, P1663; YAMAUCHI PS, 1993, J NEUROCHEM, V60, P817, DOI 10.1111/j.1471-4159.1993.tb03225.x; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	47	54	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21975	21980		10.1074/jbc.M000688200	http://dx.doi.org/10.1074/jbc.M000688200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10764751	hybrid			2022-12-27	WOS:000088363800032
J	Boehning, D; Joseph, SK				Boehning, D; Joseph, SK			Functional properties of recombinant type I and type III inositol 1,4,5-trisphosphate receptor isoforms expressed in COS-7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRISPHOSPHATE RECEPTORS; ENDOPLASMIC-RETICULUM; INSP(3) RECEPTOR; CALCIUM RELEASE; L-FIBROBLASTS; CHANNEL; CA2+; ASSOCIATION; COMPLEX; BINDING	Inositol 1,4,5-trisphosphate receptors (IP(3)Rs) are ubiquitous intracellular Ca2+ release channels whose functional characterization by transfection has proved difficult due to the background contribution of endogenous channels. In order to develop a functional assay to measure recombinant channels, we transiently transfected the rat type I IP3R into COS-7 cells. Saponin-permeabilized COS cells transfected with type I IP3R showed a 50% increase in inositol 1,4,5-trisphosphate (IP3)-mediated Ca2+ release at saturating [IP3] (10 mu M) but no enhancement at subsaturating [IP3] (300 nM). However, cotransfection of the IP3R and human sarco/endoplasmic reticulum ATPase (SERCA)-2b ATPase cDNA resulted in 60 and 110% increases in Ca2+ release at subsaturating and saturating doses of IP3, respectively. IP3 or adenophostin A failed to release Ca-45(2+) from microsomal vesicles prepared from cells expressing either type I IP3R or SERCA cDNAs alone. However, microsomal vesicles prepared from cells doubly transfected with IP3R and SERCA cDNAs released 33.0 +/- 0.04% of the A23187-sensitive pool within 30 a of 1 mu M adenophostin A addition. Similarly, the initial rate of Ca-45(2+) influx into oxalate-loaded microsomal vesicles was inhibited by IP3 only when the microsomes were prepared from COS cells doubly transfected with SERCA-2b and IP3R DNA. The absence of a functional contribution from endogenous IP(3)Rs has enabled the use of this assay to measure the Ca2+ sensitivities of IP3-mediated Ca-45(2+) fluxes through recombinant neuronal type I (SII(+)), peripheral type I (SII(-)), and type III IP(3)Rs. All three channels displayed a biphasic dependence upon [Ca2+](cyt). Introduction of mutations D2550A and D2550N in the putative pore-forming region of the type I IP3R inhibited IP3-mediated Ca-45(2+) fluxes, whereas the conservative substitution D2550E was without effect. This assay therefore provides a useful tool for studying the regulatory properties of individual IP3R isoforms as well as for screening pore mutations prior to more detailed electrophysiological analyses.	Thomas Jefferson Univ, Dept Pathol & Cell Biol, Sch Med, Philadelphia, PA 19107 USA	Jefferson University	Joseph, SK (corresponding author), Thomas Jefferson Univ, Dept Pathol & Cell Biol, Sch Med, 1020 Locust St,Rm 230A,JAH, Philadelphia, PA 19107 USA.	suresh.k.joseph@mail.tju.edu	Boehning, Darren/I-8539-2015	Boehning, Darren/0000-0001-7920-6922	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [T32AA007463] Funding Source: NIH RePORTER; NIAAA NIH HHS [T32-AA07463] Funding Source: Medline; NIDDK NIH HHS [R01-DK34804] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEZPROZVANNY I, 1995, J MEMBRANE BIOL, V145, P205; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; Cameron AM, 1997, J BIOL CHEM, V272, P27582, DOI 10.1074/jbc.272.44.27582; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; Davis RJ, 1999, BIOCHEM J, V341, P813, DOI 10.1042/0264-6021:3410813; DAWSON AP, 1985, FEBS LETT, V185, P147, DOI 10.1016/0014-5793(85)80759-6; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Dufour JF, 1999, HEPATOLOGY, V30, P1018, DOI 10.1002/hep.510300421; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; Hagar RE, 1998, NATURE, V396, P81, DOI 10.1038/23954; Joseph SK, 2000, J BIOL CHEM, V275, P16084, DOI 10.1074/jbc.M000506200; Joseph SK, 1997, J BIOL CHEM, V272, P1579, DOI 10.1074/jbc.272.3.1579; JOSEPH SK, 1995, BIOCHEM J, V307, P859, DOI 10.1042/bj3070859; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; JOSEPH SK, 1995, J BIOL CHEM, V270, P23310, DOI 10.1074/jbc.270.40.23310; Joseph SK, 1999, BIOCHEM J, V342, P153, DOI 10.1042/0264-6021:3420153; JOSEPH SK, 1988, BIOCHIM BIOPHYS ACTA, V945, P185, DOI 10.1016/0005-2736(88)90481-6; Kaznacheyeva E, 1998, J GEN PHYSIOL, V111, P847, DOI 10.1085/jgp.111.6.847; KIRSCH GE, 1995, BIOPHYS J, V68, P1804, DOI 10.1016/S0006-3495(95)80357-7; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Lin C, 2000, J BIOL CHEM, V275, P2305, DOI 10.1074/jbc.275.4.2305; LYTTON J, 1992, J BIOL CHEM, V267, P14483; Mackrill JJ, 1996, BIOCHEM J, V318, P871, DOI 10.1042/bj3180871; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; Mak DOD, 1998, AM J PHYSIOL-CELL PH, V275, pC179, DOI 10.1152/ajpcell.1998.275.1.C179; Mak DOD, 2000, J GEN PHYSIOL, V115, P241, DOI 10.1085/jgp.115.3.241; Mak DOD, 1999, J BIOL CHEM, V274, P22231, DOI 10.1074/jbc.274.32.22231; Michikawa T, 1999, NEURON, V23, P799, DOI 10.1016/S0896-6273(01)80037-4; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; MOLINA A, 1998, J PHYSIOL-LONDON, P237; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; MULLANEY JM, 1988, P NATL ACAD SCI USA, V85, P2499, DOI 10.1073/pnas.85.8.2499; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; Nucifora FC, 1996, MOL BIOL CELL, V7, P949, DOI 10.1091/mbc.7.6.949; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Ramos-Franco J, 1998, BIOPHYS J, V75, P2783, DOI 10.1016/S0006-3495(98)77721-5; Ramos-Franco J, 1999, J GEN PHYSIOL, V114, P243, DOI 10.1085/jgp.114.2.243; Ramos-Franco J, 1998, BIOPHYS J, V75, P834, DOI 10.1016/S0006-3495(98)77572-1; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; Swatton JE, 1999, BIOCHEM J, V344, P55, DOI 10.1042/0264-6021:3440055; Taylor CW, 1999, CELL CALCIUM, V26, P237, DOI 10.1054/ceca.1999.0090; THOMAS AP, 1988, J BIOL CHEM, V263, P2704; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; WOJCIKIEWICZ RJH, 1995, BIOCHEM BIOPH RES CO, V213, P334, DOI 10.1006/bbrc.1995.2134; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; Zhao MC, 1999, J BIOL CHEM, V274, P25971, DOI 10.1074/jbc.274.37.25971	57	72	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21492	21499		10.1074/jbc.M001724200	http://dx.doi.org/10.1074/jbc.M001724200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10764774	hybrid			2022-12-27	WOS:000088230600072
J	Cassina, AM; Hodara, R; Souza, JM; Thomson, L; Castro, L; Ischiropoulos, H; Freeman, BA; Radi, R				Cassina, AM; Hodara, R; Souza, JM; Thomson, L; Castro, L; Ischiropoulos, H; Freeman, BA; Radi, R			Cytochrome c nitration by peroxynitrite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ELECTRON-TRANSPORT; MANGANESE-SUPEROXIDE-DISMUTASE; NITRIC-OXIDE SYNTHASE; TYROSINE NITRATION; HYDROGEN-PEROXIDE; HORSERADISH-PEROXIDASE; REVERSIBLE INHIBITION; CATALYZED OXIDATION; LIPID-PEROXIDATION; RESPIRATION	Peroxynitrite (ONOO-), the product of superoxide (O-2(.-)) and nitric oxide ((NO)-N-.) reaction, inhibits mitochondrial respiration and can stimulate apoptosis. Cytochrome c, a mediator of these two aspects of mitochondrial function, thus represents an important potential target of ONOO- during conditions involving accelerated rates of oxygen radical and (NO)-N-. generation. Horse heart cytochrome c(3+) was nitrated by ONOO-, as indicated by spectral changes, Western blot analysis, and mass spectrometry. A dose-dependent loss of cytochrome c(3+) 695 nm absorption occurred, inferring that nitration of a critical heme-vicinal tyrosine (Tyr-67) promoted a conformational change, displacing the Met-80 heme ligand. Nitration was confirmed by cross-reactivity with a specific antibody against 3-nitrotyrosine and by increased molecular mass compatible with the addition of a nitro-(-NO2) group. Mass analysis of tryptic digests indicated the preferential nitration of Tyr-67 among the four conserved tyrosine residues in cytochrome c. Cytochrome c(3+) was more extensively nitrated than cytochrome c(2+) because of the preferential oxidation of the reduced heme by ONOO-. Similar protein nitration patterns were obtained by ONOO- reaction in the presence of carbon dioxide, whereupon secondary nitrating species arise from the decomposition of the nitroso-peroxocarboxylate (ONOOCO2-) intermediate. Peroxynitrite-nitrated cytochrome c displayed significant changes in redox properties, including (a) increased peroxidatic activity, (b) resistance to reduction by ascorbate, and (c) impaired support of state 4-dependent respiration in intact rat heart mitochondria. These results indicate that cytochrome c nitration may represent both oxidative and signaling events occurring during (NO)-N-.- and ONOO--mediated cell injury.	Univ Republ, Fac Med, Dept Bioquim, Montevideo 11800, Uruguay; Univ Republ, Fac Ciencias, Inst Quim Biol, Lab Enzimol, Montevideo 11800, Uruguay; Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; Univ Alabama, Dept Anesthesiol, Birmingham, AL 35233 USA; Univ Alabama, Dept Biochem, Birmingham, AL 35233 USA; Univ Alabama, Dept Mol Genet, Birmingham, AL 35233 USA; Univ Alabama, UAB Ctr Rad Biol, Birmingham, AL 35233 USA	Universidad de la Republica, Uruguay; Universidad de la Republica, Uruguay; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Radi, R (corresponding author), Univ Republ, Fac Med, Dept Bioquim, Ave Gen Flores 2125, Montevideo 11800, Uruguay.		Freeman, Bruce A/H-9342-2012; Thomson, Leonor/C-4684-2008	Thomson, Leonor/0000-0002-2574-8520	FIC NIH HHS [R03-TW0099] Funding Source: Medline; NHLBI NIH HHS [HL54926] Funding Source: Medline; NIA NIH HHS [AG13966] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013966] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; BATES TE, 1995, BIOCHEM BIOPH RES CO, V213, P896, DOI 10.1006/bbrc.1995.2213; BECHMAN G, 1992, MOL MECHANISMS BIOEN, V23, P199; Berlett BS, 1998, P NATL ACAD SCI USA, V95, P2784, DOI 10.1073/pnas.95.6.2784; Boczkowski J, 1999, FASEB J, V13, P1637, DOI 10.1096/fasebj.13.12.1637; Borutaite V, 1999, BBA-MOL BASIS DIS, V1453, P41, DOI 10.1016/S0925-4439(98)00082-9; Borutaite V, 1996, BIOCHEM J, V315, P295, DOI 10.1042/bj3150295; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brito C, 1999, J IMMUNOL, V162, P3356; BROWN GC, 1994, FEBS LETT, V356, P295, DOI 10.1016/0014-5793(94)01290-3; Cassina A, 1996, ARCH BIOCHEM BIOPHYS, V328, P309, DOI 10.1006/abbi.1996.0178; Chauhan D, 1997, J BIOL CHEM, V272, P29995, DOI 10.1074/jbc.272.48.29995; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631; Denicola A, 1998, P NATL ACAD SCI USA, V95, P3566, DOI 10.1073/pnas.95.7.3566; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; Dickerson R., 1975, ENZYMES, V11, P397; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; FLORENCE TM, 1985, J INORG BIOCHEM, V23, P131, DOI 10.1016/0162-0134(85)83017-8; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; Goodwin DC, 1999, FASEB J, V13, P1121, DOI 10.1096/fasebj.13.10.1121; Grisham MB, 1999, AM J PHYSIOL-GASTR L, V276, pG315, DOI 10.1152/ajpgi.1999.276.2.G315; Hampton MB, 1998, BIOCHEM J, V329, P95; Hortelano S, 1999, FASEB J, V13, P2311, DOI 10.1096/fasebj.13.15.2311; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Lemercier JN, 1997, ARCH BIOCHEM BIOPHYS, V345, P160, DOI 10.1006/abbi.1997.0240; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lizasoain I, 1996, BIOCHEM J, V314, P877, DOI 10.1042/bj3140877; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; Millett F., 1996, CYTOCHROME C MULTIDI, P475; Quaroni L, 1999, BIOSPECTROSCOPY, V5, pS71, DOI 10.1002/(SICI)1520-6343(1999)5:5+<S71::AID-BSPY8>3.0.CO;2-T; RADI R, 1991, J BIOL CHEM, V266, P4244; Radi R, 1998, CHEM RES TOXICOL, V11, P720, DOI 10.1021/tx980096z; RADI R, 1993, FREE RADICAL BIO MED, V15, P653, DOI 10.1016/0891-5849(93)90169-U; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P112, DOI 10.1016/0003-9861(91)90171-E; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P118, DOI 10.1016/0003-9861(91)90172-F; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; Salamon Z, 1997, J BIOENERG BIOMEMBR, V29, P211, DOI 10.1023/A:1022401825287; Sampson JB, 1996, METHOD ENZYMOL, V269, P210; Sampson JB, 1998, ARCH BIOCHEM BIOPHYS, V356, P207, DOI 10.1006/abbi.1998.0772; Scarlett JL, 1997, FEBS LETT, V418, P282, DOI 10.1016/S0014-5793(97)01391-4; SCHEJTER A, 1970, BIOCHEMISTRY-US, V9, P5118, DOI 10.1021/bi00828a012; SCHWEIZER M, 1994, BIOCHEM BIOPH RES CO, V204, P169, DOI 10.1006/bbrc.1994.2441; Sharpe MA, 1998, BIOCHEM J, V332, P9, DOI 10.1042/bj3320009; SKOV K, 1969, CAN J BIOCHEM CELL B, V47, P750, DOI 10.1139/o69-114; Skulachev VP, 1998, FEBS LETT, V423, P275, DOI 10.1016/S0014-5793(98)00061-1; SOKOLOVS.M, 1970, BIOCHEMISTRY-US, V9, P5113, DOI 10.1021/bi00828a011; SOKOLOVS.M, 1966, BIOCHEMISTRY-US, V5, P3582, DOI 10.1021/bi00875a029; Souza JM, 1999, ARCH BIOCHEM BIOPHYS, V371, P169, DOI 10.1006/abbi.1999.1480; Tatoyan A, 1998, J BIOL CHEM, V273, P11044, DOI 10.1074/jbc.273.18.11044; THOMSON L, 1995, ARCH BIOCHEM BIOPHYS, V319, P491, DOI 10.1006/abbi.1995.1321; TORRES J, 1995, BIOCHEM J, V312, P169, DOI 10.1042/bj3120169; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; VOET D, 1995, BIOCHEMISTRY-US, P191; Welter R, 1996, ARCH BIOCHEM BIOPHYS, V331, P9, DOI 10.1006/abbi.1996.0276; WIKSTROM M, 1984, NEW COMPREHENSIVE BI, P49; Wu WJ, 1999, J BIOL CHEM, V274, P25933, DOI 10.1074/jbc.274.36.25933; Yamakura F, 1998, J BIOL CHEM, V273, P14085, DOI 10.1074/jbc.273.23.14085	59	295	306	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21409	21415		10.1074/jbc.M909978199	http://dx.doi.org/10.1074/jbc.M909978199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10770952	hybrid			2022-12-27	WOS:000088230600061
J	Dixit, BL; Balendiran, GK; Watowich, SJ; Srivastava, S; Ramana, KV; Petrash, JM; Bhatnagar, A; Srivastava, SK				Dixit, BL; Balendiran, GK; Watowich, SJ; Srivastava, S; Ramana, KV; Petrash, JM; Bhatnagar, A; Srivastava, SK			Kinetic and structural characterization of the glutathione-binding site of aldose reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION PRODUCT; DIRECTED MUTAGENESIS; ACTIVE-SITE; CRYSTAL-STRUCTURES; HUMAN GLYOXALASE; KETO REDUCTASE; INHIBITION; GENE; INVOLVEMENT; RESOLUTION	Aldose reductase (AR), a member of the aldo-keto reductase superfamily, has been implicated in the etiology of secondary diabetic complications. However, the physiological functions of AR under euglycemic conditions remain unclear. We have recently demonstrated that, in intact heart, AR catalyzes the reduction of the glutathione conjugate of the lipid peroxidation product 4-hydroxy-trans-2-nonenal (Srivastava, S., Chandra, k, Wang, L., Seifert, W. E., dr., DaGue, B. B., Ansari, N. H., Srivastava, S. K., and Bhatnagar, A. (1998) J. Biol. Chem. 273, 10893-10900), consistent with a possible role of AR in the metabolism of glutathione conjugates of aldehydes. Herein,we present several lines of evidence suggesting that the active site of AR forms a specific glutathione-binding domain. The catalytic efficiency of AR in the reduction of the glutathione conjugates of acrolein, trans-2-hexeual, trans-2-nonenal, and trans,trans-2,4-decadienal was 4-1000-fold higher than for the corresponding free alkanal. Alterations in the structure of glutathione diminished the catalytic efficiency in the reduction of the acrolein adduct, consistent with the presence of specific interactions between the amino acid residues of glutathione and the AR active site. In addition, non-aldehydic conjugates of glutathione or glutathione analogs displayed active-site inhibition. Molecular dynamics calculations suggest that the conjugate adopts a specific low energy configuration at the active site, indicating selective binding. These observations support an important role of AR in the metabolism of glutathione conjugates of endogenous and xenobiotic aldehydes and demonstrate, for the first time, efficient binding of glutathione conjugates to an aldo-keto reductase.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Texas A&M Univ, Dept Biochem Biophys, College Stn, TX 77843 USA; Univ Louisville, Dept Med, Div Cardiol, Louisville, KY 40202 USA	University of Texas System; University of Texas Medical Branch Galveston; Washington University (WUSTL); Washington University (WUSTL); Texas A&M University System; Texas A&M University College Station; University of Louisville	Srivastava, SK (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Rm 6-644,Basic Sci Bldg, Galveston, TX 77555 USA.	ssrivast@utmb.edu	Ramana, Kota/C-5460-2012; Srivastava, Sanjay/D-3921-2012	Ramana, Kota/0000-0001-6502-7800	NHLBI NIH HHS [HL59378, HL55477] Funding Source: Medline; NIDDK NIH HHS [DK36118] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055477, R01HL059378] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK036118, R01DK036118] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADANG AEP, 1989, BIOCHEM J, V264, P759, DOI 10.1042/bj2640759; ANDERSSON C, 1991, J BIOL CHEM, V266, P2076; Becker K, 1998, NAT STRUCT BIOL, V5, P267, DOI 10.1038/nsb0498-267; BHATNAGAR A, 1992, BIOCHEM MED METAB B, V48, P91, DOI 10.1016/0885-4505(92)90055-4; BHATNAGAR A, 1990, BIOCHEM PHARMACOL, V39, P1115, DOI 10.1016/0006-2952(90)90292-S; BHATNAGAR A, 1989, MOL PHARMACOL, V36, P825; BRUNGER AT, 1992, XPLOR MANUAL VERSION; BURG MB, 1995, AM J PHYSIOL-RENAL, V268, pF983, DOI 10.1152/ajprenal.1995.268.6.F983; Cameron AD, 1997, EMBO J, V16, P3386, DOI 10.1093/emboj/16.12.3386; Cappiello M, 1996, J BIOL CHEM, V271, P33539, DOI 10.1074/jbc.271.52.33539; Cleland W W, 1979, Methods Enzymol, V63, P103; DONOHUE PJ, 1994, J BIOL CHEM, V269, P8604; EPP O, 1983, EUR J BIOCHEM, V133, P51, DOI 10.1111/j.1432-1033.1983.tb07429.x; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; GIUGLIANO D, 1995, METABOLISM, V44, P363, DOI 10.1016/0026-0495(95)90167-1; GRIMSHAW CE, 1995, BIOCHEMISTRY-US, V34, P14366, DOI 10.1021/bi00044a013; GRIMSHAW CE, 1995, BIOCHEMISTRY-US, V34, P14374, DOI 10.1021/bi00044a014; HARRISON DH, 1994, BIOCHEMISTRY-US, V33, P2011, DOI 10.1021/bi00174a006; HERS HG, 1956, BIOCHIM BIOPHYS ACTA, V22, P202, DOI 10.1016/0006-3002(56)90247-5; Hohman TC, 1998, EUR J BIOCHEM, V256, P310, DOI 10.1046/j.1432-1327.1998.2560310.x; Hsu DKW, 1997, BIOCHEM J, V328, P593, DOI 10.1042/bj3280593; JacquinBecker C, 1997, GLIA, V20, P135, DOI 10.1002/(SICI)1098-1136(199706)20:2<135::AID-GLIA5>3.0.CO;2-8; JAGT DLV, 1995, BBA-PROTEIN STRUCT M, V1249, P117; Jez JM, 1997, BIOCHEM J, V326, P625, DOI 10.1042/bj3260625; KADOR PF, 1985, ANNU REV PHARMACOL, V25, P691, DOI 10.1146/annurev.pa.25.040185.003355; KARPLUS PA, 1989, EUR J BIOCHEM, V178, P693, DOI 10.1111/j.1432-1033.1989.tb14500.x; KUBISESKI TJ, 1992, J BIOL CHEM, V267, P6510; LEE AYW, 1995, P NATL ACAD SCI USA, V92, P2780, DOI 10.1073/pnas.92.7.2780; LIU SQ, 1992, BIOCHEM PHARMACOL, V44, P2427, DOI 10.1016/0006-2952(92)90693-D; Nakano T, 1996, BIOCHEMISTRY-US, V35, P11196, DOI 10.1021/bi9608121; NIKKOLA M, 1991, J BIOL CHEM, V266, P16105; Nordstrand K, 1999, J MOL BIOL, V286, P541, DOI 10.1006/jmbi.1998.2444; PARK YS, 1991, BIOCHEM BIOPH RES CO, V175, P738, DOI 10.1016/0006-291X(91)91628-P; PETRASH JM, 1992, J BIOL CHEM, V267, P24833; Ridderstrom M, 1998, J BIOL CHEM, V273, P21623, DOI 10.1074/jbc.273.34.21623; ROSEVEAR PR, 1984, J BIOL CHEM, V259, P1436; Sarges R, 1993, Prog Drug Res, V40, P99; SIES H, 1993, FREE RADICAL BIO MED, V14, P313, DOI 10.1016/0891-5849(93)90028-S; Srivastava S, 1998, BIOCHEMISTRY-US, V37, P12909, DOI 10.1021/bi9804333; Srivastava S, 1999, BIOCHEMISTRY-US, V38, P42, DOI 10.1021/bi981794l; Srivastava S, 1995, BIOCHEM BIOPH RES CO, V217, P741, DOI 10.1006/bbrc.1995.2835; Srivastava S, 1998, J BIOL CHEM, V273, P10893, DOI 10.1074/jbc.273.18.10893; TONG L, 1995, J MOL BIOL, V250, P211, DOI 10.1006/jmbi.1995.0372; Urzhumtsev A, 1997, STRUCTURE, V5, P601, DOI 10.1016/S0969-2126(97)00216-5; WEINANDER R, 1994, J BIOL CHEM, V269, P71; WERMUTH B, 1983, EUR J BIOCHEM, V131, P423, DOI 10.1111/j.1432-1033.1983.tb07280.x; WILSON DK, 1993, P NATL ACAD SCI USA, V90, P9847, DOI 10.1073/pnas.90.21.9847; Yabe-Nishimura C, 1998, PHARMACOL REV, V50, P21; ZEINDLEBERHART E, 1994, J BIOL CHEM, V269, P14589	49	86	89	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21587	21595		10.1074/jbc.M909235199	http://dx.doi.org/10.1074/jbc.M909235199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10764810	hybrid			2022-12-27	WOS:000088230600084
J	Maeshima, Y; Colorado, PC; Torre, A; Holthaus, KA; Grunkemeyer, JA; Ericksen, MB; Hopfer, H; Xiao, YW; Stillman, IE; Kalluri, R				Maeshima, Y; Colorado, PC; Torre, A; Holthaus, KA; Grunkemeyer, JA; Ericksen, MB; Hopfer, H; Xiao, YW; Stillman, IE; Kalluri, R			Distinct antitumor properties of a type IV collagen domain derived from basement membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESANGIAL CELL-PROLIFERATION; ANNEXIN-V; IN-VITRO; INTEGRIN ALPHA(V)BETA(3); GOODPASTURE AUTOANTIGEN; EXTRACELLULAR-MATRIX; ALPHA-3(IV) CHAIN; ALPORT-SYNDROME; GROWTH-FACTOR; TUMOR-GROWTH	Vascular basement membrane is an important structural component of blood vessels. During angiogenesis this membrane undergoes many alterations and these changes are speculated to influence the formation of new capillaries. Type IV collagen is a major component of vascular basement membrane, and recently we identified a fragment of type IV collagen alpha 2 chain with specific anti-angiogenic properties (Kamphaus, G. D., Colorado, P. C., Panka, D. J., Hopfer, H., Ramchandran, R., Tome, A., Maeshima, Y., Mier, J. W., Sukhatme, V. P., and Karlluri, R. (2000) J. Biol. Chem. 275, 1209-1215), In the present study we characterize two different antitumor activities associated with the noncollagenous 1 (NC1) domain of the alpha 3 chain of type IV collagen. This domain was previously discovered to possess a C-terminal peptide sequence (amino acids 185-203) that inhibits melanoma cell proliferation (Han, J., Ohno, N., Pasco, S., Monboisse, J. C., Borel, J. P., and Kefalides, N. A. (1997) J. Biol. Chem. 272, 20395-20401). In the present study, we identify the anti-angiogenic capacity of this domain using several in vitro and in vivo assays. The alpha 3(IV)NC1 inhibited in vivo neovascularization in matrigel plug assays and suppressed tumor growth of human renal cell carcinoma (786-O) and prostate carcinoma (PC-3) in mouse xenograft models associated with in vivo endothelial cell-specific apoptosis. The anti-angiogenic activity was localized to amino acids 54-132 using deletion mutagenesis. This anti-angiogenic region is separate from the 185-203 amino acid region responsible for the antitumor cell activity. Additionally, our experiments indicate that the antitumor cell activity is not realized until the peptide region is exposed by truncation of the alpha 3(IV)NC1 domain, a requirement not essential for the anti-angiogenic activity of this domain. Collectively, these results effectively highlight the distinct and unique antitumor properties of the alpha 3(IV)NC1 domain and the potential use of this molecule for inhibition of tumor growth.	Beth Israel Deaconess Med Ctr, Dept Med Pathol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Ctr Canc, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Kalluri, R (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Nephrol, RW 563A,330 Brookline Ave, Boston, MA 02215 USA.		Hopfer, Helmut/T-5954-2019; Stillman, Isaac E/ABC-7278-2020; Peng, Chunwei/F-6788-2010; Kalluri, Raghu/E-2677-2015	Kalluri, Raghu/0000-0002-2190-547X; Hopfer, Helmut/0000-0003-1755-2170	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009946, R01DK051711] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-55001, DK-51711, F32 DK09946] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Colorado PC, 2000, CANCER RES, V60, P2520; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; Dhanabal M, 1999, CANCER RES, V59, P189; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; Frojdman K, 1998, DIFFERENTIATION, V63, P125, DOI 10.1046/j.1432-0436.1998.6330125.x; GRANT DS, 1994, PATHOL RES PRACT, V190, P854; Han J, 1997, J BIOL CHEM, V272, P20395, DOI 10.1074/jbc.272.33.20395; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HARALABOPOULOS GC, 1994, LAB INVEST, V71, P575; Hellmark T, 1999, J BIOL CHEM, V274, P25862, DOI 10.1074/jbc.274.36.25862; Hellmark T, 1999, KIDNEY INT, V55, P936, DOI 10.1046/j.1523-1755.1999.055003936.x; Herlyn M, 1990, Adv Cancer Res, V54, P213, DOI 10.1016/S0065-230X(08)60812-X; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; Isik FF, 1998, J CELL PHYSIOL, V175, P149, DOI 10.1002/(SICI)1097-4652(199805)175:2<149::AID-JCP4>3.0.CO;2-O; Kalluri R, 1996, J BIOL CHEM, V271, P9062, DOI 10.1074/jbc.271.15.9062; Kalluri R, 1997, J CLIN INVEST, V99, P2470, DOI 10.1172/JCI119431; Kamphaus GD, 2000, J BIOL CHEM, V275, P1209, DOI 10.1074/jbc.275.2.1209; Kashihara N, 1997, EXP NEPHROL, V5, P126; Kashtan CE, 1998, J AM SOC NEPHROL, V9, P1736; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Liu SG, 1997, CLIN BIOCHEM, V30, P455, DOI 10.1016/S0009-9120(97)00049-0; Madri JA, 1997, TRANSPL IMMUNOL, V5, P179, DOI 10.1016/S0966-3274(97)80035-4; MADRI JA, 1986, J HISTOCHEM CYTOCHEM, V34, P85, DOI 10.1177/34.1.2416801; Maeshima Y, 1996, J AM SOC NEPHROL, V7, P2219; Maeshima Y, 1998, J CLIN INVEST, V101, P2589, DOI 10.1172/JCI429; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MARAGOUDAKIS ME, 1995, MICROVASC RES, V50, P215, DOI 10.1006/mvre.1995.1054; MARAGOUDAKIS ME, 1993, KIDNEY INT, V43, P147, DOI 10.1038/ki.1993.24; NEILSON EG, 1993, J BIOL CHEM, V268, P8402; Netzer KO, 1999, J BIOL CHEM, V274, P11267, DOI 10.1074/jbc.274.16.11267; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PASSANITI A, 1992, LAB INVEST, V67, P519; PAULSSON M, 1992, CRIT REV BIOCHEM MOL, V27, P93; Polette M, 1997, J PATHOL, V182, P185, DOI 10.1002/(SICI)1096-9896(199706)182:2<185::AID-PATH828>3.0.CO;2-F; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Ramchandran R, 1999, BIOCHEM BIOPH RES CO, V255, P735, DOI 10.1006/bbrc.1999.0248; RAY JM, 1994, EUR RESPIR J, V7, P2062; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Shahan TA, 1999, CANCER RES, V59, P4584; SIEBOLD B, 1988, EUR J BIOCHEM, V176, P617, DOI 10.1111/j.1432-1033.1988.tb14321.x; Sugiyama H, 1998, KIDNEY INT, V54, P1188, DOI 10.1046/j.1523-1755.1998.00116.x; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; TSILIBARY EC, 1990, J CELL BIOL, V111, P1583, DOI 10.1083/jcb.111.4.1583; TURNER N, 1992, J CLIN INVEST, V89, P592, DOI 10.1172/JCI115625; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; VERNON RB, 1995, IN VITRO CELL DEV-AN, V31, P120; WILSON C, 1996, KIDNEY, P1519; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; Yoshiji H, 1997, CANCER RES, V57, P3924; Zhang GH, 1997, BIOTECHNIQUES, V23, P525, DOI 10.2144/97233pf01; ZHANG XM, 1994, DEV BIOL, V164, P10, DOI 10.1006/dbio.1994.1176	59	287	340	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21340	21348		10.1074/jbc.M001956200	http://dx.doi.org/10.1074/jbc.M001956200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10766752	hybrid			2022-12-27	WOS:000088230600052
J	Pagani, F; Buratti, E; Stuani, C; Romano, M; Zuccato, E; Niksic, M; Giglio, L; Faraguna, D; Baralle, FE				Pagani, F; Buratti, E; Stuani, C; Romano, M; Zuccato, E; Niksic, M; Giglio, L; Faraguna, D; Baralle, FE			Splicing factors induce cystic fibrosis transmembrane regulator exon 9 skipping through a nonevolutionary conserved intronic element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SMALL NUCLEAR RIBONUCLEOPROTEIN; ROUS-SARCOMA VIRUS; TISSUE-SPECIFIC EXPRESSION; FIBRONECTIN EDA EXON; SR PROTEINS; VAS-DEFERENS; NEGATIVE REGULATOR; CONGENITAL ABSENCE; PARTIAL PENETRANCE	In monosymptomatic forms of cystic fibrosis such as congenital bilateral absence of vas deferens, variations in the TG(m) and T-n polymorphic repeats at the 3' end of intron 8 of the cystic fibrosis transmembrane regulator (CFTR) gene are associated with the alternative splicing of exon 9, which results in a nonfunctional CFTR protein. Using a minigene model system, we have previously shown a direct relationship between the TG(m)T(n) polymorphism and exon 9 splicing. We have now evaluated the role of splicing factors in the regulation of the alternative splicing of this exon. Serine-arginine-rich proteins and the heterogeneous nuclear ribonucleoprotein Al induced exon skipping in the human gene but not in its mouse counterpart. The effect of these proteins on exon 9 exclusion was strictly dependent on the composition of the TG(m) and T-n polymorphic repeats. The comparative and functional analysis of the human and mouse CFTR genes showed that a region of about 150 nucleotides, present only in the human intron 9, mediates the exon 9 splicing inhibition in association with exonic regulatory elements. This region, defined as the CFTR exon 9 intronic splicing silencer, is a target for serine-arginine-rich protein interactions. Thus, the nonevolutionary conserved CFTR exon 9 alternative splicing is modulated by the TG(m) and T-n polymorphism at the 3' splice region, enhancer and silencer exonic elements, and the intronic splicing silencer in the proximal 5' intronic region. Tissue levels and individual variability of splicing factors would determine the penetrance of the TG(m)T(n) locus in monosymptomatic forms of cystic fibrosis.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, TS, Italy; IRCCS, I-34012 Trieste, TS, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Baralle, FE (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, TS, Italy.		Romano, Maurizio/G-9431-2012; Buratti, Emanuele/K-4691-2016	Romano, Maurizio/0000-0002-4820-2897; Buratti, Emanuele/0000-0002-1356-9074; Pagani, Franco/0000-0002-2678-3459; Baralle, Francisco/0000-0002-4645-2809	Telethon [E.1038] Funding Source: Medline	Telethon(Fondazione Telethon)		AYANE M, 1991, NUCLEIC ACIDS RES, V19, P1273, DOI 10.1093/nar/19.6.1273; Blanchette M, 1999, EMBO J, V18, P1939, DOI 10.1093/emboj/18.7.1939; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; CAPUTI M, 1994, NUCLEIC ACIDS RES, V22, P1018, DOI 10.1093/nar/22.6.1018; CHILLON M, 1995, NEW ENGL J MED, V332, P1475, DOI 10.1056/NEJM199506013322204; CHU CS, 1993, NAT GENET, V3, P151, DOI 10.1038/ng0293-151; Cook CR, 1999, J VIROL, V73, P2394, DOI 10.1128/JVI.73.3.2394-2400.1999; COSTES B, 1995, EUR J HUM GENET, V3, P285; Cote J, 1999, NUCLEIC ACIDS RES, V27, P2529, DOI 10.1093/nar/27.12.2529; Cramer P, 1999, MOL CELL, V4, P251, DOI 10.1016/S1097-2765(00)80372-X; Cramer P, 1997, P NATL ACAD SCI USA, V94, P11456, DOI 10.1073/pnas.94.21.11456; Cuppens H, 1998, J CLIN INVEST, V101, P487, DOI 10.1172/JCI639; DELANEY SJ, 1993, NAT GENET, V4, P426, DOI 10.1038/ng0893-426; Faura M, 1995, BIOCHEM BIOPH RES CO, V217, P554, DOI 10.1006/bbrc.1995.2811; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; Gallego ME, 1997, EMBO J, V16, P1772, DOI 10.1093/emboj/16.7.1772; Grabowski PJ, 1998, CELL, V92, P709, DOI 10.1016/S0092-8674(00)81399-9; Hanamura A, 1998, RNA, V4, P430; Kamma H, 1999, EXP CELL RES, V246, P399, DOI 10.1006/excr.1998.4323; KAMMA H, 1995, EXP CELL RES, V221, P187, DOI 10.1006/excr.1995.1366; Kanopka A, 1996, NATURE, V381, P535, DOI 10.1038/381535a0; Kazazian HH, 1998, CURR OPIN GENET DEV, V8, P343, DOI 10.1016/S0959-437X(98)80092-0; Larriba S, 1998, HUM MOL GENET, V7, P1739, DOI 10.1093/hmg/7.11.1739; Lin CLG, 1998, NEURON, V20, P589, DOI 10.1016/S0896-6273(00)80997-6; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; McNally LM, 1996, J VIROL, V70, P1163, DOI 10.1128/JVI.70.2.1163-1172.1996; McNally LM, 1999, J VIROL, V73, P2385, DOI 10.1128/JVI.73.3.2385-2393.1999; McNally LM, 1998, MOL CELL BIOL, V18, P3103, DOI 10.1128/MCB.18.6.3103; Muro AF, 1999, MOL CELL BIOL, V19, P2657; Niksic M, 1999, HUM MOL GENET, V8, P2339, DOI 10.1093/hmg/8.13.2339; Pignatti PF, 1996, AM J HUM GENET, V58, P889; RAMCHATESINGH J, 1995, MOL CELL BIOL, V15, P4898; RaveHarel N, 1997, AM J HUM GENET, V60, P87; Rozmahel R, 1997, GENOMICS, V45, P554, DOI 10.1006/geno.1997.4968; STRONG TV, 1993, HUM MOL GENET, V2, P225, DOI 10.1093/hmg/2.3.225; Teng H, 1997, HUM MOL GENET, V6, P85, DOI 10.1093/hmg/6.1.85; VELLARD M, 1992, P NATL ACAD SCI USA, V89, P2511, DOI 10.1073/pnas.89.7.2511; Wang J, 1998, GENE DEV, V12, P2222, DOI 10.1101/gad.12.14.2222; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; ZAHLER AM, 1995, P NATL ACAD SCI USA, V92, P2642, DOI 10.1073/pnas.92.7.2642; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZERIVITZ K, 1989, GENE ANAL TECH, V6, P101, DOI 10.1016/0735-0651(89)90016-2	43	144	146	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21041	21047		10.1074/jbc.M910165199	http://dx.doi.org/10.1074/jbc.M910165199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10766763	hybrid			2022-12-27	WOS:000088230600012
J	Spicer, Z; Miller, ML; Andringa, A; Riddle, TM; Duffy, JJ; Doetschman, T; Shull, GE				Spicer, Z; Miller, ML; Andringa, A; Riddle, TM; Duffy, JJ; Doetschman, T; Shull, GE			Stomachs of mice lacking the gastric H,K-ATPase alpha-subunit have achlorhydria, abnormal parietal cells, and ciliated metaplasia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASES; BETA-SUBUNIT; TRANSGENIC MICE; ACID-SECRETION; MITOCHONDRIAL MYOPATHY; LACTIC-ACIDOSIS; GENE-EXPRESSION; DEFICIENT MICE; RAT STOMACH; OMEPRAZOLE	The H,K-ATPase of the gastric parietal cell is the most critical component of the ion transport system mediating acid secretion in the stomach. To study the requirement of this enzyme in the development, maintenance, and function of the gastric mucosa, we used gene targeting to prepare mice lacking the alpha-subunit. Homozygous mutant (Atp4a(-/-)) mice appeared healthy and exhibited normal systemic electrolyte and acid-base status but were achlorhydric and hypergastrinemic. Immunocytochemical, histological, and ultrastructural analyses of Atp4a(-/-) stomachs revealed the presence of chief cells, demonstrating that the lack of acid secretion does not interfere with their differentiation. Parietal cells were also present in normal numbers, and despite the absence of alpha-subunit mRNA and protein, the beta-subunit was expressed. However, Atp4a(-/-) parietal cells had dilated canaliculi and lacked typical canalicular microvilli and tubulovesicles, and subsets of these cells contained abnormal mitochondria and/or massive glycogen stores. Stomachs of adult Atp4a(-/-) mice exhibited metaplasia, which included the presence of ciliated cells, We conclude that ablation of the H,K-ATPase cw-subunit causes achlorhydria and hypergastrinemia, severe perturbations in the secretory membranes of the parietal cell, and metaplasia of the gastric mucosa; however, the absence of the pump appears not to perturb parietal cell viability or chief cell differentiation.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Shull, GE (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Bethesda Ave, Cincinnati, OH 45267 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050594, R37DK050594] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK50594] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDWIN GS, 1990, FEBS LETT, V272, P159, DOI 10.1016/0014-5793(90)80473-V; BEHBEHANI AW, 1984, EUR J PEDIATR, V143, P67, DOI 10.1007/BF00442753; BRAND SJ, 1995, GASTROENTEROLOGY, P25; CHAN WY, 1993, HUM PATHOL, V24, P1107, DOI 10.1016/0046-8177(93)90191-I; CHOW DC, 1995, J EXP BIOL, V198, P1; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CourtoisCoutry N, 1997, CELL, V90, P501, DOI 10.1016/S0092-8674(00)80510-3; DIMAURO S, 1980, NEUROLOGY, V30, P795, DOI 10.1212/WNL.30.8.795; Dunbar LA, 1998, ACTA PHYSIOL SCAND, V163, P289; Forte JG, 1996, TRENDS CELL BIOL, V6, P45, DOI 10.1016/0962-8924(96)81009-9; GOTTARDI CJ, 1993, J BIOL CHEM, V268, P14342; HELANDER HF, 1990, SCAND J GASTROENTERO, V25, P799, DOI 10.3109/00365529008999218; HOPPEL CL, 1987, J CLIN INVEST, V80, P71, DOI 10.1172/JCI113066; KAKEI N, 1995, BIOCHEM BIOPH RES CO, V214, P861, DOI 10.1006/bbrc.1995.2366; KAKEI N, 1993, BIOCHEM BIOPH RES CO, V195, P997, DOI 10.1006/bbrc.1993.2143; KARAM SM, 1994, AM J PHYSIOL, V266, pG745, DOI 10.1152/ajpgi.1994.266.4.G745; KARASAWA H, 1988, Gastroenterologia Japonica, V23, P1, DOI 10.1007/BF02918848; Karet FE, 1999, NAT GENET, V21, P84, DOI 10.1038/5022; Langhans N, 1997, GASTROENTEROLOGY, V112, P280, DOI 10.1016/S0016-5085(97)90000-7; LEHY T, 1972, AM J DIG DIS, V17, P887, DOI 10.1007/BF02239527; Li QT, 1996, J BIOL CHEM, V271, P3671, DOI 10.1074/jbc.271.7.3671; LI QT, 1995, J BIOL CHEM, V270, P15777, DOI 10.1074/jbc.270.26.15777; LORENZ RG, 1993, J BIOL CHEM, V268, P26559; MAEDA M, 1995, J BIOCHEM-TOKYO, V117, P1305, DOI 10.1093/oxfordjournals.jbchem.a124859; MATHEW SPM, 1995, AM J PHYSIOL, V268, pC1207; Meneton P, 1998, J CLIN INVEST, V101, P536, DOI 10.1172/JCI1720; Nakamura S, 1999, AM J PHYSIOL-RENAL, V276, pF914, DOI 10.1152/ajprenal.1999.276.6.F914; RUBIO CA, 1991, JPN J CANCER RES, V82, P86, DOI 10.1111/j.1349-7006.1991.tb01750.x; RUBIO CA, 1986, JPN J CANCER RES, V77, P282; RUBIO CA, 1988, AM J SURG PATHOL, V12, P786, DOI 10.1097/00000478-198810000-00008; Rubio Carlos A., 1994, Journal of Environmental Pathology Toxicology and Oncology, V13, P243; Scarff KL, 1999, GASTROENTEROLOGY, V117, P605, DOI 10.1016/S0016-5085(99)70453-1; Schultheis PJ, 1998, J CLIN INVEST, V101, P1243, DOI 10.1172/JCI1249; SHAH AJ, 1982, J NEUROL SCI, V55, P25, DOI 10.1016/0022-510X(82)90167-8; SHULL GE, 1990, J BIOL CHEM, V265, P12123; SHULL GE, 1986, J BIOL CHEM, V261, P6788; Silver RB, 1999, AM J PHYSIOL-RENAL, V276, pF799, DOI 10.1152/ajprenal.1999.276.6.F799; STECHSCHULTE DJ, 1990, AM J PHYSIOL, V259, pG41, DOI 10.1152/ajpgi.1990.259.1.G41	38	130	143	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21555	21565		10.1074/jbc.M001558200	http://dx.doi.org/10.1074/jbc.M001558200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10764766	hybrid			2022-12-27	WOS:000088230600080
J	Liang, FQ; Atakilit, A; Gardner, DG				Liang, FQ; Atakilit, A; Gardner, DG			Integrin dependence of brain natriuretic peptide gene promoter activation by mechanical strain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; RAT CARDIAC MYOCYTES; JUN NH2-TERMINAL KINASE; SMOOTH-MUSCLE CELLS; SIGNAL-TRANSDUCTION; VENTRICULAR MYOCYTES; EXTRACELLULAR-MATRIX; PROTEIN-KINASE; IN-VITRO; CARDIOCYTE HYPERTROPHY	Expression of the brain natriuretic peptide (BNP) gene in cultured neonatal rat ventricular myocytes is activated by mechanical strain in vitro. We explored the role of cell-matrix contacts in initiating the strain-dependent increment in human BNP (hBNP) promoter activity. Coating the culture surface with fibronectin effected a dose-dependent increase in basal hBNP luciferase activity and amplification of the response to strain. Preincubation of myocytes with an RGD peptide (GRGDSP) or with soluble fibronectin, each of which would be predicted to compete for cell-matrix interactions, resulted in a dose dependent reduction in strain-dependent hBNP promoter activity. A functionally inert RGE peptide (GRGESP) was without effect. Using fluorescence-activated cell sorting, we demonstrated the presence of beta(1), beta(3), and alpha(V)beta(5) integrins in myocytes as well as non-myocytes and alpha 1 only in non-myocytes in our cultures. Inclusion of antibodies directed against beta(1), beta(3), or alpha(V)beta(5) but not alpha(1), alpha(2), or cadherin, was effective in blocking the BNP promoter response to mechanical strain. These same antibodies (anti-beta(3), -beta(1), and -alpha(V)beta(5)) had a similar inhibitory effect on strain-stimulated ERK, p38 MAPK, and, to a lesser extent, JNK activities in these cells. Cotransfection with chimeric integrin receptors capable of acting as dominant-negative inhibitors of integrin function demonstrated suppression of strain-dependent BNP promoter activity when vectors encoding beta(1) or beta(3), but not beta(5), alpha(5), or a carboxyl-terminal deletion mutant of beta(3) (beta(3)B), were employed. These studies underscore the importance of cell-matrix interactions in controlling cardiac gene expression and suggest a potentially important role for these interactions in signaling responses to mechanical stimuli within the myocardium.	Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA; Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Gardner, DG (corresponding author), Univ Calif San Francisco, Metab Res Unit, 513 Parnassus Ave,POB 0540, San Francisco, CA 94143 USA.	gardner@itsa.ucsf.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035753] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 35753] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHUMADA GG, 1984, J HISTOCHEM CYTOCHEM, V32, P383, DOI 10.1177/32.4.6707462; AKIYAMA SK, 1994, J BIOL CHEM, V269, P15961; BENES AJ, 1985, J CELL SCI, V75, P35; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Clerk A, 1998, J CELL BIOL, V142, P523, DOI 10.1083/jcb.142.2.523; COLLO G, 1993, J BIOL CHEM, V268, P19019; DAVIES PF, 1993, CIRC RES, V72, P239, DOI 10.1161/01.RES.72.2.239; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Esparza J, 1999, BLOOD, V94, P2754, DOI 10.1182/blood.V94.8.2754.420k09_2754_2766; Fassler R, 1996, J CELL SCI, V109, P2989; GERBES AL, 1994, J CLIN ENDOCR METAB, V78, P1307, DOI 10.1210/jc.78.6.1307; GILBERT JA, 1989, ANSYS C P SWANS AN S; HANFORD DS, 1994, J BIOL CHEM, V269, P26227; Harada M, 1997, CIRCULATION, V96, P3737; HASEGAWA K, 1993, CIRCULATION, V88, P372, DOI 10.1161/01.CIR.88.2.372; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575; Ivaska J, 1999, J CELL BIOL, V147, P401, DOI 10.1083/jcb.147.2.401; KAMBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P599, DOI 10.1016/S0006-291X(05)80077-4; Kawano H, 2000, HYPERTENSION, V35, P273, DOI 10.1161/01.HYP.35.1.273; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; KOHNO M, 1992, HYPERTENSION, V19, P206, DOI 10.1161/01.HYP.19.2.206; Kuppuswamy D, 1997, J BIOL CHEM, V272, P4500, DOI 10.1074/jbc.272.7.4500; Kuwahara K, 1999, CIRCULATION, V100, P1116, DOI 10.1161/01.CIR.100.10.1116; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LaPointe MC, 1996, HYPERTENSION, V27, P715, DOI 10.1161/01.HYP.27.3.715; Lee AA, 1999, J MOL CELL CARDIOL, V31, P1833, DOI 10.1006/jmcc.1999.1017; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; Liang FQ, 1998, J BIOL CHEM, V273, P14612, DOI 10.1074/jbc.273.23.14612; Liang FQ, 1999, J CLIN INVEST, V104, P1603, DOI 10.1172/JCI7362; Liang PQ, 1997, J BIOL CHEM, V272, P28050, DOI 10.1074/jbc.272.44.28050; MacKenna DA, 1998, J CLIN INVEST, V101, P301, DOI 10.1172/JCI1026; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Mainiero F, 1998, J EXP MED, V188, P1267, DOI 10.1084/jem.188.7.1267; NAKAGAWA O, 1995, J CLIN INVEST, V96, P1280, DOI 10.1172/JCI118162; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Ross RS, 1998, CIRC RES, V82, P1160, DOI 10.1161/01.RES.82.11.1160; Saito S, 1999, J BIOL CHEM, V274, P30756, DOI 10.1074/jbc.274.43.30756; SAMUEL JL, 1991, J CLIN INVEST, V88, P1737, DOI 10.1172/JCI115492; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; SCHLAEPFER DD, 1994, NATURE, V372, P786; SIMPSON DG, 1994, J CELL PHYSIOL, V161, P89, DOI 10.1002/jcp.1041610112; TERRACIO L, 1991, CIRC RES, V68, P734, DOI 10.1161/01.RES.68.3.734; TOTH M, 1994, AM J PHYSIOL, V266, pH1572, DOI 10.1152/ajpheart.1994.266.4.H1572; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; VILLARREAL FJ, 1992, AM J PHYSIOL, V262, pH1861, DOI 10.1152/ajpheart.1992.262.6.H1861; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WILSON E, 1993, J CELL BIOL, V123, P741, DOI 10.1083/jcb.123.3.741; WILSON E, 1995, J CLIN INVEST, V96, P2364, DOI 10.1172/JCI118293; WU JP, 1989, J BIOL CHEM, V264, P6472; YAMAZAKI T, 1995, CIRC RES, V77, P258, DOI 10.1161/01.RES.77.2.258; Yasuda T, 1996, J CLIN INVEST, V98, P1991, DOI 10.1172/JCI119003	53	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20355	20360		10.1074/jbc.M001660200	http://dx.doi.org/10.1074/jbc.M001660200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10764770	hybrid			2022-12-27	WOS:000088084500020
J	Chevalier, M; Rhee, H; Elguindi, EC; Blond, SY				Chevalier, M; Rhee, H; Elguindi, EC; Blond, SY			Interaction of murine BiP/GRP78 with the DnaJ homologue MTJ1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNAJ; MOLECULAR CHAPERONE DNAK; POSTTRANSLATIONAL PROTEIN TRANSLOCATION; YEAST ENDOPLASMIC-RETICULUM; PEPTIDE-BINDING DOMAIN; SHOCK COGNATE PROTEIN; FINGER-LIKE DOMAIN; SUBSTRATE-BINDING; ATPASE ACTIVITY; POLYPEPTIDE TRANSLOCATION	The activity of Hsp70 proteins is regulated by accessory proteins, among which the most studied are the members of the DnaJ-like protein family. BiP/GRP78 chaperones the translocation and maturation of secreted and membrane proteins in the endoplasmic reticulum. No DnaJ-like partner has been described so far to regulate the function of mammalian BiP/GRP78. We show here that murine BiP/GRP78 interacts with the lumenal J domain of the murine transmembrane protein MTJ1 (J-MTJ1). J-MTJ1 stimulates the ATPase activity of BiP/GRP78 at stoichiometric concentrations. The C-terminal tail of BiP/GRP78 is not required for the interaction with J-MTJ1, leaving the function of this portion of the molecule still unclear. Physical interactions between J-MTJ1 and BiP/GRP78 are stable and can be abolished by a single histidine --> glutamine substitution in the highly conserved HPD motif shared by all DnaJ-like proteins. The J-MTJ1 fragment, but not the mutant J-MTJ1:H89Q fragment, stimulates the ATPase activity of Escherichia coli DnaK, although at a higher concentration than its genuine partner DnaJ. Full-length DnaJ does not stimulate BiP over the range of concentrations investigated. These results indicate that the J domain of MTJ1 is sufficient for its interaction with BiP/GRP78 and cannot be substituted by E. coli DnaJ.	Univ Illinois, Ctr Pharmaceut Biotechnol MC 870, Coll Pharm, Dept Med Chem & Pharmacognosy, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Blond, SY (corresponding author), Univ Illinois, Ctr Pharmaceut Biotechnol MC 870, Coll Pharm, Dept Med Chem & Pharmacognosy, Mol Biol Res Bldg,900 S Ashland Ave, Chicago, IL 60607 USA.	blond@uic.edu			NIGMS NIH HHS [GM58107, R01 GM058107-03, R01 GM058107-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058107] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banecki B, 1996, J BIOL CHEM, V271, P6137, DOI 10.1074/jbc.271.11.6137; Banecki B, 1996, J BIOL CHEM, V271, P14840, DOI 10.1074/jbc.271.25.14840; Bertelsen EB, 1999, PROTEIN SCI, V8, P343; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGHTMAN SE, 1995, GENE, V153, P249, DOI 10.1016/0378-1119(94)00741-A; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; BRODSKY JL, 1995, P NATL ACAD SCI USA, V92, P9643, DOI 10.1073/pnas.92.21.9643; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Campbell KS, 1997, GENE DEV, V11, P1098, DOI 10.1101/gad.11.9.1098; CARLINO A, 1992, P NATL ACAD SCI USA, V89, P2081, DOI 10.1073/pnas.89.6.2081; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; Chevalier M, 1998, J BIOL CHEM, V273, P26827, DOI 10.1074/jbc.273.41.26827; Chevalier M, 1998, METHOD ENZYMOL, V290, P384, DOI 10.1016/S0076-6879(98)90033-7; Corsi AK, 1997, J CELL BIOL, V137, P1483, DOI 10.1083/jcb.137.7.1483; Corsi AK, 1996, J BIOL CHEM, V271, P30299, DOI 10.1074/jbc.271.48.30299; CYR DM, 1994, J BIOL CHEM, V269, P9798; Farr CD, 1998, J BIOL CHEM, V273, P9744, DOI 10.1074/jbc.273.16.9744; Fedorov AN, 1997, J BIOL CHEM, V272, P32715, DOI 10.1074/jbc.272.52.32715; FELDHEIM D, 1993, MOL BIOL CELL, V4, P931, DOI 10.1091/mbc.4.9.931; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; Fouchaq B, 1999, EUR J BIOCHEM, V259, P379, DOI 10.1046/j.1432-1327.1999.00053.x; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; Gamer J, 1996, EMBO J, V15, P607, DOI 10.1002/j.1460-2075.1996.tb00393.x; Gassler CS, 1998, P NATL ACAD SCI USA, V95, P15229, DOI 10.1073/pnas.95.26.15229; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HA JH, 1994, BIOCHEMISTRY-US, V33, P14625, DOI 10.1021/bi00252a031; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HILL RB, 1995, BIOCHEMISTRY-US, V34, P5587, DOI 10.1021/bi00016a033; Holstein SEH, 1996, J CELL BIOL, V135, P925, DOI 10.1083/jcb.135.4.925; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HUGHES R, 1995, GENOMICS, V29, P546, DOI 10.1006/geno.1995.9969; Inoue T, 1999, BIOCHEM BIOPH RES CO, V266, P147, DOI 10.1006/bbrc.1999.1779; James P, 1997, SCIENCE, V275, P387, DOI 10.1126/science.275.5298.387; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; Karzai AW, 1996, J BIOL CHEM, V271, P11236, DOI 10.1074/jbc.271.19.11236; Kelley WL, 1997, P NATL ACAD SCI USA, V94, P3679, DOI 10.1073/pnas.94.8.3679; King L, 1999, BIOCHEM BIOPH RES CO, V263, P181, DOI 10.1006/bbrc.1999.1321; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; Leng CH, 1998, PROTEIN SCI, V7, P1186, DOI 10.1002/pro.5560070513; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Lievremont JP, 1997, J BIOL CHEM, V272, P30873, DOI 10.1074/jbc.272.49.30873; Liu JS, 1998, J BIOL CHEM, V273, P30704, DOI 10.1074/jbc.273.46.30704; Lu Z, 1998, J BIOL CHEM, V273, P5970, DOI 10.1074/jbc.273.10.5970; Lyman SK, 1997, CELL, V88, P85, DOI 10.1016/S0092-8674(00)81861-9; Matlack KES, 1999, CELL, V97, P553, DOI 10.1016/S0092-8674(00)80767-9; MatsumotoTaniura N, 1996, MOL BIOL CELL, V7, P1455, DOI 10.1091/mbc.7.9.1455; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; McClellan AJ, 1998, MOL BIOL CELL, V9, P3533, DOI 10.1091/mbc.9.12.3533; Misselwitz E, 1999, J BIOL CHEM, V274, P20110, DOI 10.1074/jbc.274.29.20110; MORRISON HG, 1993, BIOTECHNIQUES, V14, P454; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Packschies L, 1997, BIOCHEMISTRY-US, V36, P3417, DOI 10.1021/bi962835l; Pellecchia M, 1996, J MOL BIOL, V260, P236, DOI 10.1006/jmbi.1996.0395; Pierpaoli EV, 1997, J MOL BIOL, V269, P757, DOI 10.1006/jmbi.1997.1072; Qian YQ, 1996, J MOL BIOL, V260, P224, DOI 10.1006/jmbi.1996.0394; Russell R, 1999, BIOCHEMISTRY-US, V38, P4165, DOI 10.1021/bi9824036; Russell R, 1998, BIOCHEMISTRY-US, V37, P596, DOI 10.1021/bi972025p; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHLENSTEDT G, 1995, J CELL BIOL, V129, P979, DOI 10.1083/jcb.129.4.979; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SCIDMORE MA, 1993, MOL BIOL CELL, V4, P1145, DOI 10.1091/mbc.4.11.1145; SHOJI W, 1995, J BIOL CHEM, V270, P24818, DOI 10.1074/jbc.270.42.24818; Skowronek MH, 1999, BIOL CHEM, V380, P1133, DOI 10.1515/BC.1999.142; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; SZYPERSKI T, 1994, P NATL ACAD SCI USA, V91, P11343, DOI 10.1073/pnas.91.24.11343; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; Tsai J, 1996, J BIOL CHEM, V271, P9347, DOI 10.1074/jbc.271.16.9347; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; Ungewickell E, 1997, J BIOL CHEM, V272, P19594, DOI 10.1074/jbc.272.31.19594; WALL D, 1994, J BIOL CHEM, V269, P5446; Wang H, 1998, BIOCHEMISTRY-US, V37, P7929, DOI 10.1021/bi9800855; WICKNER S, 1992, P NATL ACAD SCI USA, V89, P10345, DOI 10.1073/pnas.89.21.10345; Yan W, 1998, EMBO J, V17, P4809, DOI 10.1093/emboj/17.16.4809; ZHANG SG, 1992, EMBO J, V11, P3787, DOI 10.1002/j.1460-2075.1992.tb05464.x; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	86	77	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19620	19627		10.1074/jbc.M001333200	http://dx.doi.org/10.1074/jbc.M001333200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10777498	Green Accepted, hybrid			2022-12-27	WOS:000087941300026
J	Kwon, FJ; Park, HS; Kim, YS; Oh, EJ; Nishida, Y; Matsukage, A; Yoo, MA; Yamaguchi, M				Kwon, FJ; Park, HS; Kim, YS; Oh, EJ; Nishida, Y; Matsukage, A; Yoo, MA; Yamaguchi, M			Transcriptional regulation of the Drosophila raf proto-oncogene by Drosophila STAT during development and in immune response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION-RELATED ELEMENT; CELL-NUCLEAR-ANTIGEN; DNA-POLYMERASE-BETA; SIGNAL-TRANSDUCTION; HOMEODOMAIN PROTEIN; TRANSGENIC FLIES; ACTS DOWNSTREAM; FACTOR DREF; GENE; KINASE	The Drosophila raf (D-raf) gene promoter contains a recognition consensus sequence for Drosophila STAT (D-STAT). By band mobility shift assay, we detected a factor binding to the D-STAT-recognition sequence in extracts of cultured Drosophila cells treated with vanadate peroxide, UV-cross-linking analyses suggested the size of the binding factor to be almost same as that of D-STAT. Furthermore, the binding activity was increased in cells cotransfected with HOP and D-STAT expression plasmids. These results strongly suggest that D-STAT binds to the D-STAT recognition sequence in the D-raf gene promoter. Transient luciferase expression assay using Schneider 2 cells indicated that the D-raf gene promoter is activated by D-STAT through the D-STAT-binding site. Furthermore, analyses with transgenic flies carrying Draf-lacZ fusion genes with and without mutations in the D-STAT-binding site pointed to an important role in D-raf gene promoter activity throughout development. We also found that the D-STAT-binding site is required for injury-induced activation of the D-raf gene promoter. Here we propose that D-STAT can participate in regulation of the mitogen-activated protein kinase cascade through D-raf gene activation.	Pusan Natl Univ, Coll Nat Sci, Dept Mol Biol, Pusan 609735, South Korea; Aichi Canc Ctr, Res Inst, Cell Biol Lab, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Pusan National University; Aichi Cancer Center; Nagoya University	Yoo, MA (corresponding author), Pusan Natl Univ, Coll Nat Sci, Dept Mol Biol, Pusan 609735, South Korea.			Yamaguchi, Masamitsu/0000-0002-6321-9750				AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; ASHBURNER M, 1989, DROSOPHILA LAB MANUA, P163; Barillas-Mury C, 1999, EMBO J, V18, P959, DOI 10.1093/emboj/18.4.959; BINARI R, 1994, GENE DEV, V8, P300, DOI 10.1101/gad.8.3.300; CECIL MK, 1997, J BIOL CHEM, V272, P11541; CROSS DP, 1978, J EMBRYOL EXP MORPH, V45, P161; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DATE T, 1988, BIOCHEMISTRY-US, V27, P2983, DOI 10.1021/bi00408a048; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Gateff E., 1998, Molecular mechanisms of immune responses in insects., P189; GETEFF E, 1978, SCIENCE, V200, P1448; Ha HY, 1997, KOREAN J GENETIC, V19, P267; HATA M, 1994, INT J DEV BIOL, V38, P329; Hayashi Y, 1997, J BIOL CHEM, V272, P22848, DOI 10.1074/jbc.272.36.22848; HIROSE F, 1994, J BIOL CHEM, V269, P2937; Hirose F, 1996, J BIOL CHEM, V271, P3930; HIROSE F, 1993, J BIOL CHEM, V268, P2092; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; KAPPLER C, 1993, EMBO J, V12, P1561, DOI 10.1002/j.1460-2075.1993.tb05800.x; Kwon Eun Jeong, 1998, Korean Journal of Biological Sciences, V2, P117; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; LEE JE, 1994, GENOMICS, V20, P43, DOI 10.1006/geno.1994.1125; NEIMAN AM, 1993, MOL BIOL CELL, V4, P107, DOI 10.1091/mbc.4.1.107; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; Ohno K, 1996, NUCLEIC ACIDS RES, V24, P3942, DOI 10.1093/nar/24.20.3942; PERRIMON N, 1986, DEV BIOL, V118, P28, DOI 10.1016/0012-1606(86)90070-9; RAPP UR, 1991, ONCOGENE, V6, P495; Ryu JR, 1996, KOREAN J GENETIC, V18, P73; Ryu JR, 1997, NUCLEIC ACIDS RES, V25, P794, DOI 10.1093/nar/25.4.794; SAMAKOVLIS C, 1992, BIOCHEM BIOPH RES CO, V188, P1169, DOI 10.1016/0006-291X(92)91354-S; Sawado T, 1998, J BIOL CHEM, V273, P26042, DOI 10.1074/jbc.273.40.26042; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Small S, 1996, DEV BIOL, V175, P314, DOI 10.1006/dbio.1996.0117; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; SWEITZER SM, 1995, J BIOL CHEM, V270, P16510, DOI 10.1074/jbc.270.28.16510; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; TUMMEL CS, 1988, GENE AMST, V74, P445; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YAMAGUCHI M, 1994, EUR J BIOCHEM, V221, P227, DOI 10.1111/j.1432-1033.1994.tb18733.x; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P15808, DOI 10.1074/jbc.270.26.15808; Yamaguchi Masamitsu, 1995, Gene Expression, V4, P183; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yan RQ, 1996, P NATL ACAD SCI USA, V93, P5842, DOI 10.1073/pnas.93.12.5842; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; YOSHAR BM, 1993, MOL CELL BIOL, V13, P5738; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	49	39	39	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19824	19830		10.1074/jbc.M001114200	http://dx.doi.org/10.1074/jbc.M001114200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10764759	hybrid			2022-12-27	WOS:000087941300054
J	Muller, MO; Meylan-Bettex, M; Eckstein, F; Martinoia, E; Siegenthaler, PA; Bovet, L				Muller, MO; Meylan-Bettex, M; Eckstein, F; Martinoia, E; Siegenthaler, PA; Bovet, L			Lipid phosphorylation in chloroplast envelopes - Evidence for galactolipid CTP-dependent kinase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT-CELLS; IN-VITRO; PHOSPHOINOSITIDE KINASES; PLASTID ENVELOPE; MEMBRANES; PROTEINS; BINDING; BIOSYNTHESIS; METABOLISM; FARNESOL	Lipid phosphorylation takes place within the chloroplast envelope. In addition to phosphatidic acid, phosphatidylinositol phosphate, and their corresponding lyse-derivatives, we found that two novel lipids underwent phosphorylation in envelopes, particularly in the presence of carrier-free [gamma-P-32]ATP, These two lipids incorporated radioactive phosphate in chloroplasts in the presence of [gamma-P-32]ATP or [P-32]P-i and light. Interestingly, these two lipids were preferentially phosphorylated in envelope membranes in the presence [gamma-P-32]CTP, as the phosphoryl donor, or [gamma-P-32]ATP, when supplemented with CDP and nucleoside diphosphate kinase II. The lipid kinase activity involved in this reaction was specifically inhibited in the presence of cytosine 5'-O-(thiotriphosphate) (CTP gamma S) and sensitive to CTP chase, thereby showing that both lipids are phosphorylated by an envelope CTP-dependent lipid kinase. The lipids were identified as phosphorylated galactolipids by using an acid hydrolysis procedure that generated galactose B-phosphate, CTP gamma S did not affect the import of the small ribulose-bisphosphate carboxylase/oxygenase subunit into chloroplasts, the possible physiological role of this novel CTP-dependent galactolipid kinase activity in the chloroplast envelope is discussed.	Univ Neuchatel, Lab Plant Physiol, CH-2007 Neuchatel, Switzerland; Max Planck Inst Expt Med, D-37075 Gottingen, Germany	University of Neuchatel; Max Planck Society	Bovet, L (corresponding author), Univ Neuchatel, Lab Physiol Vegetale, 13 Emile Argand, CH-2007 Neuchatel, Switzerland.	lucien.bovet@bota.unine.ch	Martinoia, Enrico/AAH-8712-2021					[Anonymous], METHODS CHLOROPLAST; BLITTERIJK WJ, 1999, CHEM PHYS LIPIDS, V98, P95; BOSS WF, 1989, 2ND MESSENGERS PLANT, V6, P29; Bovet L, 1997, PLANT SCI, V128, P169, DOI 10.1016/S0168-9452(97)00160-X; BOVET L, 1995, PLANTA, V195, P563, DOI 10.1007/BF00195716; BOVET L, 1999, PLANT PHYSIOL BIOCH, V37, P1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruce BD, 1998, PLANT MOL BIOL, V38, P223, DOI 10.1023/A:1006094308805; BRUINSMA J, 1961, BIOCHIM BIOPHYS ACTA, V52, P576, DOI 10.1016/0006-3002(61)90418-8; Chrispeels MJ, 1999, BIOL RES, V32, P35; CORVEN EJ, 1992, BIOCHEM J, V281, P163; DORNE AJ, 1982, FEBS LETT, V145, P30, DOI 10.1016/0014-5793(82)81200-3; Drobak BK, 1999, INT REV CYTOL, V189, P95, DOI 10.1016/S0074-7696(08)61386-8; ECKSTEIN F, 1976, BIOCHEMISTRY-US, V15, P1685, DOI 10.1021/bi00653a015; English D, 1996, CELL SIGNAL, V8, P341, DOI 10.1016/0898-6568(95)00076-3; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; GOODY RS, 1972, BIOCHIM BIOPHYS ACTA, V276, P155, DOI 10.1016/0005-2744(72)90016-2; HEEMSKERK JWM, 1990, PLANT PHYSIOL, V93, P1286, DOI 10.1104/pp.93.4.1286; HEIM S, 1986, BIOCHEM BIOPH RES CO, V134, P1175, DOI 10.1016/0006-291X(86)90374-8; HORST MN, 1989, J EXP ZOOL, V252, P16, DOI 10.1002/jez.1402520104; JOYARD J, 1991, EUR J BIOCHEM, V199, P489, DOI 10.1111/j.1432-1033.1991.tb16148.x; Joyard J, 1998, PLANT PHYSIOL, V118, P715, DOI 10.1104/pp.118.3.715; Katagiri T, 1996, PLANT MOL BIOL, V30, P647, DOI 10.1007/BF00049339; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marechal E, 1997, PHYSIOL PLANTARUM, V100, P65, DOI 10.1034/j.1399-3054.1997.1000106.x; Moller SG, 1999, J MOL BIOL, V293, P219, DOI 10.1006/jmbi.1999.2992; Morris Andrew J., 1999, Trends in Pharmacological Sciences, V20, P393, DOI 10.1016/S0165-6147(99)01390-5; MOURIOUX G, 1981, PLANT PHYSIOL, V67, P470, DOI 10.1104/pp.67.3.470; Munnik T, 1998, BBA-LIPID LIPID MET, V1389, P222, DOI 10.1016/S0005-2760(97)00158-6; Nietgen GW, 1998, CELL ADHES COMMUN, V5, P221, DOI 10.3109/15419069809040293; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; PAIN D, 1987, P NATL ACAD SCI USA, V84, P3288, DOI 10.1073/pnas.84.10.3288; Pinnaduwage P, 1996, J BIOL CHEM, V271, P32907, DOI 10.1074/jbc.271.51.32907; RAWYLER A, 1982, BIOCHIM BIOPHYS ACTA, V1104, P331; Riedel B, 1997, PLANT SCI, V128, P1, DOI 10.1016/S0168-9452(97)00120-9; SASAKI Y, 1991, FEBS LETT, V293, P124, DOI 10.1016/0014-5793(91)81166-6; Scherer G F, 1994, Symp Soc Exp Biol, V48, P229; SIEGENTHALER PA, 1990, PLANT CELL PHYSIOL, V31, P1101; Siegenthaler PA, 1997, FEBS LETT, V416, P57, DOI 10.1016/S0014-5793(97)01168-X; SZKOPINSKA A, 1988, ARCH BIOCHEM BIOPHYS, V266, P124, DOI 10.1016/0003-9861(88)90242-1; Szkopinska A, 1996, BIOCHIMIE, V78, P111, DOI 10.1016/0300-9084(96)82642-3; SZKOPINSKA A, 1990, ACTA BIOCHIM POL, V37, P81; Thai L, 1999, P NATL ACAD SCI USA, V96, P13080, DOI 10.1073/pnas.96.23.13080; Westfall D, 1997, BIOCHEM BIOPH RES CO, V230, P562, DOI 10.1006/bbrc.1996.6014; Xu YN, 1996, LIPIDS, V31, P223, DOI 10.1007/BF02522624	46	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19475	19481		10.1074/jbc.M002575200	http://dx.doi.org/10.1074/jbc.M002575200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10777505	hybrid			2022-12-27	WOS:000087941300008
J	Lafont, V; Liautard, J; Gross, A; Liautard, JP; Favero, J				Lafont, V; Liautard, J; Gross, A; Liautard, JP; Favero, J			Tumor necrosis factor-alpha production is differently regulated in gamma delta and alpha beta human T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NONPEPTIDIC MYCOBACTERIAL LIGANDS; N-TERMINAL KINASE; CELL RECEPTOR; BACTERIAL LIPOPOLYSACCHARIDE; PLASMODIUM-FALCIPARUM; BEARING LYMPHOCYTES; CYTOKINE ANALYSIS; GENE-EXPRESSION; HUMAN MONOCYTES	Tumor necrosis factor-alpha (TNF-alpha) plays a crucial role in the early defense against pathogens. This cytokine is produced by several cell types including T lymphocytes expressing the alpha beta as well as the gamma delta T cell receptor (TcR), In human, the circulating gamma delta T cells, which mostly express V gamma 9V delta 2 TcR, have been strongly suggested to play an important protective role against infectious agents. These activated cells early produce high amounts of TNF-alpha, which induce a determinant beneficial effect against development of intracellular pathogens; however, sustained production of this cytokine can result in immunopathological diseases. The signals that regulate TNF-alpha production in V gamma 9V delta 2 T cells are totally unknown. In primary alpha beta T cells, TNF-alpha production was shown to necessitate engagement of the TcR and CD28, and to be independent of the p38 mitogen activated protein kinase pathway. We demonstrate herein that, in contrast to alpha beta T cells, TNF-alpha production in V gamma 9V delta 2 T lymphocytes is independent of CD28 costimulation and highly dependent on TcR-induced p38 kinase and extracellular signal-regulated kinase 2 pathway activation for optimal cytokine release. Moreover, we bring elements supporting the idea that the "activation threshold" of gamma delta T cells leading to cytokine production is lower than that of alpha beta T cells.	Univ Montpellier 2, INSERM, U431, F-34095 Montpellier 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Lafont, V (corresponding author), Univ Montpellier 2, INSERM, U431, Pl Eugene Bataillon,CC 100, F-34095 Montpellier 05, France.	favero@crit.univ-montp2.fr	GROSS, Antoine/ABA-3418-2021; GROSS, Antoine/J-2978-2013; GROSS, Antoine/A-4195-2010; Lafont, Virginie/R-9356-2017	GROSS, Antoine/0000-0002-4553-524X; Lafont, Virginie/0000-0001-9612-3934				ARDITI M, 1995, J IMMUNOL, V155, P3994; Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453; Balkwill F, 1999, GUT, V45, P483, DOI 10.1136/gut.45.4.483; BARNES PF, 1992, J INFECT DIS, V165, P506, DOI 10.1093/infdis/165.3.506; Battistini L, 1997, J IMMUNOL, V159, P3723; BERTOTTO A, 1993, EUR J IMMUNOL, V23, P1177, DOI 10.1002/eji.1830230531; Brinkman BMN, 1999, J BIOL CHEM, V274, P30882, DOI 10.1074/jbc.274.43.30882; BUKOWSKI JF, 1995, J IMMUNOL, V154, P998; Bukowski JF, 1999, IMMUNITY, V11, P57, DOI 10.1016/S1074-7613(00)80081-3; BURK MR, 1995, EUR J IMMUNOL, V25, P2052, DOI 10.1002/eji.1830250737; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CONSTANT P, 1994, SCIENCE, V264, P267, DOI 10.1126/science.8146660; Cross AH, 1999, EUR J IMMUNOL, V29, P3140, DOI 10.1002/(SICI)1521-4141(199910)29:10<3140::AID-IMMU3140>3.3.CO;2-N; DEPAOLI P, 1991, CLIN EXP IMMUNOL, V83, P187, DOI 10.1111/j.1365-2249.1991.tb05612.x; DEPAOLI P, 1990, J INFECT DIS, V161, P1013, DOI 10.1093/infdis/161.5.1013; FOLLOWS GA, 1992, INFECT IMMUN, V60, P1229, DOI 10.1128/IAI.60.3.1229-1231.1992; Garcia VE, 1997, J IMMUNOL, V159, P1328; GOODIER MR, 1995, PARASITE IMMUNOL, V17, P413, DOI 10.1111/j.1365-3024.1995.tb00909.x; GROH V, 1989, J EXP MED, V169, P1277, DOI 10.1084/jem.169.4.1277; HAAS W, 1993, ANNU REV IMMUNOL, V11, P637, DOI 10.1146/annurev.immunol.11.1.637; Hambleton J, 1996, P NATL ACAD SCI USA, V93, P2774, DOI 10.1073/pnas.93.7.2774; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HARA T, 1992, J CLIN INVEST, V90, P204, DOI 10.1172/JCI115837; HO M, 1990, IMMUNOL LETT, V25, P139, DOI 10.1016/0165-2478(90)90105-Y; Hoffmeyer A, 1999, J BIOL CHEM, V274, P4319, DOI 10.1074/jbc.274.7.4319; JouenBeades F, 1997, INFECT IMMUN, V65, P4267, DOI 10.1128/IAI.65.10.4267-4272.1997; Kabelitz D, 1999, SPRINGER SEMIN IMMUN, V21, P55, DOI 10.1007/BF00815178; Kollias G, 1999, IMMUNOL REV, V169, P175, DOI 10.1111/j.1600-065X.1999.tb01315.x; LANG F, 1995, J IMMUNOL, V154, P5986; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; LIU MK, 1994, J IMMUNOL, V153, P2642; McClane SJ, 1999, JPEN-PARENTER ENTER, V23, pS20, DOI 10.1177/014860719902300506; Niedergang F, 1998, J IMMUNOL, V161, P6054; PERERA MK, 1994, J EXP MED, V179, P311, DOI 10.1084/jem.179.1.311; POGGI A, 1987, EUR J IMMUNOL, V17, P1065, DOI 10.1002/eji.1830170725; Poquet Y, 1998, INFECT IMMUN, V66, P2107, DOI 10.1128/IAI.66.5.2107-2114.1998; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; RAZIUDDIN S, 1992, EUR J IMMUNOL, V22, P1143, DOI 10.1002/eji.1830220506; Romas E, 1997, OSTEOPOROSIS INT, V7, P47, DOI 10.1007/BF03194342; Sanghera JS, 1996, J IMMUNOL, V156, P4457; SCALISE F, 1992, IMMUNOLOGY, V76, P668; Schafer PH, 1999, J IMMUNOL, V162, P659; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SPERLING AI, 1993, J IMMUNOL, V151, P6043; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Swart JM, 2000, J IMMUNOL, V164, P2311, DOI 10.4049/jimmunol.164.5.2311; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; TANAKA Y, 1995, NATURE, V375, P155, DOI 10.1038/375155a0; TANAKA Y, 1994, P NATL ACAD SCI USA, V91, P8175, DOI 10.1073/pnas.91.17.8175; TESTI R, 1989, EUR J IMMUNOL, V19, P185, DOI 10.1002/eji.1830190129; THIBAULT G, 1995, J IMMUNOL, V154, P3814; van der Bruggen T, 1999, INFECT IMMUN, V67, P3824, DOI 10.1128/IAI.67.8.3824-3829.1999; Wadsworth SA, 1999, J PHARMACOL EXP THER, V291, P680; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; Zhu T, 2000, J BIOL CHEM, V275, P2103, DOI 10.1074/jbc.275.3.2103	55	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19282	19287		10.1074/jbc.M910487199	http://dx.doi.org/10.1074/jbc.M910487199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10764820	hybrid			2022-12-27	WOS:000087815900087
J	Wolfman, JC; Wolfman, A				Wolfman, JC; Wolfman, A			Endogenous c-N-Ras provides a steady-state anti-apoptotic signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE DISSOCIATION STIMULATOR; PROTEIN-KINASE CASCADE; GROWTH-FACTOR; BCL-2 FAMILY; CELL-DEATH; TRANSDUCTION PATHWAYS; BAD PHOSPHORYLATION; COMPLEX-FORMATION; MOLECULAR SWITCH; HA-RAS	We report that c-N-Ras possesses an isoform-specific, functional role in cell survival under steady-state conditions. This function includes protection from programmed cell death by serum deprivation or upon treatment with apoptosis-inducing agents. The data demonstrate that c-N-Ras may play a functional role in the regulation of steady-state phosphorylated Akt and serine 136-phosphorylated Bad (Ser(136)-pBad). Immortalized N-Ras knockout fibroblasts possess nearly undetectable levels of steady-state Ser(136)-pBad. In contrast, wild-type control cells and the N-Ras knockout cells ectopically expressing c-N-Ras at control levels maintained easily detectable levels of Ser(136)-pBad both at steady-state and following treatment with tumor necrosis factor alpha. Similar results were seen with Ser(112)-pBad. These differences did not arise from differences in total Bad protein levels. These data correlate with the observation that the N-Ras knockout cells exhibit a heightened susceptibility to the induction of apoptosis. Ectopic expression of c-N-Ras in the N-Ras knockout cells at endogenous levels, compared with control cells, significantly rescues the apoptotically sensitive phenotype. Elevated expression of either c-Kirsten A-Res or c-Kirsten B-Bas did not reverse the apoptotic sensitivity of the N-Ras knockout cells or result in increased levels of either phospho-Akt or phospho Bad. Our results indicate that, at steady state, c-N-Ras possesses an isoform-specific, functional role in cell survival.	Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Wolfman, JC (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, NC10,9500 Euclid Ave, Cleveland, OH 44195 USA.	wolfmaj@ccf.org						AHN NG, 1991, J BIOL CHEM, V266, P4220; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chang MY, 1999, EXP CELL RES, V248, P589, DOI 10.1006/excr.1999.4436; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; DIBATTISTE D, 1993, ONCOGENE, V8, P637; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hamilton M, 1998, ONCOGENE, V16, P1417, DOI 10.1038/sj.onc.1201653; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Joneson T, 1999, MOL CELL BIOL, V19, P5892; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Klarlund JK, 1996, J BIOL CHEM, V271, P16674, DOI 10.1074/jbc.271.28.16674; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Ma JP, 1997, P NATL ACAD SCI USA, V94, P11905, DOI 10.1073/pnas.94.22.11905; MacKenzie KL, 1999, BLOOD, V93, P2043, DOI 10.1182/blood.V93.6.2043.406k17_2043_2056; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Martin JL, 1999, J BIOL CHEM, V274, P16407, DOI 10.1074/jbc.274.23.16407; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MURIBARA R, 1999, MOL CELL BIOL, V19, P2754; Navarro P, 1999, J BIOL CHEM, V274, P18857, DOI 10.1074/jbc.274.27.18857; Pastorino JG, 1999, J BIOL CHEM, V274, P19411, DOI 10.1074/jbc.274.27.19411; Peli J, 1999, EMBO J, V18, P1824, DOI 10.1093/emboj/18.7.1824; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; RodriguezViciana P, 1996, PHILOS T ROY SOC B, V351, P225, DOI 10.1098/rstb.1996.0020; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P; Wolthuis RMF, 1996, ONCOGENE, V13, P353; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	63	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19315	19323		10.1074/jbc.M000250200	http://dx.doi.org/10.1074/jbc.M000250200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10777478	hybrid			2022-12-27	WOS:000087815900091
J	Hresko, RC; Mueckler, M				Hresko, RC; Mueckler, M			A novel 68-kDa adipocyte protein phosphorylated on tyrosine in response to insulin and osmotic shock	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3T3-L1 ADIPOCYTES; MAP KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; DIFFERENTIAL REGULATION; DOCKING PROTEIN; BINDING-PROTEIN; GROWTH-FACTOR; SH3 DOMAINS; SRC; ASSOCIATION	Osmotic shock can cause insulin resistance in 3T3-L1 adipocytes by inhibiting insulin activation of glucose transport, p70S6 kinase, glycogen synthesis, and lipogenesis. By further investigating the relationship between insulin and hypertonic stress, we have discovered that osmotic shock enhanced by 10-fold the insulin-stimulated tyrosine phosphorylation of a 68-hDa protein. Phosphorylation by insulin was maximal after 1 min and was saturated with 50-100 nM insulin. The effect of sorbitol was completely reversible by 2.5 min. pp68 was a peripheral protein that was localized to the detergent insoluble fraction of the low density microsomes but was not associated with the cytoskeleton. Stimulation of the p42/44 and the p38 MAP kinase pathways by osmotic shock had no effect on pp68 phosphorylation. Treatment of adipocytes with the phosphotyrosine phosphatase inhibitor phenylarsine oxide also enhanced insulin-activated tyrosine phosphorylation of pp68 suggesting that osmotic shock may increase pp68 phosphorylation by inhibiting a phosphotyrosine phosphatase. Dissociation of pp68 from the low density microsomes with RNase A indicated that pp68 binds to RNA. Failure to immunoprecipitate pp68 using antibodies directed against known 60-70-kDa tyrosine-phosphorylated proteins suggest that pp68 may be a novel cellular target that lies downstream of the insulin receptor.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Mueckler, M (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	mike@cellbio.wustl.edu	Mueckler, Mike M/F-6115-2012		NIDDK NIH HHS [DK38495, DK50332] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050332, R01DK038495] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Chen D, 1999, MOL CELL BIOL, V19, P4684; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Fusaki N, 1997, J BIOL CHEM, V272, P6214, DOI 10.1074/jbc.272.10.6214; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hill MM, 1997, ELECTROPHORESIS, V18, P2629, DOI 10.1002/elps.1150181419; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; KELLY KL, 1993, J BIOL CHEM, V268, P4391; Lawe DC, 1997, ONCOGENE, V14, P223, DOI 10.1038/sj.onc.1200821; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIAO K, 1991, J BIOL CHEM, V266, P6544; MADOFF DH, 1988, BIOCHEM J, V252, P7, DOI 10.1042/bj2520007; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; Medema JP, 1996, CELL GROWTH DIFFER, V7, P543; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; Ostrowski J, 2000, J BIOL CHEM, V275, P3619, DOI 10.1074/jbc.275.5.3619; Parrott LA, 1999, J BIOL CHEM, V274, P24731, DOI 10.1074/jbc.274.35.24731; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; PONS S, 1995, MOL CELL BIOL, V15, P4453; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; Suga J, 1997, DIABETES, V46, P735, DOI 10.2337/diabetes.46.5.735; Sun XJ, 1996, J BIOL CHEM, V271, P10583, DOI 10.1074/jbc.271.18.10583; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Wojtaszewski JFP, 1999, AM J PHYSIOL-ENDOC M, V277, pE724, DOI 10.1152/ajpendo.1999.277.4.E724; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3	39	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18114	18120		10.1074/jbc.M001937200	http://dx.doi.org/10.1074/jbc.M001937200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10764780	hybrid			2022-12-27	WOS:000087659400030
J	Lee, SK; Kim, JH; Lee, YC; Cheong, JH; Lee, JW				Lee, SK; Kim, JH; Lee, YC; Cheong, JH; Lee, JW			Silencing mediator of retinoic acid and thyroid hormone receptors, as a novel transcriptional corepressor molecule of activating protein-1, nuclear factor-kappa B, and serum response factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-COR; HISTONE DEACETYLASE; COACTIVATOR-1 INTERACTS; P65 SUBUNIT; REPRESSION; EXPRESSION; COMPLEX; TRANSACTIVATIONS; MSIN3; INHIBITION	Silencing mediator of retinoic acid and thyroid hormone receptors (SMRT) is known to interact with Sin3 and recruit the histone deacetylases (HDACs) that lead to hypoacetylation of histones and transrepression of target transcription factors. Herein, we found that coexpression of SMRT significantly repressed transactivations by activating protein-1 (AP-1), nuclear factor-kappa B (NF kappa B), and serum response factor (SRF) in a dose-dependent manner, but not in the presence of trichostatin A, a specific inhibitor of HDAC. Similarly, coexpression of HDAC1 and mSin3A also showed repressive effects. Consistent with these results, the C-terminal region of SMRT directly interacted with SRF, the AP-1 components c-Jun and c-Fos, and the NF kappa B components p50 and p65, as demonstrated by the yeast and mammalian two hybrid tests as well as the glutathione S-transferase pull down assays. Thus, we concluded that SMRT serves to recruit Sin3/HDACs to SRF, NF kappa B, and AP-1 in vivo and modulate their transactivation.	Chonnam Natl Univ, Ctr Ligand & Transcript, Kwangju 500757, South Korea; Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea	Chonnam National University; Chonnam National University	Lee, JW (corresponding author), Chonnam Natl Univ, Ctr Ligand & Transcript, Kwangju 500757, South Korea.	jlee@chonnam.chonnam.ac.kr						Bailey P, 1999, MOL ENDOCRINOL, V13, P1155, DOI 10.1210/me.13.7.1155; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; GauthierRouviere C, 1996, MOL BIOL CELL, V7, P719, DOI 10.1091/mbc.7.5.719; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Kim HJ, 1998, J BIOL CHEM, V273, P28564, DOI 10.1074/jbc.273.44.28564; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; Laj A, 1999, MOL CELL BIOL, V19, P6632; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Misiti S, 1998, ENDOCRINOLOGY, V139, P2493, DOI 10.1210/en.139.5.2493; Moore DD, 1995, GLOB MOB SURV; Muscat GEO, 1998, NUCLEIC ACIDS RES, V26, P2899, DOI 10.1093/nar/26.12.2899; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Na SY, 1999, J BIOL CHEM, V274, P7674, DOI 10.1074/jbc.274.12.7674; Na SY, 1999, J BIOL CHEM, V274, P28491, DOI 10.1074/jbc.274.40.28491; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Shibata H, 1998, ENDOCR RES, V24, P881, DOI 10.3109/07435809809032703; Soderstrom M, 1997, MOL ENDOCRINOL, V11, P682, DOI 10.1210/me.11.6.682; Treisman R, 1990, Semin Cancer Biol, V1, P47; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	33	110	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12470	12474		10.1074/jbc.275.17.12470	http://dx.doi.org/10.1074/jbc.275.17.12470			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777532	hybrid			2022-12-27	WOS:000086762300016
J	Fiedler, TJ; Davey, CA; Fenna, RE				Fiedler, TJ; Davey, CA; Fenna, RE			X-ray crystal structure and characterization of halide-binding sites of human myeloperoxidase at 1.8 angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; DIRECTED MUTAGENESIS; CATALYTIC ACTIVITY; PROSTHETIC GROUP; NEUTRAL PH; COMPOUND-I; HEME; LACTOPEROXIDASE; THIOCYANATE; CHLORIDE	The x-ray crystal structure of human myeloperoxidase has been extended to 1.8 Angstrom resolution, using x-ray data recorded at -180 degrees C (r = 0,197, free r = 0,239), Results confirm that the heme is covalently attached to the protein via two ester linkages between the carboxyl groups of Glu(242) and Asp(94) and modified methyl groups on pyrrole rings A and C of the heme as well as a sulfonium ion linkage between the sulfur atom of Met(243) and the beta-carbon of the vinyl group on pyrrole ring A. In the native enzyme a bound chloride ion has been identified at the amino terminus of the helix containing the proximal His(336). Determination of the x-ray crystal structure of a myeloperoxidase-bromide complex (r = 0.243, free r = 0.296) has shown that this chloride ion can be replaced by bromide. Bromide is also seen to bind, at partial occupancy, in the distal heme cavity, in close proximity to the distal His(95), where it replaces the mater molecule hydrogen bonded to Gln(91). The bromide-binding site in the distal cavity appears to be the halide-binding site responsible for shifts in the Soret band of the absorption spectrum of myeloperoxidase. It is proposed that halide binding to this site inhibits the enzyme by effectively competing with H2O2 for access to the distal histidine, whereas in compound I, the same site may be the halide substrate-binding site.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami	Fenna, RE (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, POB 016129, Miami, FL 33101 USA.		Davey, Curt A/A-2182-2011		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049149] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 49149] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agner K., 1941, ACTA PHYSIOL SCAND, V2, P1; AKIN DT, 1986, J BIOL CHEM, V261, P8370; ANDREWS PC, 1981, J BIOL CHEM, V256, P4211; ANDREWS PC, 1982, J BIOL CHEM, V257, P13240; BAKKENIST ARJ, 1980, BIOCHIM BIOPHYS ACTA, V613, P337, DOI 10.1016/0005-2744(80)90088-1; BELDING ME, 1970, SCIENCE, V167, P195, DOI 10.1126/science.167.3915.195; BOLSCHER BGJM, 1984, BIOCHIM BIOPHYS ACTA, V788, P1, DOI 10.1016/0167-4838(84)90290-5; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR VERSION 3 1; CALS MM, 1991, EUR J BIOCHEM, V198, P733, DOI 10.1111/j.1432-1033.1991.tb16073.x; Davey CA, 1996, BIOCHEMISTRY-US, V35, P10967, DOI 10.1021/bi960577m; DePillis GD, 1997, J BIOL CHEM, V272, P8857; DOLPHIN D, 1971, P NATL ACAD SCI USA, V68, P614, DOI 10.1073/pnas.68.3.614; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; ERMAN JE, 1989, BIOCHEMISTRY-US, V28, P7992, DOI 10.1021/bi00446a004; FENNA R, 1995, ARCH BIOCHEM BIOPHYS, V316, P653, DOI 10.1006/abbi.1995.1086; FLORIS R, 1995, J AM CHEM SOC, V117, P3907, DOI 10.1021/ja00119a003; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; IKEDASAITO M, 1987, BIOCHEMISTRY-US, V26, P4344, DOI 10.1021/bi00388a024; JACQUET A, 1994, BIOCHEM BIOPH RES CO, V202, P73, DOI 10.1006/bbrc.1994.1895; JOHNSON KR, 1987, NUCLEIC ACIDS RES, V15, P2013, DOI 10.1093/nar/15.5.2013; KIMURA S, 1988, PROTEINS, V3, P113, DOI 10.1002/prot.340030206; KLEBANOFF SJ, 1970, SCIENCE, V169, P1096; KOEFFLER HP, 1985, BLOOD, V65, P484; Kooter IM, 1999, J BIOL CHEM, V274, P26794, DOI 10.1074/jbc.274.38.26794; Kooter IM, 1997, J BIOL INORG CHEM, V2, P191, DOI 10.1007/s007750050124; Kooter IM, 1997, J AM CHEM SOC, V119, P11542, DOI 10.1021/ja9725460; LASKOWSKI RA, 1992, PROCHECK V2; LEE HC, 1991, BIOCHIM BIOPHYS ACTA, V1076, P317, DOI 10.1016/0167-4838(91)90285-8; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MORISHITA K, 1987, J BIOL CHEM, V262, P3844; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; POULOS TL, 1994, MET IONS BIOL SYST, V30, P26; STELMASZYNSKA T, 1974, EUR J BIOCHEM, V45, P305, DOI 10.1111/j.1432-1033.1974.tb03555.x; SUTTON BJ, 1988, J MOL BIOL, V199, P395, DOI 10.1016/0022-2836(88)90325-7; TAYLOR KL, 1995, ARCH BIOCHEM BIOPHYS, V316, P635, DOI 10.1006/abbi.1995.1083; vanDalen CJ, 1997, BIOCHEM J, V327, P487; WEVER R, 1981, BIOCHIM BIOPHYS ACTA, V661, P235, DOI 10.1016/0005-2744(81)90009-7; WEVER R, 1982, BIOCHIM BIOPHYS ACTA, V709, P212, DOI 10.1016/0167-4838(82)90463-0; YONETANI T, 1966, J BIOL CHEM, V241, P3240; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5; ZGLICZYNSKI JM, 1977, P SOC EXP BIOL MED, V154, P418	43	306	311	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11964	11971		10.1074/jbc.275.16.11964	http://dx.doi.org/10.1074/jbc.275.16.11964			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766826	hybrid			2022-12-27	WOS:000086695500061
J	Stanley, NR; Palmer, T; Berks, BC				Stanley, NR; Palmer, T; Berks, BC			The twin arginine consensus motif of Tat signal peptides is involved in Sec-independent protein targeting in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-PH PATHWAY; TRANSLOCATION PATHWAY; CYTOPLASMIC MEMBRANE; PERIPLASMIC PROTEIN; THYLAKOID MEMBRANE; EXPORT SYSTEM; TRANSPORT; BACTERIOPHAGE; SPECIFICITY; HYDROGENASE	In Escherichia coli a subset of periplasmic proteins is exported through the Tat pathway to which substrates are directed by an NH2-terminal signal peptide containing a consensus SRRXFLK "twin arginine" motif. The importance of the individual amino acids of the consensus motif for in vivo Tat transport has been assessed by site-directed mutagenesis of the signal peptide of the Tat substrate pre-SufI. Although the invariant arginine residues are crucial for efficient export, we find that slow transport of SufI is still possible if a single arginine is conservatively substituted by a lysine residue. Thus, in at least one signal peptide context there is no absolute dependence of Tat transport on the arginine pair. The consensus phenylalanine residue was found to be a critical determinant for efficient export but could be functionally substituted by leucine, another amino acid with a highly hydrophobic side chain. Unexpectedly, the consensus lysine residue was found to retard Tat transport. These observations and others suggest that the sequence conservation of the Tat consensus motif is a reflection of the functional importance of the consensus residues. Tat signal peptides characteristically have positively charged carboxyl-terminal regions. However, changing the sign of this charge does not affect export of SufI.	Univ E Anglia, Sch Biol Sci, Ctr Met Prot Spect & Biol, Norwich NR4 7TJ, Norfolk, England; John Innes Ctr Plant Sci Res, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England	University of East Anglia; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Berks, BC (corresponding author), Univ E Anglia, Sch Biol Sci, Ctr Met Prot Spect & Biol, Norwich NR4 7TJ, Norfolk, England.	b.berks@uea.ac.uk		Stanley-Wall, Nicola/0000-0002-5936-9721; Palmer, Tracy/0000-0001-9043-2592; Berks, Ben/0000-0001-9685-4067				Berks BC, 2000, MOL MICROBIOL, V35, P260, DOI 10.1046/j.1365-2958.2000.01719.x; Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; Bogsch E, 1997, EMBO J, V16, P3851, DOI 10.1093/emboj/16.13.3851; Bogsch EG, 1998, J BIOL CHEM, V273, P18003, DOI 10.1074/jbc.273.29.18003; Brink S, 1998, FEBS LETT, V434, P425, DOI 10.1016/S0014-5793(98)01028-X; Bruser T, 1998, FEMS MICROBIOL LETT, V164, P329; CASADABAN MJ, 1979, P NATL ACAD SCI USA, V76, P4530, DOI 10.1073/pnas.76.9.4530; CHADDOCK AM, 1995, EMBO J, V14, P2715, DOI 10.1002/j.1460-2075.1995.tb07272.x; Cristobal S, 1999, EMBO J, V18, P2982, DOI 10.1093/emboj/18.11.2982; Danese PN, 1998, ANNU REV GENET, V32, P59, DOI 10.1146/annurev.genet.32.1.59; Doig AJ, 1997, PROTEIN SCI, V6, P147; Dreusch A, 1997, BBA-BIOENERGETICS, V1319, P311, DOI 10.1016/S0005-2728(96)00174-0; Fekkes P, 1999, MICROBIOL MOL BIOL R, V63, P161, DOI 10.1128/MMBR.63.1.161-173.1999; Gross R, 1999, ARCH MICROBIOL, V172, P227, DOI 10.1007/s002030050764; Halbig D, 1999, EUR J BIOCHEM, V263, P543, DOI 10.1046/j.1432-1327.1999.00536.x; Halbig D, 1999, FEBS LETT, V447, P95, DOI 10.1016/S0014-5793(99)00269-0; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HENRY R, 1994, J BIOL CHEM, V269, P10189; Henry R, 1997, J CELL BIOL, V136, P823, DOI 10.1083/jcb.136.4.823; IZARD JW, 1994, MOL MICROBIOL, V13, P765, DOI 10.1111/j.1365-2958.1994.tb00469.x; KATO JI, 1988, J BACTERIOL, V170, P3967, DOI 10.1128/jb.170.9.3967-3977.1988; Keegstra K, 1999, PLANT CELL, V11, P557, DOI 10.1105/tpc.11.4.557; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI P, 1988, P NATL ACAD SCI USA, V85, P7685, DOI 10.1073/pnas.85.20.7685; LYONS LB, 1972, VIROLOGY, V49, P45, DOI 10.1016/S0042-6822(72)80006-0; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Mori H, 1998, J BIOL CHEM, V273, P11405, DOI 10.1074/jbc.273.19.11405; NIVIERE V, 1992, J GEN MICROBIOL, V138, P2173, DOI 10.1099/00221287-138-10-2173; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; ROBINSON C, 1994, EMBO J, V13, P279, DOI 10.1002/j.1460-2075.1994.tb06260.x; Rodrigue A, 1999, J BIOL CHEM, V274, P13223, DOI 10.1074/jbc.274.19.13223; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Sargent F, 1999, J BIOL CHEM, V274, P36073, DOI 10.1074/jbc.274.51.36073; SASAKI S, 1990, J BIOL CHEM, V265, P4358; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; Wexler M, 1998, FEBS LETT, V431, P339, DOI 10.1016/S0014-5793(98)00790-X; Yates MG, 1997, SOIL BIOL BIOCHEM, V29, P863, DOI 10.1016/S0038-0717(96)00213-1; [No title captured]	43	243	252	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11591	11596		10.1074/jbc.275.16.11591	http://dx.doi.org/10.1074/jbc.275.16.11591			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766774	hybrid			2022-12-27	WOS:000086695500009
J	Wang, DM; Yu, X; Cohen, RA; Brecher, P				Wang, DM; Yu, X; Cohen, RA; Brecher, P			Distinct effects of N-acetylcysteine and nitric oxide on angiotensin II-induced epidermal growth factor receptor phosphorylation and intracellular Ca2+ levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; PROTEIN-COUPLED RECEPTORS; RAT CARDIAC FIBROBLASTS; KINASE ACTIVATION; TYROSINE KINASES; EGF RECEPTOR; CELLS; TRANSACTIVATION; CALCIUM; MECHANISM	These studies describe inhibitory effects of N-acetylcysteine on several biochemical events associated with the activation of extracellular signal-regulated kinases (ERK) by angiotensin II in the cardiac fibroblast and compare these effects with those of the nitric oxide donor, S-nitroso-N-acetylpenicillamine, an agent we showed previously to inhibit angiotensin II-induced ERK activation and the concomitant phosphorylation of proline-rich tyrosine kinase 2 (Wang, D,, Yu, X., and Brecher, P, (1999) J. Biol. Chem. 274, 24342-24348). The transactivation of the epidermal growth factor receptor by angiotensin II, a process required for the activation of ERK, was inhibited by N-acetylcysteine but not by nitric oxide, The transactivation of the epidermal growth factor receptor by angiotensin II was shown to be independent of intracellular calcium increases. Nitric oxide, but not N-acetylcysteine, inhibited the angiotensin II-induced increase in intracellular Ca2+. Neither nitric oxide nor N-acetylcysteine inhibited either phospholipase C activation or inositol triphosphate generation in response to angiotensin II. N-Acetylcysteine did inhibit the phosphorylation of the calcium sensitive tyrosine kinases PYK2 and Src, effects that also occurred using nitric oxide. These studies describe a novel effect of N-acetylcysteine on cross-talk between a G protein-linked receptor and a tyrosine kinase receptor and offer additional molecular insight to explain how N-acetylcysteine and nitric oxide act at different sites and might have an additive effect on specific hormonal responses.	Boston Univ, Sch Med, Dept Biochem & Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA	Boston University; Boston University	Brecher, P (corresponding author), Boston Univ, Sch Med, Dept Biochem & Med, 715 Albany St, Boston, MA 02118 USA.			Brecher, Peter/0000-0002-9347-6643; /0000-0002-1070-6408	NHLBI NIH HHS [HL53471, HL55620] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055620, R01HL053471] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berk BC, 1997, CIRC RES, V80, P607, DOI 10.1161/01.RES.80.5.607; Clementi E, 1998, BIOCHEM PHARMACOL, V55, P713, DOI 10.1016/S0006-2952(97)00375-4; Cohen RA, 1999, CIRC RES, V84, P210, DOI 10.1161/01.RES.84.2.210; Cotgreave I A, 1997, Adv Pharmacol, V38, P205; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Dorn GW, 1999, TRENDS CARDIOVAS MED, V9, P26, DOI 10.1016/S1050-1738(99)00004-3; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Farivar RS, 1996, CIRC RES, V78, P759; Faruqi RM, 1997, AM J PHYSIOL-HEART C, V273, pH817, DOI 10.1152/ajpheart.1997.273.2.H817; Haugh JM, 1999, J BIOL CHEM, V274, P8958, DOI 10.1074/jbc.274.13.8958; Horiuchi M, 1998, ENDOCR RES, V24, P307, DOI 10.3109/07435809809032610; Inagami T, 1999, J AM SOC NEPHROL, V10, pS57; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Keely SJ, 1998, J BIOL CHEM, V273, P27111, DOI 10.1074/jbc.273.42.27111; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; Murasawa S, 1998, CIRC RES, V82, P1338, DOI 10.1161/01.RES.82.12.1338; Raij L, 1998, HYPERTENSION, V31, P189, DOI 10.1161/01.HYP.31.1.189; Sen CK, 1998, BIOCHEM PHARMACOL, V55, P1747, DOI 10.1016/S0006-2952(97)00672-2; Tamura K, 1998, J BIOL CHEM, V273, P26487, DOI 10.1074/jbc.273.41.26487; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P19772, DOI 10.1074/jbc.273.31.19772; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Venema RC, 1998, J BIOL CHEM, V273, P7703, DOI 10.1074/jbc.273.13.7703; Wang DM, 1998, J BIOL CHEM, V273, P33027, DOI 10.1074/jbc.273.49.33027; Wang DM, 1999, J BIOL CHEM, V274, P24342, DOI 10.1074/jbc.274.34.24342; Weisbrod RM, 1998, BRIT J PHARMACOL, V125, P1695, DOI 10.1038/sj.bjp.0702233; Yang LJ, 1999, BIOCHEM PHARMACOL, V57, P425, DOI 10.1016/S0006-2952(98)00308-6; YUN CYI, 1995, J BIOL CHEM, V270, P26827; Zwick E, 1999, J BIOL CHEM, V274, P20989, DOI 10.1074/jbc.274.30.20989	29	56	68	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12223	12230		10.1074/jbc.275.16.12223	http://dx.doi.org/10.1074/jbc.275.16.12223			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766859	hybrid			2022-12-27	WOS:000086695500094
J	Wei, LN; Hu, XL; Chinpaisal, C				Wei, LN; Hu, XL; Chinpaisal, C			Constitutive activation of retinoic acid receptor beta 2 promoter by orphan nuclear receptor TR2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LUNG-CANCER; RESPONSE ELEMENT; EMBRYONIC-DEVELOPMENT; CELL-DIFFERENTIATION; RAR-BETA-2 PROMOTER; STEROID-RECEPTOR; A-SPERMATOGONIA; GENE; PATHWAY; CREM	The orphan nuclear receptor TR2 functions as a constitutive activator for the endogenous retinoic acid receptor beta 2 (RAR(beta 2)) gene expression in P19 embryonal carcinoma cells and for reporters driven by the RAR(beta 2) promoter in COS-l cells. The activation of RARE, by TR2 is mediated by the direct repeat-5 (DR5) element located in the RARE, promoter. Furthermore, cAMP exerts an enhancing effect on the activation of RARE, by TR2, which is mediated by the cAMP response element located in the 5'-flanking region of the DR5. The constitutive activation function-1 (AF-1) of TR2 is mapped to amino acid residues 10-30 in its N-terminal A segment. A direct molecular interaction occurs between CREM tau and TR2, detected by co-immunoprecipitation, which is mediated by the N-terminal AB segment of TR2, In gel mobility shift assays, TR2 competes with P19 nuclear factor binding to the RAR(beta 2) promoter, and TR2 and CREM tau bind simultaneously to this DNA fragment. The role of TR2 in the early events of RA signaling process is discussed.	Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Wei, LN (corresponding author), Univ Minnesota, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	weixx009@maroon.tc.umn.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054733] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54733] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAIN G, 1994, BIOESSAYS, V16, P343, DOI 10.1002/bies.950160509; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CHANG C, 1989, BIOCHEM BIOPH RES CO, V165, P735, DOI 10.1016/S0006-291X(89)80028-2; Chinpaisal C, 1998, J BIOL CHEM, V273, P18077, DOI 10.1074/jbc.273.29.18077; Chinpaisal C, 1997, BIOCHEMISTRY-US, V36, P14088, DOI 10.1021/bi971598z; COLBERT MC, 1993, P NATL ACAD SCI USA, V90, P6572, DOI 10.1073/pnas.90.14.6572; DAVIS KD, 1993, ENDOCRINOLOGY, V132, P1469, DOI 10.1210/en.132.4.1469; DELMAS V, 1994, MOL CELL ENDOCRINOL, V100, P121, DOI 10.1016/0303-7207(94)90290-9; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; Gaemers IC, 1996, ENDOCRINOLOGY, V137, P479, DOI 10.1210/en.137.2.479; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Gonzalez FJ, 1995, TOXICOL LETT, V82-3, P117, DOI 10.1016/0378-4274(95)03548-6; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KRUYT FAE, 1992, NUCLEIC ACIDS RES, V20, P6393, DOI 10.1093/nar/20.23.6393; KRUYT FAE, 1991, MECH DEVELOP, V33, P171, DOI 10.1016/0925-4773(91)90025-2; LAZAR MA, 1990, J CLIN INVEST, V86, P1777, DOI 10.1172/JCI114906; Lee CH, 1997, J ENDOCRINOL, V152, P245, DOI 10.1677/joe.0.1520245; Lee CH, 1998, J BIOL CHEM, V273, P25209, DOI 10.1074/jbc.273.39.25209; Lee CH, 1998, MOL CELL BIOL, V18, P6745, DOI 10.1128/MCB.18.11.6745; LEE CH, 1995, GENOMICS, V30, P46, DOI 10.1006/geno.1995.0007; Lee YF, 1998, J BIOL CHEM, V273, P13437, DOI 10.1074/jbc.273.22.13437; LIN TM, 1995, J BIOL CHEM, V270, P30121; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MENDELSOHN C, 1994, MECH DEVELOP, V45, P227, DOI 10.1016/0925-4773(94)90010-8; MENDELSOHN C, 1991, DEVELOPMENT, V113, P723; Misro M. M., 1997, Indian Journal of Experimental Biology, V35, P576; MOGHAL N, 1995, MOL CELL BIOL, V15, P3945; NAKSHATRI H, 1994, J BIOL CHEM, V269, P890; Parker KL, 1998, MOL CELL ENDOCRINOL, V145, P15, DOI 10.1016/S0303-7207(98)00164-6; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Qiu YH, 1997, GENE DEV, V11, P1925, DOI 10.1101/gad.11.15.1925; ROY DY, 1995, MOL CELL BIOL, V15, P6481; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; VANPELT AMM, 1995, BIOL REPROD, V53, P570, DOI 10.1095/biolreprod53.3.570; Walker WH, 1996, TRENDS ENDOCRIN MET, V7, P133, DOI 10.1016/1043-2760(96)00035-5; WEI LN, 1994, DEV GROWTH DIFFER, V36, P187; WEI LN, 1989, MOL ENDOCRINOL, V3, P454, DOI 10.1210/mend-3-3-454; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; Zhang X, 1997, BIOTECHNIQUES, V22, P848, DOI 10.2144/97225bm13; ZHANG XK, 1994, CANCER RES, V54, P5663; ZHANG XK, 1994, PROG CLIN BIOL RES, V387, P59; ZIMMER A, 1992, DEVELOPMENT, V116, P977	50	19	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11907	11914		10.1074/jbc.275.16.11907	http://dx.doi.org/10.1074/jbc.275.16.11907			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766818	hybrid			2022-12-27	WOS:000086695500053
J	Hayakawa, Y; Hayashi, T; Lee, JB; Ozawa, T; Sakuragawa, N				Hayakawa, Y; Hayashi, T; Lee, JB; Ozawa, T; Sakuragawa, N			Activation of heparin cofactor II by calcium spirulan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-T-THROMBIN; DERMATAN SULFATE; ARTEMISIA-PRINCEPS; ANTITHROMBIN-III; ALPHA-THROMBIN; ACIDIC DOMAIN; INHIBITION; BINDING; GLYCOSAMINOGLYCANS; PLATENSIS	Heparin cofactor II (HCII) is a plasma serine protease inhibitor whose ability to inhibit alpha-thrombin is accelerated by a variety of sulfated polysaccharides in addition to heparin and dermatan sulfate. Previous investigations have indicated that calcium spirulan (Ca-SP), a novel sulfated polysaccharide, enhanced the rate of inhibition of alpha-thrombin by HCII. In this study, we investigated the mechanism of the activation of HCII by Ca-SP, Interestingly, in the presence of Ca-SP, an N-terminal deletion mutant of HCII (rHCII-Delta 74) inhibited alpha-thrombin, as native recombinant HCII (native rH-CII) did. The second-order rate constant for the inhibition of alpha-thrombin by rHCII-Delta 74 was 2.0 x 10(8) M-1 min(-1) in the presence of 50 mu g/ml Ca-SP and 10,000-fold higher than in the absence of Ca-SP, The rates of native rHCII and rHCII-Delta 74 for the inhibition of gamma-thrombin were increased only 80- and 120-fold, respectively, Our results suggested that the anion-binding exosite I of cu-thrombin was essential for the rapid inhibition reaction by HCII in the presence of Ca-SP and that the N-terminal acidic domain of HCII was not required. Therefore, we proposed a mechanism by which HCII was activated allosterically by Ca-SP and could interact with the anion-binding exosite I of thrombin not through the N-terminal acidic domain of HCII. The Arg(103) --> Leu mutant bound to Ca-SP-Toyopearl with normal affinity and inhibited alpha-thrombin in a manner similar to native rHCII, These results indicate that Arg(103) in HCII molecule is not critical for the interaction with Ca-SP.	Toyama Med & Pharmaceut Univ, Fac Med, Dept Clin Lab Med, Toyama 9300194, Japan; Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Pharmacognosy, Toyama 9300194, Japan	University of Toyama; University of Toyama	Hayakawa, Y (corresponding author), Toyama Med & Pharmaceut Univ, Fac Med, Dept Clin Lab Med, 2630 Sugitani, Toyama 9300194, Japan.			Lee, Jung-Bum/0000-0002-8732-7457				Becker DL, 1999, J BIOL CHEM, V274, P6226, DOI 10.1074/jbc.274.10.6226; BLINDER MA, 1989, J BIOL CHEM, V264, P5128; BLINDER MA, 1988, BIOCHEMISTRY-US, V27, P752, DOI 10.1021/bi00402a039; BLINDER MA, 1990, J BIOL CHEM, V265, P286; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; Ciaccia AV, 1997, J BIOL CHEM, V272, P14074, DOI 10.1074/jbc.272.22.14074; Colwell NS, 1999, BBA-PROTEIN STRUCT M, V1431, P148, DOI 10.1016/S0167-4838(99)00051-5; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; FENTON JW, 1991, BLOOD COAGUL FIBRIN, V2, P69, DOI 10.1097/00001721-199102000-00011; FENTON JW, 1988, SEMIN THROMB HEMOST, V14, P234, DOI 10.1055/s-2007-1002783; HAYAKAWA Y, 1995, BLOOD COAGUL FIBRIN, V6, P643, DOI 10.1097/00001721-199510000-00004; Hayakawa Y, 1996, BLOOD COAGUL FIBRIN, V7, P554, DOI 10.1097/00001721-199607000-00007; HAYASHI K, 1993, PHYTOTHER RES, V7, P76, DOI 10.1002/ptr.2650070118; Hayashi T, 1996, J NAT PROD, V59, P83, DOI 10.1021/np960017o; Hayashi T, 1997, THROMB RES, V87, P105, DOI 10.1016/S0049-3848(97)00109-6; Hogg PJ, 1996, J BIOL CHEM, V271, P26088, DOI 10.1074/jbc.271.42.26088; KOIDE T, 1984, P NATL ACAD SCI-BIOL, V81, P289, DOI 10.1073/pnas.81.2.289; Lee JB, 1998, J NAT PROD, V61, P1101, DOI 10.1021/np980143n; MCLELLAN DS, 1992, BLOOD COAGUL FIBRIN, V3, P69, DOI 10.1097/00001721-199202000-00011; Monagle P, 1998, J BIOL CHEM, V273, P33566, DOI 10.1074/jbc.273.50.33566; OLSON ST, 1992, J BIOL CHEM, V267, P12528; Pereira MS, 1999, J BIOL CHEM, V274, P7656, DOI 10.1074/jbc.274.12.7656; PHILLIPS JE, 1993, J BIOL CHEM, V268, P3321; RAGG H, 1990, J BIOL CHEM, V265, P5211; RAGG H, 1990, J BIOL CHEM, V265, P22386; ROGERS SJ, 1992, J BIOL CHEM, V267, P3613; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEEHAN JP, 1993, J BIOL CHEM, V268, P3639; SHEEHAN JP, 1994, J BIOL CHEM, V269, P32747; STONE SR, 1991, BIOCHEMISTRY-US, V30, P3950, DOI 10.1021/bi00230a021; TOLLEFSEN DM, 1995, THROMB HAEMOSTASIS, V74, P1209; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; WHINNA HC, 1991, J BIOL CHEM, V266, P8129	34	34	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11379	11382		10.1074/jbc.275.15.11379	http://dx.doi.org/10.1074/jbc.275.15.11379			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753952	hybrid			2022-12-27	WOS:000086466600094
J	Monnet, E; Fauvel-Lefeve, F				Monnet, E; Fauvel-Lefeve, F			A new platelet receptor specific to type III collagen - Type III collagen-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; I COLLAGEN; TYROSINE PHOSPHORYLATION; INTEGRIN ALPHA(2)BETA(1); BLOOD-PLATELETS; GLYCOPROTEIN-VI; ADHESION; PEPTIDE; IDENTIFICATION; OCTAPEPTIDE	Platelet interaction with type III collagen is mediated by several platelet receptors that recognize specific sequences in collagen. We previously described an octapeptide KP*GEP*GPK within the alpha(1)III-CB4 fragment that binds to platelets and specifically inhibits platelet aggregation induced by type III collagen. In this study, we demonstrated that the octapeptide prevented platelet contact and spreading on type III collagen and subendothelium under static and flow conditions. Platelets adhered to the immobilized octapeptide, and antibodies directed against other platelet collagen receptors (glycoprotein (GP) Ia/IIa, GP IV, p65, p47) did not impair this adhesion. The platelet octapeptide receptor was identified by ligand blotting as a protein doublet with molecular masses of 68 and 72 kDa and does not correspond to any other already known platelet collagen receptors (GP Ia, GP TV GP VI, and p65), Our results indicate that a specific type III collagen receptor, expressed on the platelet surface, is involved in the first stages of platelet type III collagen interaction.	Univ Paris 07, Inst Hematol, Hop St Louis, INSERM,U353, F-75475 Paris 10, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Fauvel-Lefeve, F (corresponding author), Univ Paris 07, Inst Hematol, Hop St Louis, INSERM,U353, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.							Asselin J, 1997, BLOOD, V89, P1235, DOI 10.1182/blood.V89.4.1235; BELLAVITE P, 1994, ANAL BIOCHEM, V216, P444, DOI 10.1006/abio.1994.1066; Chiang TM, 1997, J CLIN INVEST, V100, P2079, DOI 10.1172/JCI119741; Chiang TM, 1997, J CLIN INVEST, V100, P514, DOI 10.1172/JCI119560; Chiang TM, 1999, HISTOL HISTOPATHOL, V14, P579, DOI 10.14670/HH-14.579; CHIANG TM, 1993, THROMB RES, V71, P443, DOI 10.1016/0049-3848(93)90118-8; CHIANG TM, 1987, J IMMUNOL, V139, P887; FAUVEL F, 1978, THROMB RES, V12, P273, DOI 10.1016/0049-3848(78)90298-0; FAUVEL F, 1978, THROMB RES, V12, P841, DOI 10.1016/0049-3848(78)90278-5; FAUVEL F, 1980, THROMB RES, V17, P285, DOI 10.1016/0049-3848(80)90317-5; FAUVEL F, 1978, THROMB RES, V13, P269; FAUVELLAFEVE F, 1993, THROMB RES, V71, P193, DOI 10.1016/0049-3848(93)90094-5; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; KARNIGUIAN A, 1983, THROMB RES, V32, P593, DOI 10.1016/0049-3848(83)90061-0; KARNIGUIAN A, 1987, BIOCHEM BIOPH RES CO, V146, P277, DOI 10.1016/0006-291X(87)90722-4; KARNIGUIAN A, 1983, ACTUAL HEMATOL, V17, P36; Kehrel B, 1998, BLOOD, V91, P491; KEHREL B, 1993, BLOOD, V82, P3364; Knight CG, 1999, CARDIOVASC RES, V41, P450, DOI 10.1016/S0008-6363(98)00306-X; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGRAND YJ, 1980, BIOCHEM BIOPH RES CO, V96, P1579, DOI 10.1016/0006-291X(80)91354-6; MONNET E, 2000, IN PRESS THROMB RES; Moroi M, 1997, THROMB HAEMOSTASIS, V78, P439; Morton LF, 1997, J BIOL CHEM, V272, P11044; MORTON LF, 1994, BIOCHEM J, V299, P791, DOI 10.1042/bj2990791; PINTIGNY D, 1985, BIOCHEM BIOPH RES CO, V128, P547, DOI 10.1016/0006-291X(85)90081-6; SAKARIASSEN KS, 1983, J LAB CLIN MED, V102, P522; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; TANDON NN, 1989, J BIOL CHEM, V264, P7576; Verkleij MW, 1998, BLOOD, V91, P3808; Verkleij MW, 1999, THROMB HAEMOSTASIS, V82, P1137	32	49	52	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10912	10917		10.1074/jbc.275.15.10912	http://dx.doi.org/10.1074/jbc.275.15.10912			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753889	hybrid			2022-12-27	WOS:000086466600031
J	Oki, N; Takahashi, S; Hidaka, H; Conti, M				Oki, N; Takahashi, S; Hidaka, H; Conti, M			Short term feedback regulation of cAMP in FRTL-5 thyroid cells - Role of PDE4D3 phosphodiesterase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADRENERGIC-RECEPTOR FUNCTION; LEYDIG TUMOR-CELLS; GONADOTROPIN RECEPTORS; STIMULATING-HORMONE; BETA-ARRESTIN; RAT-BRAIN; PHOSPHORYLATION; DESENSITIZATION	Together with a transient accumulation of intracellular cAMP, thyrotropin (TSH) stimulation of the FRTL-5 thyroid cell induces phosphorylation and activation of a cAMP-specific phosphodiesterase (PDE4D3), Here we have investigated the impact of PDE4D3 activation on hormone responsiveness. Stimulation of FRTL-5 cells with TSH caused an increase in PDE activity within 3 min, with a maximal stimulation reached after 5 min. Preincubation with the protein kinase A (PKA) inhibitor H89 or (R-P)-cAMPS, but not with the inactive isomer H85, blocked this activation. Preincubation with PKA inhibitors also blocked the shift in mobility of the PDE4D3 protein. Under these conditions, H89, but not H85, potentiated the cAMP accumulation induced by TSH, Incubation of FRTL-5 cells with the PKA activator 8-(4-chlorophenylthio)adenosine-cAMP caused an increase in PDE activity and a decrease in the endogenous cAMP, confirming the presence of a PKA-PDE feedback loop. MA-10 Leydig tumor cells stably transfected with either a wild type PDE4D3 or a PDE4D3 with mutations in the PKA phosphorylation sites showed an increase in PDE activity when compared with control cells. Human choriogonadotropin or Bt,cAMP treatment induced a stimulation of PDE activity in cells transfected with wild type PDE4D3, whereas the activation was absent in mutant- and control-transfected cells. The increase in cAMP accumulation elicited by human choriogonadotropin was reduced in cells transfected with the wild type PDE4D3, but not in cells transfected with the mutant PDE, Rolipram, a specific inhibitor of PDE4, restored the cAMP accumulation in the PDE4D3-transfected cells. These data provide evidence that a rapid activation of PDE4D3 is one of the mechanisms determining the intensity of the cAMP signal.	Stanford Univ, Sch Med, Dept Gynecol & Obstet, Div Reprod Biol, Stanford, CA 94305 USA; Univ Tokyo, Grad Sch Agr & Life Sci, Tokyo 113, Japan; Nagoya Univ, Sch Med, Dept Pharmacol, Nagoya, Aichi 467, Japan	Stanford University; University of Tokyo; Nagoya University	Conti, M (corresponding author), Stanford Univ, Sch Med, Dept Gynecol & Obstet, Div Reprod Biol, Stanford, CA 94305 USA.			Takahashi, Shin-Ichiro/0000-0002-2323-2010	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020788] Funding Source: NIH RePORTER; NICHD NIH HHS [HD20788] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ahlstrom M, 1997, J BONE MINER RES, V12, P172, DOI 10.1359/jbmr.1997.12.2.172; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; Ascoli M, 1996, BIOCHEM PHARMACOL, V52, P1647, DOI 10.1016/S0006-2952(96)00553-9; BALL EH, 1980, J BIOL CHEM, V255, P2962; Barber R, 1978, Adv Cyclic Nucleotide Res, V9, P507; BEEBE SJ, 1995, ENZYMES, P43; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONTI M, 1995, ENDOCR REV, V16, P370, DOI 10.1210/er.16.3.370; CONTI M, 1982, ENDOCRINOLOGY, V110, P1189, DOI 10.1210/endo-110-4-1189; CORBIN JD, 1985, J BIOL CHEM, V260, P8731; CORBIN JD, 1988, METHOD ENZYMOL, V159, P74; Ekholm D, 1997, BBA-MOL CELL RES, V1356, P64, DOI 10.1016/S0167-4889(96)00159-0; GETTYS TW, 1987, J BIOL CHEM, V262, P333; GETTYS TW, 1988, J BIOL CHEM, V263, P10359; GRANT PG, 1988, P NATL ACAD SCI USA, V85, P9071, DOI 10.1073/pnas.85.23.9071; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HIDAKA H, 1991, METHOD ENZYMOL, V201, P328; Iona S, 1998, MOL PHARMACOL, V53, P23, DOI 10.1124/mol.53.1.23; IWAMI G, 1995, J BIOL CHEM, V270, P12481, DOI 10.1074/jbc.270.21.12481; Jin SLC, 1999, P NATL ACAD SCI USA, V96, P11998, DOI 10.1073/pnas.96.21.11998; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACPHEE CH, 1986, J CYCLIC NUCL PROT, V11, P487; MACPHEE CH, 1986, P NATL ACAD SCI USA, V83, P6660, DOI 10.1073/pnas.83.17.6660; MANGANIELLO VC, 1986, J CYCLIC NUCL PROT, V11, P497; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; PETERSON GL, 1979, ANAL BIOCHEM, V100, P201, DOI 10.1016/0003-2697(79)90222-7; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; SETTE C, 1994, J BIOL CHEM, V269, P9245; SETTE C, 1994, J BIOL CHEM, V269, P18271; SODERLING TR, 1973, J BIOL CHEM, V248, P1822; STEINER AL, 1972, J BIOL CHEM, V247, P1114; SU YF, 1976, J CYCLIC NUCL PROT, V2, P257; SWINNEN JV, 1991, J BIOL CHEM, V266, P14383; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311	39	96	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10831	10837		10.1074/jbc.275.15.10831	http://dx.doi.org/10.1074/jbc.275.15.10831			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753877	hybrid			2022-12-27	WOS:000086466600019
J	Rubbo, H; Radi, R; Anselmi, D; Kirk, M; Barnes, S; Butler, J; Eiserich, JP; Freeman, BA				Rubbo, H; Radi, R; Anselmi, D; Kirk, M; Barnes, S; Butler, J; Eiserich, JP; Freeman, BA			Nitric oxide reaction with lipid peroxyl radicals spares alpha-tocopherol during lipid peroxidation - Greater oxidant protection from the pair nitric oxide/alpha-tocopherol than alpha-tocopherol/ascorbate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; VITAMIN-E; SYNERGISTIC INHIBITION; NITROGEN-DIOXIDE; CHARGE-TRANSFER; OXIDATION; SUPEROXIDE; PEROXYNITRITE; TYROSINE; DERIVATIVES	The reactions of nitric oxide ((NO)-N-.) and alpha-tocopherol (alpha-TH) during membrane lipid oxidation were examined and compared with the pair alpha-TH/ascorbate. Nitric oxide serves as a more potent inhibitor of lipid peroxidation propagation reactions than alpha-TH and protects alpha-TH from oxidation, Mass spectrometry, oxygen and (NO)-N-. consumption, conjugated diene analyses, and alpha-TH fluorescence determinations all demonstrated that (NO)-N-. preferentially reacts with lipid radical species, with alpha-TH consumption not occurring until (NO)-N-. concentrations fell below a critical level. In addition, alpha-TH and (NO)-N-. cooperatively inhibit lipid peroxidation, exhibiting greater antioxidant capacity than the pair alpha-TH/ascorbate. Pulse radiolysis analysis showed no direct reaction between (NO)-N-. and alpha-tocopheroxyl radical (alpha-T-.), inferring that peroxyl radical termination reactions are the principal lipid-protective mechanism mediated by (NO)-N-.. These observations support the concept that (NO)-N-. is a potent chain breaking antioxidant toward peroxidizing lipids, due to facile radical-radical termination reactions with lipid radical species, thus preventing alpha-TH loss. The reduction of alpha-T-. by ascorbate was a comparatively less efficient mechanism for preserving alpha-TH than (NO)-N-.-mediated termination of peroxyl radicals, due to slower reaction kinetics and limited transfer of reducing equivalents from the aqueous phase. Thus, the high lipid/water partition coefficient of (NO)-N-., its capacity to diffuse and concentrate in lipophilic milieu, and a potent reactivity toward lipid radical species reveal how (NO)-N-. can play a critical role in regulating membrane and lipoprotein lipid oxidation reactions.	Univ Republ, Fac Med, Dept Bioquim, Montevideo 11800, Uruguay; Univ Alabama, Dept Anesthesiol, Birmingham, AL 35233 USA; Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35233 USA; Univ Alabama, Dept Pharmacol & Toxicol, Birmingham, AL 35233 USA; Univ Alabama, Ctr Free Radical Biol, Birmingham, AL 35233 USA; Univ Salford, Dept Biol Sci, Salford M5 4WT, Lancs, England	Universidad de la Republica, Uruguay; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Salford	Rubbo, H (corresponding author), Univ Republ, Fac Med, Dept Bioquim, Gen Flores 2125, Montevideo 11800, Uruguay.		Anselmi, Damiano/AFQ-4017-2022; Freeman, Bruce A/H-9342-2012	Anselmi, Damiano/0000-0001-6674-1328; Rubbo, Homero/0000-0002-7897-6551	FOGARTY INTERNATIONAL CENTER [R03TW000489] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064937, R01HL058115] Funding Source: NIH RePORTER; FIC NIH HHS [R03 TW00489] Funding Source: Medline; NHLBI NIH HHS [R01-HL 58115, R01-HL64937] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABE K, 1975, J NUTR SCI VITAMINOL, V21, P183, DOI 10.3177/jnsv.21.183; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BURTON GW, 1990, LIPIDS, V25, P199, DOI 10.1007/BF02535748; BURTON GW, 1986, ACCOUNTS CHEM RES, V19, P194, DOI 10.1021/ar00127a001; BUTLER J, 1982, BIOCHIM BIOPHYS ACTA, V705, P150, DOI 10.1016/0167-4838(82)90173-X; Chamulitrat W, 1998, ARCH BIOCHEM BIOPHYS, V355, P206, DOI 10.1006/abbi.1998.0731; COOKE JP, 1992, J CLIN INVEST, V90, P1168, DOI 10.1172/JCI115937; DAVIES MJ, 1988, BIOCHEM J, V255, P513; DEGROOT H, 1993, FEBS LETT, V315, P139, DOI 10.1016/0014-5793(93)81150-X; DURCKHEIMER W, 1964, J AM CHEM SOC, V86, P4388, DOI 10.1021/ja01074a033; EISERICH JP, 1995, BIOCHEM J, V310, P745, DOI 10.1042/bj3100745; Gorbunov NV, 1996, BIOCHEM BIOPH RES CO, V219, P835, DOI 10.1006/bbrc.1996.0319; GOSS SPA, 1995, CHEM RES TOXICOL, V8, P800, DOI 10.1021/tx00047a021; Goss SPA, 1999, ARCH BIOCHEM BIOPHYS, V363, P333, DOI 10.1006/abbi.1998.1094; HAM AJL, 1995, BIOCHEMISTRY-US, V34, P5754, DOI 10.1021/bi00017a007; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; HOGG N, 1995, J LIPID RES, V36, P1756; HOGG N, 1993, FEBS LETT, V334, P170, DOI 10.1016/0014-5793(93)81706-6; Hogg N, 1996, BIOCHEM BIOPH RES CO, V224, P696, DOI 10.1006/bbrc.1996.1086; ISCHIA M, 1999, TETRAHEDRON, V55, P9297; JANZEN EG, 1993, J ORG CHEM, V58, P3597, DOI 10.1021/jo00066a001; KAGAN VE, 1994, METHOD ENZYMOL, V234, P316; KAGAN VE, 1992, J LIPID RES, V33, P385; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; MALINSKI T, 1993, BIOCHEM BIOPH RES CO, V193, P1076, DOI 10.1006/bbrc.1993.1735; NIKI E, 1990, METHOD ENZYMOL, V186, P100; NIKI E, 1985, B CHEM SOC JPN, V58, P1971, DOI 10.1246/bcsj.58.1971; O'Donnell VB, 1999, J BIOL CHEM, V274, P20083, DOI 10.1074/jbc.274.29.20083; ODonnell VB, 1997, BIOCHEMISTRY-US, V36, P15216, DOI 10.1021/bi971891z; PACKER JE, 1979, NATURE, V278, P737, DOI 10.1038/278737a0; PADMAJA S, 1993, BIOCHEM BIOPH RES CO, V195, P539, DOI 10.1006/bbrc.1993.2079; PRUTZ WA, 1985, ARCH BIOCHEM BIOPHYS, V243, P125, DOI 10.1016/0003-9861(85)90780-5; PRUTZ WA, 1981, J CHEM SOC FARAD T 1, V77, P281, DOI 10.1039/f19817700281; PRYOR WA, 1993, J ORG CHEM, V58, P3521, DOI 10.1021/jo00065a013; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RUBBO H, 1994, J BIOL CHEM, V269, P26066; Rubbo H, 1995, ARCH BIOCHEM BIOPHYS, V324, P15, DOI 10.1006/abbi.1995.9935; Rubbo H, 1996, CHEM RES TOXICOL, V9, P809, DOI 10.1021/tx960037q; SATO K, 1990, ARCH BIOCHEM BIOPHYS, V279, P402, DOI 10.1016/0003-9861(90)90508-V; SERBINOVA EA, 1994, METHOD ENZYMOL, V234, P354; Singh RJ, 1998, P NATL ACAD SCI USA, V95, P12912, DOI 10.1073/pnas.95.22.12912; SMITH D, 1993, BIOCHEM PHARMACOL, V45, P195; STAMLER JS, 1992, ANAL CHEM, V64, P779, DOI 10.1021/ac00031a014; STEENKEN S, 1982, J PHYS CHEM-US, V86, P3661, DOI 10.1021/j100215a033; VONDERLEYEN HE, 1995, P NATL ACAD SCI USA, V92, P1137, DOI 10.1073/pnas.92.4.1137; WHITE CR, 1994, P NATL ACAD SCI USA, V91, P1044, DOI 10.1073/pnas.91.3.1044; WILCOX AL, 1993, CHEM RES TOXICOL, V6, P413, DOI 10.1021/tx00034a003; WINTERLE J, 1984, J ORG CHEM, V49, P491, DOI 10.1021/jo00177a021	49	155	166	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10812	10818		10.1074/jbc.275.15.10812	http://dx.doi.org/10.1074/jbc.275.15.10812			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753874	hybrid			2022-12-27	WOS:000086466600016
J	Wang, AM; Martin, JA; Lembke, LA; Midura, RJ				Wang, AM; Martin, JA; Lembke, LA; Midura, RJ			Reversible suppression of in vitro biomineralization by activation of protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE SIALOPROTEIN BSP; GROWTH-FACTOR-I; HORMONE-RELATED PEPTIDE; OSTEOBLAST-LIKE CELLS; PARATHYROID-HORMONE; OSTEOSARCOMA CELLS; FIBROUS DYSPLASIA; FACTOR-BETA; EXPRESSION; MATRIX	Parathyroid hormone (PTH-(1-34)) potently suppresses apatite deposition in osteoblastic cultures. These inhibitory effects are mediated through signaling events following PTH receptor binding. Using both selective inhibitors and activators of protein kinase A (PKA), this study shows that a transient activation of PKA is sufficient to account for PTH's inhibition of apatite deposition. This inhibition is not a result of reduced cell proliferation, reduced alkaline phosphatase activity, increased collagenase production, or lowering medium pH. Rather, data suggest a functional relationship between matrix assembly and apatite deposition in vitro. Bone sialoprotein (BSP) and apatite co-localize in the extracellular matrix of mineralizing cultures, with matrix deposition of BSP temporally preceding that of apatite. Transient activation of PKA by either PTH-(1-34) or short term cAMP analog treatment blocks the deposition of BSP in the extracellular matrix without a significant reduction in the total amount of BSP synthesized and secreted. This effect is reversible after allowing the cultures to recover in the absence of PKA activators for several days. Thus, a transient activation of PKA may suppress mineral deposition in vitro as a consequence of altering the assembly of an extracellular matrix permissive for apatite formation.	Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, Cleveland, OH 44195 USA; Univ Iowa, Coll Med, Dept Orthopaed Surg, Iowa City, IA 52242 USA	Cleveland Clinic Foundation; University of Iowa	Midura, RJ (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, ND20,9500 Euclid Ave, Cleveland, OH 44195 USA.			Martin, James/0000-0001-5085-0108				ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; AZARANI A, 1995, J BIOL CHEM, V270, P23166, DOI 10.1074/jbc.270.39.23166; BELLOWS CG, 1990, ENDOCRINOLOGY, V127, P3111, DOI 10.1210/endo-127-6-3111; BIANCO P, 1993, J HISTOCHEM CYTOCHEM, V41, P193, DOI 10.1177/41.2.8419459; BIANCO P, 1991, CALCIFIED TISSUE INT, V49, P421, DOI 10.1007/BF02555854; BONUCCI E, 1992, BONE MINER, V17, P219, DOI 10.1016/0169-6009(92)90740-5; BOWERS GN, 1988, METHOD ENZYMOL, V158, P302, DOI 10.1016/0076-6879(88)58062-X; CHEN JK, 1992, J BONE MINER RES, V7, P987; CHEN JK, 1991, MATRIX, V11, P133, DOI 10.1016/S0934-8832(11)80217-9; Chen TL, 1989, GROWTH FACTORS, V1, DOI 10.3109/08977198909000257; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHOMCZYNSKI P, 1995, BIOTECHNIQUES, V19, P942; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CIVITELLI R, 1989, ENDOCRINOLOGY, V124, P2928, DOI 10.1210/endo-124-6-2928; CIVITELLI R, 1988, AM J PHYSIOL, V255, P660; ECAROTCHARRIER B, 1989, J BIOL CHEM, V264, P20049; FISHER LW, 1990, J BIOL CHEM, V265, P2347; FLETCHER AE, 1986, FEBS LETT, V208, P263, DOI 10.1016/0014-5793(86)81029-8; FORREST SM, 1985, CALCIFIED TISSUE INT, V37, P51, DOI 10.1007/BF02557679; FUJIMORI A, 1991, ENDOCRINOLOGY, V128, P3032, DOI 10.1210/endo-128-6-3032; FUJIMORI A, 1992, ENDOCRINOLOGY, V130, P29, DOI 10.1210/en.130.1.29; GONG Z, 1992, BIOTECHNIQUES, V12, P74; GUENTHER HL, 1988, J BONE MINER RES, V3, P269; GUNNESS M, 1995, BONE, V16, P199, DOI 10.1016/8756-3282(94)00030-4; HRUSKA KA, 1991, CONTRIB NEPHROL, V91, P38; HRUSKA KA, 1995, CALCIFIED TISSUE INT, V56, pS35, DOI 10.1007/BF03354651; HULTENBY K, 1994, EUR J CELL BIOL, V63, P230; IBBOTSON KJ, 1989, J BONE MINER RES, V4, P37; IWAMOTO M, 1993, EXP CELL RES, V207, P413, DOI 10.1006/excr.1993.1209; KATO Y, 1990, ENDOCRINOLOGY, V127, P114, DOI 10.1210/endo-127-1-114; KLEIN BY, 1993, J CELL BIOCHEM, V53, P114, DOI 10.1002/jcb.240530204; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN KJ, 1989, ENDOCRINOLOGY, V125, P295, DOI 10.1210/endo-125-1-295; MERRITT BS, 1992, J CELL PHYSIOL, V152, P520, DOI 10.1002/jcp.1041520311; MIDURA RJ, 1994, J BIOL CHEM, V269, P13200; Midura RJ, 1996, GLYCOBIOLOGY, V6, P677, DOI 10.1093/glycob/6.7.677; MIDURA RJ, 1990, J BIOL CHEM, V265, P5285; MIYAKE R, 1984, BIOCHEM BIOPH RES CO, V121, P649, DOI 10.1016/0006-291X(84)90231-6; NUTT RF, 1990, ENDOCRINOLOGY, V127, P491, DOI 10.1210/endo-127-1-491; OLDBERG A, 1988, J BIOL CHEM, V263, P19430; OTTO F, 1997, CELL, V89, P747; PARTRIDGE NC, 1981, ENDOCRINOLOGY, V108, P220, DOI 10.1210/endo-108-1-220; PARTRIDGE NC, 1983, CANCER RES, V43, P4308; PARTRIDGE NC, 1982, ENDOCRINOLOGY, V111, P178, DOI 10.1210/endo-111-1-178; PFEILSCHIFTER J, 1990, ENDOCRINOLOGY, V127, P69, DOI 10.1210/endo-127-1-69; RIGGS BL, 1993, AM J MED S5A, V95, P62; RIMINUCCI M, 1995, CALCIFIED TISSUE INT, V57, P277, DOI 10.1007/BF00298883; ROACH HI, 1994, CELL BIOL INT, V18, P617, DOI 10.1006/cbir.1994.1088; ROSENBLATT M, 1977, J BIOL CHEM, V252, P5847; Salih E, 1996, J BIOL CHEM, V271, P16897, DOI 10.1074/jbc.271.28.16897; SEGRE GV, 1979, J BIOL CHEM, V254, P6980; SHENKER A, 1994, J CLIN ENDOCR METAB, V79, P750, DOI 10.1210/jc.79.3.750; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Spiegel AM, 1997, HORM RES, V47, P89, DOI 10.1159/000185441; STANFORD CM, 1995, J BIOL CHEM, V270, P9420, DOI 10.1074/jbc.270.16.9420; STEWART PJ, 1991, HORM METAB RES, V23, P535, DOI 10.1055/s-2007-1003748; SUGIMOTO T, 1992, J CELL PHYSIOL, V152, P28, DOI 10.1002/jcp.1041520105; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; VOYTEK TM, 1995, AM J SURG PATHOL, V19, P775, DOI 10.1097/00000478-199507000-00005; WATSON P, 1995, BONE, V16, P357, DOI 10.1016/8756-3282(94)00051-4; YEE JA, 1993, J CELL PHYSIOL, V157, P528, DOI 10.1002/jcp.1041570312	62	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11082	11091		10.1074/jbc.275.15.11082	http://dx.doi.org/10.1074/jbc.275.15.11082			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753913	hybrid			2022-12-27	WOS:000086466600055
J	Truneh, A; Sharma, S; Silverman, C; Khandekar, S; Reddy, MP; Deen, KC; Mclaughlin, MM; Srinivasula, SM; Livi, GP; Marshall, LA; Alnemri, ES; Williams, WV; Doyle, ML				Truneh, A; Sharma, S; Silverman, C; Khandekar, S; Reddy, MP; Deen, KC; Mclaughlin, MM; Srinivasula, SM; Livi, GP; Marshall, LA; Alnemri, ES; Williams, WV; Doyle, ML			Temperature-sensitive differential affinity of TRAIL for its receptors - DR5 is the highest affinity receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOTOXIC LIGAND TRAIL; NF-KAPPA-B; DEATH DOMAIN; CRYSTAL-STRUCTURE; INDUCED APOPTOSIS; PICHIA-PASTORIS; BINDING; MEMBER; FAMILY; CELLS	TRAIL is a member of the tumor necrosis factor (TNF) family of cytokines which induces apoptotic cell death in a variety of tumor cell lines. It mediates its apoptotic effects through one of two receptors, DR4 and DR5, which are members of of the TNF receptor family, and whose cytoplasmic regions contain death domains. In addition, TRAIL also binds to 3 "decoy" receptors, DcR2, a receptor with a truncated death domain, DcR1, a glycosylphosphatidylinositol-anchored receptor, and OPG a secreted protein which is also known to bind to another member of the TNF family, RANKL. However, although apoptosis depends on the expression of one or both of the death domain containing receptors DR4 and/or DR5, resistance to TRAIL-induced apoptosis does not correlate with the expression of the "decoy" receptors. Previously, TRAIL has been described to bind to all its receptors with equivalent high affinities. In the present work, we show, by isothermal titration calorimetry and competitive enzyme-linked immunosorbent assay, that the rank order of affinities of TRAIL for the recombinant soluble forms of its receptors is strongly temperature dependent. Although DR4, DR5, DcR1, and OPG, show similar affinities for TRAIL at 4 degrees C, their rank-ordered affinities are substantially different at 37 degrees C, with DR5 having the highest affinity (K-D less than or equal to 2 nM) and OPG having the weakest (K-D = 400 nM). Preferentially enhanced binding of TRAIL to DR5 was also observed at the cell surface. These results reveal that the rank ordering of affinities for protein-protein interactions in general can be a strong function of temperature, and indicate that sizeable, but hitherto unobserved, TRAIL affinity differences exist at physiological temperature, and should be taken into account in order to understand the complex physiological and/or pathological roles of TRAIL.	SmithKline Beecham Pharmaceut, Dept Immunol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Prot Biochem, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Comparat Genet, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Biol Struct, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Clin Pharmacol Unit, King Of Prussia, PA 19406 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Jefferson University	Truneh, A (corresponding author), SmithKline Beecham Pharmaceut, Dept Immunol, 709 Swedeland Rd, King Of Prussia, PA 19406 USA.		Truneh, Alem/ABB-7891-2020	Williams, William/0000-0003-3611-9284; Doyle, Michael/0000-0003-4569-6315	NCI NIH HHS [CA78890] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078890] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cha SS, 1999, IMMUNITY, V11, P253, DOI 10.1016/S1074-7613(00)80100-4; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Doyle M, 1999, CURRENT PROTOCOLS PR, P2041; Doyle ML, 1998, METHOD ENZYMOL, V295, P88; ELLIS SB, 1985, MOL CELL BIOL, V5, P1111, DOI 10.1128/MCB.5.5.1111; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Goodwin RG, 1998, APOPTOSIS, V3, P83, DOI 10.1023/A:1009640823621; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1999, J IMMUNOL, V162, P2597; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Harrop JA, 1998, J BIOL CHEM, V273, P27548, DOI 10.1074/jbc.273.42.27548; Hymowitz SG, 2000, BIOCHEMISTRY-US, V39, P633, DOI 10.1021/bi992242l; Hymowitz SG, 1999, MOL CELL, V4, P563, DOI 10.1016/S1097-2765(00)80207-5; JOHANSON K, 1995, J BIOL CHEM, V270, P9459, DOI 10.1074/jbc.270.16.9459; KUMAR S, 1995, J BIOL CHEM, V270, P27905, DOI 10.1074/jbc.270.46.27905; Kwon BS, 1997, J BIOL CHEM, V272, P14272, DOI 10.1074/jbc.272.22.14272; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Mongkolsapaya J, 1999, NAT STRUCT BIOL, V6, P1048; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Tan KB, 1997, GENE, V204, P35, DOI 10.1016/S0378-1119(97)00509-X; Truneh A, 1996, MOL IMMUNOL, V33, P321, DOI 10.1016/0161-5890(95)00077-1; TSCHOPP JF, 1987, NUCLEIC ACIDS RES, V15, P3859, DOI 10.1093/nar/15.9.3859; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Willcox BE, 1999, IMMUNITY, V10, P357, DOI 10.1016/S1074-7613(00)80035-7; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141	37	211	273	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23319	23325		10.1074/jbc.M910438199	http://dx.doi.org/10.1074/jbc.M910438199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10770955	hybrid			2022-12-27	WOS:000088419400099
J	Yalamanchili, P; Lu, CF; Oxvig, C; Springer, TA				Yalamanchili, P; Lu, CF; Oxvig, C; Springer, TA			Folding and function of I domain-deleted Mac-1 and lymphocyte function-associated antigen-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; INTEGRIN CR3 CD11B/CD18; BETA-PROPELLER DOMAIN; COMPLEMENT RECEPTOR TYPE-3; GLYCOPROTEIN-IIB-IIIA; LEUKOCYTE ADHESION; ALPHA-SUBUNIT; BINDING-SITE; CRYSTAL-STRUCTURE; LIGAND-BINDING	In those integrins that contain it, the I domain is a major ligand recognition site. The I domain is inserted between beta-sheets 2 and 3 of the predicted beta-propeller domain of the integrin alpha subunit, We deleted the I domain from the integrin alpha(M) and alpha(L) subunits to give I-less Mac-1 and lymphocyte function-associated antigen-1 (LFA-1), respectively. The I-less alpha(M) and alpha(L) subunits were expressed in association with the wild-type beta(2) subunit on the surface of transfected cells and bound to all the monoclonal antibodies mapped to the putative beta-propeller and C-terminal regions of the a, and a, subunits, suggesting that the folding of these domains is independent of the I domain. I-less Mac-1 bound to the ligands iC3b and factor X, but this binding was reduced compared with wild-type Mac-1. In contrast, I-less Mac-1 did not bind to fibrinogen or denatured bovine serum albumin. Binding to iC3b and factor X by I-less Mac-1 was inhibited by the function-blocking antibody CBRM1/32, which binds to the beta-propeller domain of the a, subunit, I-less LFA-1 did not bind its ligands intercellular adhesion molecule-1 and -3. Thus, the I domain is not essential for the folding, heterodimer formation, and surface expression of Mac-1 and LFA-1 and is required for binding to some ligands, but not others.	Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School	Springer, TA (corresponding author), Harvard Univ, Sch Med, Ctr Blood Res, 200 Longwood Ave, Boston, MA 02115 USA.			Oxvig, Claus/0000-0002-4715-9719	NCI NIH HHS [CA31799] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA031799, R01CA031799] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTIERI DC, 1990, J BIOL CHEM, V265, P12119; ALTIERI DC, 1988, P NATL ACAD SCI USA, V85, P7462, DOI 10.1073/pnas.85.20.7462; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ANDERSON DC, 1986, J IMMUNOL, V137, P15; ARNAOUT MA, 1990, J CLIN INVEST, V85, P977, DOI 10.1172/JCI114529; BAJT ML, 1995, J BIOL CHEM, V270, P94, DOI 10.1074/jbc.270.1.94; BELLER DI, 1982, J EXP MED, V156, P1000, DOI 10.1084/jem.156.4.1000; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DAVIS GE, 1992, EXP CELL RES, V200, P242, DOI 10.1016/0014-4827(92)90170-D; DEFOUGEROLLES AR, 1994, J EXP MED, V179, P619, DOI 10.1084/jem.179.2.619; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Gahmberg CG, 1997, EUR J BIOCHEM, V245, P215, DOI 10.1111/j.1432-1033.1997.00215.x; HEINZEL SS, 1988, J VIROL, V62, P3738, DOI 10.1128/JVI.62.10.3738-3746.1988; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; Huang CC, 1997, P NATL ACAD SCI USA, V94, P3156, DOI 10.1073/pnas.94.7.3156; Huang CC, 1997, P NATL ACAD SCI USA, V94, P3162, DOI 10.1073/pnas.94.7.3162; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Irie A, 1997, P NATL ACAD SCI USA, V94, P7198, DOI 10.1073/pnas.94.14.7198; Knorr R, 1997, J EXP MED, V186, P719, DOI 10.1084/jem.186.5.719; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Leitinger B, 2000, MOL BIOL CELL, V11, P677, DOI 10.1091/mbc.11.2.677; Lu CF, 1998, J BIOL CHEM, V273, P15138, DOI 10.1074/jbc.273.24.15138; Lu CF, 1997, J IMMUNOL, V159, P268; Lub M, 1997, MOL BIOL CELL, V8, P719, DOI 10.1091/mbc.8.4.719; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MOYLE M, 1994, J BIOL CHEM, V269, P10008; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; Nolte M, 1999, FEBS LETT, V452, P379, DOI 10.1016/S0014-5793(99)00666-3; Oxvig C, 1998, P NATL ACAD SCI USA, V95, P4870, DOI 10.1073/pnas.95.9.4870; PETRUZZELLI L, 1995, J IMMUNOL, V155, P854; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; RANDI AM, 1994, J BIOL CHEM, V269, P12395; Rich RL, 1999, J BIOL CHEM, V274, P24906, DOI 10.1074/jbc.274.35.24906; RIEU P, 1994, J CELL BIOL, V127, P2081, DOI 10.1083/jcb.127.6.2081; ROSS GD, 1985, J IMMUNOL, V134, P3307; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SPRINGER TA, 1986, CIBA F SYMP, V118, P102, DOI 10.1002/9780470720998.ch8; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; STANLEY P, 1994, EMBO J, V13, P1790, DOI 10.1002/j.1460-2075.1994.tb06447.x; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; vanKooyk Y, 1996, J EXP MED, V183, P1247, DOI 10.1084/jem.183.3.1247; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; WIPPLER J, 1994, J BIOL CHEM, V269, P8754; WRIGHT SD, 1986, J EXP MED, V164, P1876, DOI 10.1084/jem.164.6.1876; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	57	71	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21877	21882		10.1074/jbc.M908868199	http://dx.doi.org/10.1074/jbc.M908868199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10764808	hybrid			2022-12-27	WOS:000088363800019
J	Ahn, J; Wong, JT; Molday, RS				Ahn, J; Wong, JT; Molday, RS			The effect of lipid environment and retinoids on the ATPase activity of ABCR, the photoreceptor ABC transporter responsible for Stargardt macular dystrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE GENE ABCR; ADENOSINE-TRIPHOSPHATASE ACTIVITY; HAMSTER P-GLYCOPROTEIN; ROD OUTER SEGMENTS; RIM PROTEIN; RETINITIS-PIGMENTOSA; EXPORT PUMP; OVARY CELLS; MEMBRANE; RECONSTITUTION	ABCR is a photoreceptor-specific ATP-binding cassette transporter that has been linked to various retinal diseases, including Stargardt macular dystrophy, and implicated in retinal transport across rod outer segment (ROS) membranes, We have examined the ATPase and GTPase activity of detergent-solubilized and reconstituted ABCR, 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonic acid-solubilized ABCR had ATPase and GTPase activity (K-m similar to 75 mu M; V-max similar to 200 nmol/min/mg) that was stimulated 1.5-2-fold by all-trans-retinal and dependent on phospholipid and dithiothreitol. The K-m for ATP decreased to similar to 25 mu M after reconstitution, whereas the V-max was strongly dependent on the lipid used for reconstitution. ABCR reconstituted in ROS phospholipid had a V-max for basal and retinal activated ATPase activity that was 4-6 times higher than for ABCR in soybean or brain phospholipid. This enhanced activity was mainly due to the high phosphatidylethanolamine (PE) content of ROS membranes. PE was also required for retinoid-stimulated ATPase activity. ATPase activity of ABCR was stimulated by the addition of N-retinylidene-PE but not the reduced derivative, retinyl-PE. ABCR expressed in COS-1 cells also exhibited retinal-stimulated ATPase activity similar to that of the native protein, These results support the view that ABCR is an active retinoid transporter, the nucleotidase activity of which is strongly influenced by its lipid environment.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Molday, RS (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	molday@interchange.ubc.ca			NATIONAL EYE INSTITUTE [R01EY002422] Funding Source: NIH RePORTER; NEI NIH HHS [EY 02422] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805; ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; ANDERSON RE, 1970, BIOCHEMISTRY-US, V9, P3624, DOI 10.1021/bi00820a019; Azarian SM, 1997, FEBS LETT, V409, P247, DOI 10.1016/S0014-5793(97)00517-6; Chang XB, 1997, J BIOL CHEM, V272, P30962, DOI 10.1074/jbc.272.49.30962; Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355; DELAEY JJ, 1995, RETINA-J RET VIT DIS, V15, P399, DOI 10.1097/00006982-199515050-00005; Dong MQ, 1996, J BIOL CHEM, V271, P28875, DOI 10.1074/jbc.271.46.28875; ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0; Fishman GA, 1999, ARCH OPHTHALMOL-CHIC, V117, P504, DOI 10.1001/archopht.117.4.504; FOLCH J, 1957, J BIOL CHEM, V226, P497; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; Hagmann W, 1999, EUR J BIOCHEM, V265, P281, DOI 10.1046/j.1432-1327.1999.00735.x; HUBBARD R., 1971, Methods in Enzymology, V18C, P615, DOI 10.1016/S0076-6879(71)18045-7; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; Kliffen M, 1997, MICROSC RES TECHNIQ, V36, P106, DOI 10.1002/(SICI)1097-0029(19970115)36:2<106::AID-JEMT4>3.3.CO;2-E; Lewis RA, 1999, AM J HUM GENET, V64, P422, DOI 10.1086/302251; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Liu CE, 1997, J BIOL CHEM, V272, P21883, DOI 10.1074/jbc.272.35.21883; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; Martinez-Mir A, 1998, NAT GENET, V18, P11, DOI 10.1038/ng0198-11; MOLDAY RS, 1987, J CELL BIOL, V105, P2589, DOI 10.1083/jcb.105.6.2589; Nasonkin I, 1998, HUM GENET, V102, P21, DOI 10.1007/s004390050649; NIELSEN NC, 1970, BIOCHIM BIOPHYS ACTA, V211, P10, DOI 10.1016/0005-2736(70)90118-5; PAPERMASTER DS, 1978, J CELL BIOL, V78, P415, DOI 10.1083/jcb.78.2.415; Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609; PLACK PA, 1969, BIOCHEM J, V115, P927, DOI 10.1042/bj1150927; POINCELOT RP, 1969, NATURE, V221, P256, DOI 10.1038/221256a0; Romsicki Y, 1999, BIOCHEMISTRY-US, V38, P6887, DOI 10.1021/bi990064q; Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHAROM FJ, 1995, BIOCHEM J, V308, P381, DOI 10.1042/bj3080381; Souied EH, 1999, INVEST OPHTH VIS SCI, V40, P2740; Souied EH, 1999, AM J OPHTHALMOL, V128, P173, DOI 10.1016/S0002-9394(99)00145-2; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15; URBATSCH IL, 1995, ARCH BIOCHEM BIOPHYS, V316, P135, DOI 10.1006/abbi.1995.1020; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; ZHOU X, 1992, J LIPID RES, V33, P1233	43	99	103	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20399	20405		10.1074/jbc.M000555200	http://dx.doi.org/10.1074/jbc.M000555200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10767284	hybrid			2022-12-27	WOS:000088084500026
J	Juan, LJ; Shia, WJ; Chen, MH; Yang, WM; Seto, E; Lin, YS; Wu, CW				Juan, LJ; Shia, WJ; Chen, MH; Yang, WM; Seto, E; Lin, YS; Wu, CW			Histone deacetylases specifically down-regulate p53-dependent gene activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; TRANSCRIPTIONAL REPRESSION; IN-VIVO; DNA METHYLATION; ACETYLATION; CBP; ACETYLTRANSFERASES; EXPRESSION; CHROMATIN; FAMILY	p53, the most commonly mutated gene in cancer cells, directs cell cycle arrest or induces programmed cell death (apoptosis) in response to stress. It has been demonstrated that p53 activity is up-regulated in part by posttranslational acetylation. In agreement with these observations, here we show that mammalian histone deacetylase (HDAC)-1, -2, and -3 are all capable of downregulating p53 function. Down-regulation of p53 activity by HDACs is HDAC dosage-dependent, requires the deacetylase activity of HDACs, and depends on the region of p53 that is acetylated by p300/CREB-binding protein (CBP). These results suggest that interactions of p53 and HDACs likely result in p53 deacetylation, thereby reducing its transcriptional activity. In support of this idea, GST pull-down and immunoprecipitation assays show that p53 interacts with HDAC1 both in vitro and in vivo. Furthermore, a pre-acetylated p53 peptide was significantly deacetylated by immunoprecipitated wild type HDAC1 but not deacetylase mutant. Also, coexpression of HDAC1 greatly reduced the in vivo acetylation level of p53. Finally, we report that the activation potential of p53 on the BAX promoter, a natural p53-responsive system, is reduced in the presence of HDACs. Taken together; our findings indicate that deacetylation of p53 by histone deacetylases is likely to be part of the mechanisms that control the physiological activity of p53.	Natl Hlth Res Inst, Taipei 115, Taiwan; Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA	National Health Research Institutes - Taiwan; Academia Sinica - Taiwan; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Wu, CW (corresponding author), Natl Hlth Res Inst, 128 Yen Chiu Yuan Rd,Sec 2, Taipei 115, Taiwan.		Juan, Li-Jung/H-6631-2015	Yang, Wen-Ming/0000-0002-5871-5979				Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; HSU YS, 1995, J BIOL CHEM, V270, P6966, DOI 10.1074/jbc.270.12.6966; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kadosh D, 1998, GENE DEV, V12, P797, DOI 10.1101/gad.12.6.797; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Li Q, 1998, EMBO J, V17, P6300, DOI 10.1093/emboj/17.21.6300; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; Liu L, 1999, MOL CELL BIOL, V19, P1202; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; MIYASHITA T, 1995, CELL, V80, P293; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tomita A, 2000, ONCOGENE, V19, P444, DOI 10.1038/sj.onc.1203329; Tsai HL, 1996, J BIOL CHEM, V271, P3534; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	48	347	394	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20436	20443		10.1074/jbc.M000202200	http://dx.doi.org/10.1074/jbc.M000202200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10777477	hybrid			2022-12-27	WOS:000088084500031
J	Chen, Z; Sun, JZ; Pradines, A; Favre, G; Adnane, J; Sebti, SM				Chen, Z; Sun, JZ; Pradines, A; Favre, G; Adnane, J; Sebti, SM			Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS TRANSFORMATION; FARNESYLTRANSFERASE INHIBITORS; PRENYLATION; CANCER	Whereas the GTPase RhoA has been shown to promote proliferation and malignant transformation, the involvement of RhoB in these processes is not well understood. In this manuscript RhoB is shown to be a potent suppressor of transformation and human tumor growth in nude mice. In several human cancer cell lines, RhoA promotes focus formation whereas RhoB is as potent as the tumor suppressor p53 at inhibiting transformation in this assay. RhoB is both farnesylated (F) and geranylgeranylated (GG), and RhoB-F has been suggested as a target for the antitumor activity of farnesyltransferase inhibitors. Here we demonstrate that both RhoB-F and RhoB-GG inhibit anchorage-dependent and -independent growth, induce apoptosis, inhibit constitutive activation of Erk and insulin-like growth factor-1 stimulation of Akt, and suppress tumor growth in nude mice. The data demonstrate that RhoB is a potent suppressor of human tumor growth and that RhoB-F is not a target for farnesyltransferase inhibitors.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program,Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ Toulouse 3, UPRES EA 2048, F-31052 Toulouse, France; Ctr Lutte Contre Lanc Claudius Regaud, F-31052 Toulouse, France	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; UNICANCER; Institut Claudius Regaud	Sebti, SM (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program,Dept Biochem & Mol Biol, 12902 Magnolia Dr, Tampa, FL 33612 USA.		Pradines, Anne/M-3935-2014; FAVRE, Gilles/K-9189-2014	Pradines, Anne/0000-0002-2449-678X; FAVRE, Gilles/0000-0002-2344-1883	NATIONAL CANCER INSTITUTE [U19CA067771] Funding Source: NIH RePORTER; NCI NIH HHS [CA67771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cox AD, 1997, BIOCHIM BIOPHYS ACTA, V1333, P51; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Lebowitz PF, 1998, ONCOGENE, V17, P1439, DOI 10.1038/sj.onc.1202175; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; Mellor H, 1998, J BIOL CHEM, V273, P4811, DOI 10.1074/jbc.273.9.4811; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Sebti SM, 1997, PHARMACOL THERAPEUT, V74, P103, DOI 10.1016/S0163-7258(97)00014-4; Sun JZ, 1999, CANCER RES, V59, P4919; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	19	168	176	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					17974	17978		10.1074/jbc.C000145200	http://dx.doi.org/10.1074/jbc.C000145200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10770919	hybrid			2022-12-27	WOS:000087659400011
J	Bocker, U; Schottelius, A; Watson, JM; Holt, L; Licato, LL; Brenner, DA; Sartor, RB; Jobin, C				Bocker, U; Schottelius, A; Watson, JM; Holt, L; Licato, LL; Brenner, DA; Sartor, RB; Jobin, C			Cellular differentiation causes a selective down-regulation of interleukin (IL)-1 beta-mediated NF-kappa B activation and IL-8 gene expression in intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; RECEPTOR-ASSOCIATED FACTOR-2; PROTEIN-KINASE; HUMAN COLON; IKK-ALPHA; PHOSPHORYLATION; HT-29; LINE; INHIBITION; COMPLEX	Interleukin (IL)-1 beta signals through various adapter proteins and kinases that lead to activation of numerous downstream targets, including the transcription factors including NF-kappa B. In this study, we analyzed and characterized the effect of the differentiation of intestinal epithelial cells on IL-1 beta-mediated NF-kappa B activation and IL-8 gene expression. We report that IL-8 mRNA accumulation and protein secretion were down-regulated in IL-1 beta- and lipopolysaccharide-stimulated differentiated HT-29 cells (HT-29/MTX, where MTX is methotrexate) compared with undifferentiated cells (HT-29/p), whereas no differential effects were found following tumor necrosis factor (TNF)-alpha or phorbol myristate acetate stimulation. Cross-linking and affinity binding studies reveal that IL-1 beta exclusively binds the type I receptor (IL-1RI) and not IL-1RII in both HT-29/p and HT-29/MTX cells. IL-1 beta-mediated I kappa B kinase and c-Jun N-terminal kinase (JNK) activity were both diminished in differentiated HT-29 cells. DNA binding activity in differentiated HT-29 cells relative to HT-29/p cells was strongly reduced following IL-1 beta exposure but not after TNF-alpha stimulation. The proximal IL-1 signaling molecule IL-1 receptor-associated kinase was not degraded in IL-1 beta-stimulated HT-29 cells, in contrast to Caco-2 cells, kappa B-luciferase reporter gene activity was 16-fold higher following TNF receptor-associated factor-6 transfection after IL-1 beta stimulation in HT-29/MTX cells. We conclude that cellular differentiation of HT-29 cells selectively impairs the IL-1 beta signaling pathway inhibiting both NF-kappa B and JNK activity in response to IL-1 beta. This relative unresponsiveness to IL-1 beta may represent an important regulatory mechanism of differentiated intestinal epithelial cells.	Univ N Carolina, Dept Med, Div Digest Dis & Nutr, Ctr Gastrointestinal Biol & Dis, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Jobin, C (corresponding author), Univ N Carolina, Dept Med, Div Digest Dis & Nutr, Ctr Gastrointestinal Biol & Dis, 146 Glaxo Bldg, Chapel Hill, NC 27599 USA.			Brenner, David/0000-0003-2573-525X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047700] Funding Source: NIH RePORTER; NIDDK NIH HHS [R0I DK 47700, DK 34087] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERTINI R, 1992, CYTOKINE, V4, P44, DOI 10.1016/1043-4666(92)90035-P; Bocker U, 1998, GASTROENTEROLOGY, V115, P1426, DOI 10.1016/S0016-5085(98)70021-6; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; COCONNIER MH, 1994, DIFFERENTIATION, V58, P87, DOI 10.1046/j.1432-0436.1994.5810087.x; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; ECKMANN L, 1993, GASTROENTEROLOGY, V105, P1689, DOI 10.1016/0016-5085(93)91064-O; Elewaut D, 1999, J IMMUNOL, V163, P1457; GALANG CK, 1994, ONCOGENE, V9, P2913; Hoshino K, 1999, J IMMUNOL, V162, P3749; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Huang N, 1997, CYTOKINE, V9, P27, DOI 10.1006/cyto.1996.0132; Huang N, 1997, ADV EXP MED BIOL, V427, P145; Jobin C, 1997, INFLAMMATION, V21, P235, DOI 10.1023/A:1027326405788; Jobin C, 1997, J IMMUNOL, V158, P226; Jobin C, 1999, J IMMUNOL, V162, P4447; Jobin C, 1999, J IMMUNOL, V163, P3474; Jobin C, 1998, J IMMUNOL, V160, P410; Jobin C, 1998, IMMUNOLOGY, V95, P537; Jobin C, 1998, GUT, V42, P779, DOI 10.1136/gut.42.6.779; Kanakaraj P, 1998, J EXP MED, V187, P2073, DOI 10.1084/jem.187.12.2073; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; LESUFFLEUR T, 1990, CANCER RES, V50, P6334; Lesuffleur T, 1998, INT J CANCER, V76, P383, DOI 10.1002/(SICI)1097-0215(19980504)76:3<383::AID-IJC16>3.3.CO;2-M; Licato LL, 1998, DIGEST DIS SCI, V43, P1454, DOI 10.1023/A:1018894227169; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; LOUVARD D, 1992, ANNU REV CELL BIOL, V8, P157, DOI 10.1146/annurev.cb.08.110192.001105; McGee DW, 1996, CELL IMMUNOL, V168, P276, DOI 10.1006/cimm.1996.0076; Mengheri E, 1996, LIFE SCI, V59, P1227, DOI 10.1016/0024-3205(96)00446-8; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; Ohno Y, 1997, P NATL ACAD SCI USA, V94, P10279, DOI 10.1073/pnas.94.19.10279; Panja A, 1998, J IMMUNOL, V161, P3675; RADEMA SA, 1991, GASTROENTEROLOGY, V100, P1180; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rauschmayr T, 1997, P NATL ACAD SCI USA, V94, P5814, DOI 10.1073/pnas.94.11.5814; Rogler G, 1998, GASTROENTEROLOGY, V115, P357, DOI 10.1016/S0016-5085(98)70202-1; RUSSO MP, IN PRESS GASTROENTER; Saitoh O, 1997, J GASTROENTEROL, V32, P605, DOI 10.1007/BF02934109; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; SUTHERLAND DB, 1994, AM J PHYSIOL, V266, pC1198, DOI 10.1152/ajpcell.1994.266.5.C1198; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wong MH, 1999, GASTROENTEROLOGY, V116, P208, DOI 10.1016/S0016-5085(99)70245-3; Wright SD, 1999, J EXP MED, V189, P605, DOI 10.1084/jem.189.4.605; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611; Zweibaum A., 1991, HDB PHYSL GASTROINTE, P223	55	50	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12207	12213		10.1074/jbc.275.16.12207	http://dx.doi.org/10.1074/jbc.275.16.12207			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766857	hybrid			2022-12-27	WOS:000086695500092
J	Giovanni, A; Keramaris, E; Morris, EJ; Hou, ST; O'Hare, M; Dyson, N; Robertson, GS; Slack, RS; Park, DS				Giovanni, A; Keramaris, E; Morris, EJ; Hou, ST; O'Hare, M; Dyson, N; Robertson, GS; Slack, RS; Park, DS			E2F1 mediates death of B-amyloid-treated cortical neurons in a manner independent of p53 and dependent on Bax and caspase 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE BRAIN; ABL TYROSINE KINASE; CELL-CYCLE; RETINOBLASTOMA PROTEIN; BETA-PEPTIDE; TRANSCRIPTION FACTOR; INDUCED APOPTOSIS; TRANSGENIC MICE; NERVOUS-SYSTEM; RB	Although B-amyloid (AB) is suggested to play an important role in Alzheimer's disease, the mechanisms that control AB-evoked toxicity are unclear. We demonstrated previously that the cell cycle-related cyclin-dependent kinase 4/6/retinoblastoma protein pathway is required for AB-mediated death. However, the downstream target(s) of this pathway are unknown. We show here that neurons lacking E2F1, a transcription factor regulated by the retinoblastoma protein, are significantly protected from death evoked by AB, Moreover, p53 deficiency does not protect neurons from death, indicating that E2F1-mediated death occurs independently of p53. Neurons protected by E2F1 deficiency have reduced Bax-dependent caspase 3-like activity. However, protection afforded by E2F1, Bax, or caspase 3 deficiency is transient. In the case of E2F1, but not with Bax or caspase 3 deficiency, delayed death is accompanied by DEVD-AFC cleavage activity. Taken together, these results demonstrate the required role of E2F1, Bax, and caspase 3 in AB evoked death, but also suggest the participation of elements independent of these apoptosis regulators.	Univ Ottawa, Neurosci Res Inst, Ottawa, ON K1H 8M5, Canada; Hoechst Marion Roussel, Neurosci, Bridgewater, NJ 08807 USA; Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Merck Frosst Canada Inc, Pointe Claire, PQ H9R 4P8, Canada	University of Ottawa; Harvard University; Massachusetts General Hospital; National Research Council Canada; Merck & Company	Park, DS (corresponding author), Univ Ottawa, Neurosci Res Inst, Ottawa, ON K1H 8M5, Canada.	dpark@uottawa.ca	Hou, Sheng Tao/O-3202-2018; Hou, Sheng Tao/AAM-7756-2020	Robertson, George/0000-0001-8411-7721; Slack, Ruth/0000-0002-1552-2835; Hou, Sheng Tao/0000-0001-9736-342X; Park, David/0000-0002-4490-3784				BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; Berry DE, 1996, ONCOGENE, V12, P1809; BURDICK D, 1992, J BIOL CHEM, V267, P546; Busser J, 1998, J NEUROSCI, V18, P2801; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Cotman Carl W., 1994, P305; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Dirks PB, 1998, ONCOGENE, V17, P867, DOI 10.1038/sj.onc.1202008; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fan GS, 1996, ONCOGENE, V12, P1909; Giovanni A, 1999, J BIOL CHEM, V274, P19011, DOI 10.1074/jbc.274.27.19011; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; Holmberg C, 1998, ONCOGENE, V17, P143, DOI 10.1038/sj.onc.1201915; Hou ST, 1997, BIOCHEM CELL BIOL, V75, P383, DOI 10.1139/bcb-75-4-383; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Huang YY, 1997, ONCOGENE, V15, P1947, DOI 10.1038/sj.onc.1201376; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KERAMARIS E, 2000, IN PRESS MOL CELL NE; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MARK RJ, 1995, J NEUROSCI, V15, P6239; McGinnis KM, 1999, J NEUROCHEM, V72, P1899, DOI 10.1046/j.1471-4159.1999.0721899.x; McShea A, 1997, AM J PATHOL, V150, P1933; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RUSH DK, 1992, NEUROBIOL AGING, V13, P591, DOI 10.1016/0197-4580(92)90061-2; Saikumar P, 1998, ONCOGENE, V17, P3341, DOI 10.1038/sj.onc.1202579; Stefanis L, 1996, J BIOL CHEM, V271, P30663, DOI 10.1074/jbc.271.48.30663; Stefanis L, 1999, J NEUROSCI, V19, P6235; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Vincent I, 1997, J NEUROSCI, V17, P3588; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wu CL, 1996, MOL CELL BIOL, V16, P3698; Xiang H, 1996, J NEUROSCI, V16, P6753; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; Yankner BA, 1996, NAT MED, V2, P850, DOI 10.1038/nm0896-850; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X	49	187	197	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11553	11560		10.1074/jbc.275.16.11553	http://dx.doi.org/10.1074/jbc.275.16.11553			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766769	hybrid			2022-12-27	WOS:000086695500004
J	Harrod, R; Kuo, YL; Tang, Y; Yao, Y; Vassilev, A; Nakatani, Y; Giam, CZ				Harrod, R; Kuo, YL; Tang, Y; Yao, Y; Vassilev, A; Nakatani, Y; Giam, CZ			p300 and p300/cAMP-responsive element-binding protein associated factor interact with human T-cell lymphotropic virus type-1 Tax in a multi-histone acetyltransferase/activator-enhancer complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HTLV-I TAX; TRANSCRIPTIONAL ACTIVATOR TAX; ADENOVIRAL ONCOPROTEIN E1A; SERUM RESPONSE FACTOR; CREB-BINDING; TRANSACTIVATOR TAX; 21-BASE-PAIR REPEATS; COACTIVATOR CBP; LEUKEMIA	The human T-cell lymphotropic virus, type (HTLV)-1 trans-activator, Tax, coordinates with cAMP-responsive element-binding protein (CREB) and the transcriptional co-activators p300/CBP on three 21-base pair repeat elements in the proviral long terminal repeat (LTR) to promote viral mRNA transcription. Recruitment of p300/CBP to the activator-enhancer complex, however, is insufficient to support Tax-dependent LTR trans-activation. Here, we report that the p300/CBP-associated factor (P/CAF) is a critical and integral component of the functional HTLV-1 activator-enhancer complex. The HTLV-1 Tax protein directly binds P/CAF in vitro and co-immunoprecipitates with this co-activator in vivo. The Tax mutants (K88A and V89A) defective for p300/CBP-binding and LTR trans-activation, retained their abilities to interact with P/CAF. The M47 mutant (L319R, L320S) protein, which has previously been shown to interact with p300/CBP, by contrast, failed to form complexes with P/CAF and is impaired in LTR trans-activation. Furthermore, LTR trans-activation by Tax is competitively inhibited by the adenoviral E1A 12S gene product, which displaces P/CAF from p300/CBP and inhibits the histone acetyltransferase activities of both P/CAF and p300/CBP. This inhibition is partially reversed by exogenously added P/CAF. These results imply that simultaneous recruitment of two distinct coactivators (p300/CBP and P/CAF) by Tax is essential for the assembly of a trans-activation competent, nucleoprotein complex.	Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA; NICHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA	Uniformed Services University of the Health Sciences - USA; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Giam, CZ (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA.				NATIONAL CANCER INSTITUTE [R01CA048709, R01CA075688] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA/GM 75688, R01 CA48709] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADYA N, 1995, J VIROL, V69, P1834, DOI 10.1128/JVI.69.3.1834-1841.1995; ADYA N, 1994, P NATL ACAD SCI USA, V91, P5642, DOI 10.1073/pnas.91.12.5642; Adya N, 1994, MOL CELL BIOL, V14, P456; Akagi T, 1996, ONCOGENE, V12, P1645; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Bantignies F, 1996, MOL CELL BIOL, V16, P2174; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; Curtiss VE, 1996, MOL CELL BIOL, V16, P3567; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; FUJII M, 1995, ONCOGENE, V11, P7; GESSAIN A, 1985, LANCET, V2, P407; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; KANNO T, 1994, P NATL ACAD SCI USA, V91, P12634, DOI 10.1073/pnas.91.26.12634; Kimzey AL, 1998, J BIOL CHEM, V273, P13768, DOI 10.1074/jbc.273.22.13768; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Krumm A, 1998, P NATL ACAD SCI USA, V95, P13501, DOI 10.1073/pnas.95.23.13501; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lenzmeier BA, 1998, MOL CELL BIOL, V18, P721, DOI 10.1128/MCB.18.2.721; Lundblad JR, 1998, J BIOL CHEM, V273, P19251, DOI 10.1074/jbc.273.30.19251; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; Nicot C, 1998, J VIROL, V72, P6777, DOI 10.1128/JVI.72.8.6777-6784.1998; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OSAME M, 1987, ANN NEUROL, V21, P117, DOI 10.1002/ana.410210203; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; Perissi V, 1999, P NATL ACAD SCI USA, V96, P3652, DOI 10.1073/pnas.96.7.3652; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Shnyreva M, 1996, J VIROL, V70, P7478, DOI 10.1128/JVI.70.11.7478-7484.1996; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; SUZUKI T, 1995, ONCOGENE, V10, P1199; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; SUZUKI T, 1993, ONCOGENE, V8, P2391; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Tang Y, 1998, J BIOL CHEM, V273, P27339, DOI 10.1074/jbc.273.42.27339; Tie F, 1996, J VIROL, V70, P8368, DOI 10.1128/JVI.70.12.8368-8374.1996; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659; Yamagata T, 1997, MOL CELL BIOL, V17, P4272, DOI 10.1128/MCB.17.8.4272; YAMAOKA S, 1992, ONCOGENE, V7, P433; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yan JP, 1998, J MOL BIOL, V281, P395, DOI 10.1006/jmbi.1998.1951; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YIN MJ, 1995, J VIROL, V69, P3420, DOI 10.1128/JVI.69.6.3420-3432.1995; Yin MJ, 1996, J MOL BIOL, V264, P20, DOI 10.1006/jmbi.1996.0620; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Yin MJ, 1996, MOL CELL BIOL, V16, P3156; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	69	100	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11852	11857		10.1074/jbc.275.16.11852	http://dx.doi.org/10.1074/jbc.275.16.11852			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766811	hybrid			2022-12-27	WOS:000086695500046
J	Bergel, M; Herrera, JE; Thatcher, BJ; Prymakowska-Bosak, M; Vassilev, A; Nakatani, Y; Martin, B; Bustin, M				Bergel, M; Herrera, JE; Thatcher, BJ; Prymakowska-Bosak, M; Vassilev, A; Nakatani, Y; Martin, B; Bustin, M			Acetylation of novel sites in the nucleosomal binding domain of chromosomal protein HMG-14 by p300 alters its interaction with nucleosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASE ACTIVITY; TRANSCRIPTIONAL REPRESSION; ADA-COMPLEX; IN-VIVO; CHROMATIN; YEAST; EXPRESSION; ACTIVATION; DISTINCT; GCN5	The reversible acetylation of histones is associated with structural alterations in the chromatin fiber that affect various DNA-related activities. Here we show that the histone acetyltransferase p300 specifically acetylates HMG-14, a nonhistone structural protein that binds to nucleosomes and reduces the compactness of the chromatin fiber. We identify 7 major acetylation sites, 6 of which are novel and have not been known to be acetylated in either HMG-14 or the closely related HMG-17 protein. All the acetylation sites involve evolutionarily conserved residues: 3 within the HMG-14/-17 nucleosomal binding domain and 4 in or near the bipartite nuclear localization domains of the proteins. In tissue culture cells the acetylation pattern is indicative of a selective process in which a subfraction of HMG-14 is preferentially acetylated. We find that the nucleosomal binding domain is a major target for acetylation in vivo and that the specific acetylation of HMG-14 by p300 weakens its interaction with nucleosome cores. Our results suggest that p300 modulates the interaction of HMG-14 with nucleosomes. Thus, p300 may affect chromatin-related activities not only by modifying histones or transcription factors but also by targeting structural nonhistone proteins.	NCI, Prot Sect, Div Basic Sci, NIH, Bethesda, MD 20892 USA; NIMH, Unit Mol Struct, Clin Neurosci Branch, NIH, Bethesda, MD 20892 USA; NICHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Bergel, M (corresponding author), NCI, Prot Sect, Div Basic Sci, NIH, Bldg 37,Rm 3D-20, Bethesda, MD 20892 USA.		Bustin, Michael/G-6155-2015	Bustin, Michael/0000-0002-5147-7242				ALFONSO PJ, 1994, J MOL BIOL, V236, P189, DOI 10.1006/jmbi.1994.1128; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; BRAUNSTEIN M, 1996, MOL CELL BIOL, V16, P4249; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Davie JR, 1998, CURR OPIN GENET DEV, V8, P173, DOI 10.1016/S0959-437X(98)80138-X; Ding HF, 1997, MOL CELL BIOL, V17, P5843, DOI 10.1128/MCB.17.10.5843; FLETCHER TM, 1995, J BIOL CHEM, V270, P25359, DOI 10.1074/jbc.270.43.25359; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; Herrera JE, 1999, MOL CELL BIOL, V19, P3466; Hock R, 1998, EMBO J, V17, P6992, DOI 10.1093/emboj/17.23.6992; Hock R, 1998, J CELL BIOL, V143, P1427, DOI 10.1083/jcb.143.6.1427; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Lenfant F, 1996, EMBO J, V15, P3974, DOI 10.1002/j.1460-2075.1996.tb00771.x; Liu L, 1999, MOL CELL BIOL, V19, P1202; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONEILL LP, 1995, EMBO J, V14, P3946, DOI 10.1002/j.1460-2075.1995.tb00066.x; POSTNIKOV YV, 1994, NUCLEIC ACIDS RES, V22, P4520, DOI 10.1093/nar/22.21.4520; Postnikov YV, 1997, J MOL BIOL, V274, P454, DOI 10.1006/jmbi.1997.1391; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SANDEEN G, 1980, NUCLEIC ACIDS RES, V8, P3757, DOI 10.1093/nar/8.17.3757; STERNER R, 1981, J BIOL CHEM, V256, P8892; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Syntichaki P, 1998, J BIOL CHEM, V273, P24414, DOI 10.1074/jbc.273.38.24414; TRIESCHMANN L, 1995, MOL CELL BIOL, V15, P6663; TRIESCHMANN L, 1995, EMBO J, V14, P1478, DOI 10.1002/j.1460-2075.1995.tb07134.x; Vestner B, 1998, J BIOL CHEM, V273, P9409, DOI 10.1074/jbc.273.16.9409; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	39	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11514	11520		10.1074/jbc.275.15.11514	http://dx.doi.org/10.1074/jbc.275.15.11514			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753971	hybrid			2022-12-27	WOS:000086466600113
J	Sun, YB; Cheung, JM; Martel-Pelletier, J; Pelletier, JP; Wenger, L; Altman, RD; Howell, DS; Cheung, HS				Sun, YB; Cheung, JM; Martel-Pelletier, J; Pelletier, JP; Wenger, L; Altman, RD; Howell, DS; Cheung, HS			Wild type and mutant p53 differentially regulate the gene expression of human collagenase-3 (hMMP-13)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHEUMATOID-ARTHRITIS SYNOVIUM; TUMOR-SUPPRESSOR PROTEIN; FIBROBLAST-GROWTH-FACTOR; MATRIX METALLOPROTEINASE-13; RESPONSE ELEMENT; DNA-BINDING; PROMOTER; TRANSCRIPTION; REPRESSION; ACTIVATION	Matrix metalloproteinases (MMPs) are a family of secreted or transmembrane proteins that can degrade all the proteins of the extracellular matrix and have been implicated in many abnormal physiological conditions including arthritis and cancer metastasis. Recently we have shown for the first time that the human MMP-1 gene is a p53 target gene subject to repression by wild type p53 (Sun, Y., Sun, Y. I., Wenger, L., Rutter, J. L., Brinckerhoff, C, E., and Cheung, H, S. (1999) J. Biol. Chem 274, 11535-11540), Here, we report that cotransfection of fibroblast-like synoviocytes with p53 expression and hMMP13CAT reporter plasmids revealed that (i) hMMP13, another member of the human MMP family, was down-regulated by wild type p53, whereas all six of the p53 mutants tested lost the wild type p53 repressor activity in fibroblast-like synoviocytes; Iii) this repression of hMMP-13 gene expression by wild type p53 could be reversed by overexpression of p53 mutants p53-143A, p53-248W, p53-273H, and p53-281G; (iii) the dominant effect of p53 mutants over wild type p53 appears to be a promoter- and mutant-specific effect. An intriguing finding was that p53 mutant p53-281G could conversely stimulate the promoter activity of hMMP13 up to 2-4-fold and that it was dominant over wild type p53, Northern analysis confirmed these findings. Although the significance of these findings is currently unknown, they suggest that in addition to the effect of cytokines activation, the gene expression of hMMP13 could be dysregulated during the disease progression of rheumatoid arthritis (or cancer) associated with p53 inactivation. Since hMMP13 is 5-10 times as active as hMMP1 in its ability to digest type II collagen, the dysregulation or up-modulation of MMPI3 gene expression due to the inactivation of p53 may contribute to the joint degeneration in rheumatoid arthritis.	Univ Miami, Sch Med, Dept Med, Arthrit Div D26, Miami, FL 33101 USA; Vet Adm Med Ctr, Res Serv, Miami, FL 33103 USA; Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Miami, FL 33103 USA; Univ Montreal, Ctr Hosp, Osteoarthrit Res Unit, Montreal, PQ H2L 4M1, Canada	University of Miami; US Department of Veterans Affairs; Veterans Health Administration (VHA); Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Universite de Montreal	Cheung, HS (corresponding author), Univ Miami, Sch Med, Dept Med, Arthrit Div D26, POB 016960, Miami, FL 33101 USA.	hcheung@mednet.med.miami.edu	Pelletier, Jean-Pierre/AAG-2896-2019; Martel-Pelletier, Johanne/AAG-2928-2019		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR008662, R37AR008662, R01AR038421] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR38421, AR08662-33] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Desdouets C, 1996, FEBS LETT, V385, P34, DOI 10.1016/0014-5793(96)00330-4; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FASSBENDER HG, 1983, COLLAGEN REL RES, V3, P141; Firestein GS, 1996, ARTHRITIS RHEUM, V39, P1781, DOI 10.1002/art.1780391103; Firestein GS, 1996, AM J PATHOL, V149, P2143; Firestein GS, 1997, P NATL ACAD SCI USA, V94, P10895, DOI 10.1073/pnas.94.20.10895; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GAY S, 1993, ANN RHEUM DIS, V3, P141; HAMILTON JA, 1983, J RHEUMATOL, V10, P845; HARRIS DE, 1993, TXB RHEUMATOLOGY, P833; HARRIS ED, 1976, ARTHRITIS RHEUM-US, V19, P68, DOI 10.1002/art.1780190111; Ioachim EE, 1998, ANTICANCER RES, V18, P1665; Johansson N, 1997, AM J PATHOL, V151, P499; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KLEY N, 1992, NUCLEIC ACIDS RES, V20, P4083, DOI 10.1093/nar/20.15.4083; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Lindy O, 1997, ARTHRITIS RHEUM-US, V40, P1391, DOI 10.1002/art.1780400806; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Maiyar AC, 1997, MOL ENDOCRINOL, V11, P312, DOI 10.1210/me.11.3.312; MARGULIES L, 1993, J BIOL CHEM, V268, P15096; MARTELPELLETIER J, 1994, LAB INVEST, V70, P807; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; MULLERLADNER U, 1995, RHEUM DIS CLIN N AM, V21, P675; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Ozdemir E, 1997, J UROLOGY, V158, P206, DOI 10.1097/00005392-199707000-00072; Petrow PK, 1998, ARTHRITIS RHEUM, V41, pS276; RAGIMOV N, 1993, ONCOGENE, V8, P1183; Reboul P, 1996, J CLIN INVEST, V97, P2011, DOI 10.1172/JCI118636; Reme T, 1998, CLIN EXP IMMUNOL, V111, P353; Roivainen A, 1997, ARTHRITIS RHEUM-US, V40, P1636, DOI 10.1002/art.1780400913; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; Sioud M, 1998, CLIN EXP RHEUMATOL, V16, P125; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; Tardif G, 1997, BIOCHEM J, V323, P13, DOI 10.1042/bj3230013; TRABANDT A, 1992, APMIS, V100, P861, DOI 10.1111/j.1699-0463.1992.tb04012.x; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; Uria JA, 1998, AM J PATHOL, V153, P91, DOI 10.1016/S0002-9440(10)65549-6; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; Wernicke D, 1996, J RHEUMATOL, V23, P590; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	57	80	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11327	11332		10.1074/jbc.275.15.11327	http://dx.doi.org/10.1074/jbc.275.15.11327			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753945	hybrid			2022-12-27	WOS:000086466600087
J	Li, L; Guerin, D; Carafoli, E				Li, L; Guerin, D; Carafoli, E			Calcineurin controls the transcription of Na+/Ca2+ exchanger isoforms in developing cerebellar neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC NA+-CA2+ EXCHANGER; SODIUM-CALCIUM EXCHANGER; MEMBRANE CA2+ PUMP; VASCULAR SMOOTH-MUSCLE; PLASMA-MEMBRANE; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; CA2+-BINDING DOMAIN; SIGNAL SEQUENCE; MESSENGER-RNA	The Na+/Ca2+ exchanger (NCX) and the plasma membrane Ca2+-ATPase export Ca2+ from the cytosol to the extracellular space. Three NCX genes (NCX1, NCX2, and NCX3), encoding proteins with very similar properties, are expressed at different levels in tissues. Essentially, no information is available on the mechanisms that regulate their expression. Specific antibodies have been prepared and used to explore the expression of NCX1 and NCX2 in rat cerebellum. The expression of NCX2 became strongly up-regulated during development, whereas comparatively minor effects were seen for NCX1. This was also observed in cultured granule cells induced to mature in physiological concentrations of potassium. By contrast, higher K+ concentrations, which induce partial depolarization of the plasma membrane and promote the influx of Ca2+, caused the complete disappearance of NCX2, Reverse transcription-polymerase chain reaction analysis showed that the process occurred at the transcriptional level and depended on the activation of the Ca2+ calmodulin-dependent protein phosphatase, calcineurin. The NCX1 and NCX3 genes were also affected by the depolarizing treatment: the transcription of the latter became upregulated, and the pattern of expression of the splice variants of the former changed. The effects on the NCX1 and NCX3 genes were calcineurin-independent.	Swiss Fed Inst Technol, Inst Biochem, CH-8092 Zurich, Switzerland; Novartis AG, Lab Metab & Cardiovasc Dis, CH-4002 Basel, Switzerland; Univ Padua, Dept Biochem, I-35121 Padua, Italy	Swiss Federal Institutes of Technology Domain; ETH Zurich; Novartis; University of Padua	Carafoli, E (corresponding author), Swiss Fed Inst Technol, Inst Biochem, CH-8092 Zurich, Switzerland.	carafoli@civ.bio.unipd.it	Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094				ACETO JF, 1992, ARCH BIOCHEM BIOPHYS, V298, P553, DOI 10.1016/0003-9861(92)90449-7; Barnes KV, 1997, J BIOL CHEM, V272, P11510, DOI 10.1074/jbc.272.17.11550; BESSHO Y, 1994, NEURON, V12, P87, DOI 10.1016/0896-6273(94)90154-6; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; BOERTH SR, 1994, CIRC RES, V74, P354, DOI 10.1161/01.RES.74.2.354; Carafoli E, 1999, BIOCHEM BIOPH RES CO, V266, P624, DOI 10.1006/bbrc.1999.1879; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; CARMICHAEL J, 1987, CANCER RES, V47, P943; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FOLETTI D, 1995, FASEB J, V9, P670, DOI 10.1096/fasebj.9.8.7768360; FURMAN I, 1995, J BIOL CHEM, V270, P19120, DOI 10.1074/jbc.270.32.19120; GALLO V, 1987, J NEUROSCI, V7, P2203; Genazzani AA, 1999, P NATL ACAD SCI USA, V96, P5797, DOI 10.1073/pnas.96.10.5797; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; Guerini D, 1998, ACTA PHYSIOL SCAND, V163, P265; Guerini D, 2000, J BIOL CHEM, V275, P3706, DOI 10.1074/jbc.275.5.3706; Guerini D, 1999, J BIOL CHEM, V274, P1667, DOI 10.1074/jbc.274.3.1667; He SW, 1998, J NEUROSCI, V18, P4833; HRYSHKO LV, 1993, BIOCHIM BIOPHYS ACTA, V1151, P35, DOI 10.1016/0005-2736(93)90068-B; Iwata T, 1996, ANN NY ACAD SCI, V779, P37, DOI 10.1111/j.1749-6632.1996.tb44768.x; IWATA T, 1995, CELL CALCIUM, V17, P263, DOI 10.1016/0143-4160(95)90072-1; KENT RL, 1993, AM J PHYSIOL, V265, pH1024, DOI 10.1152/ajpheart.1993.265.3.H1024; Kim I, 1996, ANN NY ACAD SCI, V779, P126, DOI 10.1111/j.1749-6632.1996.tb44779.x; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; KOFUJI P, 1994, J BIOL CHEM, V269, P5145; KOMURO I, 1992, P NATL ACAD SCI USA, V89, P4769, DOI 10.1073/pnas.89.10.4769; LEE SL, 1994, J BIOL CHEM, V269, P14849; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22847; LI ZP, 1994, J BIOL CHEM, V269, P17434; Linck B, 1998, AM J PHYSIOL-CELL PH, V274, pC415, DOI 10.1152/ajpcell.1998.274.2.C415; LOO TW, 1995, J BIOL CHEM, V270, P19345, DOI 10.1074/jbc.270.33.19345; LOW W, 1993, FEBS LETT, V316, P63, DOI 10.1016/0014-5793(93)81737-K; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; Menick D R, 1996, J Card Fail, V2, pS69, DOI 10.1016/S1071-9164(96)80061-3; Nicholas SB, 1998, AM J PHYSIOL-HEART C, V274, pH217, DOI 10.1152/ajpheart.1998.274.1.H217; Nicoll DA, 1999, J BIOL CHEM, V274, P910, DOI 10.1074/jbc.274.2.910; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; O'Brien RJ, 1998, CURR OPIN NEUROBIOL, V8, P364, DOI 10.1016/S0959-4388(98)80062-7; PHILIPSON K D, 1992, Current Opinion in Cell Biology, V4, P678, DOI 10.1016/0955-0674(92)90089-U; Quednau BD, 1997, AM J PHYSIOL-CELL PH, V272, pC1250, DOI 10.1152/ajpcell.1997.272.4.C1250; Ruknudin A, 1997, AM J PHYSIOL-CELL PH, V273, pC257, DOI 10.1152/ajpcell.1997.273.1.C257; SAHINTOTH M, 1995, BIOCHEM BIOPH RES CO, V212, P968, DOI 10.1006/bbrc.1995.2064; Santacruz-Toloza L, 2000, J BIOL CHEM, V275, P182, DOI 10.1074/jbc.275.1.182; Scheller T, 1998, J BIOL CHEM, V273, P7643, DOI 10.1074/jbc.273.13.7643; Schwarzer A, 1997, BIOCHEMISTRY-US, V36, P13667, DOI 10.1021/bi9710232; SMITH L, 1995, AM J PHYSIOL-CELL PH, V269, pC457, DOI 10.1152/ajpcell.1995.269.2.C457; SMITH L, 1994, J BIOL CHEM, V269, P27527; SOLDATI L, 1985, J BIOL CHEM, V260, P3321; Stathopoulos-Gerontides A, 1999, GENE DEV, V13, P798, DOI 10.1101/gad.13.7.798; Stauffer TP, 1997, BRAIN RES, V748, P21, DOI 10.1016/S0006-8993(96)01282-6; STAUFFER TP, 1995, J BIOL CHEM, V270, P12184, DOI 10.1074/jbc.270.20.12184; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; TSURUYA Y, 1994, BBA-BIOMEMBRANES, V1196, P97, DOI 10.1016/0005-2736(94)90301-8; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147	57	81	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20903	20910		10.1074/jbc.M000995200	http://dx.doi.org/10.1074/jbc.M000995200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10767288	hybrid			2022-12-27	WOS:000088084500096
J	Girrbach, V; Zeller, T; Priesmeier, M; Strahl-Bolsinger, S				Girrbach, V; Zeller, T; Priesmeier, M; Strahl-Bolsinger, S			Structure-function analysis of the dolichyl phosphate-mannose: Protein O-mannosyltransferase ScPmt1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GLYCOSYL TRANSFER; CANDIDA-ALBICANS; N-GLYCOSYLATION; GENE FAMILY; YEAST; LOCALIZATION; GOLGI; GLYCOPROTEIN; CELLS	Protein O-mannosylation is an essential protein modification. It is initiated at the endoplasmic reticulum by a family of dolichyl phosphate-mannose:protein O-mannosyltransferases (Pmts), which is evolutionarily conserved from yeast to humans. Saccharomyces cerevisiae Pmt1p is an integral membrane protein of the endoplasmic reticulum. ScPmt1p forms a complex with ScPmt2p that is required for maximum transferase activity. Recently, we proposed a seven-transmembrane structural model for ScPmt1p. A large, hydrophilic, endoplasmic reticulum-oriented segment is flanked by five aminoterminal and two carboxyl-terminal membrane-spanning domains. Based on this model, a structure-function analysis of ScPmt1p was performed. Deletion mutagenesis identified the N-terminal third of the transferase as being essential for the formation of a functional ScPmt1p ScPmt2p complex. Deletion of the central hydrophilic loop eliminates mannosyltransferase activity, but not ScPmt1p-ScPmt2p interactions. Alignment of all fully characterized PMT family members revealed that this central loop region contains three highly conserved peptide motifs, which can be considered as signatures of the PMT family, In addition, a number of invariant amino acid residues were identified throughout the entire protein sequence. In order to evaluate the functional significance of these conserved residues site-directed mutagenesis was performed. We show that several amino acid substitutions in the conserved motifs significantly reduce ScPmt1p activity. Further, the invariant residues Arg-64, Glu-78, Arg-138, and Leu-408 are essential for ScPmt1p function. In particular, Arg-138 is crucial for ScPmt1p-ScPmt2p complex formation.	Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, D-93040 Regensburg, Germany	University of Regensburg	Strahl-Bolsinger, S (corresponding author), Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, D-93040 Regensburg, Germany.	sabine.strahl-bolsinger@biologie.uni-regensburg.de						BAUSE E, 1979, EUR J BIOCHEM, V101, P531, DOI 10.1111/j.1432-1033.1979.tb19748.x; Bourdineaud JP, 1998, MOL MICROBIOL, V27, P85, DOI 10.1046/j.1365-2958.1998.00660.x; Burda P, 1999, BBA-GEN SUBJECTS, V1426, P239, DOI 10.1016/S0304-4165(98)00127-5; Buurman ET, 1998, P NATL ACAD SCI USA, V95, P7670, DOI 10.1073/pnas.95.13.7670; Dan N, 1997, J BIOL CHEM, V272, P14214, DOI 10.1074/jbc.272.22.14214; DOTSON SB, 1995, ARCH BIOCHEM BIOPHYS, V316, P773, DOI 10.1006/abbi.1995.1103; GAFVELIN G, 1994, CELL, V77, P401, DOI 10.1016/0092-8674(94)90155-4; GENTZSCH M, 1995, GLYCOBIOLOGY, V5, P77, DOI 10.1093/glycob/5.1.77; Gentzsch M, 1995, FEBS LETT, V377, P128, DOI 10.1016/0014-5793(95)01324-5; Gentzsch M, 1996, EMBO J, V15, P5752, DOI 10.1002/j.1460-2075.1996.tb00961.x; Gentzsch M, 1997, GLYCOBIOLOGY, V7, P481, DOI 10.1093/glycob/7.4.481; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Guerreiro P, 1996, YEAST, V12, P273, DOI 10.1002/(SICI)1097-0061(19960315)12:3<273::AID-YEA898>3.0.CO;2-1; Harlow E., 1988, ANTIBODIES LAB MANUA; HASELBECK A, 1983, FEBS LETT, V158, P335, DOI 10.1016/0014-5793(83)80608-5; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; IMMERVOLL T, 1995, YEAST, V11, P1345, DOI 10.1002/yea.320111403; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; Jungmann J, 1998, EMBO J, V17, P423, DOI 10.1093/emboj/17.2.423; Jungmann J, 1999, J BIOL CHEM, V274, P6579, DOI 10.1074/jbc.274.10.6579; Jurado LAP, 1999, GENOMICS, V58, P171, DOI 10.1006/geno.1999.5819; Kaiser C., 1994, METHODS YEAST GENETI, P209; Ketela T, 1999, J BACTERIOL, V181, P3330, DOI 10.1128/JB.181.11.3330-3340.1999; Knauer R, 1999, J BIOL CHEM, V274, P17249, DOI 10.1074/jbc.274.24.17249; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; LARRIBA G, 1976, FEBS LETT, V71, P316, DOI 10.1016/0014-5793(76)80960-X; LEHLE L, 1984, BIOCHIM BIOPHYS ACTA, V799, P246, DOI 10.1016/0304-4165(84)90267-8; LEHLE L, 1978, EUR J BIOCHEM, V83, P563, DOI 10.1111/j.1432-1033.1978.tb12124.x; Lodder AL, 1999, GENETICS, V152, P1487; LORENZ C, 1992, EUR J BIOCHEM, V205, P1163, DOI 10.1111/j.1432-1033.1992.tb16886.x; LUSSIER M, 1995, J BIOL CHEM, V270, P2770, DOI 10.1074/jbc.270.6.2770; MARRIOTT M, 1979, J BACTERIOL, V139, P565, DOI 10.1128/JB.139.2.566-572.1979; MartinBlanco E, 1996, P NATL ACAD SCI USA, V93, P6048, DOI 10.1073/pnas.93.12.6048; NAKAYAMA K, 1992, EMBO J, V11, P2511, DOI 10.1002/j.1460-2075.1992.tb05316.x; Orlean P., 1997, MOL CELLULAR BIOL YE, V21, P229; PALAMARCZYK G, 1980, EUR J BIOCHEM, V105, P517, DOI 10.1111/j.1432-1033.1980.tb04527.x; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; Roemer T, 1996, GENE DEV, V10, P777, DOI 10.1101/gad.10.7.777; RUSSO P, 1992, P NATL ACAD SCI USA, V89, P3671, DOI 10.1073/pnas.89.9.3671; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sanders SL, 1999, J CELL BIOL, V145, P1177, DOI 10.1083/jcb.145.6.1177; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; Strahl-Bolsinger S, 1999, J BIOL CHEM, V274, P9068, DOI 10.1074/jbc.274.13.9068; Strahl-Bolsinger S, 1999, BBA-GEN SUBJECTS, V1426, P297, DOI 10.1016/S0304-4165(98)00131-7; STRAHLBOLSINGER S, 1993, P NATL ACAD SCI USA, V90, P8164, DOI 10.1073/pnas.90.17.8164; STRAHLBOLSINGER S, 1991, EUR J BIOCHEM, V196, P185, DOI 10.1111/j.1432-1033.1991.tb15802.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Timpel C, 1998, J BIOL CHEM, V273, P20837, DOI 10.1074/jbc.273.33.20837; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	53	88	92	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19288	19296		10.1074/jbc.M001771200	http://dx.doi.org/10.1074/jbc.M001771200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10764776	hybrid			2022-12-27	WOS:000087815900088
J	Bernstein, LS; Grillo, AA; Loranger, SS; Linder, ME				Bernstein, LS; Grillo, AA; Loranger, SS; Linder, ME			RGS4 binds to membranes through an amphipathic alpha-helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; GTPASE-ACTIVATING PROTEIN; ACTIVITY IN-VITRO; ESCHERICHIA-COLI; PLASMA-MEMBRANE; CORE DOMAIN; ASSOCIATION; GAIP; EXPRESSION; SUBUNITS	RGS4 a mammalian GTPase-activating protein for G protein alpha subunits, requires its N-terminal 33 amino acids for plasma membrane localization and biological activity (Srinivasa, S. P., Bernstein, L. S., Blumer, K. J,, and Linder, M. E. (1998) Proc. Natl. Acad Sci U. S. A. 95, 5584-5589). In this study, we tested the hypothesis that the N-terminal domain mediates membrane binding by forming an amphipathic alpha-helix. RGS4 bound to liposomes containing anionic phospholipids in a manner dependent on the first 33 amino acids. Circular dichroism spectroscopy of a peptide corresponding to amino acids 1-31 of RGS4 revealed that the peptide adopted an ct-helical conformation in the presence of anionic phospholipids, Point mutations that either neutralized positive charges on the hydrophilic face or substituted polar residues on the hydrophobic face of the model helix disrupted plasma membrane targeting and biological activity of RGS4 expressed in yeast. Recombinant mutant proteins were active as GTPase-activating proteins in solution but exhibited diminished binding to anionic liposomes. Peptides corresponding to mutants with the most pronounced phenotypes were also defective in forming an a-helix as measured by circular dichroism spectroscopy. These results support a model for direct interaction of RGS4 with membranes through hydrophobic and electrostatic interactions of an N-terminal alpha-helix.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Linder, ME (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave,Box 8228, St Louis, MO 63110 USA.		Linder, Maurine/AAU-9999-2021	Linder, Maurine/0000-0003-2202-9712	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008151, R01GM051466, T32GM007067] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51466, T32GM07067, T32GM8151] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bucci M, 1997, J CELL BIOL, V136, P1185, DOI 10.1083/jcb.136.6.1185; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; Chen CH, 1999, J BIOL CHEM, V274, P19799, DOI 10.1074/jbc.274.28.19799; Chen CH, 1998, FEBS LETT, V422, P359, DOI 10.1016/S0014-5793(98)00042-8; De Vries L, 1998, P NATL ACAD SCI USA, V95, P12340, DOI 10.1073/pnas.95.21.12340; DEVAUX PF, 1992, ANNU REV BIOPH BIOM, V21, P417, DOI 10.1146/annurev.bb.21.060192.002221; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; Diverse-Pierluissi MA, 1999, J BIOL CHEM, V274, P14490, DOI 10.1074/jbc.274.20.14490; Druey KM, 1999, J BIOL CHEM, V274, P18836, DOI 10.1074/jbc.274.26.18836; Druey KM, 1998, J BIOL CHEM, V273, P18405, DOI 10.1074/jbc.273.29.18405; Dulin NO, 1999, MOL CELL BIOL, V19, P714; Dunne SJ, 1996, BIOCHEMISTRY-US, V35, P11975, DOI 10.1021/bi960821+; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; JOHNSON JE, 1994, BIOCHEMISTRY-US, V33, P4327, DOI 10.1021/bi00180a029; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; LEE E, 1994, METHOD ENZYMOL, V237, P146; Li Y, 1998, J BIOL CHEM, V273, P29830, DOI 10.1074/jbc.273.45.29830; LINDER ME, 1990, J BIOL CHEM, V265, P8243; MACALA LJ, 1983, J LIPID RES, V24, P1243; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Srinivasa SP, 1998, J BIOL CHEM, V273, P1529, DOI 10.1074/jbc.273.3.1529; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Vergeres G, 1998, BIOCHEM J, V330, P5, DOI 10.1042/bj3300005; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; WANG Y, 1995, J BIOL CHEM, V270, P18948, DOI 10.1074/jbc.270.32.18948; Wieland T, 1997, J BIOL CHEM, V272, P8853; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687	36	106	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18520	18526		10.1074/jbc.M000618200	http://dx.doi.org/10.1074/jbc.M000618200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10764749	hybrid			2022-12-27	WOS:000087659400083
J	Chan, SL; Yee, KSY; Tan, KML; Yu, VC				Chan, SL; Yee, KSY; Tan, KML; Yu, VC			Accelerated Publication - The Caenorhabditis elegans sex determination protein FEM-1 is a CED-3 substrate that associates with CED-4 and mediates apoptosis in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ELEGANS; DETERMINING GENE; NEUROBLASTOMA-CELLS; DEATH; ACTIVATION; EGL-1; SH-SY5Y; TRA-1	Sex-specific elimination of cells by apoptosis plays a role in sex determination in Caenorhabditis elegans. Recently, a mammalian pro-apoptotic protein named F1A alpha has been identified. F1A alpha shares extensive homology throughout the entire protein with the C. elegans protein, FEM-1, which is essential for achieving all aspects of the male phenotype in the nematode. In this report, the role of FEM-1 in apoptosis was investigated. Overexpression of FEM-1 induces caspase-dependent apoptosis in mammalian cells. FEM-1 is cleaved in vitro by the C. elegans caspase, CED-3, generating an N-terminal cleavage product that corresponds to the minimal effector domain for apoptosis. Furthermore, CED-4 associates with FEM-1 in vitro and in vivo in mammalian cells and potentiates FEM-1-mediated apoptosis. Similarly, Apaf-1, the mammalian homologue of CED-4 was found to associate with F1A alpha. These data suggest that FEM-1 and F1A alpha may mediate apoptosis by communicating directly with the core machinery of apoptosis.	Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Yu, VC (corresponding author), Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.	mcbyuck@imcb.nus.edu.sg	Yu, Victor/A-7899-2015; Chan, S.L./X-4154-2018	Yu, Victor/0000-0003-3270-4734; Chan, S.L./0000-0002-3270-0525; Tan, Karen/0000-0002-7768-037X				Chan SL, 1999, J BIOL CHEM, V274, P32461, DOI 10.1074/jbc.274.45.32461; Chinnaiyan AM, 1997, NATURE, V388, P728, DOI 10.1038/41913; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Conradt B, 1999, CELL, V98, P317, DOI 10.1016/S0092-8674(00)81961-3; deBono M, 1996, GENETICS, V144, P587; del Peso L, 1998, J BIOL CHEM, V273, P33495, DOI 10.1074/jbc.273.50.33495; DONIACH T, 1984, DEV BIOL, V106, P223, DOI 10.1016/0012-1606(84)90077-0; Gaudet J, 1996, MOL BIOL CELL, V7, P1107, DOI 10.1091/mbc.7.7.1107; Hansen D, 1999, MECH DEVELOP, V83, P3, DOI 10.1016/S0925-4773(99)00024-6; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Hengartner MO, 1998, NATURE, V391, P441, DOI 10.1038/35036; HODGKIN J, 1991, NEURON, V6, P177, DOI 10.1016/0896-6273(91)90354-3; HODGKIN J, 1987, GENE DEV, V1, P731, DOI 10.1101/gad.1.7.731; Horvitz HR, 1999, CANCER RES, V59, p1701S; KIMBLE J, 1984, DEV BIOL, V105, P234, DOI 10.1016/0012-1606(84)90279-3; KUWABARA PE, 1992, TRENDS GENET, V8, P164, DOI 10.1016/0168-9525(92)90218-S; Ronca F, 1997, J BIOL CHEM, V272, P4252, DOI 10.1074/jbc.272.7.4252; Ronca F, 1999, J BIOL CHEM, V274, P18128, DOI 10.1074/jbc.274.25.18128; Shaham S, 1999, GENETICS, V153, P1655; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; SPENCE AM, 1990, CELL, V60, P981, DOI 10.1016/0092-8674(90)90346-G; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Ventura-Holman T, 2000, BIOCHEM BIOPH RES CO, V267, P317, DOI 10.1006/bbrc.1999.1942; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Yee KSY, 1998, J BIOL CHEM, V273, P5366, DOI 10.1074/jbc.273.9.5366; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	29	26	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					17925	17928		10.1074/jbc.C000146200	http://dx.doi.org/10.1074/jbc.C000146200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10764728	hybrid			2022-12-27	WOS:000087659400003
J	Imai, Y; Moralez, A; Andag, U; Clarke, JB; Busby, WH; Clemmons, DR				Imai, Y; Moralez, A; Andag, U; Clarke, JB; Busby, WH; Clemmons, DR			Substitutions for hydrophobic amino acids in the N-terminal domains of IGFBP-3 and-5 markedly reduce IGF-I binding and alter their biologic actions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-II; HUMAN FIBROBLASTS; LABILE SUBUNIT; CANCER-CELLS; PROTEIN-5; RECEPTOR; FORMS; SITE; LOCALIZATION; INHIBITOR	Insulin-like growth factor-binding protein-3 and -5 (IGFBP-3 and -5) have been shown to bind insulin-like growth factor-I and -II (IGF-I and -II) with high affinity. Precious studies have proposed that the N-terminal region of IGFBP-5 contains a hydrophobic patch between residues 49 and 74 that is required for high affinity binding. These studies were undertaken to determine if mutagenesis of several of these residues resulted in a reduction of the affinity of IGFBP-3 and -5 for IGF-I. Substitutions for residues 68, 69, 70, 73, and 74 in IGFBP-5 (changing one charged residue, Lys(68), to a neutral one and the four hydrophobic residues to nonhydrophobic residues) resulted in an similar to 1000-fold reduction in the affinity of IGFBP-5 for IGF-I. Substitutions for homologous residues in IGFBP-3 also resulted in a >1000-fold reduction in affinity, The physiologic consequence of this reduction was that IGFBP-5 and -5 became very weak inhibitors of IGF-I-stimulated cell migration and DNA synthesis. Likewise, the ability of IGFBP-5 to inhibit IGF-I-stimulated receptor phosphorylation was attenuated. These changes did not appear to be because of alterations in protein folding induced by mutagenesis, because the IGFBP-5 mutant was fully susceptible to proteolytic cleavage by a specific IGFBP-5 protease, In summary, residues 68, 69, 70, 73, and 74 in IGFBP-5 appear to be critical for high affinity binding to IGF-I. Homologous residues in IGFBP-3 are also required, suggesting that they form a similar binding pocket and that for both proteins these residues form an important component of the core binding site. The availability of these mutants will make it possible to determine if there are direct, non-IGF-I-dependent effects of IGFBP-3 and -5 on cellular physiologic processes in cell types that secrete IGF-I.	Univ N Carolina, Div Endocrinol, Sch Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Clemmons, DR (corresponding author), Univ N Carolina, Div Endocrinol, Sch Med, CB 7170,6111 Thurston Bowles, Chapel Hill, NC 27599 USA.			Imai, Yumi/0000-0001-5046-4223	NHLBI NIH HHS [HL 56580] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRESS DL, 1993, BIOCHEM BIOPH RES CO, V195, P25, DOI 10.1006/bbrc.1993.2004; Arai T, 1996, J BIOL CHEM, V271, P6099, DOI 10.1074/jbc.271.11.6099; BACH LA, 1993, J BIOL CHEM, V268, P9246; Bramani S, 1999, J MOL ENDOCRINOL, V23, P117, DOI 10.1677/jme.0.0230117; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; CHERNAUSEK SD, 1995, J BIOL CHEM, V270, P11377, DOI 10.1074/jbc.270.19.11377; Clemmons David R., 1997, Cytokine and Growth Factor Reviews, V8, P45, DOI 10.1016/S1359-6101(96)00053-6; CLEMMONS DR, 1992, ENDOCRINOLOGY, V131, P890, DOI 10.1210/en.131.2.890; CLEMMONS DR, 1993, MOL REPROD DEV, V35, P368, DOI 10.1002/mrd.1080350409; Conover Cheryl A., 1995, Progress in Growth Factor Research, V6, P301, DOI 10.1016/0955-2235(95)00032-1; COOKE RM, 1991, BIOCHEMISTRY-US, V30, P5484, DOI 10.1021/bi00236a022; DONG Y, 1995, ENDOCRINOLOGY, V136, P2000, DOI 10.1210/en.136.5.2000; Forbes BE, 1998, J BIOL CHEM, V273, P4647, DOI 10.1074/jbc.273.8.4647; FOWLKES JL, 1995, J BIOL CHEM, V270, P27481, DOI 10.1074/jbc.270.46.27481; Hashimoto R, 1997, J BIOL CHEM, V272, P27936, DOI 10.1074/jbc.272.44.27936; Heding A, 1996, J BIOL CHEM, V271, P13948, DOI 10.1074/jbc.271.24.13948; Ho MN, 1997, FERTIL STERIL, V67, P870, DOI 10.1016/S0015-0282(97)81399-4; Ho PJ, 1997, ENDOCRINOLOGY, V138, P3811, DOI 10.1210/en.138.9.3811; Hobba GD, 1996, J BIOL CHEM, V271, P30529, DOI 10.1074/jbc.271.48.30529; Imai Y, 1997, J CLIN INVEST, V100, P2596, DOI 10.1172/JCI119803; Imai Y, 1997, J CLIN ENDOCR METAB, V82, P4201, DOI 10.1210/jc.82.12.4201; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; JONES JI, 1996, P NATL ACAD SCI USA, V93, P2462; Kalus W, 1998, EMBO J, V17, P6558, DOI 10.1093/emboj/17.22.6558; Karas M, 1997, J BIOL CHEM, V272, P16514, DOI 10.1074/jbc.272.26.16514; MARTIN JL, 1999, IGF SYSTEM MOL BIOL, P227; MCCUSKER RH, 1988, ENDOCRINOLOGY, V122, P2071, DOI 10.1210/endo-122-5-2071; MCCUSKER RH, 1990, J CELL PHYSIOL, V144, P244, DOI 10.1002/jcp.1041440210; NAM TJ, 1994, ENDOCRINOLOGY, V135, P1385, DOI 10.1210/en.135.4.1385; OH YM, 1993, J BIOL CHEM, V268, P14964; QIN X, 1997, J BIOL CHEM, V273, P23509; Spencer E. Martin, 1995, Progress in Growth Factor Research, V6, P209; Standker L, 1998, FEBS LETT, V441, P281, DOI 10.1016/S0014-5793(98)01497-5; TERESAWA H, 1994, EMBO J, V13, P5590; TORRES AM, 1995, J MOL BIOL, V248, P385, DOI 10.1006/jmbi.1995.0229; Twigg SM, 1998, J BIOL CHEM, V273, P6074, DOI 10.1074/jbc.273.11.6074; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; WANG JF, 1988, BIOCHEM BIOPH RES CO, V157, P718, DOI 10.1016/S0006-291X(88)80309-7	38	99	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18188	18194		10.1074/jbc.M000070200	http://dx.doi.org/10.1074/jbc.M000070200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10766744	Green Published, hybrid			2022-12-27	WOS:000087659400039
J	Horstman, AL; Kuehn, MJ				Horstman, AL; Kuehn, MJ			Enterotoxigenic Escherichia coli secretes active heat-labile enterotoxin via outer membrane vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIBRIO-CHOLERAE; PSEUDOMONAS-AERUGINOSA; NEISSERIA-GONORRHOEAE; FUNCTIONAL-CHARACTERIZATION; EXTRACELLULAR VESICLES; POLYACRYLAMIDE GELS; MOLECULAR-CLONING; VIRULENCE FACTORS; TOXIN SECRETION; PROTEIN OMPX	Escherichia coli and other Gram-negative bacteria produce outer membrane vesicles during normal growth. Vesicles may contribute to bacterial pathogenicity by serving as vehicles for toxins to encounter host cells. Enterotoxigenic E. coli (ETEC) vesicles were isolated from culture supernatants and purified on velocity gradients, thereby removing any soluble proteins and contaminants from the crude preparation. Vesicle protein profiles were similar but not identical to outer membranes and differed between strains. Most vesicle proteins were resistant to dissociation, suggesting they were integral or internal. Thin layer chromatography revealed that major outer membrane lipid components are present in vesicles. Cytoplasmic membranes and cytosol were absent in vesicles; however, alkaline phosphatase and AcrA, periplasmic residents, were localized to vesicles. In addition, physiologically active heat-labile enterotoxin (LT) was associated with ETEC vesicles. LT activity correlated directly with the gradient peak of vesicles, suggesting specific association, but could be removed from vesicles under dissociating conditions. Further analysis revealed that LT is enriched in vesicles and is located both inside and on the exterior of vesicles. The distinct protein composition of ETEC vesicles and their ability to carry toxin may contribute to the pathogenicity of ETEC strains.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Kuehn, MJ (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Box 3711, Durham, NC 27710 USA.		Kuehn, Meta/AAL-2950-2021	Kuehn, Meta/0000-0003-0519-3019	NIAID NIH HHS [R21 AI063239] Funding Source: Medline; NIGMS NIH HHS [GM-07184, T32 GM007184] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI063239] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007184] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldermann C, 1998, J BACTERIOL, V180, P3741, DOI 10.1128/JB.180.15.3741-3749.1998; Beveridge TJ, 1999, J BACTERIOL, V181, P4725, DOI 10.1128/JB.181.16.4725-4733.1999; BLAKESLEY RW, 1977, ANAL BIOCHEM, V82, P580, DOI 10.1016/0003-2697(77)90197-X; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; CASSEL D, 1977, P NATL ACAD SCI USA, V74, P3307, DOI 10.1073/pnas.74.8.3307; CLEMENTS JD, 1979, INFECT IMMUN, V24, P760, DOI 10.1128/IAI.24.3.760-769.1979; CONNELL TD, 1995, INFECT IMMUN, V63, P4091, DOI 10.1128/IAI.63.10.4091-4098.1995; DONTA ST, 1974, SCIENCE, V183, P334, DOI 10.1126/science.183.4122.334; DORWARD DW, 1989, J BACTERIOL, V171, P4196, DOI 10.1128/JB.171.8.4196-4201.1989; DORWARD DW, 1989, J BACTERIOL, V171, P2499, DOI 10.1128/jb.171.5.2499-2505.1989; EVANS DG, 1977, INFECT IMMUN, V18, P330, DOI 10.1128/IAI.18.2.330-337.1977; Francetic O, 1996, J BACTERIOL, V178, P3544, DOI 10.1128/jb.178.12.3544-3549.1996; FUKUTA S, 1988, INFECT IMMUN, V56, P1748, DOI 10.1128/IAI.56.7.1748-1753.1988; GANKEMA H, 1980, INFECT IMMUN, V29, P704; GILL DM, 1979, J SUPRAMOL STR CELL, V10, P151, DOI 10.1002/jss.400100205; GRENIER D, 1987, INFECT IMMUN, V55, P111, DOI 10.1128/IAI.55.1.111-117.1987; GUYCAFFEY JK, 1992, J BACTERIOL, V174, P2460, DOI 10.1128/jb.174.8.2460-2465.1992; GYLES CL, 1992, CAN J MICROBIOL, V38, P734, DOI 10.1139/m92-120; HIRST TR, 1987, P NATL ACAD SCI USA, V84, P7418, DOI 10.1073/pnas.84.21.7418; HIRST TR, 1987, J BACTERIOL, V169, P1037, DOI 10.1128/jb.169.3.1037-1045.1987; HIRST TR, 1984, J BACTERIOL, V157, P637, DOI 10.1128/JB.157.2.637-642.1984; HIRST TR, 1984, P NATL ACAD SCI-BIOL, V81, P7752, DOI 10.1073/pnas.81.24.7752; HOEKSTRA D, 1976, BIOCHIM BIOPHYS ACTA, V455, P889, DOI 10.1016/0005-2736(76)90058-4; HOFSTRA H, 1984, J BIOL CHEM, V259, P5182; Jobling MG, 1997, PLASMID, V38, P158, DOI 10.1006/plas.1997.1309; KADURUGAMUWA JL, 1993, ANTIMICROB AGENTS CH, V37, P715, DOI 10.1128/AAC.37.4.715; Kadurugamuwa JL, 1998, ANTIMICROB AGENTS CH, V42, P1476, DOI 10.1128/AAC.42.6.1476; Kadurugamuwa JL, 1997, J ANTIMICROB CHEMOTH, V40, P615, DOI 10.1093/jac/40.5.615; Kadurugamuwa JL, 1996, J BACTERIOL, V178, P2767, DOI 10.1128/jb.178.10.2767-2774.1996; KADURUGAMUWA JL, 1995, J BACTERIOL, V177, P3998, DOI 10.1128/jb.177.14.3998-4008.1995; Kolling GL, 1999, APPL ENVIRON MICROB, V65, P1843; KUNKEL SL, 1979, INFECT IMMUN, V25, P586, DOI 10.1128/IAI.25.2.586-596.1979; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li ZS, 1998, J BACTERIOL, V180, P5478, DOI 10.1128/JB.180.20.5478-5483.1998; Lindenthal C, 1999, INFECT IMMUN, V67, P4084, DOI 10.1128/IAI.67.8.4084-4091.1999; MA D, 1993, J BACTERIOL, V175, P6299, DOI 10.1128/JB.175.19.6299-6313.1993; MILLER VL, 1990, J BACTERIOL, V172, P1062, DOI 10.1128/jb.172.2.1062-1069.1990; Odegaard TJ, 1997, J BIOL CHEM, V272, P19688, DOI 10.1074/jbc.272.32.19688; OSBORN MJ, 1972, J BIOL CHEM, V247, P3973; PEARSON GDN, 1982, P NATL ACAD SCI-BIOL, V79, P2976, DOI 10.1073/pnas.79.9.2976; PETTIT RK, 1992, MOL MICROBIOL, V6, P729, DOI 10.1111/j.1365-2958.1992.tb01522.x; PHILLIPS AT, 1994, METHODS GEN MOL BACT, P574; Rodighiero C, 1999, J BIOL CHEM, V274, P3962, DOI 10.1074/jbc.274.7.3962; Sambrook J., 2002, MOL CLONING LAB MANU; Sandkvist M, 1997, J BACTERIOL, V179, P6994, DOI 10.1128/jb.179.22.6994-7003.1997; Saunders NB, 1999, INFECT IMMUN, V67, P113, DOI 10.1128/IAI.67.1.113-119.1999; Sengupta TK, 1998, FEMS MICROBIOL LETT, V160, P183, DOI [10.1016/S0378-1097(98)00012-3, 10.1111/j.1574-6968.1998.tb12909.x]; SHOBERG RJ, 1993, INFECT IMMUN, V61, P3892, DOI 10.1128/IAI.61.9.3892-3900.1993; SPANGLER BD, 1992, MICROBIOL REV, V56, P622, DOI 10.1128/MMBR.56.4.622-647.1992; STOORVOGEL J, 1991, J BACTERIOL, V173, P156, DOI 10.1128/jb.173.1.156-160.1991; STOORVOGEL J, 1991, J BACTERIOL, V173, P161, DOI 10.1128/jb.173.1.161-167.1991; SVENNERHOLM AM, 1978, CURR MICROBIOL, V1, P19, DOI 10.1007/BF02601701; VANBEILEN JB, 1992, MOL MICROBIOL, V6, P3121; VERLINDE CLMJ, 1994, PROTEIN SCI, V3, P1670, DOI 10.1002/pro.5560031006; WAI SN, 1995, MICROBIOL IMMUNOL, V39, P451, DOI 10.1111/j.1348-0421.1995.tb02228.x; WENSINK J, 1978, BIOCHIM BIOPHYS ACTA, V514, P128, DOI 10.1016/0005-2736(78)90082-2	56	294	311	1	47	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12489	12496		10.1074/jbc.275.17.12489	http://dx.doi.org/10.1074/jbc.275.17.12489			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777535	hybrid, Green Accepted			2022-12-27	WOS:000086762300019
J	Domin, J; Gaidarov, I; Smith, MEK; Keen, JH; Waterfield, MD				Domin, J; Gaidarov, I; Smith, MEK; Keen, JH; Waterfield, MD			The class II phosphoinositide 3-kinase PI3K-C2 alpha is concentrated in the trans-Golgi network and present in clathrin-coated vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH-FACTOR; ASSEMBLY PROTEINS; PLASMA-MEMBRANE; RECEPTOR TRAFFICKING; TYROSINE KINASE; SORTING SIGNALS; AP-2 COMPLEXES; GAMMA-ADAPTIN; BREFELDIN-A	In recent years, a large family of phosphoinositide 3-kinase (PI3K) isozymes has been characterized and cloned. Several of these PI3K enzymes have overlapping tissue distributions and it remains unclear if and how their 3-phosphoinositide products elicit differential, intracellular effects. One possibility is that the PI3K enzymes display a restricted distribution within the cell to produce their 3-phospholipid products in specific, subcellular compartments. In the present study we characterize the subcellular distribution of the novel class II PI3K isozyme PI3K-C2 alpha in several mammalian cell types. Differential centrifugation of COS-1 and U937 cells together with Western blot analysis demonstrated that PI3K-C2 alpha is constitutively associated with phospholipid membranes. Centrifugation of rat brain homogenates and Western blotting revealed that in contrast to the class IA PI3K enzymes, PI3K-C2 alpha could be copurified with a population of clathrin-coated vesicles (CCVs). Furthermore, a PI3K activity refractory to wortmannin treatment was detected in CCV preparations consistent with the presence of the PI3K-C2 alpha isozyme. These biochemical observations were supported by immunofluorescence analysis that revealed PI3K-C2a to have a punctate distribution and an enrichment of immunoreactivity within a perinuclear site consistent with its presence in the endoplasmic reticulum or Golgi apparatus. Dual label immunofluorescence demonstrated that in this region, the distribution of PI3K-C2a closely paralleled that of gamma-adaptin, a component of the AP-1 adaptor that is present in the trans-Golgi and the trans-Golgi network (TGN) resident protein TGN-46. Neither the phospholipid association nor the subcellular localization of PI3K-C2a was dependent upon either its COOH-terminal PX or C2 domains. Mutants lacking these domains demonstrated a similar distribution to the wild type enzyme when expressed as recombinant proteins. Treatment of cells with brefeldin A disrupted the perinuclear staining pattern of both PI3K-C2 alpha and the AP-1 complex demonstrating that the localization of both molecules at the TGN is dependent upon ADP-ribosylation factor GTPase activity.	UCL, Ludwig Inst Canc Res, London W1P 8BT, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; Thomas Jefferson Univ, Dept Pharmacol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Ludwig Institute for Cancer Research; University of London; University College London; University of London; University College London; Jefferson University; Jefferson University	Domin, J (corresponding author), Imperial Coll Sch Med, Renal Sect, Du Cane Rd, London W12 0NN, England.	jdomin@ic.ac.uk			NIGMS NIH HHS [GM-49217] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049217] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; Arcaro A, 1998, J BIOL CHEM, V273, P33082, DOI 10.1074/jbc.273.49.33082; BECK KA, 1991, J BIOL CHEM, V266, P4442; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; Brown RA, 1999, J BIOL CHEM, V274, P14529, DOI 10.1074/jbc.274.21.14529; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Domin J, 1996, J BIOL CHEM, V271, P21614, DOI 10.1074/jbc.271.35.21614; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Futter CE, 1998, J CELL BIOL, V141, P611, DOI 10.1083/jcb.141.3.611; Gaidarov I, 1999, EMBO J, V18, P871, DOI 10.1093/emboj/18.4.871; Gaidarov I, 1999, J CELL BIOL, V146, P755, DOI 10.1083/jcb.146.4.755; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; GOODMAN OB, 1995, J BIOL CHEM, V270, P23768, DOI 10.1074/jbc.270.40.23768; Hickinson DM, 1997, CURR BIOL, V7, P987, DOI 10.1016/S0960-9822(06)00418-0; Iannolo G, 1997, CANCER RES, V57, P240; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; Jones SM, 1998, J BIOL CHEM, V273, P10349, DOI 10.1074/jbc.273.17.10349; Jones SM, 1997, J CELL BIOL, V139, P339, DOI 10.1083/jcb.139.2.339; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; Karlsson K, 1998, J BIOL CHEM, V273, P18966, DOI 10.1074/jbc.273.30.18966; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; Layton MJ, 1998, J BIOL CHEM, V273, P33379, DOI 10.1074/jbc.273.50.33379; LeBorgne R, 1996, J BIOL CHEM, V271, P2162; Lock P, 1998, EMBO J, V17, P4346, DOI 10.1093/emboj/17.15.4346; Macdougall LK, 1995, CURR BIOL, V5, P1404, DOI 10.1016/S0960-9822(95)00278-8; Mallet WG, 1996, J CELL SCI, V109, P3059; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; Misawa H, 1998, BIOCHEM BIOPH RES CO, V244, P531, DOI 10.1006/bbrc.1998.8294; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; Ono F, 1998, J BIOL CHEM, V273, P7731, DOI 10.1074/jbc.273.13.7731; Panaretou C, 1997, J BIOL CHEM, V272, P2477; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Sorkina T, 1999, J CELL SCI, V112, P317; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; Turner SJ, 1998, J BIOL CHEM, V273, P25987, DOI 10.1074/jbc.273.40.25987; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; WALSH JP, 1991, P NATL ACAD SCI USA, V88, P9184, DOI 10.1073/pnas.88.20.9184; Wendland B, 1998, CURR OPIN CELL BIOL, V10, P513, DOI 10.1016/S0955-0674(98)80067-7; Yu JH, 1998, J BIOL CHEM, V273, P30199, DOI 10.1074/jbc.273.46.30199; Zhang J, 1998, J BIOL CHEM, V273, P14081, DOI 10.1074/jbc.273.23.14081; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	65	115	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11943	11950		10.1074/jbc.275.16.11943	http://dx.doi.org/10.1074/jbc.275.16.11943			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766823	hybrid			2022-12-27	WOS:000086695500058
J	Hatano, E; Bradham, CA; Stark, A; Iimuro, Y; Lemasters, JJ; Brenner, DA				Hatano, E; Bradham, CA; Stark, A; Iimuro, Y; Lemasters, JJ; Brenner, DA			The mitochondrial permeability transition augments Fas-induced apoptosis in mouse hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CYTOCHROME-C RELEASE; NECROSIS-FACTOR RECEPTOR; CERAMIDE-INDUCED APOPTOSIS; ACTIVATED PROTEIN-KINASES; ALPHA-INDUCED APOPTOSIS; CELL-DEATH; MEDIATED APOPTOSIS; LIVER-REGENERATION; GD3 GANGLIOSIDE	Tumor necrosis factor-alpha receptor 1 and Fas recruit overlapping signaling pathways. To clarify the differences between tumor necrosis factor alpha (TNF alpha) and Fas pathways in hepatocyte apoptosis, primary mouse hepatocytes were treated with TNF alpha or an agonist anti-Fas antibody after infection with an adenovirus expressing an I kappa B superrepressor (Ad5I kappa B). Treatment with TNF alpha induced apoptosis in Ad5I kappa B-infected mouse hepatocytes, as we previously reported for rat hepatocytes. Ad5I kappa B plus anti-Fas antibody or actinomycin D plus anti-Fas antibody rapidly induced apoptosis, whereas anti-Fas antibody alone produced little cytotoxicity. The proteasome inhibitor (MG-132) and a dominant-negative mutant of nuclear factor-kappa B-inducing kinase also promoted TNF alpha- and Fas-mediated apoptosis. Expression of either crmA or a dominant-negative mutant of the Fas-associated death domain protein prevented TNF alpha- and Fas-mediated apoptosis. In addition, the caspase inhibitors, DEVD-cho and IETD-fmk, inhibited TNF alpha- and Fas-mediated apoptosis. In Ad5I kappa B-infected hepatocytes, caspases-3 and -8 were activated within 2 h after treatment with anti-Fas antibody or within 6 h after TNF alpha treatment. Confocal microscopy demonstrated onset of the mitochondrial permeability transition (MPT) and mitochondrial depolarization by 2-3 h after anti-Fas antibody treatment and 8-10 h after TNF alpha treatment, followed by cytochrome c release. The combination of the MPT inhibitors, cyclosporin A, and trifluoperazine, protected Ad5I kappa B-infected hepatocytes from TNF alpha-mediated apoptosis. After anti-Fas antibody, cyclosporin A and trifluoperazine decreased cytochrome c release but did not prevent caspase-3 activation and cell-death. In conclusion, nuclear factor-kappa B activation protects mouse hepatocytes against both TNF alpha- and Fas-mediated apoptosis. TNF alpha and Fas recruit similar but nonidentical, pathways signaling apoptosis. The MPT is obligatory for TNF alpha-induced apoptosis. In Fas-mediated apoptosis, the MPT accelerates the apoptogenic events but is not obligatory for them.	Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Cell Biol & Anat, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Brenner, DA (corresponding author), Univ N Carolina, Dept Med, CB 7080, Chapel Hill, NC 27599 USA.		Hatano, Etsuro/AAX-2407-2020; Bradham, Cynthia/GXV-9373-2022; Stark, Alexander/D-1473-2012	Hatano, Etsuro/0000-0003-3407-1918; Stark, Alexander/0000-0003-2611-0841; Brenner, David/0000-0003-2573-525X	NIAAA NIH HHS [AA11605] Funding Source: Medline; NIDDK NIH HHS [DK34987] Funding Source: Medline; NIGMS NIH HHS [GM41804] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P60AA011605, P50AA011605] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ANTON M, 1995, J VIROL, V69, P4600, DOI 10.1128/JVI.69.8.4600-4606.1995; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Bradham CA, 1997, HEPATOLOGY, V25, P1128, DOI 10.1002/hep.510250514; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; de Moissac D, 1998, J BIOL CHEM, V273, P23946, DOI 10.1074/jbc.273.37.23946; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dimmeler S, 1998, CELL GROWTH DIFFER, V9, P415; Fladmark KE, 1997, BIOCHEM BIOPH RES CO, V232, P20, DOI 10.1006/bbrc.1997.6214; Galle PR, 1998, SEMIN LIVER DIS, V18, P141, DOI 10.1055/s-2007-1007150; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; Jobin C, 1998, GUT, V42, P779, DOI 10.1136/gut.42.6.779; Jones BE, 1999, HEPATOLOGY, V30, P215, DOI 10.1002/hep.510300146; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kim YM, 1998, J BIOL CHEM, V273, P31437, DOI 10.1074/jbc.273.47.31437; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kristal BS, 1999, J BIOL CHEM, V274, P23169, DOI 10.1074/jbc.274.33.23169; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; LEIST M, 1995, J IMMUNOL, V154, P1307; Leist M, 1996, MOL MED, V2, P109, DOI 10.1007/BF03402207; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Malisan F, 1999, FEBS LETT, V452, P100, DOI 10.1016/S0014-5793(99)00543-8; Melino G, 1997, NATURE, V388, P432, DOI 10.1038/41237; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Moldeus P, 1978, Methods Enzymol, V52, P60; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079; NI R, 1994, EXP CELL RES, V215, P332, DOI 10.1006/excr.1994.1349; Nieminen AL, 1997, AM J PHYSIOL-CELL PH, V272, pC1286; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; Perry DK, 1998, BBA-MOL CELL BIOL L, V1436, P233, DOI 10.1016/S0005-2760(98)00145-3; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; Qian T, 1999, TOXICOL APPL PHARM, V154, P117, DOI 10.1006/taap.1998.8580; Qian T, 1997, AM J PHYSIOL-CELL PH, V273, pC1783, DOI 10.1152/ajpcell.1997.273.6.C1783; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rouquet N, 1996, BIOCHEM BIOPH RES CO, V229, P27, DOI 10.1006/bbrc.1996.1753; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Takehara T, 1998, HEPATOLOGY, V27, P1643, DOI 10.1002/hep.510270625; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xu Y, 1998, AM J PHYSIOL-CELL PH, V275, pC1058, DOI 10.1152/ajpcell.1998.275.4.C1058; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zamzami N, 1996, FEBS LETT, V384, P53, DOI 10.1016/0014-5793(96)00280-3; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355; ZHOU Q, 1997, J BIOL CHEM, V272, P797	75	128	129	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11814	11823		10.1074/jbc.275.16.11814	http://dx.doi.org/10.1074/jbc.275.16.11814			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766806	Green Published, hybrid			2022-12-27	WOS:000086695500041
J	He, XY; Hohn, T; Futterer, J				He, XY; Hohn, T; Futterer, J			Transcriptional activation of the rice tungro bacilliform virus gene is critically dependent on an activator element located immediately upstream of the TATA box	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; DNA-BINDING PROTEINS; NUCLEAR FACTOR; PROMOTER; EXPRESSION; TOBACCO; INITIATION; SEQUENCE; COMPLEX; PLANTS	To investigate the transcriptional mechanisms of rice tungro bacilliform virus, we have systematically analyzed an activator element located immediately upstream of the TATA box in the rice tungro bacilliform virus promoter and its cognate trans-acting factors. Using electrophoretic mobility shift assays, we showed that rice nuclear proteins bind to the activator element, forming multiple specific DNA-protein complexes via protein-protein interactions, Copper-phenanthroline footprinting and DNA methylation interference analysis indicated that multiple DNA-protein complexes share a common binding site located between positions -60 to -39, and the proteins contact the activator element in the major groove. DNA UV cross-linking assays further showed that two nuclear proteins (36 and 33 kDa), found in rice cell suspension and shoot nuclear extracts, and one (27 kDa), present in root nuclear extracts, bind to this activator element. In protoplasts derived from a rice (Oryza sativa) suspension culture, the activator element is a prerequisite for promoter activity and its function is critically dependent on its position relative to the TATA box. Thus, transcriptional activation may function via interactions with the basal transcriptional machinery, and we propose that this activation is mediated by protein-protein interactions in a position-dependent mechanism.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland; Swiss Fed Inst Technol, Inst Plant Sci, CH-8092 Zurich, Switzerland	Friedrich Miescher Institute for Biomedical Research; Swiss Federal Institutes of Technology Domain; ETH Zurich	Hohn, T (corresponding author), Friedrich Miescher Inst, POB 2543, CH-4002 Basel, Switzerland.							Ausubel FM, 1988, MOL REPROD DEV; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAO YM, 1994, VIROLOGY, V204, P626, DOI 10.1006/viro.1994.1577; BENFEY PN, 1990, SCIENCE, V250, P959, DOI 10.1126/science.250.4983.959; BHATTACHARYYAPAKRASI M, 1993, PLANT J, V4, P71, DOI 10.1046/j.1365-313X.1993.04010071.x; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN G, 1994, VIROLOGY, V204, P91, DOI 10.1006/viro.1994.1513; Chen G, 1996, J VIROL, V70, P8411, DOI 10.1128/JVI.70.12.8411-8421.1996; DATTA SK, 1990, BIO-TECHNOL, V8, P736, DOI 10.1038/nbt0890-736; DESPRES C, 1995, PLANT CELL, V7, P589, DOI 10.1105/tpc.7.5.589; Droog F, 1995, PLANT MOL BIOL, V29, P413, DOI 10.1007/BF00020974; FROMM H, 1989, PLANT CELL, V1, P977, DOI 10.1105/tpc.1.10.977; FUTTERER J, 1991, EMBO J, V10, P3887, DOI 10.1002/j.1460-2075.1991.tb04958.x; GARABEDIAN MJ, 1993, GENE TRANSCRIPTION P, P243; GREEN PJ, 1987, EMBO J, V6, P2543, DOI 10.1002/j.1460-2075.1987.tb02542.x; GUARENTE L, 1995, TRENDS BIOCHEM SCI, V20, P517, DOI 10.1016/S0968-0004(00)89120-3; GUILFOYLE TJ, 1997, GENET ENG P, V19, P15; Hahn S, 1998, CELL, V95, P579, DOI 10.1016/S0092-8674(00)81625-6; HAY JM, 1991, NUCLEIC ACIDS RES, V19, P2615, DOI 10.1093/nar/19.10.2615; Hohn T, 1997, CRIT REV PLANT SCI, V16, P133, DOI 10.1080/713608145; INOKUCHI K, 1991, NUCLEIC ACIDS RES, V19, P3099, DOI 10.1093/nar/19.11.3099; Jackson S. P., 1993, Gene transcription: a practical approach., P189; Jin G, 1998, PLANT MOL BIOL, V38, P713, DOI 10.1023/A:1006034932322; KATAGIRI F, 1990, GENE DEV, V4, P1899, DOI 10.1101/gad.4.11.1899; KATAGIRI F, 1989, NATURE, V340, P727, DOI 10.1038/340727a0; KAWATA T, 1992, PLANT MOL BIOL, V19, P867, DOI 10.1007/BF00027083; Kloti A, 1999, PLANT MOL BIOL, V40, P249, DOI 10.1023/A:1006119517262; Kremer A, 1998, VIROLOGY, V249, P336, DOI 10.1006/viro.1998.9288; LAM E, 1989, P NATL ACAD SCI USA, V86, P7890, DOI 10.1073/pnas.86.20.7890; Larkin RM, 1998, J BIOL CHEM, V273, P5631, DOI 10.1074/jbc.273.10.5631; Le Gourrierec J, 1999, PLANT J, V18, P663, DOI 10.1046/j.1365-313x.1999.00482.x; LI H, 1994, EMBO J, V13, P3580, DOI 10.1002/j.1460-2075.1994.tb06665.x; Li YF, 1999, PLANT MOL BIOL, V39, P515, DOI 10.1023/A:1006139724849; MALDONADO E, 1995, CURR OPIN CELL BIOL, V7, P352, DOI 10.1016/0955-0674(95)80090-5; MARTINOCATT SJ, 1994, PLANT MOL BIOL MANUA, P1; Mayo MA, 1998, J GEN VIROL, V79, P649, DOI 10.1099/0022-1317-79-4-649; Meisel L, 1997, Genet Eng (N Y), V19, P183; Morishima A, 1998, PLANT MOL BIOL, V38, P633, DOI 10.1023/A:1006085812507; Neustaedter DA, 1999, PLANT J, V18, P77, DOI 10.1046/j.1365-313X.1999.00430.x; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; QU RD, 1991, VIROLOGY, V185, P354, DOI 10.1016/0042-6822(91)90783-8; ROBERTS SGE, 1995, CURR BIOL, V5, P508, DOI 10.1016/S0960-9822(95)00103-5; ROTHNIE HM, 1994, ADV VIRUS RES, V44, P1, DOI 10.1016/S0065-3527(08)60327-9; Sambrook J., 2002, MOL CLONING LAB MANU; SCHINDLER U, 1992, PLANT CELL, V4, P1309, DOI 10.1105/tpc.4.10.1309; SHILLITO RD, 1985, BIO-TECHNOL, V3, P1099, DOI 10.1038/nbt1285-1099; Singh KB, 1998, PLANT PHYSIOL, V118, P1111, DOI 10.1104/pp.118.4.1111; Strompen G, 1998, PLANT MOL BIOL, V37, P871, DOI 10.1023/A:1006003916284; TAKAHASHI K, 1986, NATURE, V319, P121, DOI 10.1038/319121a0; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VILEN BJ, 1991, MOL CELL BIOL, V11, P2406, DOI 10.1128/MCB.11.5.2406; Willmott RL, 1998, PLANT MOL BIOL, V38, P817, DOI 10.1023/A:1006084104041; YAMAZAKI K, 1990, P NATL ACAD SCI USA, V87, P7035, DOI 10.1073/pnas.87.18.7035; Yin YH, 1997, EMBO J, V16, P5247, DOI 10.1093/emboj/16.17.5247; Yin YH, 1997, PLANT J, V12, P1179, DOI 10.1046/j.1365-313X.1997.12051179.x; YIN YH, 1995, PLANT J, V7, P969, DOI 10.1046/j.1365-313X.1995.07060969.x	59	22	24	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11799	11808		10.1074/jbc.275.16.11799	http://dx.doi.org/10.1074/jbc.275.16.11799			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766804	hybrid			2022-12-27	WOS:000086695500039
J	Meibom, KL; Kallipolitis, BH; Ebright, RH; Valentin-Hansen, P				Meibom, KL; Kallipolitis, BH; Ebright, RH; Valentin-Hansen, P			Identification of the subunit of cAMP receptor protein (CRP) that functionally interacts with CytR in CRP-CytR-mediated transcriptional repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE ACTIVATOR PROTEIN; CAP-DEPENDENT PROMOTERS; LAMBDA-ATTACHMENT SITE; CLASS-II PROMOTERS; ESCHERICHIA-COLI; RNA-POLYMERASE; DEOP2 PROMOTER; DNA COMPLEX; NUCLEOTIDE-SEQUENCE; RECOGNITION	At promoters of the Escherichia coli CytR regulon, the cAMP receptor protein (CRP) interacts with the repressor CytR to form transcriptionally inactive CRP-CytR- promoter or (CRP)(2)-CytR-promoter complexes. Here, using "oriented heterodimer" analysis, we show that only one subunit of the CRP dimer, the subunit proximal to CytR, functionally interacts with CytR in CRP-CytR-promoter and (CRP)(2)-CytR-promoter complexes. Our results provide information about the architecture of CRP-CytR-promoter and (CRP)(2)-CytR-promoter complexes and rule out the proposal that masking of activating region 2 of CRP is responsible for the transcriptional inactivity of the complexes.	Odense Univ, Dept Mol Biol, DK-5230 Odense M, Denmark; Rutgers State Univ, Waksman Inst, Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Chem, Piscataway, NJ 08854 USA	University of Southern Denmark; Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Meibom, KL (corresponding author), Odense Univ, Dept Mol Biol, Campusvej 55, DK-5230 Odense M, Denmark.		Ebright, Richard/O-3321-2019	Ebright, Richard/0000-0001-8915-7140; Kallipolitis, Birgitte H./0000-0003-1233-9776; Meibom, Karin/0000-0002-2612-6424	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041376, R37GM041376] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41376] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATLUNG T, 1991, GENE, V107, P11, DOI 10.1016/0378-1119(91)90291-I; BELL A, 1990, NUCLEIC ACIDS RES, V18, P7243, DOI 10.1093/nar/18.24.7243; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; Busby S, 1997, MOL MICROBIOL, V23, P853, DOI 10.1046/j.1365-2958.1997.2771641.x; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; CLARK DJ, 1967, J MOL BIOL, V23, P99, DOI 10.1016/S0022-2836(67)80070-6; DIEDERICH L, 1992, PLASMID, V28, P14, DOI 10.1016/0147-619X(92)90032-6; EBRIGHT RH, 1984, NATURE, V311, P232, DOI 10.1038/311232a0; EBRIGHT RH, 1993, MOL MICROBIOL, V8, P797, DOI 10.1111/j.1365-2958.1993.tb01626.x; EBRIGHT RH, 1987, P NATL ACAD SCI USA, V84, P6083, DOI 10.1073/pnas.84.17.6083; Kallipolitis BH, 1997, CELL, V89, P1101, DOI 10.1016/S0092-8674(00)80297-4; Kallipolitis BH, 1998, MOL MICROBIOL, V29, P1091, DOI 10.1046/j.1365-2958.1998.00999.x; Kristensen HH, 1997, J MOL BIOL, V266, P866, DOI 10.1006/jmbi.1996.0852; Meibom KL, 1999, MOL MICROBIOL, V32, P497, DOI 10.1046/j.1365-2958.1999.01362.x; MOLLEGAARD NE, 1993, J BIOL CHEM, V268, P17471; Niu W, 1996, CELL, V87, P1123, DOI 10.1016/S0092-8674(00)81806-1; Parkinson G, 1996, J MOL BIOL, V260, P395, DOI 10.1006/jmbi.1996.0409; PEDERSEN H, 1992, J MOL BIOL, V227, P396, DOI 10.1016/0022-2836(92)90896-R; PEDERSEN H, 1991, J BIOL CHEM, V266, P17804; Pedersen H, 1997, EMBO J, V16, P2108, DOI 10.1093/emboj/16.8.2108; RASMUSSEN PB, 1993, NUCLEIC ACIDS RES, V21, P879, DOI 10.1093/nar/21.4.879; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SOGAARDANDERSEN L, 1993, CELL, V75, P557, DOI 10.1016/0092-8674(93)90389-8; SOGAARDANDERSEN L, 1991, P NATL ACAD SCI USA, V88, P4921, DOI 10.1073/pnas.88.11.4921; Thomsen LE, 1999, J MOL BIOL, V288, P165, DOI 10.1006/jmbi.1999.2668; ValentinHansen P, 1996, MOL MICROBIOL, V20, P461, DOI 10.1046/j.1365-2958.1996.5341056.x; VALENTINHANSEN P, 1986, NUCLEIC ACIDS RES, V14, P2215, DOI 10.1093/nar/14.5.2215; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; Williams RM, 1996, NUCLEIC ACIDS RES, V24, P1112, DOI 10.1093/nar/24.6.1112; ZHANG XP, 1992, J BIOL CHEM, V267, P8136; ZHOU YH, 1994, EMBO J, V13, P4549, DOI 10.1002/j.1460-2075.1994.tb06776.x; ZHOU YH, 1993, P NATL ACAD SCI USA, V90, P6081, DOI 10.1073/pnas.90.13.6081; ZHOU YH, 1993, CELL, V73, P375, DOI 10.1016/0092-8674(93)90236-J	33	10	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11951	11956		10.1074/jbc.275.16.11951	http://dx.doi.org/10.1074/jbc.275.16.11951			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766824	hybrid			2022-12-27	WOS:000086695500059
J	Murga, C; Fukuhara, S; Gutkind, JS				Murga, C; Fukuhara, S; Gutkind, JS			A novel role for phosphatidylinositol 3-kinase beta in signaling from G protein-coupled receptors to Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; PHOSPHOINOSITIDE 3-KINASE; GAMMA-SUBUNITS; KINASE-B; DEPENDENT ACTIVATION; JUN KINASE; PATHWAY; P85; INSULIN; CLONING	The protein kinase Akt plays a central role in a number of key biological functions including protein synthesis, glucose homeostasis, and the regulation of cell survival or death, The mechanism by which tyrosine kinase growth factor receptors stimulate Akt has been recently defined. In contrast, the mechanism of activation of Akt by other cell surface receptors is much less understood. For G protein-coupled receptors (GPCRs), conflicting data suggest that these receptors stimulate Akt in a cell type-specific manner by a set to be fully elucidated mechanism. Here, we took advantage of the availability of cells, where Akt activity could not be enhanced by agonists acting on this large family of cell surface receptors, such as NIH 3T3 cells, to investigate the pathway linking GPCRs to Akt. We present evidence that expression of phosphatidylinositol 3-kinase (PI3K) beta is necessary and sufficient to transmit signals from G proteins to Akt in these murine fibroblasts and that the activation of PI3K beta may represent the most likely mechanism whereby GPCRs stimulate Akt, as the vast majority of cells do not express PI3K gamma, a known G protein-sensitive PI3K isoform. Furthermore, available evidence indicates that GPCRs activate Akt by a pathway distinct from that utilized by growth factor receptors, as it involves the tyrosine phosphorylation-independent activation of PI3K beta by G protein beta gamma dimers.	NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gutkind, JS (corresponding author), NIDCR, Oral & Pharyngeal Canc Branch, NIH, 9000 Rockville Pike,Bldg 30,Rm 211, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/J-1201-2016; Murga, Cristina/E-1965-2014; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; Murga, Cristina/0000-0002-8964-4077; 	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bernstein HG, 1998, CELL MOL BIOL, V44, P973; Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Coso OA, 1996, J BIOL CHEM, V271, P3963; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Fukui Y, 1998, J BIOCHEM-TOKYO, V124, P1; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Hazeki O, 1998, LIFE SCI, V62, P1555, DOI 10.1016/S0024-3205(98)00106-4; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; Lopez-Ilasaca M, 1998, J BIOL CHEM, V273, P2505, DOI 10.1074/jbc.273.5.2505; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Maier U, 1999, J BIOL CHEM, V274, P29311, DOI 10.1074/jbc.274.41.29311; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Okada T, 1996, BIOCHEM J, V317, P475, DOI 10.1042/bj3170475; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Roche S, 1998, MOL CELL BIOL, V18, P7119, DOI 10.1128/MCB.18.12.7119; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; Stephens L, 1996, PHILOS T R SOC B, V351, P211, DOI 10.1098/rstb.1996.0018; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Walker EH, 1999, NATURE, V402, P313, DOI 10.1038/46319; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8	38	176	177	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12069	12073		10.1074/jbc.275.16.12069	http://dx.doi.org/10.1074/jbc.275.16.12069			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766839	hybrid			2022-12-27	WOS:000086695500074
J	Waugh, DJJ; Zhao, MM; Zuscik, MJ; Perez, DM				Waugh, DJJ; Zhao, MM; Zuscik, MJ; Perez, DM			Novel aromatic residues in transmembrane domains IV and V involved in agonist binding at alpha(1a)-adrenergic receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; EXTRACELLULAR LOOP; BETA(2)-ADRENERGIC RECEPTOR; CONSTITUTIVE ACTIVATION; POINT MUTATION; LIGAND-BINDING; IDENTIFICATION; AFFINITY; PHENYLALANINE; ANTAGONISTS	We examined the role that aromatic residues located in the transmembrane helices of the alpha(1a)-adrenergic receptor play in promoting antagonist binding. Since alpha(1)-antagonists display low affinity binding at beta(2)-adrenergic receptors, two phenylalanine residues, Phe-163 and Phe-187, of the alpha(1a)-AR were mutated to the corresponding beta(2)-residue. Neither F163Q nor F187A mutations of the alpha(1a) had any effect on the affinity of the alpha(1)-antagonists. However, the affinity of the endogenous agonist epinephrine was reduced 12.5- and 8-fold by the F163Q and F187A mutations, respectively. An additive loss in affinity (150-fold) for epinephrine was observed at an alpha(1a) containing both mutations. The loss of agonist affinity scenario could be reversed by a gain of affinity with mutation of the corresponding residues in the beta(2) to the phenylalanine residues in the alpha(1a). We propose that both Phe-163 and Phe-187 are involved in independent aromatic interactions with the catechol ring of agonists, The potency but not the efficacy of epinephrine in stimulating phosphatidylinnostto hydrolysis was reduced 35-fold at the F163Q/F187A alpha(1a) relative to the wild type receptor. Therefore, Phe-163 and Phe-187 represent novel binding contacts in the agonist binding pocket of the alpha(1a)-AR, but are not involved directly in receptor activation.	Cleveland Clin Fdn, Dept Mol Cardiol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Perez, DM (corresponding author), Cleveland Clin Fdn, Dept Mol Cardiol, Lerner Res Inst, 9500 Euclid Ave,NB5, Cleveland, OH 44195 USA.	perezd@ccf.org		WAUGH, DAVID/0000-0002-4022-3765; Zuscik, Michael/0000-0003-0461-8708	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061438] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL61438] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; Chen SH, 1999, J BIOL CHEM, V274, P16320, DOI 10.1074/jbc.274.23.16320; CHO W, 1995, J NEUROCHEM, V65, P2105, DOI 10.1046/j.1471-4159.1995.65052105.x; CHOUDHARY MS, 1993, MOL PHARMACOL, V43, P755; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; Easson LH, 1933, BIOCHEM J, V27, P1257, DOI 10.1042/bj0271257; Hamaguchi N, 1996, BIOCHEMISTRY-US, V35, P14312, DOI 10.1021/bi961024e; Hwa J, 1996, J BIOL CHEM, V271, P6322, DOI 10.1074/jbc.271.11.6322; HWA J, 1996, AUTONOMIC NERVOUS SY, V9; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; NODA K, 1994, J BIOL CHEM, V269, P6743; Perez DM, 1996, MOL PHARMACOL, V49, P112; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; RUFFOLO RR, 1977, J PHARM PHARMACOL, V29, P378, DOI 10.1111/j.2042-7158.1977.tb11344.x; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; STRADER CD, 1989, J BIOL CHEM, V264, P13572; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; SURYANARAYANA S, 1991, J BIOL CHEM, V266, P15488; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; Wieland K, 1996, P NATL ACAD SCI USA, V93, P9276, DOI 10.1073/pnas.93.17.9276; Zhao MM, 1996, MOL PHARMACOL, V50, P1118; Zhao MM, 1998, MOL PHARMACOL, V53, P524, DOI 10.1124/mol.53.3.524	24	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11698	11705		10.1074/jbc.275.16.11698	http://dx.doi.org/10.1074/jbc.275.16.11698			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766790	hybrid			2022-12-27	WOS:000086695500025
J	Wilks, A; Moenne-Loccoz, P				Wilks, A; Moenne-Loccoz, P			Identification of the proximal ligand His-20 in heme oxygenase (Hmu O) from Corynebacterium diphtheriae - Oxidative cleavage of the heme macrocycle does not require the proximal histidine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTRA; CATALYTIC SITE; IRON-LIGAND; YERSINIA-ENTEROCOLITICA; COUPLED OXIDATION; IX-ALPHA; TRANSPORT; HEMOGLOBIN; COMPLEX; SYSTEM	The coordination and spin-state of the Corynebacterium diphtheriae heme oxygenase (Hmu O) and the proximal Hmu O H20A mutant have been characterized by UV-visible and resonance Raman (RR) spectrophotometry. At neutral pH the ferric heme-Hmu O complex is a mixture of six-coordinate high spin and six-coordinate low spin species. Changes in the UV-visible and high frequency RR spectra are observed as a function of pH and temperature, with the six-coordinate high spin species being converted to six-coordinate low spin. The low frequency region of the ferrous RR spectrum identified the proximal ligand to the heme as a neutral imidazole with a Fe-His stretching mode at 222 cm(-1). The RR characterization of the heme-CO complex in wt-Hmu O confirms that the proximal imidazole is neither ionized or strongly hydrogen-bonded. Based on sequence identity with the mammalian enzymes the proximal ligand in HO-1 (His-25) and HO-2 (His-45) is conserved (His-20) in the bacterial enzyme. Site-specific mutagenesis identified His-20 as the proximal mutant based on electronic and resonance Raman spectrophotometric analysis. Titration of the heme-Hmu O complex with imidazole restored full catalytic activity to the enzyme, and the coordination of imidazole to the heme was confirmed by RR. However, in the absence of imidazole, the H20A Hmu O mutant was found to catalyze the initial alpha-meso-hydroxylation of the heme. The product of the aerobic reaction was determined to be ferrous verdoheme. Hydrolytic conversion of the verdoheme product to biliverdin concluded that oxidative cleavage of the porphyrin macrocycle was specific for the alpha-meso-carbon. The present data show that, in marked contrast to the human HO-1, the proximal ligand is not essential for the initial alpha-meso-hydroxylation of heme in the C. diphtheriae heme oxygenase-catalyzed reaction.	Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; Oregon Grad Inst Sci & Technol, Dept Biochem & Mol Biol, Portland, OR 97291 USA	University System of Maryland; University of Maryland Baltimore	Wilks, A (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA.			MOENNE-LOCCOZ, PIERRE/0000-0002-7684-7617	NIGMS NIH HHS [GM34468] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034468] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHER SA, 1977, BIOCHEMISTRY-US, V16, P5849, DOI 10.1021/bi00645a032; BOYD J, 1990, P NATL ACAD SCI USA, V87, P5968, DOI 10.1073/pnas.87.15.5968; Braun V, 1998, MET IONS BIOL SYST, V35, P67; Braun V, 1999, TRENDS BIOCHEM SCI, V24, P104, DOI 10.1016/S0968-0004(99)01359-6; BRAUN V, 1995, FEMS MICROBIOL REV, V16, P295, DOI 10.1111/j.1574-6976.1995.tb00177.x; CHRISTIE AB, 1987, INFECT DIS EPIDEMIOL, V2, P1183; Chu GC, 1999, J BIOL CHEM, V274, P21319, DOI 10.1074/jbc.274.30.21319; Chu GC, 1999, J BIOL CHEM, V274, P24490, DOI 10.1074/jbc.274.35.24490; Crusats J, 1998, J ORG CHEM, V63, P602, DOI 10.1021/jo9714728; DESBOIS A, 1979, BIOCHEMISTRY-US, V18, P1510, DOI 10.1021/bi00575a019; EFSTRATIOU A, 1993, LANCET, V341, P1592, DOI 10.1016/0140-6736(93)90727-X; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; KINCAID J, 1979, P NATL ACAD SCI USA, V76, P549, DOI 10.1073/pnas.76.2.549; KITAGAWA T, 1979, FEBS LETT, V104, P376, DOI 10.1016/0014-5793(79)80856-X; LAGARIAS JC, 1982, BIOCHIM BIOPHYS ACTA, V717, P12, DOI 10.1016/0304-4165(82)90373-7; Liu Y, 1999, BIOCHEMISTRY-US, V38, P3733, DOI 10.1021/bi982707s; Liu Y, 1997, J BIOL CHEM, V272, P6909, DOI 10.1074/jbc.272.11.6909; LOEHR TM, 1993, METHOD ENZYMOL, V226, P431; Lukat-Rodgers GS, 1998, J BIOL INORG CHEM, V3, P274, DOI 10.1007/s007750050232; MILLS M, 1995, J BACTERIOL, V177, P3004, DOI 10.1128/jb.177.11.3004-3009.1995; OCARRA P, 1969, FEBS LETT, V5, P295; OTTO BR, 1992, CRIT REV MICROBIOL, V18, P217, DOI 10.3109/10408419209114559; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; Rodriguez JC, 1998, BIOCHEMISTRY-US, V37, P13082, DOI 10.1021/bi9809324; SAITO S, 1982, P NATL ACAD SCI-BIOL, V79, P1393, DOI 10.1073/pnas.79.5.1393; Sambrook J., 2002, MOL CLONING LAB MANU; SANO S, 1986, P NATL ACAD SCI USA, V83, P531, DOI 10.1073/pnas.83.3.531; SCHMITT MP, 1991, INFECT IMMUN, V59, P1899, DOI 10.1128/IAI.59.6.1899-1904.1991; Schmitt MP, 1997, J BACTERIOL, V179, P838, DOI 10.1128/jb.179.3.838-845.1997; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; SITTER AJ, 1988, J BIOL CHEM, V263, P13032; STOEBNER JA, 1988, INFECT IMMUN, V56, P2891, DOI 10.1128/IAI.56.11.2891-2895.1988; STOJILJKOVIC I, 1994, MOL MICROBIOL, V13, P719, DOI 10.1111/j.1365-2958.1994.tb00465.x; STOJILJKOVIC I, 1992, EMBO J, V11, P4359, DOI 10.1002/j.1460-2075.1992.tb05535.x; SUN J, 1993, BIOCHEMISTRY-US, V32, P14151, DOI 10.1021/bi00214a012; SUN J, 1994, BIOCHEMISTRY-US, V33, P13734, DOI 10.1021/bi00250a026; TAKAHASHI S, 1994, J BIOL CHEM, V269, P1010; TAKAHASHI S, 1994, BIOCHEMISTRY-US, V33, P5531, DOI 10.1021/bi00184a023; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; WILKS A, 1995, J AM CHEM SOC, V117, P2925, DOI 10.1021/ja00115a027; Wilks A, 1998, J BIOL CHEM, V273, P837, DOI 10.1074/jbc.273.2.837; YOSHIDA T, 1979, J BIOL CHEM, V254, P4487	43	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11686	11692		10.1074/jbc.275.16.11686	http://dx.doi.org/10.1074/jbc.275.16.11686			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766788	hybrid			2022-12-27	WOS:000086695500023
J	Alpert, D; Vilcek, J				Alpert, D; Vilcek, J			Inhibition of I kappa B kinase activity by sodium salicylate in vitro does not reflect its inhibitory mechanism in intact cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ALPHA PHOSPHORYLATION; COMPLEX; ASPIRIN; BETA; SB-203580; PATHWAY; TNF	Sodium salicylate inhibits activation of the transcription factor NF-kappa B by blocking the phosphorylation and degradation of the NF-kappa B inhibitor I kappa B alpha. We previously demonstrated that salicylate inhibits I kappa B alpha degradation induced by tumor necrosis factor (TNF) but not by interleukin-1 (IL-1) and implicated p38 mitogen-activated protein kinase activation by salicylate in the inhibition of TNF-induced I kappa B alpha phosphorylation. Both TNF and IL-1 rapidly activate the I kappa B kinase (IKK) complex, containing the catalytic subunits IKK alpha and IKK beta, which directly phosphorylates I kappa B proteins. Others have recently suggested that salicylate inhibits NF-kappa B activation by directly binding to IKK beta. To clarify the mechanism whereby salicylate inhibits IKK activity, we examined its effects upon cytokine-induced IKK activity in intact cells and in vitro, Treatment of intact cells with salicylate inhibited TNF-induced but not IL-1-induced IKK activity, and this inhibition was prevented by the p38 inhibitor SB203580. In contrast, inhibition of IKK activity by salicylate in vitro was neither selective for TNF nor affected by SB203580. In vitro, salicylate treatment comparably inhibited the kinase activity of overexpressed IKK alpha and IKK beta and also decreased p38 kinase activity. Therefore, direct inhibition of IRK activity in vitro does not reflect the inhibitory mechanism of salicylate in intact cells, which involves interference with TNF signaling.	NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA	New York University	Vilcek, J (corresponding author), NYU, Sch Med, Dept Microbiol, 550 1st Ave, New York, NY 10016 USA.	vilcek@med.nyu.edu			NCI NIH HHS [R01-CA75071, R35-CA49731] Funding Source: Medline; NIGMS NIH HHS [5T32-GM07308] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075071, R35CA049731] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007308] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMSON SB, 1989, ARTHRITIS RHEUM, V32, P1, DOI 10.1002/anr.1780320102; Alpert D, 1999, J BIOL CHEM, V274, P22176, DOI 10.1074/jbc.274.32.22176; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; Bowie A. G., 1999, Cytokine, V11, P934; BROOKS PM, 1991, NEW ENGL J MED, V324, P1716; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; Clerk A, 1998, FEBS LETT, V426, P93, DOI 10.1016/S0014-5793(98)00324-X; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Engelman JA, 1999, J BIOL CHEM, V274, P35630, DOI 10.1074/jbc.274.50.35630; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Madge LA, 1999, J BIOL CHEM, V274, P13643, DOI 10.1074/jbc.274.19.13643; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; OETH P, 1995, BLOOD, V86, P4144, DOI 10.1182/blood.V86.11.4144.bloodjournal86114144; Pierce JW, 1996, J IMMUNOL, V156, P3961; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Schwenger P, 1999, J CELL PHYSIOL, V179, P109, DOI 10.1002/(SICI)1097-4652(199904)179:1<109::AID-JCP13>3.0.CO;2-W; Schwenger P, 1996, J BIOL CHEM, V271, P8089, DOI 10.1074/jbc.271.14.8089; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; Stevenson MA, 1999, J IMMUNOL, V163, P5608; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; WEISSMANN G, 1991, SCI AM, V264, P84, DOI 10.1038/scientificamerican0191-84; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1999, MOL CELL BIOL, V19, P4547	43	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10925	10929		10.1074/jbc.275.15.10925	http://dx.doi.org/10.1074/jbc.275.15.10925			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753891	hybrid			2022-12-27	WOS:000086466600033
J	Linder, JU; Hoffmann, T; Kurz, U; Schultz, JE				Linder, JU; Hoffmann, T; Kurz, U; Schultz, JE			A guanylyl cyclase from Paramecium with 22 transmembrane spans - Expression of the catalytic domains and formation of chimeras with the catalytic domains of mammalian adenylyl cyclases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC DOMAINS; SITE; FORSKOLIN; CONDUCTANCE; INHIBITION; BINDING; FORM	Paramecium has a 280-kDa guanylyl cyclase. The N terminus resembles a P-type ATPase, and the C terminus is a guanylyl cyclase with the membrane topology of canonical mammalian adenylyl cyclases, yet with the cytosolic loops, C1 and C2, inverted compared with the mammalian order. We expressed in Escherichia coli the cytoplasmic domains of the protozoan guanylyl cyclase, independently and linked by a peptide, as soluble proteins. The His(6)-tagged proteins were enriched by affinity chromatography and analyzed by immunoblotting. Guanylyl cyclase activity was reconstituted upon mixing of the recombinant C1a- and C2-positioned domains and in a linked C1a-C2 construct, Adenylyl cyclase activity was minimal. The nucleotide substrate specificity was switched from GTP to ATP upon mutation of the substrate defining amino acids Glu(1681) and Ser(1748) in the C1-positioned domain to the adenylyl cyclase specific amino acids Lys and Asp. Using the C2 domains of mammalian adenylyl cyclases type II or IX and the C2-positioned domain from the Paramecium guanylyl cyclase we reconstituted a soluble, all C2 adenylyl cyclase, All enzymes containing protozoan domains were not affected by G alpha(s)/GTP or forskolin, and P site inhibitors were only slightly effective.	Univ Tubingen, Fak Chem & Pharm, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Schultz, JE (corresponding author), Inst Pharmazeut, Morgenstelle 8, D-72076 Tubingen, Germany.							DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Dessauer CW, 1998, J BIOL CHEM, V273, P25831, DOI 10.1074/jbc.273.40.25831; Dessauer CW, 1997, J BIOL CHEM, V272, P22272, DOI 10.1074/jbc.272.35.22272; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; Dessauer CW, 1996, J BIOL CHEM, V271, P16967, DOI 10.1074/jbc.271.28.16967; Friebe A, 1997, BIOCHEMISTRY-US, V36, P1194, DOI 10.1021/bi962047w; JOHNSON RA, 1989, MOL PHARMACOL, V35, P681; KLUMPP S, 1982, EUR J BIOCHEM, V124, P317; Linder JU, 1999, EMBO J, V18, P4222, DOI 10.1093/emboj/18.15.4222; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Scholich K, 1997, P NATL ACAD SCI USA, V94, P2915, DOI 10.1073/pnas.94.7.2915; SCHULTZ JE, 1986, NATURE, V322, P271, DOI 10.1038/322271a0; SCHULTZ JE, 1994, FEBS LETT, V356, P322, DOI 10.1016/0014-5793(94)01300-4; SCHULTZ JE, 1992, SCIENCE, V255, P600, DOI 10.1126/science.1371017; Sunahara RK, 1998, J BIOL CHEM, V273, P16332, DOI 10.1074/jbc.273.26.16332; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; Tucker CL, 1998, P NATL ACAD SCI USA, V95, P5993, DOI 10.1073/pnas.95.11.5993; Weitmann S, 1999, BIOCHEMISTRY-US, V38, P3409, DOI 10.1021/bi982229l; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; Yan SZ, 1997, J BIOL CHEM, V272, P12342, DOI 10.1074/jbc.272.19.12342; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0	27	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11235	11240		10.1074/jbc.275.15.11235	http://dx.doi.org/10.1074/jbc.275.15.11235			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753932	hybrid			2022-12-27	WOS:000086466600074
J	Marzio, G; Wagener, C; Gutierrez, MI; Cartwright, P; Helin, K; Giacca, M				Marzio, G; Wagener, C; Gutierrez, MI; Cartwright, P; Helin, K; Giacca, M			E2F family members are differentially regulated by reversible acetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR E2F; CELL-CYCLE REGULATION; RETINOBLASTOMA PROTEIN; HISTONE ACETYLTRANSFERASES; BINDING PROTEIN; REPRESS TRANSCRIPTION; CBP COACTIVATOR; IN-VIVO; S-PHASE; DEACETYLASE	The six members of the E2F family of transcription factors play a key role in the control of cell cycle progression by regulating the expression of genes involved in DNA replication and cell proliferation. E2F-1, -2, and -3 belong to a structural and functional subfamily distinct from those of the other E2F family members. Here we report that E2F-1, -2, and -3, but not E2F-4, -5, and -6, associate with and are acetylated by p300 and cAMP-response element-binding protein acetyltransferases. Acetylation occurs at three conserved lysine residues located at the N-terminal boundary of their DNA binding domains. Acetylation of E2F-1 in vitro and in vivo markedly increases its binding affinity for a consensus E2F DNA-binding site, which is paralleled by enhanced transactivation of an E2F-responsive promoter. Acetylation of E2F-1 can be reversed by histone deacetylase-1, indicating that reversible acetylation is a mechanism for regulation also of non-histone proteins.	Int Ctr Genet Engn & Biotechnol, Mol Med Lab, I-34012 Trieste, Italy; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB); IRCCS European Institute of Oncology (IEO)	Giacca, M (corresponding author), Int Ctr Genet Engn & Biotechnol, Mol Med Lab, Area Sci Pk,Padriciano 99, I-34012 Trieste, Italy.		Helin, Kristian/HDM-8306-2022; Giacca, Mauro/J-9287-2016; Helin, Kristian/K-2526-2019	Helin, Kristian/0000-0003-1975-6097; Giacca, Mauro/0000-0003-2927-7225; 				Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Demarchi F, 1999, J VIROL, V73, P7080, DOI 10.1128/JVI.73.8.7080-7086.1999; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EMILI A, 1995, J BIOL CHEM, V270, P13674, DOI 10.1074/jbc.270.23.13674; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lavia P, 1999, BIOESSAYS, V21, P221; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Morkel M, 1997, NATURE, V390, P567, DOI 10.1038/37507; Muller H, 1997, MOL CELL BIOL, V17, P5508; Nevins JR, 1997, METHOD ENZYMOL, V283, P205; NEVINS JR, 1992, SCIENCE, V258, P424; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Steger David J., 1996, Bioessays, V18, P875, DOI 10.1002/bies.950181106; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; WU CL, 1995, MOL CELL BIOL, V15, P2536; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666	60	177	186	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10887	10892		10.1074/jbc.275.15.10887	http://dx.doi.org/10.1074/jbc.275.15.10887			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753885	hybrid			2022-12-27	WOS:000086466600027
J	de Rooij, J; Rehmann, H; van Triest, M; Cool, RH; Wittinghofer, A; Bos, JL				de Rooij, J; Rehmann, H; van Triest, M; Cool, RH; Wittinghofer, A; Bos, JL			Mechanism of regulation of the Epac family of cAMP-dependent RapGEFs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; SMALL GTPASE RAP1; HUMAN NEUTROPHILS; CELL-ADHESION; G-PROTEIN; ACTIVATION; RAS; KINASE; FIBROBLASTS; RECEPTOR	Epac1 (cAMP-GEFI) and Epac2 (cAMP-GEFII) are closely related guanine nucleotide exchange factors (GEFs) for the small GTPase Rap1, which are directly regulated by cAMP. Here we show that both GEFs efficiently activate Rapa as well. A third member of the family, Repac (GFR), which lacks the cAMP dependent regulatory sequences, is a constitutive activator of both Rap1 and Rap2. In contrast to Epac1, Epac2 contains a second cAMP binding domain at the N terminus, as does the Epac homologue from Caenorhabditis elegans, Affinity measurements show that this distal cAMP binding domain (the A-site) binds cAMP with much lower affinity than the cAMP binding domain proximal to the catalytic domain (the B-site), which is present in both Epac1 and Epac2. Deletion mutant analysis shows that the high affinity cAMP binding domains are sufficient to regulate the GEFs in vitro. Interestingly, isolated fragments containing the B-sites of either Epac1 or Epac2, but not the A-site from Epac2, inhibit the catalytic domains in trans. This inhibition is relieved by the addition of cAMP. In addition to the cAMP binding domains, both Epac1 and Epac2 have a DEP domain. Deletion of this domain does not affect regulation of Epac1 activity but affects membrane localization. From these results, we conclude that all three members of the Epac family regulate both Rap1 and Rap2, Furthermore, we conclude that the catalytic activity of Epac1 is constrained by a direct interaction between GEF and high affinity cAMP binding domains in the absence of cAMP. Epac1 becomes activated by a release of this inhibition when cAMP is bound.	Univ Utrecht, Med Ctr, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; Univ Utrecht, Med Ctr, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany	Utrecht University; Utrecht University; Max Planck Society	Bos, JL (corresponding author), Univ Utrecht, Med Ctr, Dept Physiol Chem, Univ Weg 100, NL-3584 CG Utrecht, Netherlands.		de rooij, johan/C-1325-2019	Cool, Robbert/0000-0002-9845-2202				Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; de Rooij J, 1999, J BIOL CHEM, V274, P38125, DOI 10.1074/jbc.274.53.38125; DEVRIESSMITS AMM, 1995, METHOD ENZYMOL, V255, P156; EKANGER R, 1985, J BIOL CHEM, V260, P3393; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Ichiba T, 1999, FEBS LETT, V457, P85, DOI 10.1016/S0014-5793(99)01012-1; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Liao YH, 1999, J BIOL CHEM, V274, P37815, DOI 10.1074/jbc.274.53.37815; M'Rabet L, 1999, J BIOL CHEM, V274, P21847, DOI 10.1074/jbc.274.31.21847; M'Rabet L, 1998, BLOOD, V92, P2133, DOI 10.1182/blood.V92.6.2133.418k19_2133_2140; McLeod SJ, 1998, J BIOL CHEM, V273, P29218, DOI 10.1074/jbc.273.44.29218; Ohtsuka T, 1999, BIOCHEM BIOPH RES CO, V265, P38, DOI 10.1006/bbrc.1999.1619; POLAKIS P, 1992, J BIOL CHEM, V267, P10780; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; Reedquist KA, 1998, J BIOL CHEM, V273, P4944, DOI 10.1074/jbc.273.9.4944; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; Zwartkruis FJT, 1999, EXP CELL RES, V253, P157, DOI 10.1006/excr.1999.4695; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	27	304	316	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20829	20836		10.1074/jbc.M001113200	http://dx.doi.org/10.1074/jbc.M001113200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10777494	hybrid			2022-12-27	WOS:000088084500086
J	Eklund, EA; Jalava, A; Kakar, R				Eklund, EA; Jalava, A; Kakar, R			Tyrosine phosphorylation of HoxA10 decreases DNA binding and transcriptional repression during interferon gamma-induced differentiation of myeloid leukemia cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT DISPLACEMENT PROTEIN; GP91(PHOX) EXPRESSION; HOMEODOMAIN PROTEINS; HEMATOPOIETIC-CELLS; HOMEOBOX GENE; IDENTIFICATION; ACTIVATORS; COMPLEXES; PROMOTER; PATTERN	The DNA binding affinity of HoxA10 is increased by partnering with Pbx proteins. A consensus sequence for Pbx1-HoxA10 DNA binding has been derived, but genuine target genes have not been identified. We noted that the derived Pbx-HoxA10 DNA-binding consensus is similar to a repressor element in the CYBB promoter. The CYBB gene, which encodes the respiratory burst oxidase component gp91(phox), is expressed only in myeloid cells that have differentiated beyond the promyelocyte stage, In these studies, we demonstrate that interferon gamma (IFN-gamma)-induced differentiation of myeloid cell lines abolishes in vitro Pbx-HoxA10 binding to either the derived consensus or the similar CYBB sequence. We also demonstrate that HoxA10, overexpressed in myeloid cell lines, represses reporter gene expression from artificial promoter constructs with Pbx-HoxA10 binding sites. We determine that HoxA10 has endogenous repression domains that are not functionally altered by IFN-gamma treatment. However, IFN-gamma-induced differentiation of myeloid cell lines leads to HoxA10 tyrosine phosphorylation, which decreases in vitro DNA binding to Pbx-HoxA10 binding sites. Therefore, these investigations identify the CYBB gene as a potential target for HoxA10 and define repression of genes expressed in mature myeloid cells as a novel role for HoxA10 during myeloid differentiation.	Univ Alabama, Lurleen B Wallace Tumor Inst, Dept Hematol & Oncol, Birmingham, AL 35294 USA; Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA; Birmingham Vet Affairs Hosp, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Eklund, EA (corresponding author), Univ Alabama, Lurleen B Wallace Tumor Inst, Dept Hematol & Oncol, Birmingham, AL 35294 USA.				NHLBI NIH HHS [HL5400] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENSON GV, 1995, MOL CELL BIOL, V15, P1591; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; Chang CP, 1996, MOL CELL BIOL, V16, P1734; CUATRECASAS P, 1970, J BIOL CHEM, V245, P3059; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; Eklund EA, 1999, J IMMUNOL, V163, P6095; Eklund EA, 1997, J BIOL CHEM, V272, P9344; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; LARRICK JW, 1980, J IMMUNOL, V125, P6; LAWRENCE HJ, 1995, EXP HEMATOL, V23, P1160; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LIEVENS PMJ, 1995, J BIOL CHEM, V270, P12745, DOI 10.1074/jbc.270.21.12745; LOWNEY P, 1991, NUCLEIC ACIDS RES, V19, P3443, DOI 10.1093/nar/19.12.3443; LUI J, 1999, MOL CELL BIOL, V19, P4918; Luo W, 1996, J BIOL CHEM, V271, P18203, DOI 10.1074/jbc.271.30.18203; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; Neuteboom STC, 1997, MOL CELL BIOL, V17, P4696, DOI 10.1128/MCB.17.8.4696; Pinsonneault J, 1997, EMBO J, V16, P2032, DOI 10.1093/emboj/16.8.2032; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sambrook J., 2002, MOL CLONING LAB MANU; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Shen WF, 1999, MOL CELL BIOL, V19, P3051; Shen WF, 1997, J BIOL CHEM, V272, P8198, DOI 10.1074/jbc.272.13.8198; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; TAKEBE Y, 1988, MOL CELL BIOL; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495	33	75	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					20117	20126		10.1074/jbc.M907915199	http://dx.doi.org/10.1074/jbc.M907915199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10766757	hybrid			2022-12-27	WOS:000087941300093
J	Pan, Z; Damron, D; Nieminen, AL; Bhat, MB; Ma, JJ				Pan, Z; Damron, D; Nieminen, AL; Bhat, MB; Ma, JJ			Depletion of intracellular Ca2+ by caffeine and ryanodine induces apoptosis of Chinese hamster ovary cells transfected with ryanodine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; ENDOPLASMIC-RETICULUM; SKELETAL-MUSCLE; RELEASE CHANNEL; STORE DEPLETION; CALCIUM STORES; BCL-2; DEATH; MITOCHONDRIA; PROTEIN	Recent studies have suggested a central role for Ca2+ in the signaling pathway of apoptosis and certain anti-apoptotic effects of Bcl-2 family of proteins have been attributed to changes in intracellular Ca2+ homeostasis, Here we report that depletion of Ca2+ from endoplasmic reticulum (ER) leads to apoptosis in Chinese hamster ovary cells. Stable expression of ryanodine receptor (RyR) in these cells enables rapid and reversible changes of both cytosolic Ca2+ and ER Ca2+ content via activation of the RyR/Ca2+ release channel by caffeine and ryanodine. Sustained depletion of the ER Ca2+ store leads to apoptosis in Chinese hamster ovary cells, whereas co-expression of Bcl-xL and RyR in these cells prevents apoptotic cell death but not necrotic cell death. The anti-apoptotic effect of Bcl-xL does not correlate with changes in either the Ca2+ release process from the ER or the capacitative Ca2+ entry through the plasma membrane. The data suggest that Bcl-xL likely prevents apoptosis of cells at a stage downstream of ER Ca2+ release and capacitative Ca2+ entry.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Anat, Cleveland, OH 44106 USA; Cleveland Clin Educ Fdn, Ctr Anesthesiol Res, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Cleveland Clinic Foundation	Ma, JJ (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA.	jxm63@po.cwru.edu		Pan, Zui/0000-0003-4105-901X	NIA NIH HHS [R01-AG15556] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG015556] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; AIREY JA, 1990, J BIOL CHEM, V265, P14187; Amundson J, 1993, Curr Opin Neurobiol, V3, P375, DOI 10.1016/0959-4388(93)90131-H; Andjelic S, 1997, J IMMUNOL, V158, P2527; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BEZPROZVANNY I, 1995, J MEMBRANE BIOL, V145, P205; BRODIE AE, 1991, BIOCHEM BIOPH RES CO, V176, P276, DOI 10.1016/0006-291X(91)90920-3; Chen SRW, 1998, J BIOL CHEM, V273, P14675, DOI 10.1074/jbc.273.24.14675; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; Guo Q, 1997, J NEUROSCI, V17, P4212; Hamada H, 1997, CIRC RES, V81, P812; Hayek SM, 1999, FEBS LETT, V461, P157, DOI 10.1016/S0014-5793(99)01464-7; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Holda JR, 1998, NEWS PHYSIOL SCI, V13, P157; Ichimiya M, 1998, AM J PHYSIOL-CELL PH, V275, pC832, DOI 10.1152/ajpcell.1998.275.3.C832; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; Lam M, 1998, J BIOL CHEM, V273, P17307, DOI 10.1074/jbc.273.28.17307; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LI JF, 1995, J BIOL CHEM, V270, P3203, DOI 10.1074/jbc.270.7.3203; Maloney JA, 1999, AM J PHYSIOL-CELL PH, V276, pC221, DOI 10.1152/ajpcell.1999.276.1.C221; Manjunatha B, 1997, J GEN PHYSIOL, V110, P749, DOI 10.1085/jgp.110.6.749; MARTIKAINEN P, 1991, CANCER RES, V51, P4693; McConkey David J., 1996, Scanning Microscopy, V10, P777; MCCONKEY DJ, 1989, J IMMUNOL, V143, P1801; McGahon A. J., 1995, METHOD CELL BIOL, V46, P172; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Pan Z, 2000, BIOPHYS J, V78, p191A; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Putney JW, 1998, SCIENCE, V279, P191, DOI 10.1126/science.279.5348.191; Reynolds JE, 1996, EXP CELL RES, V225, P430, DOI 10.1006/excr.1996.0194; Reynolds JE, 1996, J BIOL CHEM, V271, P27739, DOI 10.1074/jbc.271.44.27739; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Rizzuto R, 1999, CELL CALCIUM, V26, P193, DOI 10.1054/ceca.1999.0076; Schulze-Lohoff E, 1998, AM J PHYSIOL-RENAL, V275, pF962, DOI 10.1152/ajprenal.1998.275.6.F962; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VANDEWALLE B, 1994, CANCER LETT, V85, P47, DOI 10.1016/0304-3835(94)90237-2; Wei HF, 1998, J NEUROCHEM, V70, P2305; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zhu LP, 1999, J BIOL CHEM, V274, P33267, DOI 10.1074/jbc.274.47.33267	48	83	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19978	19984		10.1074/jbc.M908329199	http://dx.doi.org/10.1074/jbc.M908329199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10764805	hybrid			2022-12-27	WOS:000087941300075
J	Bai, JX; Cederbaum, AI				Bai, JX; Cederbaum, AI			Overexpression of catalase in the mitochondrial or cytosolic compartment increases sensitivity of HepG2 cells to tumor necrosis factor-alpha-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SUPEROXIDE-DISMUTASE; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; ACTIVATION; DEATH; INVOLVEMENT; CYTOTOXICITY; INDUCTION; CACHECTIN	The sensitivity of HepG2 cells overexpressing catalase in either the cytosolic or mitochondrial compartment to tumor necrosis factor-alpha (TNP-alpha) and cycloheximide was studied. Cells overexpressing catalase in the cytosol (C33 cells) and especially in mitochondria (mC5 cells) were more sensitive to TNF-alpha-induced apoptosis than were control cells (Hp cells). The activities of caspase-3 and -8 were increased by TNF-alpha, with the highest activities found in mC5 cells. Sodium azide, an inhibitor of catalase, reduced the increased sensitivity of mC5 and C33 cells to TNF-alpha to the level of toxicity found with control Hp cells. Azide also decreased the elevated caspase-3 activity of mC5 cells. A pan-caspase inhibitor prevented the TNF-alpha-induced apoptosis and toxicity produced by catalase overexpression, Addition of H2O2 prevented TNF-alpha-induced apoptosis and caspase activation, an effect prevented by simultaneous addition of catalase, TNF-alpha plus cycloheximide increased ATP levels, with higher levels in C33 and mC5 cells compared with Hp cells. TNF-alpha did not produce apoptosis in mC5 cells maintained in a low energy state. TNF-alpha signaling was not altered by the overexpression of catalase, as activation of nuclear factor kappa B and AP-1 by TNF-alpha was similar in the three cell lines. These results suggest that catalase, overexpressed in the cytosolic or especially the mitochondrial compartment, potentiates TNF-alpha induced apoptosis and activation of caspases by removal of H2O2.	CUNY Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Cederbaum, AI (corresponding author), CUNY Mt Sinai Sch Med, Dept Biochem & Mol Biol, POB 1020,1 Gustave L Levy Pl, New York, NY 10029 USA.	Acederb@smtplink.mssm.edu			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA006610, R01AA003312, R01AA006610, R56AA003312] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA06610, AA03312] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Bai JX, 1999, J BIOL CHEM, V274, P26217, DOI 10.1074/jbc.274.37.26217; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; BLAZKA ME, 1995, TOXICOL APPL PHARM, V133, P43, DOI 10.1006/taap.1995.1125; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; CHEVALIER M, 1990, J BIOL CHEM, V265, P40; Czaja MJ, 1989, GROWTH FACTORS, V1, P219, DOI 10.3109/08977198908997998; Eguchi Y, 1997, CANCER RES, V57, P1835; Eguchi Y, 1999, CANCER RES, V59, P2174; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Gores GJ, 1998, BBA-BIOENERGETICS, V1366, P167, DOI 10.1016/S0005-2728(98)00111-X; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hagar H, 1996, AM J PHYSIOL-RENAL, V271, pF209, DOI 10.1152/ajprenal.1996.271.1.F209; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; Hildeman DA, 1999, IMMUNITY, V10, P735, DOI 10.1016/S1074-7613(00)80072-2; HILL DB, 1995, HEPATOLOGY, V21, P1114, DOI 10.1002/hep.1840210434; Hirokawa M, 1998, ALCOHOL CLIN EXP RES, V22, p111S, DOI 10.1111/acer.1998.22.s3_part1.111s; Hu WH, 1999, J BIOL CHEM, V274, P30603, DOI 10.1074/jbc.274.43.30603; Kitamura M, 1999, EUR J IMMUNOL, V29, P1647; Kohler HBK, 1999, VET IMMUNOL IMMUNOP, V71, P125, DOI 10.1016/S0165-2427(99)00097-5; Lee Y, 1999, J BIOL CHEM, V274, P19792, DOI 10.1074/jbc.274.28.19792; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Lemasters JJ, 1998, BIOFACTORS, V8, P283, DOI 10.1002/biof.5520080316; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; MCCLAIN CJ, 1989, HEPATOLOGY, V9, P349, DOI 10.1002/hep.1840090302; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; Nicotera P, 1998, TOXICOL LETT, V103, P139; ODONNELL VB, 1995, BIOCHEM J, V310, P133, DOI 10.1042/bj3100133; Samali A, 1999, BIOCHEM BIOPH RES CO, V255, P6, DOI 10.1006/bbrc.1998.0139; SanchezAlcazar JA, 1997, J BIOL CHEM, V272, P30167, DOI 10.1074/jbc.272.48.30167; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; Sidoti-de Fraisse C, 1998, ONCOGENE, V17, P1639, DOI 10.1038/sj.onc.1202094; Solary Eric, 1998, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V192, P1065; Sumitomo M, 1999, J UROLOGY, V161, P674, DOI 10.1016/S0022-5347(01)61993-1; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TRACEY KJ, 1988, J EXP MED, V167, P1211, DOI 10.1084/jem.167.3.1211; Wang CY, 1999, MOL CELL BIOL, V19, P5923; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Xu Y, 1999, DNA CELL BIOL, V18, P709, DOI 10.1089/104454999314999; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YOSHIOKA K, 1989, HEPATOLOGY, V10, P769, DOI 10.1002/hep.1840100504; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZIMMERMAN RJ, 1989, CANCER RES, V49, P1644	47	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19241	19249		10.1074/jbc.M000438200	http://dx.doi.org/10.1074/jbc.M000438200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10764744	hybrid			2022-12-27	WOS:000087815900082
J	Cristofari, G; Ficheux, D; Darlix, JL				Cristofari, G; Ficheux, D; Darlix, JL			The Gag-like protein of the yeast Ty1 retrotransposon contains a nucleic acid chaperone domain analogous to retroviral nucleocapsid proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PRIMER-BINDING-SITE; RNA ANNEALING ACTIVITIES; PROVIRAL DNA-SYNTHESIS; REVERSE TRANSCRIPTION; STRAND TRANSFER; SACCHAROMYCES-CEREVISIAE; GENOMIC RNA; ELEMENT TRANSPOSITION; POSSIBLE ROLES	The reverse transcription process for retroviruses and retrotransposons takes place in a nucleocore structure in the virus or virus-like particle. In retroviruses the major protein of the nucleocore is the nucleocapsid protein (NC protein), which derives from the C-terminal region of GAG. Retroviral NC proteins are formed of either one or two CCHC zinc finger(s) flanked by basic residues and have nucleic acid chaperone and matchmaker properties essential for virus replication. Interestingly, the GAG protein of a number of retroelements including Spumaviruses does not possess the hallmarks of retroviral GAGs and in particular lacks a canonical NC protein. In an attempt to search for a nucleic acid chaperone activity in this class of retroelements we used the yeast Ty1 retrotransposon as a model system. Results shows that the C-terminal region of Ty1 GAG contains a nucleic acid chaperone domain capable of promoting the annealing of primer tRNA(i)(Met) to the multipartite primer binding site, Ty1 RNA dimerization and initiation of reverse transcription, Moreover Ty1 RNA dimerization, in a manner similar to Ty3 but unlike retroviral RNAs, appears to be mediated by tRNA(i)(Met). These findings suggest that nucleic acid chaperone proteins probably are general co-factors for reverse transcriptases.	Ecole Normale Super Lyon, INSERM, U412, Unite Virol Humaine, F-69364 Lyon 07, France; Inst Biol & Chim Prot, F-69367 Lyon, France	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)	Darlix, JL (corresponding author), Ecole Normale Super Lyon, INSERM, U412, Unite Virol Humaine, LaboRetro, F-69364 Lyon 07, France.		Cristofari, Gael/A-2831-2011; LUC, DARLIX JEAN/AAE-9268-2020	Cristofari, Gael/0000-0001-5620-3091; 				ALLAIN B, 1994, EMBO J, V13, P973, DOI 10.1002/j.1460-2075.1994.tb06342.x; Auxilien S, 1999, J BIOL CHEM, V274, P4412, DOI 10.1074/jbc.274.7.4412; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; Boeke J. D., 1997, P343; CHAPMAN KB, 1992, P NATL ACAD SCI USA, V89, P3236, DOI 10.1073/pnas.89.8.3236; Cristofari G, 1999, J BIOL CHEM, V274, P36643, DOI 10.1074/jbc.274.51.36643; DARLIX JL, 1993, CR ACAD SCI III-VIE, V316, P763; DARLIX JL, 1990, J MOL BIOL, V216, P689, DOI 10.1016/0022-2836(90)90392-Y; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; Dawson A, 1997, EMBO J, V16, P4448, DOI 10.1093/emboj/16.14.4448; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; DERR LK, 1991, CELL, V67, P355, DOI 10.1016/0092-8674(91)90187-4; EICHINGER DJ, 1988, CELL, V54, P955, DOI 10.1016/0092-8674(88)90110-9; Enssle J, 1997, J VIROL, V71, P7312, DOI 10.1128/JVI.71.10.7312-7317.1997; Esnault C, 2000, NAT GENET, V24, P363, DOI 10.1038/74184; Feng YX, 1999, J VIROL, V73, P4251, DOI 10.1128/JVI.73.5.4251-4256.1999; FINK GR, 1987, CELL, V49, P5, DOI 10.1016/0092-8674(87)90746-X; FLAVELL AJ, 1994, CURR OPIN GENET DEV, V4, P838, DOI 10.1016/0959-437X(94)90068-X; Friant S, 1998, MOL CELL BIOL, V18, P799, DOI 10.1128/MCB.18.2.799; Friant S, 1996, NUCLEIC ACIDS RES, V24, P441, DOI 10.1093/nar/24.3.441; Gabus C, 1998, EMBO J, V17, P4873, DOI 10.1093/emboj/17.16.4873; GARFINKEL DJ, 1985, CELL, V42, P507, DOI 10.1016/0092-8674(85)90108-4; Guo JH, 1997, J VIROL, V71, P5178, DOI 10.1128/JVI.71.7.5178-5188.1997; Hajek K, 1998, J VIROL, V72, P8718, DOI 10.1128/JVI.72.11.8718-8724.1998; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; Kazazian HH, 1998, NAT GENET, V19, P19, DOI 10.1038/ng0598-19; KEENEY JB, 1995, MOL CELL BIOL, V15, P217, DOI 10.1128/MCB.15.1.217; Kim JK, 1997, J BIOL CHEM, V272, P16769, DOI 10.1074/jbc.272.27.16769; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; Klenerman P, 1997, NATURE, V390, P298, DOI 10.1038/36876; LaBranche H, 1998, NAT GENET, V19, P199, DOI 10.1038/575; LapadatTapolsky M, 1997, J MOL BIOL, V268, P250, DOI 10.1006/jmbi.1997.0978; LAPADATTAPOLSKY M, 1995, NUCLEIC ACIDS RES, V23, P2434, DOI 10.1093/nar/23.13.2434; MELLOR J, 1985, NATURE, V318, P583, DOI 10.1038/318583a0; MELLOR J, 1985, NUCLEIC ACIDS RES, V13, P6249, DOI 10.1093/nar/13.17.6249; MELLOR J, 1985, NATURE, V313, P243, DOI 10.1038/313243a0; Merkulov GV, 1996, J VIROL, V70, P5548, DOI 10.1128/JVI.70.8.5548-5556.1996; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; Moran JV, 1999, SCIENCE, V283, P1530, DOI 10.1126/science.283.5407.1530; Nakamura TM, 1998, CELL, V92, P587, DOI 10.1016/S0092-8674(00)81123-X; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; PORTMAN DS, 1994, EMBO J, V13, P213, DOI 10.1002/j.1460-2075.1994.tb06251.x; PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x; Rascle JB, 1998, J MOL BIOL, V280, P215, DOI 10.1006/jmbi.1998.1873; Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0; Rong LW, 1998, J VIROL, V72, P9353, DOI 10.1128/JVI.72.11.9353-9358.1998; Sandmeyer SB, 1996, CURR TOP MICROBIOL, V214, P261; SENGER B, 1992, P NATL ACAD SCI USA, V89, P10768, DOI 10.1073/pnas.89.22.10768; TANCHOU V, 1995, J MOL BIOL, V252, P563, DOI 10.1006/jmbi.1995.0520; Wakefield JK, 1996, J VIROL, V70, P966, DOI 10.1128/JVI.70.2.966-975.1996; WESSLER SR, 1995, CURR OPIN GENET DEV, V5, P814, DOI 10.1016/0959-437X(95)80016-X; Wilhelm M, 1999, J MOL BIOL, V288, P505, DOI 10.1006/jmbi.1999.2723; WILHELM M, 1994, NUCLEIC ACIDS RES, V22, P4560, DOI 10.1093/nar/22.22.4560; Wu TY, 1999, J VIROL, V73, P4794, DOI 10.1128/JVI.73.6.4794-4805.1999; YOUNGREN SD, 1988, MOL CELL BIOL, V8, P1421, DOI 10.1128/MCB.8.4.1421; Yu SF, 1996, J VIROL, V70, P8255, DOI 10.1128/JVI.70.12.8255-8262.1996; [No title captured]	58	51	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19210	19217		10.1074/jbc.M001371200	http://dx.doi.org/10.1074/jbc.M001371200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10766747	hybrid			2022-12-27	WOS:000087815900078
J	Liu, A; Graslund, A				Liu, A; Graslund, A			Electron paramagnetic resonance evidence for a novel interconversion of [3Fe-4S](+) and [4Fe-4S](+) clusters with endogenous iron and sulfide in anaerobic ribonucleotide reductase activase in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE FORMATE-LYASE; PYROCOCCUS-FURIOSUS FERREDOXIN; SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; S-ADENOSYLMETHIONINE; LYSINE 2,3-AMINOMUTASE; SULFUR CLUSTERS; TRIPHOSPHATE REDUCTASE; SPECTROSCOPIC EVIDENCE; 4FE-4S CLUSTERS	We report an EPR study of the iron-sulfur enzyme, anaerobic ribonucleotide reductase activase from Lactococcus lactis. The activase (nrdG gene) together with S-adenosyl-L-methionine (AdoMet) give rise to a glycyl radical in the NrdD component. A semi-reduced [4Fe-4S](+) cluster with an axially symmetric EPR signal was produced upon photochemical reduction of the activase, Air exposure of the reduced enzyme gave a [3Fe-4S](+) cluster. The Fe3S4 cluster was convertible to the EPR-active [4Fe-4S]+ cluster by renewed treatment with reducing agents, demonstrating a reversible [3Fe-4S](+) to-[4Fe-4S](+) cluster conversion without exogenous addition of iron or sulfide, Anaerobic reduction of the activase by a moderate concentration of dithionite also resulted in a semi-reduced [4Fe-4S]+ cluster. Prolonged reduction gave an EPR-silent fully reduced state, which was enzymatically inactive. Both reduced states gave the [3Fe-4S](+) EPR signal after air exposure. The iron-sulfur cluster interconversion was also studied in the presence of AdoMet. The EPR signal of semi-reduced activase-AdoMet had rhombic symmetry and was independent of which reductant was applied, whereas the EPR signal of the [3Fe-4S](+) cluster after air exposure was unchanged. The results indicate that an AdoMet-mediated [4Fe-4S](+) center is the native active species that induces the formation of a glycyl radical in the NrdD component.	Stockholm Univ, Arrhenius Labs, Dept Biophys, S-10691 Stockholm, Sweden	Stockholm University	Graslund, A (corresponding author), Stockholm Univ, Arrhenius Labs, Dept Biophys, S-10691 Stockholm, Sweden.		Liu, Aimin/C-1572-2017	Liu, Aimin/0000-0002-4182-8176				Angove HC, 1998, J BIOL CHEM, V273, P26330, DOI 10.1074/jbc.273.41.26330; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; Busch JLH, 1997, BIOCHEM J, V323, P95, DOI 10.1042/bj3230095; CAMMACK R, 1992, ADV INORG CHEM, V38, P281, DOI 10.1016/S0898-8838(08)60066-5; CONOVER RC, 1990, J BIOL CHEM, V265, P8533; CUNNINGHAM RP, 1989, BIOCHEMISTRY-US, V28, P4450, DOI 10.1021/bi00436a049; Duderstadt RE, 1998, J AM CHEM SOC, V120, P8525, DOI 10.1021/ja9815834; ELIASSON R, 1990, P NATL ACAD SCI USA, V87, P3314, DOI 10.1073/pnas.87.9.3314; FONTECAVE M, 1989, P NATL ACAD SCI USA, V86, P2147, DOI 10.1073/pnas.86.7.2147; FREY M, 1994, J BIOL CHEM, V269, P12432; FREY PA, 1993, FASEB J, V7, P662, DOI 10.1096/fasebj.7.8.8500691; Gao-Sheridan HS, 1998, J BIOL CHEM, V273, P33692, DOI 10.1074/jbc.273.50.33692; Guigliarelli B, 1999, ADV INORG CHEM, V47, P421, DOI 10.1016/S0898-8838(08)60084-7; HARDER J, 1992, J BIOL CHEM, V267, P25548; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KENNEDY MC, 1984, J BIOL CHEM, V259, P4463; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; KENT TA, 1982, P NATL ACAD SCI-BIOL, V79, P1096, DOI 10.1073/pnas.79.4.1096; Khoroshilova N, 1997, P NATL ACAD SCI USA, V94, P6087, DOI 10.1073/pnas.94.12.6087; KING DS, 1995, BIOCHEM BIOPH RES CO, V206, P731, DOI 10.1006/bbrc.1995.1103; Leenhouts K, 1996, MOL GEN GENET, V253, P217, DOI 10.1007/s004380050315; Lieder KW, 1998, BIOCHEMISTRY-US, V37, P2578, DOI 10.1021/bi972417w; Magnusson OT, 1999, J AM CHEM SOC, V121, P9764, DOI 10.1021/ja9925507; MANODORI A, 1992, BIOCHEMISTRY-US, V31, P2703, DOI 10.1021/bi00125a010; MOURA JJG, 1982, J BIOL CHEM, V257, P6259; MULLIEZ E, 1993, J BIOL CHEM, V268, P2296; Ollagnier S, 1996, J BIOL CHEM, V271, P9410, DOI 10.1074/jbc.271.16.9410; Ollagnier S, 1999, J AM CHEM SOC, V121, P6344, DOI 10.1021/ja990073m; Ollagnier S, 1997, J BIOL CHEM, V272, P24216, DOI 10.1074/jbc.272.39.24216; Ollagnier-de Choudens S, 1999, FEBS LETT, V453, P25, DOI 10.1016/S0014-5793(99)00694-8; Popescu CV, 1998, P NATL ACAD SCI USA, V95, P13431, DOI 10.1073/pnas.95.23.13431; REICHARD P, 1993, J BIOL CHEM, V268, P8383; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; Rousset M, 1998, P NATL ACAD SCI USA, V95, P11625, DOI 10.1073/pnas.95.20.11625; SAHLIN M, 1986, J MAGN RESON, V67, P135, DOI 10.1016/0022-2364(86)90417-8; Sawers G, 1998, J BACTERIOL, V180, P3509, DOI 10.1128/JB.180.14.3509-3516.1998; SJOBERG BM, 1977, J BIOL CHEM, V252, P536; SUN XY, 1995, J BIOL CHEM, V270, P2443, DOI 10.1074/jbc.270.6.2443; SUN XY, 1993, P NATL ACAD SCI USA, V90, P577, DOI 10.1073/pnas.90.2.577; Tamarit J, 1999, J BIOL CHEM, V274, P31291, DOI 10.1074/jbc.274.44.31291; TONG JJ, 1994, J BIOL CHEM, V269, P24920; Torrents E, 2000, J BIOL CHEM, V275, P2463, DOI 10.1074/jbc.275.4.2463; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; Yoo SJ, 1999, J AM CHEM SOC, V121, P2534, DOI 10.1021/ja9837405; YOUNG P, 1994, J BIOL CHEM, V269, P27815	47	39	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12367	12373		10.1074/jbc.275.17.12367	http://dx.doi.org/10.1074/jbc.275.17.12367			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777518	hybrid			2022-12-27	WOS:000086762300002
J	Marx, PF; Hackeng, TM; Dawson, PE; Griffin, JH; Meijers, JCM; Bouma, BN				Marx, PF; Hackeng, TM; Dawson, PE; Griffin, JH; Meijers, JCM; Bouma, BN			Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCARBOXYPEPTIDASE-B; INTRINSIC PATHWAY; HUMAN PLASMA; FACTOR-XI; COAGULATION; TAFI; CARBOXYPEPTIDASE; PURIFICATION; ACTIVATION; THROMBOMODULIN	Thrombin-activable fibrinolysis inhibitor (TAFI) is present in the circulation as an inactive zymogen. Thrombin converts TAFI to a carboxypeptidase B-like enzyme (TAFIa) by cleaving at Arg(92) in a process accelerated by the cofactor, thrombomodulin. TAFIa attenuates fibrinolysis. TAFIa can be inactivated by both proteolysis by thrombin and spontaneous temperature-dependent loss of activity. The identity of the thrombin cleavage site responsible for loss of TAFIa activity was suggested to be Arg(330), but site-directed mutagenesis of this residue did not prevent inactivation of TAFIa by thrombin, In this study we followed TAFI activation and TAFIa inactivation by thrombin/thrombomodulin in time and characterized the cleavage pattern of TAFI using matrix-assisted laser desorption ionization mass spectrometry, Mass matching of the fragments revealed that TAFIa was cleaved at Ar-302. Studies of a mutant R302Q-TAFI confirmed identification of this thrombin cleavage site and, furthermore, suggested that inactivation of TAFIa is based on its conformational instability rather than proteolytic cleavage at Arg(302).	Univ Med Ctr, Dept Haematol, Thrombosis & Haemostasis Lab, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Inst Biomembranes, NL-3584 CA Utrecht, Netherlands; Scripps Res Inst, Dept Cell Biol & Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Utrecht University; Utrecht University Medical Center; Utrecht University; Scripps Research Institute; Scripps Research Institute	Marx, PF (corresponding author), Univ Utrecht Hosp, Dept Haematol, G03-647,POB 85500, NL-3508 GA Utrecht, Netherlands.		Meijers, J.C.M./S-5981-2019	Meijers, J.C.M./0000-0002-4198-6780; Hackeng, Tilman/0000-0003-0142-0843	NHLBI NIH HHS [HL21544] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021544] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; BOFFA M, 1997, THROMB HAEMOST S, P596; Boffa MB, 1998, J BIOL CHEM, V273, P2127, DOI 10.1074/jbc.273.4.2127; Bouma BN, 1998, THROMB HAEMOSTASIS, V80, P24; BURGOS FJ, 1991, BIOCHEMISTRY-US, V30, P4082, DOI 10.1021/bi00230a038; COX DJ, 1962, BIOCHEMISTRY-US, V1, P1078, DOI 10.1021/bi00912a018; EATON DL, 1991, J BIOL CHEM, V266, P21833; HENDRIKS D, 1990, BIOCHIM BIOPHYS ACTA, V1034, P86, DOI 10.1016/0304-4165(90)90157-R; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; MEIJERS JCM, 1992, BLOOD, V79, P1435; Mosnier LO, 1998, THROMB HAEMOSTASIS, V80, P829; Nesheim M, 1997, THROMB HAEMOSTASIS, V78, P386; Nesheim M. E., 1996, Fibrinolysis, V10, P126; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; PASCUAL R, 1989, EUR J BIOCHEM, V179, P609, DOI 10.1111/j.1432-1033.1989.tb14590.x; REDLITZ A, 1995, J CLIN INVEST, V96, P2534, DOI 10.1172/JCI118315; SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x; TAN AK, 1995, BIOCHEMISTRY-US, V34, P5811, DOI 10.1021/bi00017a012; VANHOOF G, 1997, FIBRINOLYSIS PROTEOL, V11, P41; WANG W, 1994, J BIOL CHEM, V269, P15937; Zhao L, 1998, THROMB HAEMOSTASIS, V80, P949	22	87	92	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12410	12415		10.1074/jbc.275.17.12410	http://dx.doi.org/10.1074/jbc.275.17.12410			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777524	hybrid			2022-12-27	WOS:000086762300008
J	Soutoglou, E; Papafotiou, G; Katrakili, N; Talianidis, I				Soutoglou, E; Papafotiou, G; Katrakili, N; Talianidis, I			Transcriptional activation by hepatocyte nuclear factor-1 requires synergism between multiple coactivator proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE RECEPTOR SUPERFAMILY; LIVER-SPECIFIC TRANSCRIPTION; ADENOVIRAL ONCOPROTEIN E1A; HEPATIC GENE-EXPRESSION; HISTONE ACETYLTRANSFERASE; DNA-BINDING; FACTOR-I; P300; CBP; DIMERIZATION	Hepatocyte nuclear factor-1 (HNF-1) plays an important role in the regulation of a large number of genes expressed in the liver, kidney, and pancreatic beta-cells, In exploring the molecular mechanism involved in HNF-1-dependent gene activation in the in vivo chromatin context, we found that HNF-1 can physically interact with the histone acetyltransferases (HATs) CREB-binding protein (CBP), p300/CBP-associated factor (P/CAF), Src-1, and RAC3. The transcriptional activation potential of HNF-1 on a genome integrated promoter was strictly dependent on the synergistic action of CBP and P/CAF, which can independently interact with the N-terminal and C-terminal domain of HNF-1, respectively. Moreover, the HAT activity of both coactivators was important, as opposed to the selective requirement for the HAT activity of P/CAF in activation from a transiently transfected reporter. Interaction of CBP with the N-terminal domain of HNF-1 greatly increased the binding affinity for P/CAF with the C-terminal activation domain, which may represent the molecular basis for the observed functional synergism, The results support a model that involves the combined action of multiple coactivators recruited by HNF-1, which activate transcription by coupling nucleosome modification and recruitment of the general transcription machinery.	Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, Herakleion Crete 71110, Greece	Foundation for Research & Technology - Hellas (FORTH)	Talianidis, I (corresponding author), Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, POB 1527, Herakleion Crete 71110, Greece.		Talianidis, Iannis/F-7556-2016	Talianidis, Iannis/0000-0002-1209-3609; Papafotiou, George/0000-0003-0594-5014; Soutoglou, Evi/0000-0002-3724-5613				ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BACH I, 1991, NUCLEIC ACIDS RES, V19, P3553, DOI 10.1093/nar/19.13.3553; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Johnen G, 1997, P NATL ACAD SCI USA, V94, P13469, DOI 10.1073/pnas.94.25.13469; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KRITIS AA, 1993, NUCLEIC ACIDS RES, V21, P5882, DOI 10.1093/nar/21.25.5882; Ktistaki E, 1997, MOL CELL BIOL, V17, P2790, DOI 10.1128/MCB.17.5.2790; Ktistaki E, 1997, SCIENCE, V277, P109, DOI 10.1126/science.277.5322.109; KTISTAKI E, 1995, P NATL ACAD SCI USA, V92, P9876, DOI 10.1073/pnas.92.21.9876; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; Lee YH, 1998, MOL CELL BIOL, V18, P3059, DOI 10.1128/MCB.18.5.3059; Li H, 1998, J BIOL CHEM, V273, P5948, DOI 10.1074/jbc.273.10.5948; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Perissi V, 1999, P NATL ACAD SCI USA, V96, P3652, DOI 10.1073/pnas.96.7.3652; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; Pontoglio M, 1997, MOL CELL BIOL, V17, P4948, DOI 10.1128/MCB.17.9.4948; Pontoglio M, 1998, J CLIN INVEST, V101, P2215, DOI 10.1172/JCI2548; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Rollini P, 1999, P NATL ACAD SCI USA, V96, P10308, DOI 10.1073/pnas.96.18.10308; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; TIAN JM, 1991, GENE DEV, V5, P2225, DOI 10.1101/gad.5.12a.2225; TRONCHE F, 1992, BIOESSAYS, V14, P579, DOI 10.1002/bies.950140902; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	48	115	116	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12515	12520		10.1074/jbc.275.17.12515	http://dx.doi.org/10.1074/jbc.275.17.12515			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777539	hybrid			2022-12-27	WOS:000086762300023
J	Stargell, LA; Moqtaderi, Z; Dorris, DR; Ogg, RC; Struhl, K				Stargell, LA; Moqtaderi, Z; Dorris, DR; Ogg, RC; Struhl, K			TFIIA has activator-dependent and core promoter functions in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; RNA-POLYMERASE-II; TRANSCRIPTION FACTOR IIA; YEAST TFIIA/TBP/DNA COMPLEX; CELL-CYCLE PROGRESSION; IN-VIVO; SACCHAROMYCES-CEREVISIAE; GENE ACTIVATION; DNA-BINDING; DIFFERENTIAL UTILIZATION	The physiological role of TFILA was investigated by analyzing transcription in a yeast strain that contains a TATA-binding protein (TBP) mutant (N2-1) defective for interacting with TFILA. In cells containing N2-1, transcription from a set of artificial his3 promoters depend ent on different activators is generally reduced by a similar extent, indicating that TFILA function is largely nonselective for activators. In addition, TATA element utilization, a core promoter function, is altered at his3 promoters dependent on weak activators. Genomic expression analysis reveals that 3% of the genes are preferentially affected by a factor of 4 or more. Chimeras of affected promoters indicate that the sensitivity to the TFILA-TBP interaction can map either to the upstream or core promoter region. Unlike wild-type TBP or TFILA, the N2-1 derivative does not activate transcription when artificially recruited to the promoter via a heterologous DNA binding domain, indicating that TFILA is important for transcription even in the absence of an activation domain. Taken together, these results suggest that TFILA plays an important role in both activator-dependent and core promoter functions in vine. Further, they suggest that TFILA function may not be strictly related to the recruitment of TBP to promoters but may also involve a step after TBP recruitment.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	Harvard University; Harvard Medical School; Colorado State University	Struhl, K (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	kevin@hms.harvard.edu	Stargell, Laurie/GWC-7423-2022		NIGMS NIH HHS [GM56884, GM30186] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030186, R01GM056884, R37GM030186] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; ARNDT KM, 1995, EMBO J, V14, P1490, DOI 10.1002/j.1460-2075.1995.tb07135.x; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; Bryant GO, 1996, GENE DEV, V10, P2491, DOI 10.1101/gad.10.19.2491; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; Chi TH, 1996, GENE DEV, V10, P2540, DOI 10.1101/gad.10.20.2540; Clemens KE, 1996, MOL CELL BIOL, V16, P4656; COLLART MA, 1993, EMBO J, V12, P177, DOI 10.1002/j.1460-2075.1993.tb05643.x; Collart MA, 1996, MOL CELL BIOL, V16, P6668; Damania B, 1998, MOL CELL BIOL, V18, P3926, DOI 10.1128/MCB.18.7.3926; Emami KH, 1997, GENE DEV, V11, P3007, DOI 10.1101/gad.11.22.3007; EMILI A, 1995, J BIOL CHEM, V270, P13674, DOI 10.1074/jbc.270.23.13674; Farrell S, 1996, GENE DEV, V10, P2359, DOI 10.1101/gad.10.18.2359; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; Gaudreau L, 1999, P NATL ACAD SCI USA, V96, P2668, DOI 10.1073/pnas.96.6.2668; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; GonzalezCouto E, 1997, P NATL ACAD SCI USA, V94, P8036, DOI 10.1073/pnas.94.15.8036; Goppelt A, 1996, EMBO J, V15, P3105, DOI 10.1002/j.1460-2075.1996.tb00673.x; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; Iyer V, 1996, P NATL ACAD SCI USA, V93, P5208, DOI 10.1073/pnas.93.11.5208; IYER V, 1995, MOL CELL BIOL, V15, P7059; JIANG YW, 1992, MOL CELL BIOL, V12, P4503, DOI 10.1128/MCB.12.10.4503; KANG JJ, 1995, MOL CELL BIOL, V15, P1234; Keaveney M, 1998, MOL CELL, V1, P917, DOI 10.1016/S1097-2765(00)80091-X; Kim J, 1996, J BIOL CHEM, V271, P18405, DOI 10.1074/jbc.271.31.18405; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KOBAYASHI N, 1995, MOL CELL BIOL, V15, P6465; Kokubo T, 1998, MOL CELL BIOL, V18, P1003, DOI 10.1128/MCB.18.2.1003; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; Lee M, 1997, MOL CELL BIOL, V17, P1336, DOI 10.1128/MCB.17.3.1336; LEE M, 1995, MOL CELL BIOL, V15, P5461; Li XY, 1999, NATURE, V399, P605, DOI 10.1038/21232; Li YF, 1999, PLANT MOL BIOL, V39, P515, DOI 10.1023/A:1006139724849; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Mermelstein F, 1996, GENE DEV, V10, P1033, DOI 10.1101/gad.10.8.1033; Moqtaderi Z, 1998, MOL CELL, V2, P675, DOI 10.1016/S1097-2765(00)80165-3; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Ozer J, 1996, J BIOL CHEM, V271, P11182, DOI 10.1074/jbc.271.19.11182; OZER J, 1994, GENE DEV, V8, P2324, DOI 10.1101/gad.8.19.2324; Ozer J, 1998, MOL CELL BIOL, V18, P2559, DOI 10.1128/MCB.18.5.2559; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; Ranish JA, 1999, GENE DEV, V13, P49, DOI 10.1101/gad.13.1.49; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SHYKIND BM, 1995, GENE DEV, V9, P1354, DOI 10.1101/gad.9.11.1354; Stargell LA, 1996, MOL CELL BIOL, V16, P4456; STARGELL LA, 1995, SCIENCE, V269, P75, DOI 10.1126/science.7604282; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; STRUHL K, 1989, ANNU REV BIOCHEM, V58, P1051, DOI 10.1146/annurev.bi.58.070189.005155; STRUHL K, 1986, MOL CELL BIOL, V6, P3847, DOI 10.1128/MCB.6.11.3847; Tan S, 1996, NATURE, V381, P127, DOI 10.1038/381127a0; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; XIAO H, 1995, MOL CELL BIOL, V15, P5757; Yokomori K, 1998, P NATL ACAD SCI USA, V95, P6722, DOI 10.1073/pnas.95.12.6722	67	24	27	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12374	12380		10.1074/jbc.275.17.12374	http://dx.doi.org/10.1074/jbc.275.17.12374			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777519	hybrid			2022-12-27	WOS:000086762300003
J	Tokoyoda, K; Takemoto, Y; Nakayama, T; Arai, T; Kubo, M				Tokoyoda, K; Takemoto, Y; Nakayama, T; Arai, T; Kubo, M			Synergism between the calmodulin-binding and autoinhibitory domains on calcineurin is essential for the induction of their phosphatase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL RYANODINE RECEPTOR; TRANSCRIPTION FACTOR NFAT1; KEY SIGNALING ENZYME; ACTIVATED T-CELLS; NF-AT; PROTEIN PHOSPHATASE; CATALYTIC SUBUNIT; CYCLOSPORINE-A; NUCLEAR IMPORT; IDENTIFICATION	Elevation of the intracellular calcium concentration is necessary for cell growth and the activation of several lymphokine genes. The immunosuppressive drugs cyclosporin A and FK506 profoundly inhibit the calcium-dependent signaling pathway in T lymphocytes by interfering with the activity of the calcium/calmodulin (CaM)-dependent serine/threonine phosphatase, calcineurin (CN). Little is known, however, about how activation of CN enzyme activity or interaction with its substrate, nuclear factor of activated T cell (NF-AT), is regulated. We show here that the binding of CaM to CN may affect the conformation of CN at both the CaM-binding and the autoinhibitory (AI) domains and that this is critical for activation of CN to dephosphorylate NF-AT. Dissociation of the AT domain from the enzyme active site on CN leads to expose a binding site for NF-AT at the N terminus of CN and allows the CN binding to NF-AT. Since the cytoplasmic form of NF-AT can interact with CN mutants lacking enzyme activity, the interaction of the two molecules is independent of CN enzyme activity and occurs prior to the dephosphorylation of NF-AT. Dephosphorylation converts NF-AT from the cytoplasmic to the nuclear form by exposing the DNA-binding domain on NF-AT, and the nuclear form of NF-AT brings CN together into the nuclei. We therefore propose that the activation of CN by the CaM binding independently regulates the interaction with NF-AT and the dephosphorylation of NF-AT.	Sci Univ Tokyo, Res Inst Biol Sci, Div Immunobiol, Noda, Chiba 2780022, Japan; Nippon Glaxo Ltd, Tsukuba Res Labs, Tsukuba, Ibaraki 30042, Japan; Chiba Univ, GRad Sch med, Dept Mol Immunol, Chuo Ku, Chiba 2608670, Japan; Sci Univ Tokyo, Dept Appl Biol Sci, Chiba 2788510, Japan	Tokyo University of Science; Eisai Co Ltd; GlaxoSmithKline; Chiba University; Tokyo University of Science	Kubo, M (corresponding author), Sci Univ Tokyo, Res Inst Biol Sci, Div Immunobiol, 2669 Yamazaki, Noda, Chiba 2780022, Japan.		Nakayama, Toshinori/E-1067-2017	Nakayama, Toshinori/0000-0002-1434-2007; Tokoyoda, Koji/0000-0001-6101-4826				Aramburu J, 1998, MOL CELL, V1, P627, DOI 10.1016/S1097-2765(00)80063-5; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; Cameron AM, 1997, J BIOL CHEM, V272, P27582, DOI 10.1074/jbc.272.44.27582; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CLIPSTONE NA, 1993, ANN NY ACAD SCI, V696, P20; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; FRUMAN DA, 1995, MOL CELL BIOL, V15, P3857; Garcia-Cozar FJ, 1998, J BIOL CHEM, V273, P23877, DOI 10.1074/jbc.273.37.23877; GIRI PR, 1991, BIOCHEM BIOPH RES CO, V181, P252; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; Kashishian A, 1998, J BIOL CHEM, V273, P27412, DOI 10.1074/jbc.273.42.27412; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; KUBO M, 1994, INT IMMUNOL, V6, P179, DOI 10.1093/intimm/6.2.179; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; Masuda ES, 1997, MOL CELL BIOL, V17, P2066, DOI 10.1128/MCB.17.4.2066; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MURAMATSU T, 1992, P NATL ACAD SCI USA, V89, P529, DOI 10.1073/pnas.89.2.529; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PARSONS JN, 1994, J BIOL CHEM, V269, P19610; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SIKKINK R, 1995, BIOCHEMISTRY-US, V34, P8348, DOI 10.1021/bi00026a016; Sun L, 1998, IMMUNITY, V8, P703, DOI 10.1016/S1074-7613(00)80575-0; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; WATANABE Y, 1995, J BIOL CHEM, V270, P456, DOI 10.1074/jbc.270.1.456; Winder DG, 1998, CELL, V92, P25, DOI 10.1016/S0092-8674(00)80896-X; Wolfe SA, 1997, NATURE, V385, P172, DOI 10.1038/385172a0; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	45	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11728	11734		10.1074/jbc.275.16.11728	http://dx.doi.org/10.1074/jbc.275.16.11728			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766794	hybrid			2022-12-27	WOS:000086695500029
J	Cohen, P; Bouaboula, M; Bellis, M; Baron, V; Jbilo, O; Poinot-Chazel, C; Galiegue, S; Hadibi, EH; Casellas, P				Cohen, P; Bouaboula, M; Bellis, M; Baron, V; Jbilo, O; Poinot-Chazel, C; Galiegue, S; Hadibi, EH; Casellas, P			Monitoring cellular responses to Listeria monocytogenes with oligonucleotide arrays	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; GENE-EXPRESSION PATTERNS; CDNA FILTER ANALYSIS; MESSENGER-RNA; QUANTITATIVE HYBRIDIZATION; LARGE-SCALE; HUMAN BRAIN; CELLS; MACROPHAGES; MICROARRAY	Listeria monocytogenes is a pathogenic intracellular microorganism whose infection induces pleiotropic biological changes associated with host cell gene expression regulation, Here we define the gene expression profiles of the human promyelocytic THP1 cell line before and after L. monocytogenes infection. Gene expression was measured on a large scale via oligonucleotide microarrays with probe sets corresponding to 6,800 human genes. We assessed and discussed the reproducibility of the hybridization signatures. In addition to oligonucleotide arrays, we also performed the large scale gene expression measurement with two high-density membranes, assaying for 588 and 18,376 human genes, respectively, This work allowed the reproducible identification of 74 up-regulated RNAs and 23 down-regulated RNAs as a consequence oft. monocytogenes infection of THP1, The reliability of these data was reinforced by performing independent infections. Some of these detected RNAs were consistent with previous results, while some newly identified RNAs encode gene products that may play key roles in L, monocytogenes infection. These findings will undoubtedly enhance the understanding of L, monocytogenes molecular physiology and may help identify new therapeutic targets.	Sanofi Synthelabo, F-34184 Montpellier, France	Sanofi-Aventis; Sanofi France	Casellas, P (corresponding author), 371 Rue Prof J Blayac, F-34184 Montpellier 04, France.		Cohen, Pascale/I-5875-2012	Cohen, Pascale/0000-0001-7016-9598				BLEICHER PA, 1990, SCIENCE, V250, P679, DOI 10.1126/science.1700477; BOUABOULA M, 1995, J BIOL CHEM, V270, P13973, DOI 10.1074/jbc.270.23.13973; BOUABOULA M, 1992, J BIOL CHEM, V267, P21830; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Cossart P, 1998, EMBO J, V17, P3797, DOI 10.1093/emboj/17.14.3797; Demuth A, 1996, INFECT IMMUN, V64, P3475, DOI 10.1128/IAI.64.9.3475-3483.1996; DeRisi J, 1996, NAT GENET, V14, P457; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Finlay BB, 1997, SCIENCE, V276, P718, DOI 10.1126/science.276.5313.718; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jordan BR, 1998, J BIOCHEM-TOKYO, V124, P251, DOI 10.1093/oxfordjournals.jbchem.a022104; KLEBANOFF SJ, 1982, J EXP MED, V156, P1262, DOI 10.1084/jem.156.4.1262; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LENNON GG, 1991, TRENDS GENET, V7, P314, DOI 10.1016/0168-9525(91)90420-U; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Lorber B, 1997, CLIN INFECT DIS, V24, P1, DOI 10.1093/clinids/24.1.1; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; NGUYEN C, 1995, GENOMICS, V29, P207, DOI 10.1006/geno.1995.1233; Pietu G, 1996, GENOME RES, V6, P492, DOI 10.1101/gr.6.6.492; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Shuford WW, 1997, J EXP MED, V186, P47, DOI 10.1084/jem.186.1.47; SOARES MB, 1994, P NATL ACAD SCI USA, V91, P9228, DOI 10.1073/pnas.91.20.9228; TAKAHASHI N, 1995, GENE, V164, P219, DOI 10.1016/0378-1119(95)00396-N; Villalta F, 1998, INFECT IMMUN, V66, P4690, DOI 10.1128/IAI.66.10.4690-4695.1998; Wilson SL, 1998, J INFECT DIS, V178, P1658, DOI 10.1086/314490; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Yamashiro S, 1998, MOL BIOL CELL, V9, P993, DOI 10.1091/mbc.9.5.993; ZHAO ND, 1995, GENE, V156, P207, DOI 10.1016/0378-1119(95)00023-Y	30	85	95	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11181	11190		10.1074/jbc.275.15.11181	http://dx.doi.org/10.1074/jbc.275.15.11181			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753925	hybrid			2022-12-27	WOS:000086466600067
J	Arthur, TM; Anthony, LC; Burgess, RR				Arthur, TM; Anthony, LC; Burgess, RR			Mutational analysis of beta '(260-309), a sigma(70) binding site located on Escherichia coli core RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTER RECOGNITION; CRYSTAL-STRUCTURE; BETA' SUBUNIT; COILED COILS; INHIBITORS; REGIONS; ENZYME; LOCALIZATION; PURIFICATION; PROTEINS	eubacteria, the a subunit binds to the core RNA polymerase and directs transcription initiation from any of its cognate set of promoters, Previously, our laboratory defined a region of the beta' subunit that interacts with sigma(70) in vitro. This region of beta' contained heptad repeat motifs indicative of coiled coils. In this work, we used 10 single point mutations of the predicted coiled coils, located within residues 260-309 of beta', to look at disruption of the sigma(70)-core interaction, Several of the mutants mere defective for binding sigma(70) in vitro. Of these mutants, three (R275Q, E295K, and A302D) caused cells to be inviable in an in vivo assay in which the mutant beta' is the sole source of beta' subunit for the cell. All of the mutants were able to assemble into the core enzyme; however, R275Q, E295K, A302D were defective for E sigma(70) holoenzyme formation. Several of the mutants were also defective for holoenzyme assembly with various minor a factors. In the recently published crystal structure of Thermus aquaticus core RNA polymerase (Zhang, G., Campbell, E. k, Minakhin, L,, Richter, C,, Severinov,,, and Darst, S, A. (1999) Cell 98, 811-824), the region homologous to beta'(260-309) of Escherichia coli forms a coiled coil. Modeling of our mutations onto that coiled coil places the most defective mutations on one face of the coiled coil.	Univ Wisconsin, Mcardle Lab Canc Res, Madison, WI 53706 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Burgess, RR (corresponding author), Univ Wisconsin, Mcardle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	burgess@oncology.wisc.edu		Burgess, Richard/0000-0001-9545-3165; Arthur, Terrance/0000-0001-9035-0474	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028575] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28575] Funding Source: Medline; OHS HRSA HHS [ST32GM08349] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OHS HRSA HHS		Arthur TM, 1998, J BIOL CHEM, V273, P31381, DOI 10.1074/jbc.273.47.31381; Brodolin K, 2000, J BIOL CHEM, V275, P3661, DOI 10.1074/jbc.275.5.3661; Burgess RR, 1998, COLD SPRING HARB SYM, V63, P277, DOI 10.1101/sqb.1998.63.277; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; Callaci S, 1998, J BIOL CHEM, V273, P32995, DOI 10.1074/jbc.273.49.32995; Chao HM, 1998, J CHROMATOGR B, V715, P307, DOI 10.1016/S0378-4347(98)00172-8; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; Eckert DM, 1999, CELL, V99, P103, DOI 10.1016/S0092-8674(00)80066-5; ElKettani MAEC, 1996, CR ACAD SCI III-VIE, V319, P161; Farewell A, 1998, MOL MICROBIOL, V29, P1039, DOI 10.1046/j.1365-2958.1998.00990.x; FISHER R, 1980, J BIOL CHEM, V255, P1056; FrereGallois V, 1997, EUR J BIOCHEM, V249, P142, DOI 10.1111/j.1432-1033.1997.t01-1-00142.x; Fujita M, 2000, GENES CELLS, V5, P79, DOI 10.1046/j.1365-2443.2000.00307.x; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; Gross CA, 1996, PHILOS T R SOC B, V351, P475, DOI 10.1098/rstb.1996.0045; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; Grum VL, 1999, CELL, V98, P523, DOI 10.1016/S0092-8674(00)81980-7; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; Hsieh M, 1999, MICROBIOL-UK, V145, P3081, DOI 10.1099/00221287-145-11-3081; Jishage M, 1996, J BACTERIOL, V178, P5447, DOI 10.1128/jb.178.18.5447-5451.1996; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; Joo DM, 1998, J BACTERIOL, V180, P1095, DOI 10.1128/JB.180.5.1095-1102.1998; Ju JL, 1999, J BACTERIOL, V181, P4969, DOI 10.1128/JB.181.16.4969-4977.1999; LESLEY SA, 1989, BIOCHEMISTRY-US, V28, P7728, DOI 10.1021/bi00445a031; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Malhotra A, 1996, CELL, V87, P127, DOI 10.1016/S0092-8674(00)81329-X; McMahan SA, 1999, BIOCHEMISTRY-US, V38, P12424, DOI 10.1021/bi990824x; MUNOZ V, 1994, NAT STRUCT BIOL, V1, P399, DOI 10.1038/nsb0694-399; Nagai H, 1997, GENES CELLS, V2, P725, DOI 10.1046/j.1365-2443.1997.1600357.x; Owens JT, 1998, P NATL ACAD SCI USA, V95, P6021, DOI 10.1073/pnas.95.11.6021; RIDLEY SP, 1982, J BACTERIOL, V152, P736; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Sharp MM, 1999, GENE DEV, V13, P3015, DOI 10.1101/gad.13.22.3015; SHULER MF, 1995, J BACTERIOL, V177, P3687, DOI 10.1128/jb.177.13.3687-3694.1995; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; THOMPSON NE, 1992, BIOCHEMISTRY-US, V31, P7003, DOI 10.1021/bi00145a019; Traviglia SL, 1999, BIOCHEMISTRY-US, V38, P15774, DOI 10.1021/bi9917232; WALDBURGER C, 1990, J MOL BIOL, V215, P267, DOI 10.1016/S0022-2836(05)80345-6; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; WEILBAECHER R, 1994, GENE DEV, V8, P2913, DOI 10.1101/gad.8.23.2913; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	44	63	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23113	23119		10.1074/jbc.M002040200	http://dx.doi.org/10.1074/jbc.M002040200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10764785	hybrid			2022-12-27	WOS:000088419400069
J	Jensen, PH; Islam, K; Kenney, J; Nielsen, MS; Power, J; Gai, WP				Jensen, PH; Islam, K; Kenney, J; Nielsen, MS; Power, J; Gai, WP			Microtubule-associated protein 1B is a component of cortical Lewy bodies and binds alpha-synuclein filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPORADIC PARKINSONS-DISEASE; MULTIPLE SYSTEM ATROPHY; A-BETA COMPONENT; NERVOUS-SYSTEM; HUMAN BRAIN; DEMENTIA; PHOSPHORYLATION; INCLUSIONS; MUTATION; MAP1B	Lewy bodies, neuropathological hallmarks of Parkinson's disease and dementia with Lewy bodies, comprise alpha-synuclein filaments and other less defined proteins. Characterization of Lewy body proteins that interact with alpha-synuclein may provide insight into the mechanism of Lewy body formation. Double immunofluorescence labeling and confocal microscopy revealed approximately 80% of cortical Lewy bodies contained microtubule-associated protein 1B (MAP-1B) that overlapped with alpha-synuclein. Lewy bodies were isolated using an immunomagnetic technique from brain tissue of patients dying with dementia with Lewy bodies. Lewy body proteins were resolved by polyacrylamide gel electrophoresis. Immunoblotting confirmed the presence of MAP-1B and alpha-synuclein in purified Lewy bodies. Direct binding studies revealed a high affinity interaction (IC,, similar to 20 nM) between MAP-1B and alpha-synuclein. The MAP-1B-binding sites were mapped to the last 45 amino acids of the alpha-synuclein C terminus. MAP-1B also bound in vitro assembled alpha-synuclein fibrils. Thus, MAP-1B may be involved in the pathogenesis of Lewy bodies via its interaction with monomeric and fibrillar alpha-synuclein.	Aarhus Univ, Dept Biochem Med, DK-8000 Aarhus C, Denmark; Arpida AG, CH-4142 Munchenstein, Switzerland; Univ Aarhus, Inst Storage Ring Facil, DK-8000 Aarhus C, Denmark; Flinders Univ S Australia, Dept Human Physiol, Bedford Pk, SA 5042, Australia; Flinders Univ S Australia, Ctr Neurosci, Bedford Pk, SA 5042, Australia	Aarhus University; Aarhus University; Flinders University South Australia; Flinders University South Australia	Jensen, PH (corresponding author), Aarhus Univ, Dept Biochem Med, Bldg 170, DK-8000 Aarhus C, Denmark.		Nielsen, Morten Schallburg/G-9498-2016; Gai, Wei-Ping/A-3700-2008	Nielsen, Morten Schallburg/0000-0001-9863-9694; Jensen, Poul Henning/0000-0002-4439-9020				Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Arima K, 1999, BRAIN RES, V843, P53, DOI 10.1016/S0006-8993(99)01848-X; AVILA J, 1994, INT J DEV BIOL, V38, P13; Baba M, 1998, AM J PATHOL, V152, P879; Braak H, 1999, NEUROSCI LETT, V265, P67, DOI 10.1016/S0304-3940(99)00208-6; Burg MA, 1997, J MOL NEUROSCI, V9, P177, DOI 10.1007/BF02800500; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Crowther RA, 1998, FEBS LETT, V436, P309, DOI 10.1016/S0014-5793(98)01146-6; Culvenor JG, 1999, AM J PATHOL, V155, P1173, DOI 10.1016/S0002-9440(10)65220-0; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; Gai WP, 1996, ACTA NEUROPATHOL, V91, P78; Gai WP, 1999, J NEUROCHEM, V73, P2093; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Jensen PH, 1999, EUR J NEUROSCI, V11, P3369, DOI 10.1046/j.1460-9568.1999.00754.x; Jensen PH, 1997, BIOCHEM J, V323, P539, DOI 10.1042/bj3230539; Jensen PH, 1999, J BIOL CHEM, V274, P25481, DOI 10.1074/jbc.274.36.25481; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; McKeith IG, 1999, NEUROLOGY, V53, P902, DOI 10.1212/WNL.53.5.902; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Ohyu J, 1997, BRAIN DEV-JPN, V19, P541, DOI 10.1016/S0387-7604(97)00075-2; PEDROTTI B, 1995, CELL MOTIL CYTOSKEL, V30, P301, DOI 10.1002/cm.970300407; Pedrotti B, 1996, BIOCHEMISTRY-US, V35, P3016, DOI 10.1021/bi951314f; POLLANEN MS, 1993, J NEUROPATH EXP NEUR, V52, P183, DOI 10.1097/00005072-199305000-00001; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Sian J, 1998, ACTA NEUROPATHOL, V96, P111, DOI 10.1007/s004010050869; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; VIERECK C, 1989, J NEUROSCI, V9, P3547	35	119	125	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21500	21507		10.1074/jbc.M000099200	http://dx.doi.org/10.1074/jbc.M000099200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10764738	hybrid			2022-12-27	WOS:000088230600073
J	Miele, C; Rochford, JJ; Filippa, N; Giorgetti-Peraldi, S; Van Obberghen, E				Miele, C; Rochford, JJ; Filippa, N; Giorgetti-Peraldi, S; Van Obberghen, E			Insulin and insulin-like growth factor-I induce vascular endothelial growth factor mRNA expression via different signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; FACTOR GENE-EXPRESSION; SMOOTH-MUSCLE CELLS; TRANSCRIPTIONAL REGULATION; DIABETIC-RETINOPATHY; FACTOR FAMILY; HA-RAS; RECEPTOR; HYPOXIA; ANGIOGENESIS	In this study we have investigated the molecular mechanisms of insulin and insulin-like growth factor-I (IGF-I) action on vascular endothelial growth factor (VEGF) gene expression. Treatment with insulin or IGF-I for 4 h increased the abundance of VEGF mRNA in NIH3T3 fibroblasts expressing either the human insulin receptor (NIH-IR) or the human IGF-I receptor (NIH-IGFR) by 6- and 8-fold, respectively. The same elevated levels of mRNA were maintained after 24 h of stimulation with insulin, whereas IGF-I treatment further increased VEGF mRNA expression to 12-fold after 24 h. Pre-incubation with the phosphatidylinositol 3-kinase inhibitor wortmannin abolished the effect of insulin on VEGF mRNA expression in NIH-IR cells but did not modify the IGF-I-induced VEGF mRNA expression in NIH-IGFR cells. Blocking mitogen-activated protein kinase activation with the MEK inhibitor PD98059 abolished the effect of IGF-I on VEGF mRNA expression in NIH-IGFR cells but had no effect on insulin-induced VEGF mRNA expression in NIH-IR cells. Expression of a constitutively active PKB in NIH-IR cells induced the expression of VEGF mRNA, which was not further modified by insulin treatment. We conclude that VEGF induction by insulin and IGF-I occurs via different signaling pathways, the former involving phosphatidylinositol 3-kinase/protein kinase B and the latter involving MEK/mitogen-activated protein kinase.	Fac Med Nice, INSERM, U145, F-06107 Nice 2, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Miele, C (corresponding author), Fac Med Nice, INSERM, U145, IFR50, F-06107 Nice 2, France.			Giorgetti-Peraldi, Sophie/0000-0002-2751-2618; Rochford, Justin/0000-0002-5020-4939				Aiello LP, 1998, DIABETES CARE, V21, P143, DOI 10.2337/diacare.21.1.143; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; BARBIERI B, 1981, P SOC EXP BIOL MED, V168, P204; Barthel A, 1999, J BIOL CHEM, V274, P20281, DOI 10.1074/jbc.274.29.20281; BASERGA R, 1995, CANCER RES, V55, P249; Blakesley Vicky A., 1996, Cytokine and Growth Factor Reviews, V7, P153, DOI 10.1016/1359-6101(96)00015-9; BROGI E, 1994, CIRCULATION, V90, P649, DOI 10.1161/01.CIR.90.2.649; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; Filippa N, 1999, MOL CELL BIOL, V19, P4989; FINKENZELLER G, 1992, CANCER RES, V52, P4821; Firestein GS, 1999, J CLIN INVEST, V103, P3, DOI 10.1172/JCI5929; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Folkman J, 1992, Semin Cancer Biol, V3, P65; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Frasca F, 1999, MOL CELL BIOL, V19, P3278, DOI 10.1128/mcb.19.5.3278; Frittitta L, 1999, CANCER-AM CANCER SOC, V85, P492, DOI 10.1002/(SICI)1097-0142(19990115)85:2<492::AID-CNCR30>3.0.CO;2-I; Goad DL, 1996, ENDOCRINOLOGY, V137, P2262, DOI 10.1210/en.137.6.2262; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Haller H, 1996, CLIN NEPHROL, V46, P246; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; King GL, 1996, ANN MED, V28, P427, DOI 10.3109/07853899608999103; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; LAMPHERE L, 1992, ENDOCRINOLOGY, V131, P2196, DOI 10.1210/en.131.5.2196; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; MASTICK CC, 1994, ENDOCRINOLOGY, V135, P214, DOI 10.1210/en.135.1.214; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Miller JW, 1997, DIABETES METAB REV, V13, P37, DOI 10.1002/(SICI)1099-0895(199703)13:1<37::AID-DMR174>3.0.CO;2-K; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Nakae J, 2000, EMBO J, V19, P989, DOI 10.1093/emboj/19.5.989; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Pandini G, 1999, CLIN CANCER RES, V5, P1935; PFEIFFER A, 1997, DIABETES S2, V46, P26; Punglia RS, 1997, DIABETES, V46, P1619, DOI 10.2337/diabetes.46.10.1619; Rak J, 2000, CANCER RES, V60, P490; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; SANCHEZMARGALET V, 1994, BIOCHEM BIOPH RES CO, V204, P446, DOI 10.1006/bbrc.1994.2480; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; TARTARE S, 1994, J BIOL CHEM, V269, P11449; TAYLOR R, 1991, CLIN ENDOCRINOL, V34, P159, DOI 10.1111/j.1365-2265.1991.tb00287.x; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; TISCHER E, 1991, J BIOL CHEM, V266, P11947; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Urso B, 1999, J BIOL CHEM, V274, P30864, DOI 10.1074/jbc.274.43.30864; Warren RS, 1996, J BIOL CHEM, V271, P29483, DOI 10.1074/jbc.271.46.29483; Yamagishi S, 1999, MICROVASC RES, V57, P329, DOI 10.1006/mvre.1999.2145; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	67	173	185	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21695	21702		10.1074/jbc.M000805200	http://dx.doi.org/10.1074/jbc.M000805200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10777488	hybrid			2022-12-27	WOS:000088230600097
J	Iannello, RC; Gould, JA; Young, JC; Giudice, A; Medcalf, R; Kola, I				Iannello, RC; Gould, JA; Young, JC; Giudice, A; Medcalf, R; Kola, I			Methylation-dependent silencing of the testis-specific Pdha-2 basal promoter occurs through selective targeting of an activating transcription factor/cAMP-responsive element-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLATION; REPRESS TRANSCRIPTION; PROXIMAL PROMOTER; CPG METHYLATION; GENE-EXPRESSION; MOUSE; SPERMATOGENESIS; SUBUNIT	In this study, we demonstrate that methylation-dependent repression of the Pdha-2 core promoter is mediated regionally through a consensus activating transcription factor/cAMP-responsive element-binding site located between nucleotides -54 and -62 upstream of the major transcriptional start site. Targeting of the CpG dinucleotide within this cis-element significantly disrupts the ability of this basal promoter to activate gene expression in vitro and completely abolishes promoter activity in vivo, DNase I footprinting experiments indicated that availability of the nuclear factor(s) binding this element is limiting in sexually immature mouse testis, and as such, these factors may play an important role in the coordinate activation of early spermatogenic gene expression. Interestingly, CpG dinucleotides associated with the hypersensitive region flanking the activating transcription factor/cAMP-responsive element-binding site appear to confer some conformational structure on the promoter since mutations at these specific CpG dinucleotides result in elevated basal levels of transcription. This raises the possibility of a potential bifunctional role for CpG dinucleotides in either methylation-dependent or -independent processes. Our data support the notion that hypomethylation and transcription factor recruitment are necessary events that precede gene activation at the early stages of spermatogenesis.	Monash Med Ctr, Monash Inst Reprod & Dev, Ctr Funct Genom & Human Dis, Clayton, Vic 3168, Australia; Box Hill Hosp, Dept Med, Box Hill, Vic 3128, Australia	Monash University; Box Hill Hospital	Iannello, RC (corresponding author), Monash Med Ctr, Monash Inst Reprod & Dev, Ctr Funct Genom & Human Dis, 246 Clayton Rd, Clayton, Vic 3168, Australia.		Kola, Ismail/C-5254-2013; Young, Julia/A-7219-2013; Medcalf, Robert L/E-9632-2011	Young, Julia/0000-0001-7219-7824				ARIEL M, 1994, NAT GENET, V7, P59, DOI 10.1038/ng0594-59; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOGAN B, 1986, MANIPULATING MOUSE E; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; Iannello R C, 1995, Methods Mol Biol, V37, P379; IANNELLO RC, 1993, J BIOL CHEM, V268, P22581; IANNELLO RC, 1992, BIOL REPROD, V47, P48, DOI 10.1095/biolreprod47.1.48; Iannello RC, 1997, MOL CELL BIOL, V17, P612, DOI 10.1128/MCB.17.2.612; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; JacksonGrusby L, 1996, SEMIN CANCER BIOL, V7, P261, DOI 10.1006/scbi.1996.0034; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; Kramer JA, 1998, DEVELOPMENT, V125, P4749; MayerJung C, 1997, J MOL BIOL, V270, P328, DOI 10.1006/jmbi.1997.1137; SIEGFRIED Z, 1997, CURR BIOL, V7, P305; Steger K, 1999, ANAT EMBRYOL, V199, P471, DOI 10.1007/s004290050245; TAKAKUBO F, 1992, EXP CELL RES, V199, P39, DOI 10.1016/0014-4827(92)90459-L; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Zhang LP, 1998, BIOL REPROD, V59, P284, DOI 10.1095/biolreprod59.2.284	20	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19603	19608		10.1074/jbc.M001867200	http://dx.doi.org/10.1074/jbc.M001867200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10766751	hybrid			2022-12-27	WOS:000087941300024
J	Ohba, Y; Mochizuki, N; Yamashita, S; Chan, AM; Schrader, JW; Hattori, S; Nagashima, K; Matsuda, M				Ohba, Y; Mochizuki, N; Yamashita, S; Chan, AM; Schrader, JW; Hattori, S; Nagashima, K; Matsuda, M			Regulatory proteins of R-Ras, TC21/R-Ras2, and M-Ras/R-Ras3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-EXCHANGE; GTPASE-ACTIVATING PROTEIN; SIGNALING PATHWAYS; MOLECULAR-CLONING; BINDING PROTEINS; GENE-PRODUCT; CELL-LINE; RAP1; TC21; EXPRESSION	We studied the regulation of three closely related members of Pas family G proteins, R-Ras, TC21 (also known as R-Ras2), and M-Ras (R-Ras3). Guanine nucleotide exchange of R-Ras and TC21 was promoted by RasGRF, C3G, CalDAG-GEFI, CalDAG-GEFII (RasGRP), and CalDAG-GEFIII both in 293T cells and in vitro. By contrast, guanine nucleotide exchange of M-Ras was promoted by the guanine nucleotide exchange factors (GEFs) for the classical Pas (Ha-, K-, and N-), including mSos, RasGRF, CalDAG-GEFII, and CalDAG-GEFIII. GTPase-activating proteins (GAPs) for Pas, Gap1(m), p120 GAP, and NF-1 stimulated all of the R-Ras, TC21, and M-Ras proteins, whereas R-Ras GAP stimulated R-Ras and TC21 but not M-Ras. We did not find any remarkable difference in the subcellular localization of R-Ras, TC21, or M-Ras when these were expressed with a green fluorescent protein tag in 293T cells and MDCK cells. In conclusion, TC21 and R-Ras were regulated by the same GEFs and GAPs, whereas M-Ras was regulated as the classical Ras.	Int Med Ctr Japan, Res Inst, Dept Pathol, Shinjuku Ku, Tokyo 1828655, Japan; Hokkaido Univ, Sch Med, Lab Mol & Cellular Pathol, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Div Biochem & Cellular Biol, Tokyo 1878502, Japan; CUNY Mt Sinai Sch Med, Dernald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada	National Center for Global Health & Medicine - Japan; Hokkaido University; National Center for Neurology & Psychiatry - Japan; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of British Columbia	Matsuda, M (corresponding author), Int Med Ctr Japan, Res Inst, Dept Pathol, Shinjuku Ku, 1-21-1 Toyama, Tokyo 1828655, Japan.		Chan, Andrew Man-Lok/J-9497-2013; Chan, Andrew/AAC-1145-2020; Ohba, Yusuke/E-7944-2011	Chan, Andrew Man-Lok/0000-0001-9923-5464; Chan, Andrew/0000-0001-9923-5464; Matsuda, Michiyuki/0000-0002-5876-9969				Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Bos JL, 1997, BBA-REV CANCER, V1333, pM19, DOI 10.1016/S0304-419X(97)00015-2; Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Clark GJ, 1996, ONCOGENE, V12, P169; COX AD, 1994, ONCOGENE, V9, P3281; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; de Rooij J, 1999, J BIOL CHEM, V274, P38125, DOI 10.1074/jbc.274.53.38125; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Ehrhardt GRA, 1999, BLOOD, V94, P2433, DOI 10.1182/blood.V94.7.2433.419k31_2433_2444; EMKEY R, 1991, J BIOL CHEM, V266, P9703; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; Graham SM, 1996, MOL CELL BIOL, V16, P6132; Graham SM, 1999, ONCOGENE, V18, P2107, DOI 10.1038/sj.onc.1202517; HATTORI S, 1992, ONCOGENE, V7, P481; HUANG Y, 1995, ONCOGENE, V11, P1255; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; Ichiba T, 1999, FEBS LETT, V457, P85, DOI 10.1016/S0014-5793(99)01012-1; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; Kozian DH, 1997, FEBS LETT, V414, P239, DOI 10.1016/S0014-5793(97)01038-7; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; Liao YH, 1999, J BIOL CHEM, V274, P37815, DOI 10.1074/jbc.274.53.37815; Louahed J, 1999, BLOOD, V94, P1701, DOI 10.1182/blood.V94.5.1701.417k29_1701_1710; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; Matsumoto K, 1997, ONCOGENE, V15, P2409, DOI 10.1038/sj.onc.1201416; Movilla N, 1999, ONCOGENE, V18, P5860, DOI 10.1038/sj.onc.1202968; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ohtsuka T, 1999, BIOCHEM BIOPH RES CO, V265, P38, DOI 10.1006/bbrc.1999.1619; Quilliam LA, 1999, J BIOL CHEM, V274, P23850, DOI 10.1074/jbc.274.34.23850; REY I, 1994, ONCOGENE, V9, P685; Rosario M, 1999, EMBO J, V18, P1270, DOI 10.1093/emboj/18.5.1270; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; Suzuki J, 1997, ONCOGENE, V15, P1689, DOI 10.1038/sj.onc.1201333; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tognon CE, 1998, MOL CELL BIOL, V18, P6995, DOI 10.1128/MCB.18.12.6995; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; van den Berghe N, 1999, J BIOL CHEM, V274, P11078, DOI 10.1074/jbc.274.16.11078; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; Yamamoto T, 1995, J BIOL CHEM, V270, P30557, DOI 10.1074/jbc.270.51.30557; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zwartkruis FJT, 1999, EXP CELL RES, V253, P157, DOI 10.1006/excr.1999.4695	48	119	124	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					20020	20026		10.1074/jbc.M000981200	http://dx.doi.org/10.1074/jbc.M000981200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10777492	hybrid			2022-12-27	WOS:000087941300080
J	Byrd, JC; Park, JHY; Schaffer, BS; Garmroudi, F; MacDonald, RG				Byrd, JC; Park, JHY; Schaffer, BS; Garmroudi, F; MacDonald, RG			Dimerization of the insulin-like growth factor II/mannose 6-phosphate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II RECEPTOR; MANNOSE 6-PHOSPHATE; LIGAND-BINDING; IGF-II; CONFORMATIONAL-CHANGES; QUATERNARY STRUCTURE; UROKINASE RECEPTOR; CRYSTAL-STRUCTURE; TYROSINE KINASE; ACTIVATION	The insulin-like growth factor II/mannose 6-phosphate receptor (IGF2R) interacts with lysosomal enzymes through two binding domains in its extracytoplasmic domain. We report in the accompanying article (Byrd, J. C., and MacDonald, R. G. (2000) J. Biol. Chem. 275, 18638-18646) that only one of the two extracytoplasmic mannose 6-phosphate (Man-6-P) binding domains is necessary for high affinity Man-6-P ligand binding, suggesting that, like the cation-dependent Man-6-P receptor, oligomerization of the IGF2R contributes to high affinity interaction with lysosomal enzymes. In the present study, we have directly characterized both naturally occurring and engineered forms of the IGF2R for their ability to form oligomeric structures. Whereas gel filtration chromatography suggested that purified bovine IGF2R species exist in a monomeric form, native gel electrophoresis allowed for the separation of dimeric and monomeric forms of the receptors with distinct phosphomannosyl ligand binding characteristics. The ability of the IGF2R to form oligomeric complexes was confirmed and localized to the extracytoplasmic domain through the use of epitope-tagged soluble IGF2R constructs bearing deletions of the transmembrane and cytoplasmic domains. Finally, chimeric receptors were engineered containing the extracytoplasmic and transmembrane domains of the IGF2R fused to the cytoplasmic domain of the epidermal growth factor receptor with which dimerization of the chimeras could be monitored by measuring autophosphorylation. Collectively, these results show that the IGF2R is capable of forming oligomeric complexes, most likely dimers, in the absence of Man-6-P ligands.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Hallym Univ, Div Life Sci, Chunchon 200702, South Korea	University of Nebraska System; University of Nebraska Medical Center; Hallym University	MacDonald, RG (corresponding author), 984525 Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.				NCI NIH HHS [CA36727] Funding Source: Medline; NIDDK NIH HHS [DK44212] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA036727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044212] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AULETTA M, 1992, J NEUROSCI RES, V31, P14, DOI 10.1002/jnr.490310103; BARON V, 1992, J BIOL CHEM, V267, P23290; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; Byrd JC, 2000, J BIOL CHEM, V275, P18638, DOI 10.1074/jbc.M000010200; Byrd JC, 1999, J BIOL CHEM, V274, P24408, DOI 10.1074/jbc.274.34.24408; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; DEMEYTS P, 1994, DIABETOLOGIA, V37, pS135, DOI 10.1007/BF00400837; DINTZIS SM, 1994, J BIOL CHEM, V269, P12159; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Garmroudi F, 1996, MOL ENDOCRINOL, V10, P642, DOI 10.1210/me.10.6.642; GELATO MC, 1988, J CLIN ENDOCR METAB, V67, P669, DOI 10.1210/jcem-67-4-669; Gleizes PE, 1997, STEM CELLS, V15, P190, DOI 10.1002/stem.150190; Godar S, 1999, EUR J IMMUNOL, V29, P1004, DOI 10.1002/(SICI)1521-4141(199903)29:03<1004::AID-IMMU1004>3.0.CO;2-Q; HOFLACK B, 1985, J BIOL CHEM, V260, P2008; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Joneson T, 1998, J BIOL CHEM, V273, P7743, DOI 10.1074/jbc.273.13.7743; KIESS W, 1987, P NATL ACAD SCI USA, V84, P7720, DOI 10.1073/pnas.84.21.7720; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUEHN L, 1980, FEBS LETT, V113, P189, DOI 10.1016/0014-5793(80)80588-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee J, 1997, BIOCHEMISTRY-US, V36, P2701, DOI 10.1021/bi961815g; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; LOBEL P, 1988, J BIOL CHEM, V263, P2563; Luo RZT, 1999, SCIENCE, V285, P1077, DOI 10.1126/science.285.5430.1077; MA ZM, 1992, J BIOL CHEM, V267, P19017; MACDONALD RG, 1989, J BIOL CHEM, V264, P3256; MACDONALD RG, 1991, ENDOCRINOLOGY, V128, P413, DOI 10.1210/endo-128-1-413; Marron-Terada PG, 1998, BIOCHEMISTRY-US, V37, P17223, DOI 10.1021/bi981883y; Marron-Terada PG, 1998, J BIOL CHEM, V273, P22358, DOI 10.1074/jbc.273.35.22358; Meng TC, 1998, J BIOL CHEM, V273, P22096, DOI 10.1074/jbc.273.34.22096; NIELSEN FC, 1991, J NEUROCHEM, V56, P12, DOI 10.1111/j.1471-4159.1991.tb02556.x; Nykjaer A, 1998, J CELL BIOL, V141, P815, DOI 10.1083/jcb.141.3.815; OKA Y, 1986, J BIOL CHEM, V261, P9090; OKA Y, 1985, J BIOL CHEM, V260, P9435; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; PERDUE JF, 1983, J BIOL CHEM, V258, P7800; Punnonen EL, 1996, EUR J BIOCHEM, V237, P809, DOI 10.1111/j.1432-1033.1996.0809p.x; Roberts DL, 1998, CELL, V93, P639, DOI 10.1016/S0092-8674(00)81192-7; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; STEIN M, 1987, BIOL CHEM H-S, V368, P927, DOI 10.1515/bchm3.1987.368.2.927; STEIN M, 1987, BIOL CHEM H-S, V368, P937, DOI 10.1515/bchm3.1987.368.2.937; SWEET LJ, 1987, J BIOL CHEM, V262, P6939; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VALENZANO KJ, 1993, ANAL BIOCHEM, V209, P156, DOI 10.1006/abio.1993.1096; WAHEED A, 1990, BIOCHEMISTRY-US, V29, P2449, DOI 10.1021/bi00462a003; WENDLAND M, 1989, BIOCHEM J, V260, P201, DOI 10.1042/bj2600201; WESTLUND B, 1991, J BIOL CHEM, V266, P23233; York SJ, 1999, J BIOL CHEM, V274, P1164, DOI 10.1074/jbc.274.2.1164	54	49	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18647	18656		10.1074/jbc.M001273200	http://dx.doi.org/10.1074/jbc.M001273200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10764761	hybrid			2022-12-27	WOS:000087815900006
J	Endo, K; Oki, E; Biedermann, V; Kojima, H; Yoshida, K; Johannes, FJ; Kufe, D; Datta, R				Endo, K; Oki, E; Biedermann, V; Kojima, H; Yoshida, K; Johannes, FJ; Kufe, D; Datta, R			Proteolytic cleavage and activation of protein kinase C mu by caspase-3 in the apoptotic response of cells to 1-beta-D-arabinofuranosylcytosine and other genotoxic agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNUCLEOSOMAL DNA FRAGMENTATION; LEUKEMIA-CELLS; CYTOCHROME-C; PKC-MU; INDUCTION; FAMILY; DOMAIN; DIACYLGLYCEROL; INVOLVEMENT; INHIBITION	Protein kinase C (PKC) mu is a novel member of the PKC family that differs from the other isozymes in structural and biochemical properties, The precise function of PKC mu is not known. The present studies demonstrate that PKC mu is cleaved during apoptosis induced by 1-beta-D-arabinofuranosylcytosine (ara C) and other genotoxic agents, PKC mu cleavage is blocked in cells that overexpress the anti-apoptotic Bcl-x(L) protein or the baculovirus p35 protein, Our results demonstrate that PKC mu is cleaved by caspase-3 at the CQND(378)S site. Cleavage of PKC mu is associated with release of the catalytic domain and activation of its kinase function. We also show that, unlike the cleaved fragments of PKC delta and theta, overexpression of the PKC mu catalytic domain is not lethal. Cells stably expressing the catalytic fragment of PKC mu, however, are more sensitive to apoptosis induced by genotoxic stress. In addition, expression of the caspase-resistant PKC mu mutant partially inhibits DNA damage-induced apoptosis, These findings demonstrate that PKC mu is cleaved by caspase-3 and that expression of the catalytic domain sensitizes cells to the cytotoxic effects of ara-C and other anticancer agents.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Univ Stuttgart, Inst Cell Biol & Immunol, D-7000 Stuttgart, Germany	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Stuttgart	Datta, R (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.	rakesh_datta@dfci.harvard.edu			NCI NIH HHS [CA29431] Funding Source: Medline; NIGMS NIH HHS [GM58200] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029431] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058200] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; DATTA R, 1995, CELL GROWTH DIFFER, V6, P363; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; Deacon EM, 1997, J CLIN PATHOL-MOL PA, V50, P124, DOI 10.1136/mp.50.3.124; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Dieterich S, 1996, FEBS LETT, V381, P183, DOI 10.1016/0014-5793(96)00116-0; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FRAM RJ, 1982, CANCER RES, V42, P4050; Frutos S, 1999, J BIOL CHEM, V274, P10765, DOI 10.1074/jbc.274.16.10765; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GUNJI H, 1991, CANCER RES, V51, P741; HALL EJ, 1988, AM J CLIN ONCOL-CANC, V11, P220, DOI 10.1097/00000421-198806000-00003; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; Hayashi A, 1999, BBA-MOL CELL RES, V1450, P99, DOI 10.1016/S0167-4889(99)00040-3; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6; JOHANNES FJ, 1995, EUR J BIOCHEM, V227, P303, DOI 10.1111/j.1432-1033.1995.tb20389.x; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johannes FJ, 1998, EUR J BIOCHEM, V257, P47, DOI 10.1046/j.1432-1327.1998.2570047.x; KAUFMANN SH, 1989, CANCER RES, V49, P5870; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; KISHIMOTO A, 1990, ADV SEC MESS PHOSPH, V24, P472; KUFE DW, 1980, J BIOL CHEM, V255, P8997; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIU LF, 1983, J BIOL CHEM, V258, P5365; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nishikawa K, 1998, J BIOL CHEM, V273, P23126, DOI 10.1074/jbc.273.36.23126; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Samejima K, 1999, J BIOL CHEM, V274, P4335, DOI 10.1074/jbc.274.7.4335; SHERMAN SE, 1987, CHEM REV, V87, P1153, DOI 10.1021/cr00081a013; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455	41	93	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18476	18481		10.1074/jbc.M002266200	http://dx.doi.org/10.1074/jbc.M002266200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10764790	hybrid			2022-12-27	WOS:000087659400077
J	Askjaer, P; Rosendahl, R; Kjems, K				Askjaer, P; Rosendahl, R; Kjems, K			Nuclear export of the DEAD box An3 protein by CRM1 is coupled to An3 helicase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT RNA HELICASE; VIRUS NS3 PROTEIN; INITIATION-FACTOR EIF-4A; TRANSLATION INITIATION; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; NUCLEOSIDE TRIPHOSPHATASE; MUTATIONAL ANALYSIS; CRYSTAL-STRUCTURE; KINETIC-ANALYSIS	We have recently identified the Xenopus laevis An3 protein as a bona fide substrate for the nuclear export receptor CRM1 (Exportin 1). An3 binds directly to CRM1 with high affinity via a leucine-rich nuclear export signal located in the extreme N terminus. An3 is a member of the DEAD box family of RNA helicases, which unwind RNA duplexes. RNA unwinding is coupled to hydrolysis of nucleoside triphosphates by the helicase, and the ATPase activity of several helicases is greatly stimulated by various polynucleotides. Here we report that dATP hydrolysis by An3 is stimulated similar to 6-fold by total RNA from X. laevis oocytes, whereas poly(U) RNA fails to enhance hydrolysis, suggesting the existence of a specific RNA activator for An3, Kinetic analysis reveals that a mutation within the conserved DEAD box motif reduces the rate of dATP hydrolysis by similar to 6-fold. In accordance with this, the DEAD box mutant is unable to unwind double-stranded RNA. Microinjection of the An3 DEAD box mutant into X, laevis oocytes nuclei reveals a significantly lower export rate as compared with wildtype An3 protein. This is not because the mutant has lower affinity toward CRM1, nor is it due to altered RNA binding capacity. This suggests that nuclear export of An3 protein by CRM1 is coupled to An3 helicase activity.	Aarhus Univ, Dept Biol Mol & Struct, DK-8000 Aarhus C, Denmark	Aarhus University	Kjems, K (corresponding author), Aarhus Univ, Dept Biol Mol & Struct, CF Mollers Alle,Bldg 130, DK-8000 Aarhus C, Denmark.		Askjaer, Peter/I-3316-2012; Kjems, Jorgen/I-3490-2016	Askjaer, Peter/0000-0003-3192-4428; Kjems, Jorgen/0000-0003-4128-9317				Askjaer P, 1998, J BIOL CHEM, V273, P33414, DOI 10.1074/jbc.273.50.33414; Askjaer P, 1999, MOL CELL BIOL, V19, P6276; Benz J, 1999, STRUCTURE, V7, P671, DOI 10.1016/S0969-2126(99)80088-4; Boddeker N, 1997, NUCLEIC ACIDS RES, V25, P537, DOI 10.1093/nar/25.3.537; Chuang RY, 1997, SCIENCE, V275, P1468, DOI 10.1126/science.275.5305.1468; de la Cruz J, 1999, TRENDS BIOCHEM SCI, V24, P192, DOI 10.1016/S0968-0004(99)01376-6; FLORESROZAS H, 1993, J BIOL CHEM, V268, P21372; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fuller-Pace Frances V., 1994, Trends in Cell Biology, V4, P271, DOI 10.1016/0962-8924(94)90210-0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Gross CH, 1998, J VIROL, V72, P4729, DOI 10.1128/JVI.72.6.4729-4736.1998; GROSS CH, 1995, J VIROL, V69, P4727, DOI 10.1128/JVI.69.8.4727-4736.1995; GURURAJAN R, 1994, P NATL ACAD SCI USA, V91, P2056, DOI 10.1073/pnas.91.6.2056; GURURAJAN R, 1991, NATURE, V349, P717, DOI 10.1038/349717a0; Heilek GM, 1997, J VIROL, V71, P6264, DOI 10.1128/JVI.71.8.6264-6266.1997; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; Hodge CA, 1999, EMBO J, V18, P5778, DOI 10.1093/emboj/18.20.5778; Iost I, 1999, J BIOL CHEM, V274, P17677, DOI 10.1074/jbc.274.25.17677; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; JAMIESON DJ, 1991, NATURE, V349, P715, DOI 10.1038/349715a0; JAMIESON DJ, 1991, MOL MICROBIOL, V5, P805, DOI 10.1111/j.1365-2958.1991.tb00753.x; JENSEN TH, 1995, GENE, V162, P235, DOI 10.1016/0378-1119(95)00328-4; Jones PG, 1996, P NATL ACAD SCI USA, V93, P76, DOI 10.1073/pnas.93.1.76; Kim DW, 1997, J VIROL, V71, P9400, DOI 10.1128/JVI.71.12.9400-9409.1997; KIM DW, 1995, BIOCHEM BIOPH RES CO, V215, P160, DOI 10.1006/bbrc.1995.2447; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Lahn BT, 1997, SCIENCE, V278, P675, DOI 10.1126/science.278.5338.675; Lee CG, 1997, EMBO J, V16, P2671, DOI 10.1093/emboj/16.10.2671; LEE CG, 1992, J BIOL CHEM, V267, P4398; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; Li JZ, 1999, P NATL ACAD SCI USA, V96, P709, DOI 10.1073/pnas.96.2.709; LIANG L, 1994, DEVELOPMENT, V120, P1201; Longo FJ, 1996, MOL REPROD DEV, V45, P491, DOI 10.1002/(SICI)1098-2795(199612)45:4<491::AID-MRD12>3.0.CO;2-#; Lorsch JR, 1998, BIOCHEMISTRY-US, V37, P2180, DOI 10.1021/bi972430g; Mamiya N, 1999, J BIOL CHEM, V274, P15751, DOI 10.1074/jbc.274.22.15751; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; ODay CL, 1996, J BIOL CHEM, V271, P33261, DOI 10.1074/jbc.271.52.33261; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Olsen LC, 1997, MECH DEVELOP, V66, P95, DOI 10.1016/S0925-4773(97)00099-3; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; Preugschat F, 1996, J BIOL CHEM, V271, P24449, DOI 10.1074/jbc.271.40.24449; Raghunathan PL, 1998, CURR BIOL, V8, P847, DOI 10.1016/S0960-9822(07)00345-4; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; Rogers GW, 1999, J BIOL CHEM, V274, P12236, DOI 10.1074/jbc.274.18.12236; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Schmitt C, 1999, EMBO J, V18, P4332, DOI 10.1093/emboj/18.15.4332; SCHWER B, 1992, MOL CELL BIOL, V12, P3540, DOI 10.1128/MCB.12.8.3540; Schwer B, 1998, EMBO J, V17, P2086, DOI 10.1093/emboj/17.7.2086; Snay-Hodge CA, 1998, EMBO J, V17, P2663, DOI 10.1093/emboj/17.9.2663; SOWDEN J, 1995, BIOCHEM J, V308, P839, DOI 10.1042/bj3080839; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; SUZICH JA, 1993, J VIROL, V67, P6152, DOI 10.1128/JVI.67.10.6152-6158.1993; Tang H, 1999, MOL CELL BIOL, V19, P3540; Tang HL, 1997, SCIENCE, V276, P1412, DOI 10.1126/science.276.5317.1412; Tseng SSL, 1998, EMBO J, V17, P2651, DOI 10.1093/emboj/17.9.2651; Tsu CA, 1998, BIOCHEMISTRY-US, V37, P16989, DOI 10.1021/bi981837y; Wagner JDO, 1998, EMBO J, V17, P2926, DOI 10.1093/emboj/17.10.2926; Wang Y, 1998, CURR BIOL, V8, P441, DOI 10.1016/S0960-9822(98)70178-2; WARRENER P, 1995, J VIROL, V69, P1720, DOI 10.1128/JVI.69.3.1720-1726.1995; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999	64	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11561	11568		10.1074/jbc.275.16.11561	http://dx.doi.org/10.1074/jbc.275.16.11561			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766770	hybrid			2022-12-27	WOS:000086695500005
J	Banzai, Y; Miki, H; Yamaguchi, H; Takenawa, T				Banzai, Y; Miki, H; Yamaguchi, H; Takenawa, T			Essential role of neural Wiskott-Aldrich syndrome protein in neurite extension in PC12 cells and rat hippocampal primary culture cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-DEPOLYMERIZING PROTEIN; N-WASP; ARP2/3 COMPLEX; DIRECT BINDING; GROWTH-FACTOR; IDENTIFICATION; GTPASES; CDC42HS; RHO; THROMBOCYTOPENIA	Neural Wiskott-Aldrich syndrome protein (N-WASP) is an actin-regulating protein that induces filopodium formation downstream of Cdc42, It has been shown that filopodia actively extend from the growth cone, a guidance apparatus located at the tip of neurites, suggesting their role in neurite extension. Here we examined the possible involvement of N-WASP in the neurite extension process. Since verprolin, cofilin homology and acidic region (VCA) of N-WASP is known to be required for the activation of Arp2/3 complex that induces actin polymerization, we prepared a mutant (Delta cof) lacking four amino acid residues in the cofilin homology region. The corresponding residues in WASP had been reported to be mutated in some Wiskott-Aldrich syndrome patients. Expression of Delta cof N-WASP suppressed neurite extension of PC12 cells. In support of this, the VCA region of Delta cof cannot activate Arp2/3 complex enough compared with wild-type VCA. Furthermore, H208D mutant, which has been shown unable to bind to Cdc42, also works as a dominant negative mutant in neurite extension assay. Interestingly, the expression of H208D-Delta cof double mutant has no significant dominant negative effect. Finally, the expression of the Delta cof mutant also severely inhibited the neurite extension of primary neurons from rat hippocampus, Thus, N-WASP is thought to be a general regulator of the actin cytoskeleton indispensable for neurite extension, which is probably caused through Cdc42 signaling and Arp2/3 complex-induced actin polymerization.	Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 108, Japan	University of Tokyo	Takenawa, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, 4-6-1 Shirokanedai, Tokyo 108, Japan.		Yamaguchi, Hideki/AAP-1767-2021	Yamaguchi, Hideki/0000-0003-2125-9655				Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; DERRY JMJ, 1995, HUM MOL GENET, V4, P1127, DOI 10.1093/hmg/4.7.1127; FISCHER G, 1982, NEUROSCI LETT, V28, P325, DOI 10.1016/0304-3940(82)90079-9; Fukuoka M, 1997, GENE, V196, P43, DOI 10.1016/S0378-1119(97)00184-4; GUNNING PW, 1981, J CELL BIOL, V89, P240, DOI 10.1083/jcb.89.2.240; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kato M, 1999, J BIOL CHEM, V274, P27225, DOI 10.1074/jbc.274.38.27225; KOLLURI R, 1995, HUM MOL GENET, V4, P1119, DOI 10.1093/hmg/4.7.1119; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Ma L, 1998, P NATL ACAD SCI USA, V95, P15362, DOI 10.1073/pnas.95.26.15362; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; MARK MD, 1995, J CELL BIOL, V130, P701, DOI 10.1083/jcb.130.3.701; MARSH L, 1984, J CELL BIOL, V99, P2041, DOI 10.1083/jcb.99.6.2041; Miki H, 1998, BIOCHEM BIOPH RES CO, V243, P73, DOI 10.1006/bbrc.1997.8064; MIKI H, 1994, J BIOL CHEM, V269, P5489; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Miura K, 1996, BIOCHEM J, V316, P639, DOI 10.1042/bj3160639; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; SAITO I, 1985, J VIROL, V54, P711, DOI 10.1128/JVI.54.3.711-719.1985; Suetsugu S, 1999, BIOCHEM BIOPH RES CO, V260, P296, DOI 10.1006/bbrc.1999.0894; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8	30	76	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11987	11992		10.1074/jbc.275.16.11987	http://dx.doi.org/10.1074/jbc.275.16.11987			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766829	hybrid			2022-12-27	WOS:000086695500064
J	Dixon, DA; Kaplan, CD; McIntyre, TM; Zimmerman, GA; Prescott, SM				Dixon, DA; Kaplan, CD; McIntyre, TM; Zimmerman, GA; Prescott, SM			Post-transcriptional control of cyclooxygenase-2 gene expression - The role of the 3 '-untranslated region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING-PROTEIN; 3' UNTRANSLATED REGION; AU-RICH ELEMENT; PROSTAGLANDIN-H SYNTHASE-2; HUMAN COLON-CANCER; MYC MESSENGER-RNA; RESPONSE ELEMENT; C-FOS; POSTTRANSCRIPTIONAL REGULATION; ENDOTHELIAL-CELLS	The cyclooxygenase (COX)-2 enzyme is responsible for increased prostaglandin formation in inflammatory states and is the major target of nonsteroidal anti-inflammatory drugs. Normally COX-2 expression is tightly regulated, however, constitutive overexpression plays a hey role in colon carcinogenesis. To understand the mechanisms controlling COX-2 expression, we examined the ability of the 3'-untranslated region of the COX-2 mRNA to regulate post-transcriptional events. When fused to a reporter gene, the 3'-untranslated region mediated rapid mRNA decay (t(1/2) = 30 min), which was comparable to endogenous COX-2 mRNA turnover in serum-induced fibroblasts treated with actinomycin D or dexamethasone. Deletion analysis demonstrated that a conserved 116-nucleotide AU-rich sequence element (ARE) mediated mRNA degradation. In transiently transfected cells, this region inhibited protein synthesis approximately 3-fold. However, this inhibition did not occur through changes in mRNA stability since mRNA half-life and steady-state mRNA levels were unchanged. RNA mobility shift assays demonstrated a complex of cytoplasmic proteins that bound specifically to the ARE, and UV cross-linking studies identified proteins ranging from 90 to 35 kDa. Fractionation of the cytosol showed differential association of ARE-binding proteins to polysomes and S130 fractions. We propose that these factors influence expression at a post-transcriptional step and, if dysregulated, may increase COX-2 protein as detected in colon cancer.	Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Eccles Program Human Mol Biol & Genet, Dept Oncol Sci, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Dixon, DA (corresponding author), Univ Utah, Huntsman Canc Inst, 2000 Circle Hope, Salt Lake City, UT 84112 USA.		Kaplan, Craig/AAO-4500-2021	Kaplan, Craig/0000-0002-7518-695X	NATIONAL CANCER INSTITUTE [P30CA042014, P01CA073992] Funding Source: NIH RePORTER; NCI NIH HHS [CA42014, CA73992] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGHIB DF, 1990, ONCOGENE, V5, P707; AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; BABU N, 1993, FASEB J, V7, P702; BICKEL M, 1992, P NATL ACAD SCI USA, V89, P10001, DOI 10.1073/pnas.89.21.10001; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; CURATOLA AM, 1995, MOL CELL BIOL, V15, P6331; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; Dixon DA, 1998, BIOTECHNIQUES, V24, P732, DOI 10.2144/98245bm07; DuBois RN, 1996, GASTROENTEROLOGY, V110, P1259, DOI 10.1053/gast.1996.v110.pm8613017; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Esnault S, 1998, P ASSOC AM PHYSICIAN, V110, P575; EVETT GE, 1993, ARCH BIOCHEM BIOPHYS, V306, P169, DOI 10.1006/abbi.1993.1496; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; GILLIS P, 1991, J BIOL CHEM, V266, P3172; Gueydan C, 1999, J BIOL CHEM, V274, P2322, DOI 10.1074/jbc.274.4.2322; HABIB A, 1993, J BIOL CHEM, V268, P23448; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; JONES DA, 1993, J BIOL CHEM, V268, P9049; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KARGMAN SL, 1995, CANCER RES, V55, P2556; KATZ DA, 1994, NUCLEIC ACIDS RES, V22, P238, DOI 10.1093/nar/22.2.238; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; KRUYS V, 1987, P NATL ACAD SCI USA, V84, P6030, DOI 10.1073/pnas.84.17.6030; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; KRUYS V, 1990, ENZYME, V44, P193, DOI 10.1159/000468757; KRUYS VI, 1988, GENE, V72, P191, DOI 10.1016/0378-1119(88)90144-8; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MARNETT LJ, 1992, CANCER RES, V52, P5575; Meade EA, 1999, J BIOL CHEM, V274, P8328, DOI 10.1074/jbc.274.12.8328; MULLER WEG, 1992, J MOL BIOL, V226, P721, DOI 10.1016/0022-2836(92)90628-W; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; NAKAGAWA J, 1995, P NATL ACAD SCI USA, V92, P2051, DOI 10.1073/pnas.92.6.2051; NAKAMAKI T, 1995, J CELL PHYSIOL, V165, P484, DOI 10.1002/jcp.1041650306; NANBU R, 1993, J BIOCHEM-TOKYO, V114, P432, DOI 10.1093/oxfordjournals.jbchem.a124193; Newton R, 1998, J BIOL CHEM, V273, P32312, DOI 10.1074/jbc.273.48.32312; Newton R, 1997, BIOCHEM BIOPH RES CO, V234, P85, DOI 10.1006/bbrc.1997.6586; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; Rajagopalan LE, 1996, J BIOL CHEM, V271, P19871, DOI 10.1074/jbc.271.33.19871; RAJAGOPALAN LE, 1994, J BIOL CHEM, V269, P23882; RAYMOND V, 1989, ONCOGENE RES, V5, P1; RAZ A, 1989, P NATL ACAD SCI USA, V86, P1657, DOI 10.1073/pnas.86.5.1657; RIGAS B, 1993, J LAB CLIN MED, V122, P518; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325; ROSS HJ, 1991, BLOOD, V77, P1787; Sambrook J., 2002, MOL CLONING LAB MANU; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SCHIAVI SC, 1994, J BIOL CHEM, V269, P3441; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Sheng HM, 1998, J BIOL CHEM, V273, P22120, DOI 10.1074/jbc.273.34.22120; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Spirio LN, 1998, CANCER RES, V58, P4909; SRIVASTAVA SK, 1994, AM PHYSL SOC, V94, P504; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	77	308	322	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11750	11757		10.1074/jbc.275.16.11750	http://dx.doi.org/10.1074/jbc.275.16.11750			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766797	hybrid			2022-12-27	WOS:000086695500032
J	Steinkamp, T; Hill, H; Hinnah, SC; Wagner, R; Rohl, T; Pohlmeyer, K; Soll, J				Steinkamp, T; Hill, H; Hinnah, SC; Wagner, R; Rohl, T; Pohlmeyer, K; Soll, J			Identification of the pore-forming region of the outer chloroplast envelope protein OEP16	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL INNER MEMBRANE; PLANAR LIPID BILAYERS; ESCHERICHIA-COLI; SECONDARY STRUCTURE; SOLUTE CHANNEL; VDAC CHANNELS; PHOE PORIN; IMPORT; SEQUENCE; YEAST	The chloroplast outer envelope protein OEP16 forms a cation-selective high conductance channel with permeability to amines and amino acids. The region of OEP16 directly involved in channel formation has been identified by electrophysiological analysis of a selection of reconstituted OEP16 mutants. Because analysis of these mutants depended on the use of recombinant protein, we evaluated the electrophysiological properties of OEP16 isolated directly from pea chloroplasts and of the recombinant protein produced in Escherichia coli. The results show that the basic properties like conductance, selectivity, and open probability of the channel formed by native pea OEP16 are comparable with the channel activity formed by the recombinant source of the protein. Following electrophysiological analysis of OEP16 mutants we found that point mutations and insertion of additional amino acid residues in the region of the putative helix 1 (Glu(73) to Val(91)) did not change the properties of the OEP16 channel. The only exception was a Cys(71)-->Ser mutation, which led to a loss of the CuCl2 sensitivity of the channel. Analysis of N- and C-terminal deletion mutants of OEP16 and mutants containing defined shuffled domains indicated that the minimal continuous region of OEP16, which is able to form a channel in liposomes, lies in the first half of the protein between amino acid residues 21 and 93.	Univ Osnabruck, Fachbereich Biol Chem, D-49034 Osnabruck, Germany; Univ Kiel, Inst Bot, D-24098 Kiel, Germany	University Osnabruck; University of Kiel	Wagner, R (corresponding author), Univ Osnabruck, Biophys Fachbereich Biol Chem, Barbarastr 11,Postfach 4469, D-49076 Osnabruck, Germany.							Bainbridge G, 1998, FEBS LETT, V431, P305, DOI 10.1016/S0014-5793(98)00761-3; Baldermann C, 1998, J BACTERIOL, V180, P3741, DOI 10.1128/JB.180.15.3741-3749.1998; Bashford CL, 1996, J MEMBRANE BIOL, V150, P37, DOI 10.1007/s002329900028; Berrier C, 1997, J MEMBRANE BIOL, V156, P105, DOI 10.1007/s002329900193; BISHOP ND, 1994, FEBS LETT, V349, P69, DOI 10.1016/0014-5793(94)00639-3; Bolter B, 1999, EMBO J, V18, P5505, DOI 10.1093/emboj/18.20.5505; Bolter B, 1998, P NATL ACAD SCI USA, V95, P15831, DOI 10.1073/pnas.95.26.15831; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DEKKER PJT, 1993, FEBS LETT, V330, P66, DOI 10.1016/0014-5793(93)80921-G; Flugge UI, 1998, CURR OPIN PLANT BIOL, V1, P201, DOI 10.1016/S1369-5266(98)80105-2; GILBERT RJ, 1992, J MOL GRAPHICS, V10, P112, DOI 10.1016/0263-7855(92)80064-K; Gouaux E, 1997, CURR OPIN STRUC BIOL, V7, P566, DOI 10.1016/S0959-440X(97)80123-6; HIGUCHI M, 1990, B CHEM SOC JPN, V63, P1916, DOI 10.1246/bcsj.63.1916; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Hinnah SC, 1997, EMBO J, V16, P7351, DOI 10.1093/emboj/16.24.7351; HINNAH SC, 1999, THESIS U OSNABRUCK; Hodge T, 1997, J MEMBRANE BIOL, V157, P271, DOI 10.1007/s002329900235; Jap BK, 1996, PHYSIOL REV, V76, P1073, DOI 10.1152/physrev.1996.76.4.1073; Jiang XQ, 1997, SCIENCE, V276, P1261, DOI 10.1126/science.276.5316.1261; KELLER TA, 1994, BIOCHEM BIOPH RES CO, V199, P767, DOI 10.1006/bbrc.1994.1295; Klebba PE, 1998, CURR OPIN MICROBIOL, V1, P238, DOI 10.1016/S1369-5274(98)80017-9; KOEBNIK R, 1996, EMBO J, V15, P3527; Lacy DB, 1998, CURR OPIN STRUC BIOL, V8, P778; Lee AC, 1998, J MEMBRANE BIOL, V161, P173, DOI 10.1007/s002329900324; MAARSE AC, 1994, FEBS LETT, V349, P215, DOI 10.1016/0014-5793(94)00669-5; Mannella CA, 1996, J BIOENERG BIOMEMBR, V28, P163, DOI 10.1007/BF02110647; Martin W, 1998, NATURE, V392, P37, DOI 10.1038/32096; Montal M, 1996, CURR OPIN STRUC BIOL, V6, P499, DOI 10.1016/S0959-440X(96)80115-1; MUELLER P, 1962, CIRCULATION, V26, P1167, DOI 10.1161/01.CIR.26.5.1167; NIKAIDO H, 1994, J BIOL CHEM, V269, P3905; NIKAIDO H, 1991, J BIOL CHEM, V266, P770; Pohlmeyer K, 1997, P NATL ACAD SCI USA, V94, P9504, DOI 10.1073/pnas.94.17.9504; Pohlmeyer K, 1998, PLANT CELL, V10, P1207, DOI 10.1105/tpc.10.7.1207; Rassow J, 1999, J MOL BIOL, V286, P105, DOI 10.1006/jmbi.1998.2455; Rohl T, 1999, FEBS LETT, V460, P491, DOI 10.1016/S0014-5793(99)01399-X; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rudel T, 1996, CELL, V85, P391, DOI 10.1016/S0092-8674(00)81117-4; SALOMON M, 1990, P NATL ACAD SCI USA, V87, P5778, DOI 10.1073/pnas.87.15.5778; Samartzidou H, 1998, EMBO J, V17, P93, DOI 10.1093/emboj/17.1.93; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; Song JM, 1996, J BIOENERG BIOMEMBR, V28, P153, DOI 10.1007/BF02110646; STEINKAMP T, 2000, THESIS U OSNABRUCK; SUGAWARA E, 1992, J BIOL CHEM, V267, P2507; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x; Waegemann K, 1996, J BIOL CHEM, V271, P6545, DOI 10.1074/jbc.271.11.6545; Wimley WC, 1998, J MOL BIOL, V277, P1091, DOI 10.1006/jmbi.1998.1640	48	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11758	11764		10.1074/jbc.275.16.11758	http://dx.doi.org/10.1074/jbc.275.16.11758			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766798	hybrid			2022-12-27	WOS:000086695500033
J	An, SJ; Hansen, NJ; Hodel, A; Jahn, R; Edwardson, JM				An, SJ; Hansen, NJ; Hodel, A; Jahn, R; Edwardson, JM			Analysis of the association of syncollin with the membrane of the pancreatic zymogen granule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACINAR-CELLS; PROTEIN; SYNTAXIN; FUSION; OSCILLATIONS	Syncollin is a pancreatic zymogen granule protein that was isolated through its ability to bind to syntaxin, Here we show that syncollin has a cleavable signal sequence and can be removed from granule membranes by washing with sodium carbonate. When membranes were subjected to Triton X-114 partitioning, syncollin was found predominantly in the aqueous phase, indicating that it is not sufficiently hydrophobic to be embedded in the membrane. Syncollin has intramolecular disulfide bonds and was accessible to water-soluble cross-linking and biotinylating reagents only when granules were lysed by sonication. These results indicate that syncollin is tightly bound to the luminal surface of the granule membrane. In situ, syncollin was resistant to proteases such as trypsin, When granule membranes were solubilized in ionic detergents such as deoxycholate, this trypsin resistance was maintained, and syncollin migrated on sucrose density gradients as a large (150 kDa) protein, In contrast, in non-ionic detergents such as Triton X-100, syncollin became partially sensitive to trypsin and behaved as a monomer. Syncollin in alkaline extracts of granule membranes was also monomeric. However, reduction of the pH regenerated the oligomeric form, which was insoluble. We conclude that syncollin exists as a homo-oligomer and that its ability to self-associate can be reversibly modulated via changes in pH, In light of our findings, we reassess the likely role of syncollin in the pancreatic acinar cell.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1QJ, England; Max Planck Inst Biophys Chem, Dept Neurobiol, D-3700 Wernigerode, Germany	University of Cambridge; Max Planck Society	Edwardson, JM (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1QJ, England.			Jahn, Reinhard/0000-0003-1542-3498				BORDIER C, 1981, J BIOL CHEM, V256, P1604; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; Edwardson JM, 1997, CELL, V90, P325, DOI 10.1016/S0092-8674(00)80340-2; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Gaisano HY, 1997, FEBS LETT, V414, P298, DOI 10.1016/S0014-5793(97)01013-2; Gaisano HY, 1996, MOL BIOL CELL, V7, P2019, DOI 10.1091/mbc.7.12.2019; GAISANO HY, 1994, J BIOL CHEM, V269, P17062; Hansen NJ, 1999, J BIOL CHEM, V274, P22871, DOI 10.1074/jbc.274.32.22871; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kubista H, 1999, CURR BIOL, V9, P1403, DOI 10.1016/S0960-9822(00)80085-8; Langen R, 1998, P NATL ACAD SCI USA, V95, P14060, DOI 10.1073/pnas.95.24.14060; NADIN CY, 1989, J CELL BIOL, V109, P2801, DOI 10.1083/jcb.109.6.2801; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; von Heijne G, 1998, NATURE, V396, P111, DOI 10.1038/24036; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X	20	23	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11306	11311		10.1074/jbc.275.15.11306	http://dx.doi.org/10.1074/jbc.275.15.11306			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753942	Green Published, hybrid			2022-12-27	WOS:000086466600084
J	Dickinson, JR; Harrison, SJ; Dickinson, JA; Hewlins, MJE				Dickinson, JR; Harrison, SJ; Dickinson, JA; Hewlins, MJE			An investigation of the metabolism of isoleucine to active amyl alcohol in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHYDROGENASE COMPLEX; GENE	The metabolism of isoleucine to active amyl alcohol (2-methylbutanol) in yeast was examined by the use of C-13 nuclear magnetic resonance spectroscopy, combined gas chromatography-mass spectrometry, and a variety of mutants. From the identified metabolites a number of routes between isoleucine and active amyl alcohol seemed possible, All involved the initial decarboxylation of isoleucine to alpha-beto-beta-methylvalerate. The first, via branched chain alpha-ketoacid dehydrogenase to alpha-methylbutyryl-CoA, was eliminated because abolition of branched-chain alpha-ketoacid dehydrogenase in an lpd1 disruption mutant did not prevent the formation of active amyl alcohol. However, the lpd1 mutant still produced large amounts of alpha-methylbutyrate which initially seemed contradictory because it had been assumed that alpha-methylbutyrate was derived from alpha-methylbutyryl-CoA via acyl-CoA hydrolase, Subsequently it was observed that alpha-methylbutyrate arises from the non-enzymic oxidation of alpha-methylbutyraldehyde (the immediate decarboxylation product of alpha-keto-beta-methylvalerate), Mutant studies showed that one of the decarboxylases encoded by PDC1, PDC5, PDC6, YDL080c, or YDR380w must be present to allow yeast to utilize alpha-keto-beta-methylvalerate. Apparently, any one of this family of decarboxylases is sufficient to allow the catabolism of isoleucine to active amyl alcohol. This is the first demonstration of a role for the gene product of YDR380w, and it also shows that the decarboxylation steps for each ru-keto acid in the catabolic pathways of leucine, valine, and isoleucine are accomplished in subtly different ways. In leucine catabolism, the enzyme encoded by YDL080c is solely responsible for the decarboxylation of alpha-ketoisocaproate, whereas in valine catabolism any one of the isozymes of pyruvate decarboxylase will decarboxylate alpha-ketoisovalerate.	Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3TL, S Glam, Wales; ThermoQuest Finnigan PLC, MassLab Grp, Manchester M23 9BE, Lancs, England; Cardiff Univ, Dept Chem, Cardiff CF10 3TB, S Glam, Wales	Cardiff University; Cardiff University	Dickinson, JR (corresponding author), Cardiff Univ, Cardiff Sch Biosci, POB 915, Cardiff CF10 3TL, S Glam, Wales.							DEINERI D, 1999, GENETICS, V153, P1591; DEINERI D, 1999, YEAST, V15, P1681; DICKINSON JR, 1986, MOL GEN GENET, V204, P103; Dickinson JR, 1998, J BIOL CHEM, V273, P25751, DOI 10.1074/jbc.273.40.25751; Dickinson JR, 1997, J BIOL CHEM, V272, P26871, DOI 10.1074/jbc.272.43.26871; DICKINSON JR, 1992, J GEN MICROBIOL, V138, P2029, DOI 10.1099/00221287-138-10-2029; Ehrlich F, 1907, BER DTSCH CHEM GES, V40, P1027, DOI 10.1002/cber.190704001156; Hohmann S, 1998, BBA-PROTEIN STRUCT M, V1385, P201, DOI 10.1016/S0167-4838(98)00069-7; HOHMANN S, 1991, J BACTERIOL, V173, P7963, DOI 10.1128/jb.173.24.7963-7969.1991; Iraqui I, 1999, MOL CELL BIOL, V19, P3360; Lanterman MM, 1996, HUM MOL GENET, V5, P1643, DOI 10.1093/hmg/5.10.1643; Mortimer R K, 1975, Methods Cell Biol, V11, P221, DOI 10.1016/S0091-679X(08)60325-8; NISHIMURA H, 1992, J BACTERIOL, V174, P4701, DOI 10.1128/JB.174.14.4701-4706.1992; REPETTO B, 1991, MOL CELL BIOL, V11, P3931, DOI 10.1128/MCB.11.8.3931; Sherman F, 1975, Methods Cell Biol, V11, P189, DOI 10.1016/S0091-679X(08)60323-4; SINCLAIR DA, 1995, GENETICS, V140, P1213; SINCLAIR DA, 1993, BIOCHEM MOL BIOL INT, V31, P911; WEBB A. DINSMOOR, 1963, ADVAN APPL MICROBIOL, V5, P317, DOI 10.1016/S0065-2164(08)70014-5; WILLIAMSON VM, 1987, MOL GEN GENET, V209, P374, DOI 10.1007/BF00329668; YOUNG ET, 1982, BASIC LIFE SCI, V19, P335	20	97	111	1	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10937	10942		10.1074/jbc.275.15.10937	http://dx.doi.org/10.1074/jbc.275.15.10937			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753893	hybrid			2022-12-27	WOS:000086466600035
J	Malhotra, JD; Kazen-Gillespie, K; Hortsch, M; Isom, LL				Malhotra, JD; Kazen-Gillespie, K; Hortsch, M; Isom, LL			Sodium channel beta subunits mediate homophilic cell adhesion and recruit ankyrin to points of cell-cell contact	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ CHANNEL; ALPHA-SUBUNITS; BINDING DOMAIN; STRUCTURAL REQUIREMENTS; FUNCTIONAL EXPRESSION; BRAIN; DROSOPHILA; NEUROFASCIN; MOLECULES; RANVIER	Sodium channels isolated from mammalian brain are composed of alpha, beta 1, and beta 2 subunits, The auxiliary beta subunits do not form the ion conducting pore, yet play important roles in channel modulation and plasma membrane expression, beta 1 and beta 2 are transmembrane proteins with one extracellular V-set immunoglobulin (Ig) protein domain. It has been shown recently that beta 1 and beta 2 interact with the extracellular matrix proteins tenascin-C and tenascin-R, In the present study we show that rat brain beta 1 and beta 2, but not alpha IIA, subunits interact in a trans-homophilic fashion, resulting in recruitment of the cytoskeletal protein ankyrin to sites of cell-cell contact in transfected Drosophila S2 cells. Whereas alpha IIA subunits expressed alone do not cause cellular aggregation, beta subunits co-expressed with alpha IIA retain the ability to adhere and recruit ankyrin, Truncated beta subunits lacking cytoplasmic domains interact homophilically to produce cell aggregation but do not recruit ankyrin, Thus, the cytoplasmic domains of beta 1 and beta 2 are required for cytoskeletal interactions. It is hypothesized that sodium channel beta subunits serve as a critical communication link between the extracellular and intracellular environments of the neuron and may play a role in sodium channel placement at nodes of Ranvier.	Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Isom, LL (corresponding author), Univ Michigan, Dept Pharmacol, 1301 MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	lisom@umich.edu		Hortsch, Michael/0000-0002-3750-737X; Isom, Lori/0000-0002-9479-6729	NICHD NIH HHS [HD29388] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029388, R29HD029388] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BENNETT V, 1992, J BIOL CHEM, V267, P8703; BIEBER AJ, 1994, METHOD CELL BIOL, V44, P683, DOI 10.1016/S0091-679X(08)60938-3; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; DAVIS JQ, 1993, J CELL BIOL, V121, P121, DOI 10.1083/jcb.121.1.121; Davis JQ, 1996, J CELL BIOL, V135, P1355, DOI 10.1083/jcb.135.5.1355; Dubreuil RR, 1996, J CELL BIOL, V133, P647, DOI 10.1083/jcb.133.3.647; Golding NL, 1998, NEURON, V21, P1189, DOI 10.1016/S0896-6273(00)80635-2; Hortsch M, 1998, J CELL BIOL, V142, P251, DOI 10.1083/jcb.142.1.251; HORTSCH M, 1995, J BIOL CHEM, V270, P18809, DOI 10.1074/jbc.270.32.18809; Hortsch M, 1998, CELL ADHES COMMUN, V5, P61, DOI 10.3109/15419069809005599; HORTSCH M, 1991, TRENDS BIOCHEM SCI, V16, P283, DOI 10.1016/0968-0004(91)90116-D; Isom LL, 1996, NATURE, V383, P307, DOI 10.1038/383307b0; ISOM LL, 1995, J BIOL CHEM, V270, P3306, DOI 10.1074/jbc.270.7.3306; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; JOE EH, 1992, NATURE, V356, P333, DOI 10.1038/356333a0; JOE EH, 1993, J NEUROSCI, V13, P2993; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; KORDELI E, 1990, J CELL BIOL, V110, P1341, DOI 10.1083/jcb.110.4.1341; Lipowsky R, 1996, J NEUROPHYSIOL, V76, P2181, DOI 10.1152/jn.1996.76.4.2181; Malhotra JD, 1998, J BIOL CHEM, V273, P33354, DOI 10.1074/jbc.273.50.33354; McCormick KA, 1998, J BIOL CHEM, V273, P3954, DOI 10.1074/jbc.273.7.3954; Meir A, 1999, PHYSIOL REV, V79, P1019, DOI 10.1152/physrev.1999.79.3.1019; MICHAELY P, 1993, J BIOL CHEM, V268, P22703; Michaely P, 1995, J BIOL CHEM, V270, P31298, DOI 10.1074/jbc.270.52.31298; OH YS, 1994, P NATL ACAD SCI USA, V91, P9985, DOI 10.1073/pnas.91.21.9985; PATTON DE, 1994, J BIOL CHEM, V269, P17649; Salzer JL, 1997, NEURON, V18, P843, DOI 10.1016/S0896-6273(00)80323-2; Song JY, 1999, P NATL ACAD SCI USA, V96, P1100, DOI 10.1073/pnas.96.3.1100; Srinivasan J, 1998, P NATL ACAD SCI USA, V95, P15753, DOI 10.1073/pnas.95.26.15753; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; Vabnick I, 1998, J NEUROBIOL, V37, P80, DOI 10.1002/(SICI)1097-4695(199810)37:1<80::AID-NEU7>3.0.CO;2-4; Warmke JW, 1997, J GEN PHYSIOL, V110, P119, DOI 10.1085/jgp.110.2.119; WEST JW, 1992, NEURON, V8, P59, DOI 10.1016/0896-6273(92)90108-P; Wood SJ, 1998, J CELL BIOL, V140, P675, DOI 10.1083/jcb.140.3.675; Xiao ZC, 1999, J BIOL CHEM, V274, P26511, DOI 10.1074/jbc.274.37.26511; Zhang X, 1998, J BIOL CHEM, V273, P30785, DOI 10.1074/jbc.273.46.30785; Zhang ZS, 1998, J BIOL CHEM, V273, P18681, DOI 10.1074/jbc.273.30.18681; Zhu D, 1998, CELL MOTIL CYTOSKEL, V39, P209, DOI 10.1002/(SICI)1097-0169(1998)39:3<209::AID-CM4>3.0.CO;2-#	41	225	228	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11383	11388		10.1074/jbc.275.15.11383	http://dx.doi.org/10.1074/jbc.275.15.11383			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753953	hybrid			2022-12-27	WOS:000086466600095
J	Rafty, LA; Khachigian, LM				Rafty, LA; Khachigian, LM			Novel negative regulatory element in the platelet-derived growth factor B chain promoter that mediates ERK-dependent transcriptional repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR ENDOTHELIAL-CELLS; FACTOR-A-CHAIN; GENE-EXPRESSION; OSTEOSARCOMA CELLS; PORCINE ARTERIES; MESSENGER-RNA; FAMILY; MUSCLE; IDENTIFICATION; ANGIOPLASTY	Platelet-derived growth factor (PDGF), which consists of an A and/or B chain, stimulates migration and proliferation in vascular smooth muscle cells as well as a large number of other cell types. Investigations over recent years have defined roles for several positive regulatory transcription factors in the PDGF-B promoter. However, little is known about the transcriptional mechanisms that negatively regulate this gene. Here, we used transient transfection and 5' deletion analysis to define a specific region in the PDGF-B promoter-mediating repression in vascular smooth muscle cells. Gel retardation assays revealed this region is bound by nuclear protein(s) in a specific manner. Supershift assays excluded the direct association of Sp1, Sp3, and Egr-1. Mutation of the negative regulatory element no longer supported nucleoprotein complex formation and, when introduced into the PDGF-B promoter, rescued the promoter from repression. Promoter activity was also restored by transfection of oligonucleotide decoys bearing the repressor binding site. The MEK1/2 inhibitor, PD98059, and a dominant negative construct generating inactive ERK1 increased reporter expression driven by the PDGF-B promoter, In contrast, the MEK inhibitor had no effect on the activity of the mutant PDGF-B promoter. These effects were cell type-specific, since neither suppression of the PDGF-B promoter nor nucleoprotein complex formation was observed in vascular endothelial cells, These findings define a distinct negative regulatory element in the PDGF-B promoter that interacts with nuclear protein(s) and inhibits PDGF-B promoter-dependent gene expression in an ERK-dependent manner.	Univ New S Wales, Sch Med, Ctr Thrombosis & Vasc Res, Sydney, NSW 2052, Australia; Prince Wales Hosp, Dept Haematol, Sydney, NSW, Australia	University of New South Wales Sydney	Khachigian, LM (corresponding author), Univ New S Wales, Sch Med, Ctr Thrombosis & Vasc Res, Sydney, NSW 2052, Australia.		Khachigian, Levon/AAZ-7458-2020	Khachigian, Levon/0000-0003-3446-0323				BARRETT TB, 1987, P NATL ACAD SCI USA, V84, P1099, DOI 10.1073/pnas.84.4.1099; BARRETT TB, 1988, P NATL ACAD SCI USA, V85, P2810, DOI 10.1073/pnas.85.8.2810; BARTRAM CR, 1984, BLOOD, V63, P223; BETSHOLTZ C, 1986, NATURE, V323, P6440; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; DIRKS RPH, 1995, NUCLEIC ACIDS RES, V23, P1119, DOI 10.1093/nar/23.7.1119; Ferns GAA, 1990, GROWTH FACTORS, V3, P315, DOI 10.3109/08977199009003674; Goldman D, 1998, BIOCHEM J, V335, P267, DOI 10.1042/bj3350267; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; JIN HM, 1993, P NATL ACAD SCI USA, V90, P7563, DOI 10.1073/pnas.90.16.7563; JIN HM, 1994, J BIOL CHEM, V269, P28648; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; KHACHIGIAN LM, 1995, J CLIN INVEST, V96, P1169, DOI 10.1172/JCI118106; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; NABEL EG, 1993, J CLIN INVEST, V91, P1822, DOI 10.1172/JCI116394; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; PECH M, 1989, MOL CELL BIOL, V9, P396, DOI 10.1128/MCB.9.2.396; POMPILI VJ, 1995, ARTERIOSCL THROM VAS, V15, P2254, DOI 10.1161/01.ATV.15.12.2254; Rafty LA, 1998, J BIOL CHEM, V273, P5758, DOI 10.1074/jbc.273.10.5758; SEIFERT RA, 1984, NATURE, V311, P669, DOI 10.1038/311669a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SWAN DC, 1982, P NATL ACAD SCI-BIOL, V79, P4691, DOI 10.1073/pnas.79.15.4691; Ueda M, 1996, AM J PATHOL, V149, P831; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P22143, DOI 10.1074/jbc.270.38.22143	27	4	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11478	11483		10.1074/jbc.275.15.11478	http://dx.doi.org/10.1074/jbc.275.15.11478			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753966	hybrid			2022-12-27	WOS:000086466600108
J	Vallenius, T; Luukko, K; Makela, TP				Vallenius, T; Luukko, K; Makela, TP			CLP-36 PDZ-LIM protein associates with nonmuscle alpha-actinin-1 and alpha-actinin-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-CONTAINING CYTOSKELETON; ALPHA-ACTININ; DOMAIN PROTEIN; RIL; IDENTIFICATION; LOCALIZATION; EXPRESSION; MOTIFS; GENE; RET/PTC2	The PDZ-LIM family of proteins (Enigma/LMP-1, ENH, ZASP/Cypher, RIL, ALP, and CLP-36) has been suggested to act as adapters that direct LIM-binding proteins to the cytoskeleton, Most interactions of PDZ-LIM proteins with the cytoskeleton have been identified in striated muscle, where several PDZ-LIM proteins are predominantly expressed. By contrast, CLP-36 mRNA is expressed in several nonmuscle tissues, and here we demonstrate high expression of CLP-36 in epithelial cells by in situ hybridization analysis. Our subcellular localization studies indicate that in nonmuscle cells, CLP-36 protein localizes to actin stress fibers. This localization is mediated via the PDZ domain of CLP-36 that associates with the spectrin-like repeats of alpha-actinin. Interestingly, immunoprecipitation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis indicate that both nonmuscle alpha-actinin-1 and alpha-actinin-4 form complexes with CLP-36, The high expression of alpha-actinin-4 in the colon, together with these results, suggests a specific function for the alpha-actinin-4-CLP-36 complex in the colonic epithelium, More generally, results presented here demonstrate that the association of PDZ-LIM proteins with the cytoskeleton extends to the actin stress fibers of nonmuscle cells.	Univ Helsinki, Haartman Inst, FIN-00014 Helsinki, Finland; Univ Helsinki, Bioctr Helsinki, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki	Makela, TP (corresponding author), Univ Helsinki, Haartman Inst, FIN-00014 Helsinki, Finland.		makela, tomi/B-3734-2009	makela, tomi/0000-0002-4869-8044				Bashirova AA, 1998, GENE, V210, P239, DOI 10.1016/S0378-1119(98)00080-8; BLANCHARD A, 1989, J MUSCLE RES CELL M, V10, P280, DOI 10.1007/BF01758424; Boden SD, 1998, ENDOCRINOLOGY, V139, P5125, DOI 10.1210/en.139.12.5125; CARPEN O, 1992, J CELL BIOL, V118, P1223, DOI 10.1083/jcb.118.5.1223; Cuppen E, 1998, MOL BIOL CELL, V9, P671, DOI 10.1091/mbc.9.3.671; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Djinovic-Carugo K, 1999, CELL, V98, P537, DOI 10.1016/S0092-8674(00)81981-9; Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; ENDO T, 1984, J CELL BIOL, V99, P2322, DOI 10.1083/jcb.99.6.2322; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Faulkner G, 1999, J CELL BIOL, V146, P465, DOI 10.1083/jcb.146.2.465; FLOOD G, 1995, J MOL BIOL, V252, P227, DOI 10.1006/jmbi.1995.0490; FUJIWARA K, 1978, J CELL BIOL, V79, P268, DOI 10.1083/jcb.79.1.268; Guy PM, 1999, MOL BIOL CELL, V10, P1973, DOI 10.1091/mbc.10.6.1973; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; IMAMURA M, 1988, J BIOL CHEM, V263, P7800; KIESS M, 1995, ONCOGENE, V10, P61; Kotaka M, 1999, J CELL BIOCHEM, V72, P279, DOI 10.1002/(SICI)1097-4644(19990201)72:2<279::AID-JCB12>3.0.CO;2-7; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; LAZARIDES E, 1975, CELL, V6, P289, DOI 10.1016/0092-8674(75)90180-4; Luukko K, 1996, DEV DYNAM, V206, P87, DOI 10.1002/(SICI)1097-0177(199605)206:1<87::AID-AJA8>3.0.CO;2-X; MIZUNO K, 1994, ONCOGENE, V9, P1605; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; Sainio M, 1997, J CELL SCI, V110, P2249; Salmikangas P, 1999, HUM MOL GENET, V8, P1329, DOI 10.1093/hmg/8.7.1329; Sambrook J., 2002, MOL CLONING LAB MANU; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Ueki N, 1999, J HUM GENET, V44, P256, DOI 10.1007/s100380050155; WACHSSTOCK DH, 1987, BIOCHEM BIOPH RES CO, V146, P554, DOI 10.1016/0006-291X(87)90564-X; WANG HC, 1995, GENE, V165, P267, DOI 10.1016/0378-1119(95)00542-E; WU RY, 1994, J BIOL CHEM, V269, P25085; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; Xia HH, 1997, J CELL BIOL, V139, P507, DOI 10.1083/jcb.139.2.507; YOUSSOUFIAN H, 1990, AM J HUM GENET, V47, P62; Zhou Q, 1999, J BIOL CHEM, V274, P19807, DOI 10.1074/jbc.274.28.19807	37	115	119	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11100	11105		10.1074/jbc.275.15.11100	http://dx.doi.org/10.1074/jbc.275.15.11100			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753915	hybrid			2022-12-27	WOS:000086466600057
J	Balendran, A; Biondi, RM; Cheung, PCF; Casamayor, A; Deak, M; Alessi, DR				Balendran, A; Biondi, RM; Cheung, PCF; Casamayor, A; Deak, M; Alessi, DR			A 3-phosphoinositide-dependent protein kinase-1 (PDK1) docking site is required for the phosphorylation of protein kinase C zeta (PKC zeta) and PKC-related kinase 2 by PDK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL S6 KINASE; RAT-LIVER; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; PHOSPHOINOSITIDE 3-KINASE; SMALL GTPASE; ACTIVATION; EXPRESSION; INSULIN; MECHANISM; EFFECTOR	Members of the AGC subfamily of protein kinases including protein kinase B, p70 S6 kinase, and protein kinase C (PKC) isoforms are activated and/or stabilized by phosphorylation of two residues, one that resides in the T-loop of the kinase domain and the other that is located C-terminal to the kinase domain in a region known as the hydrophobic motif. Atypical PKC isoforms, such as PKC zeta, and the PKC-related kinases, like PRK2, are also activated by phosphorylation of their T-loop site but, instead of possessing a phosphorylatable Ser/Thr in their hydrophobic motif, contain an acidic residue. The 3-phosphoinositide-dependent protein kinase (PDK1) activates many members of the AGC subfamily of kinases in vitro, including PKC zeta and PRK2 by phosphorylating the T-loop residue. In the present study we demonstrate that the hydrophobic motifs of PKC zeta and PKC iota, as well as PRK1 and PRK2, interact with the kinase domain of PDK1. Mutation of the conserved residues of the hydrophobic motif of full-length PKC zeta, fulllength PRK2, or PRK2 lacking its N-terminal regulatory domain abolishes or significantly reduces the ability of these kinases to interact with PDK1 and to become phosphorylated at their T-loop sites in rtiao. Furthermore, overexpression of the hydrophobic motif of PRK2 in cells prevents the T-loop phosphorylation and thus inhibits the activation of PRK2 and PKC zeta. These findings indicate that the hydrophobic motif of PRK2 and PKC zeta acts as a "docking site" enabling the recruitment of PDK1 to these substrates. This is essential for their phosphorylation by PDK1 in cells.	Univ Dundee, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland; Univ Dundee, Div Signal Transduct Therapy, Dundee DD1 5EH, Scotland	University of Dundee; University of Dundee	Alessi, DR (corresponding author), Univ Dundee, MRC, Prot Phosphorylat Unit, MSI WTB Complex,Dow St, Dundee DD1 5EH, Scotland.		Cheung, Peter/A-2213-2011; Casamayor, Antonio/C-2509-2017; Casamayor, Antonio/A-3190-2012	Casamayor, Antonio/0000-0003-2788-7329; Biondi, Ricardo/0000-0002-8873-7167; Alessi, Dario/0000-0002-2140-9185				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; CHEN SJ, 1993, BIOCHEMISTRY-US, V32, P1032, DOI 10.1021/bi00055a006; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Coffer PJ, 1998, BIOCHEM J, V335, P1; Dong LQ, 1999, J BIOL CHEM, V274, P8117, DOI 10.1074/jbc.274.12.8117; Dong LQ, 2000, P NATL ACAD SCI USA, V97, P5089, DOI 10.1073/pnas.090491897; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Flynn P, 2000, J BIOL CHEM, V275, P11064, DOI 10.1074/jbc.275.15.11064; Flynn P, 1998, J BIOL CHEM, V273, P2698, DOI 10.1074/jbc.273.5.2698; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9; Garcia-Paramio P, 1998, BIOCHEM J, V333, P631, DOI 10.1042/bj3330631; Holland PM, 1999, CURR BIOL, V9, pR329, DOI 10.1016/S0960-9822(99)80205-X; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Maesaki R, 1999, MOL CELL, V4, P793, DOI 10.1016/S1097-2765(00)80389-5; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mellor H, 1998, J BIOL CHEM, V273, P4811, DOI 10.1074/jbc.273.9.4811; Mendez R, 1997, MOL CELL BIOL, V17, P5184, DOI 10.1128/MCB.17.9.5184; MORRICE NA, 1994, FEBS LETT, V351, P171, DOI 10.1016/0014-5793(94)00854-X; MORRICE NA, 1994, J BIOL CHEM, V269, P20040; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V204, P348, DOI 10.1006/bbrc.1994.2466; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Peterson RT, 1999, CURR BIOL, V9, pR521, DOI 10.1016/S0960-9822(99)80326-1; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Richards SA, 1999, CURR BIOL, V9, P810, DOI 10.1016/S0960-9822(99)80364-9; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Standaert ML, 1999, J BIOL CHEM, V274, P25308, DOI 10.1074/jbc.274.36.25308; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Takahashi M, 1998, P NATL ACAD SCI USA, V95, P11566, DOI 10.1073/pnas.95.20.11566; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; Weinkove D, 1999, CURR BIOL, V9, P1019, DOI 10.1016/S0960-9822(99)80450-3; Yu WP, 1997, J BIOL CHEM, V272, P10030	57	150	159	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20806	20813		10.1074/jbc.M000421200	http://dx.doi.org/10.1074/jbc.M000421200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10764742	hybrid			2022-12-27	WOS:000088084500083
J	Chang, WH; Chen, TH; Pratt, S; Shoback, D				Chang, WH; Chen, TH; Pratt, S; Shoback, D			Amino acids in the second and third intracellular loops of the parathyroid Ca2+-sensing receptor mediate efficient coupling to phospholipase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; CALCIUM-SENSING RECEPTOR; CATION-PI INTERACTIONS; SIGNAL-TRANSDUCTION; G-PROTEINS; EXPRESSION; ACTIVATION; MUTATIONS; CLONING; DOMAIN	To determine the role of amino acids in the second and third intracellular (IC) loops of the Ca2+-sensing receptor (CaR) in phospholipase C (PLC) activation, we mutated residues in these loops either singly or in tandem to Ala and assessed PLC activity by measuring high extracellular [Ca2+] ([Ca2+](o))-induced inositol phosphate accumulation and protein expression by immunoblotting and immunocytochemistry in human embryonic kidney 293 cells, Two CaR constructs in the second IC loop, F707A CaR and to a lesser extent L704A CaR, demonstrated reduced activation of PLC, despite levels of protein expression comparable with the wild-type (wt) CaR, Substitution of Tyr or His for Phe-707, brit not Leu, Val, Glu, or Trp, partially restored the ability of high [Ca2+](o) to activate PLC. Eight residues in the third IC loop were involved in PLC signaling. The responses to high [Ca2+](o) in cells expressing CaRs with Ala substitutions at these sites were <35% of the wt CaR, The L798A, F802A, and E804A CaRs were dramatically impaired in their responses to [Ca2+](o) even up to 30 mM. Substitutions of Leu-798 with other hydrophobic residues (Ile, Val, or Phe), but not with acidic, basic, or polar residues, produced reduced responses compared with wt. Phe-802 could be replaced with either Tyr or Trp with partial retention of the ability to activate PLC, Glu-804 could only be substituted with Asp or Gln and maintain its signaling capacity. Cell surface expression of the CaRs mutated at Leu-798 and Phe-802 appeared normal compared with wt CaR, Cell surface CaR expression was, however, reduced substantially in cells expressing several mutants at position Glu-804 by confocal microscopy, These studies strongly implicate specific hydrophobic and acidic residues in the second and third IC loops of the parathyroid CaR (and potentially larger stretches of the third loop) in mediating efficient high [Ca2+](o)-induced PLC activation and or CaR expression.	Univ Calif San Francisco, Dept Med, Dept Vet Affairs Med Ctr, Endocrine Res Unit, San Francisco, CA 94121 USA	University of California System; University of California San Francisco	Shoback, D (corresponding author), Univ Calif San Francisco, Dept Med, Dept Vet Affairs Med Ctr, Endocrine Res Unit, 111N,4150 Clement St, San Francisco, CA 94121 USA.		Centeno, Patricia Pacios/O-8368-2016		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055846] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 55846, DK 43400] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai M, 1999, INT J MOL MED, V4, P115; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Brauner-Osborne H, 1999, J BIOL CHEM, V274, P18382, DOI 10.1074/jbc.274.26.18382; Brown E M, 1993, Curr Opin Nephrol Hypertens, V2, P541, DOI 10.1097/00041552-199307000-00004; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Cao YX, 1998, P NATL ACAD SCI USA, V95, P11987, DOI 10.1073/pnas.95.20.11987; Chang WH, 1999, ENDOCRINOLOGY, V140, P1911, DOI 10.1210/en.140.4.1911; Chang WH, 1998, AM J PHYSIOL-ENDOC M, V275, pE213, DOI 10.1152/ajpendo.1998.275.2.E213; Chang WH, 1998, J BONE MINER RES, V13, P570, DOI 10.1359/jbmr.1998.13.4.570; Chattopadhyay N, 1999, GLIA, V26, P64, DOI 10.1002/(SICI)1098-1136(199903)26:1<64::AID-GLIA7>3.0.CO;2-X; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Fan GF, 1998, FEBS LETT, V436, P353, DOI 10.1016/S0014-5793(98)01165-X; Francesconi A, 1998, J BIOL CHEM, V273, P5615, DOI 10.1074/jbc.273.10.5615; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; Huang ZM, 1996, J BIOL CHEM, V271, P33382, DOI 10.1074/jbc.271.52.33382; IidaKlein A, 1997, J BIOL CHEM, V272, P6882, DOI 10.1074/jbc.272.11.6882; IPPOLITO JA, 1990, J MOL BIOL, V215, P457, DOI 10.1016/S0022-2836(05)80364-X; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; Mary S, 1998, J BIOL CHEM, V273, P425, DOI 10.1074/jbc.273.1.425; Parmentier ML, 1998, MOL PHARMACOL, V53, P778, DOI 10.1124/mol.53.4.778; Pearce SHS, 1995, J CLIN INVEST, V96, P2683, DOI 10.1172/JCI118335; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; SHOBACK DM, 1988, ENDOCRINOLOGY, V122, P2833, DOI 10.1210/endo-122-6-2833; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Ye CP, 1996, BIOCHEM BIOPH RES CO, V224, P271, DOI 10.1006/bbrc.1996.1019	30	69	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19955	19963		10.1074/jbc.M909613199	http://dx.doi.org/10.1074/jbc.M909613199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10764812	hybrid			2022-12-27	WOS:000087941300072
J	Cobb, JA; Roberts, DM				Cobb, JA; Roberts, DM			Structural requirements for N-trimethylation of lysine 115 of calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; CENTRAL HELIX; CALCIUM; METHYLTRANSFERASE; METHYLATION; PURIFICATION; BINDING; BRAIN; GENE; PHOSPHORYLATION	Calmodulin is trimethylated at lysine 115 by a highly specific methyltransferase that utilizes S-adenosylmethionine as a co-substrate. Lysine 115 is found within a highly conserved six-amino acid loop (LGEKLT) that forms a 90 degrees turn between EF-hand III and EF-hand IV in the carboxyl-terminal lobe, In the present work a mutagenesis approach was used to investigate the structural features of the carboxyl-terminal lobe that lead to the specificity of calmodulin methylation. Three structural regions within the carboxyl-terminal lobe appear to be involved in methyltransferase recognition: the highly conserved six-amino acid loop-turn region that contains lysine 115 as well as the adjacent alpha-helices (helix 6 and helix 7) from EF-hands III and IV. Site-directed mutagenesis of residues in the loop show that three residues, glycine 113, glutamate 114, and leucine 116 are essential for methylation, In addition, subdomain (individual helix or Ca2+ binding loop) exchange mutants show that the substitutions of either helix 6 (EF-hand III) with helix 2 (EF-hand I) or helix 7 (EF-hand IV) with helix 3 (EF-hand II) compromises methylation, Charge-to-alanine mutations in helix 7 show that substitution of conserved charged residues at positions 118, 120, 122, 126, and 127 reduced lysine 115 methylation rates, suggesting possible electrostatic interactions between this helix and the methyltransferase, Single substitutions in helix 6 did not affect calmodulin methylation, suggesting this region may play a more indirect role in stabilizing the conformation of the methyltransferase recognition sequence.	Univ Tennessee, Dept Biochem Cellular & Mol Biol, Knoxville, TN 37996 USA	University of Tennessee System; University of Tennessee Knoxville	Roberts, DM (corresponding author), Univ Tennessee, Dept Biochem Cellular & Mol Biol, Knoxville, TN 37996 USA.			Roberts, Daniel/0000-0002-0780-7056				BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BAUDIER J, 1991, J BIOL CHEM, V266, P229; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; Cobb JA, 1999, BIOCHEM J, V340, P417, DOI 10.1042/0264-6021:3400417; GREGORI L, 1985, J BIOL CHEM, V260, P5232; Han CH, 1997, EUR J BIOCHEM, V244, P904, DOI 10.1111/j.1432-1033.1997.00904.x; HAN CH, 1993, BIOCHEMISTRY-US, V32, P13974, DOI 10.1021/bi00213a030; Harding SA, 1997, EMBO J, V16, P1137, DOI 10.1093/emboj/16.6.1137; KUBONIWA H, 1995, NAT STRUCT BIOL, V2, P768, DOI 10.1038/nsb0995-768; LUKAS TJ, 1989, P NATL ACAD SCI USA, V86, P7331, DOI 10.1073/pnas.86.19.7331; LUKAS TJ, 1987, CALCIUM BINDING PROT, P533; Malmendal A, 1999, J MOL BIOL, V293, P883, DOI 10.1006/jmbi.1999.3188; MORINO H, 1987, J NEUROCHEM, V48, P1201, DOI 10.1111/j.1471-4159.1987.tb05647.x; PECH LL, 1994, BBA-GEN SUBJECTS, V1199, P183, DOI 10.1016/0304-4165(94)90114-7; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; ROBERTS DM, 1986, J BIOL CHEM, V261, P1491; ROBERTS DM, 1985, BIOCHEMISTRY-US, V24, P5090, DOI 10.1021/bi00340a020; ROBERTS DM, 1992, P NATL ACAD SCI USA, V89, P8394, DOI 10.1073/pnas.89.17.8394; ROBERTS DM, 1987, METHOD ENZYMOL, V139, P290; ROWE PM, 1986, J BIOL CHEM, V261, P7060; ROWE PM, 1983, ANAL BIOCHEM, V133, P394, DOI 10.1016/0003-2697(83)90100-8; SHARMA RK, 1980, J BIOL CHEM, V255, P5916; Siegel F. L., 1990, PROTEIN METHYLATION, P33; Tsvetkov PO, 1999, J BIOL CHEM, V274, P18161, DOI 10.1074/jbc.274.26.18161; URBAUER JL, 1995, BIOCHEMISTRY-US, V34, P8099, DOI 10.1021/bi00025a016; VANHOOFF COM, 1988, J NEUROSCI, V8, P1789; WEBER PC, 1989, PROTEINS, V6, P70, DOI 10.1002/prot.340060107; Wright LS, 1996, J BIOL CHEM, V271, P12737, DOI 10.1074/jbc.271.22.12737; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758	30	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18969	18975		10.1074/jbc.M002332200	http://dx.doi.org/10.1074/jbc.M002332200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10766755	hybrid			2022-12-27	WOS:000087815900048
J	Huffman, DL; O'Halloran, TV				Huffman, DL; O'Halloran, TV			Energetics of copper trafficking between the Atx1 metallochaperone and the intracellular copper transporter, Ccc2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILSON-DISEASE GENE; SACCHAROMYCES-CEREVISIAE; MENKES-DISEASE; SUPEROXIDE-DISMUTASE; CANDIDATE GENE; IRON TRANSPORT; FUNCTIONAL EXPRESSION; BINDING-PROTEIN; UNEXPECTED ROLE; ATPASE	The Atx1 metallochaperone protein is a cytoplasmic Cu(I) receptor that functions in intracellular copper trafficking pathways in plants, microbes, and humans. A key physiological partner of the Saccharomyces cerevisiae Atx1 is Ccc2, a cation transporting P-type ATPase located in secretory vesicles. Here, we show that Atx1 donates its metal ion cargo to the first N-terminal Atx1-like domain of Ccc2 in a direct and reversible manner. The thermodynamic gradient for metal transfer is shallow (K-exchange = 1.4 +/- 0.2), establishing that vectorial delivery of copper by Atx1 is not based on a higher copper affinity of the target domain. Instead, Atx1 allows rapid metal transfer to its partner. This equilibrium is unaffected by a 50-fold excess of the Cu(I) competitor, glutathione, indicating that Atx1 also protects Cu(I) from nonspecific reactions. Mechanistically, we propose that a low activation barrier for transfer between partners results from complementary electrostatic forces that ultimately orient the metal-binding loops of Atx1 and Ccc2 for formation of copper-bridged intermediates. These thermodynamic and kinetic considerations suggest that copper trafficking proteins overcome the extraordinary copper chelation capacity of the eukaryotic cytoplasm by catalyzing the rate of copper transfer between physiological partners. In this sense, metallochaperones work like enzymes, carefully tailoring energetic barriers along specific reaction pathways: but not others.	Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University; Northwestern University	O'Halloran, TV (corresponding author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.	t-ohalloran@nwu.edu	O'Halloran, Thomas/ABE-6125-2021	O'Halloran, Thomas/0000-0001-8732-5059	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007284] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054111] Funding Source: NIH RePORTER; NIEHS NIH HHS [5T32ES07284] Funding Source: Medline; NIGMS NIH HHS [R01 GM054111, GM54111] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amaravadi R, 1997, HUM GENET, V99, P329, DOI 10.1007/s004390050367; Askwith C, 1998, TRENDS BIOCHEM SCI, V23, P135, DOI 10.1016/S0968-0004(98)01192-X; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DASILVA JRR, 1991, BIOL CHEM ELEMENTS, P396; Davis-Kaplan SR, 1998, P NATL ACAD SCI USA, V95, P13641, DOI 10.1073/pnas.95.23.13641; Forbes JR, 1999, J BIOL CHEM, V274, P12408, DOI 10.1074/jbc.274.18.12408; FU DD, 1995, YEAST, V11, P283, DOI 10.1002/yea.320110310; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Hung IH, 1998, J BIOL CHEM, V273, P1749, DOI 10.1074/jbc.273.3.1749; Kaplan J, 1996, SCIENCE, V271, P1510, DOI 10.1126/science.271.5255.1510; Klomp LWJ, 1997, J BIOL CHEM, V272, P9221, DOI 10.1074/jbc.272.14.9221; Lamb AL, 1999, NAT STRUCT BIOL, V6, P724; Larin D, 1999, J BIOL CHEM, V274, P28497, DOI 10.1074/jbc.274.40.28497; Lin SJ, 1997, J BIOL CHEM, V272, P9215; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; OSTERBERG R, 1979, J INORG BIOCHEM, V10, P341, DOI 10.1016/S0162-0134(00)80200-7; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Portnoy ME, 1999, J BIOL CHEM, V274, P15041, DOI 10.1074/jbc.274.21.15041; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rosenzweig AC, 2000, CURR OPIN CHEM BIOL, V4, P140, DOI 10.1016/S1367-5931(99)00066-6; Rosenzweig AC, 1999, STRUCTURE, V7, P605, DOI 10.1016/S0969-2126(99)80082-3; Schmidt PJ, 1999, J BIOL CHEM, V274, P36952, DOI 10.1074/jbc.274.52.36952; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; Voskoboinik N, 1999, J BIOL CHEM, V274, P22008, DOI 10.1074/jbc.274.31.22008; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; Vulpe CD, 1999, NAT GENET, V21, P195, DOI 10.1038/5979; Yuan DS, 1997, J BIOL CHEM, V272, P25787, DOI 10.1074/jbc.272.41.25787; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; Zhou B, 1997, P NATL ACAD SCI USA, V94, P7481, DOI 10.1073/pnas.94.14.7481	38	168	169	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18611	18614		10.1074/jbc.C000172200	http://dx.doi.org/10.1074/jbc.C000172200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10764731	hybrid			2022-12-27	WOS:000087815900001
J	Oppenheim, EW; Nasrallah, IM; Mastri, MG; Stover, PJ				Oppenheim, EW; Nasrallah, IM; Mastri, MG; Stover, PJ			Mimosine is a cell-specific antagonist of folate metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE HYDROXYMETHYLTRANSFERASE GENE; ONE-CARBON METABOLISM; DNA-REPLICATION; CYCLE PROGRESSION; MAMMALIAN-CELLS; IRON; REMETHYLATION; DEFICIENCY; METHIONINE; FERRITIN	Iron deficiency and iron chelators are known to alter folate metabolism in mammals, but the underlying biochemical mechanisms have not been established. Although many studies have demonstrated that the iron chelators mimosine and deferoxamine inhibit DNA replication in mammalian cells, their mechanism of action remains controversial. The effects of mimosine on folate metabolism were investigated in human MCF-7 cells and SH-SY5Y neuroblastoma. Our findings indicate that mimosine is a folate antagonist and that its effects are cell-specific, MCF-7 cells cultured in the presence of 350 mu M mimosine were growth-arrested, whereas mimosine had no effect on SH-SY5Y cell proliferation. Mimosine altered the distribution of folate cofactor forms in MCF-7 cells, indicating that mimosine targets folate metabolism. However, mimosine does not influence folate metabolism in SH-SY5Y neuroblastoma, The effect of mimosine on folate metabolism is associated with decreased cytoplasmic serine hydroxymethyltransferase (cSHMT) expression in MCF-7 cells but not in SH-SY5Y cells. MCF-7 cells exposed to mimosine for 24 h have a 95% reduction in cSHMT protein, and cSHMT promoter activity is reduced over 95%. Transcription of the cSHMT gene is also inhibited by deferoxamine in MCF-7 cells, indicating that mimosine inhibits cSHMT transcription by chelating iron. Analyses of mimosine-resistant MCF-7 cell lines demonstrate that although the effect of mimosine on cell cycle is independent of its effects on cSHMT expression, it inhibits both processes through a common regulatory mechanism.	Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA	Cornell University	Stover, PJ (corresponding author), Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK049621, T32DK007158] Funding Source: NIH RePORTER; NICHD NIH HHS [HD35678] Funding Source: Medline; NIDDK NIH HHS [DK49621, DK07158-21] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alpan RS, 1996, CELL GROWTH DIFFER, V7, P893; APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; CHANARIN I, 1980, J CLIN PATHOL, V33, P909, DOI 10.1136/jcp.33.10.909; CHANARIN I, 1965, BMJ-BRIT MED J, V1, P480, DOI 10.1136/bmj.1.5433.480; COLLINS A, 1987, EUR J BIOCHEM, V169, P299, DOI 10.1111/j.1432-1033.1987.tb13612.x; DAS KC, 1978, BRIT J HAEMATOL, V39, P357, DOI 10.1111/j.1365-2141.1978.tb01108.x; DIJKWEL PA, 1992, MOL CELL BIOL, V12, P3715, DOI 10.1128/MCB.12.9.3715; DRUMMOND JT, 1995, ANAL BIOCHEM, V228, P323, DOI 10.1006/abio.1995.1358; Fowler B, 1997, PEDIATR RES, V41, P145, DOI 10.1203/00006450-199701000-00023; GILBERT DM, 1995, J BIOL CHEM, V270, P9597, DOI 10.1074/jbc.270.16.9597; Girgis S, 1998, GENE, V210, P315, DOI 10.1016/S0378-1119(98)00085-7; Girgis S, 1997, J BIOL CHEM, V272, P4729, DOI 10.1074/jbc.272.8.4729; HORNE DW, 1981, ANAL BIOCHEM, V116, P393, DOI 10.1016/0003-2697(81)90378-X; Kalejta RF, 1997, EXP CELL RES, V231, P173, DOI 10.1006/excr.1996.3444; Kulp KS, 1996, TOXICOL APPL PHARM, V139, P356, DOI 10.1006/taap.1996.0176; LIN BF, 1993, J BIOL CHEM, V268, P21674; Lin HB, 1996, J BIOL CHEM, V271, P2548, DOI 10.1074/jbc.271.5.2548; OCONNOR DL, 1987, J NUTR, V117, P1715, DOI 10.1093/jn/117.10.1715; PFENDNER W, 1980, ARCH BIOCHEM BIOPHYS, V200, P503, DOI 10.1016/0003-9861(80)90382-3; Picard V, 1996, BLOOD, V87, P2057; Picard V, 1998, J BIOL CHEM, V273, P15382, DOI 10.1074/jbc.273.25.15382; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; Savage D.G., 1995, FOLATE HLTH DIS, V1st, P237; Schmutte C, 1996, CANCER RES, V56, P2375; SHANE B, 1989, VITAM HORM, V45, P273; Stover PJ, 1997, J BIOL CHEM, V272, P1842, DOI 10.1074/jbc.272.3.1842; Suh JR, 1997, CHEMISTRY AND BIOLOGY OF PTERIDINES AND FOLATES 1997, P381; VITALE JJ, 1965, LANCET, V2, P393; Wang G, 2000, EXP CELL RES, V254, P64, DOI 10.1006/excr.1999.4743; WANG Y, 1995, EXP CELL RES, V217, P84, DOI 10.1006/excr.1995.1066; Wise CK, 1997, J CHROMATOGR B, V696, P145, DOI 10.1016/S0378-4347(97)00213-2	31	39	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19268	19274		10.1074/jbc.M001610200	http://dx.doi.org/10.1074/jbc.M001610200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10766749	hybrid			2022-12-27	WOS:000087815900085
J	Quevedo, C; Alcazar, A; Salinas, M				Quevedo, C; Alcazar, A; Salinas, M			Two different signal transduction pathways are implicated in the regulation of initiation factor 2B activity in insulin-like growth factor-1-stimulated neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; GUANINE-NUCLEOTIDE-EXCHANGE; POLYPEPTIDE-CHAIN INITIATION; PROTEIN-SYNTHESIS; FACTOR EIF2B; RABBIT RETICULOCYTES; SKELETAL-MUSCLE; FACTOR 2-ALPHA; ACTIVATION; INHIBITION	Eukaryotic initiation factor eIF-2B plays an important role in translation regulation and has been suggested to be implicated in the increased protein synthesis promoted in response to growth factors. We have used primary cultured neurons to delineate the signaling pathways by which insulin-like growth factor-1 (IGF-1), which plays a critical role in the survival of neuronal cells, promotes eIF-2B and protein synthesis activation. Treatment of cortical neurons with IGF-1 (100 ng/ml) for 30 min stimulates [H-3]methionine incorporation, and a parallel increase in eIF-2B activity was observed. Wortmannin and LY294002 reversed both effects, indicating that phosphatidylinositol 3-kinase mediates IGF-1-induced protein synthesis and eIF-2B activation. IGF-1 induced glycogen synthase kinase-3 (GSK-3) inactivation in a phosphatidylinositol 3-kinase-dependent fashion because it is inhibited by wortmannin and LY294002. By using GSK-3 immunoprecipitated from untreated and IGF-1-treated cells, we demonstrate the phosphorylation of eIF-2B coincident with its inactivation. The treatment of cortical neurons with IGF-1 also promoted the activation of mitogen-activated protein kinase (MAPK). The MAPK-activating kinase (MEK) inhibitor PD98059 inhibited MAPK activation and reversed IGF-1-induced protein synthesis and eIF-2B activation. These findings suggest that IGF-1-induced eIF-2B activation on neurons is promoted through phosphatidylinositol S-kinase and GSK-3 kinase, and we report an IGF-1-induced MEK/MAPK activation pathway implicated in eIF-2B activation.	Hosp Ramon y Cajal, Serv Bioquim Invest, E-28034 Madrid, Spain	Hospital Universitario Ramon y Cajal	Alcazar, A (corresponding author), Hosp Ramon y Cajal, Serv Bioquim Invest, Ctra Comenar Km 9,1, E-28034 Madrid, Spain.							Alcazar A, 1996, MOL BRAIN RES, V38, P101, DOI 10.1016/0169-328X(95)00335-P; ALCAZAR A, 1995, J NEUROCHEM, V65, P754; Alcazar A, 1997, J NEUROCHEM, V69, P1703; AROOR AR, 1995, EXP HEMATOL, V23, P1204; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; D MSR, 1997, J NEUROSCI, V17, P1548; DHOLAKIA JN, 1988, P NATL ACAD SCI USA, V85, P51, DOI 10.1073/pnas.85.1.51; DHOLAKIA JN, 1986, P NATL ACAD SCI USA, V83, P6746, DOI 10.1073/pnas.83.18.6746; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; Gilligan M, 1996, J BIOL CHEM, V271, P2121, DOI 10.1074/jbc.271.4.2121; Heck S, 1999, J BIOL CHEM, V274, P9828, DOI 10.1074/jbc.274.14.9828; Hershey JWB, 1996, TRANSLATIONAL CONTRO; Jefferson LS, 1999, INT J BIOCHEM CELL B, V31, P191, DOI 10.1016/S1357-2725(98)00141-1; KARINCH AM, 1993, AM J PHYSIOL, V264, pE101, DOI 10.1152/ajpendo.1993.264.1.E101; Kimball SR, 1999, INT J BIOCHEM CELL B, V31, P25, DOI 10.1016/S1357-2725(98)00128-9; Kimball SR, 1998, J BIOL CHEM, V273, P30945, DOI 10.1074/jbc.273.47.30945; Kleijn M, 1998, J BIOL CHEM, V273, P5536, DOI 10.1074/jbc.273.10.5536; Lavandero S, 1998, FEBS LETT, V422, P193, DOI 10.1016/S0014-5793(98)00008-8; Manchester KL, 1997, BIOCHEM BIOPH RES CO, V239, P223, DOI 10.1006/bbrc.1997.7462; Miller TM, 1997, J BIOL CHEM, V272, P9847; OCHOA S, 1983, ARCH BIOCHEM BIOPHYS, V223, P325, DOI 10.1016/0003-9861(83)90598-2; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Paschen W, 1999, J CEREBR BLOOD F MET, V19, P1, DOI 10.1097/00004647-199901000-00001; Proud CG, 1997, BIOCHEM J, V328, P329; Rhoads RE, 1999, J BIOL CHEM, V274, P30337, DOI 10.1074/jbc.274.43.30337; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; SCHUMACHER R, 1993, J BIOL CHEM, V268, P1087; Singh LP, 1996, BIOCHEMISTRY-US, V35, P3206, DOI 10.1021/bi9522099; Torres-Aleman I, 1998, NEUROLOGY, V50, P772, DOI 10.1212/WNL.50.3.772; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; VANLINT J, 1993, ANAL BIOCHEM, V208, P132, DOI 10.1006/abio.1993.1018; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WELSH GI, 1992, BIOCHEM J, V284, P19, DOI 10.1042/bj2840019; Welsh GI, 1997, ANAL BIOCHEM, V244, P16, DOI 10.1006/abio.1996.9838; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; Welsh GI, 1996, J BIOL CHEM, V271, P11410, DOI 10.1074/jbc.271.19.11410; Welsh GI, 1997, FEBS LETT, V410, P418, DOI 10.1016/S0014-5793(97)00579-6; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2	42	57	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19192	19197		10.1074/jbc.M000238200	http://dx.doi.org/10.1074/jbc.M000238200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10764740	hybrid			2022-12-27	WOS:000087815900076
J	Chan, SL; Mayne, M; Holden, CP; Geiger, JD; Mattson, MP				Chan, SL; Mayne, M; Holden, CP; Geiger, JD; Mattson, MP			Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; RAT-BRAIN; ENDOPLASMIC-RETICULUM; LINKED PRESENILIN-1; MUTANT PRESENILIN-1; CULTURED NEURONS; CA2+ RELEASE; BETA-PEPTIDE	Many cases of early-onset inherited Alzheimer's disease (AD) are caused by mutations in the presenilin-1 (PSI) gene. PS1 mutations may perturb cellular Ca2+ homeostasis and thereby render neurons vulnerable to excitotoxicity and apoptosis. We now report that PC12 cells expressing PS1 mutations and primary hippocampal neurons from PS1 mutant knockin mice exhibit greatly increased levels of ryanodine receptors (RyR) and enhanced Ca2+ release following stimulation with caffeine. Double-labeling immunostaining and co-immunoprecipitation analyses indicate that PS1 and RyR are colocalized and interact physically, Caffeine treatment sensitizes neurons expressing mutant PS1 to apoptosis induced by amyloid beta-peptide, a neurotic peptide linked to the pathogenesis of AD. When taken together with recent evidence for alterations in RyR in brains of AD patients, our data suggest that PS1 mutations may promote neuronal degeneration in AD by increasing transcription and translation of RyR and altering functional properties of ryanodine-sensitive Ca2+ pools.	NIA, Neurosci Lab, NIH, Baltimore, MD 21224 USA; Univ Kentucky, Sanders Brown Res Ctr Aging, Lexington, KY 40536 USA; Univ Manitoba, Fac Med, Dept Pharmacol & Therapeut, Winnipeg, MB R3E 0W3, Canada	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Kentucky; University of Manitoba	Mattson, MP (corresponding author), NIA, Neurosci Lab, NIH, GRC 4F01,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.				NATIONAL INSTITUTE ON AGING [ZIAAG000312, Z01AG000312] Funding Source: NIH RePORTER; NIA NIH HHS [P01AG10386] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alcazar A, 1997, J NEUROCHEM, V69, P1703; Ancolio K, 1997, J NEUROCHEM, V69, P2494, DOI 10.1046/j.1471-4159.1997.69062494.x; Anderson CM, 1999, J NEUROCHEM, V73, P867, DOI 10.1046/j.1471-4159.1999.0730867.x; Begley JG, 1999, J NEUROCHEM, V72, P1030, DOI 10.1046/j.1471-4159.1999.0721030.x; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Erikson A, 1997, BAILLIERE CLIN HAEM, V10, P711, DOI 10.1016/S0950-3536(97)80035-2; FRANDSEN A, 1991, J NEUROCHEM, V56, P1075, DOI 10.1111/j.1471-4159.1991.tb02031.x; FRIEL DD, 1995, CIBA F SYMP, V188, P210; Guo Q, 1998, J BIOL CHEM, V273, P12341, DOI 10.1074/jbc.273.20.12341; Guo Q, 1999, NAT MED, V5, P101, DOI 10.1038/4789; Guo Q, 1996, NEUROREPORT, V8, P379, DOI 10.1097/00001756-199612200-00074; Guo Q, 1997, J NEUROSCI, V17, P4212; Guo Q, 1999, P NATL ACAD SCI USA, V96, P4125, DOI 10.1073/pnas.96.7.4125; Hagan MP, 1997, RADIAT RES, V147, P674, DOI 10.2307/3579479; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; Kelliher M, 1999, NEUROSCIENCE, V92, P499, DOI 10.1016/S0306-4522(99)00042-1; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; Korkotian E, 1999, J BIOL CHEM, V274, P21673, DOI 10.1074/jbc.274.31.21673; Kruman I, 1997, J NEUROSCI, V17, P5089; LOCK RB, 1994, CANCER RES, V54, P4933; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MATTSON MP, 1995, METHOD CELL BIOL, V46, P187; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Mattson MP, 1998, J NEUROCHEM, V70, P1; Mayne M, 1999, ANN NEUROL, V45, P633, DOI 10.1002/1531-8249(199905)45:5<633::AID-ANA12>3.0.CO;2-X; Padua RA, 1996, EUR J PHARMACOL, V298, P185, DOI 10.1016/0014-2999(95)00797-0; Parent A, 1999, NEUROBIOL DIS, V6, P56, DOI 10.1006/nbdi.1998.0207; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SHARP AH, 1993, J NEUROSCI, V13, P3051; Small GW, 1997, JAMA-J AM MED ASSOC, V278, P1363, DOI 10.1001/jama.278.16.1363; Tasker RC, 1998, J CEREBR BLOOD F MET, V18, P1346, DOI 10.1097/00004647-199812000-00009; Wei HF, 1996, J NEUROCHEM, V67, P2390; ZHANG L, 1993, NEUROSCI LETT, V158, P105, DOI 10.1016/0304-3940(93)90623-S	37	255	264	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18195	18200		10.1074/jbc.M000040200	http://dx.doi.org/10.1074/jbc.M000040200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10764737	hybrid			2022-12-27	WOS:000087659400040
J	Kim, I; Kim, JH; Ryu, YS; Jung, SH; Nah, JJ; Koh, GY				Kim, I; Kim, JH; Ryu, YS; Jung, SH; Nah, JJ; Koh, GY			Characterization and expression of a novel alternatively spliced human angiopoietin-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; TIE2 RECEPTOR; ANGIOGENESIS; DIFFERENTIATION; CLONING; LIGAND; CELLS; CD36; MACROPHAGE; HYPOXIA	Angiopoietin-2 (Ang2) is a naturally occurring antagonist of angiopoietin-1 (Ang1) that competes for binding to the Tie2 receptor and blocks Ang1-induced Tie2 autophosphorylation during vasculogenesis. Using the polymerase chain reaction, we isolated a cDNA encoding a novel shorter form of Ang2 from human umbilical vein endothelial cell cDNA and have designated it angiopoietin-2(443) (Ang2(443)), because it contains 443 amino acids. Part of the coiled-coil domain (amino acids 96-148) is absent in Ang2(443) because of alternative splicing of the gene. Like Ang2, recombinant Ang2(443) expressed in COS-7 cells is secreted as a glycosylated homodimeric protein. Recombinant Ang2, binds to the Tie2 receptor but does not induce Tie2 phosphorylation. Pre-occupation of Ang2(443) on Tie2 inhibits Ang1 or Ang2 binding and inhibits Ang1-induced phosphorylation, Expression of Ang2(443) mRNA is detectable in primary endothelial cells, several nonendothelial tumor cell lines, and primary tumor tissues. Interestingly, two cervical carcinoma cell lines express relatively moderate levels of Ang2(443) mRNA. and protein. Macrophages express mainly Ang2 mRNA, but the expression of Ang2(443) mRNA is temporarily up-regulated during macrophage differentiation. These results suggest that Ang2(443) is a functional antagonist of Ang1 and could be an important regulator of angiogenesis during some tumorigenic and inflammatory processes.	Chonbuk Univ, Sch Med, Natl Creat Res Initiat Ctr Cardiac Regenerat, Chonju 560180, South Korea; Chonbuk Univ, Sch Med, Cardiol Res Inst, Chonju 560180, South Korea; Chonbuk Univ, Sch Med, Dept Gen Surg, Chonju 560180, South Korea	Jeonbuk National University; Jeonbuk National University; Jeonbuk National University	Koh, GY (corresponding author), Chonbuk Univ, Sch Med, Natl Creat Res Initiat Ctr Cardiac Regenerat, San 2-20,Keum Am Dong, Chonju 560180, South Korea.	gykoh@moak.chonbuk.ac.kr	Kim, Injune/C-1710-2011; Koh, Gou Young/C-1615-2011	Kim, Injune/0000-0001-9244-815X; 				ACTON SL, 1994, J BIOL CHEM, V269, P21003; Alessio M, 1996, J BIOL CHEM, V271, P1770, DOI 10.1074/jbc.271.3.1770; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Freeman M W, 1997, Curr Opin Hematol, V4, P41; Huh HY, 1996, BLOOD, V87, P2020; Kim I, 1999, FEBS LETT, V443, P353, DOI 10.1016/S0014-5793(99)00008-3; Kim I, 1999, J BIOL CHEM, V274, P26523, DOI 10.1074/jbc.274.37.26523; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Mandriota SJ, 1998, CIRC RES, V83, P852, DOI 10.1161/01.RES.83.8.852; Mezquita J, 1999, BIOCHEM BIOPH RES CO, V260, P492, DOI 10.1006/bbrc.1999.0934; Nakata A, 1999, ARTERIOSCL THROM VAS, V19, P1333, DOI 10.1161/01.ATV.19.5.1333; Oh H, 1999, J BIOL CHEM, V274, P15732, DOI 10.1074/jbc.274.22.15732; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; Polverini P J, 1997, EXS, V79, P11; Procopio WN, 1999, J BIOL CHEM, V274, P30196, DOI 10.1074/jbc.274.42.30196; Schwende H, 1996, J LEUKOCYTE BIOL, V59, P555, DOI 10.1002/jlb.59.4.555; Stratmann A, 1998, AM J PATHOL, V153, P1459, DOI 10.1016/S0002-9440(10)65733-1; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Tanaka S, 1999, J CLIN INVEST, V103, P341, DOI 10.1172/JCI4891; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Valenzuela DM, 1999, P NATL ACAD SCI USA, V96, P1904, DOI 10.1073/pnas.96.5.1904; Veikkola T, 1999, SEMIN CANCER BIOL, V9, P211, DOI 10.1006/scbi.1998.0091; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	26	52	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18550	18556		10.1074/jbc.M910084199	http://dx.doi.org/10.1074/jbc.M910084199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10766762	hybrid			2022-12-27	WOS:000087659400087
J	Imbeault, NYR; Powlowski, JB; Colbert, CL; Bolin, JT; Eltis, LD				Imbeault, NYR; Powlowski, JB; Colbert, CL; Bolin, JT; Eltis, LD			Steady-state kinetic characterization and crystallization of a polychlorinated biphenyl-transforming dioxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP STRAIN LB400; PSEUDOMONAS-CEPACIA; OXYGENASE COMPONENT; NAPHTHALENE DIOXYGENASE; PURIFICATION; DEGRADATION; 2,3-DIOXYGENASE; IDENTIFICATION; CHLOROBIPHENYL; SPECIFICITY	The oxygenase component of biphenyl dioxygenase (BPDO) from Comamonas testosteroni B-356 dihydroxylates biphenyl and some polychlorinated biphenyls (PCBs), thereby initiating their degradation. Overexpressed, anaerobically purified BPDO had a specific activity of 4.9 units/mg, and its oxygenase component appeared to contain a full complement of Fe2S2 center and catalytic iron. Oxygenase crystals in space group R3 were obtained under anaerobic conditions using polyethylene glycol as the precipitant. X-ray diffraction was measured to 1.6 Angstrom. Steady-state kinetics assays demonstrated that BPDO had an apparent K-cat/K-m for biphenyl of (1.2 +/- 0.1) x 10(6) M-1 s(-1) in air-saturated buffer. Moreover, BPDO transformed dichlorobiphenyls (diClBs) in the following order of apparent specificities: 3,3'- > 2,2'- > 4,4'-diClB. Strikingly, the ability of BPDO to utilize O-2 depended strongly on the biphenyl substrate; k(cat)/K-m(O2) = (3.6 +/- 0.3), (0.06 +/- 0.02), and (0.4 +/- 0.07) x 10(5) M-1 S-1 the presence of biphenyl and 2,2'- and 3,3'-diClBs, respectively. Moreover, biphenyl/O-2 consumed was 0.97, 0.44, 0.63, and 0.48 in the presence of biphenyl and 2,2'-, 3,3'-, and 4,4'-diClBs, respectively. Within experimental error, the balance of consumed O-2 was detected as H2O2. Thus, PCB congeners such as 2,2' diClB exact a high energetic cost, produce a cytotoxic compound (H2O2), and can inhibit degradation of other congeners. Each of these effects would be predicted to inhibit the aerobic microbial catabolism of PCBs.	Concordia Univ, Dept Chem & Biochem, Montreal, PQ H3G 1M8, Canada; Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Univ Laval, Dept Biochem, Quebec City, PQ G1K 7P4, Canada	Concordia University - Canada; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Laval University	Powlowski, JB (corresponding author), Concordia Univ, Dept Chem & Biochem, 1455 Maisonneuve Blvd W, Montreal, PQ H3G 1M8, Canada.	Powlow@vax2.concordia.ca	Eltis, Lindsay D/J-8272-2015	Eltis, Lindsay D/0000-0002-6774-8158	NIGMS NIH HHS [GM-52381] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barriault D, 1997, INT BIODETER BIODEGR, V39, P311, DOI 10.1016/S0964-8305(97)00027-9; BATIE CJ, 1987, J BIOL CHEM, V262, P1510; BERGERON J, 1994, CAN J MICROBIOL, V40, P743, DOI 10.1139/m94-118; BROWN RE, 1989, ANAL BIOCHEM, V180, P136, DOI 10.1016/0003-2697(89)90101-2; Bruhlmann F, 1999, BIOTECHNOL BIOENG, V63, P544, DOI 10.1002/(SICI)1097-0290(19990605)63:5<544::AID-BIT4>3.0.CO;2-6; Butler CS, 1997, ADV MICROB PHYSIOL, V38, P47; Chebrou H, 1999, J BACTERIOL, V181, P4805, DOI 10.1128/JB.181.16.4805-4811.1999; CHEN JS, 1977, ANAL BIOCHEM, V79, P157, DOI 10.1016/0003-2697(77)90390-6; CHO JH, 1995, BIOTECHNOL TECH, V9, P41, DOI 10.1007/BF00152998; Cornish-Bowden A., 1995, ANAL ENZYME KINETIC; FISHER MT, 1985, J AM CHEM SOC, V107, P5018, DOI 10.1021/ja00303a045; FOCHT DD, 1995, CURR OPIN BIOTECH, V6, P341, DOI 10.1016/0958-1669(95)80057-3; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; GASSNER GT, 1993, BIOCHEMISTRY-US, V32, P4820, DOI 10.1021/bi00069a017; GIBSON DT, 1993, J BACTERIOL, V175, P4561, DOI 10.1128/JB.175.14.4561-4564.1993; HADDOCK JD, 1995, J BACTERIOL, V177, P5834, DOI 10.1128/jb.177.20.5834-5839.1995; HADDOCK JD, 1995, J BACTERIOL, V177, P20, DOI 10.1128/jb.177.1.20-26.1995; HAIGLER BE, 1990, J BACTERIOL, V172, P457, DOI 10.1128/JB.172.1.457-464.1990; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HERRERO M, 1990, J BACTERIOL, V172, P6557, DOI 10.1128/jb.172.11.6557-6567.1990; Hurtubise Y, 1996, J BIOL CHEM, V271, P8152, DOI 10.1074/jbc.271.14.8152; HURTUBISE Y, 1995, J BACTERIOL, V177, P6610, DOI 10.1128/jb.177.22.6610-6618.1995; Hurtubise Y, 1998, J BACTERIOL, V180, P5828, DOI 10.1128/JB.180.22.5828-5835.1998; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; Kimura N, 1997, J BACTERIOL, V179, P3936, DOI 10.1128/jb.179.12.3936-3943.1997; Kumamaru T, 1998, NAT BIOTECHNOL, V16, P663, DOI 10.1038/nbt0798-663; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee K, 1999, J BACTERIOL, V181, P2719, DOI 10.1128/JB.181.9.2719-2725.1999; LORENZO V, 1993, GENE, V123, P17, DOI DOI 10.1016/0378-1119(93)90533-9; Mackay D.M., 1992, ILLUSTRATED HDB PHYS, DOI DOI 10.1201/9781420044393; Mondello FJ, 1997, APPL ENVIRON MICROB, V63, P3096, DOI 10.1128/AEM.63.8.3096-3103.1997; Ortiz de Montellano PR, 1986, CYTOCHROME P450 STRU, P217; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parales RE, 1998, J BACTERIOL, V180, P2337, DOI 10.1128/JB.180.9.2337-2344.1998; Pavel E G, 1994, Chem Biol, V1, P173, DOI 10.1016/1074-5521(94)90007-8; RAAG R, 1991, BIOCHEMISTRY-US, V30, P2674, DOI 10.1021/bi00224a016; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Seah SYK, 1998, J BIOL CHEM, V273, P22943, DOI 10.1074/jbc.273.36.22943; Seeger M, 1999, APPL ENVIRON MICROB, V65, P3614; Sylvestre M, 1996, GENE, V174, P195, DOI 10.1016/0378-1119(96)00039-X; TIMMIS KN, 1994, ANNU REV MICROBIOL, V48, P525, DOI 10.1146/annurev.mi.48.100194.002521; Tsang HT, 1996, J BIOL INORG CHEM, V1, P24, DOI 10.1007/s007750050019; Vaillancourt FH, 1998, J BIOL CHEM, V273, P34887, DOI 10.1074/jbc.273.52.34887; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yeates TO, 1997, METHOD ENZYMOL, V276, P344, DOI 10.1016/S0076-6879(97)76068-3	47	58	58	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12430	12437		10.1074/jbc.275.17.12430	http://dx.doi.org/10.1074/jbc.275.17.12430			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777527	hybrid			2022-12-27	WOS:000086762300011
J	Ali, S; Palmer, ACV; Banerjee, B; Fritchley, SJ; Kirby, JA				Ali, S; Palmer, ACV; Banerjee, B; Fritchley, SJ; Kirby, JA			Examination of the function of RANTES, MIP-1 alpha, and MIP-1 beta following interaction with heparin-like glycosaminoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; BINDING-SITE; CELL-SURFACE; SULFATE PROTEOGLYCANS; CHEMOKINE RECEPTORS; INTERFERON-GAMMA; INTERLEUKIN-8; ACTIVATION; AFFINITY; IDENTIFICATION	Chemokines are a group of small proteins that have a variety of functions, including the activation and recruitment of immune cells during episodes of inflammation. In common with many cytokines, it has been observed that chemokines have the potential to bind heparin-like glycosaminoglycan molecules, which are normally expressed an proteoglycan components of the cell surface and extracellular matrix. The significance of this interaction for chemokine activity remains a subject of debate. In this study, Chinese hamster ovary cells were transfected separately with the human chemokine receptors CCR1 and CCR5, and these receptors were shown to induce an intracytoplasmic Ca2+ flux and cellular chemotaxis following stimulation with the natural CC chemokine ligands (MIP-1 alpha, RANTES (regulated on activation normal T cell expressed), and MIP-1 beta). In further experiments, mutant CHO cells, with a defect in normal glycosaminoglycan (GAG) expression, were also transfected with, and shown to express similar levels of, CCR1 and CCR5. Although these receptors were functional, it was found that the mutant cells required exposure to higher concentrations of ligands than the wild-type cells in order to produce the same intracytoplasmic Ca2+ flux. Radioligand binding experiments demonstrated that specific chemokine receptors expressed by wild-type cells had a significantly greater affinity for MIP-1 alpha than similar receptors expressed by GAG-deficient mutants. However, there was no significant difference between these cells in their affinity for RANTES or MIP-1 beta. In conclusion, it has been demonstrated clearly that GAG expression is not necessary for the biological activity of the chemokines MIP-1 alpha, RANTES, or MIP-1 beta. However, the presence of cell surface GAGs does enhance the activity of low concentrations of these chemokines by a mechanism that appears to involve sequestration onto the cell surface.	Univ Newcastle Upon Tyne, Sch Med, Dept Surg, Immunobiol Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Ali, S (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Dept Surg, Immunobiol Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.			Kirby, John/0000-0003-2543-4131				BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Bonini JA, 1997, DNA CELL BIOL, V16, P1249, DOI 10.1089/dna.1997.16.1249; Burns JM, 1998, J EXP MED, V188, P1917, DOI 10.1084/jem.188.10.1917; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Douglas MS, 1997, IMMUNOLOGY, V92, P512, DOI 10.1046/j.1365-2567.1997.00385.x; Douglas MS, 1997, CLIN EXP IMMUNOL, V107, P578, DOI 10.1046/j.1365-2249.1997.3141206.x; ESKO JD, 1986, J BIOL CHEM, V261, P5725; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; GILAT D, 1994, J IMMUNOL, V153, P4899; Graham GJ, 1996, EMBO J, V15, P6506, DOI 10.1002/j.1460-2075.1996.tb01041.x; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; Husman AMD, 1998, TRENDS MICROBIOL, V6, P244, DOI 10.1016/S0966-842X(98)01249-9; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; Kirby John A., 1996, P137; Koopmann W, 1997, J BIOL CHEM, V272, P10103; Koopmann W, 1999, J IMMUNOL, V163, P2120; Kuschert GSV, 1998, BIOCHEMISTRY-US, V37, P11193, DOI 10.1021/bi972867o; LORTAT-JACOB H, 1992, BIOCHIM BIOPHYS ACTA, V1117, P126, DOI 10.1016/0304-4165(92)90069-7; LUSTER AD, 1995, J EXP MED, V182, P219, DOI 10.1084/jem.182.1.219; MAIONE TE, 1991, CANCER RES, V51, P2077; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; Moy FJ, 1997, BIOCHEMISTRY-US, V36, P4782, DOI 10.1021/bi9625455; Oravecz T, 1997, J IMMUNOL, V159, P4587; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; ROT A, 1993, EUR J IMMUNOL, V23, P303, DOI 10.1002/eji.1830230150; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Tanaka Y, 1998, TRENDS GLYCOSCI GLYC, V10, P153, DOI 10.4052/tigg.10.153; Tanaka Y, 1998, P ASSOC AM PHYSICIAN, V110, P118; Wagner L, 1998, NATURE, V391, P908, DOI 10.1038/36129; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	38	120	120	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11721	11727		10.1074/jbc.275.16.11721	http://dx.doi.org/10.1074/jbc.275.16.11721			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766793	hybrid			2022-12-27	WOS:000086695500028
J	Arnold, DA; Kowalczykowski, SC				Arnold, DA; Kowalczykowski, SC			Facilitated loading of RecA protein is essential to recombination by RecBCD enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JOINT MOLECULE FORMATION; ESCHERICHIA-COLI; HELICASE ACTIVITY; NUCLEASE ACTIVITY; HOMOLOGOUS RECOMBINATION; RECB(2109)CD ENZYME; ATP HYDROLYSIS; EXONUCLEASE-V; CHI; DNA	Although the RecB(2109)CD enzyme retains most of the biochemical functions associated with the wild-type RecBCD enzyme, it is completely defective for genetic recombination. Here, we demonstrate that the mutant enzyme exhibits an aberrant double stranded DNA exonuclease activity, intrinsically producing a 3'-terminal single-stranded DNA overhang that is an ideal substrate for RecA protein-promoted strand invasion. Thus, the mutant enzyme constitutively processes double-stranded DNA in the same manner as the chi-modified wild-type RecBCD enzyme. However, we further show that the RecB(2109)CD enzyme is unable to coordinate the loading of RecA protein onto the single-stranded DNA produced, and we conclude that this inability results in the recombination-defective phenotype of the recB2109 allele. Our findings argue that the facilitated loading of RecA protein by the chi-activated RecBCD enzyme is essential for RecBCD-mediated homologous recombination in vivo.	Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Univ Calif Davis, Genet Grad Grp, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Microbiol Sect, 1 Shields Ave, Davis, CA 95616 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041347] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-41347] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMUNDSEN SK, 1990, GENETICS, V126, P25; AMUNDSEN SK, 1986, P NATL ACAD SCI USA, V83, P5558, DOI 10.1073/pnas.83.15.5558; Anderson DG, 1997, CELL, V90, P77, DOI 10.1016/S0092-8674(00)80315-3; Anderson DG, 1997, GENE DEV, V11, P571, DOI 10.1101/gad.11.5.571; Anderson DG, 1997, GENES CELLS, V2, P117, DOI 10.1046/j.1365-2443.1997.1130311.x; Arnold DA, 1998, J BIOL CHEM, V273, P16476, DOI 10.1074/jbc.273.26.16476; ARNOLD DA, 1999, THESIS U CALIFORNIA; BIEK DP, 1986, J BACTERIOL, V167, P594, DOI 10.1128/jb.167.2.594-603.1986; CHAUDHURY AM, 1984, P NATL ACAD SCI-BIOL, V81, P7850, DOI 10.1073/pnas.81.24.7850; Churchill JJ, 1999, GENE DEV, V13, P901, DOI 10.1101/gad.13.7.901; DIXON DA, 1991, CELL, V66, P361, DOI 10.1016/0092-8674(91)90625-9; DIXON DA, 1993, CELL, V73, P87, DOI 10.1016/0092-8674(93)90162-J; DIXON DA, 1995, J BIOL CHEM, V270, P16360, DOI 10.1074/jbc.270.27.16360; DOWER NA, 1988, P NATL ACAD SCI USA, V78, P7033; EGGLESTON AK, 1993, J MOL BIOL, V231, P621, DOI 10.1006/jmbi.1993.1314; EGGLESTON AK, 1993, J MOL BIOL, V231, P605, DOI 10.1006/jmbi.1993.1313; EICHLER DC, 1977, J BIOL CHEM, V252, P499; EMMERSON PT, 1968, GENETICS, V60, P19; KONFORTI BB, 1987, P NATL ACAD SCI USA, V84, P690, DOI 10.1073/pnas.84.3.690; KONFORTI BB, 1990, J BIOL CHEM, V265, P6916; KORANGY F, 1993, BIOCHEMISTRY-US, V32, P4873, DOI 10.1021/bi00069a024; KOWALCZYKOWSKI SC, 1991, BIOCHIMIE, V73, P289, DOI 10.1016/0300-9084(91)90216-N; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; LOVETT ST, 1988, GENETICS, V120, P37; MYERS RS, 1994, ANNU REV GENET, V28, P49, DOI 10.1146/annurev.ge.28.120194.000405; PALAS KM, 1990, J BIOL CHEM, V265, P3447; PONTICELLI AS, 1985, CELL, V41, P145, DOI 10.1016/0092-8674(85)90069-8; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; ROMAN LJ, 1992, J BIOL CHEM, V267, P4207; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2873, DOI 10.1021/bi00433a019; SMITH GR, 1981, CELL, V24, P429, DOI 10.1016/0092-8674(81)90333-0; SMITH GR, 1991, CELL, V64, P19, DOI 10.1016/0092-8674(91)90205-D; STAHL FW, 1977, GENETICS, V86, P715; THALER DS, 1989, GENOME, V31, P53, DOI 10.1139/g89-013; Tracy RB, 1996, GENE DEV, V10, P1890, DOI 10.1101/gad.10.15.1890; Yu M, 1998, P NATL ACAD SCI USA, V95, P981, DOI 10.1073/pnas.95.3.981	36	56	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12261	12265		10.1074/jbc.275.16.12261	http://dx.doi.org/10.1074/jbc.275.16.12261			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766864	Green Published, hybrid			2022-12-27	WOS:000086695500099
J	Casarotto, MG; Gibson, F; Pace, SM; Curtis, SM; Mulcair, M; Dulhunty, AF				Casarotto, MG; Gibson, F; Pace, SM; Curtis, SM; Mulcair, M; Dulhunty, AF			A structural requirement for activation of skeletal ryanodine receptors by peptides of the dihydropyridine receptor II-III loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE; EXCITATION; PROTEINS; IDENTIFICATION; SPECTROSCOPY; SER(687); SEQUENCE; REGIONS; SEGMENT; SPECTRA	The solution structures of three related peptides (A1, A2, and A9) corresponding to the Thr(671)-Leu(690) region of the skeletal muscle dihydropyridine receptor II-III loop have been investigated using nuclear magnetic resonance spectroscopy. Peptide A1, the native sequence, is less effective in activating ryanodine receptor calcium release channels than A2 (Ser(687) to Ala substitution). Peptide A9, Arg(681)-Ser(687), does not activate ryanodine receptors. A1 and A2 are helical from their N terminus to Lys(685) but are generally unstructured from Lys(685) to the C terminus. The basic residues Arg(681)-Lys(685), essential for A1 activation of ryanodine receptors, are located at the C-terminal end of the alpha-helix, Peptide A9 was found to be unstructured. Differences between A1 and A2 were observed in the C-terminal end of the helix (residues 681-685), which was less ordered in A1, and in the C-terminal region of the peptide, which exhibited greater flexibility in A1. Predicted low energy models suggest that an electrostatic interaction between the hydroxyl oxygen of Ser(687) and the guanidino moiety of Arg(683) is lost with the Ser(687)Ala substitution. The results show that the more structured peptides are more effective in activating ryanodine receptors.	Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Canberra, ACT 2601, Australia	Australian National University; John Curtin School of Medical Research	Casarotto, MG (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, GPO Box 334, Canberra, ACT 2601, Australia.	casarotto@anu.edu.au	Casarotto, Marco/D-8704-2011; Dulhunty, Angela/AAO-5421-2020	Casarotto, Marco/0000-0002-0571-7671; Dulhunty, Angela/0000-0001-9493-4944				BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BODENHAUSEN G, 1984, J MAGN RESON, V46, P269; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRUNGER AT, 1986, P NATL ACAD SCI USA, V83, P3801, DOI 10.1073/pnas.83.11.3801; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DESLAURIERS R, 1980, BIOL MAGN RESON, V2, P243; Dulhunty AF, 1999, BIOPHYS J, V77, P189, DOI 10.1016/S0006-3495(99)76881-5; DULHUNTY AF, 1999, BIOPHYS J, V76, P466; El-Hayek R, 1998, BIOCHEMISTRY-US, V37, P7015, DOI 10.1021/bi972907o; ELHAYEK R, 1995, J BIOL CHEM, V270, P22116, DOI 10.1074/jbc.270.38.22116; Gurrola GB, 1999, J BIOL CHEM, V274, P7879, DOI 10.1074/jbc.274.12.7879; LAVER DR, 1995, J MEMBRANE BIOL, V147, P7; Leong P, 1998, J BIOL CHEM, V273, P7791, DOI 10.1074/jbc.273.14.7791; LU XY, 1995, J BIOL CHEM, V270, P18459, DOI 10.1074/jbc.270.31.18459; LU XY, 1994, J BIOL CHEM, V269, P6511; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; Nakai J, 1998, J BIOL CHEM, V273, P24983, DOI 10.1074/jbc.273.39.24983; O'Reilly FM, 1999, BIOPHYS J, V76, pA466; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TRIMBLE LA, 1994, J MAGN RESON SER B, V105, P67, DOI 10.1006/jmrb.1994.1102; Vieille C, 1996, TRENDS BIOTECHNOL, V14, P183, DOI 10.1016/0167-7799(96)10026-3; Vijayakumar M, 1999, PROTEINS, V34, P497, DOI 10.1002/(SICI)1097-0134(19990301)34:4<497::AID-PROT9>3.3.CO;2-7; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Zhu XS, 1999, FEBS LETT, V450, P221, DOI 10.1016/S0014-5793(99)00496-2	29	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11631	11637		10.1074/jbc.275.16.11631	http://dx.doi.org/10.1074/jbc.275.16.11631			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766780	hybrid			2022-12-27	WOS:000086695500015
J	Chellaiah, MA; Soga, N; Swanson, S; McAllister, S; Alvarez, U; Wang, DM; Dowdy, SF; Hruska, KA				Chellaiah, MA; Soga, N; Swanson, S; McAllister, S; Alvarez, U; Wang, DM; Dowdy, SF; Hruska, KA			Rho-A is critical for osteoclast podosome organization, motility, and bone resorption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; ACTIN STRESS FIBERS; EXPRESS HIGH-LEVELS; SWISS 3T3 CELLS; FOCAL ADHESIONS; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; ALPHA(V)BETA(3) INTEGRIN; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS	Rho plays a regulatory role in the formation of actin stress fibers and focal adhesions, and it is also involved in integrin-mediated signaling events. To study the role of Rho in alpha(v)beta(3)/gelsolin-dependent signaling, the HIV-Tat peptide, hemagglutinin (HA)-taffged Rho(Val-14) (constitutively active) and Rho(Asn-19) (dominant negative) were transduced into avian osteoclasts. Protein transduction by HA-Tat was highly efficient, and 90-100% of the cells were transduced with HA-tagged proteins. We demonstrate here that Rho(Val-14) transduction (100 nM) stimulated gelsolin-associated phosphatidylinositol 3-kinase activity, podosome assembly, stress fiber formation, osteoclast motility, and bone resorption, mimicking osteoclast stimulation by osteopontin/alpha(v)beta(3). The effects of Rho(Val-14) transduction stimulation was time-dependent. C3 exoenzyme blocked the effects of Rho(Val-14) and induced podosome disassembly, loss of motility, and inhibition of bone resorption, Transduction of Rho(Asn-19) produced podosome disassembly, and blocked osteopontin stimulation. These data demonstrate that integrin-dependent activation of phosphoinositide synthesis, actin stress fiber formation, podosome reorganization for osteoclast motility, and bone resorption require Rho stimulation.	Washington Univ, Sch Med, Barnes Jewish Hosp, Howard Hughes Med Inst,Div Renal, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	Barnes-Jewish Hospital; Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL)	Hruska, KA (corresponding author), Washington Univ, Sch Med, Barnes Jewish Hosp, Howard Hughes Med Inst,Div Renal, 216 S Kingshighway, St Louis, MO 63110 USA.	khruska@imgate.wustl.edu	McAllister, Sandra/J-7373-2012		NIAMS NIH HHS [AR41677] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041677] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABERCROMBIE M, 1980, PROC R SOC SER B-BIO, V207, P129, DOI 10.1098/rspb.1980.0017; Albini A, 1996, ONCOGENE, V12, P289; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; BARKALOW K, 1995, CURR BIOL, V5, P1000, DOI 10.1016/S0960-9822(95)00200-4; BARRY ST, 1994, J CELL SCI, V107, P2033; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Burridge K, 1997, TRENDS CELL BIOL, V7, P342, DOI 10.1016/S0962-8924(97)01127-6; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Chellaiah M, 1996, MOL BIOL CELL, V7, P743, DOI 10.1091/mbc.7.5.743; Chellaiah M, 1998, J BIOL CHEM, V273, P11908, DOI 10.1074/jbc.273.19.11908; Chellaiah M, 1997, J BONE MINER RES, V12, P138; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; DILLON ST, 1995, METHOD ENZYMOL, V256, P174; Faccio R, 1998, BIOCHEM BIOPH RES CO, V249, P522, DOI 10.1006/bbrc.1998.9180; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; Gupta A, 1996, BONE, V18, P87, DOI 10.1016/8756-3282(95)00455-6; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HORNE WC, 1992, J CELL BIOL, V119, P1003, DOI 10.1083/jcb.119.4.1003; HRUSKA KA, 1995, ENDOCRINOLOGY, V136, P2984, DOI 10.1210/en.136.7.2984; KANEHISA J, 1988, BONE, V9, P73, DOI 10.1016/8756-3282(88)90106-8; KANEHISA J, 1990, BONE, V11, P287, DOI 10.1016/8756-3282(90)90082-A; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; Lakkakorpi PT, 1996, MICROSC RES TECHNIQ, V33, P171, DOI 10.1002/(SICI)1097-0029(19960201)33:2<171::AID-JEMT7>3.0.CO;2-W; LAKKAKORPI PT, 1991, J BONE MINER RES, V6, P817; LAKKAKORPI PT, 1993, J CELL SCI, V104, P663; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; MaejimaIkeda A, 1997, BIOCHEM J, V322, P245, DOI 10.1042/bj3220245; MARCHISIO PC, 1984, J CELL BIOL, V99, P1696, DOI 10.1083/jcb.99.5.1696; MARCHISIO PC, 1987, EXP CELL RES, V169, P202, DOI 10.1016/0014-4827(87)90238-2; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; MEDHORA MM, 1993, J BIOL CHEM, V268, P1456; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Nakamura I, 1997, J CELL PHYSIOL, V172, P230, DOI 10.1002/(SICI)1097-4652(199708)172:2<230::AID-JCP10>3.0.CO;2-D; NAKAMURA I, 1995, FEBS LETT, V361, P79, DOI 10.1016/0014-5793(95)00153-Z; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Pilkington MF, 1998, J BONE MINER RES, V13, P688, DOI 10.1359/jbmr.1998.13.4.688; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ren XD, 1998, CURR OPIN GENET DEV, V8, P63, DOI 10.1016/S0959-437X(98)80063-4; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; RIELDY AJ, 1999, NAT CELL BIOL, V1, pE64; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835; Senger DR, 1996, AM J PATHOL, V149, P293; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TAKADA Y, 1992, BONE MINER, V17, P347, DOI 10.1016/0169-6009(92)90785-C; TANAKA S, 1992, FEBS LETT, V313, P85, DOI 10.1016/0014-5793(92)81190-W; Tate MLK, 1998, BONE, V22, P107; TAYLOR ML, 1989, ANAT EMBRYOL, V180, P427, DOI 10.1007/BF00305117; TETI A, 1991, AM J PHYSIOL, V261, pC1, DOI 10.1152/ajpcell.1991.261.1.C1; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; TURKSEN K, 1988, J BONE MINER RES, V3, P389; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; ZAMBONINZALLONE A, 1988, J BONE MINER RES, V3, P517; ZHANG D, 1995, J CELL SCI, V108, P2285; ZHANG D, 1994, J BONE MINER RES, V9, pS131; ZHANG J, 1993, J BIOL CHEM, V268, P22251; [No title captured]	72	215	223	1	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11993	12002		10.1074/jbc.275.16.11993	http://dx.doi.org/10.1074/jbc.275.16.11993			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766830	hybrid			2022-12-27	WOS:000086695500065
J	Reinhardt, DP; Ono, RN; Notbohm, H; Muller, PK; Bachinger, HP; Sakai, LY				Reinhardt, DP; Ono, RN; Notbohm, H; Muller, PK; Bachinger, HP; Sakai, LY			Mutations in calcium-binding epidermal growth factor modules render fibrillin-1 susceptible to proteolysis - A potential disease-causing mechanism in Marfan syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-LIKE DOMAINS; MATRIX METALLOPROTEINASES; POINT MUTATIONS; FBN1 MUTATIONS; GENE; MICROFIBRILS; EXPRESSION; DATABASE; EDITION; PROTEIN	Most extracellular proteins consist of various modules with distinct functions. Mutations in one common type, the calcium-binding epidermal growth factor-like module (cbEGF), can lead to a variety of genetic disorders. Here, we describe as a model system structural and functional consequences of two typical mutations in cbEGF modules of fibrillin-1 (N548I, E1073K), resulting in the Marfan syndrome. Large (80-120 kDa) wild-type and mutated polypeptides were recombinantly expressed in mammalian cells. Both mutations did not alter synthesis and secretion of the polypeptides into the culture medium. Electron microscopy after rotary shadowing and comparison of circular dichroism spectra exhibited minor structural differences between the wild-type and mutated forms. The mutated polypeptides were significantly more susceptible to proteolytic degradation by a variety of proteases as compared with their wild-type counterparts. Most of the sensitive cleavage sites were mapped close to the mutations, indicating local structural changes within the mutated cbEGF modules. Other cleavage sites, however, were observed at distances beyond the domain containing the mutation, suggesting longer range structural effects within tandemly repeated cbEGF modules. We suggest that proteolytic degradation of mutated fibrillin-1 may play an important role in the pathogenesis of Marfan syndrome and related disorders.	Med Univ Lubeck, Dept Med Mol Biol, D-23538 Lubeck, Germany; Shriners Hosp Crippled Children, Dept Res, Portland, OR 97201 USA	University of Lubeck	Reinhardt, DP (corresponding author), Med Univ Lubeck, Dept Med Mol Biol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.		Reinhardt, Dieter P/A-3102-2008	Reinhardt, Dieter P/0000-0001-6535-9872				AOYAMA T, 1994, J CLIN INVEST, V94, P130, DOI 10.1172/JCI117298; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; Collod-Beroud G, 1998, NUCLEIC ACIDS RES, V26, P229, DOI 10.1093/nar/26.1.229; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; DIETZ HC, 1995, HUM MOL GENET, V4, P1799, DOI 10.1093/hmg/4.suppl_1.1799; DIETZ HC, 1993, GENOMICS, V17, P468, DOI 10.1006/geno.1993.1349; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; GANDRILLE S, 1995, BLOOD, V85, P130, DOI 10.1182/blood.V85.1.130.bloodjournal851130; Giannelli F, 1998, NUCLEIC ACIDS RES, V26, P265, DOI 10.1093/nar/26.1.265; GLANVILLE RW, 1994, J BIOL CHEM, V269, P26630; HANDFORD P, 1995, J BIOL CHEM, V270, P6751, DOI 10.1074/jbc.270.12.6751; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Keene DR, 1997, J HISTOCHEM CYTOCHEM, V45, P1069, DOI 10.1177/002215549704500805; Kettle S, 1999, J MOL BIOL, V285, P1277, DOI 10.1006/jmbi.1998.2368; LONNQVIST L, 1994, GENOMICS, V19, P573, DOI 10.1006/geno.1994.1110; MAYER U, 1995, FEBS LETT, V365, P129, DOI 10.1016/0014-5793(95)00438-F; Mignatti P, 1996, ENZYME PROTEIN, V49, P117, DOI 10.1159/000468621; MILEWICZ DM, 1992, J CLIN INVEST, V89, P79, DOI 10.1172/JCI115589; NIJBROEK G, 1995, AM J HUM GENET, V57, P8; Park ES, 1998, AM J MED GENET, V78, P350, DOI 10.1002/(SICI)1096-8628(19980724)78:4<350::AID-AJMG9>3.3.CO;2-#; Pereira L, 1997, NAT GENET, V17, P218, DOI 10.1038/ng1097-218; Pereira L, 1999, P NATL ACAD SCI USA, V96, P3819, DOI 10.1073/pnas.96.7.3819; PERSSON E, 1989, J BIOL CHEM, V264, P16897; Putnam EA, 1996, AM J MED GENET, V62, P233, DOI 10.1002/(SICI)1096-8628(19960329)62:3<233::AID-AJMG7>3.0.CO;2-U; Rand MD, 1997, PROTEIN SCI, V6, P2059; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; Reinhardt DP, 1996, J BIOL CHEM, V271, P19489, DOI 10.1074/jbc.271.32.19489; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; Reinhardt DP, 1997, J BIOL CHEM, V272, P1231, DOI 10.1074/jbc.272.2.1231; Reinhardt DP, 1997, J BIOL CHEM, V272, P7368, DOI 10.1074/jbc.272.11.7368; SAKAI LY, 1994, METHOD ENZYMOL, V245, P29; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; Sasaki T, 1996, EUR J BIOCHEM, V240, P427, DOI 10.1111/j.1432-1033.1996.0427h.x; Smallridge RS, 1999, J MOL BIOL, V286, P661, DOI 10.1006/jmbi.1998.2536; Varret M, 1998, NUCLEIC ACIDS RES, V26, P248, DOI 10.1093/nar/26.1.248; Wang M, 1997, HUM MUTAT, V9, P359, DOI 10.1002/(SICI)1098-1004(1997)9:4<359::AID-HUMU10>3.0.CO;2-1; Whiteman P, 1998, J BIOL CHEM, V273, P7807, DOI 10.1074/jbc.273.14.7807; WU YS, 1995, CHEM BIOL, V2, P91, DOI 10.1016/1074-5521(95)90281-3; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	41	85	95	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12339	12345		10.1074/jbc.275.16.12339	http://dx.doi.org/10.1074/jbc.275.16.12339			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766875	hybrid			2022-12-27	WOS:000086695500110
J	Hastings, ML; Ingle, HA; Lazar, MA; Munroe, SH				Hastings, ML; Ingle, HA; Lazar, MA; Munroe, SH			Post-transcriptional regulation of thyroid hormone receptor expression by cis-acting sequences and a naturally occurring antisense RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REV-ERBA-ALPHA; DOMINANT-NEGATIVE ACTIVITY; PRE-MESSENGER-RNA; VARIANT ALPHA-2; OPPOSITE STRAND; SPLICING ENHANCER; GENOMIC LOCUS; BINDING-SITES; DNA-BINDING; GENE	Thyroid hormone (T-3) coordinates growth, differentiation, and metabolism by binding to nuclear thyroid hormone receptors (TRs), The TR alpha gene encodes T-3-activated TR alpha 1 (NR1Ala) as well as an antagonistic, non-T-3-binding alternatively spliced product, TR alpha 2 (NR1Alb). Thus, the TR alpha 1/TR alpha 2 ratio is a critical determinant of T-3 action. However, the mechanisms underlying this post-transcriptional regulation are unknown. We have identified a non-consensus, TR alpha 2-specific 5' splice site and conserved intronic sequences as key determinants of TR alpha mRNA processing. In addition to these cis-acting elements, a novel regulatory feature is the orphan receptor RevErbA alpha (NR1D1) gene, which is transcribed from the opposite direction at the same locus and overlaps the TR alpha 2 coding region. RevErbA alpha gene expression correlates with a high TR alpha 1/TR alpha 2 ratio in a number of tissues. Here we demonstrate that coexpression of RevErbA alpha and TR alpha regulates the TR alpha 1/TR alpha 2 ratio in intact cells. Thus, both cis- and trans-regulatory mechanisms contribute to cell-specific post-transcriptional regulation of TR gene expression and T-3 action.	Marquette Univ, Dept Biol, Milwaukee, WI 53201 USA; Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA	Marquette University; University of Pennsylvania; University of Pennsylvania	Munroe, SH (corresponding author), Marquette Univ, Dept Biol, Wehr Life Sci Bldg,POB 1881, Milwaukee, WI 53201 USA.		Lazar, Mitchell A/AAF-3738-2019; Hastings, MICHELLE L./AAK-6627-2021	Hastings, Michelle L./0000-0002-4253-9261	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R15DK048034, R01DK045586] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM055922] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 48034, DK45586] Funding Source: Medline; NIGMS NIH HHS [GM 55922] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Auwerx J, 1999, CELL, V97, P161; BRENT GA, 1991, MOL ENDOCRINOL, V5, P542, DOI 10.1210/mend-5-4-542; Burge CB, 1999, RNA WORLD, P525; CHAWLA A, 1993, J BIOL CHEM, V268, P16265; Elrick LL, 1998, MOL CELL BIOL, V18, P343, DOI 10.1128/MCB.18.1.343; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; HARDING HP, 1995, MOL CELL BIOL, V15, P4791; Hastings ML, 1997, NUCLEIC ACIDS RES, V25, P4296, DOI 10.1093/nar/25.21.4296; Hertel KJ, 1997, CURR OPIN CELL BIOL, V9, P350, DOI 10.1016/S0955-0674(97)80007-5; HODIN RA, 1994, ENDOCRINOLOGY, V135, P564, DOI 10.1210/en.135.2.564; HUMPHREY MB, 1995, MOL CELL BIOL, V15, P3979; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; JANNINI EA, 1992, BIOCHEM BIOPH RES CO, V184, P739, DOI 10.1016/0006-291X(92)90652-2; Kanopka A, 1996, NATURE, V381, P535, DOI 10.1038/381535a0; KATZ D, 1993, J BIOL CHEM, V268, P20904; KATZ D, 1992, MOL ENDOCRINOL, V6, P805, DOI 10.1210/me.6.5.805; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; Kosaki A, 1998, J BIOL CHEM, V273, P10331, DOI 10.1074/jbc.273.17.10331; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; Kumar M, 1998, MICROBIOL MOL BIOL R, V62, P1415, DOI 10.1128/MMBR.62.4.1415-1434.1998; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P893, DOI 10.1210/mend-2-10-893; LAZAR MA, 1990, J BIOL CHEM, V265, P12859; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LAZAR MA, 1989, P NATL ACAD SCI USA, V86, P7771, DOI 10.1073/pnas.86.20.7771; LAZAR MA, 1990, DNA CELL BIOL, V9, P77, DOI 10.1089/dna.1990.9.77; LIU RT, 1995, MOL ENDOCRINOL, V9, P86, DOI 10.1210/me.9.1.86; McCullough AJ, 1997, MOL CELL BIOL, V17, P4562, DOI 10.1128/MCB.17.8.4562; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; MCNALLY MT, 1991, VIROLOGY, V185, P99, DOI 10.1016/0042-6822(91)90758-4; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; MIYAJIMA N, 1989, CELL, V57, P31, DOI 10.1016/0092-8674(89)90169-4; MUNROE SH, 1991, J BIOL CHEM, V266, P22083; OPPENHEIMER JH, 1974, ENDOCRINOLOGY, V95, P897, DOI 10.1210/endo-95-3-897; OPPENHEIMER JH, 1994, EUR J ENDOCRINOL, V130, P15, DOI 10.1530/eje.0.1300015; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; Tagami T, 1998, ENDOCRINOLOGY, V139, P2535, DOI 10.1210/en.139.5.2535; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; Wikstrom L, 1998, EMBO J, V17, P455, DOI 10.1093/emboj/17.2.455; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660; Yang YZ, 1996, J BIOL CHEM, V271, P28235, DOI 10.1074/jbc.271.45.28235; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zhao Q, 1998, MOL CELL, V1, P849, DOI 10.1016/S1097-2765(00)80084-2	47	110	113	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11507	11513		10.1074/jbc.275.15.11507	http://dx.doi.org/10.1074/jbc.275.15.11507			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753970	hybrid			2022-12-27	WOS:000086466600112
J	Mellet, P; Bieth, JG				Mellet, P; Bieth, JG			Evidence that translocation of the proteinase precedes its acylation in the serpin inhibition pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASE COMPLEXES; ALPHA(1)-PROTEINASE INHIBITOR; MECHANISM; BINDING; ELASTASE; LOOP; SITE; ALPHA(1)-ANTITRYPSIN; ALPHA-2-ANTIPLASMIN; ANTITHROMBIN	The inhibition of proteinases by serpins involves cleavage of the serpin, acylation, and translocation of the proteinase, To see whether acylation precedes or follows translocation, we have investigated the pH dependence of the interaction of fluorescein isothiocyanate-elastase with rhodamine alpha(1)-proteinase inhibitor (alpha(1)PI) using two independent methods: (i) kinetics of fluorescence energy transfer which yields k(2,f), the rate constant for the fluorescently detected decay of the Michaelis-type complex (Mellet, P., Boudier, C., Mely, Y., and Bieth, J. G. (1998) J. Biol. Chem. 273, 9119-9123); (ii) kinetics of elastase-catalyzed hydrolysis of a substrate in the presence of alpha(1)PI, which yields k(2,e), the rate constant for the conversion of the Michaelis-type complex into irreversibly inhibited elastase. Both rate constants were found to be pH-independent and close to each other, indicating that acylation, a pH-dependent phenomenon, does not govern the decay of the Michaelis-type complex and, therefore, follows translocation, On the other hand, anhydro-elastase reacts with alpha(1)PI to form a Michaelis-type complex that translocates into a second complex with a rate constant close to that measured with active elastase, confirming that acylation is not a prerequisite for translocation, Moreover, the anhydro-elastase-alpha(1)PI complex was found to be thermodynamically reversible, suggesting that translocation of active elastase might also be reversible. We propose that serpins form a Michaelis-type complex EIM, which reversibly translocates into EItr whose acylation yields the irreversible complex EIac. [GRAPHICS]	Univ Louis Pasteur Strasbourg 1, INSERM, U392, Enzymol Lab, F-67400 Illkirch, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Bieth, JG (corresponding author), Fac Pharm, INSERM, U392, 74 Route Rhin, F-67400 Illkirch, France.			Mellet, Philippe/0000-0001-5499-9735				AKO H, 1974, BIOCHEMISTRY-US, V13, P132, DOI 10.1021/bi00698a021; BOUDIER C, 1992, J BIOL CHEM, V267, P4370; Carrell RW, 1996, BIOL CHEM H-S, V377, P1; Duranton J, 1998, BIOCHEMISTRY-US, V37, P11239, DOI 10.1021/bi980223q; Egelund R, 1998, BIOCHEMISTRY-US, V37, P6375, DOI 10.1021/bi973043+; Elliott PR, 1998, J MOL BIOL, V275, P419, DOI 10.1006/jmbi.1997.1458; FALLER B, 1990, BIOCHEM J, V270, P639, DOI 10.1042/bj2700639; Futamura A, 1998, BIOCHEMISTRY-US, V37, P13110, DOI 10.1021/bi981234m; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; Kvassman JO, 1998, BIOCHEMISTRY-US, V37, P15491, DOI 10.1021/bi9814787; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LOBERMANN H, 1984, J MOL BIOL, V177, P531; LONGSTAFF C, 1991, BIOCHEMISTRY-US, V30, P979, DOI 10.1021/bi00218a014; MELLET P, 1995, BIOCHEMISTRY-US, V34, P2645, DOI 10.1021/bi00008a031; Mellet P, 1998, J BIOL CHEM, V273, P9119, DOI 10.1074/jbc.273.15.9119; MOROI M, 1977, BIOCHIM BIOPHYS ACTA, V482, P412, DOI 10.1016/0005-2744(77)90255-8; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Schechter NM, 1997, J BIOL CHEM, V272, P24499, DOI 10.1074/jbc.272.39.24499; Schick C, 1998, BIOCHEMISTRY-US, V37, P5258, DOI 10.1021/bi972521d; SCHULZE AJ, 1992, BIOCHEMISTRY-US, V31, P7560, DOI 10.1021/bi00148a017; SHIEH BH, 1989, J BIOL CHEM, V264, P13420; Shotton D. M., 1970, METHOD ENZYMOL, V19, P113, DOI 10.1016/0076-6879(70)19009-4; Stone SR, 1997, J MOL BIOL, V265, P344, DOI 10.1006/jmbi.1996.0727; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; Stratikos E, 1998, J BIOL CHEM, V273, P15582, DOI 10.1074/jbc.273.25.15582; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; Verhamme I, 1999, J BIOL CHEM, V274, P17511, DOI 10.1074/jbc.274.25.17511; Whisstock J, 1996, PROTEINS, V26, P288, DOI 10.1002/(SICI)1097-0134(199611)26:3<288::AID-PROT5>3.0.CO;2-A; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354; WILLIAMS HR, 1987, BIOCHEM J, V242, P267, DOI 10.1042/bj2420267	32	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10788	10795		10.1074/jbc.275.15.10788	http://dx.doi.org/10.1074/jbc.275.15.10788			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753871	hybrid			2022-12-27	WOS:000086466600013
J	Zhu, QZ; Wani, MA; El-mahdy, M; Wani, AA				Zhu, QZ; Wani, MA; El-mahdy, M; Wani, AA			Decreased DNA repair efficiency by loss or disruption of p53 function preferentially affects removal of cyclobutane pyrimidine dimers from non-transcribed strand and slow repair sites in transcribed strand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; LI-FRAUMENI SYNDROME; XERODERMA-PIGMENTOSUM; ULTRAVIOLET-LIGHT; HUMAN FIBROBLASTS; HUMAN-CELLS; GENE; E6; DEFICIENT; DAMAGE	The tumor suppressor protein p53 plays a central role in modulating the cellular responses to DNA damage. Several recent studies, undertaken with the whole genomic DNA or full-length gene segments, have shown that p53 is involved in nucleotide excision repair and it selectively influences the adduct removal from the nontranscribed strand in the genome. In this study, we have analyzed the damage induction at nucleotide resolution by ligase-mediated polymerase chain reaction and compared the repair of ultraviolet radiation-induced cyclobutane pyrimidine dimers within exon 8 of p53 gene in normal and Li-Fraumeni syndrome fibroblasts as well as in normal and human papillomavirus 16 E6 and E7 protein-expressing human mammary epithelial cells. The results demonstrate that (i) loss or disruption of p53 function decreases efficiency of DNA repair, by preferentially affecting the repair of non-transcribed strand and of intrinsically slow repair sites in transcribed strand; (ii) mutant p53 protein affects DNA repair, at least of non-transcribed strand, in a dominant negative manner; and (iii) pRb does not have an effect on the repair of DNA damage within transcribed or non-transcribed strand. The overall data suggest that p53 could regulate excision repair or related events through direct protein-protein interaction.	Ohio State Univ, Dept Radiol, Columbus, OH 43210 USA; Ohio State Univ, Bioengn Program, Columbus, OH 43210 USA; Ohio State Univ, James Canc Hosp & Res Inst, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Wani, AA (corresponding author), Mol Carcinogenesis Lab, 103 Wiseman Hall,400 W 12th Ave, Columbus, OH 43210 USA.		Zhu, Qianzheng/A-4902-2013		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES023888] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES23888] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Baxter BK, 1998, J BIOL CHEM, V273, P17517, DOI 10.1074/jbc.273.28.17517; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Dammann R, 1997, MOL CELL BIOL, V17, P219, DOI 10.1128/MCB.17.1.219; DRAPKIN R, 1994, CELL, V77, P9, DOI 10.1016/0092-8674(94)90228-3; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; Ford JM, 1998, CANCER RES, V58, P599; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Frit P, 1999, BIOCHIMIE, V81, P27, DOI 10.1016/S0300-9084(99)80035-2; HANAWALT PC, 1994, CURR BIOL, V4, P518, DOI 10.1016/S0960-9822(00)00112-3; Hanawalt PC, 1998, MUTAT RES-FUND MOL M, V400, P117, DOI 10.1016/S0027-5107(98)00084-0; HOEIJMAKERS JHJ, 1994, NATURE, V371, P654, DOI 10.1038/371654a0; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Jia L, 1999, INT J CANCER, V80, P875, DOI 10.1002/(SICI)1097-0215(19990315)80:6<875::AID-IJC13>3.3.CO;2-Q; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lindahl T, 1997, CURR OPIN GENET DEV, V7, P158, DOI 10.1016/S0959-437X(97)80124-4; McKay BC, 1999, CARCINOGENESIS, V20, P1389, DOI 10.1093/carcin/20.8.1389; McKay BC, 1997, CARCINOGENESIS, V18, P245, DOI 10.1093/carcin/18.2.245; Mirzayans R, 1996, CARCINOGENESIS, V17, P691, DOI 10.1093/carcin/17.4.691; Mullenders LHF, 1998, MUTAT RES-DNA REPAIR, V409, P59, DOI 10.1016/S0921-8777(98)00048-2; Oren M, 1999, CELL MOL LIFE SCI, V55, P9, DOI 10.1007/s000180050265; Petit C, 1999, BIOCHIMIE, V81, P15, DOI 10.1016/S0300-9084(99)80034-0; Prost S, 1998, J BIOL CHEM, V273, P33327, DOI 10.1074/jbc.273.50.33327; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SMITH ML, 1995, ONCOGENE, V10, P1053; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; Tornaletti S, 1999, BIOCHIMIE, V81, P139, DOI 10.1016/S0300-9084(99)80046-7; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; Tornaletti Silvia, 1996, P199; Tu YQ, 1996, EMBO J, V15, P675, DOI 10.1002/j.1460-2075.1996.tb00400.x; Tu YQ, 1997, J BIOL CHEM, V272, P20747, DOI 10.1074/jbc.272.33.20747; VENKATACHALAM S, 1995, CARCINOGENESIS, V16, P2029, DOI 10.1093/carcin/16.9.2029; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wani MA, 1999, CARCINOGENESIS, V20, P765, DOI 10.1093/carcin/20.5.765; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; [No title captured]	39	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11492	11497		10.1074/jbc.275.15.11492	http://dx.doi.org/10.1074/jbc.275.15.11492			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753968	hybrid			2022-12-27	WOS:000086466600110
J	Chang, DK; Cheng, SF; Trivedi, VD; Yang, SH				Chang, DK; Cheng, SF; Trivedi, VD; Yang, SH			The amino-terminal region of the fusion peptide of influenza virus hemagglutinin HA2 inserts into sodium dodecyl sulfate micelle with residues 16-18 at the aqueous boundary at acidic pH - Oligomerization and the conformational flexibility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED MEMBRANE-FUSION; LIPID BILAYERS; PHOSPHOLIPID-VESICLES; MECHANISM; GP41; ORIENTATION; FLUORESCENCE; RESOLUTION; HEMIFUSION; TOPOLOGY	The conformation and interactions with membrane mimics of the NH2-terminal fragment 1-25 of HA2, HA2(1-25), of influenza virus were studied by spectroscopic methods. Secondary structure analysis of circular dichroism data revealed 45% helix for the peptide at pH 5.0. Tryptophan fluorescence quenching by acrylamide and NMR experiments established that the Trp(14) is in side the vesicular interior and residues 16-18 are at the micellar aqueous boundary. NBD fluorescence enhancement of the NH2-terminal labeled fluorophore on the vesicle bound peptide indicated that the NH2 terminus of the fusion peptide was located in the hydrophobic region of the lipid bilayer. No significant change in insertion depth was observed between pH 5.0 and 7.4. Collectively, these spectroscopic measurements pointed to an equilibrium between helix and non-helix conformations, with helix being the dominant form, for the segment in the micellar interior. The conformational transition may be facilitated by the high content of glycine, a conformationally flexible amino acid, within the fusion peptide sequence. Self-association of the 25-mer peptide was observed in the N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine SDS-gel electrophoresis experiments, Incorporating the NMR signal attenuation, fluorescence, and gel electrophoresis data, a working model for the organization of the fusion peptide in membrane bilayers was proposed.	Acad Sinica, Inst Chem, Taipei 11529, Taiwan	Academia Sinica - Taiwan	Chang, DK (corresponding author), Acad Sinica, Inst Chem, Taipei 11529, Taiwan.		Chang, Ding-Kwo/E-7079-2015; Cheng, Shu-Fang/ABE-1287-2020	Cheng, Shu-Fang/0000-0003-0536-4404				BARRATT MD, 1974, BIOCHIM BIOPHYS ACTA, V363, P127, DOI 10.1016/0005-2736(74)90011-X; Breukink E, 1998, BIOCHEMISTRY-US, V37, P8153, DOI 10.1021/bi972797l; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; Chang DK, 1998, J BIOMOL NMR, V12, P549, DOI 10.1023/A:1008399304450; Chang DK, 1999, J BIOL CHEM, V274, P5299, DOI 10.1074/jbc.274.9.5299; Chang DK, 1997, J VIROL, V71, P6593, DOI 10.1128/JVI.71.9.6593-6602.1997; CLAGUE MJ, 1991, BIOCHEMISTRY-US, V30, P5491, DOI 10.1021/bi00236a023; DANIELS RS, 1983, J GEN VIROL, V64, P1657, DOI 10.1099/0022-1317-64-8-1657; Durrer P, 1996, J BIOL CHEM, V271, P13417, DOI 10.1074/jbc.271.23.13417; GETHING MJ, 1986, J CELL BIOL, V102, P11, DOI 10.1083/jcb.102.1.11; Gray C, 1996, BIOPHYS J, V70, P2275, DOI 10.1016/S0006-3495(96)79793-X; HARTER C, 1989, J BIOL CHEM, V264, P6459; HARTER C, 1988, BIOCHEMISTRY-US, V27, P1856, DOI 10.1021/bi00406a010; HENNESSEY JP, 1981, BIOCHEMISTRY-US, V20, P1085, DOI 10.1021/bi00508a007; ISHIGURO R, 1993, BIOCHEMISTRY-US, V32, P9792, DOI 10.1021/bi00088a034; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; KLENK HD, 1975, VIROLOGY, V68, P426, DOI 10.1016/0042-6822(75)90284-6; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LEAR JD, 1987, J BIOL CHEM, V262, P6500; Longo ML, 1997, BIOPHYS J, V73, P1430, DOI 10.1016/S0006-3495(97)78175-X; LUNEBERG J, 1995, J BIOL CHEM, V270, P27606; Macosko JC, 1997, J MOL BIOL, V267, P1139, DOI 10.1006/jmbi.1997.0931; Melikyan GB, 1997, J CELL BIOL, V136, P995, DOI 10.1083/jcb.136.5.995; MORRIS SJ, 1989, J BIOL CHEM, V264, P3972; Pecheur EI, 1999, J MEMBRANE BIOL, V167, P1, DOI 10.1007/s002329900466; Pritsker M, 1999, BIOCHEMISTRY-US, V38, P11359, DOI 10.1021/bi990232e; RAFALSKI M, 1991, BIOCHEMISTRY-US, V30, P10211, DOI 10.1021/bi00106a020; RAJARATHNAM K, 1989, BIOCHEMISTRY-US, V28, P3168, DOI 10.1021/bi00434a009; RAPAPORT D, 1991, J BIOL CHEM, V266, P23769; Razinkov V, 1999, EUR J BIOCHEM, V262, P890, DOI 10.1046/j.1432-1327.1999.00460.x; SCHIGGER H, 1987, ANAL BIOCHEM, V166, P368; SCHOCH C, 1993, J BIOL CHEM, V268, P9267; SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968; SONG LY, 1991, BIOCHIM BIOPHYS ACTA, V1065, P54, DOI 10.1016/0005-2736(91)90010-6; STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155; STEGMANN T, 1991, J BIOL CHEM, V266, P18404; STEINHAUER DA, 1995, J VIROL, V69, P6643, DOI 10.1128/JVI.69.11.6643-6651.1995; TSURUDOME M, 1992, J BIOL CHEM, V267, P20225; WHARTON SA, 1988, J GEN VIROL, V69, P1847, DOI 10.1099/0022-1317-69-8-1847; WHARTON SA, 1995, EMBO J, V14, P240, DOI 10.1002/j.1460-2075.1995.tb06997.x; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; Wuthrich K, 1986, NMR PROTEINS NUCL AC	45	43	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19150	19158		10.1074/jbc.M907148199	http://dx.doi.org/10.1074/jbc.M907148199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10764801	hybrid			2022-12-27	WOS:000087815900071
J	Goetze, S; Kintscher, U; Kawano, H; Kawano, Y; Wakino, S; Fleck, E; Hsueh, WA; Law, RE				Goetze, S; Kintscher, U; Kawano, H; Kawano, Y; Wakino, S; Fleck, E; Hsueh, WA; Law, RE			Tumor necrosis factor alpha inhibits insulin-induced mitogenic signaling in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TNF-ALPHA; GROWTH-FACTOR; RECEPTOR SUBSTRATE-1; ATHEROMATOUS PLAQUES; GLUCOSE-UPTAKE; EXPRESSION; RESISTANCE; MIGRATION; PHOSPHORYLATION	Tumor necrosis factor alpha (TNF alpha) interferes with insulin signaling in adipose tissue and may promote insulin resistance. Insulin binding to the insulin receptor (IR) triggers its autophosphorylation, resulting in phosphorylation of Shc and the downstream activation of p42/p44 extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase (ERK1/2), which mediates insulin-induced proliferation in vascular smooth muscle cells (VSMC). Since insulin resistance is a risk factor for vascular disease, we examined the effects of TNF alpha on mitogenic signaling by insulin. In rat aortic VSMC, insulin induced rapid phosphorylation of the IR and Shc and caused a 5.3-fold increase in activated, phosphorylated ERK1/2 at 10 min. Insulin induced a biphasic ERK1/2 activation with a transient peak at 10 min and a sustained late phase after 2 h, Preincubation (30-120 min) with TNF alpha had no effect on insulin-induced IR phosphorylation, In contrast, TNF alpha transiently suppressed insulin-induced ERK1/2 activation. Insulin-induced phosphorylation of Shc was inhibited by TNF alpha in a similar pattern. Since mitogenic signaling by insulin in VSMC requires ERK1/2 activation, we examined the effect of TNF alpha on insulin-induced proliferation. Insulin alone induced a 3.4-fold increase in DNA synthesis, which TNF alpha inhibited by 48%. TNF alpha alone was not mitogenic, Inhibition of ERK1/2 activation with PD98059 also inhibited insulin-stimulated DNA synthesis by 57%, TNF alpha did not inhibit platelet-derived growth factor induced ERK1/2 activation or DNA synthesis in VSMC, Thus, TNF alpha selectively interferes with insulin-induced mitogenic signaling by inhibiting the phosphorylation of Shc and the downstream activation of ERK1/2.	Univ Calif Los Angeles, Sch Med, Div Endocrinol Diabet & Metab, Los Angeles, CA 90095 USA; Humboldt Univ, Dept Med Cardiol, Klinikum Rudolf Virchow, D-13353 Berlin, Germany; German Heart Inst, D-13353 Berlin, Germany	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; German Heart Center Berlin	Law, RE (corresponding author), Univ Calif Los Angeles, Sch Med, Div Endocrinol Diabet & Metab, Warren Hall,2nd Floor,Suite 24-130,900 Vet Ave,Bo, Los Angeles, CA 90095 USA.			Kawano, Hiroaki/0000-0002-0452-4384; Kintscher, Ulrich/0000-0001-7386-0990	NHLBI NIH HHS [HL58328-03] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058328] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARATH P, 1990, AM J PATHOL, V137, P503; Begum N, 1996, EUR J BIOCHEM, V238, P214, DOI 10.1111/j.1432-1033.1996.0214q.x; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; CLAUSELL N, 1995, BRIT HEART J, V73, P534; Cruzado M, 1998, AM J HYPERTENS, V11, P54, DOI 10.1016/S0895-7061(97)00324-5; Del Aguila LF, 1999, AM J PHYSIOL-ENDOC M, V276, pE849, DOI 10.1152/ajpendo.1999.276.5.E849; Desbois-Mouthon C, 1998, BIOCHEM BIOPH RES CO, V243, P765, DOI 10.1006/bbrc.1998.8181; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; Goetze S, 1999, HYPERTENSION, V33, P183, DOI 10.1161/01.HYP.33.1.183; Hoshiya M, 1998, HYPERTENSION, V31, P665, DOI 10.1161/01.HYP.31.2.665; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; Jovinge S, 1997, ARTERIOSCL THROM VAS, V17, P490, DOI 10.1161/01.ATV.17.3.490; Kihara S, 1998, ATHEROSCLEROSIS, V136, P163, DOI 10.1016/S0021-9150(97)00207-4; KLETZIEN RF, 1994, DIABETES, V43, P82; Kroder G, 1996, J CLIN INVEST, V97, P1471, DOI 10.1172/JCI118569; Krook A, 1997, J BIOL CHEM, V272, P30208, DOI 10.1074/jbc.272.48.30208; Moule SK, 1997, AM J CARDIOL, V80, pA41, DOI 10.1016/S0002-9149(97)00457-8; Nelson PR, 1998, J VASC SURG, V27, P117, DOI 10.1016/S0741-5214(98)70298-8; Peraldi P, 1996, J BIOL CHEM, V271, P13018, DOI 10.1074/jbc.271.22.13018; Peraldi P, 1997, J CLIN INVEST, V100, P1863, DOI 10.1172/JCI119715; Peuler JD, 1996, AM J HYPERTENS, V9, P188, DOI 10.1016/0895-7061(95)00393-2; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; Rao GN, 1996, J BIOL CHEM, V271, P20805, DOI 10.1074/jbc.271.34.20805; Rayment NB, 1996, CARDIOVASC RES, V32, P1123, DOI 10.1016/S0008-6363(96)00145-9; SALTIEL AR, 1996, AM J PHYSIOL, V270, P375; Sasaoka T, 1996, ENDOCRINOLOGY, V137, P4427, DOI 10.1210/en.137.10.4427; Schreyer SA, 1996, J BIOL CHEM, V271, P26174, DOI 10.1074/jbc.271.42.26174; Tanaka H, 1996, ARTERIOSCL THROM VAS, V16, P12, DOI 10.1161/01.ATV.16.1.12; TIPPING PG, 1993, AM J PATHOL, V142, P1721; Xi XP, 1997, FEBS LETT, V417, P283, DOI 10.1016/S0014-5793(97)01303-3; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; [No title captured]	36	19	20	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18279	18283		10.1074/jbc.M909795199	http://dx.doi.org/10.1074/jbc.M909795199			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10764814	hybrid			2022-12-27	WOS:000087659400051
J	Kwon, Y; Shin, BS; Chung, IK				Kwon, Y; Shin, BS; Chung, IK			The p53 tumor suppressor stimulates the catalytic activity of human topoisomerase II alpha by enhancing the rate of ATP hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED DNA CLEAVAGE; WILD-TYPE P53; BREAKAGE-REUNION REACTION; ANTINEOPLASTIC DRUGS; GENE-EXPRESSION; MECHANISM; PROTEIN; CYCLE; ENZYME; INHIBITORS	DNA topoisomerase II is an essential nuclear enzyme for proliferation of eukaryotic cells and plays important roles in many aspects of DNA processes. In this report, we have demonstrated that the catalytic activity of topoisomerase II alpha, as measured by decatenation of kinetoplast DNA and by relaxation of negatively supercoiled DNA,was stimulated similar to 2-3-fold by the tumor suppressor p53 protein. In order to determine the mechanism by which p53 activates the enzyme, the effects of p53 on the topoisomerase II alpha-mediated DNA cleavage/religation equilibrium were assessed using the prototypical topoisomerase II poison, etoposide, p53 had no effect on the ability of the enzyme to make double-stranded DNA break and religate linear DNA, indicating that the stimulation of the enzyme catalytic activity by p53 was not due to alteration in the formation of covalent cleavable complexes formed between topoisomerase II alpha and DNA, The effects of p53 on the catalytic inhibition of topoisomerase II alpha were examined using a specific catalytic inhibitor, ICRF-193, which blocks the ATP hydrolysis step of the enzyme catalytic cycle. Clearly manifested in decatenation and relaxation assays, p53 reduced the catalytic inhibition of topoisomerase II alpha by ICRF-193. ATP hydrolysis assays revealed that the ATPase activity of topoisomerase IIa was specifically enhanced by p53, Immunoprecipitation experiments revealed that p53 physically interacts with topoisomerase II alpha to form molecular complexes without a double-stranded DNA intermediary in vitro. To investigate whether p53 stimulates the catalytic activity of topoisomerase II in vivo, we expressed wild-type and mutant p53 in Saos-2 osteosarcoma cells lacking functional p53. Wild-type, but not mutant, p53 stimulated topoisomerase II activity in nuclear extract from these transfected cells. Our data propose a new role for p53 to modulate the catalytic activity of topoisomerase II alpha. Taken together, we suggest that the p53-mediated response of the cell cycle to DNA damage may involve activation of topoisomerase II alpha.	Yonsei Univ, Coll Sci, Dept Biol, Seoul 120749, South Korea	Yonsei University	Chung, IK (corresponding author), Yonsei Univ, Coll Sci, Dept Biol, 134 Shinchon Dong, Seoul 120749, South Korea.	topoviro@yonsei.ac.kr		Kwon, Young/0000-0002-8937-3182				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Albor A, 1998, CANCER RES, V58, P2091; Anderson H, 1996, CELL GROWTH DIFFER, V7, P83; BAE YS, 1988, P NATL ACAD SCI USA, V85, P2076, DOI 10.1073/pnas.85.7.2076; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BECK WT, 1994, CANCER CHEMOTH PHARM, V34, pS14, DOI 10.1007/BF00684858; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Bhat UG, 1999, P NATL ACAD SCI USA, V96, P7859, DOI 10.1073/pnas.96.14.7859; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CHEN GL, 1984, J BIOL CHEM, V259, P3560; CHUNG TDY, 1989, P NATL ACAD SCI USA, V86, P9431, DOI 10.1073/pnas.86.23.9431; CORBETT AH, 1992, J BIOL CHEM, V267, P20513; CORBETT AH, 1993, BIOCHEMISTRY-US, V32, P2090, DOI 10.1021/bi00059a029; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; Cowell IG, 2000, EXP CELL RES, V255, P86, DOI 10.1006/excr.1999.4772; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; DRAKE FH, 1989, CANCER RES, V49, P2578; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Gobert C, 1996, BIOCHEMISTRY-US, V35, P5778, DOI 10.1021/bi952327w; Goswami PC, 1996, MOL CELL BIOL, V16, P1500; Hao YW, 1997, BIOCHEM BIOPH RES CO, V234, P194, DOI 10.1006/bbrc.1997.6539; HARPER JW, 1993, CELL, V75, P805; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HSIANG YH, 1989, J BIOL CHEM, V264, P9713; JENKINS JR, 1992, NUCLEIC ACIDS RES, V20, P5587, DOI 10.1093/nar/20.21.5587; JENSEN PB, 1990, CANCER RES, V50, P3311; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kim JC, 1998, J BIOL CHEM, V273, P26130, DOI 10.1074/jbc.273.40.26130; Kim SA, 1998, BIOCHEMISTRY-US, V37, P16316, DOI 10.1021/bi9810961; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lassota P, 1996, J BIOL CHEM, V271, P26418, DOI 10.1074/jbc.271.42.26418; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; PERMANA PA, 1994, BIOCHEMISTRY-US, V33, P11333, DOI 10.1021/bi00203a031; POMMIER Y, 1994, CANCER INVEST, V12, P530, DOI 10.3109/07357909409021413; Redwood C, 1998, J BIOL CHEM, V273, P3635, DOI 10.1074/jbc.273.6.3635; ROBINSON MJ, 1990, BIOCHEMISTRY-US, V29, P2511, DOI 10.1021/bi00462a012; ROBINSON MJ, 1991, J BIOL CHEM, V266, P14585; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; Sandri MI, 1996, NUCLEIC ACIDS RES, V24, P4464, DOI 10.1093/nar/24.22.4464; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; Son YS, 1998, CANCER CHEMOTH PHARM, V41, P353, DOI 10.1007/s002800050751; STEWART N, 1995, ONCOGENE, V10, P109; TAN KB, 1992, CANCER RES, V52, P231; TANABE K, 1991, CANCER RES, V51, P4903; TEWEY KM, 1984, J BIOL CHEM, V259, P9182; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	64	16	16	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18503	18510		10.1074/jbc.M002081200	http://dx.doi.org/10.1074/jbc.M002081200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10764786	hybrid			2022-12-27	WOS:000087659400081
J	Dianov, GL; Thybo, T; Dianova, II; Lipinski, LJ; Bohr, VA				Dianov, GL; Thybo, T; Dianova, II; Lipinski, LJ; Bohr, VA			Single nucleotide patch base excision repair is the major pathway for removal of thymine glycol from DNA in human cell extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI ENDONUCLEASE-III; COCKAYNE-SYNDROME PATIENTS; ESCHERICHIA-COLI; OXIDATIVE DAMAGE; MAMMALIAN-CELLS; HUMAN HOMOLOG; TRANSCRIPTION; INVITRO; RESIDUES; RECONSTITUTION	The repair pathways involved in the removal of thymine glycol (TG) from DNA by human cell extracts have been examined. Closed circular DNA constructs containing a single TG at a defined site were used as substrates to determine the patch size generated after in vitro repair by cell extracts. Restriction analysis of the repair incorporation in the vicinity of the lesion indicated that the majority of TG was repaired through the base excision repair (BER) pathways. Repair incorporation 5' to the lesion, characteristic for the nucleotide excision repair pathway, was not found. More than 80% of the TG repair was accomplished by the single-nucleotide repair mechanism, and the remaining TGs were removed by the long patch BER pathway. We also analyzed the role of the xeroderma pigmentosum, complementation group G (XPG) protein in the excision step of BER. Cell extracts deficient in XPG protein had an average 25% reduction in TG incision. These data show that BER is the primary pathway for repair of TG in DNA and that XPG protein may be involved in repair of TG as an accessory factor.	NIA, Genet Mol Lab, NIH, Baltimore, MD 21224 USA; Univ Aarhus, Dept Biol Mol & Struct, DK-8000 Aarhus C, Denmark	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Aarhus University	Dianov, GL (corresponding author), NIA, Genet Mol Lab, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Bohr, Vilhelm/AAP-5931-2020					Aspinwall R, 1997, P NATL ACAD SCI USA, V94, P109, DOI 10.1073/pnas.94.1.109; Bessho T, 1999, NUCLEIC ACIDS RES, V27, P979, DOI 10.1093/nar/27.4.979; BREIMER LH, 1984, J BIOL CHEM, V259, P5543; CLARK JM, 1984, MUTAT RES, V132, P1, DOI 10.1016/0167-8817(84)90061-0; CLARK JM, 1987, BIOCHEMISTRY-US, V26, P5398, DOI 10.1021/bi00391a027; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DEMPLE B, 1980, NATURE, V287, P203, DOI 10.1038/287203a0; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; Dianov GL, 1999, BIOCHEMISTRY-US, V38, P11021, DOI 10.1021/bi9908890; DIZDAROGLU M, 1992, MUTAT RES, V275, P331, DOI 10.1016/0921-8734(92)90036-O; DIZDAROGLU M, 1991, FREE RADICAL BIO MED, V10, P225, DOI 10.1016/0891-5849(91)90080-M; Fortini P, 1999, J BIOL CHEM, V274, P15230, DOI 10.1074/jbc.274.21.15230; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; HATAHET Z, 1994, ANN NY ACAD SCI, V726, P346, DOI 10.1111/j.1749-6632.1994.tb52847.x; HTUN H, 1992, METHOD ENZYMOL, V212, P272; IDE H, 1985, NUCLEIC ACIDS RES, V13, P8035, DOI 10.1093/nar/13.22.8035; Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585; Imai K, 1998, GENE, V222, P287, DOI 10.1016/S0378-1119(98)00485-5; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Klungland A, 1999, MOL CELL, V3, P33, DOI 10.1016/S1097-2765(00)80172-0; KLYSIK J, 1990, BIOCHEMISTRY-US, V29, P9831, DOI 10.1021/bi00494a012; KOW YW, 1990, MUTAT RES, V235, P147, DOI 10.1016/0921-8777(90)90068-G; Kung HC, 1997, J BIOL CHEM, V272, P9227; LIN JJ, 1989, BIOCHEMISTRY-US, V28, P7979, DOI 10.1021/bi00446a002; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Lindahl T, 1997, CURR OPIN GENET DEV, V7, P158, DOI 10.1016/S0959-437X(97)80124-4; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; Nouspikel T, 1997, P NATL ACAD SCI USA, V94, P3116, DOI 10.1073/pnas.94.7.3116; PALECEK E, 1992, METHOD ENZYMOL, V212, P139; Reardon JT, 1997, P NATL ACAD SCI USA, V94, P9463, DOI 10.1073/pnas.94.17.9463; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; WOOD R, 1988, CELL, V52, P93; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465	36	72	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11809	11813		10.1074/jbc.275.16.11809	http://dx.doi.org/10.1074/jbc.275.16.11809			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766805	hybrid			2022-12-27	WOS:000086695500040
J	Kaplan, RS; Mayor, JA; Brauer, D; Kotaria, R; Walters, DE; Dean, AM				Kaplan, RS; Mayor, JA; Brauer, D; Kotaria, R; Walters, DE; Dean, AM			The yeast mitochondrial citrate transport protein - Probing the secondary structure of transmembrane domain IV and identification of residues that likely comprise a portion of the citrate translocation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; MEMBRANE-SPANNING SEGMENT; CHANNEL-LINING RESIDUES; DOPAMINE D2 RECEPTOR; BINDING-SITE CREVICE; FATTY-ACID SYNTHESIS; TRICARBOXYLATE CARRIER; CONDUCTANCE REGULATOR; PURIFICATION; EXPRESSION	The mitochondrial citrate transport protein (CTP) has been investigated by replacing 22 consecutive residues within transmembrane domain IV, one at a time, with cysteine. A cysteine-less CTP retaining wild-type functional properties served as the starting template. The single Cys CTP variants were overexpressed in Escherichia coli, isolated, and functionally reconstituted in a liposomal system. The accessibility of each single Cys mutant to three methanethiosulfonate reagents was evaluated by determining the pseudo first order rate constants for inhibition of CTP function, These rate constants varied by seven orders of magnitude. With three independent data sets we observed peaks and troughs in the rate constant data at identical amino acid positions and a periodicity of four was observed from residues 177-193, Based on the pattern of accessibility we conclude that residues 177-193 exist as an alpha-helix. Furthermore, a water-accessible face of the helix has been defined consisting of Pro-177, Val-178, Arg-181, Gln-182, Asn-185, Gln-186, Arg-189, Leu-190, and Tyr-193, and a water-inaccessible face has been delineated consisting of Ser-179, Met-180, Ala-183, Ala-184, Ala-187, Val-188, Gly-191, and Ser-192. We infer that the water-accessible face comprises a portion of the substrate translocation pathway through the CTP, whereas the water-inaccessible surface faces the lipid bilayer.	Finch Univ Hlth Sci Chicago Med Sch, Dept Biochem & Mol Biol, N Chicago, IL 60064 USA; BPTI Gortner Labs 240, St Paul, MN 55108 USA	Chicago Medical School	Kaplan, RS (corresponding author), Finch Univ Hlth Sci Chicago Med Sch, Dept Biochem & Mol Biol, 3333 Green Bay Rd, N Chicago, IL 60064 USA.		Walters, D. Eric/C-9626-2010; Mayor, June/AAP-1544-2021	Walters, D. Eric/0000-0002-1513-3522; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054642] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-54642] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1994, J BIOL CHEM, V269, P14865; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; BISACCIA F, 1990, BIOCHIM BIOPHYS ACTA, V1019, P250, DOI 10.1016/0005-2728(90)90201-E; BISACCIA F, 1989, BIOCHIM BIOPHYS ACTA, V977, P171, DOI 10.1016/S0005-2728(89)80068-4; Briggs C, 1999, BIOCHEMISTRY-US, V38, P5096, DOI 10.1021/bi982945n; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNENGR.H, 1973, FEBS LETT, V36, P130, DOI 10.1016/0014-5793(73)80353-9; Cheung M, 1996, BIOPHYS J, V70, P2688, DOI 10.1016/S0006-3495(96)79838-7; CONOVER TE, 1987, TRENDS BIOCHEM SCI, V12, P88, DOI 10.1016/0968-0004(87)90042-9; DEWAR MJS, 1977, J AM CHEM SOC, V99, P4899, DOI 10.1021/ja00457a004; ENDEMANN G, 1982, J BIOL CHEM, V257, P3434; Fu DY, 1996, BIOCHEMISTRY-US, V35, P11278, DOI 10.1021/bi960928x; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; JAVITCH JA, 1995, NEURON, V14, P825, DOI 10.1016/0896-6273(95)90226-0; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; KAPLAN RS, 1993, J BIOL CHEM, V268, P13682; KAPLAN RS, 1990, J BIOL CHEM, V265, P13379; KAPLAN RS, 1995, J BIOL CHEM, V270, P4108, DOI 10.1074/jbc.270.8.4108; KURZ LL, 1995, BIOPHYS J, V68, P900, DOI 10.1016/S0006-3495(95)80266-3; Muller V, 1996, BIOCHEMISTRY-US, V35, P16132, DOI 10.1021/bi960667r; PALMIERI F, 1972, EUR J BIOCHEM, V26, P587, DOI 10.1111/j.1432-1033.1972.tb01801.x; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; WATSON JA, 1970, J BIOL CHEM, V245, P5993; Winkler E, 1997, BIOCHEMISTRY-US, V36, P148, DOI 10.1021/bi962178x; XU Y, 1995, BIOCHEM BIOPH RES CO, V207, P783, DOI 10.1006/bbrc.1995.1255	26	51	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12009	12016		10.1074/jbc.275.16.12009	http://dx.doi.org/10.1074/jbc.275.16.12009			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766832	hybrid			2022-12-27	WOS:000086695500067
J	Ohlmann, T; Lopez-Lastra, M; Darlix, JL				Ohlmann, T; Lopez-Lastra, M; Darlix, JL			An internal ribosome entry segment promotes translation of the simian immunodeficiency virus genomic RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DICISTRONIC RETROVIRAL VECTORS; MESSENGER-RNA; PROTEIN-SYNTHESIS; LEUKEMIA-VIRUS; ALTERNATIVE TRANSLATION; PROTEOLYTIC CLEAVAGE; RETICULOCYTE LYSATE; GENE-TRANSFER; PHAS-I; INITIATION	The retroviral genomic RNA is the messenger for the synthesis of the group-specific antigen (gag) and polymerase precursors of the major structural proteins and enzymes of the virion. The 5'-untranslated leader of the simian immunodeficiency virus (SIV) genomic RNA is formed of highly structured domains involved in key steps of the viral life cycle. Thus, the presence of stable RNA structures between the 5'-cap and the gag start codon are thought to strongly inhibit scanning of a 43 S preinitiation ribosomal complex. This prompted us to look for an alternative to the canonical ribosome scanning. By using a standard bicistronic assay in the rabbit reticulocyte lysate, we show that the SIVmac 5'-leader contains an internal ribosome entry segment (IRES) and that gene expression driven by this IRES is stimulated upon cleavage of eukaryotic initiation factor 4G. Deletion analysis revealed that the sequence between the major splice donor and the gag AUG codon is required for IRES activity. DNA transfection and viral transduction experiments in both NIH-3T3 and COS-7 cells confirmed that translation driven by the SIV leader is IRES-dependent and thus insensitive to the immunosuppressant rapamycin. Identification of an IRES in SIV is of particular interest for the understanding of lentivirus replication and also for the design of novel lentiviral vectors suitable for gene transfer.	Ecole Normale Super Lyon, INSERM, U412, LaboRetro, F-69364 Lyon 07, France	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)	Ohlmann, T (corresponding author), Ecole Normale Super Lyon, INSERM, U412, LaboRetro, 46 Allee Italie, F-69364 Lyon 07, France.		Ohlmann, Theophile/H-6522-2016; Lopez-Lastra, Marcelo/HHM-9832-2022; LUC, DARLIX JEAN/AAE-9268-2020; ohlmann, Theophile/M-4463-2014	ohlmann, Theophile/0000-0002-2001-8916; Lopez-Lastra, Marcelo/0000-0002-7936-8478				Attal J, 1996, FEBS LETT, V392, P220, DOI 10.1016/0014-5793(96)00815-0; BENDER MA, 1987, J VIROL, V61, P1639, DOI 10.1128/JVI.61.5.1639-1646.1987; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BERLIOZ C, 1995, J VIROL, V69, P6400, DOI 10.1128/JVI.69.10.6400-6407.1995; BERLIOZ C, 1995, J VIROL, V69, P2214, DOI 10.1128/JVI.69.4.2214-2222.1995; BORMAN AM, 1995, NUCLEIC ACIDS RES, V23, P3656, DOI 10.1093/nar/23.18.3656; Borman AM, 1997, RNA, V3, P186; Borman AM, 1997, NUCLEIC ACIDS RES, V25, P925, DOI 10.1093/nar/25.5.925; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Chon SK, 1998, VIROLOGY, V251, P370, DOI 10.1006/viro.1998.9425; Ehrenfeld E, 1995, CURR TOP MICROBIOL, V203, P65; Gan WN, 1998, J BIOL CHEM, V273, P5006, DOI 10.1074/jbc.273.9.5006; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hellen CUT, 1995, CURR TOP MICROBIOL, V203, P31; Jackson RJ, 1995, RNA, V1, P985; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; JOHANSSON HE, 1994, NUCLEIC ACIDS RES, V22, P4591, DOI 10.1093/nar/22.22.4591; LAMOND AI, 1993, FEBS LETT, V325, P123, DOI 10.1016/0014-5793(93)81427-2; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Le Tinevez R, 1998, NUCLEIC ACIDS RES, V26, P2273, DOI 10.1093/nar/26.10.2273; LEVIN JG, 1976, P NATL ACAD SCI USA, V73, P1154, DOI 10.1073/pnas.73.4.1154; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; Lopez-Lastra M, 1999, J VIROL, V73, P8393; LopezLastra M, 1997, HUM GENE THER, V8, P1855, DOI 10.1089/hum.1997.8.16-1855; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MESSER LI, 1981, J VIROL, V40, P683, DOI 10.1128/JVI.40.3.683-690.1981; Miele G, 1996, J VIROL, V70, P944, DOI 10.1128/JVI.70.2.944-951.1996; MILLER AD, 1991, J VIROL, V65, P2220, DOI 10.1128/JVI.65.5.2220-2224.1991; Morley SJ, 1997, RNA, V3, P1085; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; Ohlmann T, 1996, EMBO J, V15, P1371, DOI 10.1002/j.1460-2075.1996.tb00479.x; OHLMANN T, 1995, NUCLEIC ACIDS RES, V23, P334; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Pestova TV, 1996, MOL CELL BIOL, V16, P6870; Pestova TV, 1996, MOL CELL BIOL, V16, P6859, DOI 10.1128/mcb.16.12.6859; Rau M, 1996, J BIOL CHEM, V271, P8983, DOI 10.1074/jbc.271.15.8983; Rijnbrand R, 1997, J VIROL, V71, P451, DOI 10.1128/JVI.71.1.451-457.1997; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Torrent C, 1996, HUM GENE THER, V7, P603, DOI 10.1089/hum.1996.7.5-603; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; VAGNER S, 1995, J BIOL CHEM, V270, P20376, DOI 10.1074/jbc.270.35.20376; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; ZIEGLER E, 1995, VIROLOGY, V213, P549; ZIEGLER E, 1995, J VIROL, V69, P3465, DOI 10.1128/JVI.69.6.3465-3474.1995	50	71	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11899	11906		10.1074/jbc.275.16.11899	http://dx.doi.org/10.1074/jbc.275.16.11899			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766817	hybrid			2022-12-27	WOS:000086695500052
J	Tichelaar, JW; Lu, W; Whitsett, JK				Tichelaar, JW; Lu, W; Whitsett, JK			Conditional expression of fibroblast growth factor-7 in the developing and mature lung	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; BRANCHING MORPHOGENESIS; RESPIRATORY EPITHELIUM; DEVELOPMENT SUGGESTS; MOUSE LUNG; IN-VIVO; CELL; GENE; RATS; LIMB	Effects of fibroblast growth factor-7 (FGF-7) on lung morphogenesis, respiratory epithelial cell differentiation, and proliferation mere assessed in transgenic mice in which the human FGF-7 cDNA was controlled by a conditional promoter under the direction of regulatory elements from either the human surfactant protein-C (SP-C) or rat Clara cell secretory protein (ccsp) genes. Expression of FGF-7 was induced in respiratory epithelial cells of the fetal lung by administration of doxycycline to the dam. Prenatally, doxycycline induced FGF-7 mRNA in respiratory epithelial cells in both Sp-c and Ccsp transgenic lines, increasing lung size and causing cystadenomatoid malformation. Postnatally, mice bearing both Ccsp-rtta and (Teto)(7)-cmv-fgf-7 transgenes survived, and lung morphology was normal, Induction of FGF-7 expression by doxycycline in the Ccsp-rtta x (Teto)(7)-cmv-fgf-7 mice caused marked epithelial cell proliferation, adenomatous hyperplasia, and pulmonary infiltration with mononuclear cells. Epithelial cell hyperplasia caused by FGF-7 was largely resolved after removal of doxycycline. Surfactant proteins, TTF-1, and aquaporin 5 expression were conditionally induced by doxycycline. The Sp-c-rtta and Ccsp-rtta activator mice provide models in which expression is conditionally controlled in respiratory epithelial cells in the developing and mature lung, altering lung morphogenesis, differentiation, and proliferation.	Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center	Whitsett, JK (corresponding author), Childrens Hosp, Med Ctr, Div Pulm Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	jeff.whitsett@chmcc.org	Tichelaar, Jay/B-9148-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056387, P01HL041496, P50HL056387] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-41496, HL-56387] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adamson IYR, 1997, AM J RESP CELL MOL, V16, P650, DOI 10.1165/ajrcmb.16.6.9191466; Arman E, 1999, P NATL ACAD SCI USA, V96, P11895, DOI 10.1073/pnas.96.21.11895; Bellusci S, 1997, DEVELOPMENT, V124, P4867; Blaisdell CJ, 1999, AM J RESP CELL MOL, V20, P842, DOI 10.1165/ajrcmb.20.4.3431; Borok Z, 1999, AM J PHYSIOL-CELL PH, V276, pC1352, DOI 10.1152/ajpcell.1999.276.6.C1352; Borok Z, 1998, AM J RESP CELL MOL, V18, P554, DOI 10.1165/ajrcmb.18.4.2838; Borok Z, 1998, AM J PHYSIOL-LUNG C, V274, pL149, DOI 10.1152/ajplung.1998.274.1.L149; BRAUKER JH, 1991, DEV BIOL, V147, P285, DOI 10.1016/0012-1606(91)90286-C; Charafeddine L, 1999, AM J PHYSIOL-LUNG C, V276, pL105, DOI 10.1152/ajplung.1999.276.1.L105; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Colby TV, 1999, LUNG BIOL HEALTH DIS, V124, P61; Deterding RR, 1996, AM J PHYSIOL-LUNG C, V271, pL495, DOI 10.1152/ajplung.1996.271.4.L495; Deterding RR, 1997, P ASSOC AM PHYSICIAN, V109, P254; Fehrenbach H, 1999, EUR RESPIR J, V14, P534, DOI 10.1034/j.1399-3003.1999.14c10.x; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; FINCH PW, 1995, DEV DYNAM, V203, P223, DOI 10.1002/aja.1002030210; GLASSER SW, 1991, AM J PHYSIOL, V261, pL349, DOI 10.1152/ajplung.1991.261.4.L349; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Graeff RW, 1999, PEDIATR RES, V46, P523, DOI 10.1203/00006450-199911000-00006; Guery RPH, 1997, AM J RESP CRIT CARE, V155, P1777, DOI 10.1164/ajrccm.155.5.9154891; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; Igarashi M, 1998, J BIOL CHEM, V273, P13230, DOI 10.1074/jbc.273.21.13230; Kan M, 1996, J BIOL CHEM, V271, P26143, DOI 10.1074/jbc.271.42.26143; Krane CM, 1999, MAMM GENOME, V10, P498, DOI 10.1007/s003359901030; Luo YD, 1998, BIOCHEMISTRY-US, V37, P16506, DOI 10.1021/bi9816599; MASON IJ, 1994, MECH DEVELOP, V45, P15, DOI 10.1016/0925-4773(94)90050-7; Min HS, 1998, GENE DEV, V12, P3156, DOI 10.1101/gad.12.20.3156; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; PANOS RJ, 1995, J CLIN INVEST, V96, P2026, DOI 10.1172/JCI118250; Park WY, 1998, DEV BIOL, V201, P125, DOI 10.1006/dbio.1998.8994; PETERS KG, 1992, DEVELOPMENT, V114, P233; Ray P, 1997, J CLIN INVEST, V100, P2501, DOI 10.1172/JCI119792; Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096; Simonet WS, 1995, P NATL ACAD SCI USA, V92, P12461, DOI 10.1073/pnas.92.26.12461; STRIPP BR, 1992, J BIOL CHEM, V267, P14703; ULICH TR, 1994, J CLIN INVEST, V93, P1298, DOI 10.1172/JCI117086; Wang YB, 1999, J APPL PHYSIOL, V87, P1852, DOI 10.1152/jappl.1999.87.5.1852; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; Xie W, 1999, ONCOGENE, V18, P3593, DOI 10.1038/sj.onc.1202673; Yano T, 1996, AM J RESP CELL MOL, V15, P433, DOI 10.1165/ajrcmb.15.4.8879176; Yi ES, 1996, AM J PATHOL, V149, P1963; Yi ES, 1998, INFLAMMATION, V22, P315, DOI 10.1023/A:1022304317111; Zhang LQ, 1997, BBA-GENE STRUCT EXPR, V1350, P359, DOI 10.1016/S0167-4781(96)00180-7; Zhou L, 1996, AM J PHYSIOL-LUNG C, V271, pL987, DOI 10.1152/ajplung.1996.271.6.L987; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084; Zsengeller ZK, 1999, HUM GENE THER, V10, P341, DOI 10.1089/10430349950018797	46	265	268	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11858	11864		10.1074/jbc.275.16.11858	http://dx.doi.org/10.1074/jbc.275.16.11858			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766812	hybrid			2022-12-27	WOS:000086695500047
J	Barbato, R; Bergo, E; Szabo, I; Dalla Vecchia, F; Giacometti, GM				Barbato, R; Bergo, E; Szabo, I; Dalla Vecchia, F; Giacometti, GM			Ultraviolet B exposure of whole leaves of barley affects structure and functional organization of photosystem II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; REACTION-CENTER D1-PROTEIN; REACTION CENTER PROTEIN; D1 PROTEIN; ELECTRON-TRANSPORT; OZONE DEPLETION; ACTION SPECTRUM; GRANA STACKING; CORE PROTEINS; DNA-DAMAGE	This study examines the effects of ecologically important levels of ultraviolet B radiation on protein D1 turnover and stability and lateral redistribution of photosystem II. It is shown that ultraviolet B light supported only limited synthesis of protein D1, one of the most important components of photosystem II, whereas it promoted significant degradation of proteins D1 and D2, Furthermore, dephosphorylation of photosystem II subunits was specifically elicited upon exposure to ultraviolet B light. Structural modifications of photosystem II and changes in its lateral distribution between granum membranes and stroma-exposed lamellae were found to be different from those observed after photoinhibition by strong visible light. In particular, more complete dismantling of photosystem II cores was observed. Altogether, the data reported here suggest that ultraviolet B radiation alone fails to activate the photosystem TT repair cycle, as hypothesized for visible light. This failure may contribute to the toxic effect of ultraviolet B radiation, which is increasing as a consequence of depletion of stratospheric ozone.	Univ Padua, Dept Biol, I-35121 Padua, Italy; Univ Piemonte Orientale Amedeo Avogadro, Dept Sci & Adv Technol, I-15100 Alessandria, Italy	University of Padua; University of Eastern Piedmont Amedeo Avogadro	Giacometti, GM (corresponding author), Univ Padua, Dept Biol, Viale Giuseppe Colombo 3, I-35121 Padua, Italy.		Szabo, Ildiko/AAW-5972-2021; Padova, Ildiko/K-5344-2016	Szabo, Ildiko/0000-0002-3637-3947; 				ADIR N, 1990, J BIOL CHEM, V265, P12563; ANDERSON JM, 1986, ANNU REV PLANT PHYS, V37, P93, DOI 10.1146/annurev.arplant.37.1.93; ANDERSON JM, 1994, PHOTOSYNTH RES, V41, P315, DOI 10.1007/BF00019409; ANDERSON JM, 1982, PHOTOBIOCH PHOTOBIOP, V3, P225; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P13; Baena-Gonzalez E, 1999, PLANTA, V208, P196, DOI 10.1007/s004250050550; Barbato R, 1999, J PHOTOCH PHOTOBIO B, V48, P189, DOI 10.1016/S1011-1344(99)00027-5; BARBATO R, 1991, BIOCHEMISTRY-US, V30, P10220, DOI 10.1021/bi00106a021; BARBATO R, 1995, EUR J BIOCHEM, V227, P723, DOI 10.1111/j.1432-1033.1995.tb20194.x; BARBATO R, 1992, J CELL BIOL, V119, P325, DOI 10.1083/jcb.119.2.325; BASSI R, 1985, CARLSBERG RES COMMUN, V50, P347, DOI 10.1007/BF02907157; BORNMAN JF, 1984, PHOTOBIOCH PHOTOBIOP, V8, P305; Britt AB, 1996, ANNU REV PLANT PHYS, V47, P75, DOI 10.1146/annurev.arplant.47.1.75; Bruick RK, 1999, TRENDS PLANT SCI, V4, P190, DOI 10.1016/S1360-1385(99)01402-8; DAY TA, 1995, PHYSIOL PLANTARUM, V94, P433, DOI 10.1111/j.1399-3054.1995.tb00950.x; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; Ebbert V, 1996, PHOTOSYNTH RES, V50, P257, DOI 10.1007/BF00033124; ELICH TD, 1992, J BIOL CHEM, V267, P3523; FRISO G, 1994, FEBS LETT, V339, P217, DOI 10.1016/0014-5793(94)80419-2; FRISO G, 1994, BBA-BIOENERGETICS, V1184, P78, DOI 10.1016/0005-2728(94)90156-2; GHIRARDI ML, 1990, CURRENT RES PHOTOSYN, V2, P733; Giacometti GM, 1996, EUR J BIOCHEM, V242, P799, DOI 10.1111/j.1432-1033.1996.0799r.x; GREENBERG BM, 1989, P NATL ACAD SCI USA, V86, P6617, DOI 10.1073/pnas.86.17.6617; IWANZIK W, 1983, PHYSIOL PLANTARUM, V58, P401, DOI 10.1111/j.1399-3054.1983.tb04201.x; Jansen MAK, 1996, PHOTOCHEM PHOTOBIOL, V63, P814, DOI 10.1111/j.1751-1097.1996.tb09636.x; JONES LW, 1966, PLANT PHYSIOL, V41, P1037, DOI 10.1104/pp.41.6.1037; KERR JB, 1993, SCIENCE, V262, P1032, DOI 10.1126/science.262.5136.1032; KETTUNEN R, 1992, RES PHOTOSYNTHESIS, V4, P806; KOMENDA J, 1995, BIOCHEMISTRY-US, V34, P9625, DOI 10.1021/bi00029a040; KYLE DJ, 1984, BIOCHIM BIOPHYS ACTA, V765, P89, DOI 10.1016/0005-2728(84)90001-X; Landry LG, 1997, P NATL ACAD SCI USA, V94, P328, DOI 10.1073/pnas.94.1.328; Mate Z, 1998, J BIOL CHEM, V273, P17439, DOI 10.1074/jbc.273.28.17439; MATTOO AK, 1981, P NATL ACAD SCI-BIOL, V78, P1572, DOI 10.1073/pnas.78.3.1572; MELIS A, 1992, BIOCHIM BIOPHYS ACTA, V1100, P312, DOI 10.1016/0167-4838(92)90487-X; QUAITE FE, 1992, NATURE, V358, P576, DOI 10.1038/358576a0; RASCIO N, 1994, J PLANT PHYSIOL, V144, P314, DOI 10.1016/S0176-1617(11)81193-4; RENGER G, 1989, PHOTOCHEM PHOTOBIOL, V49, P97, DOI 10.1111/j.1751-1097.1989.tb04083.x; Rintamaki E, 1997, J BIOL CHEM, V272, P30476, DOI 10.1074/jbc.272.48.30476; Rintamaki E, 1996, J BIOL CHEM, V271, P14870, DOI 10.1074/jbc.271.25.14870; RYRIE IJ, 1980, EUR J BIOCHEM, V107, P345; TEVINI M, 1989, PHOTOCHEM PHOTOBIOL, V50, P479, DOI 10.1111/j.1751-1097.1989.tb05552.x; VANWIJK KJ, 1995, J BIOL CHEM, V270, P25685, DOI 10.1074/jbc.270.43.25685; Vass I, 1996, BIOCHEMISTRY-US, V35, P8964, DOI 10.1021/bi9530595; VASS I, 1996, HDB PHOTOSYNTHESIS, P931; YERKES CT, 1990, CURRENT RES PHOTOSYN, V4, P381	45	29	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10976	10982		10.1074/jbc.275.15.10976	http://dx.doi.org/10.1074/jbc.275.15.10976			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753898	hybrid			2022-12-27	WOS:000086466600040
J	Christiansen, J; Cash, VL; Seefeldt, LC; Dean, DR				Christiansen, J; Cash, VL; Seefeldt, LC; Dean, DR			Isolation and characterization of an acetylene-resistant nitrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOTOBACTER-VINELANDII NITROGENASE; IRON-MOLYBDENUM COFACTOR; MOFE PROTEIN; ELECTRON-TRANSFER; FE-PROTEIN; P-CLUSTER; MECHANISM; CATALYSIS; FIXATION; BINDING	A genetic strategy was developed for the isolation of a mutant strain of Azotobacter vinelandii that exhibits in vivo nitrogenase activity resistant to inhibition by acetylene, Examination of the kinetic features of the altered nitrogenase MoFe protein produced by this strain, which has serine substituted for the alpha-subunit Gly(69) residue, is consistent with other studies that indicate the MoFe protein normally contains at least two acetylene binding/reduction sites. The first of these is a high affinity site and is the one primarily accessed during typical acetylene reduction assays. Results of the present work indicate that this acetylene binding/reduction site is not directly relevant to the mechanism of nitrogen reduction because it can be eliminated or severely altered without significantly affecting nitrogen reduction. Elimination of this site also results in the manifestation of a low affinity acetylene-binding site to which both acetylene and nitrogen are able to bind with approximately the same affinity. In contrast to the normal enzyme, nitrogen and acetylene binding to the altered MoFe protein are mutually competitive. The location of the alpha-Ser(69) substitution is interpreted to indicate that the 4Fe-4S face of the FeMo cofactor capped by the cu-subunit Val(70) residue is the most likely region within FeMo cofactor to which acetylene binds with high affinity.	Virginia Tech, Dept Biochem, Blacksburg, VA 24061 USA; Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA	Virginia Polytechnic Institute & State University; Utah System of Higher Education; Utah State University	Dean, DR (corresponding author), Virginia Tech, Dept Biochem, Blacksburg, VA 24061 USA.	seefeldt@cc.usu.edu; deandr@vt.edu		Seefeldt, Lance/0000-0002-6457-9504	NIGMS NIH HHS [R01-GM59087] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059087] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; BURGESS BK, 1990, CHEM REV, V90, P1377, DOI 10.1021/cr00106a002; Burris R. H., 1979, A treatise on dinitrogen fixation. Inorganic and physical chemistry and biochemistry, P569; Christiansen J, 1998, BIOCHEMISTRY-US, V37, P12611, DOI 10.1021/bi981165b; CHROMY V, 1974, CLIN CHEM, V20, P1362; Dance I, 1996, J BIOL INORG CHEM, V1, P581, DOI 10.1007/s007750050096; DAVIS LC, 1979, BIOCHEMISTRY-US, V18, P4860, DOI 10.1021/bi00589a014; DAVIS LC, 1975, BIOCHIM BIOPHYS ACTA, V403, P67, DOI 10.1016/0005-2744(75)90009-1; DEAN DR, 1993, J BACTERIOL, V175, P6737, DOI 10.1128/jb.175.21.6737-6744.1993; DILWORTH MJ, 1992, ANAL BIOCHEM, V207, P6, DOI 10.1016/0003-2697(92)90491-O; DILWORTH MJ, 1966, BIOCHIM BIOPHYS ACTA, V127, P285, DOI 10.1016/0304-4165(66)90383-7; Eady RR, 1996, CHEM REV, V96, P3013, DOI 10.1021/cr950057h; Howard JB, 1996, CHEM REV, V96, P2965, DOI 10.1021/cr9500545; HOWARD JB, 1993, ACS SYM SER, V535, P271; HWANG JC, 1973, BIOCHIM BIOPHYS ACTA, V292, P256, DOI 10.1016/0005-2728(73)90270-3; JACOBSON MR, 1989, MOL GEN GENET, V219, P49, DOI 10.1007/BF00261156; JOERGER RD, 1990, J BACTERIOL, V172, P3400, DOI 10.1128/jb.172.6.3400-3408.1990; KIM CH, 1995, BIOCHEMISTRY-US, V34, P2798, DOI 10.1021/bi00009a008; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lanzilotta WN, 1998, BIOCHEMISTRY-US, V37, P11376, DOI 10.1021/bi980048d; Lee HI, 1998, BIOCHEMISTRY-US, V37, P13370, DOI 10.1021/bi980956a; LOWE DJ, 1978, BIOCHEM J, V173, P277, DOI 10.1042/bj1730277; LOWERY RG, 1989, BIOCHEMISTRY-US, V28, P1206, DOI 10.1021/bi00429a038; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NEWTON WE, 1993, ACS SYM SER, V535, P216; PAGE WJ, 1979, J BACTERIOL, V139, P1058, DOI 10.1128/JB.139.3.1058-1061.1979; Peters JW, 1997, BIOCHEMISTRY-US, V36, P1181, DOI 10.1021/bi9626665; PETERS JW, 1994, J BIOL CHEM, V269, P28076; PETERS JW, 1995, J BIOL CHEM, V270, P27007, DOI 10.1074/jbc.270.45.27007; PETERS JW, 1995, ANNU REV MICROBIOL, V49, P335, DOI 10.1146/annurev.mi.49.100195.002003; RIVERAORTIZ JM, 1975, J BACTERIOL, V123, P537, DOI 10.1128/JB.123.2.537-545.1975; ROBINSON AC, 1986, J BACTERIOL, V166, P180, DOI 10.1128/jb.166.1.180-186.1986; Schindelin N, 1997, NATURE, V387, P370, DOI 10.1038/387370a0; Seefeldt LC, 1997, ACCOUNTS CHEM RES, V30, P260, DOI 10.1021/ar960260e; Shen J, 1997, BIOCHEMISTRY-US, V36, P4884, DOI 10.1021/bi9628578; STRANDBERG GW, 1968, CAN J MICROBIOL, V14, P25, DOI 10.1139/m68-005; Thorneley R. N. F., 1985, MOLYBDENUM ENZYMES, P221; WOLLE D, 1992, J BIOL CHEM, V267, P3667; YATES MG, 1991, BIOL NITROGEN FIXATI, P685	43	73	74	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11459	11464		10.1074/jbc.275.15.11459	http://dx.doi.org/10.1074/jbc.275.15.11459			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753963	hybrid			2022-12-27	WOS:000086466600105
J	Lubas, WA; Hanover, JA				Lubas, WA; Hanover, JA			Functional expression of O-linked GlcNAc transferase - Domain structure and substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-N-ACETYLGLUCOSAMINYLTRANSFERASE; INSULIN-RESISTANCE; CYTOPLASMIC PROTEINS; NUCLEAR-PORE; TETRATRICOPEPTIDE REPEATS; GLYCOSYLATION; PATHWAY; GLYCOPROTEINS; GLUCOSAMINE; TPR	O-GlcNAc transferase (OGT) modifies nuclear pore proteins and transcription factors. In Arabidopsis, the OGT homolog participates in the gibberellin signaling pathway. We and others have proposed that mammalian OGT is the terminal step in a glucose-sensitive signal transduction pathway that becomes disregulated in insulin resistance. To facilitate mutational analysis of OGT in the absence of competing endogenous activity, we expressed the 103-kDa human. OGT in Escherichia coli. Kinetic parameters for the purified recombinant enzyme (K-m = 1.2 mu M for Nup 62; K-m = 0.5 mu M for UDP-GlcNAc) are nearly identical to purified mammalian OGT. Deletions in the highly conserved C terminus result in a complete loss of activity. The N-terminal tetratricopeptide repeat domain is required for optimal recognition of substrates, Removal of the first three tetratricopeptide repeats greatly reduces the O-GlcNAc addition to macromolecular substrates. However, this altered enzyme retains full activity against appropriate synthetic peptides. Autoglycosylation of OGT is augmented when the first six tetratricopeptide repeats are removed showing that these repeats are not required for catalysis. Given its proposed role in modulating insulin action, OGT may modify kinases involved in this signaling cascade. Among the many kinases tested, OGT glycosylates glycogen synthase kinase-3 and casein kinase II, two enzymes critical in the regulation of glycogen synthesis.	NIDDK, Lab Cell Biochem & Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Hanover, JA (corresponding author), NIDDK, Lab Cell Biochem & Biol, NIH, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK060000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILER SM, 1995, PROTEIN EXPRES PURIF, V6, P546, DOI 10.1006/prep.1995.1072; CHOU CF, 1992, J BIOL CHEM, V267, P3901; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; Haltiwanger RS, 1997, BIOCHEM BIOPH RES CO, V231, P237, DOI 10.1006/bbrc.1997.6110; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; Hanover JA, 1999, ARCH BIOCHEM BIOPHYS, V362, P38, DOI 10.1006/abbi.1998.1016; HANOVER JA, 1987, J BIOL CHEM, V262, P9887; Hawkins M, 1997, J CLIN INVEST, V99, P2173, DOI 10.1172/JCI119390; Hebert LF, 1996, J CLIN INVEST, V98, P930, DOI 10.1172/JCI118876; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; Jacobsen SE, 1996, P NATL ACAD SCI USA, V93, P9292, DOI 10.1073/pnas.93.17.9292; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; Kreppel LK, 1999, J BIOL CHEM, V274, P32015, DOI 10.1074/jbc.274.45.32015; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Lubas WA, 1997, J BIOL CHEM, V272, P9316; LUBAS WA, 1995, BIOCHEMISTRY-US, V34, P1684; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; McClain DA, 1996, DIABETES, V45, P1003, DOI 10.2337/diabetes.45.8.1003; Miller MW, 1999, ARCH BIOCHEM BIOPHYS, V367, P51, DOI 10.1006/abbi.1999.1237; Ogas J, 1998, CURR BIOL, V8, pR165, DOI 10.1016/S0960-9822(98)70101-0; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; Roquemore EP, 1996, BIOCHEMISTRY-US, V35, P3578, DOI 10.1021/bi951918j; Sayeski PP, 1996, J BIOL CHEM, V271, P15237, DOI 10.1074/jbc.271.25.15237; Shaw P, 1996, ONCOGENE, V12, P921; TERLECKY SR, 1995, EMBO J, V14, P3627, DOI 10.1002/j.1460-2075.1995.tb00032.x; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; Wang JL, 1998, NATURE, V393, P684, DOI 10.1038/31474; Yki-Jarvinen H, 1998, METABOLISM, V47, P449, DOI 10.1016/S0026-0495(98)90058-0	32	249	274	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10983	10988		10.1074/jbc.275.15.10983	http://dx.doi.org/10.1074/jbc.275.15.10983			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753899	hybrid			2022-12-27	WOS:000086466600041
J	Maquoi, E; Frankenne, F; Baramova, E; Munaut, C; Sounni, NE; Remacle, A; Noel, A; Murphy, G; Foidar, JM				Maquoi, E; Frankenne, F; Baramova, E; Munaut, C; Sounni, NE; Remacle, A; Noel, A; Murphy, G; Foidar, JM			Membrane type 1 matrix metalloproteinase-associated degradation of tissue inhibitor of metalloproteinase 2 in human tumor cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GELATINASE-A ACTIVATION; PROGELATINASE-A; CATALYTIC DOMAIN; SURFACE BINDING; IV COLLAGENASE; TIMP-2; RECEPTOR; INVASION; METASTASIS; EXPRESSION	Tissue inhibitor of metalloproteinase 2 (TIMP-2) is required for the membrane type 1 matrix metalloproteinase (MT1-MMP)-dependent activation of pro-MMP-2 on the cell surface. MT1-MMP-bound TIMP-2 has been shown to function as a receptor for secreted pro-MMP-2, resulting in the formation of a trimolecular complex. In the presence of uncomplexed active MT1-MMP, the prodomain of cell surface-associated MMP-2 is cleaved, and activated MMP-2 is released. However, the behavior of MT1-MMP-bound TIMP-2 during MMP-2 activation is currently unknown. In this study, I-125-labeled recombinant TIMP-2 (I-125-rTIMP-2) was used to investigate the fate of TIMP-2 during pro-MMP-2 activation by HT1080 and transfected A2058 cells. HT1080 and A2058 cells transfected with MT1-MMP cDNA (but not vector-transfected A2058 cells) were able to bind I-125-rTIMP-2, to activate pro-MMP-2, and to process MT1-MMP into an inactive 43-kDa form, Under these conditions, I-125-rTIMP-2 bound to the cell surface was rapidly internalized and degraded in intracellular organelles through a bafilomycin A(1)-sensitive mechanism, and I-125-bearing low molecular mass fragment(s) were released in the culture medium. These different processes were inhibited by hydroxamic acid-based synthetic MMP inhibitors and rTIMP-2, but not by rTIMP-1 or cysteine, serine, or aspartic proteinase inhibitors. These results support the concept that the MT1-MMP-dependent internalization and degradation of TIMP-2 by some tumor cells might be involved in the regulation of pericellular proteolysis.	Univ Liege, Lab Tumor & Dev Biol, B-4000 Liege, Belgium; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	University of Liege; University of East Anglia	Foidar, JM (corresponding author), Univ Liege, Lab Tumor & Dev Biol, Tour Pathol B23, B-4000 Liege, Belgium.	jm.foidart@ulg.ac.be	Munaut, Carine/K-8138-2019; Sounni, Nor Eddine/AAY-8766-2021	Sounni, Nor Eddine/0000-0001-9962-9236; Noel, Agnes/0000-0002-7670-6179				Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; Baramova EN, 1997, FEBS LETT, V405, P157, DOI 10.1016/S0014-5793(97)00175-0; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Brown PD, 1995, ANN ONCOL, V6, P967, DOI 10.1093/oxfordjournals.annonc.a059091; Brown PD, 1999, APMIS, V107, P174, DOI 10.1111/j.1699-0463.1999.tb01541.x; BROWN PD, 1993, Patent No. 21942; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; CAMPION C, 1990, Patent No. 05719; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; Cao JA, 1996, J BIOL CHEM, V271, P30174, DOI 10.1074/jbc.271.47.30174; CASTELHANO AL, 1995, Patent No. 04735; CLAGUE MJ, 1994, J BIOL CHEM, V269, P21; Cowell S, 1998, BIOCHEM J, V331, P453, DOI 10.1042/bj3310453; d'Ortho MP, 1998, FEBS LETT, V421, P159, DOI 10.1016/S0014-5793(97)01555-X; DECLERCK YA, 1992, CANCER RES, V52, P701; Ellerbroek SM, 1999, CANCER RES, V59, P1635; EMMERTBUCK MR, 1995, FEBS LETT, V364, P28, DOI 10.1016/0014-5793(95)00345-A; Farina AR, 1998, CANCER RES, V58, P2957; Fini ME, 1998, BIOL EXTRAC, P299; Foda HD, 1996, LAB INVEST, V74, P538; Gohji K, 1996, CANCER RES, V56, P3196; GRIGIONI WF, 1994, MODERN PATHOL, V7, P220; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; Imren S, 1996, CANCER RES, V56, P2891; JENSENIUS JC, 1981, J IMMUNOL METHODS, V46, P63, DOI 10.1016/0022-1759(81)90333-1; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1991, CANCER INVEST, V9, P543, DOI 10.3109/07357909109018952; Lohi J, 1996, EUR J BIOCHEM, V239, P239, DOI 10.1111/j.1432-1033.1996.0239u.x; Maquoi E, 1998, FEBS LETT, V424, P262, DOI 10.1016/S0014-5793(98)00187-2; MONTGOMERY AMP, 1994, CANCER RES, V54, P5467; MOSES MA, 1990, SCIENCE, V248, P1408, DOI 10.1126/science.1694043; Nagase H, 1997, BIOL CHEM, V378, P151; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; NG GYK, 1995, P NATL ACAD SCI USA, V92, P10157, DOI 10.1073/pnas.92.22.10157; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; ODA K, 1991, BIOCHEM BIOPH RES CO, V178, P369, DOI 10.1016/0006-291X(91)91823-U; ONISTO M, 1995, INT J CANCER, V63, P621, DOI 10.1002/ijc.2910630504; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; RAY JM, 1995, EMBO J, V14, P908, DOI 10.1002/j.1460-2075.1995.tb07072.x; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V385, P238, DOI 10.1016/0014-5793(96)00389-4; Sato H, 1996, J BIOCHEM-TOKYO, V119, P209; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; SCHWARTZ AL, 1995, PEDIATR RES, V38, P835, DOI 10.1203/00006450-199512000-00003; Shofuda K, 1998, J BIOCHEM-TOKYO, V124, P462, DOI 10.1093/oxfordjournals.jbchem.a022136; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; THEKKUMKARA TJ, 1995, MOL CELL BIOCHEM, V146, P79, DOI 10.1007/BF00926885; Valente P, 1998, INT J CANCER, V75, P246, DOI 10.1002/(SICI)1097-0215(19980119)75:2<246::AID-IJC13>3.0.CO;2-B; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; Woessner JF, 1998, BIOL EXTRAC, P1; WojtowiczPraga SM, 1997, INVEST NEW DRUG, V15, P61, DOI 10.1023/A:1005722729132; Yu AE, 1996, BIOCHEM CELL BIOL, V74, P823, DOI 10.1139/o96-088; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	59	81	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11368	11378		10.1074/jbc.275.15.11368	http://dx.doi.org/10.1074/jbc.275.15.11368			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753951	Green Submitted, hybrid			2022-12-27	WOS:000086466600093
J	Miller, WE; Maudsley, S; Ahn, S; Khan, KD; Luttrell, LM; Lefkowitz, RJ				Miller, WE; Maudsley, S; Ahn, S; Khan, KD; Luttrell, LM; Lefkowitz, RJ			beta-arrestin1 interacts with the catalytic domain of the tyrosine kinase c-SRC - Role of beta-arrestin1-dependent targeting of c-SRC in receptor endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ADRENERGIC-RECEPTOR; CLATHRIN-MEDIATED ENDOCYTOSIS; MIDDLE-T-ANTIGEN; BETA(2)-ADRENERGIC RECEPTOR; ARRESTIN/CLATHRIN INTERACTION; TRANSFORMING PROTEIN; EGF RECEPTOR; SH3 DOMAINS; ACTIVATION	beta-Arrestins can act as adapter molecules, coupling G-protein-coupled receptors to proteins involved in mitogenic as well as endocytic pathways. We have previously identified c-SRC as a molecule that is rapidly recruited to the beta 2-adrenergic receptor in a beta-arrestin1-dependent manner, Recruitment of c-SRC to the receptor appears to be involved in pathways leading to receptor internalization and mitogen-activated protein kinase activation. This recruitment of c-SRC to the receptor involves an interaction between the amino-terminal proline-rich region of beta-arrestin1 and the Src homology 3 (SH3) domain of c-SRC, but deletion of the proline-rich domain does not totally ablate the interaction. We have found that a major interaction also exists between beta-arrestin1 and the catalytic or kinase domain (SH1) of c-SRC, We therefore hypothesized that a catalytically inactive mutant of the isolated catalytic subunit, SH1 (kinase dead) (SH1(KD)), would specifically block those cellular actions of c-SRC that are mediated by beta-arrestin1 recruitment to the G-protein-coupled receptor. In contrast, the majority of cellular phosphorylations catalyzed by c-SRC, which do not involve interaction with the SH1 domain, would be predicted to be unaffected. The SH1(KD) mutant did indeed block beta 2-adrenergic receptor internalization and receptor-stimulated tyrosine phosphorylation of dynamin, actions previously shown to be c-SRC-dependent, In contrast, SAM-68 and whole cell tyrosine phosphorylation by c-SRC was unaffected, indicating that the SH1(KD) mutant did not inhibit c-SRC tyrosine kinase activity in general. These results not only clarify the nature of the beta-arrestin1/c-SRC interaction but also implicate beta-arrestin1 as an important mediator of receptor internalization by recruiting tyrosine kinase activity to the cell surface to phosphorylate key endocytic intermediates, such as dynamin.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Box 3821, Durham, NC 27710 USA.		Lefkowitz, Robert/AAW-2649-2021; Maudsley, Stuart/AAV-9929-2021; Maudsley, Stuart/Q-4782-2019	Maudsley, Stuart/0000-0002-1868-184X; Luttrell, Louis/0000-0003-2805-6949	NHLBI NIH HHS [HL16037] Funding Source: Medline; NIDDK NIH HHS [DK55524] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK055524, R01DK055524] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BARAK LS, 1994, J BIOL CHEM, V269, P2790; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CHEN YH, 1994, J BIOL CHEM, V269, P27372; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Dunant NM, 1996, J VIROL, V70, P1323, DOI 10.1128/JVI.70.3.1323-1330.1996; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Glover HR, 1999, ONCOGENE, V18, P4364, DOI 10.1038/sj.onc.1202816; Gonfloni S, 1997, EMBO J, V16, P7261, DOI 10.1093/emboj/16.24.7261; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; Lin FT, 1999, J BIOL CHEM, V274, P15971, DOI 10.1074/jbc.274.23.15971; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; Lohi O, 1998, FEBS LETT, V432, P225, DOI 10.1016/S0014-5793(98)00874-6; LUTON F, 1994, J IMMUNOL, V153, P63; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MARTINPEREZ J, 1989, J CELL BIOL, V109, P577, DOI 10.1083/jcb.109.2.577; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; McDonald PH, 1999, J BIOL CHEM, V274, P10677, DOI 10.1074/jbc.274.16.10677; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; Shalloway D, 1997, TRENDS CELL BIOL, V7, P215; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	60	167	174	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11312	11319		10.1074/jbc.275.15.11312	http://dx.doi.org/10.1074/jbc.275.15.11312			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753943	hybrid			2022-12-27	WOS:000086466600085
J	Paine, E; Palmantier, R; Akiyama, SK; Olden, K; Roberts, JD				Paine, E; Palmantier, R; Akiyama, SK; Olden, K; Roberts, JD			Arachidonic acid activates mitogen-activated protein (MAP) kinase-activated protein kinase 2 and mediates adhesion of a human breast carcinoma cell line to collagen type IV through a p38 MAP kinase-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; HEAT-SHOCK PROTEIN-27; CAP-BINDING-PROTEIN; N-TERMINAL KINASE; GENE-EXPRESSION; EXTRACELLULAR-MATRIX; CANCER METASTASIS; LINOLEIC-ACID; TYROSINE PHOSPHORYLATION; HELA-CELLS	Adhesion of metastatic human mammary carcinoma MDA-MB-435 cells to the basement membrane protein collagen type TV can be activated by treatment with arachidonic acid. We initially observed that this arachidonic acid-mediated adhesion was inhibited by the tyrosine kinase inhibitor genistein, Therefore, we examined the role of the mitogen-activated protein (MAP) kinase family tyrosine phosphorylation-regulated pathways in arachidonic acid-stimulated cell adhesion. Arachidonic acid stimulated the phosphorylation of p38, the activation of MAP kinase-activated protein kinase 2 (MAPKAPK2, a downstream substrate of p38), and the phosphorylation of heat shock protein 27 (a downstream substrate of MAP kinase-activated protein kinase 2), Treatment with the p38 inhibitor PD169316 completely and specifically inhibited arachidonic acid-mediated cell adhesion to collagen type TV. p38 activity was specifically associated with arachidonic acid-stimulated adhesion; this was demonstrated by the observation that 12-O-tetradecanoylphorbol 13-acetate-activated cell adhesion was not blocked by inhibiting p38 activity. Extracellular signal-regulated protein kinases (ERKs) 1 and 2 were also activated by arachidonic acid; however, cell adhesion to collagen type TV was not highly sensitive to PD98059, an inhibitor of MAP kinase kinase/ERK kinase 1 (MEK1) that blocks activation of the ERKs. c-Jun NH2-terminal kinase was not activated by arachidonic acid treatment of these cells. Together, these data suggest a novel role for p38 MAP kinase in regulating adhesion of breast cancer cells to collagen type IV.	NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Roberts, JD (corresponding author), NIEHS, Mol Carcinogenesis Lab, NIH, Mail Drop C2-14, Res Triangle Pk, NC 27709 USA.	Roberts1@niehs.nih.gov			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES023025, Z01ES023018, ZIAES023025] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAMS JC, 1993, DEVELOPMENT, V117, P1183; AKIYAMA SK, 1995, CANCER METAST REV, V14, P173, DOI 10.1007/BF00690290; ALBELDA SM, 1993, LAB INVEST, V68, P4; ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; BRODT P, 1991, CANCER METAST REV, V10, P23, DOI 10.1007/BF00046841; BRONNERFRASER M, 1985, J CELL BIOL, V101, P610, DOI 10.1083/jcb.101.2.610; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHUN JS, 1992, MOL BIOL CELL, V3, P481, DOI 10.1091/mbc.3.5.481; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; Cui XL, 1997, P NATL ACAD SCI USA, V94, P3771, DOI 10.1073/pnas.94.8.3771; Danen EHJ, 1998, CELL ADHES COMMUN, V6, P217, DOI 10.3109/15419069809004477; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DESIMONE DW, 1994, CURR OPIN CELL BIOL, V6, P747, DOI 10.1016/0955-0674(94)90103-1; Detmers PA, 1998, J IMMUNOL, V161, P1921; FIDLER IJ, 1991, BRIT MED BULL, V47, P157, DOI 10.1093/oxfordjournals.bmb.a072453; FINNEY DJ, 1964, STAT METHODS BIOL AS, P125; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; GAESTEL M, 1991, J BIOL CHEM, V266, P14721; GAILIT J, 1994, CURR OPIN CELL BIOL, V6, P717, DOI 10.1016/0955-0674(94)90099-X; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; GIANCOTTI FG, 1994, BBA-REV CANCER, V1198, P47, DOI 10.1016/0304-419X(94)90005-1; GLASER KB, 1993, TRENDS PHARMACOL SCI, V14, P92, DOI 10.1016/0165-6147(93)90071-Q; GROSSI IM, 1989, CANCER RES, V49, P1029; Guan JL, 1996, INT REV CYTOL, V168, P81, DOI 10.1016/S0074-7696(08)60883-9; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HAN JH, 1993, J BIOL CHEM, V268, P25009; HII CST, 1995, J BIOL CHEM, V270, P4201, DOI 10.1074/jbc.270.9.4201; Hii CST, 1998, J BIOL CHEM, V273, P19277, DOI 10.1074/jbc.273.30.19277; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; HUBBARD NE, 1987, CANCER RES, V47, P6171; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Jarvis WD, 1997, MOL PHARMACOL, V52, P935, DOI 10.1124/mol.52.6.935; JOHANNING GL, 1995, NUTR CANCER, V24, P57, DOI 10.1080/01635589509514393; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lafrenie R M, 1993, Cell Biophys, V23, P3; LANDRY J, 1992, J BIOL CHEM, V267, P794; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lemieux P, 1999, J BONE MINER RES, V14, P1570, DOI 10.1359/jbmr.1999.14.9.1570; Lemieux Pierre, 1997, Invasion and Metastasis, V17, P113; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MALMSTEN CL, 1986, AM J MED, V80, P11, DOI 10.1016/0002-9343(86)90073-2; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; MILLER RG, 1966, SIMULTANEOUS STATIST, P90; MONCADA S, 1988, ANN NY ACAD SCI, V522, P454; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; MOULD AP, 1994, J BIOL CHEM, V269, P27224; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Palmantier R, 1996, CANCER RES, V56, P2206; PRICE JE, 1990, CANCER RES, V50, P717; PRICE JE, 1990, CANCER-AM CANCER SOC, V66, P1313, DOI 10.1002/1097-0142(19900915)66:14+<1313::AID-CNCR2820661403>3.0.CO;2-4; Price JT, 1997, CRIT REV BIOCHEM MOL, V32, P175, DOI 10.3109/10409239709082573; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RAO GN, 1994, J BIOL CHEM, V269, P32586; Reunanen N, 1998, J BIOL CHEM, V273, P5137, DOI 10.1074/jbc.273.9.5137; ROSE DP, 1993, CANCER RES, V53, P4686; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Serhan C N, 1994, Curr Opin Hematol, V1, P69; SONENBERG N, 1979, P NATL ACAD SCI USA, V76, P4345, DOI 10.1073/pnas.76.9.4345; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; TIMAR J, 1992, INT J CANCER, V52, P594, DOI 10.1002/ijc.2910520418; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Weaver VM, 1996, BIOCHEM CELL BIOL, V74, P833, DOI 10.1139/o96-089; WELCH WJ, 1985, J BIOL CHEM, V260, P3058; YAMADA KM, 1984, J CELL BIOL, V99, P29, DOI 10.1083/jcb.99.1.29; Zutter MM, 1998, CURR TOP MICROBIOL, V231, P167	90	82	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11284	11290		10.1074/jbc.275.15.11284	http://dx.doi.org/10.1074/jbc.275.15.11284			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753939	hybrid			2022-12-27	WOS:000086466600081
J	Pepinsky, RB; Rayhorn, P; Day, ES; Dergay, A; Williams, KP; Galdes, A; Taylor, FR; Boriack-Sjodin, PA; Garber, EA				Pepinsky, RB; Rayhorn, P; Day, ES; Dergay, A; Williams, KP; Galdes, A; Taylor, FR; Boriack-Sjodin, PA; Garber, EA			Mapping Sonic hedgehog-receptor interactions by steric interference	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTOR-NEURON INDUCTION; CUBITUS-INTERRUPTUS; FLOOR PLATE; PROTEIN; BINDING; DROSOPHILA; AUTOPROTEOLYSIS; IDENTIFICATION; POLARITY; ENCODES	We have defined regions in the Sonic hedgehog (Shh) molecule that are important for Patched (Ptc) receptor binding by targeting selected surface amino acid residues with probes of diverse sizes and shapes and assessing the effects of these modifications on function. Eleven amino acid residues that surround the surface of the protein were chosen for these studies and mutated to cysteine residues. These cysteines were then selectively modified with thiol-specific probes, and the modified proteins were tested for hedgehog receptor binding activity and their ability to induce differentiation of C3H10T1/2 cells into osteoblasts, Based on these analyses, approximately one-third of the Shh surface can be modified without effect on function regardless of the size of the attachment. These sites are located near to where the C terminus protrudes from the surface of the protein. All other sites were sensitive to modification, indicating that the interaction of Shh with its primary receptor Ptc is mediated over a large surface of the Shh protein. For sites Asn-50 and Ser-156, function was lost with the smallest of the probes tested, indicating that these residues are in close proximity to the Ptc-binding site. The epitope for the neutralizing mAb 5E1 mapped to a close but distinct region of the structure. The structure-activity data provide a unique view of the interactions between Shh and Ptc that is not readily attainable by conventional mapping strategies.	Biogen Inc, Dept Prot Chem, Cambridge, MA 02142 USA	Biogen	Pepinsky, RB (corresponding author), Biogen Inc, Dept Prot Chem, 14 Cambridge Ctr, Cambridge, MA 02142 USA.		Day, Eric S/C-5020-2009					Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; BUMCROT DA, 1995, MOL CELL BIOL, V15, P2294; Chen LL, 1998, BIOCHEMISTRY-US, V37, P8743, DOI 10.1021/bi980311a; Chen Y, 1998, DEVELOPMENT, V125, P4943; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Chuang PT, 1999, NATURE, V397, P617, DOI 10.1038/17611; Day ES, 1999, BIOCHEMISTRY-US, V38, P14868, DOI 10.1021/bi9910068; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Fuse N, 1999, P NATL ACAD SCI USA, V96, P10992, DOI 10.1073/pnas.96.20.10992; Greenspan NS, 1999, NAT BIOTECHNOL, V17, P936, DOI 10.1038/13590; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; JOHNSON RL, 1995, CELL, V81, P313, DOI 10.1016/0092-8674(95)90381-X; Johnson RL, 1998, CURR OPIN GENET DEV, V8, P450, DOI 10.1016/S0959-437X(98)80117-2; Kinto N, 1997, FEBS LETT, V404, P319, DOI 10.1016/S0014-5793(97)00014-8; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Motoyama J, 1998, NAT GENET, V18, P104, DOI 10.1038/ng0298-104; PEPINSKY RB, 1983, J BIOL CHEM, V258, P1229; Pepinsky RB, 1998, J BIOL CHEM, V273, P14037, DOI 10.1074/jbc.273.22.14037; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; Roessler E, 1998, J INHERIT METAB DIS, V21, P481, DOI 10.1023/A:1005406719292; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; TANAKAHALL TM, 1995, NATURE, V378, P212; Therond PP, 1996, P NATL ACAD SCI USA, V93, P4224, DOI 10.1073/pnas.93.9.4224; WANG MZ, 1995, NAT MED, V1, P1184, DOI 10.1038/nm1195-1184; Williams KP, 1999, J CELL SCI, V112, P4405; Yang Y, 1997, DEVELOPMENT, V124, P4393	37	86	91	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10995	11001		10.1074/jbc.275.15.10995	http://dx.doi.org/10.1074/jbc.275.15.10995			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753901	hybrid			2022-12-27	WOS:000086466600043
J	Rattner, A; Smallwood, PM; Nathans, J				Rattner, A; Smallwood, PM; Nathans, J			Identification and characterization of all-trans-retinol dehydrogenase from photoreceptor outer segments, the visual cycle enzyme that reduces all-trans-retinal to all-trans-retinol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECESSIVE RETINITIS-PIGMENTOSA; DISEASE GENE ABCR; VITAMIN-A COMPOUNDS; STARGARDT-DISEASE; MACULAR DEGENERATION; CONGENITAL AMAUROSIS; TERMINAL CYSTEINE; RHODOPSIN; MEMBRANE; BINDING	Retinol dehydrogenase (RDH), the enzyme that catalyzes the reduction of all-trans-retinal to all-trans-retinol within the photoreceptor outer segment, was the first visual cycle enzymatic activity to be identified, Previous work has shown that this enzyme utilizes NADPH, shows a marked preference for all-trans-retinal over 11-cis-retinal, and is tightly associated with the outer segment membrane. This paper reports the identification of a novel member of the short chain dehydrogenase/reductase family, photoreceptor RDH (prRDH), using subtraction and normalization of retina cDNA high throughput sequencing, and data base homology searches to detect retina-specific genes. Bovine and human prRDH are highly homologous and are most closely related to 17-beta-hydroxysteroid dehydrogenase 1, The enzymatic properties of recombinant bovine prRDH closely match those previously reported for RDH activity in crude bovine rod outer segment preparations. In situ hybridization and RNA blotting show that the PRRDH gene is expressed specifically in photoreceptor cells, and protein blotting and immunocytochemistry show that prRDH localizes exclusively to both rod and cone outer segments and that prRDH is tightly associated with outer segment membranes. Taken together, these data indicate that prRDH is the enzyme responsible for the reduction of all-trans-retinal to all-trans-retinol within the photoreceptor outer segment.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University	Nathans, J (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, 805 PCTB,725 N Wolfe St, Baltimore, MD 21205 USA.	jnathans@jhmi.edu		Rattner, Amir/0000-0001-9542-6212; Nathans, Jeremy/0000-0001-8106-5460				Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805; ALPERN M, 1971, J PHYSIOL-LONDON, V217, P447, DOI 10.1113/jphysiol.1971.sp009580; ALPERN M, 1970, J PHYSIOL-LONDON, V207, P449, DOI 10.1113/jphysiol.1970.sp009072; AWICKI MW, 1999, P NATL ACAD SCI USA, V96, P840; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P589; BLISS AF, 1951, ARCH BIOCHEM BIOPHYS, V31, P197, DOI 10.1016/0003-9861(51)90206-8; Burstedt MSI, 1999, INVEST OPHTH VIS SCI, V40, P995; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; COHEN GB, 1992, BIOCHEMISTRY-US, V31, P12592, DOI 10.1021/bi00165a008; Corson DW, 1996, PHOTOCHEM PHOTOBIOL, V63, P595, DOI 10.1111/j.1751-1097.1996.tb05661.x; Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355; DEPONT JJHH, 1970, ARCH BIOCHEM BIOPHYS, V140, P275, DOI 10.1016/0003-9861(70)90032-9; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; DOWLING JE, 1960, NATURE, V188, P114, DOI 10.1038/188114a0; ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0; ELDRED GE, 1998, RETINAL PIGMENT EPIT, P651; Fain GL, 1996, TRENDS NEUROSCI, V19, P502, DOI 10.1016/S0166-2236(96)10056-4; FUKADA Y, 1981, BIOCHIM BIOPHYS ACTA, V675, P195, DOI 10.1016/0304-4165(81)90226-9; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FUTTERMAN A, 1974, BIOCHIM BIOPHYS ACTA, V337, P390, DOI 10.1016/0005-2760(74)90114-3; FUTTERMAN S, 1970, J NEUROCHEM, V17, P149, DOI 10.1111/j.1471-4159.1970.tb02195.x; FUTTERMAN S, 1963, J BIOL CHEM, V238, P1147; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194; Haeseleer F, 1998, J BIOL CHEM, V273, P21790, DOI 10.1074/jbc.273.34.21790; HAGEMAN GS, 1986, J COMP NEUROL, V249, P499, DOI 10.1002/cne.902490406; Harlow E., 1988, ANTIBODIES LAB MANUA; HODGES RS, 1988, J BIOL CHEM, V263, P11768; HSU SC, 1994, J BIOL CHEM, V269, P17954; HSU SC, 1990, J BIOL CHEM, V265, P13308; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; Jager S, 1996, BIOCHEMISTRY-US, V35, P2901, DOI 10.1021/bi9524068; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Kuhne Wilhelm, 1878, PHOTOCHEMISTRY RETIN; LAMB TD, 1980, NATURE, V287, P349, DOI 10.1038/287349a0; Lewis RA, 1999, AM J HUM GENET, V64, P422, DOI 10.1086/302251; Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139; Martinez-Mir A, 1998, NAT GENET, V18, P11, DOI 10.1038/ng0198-11; Maw MA, 1997, NAT GENET, V17, P198, DOI 10.1038/ng1097-198; MERBS SL, 1992, PHOTOCHEM PHOTOBIOL, V56, P869, DOI 10.1111/j.1751-1097.1992.tb09708.x; Morimura H, 1999, INVEST OPHTH VIS SCI, V40, P1000; Morimura H, 1998, P NATL ACAD SCI USA, V95, P3088, DOI 10.1073/pnas.95.6.3088; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; ONG OC, 1989, P NATL ACAD SCI USA, V86, P9238, DOI 10.1073/pnas.86.23.9238; PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609; RANDO RR, 1990, ANGEW CHEM INT EDIT, V29, P461, DOI 10.1002/anie.199004611; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Rodieck R.W., 1998, 1 STEPS SEEING; Saari JC, 1998, VISION RES, V38, P1325, DOI 10.1016/S0042-6989(97)00198-3; Saari John C., 1994, P351; Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988; Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798; Sun H, 1997, P NATL ACAD SCI USA, V94, P8860, DOI 10.1073/pnas.94.16.8860; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15; SURYA A, 1995, J BIOL CHEM, V270, P5024, DOI 10.1074/jbc.270.10.5024; Tsigelny I, 1996, BIOCHEM BIOPH RES CO, V226, P118, DOI 10.1006/bbrc.1996.1320; VANKUIJK FJGM, 1985, J CHROMATOGR, V348, P241, DOI 10.1016/S0021-9673(01)92458-6; Wald G, 1935, J GEN PHYSIOL, V19, P351, DOI 10.1085/jgp.19.2.351; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; Yamamoto H, 1999, NAT GENET, V22, P188, DOI 10.1038/9707; ZIMMERMAN WF, 1974, NATURE, V250, P66, DOI 10.1038/250066a0; ZIMMERMAN WF, 1974, VISION RES, V14, P795, DOI 10.1016/0042-6989(74)90143-6	75	165	172	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11034	11043		10.1074/jbc.275.15.11034	http://dx.doi.org/10.1074/jbc.275.15.11034			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753906	hybrid			2022-12-27	WOS:000086466600048
J	Uebele, VN; Lagrutta, A; Wade, T; Figueroa, DJ; Liu, Y; McKenna, E; Austin, CP; Bennett, PB; Swanson, R				Uebele, VN; Lagrutta, A; Wade, T; Figueroa, DJ; Liu, Y; McKenna, E; Austin, CP; Bennett, PB; Swanson, R			Cloning and functional expression of two families of beta-subunits of the large conductance calcium-activated K+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; CEREBRAL CAVERNOUS MALFORMATION; POTASSIUM CHANNEL; SMOOTH-MUSCLE; XENOPUS-OOCYTES; FAST INACTIVATION; MOLECULAR-BASIS; HUMAN BRAIN; BINDING; VOLTAGE	We report here a characterization of two families of calcium-activated K+ channel beta-subunits, beta 2 and beta 3, which are encoded by distinct genes that map to 3q26.227, A single beta 2 family member and four alternatively spliced variants of beta 3 were investigated. These subunits have predicted molecular masses of 27.1-31.6 kDa, share similar to 30-44% amino acid identity with beta 1, and exhibit distinct but overlapping expression patterns. Coexpression of the beta 2 or beta 3a-c subunits with a BK alpha-subunit altered the functional properties of the current expressed by the alpha-subunit alone. The beta 2 subunit rapidly and completely inactivated the current and shifted the voltage dependence for activation to more polarized membrane potentials. In contrast, coexpression of the beta 5a-c subunits resulted in only partial inactivation of the current, and the beta 3b subunit conferred an apparent inward rectification. Furthermore, unlike the beta 1 and beta 2 subunits, none of the beta 3 subunits increased channel sensitivity to calcium or voltage. The tissue-specific expression of these beta-subunits may allow for the assembly of a large number of distinct BK channels in vivo, contributing to the functional diversity of native BR currents.	Merck Res Labs, W Point, PA 19486 USA	Merck & Company	Uebele, VN (corresponding author), Merck Res Labs, WP26-265, W Point, PA 19486 USA.							ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; ALLDERDICE PW, 1975, AM J HUM GENET, V27, P699; Brenner R, 2000, J BIOL CHEM, V275, P6453, DOI 10.1074/jbc.275.9.6453; Craig HD, 1998, HUM MOL GENET, V7, P1851, DOI 10.1093/hmg/7.12.1851; DEAL KK, 1994, J NEUROSCI, V14, P1666, DOI 10.1523/JNEUROSCI.14-03-01666.1994; Ferrer J, 1996, DIABETOLOGIA, V39, P891, DOI 10.1007/BF00403907; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARCIACALVO M, 1994, J BIOL CHEM, V269, P676; GIANGIACOMO KM, 1995, BIOCHEMISTRY-US, V34, P15849, DOI 10.1021/bi00048a031; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P279; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266; Gunel M, 1996, NEUROSURGERY, V38, P1265; Hanner M, 1997, P NATL ACAD SCI USA, V94, P2853, DOI 10.1073/pnas.94.7.2853; Heppner TJ, 1997, AM J PHYSIOL-CELL PH, V273, pC110; Jonasdottir A, 1997, HUM GENET, V99, P115; KHORANA HG, 1988, P NATL ACAD SCI USA, V85, P7917, DOI 10.1073/pnas.85.21.7917; KNAUS HG, 1994, J BIOL CHEM, V269, P3921; KNAUS HG, 1994, J BIOL CHEM, V269, P17274; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Lingle C J, 1996, Ion Channels, V4, P261; Lynch KR, 1999, NATURE, V399, P789; Marrion NV, 1998, NATURE, V395, P900, DOI 10.1038/27674; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; Oberst C, 1997, ONCOGENE, V14, P1109, DOI 10.1038/sj.onc.1200930; Ramanathan K, 1999, SCIENCE, V283, P215, DOI 10.1126/science.283.5399.215; Reed AL, 1998, J BIOL CHEM, V273, P21594, DOI 10.1074/jbc.273.34.21594; Riazi MA, 1999, GENOMICS, V62, P90, DOI 10.1006/geno.1999.5975; SHARMA NR, 1994, AM J PHYSIOL, V266, pH156, DOI 10.1152/ajpheart.1994.266.1.H156; SOLARO CR, 1995, J NEUROSCI, V15, P6110; Spector PS, 1996, J GEN PHYSIOL, V107, P611, DOI 10.1085/jgp.107.5.611; Stewart EA, 1997, GENOME RES, V7, P422, DOI 10.1101/gr.7.5.422; Sullivan R, 1998, AM J PHYSIOL-CELL PH, V275, pC1342, DOI 10.1152/ajpcell.1998.275.5.C1342; SWANSON R, 1992, METHOD ENZYMOL, V207, P310; TsengCrank J, 1996, P NATL ACAD SCI USA, V93, P9200, DOI 10.1073/pnas.93.17.9200; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; Valverde MA, 1999, SCIENCE, V285, P1929, DOI 10.1126/science.285.5435.1929; Vergara C, 1998, CURR OPIN NEUROBIOL, V8, P321, DOI 10.1016/S0959-4388(98)80056-1; Wallner M, 1999, P NATL ACAD SCI USA, V96, P4137, DOI 10.1073/pnas.96.7.4137; Wallner M, 1995, RECEPTOR CHANNEL, V3, P185; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; Wilson SA, 1998, NUCLEIC ACIDS RES, V26, P3460, DOI 10.1093/nar/26.15.3460; Xia XM, 1999, J NEUROSCI, V19, P5255, DOI 10.1523/jneurosci.19-13-05255.1999	43	205	210	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23211	23218		10.1074/jbc.M910187199	http://dx.doi.org/10.1074/jbc.M910187199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10766764	hybrid			2022-12-27	WOS:000088419400084
J	Williams, JG; Drugan, JK; Yi, GS; Clark, GJ; Der, CJ; Campbell, SL				Williams, JG; Drugan, JK; Yi, GS; Clark, GJ; Der, CJ; Campbell, SL			Elucidation of binding determinants and functional consequences of Ras/Raf-cysteine-rich domain interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RAF ZINC-FINGER; PLASMA-MEMBRANE; CRYSTAL-STRUCTURE; CONTAINS ZINC; HA-RAS; ACTIVATION; IDENTIFICATION; RESIDUES; TRANSFORMATION	Raf-1 is a critical downstream target of Ras and contains two distinct domains that bind Ras. The first Ras-binding site (RBS1) in Raf-1 has been shown to be essential for Ras-mediated translocation of Raf-1 to the plasma membrane, whereas the second site, in the Raf-1 cysteine rich domain (Raf-CRD), has been implicated in regulating Raf kinase activity. While recognition elements that promote Ras RBS1 complex formation have been characterized, relatively little is known about Ras/Raf-CRD interactions. In this study, we have characterized interactions important for Ras binding to the Raf-CRB. Reconciling conflicting reports, we found that these interactions are essentially independent of the guanine nucleotide bound state, but instead, are enhanced by post-translational modification of Ras. Specifically, our findings indicate that Res farnesylation is sufficient for stable association of Ras with the Raf-CRD. Furthermore, we have also identified a Raf-CRD variant that is impaired specifically in its interactions with Ras. MMR data also suggests that residues proximal to this mutation site on the Raf-CRD form contacts with Res. This Raf-CRD mutant impairs the ability of Ras to activate Raf kinase, thereby providing additional support that Ras interactions with the Raf-CRD are important for Ras-mediated activation of Raf-1.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Campbell, SL (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Campus Box 7260, Chapel Hill, NC 27599 USA.	campbesl@med.unc.edu	Yi, Gwan-Su/A-7896-2011	Yi, Gwan-Su/0000-0003-0012-6546; Der, Channing/0000-0002-7751-2747; campbell, sharon/0000-0003-0311-409X	DIVISION OF CLINICAL SCIENCES - NCI [Z01SC010279] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA042978, R29CA072644] Funding Source: NIH RePORTER; NCI NIH HHS [CA42978, CA72644-10, CA72644] Funding Source: Medline	DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; CAMPBELLBURK SL, 1995, METHOD ENZYMOL, V255, P3; CHEN WJ, 1993, J BIOL CHEM, V268, P9675; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; Cutler RE, 1998, P NATL ACAD SCI USA, V95, P9214, DOI 10.1073/pnas.95.16.9214; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Gelber S, 1998, BEHAV HEALTHC TOM, V7, P40; GHOSH S, 1994, J BIOL CHEM, V269, P30785; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HOMMEL U, 1994, NAT STRUCT BIOL, V1, P383, DOI 10.1038/nsb0694-383; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; ITOH T, 1993, P NATL ACAD SCI USA, V90, P975, DOI 10.1073/pnas.90.3.975; KURODA S, 1995, J BIOL CHEM, V270, P2460, DOI 10.1074/jbc.270.6.2460; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; MCGEADY P, 1995, J BIOL CHEM, V270, P26347, DOI 10.1074/jbc.270.44.26347; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Mineo C, 1997, J BIOL CHEM, V272, P10345; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Mott HR, 1996, P NATL ACAD SCI USA, V93, P8312, DOI 10.1073/pnas.93.16.8312; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Rommel C, 1996, ONCOGENE, V12, P609; Rosales C, 1996, CANCER RES, V56, P2302; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Schroeder H, 1997, BIOCHEMISTRY-US, V36, P13102, DOI 10.1021/bi9709497; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Winkler DG, 1998, J BIOL CHEM, V273, P21578, DOI 10.1074/jbc.273.34.21578; Xu RX, 1997, BIOCHEMISTRY-US, V36, P10709, DOI 10.1021/bi970833a; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717	44	76	78	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22172	22179		10.1074/jbc.M000397200	http://dx.doi.org/10.1074/jbc.M000397200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10777480	hybrid, Green Published			2022-12-27	WOS:000088363800059
J	Domina, AM; Smith, JH; Craig, RW				Domina, AM; Smith, JH; Craig, RW			Myeloid cell leukemia 1 is phosphorylated through two distinct pathways, one associated with extracellular signal-regulated kinase activation and the other with G(2)/M accumulation or protein phosphatase 1/2A inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 PHOSPHORYLATION; INDUCED APOPTOSIS; MAP KINASE; CANCER-CELLS; LOOP DOMAIN; DEATH; EXPRESSION; GENE; BAD; IDENTIFICATION	Protein kinase C activators and microtubule-damaging drugs stimulate BCL2 phosphorylation, which has been associated with either enhancement or inhibition of cell viability. In a Burkitt lymphoma cell line, both types of agents likewise stimulated phosphorylation of myeloid cell leukemia 1 (MCL1), another viability-promoting BCL2 family member. However, while MCL1 phosphorylation induced by the protein kinase C activator, 12-O-tetradecanoylphorbol-13-acetate (TPA), did not affect its electrophoretic mobility, microtubule-damaging agents, such as taxol, induced MCL1 phosphorylation associated with a band shift to decreased mobility. Inhibitors of extracellular signal-regulated kinase (ERK) activation blocked TPA-induced MCL1 phosphorylation but not the taxol-induced band shift, TPA-induced MCL1 phosphorylation occurred rapidly and was not associated with decreased viability, while the taxol-induced band shift occurred upon extended exposure as cells accumulated in G(2)/M followed by cell death. Protein phosphatase 1/2A inhibitors also induced the MCL1 band shift/phosphorylation. Thus, MCL1 undergoes two distinct types of phosphorylation: (i) TPA-induced, ERK-associated phosphorylation, which does not alter the electrophoretic mobility of MCL1, and (ii) ERK-independent phosphorylation, which results in an MCL1 band shift and is induced by events in G(2)/M or protein phosphatase 1/2A inhibitors.	Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA	Dartmouth College	Craig, RW (corresponding author), Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA.	Ruth.W.Craig@Dartmouth.edu			NCI NIH HHS [R01-CA57359, R01 CA057359] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057359] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Basu A, 1998, INT J ONCOL, V13, P659; Berchem GJ, 1999, ANTICANCER RES, V19, P535; Bieszczad C. K., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P134; Blagosklonny MV, 1997, CANCER RES, V57, P130; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; CRAIG RW, 1995, SEMIN CANCER BIOL, V6, P35, DOI 10.1006/scbi.1995.0005; CRAIG RW, 1994, GENOMICS, V23, P457, DOI 10.1006/geno.1994.1523; Deng XM, 2000, P NATL ACAD SCI USA, V97, P1578, DOI 10.1073/pnas.97.4.1578; DeSilva DR, 1998, J IMMUNOL, V160, P4175; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fang GF, 1998, CANCER RES, V58, P3202; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Force T, 1998, HYPERTENSION, V31, P152, DOI 10.1161/01.HYP.31.1.152; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HALDAR S, 1994, BIOCHEM CELL BIOL, V72, P455, DOI 10.1139/o94-061; Haldar S, 1996, CANCER RES, V56, P1253; Haldar S, 1998, CANCER RES, V58, P1609; Haldar S, 1997, CANCER RES, V57, P229; Huang Y, 1999, ONCOGENE, V18, P3431, DOI 10.1038/sj.onc.1202685; IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Krieser RJ, 1998, J BIOL CHEM, V273, P30909, DOI 10.1074/jbc.273.47.30909; Krieser RJ, 1999, CELL DEATH DIFFER, V6, P412, DOI 10.1038/sj.cdd.4400515; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; MAY WS, 1994, J BIOL CHEM, V269, P26865; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; REYNOLDS JE, 1999, ENCY CELL TECHNOLOGY, P536; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; Townsend KJ, 1998, ONCOGENE, V17, P1223, DOI 10.1038/sj.onc.1202035; Townsend KJ, 1999, J BIOL CHEM, V274, P1801, DOI 10.1074/jbc.274.3.1801; Tuyt LML, 1999, J IMMUNOL, V162, P4893; VRANA J, 2000, P AM ASSOC CANC RES, V41, P403; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang SJ, 1999, BIOCHEM BIOPH RES CO, V259, P67, DOI 10.1006/bbrc.1999.0669; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630; ZHUO S, 1993, J BIOL CHEM, V268, P17754	53	75	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21688	21694		10.1074/jbc.M000915200	http://dx.doi.org/10.1074/jbc.M000915200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10777489	hybrid			2022-12-27	WOS:000088230600096
J	Otera, H; Harano, T; Honsho, M; Ghaedi, K; Mukai, S; Tanaka, A; Kawai, A; Shimizu, N; Fujiki, Y				Otera, H; Harano, T; Honsho, M; Ghaedi, K; Mukai, S; Tanaka, A; Kawai, A; Shimizu, N; Fujiki, Y			The mammalian peroxin Pex5pL, the longer isoform of the mobile peroxisome targeting signal (PTS) type 1 transporter, translocates the Pex7p center dot PTS2 protein complex into peroxisomes via its initial docking site, Pex14p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARY CELL MUTANTS; COMPLETE NUCLEOTIDE-SEQUENCE; DEFICIENT ZELLWEGER-SYNDROME; AMINO-ACID-SEQUENCE; ACYL-COA OXIDASE; COMPLEMENTATION GROUP; BIOGENESIS DISORDERS; MEMBRANE-PROTEIN; RAT-LIVER; FUNCTIONAL COMPLEMENTATION	In mammals, two isoforms of the peroxisome targeting signal (PTS) type 1 receptor Pex5p, i.e. Pex5pS and Pex5pL with an internal 37-amino acid insertion, have previously been identified. Expression of either type of Pex5p complements the impaired PTS1 import in Chinese hamster ovary pex5 mutants, but only Pex5pL can rescue the PTS2 import defect noted in a subgroup of pex5 mutants such as ZP105. In this work, we found that Pex5pL directly interacts with the PTS2 receptor Pex7p, carrying its cargo PTS2 protein in the cytosol. Pex5pL, but not Pex5pS, mediated the binding of PTS2 protein to Pex14p by translocating Pex7p, demonstrating that Pex5pL plays a pivotal role in peroxisomal PTS2 import. Pex5p was localized mostly in the cytosol in wild-type CHO-K1 and Pex14p-deficient mutant cells, whereas it accumulated in the peroxisomal remnants in cell mutants defective in Pex13p or the RING family peroxins such as Pex2p and Pex12p. Furthermore, overexpression of Pex14p, but not Pex10p, Pex12p, or Pex13p, caused accumulation of Pex5p in peroxisomal membranes, with concomitant interference with PTS1 and PTS2 import. Therefore, Pex5p carrying the cargoes most likely docks with the initial site (Pex14p) in a putative import machinery, subsequently translocating to other components such as Pex13p, Pex2p, Pex10p, and Pex12p.	Kyushu Univ, Grad Sch Sci, Dept Biol, Higashi Ku, Fukuoka 8128581, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Tokyo 1700013, Japan	Kyushu University; Japan Science & Technology Agency (JST)	Fujiki, Y (corresponding author), Kyushu Univ, Grad Sch Sci, Dept Biol, Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.		Ghaedi, Kamran/X-9824-2018	Ghaedi, Kamran/0000-0002-9790-5644; Honsho, Masanori/0000-0001-6165-4516				Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; Braverman N, 1997, NAT GENET, V15, P369, DOI 10.1038/ng0497-369; Braverman N, 1998, HUM MOL GENET, V7, P1195, DOI 10.1093/hmg/7.8.1195; Brocard C, 1997, EMBO J, V16, P5491, DOI 10.1093/emboj/16.18.5491; Chang CC, 1999, J CELL BIOL, V147, P761, DOI 10.1083/jcb.147.4.761; Distel B, 1996, J CELL BIOL, V135, P1, DOI 10.1083/jcb.135.1.1; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; Elgersma Y, 1998, J CELL BIOL, V140, P807, DOI 10.1083/jcb.140.4.807; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; Erdmann R, 1996, J CELL BIOL, V135, P111, DOI 10.1083/jcb.135.1.111; Erdmann R, 1997, TRENDS CELL BIOL, V7, P400, DOI 10.1016/S0962-8924(97)01126-4; Fujiki Y, 1997, BBA-MOL BASIS DIS, V1361, P235, DOI 10.1016/S0925-4439(97)00051-3; FURUTA S, 1986, P NATL ACAD SCI USA, V83, P313, DOI 10.1073/pnas.83.2.313; Ghaedi K, 1999, EXP CELL RES, V248, P482, DOI 10.1006/excr.1999.4412; Ghaedi K, 1999, EXP CELL RES, V248, P489, DOI 10.1006/excr.1999.4413; Girzalsky W, 1999, J CELL BIOL, V144, P1151, DOI 10.1083/jcb.144.6.1151; Gould SJ, 1996, J CELL BIOL, V135, P85, DOI 10.1083/jcb.135.1.85; HESS R, 1965, NATURE, V208, P856, DOI 10.1038/208856a0; Honsho M, 1998, AM J HUM GENET, V63, P1622, DOI 10.1086/302161; Imamura A, 1998, HUM MOL GENET, V7, P2089, DOI 10.1093/hmg/7.13.2089; Imamura A, 1998, AM J HUM GENET, V62, P1539, DOI 10.1086/301881; Kinoshita N, 1998, J BIOL CHEM, V273, P24122, DOI 10.1074/jbc.273.37.24122; Kunau WH, 1998, CURR OPIN MICROBIOL, V1, P232, DOI 10.1016/S1369-5274(98)80016-7; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; Liu YF, 1999, AM J HUM GENET, V65, P621, DOI 10.1086/302534; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; MIURA S, 1994, J BIOCHEM-TOKYO, V115, P1064, DOI 10.1093/oxfordjournals.jbchem.a124458; MIYAZAWA S, 1989, MOL CELL BIOL, V9, P83, DOI 10.1128/MCB.9.1.83; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; Okumoto K, 1997, NAT GENET, V17, P265, DOI 10.1038/ng1197-265; Okumoto K, 1998, HUM MOL GENET, V7, P1399, DOI 10.1093/hmg/7.9.1399; Okumoto K, 1998, MOL CELL BIOL, V18, P4324, DOI 10.1128/MCB.18.7.4324; Otera H, 1998, MOL CELL BIOL, V18, P388, DOI 10.1128/MCB.18.1.388; Purdue PE, 1998, J CELL BIOL, V143, P1859; Purdue PE, 1996, J CELL BIOL, V134, P849, DOI 10.1083/jcb.134.4.849; RACHUBINSKI RA, 1984, J CELL BIOL, V99, P2241, DOI 10.1083/jcb.99.6.2241; Rehling P, 1996, EMBO J, V15, P2901, DOI 10.1002/j.1460-2075.1996.tb00653.x; Schliebs W, 1999, J BIOL CHEM, V274, P5666, DOI 10.1074/jbc.274.9.5666; Shimizu N, 1999, J BIOL CHEM, V274, P12593, DOI 10.1074/jbc.274.18.12593; Shimozawa N, 1999, HUM MOL GENET, V8, P1077, DOI 10.1093/hmg/8.6.1077; SHIMOZAWA N, 1992, J CLIN INVEST, V90, P1864, DOI 10.1172/JCI116063; Subramani S, 1997, NAT GENET, V15, P331, DOI 10.1038/ng0497-331; SZILARD RK, 1995, J CELL BIOL, V131, P1453, DOI 10.1083/jcb.131.6.1453; Tamura S, 1998, P NATL ACAD SCI USA, V95, P4350, DOI 10.1073/pnas.95.8.4350; Tateishi K, 1997, EUR J CELL BIOL, V73, P352; Titorenko VI, 1998, TRENDS BIOCHEM SCI, V23, P231, DOI 10.1016/S0968-0004(98)01226-2; Toyama R, 1999, HUM MOL GENET, V8, P1673, DOI 10.1093/hmg/8.9.1673; TSUKAMOTO T, 1994, MOL CELL BIOL, V14, P5458, DOI 10.1128/MCB.14.8.5458; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VANDERKLEI IJ, 1995, J BIOL CHEM, V270, P17229, DOI 10.1074/jbc.270.29.17229; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; WIEMER EAC, 1995, J CELL BIOL, V130, P51, DOI 10.1083/jcb.130.1.51; Will GK, 1999, MOL CELL BIOL, V19, P2265; Zhang JW, 1996, J CELL BIOL, V132, P325, DOI 10.1083/jcb.132.3.325	57	171	174	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21703	21714		10.1074/jbc.M000720200	http://dx.doi.org/10.1074/jbc.M000720200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10767286	hybrid			2022-12-27	WOS:000088230600098
J	Henderson, LP; Lin, L; Prasad, A; Paul, CA; Chang, TY; Maue, RA				Henderson, LP; Lin, L; Prasad, A; Paul, CA; Chang, TY; Maue, RA			Embryonic striatal neurons from Niemann-Pick type C mice exhibit defects in cholesterol metabolism and neurotrophin responsiveness	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE TYPE-C; DENSITY LIPOPROTEIN-CHOLESTEROL; DORSAL-ROOT GANGLION; ACYL-COENZYME-A; NERVOUS-SYSTEM; APOLIPOPROTEIN-E; SIGNAL-TRANSDUCTION; ACYLTRANSFERASE ACTIVITY; NEUROFIBRILLARY TANGLES; HIPPOCAMPAL-NEURONS	Niemann-Pick type C (NP-C) disease is a progressive and fatal neuropathological disorder previously characterized by abnormal cholesterol metabolism in peripheral tissues. Although a defective gene has been identified in both humans and the npc(nih) mouse model of NP-C disease, how this leads to abnormal neuronal function is unclear. Here we show that whereas embryonic striatal neurons from npc(nih) mice can take up low density lipoprotein-derived cholesterol, its subsequent hydrolysis and esterification are significantly reduced. Given the importance of cholesterol to a variety of signal transduction mechanisms, we assessed the effect of this abnormality on the ability of these neurons to respond to brain-derived neurotrophic factor (BDNF). In contrast to its effects on wild type neurons, BDNF failed to induce autophosphorylation of the TrkB receptor and to increase neurite outgrowth in npc(nih) neurons, despite expression of TrkB on the cell surface. The results suggest that abnormal cholesterol metabolism occurs in neurons in the brain during NP-C disease, even at embryonic stages of development prior to the onset of phenotypic symptoms. Moreover, this defect is associated with a lack of TrkB function and BDNF responsiveness, which may contribute to the loss of neuronal function observed in NP-C disease.	Dartmouth Med Sch, Dept Physiol, Hanover, NH 03755 USA; Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College	Maue, RA (corresponding author), Dartmouth Med Sch, Dept Physiol, Hanover, NH 03755 USA.	robert.maue@dartmouth.edu		Henderson, Leslie/0000-0003-3558-757X; Chang, Ta-Yuan/0000-0002-3249-0468				Bilderback TR, 1999, J BIOL CHEM, V274, P257, DOI 10.1074/jbc.274.1.257; Bottenstein J, 1979, Methods Enzymol, V58, P94; CADIGAN KM, 1990, J CELL BIOL, V110, P295, DOI 10.1083/jcb.110.2.295; CADIGAN KM, 1988, J BIOL CHEM, V263, P274; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; CHANG CCY, 1986, BIOCHEMISTRY-US, V25, P1693, DOI 10.1021/bi00355a038; CHAO MV, 1995, MOL CELL NEUROSCI, V6, P91, DOI 10.1006/mcne.1995.1009; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; de Chaves EIP, 1997, J BIOL CHEM, V272, P30766, DOI 10.1074/jbc.272.49.30766; de la Torre JR, 1997, NEURON, V19, P1211, DOI 10.1016/S0896-6273(00)80413-4; ERNFORS P, 1992, EUR J NEUROSCI, V4, P1140, DOI 10.1111/j.1460-9568.1992.tb00141.x; ERNFORS P, 1993, MOL BRAIN RES, V17, P217, DOI 10.1016/0169-328X(93)90005-A; ESCANDON E, 1994, J NEUROSCI, V14, P2054; Fielding CJ, 1997, J LIPID RES, V38, P1503; FINK JK, 1989, NEUROLOGY, V39, P1040, DOI 10.1212/WNL.39.8.1040; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; GAO WQ, 1995, J NEUROSCI, V15, P2656; Garver VS, 1997, BBA-MOL BASIS DIS, V1361, P272, DOI 10.1016/S0925-4439(97)00047-1; GERFEN CR, 1992, ANNU REV NEUROSCI, V15, P285, DOI 10.1146/annurev.neuro.15.1.285; GOLDIN E, 1992, BIOCHIM BIOPHYS ACTA, V1127, P303, DOI 10.1016/0005-2760(92)90236-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANDELMANN GE, 1992, J LIPID RES, V33, P1677; HARTMAN DS, 1994, J NEUROCHEM, V63, P1261; HEIDER JG, 1978, J LIPID RES, V19, P514; Hooper NM, 1999, MOL MEMBR BIOL, V16, P145, DOI 10.1080/096876899294607; Ikeda Y, 1997, DEV BRAIN RES, V98, P253, DOI 10.1016/S0165-3806(96)00183-6; IP NY, 1993, J NEUROSCI, V13, P3394; Jurevics HA, 1997, J LIPID RES, V38, P723; KAGAWA Y, 1966, J BIOL CHEM, V241, P2461; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KAWAGUCHI Y, 1995, TRENDS NEUROSCI, V18, P527, DOI 10.1016/0166-2236(95)98374-8; Knusel B, 1997, NEUROSCIENCE, V78, P851, DOI 10.1016/S0306-4522(96)00616-1; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; Liscum L, 1998, CURR OPIN LIPIDOL, V9, P131, DOI 10.1097/00041433-199804000-00009; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; LOVE S, 1995, BRAIN, V118, P119, DOI 10.1093/brain/118.1.119; March PA, 1997, ACTA NEUROPATHOL, V94, P164, DOI 10.1007/s004010050689; Masserini M, 1999, J NEUROCHEM, V73, P1, DOI 10.1046/j.1471-4159.1999.0730001.x; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; Meyer-Franke A, 1998, NEURON, V21, P681, DOI 10.1016/S0896-6273(00)80586-3; Minichiello L, 1999, NEURON, V24, P401, DOI 10.1016/S0896-6273(00)80853-3; MIZUNO K, 1994, DEV BIOL, V165, P243, DOI 10.1006/dbio.1994.1250; MORRIS MD, 1982, AM J PATHOL, V108, P140; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; MUTOH T, 1995, P NATL ACAD SCI USA, V92, P5087, DOI 10.1073/pnas.92.11.5087; Narita M, 1997, J NEUROCHEM, V68, P587; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; PATEL SC, 1987, BIOCHEM BIOPH RES CO, V143, P233, DOI 10.1016/0006-291X(87)90655-3; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; Pentchev P. G., 1995, METABOLIC MOL BASES, P2625; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; RABIN SJ, 1995, J NEUROCHEM, V65, P347; ROBERTS DCK, 1985, BIOCHEM J, V226, P319, DOI 10.1042/bj2260319; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; SHIO H, 1982, AM J PATHOL, V108, P150; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; Suh NJ, 1999, CANCER RES, V59, P336; SUZUKI K, 1995, ACTA NEUROPATHOL, V89, P227; Tint GS, 1998, J INHERIT METAB DIS, V21, P853, DOI 10.1023/A:1005474803278; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Turley SD, 1996, J LIPID RES, V37, P1953; Turley SD, 1997, NUTR METAB CARDIOVAS, V7, P195; VENTIMIGLIA R, 1995, EUR J NEUROSCI, V7, P213, DOI 10.1111/j.1460-9568.1995.tb01057.x; WEINTRAUB H, 1985, J NEUROCHEM, V45, P665, DOI 10.1111/j.1471-4159.1985.tb04044.x; WEIS FMB, 1990, J BIOL CHEM, V265, P12059; Weisgraber Karl H., 1994, Current Opinion in Lipidology, V5, P110, DOI 10.1097/00041433-199404000-00007; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554; Xie CL, 1999, AM J PHYSIOL-ENDOC M, V276, pE336, DOI 10.1152/ajpendo.1999.276.2.E336; Xie CL, 1999, P NATL ACAD SCI USA, V96, P11992, DOI 10.1073/pnas.96.21.11992; YATES AJ, 1995, J NEURO-ONCOL, V24, P65, DOI 10.1007/BF01052661	75	71	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					20179	20187		10.1074/jbc.M001793200	http://dx.doi.org/10.1074/jbc.M001793200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10770933	hybrid			2022-12-27	WOS:000087941300099
J	Vaquero, A; Espinas, ML; Azorin, F; Bernues, J				Vaquero, A; Espinas, ML; Azorin, F; Bernues, J			Functional mapping of the GAGA factor assigns its transcriptional activity to the C-terminal glutamine-rich domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-II TRANSCRIPTION; DNA-BINDING; DROSOPHILA-MELANOGASTER; CHROMATIN STRUCTURE; GENE ENCODES; IN-VITRO; ACTIVATION; INVITRO; ANTIREPRESSION; MULTIPLE	GAGA is a nuclear protein encoded by the Trithorax-like gene in Drosophila that is expressed in at least two isoforms generated by alternative splicing. By means of its specific interaction with DNA, GAGA has been involved in several nuclear transactions including regulation of gene expression. Here we have studied the GAGA(519) isoform as a transcription factor. In vitro, the transactivation domain has been assigned to the 93 C-terminal residues that correspond to a glutamine-rich domain (Q-domain). It presents an internal modular structure and acts independently of the rest of the protein. In vivo, in Drosophila SL2 cells, Q-domain can transactivate reporter genes either in the form of GAGA or Gal4BD-Q fusions, whereas a GAGA mutant deleted of the Q-domain cannot. Our results give support to the notion that GAGA can function as a transcription activating factor.	CSIC, CID, Inst Biol Mol Barcelona, Dept Mol & Cellular Biol, ES-08034 Barcelona, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion y Desarrollo Pascual Vila (CID-CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB)	Bernues, J (corresponding author), CSIC, CID, Inst Biol Mol Barcelona, Dept Mol & Cellular Biol, Jordi girona 18-26, ES-08034 Barcelona, Spain.		Vaquero, Alejandro/I-9845-2014; Vaquero, Alejandro/ABG-8634-2020; Azorin, Fernando/N-4388-2014; Bernues, Jordi/ABE-8360-2021	Vaquero, Alejandro/0000-0002-8735-4156; Azorin, Fernando/0000-0002-8426-7858; Bernues, Jordi/0000-0001-6218-8254; Espinas, M Lluisa/0000-0003-3914-2228				Agianian B, 1999, J MOL BIOL, V285, P527, DOI 10.1006/jmbi.1998.2355; Benyajati C, 1997, NUCLEIC ACIDS RES, V25, P3345, DOI 10.1093/nar/25.16.3345; BERNUES J, 1993, EMBO J, V12, P3573, DOI 10.1002/j.1460-2075.1993.tb06031.x; Bhat KM, 1996, DEVELOPMENT, V122, P1113; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; CROSTON GE, 1992, GENE DEV, V6, P2270, DOI 10.1101/gad.6.12a.2270; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; Espinas ML, 1999, J BIOL CHEM, V274, P16461, DOI 10.1074/jbc.274.23.16461; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GRANOK H, 1995, CURR BIOL, V5, P238, DOI 10.1016/S0960-9822(95)00048-0; Horowitz H, 1996, DEVELOPMENT, V122, P1859; Jimenez-Garcia E, 1998, J BIOL CHEM, V273, P24640, DOI 10.1074/jbc.273.38.24640; KAMAKAKA RT, 1991, P NATL ACAD SCI USA, V88, P1024, DOI 10.1073/pnas.88.3.1024; Katsani KR, 1999, EMBO J, V18, P698, DOI 10.1093/emboj/18.3.698; KERRIGAN LA, 1991, J BIOL CHEM, V266, P574; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; LEE HS, 1992, GENE DEV, V6, P284, DOI 10.1101/gad.6.2.284; Lehmann M, 1998, J BIOL CHEM, V273, P28504, DOI 10.1074/jbc.273.43.28504; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; Lintermann KG, 1998, DEV GENES EVOL, V208, P447, DOI 10.1007/s004270050202; LU Q, 1993, MOL CELL BIOL, V13, P2802, DOI 10.1128/MCB.13.5.2802; Mizuguchi G, 1997, MOL CELL, V1, P141, DOI 10.1016/S1097-2765(00)80015-5; Okada M, 1998, MOL CELL BIOL, V18, P2455, DOI 10.1128/MCB.18.5.2455; Omichinski JG, 1997, NAT STRUCT BIOL, V4, P122, DOI 10.1038/nsb0297-122; Pedone PV, 1996, P NATL ACAD SCI USA, V93, P2822, DOI 10.1073/pnas.93.7.2822; Pile LA, 2000, J BIOL CHEM, V275, P1398, DOI 10.1074/jbc.275.2.1398; READ D, 1990, MOL CELL BIOL, V10, P4334, DOI 10.1128/MCB.10.8.4334; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; SOELLER WC, 1993, MOL CELL BIOL, V13, P7961, DOI 10.1128/MCB.13.12.7961; Sutrias-Grau M, 1999, J BIOL CHEM, V274, P1628, DOI 10.1074/jbc.274.3.1628; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; Wilkins RC, 1999, J MOL BIOL, V285, P515, DOI 10.1006/jmbi.1998.2356	35	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19461	19468		10.1074/jbc.M000967200	http://dx.doi.org/10.1074/jbc.M000967200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10764754	hybrid, Green Published			2022-12-27	WOS:000087941300006
J	Communal, C; Colucci, WS; Singh, K				Communal, C; Colucci, WS; Singh, K			p38 mitogen-activated protein kinase pathway protects adult rat ventricular myocytes against beta-adrenergic receptor-stimulated apoptosis - Evidence for G(i)-dependent activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROVASCULAR ENDOTHELIAL-CELLS; NITRIC-OXIDE SYNTHASE; CARDIAC MYOCYTES; MAP KINASE; BETA(2)-ADRENERGIC RECEPTOR; DEPENDENT ACTIVATION; SIGNALING PATHWAYS; GAMMA-SUBUNITS; HEART-FAILURE; HYPERTROPHY	We have shown that stimulation of beta-adrenergic receptors (beta-AR) by norepinephrine (NE) increases apoptosis in adult rat ventricular myocytes (ARVMs) via a cAMP-dependent mechanism that is antagonized by activation of G(i) protein. The family of mitogen-activated protein kinases (MAPKs) is involved in the regulation of cardiac myocyte growth and apoptosis, Here we show that beta-AR stimulation activates p38 kinase, c-jun N-terminal kinases (JNKs), and extracellular signal-regulated kinase (ERK1/2) in ARVMs, Inhibition of p38 kinase with SB-202190 (10 mu M) potentiated beta-AR-stimulated apoptosis as measured by flow cytometry and terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) staining. SB-202190 at this concentration specifically blocked beta-AR-stimulated activation of p38 kinase and its downstream substrate MAPK-activated protein kinase-2 (MAPKAPK2). Pertussis toxin, an inhibitor of G(i)/G(o) proteins, blocked the activation of p38 kinase and potentiated beta-AR-stimulated apoptosis, Activation of G(i) protein with the muscarinic receptor agonist carbachol protected against beta-AR-stimulated apoptosis, Carbachol also activated p38 kinase, and the protective effect of carbachol was abolished by SB-202190. PD-98059 (10 mu M), an inhibitor of ERK1/2 pathway, blocked beta-AR-stimulated activation of ERK1/2 but had no effect on apoptosis. These data suggest that 1) beta-AR stimulation activates p38 kinase, JNKs, and ERK1/2; 2) activation of p38 kinase plays a protective role in beta-AR-stimulated apoptosis in cardiac myocytes; and 3) the protective effects of G(i) are mediated via the activation of p38 kinase.	Boston Univ, Med Ctr, Myocardial Biol Unit, Boston, MA 02118 USA; Boston Univ, Med Ctr, Div Cardiovasc, Boston, MA 02118 USA; Vet Affairs Med Ctr, Boston, MA 02118 USA; Boston Univ, Sch Med, Boston, MA 02118 USA	Boston University; Boston University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Boston University	Singh, K (corresponding author), Boston Univ, Med Ctr, Myocardial Biol Unit, 80 E Concord St, Boston, MA 02118 USA.	krishna.singh@bmc.org		Colucci, Wilson/0000-0002-0576-9420	NHLBI NIH HHS [HL-42539, HL-057947, HL-61639] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042539, R01HL057947, R01HL061639] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andre C, 1999, AM J PHYSIOL-GASTR L, V276, pG647, DOI 10.1152/ajpgi.1999.276.3.G647; Anversa P, 1996, CURR OPIN CARDIOL, V11, P245, DOI 10.1097/00001573-199605000-00004; Bogoyevitch MA, 1996, BIOCHEM J, V314, P115, DOI 10.1042/bj3140115; Clerk A, 1998, J CELL BIOL, V142, P523, DOI 10.1083/jcb.142.2.523; Colucci WS, 1996, NEW ENGL J MED, V335, P1224, DOI 10.1056/NEJM199610173351610; Communal C, 1999, CIRCULATION, V100, P2210, DOI 10.1161/01.CIR.100.22.2210; Communal C, 1998, CIRCULATION, V98, P1329, DOI 10.1161/01.CIR.98.13.1329; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; FAURE M, 1994, J BIOL CHEM, V269, P7851; Fischer TA, 1998, AM J PHYSIOL-HEART C, V275, pH906, DOI 10.1152/ajpheart.1998.275.3.H906; Force T, 1999, GENE EXPRESSION, V7, P337; Force T, 1998, HYPERTENSION, V31, P152, DOI 10.1161/01.HYP.31.1.152; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Guo JH, 1998, J BIOL CHEM, V273, P16487, DOI 10.1074/jbc.273.26.16487; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Husain S, 1999, BIOCHEM J, V342, P87, DOI 10.1042/0264-6021:3420087; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ing DJ, 1999, CIRC RES, V84, P21; Iwai-Kanai E, 1999, CIRCULATION, V100, P305, DOI 10.1161/01.CIR.100.3.305; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Kompa AR, 1999, BRIT J PHARMACOL, V128, P1399, DOI 10.1038/sj.bjp.0702920; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Li ZH, 1997, AM J PHYSIOL-HEART C, V272, pH2313, DOI 10.1152/ajpheart.1997.272.5.H2313; Mackay K, 1999, J BIOL CHEM, V274, P6272, DOI 10.1074/jbc.274.10.6272; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; NUTTALL A, 1997, BRIT J PHARMACOL, V77, P381; PARRATT JR, 1994, TRENDS PHARMACOL SCI, V15, P19, DOI 10.1016/0165-6147(94)90129-5; Sharma HS, 1996, MOL CELL BIOCHEM, V161, P217, DOI 10.1007/BF00240052; Sheng ZL, 1997, J BIOL CHEM, V272, P5783, DOI 10.1074/jbc.272.9.5783; Shizukuda Y, 1998, AM J PHYSIOL-HEART C, V275, pH961, DOI 10.1152/ajpheart.1998.275.3.H961; SINGH K, 1995, J BIOL CHEM, V270, P28471; Singh K, 1996, J BIOL CHEM, V271, P1111, DOI 10.1074/jbc.271.2.1111; Sugden PH, 1998, CIRC RES, V83, P345, DOI 10.1161/01.RES.83.4.345; Suzuki A, 1999, ENDOCRINOLOGY, V140, P3177, DOI 10.1210/en.140.7.3177; Taimor G, 1998, CIRCULATION, V98, P623; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiao RP, 1999, CIRC RES, V84, P43; XIAO RP, 1995, MOL PHARMACOL, V47, P322; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232; Zhu WD, 1999, CIRCULATION, V100, P2100, DOI 10.1161/01.CIR.100.20.2100	48	138	144	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19395	19400		10.1074/jbc.M910471199	http://dx.doi.org/10.1074/jbc.M910471199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10770956	hybrid			2022-12-27	WOS:000087815900101
J	Cruciat, CM; Brunner, S; Baumann, F; Neupert, W; Stuart, RA				Cruciat, CM; Brunner, S; Baumann, F; Neupert, W; Stuart, RA			The cytochrome bc(1) and cytochrome c oxidase complexes associate to form a single supracomplex in yeast mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME QH2-CYTOCHROME-C REDUCTASE; SACCHAROMYCES-CEREVISIAE; NUCLEAR GENE; RESPIRATORY-CHAIN; MEMBRANE SYSTEM; BC1 COMPLEX; PROTEIN; IDENTIFICATION; RESOLUTION; SYNTHASE	The mitochondrial electron transport chain complexes are large multisubunit complexes embedded in the inner membrane. We report here that in the yeast Saccharomyces cerevisiae, the cytochrome be, and cytochrome c oxidase complexes co-exist as a larger complex of similar to 1000 kDa in the mitochondrial membrane. Following solubilization with a mild detergent, the cytochrome bc(1)-cytochrome c oxidase complex remains stable. It was analyzed using the techniques of gel filtration and blue native-polyacrylamide gel electrophoresis. Direct physical. association of subunits of the cytochrome be, complex with those of the cytochrome c oxidase complex was verified by co-immunoprecipitation analysis. Our data indicate that the cytochrome be, complex is exclusively in association with the cytochrome c oxidase complex in yeast mitochondria. We term this complex the cytochrome bc(1)-cytochrome c oxidase supracomplex.	Marquette Univ, Dept Biol, Milwaukee, WI 53051 USA; Univ Munich, Inst Physiol Chem, D-80336 Munich, Germany	Marquette University; University of Munich	Stuart, RA (corresponding author), Marquette Univ, Dept Biol, POB 1881, Milwaukee, WI 53051 USA.	rosemary.stuart@marquette.edu	Baumann, Frank/F-7737-2016	Brunner, Michael/0000-0001-9798-3047				Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Arnold I, 1997, FEBS LETT, V411, P195, DOI 10.1016/S0014-5793(97)00691-1; Arnold I, 1999, J BIOL CHEM, V274, P36, DOI 10.1074/jbc.274.1.36; BEHRENS M, 1991, MOL GEN GENET, V228, P167, DOI 10.1007/BF00282462; BERRY EA, 1985, J BIOL CHEM, V260, P2458; Boumans H, 1998, J BIOL CHEM, V273, P4872, DOI 10.1074/jbc.273.9.4872; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT U, 1994, J BIOL CHEM, V269, P12947; Cruciat CM, 1999, EMBO J, V18, P5226, DOI 10.1093/emboj/18.19.5226; DEVRIES S, 1987, BIOCHIM BIOPHYS ACTA, V895, P205, DOI 10.1016/S0304-4173(87)80003-4; Folsch H, 1998, EMBO J, V17, P6508, DOI 10.1093/emboj/17.22.6508; HATEFI Y, 1967, METHOD ENZYMOL, V10, P225; Herrmann J. M., 1994, CELL BIOL LAB HDB, VI, P538; Iwasaki T, 1995, J BIOL CHEM, V270, P30881, DOI 10.1074/jbc.270.52.30881; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luttik MAH, 1998, J BIOL CHEM, V273, P24529, DOI 10.1074/jbc.273.38.24529; MAARSE AC, 1984, EMBO J, V3, P2831, DOI 10.1002/j.1460-2075.1984.tb02216.x; Mashkevich G, 1997, J BIOL CHEM, V272, P14356, DOI 10.1074/jbc.272.22.14356; PHILLIPS JD, 1990, J BIOL CHEM, V265, P20813; PHILLIPS JD, 1993, J BIOL CHEM, V268, P11727; RICH PR, 1984, BIOCHIM BIOPHYS ACTA, V768, P53, DOI 10.1016/0304-4173(84)90007-7; SADLER I, 1984, EMBO J, V3, P2137, DOI 10.1002/j.1460-2075.1984.tb02103.x; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SCHMITT ME, 1990, J BIOL CHEM, V265, P17005; SONE N, 1987, J BIOL CHEM, V262, P15386; TZAGOLOFF A, 1986, J BIOL CHEM, V261, P7163; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WU M, 1989, J BIOL CHEM, V264, P11122; YU C, 1980, BIOCHIM BIOPHYS ACTA, V591, P409, DOI 10.1016/0005-2728(80)90172-3	31	205	208	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18093	18098		10.1074/jbc.M001901200	http://dx.doi.org/10.1074/jbc.M001901200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10764779	hybrid			2022-12-27	WOS:000087659400027
J	Gu, YJ; Ihara, Y				Gu, YJ; Ihara, Y			Accelerated Publication - Evidence that collapsin response mediator protein-2 is involved in the dynamics of microtubules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH CONE COLLAPSE; AXONAL GUIDANCE; OUTGROWTH; UNC-33; FAMILY; DIHYDROPYRIMIDINASE; NEURONS; RAT	Collapsin response mediator protein-2 (CRMP-2) is a member of the CRMP/TOAD/Ulip/DRP family of cytosolic phosphoproteins involved in neuronal differentiation and axonal guidance. CRMP-2 mediates the intracellular response to collapsin 1/semaphorin 3A, a repulsive extracellular guidance cue for axonal outgrowth. The mutation of UNC-33, a Caenorhabditis elegans homolog of CRMP-2, results in abnormality of microtubules in neurites, but the mechanism of CRMP-2 action remains to be clarified. Here, we report that overexpression of human CRMP-2 in Neuro2a cells, a mouse neuroblastoma cell line, results in blebbing of the cytoplasm. Furthermore, some cells exhibited intranuclear inclusions, which were labeled with antibodies to CRMP-2 and tubulin, CRMP-2 was found to be associated with microtubule bundles in the spindles at the metaphase and in the midbodies at the late telophase in mitotic cells. Thus, it is most likely that failure of complete disassembly of the spindle microtubules during mitosis is responsible for the formation of these intranuclear inclusions. We suggest that CRMP-2 functions by regulating the dynamics of microtubules.	Univ Tokyo, Fac Med, Dept Neuropathol, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol Corp, JSP, CREST, Kawaguchi 3320012, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Ihara, Y (corresponding author), Univ Tokyo, Fac Med, Dept Neuropathol, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.							BKY T, 1996, J NEUROSCI, V16, P688; Challacombe JF, 1997, J NEUROSCI, V17, P3085; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; GREER K, 1989, CELL MOVEMENT, V2, P47; Gu YJ, 2000, BIOCHEMISTRY-US, V39, P4267, DOI 10.1021/bi992323h; Hamajima N, 1996, GENE, V180, P157, DOI 10.1016/S0378-1119(96)00445-3; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; Jin Z, 1997, J NEUROSCI, V17, P6256; KINDT RM, 1995, NEURON, V15, P79, DOI 10.1016/0896-6273(95)90066-7; LI W, 1992, GENETICS, V132, P675; MINTURN JE, 1995, J NEUROSCI, V15, P6757; Quinn CC, 1999, J NEUROBIOL, V41, P158, DOI 10.1002/(SICI)1097-4695(199910)41:1<158::AID-NEU19>3.0.CO;2-0; Shirvan A, 1999, J NEUROCHEM, V73, P961, DOI 10.1046/j.1471-4159.1999.0730961.x; TANAKA EM, 1991, J CELL BIOL, V115, P345, DOI 10.1083/jcb.115.2.345; Wang GH, 1999, NEUROREPORT, V10, P2435, DOI 10.1097/00001756-199908200-00001; Wang LH, 1996, J NEUROSCI, V16, P6197; Wang LH, 1997, J NEUROCHEM, V69, P2261; Yoshida H, 1998, J BIOL CHEM, V273, P9761, DOI 10.1074/jbc.273.16.9761	18	147	152	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					17917	17920		10.1074/jbc.C000179200	http://dx.doi.org/10.1074/jbc.C000179200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10770920	hybrid			2022-12-27	WOS:000087659400001
J	Blanchetot, C; den Hertog, J				Blanchetot, C; den Hertog, J			Multiple interactions between receptor protein-tyrosine phosphatase (RPTP) alpha and membrane-distal protein-tyrosine phosphatase domains of various RPTPs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; BINDING-SITE; PTP-ALPHA; EXPRESSION; MOLECULE; ADAPTER; LIGAND; GRB2; LAR; PHOSPHORYLATION	Receptor protein-tyrosine phosphatase (RPTP) alpha belongs to the large family of receptor protein-tyrosine phosphatases containing two tandem phosphatase domains. Most of the catalytic activity is retained in the first, membrane-proximal domain (RPTP alpha-D1), and little is known about the function of the second, membrane distal domain (RPTP alpha-D2). We investigated whether proteins bound to RPTP alpha using the two-hybrid system and found that the second domain of RPTP sigma interacted with the juxtamembrane domain of RPTP alpha, We confirmed this interaction by co-immunoprecipitation experiments. Furthermore, RPTP alpha not only interacted with RPTP sigma-D2 but also with RPTP alpha-D2, LAR-D2, RPTP delta-D2, and RPTP mu-D2, members of various RPTP subfamilies, although with different affinities. In the yeast two-hybrid system and in glutathione S-transferase pull-down assays, we show that the RPTP-D2s interacted directly with the wedge structure of RPTP alpha-D1 that has been demonstrated to be involved in inactivation of the RPTP alpha-D1/RPTP alpha-D1 homodimer, The interaction was specific because the equivalent wedge structure in LAR was unable to interact with RPTP alpha-D2 or LAR-D2. In vitro, we show that other interaction sites exist as well, including the C terminus of RPTP alpha-D2. The observation that RPTP alpha, but not LAR, bound to multiple RPTP-D2s with varying affinities suggests a specific mechanism of cross-talk between RPTPs that may regulate their biological function.	Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	den Hertog, J (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.	hertog@niob.knaw.nl		Blanchetot, christophe/0000-0001-9152-9978				Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Buist P, 1999, BIOCHEMISTRY-US, V38, P914, DOI 10.1021/bi981936b; Burden-Gulley SM, 1999, J CELL BIOL, V144, P1323, DOI 10.1083/jcb.144.6.1323; den Hertog J, 1999, MECH DEVELOP, V85, P3, DOI 10.1016/S0925-4773(99)00089-1; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; denHertog J, 1996, MECH DEVELOP, V58, P89, DOI 10.1016/S0925-4773(96)00561-8; DENHERTOG J, 1995, CELL GROWTH DIFFER, V6, P303; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; Desai CJ, 1997, DEVELOPMENT, V124, P1941; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; Felberg J, 1998, J BIOL CHEM, V273, P17839, DOI 10.1074/jbc.273.28.17839; Gershon TR, 1998, DEVELOPMENT, V125, P1183; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Haworth K, 1998, MOL CELL NEUROSCI, V12, P93, DOI 10.1006/mcne.1998.0707; Helmke S, 1998, J CELL SCI, V111, P2465; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Hoffmann KMV, 1997, J BIOL CHEM, V272, P27505, DOI 10.1074/jbc.272.44.27505; Jiang GL, 1999, NATURE, V401, P606, DOI 10.1038/44170; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; Lim KL, 1998, J BIOL CHEM, V273, P28986, DOI 10.1074/jbc.273.44.28986; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; Nam HJ, 1999, CELL, V97, P449, DOI 10.1016/S0092-8674(00)80755-2; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; O'Grady P, 1998, J CELL BIOL, V141, P1675, DOI 10.1083/jcb.141.7.1675; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; Schaapveld RQJ, 1998, MECH DEVELOP, V77, P59, DOI 10.1016/S0925-4773(98)00119-1; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; SU J, 1994, J BIOL CHEM, V269, P18731; TRACY S, 1995, J BIOL CHEM, V270, P10587, DOI 10.1074/jbc.270.18.10587; Tsai W, 1999, EMBO J, V18, P109, DOI 10.1093/emboj/18.1.109; Van der Sar AM, 1999, INT J DEV BIOL, V43, P785; Van Vactor D, 1998, CURR OPIN CELL BIOL, V10, P174, DOI 10.1016/S0955-0674(98)80139-7; Wallace MJ, 1998, MOL CELL BIOL, V18, P2608, DOI 10.1128/MCB.18.5.2608; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	40	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12446	12452		10.1074/jbc.275.17.12446	http://dx.doi.org/10.1074/jbc.275.17.12446			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777529	hybrid			2022-12-27	WOS:000086762300013
J	Adam, L; Vadlamudi, R; Mandal, M; Chernoff, J; Kumar, R				Adam, L; Vadlamudi, R; Mandal, M; Chernoff, J; Kumar, R			Regulation of microfilament reorganization and invasiveness of breast cancer cells by kinase dead p21-activated kinase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; PROTEIN-KINASE; SMOOTH-MUSCLE; RHO GTPASES; SIGNALING PATHWAY; TRANSFORMED-CELLS; HUMAN CALDESMON; ACTIN-BINDING; JUN KINASE; ALPHA-PAK	Stimulation of growth factor signaling has been implicated in the development of invasive phenotype and p21-activated kinase (PAK1) activation in human breast epithelial cancer cells. To further explore the roles of PAK1 in the invasive behavior of breast cancer cells, in the present study we investigated the influence of inhibition of PAK1 activity on the reorganization of cytoskeleton components that control motility and invasiveness of cells, using a highly invasive breast cancer MDA-MB435 as a model system. Our results demonstrate that overexpression of a kinase dead K299R PAK1 mutant leads to suppression of motile phenotypes as well as invasiveness of cells both in the absence or presence of exogenous heregulin-beta 1. In addition, these phenotypic changes were accompanied by a blockade of disassembly of focal adhesion points, stabilization of stress fibers, and enhanced cell spreading and were dependent on the presence of the kinase dead domain but independent of the presence of the Rac/cdc42 intact (Cdc42/Rac interactive binding) domain of PAK1, We also demonstrated that in K299R PAK1-expressing cells, F-actin filaments were stabilized by persistent co-localization with the actin-binding proteins tropomyosin and caldesmon. Extension of these studies to invasive breast cancer MDA-MB231 cells illustrated that conditional expression of kinase-defective K299R PAK1 was also accompanied by persistent cell spreading, multiple focal adhesion points, and reduced invasiveness, Furthermore, inhibition of PAK1 activity in breast cancer cells was associated with a reduction in c-Jun N-terminal kinase activity, inhibition of DNA binding activity of transcription factor AP-1, and suppression of in vivo transcription driven by AP-1 promoter (known to be involved in breast cancer invasion). These findings suggest that PAK1 downstream pathways have a role in the development and maintenance of invasive phenotypes in breast cancer cells.	Univ Texas, MD Anderson Canc Ctr, Cell Growth Regulat Lab, Houston, TX 77030 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	University of Texas System; UTMD Anderson Cancer Center; Fox Chase Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Cell Growth Regulat Lab, Box 36,Rm Y4-6032,1515 Holcombe Blvd, Houston, TX 77030 USA.		Chernoff, Jonathan/I-7631-2014; Mandal, Mahitosh/GMW-6195-2022	Chernoff, Jonathan/0000-0002-4803-7836; Mandal, Mahitosh/0000-0003-3861-3323	NCI NIH HHS [CA16672, CA80066, CA65746] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065746, R01CA080066, P30CA016672, U01CA065746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BHATTACHARYA B, 1990, CANCER RES, V50, P2105; BOYD J, 1995, P NATL ACAD SCI USA, V92, P11534, DOI 10.1073/pnas.92.25.11534; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dumont JA, 1996, CELL GROWTH DIFFER, V7, P351; Franzen B, 1997, ELECTROPHORESIS, V18, P582, DOI 10.1002/elps.1150180341; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HUBER PAJ, 1995, BIOCHEM J, V312, P617, DOI 10.1042/bj3120617; Ishikawa R, 1998, J BIOL CHEM, V273, P26991, DOI 10.1074/jbc.273.41.26991; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lin PJ, 1997, J BIOL CHEM, V272, P7412, DOI 10.1074/jbc.272.11.7412; Mandal M, 1996, J BIOL CHEM, V271, P30354, DOI 10.1074/jbc.271.48.30354; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MATSUMURA F, 1986, J BIOL CHEM, V261, P4655; Matsumura F, 1993, CURR OPIN CELL BIOL, V5, P70, DOI 10.1016/S0955-0674(05)80010-9; McManus MJ, 1997, P NATL ACAD SCI USA, V94, P11351, DOI 10.1073/pnas.94.21.11351; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MITCHISON TJ, 1996, CELL, V84, P871; NOVY RE, 1991, J BIOL CHEM, V266, P16917; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SOBUE K, 1991, J BIOL CHEM, V266, P12115; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; TANAKA J, 1993, J CELL SCI, V104, P595; Tang Y, 1999, MOL CELL BIOL, V19, P1881; Van Eyk JE, 1998, J BIOL CHEM, V273, P23433, DOI 10.1074/jbc.273.36.23433; Warren KS, 1996, CELL MOTIL CYTOSKEL, V34, P215, DOI 10.1002/(SICI)1097-0169(1996)34:3<215::AID-CM5>3.0.CO;2-8; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Yablonski D, 1998, EMBO J, V17, P5647, DOI 10.1093/emboj/17.19.5647; YAMASHIROMATSUMURA S, 1988, J CELL BIOL, V106, P1973, DOI 10.1083/jcb.106.6.1973; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	46	152	157	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12041	12050		10.1074/jbc.275.16.12041	http://dx.doi.org/10.1074/jbc.275.16.12041			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766836	hybrid			2022-12-27	WOS:000086695500071
J	Dickson, R; Weiss, C; Howard, RJ; Alldrick, SP; Ellis, RJ; Lorimer, G; Azem, A; Viitanen, PV				Dickson, R; Weiss, C; Howard, RJ; Alldrick, SP; Ellis, RJ; Lorimer, G; Azem, A; Viitanen, PV			Reconstitution of higher plant chloroplast chaperonin 60 tetradecamers active in protein folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; MAMMALIAN MITOCHONDRIAL CHAPERONIN-60; SUBUNIT BINDING-PROTEIN; GROES-LIKE CHAPERONIN; ESCHERICHIA-COLI; RIBULOSEBISPHOSPHATE-CARBOXYLASE; PLASTID CHAPERONIN-60; MOLECULAR CHAPERONES; PURIFICATION; IDENTIFICATION	Unlike the GroEL homologs of eubacteria and mitochondria, oligomer preparations of the higher plant chloroplast chaperonin 60 (cpn60) consist of roughly equal amounts of two divergent subunits, alpha and beta. The functional significance of these isoforms, their structural organization into tetradecamers, and their interactions with the unique binary chloroplast chaperonin 10 (cpn10) have not been elucidated. Toward this goal, we have cloned the alpha and beta subunits of the ch-cpn60 of pea (Pisum sativum), expressed them individually in Escherichia coli, and subjected the purified monomers to in vitro reconstitution experiments. In the absence of other factors, neither subunit (alone or in combination) spontaneously assembles into a higher order structure. However, in the presence of MgATP, the beta subunits form tetradecamers in a cooperative reaction that is potentiated by cpn10. In contrast, a subunits only assemble in the presence of beta subunits, Although beta and alpha/beta 14-mers are indistinguishable by electron microscopy and can both assist protein folding, their specificities for cpn10 are entirely different. Similar to the authentic chloroplast protein, the reconstituted alpha/beta 14-mers are functionally compatible with bacterial, mitochondrial, and chloroplast cpn10, In contrast, the folding reaction mediated by the reconstituted beta 14-mers is only efficient with mitochondrial cpn10. The ability to reconstitute two types of functional oligomer in vitro provides a unique tool, which will allow us to investigate the mechanism of this unusual chaperonin system.	Dupont Co, Expt Stn, Dept Cent Res & Dev, Div Mol Biol, Wilmington, DE 19880 USA; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel; Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England	DuPont; Tel Aviv University; University System of Maryland; University of Maryland College Park; University of Warwick	Viitanen, PV (corresponding author), Dupont Co, Expt Stn, Dept Cent Res & Dev, Div Mol Biol, Wilmington, DE 19880 USA.							BANEYX F, 1995, J BIOL CHEM, V270, P10695, DOI 10.1074/jbc.270.18.10695; BARRACLOUGH R, 1980, BIOCHIM BIOPHYS ACTA, V608, P19, DOI 10.1016/0005-2787(80)90129-X; BERTSCH U, 1992, P NATL ACAD SCI USA, V89, P8696, DOI 10.1073/pnas.89.18.8696; Boston RS, 1996, PLANT MOL BIOL, V32, P191, DOI 10.1007/BF00039383; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CANNON S, 1986, J CELL BIOL, V103, P1327, DOI 10.1083/jcb.103.4.1327; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHEN GG, 1994, P NATL ACAD SCI USA, V91, P11497, DOI 10.1073/pnas.91.24.11497; CLONEY LP, 1992, J BIOL CHEM, V267, P23333; CLONEY LP, 1992, J BIOL CHEM, V267, P23327; DICKSON R, 1994, J BIOL CHEM, V269, P26858; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; Gatenby Anthony A., 1996, P65, DOI 10.1016/B978-012237455-5/50004-X; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HARTMAN DJ, 1992, P NATL ACAD SCI USA, V89, P3394, DOI 10.1073/pnas.89.8.3394; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HEMMINGSEN SM, 1986, PLANT PHYSIOL, V80, P269, DOI 10.1104/pp.80.1.269; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KOONIN EV, 1995, TRENDS BIOCHEM SCI, V20, P14, DOI 10.1016/S0968-0004(00)88941-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LEHEL C, 1993, J BIOL CHEM, V268, P1799; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; LISSIN NM, 1993, FEBS LETT, V324, P41, DOI 10.1016/0014-5793(93)81528-8; LISSIN NM, 1995, FEBS LETT, V361, P55, DOI 10.1016/0014-5793(95)00151-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; MARTEL R, 1990, GENE, V94, P181, DOI 10.1016/0378-1119(90)90385-5; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MILOS P, 1984, J CELL BIOCHEM, V24, P153, DOI 10.1002/jcb.240240206; MUSGROVE JE, 1987, EUR J BIOCHEM, V163, P529, DOI 10.1111/j.1432-1033.1987.tb10900.x; Nishio K, 1999, BIOCHEM BIOPH RES CO, V266, P584, DOI 10.1006/bbrc.1999.1868; PUSHKIN AV, 1982, BIOCHIM BIOPHYS ACTA, V704, P379, DOI 10.1016/0167-4838(82)90169-8; ROSPERT S, 1993, P NATL ACAD SCI USA, V90, P10967, DOI 10.1073/pnas.90.23.10967; ROY H, 1989, PLANT CELL, V1, P1035, DOI 10.1105/tpc.1.11.1035; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TSUGEKI R, 1992, EUR J BIOCHEM, V209, P453, DOI 10.1111/j.1432-1033.1992.tb17309.x; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; Viitanen PV, 1998, METHOD ENZYMOL, V290, P218, DOI 10.1016/S0076-6879(98)90021-0; Viitanen PV, 1998, METHOD ENZYMOL, V290, P203, DOI 10.1016/S0076-6879(98)90020-9; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; VIITANEN PV, 1995, J BIOL CHEM, V270, P18158, DOI 10.1074/jbc.270.30.18158; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783	46	60	64	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11829	11835		10.1074/jbc.275.16.11829	http://dx.doi.org/10.1074/jbc.275.16.11829			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766808	hybrid			2022-12-27	WOS:000086695500043
J	Konishi, M; Mikami, T; Yamasaki, M; Miyake, A; Itoh, N				Konishi, M; Mikami, T; Yamasaki, M; Miyake, A; Itoh, N			Fibroblast growth factor-16 is a growth factor for embryonic brown adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR FAMILY; ADIPOSE-TISSUE; MESSENGER-RNAS; RAT; EXPRESSION; DIFFERENTIATION; PROLIFERATION; CELLS	In rat embryos, fibroblast growth factor (FGF)-16 is predominantly expressed in brown adipose tissue. To elucidate the role of FGF-16, we examined the expression of FGF-16 mRNA in rat embryonic brown adipose tissue at different developmental stages by Northern blotting analysis and in situ hybridization. FGF-16 mRNA was expressed abundantly in brown adipose tissue during embryonic day 17.5, embryonic days 17.5-19.5, and thereafter at lower levels into the neonatal period. The expression profile of FGF-16 mRNA well corresponds to the proliferative profile of embryonic brown adipose tissue reported. We also examined the mitogenic activity of recombinant rat FGF-16 for primary brown adipocytes prepared from rat embryonic brown adipose tissue. FGF-16 showed significant mitogenic activity for primary brown adipocytes. The mitogenic activity was found to be exerted by binding and activating FGF receptor-4 in the brown adipose tissue. As a great induction of proliferation of rat brown adipose tissue during cold acclimation was reported, we also examined the expression of FGF-16 mRNA in the brown adipose tissue during cold acclimation by Northern blotting analysis. The expression of FGF-16 mRNA was not increased, but rather decreased. The expression profile of FGF-16 mRNA and the mitogenic activity of FGF-16 reported here indicate that FGF-16 is a unique growth factor involved in proliferation of embryonic brown adipose tissue.	Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biochem Genet, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Itoh, N (corresponding author), Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biochem Genet, Sakyo Ku, Yoshida Shimoadachi, Kyoto 6068501, Japan.			Yamasaki, Masahiro/0000-0002-5296-4974				BAIRD A, 1991, CANCER CELL-MON REV, V3, P239; BOUILLAUD F, 1986, J BIOL CHEM, V261, P1487; BRONNIKOV G, 1992, J BIOL CHEM, V267, P2006; BUKOWIECKI LJ, 1986, AM J PHYSIOL, V250, pC880, DOI 10.1152/ajpcell.1986.250.6.C880; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Danilenko DM, 1999, ARCH BIOCHEM BIOPHYS, V361, P34, DOI 10.1006/abbi.1998.0967; GIRALT M, 1990, EUR J BIOCHEM, V193, P297, DOI 10.1111/j.1432-1033.1990.tb19336.x; HIMMSHAGEN J, 1990, FASEB J, V4, P2890, DOI 10.1096/fasebj.4.11.2199286; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Miyake A, 1996, J NEUROSCI RES, V45, P534, DOI 10.1002/(SICI)1097-4547(19960901)45:5<534::AID-JNR3>3.0.CO;2-D; Miyake A, 1998, BIOCHEM BIOPH RES CO, V243, P148, DOI 10.1006/bbrc.1998.8073; Nishimura T, 1999, BBA-GENE STRUCT EXPR, V1444, P148, DOI 10.1016/S0167-4781(98)00255-3; NNODIM JO, 1985, ANAT EMBRYOL, V173, P215, DOI 10.1007/BF00316302; Ohbayashi N, 1998, J BIOL CHEM, V273, P18161, DOI 10.1074/jbc.273.29.18161; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Teruel T, 1996, J CELL PHYSIOL, V166, P577, DOI 10.1002/(SICI)1097-4652(199603)166:3<577::AID-JCP12>3.0.CO;2-4; TERUEL T, 1995, BIOCHEM J, V310, P771, DOI 10.1042/bj3100771; YAZAKI N, 1994, J NEUROSCI RES, V37, P445, DOI 10.1002/jnr.490370403	20	67	69	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12119	12122		10.1074/jbc.275.16.12119	http://dx.doi.org/10.1074/jbc.275.16.12119			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766846	hybrid			2022-12-27	WOS:000086695500081
J	Lockwich, TP; Liu, XB; Singh, BB; Jadlowiec, J; Weiland, S; Ambudkar, IS				Lockwich, TP; Liu, XB; Singh, BB; Jadlowiec, J; Weiland, S; Ambudkar, IS			Assembly of Trp1 in a signaling complex associated with caveolin-scaffolding lipid raft domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; CAPACITATIVE CALCIUM-ENTRY; OPERATED HTRP3 CHANNELS; MEMBRANE DOMAINS; PLASMA-MEMBRANE; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PROTEIN; LOCALIZATION; CHOLESTEROL	Trp1 has been proposed as a component of the store-operated Ca2+ entry (SOC) channel. However, neither the molecular mechanism of SOC nor the role of Trp in this process is yet understood. We have examined possible molecular interactions involved in the regulation of SOC and Trp1 and report here for the first time that Trp1 is assembled in signaling complex associated with caveolin-scaffolding lipid raft domains. Endogenous hTrp1 and caveolin-1 were present in low density fractions of Triton X-100-extracted human submandibular gland cell. membranes. Depletion of plasma membrane cholesterol increased Triton X-100 solubility of Trp1 and inhibited carbachol-stimulated Ca2+ signaling. Importantly, thapsigargn stimulated Ca2+ influx, but not internal Ca2+ release, and inositol 1,4,5-triphosphate (IP3)-stimulated I-soc were also attenuated. Furthermore, both anti-Trp1 and anti-caveolin-1 antibodies co-immunoprecipitated hTrp1, caveolin-1, G alpha(q/11), and IP3 receptor-type 3 (IP3R3). These results demonstrate that caveolar microdomains provide a scaffold for (i) assembly of key Ca2+ signaling proteins into a complex and (ii) coordination of the molecular interactions leading to the activation of SOC. importantly, we have shown that Trp1 is also localized in this microdomain where it interacts with one or more components of this complex, including IP3R3. This finding is potentially important in elucidating the physiological function of Trp.	NIDCR, Secretory Physiol Sect, Gene Therapy & Therapeut Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Ambudkar, IS (corresponding author), Bldg 10,Rm IN-113, Bethesda, MD 20892 USA.			Singh, Brij/0000-0003-0535-5997	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000438] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000438] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Hope HR, 1996, MOL BIOL CELL, V7, P843, DOI 10.1091/mbc.7.6.843; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu XB, 1998, J BIOL CHEM, V273, P33295, DOI 10.1074/jbc.273.50.33295; Liu XB, 1998, AM J PHYSIOL-CELL PH, V275, pC571, DOI 10.1152/ajpcell.1998.275.2.C571; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Liu XB, 1999, J BIOL CHEM, V274, P25121, DOI 10.1074/jbc.274.35.25121; Lupu VD, 1998, J BIOL CHEM, V273, P14067, DOI 10.1074/jbc.273.23.14067; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Montell C, 1997, MOL PHARMACOL, V52, P755, DOI 10.1124/mol.52.5.755; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Philipp S, 1997, FEBS LETT, V413, P243, DOI 10.1016/S0014-5793(97)00877-6; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Putney JW, 1999, CELL, V99, P5, DOI 10.1016/S0092-8674(00)80056-2; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; Scheiffele P, 1999, J BIOL CHEM, V274, P2038, DOI 10.1074/jbc.274.4.2038; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SKIBBENS JE, 1989, J CELL BIOL, V108, P821, DOI 10.1083/jcb.108.3.821; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Wang WC, 1999, AM J PHYSIOL-CELL PH, V276, pC969, DOI 10.1152/ajpcell.1999.276.4.C969; Zhu X, 1998, NEWS PHYSIOL SCI, V13, P211	40	343	352	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11934	11942		10.1074/jbc.275.16.11934	http://dx.doi.org/10.1074/jbc.275.16.11934			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766822	hybrid			2022-12-27	WOS:000086695500057
J	Young, SH; Dong, WJ; Jacobs, RR				Young, SH; Dong, WJ; Jacobs, RR			Observation of a partially opened triple-helix conformation in 1 -> 3-beta-glucan by fluorescence resonance energy transfer spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOLOGICAL RESPONSE MODIFIERS; ATOMIC-FORCE MICROSCOPY; C-13 CHEMICAL-SHIFTS; COAGULATION FACTOR-G; ANTITUMOR-ACTIVITY; SOLID-STATE; BRANCHED (1->3)-BETA-D-GLUCANS; CAPILLARY ELECTROPHORESIS; SECONDARY STRUCTURE; ALKALINE-SOLUTION	This study used fluorescence resonance energy transfer (FRET) spectroscopy as an indirect method to investigate the effect of NaOH treatment on the conformation of a triple-helix (1-->3)-beta-n-glucan and then evaluated the effect of conformation on biological activity. Previous studies have suggested that treatment of the triple-helix glucans with NaOH produces single-helix conformers. FRET spectra of the triple-helix glucan, laminarin, doubly labeled with 1-aminopyrene as donor probe and fluorescein-5-isothiocyanate as acceptor probe attached at the reducing end, showed that a partially opened triple-helix conformer was formed on treatment with NaOH. increasing degrees of strand opening was associated with increasing concentrations of NaOH. Based on these observations Foe propose that a partially opened triple-helix rather than a single helix, is formed by treating the triple-helix glucans with NaOH. After neutralizing the NaOH, changes in FRET indicated that the partially opened conformer gradually reverts to the triple-helix over 8 days. Laminarian was stabilized at different degrees of partial opening and its biological activity examined using the Limulus amebocyte lysate assay and nitric oxide production by alveolar macrophage. Both Limulus amebocyte lysate activity and nitric oxide production were related to the degree of opening of the triple-helix. Partially open conformers were more biologically active than the intact triple-helix.	Univ Alabama, Sch Publ Hlth, Dept Environm Hlth, Birmingham, AL 35294 USA; Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Jacobs, RR (corresponding author), Univ Alabama, Sch Publ Hlth, Dept Environm Hlth, 317 Ryals Bldg, Birmingham, AL 35294 USA.		Dong, Wenji/A-8579-2011					AKETAGAWA J, 1993, J BIOCHEM-TOKYO, V113, P683, DOI 10.1093/oxfordjournals.jbchem.a124103; AKETAGAWA J, 1994, 3 GLUC INH TOX WORKS, P4; ATKINS EDT, 1969, PROC R SOC SER B-BIO, V173, P209, DOI 10.1098/rspb.1969.0047; Bohn JA, 1995, CARBOHYD POLYM, V28, P3, DOI 10.1016/0144-8617(95)00076-3; Cheung H.C., 1991, TOPICS FLUORESCENCE, P127; EVANGELISTA RA, 1995, ANAL CHEM, V67, P2239, DOI 10.1021/ac00109a051; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Haugland R., 1996, HDB FLUORESCENT PROB; JELSMA J, 1975, CARBOHYD RES, V43, P200, DOI 10.1016/S0008-6215(00)83988-9; Kitamura S, 1996, BIOPOLYMERS, V39, P407, DOI 10.1002/(SICI)1097-0282(199609)39:3<407::AID-BIP12>3.0.CO;2-8; KITAMURA S, 1994, CARBOHYD RES, V263, P111, DOI 10.1016/0008-6215(94)00156-1; KITAMURA S, 1992, NIPPON NOGEI KAGAKU, V66, P305; KOJIMA T, 1986, AGR BIOL CHEM TOKYO, V50, P231, DOI 10.1080/00021369.1986.10867365; Kulicke WM, 1997, CARBOHYD RES, V297, P135, DOI 10.1016/S0008-6215(96)00273-X; LIU JP, 1991, P NATL ACAD SCI USA, V88, P2302, DOI 10.1073/pnas.88.6.2302; Marchessault R H, 1967, Adv Carbohydr Chem Biochem, V22, P421; MCINTIRE TM, 1995, MACROMOLECULES, V28, P6375, DOI 10.1021/ma00122a056; McIntire TM, 1998, J AM CHEM SOC, V120, P6909, DOI 10.1021/ja981203e; MIURA NN, 1995, BIOL PHARM BULL, V18, P185; MULLER A, 1995, J CHROMATOGR B, V666, P283, DOI 10.1016/0378-4347(94)00575-P; OGAWA K, 1972, CARBOHYD RES, V23, P399, DOI 10.1016/S0008-6215(00)82709-3; Ohno N, 1996, IMMUNOL LETT, V52, P1, DOI 10.1016/0165-2478(96)02538-2; OHNO N, 1995, BIOL PHARM BULL, V18, P1242; REMILLARD JF, 1993, LAL UPDATE, V10, P1; SAITO H, 1989, B CHEM SOC JPN, V62, P392, DOI 10.1246/bcsj.62.392; SAITO H, 1987, B CHEM SOC JPN, V60, P4267, DOI 10.1246/bcsj.60.4267; SAITO H, 1987, B CHEM SOC JPN, V60, P4259, DOI 10.1246/bcsj.60.4259; SAITO H, 1991, CARBOHYD RES, V217, P181, DOI 10.1016/0008-6215(91)84128-2; STOKKE BT, 1993, INT J BIOL MACROMOL, V15, P63, DOI 10.1016/S0141-8130(05)80090-X; STOKKE BT, 1991, MACROMOLECULES, V24, P6349, DOI 10.1021/ma00023a046; Stone BA, 1992, CHEM BIOL 1 3 BETA G; Szollosi J, 1998, CYTOMETRY, V34, P159; Yadomae T., 1996, RECENT RES DEV CHEM, V1, P23; YANAKI T, 1983, BIOPHYS CHEM, V17, P337, DOI 10.1016/0301-4622(83)80018-0; YOSHIOKA Y, 1992, CHEM PHARM BULL, V40, P1221; Young SH, 1998, CARBOHYD RES, V310, P91, DOI 10.1016/S0008-6215(98)00167-0	36	76	77	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11874	11879		10.1074/jbc.275.16.11874	http://dx.doi.org/10.1074/jbc.275.16.11874			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766814	hybrid			2022-12-27	WOS:000086695500049
J	Hraiky, C; Raymond, MA; Drolet, M				Hraiky, C; Raymond, MA; Drolet, M			RNase H overproduction corrects a defect at the level of transcription elongation during rRNA synthesis in the absence of DNA topoisomerase I in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							R-LOOP FORMATION; RIBOSOMAL-RNA; STRINGENT CONTROL; GYRASE GENES; PROMOTERS; MUTATIONS; TEMPLATE; REPLICATION; GROWTH; OPERON	It has been suggested that the major function of DNA topoisomerase I in Escherichia coli is to suppress the formation of R-loops, which could inhibit growth. Although the currently available data suggest that the inhibitory effect of R-loops is exerted at the level of gene expression, this has never been demonstrated. In the present report, we show that rRNA synthesis is significantly impaired at the level of transcription elongation in a bacterial strain Lacking DNA topoisomerase I. We found that this inhibition is due to transcriptional blocks. RNase Ii overproduction is also shown to considerably reduce the extent of such transcriptional blocks during rRNA synthesis. Moreover, one of these transcriptional blockage sites is located within a region where extensive R-loop formation was previously shown to occur on a plasmid DNA in the absence of DNA topoisomerase I. Together, these results allow us to propose that an important function of DNA topoisomerase I is to inhibit the formation of R-loops, which may otherwise translate into roadblocks for RNA polymerases. Our results also highlight the potential regulatory role of DNA supercoiling at the level of transcription elongation.	Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Drolet, M (corresponding author), Univ Montreal, Dept Microbiol & Immunol, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	Marc.Drolet@umontreal.ca	Drolet, Marc/M-1328-2019					AIBA H, 1981, J BIOL CHEM, V256, P1905; Aviv M, 1996, FEMS MICROBIOL LETT, V140, P71; CONDON C, 1995, J BACTERIOL, V177, P4152, DOI 10.1128/jb.177.14.4152-4156.1995; DINARDO S, 1982, CELL, V31, P43, DOI 10.1016/0092-8674(82)90403-2; Dorman Charles J., 1993, Trends in Microbiology, V1, P92, DOI 10.1016/0966-842X(93)90114-7; DORMAN CJ, 1989, MOL MICROBIOL, V3, P531, DOI 10.1111/j.1365-2958.1989.tb00199.x; DRLICA K, 1992, MOL MICROBIOL, V6, P425, DOI 10.1111/j.1365-2958.1992.tb01486.x; DRLICA K, 1984, MICROBIOL REV, V48, P273, DOI 10.1128/MMBR.48.4.273-289.1984; DROLET M, 1995, P NATL ACAD SCI USA, V92, P3526, DOI 10.1073/pnas.92.8.3526; DROLET M, 1994, J BIOL CHEM, V269, P2068; FRIEDMAN DI, 1976, VIROLOGY, V73, P119, DOI 10.1016/0042-6822(76)90066-0; GAFNY R, 1994, J MOL BIOL, V243, P152, DOI 10.1006/jmbi.1994.1641; Gourse RL, 1996, ANNU REV MICROBIOL, V50, P645, DOI 10.1146/annurev.micro.50.1.645; GRABCZYK E, 1995, J BIOL CHEM, V270, P1791, DOI 10.1074/jbc.270.4.1791; JINKSROBERTSON S, 1983, CELL, V33, P865, DOI 10.1016/0092-8674(83)90029-6; Kogoma T, 1997, MICROBIOL MOL BIOL R, V61, P212, DOI 10.1128/.61.2.212-238.1997; KROHN M, 1992, MOL MICROBIOL, V6, P581, DOI 10.1111/j.1365-2958.1992.tb01504.x; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; MASAI H, 1994, EMBO J, V13, P5338, DOI 10.1002/j.1460-2075.1994.tb06868.x; Masse E, 1999, J MOL BIOL, V294, P321, DOI 10.1006/jmbi.1999.3264; Masse E, 1999, J BIOL CHEM, V274, P16659, DOI 10.1074/jbc.274.23.16659; Masse E, 1999, J BIOL CHEM, V274, P16654, DOI 10.1074/jbc.274.23.16654; Masse E, 1997, J BIOL CHEM, V272, P12816, DOI 10.1074/jbc.272.19.12816; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; Phoenix P, 1997, J BIOL CHEM, V272, P1473, DOI 10.1074/jbc.272.3.1473; PRUSS GJ, 1982, CELL, V31, P35, DOI 10.1016/0092-8674(82)90402-0; Qi HY, 1997, J MOL BIOL, V267, P481, DOI 10.1006/jmbi.1997.0901; Qi HY, 1996, MOL MICROBIOL, V21, P703, DOI 10.1046/j.1365-2958.1996.241390.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SARMIENTOS P, 1983, CELL, V32, P1337, DOI 10.1016/0092-8674(83)90314-8; SHARROCK RA, 1985, P NATL ACAD SCI USA, V82, P5275, DOI 10.1073/pnas.82.16.5275; SINGER M, 1989, MICROBIOL REV, V53, P1; SRIVASTAVA AK, 1990, ANNU REV MICROBIOL, V44, P105, DOI 10.1146/annurev.mi.44.100190.000541; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8	37	55	56	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11257	11263		10.1074/jbc.275.15.11257	http://dx.doi.org/10.1074/jbc.275.15.11257			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753935	hybrid			2022-12-27	WOS:000086466600077
J	Hsu, AL; Ching, TT; Wang, DS; Song, XQ; Rangnekar, VM; Chen, CS				Hsu, AL; Ching, TT; Wang, DS; Song, XQ; Rangnekar, VM; Chen, CS			The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; HUMAN COLORECTAL-CANCER; HUMAN COLON-CANCER; EPITHELIAL-CELLS; BREAST-CANCER; ASPIRIN USE; PHOSPHATIDYLINOSITOL 3-KINASE; CARCINOMA-CELLS; EXPRESSION; PROTEIN	This study investigates the apoptotic activity of the cyclooxygenase-2 (COX-2) inhibitor celecoxib in prostate carcinoma cells. COX-2 is constitutively expressed in androgen-responsive LNCaP and androgen-nonresponsive PC-3 cells. Exposure of these cells to celecoxib induces characteristic features of apoptosis, including morphological changes, DNA laddering, and caspase-3 activation, whereas piroxicam, a COX-1-specific inhibitor, displays no appreciable effect on either cancer cell line even after prolonged exposure. Moreover, the potency of celecoxib in apoptosis induction is significantly higher than that of other COX-2 inhibitors examined despite the observation that these inhibitors exhibit similar IC50 in COX-2 inhibition. It is noteworthy that normal human prostate epithelial cells, expressing a marginally detectable level of COX-2, are insensitive to the induction of apoptosis by celecoxib, These data suggest a correlation between COX-2 expression and sensitivity to the apoptotic effect of the COX-2 inhibitor. In an effort to delineate the underlying mechanism, we examined the effect of celecoxib on the expression of Bcl-2 as well as the activation of the key anti-apoptotic kinase Akt. In contrast to an earlier report that attributed the apoptotic activity of NS398 in LNCaP cells to Bcl-2 down-regulation, we provide evidence that the induction of apoptosis by celecoxib in LNCaP and PC-3 cells is independent of Bcl-2. First, treatment with celecoxib does not alter the cellular Bcl-2 level in both cell lines. Second, enforced Bcl-2 expression in PC-3 cells does not confer protection against the induction of apoptosis by celecoxib. Our data show that celecoxib treatment blocks the phosphorylation of Akt, This correlation is supported by studies showing that overexpression of constitutively active Akt protects PC-3 cells from celecoxib-induced apoptosis. Nevertheless, how celecoxib down-regulates Akt is not clear because the drug does not adversely affect phosphoinositide 3-kinase activity in vivo and okadaic acid, a protein phosphatase 2A inhibitor, cannot rescue the inhibition, In summary, our data demonstrate that inhibition of Akt activation may play a crucial role in the induction of apoptosis by celecoxib.	Univ Kentucky, Coll Pharm, Div Pharmaceut Sci, Lexington, KY 40536 USA; Univ Kentucky, Dept Surg, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Chen, CS (corresponding author), Univ Kentucky, ASTeCC Facil, Rm 323B, Lexington, KY 40506 USA.	cchenl@pop.uky.edu	Hsu, Ao-Lin Allen/AAX-1856-2020	Hsu, Ao-Lin/0000-0002-2864-3134; Ching, Tsui-Ting/0000-0001-7650-1766	NCI NIH HHS [CA60872] Funding Source: Medline; NIGMS NIH HHS [GM53448] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060872] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053448] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOSLAND MC, 1997, ENCY CANC, V2, P1283; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; COLOMBEL M, 1993, AM J PATHOL, V143, P390; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Erickson BA, 1999, J SURG RES, V81, P101, DOI 10.1006/jsre.1998.5511; Fischer Susan M., 1997, Frontiers in Bioscience, V2, pD482; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Hara A, 1997, JPN J CANCER RES, V88, P600; Harris RE, 1996, EPIDEMIOLOGY, V7, P203, DOI 10.1097/00001648-199603000-00017; Herrmann JL, 1997, EXP CELL RES, V234, P442, DOI 10.1006/excr.1997.3653; Hwang D, 1998, J NATL CANCER I, V90, P455, DOI 10.1093/jnci/90.6.455; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Lavie Y, 1996, J NEUROCHEM, V67, P1245; Liu XH, 1998, CANCER RES, V58, P4245; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; McDonnell TJ, 1997, J UROLOGY, V157, P569, DOI 10.1016/S0022-5347(01)65204-2; Narko K, 1997, J BIOL CHEM, V272, P21455, DOI 10.1074/jbc.272.34.21455; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PIAZZA GA, 1995, CANCER RES, V55, P3110; Qiu GF, 1999, ONCOGENE, V18, P623, DOI 10.1038/sj.onc.1202344; SANO H, 1995, CANCER RES, V55, P3785; Sawaoka H, 1998, AM J PHYSIOL-GASTR L, V274, pG1061, DOI 10.1152/ajpgi.1998.274.6.G1061; SCHREINEMACHERS DM, 1994, EPIDEMIOLOGY, V5, P138, DOI 10.1097/00001648-199403000-00003; Sheng GG, 1997, GASTROENTEROLOGY, V113, P1883, DOI 10.1016/S0016-5085(97)70007-6; Sheng HM, 1998, CANCER RES, V58, P362; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Subbaramaiah K, 1996, CANCER RES, V56, P4424; Taketo MM, 1998, INFLAMM RES, V47, pS112; Taketo MM, 1998, JNCI-J NATL CANCER I, V90, P1609, DOI 10.1093/jnci/90.21.1609; Taketo MM, 1998, J NATL CANCER I, V90, P1529, DOI 10.1093/jnci/90.20.1529; Thompson HJ, 1997, CANCER RES, V57, P267; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; THUN MJ, 1993, CANCER RES, V53, P1322; Tjandrawinata RR, 1997, BRIT J CANCER, V75, P1111, DOI 10.1038/bjc.1997.192; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568; Ziegler J, 1998, J NATL CANCER I, V90, P802, DOI 10.1093/jnci/90.11.802; Zimmermann KC, 1999, CANCER RES, V59, P198; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	48	599	631	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11397	11403		10.1074/jbc.275.15.11397	http://dx.doi.org/10.1074/jbc.275.15.11397			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753955	hybrid			2022-12-27	WOS:000086466600097
J	Jackman, JE; Fierke, CA; Tumey, LN; Pirrung, M; Uchiyama, T; Tahir, SH; Hindsgaul, O; Raetz, CRH				Jackman, JE; Fierke, CA; Tumey, LN; Pirrung, M; Uchiyama, T; Tahir, SH; Hindsgaul, O; Raetz, CRH			Antibacterial agents that target lipid A biosynthesis in Gram-negative bacteria - Inhibition of diverse UDP-3-O-(R-3-hydroxymyristoyl)-N-acetyglucosamine deacetylases by substrate analogs containing zinc binding motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI ENCODES; UDP-N-ACETYLGLUCOSAMINE; A BIOSYNTHESIS; ENDOTOXIN BIOSYNTHESIS; 1ST STEP; THERMOLYSIN; GENE; ACYLTRANSFERASE; INACTIVATION; PRECURSORS	UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) catalyzes the second step in the biosynthesis of lipid A, a unique amphiphilic molecule found in the outer membranes of virtually all Gramnegative bacteria. Since lipid A biosynthesis is required for bacterial growth, inhibitors of LpxC have potential utility as antibiotics. The enzymes of lipid A biosynthesis, including LpxC, are encoded by single copy genes in all sequenced Gram-negative genomes, We have now cloned, overexpressed, and purified LpxC from the hyperthermophile Aquifex aeolicus. This heat-stable LpxC variant (the most divergent of all known LpxCs) displays 32% identity and 51% similarity over 277 amino acid residues out of the 305 in Escherichia coli LpxC, Although A. aeolicus LpxC deacetylates the substrate UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine at a rate comparable with E, coli LpxC, a phenyloxazoline-based hydroxamate that inhibits E, coli LpxC with K-i of similar to 50 nM (Onishi, H, R,, Pelak, B, A, Gerckens, L, S,, Silver, L. L,, Kahan, F. M,, Chen, M, H,, Patchett, A. A., Galloway, S, M,, Hyland, S, A, Anderson, M, S,, and Raetz, C, R, H, (1996) Science 274, 980-982) does not inhibit A. aeolicus LpxC, To determine whether or not broad-spectrum deacetylase inhibitors can be found, we have designed a new class of hydroxamate-containing inhibitors of LpxC, starting with the structure of the physiological substrate. Several of these compounds inhibit both E, coli and A. aeolicus LpxC at similar concentrations. We have also identified a phosphinate-containing substrate analog that inhibits both E. coli and A. aeolicus LpxC, suggesting that the LpxC reaction proceeds by a mechanism similar to that described for other zinc metalloamidases, like carboxypeptidase A and thermolysin, The differences between the phenyloxazoline and the substrate-based LpxC inhibitors might be exploited for developing novel antibiotics targeted either against some or all Gram-negative strains. We suggest that LpxC inhibitors with antibacterial activity be termed "deacetylins."	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Chem, Durham, NC 27710 USA; Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada	Duke University; Duke University; University of Alberta	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	Raetz@biochem.duke.edu	Jackman, Jane/G-7167-2012; jackman, jane/AAE-1854-2022	jackman, jane/0000-0001-9291-8852	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310, R29GM040602, R01GM040602] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 42141] Funding Source: Medline; NIGMS NIH HHS [GM51310, GM40602] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERSON MS, 1985, J BIOL CHEM, V260, P5536; ANDERSON MS, 1988, BIOCHEMISTRY-US, V27, P1908, DOI 10.1021/bi00406a017; ANDERSON MS, 1993, J BIOL CHEM, V268, P19858; ANDERSON MS, 1987, J BIOL CHEM, V262, P5159; BARTLETT PA, 1983, BIOCHEMISTRY-US, V22, P4618, DOI 10.1021/bi00289a002; BELUNIS CJ, 1995, J BIOL CHEM, V270, P27646, DOI 10.1074/jbc.270.46.27646; Brock TD, 1994, BIOL MICROORGANISMS; Chen MH, 1999, BIOORG MED CHEM LETT, V9, P313, DOI 10.1016/S0960-894X(98)00749-5; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; de Cock H, 1999, J BIOL CHEM, V274, P5114, DOI 10.1074/jbc.274.8.5114; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; FERSHT A, 1985, ENZYME STRUCTURE MEC, P150; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; Garrett TA, 1998, J BIOL CHEM, V273, P12457, DOI 10.1074/jbc.273.20.12457; HANSON JE, 1989, BIOCHEMISTRY-US, V28, P6294, DOI 10.1021/bi00441a022; HARRIS RB, 1983, BIOCHEM BIOPH RES CO, V116, P394, DOI 10.1016/0006-291X(83)90535-1; HOLDEN HM, 1987, BIOCHEMISTRY-US, V26, P8542, DOI 10.1021/bi00400a008; HOLMES MA, 1981, BIOCHEMISTRY-US, V20, P6912, DOI 10.1021/bi00527a026; Hyland SA, 1997, J BACTERIOL, V179, P2029, DOI 10.1128/jb.179.6.2029-2037.1997; Jackman JE, 1999, BIOCHEMISTRY-US, V38, P1902, DOI 10.1021/bi982339s; KELLY TM, 1993, J BIOL CHEM, V268, P19866; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; Miller J.H., 1972, EXPT MOL GENETICS; NAIR SK, 1991, J BIOL CHEM, V266, P17320; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; Patchett A A, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P1; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Wyckoff TJO, 1998, TRENDS MICROBIOL, V6, P154, DOI 10.1016/S0966-842X(98)01230-X; Young K, 1995, J BIOL CHEM, V270, P30384, DOI 10.1074/jbc.270.51.30384; Zahringer U, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P93; 1998, Patent No. 60089679	39	142	153	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11002	11009		10.1074/jbc.275.15.11002	http://dx.doi.org/10.1074/jbc.275.15.11002			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753902	hybrid			2022-12-27	WOS:000086466600044
J	Urano, J; Tabancay, AP; Yang, WL; Tamanoi, F				Urano, J; Tabancay, AP; Yang, WL; Tamanoi, F			The Saccharomyces cerevisiae Rheb G-protein is involved in regulating canavanine resistance and arginine uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS-RELATED PROTEIN; SIGNALING PATHWAY; CELL POLARITY; YEAST-CELLS; GENE; PERMEASE; BINDING; GTPASE; FAMILY; CLONING	The new member of the Ras superfamily of G-proteins, Rheb, has been identified in rat and human, but its function has not been defined. We report here the identification of Rheb homologues in the budding yeast Saccharomyces cerevisiae (ScRheb) as well as in Schizosaccharomyces pombe, Drosophila melanogaster, zebrafish, and Ciona intestinalis, These proteins define a new class of G-proteins based on 1) their overall sequence similarity, 2) high conservation of their effector domain sequence, 3) presence of a unique arginine in their G1 box, and 4) presence of a conserved CAAX farnesylation motif. Characterization of an S. cerevisiae strain deficient in ScRheb showed that it is hypersensitive to growth inhibitory effects of canavanine and thialysine, which are analogues of arginine and lysine, respectively. Accordingly, the uptake of arginine and lysine was increased in the ScRheb-deficient strain. This increased arginine uptake requires the arginine-specific permease Can1p. The function of ScRheb is dependent on having an intact effector domain since mutations in the effector domain of ScRheb are incapable of complementing canavanine hypersensitivity of scrheb disruptant cells. Furthermore, the conserved arginine in the G1 box plays a role in the activity of ScRheb, as a mutation of this arginine to glycine significantly reduced the ability of ScRheb to complement canavanine hypersensitivity of ScRheb-deficient yeast. Finally, a mutation in the C-terminal CAAX farnesylation motif resulted in a loss of ScRheb function. This result, in combination with our finding that ScRheb is farnesylated, suggests that farnesylation plays a key role in ScRheb function. Our findings assign the regulation of arginine and lysine uptake as the first physiological function for this new farnesylated Ras superfamily G-protein.	Univ Calif Los Angeles, Inst Mol Biol, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Tamanoi, F (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Dept Microbiol & Mol Genet, 609 Charles E Young Dr E, Los Angeles, CA 90095 USA.	fuyut@microbio.ucla.edu			NCI NIH HHS [CA41996] Funding Source: Medline; NIGMS NIH HHS [GM07185] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041996] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMAD M, 1988, MOL MICROBIOL, V2, P627, DOI 10.1111/j.1365-2958.1988.tb00071.x; AHMAD M, 1986, CURR GENET, V10, P587, DOI 10.1007/BF00418125; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bianchi MM, 1999, YEAST, V15, P513, DOI 10.1002/(SICI)1097-0061(199904)15:6<513::AID-YEA370>3.3.CO;2-G; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chervitz SA, 1999, NUCLEIC ACIDS RES, V27, P74, DOI 10.1093/nar/27.1.74; Clark GJ, 1997, J BIOL CHEM, V272, P10608; COHEN L, 1994, P NATL ACAD SCI USA, V91, P12448, DOI 10.1073/pnas.91.26.12448; DAVIS RH, 1986, MICROBIOL REV, V50, P280, DOI 10.1128/MMBR.50.3.280-313.1986; DelVillar K, 1997, J BIOL CHEM, V272, P680; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Durrant I, 1994, Methods Mol Biol, V31, P147; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FINEGOLD AA, 1990, SCIENCE, V249, P165, DOI 10.1126/science.1695391; Finlin BS, 1997, J BIOL CHEM, V272, P21982, DOI 10.1074/jbc.272.35.21982; Foster R, 1996, MOL CELL BIOL, V16, P2689; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GRENSON M, 1966, BIOCHIM BIOPHYS ACTA, V127, P325, DOI 10.1016/0304-4165(66)90387-4; GRENSON M, 1970, J BACTERIOL, V103, P770, DOI 10.1128/JB.103.3.770-777.1970; GRENSON M, 1966, BIOCHIM BIOPHYS ACTA, V127, P339, DOI 10.1016/0304-4165(66)90388-6; Gromov PS, 1995, FEBS LETT, V377, P221, DOI 10.1016/0014-5793(95)01349-0; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hampsey M, 1997, YEAST, V13, P1099, DOI 10.1002/(SICI)1097-0061(19970930)13:12<1099::AID-YEA177>3.3.CO;2-Z; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Hodges PE, 1999, NUCLEIC ACIDS RES, V27, P69, DOI 10.1093/nar/27.1.69; JOHNSON DI, 1990, GENE, V90, P93, DOI 10.1016/0378-1119(90)90443-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee CHJ, 1996, J NEUROSCI, V16, P6784; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; Mizuki N, 1996, GENOMICS, V34, P114, DOI 10.1006/geno.1996.0248; Moore MS, 1998, J BIOL CHEM, V273, P22857, DOI 10.1074/jbc.273.36.22857; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Murphy MP, 1999, BBA-BIOENERGETICS, V1411, P401, DOI 10.1016/S0005-2728(99)00029-8; NAKAYAMA N, 1988, MOL CELL BIOL, V8, P5410, DOI 10.1128/MCB.8.12.5410; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; OMER CA, 1994, MOL MICROBIOL, V11, P219, DOI 10.1111/j.1365-2958.1994.tb00302.x; Opekarova M, 1998, YEAST, V14, P215, DOI 10.1002/(SICI)1097-0061(199802)14:3<215::AID-YEA214>3.0.CO;2-3; Palkova Z, 1997, NATURE, V390, P532, DOI 10.1038/37398; Park HO, 1997, P NATL ACAD SCI USA, V94, P4463, DOI 10.1073/pnas.94.9.4463; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; Robinson NCG, 1999, MOL CELL BIOL, V19, P3580; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATTLER I, 1996, REGULATION RAS SIGNA, P95; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; Svetlov VV, 1995, YEAST, V11, P1439, DOI 10.1002/yea.320111502; SYCHROVA H, 1992, CURR GENET, V21, P351, DOI 10.1007/BF00351694; SYCHROVA H, 1993, YEAST, V9, P771, DOI 10.1002/yea.320090711; TABOR CW, 1985, MICROBIOL REV, V49, P81, DOI 10.1128/MMBR.49.1.81-99.1985; TAMANOI F, 1988, J CELL BIOCHEM, V36, P261, DOI 10.1002/jcb.240360307; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; Urano J, 1999, METH MOL B, V116, P145; URANO J, 1999, THESIS U CALIFORNIA; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Wang H, 1996, ANAL BIOCHEM, V237, P145, DOI 10.1006/abio.1996.0213; Wes PD, 1996, EMBO J, V15, P5839, DOI 10.1002/j.1460-2075.1996.tb00971.x; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; Yee WM, 1997, MOL CELL BIOL, V17, P921, DOI 10.1128/MCB.17.2.921; YOSHIDA Y, 1991, BIOCHEM BIOPH RES CO, V175, P720, DOI 10.1016/0006-291X(91)91625-M; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	69	97	103	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11198	11206		10.1074/jbc.275.15.11198	http://dx.doi.org/10.1074/jbc.275.15.11198			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753927	hybrid			2022-12-27	WOS:000086466600069
J	Zondag, GCM; Reynolds, AB; Moolenaar, WH				Zondag, GCM; Reynolds, AB; Moolenaar, WH			Receptor protein-tyrosine phosphatase RPTP mu binds to and dephosphorylates the catenin p120(ctn)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-CADHERIN; KINASE SUBSTRATE; BETA-CATENIN; PTP-MU; MOLECULAR-CLONING; GENE-PRODUCT; MAM DOMAIN; IN-VIVO; PHOSPHORYLATION; ASSOCIATION	RPTP mu is a prototypic receptor-like protein-tyrosine phosphatase (RPTP) that mediates homotypic cell-cell interactions. Intracellularly, RPTP mu consists of a relatively large juxtamembrane region and two phosphatase domains, but little is still known about its substrate(s). Here we show that RPTP mu associates with the catenin p120(ctn), a tyrosine kinase substrate and an interacting partner of cadherins, No interaction is detectable between RPTP mu and beta-catenin, Furthermore, we show that tyrosine-phosphorylated p120(ctn) is dephosphorylated by RPTP mu both in vitro and in intact cells. Complex formation between RPTP mu and p120(ctn) does not require tyrosine phosphorylation of p120(ctn), Mutational analysis reveals that both the juxtamembrane region and the second phosphatase domain of RPTP mu are involved in p120(ctn) binding. The RPTP mu-interacting domain of p120(ctn) maps to its unique N terminus, a region distinct from the cadherin-interacting domain. A mutant form of p120(ctn) that fails to bind cadherins can still associate with RPTP mu. Our findings indicate that RPTP mu interacts with p120(ctn) independently of cadherins, and they suggest that this interaction may serve to control the tyrosine phosphorylation state of p120(ctn) at sites of cellcell contact.	Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA	Netherlands Cancer Institute; Vanderbilt University	Moolenaar, WH (corresponding author), Netherlands Canc Inst, Div Cellular Biochem, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.							AGHIB DF, 1995, EXP CELL RES, V218, P359, DOI 10.1006/excr.1995.1167; Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; BECKMANN G, 1993, TRENDS BIOCHEM SCI, V18, P40, DOI 10.1016/0968-0004(93)90049-S; Brady-Kalnay SM, 1998, J CELL BIOL, V141, P287, DOI 10.1083/jcb.141.1.287; BRADYKALNAY SM, 1995, CURR OPIN CELL BIOL, V7, P650, DOI 10.1016/0955-0674(95)80106-5; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Cheng J, 1997, J BIOL CHEM, V272, P7264, DOI 10.1074/jbc.272.11.7264; Crossland S, 1996, BIOCHEM J, V319, P249, DOI 10.1042/bj3190249; DANIEL JM, 1995, MOL CELL BIOL, V15, P4819; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; DOWNING JR, 1991, ONCOGENE, V6, P607; Fuchs M, 1996, J BIOL CHEM, V271, P16712, DOI 10.1074/jbc.271.28.16712; GEBBINK MFBG, 1993, BIOCHEMISTRY-US, V32, P13516, DOI 10.1021/bi00212a017; GEBBINK MFBG, 1995, J CELL BIOL, V131, P251, DOI 10.1083/jcb.131.1.251; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; Keirsebilck A, 1998, GENOMICS, V50, P129, DOI 10.1006/geno.1998.5325; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; Lampugnani MG, 1997, J CELL SCI, V110, P2065; Mo YY, 1996, CANCER RES, V56, P2633; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; Reynolds AB, 1996, EXP CELL RES, V225, P328, DOI 10.1006/excr.1996.0183; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; SHIBATA T, 1994, BIOCHEM BIOPH RES CO, V203, P519, DOI 10.1006/bbrc.1994.2213; STADDON JM, 1995, J CELL BIOL, V130, P369, DOI 10.1083/jcb.130.2.369; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; Wang HY, 1996, ONCOGENE, V12, P2555; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779; Zondag GCM, 1996, J CELL BIOL, V134, P1513, DOI 10.1083/jcb.134.6.1513; Zondag GCM, 1997, BIOCHIMIE, V79, P477, DOI 10.1016/S0300-9084(97)82739-3; ZONDAG GCM, 1995, J BIOL CHEM, V270, P14247, DOI 10.1074/jbc.270.24.14247	41	102	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11264	11269		10.1074/jbc.275.15.11264	http://dx.doi.org/10.1074/jbc.275.15.11264			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753936	hybrid			2022-12-27	WOS:000086466600078
J	Burner, U; Furtmuller, PG; Kettle, AJ; Koppenol, WH; Obinger, C				Burner, U; Furtmuller, PG; Kettle, AJ; Koppenol, WH; Obinger, C			Mechanism of reaction of myeloperoxidase with nitrite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNOVIAL-FLUID; COMPOUND-II; OXIDE; NEUTROPHILS; OXIDATION; KINETICS; SERUM; CHLORINATION; SUPEROXIDE; ACID	Myeloperoxidase (MPO) is a major neutrophil protein and may be involved in the nitration of tyrosine residues observed in a wide range of inflammatory diseases that involve neutrophils and macrophage activation. In order to clarify if nitrite could be a physiological substrate of myeloperoxidase, we investigated the reactions of the ferric enzyme and its redox intermediates, compound I and compound II, with nitrite under pre-steady state conditions by using sequential mixing stopped-flow analysis in the pH range 4-8, At 15 degrees C the rate of formation of the low spin MPO-nitrite complex is (2.5 +/- 0.2) x 10(4) M-1 s(-1) at pH: 7 and (2.2 +/- 0.7) x 10(6) M-1 s(-1) at pH 5, The dissociation constant of nitrite bound to the native enzyme is 2.3 +/- 0.1 mM at pH 7 and 31.3 +/- 0.5 mu M at pH 5, Nitrite is oxidized by two one-electron steps in the MPO peroxidase cycle. The second-order rate constant of reduction of compound I to compound II at 15 degrees C is (2.0 +/- 0.2) x 10(6) M-1 s(-1) at pH 7 and (1.1 +/- 0.2) x 10(7) M-1 s(-1) at pH 5. The rate constant of reduction of compound II to the ferric native enzyme at 15 degrees C is (5.5 +/- 0.1) x 10(2) M-1 s(-1) at pH 7 and (8.9 +/- 1.6) x 10(4) M-1 s(-1) at pH 5. pH dependence studies suggest that both complex formation between the ferric enzyme and nitrite and nitrite oxidation by compounds I and II are controlled by a residue with a pK(a) of (4.3 +/- 0.3). Protonation of this group (which is most likely the distal histidine) is necessary for optimum nitrite binding and oxidation.	Univ Agr Sci, Inst Chem, A-1190 Vienna, Austria; Christchurch Sch Med, Dept Pathol, Free Radical Res Grp, Christchurch, New Zealand; Swiss Fed Inst Technol, Inst Inorgan Chem, CH-8092 Zurich, Switzerland	University of Natural Resources & Life Sciences, Vienna; University of Otago; Swiss Federal Institutes of Technology Domain; ETH Zurich	Obinger, C (corresponding author), Univ Agr Sci, Inst Chem, Muthgasse 18, A-1190 Vienna, Austria.	cobinger@edv2.boku.ac.at	Furtmüller, Paul G./Y-5819-2018; Kettle, Anthony J/A-8520-2008; Koppenol, Willem Hendrik/H-2991-2013; Obinger, Christian/AAV-3173-2021	Furtmüller, Paul G./0000-0002-1199-2469; Kettle, Anthony J/0000-0002-8218-7766; Koppenol, Willem Hendrik/0000-0002-1620-6594; Obinger, Christian/0000-0002-7133-3430				Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Burner U, 1999, J BIOL CHEM, V274, P9494, DOI 10.1074/jbc.274.14.9494; Burner U, 1999, FEBS LETT, V443, P290, DOI 10.1016/S0014-5793(98)01727-X; COOPER CE, 1992, FEBS LETT, V314, P58, DOI 10.1016/0014-5793(92)81461-T; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; EVANS T, 1966, P NATL ACAD SCI USA, V93, P9553; FARRELL AJ, 1992, ANN RHEUM DIS, V51, P1219, DOI 10.1136/ard.51.11.1219; Furtmuller PG, 1998, BIOCHEMISTRY-US, V37, P17923, DOI 10.1021/bi9818772; Hampton MB, 1996, INFECT IMMUN, V64, P3512, DOI 10.1128/IAI.64.9.3512-3517.1996; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; Herold S, 1999, FEBS LETT, V443, P80, DOI 10.1016/S0014-5793(98)01591-9; HUIE RE, 1994, TOXICOLOGY, V89, P193, DOI 10.1016/0300-483X(94)90098-1; IKEDASAITO M, 1985, J BIOL CHEM, V260, P1688; Jiang Q, 1997, J BIOL CHEM, V272, P32767, DOI 10.1074/jbc.272.52.32767; KAUR H, 1994, FEBS LETT, V350, P9, DOI 10.1016/0014-5793(94)00722-5; KETTLE AJ, 1988, BIOCHIM BIOPHYS ACTA, V957, P185, DOI 10.1016/0167-4838(88)90271-3; KETTLE AJ, 1994, METHOD ENZYMOL, V233, P502; Klebanoff S. J, 1991, PEROXIDASES CHEM BIO, V1, P1; Klebanoff SJ., 1988, INFLAMMATION BASIC P, P391; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; MARQUEZ LA, 1990, J BIOL CHEM, V265, P5666; Marquez LA, 1995, J BIOL CHEM, V270, P30434, DOI 10.1074/jbc.270.51.30434; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Podrez EA, 1999, J CLIN INVEST, V103, P1547, DOI 10.1172/JCI5549; Sampson JB, 1998, ARCH BIOCHEM BIOPHYS, V356, P207, DOI 10.1006/abbi.1998.0772; Stanbury D. M., 1989, ADV INORG CHEM RA, V33, P69, DOI 10.1016/S0898-8838(08)60194-4; Torre D, 1996, J CLIN PATHOL, V49, P574, DOI 10.1136/jcp.49.7.574; van Dalen CJ, 2000, J BIOL CHEM, V275, P11638, DOI 10.1074/jbc.275.16.11638; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617	30	196	197	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20597	20601		10.1074/jbc.M000181200	http://dx.doi.org/10.1074/jbc.M000181200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10777476	hybrid			2022-12-27	WOS:000088084500054
J	Armah, DA; Mensa-Wilmot, K				Armah, DA; Mensa-Wilmot, K			Tetramerization of glycosylphosphatidylinositol-specific phospholipase C from Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; PURIFICATION; LOCALIZATION; PROTEINS; ANCHOR; CRUZI	Glycosylphosphatidylinositol-specific phospholipase C (GPI-PLC) is an integral membrane protein in the protozoan parasite Trypanosoma brucei, Enzyme activity appears to be suppressed in T, brucei, although the polypeptide is readily detectable. The basis for the apparent quiescence of GPI-PLC is not known. Protein oligomerization was investigated as a possible mechanism for post-translational regulation of GPI-PLC activity, An equilibrium between monomers, dimers, and tetramers of purified GPI-PLC was detected by molecular sieving and shown to be perturbed with specific detergents. Homotetramers dominated in Nonidet P-40, and dimers and monomers of GPI-PLC were the major species in 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate. The detergents were exploited as tools to study the effect of oligomerization on enzyme activity. Tetrameric GPI-PLC was 3.6-20-fold more active than the monomeric enzyme. Tetramer existence was confirmed by chemical cross-linking. In vivo cross-linking revealed the oligomeric state of GPI-PLC during latency and after enzyme activation. During quiescence, monomers were the predominant species in T, brucei, Assembly of tetrameric GPI-PLC occurred when parasites were subjected to conditions known to activate the enzyme. In Leishmania where heterologous expression of GPI-PLC causes a GPI deficiency, the enzyme existed as a tetramer, Hence, oligomerization of GPI-PLC is associated with high enzyme activity both in vivo and in vitro.	Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA	University System of Georgia; University of Georgia	Mensa-Wilmot, K (corresponding author), Univ Georgia, Dept Cellular Biol, 724 Biol Sci Bldg, Athens, GA 30602 USA.	mensawil@cb.uga.edu			NIAID NIH HHS [AI 33383] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033383, R29AI033383] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Armah DA, 1999, J BIOL CHEM, V274, P5931, DOI 10.1074/jbc.274.9.5931; BANGS JD, 1993, J CELL SCI, V105, P1101; BEST S, 1995, CURRENT PROTOCOL PRO; BLACK SJ, 1982, PARASITE IMMUNOL, V4, P233, DOI 10.1111/j.1365-3024.1982.tb00435.x; BULOW R, 1989, J CELL SCI, V93, P233; BULOW R, 1989, MOL BIOCHEM PARASIT, V32, P85, DOI 10.1016/0166-6851(89)90132-1; BULOW R, 1986, J BIOL CHEM, V261, P1918; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; DOERING TL, 1993, J BIOL CHEM, V268, P9215; FOX JA, 1986, J BIOL CHEM, V261, P5767; Garg N, 1997, INFECT IMMUN, V65, P4055, DOI 10.1128/IAI.65.10.4055-4060.1997; Garg N, 1997, J BIOL CHEM, V272, P12482, DOI 10.1074/jbc.272.19.12482; GRAB DJ, 1987, J CELL BIOL, V105, P737, DOI 10.1083/jcb.105.2.737; HERELD D, 1988, P NATL ACAD SCI USA, V85, P8914, DOI 10.1073/pnas.85.23.8914; HERELD D, 1986, J BIOL CHEM, V261, P3813; MENSAWILMOT K, 1994, J CELL BIOL, V124, P935, DOI 10.1083/jcb.124.6.935; MENSAWILMOT K, 1995, METHOD ENZYMOL, V250, P641; MENSAWILMOT K, 1992, MOL BIOCHEM PARASIT, V56, P311, DOI 10.1016/0166-6851(92)90180-R; MENSAWILMOT K, MOL BIOCH PARASITOL, V99, P103; MORRIS JC, 1995, J BIOL CHEM, V270, P2517, DOI 10.1074/jbc.270.6.2853; OCHATT CM, MOL BIOCH PARASITOL, V103, P35; Rashid MB, 1999, EUR J BIOCHEM, V264, P914, DOI 10.1046/j.1432-1327.1999.00690.x; SEYFANG A, 1990, J PROTOZOOL, V37, P546, DOI 10.1111/j.1550-7408.1990.tb01263.x; VIDUGIRIENE J, 1994, J CELL BIOL, V127, P333, DOI 10.1083/jcb.127.2.333; Webb H, 1997, J CELL BIOL, V139, P103, DOI 10.1083/jcb.139.1.103	25	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19334	19342		10.1074/jbc.M001798200	http://dx.doi.org/10.1074/jbc.M001798200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10764777	hybrid			2022-12-27	WOS:000087815900093
J	Hogan, DA; Smith, SR; Saari, EA; McCracken, J; Hausinger, RP				Hogan, DA; Smith, SR; Saari, EA; McCracken, J; Hausinger, RP			Site-directed mutagenesis of 2,4-dichlorophenoxyacetic acid/alpha-ketoglutarate dioxygenase - Identification of residues involved in metallocenter formation and substrate binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOPENICILLIN-N-SYNTHASE; ELECTRON-SPIN-ECHO; ASPARAGINYL BETA-HYDROXYLASE; HUMAN PROLYL 4-HYDROXYLASE; FERROUS ACTIVE-SITE; ALPHA-KETOGLUTARATE; ESCHERICHIA-COLI; DEPENDENT DIOXYGENASE; ENVELOPE MODULATION; HISTIDINE-RESIDUES	2,4-Dichlorophenoxyacetic acid (2,4-D)/alpha-ketoglutarate (alpha-KG) dioxygenase (TfdA) is an Fe(II)-dependent enzyme that catalyzes the first step in degradation of the herbicide 2,4-D, The active site structures of a small number of enzymes within the alpha-KG-dependent dioxygenase superfamily have been characterized and shown to have a similar HXDX50-70HX10RXS arrangement of residues that make up the binding sites for Fe(II) and alpha-KG. TfdA does not have obvious homology to the dioxygenases containing the above motif but is related in sequence to eight other enzymes in the superfamily that form a distinct consensus sequence (HX(D/E)X138-207 HX10R/K). Variants of TfdA were created to examine the roles of putative metal-binding residues and the functions of the other seven histidines in this protein. The H167A, H200A, H213A, H245A, and H262A forms of TfdA formed inclusion bodies when overproduced in Escherichia coli DH5 alpha; however, these proteins were soluble when fused to the maltose-binding protein (MBP). MBP-TfdA exhibited kinetic parameters similar to the native enzyme. The H8A and H235A variants were catalytically similar to wild-type TfdA. MBP-H213A and H216A TfdA have elevated K-m values for 2,4-D, and the former showed a decreased k(cat), suggesting these residues may affect substrate binding or catalysis, The H113A, D115A, MBP-H167A, MBP-H200A, MBP-H245A and MBP-H262A variants of TfdA were inactive. Gel filtration analysis revealed that the latter two proteins were highly aggregated. The remaining four inactive variants were examined in their Cu(II)-substituted forms by EPR and electron spin-echo envelope modulation (ESEEM) spectroscopic methods. Changes in EPR spectra upon addition of substrates indicated that copper was present at the active site in the H113A and D115A variants. ESEEM analysis revealed that two histidines are bound equatorially to the copper in the D115A and MBP-H167A TfdA variants. The experimental data and sequence analysis lead us to conclude that His-113, Asp-115, and His-262 are likely metal ligands in TfdA and that His-213 may aid in catalysis or binding of 2,4-D.	Michigan State Univ, Dept Microbiol, E Lansing, MI 48824 USA; Michigan State Univ, Ctr Microbial Ecol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Michigan State University; Michigan State University; Michigan State University; Michigan State University	Hausinger, RP (corresponding author), Michigan State Univ, Dept Microbiol, 160 Giltner Hall, E Lansing, MI 48824 USA.	Hausinge@pilot.msu.edu		Smith, Sheila/0000-0003-3805-981X; Hausinger, Robert/0000-0002-3643-2054	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054065, T32GM008350] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 54065, T32-GM08350] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BLACKWELL JR, 1991, FEBS LETT, V295, P10, DOI 10.1016/0014-5793(91)81372-F; Borovok I, 1996, BIOCHEMISTRY-US, V35, P1981, DOI 10.1021/bi951534t; Cosper NJ, 1999, J BIOL INORG CHEM, V4, P122, DOI 10.1007/s007750050295; DECAROLIS E, 1994, PHYTOCHEMISTRY, V36, P1093, DOI 10.1016/S0031-9422(00)89621-1; Eichhorn E, 1997, J BIOL CHEM, V272, P23031, DOI 10.1074/jbc.272.37.23031; FUKUMORI F, 1993, J BIOL CHEM, V268, P24311; FUKUMORI F, 1993, J BACTERIOL, V175, P2083, DOI 10.1128/JB.175.7.2083-2086.1993; HEDDEN P, 1992, BIOCHEM SOC T, V20, P373, DOI 10.1042/bst0200373; Hegg EL, 1999, BIOCHEMISTRY-US, V38, P16714, DOI 10.1021/bi991796l; Hegg EL, 1997, EUR J BIOCHEM, V250, P625, DOI 10.1111/j.1432-1033.1997.t01-1-00625.x; HOFFMAN BM, 1984, J MAGN RESON, V59, P110, DOI 10.1016/0022-2364(84)90287-7; Hogan DA, 1999, J BACTERIOL, V181, P5876, DOI 10.1128/JB.181.18.5876-5879.1999; HOGAN DA, 1999, THESIS MICHIGAN STAT; HURST GC, 1985, J AM CHEM SOC, V107, P7294, DOI 10.1021/ja00311a012; JIA S, 1994, P NATL ACAD SCI USA, V91, P7227, DOI 10.1073/pnas.91.15.7227; JIANG F, 1991, BIOCHEMISTRY-US, V30, P11437, DOI 10.1021/bi00112a010; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; Kreisberg-Zakarin R, 1999, ANTON LEEUW INT J G, V75, P33, DOI 10.1023/A:1001723202234; LAMBERG A, 1995, J BIOL CHEM, V270, P9926, DOI 10.1074/jbc.270.17.9926; LIN CP, 1985, J MAGN RESON, V65, P369, DOI 10.1016/0022-2364(85)90021-6; Lloyd MD, 1999, J MOL BIOL, V287, P943, DOI 10.1006/jmbi.1999.2594; Lukacin R, 1997, EUR J BIOCHEM, V249, P748, DOI 10.1111/j.1432-1033.1997.t01-2-00748.x; McCracken J, 1992, APPL MAGN RESON, V3, P305, DOI 10.1007/BF03166699; MCCRACKEN J, 1987, J AM CHEM SOC, V109, P4064, DOI 10.1021/ja00247a037; MCCRACKEN J, 1988, J AM CHEM SOC, V110, P1069, DOI 10.1021/ja00212a012; MCCRACKEN J, 1989, PULSED EPR NEW FIELD, P155; McGinnis K, 1996, BIOCHEMISTRY-US, V35, P3957, DOI 10.1021/bi951520n; MIMS WB, 1984, J MAGN RESON, V59, P291, DOI 10.1016/0022-2364(84)90174-4; MIMS WB, 1972, PHYS REV B-SOLID ST, V5, P2409, DOI 10.1103/PhysRevB.5.2409; MIMS WB, 1978, J CHEM PHYS, V69, P4921, DOI 10.1063/1.436479; Myllyharju J, 1997, EMBO J, V16, P1173, DOI 10.1093/emboj/16.6.1173; NIEHOLAS KB, 1997, EMB NEWS, V4, P14; Pavel EG, 1998, J AM CHEM SOC, V120, P743, DOI 10.1021/ja972408a; Pirskanen A, 1996, J BIOL CHEM, V271, P9398, DOI 10.1074/jbc.271.16.9398; Prescott AG, 1996, ANNU REV PLANT PHYS, V47, P245, DOI 10.1146/annurev.arplant.47.1.245; ROACH PL, 1995, NATURE, V375, P700, DOI 10.1038/375700a0; Roach PL, 1997, NATURE, V387, P827, DOI 10.1038/42990; ROTILIO G, 1971, BIOCHEMISTRY-US, V10, P616, DOI 10.1021/bi00780a011; Ryle MJ, 1999, BIOCHEMISTRY-US, V38, P15278, DOI 10.1021/bi9912746; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Valegard K, 1998, NATURE, V394, P805, DOI 10.1038/29575; Whiting AK, 1997, J AM CHEM SOC, V119, P3413, DOI 10.1021/ja964449x; Zhang ZH, 2000, NAT STRUCT BIOL, V7, P127	45	54	62	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12400	12409		10.1074/jbc.275.17.12400	http://dx.doi.org/10.1074/jbc.275.17.12400			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777523	hybrid			2022-12-27	WOS:000086762300007
J	Hammad, SM; Barth, JL; Knaak, C; Argraves, WS				Hammad, SM; Barth, JL; Knaak, C; Argraves, WS			Megalin acts in concert with cubilin to mediate endocytosis of high density lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; INTESTINAL COBALAMIN MALABSORPTION; FACTOR VITAMIN-B-12 RECEPTOR; CELL-SURFACE PROTEOGLYCANS; BRUSH-BORDER EXPRESSION; GLYCOPROTEIN-330; DEGRADATION; COMPLEX; INTERNALIZATION; IDENTIFICATION	Cubilin has recently been shown to function as an endocytic receptor for high density lipoproteins (HDL). The lack of apparent transmembrane and cytoplasmic domains in cubilin raises questions as to the means by which it can mediate endocytosis. Since cubilin has been reported to bind the endocytic receptor megalin, we explored the possibility that megalin acts in conjunction with cubilin to mediate HDL endocytosis. While megalin did not bind to HDL, delipidated HDL, or apoA-I, it was found to copurify with cubilin isolated by HDL-Sepharose affinity chromatography. Cubilin and megalin exhibited coincident patterns of mRNA expression in mouse tissues including the kidney, ileum, thymus, placenta, and yolk sac endoderm. The expression of both receptors in yolk sac endoderm-like cells was inducible by retinoic acid treatment but not by conditions of sterol depletion. Suppression of megalin activity or expression by treatment with either megalin antibodies or megalin antisense oligodeoxynucleotides resulted in inhibition of cubilin-mediated endocytosis of HDL. Furthermore, megalin antisense oligodeoxynucleotide treatment resulted in reduced cell surface expression of cubilin. These data demonstrate that megalin acts together with cubilin to mediate HDL endocytosis and further suggest that megalin may play a role in the intracellular trafficking of cubilin.	Med Univ S Carolina, Dept Anat & Cell Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Argraves, WS (corresponding author), Med Univ S Carolina, Dept Anat & Cell Biol, 171 Ashley Ave, Charleston, SC 29425 USA.			Hammad, Samar/0000-0002-1313-2542	NHLBI NIH HHS [HL07710] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aminoff M, 1999, NAT GENET, V21, P309, DOI 10.1038/6831; Barth JL, 1998, MATRIX BIOL, V17, P635, DOI 10.1016/S0945-053X(98)90114-7; Batuman V, 1998, AM J PHYSIOL-RENAL, V275, pF246, DOI 10.1152/ajprenal.1998.275.2.F246; FYFE JC, 1991, J BIOL CHEM, V266, P4489; FYFE JC, 1991, PEDIATR RES, V29, P24, DOI 10.1203/00006450-199101000-00006; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; Hammad SM, 1997, J BIOL CHEM, V272, P18644, DOI 10.1074/jbc.272.30.18644; Hammad SM, 1999, P NATL ACAD SCI USA, V96, P10158, DOI 10.1073/pnas.96.18.10158; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; Kounnas M Z, 1994, In Vivo, V8, P343; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P14176; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; KOUNNAS MZ, 1994, ANN NY ACAD SCI, V737, P114, DOI 10.1111/j.1749-6632.1994.tb44305.x; Kozyraki R, 1999, NAT MED, V5, P656, DOI 10.1038/9504; Kozyraki R, 1998, BLOOD, V91, P3593; Kristiansen M, 1999, J BIOL CHEM, V274, P20540, DOI 10.1074/jbc.274.29.20540; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; Moestrup SK, 1998, J BIOL CHEM, V273, P5235, DOI 10.1074/jbc.273.9.5235; Nohturfft A, 1998, P NATL ACAD SCI USA, V95, P12848, DOI 10.1073/pnas.95.22.12848; Oram J F, 1986, Methods Enzymol, V129, P645; OSBORNE JC, 1986, METHOD ENZYMOL, V128, P213; STEFANSSON S, 1995, J BIOL CHEM, V270, P19417, DOI 10.1074/jbc.270.33.19417; STEFANSSON S, 1995, J CELL SCI, V108, P2361; Xu DB, 1999, BLOOD, V94, P3604, DOI 10.1182/blood.V94.10.3604.422k22_3604_3606	25	120	130	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12003	12008		10.1074/jbc.275.16.12003	http://dx.doi.org/10.1074/jbc.275.16.12003			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766831	hybrid			2022-12-27	WOS:000086695500066
J	Huang, CF; Wang, YC; Tsao, DA; Tung, SF; Lin, YS; Wu, CW				Huang, CF; Wang, YC; Tsao, DA; Tung, SF; Lin, YS; Wu, CW			Antagonism between members of the CNC-bZIP family and the immediate-early protein IE2 of human cytomegalovirus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; SMALL MAF PROTEINS; RNA-POLYMERASE-II; TRANSCRIPTION FACTOR; DNA-BINDING; GENE-PRODUCTS; FUNCTIONAL INTERACTION; LEUCINE-ZIPPER; EARLY PROMOTER; FACTOR NF-E2	The HCMV IE2 protein negatively autoregulates its own expression as well as represses the transactivation activity of p53. Using the repression domain of IE2 as bait in the yeast two-hybrid system, Nrf1 and Nrf2, members of the CNC-bZIP family, were found to be IES-interacting proteins. Residues 331-448 encompassing the DNA-binding and the dimerization domains of Nrf1 are sufficient for the interaction. The interaction was further confirmed in vitro by a glutathione S-transferase pull-down assay and in vivo by co-immunoprecipitation. In transient transfection studies, transcription driven by six copies of an NF-E2 site or by chimeric proteins between the DNA-binding domain of LexA and members of the CNC-bZIP family is repressed by IE2, Importantly, the DNA binding activity of the Nrf1/MafK heterodimer is not impeded by IE2. In a parallel study, CNC-bZIP factors attenuate the negative autoregulation of IE2, The attenuation could be explained by the finding that Nrf1 functions alone and synergistically with its heterodimerization partner, MafK, in inhibiting the DNA binding activity of IE2, Taken together, these results demonstrate the existence of antagonism between members of the CNC-bZIP family and IE2.	Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei 100, Taiwan	Academia Sinica - Taiwan; National Defense Medical Center	Lin, YS (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan.	bmyslin@ccvax.sinica.edu.tw						Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CASWELL R, 1993, J GEN VIROL, V74, P2691, DOI 10.1099/0022-1317-74-12-2691; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; Chan JY, 1998, EMBO J, V17, P1779, DOI 10.1093/emboj/17.6.1779; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11366, DOI 10.1073/pnas.90.23.11366; Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; CHUANG JY, 1995, J BIOL CHEM, V270, P23899, DOI 10.1074/jbc.270.41.23899; Davie JR, 1998, J CELL BIOCHEM, P203; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Farmer SC, 1997, GENE DEV, V11, P786, DOI 10.1101/gad.11.6.786; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; HAGEMEIER C, 1994, EMBO J, V13, P2897, DOI 10.1002/j.1460-2075.1994.tb06584.x; HAGEMEIER C, 1992, J GEN VIROL, V73, P2385, DOI 10.1099/0022-1317-73-9-2385; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HSU YS, 1995, J BIOL CHEM, V270, P6966, DOI 10.1074/jbc.270.12.6966; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; Igarashi K, 1998, J BIOL CHEM, V273, P11783, DOI 10.1074/jbc.273.19.11783; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; JAISWAL AK, 1990, BIOCHEMISTRY-US, V29, P1899, DOI 10.1021/bi00459a034; Johnsen O, 1998, NUCLEIC ACIDS RES, V26, P512, DOI 10.1093/nar/26.2.512; JUPP R, 1993, J VIROL, V67, P5595, DOI 10.1128/JVI.67.9.5595-5604.1993; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANG D, 1993, J VIROL, V67, P323, DOI 10.1128/JVI.67.1.323-331.1993; LANG D, 1995, J VIROL, V69, P6030, DOI 10.1128/JVI.69.10.6030-6037.1995; Lee G, 1996, P NATL ACAD SCI USA, V93, P2570, DOI 10.1073/pnas.93.6.2570; MALONE CL, 1990, J VIROL, V64, P1498, DOI 10.1128/JVI.64.4.1498-1506.1990; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Novotny V, 1998, NUCLEIC ACIDS RES, V26, P5480, DOI 10.1093/nar/26.23.5480; PIZZORNO MC, 1988, J VIROL, V62, P1167, DOI 10.1128/JVI.62.4.1167-1179.1988; PIZZORNO MC, 1990, J VIROL, V64, P6154, DOI 10.1128/JVI.64.12.6154-6165.1990; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; SCULLY AL, 1995, J VIROL, V69, P6533, DOI 10.1128/JVI.69.10.6533-6540.1995; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; Toki T, 1997, ONCOGENE, V14, P1901, DOI 10.1038/sj.onc.1201024; Tsai HL, 1997, VIROLOGY, V238, P372, DOI 10.1006/viro.1997.8855; Tsai HL, 1996, J BIOL CHEM, V271, P3534; Waheed I, 1998, VIROLOGY, V252, P235, DOI 10.1006/viro.1998.9448; WATHEN MW, 1982, J VIROL, V41, P462, DOI 10.1128/JVI.41.2.462-477.1982	45	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12313	12320		10.1074/jbc.275.16.12313	http://dx.doi.org/10.1074/jbc.275.16.12313			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766871	hybrid			2022-12-27	WOS:000086695500106
J	Opat, AS; Houghton, F; Gleeson, PK				Opat, AS; Houghton, F; Gleeson, PK			Medial golgi but not late Golgi glycosyltransferases exist as high molecular weight complexes - Role of luminal domain in ln complex formation and localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-N-ACETYLGLUCOSAMINE; GDP-L-FUCOSE; HELA-CELLS; TRANSMEMBRANE DOMAIN; KIN RECOGNITION; PROTEIN; APPARATUS; RETENTION; EXPRESSION; ENZYMES	To investigate the organization of Golgi glycosyltransferases and their mechanism of localization, we have compared the properties of a number of medial and late acting Golgi enzymes. The medial Golgi enzymes, N-acetylglucosaminyltransferase I and II (GnTI and GnTII) required high salt for solubilization and migrated as high molecular weight complexes on sucrose density gradients. In contrast, the late acting Golgi enzymes, beta 1,4-galactosyltransferase and alpha 1,2-fucosyltransferase, were readily solubilized in low salt and migrated as monomers/dimers by sucrose density gradient centrifugation, Analysis of membrane-bound GnTI chimeras indicates that the formation of high molecular weight complexes does not require the transmembrane domain and cytoplasmic tail sequences of GnTI. Furthermore, a soluble form of GnTI, containing the stem region and catalytic domain, accumulated in the Golgi prior to secretion, in contrast to beta 1,4-galactosyltransferase. Soluble GnTI, which also associated with high molecular weight complexes, was comparable with membrane-bound GnTI in its ability to glycosylate newly synthesized glycoproteins in vivo. Mutation of charged residues within the stem region of GnTI, known to be important for "kin recognition", had no effect on the efficiency of Golgi localization, the inclusion into high molecular weight complexes, nor functional activity in vivo. The differences in behavior between the medial and late acting Golgi enzymes may contribute to their differential localization and their ability to glycosylate efficiently in the correct Golgi subcompartment.	Monash Univ, Sch Med, Dept Pathol & Immunol, Prahran, Vic 3181, Australia	Monash University	Gleeson, PK (corresponding author), Monash Univ, Sch Med, Dept Pathol & Immunol, Commercial Rd, Prahran, Vic 3181, Australia.	paul.gleeson@med.monash.edu.au		Gleeson, Paul/0000-0002-5336-6503; HOUGHTON, FIONA/0000-0002-4420-2953				BENDIAK B, 1987, J BIOL CHEM, V262, P5775; Bonfanti L, 1998, CELL, V95, P993, DOI 10.1016/S0092-8674(00)81723-7; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BURKE J, 1994, J BIOL CHEM, V269, P12049; CERNEUS DP, 1993, J BIOL CHEM, V268, P3150; Cho SK, 1997, J BIOL CHEM, V272, P13622, DOI 10.1074/jbc.272.21.13622; Cole NB, 1998, J CELL BIOL, V140, P1, DOI 10.1083/jcb.140.1.1; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; CUMMINGS RD, 1982, J BIOL CHEM, V257, P13421; ERNST LK, 1989, J BIOL CHEM, V264, P3436; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FARQUHAR MG, 1997, GOLGI APPARATUS, P63; FIELD MC, 1995, GLYCOBIOLOGY, V5, P463, DOI 10.1093/glycob/5.5.463; Fullekrug J, 1998, BBA-MOL CELL RES, V1404, P77, DOI 10.1016/S0167-4889(98)00048-2; Gleeson PA, 1998, HISTOCHEM CELL BIOL, V109, P517, DOI 10.1007/s004180050252; Gleeson PA, 1996, J CELL SCI, V109, P2811; GRAHAM TR, 1995, MOL BIOL CELL, V6, P809, DOI 10.1091/mbc.6.7.809; HOE MH, 1995, J BIOL CHEM, V270, P25057, DOI 10.1074/jbc.270.42.25057; HULL E, 1991, BIOCHEM BIOPH RES CO, V176, P608, DOI 10.1016/S0006-291X(05)80227-X; Jungmann J, 1998, EMBO J, V17, P423, DOI 10.1093/emboj/17.2.423; Ke SH, 1997, NUCLEIC ACIDS RES, V25, P3371, DOI 10.1093/nar/25.16.3371; Kjer-Nielsen L, 1999, J CELL SCI, V112, P1645; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; MADISON EL, 1992, GENE, V121, P179, DOI 10.1016/0378-1119(92)90179-S; Munro S, 1998, TRENDS CELL BIOL, V8, P11, DOI 10.1016/S0962-8924(97)01197-5; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; Nichols BJ, 1998, BBA-MOL CELL RES, V1404, P9, DOI 10.1016/S0167-4889(98)00044-5; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; Nilsson T, 1996, J CELL SCI, V109, P1975; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; RABOUILLE C, 1995, J CELL SCI, V108, P1617; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHACHTER H, 1991, Glycobiology, V1, P453, DOI 10.1093/glycob/1.5.453; SCHACHTER H, 1994, MOL GLYCOBIOLOGY, P88; SLUSAREWICZ P, 1994, J CELL BIOL, V124, P405, DOI 10.1083/jcb.124.4.405; STANLEY P, 1984, ANNU REV GENET, V18, P525, DOI 10.1146/annurev.ge.18.120184.002521; STANLEY P, 1975, P NATL ACAD SCI USA, V72, P3323, DOI 10.1073/pnas.72.9.3323; STROUS GJ, 1986, CRC CR REV BIOCH MOL, V21, P119, DOI 10.3109/10409238609113610; TAN J, 1995, EUR J BIOCHEM, V231, P317, DOI 10.1111/j.1432-1033.1995.tb20703.x; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; VANDENEIJNDEN DH, 1993, CURR OPIN STRUC BIOL, V3, P711, DOI 10.1016/0959-440X(93)90054-O; Varki A, 1998, TRENDS CELL BIOL, V8, P34, DOI 10.1016/S0962-8924(97)01198-7; VISCHER P, 1981, EUR J BIOCHEM, V117, P275, DOI 10.1111/j.1432-1033.1981.tb06334.x; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Zhu GF, 1998, GLYCOBIOLOGY, V8, P831, DOI 10.1093/glycob/8.8.831	49	83	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11836	11845		10.1074/jbc.275.16.11836	http://dx.doi.org/10.1074/jbc.275.16.11836			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766809	hybrid			2022-12-27	WOS:000086695500044
J	Rosorius, O; Fries, B; Stauber, RH; Hirschmann, N; Bevec, D; Hauber, J				Rosorius, O; Fries, B; Stauber, RH; Hirschmann, N; Bevec, D; Hauber, J			Human ribosomal protein L5 contains defined nuclear localization and export signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS REV; HIV-1 REV; XENOPUS OOCYTES; LIVING CELLS; NUCLEOCYTOPLASMIC TRANSPORT; NUCLEOLAR LOCALIZATION; ACTIVATION DOMAIN; GENE-EXPRESSION; RNA; BINDING	Ribosomal protein L5 is part of the 60 S ribosomal subunit and localizes in both the cytoplasm and the nucleus of eukaryotic cells, accumulating particularly in the nucleoli. L5 is known to bind specifically to 5 S rRNA and is involved in nucleocytoplasmic transport of this rRNA, Here, we report a detailed analysis of the domain organization of the human ribosomal protein L5. We show that a signal that mediates nuclear import and nucleolar localization maps to amino acids 21-37 within the 297-amino acid L5 protein. Furthermore, carboxyl-terminal residues at positions 255-297 serve as an additional nuclear/nucleolar targeting signal. Domains involved in 5 S rRNA binding are located at both the amino terminus and the carboxyl terminus of L5, Microinjection studies in somatic cells demonstrate that a nuclear export signal (NES) that maps to amino acids 101-111 resides in the central region of L5. This NES is characterized by a pronounced clustering of critical leucine residues, which creates a peptide motif not previously observed in other leucine-rich NESs. Finally, we present a refined model of the multidomain structure of human ribosomal protein L5.	Univ Erlangen Nurnberg, Inst Clin & Mol Virol, D-91054 Erlangen, Germany; Novartis Res Inst, Dept Immunol, A-1235 Vienna, Austria	University of Erlangen Nuremberg; Novartis	Hauber, J (corresponding author), Univ Erlangen Nurnberg, Inst Clin & Mol Virol, Schlossgarten 4, D-91054 Erlangen, Germany.			Stauber, Roland/0000-0002-1341-4523				ALLISON LA, 1991, DEV BIOL, V144, P129, DOI 10.1016/0012-1606(91)90485-L; ALLISON LA, 1995, DEV BIOL, V168, P284, DOI 10.1006/dbio.1995.1080; Bevec D, 1996, SCIENCE, V271, P1858, DOI 10.1126/science.271.5257.1858; COCHRANE AW, 1990, J VIROL, V64, P881, DOI 10.1128/JVI.64.2.881-885.1990; DALY TJ, 1993, BIOCHEMISTRY-US, V32, P10497, DOI 10.1021/bi00090a028; DESHMUKH M, 1995, J BIOL CHEM, V270, P30148; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FORGET BG, 1969, J BIOL CHEM, V244, P3148; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; FRIGERIO JM, 1995, BBA-GENE STRUCT EXPR, V1262, P64, DOI 10.1016/0167-4781(95)00045-I; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; HAMMERSCHMID M, 1994, J VIROL, V68, P7329, DOI 10.1128/JVI.68.11.7329-7335.1994; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Lam WC, 1998, BIOCHEMISTRY-US, V37, P1800, DOI 10.1021/bi9719096; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; Michael WM, 1996, J BIOL CHEM, V271, P11571, DOI 10.1074/jbc.271.19.11571; Murdoch KJ, 1996, EXP CELL RES, V227, P332, DOI 10.1006/excr.1996.0282; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Palmeri D, 1996, J VIROL, V70, P6442, DOI 10.1128/JVI.70.9.6442-6445.1996; Pieler T, 1997, SEMIN CELL DEV BIOL, V8, P79, DOI 10.1006/scdb.1996.0125; Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491; RINKE J, 1982, CELL, V29, P149, DOI 10.1016/0092-8674(82)90099-X; Rosorius O, 1999, BIOTECHNIQUES, V27, P350, DOI 10.2144/99272rr02; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Rudt F, 1996, EMBO J, V15, P1383, DOI 10.1002/j.1460-2075.1996.tb00480.x; RUHL M, 1993, J CELL BIOL, V123, P1309, DOI 10.1083/jcb.123.6.1309; Schatz O, 1998, P NATL ACAD SCI USA, V95, P1607, DOI 10.1073/pnas.95.4.1607; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; SOLLNERWEBB B, 1991, TRENDS BIOCHEM SCI, V16, P58, DOI 10.1016/0968-0004(91)90025-Q; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; STAUBER R, 1995, VIROLOGY, V213, P439, DOI 10.1006/viro.1995.0016; Stauber RH, 1998, BIOTECHNIQUES, V24, P462, DOI 10.2144/98243rr01; Stauber RH, 1998, VIROLOGY, V251, P38, DOI 10.1006/viro.1998.9295; STEITZ JA, 1988, J CELL BIOL, V106, P545, DOI 10.1083/jcb.106.3.545; Thomas SL, 1998, J VIROL, V72, P2935, DOI 10.1128/JVI.72.4.2935-2944.1998; Warner JR, 1990, CURR OPIN CELL BIOL, V2, P521, DOI 10.1016/0955-0674(90)90137-4; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2	46	62	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12061	12068		10.1074/jbc.275.16.12061	http://dx.doi.org/10.1074/jbc.275.16.12061			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766838	hybrid			2022-12-27	WOS:000086695500073
J	Bentahir, M; Feller, G; Aittaleb, M; Lamotte-Brasseur, J; Himri, T; Chessa, JP; Gerday, C				Bentahir, M; Feller, G; Aittaleb, M; Lamotte-Brasseur, J; Himri, T; Chessa, JP; Gerday, C			Structural, kinetic, and calorimetric characterization of the cold-active phosphoglycerate kinase from the Antarctic Pseudomonas sp TACII18	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-PHOSPHOGLYCERATE KINASE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; ESCHERICHIA-COLI; CONFORMATIONAL FLEXIBILITY; TEMPERATURE ADAPTATION; PSYCHROPHILIC ENZYMES; GLYCOLYTIC ENZYME; STABILITY; ACTIVATION; EXPRESSION	The gene encoding the phosphoglycerate kinase (PGK) from the Antarctic Pseudomonas sp, TACII18 has been cloned and found to be inserted between the genes encoding for glyceraldhyde-3-phosphate dehydrogenase and fructose aldolase, The His-tagged and the native recombinant PGK from the psychrophilic Pseudomonas were expressed in Escherichia coli. The wild-type and the native recombinant enzymes displayed identical properties, such as a decreased thermostability and a 2-fold higher catalytic efficiency at 25 degrees C when compared with the mesophilic PGK from yeast. These properties, which reflect typical features of cold-adapted enzymes, were strongly altered in the His-tagged recombinant PGK. The structural model of the psychrophilic PGK indicated that a key determinant of its low stability is the reduced number of salt bridges, surface charges, and aromatic interactions when compared with mesophilic and thermophilic PGK. Differential scanning calorimetry of the psychrophilic PGK revealed unusual variations in its conformational stability for the free and substrate-bound forms. In the free form, a heat-labile and a thermostable domain unfold independently. It is proposed that the heat-labile domain acts as a destabilizing domain, providing the required flexibility around the active site for catalysis at low temperatures.	Univ Liege, Inst Chim B6, Biochim Lab, B-4000 Liege, Belgium; Univ Liege, Inst Phys B5, Ctr Ingn Prot, B-4000 Liege 1, Belgium	University of Liege; University of Liege	Feller, G (corresponding author), Univ Liege, Inst Chim B6, Biochim Lab, B-4000 Liege, Belgium.	gfeller@ulg.ac.be						ALEFOUNDER PR, 1989, MOL MICROBIOL, V3, P723, DOI 10.1111/j.1365-2958.1989.tb00221.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Auerbach G, 1997, STRUCTURE, V5, P1475, DOI 10.1016/S0969-2126(97)00297-9; BANKS RD, 1979, NATURE, V279, P773, DOI 10.1038/279773a0; Bernstein BE, 1997, NATURE, V385, P275, DOI 10.1038/385275a0; BLAKE CCF, 1974, J MOL BIOL, V84, P585, DOI 10.1016/0022-2836(74)90118-1; BLAKE CCF, 1981, PHILOS T ROY SOC B, V293, P93, DOI 10.1098/rstb.1981.0063; Branny P, 1998, MICROBIOL-SGM, V144, P905, DOI 10.1099/00221287-144-4-905; BRYANT TN, 1974, NATURE, V247, P14, DOI 10.1038/247014a0; BUCHER T, 1955, METHOD ENZYMOL, V1, P415, DOI 10.1016/0076-6879(55)01068-9; DAVIES GJ, 1994, ACTA CRYSTALLOGR D, V50, P202, DOI 10.1107/S0907444993011138; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Feller G, 1999, BIOCHEMISTRY-US, V38, P4613, DOI 10.1021/bi982650+; Feller G, 1997, CELL MOL LIFE SCI, V53, P830, DOI 10.1007/s000180050103; Feller G, 1996, FEMS MICROBIOL REV, V18, P189, DOI 10.1016/0168-6445(96)00011-3; Fields PA, 1998, P NATL ACAD SCI USA, V95, P11476, DOI 10.1073/pnas.95.19.11476; FONTES CMGA, 1995, APPL MICROBIOL BIOT, V43, P52, DOI 10.1007/BF00170622; Gebbia JA, 1997, GENE, V188, P221, DOI 10.1016/S0378-1119(96)00811-6; Gerday C, 1997, BBA-PROTEIN STRUCT M, V1342, P119, DOI 10.1016/S0167-4838(97)00093-9; Gerday C., 1999, P257; HARLOS K, 1992, PROTEINS, V12, P133, DOI 10.1002/prot.340120207; HESS D, 1995, EUR J BIOCHEM, V233, P227, DOI 10.1111/j.1432-1033.1995.227_1.x; Hochachka P. W., 1984, BIOCH ADAPTATION; JOHNSTON IA, 1975, NATURE, V254, P74, DOI 10.1038/254074a0; JONES CE, 1995, EUR J BIOCHEM, V233, P800, DOI 10.1111/j.1432-1033.1995.800_3.x; Leharne SA, 1998, BIOCALORIMETRY, P157; LOW PS, 1973, P NATL ACAD SCI USA, V70, P430, DOI 10.1073/pnas.70.2.430; May A, 1996, PROTEINS, V24, P292; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; NOJIMA H, 1976, BIOCHIM BIOPHYS ACTA, V427, P20, DOI 10.1016/0005-2795(76)90281-6; Pace C N, 1986, Methods Enzymol, V131, P266; PEARLMAN DA, 1995, AMBER 4 1; PRIVALOV PL, 1979, J MOL BIOL, V127, P203, DOI 10.1016/0022-2836(79)90240-7; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4; RAO BDN, 1978, J BIOL CHEM, V253, P8056; SMITH TF, 1981, J MOL EVOL, V18, P38, DOI 10.1007/BF01733210; SOMERO GN, 1995, ANNU REV PHYSIOL, V57, P43, DOI 10.1146/annurev.ph.57.030195.000355; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Szilagyi AN, 1998, BIOCHEMISTRY-US, V37, P8551, DOI 10.1021/bi973072k; Thomas TM, 1998, BIOCHEM J, V330, P1087; WALKER PA, 1989, EUR J BIOCHEM, V183, P49, DOI 10.1111/j.1432-1033.1989.tb14895.x; WATSON HC, 1982, EMBO J, V1, P1635, DOI 10.1002/j.1460-2075.1982.tb01366.x; WATSON HC, 1990, BIOCHEM SOC T, V18, P187, DOI 10.1042/bst0180187; Zaiss K, 1999, BIOCHEMISTRY-US, V38, P4633, DOI 10.1021/bi982447e; Zavodszky P, 1998, P NATL ACAD SCI USA, V95, P7406, DOI 10.1073/pnas.95.13.7406	45	77	88	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11147	11153		10.1074/jbc.275.15.11147	http://dx.doi.org/10.1074/jbc.275.15.11147			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753921	Green Published, hybrid			2022-12-27	WOS:000086466600063
J	Gregory, KE; Oxford, JT; Chen, YW; Gambee, JE; Gygi, SP; Aebersold, R; Neame, PJ; Mechling, DE; Bachinger, HP; Morris, NP				Gregory, KE; Oxford, JT; Chen, YW; Gambee, JE; Gygi, SP; Aebersold, R; Neame, PJ; Mechling, DE; Bachinger, HP; Morris, NP			Structural organization of distinct domains within the non-collagenous N-terminal region of collagen type XI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; BOVINE EPIPHYSEAL CARTILAGE; ARGININE-RICH PROTEIN; STRUCTURE PREDICTION; V COLLAGEN; NH2-TERMINAL DOMAIN; CIRCULAR-DICHROISM; PRO-ALPHA-1(XI) COLLAGEN; IMMUNOGLOBULIN FOLD; FIBRIL MORPHOLOGY	Collagen XI is a heterotrimeric molecule found predominantly in heterotypic cartilage fibrils, where it is involved in the regulation of fibrillogenesis. This function is thought to involve the complex N-terminal domain. The goal of this current study was to examine its structural organization to further elucidate the regulatory mechanism. The amino-propeptide (alpha 1-Npp) alone or with isoforms of the variable region were recombinantly expressed and purified by affinity and molecular sieve chromatography, Cys-1-Cys-4 and Cys-2-Cys-3 disulfide bonds were detected by liquid chromatographytandem mass spectrometry. This pattern is identical to the homologous alpha 2-Npp, indicating that the recombinant proteins were folded correctly. Anomalous elution on molecular sieve chromatography suggested that the variable region was extended, which was confirmed using rotary shadowing the alpha 1-Npp formed a globular "head" and the variable region an extended "tail." Circular dichroism spectra analysis determined that the alpha 1-Npp comprised 33% beta-sheet, whereas the variable region largely comprised non-periodic structure. Taken together, these results imply that the alpha 1-Npp cannot be accommodated within the core of the fibril and that the variable region and/or minor helix facilitates its exclusion to the fibril surface. This provides further support for regulation of fibril diameter by steric hindrance or by interactions with other matrix components that affect fibrillogenesis.	Shriners Hosp Crippled Childrens, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Sch Dent, Portland, OR 97201 USA; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA; Shriners Hosp Crippled Children, Tampa, FL 33612 USA	Oregon Health & Science University; Oregon Health & Science University; University of Washington; University of Washington Seattle	Morris, NP (corresponding author), Shriners Hosp Crippled Childrens, 3101 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.		Oxford, Julia Thom/AAH-2842-2019	Oxford, Julia Thom/0000-0002-4850-3569; Keller, Kate/0000-0002-1616-972X				Alvares K, 1999, BIOCHEMISTRY-US, V38, P5401, DOI 10.1021/bi9821824; BIRK DE, 1990, J CELL SCI, V95, P649; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BORK P, 1992, FEBS LETT, V307, P49, DOI 10.1016/0014-5793(92)80900-2; COMPTON LA, 1987, J BIOL CHEM, V262, P13039; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; Davies GBM, 1998, DEV DYNAM, V213, P12, DOI 10.1002/(SICI)1097-0177(199809)213:1<12::AID-AJA2>3.0.CO;2-0; EIKENBERRY EF, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P133; Eyre D, 1987, STRUCTURE FUNCTION C, P261; FICHARD A, 1995, MATRIX BIOL, V14, P515, DOI 10.1016/S0945-053X(05)80001-0; Frishman D, 1997, PROTEINS, V27, P329, DOI 10.1002/(SICI)1097-0134(199703)27:3<329::AID-PROT1>3.0.CO;2-8; FURUTO DK, 1983, ARCH BIOCHEM BIOPHYS, V226, P604, DOI 10.1016/0003-9861(83)90329-6; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Garnier J, 1996, METHOD ENZYMOL, V266, P540; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; Greenfield NJ, 1996, ANAL BIOCHEM, V235, P1, DOI 10.1006/abio.1996.0084; Guermeur Y, 1999, BIOINFORMATICS, V15, P413, DOI 10.1093/bioinformatics/15.5.413; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Halaby DM, 1999, PROTEIN ENG, V12, P563, DOI 10.1093/protein/12.7.563; HEDLUND H, 1994, MATRIX BIOL, V14, P227, DOI 10.1016/0945-053X(94)90186-4; HOLMES DF, 1992, P NATL ACAD SCI USA, V89, P9855, DOI 10.1073/pnas.89.20.9855; HULMES DJS, 1983, COLLAGEN REL RES, V3, P317; Imamura Y, 1998, J BIOL CHEM, V273, P27511, DOI 10.1074/jbc.273.42.27511; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KEENE DR, 1995, J HISTOCHEM CYTOCHEM, V43, P967, DOI 10.1177/43.10.7560887; KLEMAN JP, 1992, EUR J BIOCHEM, V210, P329, DOI 10.1111/j.1432-1033.1992.tb17425.x; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; MACBEATH JRE, 1993, J BIOL CHEM, V268, P19826; Marchant JK, 1996, J CELL BIOL, V135, P1415, DOI 10.1083/jcb.135.5.1415; MAYER U, 1995, EUR J BIOCHEM, V227, P681, DOI 10.1111/j.1432-1033.1995.tb20188.x; MAYNE R, 1993, J BIOL CHEM, V268, P9381; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; Moradi-Ameli M, 1998, MATRIX BIOL, V17, P393, DOI 10.1016/S0945-053X(98)90091-9; MORADIAMELI M, 1994, MATRIX BIOL, V14, P233, DOI 10.1016/0945-053X(94)90187-2; MORADIAMELI M, 1994, EUR J BIOCHEM, V221, P987, DOI 10.1111/j.1432-1033.1994.tb18815.x; MORRIS NP, 1986, J BIOL CHEM, V261, P5638; NAH HD, 1992, J BIOL CHEM, V267, P22581; NEAME PJ, 1990, J BIOL CHEM, V265, P20401; OXFORD JT, 1994, EXP CELL RES, V213, P28, DOI 10.1006/excr.1994.1169; OXFORD JT, 1995, J BIOL CHEM, V270, P9478, DOI 10.1074/jbc.270.16.9478; PETIT B, 1993, HISTOCHEMISTRY, V100, P231, DOI 10.1007/BF00269096; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SEEGMILLER R, 1971, J CELL BIOL, V48, P580, DOI 10.1083/jcb.48.3.580; SEEGMILLER RE, 1981, CONNECT TISSUE RES, V9, P69, DOI 10.3109/03008208109160242; Sugimoto M, 1998, CELL TISSUE RES, V292, P325, DOI 10.1007/s004410051063; THOM JR, 1991, J BIOL CHEM, V266, P7262; TILLET E, 1995, EUR J BIOCHEM, V228, P160, DOI 10.1111/j.1432-1033.1995.tb20245.x; TSUMAKI N, 1995, J BIOL CHEM, V270, P2372, DOI 10.1074/jbc.270.5.2372; VITAGLIANO L, 1995, J MOL BIOL, V247, P69, DOI 10.1006/jmbi.1994.0123; Watson RB, 1998, J MOL BIOL, V278, P195, DOI 10.1006/jmbi.1998.1680; YANG BH, 1994, J CELL BIOCHEM, V56, P455, DOI 10.1002/jcb.240560406; YOSHIOKA H, 1990, J BIOL CHEM, V265, P6423; ZHIDKOVA NI, 1993, FEBS LETT, V326, P25, DOI 10.1016/0014-5793(93)81753-M; ZHIDKOVA NI, 1995, J BIOL CHEM, V270, P9486, DOI 10.1074/jbc.270.16.9486	59	48	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11498	11506		10.1074/jbc.275.15.11498	http://dx.doi.org/10.1074/jbc.275.15.11498			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753969	hybrid			2022-12-27	WOS:000086466600111
J	Ku, H; Meier, KE				Ku, H; Meier, KE			Phosphorylation of paxillin via the ERK mitogen-activated protein kinase cascade in EL4 thymoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; TYROSINE PHOSPHORYLATION; PHORBOL ESTER; T-CELL; SIGNAL-TRANSDUCTION; MOUSE THYMOMA; SERINE PHOSPHORYLATION; WILD-TYPE; C-ETA; INTEGRIN	Intracellular signals can regulate cell adhesion via several mechanisms in a process referred to as "inside-out" signaling In phorbol ester-sensitive EL4 thymoma cells, phorbol-la-myristate 13-acetate (PMA) induces activation of extracellular signal-regulated kinase (ERK) mitogen-activated protein kinases and promotes cell adhesion. In this study, clonal EL4 cell lines with varying abilities to activate ERKs in response to PIMA were used to examine signaling events occurring downstream of ERK activation. Paxillin, a multifunctional docking protein involved in cell adhesion, was phosphorylated on serine/threonine residues in response to PMA treatment. This response was correlated with the extent and time course of ERK activation. PMA-induced phosphorylation of paxillin was inhibited by compounds that block the ERK activation pathway in EL4 cells, primary murine thymocytes, and primary murine splenocytes. Paxillin was phosphorylated in vitro by purified active ERK2. Two-dimensional electrophoresis revealed that PMA treatment generated a complex pattern of phosphorylated paxillin species in intact cells, some of which were generated by ERR-mediated phosphorylation in vitro. An ERK pathway inhibitor interfered with PMA-induced adhesion of sensitive EL4 cells to substrate. These findings describe a novel inside-out signaling pathway by which the ERK cascade may regulate events involved in adhesion.	Med Univ S Carolina, Dept Cell & Mol Pharmacol, Charleston, SC 29425 USA	Medical University of South Carolina	Meier, KE (corresponding author), Med Univ S Carolina, Dept Cell & Mol Pharmacol, POB 250505,173 Ashley Ave, Charleston, SC 29425 USA.	meierke@musc.edu		Ku, Hsun/0000-0001-5662-9893				Adams JC, 1999, MOL BIOL CELL, V10, P4177, DOI 10.1091/mbc.10.12.4177; ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; AMIN NDV, 1998, J NEUROSCI, V18, P4008; Bacon KB, 1996, J EXP MED, V184, P873, DOI 10.1084/jem.184.3.873; Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; Bellis SL, 1997, BIOCHEM J, V325, P375, DOI 10.1042/bj3250375; Brown MC, 1998, NAT STRUCT BIOL, V5, P677, DOI 10.1038/1370; Brown MC, 1998, MOL BIOL CELL, V9, P1803, DOI 10.1091/mbc.9.7.1803; Cattelino A, 1996, CELL ADHES COMMUN, V4, P457; Cote JF, 1999, J BIOL CHEM, V274, P20550, DOI 10.1074/jbc.274.29.20550; Delwel GO, 1996, J BIOL CHEM, V271, P7293, DOI 10.1074/jbc.271.13.7293; DeNichilo MO, 1996, J BIOL CHEM, V271, P11016, DOI 10.1074/jbc.271.18.11016; Desrivieres S, 1997, J BIOL CHEM, V272, P2470; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FARRAR JJ, 1980, J IMMUNOL, V125, P2555; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; GAUSE KC, 1993, J BIOL CHEM, V268, P16124; Haller H, 1997, J IMMUNOL, V158, P1061; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HARRISON JR, 1987, J BIOL CHEM, V262, P234; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; Igishi T, 1999, J BIOL CHEM, V274, P30738, DOI 10.1074/jbc.274.43.30738; Irigoyen JP, 1997, J BIOL CHEM, V272, P1904, DOI 10.1074/jbc.272.3.1904; Lipsky BP, 1998, J BIOL CHEM, V273, P11709, DOI 10.1074/jbc.273.19.11709; Longhurst CM, 1998, CELL MOL LIFE SCI, V54, P514, DOI 10.1007/s000180050180; Lu Q, 1998, MOL CELL BIOL, V18, P3257, DOI 10.1128/MCB.18.6.3257; Matsuya M, 1998, J BIOL CHEM, V273, P1003, DOI 10.1074/jbc.273.2.1003; Mazaki Y, 1997, J BIOL CHEM, V272, P7437, DOI 10.1074/jbc.272.11.7437; MEIER KE, 1991, J BIOL CHEM, V266, P1914; Miron S, 1997, J LEUKOCYTE BIOL, V62, P405, DOI 10.1002/jlb.62.3.405; PEARLSTEIN KT, 1983, J NATL CANCER I, V71, P583; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; Resnick MS, 1998, J BIOL CHEM, V273, P27654, DOI 10.1074/jbc.273.42.27654; Resnick MS, 1997, CANCER RES, V57, P2209; Reszka AA, 1997, MOL BIOL CELL, V8, P1219, DOI 10.1091/mbc.8.7.1219; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; RICHARDSON AF, 1995, CELL SIGNAL, V7, P17, DOI 10.1016/0898-6568(94)00068-M; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SALOMON DR, 1994, J EXP MED, V179, P1573, DOI 10.1084/jem.179.5.1573; Sansbury HM, 1997, CARCINOGENESIS, V18, P1817, DOI 10.1093/carcin/18.9.1817; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHIBANUMA M, 1994, J BIOL CHEM, V269, P26767; Turner CE, 1998, INT J BIOCHEM CELL B, V30, P955, DOI 10.1016/S1357-2725(98)00062-4; Wei JY, 1997, J LEUKOCYTE BIOL, V61, P397, DOI 10.1002/jlb.61.4.397; Weisberg E, 1997, CRIT REV ONCOGENESIS, V8, P343, DOI 10.1615/CritRevOncog.v8.i4.40; Yamaguchi R, 1997, ONCOGENE, V15, P1753, DOI 10.1038/sj.onc.1201345; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	50	58	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11333	11340		10.1074/jbc.275.15.11333	http://dx.doi.org/10.1074/jbc.275.15.11333			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753946	hybrid			2022-12-27	WOS:000086466600088
J	Kumar, V; Sabatini, D; Pandey, P; Gingras, AC; Majumder, PK; Kumar, M; Yuan, ZM; Carmichael, G; Weichselbaum, R; Sonenberg, N; Kufe, D; Kharbanda, S				Kumar, V; Sabatini, D; Pandey, P; Gingras, AC; Majumder, PK; Kumar, M; Yuan, ZM; Carmichael, G; Weichselbaum, R; Sonenberg, N; Kufe, D; Kharbanda, S			Regulation of the rapamycin and FKBP-target 1/mammalian target of rapamycin and cap-dependent initiation of translation by the c-Abl protein-tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA TRANSLATION; CELL-CYCLE ARREST; GROWTH-FACTOR-II; P70 S6 KINASE; DNA-DAMAGE; PHAS-I; PHOSPHATIDYLINOSITOL 3-KINASE; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; STRESS-RESPONSE	The c-Abl protein-tyrosine kinase is activated by ionizing radiation and certain other DNA-damaging agents. The rapamycin and FKBP-target 1 (RAFT1), also known as FKBP12-rapamycin-associated protein (FRAP, mTOR), regulates the p70S6 kinase (p70(S6k)) and the eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1), The present results demonstrate that c-Abl binds directly to RAFT1 and phosphorylates RAFT1 in vitro and in vivo. c-Abl inhibits autophosphorylation of RAFT1 and RAFT1-mediated phosphorylation p70S6k. The functional significance of the c-Abl-RAFT1 interaction is further supported by the finding that eIF4E-dependent translation in mouse embryo fibroblasts from Abl(-/-) mice is significantly higher than that compared in wildtype cells. The results also demonstrate that exposure of cells to ionizing radiation is associated with c-Abl-mediated binding of 4E-BP1 to eIF4E and inhibition of translation. These findings with the c-Abl tyrosine kinase represent the first demonstration of a negative physiologic regulator of RAFT1-mediated 5' cap-dependent translation.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; McGill Univ, Dept Biochem, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; Univ Connecticut, Ctr Hlth, Dept Microbiol, Farmington, CT 06030 USA; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute; McGill University; University of Connecticut; University of Chicago	Kharbanda, S (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.		Gingras, Anne-Claude/ABA-8341-2020	Gingras, Anne-Claude/0000-0002-6090-4437; /0000-0002-1446-7256	NCI NIH HHS [CA75216] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075216] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 1996, CURR OPIN IMMUNOL, V8, P412, DOI 10.1016/S0952-7915(96)80132-4; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Blackshear PJ, 1997, J BIOL CHEM, V272, P31510, DOI 10.1074/jbc.272.50.31510; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CHEN PC, 1975, NATURE, V258, P427; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; Craig AWB, 1998, NATURE, V392, P520, DOI 10.1038/33198; DONZE O, 1995, NUCLEIC ACIDS RES, V23, P861, DOI 10.1093/nar/23.5.861; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; GOGA A, 1995, ONCOGENE, V11, P791; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Hentze MW, 1997, SCIENCE, V275, P500, DOI 10.1126/science.275.5299.500; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; Huang YY, 1997, ONCOGENE, V15, P1947, DOI 10.1038/sj.onc.1201376; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JEFFERIES HBJ, 1996, TRANSLATIONAL CONTRO, P389; Jin SF, 1997, J BIOL CHEM, V272, P24763, DOI 10.1074/jbc.272.40.24763; KASTAN MB, 1991, CANCER RES, V51, P6304; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Kharbanda S, 1998, ONCOGENE, V16, P1773, DOI 10.1038/sj.onc.1201934; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; Kumar M, 1997, P NATL ACAD SCI USA, V94, P3542, DOI 10.1073/pnas.94.8.3542; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Lin TA, 1996, J BIOL CHEM, V271, P30199, DOI 10.1074/jbc.271.47.30199; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MATTIONI T, 1995, ONCOGENE, V10, P1325; Merrick WC., 1996, TRANSLATION CONTROL, P31; NIELSEN FC, 1995, NATURE, V377, P358, DOI 10.1038/377358a0; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; PATERSON MC, 1979, CANCER RES, V39, P3725; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; REINHARD G, 1994, EMBO J, V1, P1557; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SONENBERG N, 1994, CURR OPIN GENET DEV, V4, P310, DOI 10.1016/S0959-437X(05)80059-0; SONENBERG N, 1996, PROTEIN TRANSLATION, P245; STAN R, 1994, J BIOL CHEM, V269, P32027; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Ueda K, 1996, J VIROL, V70, P1375, DOI 10.1128/JVI.70.3.1375-1383.1996; VONMANTEUFFEL SR, 1996, P NATL ACAD SCI USA, V93, P4070; Walkenhorst J, 1996, ONCOGENE, V12, P1513; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yuan ZM, 1997, J BIOL CHEM, V272, P23485, DOI 10.1074/jbc.272.38.23485; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	76	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10779	10787		10.1074/jbc.275.15.10779	http://dx.doi.org/10.1074/jbc.275.15.10779			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753870	hybrid			2022-12-27	WOS:000086466600012
J	Aspinwall, CA; Qian, WJ; Roper, MG; Kulkarni, RN; Kahn, CR; Kennedy, RT				Aspinwall, CA; Qian, WJ; Roper, MG; Kulkarni, RN; Kahn, CR; Kennedy, RT			Roles of insulin receptor substrate-1, phosphatidylinositol 3-kinase, and release of intracellular Ca2+ stores in insulin-stimulated insulin secretion in beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE C-GAMMA; PANCREATIC-ISLETS; TYROSINE PHOSPHORYLATION; CYTOSOLIC CA2+; S6 KINASE; GLUCOSE; EXOCYTOSIS; ACTIVATION; IRS-2; GENE	The signaling pathway by which insulin stimulates insulin secretion and increases in intracellular free Ca2+ concentration ([Ca2+](i)) in isolated mouse pancreatic beta-cells and clonal beta-cells was investigated. Application of insulin to single beta-cells resulted in increases in [Ca2+](i) that were of lower magnitude, slower onset, and longer lifetime than that observed with stimulation with tolbutamide, Furthermore, the increases in [Ca2+](i) originated from interior regions of the cell rather than from the plasma membrane as with depolarizing stimuli. The insulin-induced [Ca2+](i) changes and insulin secretion at single beta-cells were abolished by treatment with 100 nM wortmannin or 1 mu M thapsigargin; however, they were unaffected by 10 mu M U73122, 20 mu M nifedipine, or removal of Ca2+ from the medium. Insulin-stimulated insulin secretion was also abolished by treatment with 2 mu M bisin-dolylmaleimide I, but [Ca2+](i) changes were unaffected. In an insulin receptor substrate-1 gene disrupted beta-cell tumor line, insulin did not evoke either [Ca2+](i) changes or insulin secretion. The data suggest that autocrine-activated increases in [Ca2+](i) are due to release of intracellular Ca2+ stores, especially the endoplasmic reticulum, mediated by insulin receptor substrate-1 and phosphatidylinositol 3-kinase, Autocrine activation of insulin secretion is mediated by the increase in [Ca2+](i) and activation of protein kinase C.	Univ Florida, Dept Chem, Gainesville, FL 32611 USA; Harvard Univ, Sch Med, Div Res, Joslin Diabet Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	State University System of Florida; University of Florida; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Kennedy, RT (corresponding author), Univ Florida, Dept Chem, Gainesville, FL 32611 USA.	rtkenn@chem.ufl.edu	QIAN, Wei-Jun/AAC-1907-2021; Roper, Michael/G-3490-2017; Qian, Wei-Jun/C-6167-2011; Kennedy, Robert/G-9095-2016; Kahn, Ronald/AAY-2435-2021; Roper, Michael G./D-2386-2010	QIAN, Wei-Jun/0000-0002-5393-2827; Roper, Michael/0000-0002-0184-1333; Kennedy, Robert/0000-0003-2447-7471; Kahn, Ronald/0000-0002-7583-9228; Roper, Michael G./0000-0002-0184-1333; Aspinwall, Craig/0000-0002-4359-5812	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046960, R37DK031036, R37DK046960, R01DK031036, R01DK033201] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 33201, DK31036, DK46960] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Algenstaedt PM, 1997, J BIOL CHEM, V272, P23696, DOI 10.1074/jbc.272.38.23696; ALTER CA, 1995, BIOCHEM BIOPH RES CO, V208, P190, DOI 10.1006/bbrc.1995.1322; ASHCROFT SJH, 1994, DIABETOLOGIA, V37, pS21, DOI 10.1007/BF00400822; Aspinwall CA, 1999, J BIOL CHEM, V274, P6360, DOI 10.1074/jbc.274.10.6360; Aspinwall CA, 1997, J BIOL CHEM, V272, P31308, DOI 10.1074/jbc.272.50.31308; Aspinwall CA, 1999, ANAL CHEM, V71, P5551, DOI 10.1021/ac990817e; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Chanson M, 1999, J BIOL CHEM, V274, P282, DOI 10.1074/jbc.274.1.282; Chasserot-Golaz S, 1998, J NEUROCHEM, V70, P2347; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; Eliasson L, 1996, SCIENCE, V271, P813, DOI 10.1126/science.271.5250.813; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Gao ZY, 1996, DIABETES, V45, P854, DOI 10.2337/diabetes.45.7.854; GAZZANO H, 1985, BIOCHEM J, V226, P867, DOI 10.1042/bj2260867; Guerineau NC, 1998, J BIOL CHEM, V273, P10389, DOI 10.1074/jbc.273.17.10389; Harbeck MC, 1996, DIABETES, V45, P711, DOI 10.2337/diabetes.45.6.711; Holst LS, 1998, BIOCHEM BIOPH RES CO, V250, P181, DOI 10.1006/bbrc.1998.9166; HUANG L, 1995, P NATL ACAD SCI USA, V92, P9608, DOI 10.1073/pnas.92.21.9608; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Kulkarni RN, 1998, DIABETES, V47, pA57; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; Moens K, 1996, DIABETES, V45, P257, DOI 10.2337/diabetes.45.2.257; NORMAN AW, 1997, HORMONES, P193; PATEL YC, 1982, SCIENCE, V217, P1155, DOI 10.1126/science.6126003; Porzio O, 1999, J CLIN INVEST, V104, P357, DOI 10.1172/JCI5870; ROTHENBERG PL, 1995, DIABETES, V44, P802, DOI 10.2337/diabetes.44.7.802; Rutter GA, 1999, CURR BIOL, V9, pR443, DOI 10.1016/S0960-9822(99)80277-2; Schiavo G, 1996, P NATL ACAD SCI USA, V93, P13327, DOI 10.1073/pnas.93.23.13327; SCHUIT FC, 1989, DIABETOLOGIA, V32, P207, DOI 10.1007/BF00265096; Shepherd PR, 1996, TRENDS CELL BIOL, V6, P92, DOI 10.1016/0962-8924(96)80998-6; SMITH PA, 1995, PFLUG ARCH EUR J PHY, V430, P808, DOI 10.1007/BF00386180; Sun XJ, 1997, MOL ENDOCRINOL, V11, P251, DOI 10.1210/me.11.2.251; Taylor SI, 1999, CELL, V97, P9, DOI 10.1016/S0092-8674(00)80709-6; THELER JM, 1992, J BIOL CHEM, V267, P18110; Velloso LA, 1995, FEBS LETT, V377, P353, DOI 10.1016/0014-5793(95)01370-9; VERSPOHL EJ, 1980, J CLIN INVEST, V65, P1230, DOI 10.1172/JCI109778; White MF, 1997, DIABETOLOGIA, V40, pS2, DOI 10.1007/s001250051387; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Xu G, 1998, J BIOL CHEM, V273, P4485, DOI 10.1074/jbc.273.8.4485; Xu GG, 1999, J BIOL CHEM, V274, P18067, DOI 10.1074/jbc.274.25.18067; Xu GG, 1998, DIABETES, V47, P1243, DOI 10.2337/diabetes.47.8.1243; ZAWALICH WS, 1995, ENDOCRINOLOGY, V136, P4903, DOI 10.1210/en.136.11.4903; ZHOU Z, 1995, J BIOL CHEM, V270, P3498, DOI 10.1074/jbc.270.8.3498	46	137	148	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22331	22338		10.1074/jbc.M909647199	http://dx.doi.org/10.1074/jbc.M909647199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10764813	hybrid			2022-12-27	WOS:000088363800079
J	Gregorieff, A; Pyronnet, S; Sonenberg, N; Veillette, A				Gregorieff, A; Pyronnet, S; Sonenberg, N; Veillette, A			Regulation of SOCS-1 expression by translational repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PROTEIN-KINASE; CAP-DEPENDENT TRANSLATION; MESSENGER-RNA TRANSLATION; SIGNAL-TRANSDUCTION; 5'-UNTRANSLATED REGION; TRANSIENT-EXPRESSION; INTERNAL INITIATION; STAT5 ACTIVATION; IRON-METABOLISM; INDUCIBLE GENE	Accumulating evidence demonstrates that cytokine receptor signaling is negatively regulated by a family of Src homology 2 domain-containing adaptor molecules termed SOCS (Suppressor of cytokine signaling). Previous studies have indicated that the expression of SOCS-related molecules is tightly controlled at the level of transcription. Furthermore, it has been reported that SOCS polypeptides are relatively unstable in cells, unless they are associated with elongins B and C. Herein, we document the existence of a third mechanism of regulation of SOCS function. Our data showed that expression of SOCS-1, a member of the SOCS family, is strongly repressed at the level of translation initiation. Structure-function analyses indicated that this effect is mediated by the 5' untranslated region of socs-1 and that it relates to the presence of two upstream AUGs in this region. Further studies revealed that socs-1 translation is cap-dependent and that it is modulated by eIF4E-binding proteins. In combination, these results uncover a novel level of regulation of SOCS-related molecules. Moreover, coupled with previous findings, they suggest that SOCS expression is tightly regulated through multiple mechanisms, in order to avoid inappropriate interference with cytokine-mediated effects.	McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University; McGill University; McGill University	Veillette, A (corresponding author), Inst Rech Clin Montreal, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.		Pyronnet, Stéphane/P-2419-2014					ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; BELSHAM GJ, 1990, J VIROL, V64, P5389, DOI 10.1128/JVI.64.11.5389-5395.1990; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOW LML, 1992, MOL CELL BIOL, V12, P1226, DOI 10.1128/MCB.12.3.1226; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Cloutier JF, 1996, EMBO J, V15, P4909, DOI 10.1002/j.1460-2075.1996.tb00871.x; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Favre H, 1999, FEBS LETT, V453, P63, DOI 10.1016/S0014-5793(99)00681-X; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; GRENS A, 1990, J BIOL CHEM, V265, P11810; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Latour S, 1997, MOL CELL BIOL, V17, P4434, DOI 10.1128/MCB.17.8.4434; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; LIU CC, 1984, NATURE, V309, P82, DOI 10.1038/309082a0; Liu KD, 1998, CURR OPIN IMMUNOL, V10, P271, DOI 10.1016/S0952-7915(98)80165-9; Losman JA, 1999, J IMMUNOL, V162, P3770; MADER S, 1995, MOL CELL BIOL, V15, P4990; MANZELLA JM, 1990, J BIOL CHEM, V265, P11817; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Metcalf D, 1999, LEUKEMIA, V13, P926, DOI 10.1038/sj.leu.2401440; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Poulin F, 1998, J BIOL CHEM, V273, P14002, DOI 10.1074/jbc.273.22.14002; Pyronnet S, 1996, CANCER RES, V56, P1742; RESKEKUNZ AB, 1985, EUR J IMMUNOL, V15, P1048, DOI 10.1002/eji.1830151017; Rouault T, 1997, CURR TOP CELL REGUL, V35, P1, DOI 10.1016/S0070-2137(97)80001-5; Sakamoto H, 1998, BLOOD, V92, P1668, DOI 10.1182/blood.V92.5.1668.417k09_1668_1676; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Song MM, 1998, J BIOL CHEM, V273, P35056, DOI 10.1074/jbc.273.52.35056; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Suzuki R, 1998, ONCOGENE, V17, P2271, DOI 10.1038/sj.onc.1202143; Svitkin YV, 1996, EMBO J, V15, P7147, DOI 10.1002/j.1460-2075.1996.tb01106.x; Symes A, 1997, CURR BIOL, V7, P697, DOI 10.1016/S0960-9822(06)00298-3; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	64	61	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21596	21604		10.1074/jbc.M910087199	http://dx.doi.org/10.1074/jbc.M910087199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10764816	hybrid			2022-12-27	WOS:000088230600085
J	Woo, AL; James, PF; Lingrel, JB				Woo, AL; James, PF; Lingrel, JB			Sperm motility is dependent on a unique isoform of the Na,K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT; ALPHA-SUBUNIT; GAMMA-SUBUNIT; HUMAN SPERMATOZOA; ACROSOME REACTION; FUNCTIONAL-ROLE; NA+/K+-ATPASE; RAT; NA+,K+-ATPASE; EXPRESSION	The Na,K-ATPase, a member of the P-type ATPases, is composed of two subunits, alpha and beta, and is responsible for translocating Na+ out of the cell and K+ into the cell using the energy of hydrolysis of one molecule of ATP. The electrochemical gradient it generates is necessary for many cellular functions, including establishment of the plasma membrane potential and transport of sugars and ions in and out of the cell. Families of isoforms for both the alpha and beta subunits have been identified, and specific functional roles for individual isoforms are just beginning to emerge. The alpha 4 isoform is the most recently identified Na,K-ATPase alpha isoform, and its expression has been found only in testis. Here we show that expression of the alpha 4 isoform in testis is localized to spermatozoa and that inhibition of this isoform alone eliminates sperm motility. These data describe for the first time a biological function for the alpha 4 isoform of the Na,K-ATPase, revealing a critical role for this isoform in sperm motility.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Lingrel, JB (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Bethesda Ave, Cincinnati, OH 45267 USA.	Jerry.Lingrel@uc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496, R01HL028573, T32HL007382] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32HL07382, R01HL28573, P01HL41496] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arystarkhova E, 1999, J BIOL CHEM, V274, P33183, DOI 10.1074/jbc.274.47.33183; Arystarkhova E, 1997, J BIOL CHEM, V272, P22405, DOI 10.1074/jbc.272.36.22405; BECKER WM, 1991, WORLD CELL, P677; Beguin P, 1998, J BIOL CHEM, V273, P24921, DOI 10.1074/jbc.273.38.24921; Beguin P, 1997, EMBO J, V16, P4250, DOI 10.1093/emboj/16.14.4250; BEYLER SA, 1982, BIOCH MAMMALIAN REPR, P156; Blanco G, 1999, BIOCHEMISTRY-US, V38, P13661, DOI 10.1021/bi991207b; Blanco G, 1998, AM J PHYSIOL-RENAL, V275, pF633, DOI 10.1152/ajprenal.1998.275.5.F633; Calzada L, 1997, ARCH ANDROLOGY, V38, P151, DOI 10.3109/01485019708987892; EAKLE KA, 1994, J BIOL CHEM, V269, P6550; FRASER LR, 1993, J REPROD FERTIL, V97, P539, DOI 10.1530/jrf.0.0970539; Garcia MA, 1999, MOL REPROD DEV, V52, P189, DOI 10.1002/(SICI)1098-2795(199902)52:2<189::AID-MRD10>3.0.CO;2-D; GEERING K, 1991, FEBS LETT, V285, P189, DOI 10.1016/0014-5793(91)80801-9; HANG HY, 1990, SCI CHINA SER B, V33, P1304; Hasler U, 1998, J BIOL CHEM, V273, P30826, DOI 10.1074/jbc.273.46.30826; HOWARDS SS, 1997, INFERTILITY MALE, P106; James PF, 1999, MOL CELL, V3, P555, DOI 10.1016/S1097-2765(00)80349-4; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; Johnson LR, 1999, BIOL REPROD, V60, P683, DOI 10.1095/biolreprod60.3.683; Keskes L, 1998, MOL REPROD DEV, V49, P416, DOI 10.1002/(SICI)1098-2795(199804)49:4<416::AID-MRD9>3.0.CO;2-Q; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; Malik N, 1996, J BIOL CHEM, V271, P22754, DOI 10.1074/jbc.271.37.22754; MCDONOUGH AA, 1990, FASEB J, V4, P1598, DOI 10.1096/fasebj.4.6.2156741; MCGRADY A, 1979, J REPROD FERTIL, V56, P549, DOI 10.1530/jrf.0.0560549; MITCHELL P, 1979, SCIENCE, V206, P1148, DOI 10.1126/science.388618; MRSNY RJ, 1981, J CELL BIOL, V91, P77; MUNZER JS, 1994, J BIOL CHEM, V269, P16668; NALBANDOV AV, 1964, REPROD PHYSL COMP RE, P201; NELSON L, 1981, ARCH ANDROLOGY, V7, P169, DOI 10.3109/01485018108999304; ORLOWSKI J, 1988, J BIOL CHEM, V263, P10436; PELLINIEMI LJ, 1993, MOL BIOL MALE REPROD, P21; Roth TL, 1999, BIOL REPROD, V60, P493, DOI 10.1095/biolreprod60.2.493; SCHACKMANN RW, 1984, J BIOL CHEM, V259, P3914; Seed J, 1996, REPROD TOXICOL, V10, P237, DOI 10.1016/0890-6238(96)00028-7; SHAMRAJ OI, 1994, P NATL ACAD SCI USA, V91, P12952, DOI 10.1073/pnas.91.26.12952; Shull GE, 2000, AM J PHYSIOL-GASTR L, V278, pG185, DOI 10.1152/ajpgi.2000.278.2.G185; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; TALANSKY BE, 1987, J REPROD FERTIL, V79, P447, DOI 10.1530/jrf.0.0790447; Therien AG, 1996, J BIOL CHEM, V271, P7104, DOI 10.1074/jbc.271.12.7104; Therien AG, 1999, J BIOL CHEM, V274, P12252, DOI 10.1074/jbc.274.18.12252; Underhill DA, 1999, BIOCHEMISTRY-US, V38, P14746, DOI 10.1021/bi9916168; Wadi SA, 1999, J TOXICOL ENV HEAL A, V56, P513, DOI 10.1080/009841099157953; WONG PYD, 1981, EXP CELL RES, V131, P97, DOI 10.1016/0014-4827(81)90410-9; Woo AL, 1999, J MEMBRANE BIOL, V169, P39, DOI 10.1007/PL00005899	46	126	133	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20693	20699		10.1074/jbc.M002323200	http://dx.doi.org/10.1074/jbc.M002323200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10764792	hybrid			2022-12-27	WOS:000088084500067
J	Wang, XJ; Walsh, LP; Reinhart, AJ; Stocco, DM				Wang, XJ; Walsh, LP; Reinhart, AJ; Stocco, DM			The role of arachidonic acid in steroidogenesis and steroidogenic acute regulatory (StAR) gene and protein expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT LEYDIG-CELLS; LH-STIMULATED STEROIDOGENESIS; TUMOR-CELLS; CYCLIC-AMP; ADRENAL STEROIDOGENESIS; GONADOTROPIN RECEPTORS; LIPOXYGENASE PRODUCTS; CORPUS-LUTEUM; HORMONE; INVOLVEMENT	This study was conducted to examine the mechanism for arachidonic acid (AA) regulation of steroidogenic acute regulatory (StAR) protein expression and the relationship between AA and cAMP in hormone-induced steroidogenesis, Dibutyryl cyclic AMP (Bt(2)cAMP)-stimulated MA-10 Leydig cells were treated with AA and/or the phospholipase A, inhibitor, dexamethasone, Dexamethasone significantly reduced Bt(2)cAMP-stimulated progesterone production, StAR promoter activity, StAR mRNA, and StAR protein. The inhibitory effects of dexamethasone were reversed by the addition of 150 mu M AA to MA-10 cells. In addition, MA-10 cells were treated with the lipoxygenase inhibitor, nordihydroguaiaretic acid (NDGA), the 5-lipoxygenase inhibitor, AA861, the epoxygenase inhibitor, miconazole, and the cyclooxygenase inhibitor, indomethacin, Both NDGA and AA861 inhibited progesterone production and StAR protein expression. AA861-inhibited progesterone synthesis and StAR protein were partially reversed by addition of the 5-lipoxygenase metabolite, 5(S)-hydroperoxy-(6E,8Z,11Z, 14Z)-eicosatetraenoic acid. Inhibition of epoxygenase activity inhibited progesterone production significantly, but StAR protein was only slightly reduced. Indomethacin enhanced StAR protein expression and significantly increased progesterone production. Inhibition of AA release or lipoxygenase activities did not affect protein kinase A activity, whereas inhibition of protein kinase A activity using H89 reduced Bt(2)cAMP-induced StAR protein. AA alone did not induce StAR protein expression nor steroid production. These results demonstrate the essential role of AA in steroid biosynthesis and StAR gene transcription and suggest the possible involvement of the lipoxygenase pathway in steroidogenesis. This study further indicates that AA and cAMP transduce signals from trophic hormone receptors to the nucleus through two separate pathways and act to co-regulate steroid production and StAR gene expression and indicates that both pathways are required for trophic hormone-stimulated steroidogenesis.	Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Anat, Lubbock, TX 79430 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	Stocco, DM (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Anat, Lubbock, TX 79430 USA.							ABAYASEKARA DRE, 1990, MOL CELL ENDOCRINOL, V70, P147, DOI 10.1016/0303-7207(90)90154-Z; ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; BAND V, 1986, PROSTAGLANDINS, V31, P509, DOI 10.1016/0090-6980(86)90113-9; Braford MM, 1976, ANAL BIOCHEM, V72, P248; Caron KM, 1997, MOL ENDOCRINOL, V11, P138, DOI 10.1210/me.11.2.138; CHANG J, 1987, BIOCHEM PHARMACOL, V36, P2429, DOI 10.1016/0006-2952(87)90512-0; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; Cooke BA, 1999, MOL CELL ENDOCRINOL, V151, P25, DOI 10.1016/S0303-7207(98)00255-X; COOKE BA, 1991, J STEROID BIOCHEM, V40, P465, DOI 10.1016/0960-0760(91)90216-R; DIX CJ, 1984, BIOCHEM J, V219, P529, DOI 10.1042/bj2190529; Fiedler EP, 1999, BIOL REPROD, V61, P643, DOI 10.1095/biolreprod61.3.643; Finkielstein C, 1998, EUR J BIOCHEM, V256, P60, DOI 10.1046/j.1432-1327.1998.2560060.x; FLOWER RJ, 1984, ADV INFLAMMAT RES, V8, P1; HIRAI A, 1985, PROSTAGLANDINS, V30, P749, DOI 10.1016/0090-6980(85)90005-X; LAPETINA EG, 1981, J BIOL CHEM, V256, P5037; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; LOPEZRUIZ MP, 1992, ENDOCRINOLOGY, V130, P1122, DOI 10.1210/en.130.3.1122; Mele PG, 1997, ENDOCR RES, V23, P15, DOI 10.1080/07435809709031839; Mercure F, 1996, GEN COMP ENDOCR, V102, P130, DOI 10.1006/gcen.1996.0054; MIKAMI K, 1990, J ENDOCRINOL, V125, P89, DOI 10.1677/joe.0.1250089; Moraga PF, 1997, J ENDOCRINOL, V154, P201, DOI 10.1677/joe.0.1540201; NATARAJAN R, 1990, MOL CELL ENDOCRINOL, V72, P73, DOI 10.1016/0303-7207(90)90096-Q; NEDDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69; NISHIKAWA T, 1994, J BIOCHEM-TOKYO, V116, P833, DOI 10.1093/oxfordjournals.jbchem.a124603; NISHIMURA M, 1989, PROSTAGLANDINS, V38, P413, DOI 10.1016/0090-6980(89)90124-X; Reinhart AJ, 1999, MOL CELL ENDOCRINOL, V151, P161, DOI 10.1016/S0303-7207(98)00257-3; RESKO JA, 1974, ENDOCRINOLOGY, V94, P128, DOI 10.1210/endo-94-1-128; ROMANELLI F, 1995, J ENDOCRINOL INVEST, V18, P186, DOI 10.1007/BF03347801; SOLANO AR, 1988, J MOL ENDOCRINOL, V1, P147, DOI 10.1677/jme.0.0010147; Stocco DM, 1997, ENDOCRINE, V6, P99, DOI 10.1007/BF02738952; SULLIVAN MHF, 1985, BIOCHEM J, V232, P55, DOI 10.1042/bj2320055; Townson DH, 1996, BIOL REPROD, V55, P868, DOI 10.1095/biolreprod55.4.868; VANDENBOSCH H, 1980, BIOCHIM BIOPHYS ACTA, V604, P191; VANVOORHIS BJ, 1993, J CLIN ENDOCR METAB, V76, P1555, DOI 10.1210/jc.76.6.1555; WANG J, 1989, ENDOCRINOLOGY, V124, P1973, DOI 10.1210/endo-124-4-1973; Wang XJ, 1999, MOL CELL ENDOCRINOL, V158, P7, DOI 10.1016/S0303-7207(99)00130-6; Wang XJ, 1998, ENDOCRINOLOGY, V139, P3903, DOI 10.1210/en.139.9.3903; Wang XJ, 1999, ENDOCRINE, V10, P7, DOI 10.1385/ENDO:10:1:7; WILLIS AL, 1994, HDB IMMUNOPHARMACOLO, P1; Yamazaki T, 1996, ENDOCRINOLOGY, V137, P2670, DOI 10.1210/en.137.7.2670	40	120	128	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					20204	20209		10.1074/jbc.M003113200	http://dx.doi.org/10.1074/jbc.M003113200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10777507	hybrid			2022-12-27	WOS:000087941300102
J	Kariya, K; Koyama, S; Nakashima, S; Oshiro, T; Morinaka, K; Kikuchi, A				Kariya, K; Koyama, S; Nakashima, S; Oshiro, T; Morinaka, K; Kikuchi, A			Regulation of complex formation of POB1/epsin/adaptor protein complex 2 by mitotic phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE SUBSTRATE; RECEPTOR-MEDIATED ENDOCYTOSIS; EH-DOMAIN; COATED PITS; ACTIN CYTOSKELETON; INSULIN-RECEPTORS; VESICLE FORMATION; EPS15; CLATHRIN; ADAPTER	RalBP1 and POB1, the downstream molecules of small GTP-binding protein Pal, are involved in receptor-mediated endocytosis together with Epsin and Eps15. The regulation of assembly of the complex of these proteins wits examined. RalBP1, POB1, Epsin, and Eps15 formed a complex with alpha-adaptin of AP-2 in Chinese hamster ovary cells, but the formation was reduced in mitotic phase. RalBP1, POB1, Epsin, and Eps15 were all phosphorylated in mitotic phase. The phosphorylated forms of POB1 and Epsin were recognized by the antibody MPM2, which is known to detect mitotic phosphoproteins. POB1 and Epsin were phosphorylated by p34(cdc2) kinase in vitro. Their phosphorylation sites (Ser(411) of POB1 and Ser(357) Of Epsin) were determined. Phosphorylated Epsin and Epsin(S357D) formed a complex with alpha-adaptin less efficiently than wild type Epsin. Although the EH domain of POB1 bound directly to Epsin, phosphorylation of Epsin inhibited the binding. Furthermore, Epsin(S357D) but not Epsin(S357A) lost the effect of Epsin on the insulin-dependent endocytosis, These results suggest that phosphorylation of Epsin in mitotic phase inhibits receptor-mediated endocytosis by disassembly of its complex with POB1 and alpha-adaptin.	Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan	Hiroshima University	Kikuchi, A (corresponding author), Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	akikuchi@mcai.med.hiroshima-u.ac.jp						BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Biener Y, 1996, J BIOL CHEM, V271, P29489, DOI 10.1074/jbc.271.46.29489; Brodsky FM, 1997, TRENDS CELL BIOL, V7, P175, DOI 10.1016/S0962-8924(97)01038-6; Carbone R, 1997, CANCER RES, V57, P5498; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Chen H, 1999, J BIOL CHEM, V274, P3257, DOI 10.1074/jbc.274.6.3257; Coda L, 1998, J BIOL CHEM, V273, P3003, DOI 10.1074/jbc.273.5.3003; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Dell'Angelica EC, 1999, J BIOL CHEM, V274, P7278, DOI 10.1074/jbc.274.11.7278; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; DiFiore PP, 1997, TRENDS BIOCHEM SCI, V22, P411, DOI 10.1016/S0968-0004(97)01127-4; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; HARI J, 1987, J BIOL CHEM, V262, P15341; Iannolo G, 1997, CANCER RES, V57, P240; Kay BK, 1999, PROTEIN SCI, V8, P435; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; McMahon HT, 1999, CURR BIOL, V9, pR332, DOI 10.1016/S0960-9822(99)80206-1; McPherson PS, 1998, BIOCHEM BIOPH RES CO, V244, P701, DOI 10.1006/bbrc.1998.8331; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; Morinaka K, 1999, ONCOGENE, V18, P5915, DOI 10.1038/sj.onc.1202974; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; PAUL ECA, 1993, J CELL SCI, V106, P967; Pishvaee B, 1998, CELL, V95, P443, DOI 10.1016/S0092-8674(00)81611-6; PYPAERT M, 1987, EUR J CELL BIOL, V45, P23; PYPAERT M, 1991, J CELL BIOL, V114, P1159, DOI 10.1083/jcb.114.6.1159; Quaroni A, 1999, J CELL SCI, V112, P707; Robinson MS, 1997, TRENDS CELL BIOL, V7, P99, DOI 10.1016/S0962-8924(96)10048-9; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Sengar AS, 1999, EMBO J, V18, P1159, DOI 10.1093/emboj/18.5.1159; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; Tang HY, 1997, MOL CELL BIOL, V17, P4294, DOI 10.1128/MCB.17.8.4294; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VANDERSLUIJS P, 1992, EMBO J, V11, P4379, DOI 10.1002/j.1460-2075.1992.tb05538.x; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; Wendland B, 1998, J CELL BIOL, V141, P71, DOI 10.1083/jcb.141.1.71; Wendland B, 1999, EMBO J, V18, P4383, DOI 10.1093/emboj/18.16.4383; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; Yamabhai M, 1998, J BIOL CHEM, V273, P31401, DOI 10.1074/jbc.273.47.31401; Yamaguchi A, 1997, J BIOL CHEM, V272, P31230, DOI 10.1074/jbc.272.50.31230	46	53	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18399	18406		10.1074/jbc.M000521200	http://dx.doi.org/10.1074/jbc.M000521200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10764745	hybrid			2022-12-27	WOS:000087659400067
J	McCutchen-Maloney, SL; Matsuda, K; Shimbara, N; Binns, DD; Tanaka, K; Slaughter, CA; DeMartino, GN				McCutchen-Maloney, SL; Matsuda, K; Shimbara, N; Binns, DD; Tanaka, K; Slaughter, CA; DeMartino, GN			cDNA cloning, expression, and functional characterization of PI31, a proline-rich inhibitor of the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-MOLECULAR-WEIGHT; DEPENDENT PROTEIN-DEGRADATION; AMYLOID-BETA-PROTEIN; 20S PROTEASOME; MULTICATALYTIC PROTEINASE; THERMOPLASMA-ACIDOPHILUM; ENDOGENOUS INHIBITOR; 20-S PROTEASOME; 11-S REGULATOR; 26S PROTEASOME	The primary structure of PI31, a protein inhibitor of the 20 S proteasome, was deduced by cDNA cloning and sequencing. The human protein has a calculated molecular weight of 29,792, a value in excellent accord with 31,000, as estimated by SDS-polyacrylamide gel electrophoresis for purified bovine PI31, and is not similar to any other protein in current data bases. PI31 is a proline-rich protein, particularly within its carboxyl-terminal half where 26% of the amino acids are proline. Wildtype PI31 and various truncation mutants were expressed in Escherichia coli and purified to homogeneity, Recombinant wild-type PI31 displayed structural and functional properties similar to those of PI31 purified from bovine red blood cells and inhibited the hydrolysis of protein and peptide substrates by the 20 S proteasome. Analysis of truncation mutants demonstrated that proteasome inhibition was conferred by the carboxyl-terminal proline-rich domain of PI31, which appears to have an extended secondary structure. Inhibition of the 20 S proteasome by PI31 involved formation a proteasome-PI31 complex. In addition to its direct inhibition of the 20 S proteasome, PI31 inhibited the activation of the proteasome by each of two proteasome regulatory proteins, PA700 and PA28, These results suggest that PI31 plays an important role in control of proteasome function, including that in ubiquitin-dependent pathways of protein degradation.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Kobe Gakuin Univ, Fac Nutr, Nishi Ku, Kobe, Hyogo 65121, Japan; Sumitomo Elect Ind Ltd, Dept Biomed R&D, Sakae Ku, Yokohama, Kanagawa 244, Japan; Tokyo Metropolitan Inst Med Sci, Bunkyo Ku, Tokyo 1130021, Japan; Japan Sci & Technol Corp, CREST, Bunkyo Ku, Tokyo 1130021, Japan	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Kobe Gakuin University; Sumitomo Electric Industries; Tokyo Metropolitan Institute of Medical Science; Japan Science & Technology Agency (JST)	DeMartino, GN (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL006296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046181, R56DK046181] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018388] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL06296] Funding Source: Medline; NIDDK NIH HHS [DK 46181] Funding Source: Medline; NIGMS NIH HHS [1 F32 GM18388-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams GM, 1997, J MOL BIOL, V273, P646, DOI 10.1006/jmbi.1997.1334; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bochtler M, 1999, ANNU REV BIOPH BIOM, V28, P295, DOI 10.1146/annurev.biophys.28.1.295; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; DRISCOLL J, 1992, P NATL ACAD SCI USA, V89, P4986, DOI 10.1073/pnas.89.11.4986; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; GANOTH D, 1988, J BIOL CHEM, V263, P12412; Grand RJA, 1999, ONCOGENE, V18, P449, DOI 10.1038/sj.onc.1202304; GRAY CW, 1994, J MOL BIOL, V236, P7, DOI 10.1006/jmbi.1994.1113; GREGORI L, 1995, J BIOL CHEM, V270, P19702, DOI 10.1074/jbc.270.34.19702; Gregori L, 1997, J BIOL CHEM, V272, P58; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; GRZIWA A, 1991, FEBS LETT, V290, P186, DOI 10.1016/0014-5793(91)81256-8; GUO GG, 1994, J BIOL CHEM, V269, P12399; HEINEMEYER W, 1994, BIOCHEMISTRY-US, V33, P12229, DOI 10.1021/bi00206a028; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; KOPP F, 1993, J MOL BIOL, V229, P14, DOI 10.1006/jmbi.1993.1003; LI XC, 1991, BIOCHEMISTRY-US, V30, P9709, DOI 10.1021/bi00104a020; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MA CP, 1994, J BIOL CHEM, V269, P3539; MA CP, 1992, BIOCHIM BIOPHYS ACTA, V1119, P303, DOI 10.1016/0167-4838(92)90218-3; MA CP, 1992, J BIOL CHEM, V267, P10515; MCGUIRE MJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P181, DOI 10.1016/0167-4838(89)90078-2; MURAKAMI K, 1986, P NATL ACAD SCI USA, V83, P7588, DOI 10.1073/pnas.83.20.7588; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; Preckel T, 1999, SCIENCE, V286, P2162, DOI 10.1126/science.286.5447.2162; PUHLER G, 1992, EMBO J, V11, P1607, DOI 10.1002/j.1460-2075.1992.tb05206.x; Rechsteiner M, 2000, BIOCHEM J, V345, P1, DOI 10.1042/0264-6021:3450001; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; Seeger M, 1997, J BIOL CHEM, V272, P8145, DOI 10.1074/jbc.272.13.8145; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Strickland E, 2000, J BIOL CHEM, V275, P5565, DOI 10.1074/jbc.275.8.5565; TSUBUKI S, 1994, FEBS LETT, V344, P229, DOI 10.1016/0014-5793(94)00388-2; UDVARDY A, 1993, J BIOL CHEM, V268, P9055; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; WENZEL T, 1996, STRUCT BIOL, V2, P199; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; YOSHIMURA T, 1993, J STRUCT BIOL, V111, P200, DOI 10.1006/jsbi.1993.1050; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	46	98	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18557	18565		10.1074/jbc.M001697200	http://dx.doi.org/10.1074/jbc.M001697200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10764772	hybrid			2022-12-27	WOS:000087659400088
J	Wang, GS; Sondej, M; Garrett, DS; Peterkofsky, A; Clore, GM				Wang, GS; Sondej, M; Garrett, DS; Peterkofsky, A; Clore, GM			A common interface on histidine-containing phosphocarrier protein for interaction with its partner proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUGAR PHOSPHOTRANSFERASE SYSTEM; N-TERMINAL DOMAIN; ESCHERICHIA-COLI PHOSPHOENOLPYRUVATE; ENZYME-I; RESOLUTION STRUCTURE; BINDING-SITE; HPR; NMR; IDENTIFICATION; TRANSPORT	The bacterial phosphoenolpyruvate:sugar phosphotransferase system accomplishes both the transport and phosphorylation of sugars as well as the regulation of some cellular processes. An important component of this system is the histidine-containing phosphocarrier protein, HPr, which accepts a phosphoryl group from enzyme I, transfers a phosphoryl group to IIA proteins, and is an allosteric regulator of glycogen phosphorylase. Because the nature of the surface on HPr that interacts with this multiplicity of proteins from Escherichia coli was previously undefined, we investigated these interactions by nuclear magnetic resonance spectroscopy. The chemical shift changes of the backbone and side-chain amide H-1 and N-15 nuclei of uniformly N-15-labeled HPr in the absence and presence of natural abundance glycogen phosphorylase, glucose-specific enzyme ZIA, or the N-terminal domain of enzyme I have been determined. Mapping these chemical shift perturbations onto the three-dimensional structure of HPr permitted us to identify the binding surface(s) of HPr for interaction with these proteins. Here we show that the mapped interfaces on HPr are remarkably similar, indicating that HPr employs a similar surface in binding to its partners.	NHLBI, Lab Biochem Genet, NIH, Bethesda, MD 20892 USA; NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Peterkofsky, A (corresponding author), NHLBI, Lab Biochem Genet, NIH, Bldg 36,Room 4C-11, Bethesda, MD 20892 USA.		Clore, G. Marius/A-3511-2008; Clore, G Marius/L-2546-2018	Clore, G. Marius/0000-0003-3809-1027; Clore, G Marius/0000-0003-3809-1027	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK029023, Z01DK029023] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brokx SJ, 1999, BIOCHEM CELL BIOL, V77, P507; CHEN Y, 1993, BIOCHEMISTRY-US, V32, P32, DOI 10.1021/bi00052a006; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Garrett DS, 1997, BIOCHEMISTRY-US, V36, P4393, DOI 10.1021/bi970221q; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Garrett DS, 1999, NAT STRUCT BIOL, V6, P166; Garrett DS, 1997, BIOCHEMISTRY-US, V36, P2517, DOI 10.1021/bi962924y; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; HERZBERG O, 1994, CURR OPIN STRUC BIOL, V4, P814, DOI 10.1016/0959-440X(94)90262-3; JIA ZC, 1993, J BIOL CHEM, V268, P22490; Jones BE, 1997, J BIOL CHEM, V272, P26530, DOI 10.1074/jbc.272.42.26530; Liao DI, 1996, STRUCTURE, V4, P861, DOI 10.1016/S0969-2126(96)00092-5; Medek A, 2000, J AM CHEM SOC, V122, P1241, DOI 10.1021/ja993921m; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Postma P.W., 1996, ESCHERICHIA COLI SAL, P1149; Reddy P, 1991, Protein Expr Purif, V2, P179, DOI 10.1016/1046-5928(91)90069-U; Seok YJ, 1997, J BIOL CHEM, V272, P26511, DOI 10.1074/jbc.272.42.26511; Seok YJ, 1996, P NATL ACAD SCI USA, V93, P347, DOI 10.1073/pnas.93.1.347; VANNULAND NAJ, 1995, J MOL BIOL, V246, P180, DOI 10.1006/jmbi.1994.0075; VANNULAND NAJ, 1993, FEBS LETT, V315, P11, DOI 10.1016/0014-5793(93)81122-G; Zhu PP, 1998, BIOCHEMISTRY-US, V37, P11762, DOI 10.1021/bi980455p	21	29	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16401	16403		10.1074/jbc.C000167200	http://dx.doi.org/10.1074/jbc.C000167200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10764730	hybrid			2022-12-27	WOS:000087392200001
J	Lanchy, JM; Isel, C; Keith, G; Le Grice, SFJ; Ehresmann, C; Ehresmann, B; Marquet, R				Lanchy, JM; Isel, C; Keith, G; Le Grice, SFJ; Ehresmann, C; Ehresmann, B; Marquet, R			Dynamics of the HIV-1 reverse transcription complex during initiation of DNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PRIMER-BINDING-SITE; TRANSFER-RNAS; SECONDARY STRUCTURE; TYPE-1 RNA; EFFICIENT INITIATION; FOOTPRINT ANALYSIS; TRNA(3)(LYS); REPLICATION; COMPLEMENTARY	Initiation of human immunodeficiency virus-1 (HIV-1) reverse transcription requires formation of a complex containing the viral RNA (vRNA), tRNA(3)(Lys) and reverse transcriptase (RT). The vRNA and the primer tRNA(3)(Lys) form several intermolecular interactions in addition to annealing of the primer 3' end to the primer binding site (PBS). These interactions are crucial for the efficiency and the specificity of the initiation of reverse transcription. However, as they are located upstream of the PBS, they must unwind as DNA synthesis proceeds. Here, the dynamics of the complex during initiation of reverse transcription was followed by enzymatic probing. Our data revealed reciprocal effects of the tertiary structure of the vRNA . tRNA(3)(Lys) complex and reverse transcriptase (RT) at a distance from the polymerization site, The structure of the initiation complex allowed RT to interact with the template strand up to 20 nucleotides upstream from the polymerization site, Conversely, nucleotide addition by RT modified the tertiary structure of the complex at 10-14 nucleotides from the catalytic site. The viral sequences became exposed at the surface of the complex as they dissociated from the tRNA following primer extension. However, the counterpart tRNA sequences became buried inside the complex. Surprisingly, they became exposed when mutations prevented the intermolecular interactions in the initial complex, indicating that the fate of the tRNA depended on the tertiary structure of the initial complex.	Inst Biol Mol & Cellulaire, CNRS, UPR 9002, F-67084 Strasbourg, France; Case Western Reserve Univ, Sch Med, Div Infect Dis, Cleveland, OH 44106 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Case Western Reserve University	Marquet, R (corresponding author), Inst Biol Mol & Cellulaire, CNRS, UPR 9002, 15 Rue Rene Descartes, F-67084 Strasbourg, France.		Isel, Catherine/B-9406-2015; Isel, Catherine/AAH-2174-2020	Isel, Catherine/0000-0001-7258-869X; Isel, Catherine/0000-0002-8014-7525; Marquet, Roland/0000-0002-4209-3976				AIYAR A, 1994, J VIROL, V68, P611, DOI 10.1128/JVI.68.2.611-618.1994; AIYAR A, 1992, J VIROL, V66, P2464, DOI 10.1128/JVI.66.4.2464-2472.1992; Arts EJ, 1998, PROG NUCLEIC ACID RE, V58, P339; Arts EJ, 1996, J BIOL CHEM, V271, P9054, DOI 10.1074/jbc.271.15.9054; Arts EJ, 1996, P NATL ACAD SCI USA, V93, P10063, DOI 10.1073/pnas.93.19.10063; BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; BAUDIN F, 1993, J MOL BIOL, V229, P382, DOI 10.1006/jmbi.1993.1041; BERKHOUT B, 1993, NUCLEIC ACIDS RES, V21, P1171, DOI 10.1093/nar/21.5.1171; DAS AT, 1995, J VIROL, V69, P3090, DOI 10.1128/JVI.69.5.3090-3097.1995; Essink BBO, 1996, J MOL BIOL, V264, P243, DOI 10.1006/jmbi.1996.0638; Friant S, 1996, NUCLEIC ACIDS RES, V24, P441, DOI 10.1093/nar/24.3.441; GOTTE M, 1995, EMBO J, V14, P833, DOI 10.1002/j.1460-2075.1995.tb07061.x; Huang Y, 1997, J VIROL, V71, P726, DOI 10.1128/JVI.71.1.726-728.1997; Huang Y, 1996, J VIROL, V70, P4700, DOI 10.1128/JVI.70.7.4700-4706.1996; Isel C, 1998, NUCLEIC ACIDS RES, V26, P1198, DOI 10.1093/nar/26.5.1198; ISEL C, 1993, J BIOL CHEM, V268, P25269; Isel C, 1999, EMBO J, V18, P1038, DOI 10.1093/emboj/18.4.1038; ISEL C, 1995, J MOL BIOL, V247, P236, DOI 10.1006/jmbi.1994.0136; Isel C, 1996, EMBO J, V15, P917, DOI 10.1002/j.1460-2075.1996.tb00426.x; Kang SM, 1997, J VIROL, V71, P207, DOI 10.1128/JVI.71.1.207-217.1997; Lanchy JM, 1998, J BIOL CHEM, V273, P24425, DOI 10.1074/jbc.273.38.24425; Lanchy JM, 1996, EMBO J, V15, P7178, DOI 10.1002/j.1460-2075.1996.tb01109.x; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; LI XG, 1994, J VIROL, V68, P6198, DOI 10.1128/JVI.68.10.6198-6206.1994; Liang C, 1997, J VIROL, V71, P5750, DOI 10.1128/JVI.71.8.5750-5757.1997; Mak J, 1997, J VIROL, V71, P8087, DOI 10.1128/JVI.71.11.8087-8095.1997; MARQUET R, 1995, BIOCHIMIE, V77, P113, DOI 10.1016/0300-9084(96)88114-4; MARQUET R, 1991, NUCLEIC ACIDS RES, V19, P2349, DOI 10.1093/nar/19.9.2349; METZGER W, 1993, P NATL ACAD SCI USA, V90, P5909, DOI 10.1073/pnas.90.13.5909; SKALKA A, 1993, REVERSE TRANSCRIPTAS; Skripkin E, 1996, NUCLEIC ACIDS RES, V24, P509, DOI 10.1093/nar/24.3.509; Suo ZC, 1998, J BIOL CHEM, V273, P27259, DOI 10.1074/jbc.273.42.27259; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; WAKEFIELD JK, 1995, J VIROL, V69, P6021, DOI 10.1128/JVI.69.10.6021-6029.1995; Wakefield JK, 1996, J VIROL, V70, P966, DOI 10.1128/JVI.70.2.966-975.1996; WHITCOMB JM, 1995, J VIROL, V69, P6228, DOI 10.1128/JVI.69.10.6228-6238.1995; WOHRL BM, 1995, BIOCHEMISTRY-US, V34, P5343; WOHRL BM, 1995, SCIENCE, V267, P96, DOI 10.1126/science.7528942; Zhang ZJ, 1998, AIDS RES HUM RETROV, V14, P979, DOI 10.1089/aid.1998.14.979; Zhang ZJ, 1998, RNA, V4, P394	40	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12306	12312		10.1074/jbc.275.16.12306	http://dx.doi.org/10.1074/jbc.275.16.12306			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766870	hybrid			2022-12-27	WOS:000086695500105
J	Liu, MY; Parker, LL; Wadzinski, BE; Shieh, BH				Liu, MY; Parker, LL; Wadzinski, BE; Shieh, BH			Reversible phosphorylation of the signal transduction complex in Drosophila photoreceptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PDZ-DOMAIN PROTEIN; TRP CA2+ CHANNEL; ELECTROPHYSIOLOGICAL CHARACTERIZATION; GENE ENCODES; INAD; PHOSPHATASES; MEMBRANE; NORPA; PHOTOTRANSDUCTION	In the Drosophila visual cascade, the transient receptor potential (TRP) calcium channel, phospholipase C beta (no-receptor-potential A), and an eye-specific isoform of protein kinase C (eye-PKC) comprise a multimolecular signaling complex via their interaction with the scaffold protein INAD, Previously, we showed that the interaction between INAD and eye-PKC is a prerequisite for deactivation of a light response, suggesting eye-PKC phosphorylates proteins in the complex. To identify substrates of eye-PKC, we immunoprecipitated the complex from head lysates using anti-INAD antibodies and performed in vitro kinase assays. Wild-type immunocomplexes incubated with [P-32]ATP revealed phosphorylation of TRP and INAD. In contrast, immunocomplexes from inaC mutants missing eye-PKC, displayed no phosphorylation of TRP or INAD. We also investigated protein phosphatases that may be involved in the dephosphorylation of proteins in the complex, Dephosphorylation of TRP and INAD was partially suppressed by the protein phosphatase inhibitors okadaic acid, microcystin, and protein phosphatase inhibitor-2, These phosphatase activities were enriched in the cytosol of mild-type heads, but drastically reduced in extracts prepared from glass mutants, which lack photoreceptors, Our findings indicate that INAD functions as RAGE (receptor for activated PKC), allowing eye-PKC to phosphorylate INAD and TRP. Furthermore, dephosphorylation of INAD and TRP is catalyzed by PP1/PP2A-like enzymes preferentially expressed in photoreceptor cells.	Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Mol Neurosci, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Shieh, BH (corresponding author), Vanderbilt Univ, Dept Pharmacol, 402 Med Res Bldg 1, Nashville, TN 37232 USA.	bih-hwa.shieh@mcmail.vanderbilt.edu			NEI NIH HHS [EY09743] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009743] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adamski FM, 1998, J BIOL CHEM, V273, P17713, DOI 10.1074/jbc.273.28.17713; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1991, METHOD ENZYMOL, V201, P389; Craig M, 1996, BIOCHEM CELL BIOL, V74, P569, DOI 10.1139/o96-061; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; ENAN E, 1992, BIOCHEM PHARMACOL, V43, P1777, DOI 10.1016/0006-2952(92)90710-Z; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Huber A, 1998, FEBS LETT, V425, P317, DOI 10.1016/S0014-5793(98)00248-8; Huber A, 1996, J BIOL CHEM, V271, P11710, DOI 10.1074/jbc.271.20.11710; Huber A, 1996, EMBO J, V15, P7036, DOI 10.1002/j.1460-2075.1996.tb01095.x; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; MOSES K, 1989, NATURE, V340, P531, DOI 10.1038/340531a0; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; ORGAD S, 1987, EUR J BIOCHEM, V164, P31, DOI 10.1111/j.1432-1033.1987.tb10988.x; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; Pearn MT, 1996, J BIOL CHEM, V271, P4937; RANGANATHAN R, 1995, ANNU REV NEUROSCI, V18, P283; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SHIEH BH, 1995, NEURON, V14, P201, DOI 10.1016/0896-6273(95)90255-4; Shieh BH, 1997, P NATL ACAD SCI USA, V94, P12682, DOI 10.1073/pnas.94.23.12682; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; van Huizen R, 1998, EMBO J, V17, P2285, DOI 10.1093/emboj/17.8.2285; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; WONG F, 1989, NEURON, V3, P81, DOI 10.1016/0896-6273(89)90117-7	37	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12194	12199		10.1074/jbc.275.16.12194	http://dx.doi.org/10.1074/jbc.275.16.12194			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766855	hybrid			2022-12-27	WOS:000086695500090
J	Peracchi, A				Peracchi, A			Preferential activation of the 8-17 deoxyribozyme by Ca2+ ions - Evidence for the identity of 8-17 with the catalytic domain of the MG5 deoxyribozyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-CLEAVING DEOXYRIBOZYME; DIVALENT METAL-IONS; DNA ENZYMES; CLEAVAGE REACTION; HAMMERHEAD; INHIBITION; MECHANISM	The 8-17 deoxyribozyme is a small RNA-cleaving DNA molecule of potential therapeutic interest. Here, the cleavage rates of 16 variants of the 8-17 deoxyribozyme were measured in the presence of different divalent metal ions. Despite the fact that 8-17 was originally selected in vitro for activity in the presence of Mg2+ (Santoro, S. W., and Joyce, G. F. (1997) Proc. Natl. Acad. Sci. U.S. A. 94, 4262-4266) nearly all the 8-17 variants exhibited substantially higher (up to 20-fold) reaction rates in Ca2+ as compared with Mg2+, This preference for calcium ions critically depended on the nucleoside residues at two specific positions of the deoxyribozyme core. The Ca2+ specificity of 8-17 is strongly reminiscent of the properties of Mg5, an RNA phosphodiester-cleaving deoxyribozyme previously isolated by Faulhammer and Famulok (Faulhammer, D., and Famulok, M. (1996) Angew. Chem. Int. Ed. Engl. 35, 2837-2841). Indeed, analysis of the Mg5 sequence revealed the presence of a complete 8-17 motif, coincident with the conserved region of Mg5, An 8-17 deoxyribozyme modeled after the Mg5 conserved region displayed catalytic features comparable with those reported for the full-length Mg5 deoxyribozyme.	Univ Parma, Inst Biochem Sci, I-43100 Parma, Italy	University of Parma	Peracchi, A (corresponding author), Univ Parma, Inst Biochem Sci, I-43100 Parma, Italy.	peracchi@ipruniv.cce.unipr.it	Peracchi, Alessio/Q-5173-2019; Peracchi, Alessio/G-5167-2012	Peracchi, Alessio/0000-0003-3254-4099; Peracchi, Alessio/0000-0003-3254-4099				BRAUNLIN WH, 1991, BIOPOLYMERS, V31, P1343, DOI 10.1002/bip.360311111; Breaker RR, 1997, NAT BIOTECHNOL, V15, P427, DOI 10.1038/nbt0597-427; BREAKER RR, 1995, CHEM BIOL, V2, P655, DOI 10.1016/1074-5521(95)90028-4; Cairns MJ, 1999, NAT BIOTECHNOL, V17, P480, DOI 10.1038/8658; DAHM SC, 1993, BIOCHEMISTRY-US, V32, P13040, DOI 10.1021/bi00211a013; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; Faulhammer D, 1997, J MOL BIOL, V269, P188, DOI 10.1006/jmbi.1997.1036; Faulhammer D, 1996, ANGEW CHEM INT EDIT, V35, P2837, DOI 10.1002/anie.199628371; Feig AL, 1998, SCIENCE, V279, P81, DOI 10.1126/science.279.5347.81; Frausto da Silva J. J. R., 1991, BIOL CHEM ELEMENTS, P241; GRANOT J, 1982, BIOPOLYMERS, V21, P181, DOI 10.1002/bip.360210115; HERSCHLAG D, 1991, P NATL ACAD SCI USA, V88, P6921, DOI 10.1073/pnas.88.16.6921; HERTEL KJ, 1992, NUCLEIC ACIDS RES, V20, P3252, DOI 10.1093/nar/20.12.3252; KAZAKOV SA, 1996, BIOORGANIC CHEM NUCL, P244; Kuwabara T, 1997, NUCLEIC ACIDS RES, V25, P3074, DOI 10.1093/nar/25.15.3074; Li J, 2000, NUCLEIC ACIDS RES, V28, P481, DOI 10.1093/nar/28.2.481; Li YF, 1999, CURR OPIN STRUC BIOL, V9, P315, DOI 10.1016/S0959-440X(99)80042-6; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; Narlikar GJ, 1997, ANNU REV BIOCHEM, V66, P19, DOI 10.1146/annurev.biochem.66.1.19; Peracchi A, 1998, BIOCHEMISTRY-US, V37, P14765, DOI 10.1021/bi980867y; Santiago FS, 1999, NAT MED, V5, P1264, DOI 10.1038/15215; Santoro SW, 1998, BIOCHEMISTRY-US, V37, P13330, DOI 10.1021/bi9812221; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; Sen D, 1998, CURR OPIN CHEM BIOL, V2, P680, DOI 10.1016/S1367-5931(98)80103-8; Sugimoto N, 1999, J CHEM SOC PERK T 2, P1381, DOI 10.1039/a901461f; Sun LQ, 1999, J BIOL CHEM, V274, P17236, DOI 10.1074/jbc.274.24.17236; Warashina M, 1999, CHEM BIOL, V6, P237, DOI 10.1016/S1074-5521(99)80039-8; Wu YP, 1999, HUM GENE THER, V10, P2847, DOI 10.1089/10430349950016573; YARUS M, 1993, FASEB J, V7, P31, DOI 10.1096/fasebj.7.1.8422972	29	102	104	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11693	11697		10.1074/jbc.275.16.11693	http://dx.doi.org/10.1074/jbc.275.16.11693			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766789	hybrid			2022-12-27	WOS:000086695500024
J	Powell, KA; Valova, VA; Malladi, CS; Jensen, ON; Larsen, MR; Robinson, PJ				Powell, KA; Valova, VA; Malladi, CS; Jensen, ON; Larsen, MR; Robinson, PJ			Phosphorylation of dynamin I on Ser-795 by protein kinase C blocks its association with phospholipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATION-DEPENDENT DEPHOSPHORYLATION; PLECKSTRIN HOMOLOGY DOMAIN; NERVE-TERMINALS; GTPASE ACTIVITY; ACIDIC PHOSPHOLIPIDS; INTACT SYNAPTOSOMES; SYNAPTIC VESICLES; BINDS DYNAMIN; SYNAPSIN-I; CALCIUM	Dynamin I is phosphorylated in nerve terminals exclusively in the cytosolic compartment and in vitro by protein kinase C (PRC). Dephosphorylation is required for synaptic vesicle retrieval, suggesting that its phosphorylation affects its subcellular localization, An in vitro phospholipid binding assay was established that prevents lipid vesiculation and dynamin lipid insertion into the lipid. Dynamin I bound the phospholipid in a concentration-dependent and saturable manner, with an apparent affinity of 230 +/- 51 nM. Optimal binding occurred with mixtures of phosphatidylserine and phosphatidylcholine of 1:3 with little binding to phosphatidylcholine or phosphatidylserine alone. Phospholipid binding was abolished after dynamin I phosphorylation by PKC and was restored after dephosphorylation by calcineurin. Matrix-assisted laser desorption/ionization-time of flight mass spectrometry revealed the phosphorylation site in PKC alpha-phosphorylated dynamin I as a single site at Ser-795, located near a binding site for the SH3 domain of p85, the regulatory subunit of phosphatidylinositol 3-kinase. However, phosphorylation had no effect on dynamin binding to a bacterially expressed p85-SH3 domain. Thus, phosphorylation of dynamin I on Ser-795 prevents its association with phospholipid, providing a basis for the cytosolic localization of the minor pool of phospho dynamin I that mediates synaptic vesicle retrieval in nerve terminals.	Odense Univ, Dept Mol Biol, Prot Res Grp, DK-5230 Odense, Denmark; Childrens Med Res Inst, Cell Signalling Unit, Sydney, NSW 2145, Australia	University of Southern Denmark; Children's Medical Research Institute - Australia; University of Sydney	Robinson, PJ (corresponding author), Odense Univ, Dept Mol Biol, Prot Res Grp, Campusvej 55, DK-5230 Odense, Denmark.	phrobins@mail.usyd.edu.au	Jensen, Ole N/J-1763-2012; Robinson, Phillip J/G-4008-2011; Larsen, Martin Rossel/F-1411-2015	Jensen, Ole N/0000-0003-1862-8528; Robinson, Phillip J/0000-0002-7878-0313; Larsen, Martin Rossel/0000-0001-6203-0123; Malladi, Chandra/0000-0002-5882-8228; Powell, Kate/0000-0002-1826-953X				ANDO Y, 1989, J BIOL CHEM, V264, P6948; Barylko B, 1998, J BIOL CHEM, V273, P3791, DOI 10.1074/jbc.273.6.3791; Bauerfeind R, 1997, J BIOL CHEM, V272, P30984, DOI 10.1074/jbc.272.49.30984; BAZZI MD, 1992, BIOCHEMISTRY-US, V31, P1125, DOI 10.1021/bi00119a022; BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P7961, DOI 10.1021/bi00246a013; Carr JF, 1997, J BIOL CHEM, V272, P28030, DOI 10.1074/jbc.272.44.28030; Chen H, 1999, J BIOL CHEM, V274, P3257, DOI 10.1074/jbc.274.6.3257; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; Earnest S, 1996, FEBS LETT, V396, P62, DOI 10.1016/0014-5793(96)01074-5; Gobom J, 1999, J MASS SPECTROM, V34, P105, DOI 10.1002/(SICI)1096-9888(199902)34:2<105::AID-JMS768>3.0.CO;2-4; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HOSOYA H, 1994, BIOCHEM BIOPH RES CO, V202, P1127, DOI 10.1006/bbrc.1994.2045; Jensen ON, 1998, PROTEINS, P74; KENNEDY MB, 1983, J NEUROSCI, V3, P818; KIM JY, 1994, J BIOL CHEM, V269, P28214; KOENIG JH, 1989, J NEUROSCI, V9, P3844; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; KRUEGER BK, 1977, J BIOL CHEM, V252, P2764; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU JP, 1994, J BIOL CHEM, V269, P21043; LIU JP, 1994, SCIENCE, V265, P970, DOI 10.1126/science.8052858; Liu JP, 1996, J NEUROCHEM, V66, P2074; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; Marks B, 1998, CURR BIOL, V8, P740, DOI 10.1016/S0960-9822(98)70297-0; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MIKI H, 1994, J BIOL CHEM, V269, P5489; NAVONE F, 1984, SCIENCE, V226, P1209, DOI 10.1126/science.6438799; OTERO AD, 1990, BIOCHEM PHARMACOL, V39, P1399; Rasmussen RK, 1998, BIOCHEM J, V335, P119, DOI 10.1042/bj3350119; ROBILLARD JE, 1988, SEMIN PERINATOL, V12, P143; ROBINSON PJ, 1991, FEBS LETT, V282, P388, DOI 10.1016/0014-5793(91)80520-D; ROBINSON PJ, 1994, TRENDS NEUROSCI, V17, P348, DOI 10.1016/0166-2236(94)90179-1; ROBINSON PJ, 1987, J NEUROCHEM, V48, P187, DOI 10.1111/j.1471-4159.1987.tb13146.x; ROBINSON PJ, 1992, J BIOL CHEM, V267, P21637; ROBINSON PJ, 1983, J NEUROCHEM, V41, P909, DOI 10.1111/j.1471-4159.1983.tb09034.x; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; SCAIFE R, 1994, EMBO J, V13, P2574, DOI 10.1002/j.1460-2075.1994.tb06547.x; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Stowell MHB, 1999, NAT CELL BIOL, V1, P27, DOI 10.1038/8997; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TARELLI FT, 1992, NEURON, V9, P1143, DOI 10.1016/0896-6273(92)90072-L; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; TUMA PL, 1993, J BIOL CHEM, V268, P17240; VOROTNIKOV AV, 1992, BIOCHEM J, V284, P911, DOI 10.1042/bj2840911; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033	53	62	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11610	11617		10.1074/jbc.275.16.11610	http://dx.doi.org/10.1074/jbc.275.16.11610			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766777	hybrid			2022-12-27	WOS:000086695500012
J	Wan, QJ; Fang, TW; Fenick, D; Garfield, S; Bienfait, B; Marquez, VE; Blumberg, PM				Wan, QJ; Fang, TW; Fenick, D; Garfield, S; Bienfait, B; Marquez, VE; Blumberg, PM			The lipophilicity of phorbol esters as a critical factor in determining the pattern of translocation of protein kinase C delta fused to green fluorescent protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE KERATINOCYTES; 12-MYRISTATE 13-ACETATE; DIFFERENTIAL REGULATION; TUMOR PROMOTERS; LIVING CELLS; BINDING; ACTIVATION; ISOZYMES; ALPHA; BRYOSTATIN-1	Our previous study showed differential subcellular localization of protein kinase C (PKC) delta by phorbol esters and related ligands, using a green fluorescent protein-tagged construct in living cells. Here we compared the abilities of a series of symmetrically substituted phorbol 12,13-diesters to translocate PKC delta. In vitro, the derivatives bound to PBC with similar potencies but differed in rate of equilibration. In vivo, the phorbol diesters with short, intermediate, and long chain fatty acids induced distinct patterns of translocation. Phorbol 12,13-dioctanoate and phorbol 12,13-nonanoate, the intermediate derivatives and most potent tumor promoters, showed patterns of translocation typical of phorbol 12-myristate 13-acetate, with plasma membrane and subsequent nuclear membrane translocation. The more hydrophilic compounds (phorbol 12,13-dibutyrate and phorbol 12,13-dihexanoate) induced a patchy distribution in the cytoplasm, more prominent nuclear membrane translocation, and little plasma membrane localization at all concentrations examined (100 nM to 10 mu M). The highly lipophilic derivatives, phorbol 12,13-didecanoate and phorbol 12,13-diundecanoate, at 1 mu M caused either plasma membrane translocation only or no translocation at incubation times up to 60 min. Our results indicate that Lipophilicity of phorbol esters is a critical factor contributing to differential PKC delta localization and thereby potentially to their different biological activities.	NCI, Mol Mechanisms Tumor Promot Sect, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA; NCI, Expt Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; NCI, Med Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Blumberg, PM (corresponding author), NCI, Mol Mechanisms Tumor Promot Sect, Cellular Carcinogenesis & Tumor Promot Lab, NIH, 37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.		Wang, Qiming Jane/B-6064-2012; Marquez, Victor/AAP-3549-2021	Wang, Qiming Jane/0000-0002-9502-4851; 				BLUMBERG PM, 1988, CANCER RES, V48, P1; BRESCH HM, 1974, Z NATURFORSCH B, V23, P538; DONG LQ, 1993, CELL GROWTH DIFFER, V4, P793; DRIEDGER PE, 1980, P NATL ACAD SCI-BIOL, V77, P567, DOI 10.1073/pnas.77.1.567; HECKER E, 1968, CANCER RES, V28, P2338; Hurley JH, 1997, PROTEIN SCI, V6, P477; HYATT SL, 1994, BIOCHEMISTRY-US, V33, P1223, DOI 10.1021/bi00171a023; Ishii H, 1998, J MOL MED, V76, P21, DOI 10.1007/s109-1998-8101-y; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; JACOBSON K, 1975, CANCER RES, V35, P2991; KAZANIETZ MG, 1992, J BIOL CHEM, V267, P20878; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; LILLY M, 1991, LEUKEMIA, V5, P283; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; Murphy TV, 1999, EUR J PHARMACOL, V381, P77, DOI 10.1016/S0014-2999(99)00540-3; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; PARKER PJ, 1997, PROTEN KINASE; Sakai N, 1997, J CELL BIOL, V139, P1465, DOI 10.1083/jcb.139.6.1465; SCHMIDT R, 1982, COCARCINOGENESIS BIO, P57; SHARKEY NA, 1985, CANCER RES, V45, P19; Shirai Y, 1998, J CELL BIOL, V143, P511, DOI 10.1083/jcb.143.2.511; SZALLASI Z, 1994, J BIOL CHEM, V269, P27159; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; SZALLASI Z, 1995, MOL PHARMACOL, V47, P258; SZALLASI Z, 1993, CANCER RES, V53, P2507; THIELMANN HW, 1969, FORTSCHRITTE KREBSFO, P171; Wang QMJ, 1999, J BIOL CHEM, V274, P37233, DOI 10.1074/jbc.274.52.37233; ZAYED S, 1984, PLANTA MED, V34, P65; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	35	76	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12136	12146		10.1074/jbc.275.16.12136	http://dx.doi.org/10.1074/jbc.275.16.12136			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766849	hybrid			2022-12-27	WOS:000086695500084
J	Gourves, AS; Le Gac, NT; Villani, G; Boehmer, PE; Johnson, NP				Gourves, AS; Le Gac, NT; Villani, G; Boehmer, PE; Johnson, NP			Equilibrium binding of single-stranded DNA with herpes simplex virus type I-coded single-stranded DNA-binding protein, ICP8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEIC-ACID INTERACTIONS; GENE 32 PROTEIN; COOPERATIVE BINDING; HELICASE-PRIMASE; MONITOR BINDING; REPLICATION; LIGAND; RECOMBINATION; POLYMERASE; COMPLEXES	We have carried out solution equilibrium binding studies of ICP8, the major single-stranded DNA (ssDNA)-binding protein of herpes simplex virus type I, in order to determine the thermodynamic parameters for its interaction with ssDNA, Fluorescence anisotropy measurements of a 5'-fluorescein-labeled 32-mer oligonucleotide revealed that ICP8 formed a nucleoprotein filament on ssDNA with a binding site size of 10 nucleotides/ICP8 monomer, an association constant at 25 degrees C, K = 0.55 +/- 0.05 x 10(6) M-1, and a cooperativity parameter, omega = 15 +/- 3, The equilibrium constant was largely independent of salt, delta log(K omega)/delta log([NaCl]) = -2.4 +/- 0.4. Comparison of these parameters with other ssDNA-binding proteins showed that ICP8 reacted with an unusual mechanism characterized by low cooperativity and weak binding. In addition, the reaction product was more stable at high salt concentrations, and fluorescence enhancement of etheno-ssDNA by ICP8 was higher than for other ssDNA-binding proteins. These last two characteristics are also found for protein-DNA complexes formed by recombinases in their active conformation. Given the proposed role of ICP8 in promoting strand transfer reactions, they suggest that ICP8 and recombinase proteins may catalyze homologous recombination by a similar mechanism.	CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France; Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); University of Miami	Johnson, NP (corresponding author), CNRS, Inst Pharmacol & Biol Struct, 205 Route Narbonne, F-31077 Toulouse, France.	neil@ipbs.fr		Boehmer, Paul/0000-0003-4479-0529	NIAID NIH HHS [AI38335] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038335] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; Ando RA, 1998, J MOL BIOL, V283, P785, DOI 10.1006/jmbi.1998.2124; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; BAYLISS GJ, 1975, VIROLOGY, V68, P124, DOI 10.1016/0042-6822(75)90154-3; BOEHMER PE, 1993, J VIROL, V67, P711, DOI 10.1128/JVI.67.2.711-715.1993; BOEHMER PE, 1993, P NATL ACAD SCI USA, V90, P8444, DOI 10.1073/pnas.90.18.8444; Boehmer PE, 1997, ANNU REV BIOCHEM, V66, P347, DOI 10.1146/annurev.biochem.66.1.347; BORTNER C, 1993, J MOL BIOL, V231, P241, DOI 10.1006/jmbi.1993.1279; BUJALOWSKI W, 1987, BIOCHEMISTRY-US, V26, P3099, DOI 10.1021/bi00385a023; Cazaux C, 1998, J BIOL CHEM, V273, P28799, DOI 10.1074/jbc.273.44.28799; Dudas KC, 1998, J VIROL, V72, P257, DOI 10.1128/JVI.72.1.257-265.1998; DUTCH RE, 1993, J VIROL, V67, P6945, DOI 10.1128/JVI.67.12.6945-6949.1993; DUTCH RE, 1995, J VIROL, V69, P3084, DOI 10.1128/JVI.69.5.3084-3089.1995; EGELMAN EH, 1993, MICRON, V24, P309, DOI 10.1016/0968-4328(93)90056-7; EPSTEIN IR, 1978, BIOPHYS CHEM, V8, P327, DOI 10.1016/0301-4622(78)80015-5; Hammarsten O, 1997, NUCLEIC ACIDS RES, V25, P1753, DOI 10.1093/nar/25.9.1753; HERNANDEZ TR, 1990, J BIOL CHEM, V265, P11227; Johnson NP, 1996, J BIOL CHEM, V271, P19675, DOI 10.1074/jbc.271.33.19675; KIM C, 1995, BIOCHEMISTRY-US, V34, P2058, DOI 10.1021/bi00006a028; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KUIL ME, 1990, BIOCHEMISTRY-US, V29, P8184, DOI 10.1021/bi00487a028; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; Le Gac NT, 1998, J BIOL CHEM, V273, P13801, DOI 10.1074/jbc.273.22.13801; LEE CK, 1985, J VIROL, V54, P731, DOI 10.1128/JVI.54.3.731-738.1985; LeGac NT, 1996, J BIOL CHEM, V271, P21645; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; LOHMAN TM, 1991, METHOD ENZYMOL, V208, P258; Lukonis CJ, 1996, J VIROL, V70, P1751, DOI 10.1128/JVI.70.3.1751-1758.1996; Makhov AM, 1996, J MOL BIOL, V258, P789, DOI 10.1006/jmbi.1996.0287; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; Namsaraev EA, 1998, J BIOL CHEM, V273, P6177, DOI 10.1074/jbc.273.11.6177; NEWPORT JW, 1981, J MOL BIOL, V145, P105, DOI 10.1016/0022-2836(81)90336-3; ODONNELL ME, 1987, J BIOL CHEM, V262, P4260; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; ROCA IA, 1997, PROG NUCL ACID RES M, V56, P129; RUYECHAN WT, 1983, J VIROL, V46, P661, DOI 10.1128/JVI.46.2.661-666.1983; RUYECHAN WT, 1984, J VIROL, V52, P727, DOI 10.1128/JVI.52.3.727-733.1984; RUYECHAN WT, 1988, J VIROL, V62, P810, DOI 10.1128/JVI.62.3.810-817.1988; RUYECHAN WT, 1992, J VIROL, V66, P6273, DOI 10.1128/JVI.66.11.6273-6279.1992; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Zhang W, 1996, P NATL ACAD SCI USA, V93, P2511, DOI 10.1073/pnas.93.6.2511; ZLOTNICK A, 1993, J BIOL CHEM, V268, P22525	43	28	31	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10864	10869		10.1074/jbc.275.15.10864	http://dx.doi.org/10.1074/jbc.275.15.10864			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753882	hybrid			2022-12-27	WOS:000086466600024
J	Guo, DQ; Wu, LW; Dunbar, JD; Ozes, ON; Mayo, LD; Kessler, KM; Gustin, JA; Baerwald, MR; Jaffe, EA; Warren, RS; Donner, DB				Guo, DQ; Wu, LW; Dunbar, JD; Ozes, ON; Mayo, LD; Kessler, KM; Gustin, JA; Baerwald, MR; Jaffe, EA; Warren, RS; Donner, DB			Tumor necrosis factor employs a protein-tyrosine phosphatase to inhibit activation of KDR and vascular endothelial cell growth factor-induced endothelial cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-ALPHA; SIGNAL-TRANSDUCTION; PERMEABILITY FACTOR; FACTOR RECEPTOR; INDUCED ANGIOGENESIS; NEGATIVE REGULATION; TISSUE FACTOR; SH2 DOMAIN; TNF-ALPHA; EXPRESSION	Vascular endothelial cell growth factor (VEGF) binds to and promotes the activation of one of its receptors, KDR, Once activated, KDR induces the tyrosine phosphorylation of cytoplasmic signaling proteins that are important to endothelial cell proliferation. In human umbilical vein endothelial cells (HUVECs), tumor necrosis factor (TNF) inhibits the phosphorylation and activation of KDR, The ability of TNF to diminish VEGF-stimulated KDR activity was impaired by sodium orthovanadate, suggesting that the inhibitory activity of TNF was mediated by a protein-tyrosine phosphatase, KDR-initiated responses specifically associated with endothelial cell proliferation, mitogen-activated protein kinase activation and DNA synthesis, were also inhibited by TNF, and this was reversed by sodium orthovanadate. Stimulation of HUVECs with TNF induced association of the SHP-1 protein-tyrosine phosphatase with KDR, identifying this phosphatase as a candidate negative regulator of VEGF signal transduction. Heterologous receptor inactivation mediated by a protein-tyrosine phosphatase provides insight into how TNF may inhibit endothelial cell proliferative responses and modulate angiogenesis in pathological settings.	Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Interfaith Med Ctr, Dept Med, Brooklyn, NY 11238 USA; Cornell Univ, Med Ctr, New York, NY 10021 USA; SUNY Hlth Sci Ctr, Brooklyn, NY 11203 USA; Univ Calif San Francisco, Sch Med, Dept Surg, San Francisco, CA 94143 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Cornell University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; University of California System; University of California San Francisco	Donner, DB (corresponding author), Indiana Univ, Sch Med, Dept Microbiol & Immunol, 1044 W Walnut St, Indianapolis, IN 46202 USA.	ddonner@iupui.edu	Wu, Li-Wha/AAH-7768-2021	Wu, Li-Wha/0000-0001-7010-6220; Baerwald, Melinda/0000-0001-7462-5212	NATIONAL CANCER INSTITUTE [R01CA073023, R01CA067891, R55CA067891] Funding Source: NIH RePORTER; NCI NIH HHS [CA73023, CA62863, CA67891] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bousquet C, 1998, J BIOL CHEM, V273, P7099, DOI 10.1074/jbc.273.12.7099; BUSSOLINO F, 1988, J BIOL CHEM, V263, P11856; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Choi K, 1998, DEVELOPMENT, V125, P725; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; Clauss M, 1996, FEBS LETT, V390, P334, DOI 10.1016/0014-5793(96)00690-4; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; CONNOLLY DT, 1991, J CELL BIOCHEM, V47, P219, DOI 10.1002/jcb.240470306; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fong TAT, 1999, CANCER RES, V59, P99; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Giraudo E, 1998, J BIOL CHEM, V273, P22128, DOI 10.1074/jbc.273.34.22128; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GRAU GE, 1993, RES IMMUNOL, V144, P355, DOI 10.1016/S0923-2494(93)80080-I; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Kabrun N, 1997, DEVELOPMENT, V124, P2039; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Koolwijk P, 1996, J CELL BIOL, V132, P1177, DOI 10.1083/jcb.132.6.1177; Kroder G, 1996, J CLIN INVEST, V97, P1471, DOI 10.1172/JCI118569; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; OKAMURA K, 1991, J BIOL CHEM, V266, P19162; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; PARK JE, 1994, J BIOL CHEM, V269, P25646; Patterson C, 1996, J CLIN INVEST, V98, P490, DOI 10.1172/JCI118816; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SENGER DR, 1986, CANCER RES, V46, P5629; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; Shoji M, 1997, TRENDS CARDIOVAS MED, V7, P52, DOI 10.1016/S1050-1738(96)00142-9; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; Spyridopoulos I, 1997, J MOL CELL CARDIOL, V29, P1321, DOI 10.1006/jmcc.1996.0365; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Wu LW, 2000, J BIOL CHEM, V275, P6059, DOI 10.1074/jbc.275.9.6059; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; ZHANG YM, 1994, J CLIN INVEST, V94, P1320, DOI 10.1172/JCI117451	61	95	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11216	11221		10.1074/jbc.275.15.11216	http://dx.doi.org/10.1074/jbc.275.15.11216			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753929	hybrid			2022-12-27	WOS:000086466600071
J	Hu, WH; Johnson, H; Shu, HB				Hu, WH; Johnson, H; Shu, HB			Activation of NF-kappa B by FADD, Casper, and caspase-8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR; 1-ASSOCIATED PROTEIN TRADD; DOMAIN-CONTAINING PROTEIN; INDUCED CELL-DEATH; INDUCED APOPTOSIS; SIGNALING COMPLEX; CD95 FAS/APO-1; KINASE RIP; TNF; ALPHA	Fas-associated death domain protein (FADD), caspase-8-related protein (Casper), and caspase-8 are components of the tumor necrosis factor receptor type 1 (TNF-R1) and Fas signaling complexes that are involved in TNF-R1- and Fas-induced apoptosis. Here we show that overexpression of FADD and Gasper potently activates NF-kappa B, In the presence of caspase inhibitors, overexpression of caspase-8 also activates NF-kappa B. A caspase-inactive point mutant, caspase-8(C360S), activates NF-kappa B as potently as wild-type caspase-8, suggesting that caspase-8-induced apoptosis and NF-kappa B activation are uncoupled. NF-kappa B activation by FADD and Gasper is inhibited by the caspase-specific inhibitors crmA and BD-fmk, suggesting that FADD- and Gasper-induced NF-kappa B activation is mediated by caspase-8, FADD, Gasper, and caspase-8-induced NF-kappa B activation are inhibited by dominant negative mutants of TRAF2, NIK, I kappa B kinase alpha, and I kappa B kinase beta. A dominant negative mutant of RIP inhibits FADD- and caspase-8-induced but not Gasper-induced NF-kappa B activation. A mutant of Gasper and the caspase-specific inhibitors crmA and BD-fmk partially inhibit TNF-R1-, TRADD, and TNF-induced NF-kappa B activation, suggesting that FADD, Gasper, and caspase-8 function downstream of TRADD and contribute to TNF-R1-induced NF-kappa B activation. Moreover, activation of caspase-8 results in proteolytic processing of NIK, which is inhibited by crmA. When overexpressed, the processed fragments of NIK do not activate NF-kappa B, and the processed G-terminal fragment inhibits TNF-R1-induced NF-kappa B activation. These data indicate that FADD, Gasper, and pro-caspase-8 are parts of the TNF-R1-induced NF-kappa B activation pathways, whereas activated caspase-8 can negatively regulate TNF-R1-induced NF-kappa B activation by proteolytically inactivating NIK.	Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Dept Immunol, Denver, CO 80206 USA; Peking Univ, Life Sci Coll, Beijing, Peoples R China	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Peking University	Shu, HB (corresponding author), Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Dept Immunol, 1400 Jackson St, Denver, CO 80206 USA.							Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Hu WH, 1999, J BIOL CHEM, V274, P30603, DOI 10.1074/jbc.274.43.30603; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; May MJ, 1999, SCIENCE, V284, P271, DOI 10.1126/science.284.5412.271; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NATAGA S, 1997, CELL, V88, P355; Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079; Park A, 1996, J BIOL CHEM, V271, P9858, DOI 10.1074/jbc.271.16.9858; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RENSINGEHL A, 1995, J INFLAMM, V45, P161; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Sambrook J., 2002, MOL CLONING LAB MANU; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; SHU HB, 1995, J CELL SCI, V108, P2955; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681	51	247	257	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10838	10844		10.1074/jbc.275.15.10838	http://dx.doi.org/10.1074/jbc.275.15.10838			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753878	hybrid			2022-12-27	WOS:000086466600020
J	Kamberov, E; Makarova, O; Roh, M; Liu, A; Karnak, D; Straight, S; Margolis, B				Kamberov, E; Makarova, O; Roh, M; Liu, A; Karnak, D; Straight, S; Margolis, B			Molecular cloning and characterization of Pals, proteins associated with mLin-7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE EXOCYTOSIS; ELEGANS VULVAR INDUCTION; BASOLATERAL MEMBRANE; SIGNALING COMPLEX; EPITHELIAL-CELLS; DOMAINS; GENE; LOCALIZATION; ENCODES; HOMOLOG	In Caenorhabditis elegans, three PDZ domain proteins, Lin-2, Lin-7, and Lin-10, are necessary for the proper targeting of the Let-23 growth factor receptor to the basolateral surface of epithelial cells. It has been demonstrated that homologues of Lin-2, Lin-7, and Lin-10 form a heterotrimeric complex in mammalian brain. Using Far Western overlay assay, we have identified additional proteins that can bind to the amino terminus of mLin-7 and cloned the genes encoding these proteins using bacterial expression cloning. We call these proteins Pals, for proteins associated with Lin-7. These proteins, which include mammalian Lin-2, contain a conserved mLin-7 binding domain in addition to guanylate kinase, PDZ (postsynaptic density 95/discs large/zona occludens-1), and Src homology 3 domains. Using site-directed mutagenesis, we have identified the conserved residues among these proteins crucial for mLin-7 binding. Two of these proteins, Pals1 and Pals2, are newly described. Pals1 consists of 675 amino acids and maps to mouse chromosome 12. Pals2 was found to exist in two splice forms of 539 and 553 amino acids and maps to mouse chromosome 6. Like mLin-2, Pals1 and Pals2 localize to the lateral membrane in Madin-Darby canine kidney cells. Pals proteins represent a new subfamily of membrane-associated guanylate kinases that allow for multiple targeting complexes containing mLin-7.	Univ Michigan, Med Ctr, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Margolis, B (corresponding author), Univ Michigan, Med Ctr, Howard Hughes Med Inst, Rm 4570,MSRB 2,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007505] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008353] Funding Source: NIH RePORTER; NICHD NIH HHS [5-T32-HD07505] Funding Source: Medline; NIGMS NIH HHS [GM08353] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Borg JP, 1998, CURR TOP MICROBIOL, V228, P23; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1999, J NEUROSCI, V19, P1307; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; DUCLOS F, 1993, P NATL ACAD SCI USA, V90, P109, DOI 10.1073/pnas.90.1.109; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; Hata Y, 1996, J NEUROSCI, V16, P2488; Hoskins R, 1996, DEVELOPMENT, V122, P97; Huber A, 1996, EMBO J, V15, P7036, DOI 10.1002/j.1460-2075.1996.tb01095.x; Irie M, 1999, ONCOGENE, V18, P2811, DOI 10.1038/sj.onc.1202652; Jo K, 1999, J NEUROSCI, V19, P4189, DOI 10.1523/jneurosci.19-11-04189.1999; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Lin LH, 1998, BBA-GENE STRUCT EXPR, V1443, P211, DOI 10.1016/S0167-4781(98)00209-7; Lue RA, 1996, J CELL BIOL, V135, P1125, DOI 10.1083/jcb.135.4.1125; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; MARGOLIS B, 1995, DNA CLONING, V2, P1; MAZOYER S, 1995, GENOMICS, V28, P25, DOI 10.1006/geno.1995.1101; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Okamoto M, 1998, EUR J CELL BIOL, V77, P161, DOI 10.1016/S0171-9335(98)80103-9; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; RON D, 1992, BIOTECHNIQUES, V13, P866; Rongo C, 1998, CELL, V94, P751, DOI 10.1016/S0092-8674(00)81734-1; Scott K, 1998, NATURE, V395, P805, DOI 10.1038/27448; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Smith SA, 1996, GENOMICS, V31, P145, DOI 10.1006/geno.1996.0025; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Straight SW, 2000, AM J PHYSIOL-RENAL, V278, pF464, DOI 10.1152/ajprenal.2000.278.3.F464; Wu HJ, 1998, J CELL SCI, V111, P2365; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649; YAMAUCHI A, 1991, AM J PHYSIOL, V261, pF197, DOI 10.1152/ajprenal.1991.261.1.F197; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010	36	139	144	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11425	11431		10.1074/jbc.275.15.11425	http://dx.doi.org/10.1074/jbc.275.15.11425			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753959	hybrid			2022-12-27	WOS:000086466600101
J	Kim, YM; Chung, HT; Simmons, RL; Billiar, TR				Kim, YM; Chung, HT; Simmons, RL; Billiar, TR			Cellular non-heme iron content is a determinant of nitric oxide-mediated apoptosis, necrosis, and caspase inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; ALPHA-INDUCED APOPTOSIS; RAT HEPATOCYTES; CYTOCHROME-C; IN-VIVO; DEATH; MACROPHAGES; COMPLEX; NITROSATION; SUPPRESSION	In this report, we tested the hypothesis that cellular content of non-heme iron determined whether cytotoxic levels of nitric oxide (NO) resulted in apoptosis versus necrosis, The consequences of NO exposure on cell viability were tested in RAW264.7 cells (a cell type with low non-heme iron levels) and hepatocytes (cells with high non-heme iron content). Whereas micromolar concentrations of the NO donor S-nitroso;N-acetyl-DL-penicillamine induced apoptosis in RAW264.7 cells, millimolar concentrations were required to induce necrosis in hepatocytes. Caspase-3 activation and cytochrome c release were evident in RAW264.7 cells, but only cytochrome c release was detectable in hepatocytes following high dose S-nitroso-N-acetyl-DL-penicillamine exposure. Pretreating RAW264.7 cells with FeSO4 increased intracellular non-heme iron to levels similar to those measured in hepatocytes and delayed NO-induced cell death, which then occurred in the absence of caspase-3 activation. Iron loading was also associated with the formation of intracellular dinitrosyl-iron complexes (DNIC) upon NO exposure. Cytosolic preparations containing DNIC as well as pure preparations of DNIC suppressed caspase activity. These data suggest that non-heme iron content is a key factor in determining the consequence of NO on cell viability by regulating the chemical fate of NO.	Kangweon Natl Univ, Coll Med, Dept Mol & Cellular Biochem, Chunchon 200701, Kangwon Do, South Korea; Wonkwang Univ, Coll Med, Dept Microbiol & Immunol, Iksan 570749, Chonbug, South Korea; Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15261 USA	Kangwon National University; Wonkwang University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kim, YM (corresponding author), Kangweon Natl Univ, Coll Med, Dept Mol & Cellular Biochem, Chunchon 200701, Kangwon Do, South Korea.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044100, R01GM037753] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM-44100, R01-GM-37753] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBINA JE, 1993, J IMMUNOL, V150, P5080; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; Boese M, 1997, J BIOL CHEM, V272, P21767, DOI 10.1074/jbc.272.35.21767; BOESE M, 1995, J BIOL CHEM, V270, P29244, DOI 10.1074/jbc.270.49.29244; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Ceneviva GD, 1998, AM J PHYSIOL-LUNG C, V275, pL717, DOI 10.1152/ajplung.1998.275.4.L717; CHENG W, 1995, J CLIN INVEST, V96, P2247, DOI 10.1172/JCI118280; CHUN SY, 1995, ENDOCRINOLOGY, V136, P3120, DOI 10.1210/en.136.7.3120; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; FISHBEIN M, 1988, MED PROBL PERFORM AR, V3, P1; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; GRANGER DL, 1980, J CLIN INVEST, V65, P357, DOI 10.1172/JCI109679; Kazmierski WM, 1996, P NATL ACAD SCI USA, V93, P9138, DOI 10.1073/pnas.93.17.9138; Kim YM, 1998, J BIOL CHEM, V273, P31437, DOI 10.1074/jbc.273.47.31437; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; KIM YM, 1995, J BIOL CHEM, V270, P5710, DOI 10.1074/jbc.270.11.5710; KIM YM, 1995, FEBS LETT, V374, P228, DOI 10.1016/0014-5793(95)01115-U; Kim YM, 1999, J NEUROSCI, V19, P6740, DOI 10.1523/JNEUROSCI.19-16-06740.1999; Leist M, 1999, EXP CELL RES, V249, P396, DOI 10.1006/excr.1999.4514; LEIST M, 1995, AM J PATHOL, V146, P1220; Lemaire C, 1998, FEBS LETT, V425, P266, DOI 10.1016/S0014-5793(98)00252-X; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; Messmer UK, 1998, EUR J PHARMACOL, V349, P333, DOI 10.1016/S0014-2999(98)00189-7; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; MIWA M, 1987, CARCINOGENESIS, V8, P955, DOI 10.1093/carcin/8.7.955; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Okuno S, 1998, J BIOL CHEM, V273, P34272, DOI 10.1074/jbc.273.51.34272; Rosenberg PA, 1999, J NEUROCHEM, V73, P476, DOI 10.1046/j.1471-4159.1999.0730476.x; Saavedra JE, 1997, J MED CHEM, V40, P1947, DOI 10.1021/jm9701031; Samali A, 1999, BIOCHEM BIOPH RES CO, V255, P6, DOI 10.1006/bbrc.1998.0139; Seol DW, 1999, J BIOL CHEM, V274, P2072, DOI 10.1074/jbc.274.4.2072; STADLER J, 1993, ARCH BIOCHEM BIOPHYS, V302, P4, DOI 10.1006/abbi.1993.1173; STADLER J, 1991, AM J PHYSIOL, V260, P910; Stefanelli C, 1999, BBA-MOL CELL RES, V1450, P406, DOI 10.1016/S0167-4889(99)00045-2; TERENZI F, 1995, J BIOL CHEM, V270, P6017, DOI 10.1074/jbc.270.11.6017; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Ushmorov A, 1999, BLOOD, V93, P2342, DOI 10.1182/blood.V93.7.2342.407k09_2342_2352; Vanin AF, 1997, NITRIC OXIDE-BIOL CH, V1, P191, DOI 10.1006/niox.1997.0122; VEREAMMEN D, 1998, J EXP MED, V187, P1477; Yee EL, 1996, AM J PHYSIOL-LUNG C, V271, pL512, DOI 10.1152/ajplung.1996.271.4.L512	46	185	211	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10954	10961		10.1074/jbc.275.15.10954	http://dx.doi.org/10.1074/jbc.275.15.10954			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753895	hybrid			2022-12-27	WOS:000086466600037
J	Sakkab, D; Lewitzky, M; Posern, G; Schaeper, U; Sachs, M; Birchmeier, W; Feller, SM				Sakkab, D; Lewitzky, M; Posern, G; Schaeper, U; Sachs, M; Birchmeier, W; Feller, SM			Signaling of hepatocyte growth factor/scatter factor (HGF) to the small GTPase Rap1 via the large docking protein Gab1 and the adapter protein CRKL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; FOCAL ADHESION KINASE; SRC HOMOLOGY-3 DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; CELL-MIGRATION; MET RECEPTOR; C-MET; EXCHANGE FACTOR; SH3 DOMAIN; FACTOR C3G	Hepatocyte growth factor (HGF; scatter factor) is a multipotent protein with mitogenic, motogenic, and developmental functions. Upon activation, the HGF-receptor c-Met binds and phosphorylates the multisite docking protein Gab1. Besides binding motifs for phosphatidylinositol 3-kinase and Grb2, Gab 1 contains multiple Tyr-X-X-Pro (YXXP) motifs which, when phosphorylated, are potential binding sites for the adapter proteins c-Crk and Crk-like (CRKL). Stimulation of human embryonic kidney cells (HEK293) with HGF leads to Gab1 association with CRKL. The Gab1-CRKL interaction requires both, the SH2 domain of CRKL and the region containing the YXXP motifs in Gab1, CRKL binds via its first SH3 domain to several downstream signal transducers, including C3G an activator of the small GTPase Rap1. Indeed, Rap1 was rapidly activated after HGF stimulation of HEK293 cells. Rap1 activation through HGF was suppressed through transfection of a truncated C3G protein which only contains the SH3-binding motifs of C3G. Transfection of nonmutated Gab1 led to a strong increase of Rap1.GTP in the absence of HGF. In contrast, transfection of the Gab Delta YXXP mutant abolished the elevation of Rap1.GTP by HGF. A replating assay indicated that HGF decreases the adhesion of HEK293 cells. The results presented here delineate a novel signaling pathway from HGF to the GTPase Rap1 which depends on the interaction of the adapter protein CRKL with the exchange factor C3G and could be linked to cell migration.	Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, Oncol Mol Lab, MSZ, D-97078 Wurzburg, Germany; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany	University of Wurzburg; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Feller, SM (corresponding author), Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, Oncol Mol Lab, MSZ, Versbacher Str 5, D-97078 Wurzburg, Germany.	stephan.feller@mail.uni-wuerzburg.de						Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; Aprikian AG, 1997, INT J CANCER, V72, P498, DOI 10.1002/(SICI)1097-0215(19970729)72:3<498::AID-IJC19>3.3.CO;2-P; Arai A, 1999, BLOOD, V93, P3713, DOI 10.1182/blood.V93.11.3713.411a36_3713_3722; Asha H, 1999, EMBO J, V18, P605, DOI 10.1093/emboj/18.3.605; Bardelli A, 1997, CIBA F SYMP, V212, P133; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BOROS P, 1995, LANCET, V345, P293, DOI 10.1016/S0140-6736(95)90279-1; Bos JL, 1997, FEBS LETT, V410, P59, DOI 10.1016/S0014-5793(97)00324-4; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; CANTLEY LG, 1995, J AM SOC NEPHROL, V5, P1872; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Chen XQ, 1999, J BIOL CHEM, V274, P19901, DOI 10.1074/jbc.274.28.19901; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Heaney C, 1997, BLOOD, V89, P297, DOI 10.1182/blood.V89.1.297.297_297_306; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Honda H, 1999, BIOCHEM BIOPH RES CO, V262, P25, DOI 10.1006/bbrc.1999.1162; Ichiba T, 1999, J BIOL CHEM, V274, P14376, DOI 10.1074/jbc.274.20.14376; Kiyokawa E, 1997, CRIT REV ONCOGENESIS, V8, P329, DOI 10.1615/CritRevOncog.v8.i4.30; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; Ling P, 1999, MOL CELL BIOL, V19, P1359; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Nakamura T, 1997, CANCER RES, V57, P3305; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Nolan KM, 1998, GENE DEV, V12, P3337, DOI 10.1101/gad.12.21.3337; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; Reedquist KA, 1998, J BIOL CHEM, V273, P4944, DOI 10.1074/jbc.273.9.4944; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Salgia R, 1999, ONCOGENE, V18, P67, DOI 10.1038/sj.onc.1202273; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; TAJIMA H, 1992, EXP CELL RES, V202, P423, DOI 10.1016/0014-4827(92)90095-P; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; TSUCHIE H, 1989, ONCOGENE, V4, P1281; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Yule KA, 1999, EXP LUNG RES, V25, P261; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	60	112	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10772	10778		10.1074/jbc.275.15.10772	http://dx.doi.org/10.1074/jbc.275.15.10772			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753869	hybrid			2022-12-27	WOS:000086466600011
J	Tazoe, M; Ichikawa, K; Hoshino, T				Tazoe, M; Ichikawa, K; Hoshino, T			Biosynthesis of vitamin B-6 in Rhizobium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PYRIDOXOL; 5-PHOSPHATE; PRECURSOR; THIAMIN	The biosynthetic pathway of pyridoxol (vitamin B-6) in Rhizobium was clarified by studies on the incorporation of C-13- or N-15-labeled precursors into pyridoxol or its biosynthetic intermediates. Pyridoxol was formed by ring closure of two compounds, 1-deoxy-D-xylulose and 4-hydroxy-L-threonine. The former was formed from D-glyceraldehyde and pyruvate through decarboxylation of pyruvate, and the latter from glycine and glycolaldehyde.	Nippon Roche Res Ctr, Dept Appl Microbiol, Kanagawa 2478530, Japan	Roche Holding	Tazoe, M (corresponding author), Nippon Roche Res Ctr, Dept Appl Microbiol, Kanagawa 2478530, Japan.							Atkin L, 1943, IND ENG CHEM, V15, P141, DOI 10.1021/i560114a022; CHANG JY, 1981, BIOCHEM J, V199, P547, DOI 10.1042/bj1990547; Hill RE, 1996, J BIOL CHEM, V271, P30426, DOI 10.1074/jbc.271.48.30426; HILL RE, 1975, J CHEM SOC PERK T 1, P1622, DOI 10.1039/p19750001622; IWANOW A, 1984, J AM CHEM SOC, V106, P1840, DOI 10.1021/ja00318a051; LAM HM, 1990, J BACTERIOL, V172, P6518, DOI 10.1128/jb.172.11.6518-6528.1990; Lois LM, 1998, P NATL ACAD SCI USA, V95, P2105, DOI 10.1073/pnas.95.5.2105; MITCHELL RE, 1986, PHYTOCHEMISTRY, V25, P2711; ROHMER M, 1993, BIOCHEM J, V295, P517, DOI 10.1042/bj2950517; Sprenger GA, 1997, P NATL ACAD SCI USA, V94, P12857, DOI 10.1073/pnas.94.24.12857; TANI Y, 1973, J BACTERIOL, V116, P341, DOI 10.1128/JB.116.1.341-345.1973; Tazoe M, 1999, BIOSCI BIOTECH BIOCH, V63, P1378, DOI 10.1271/bbb.63.1378; THERISOD M, 1981, BIOCHEM BIOPH RES CO, V98, P374, DOI 10.1016/0006-291X(81)90850-0; VELLA GJ, 1980, J BIOL CHEM, V255, P3042; WOLF E, 1995, J CHEM SOC CHEM COMM, P1339, DOI 10.1039/c39950001339; YOKOTA A, 1986, AGR BIOL CHEM TOKYO, V50, P2517, DOI 10.1080/00021369.1986.10867789; YOKOTA A, 1984, AGR BIOL CHEM TOKYO, V48, P149, DOI 10.1080/00021369.1984.10866109	17	14	16	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11300	11305		10.1074/jbc.275.15.11300	http://dx.doi.org/10.1074/jbc.275.15.11300			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753941	hybrid			2022-12-27	WOS:000086466600083
J	Budd, DC; McDonald, JE; Tobin, AB				Budd, DC; McDonald, JE; Tobin, AB			Phosphorylation and regulation of a G(q/11)-coupled receptor by casein kinase 1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTORS; BETA-GAMMA-SUBUNITS; AGONIST-DEPENDENT-PHOSPHORYLATION; CYTOPLASMIC TAIL PHOSPHORYLATION; DOMINANT-NEGATIVE MUTANT; BETA(2)-ADRENERGIC RECEPTOR; INDUCED DESENSITIZATION; PHOSPHOINOSITIDASE-C; COUPLED RECEPTORS; M2 SUBTYPES	Agonist-mediated receptor phosphorylation by one or more of the members of the G-protein receptor kinase (GRK) family is an established model for G-protein-coupled receptor (GPCR) phosphorylation resulting in receptor desensitization. Our recent studies have, however, suggested that an alternative route to GPCR phosphorylation may be an operation involving casein kinase 1 alpha (CK1 alpha). In the current study we investigate the involvement of CK1 alpha in the phosphorylation of the human m3-muscarinic receptor in intact cells. We show that expression of a catalytically inactive mutant of CK1 alpha, designed to act in a dominant negative manner, inhibits agonist-mediated receptor phosphorylation by similar to 40% in COS-7 and HEK-293 cells. Furthermore, we present evidence that a peptide corresponding to the third intracellular loop of the m3-muscarinic receptor (Ser(345)-Leu(463)) is an inhibitor of CK1 alpha due to its ability to both act as a pseudo-substrate for CK1 alpha and form a high affinity complex with CK1 alpha. Expression of this peptide was able to reduce both basal and agonist-mediated m3-muscarinic receptor phosphorylation in intact cells. These results support the notion that CK1 alpha is able to mediate GPCR phosphorylation in an agonist-dependent manner and that this may provide a novel mechanism for GPCR phosphorylation. The functional role of phosphorylation was investigated using a mutant of the m3-muscarinic receptor that showed an similar to 80% reduction in agonist-mediated phosphorylation. Surprisingly, this mutant underwent agonist-mediated desensitization suggesting that, unlike many GPCRs, desensitization of the m3-muscarinic receptor is not mediated by receptor phosphorylation. The inositol (1,4,5)-trisphosphate response did, however, appear to be dramatically potentiated in the phosphorylation-deficient mutant indicating that phosphorylation may instead control the magnitude of the initial inositol phosphate response.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	University of Leicester	Tobin, AB (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, POB 138,Med Sci Bldg,Univ Rd, Leicester LE1 9HN, Leics, England.							ALBLAS J, 1995, J BIOL CHEM, V270, P8944, DOI 10.1074/jbc.270.15.8944; ALI H, 1993, J BIOL CHEM, V268, P24247; Blaukat A, 1996, J BIOL CHEM, V271, P32366, DOI 10.1074/jbc.271.50.32366; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; CATERINA MJ, 1995, J BIOL CHEM, V270, P8667, DOI 10.1074/jbc.270.15.8667; CHALLISS RAJ, 1988, BIOCHEM BIOPH RES CO, V157, P684, DOI 10.1016/S0006-291X(88)80304-8; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; DEBBURMAN SK, 1995, MOL PHARMACOL, V47, P224; Diviani D, 1996, J BIOL CHEM, V271, P5049; FISHER SK, 1994, NEUROCHEM RES, V19, P195; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; Haga K, 1996, J BIOL CHEM, V271, P2776, DOI 10.1074/jbc.271.5.2776; HAGA K, 1992, J BIOL CHEM, V267, P2222; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; KAMEYAMA K, 1993, J BIOL CHEM, V268, P7753; KONG GH, 1994, J BIOL CHEM, V269, P13084; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; NAKATA H, 1994, EUR J BIOCHEM, V220, P29, DOI 10.1111/j.1432-1033.1994.tb18595.x; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; PALMER TM, 1995, J BIOL CHEM, V270, P29607, DOI 10.1074/jbc.270.49.29607; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; RICHARDON RM, 1995, J BIOL CHEM, V270, P27829, DOI 10.1074/jbc.270.46.27829; RuizGomez A, 1997, J BIOL CHEM, V272, P9601; TAKANO T, 1994, J BIOL CHEM, V269, P22453; Tobin AB, 1997, J BIOL CHEM, V272, P20844, DOI 10.1074/jbc.272.33.20844; TOBIN AB, 1993, J BIOL CHEM, V268, P9817; TOBIN AB, 1993, FEBS LETT, V335, P353, DOI 10.1016/0014-5793(93)80418-T; Tobin AB, 1997, PHARMACOL THERAPEUT, V75, P135, DOI 10.1016/S0163-7258(97)00053-3; Tobin AB, 1996, J BIOL CHEM, V271, P3907; TOBIN AB, 1992, MOL PHARMACOL, V42, P1042; Tsuga H, 1998, J BIOL CHEM, V273, P5323, DOI 10.1074/jbc.273.9.5323; TSUGA H, 1994, J BIOL CHEM, V269, P32522; Tsuga H, 1998, J PHARMACOL EXP THER, V284, P1218; WAUGH MG, 1999, J BIOCHEM-TOKYO, V338, P175; Willars GB, 1999, AM J PHYSIOL-CELL PH, V277, pC859, DOI 10.1152/ajpcell.1999.277.5.C859; WOJCIKIEWICZ RJH, 1993, TRENDS PHARMACOL SCI, V14, P279, DOI 10.1016/0165-6147(93)90131-3; Wu GY, 1998, J BIOL CHEM, V273, P7197, DOI 10.1074/jbc.273.13.7197	40	63	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19667	19675		10.1074/jbc.M000492200	http://dx.doi.org/10.1074/jbc.M000492200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10777483	hybrid			2022-12-27	WOS:000087941300032
J	Pantel, J; Machinis, K; Sobrier, ML; Duquesnoy, P; Goossens, M; Amselem, S				Pantel, J; Machinis, K; Sobrier, ML; Duquesnoy, P; Goossens, M; Amselem, S			Species-specific alternative splice mimicry at the growth hormone receptor locus revealed by the lineage of retroelements during primate evolution - A novel mechanism accounting for protein diversity between and within species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; BINDING-PROTEIN; ENDOGENOUS RETROVIRUS; EXPRESSION; GENE; SEQUENCES; EXON-3; ISOFORMS; DOMAIN; RESISTANCE	In humans, growth hormone receptor (GHR) transcripts exist in two isoforms differing by the retention (GHRfl) or exclusion (GHRd3) of exon 3, whereas in mice GHRfl is solely expressed. This species-specific expression pattern is believed to result from an alternative splice event that, on the basis of conflicting data obtained in humans, has been considered to be tissue-, developmentally, and/or individual-specific, To decipher the molecular basis of this unusual trait, we isolated a 6.8-kilobase fragment spanning exon 3 from individuals expressing GHRfl. Sequence analysis revealed the existence of two 99% identical retroelements flanking this exon, Unexpectedly, individuals expressing GHRd3 displayed a 2.7-kilobase deletion involving exon 3, which most likely results from an ancestral homologous recombination between the two retroelements, The lineage of these retroelements during primate evolution revealed the species specificity of the GHRd3 allele. These findings led us to propose a model underlying the existence of the sole GHRfl allele in most species, Such a retrovirus-mediated alternative splice mimicry, which clears up several as yet unexplained phenomena (i.e. the above-mentioned expression data, the Mendelian inheritance of GHR expression patterns, and the deletion of nonconsecutive exons in growth hormone resistant patients), represents a novel physiological mechanism accounting for protein diversity between and within species.	Hop Henri Mondor, INSERM, U468, F-94010 Creteil, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Amselem, S (corresponding author), Hop Henri Mondor, INSERM, U468, F-94010 Creteil, France.		Pantel, Jacques/C-6563-2014; Sobrier, Marie-Laure/L-4820-2017	Pantel, Jacques/0000-0002-9015-6281; Sobrier, Marie-Laure/0000-0001-6396-100X				Amselem S, 1996, BAILLIERE CLIN ENDOC, V10, P353, DOI 10.1016/S0950-351X(96)80485-X; BARNARD R, 1993, ENDOCRINOLOGY, V133, P1474, DOI 10.1210/en.133.3.1474; BARTON DE, 1989, CYTOGENET CELL GENET, V50, P137, DOI 10.1159/000132743; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Bi S, 1997, J BIOL CHEM, V272, P30583, DOI 10.1074/jbc.272.48.30583; Boeke J. D., 1997, P343; CACHONGONZALEZ MB, 1994, P NATL ACAD SCI USA, V91, P7717, DOI 10.1073/pnas.91.16.7717; CHARLESWORTH B, 1994, NATURE, V371, P215, DOI 10.1038/371215a0; CHEN HR, 1984, NUCLEIC ACIDS RES, V12, P1767, DOI 10.1093/nar/12.4.1767; CONNOR J, 1993, ESSENTIAL MED GENETI, P104; Dastot F, 1996, P NATL ACAD SCI USA, V93, P10723, DOI 10.1073/pnas.93.20.10723; Dastot F, 1998, MOL CELL ENDOCRINOL, V137, P79, DOI 10.1016/S0303-7207(97)00232-3; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUQUESNOY P, 1994, EMBO J, V13, P1386, DOI 10.1002/j.1460-2075.1994.tb06392.x; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GODOWSKI PJ, 1989, P NATL ACAD SCI USA, V86, P8083, DOI 10.1073/pnas.86.20.8083; Goodman M, 1999, AM J HUM GENET, V64, P31, DOI 10.1086/302218; HARADA F, 1987, NUCLEIC ACIDS RES, V15, P9153, DOI 10.1093/nar/15.22.9153; Johnson WE, 1999, P NATL ACAD SCI USA, V96, P10254, DOI 10.1073/pnas.96.18.10254; Kazazian HH, 1998, NAT GENET, V19, P19, DOI 10.1038/ng0598-19; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MERCADO M, 1994, J CLIN ENDOCR METAB, V78, P731, DOI 10.1210/jc.78.3.731; RANDWEAVER M, 1993, TITLE, P13; Schulte AM, 1996, P NATL ACAD SCI USA, V93, P14759, DOI 10.1073/pnas.93.25.14759; SEPERACK PK, 1995, EMBO J, V14, P2326, DOI 10.1002/j.1460-2075.1995.tb07227.x; Smit AFA, 1996, CURR OPIN GENET DEV, V6, P743, DOI 10.1016/S0959-437X(96)80030-X; SOBRIER ML, 1993, FEBS LETT, V319, P16, DOI 10.1016/0014-5793(93)80028-S; StallingsMann ML, 1996, P NATL ACAD SCI USA, V93, P12394, DOI 10.1073/pnas.93.22.12394; TING CN, 1992, GENE DEV, V6, P1457, DOI 10.1101/gad.6.8.1457; URBANEK M, 1992, MOL ENDOCRINOL, V6, P279, DOI 10.1210/me.6.2.279; URBANEK M, 1993, J BIOL CHEM, V268, P19025; WICKELGREN RB, 1995, J CLIN ENDOCR METAB, V80, P2154, DOI 10.1210/jc.80.7.2154; Zogopoulos G, 1996, J CLIN ENDOCR METAB, V81, P775, DOI 10.1210/jc.81.2.775	36	165	183	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18664	18669		10.1074/jbc.M001615200	http://dx.doi.org/10.1074/jbc.M001615200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10764769	hybrid			2022-12-27	WOS:000087815900008
J	Reynaud, EG; Leibovitch, MP; Tintignac, LAJ; Pelpel, K; Guillier, M; Leibovitch, SA				Reynaud, EG; Leibovitch, MP; Tintignac, LAJ; Pelpel, K; Guillier, M; Leibovitch, SA			Stabilization of MyoD by direct binding to p57(Kip2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT-KINASE INHIBITOR; LOOP-HELIX PROTEINS; DNA-BINDING; CELL-CYCLE; MICE LACKING; SKELETAL-MUSCLE; CDK INHIBITORS; IN-VIVO; GENE; EXPRESSION	Recent data have demonstrated the role of Cdk1- and Cdk2-dependent phosphorylation of MyoD(Ser200) in the regulation of MyoD activity and protein turnover. In the present study, we show that in presence of p57(Kip2), MyoD(Ala200), a MyoD mutant that cannot be phosphorylated by cyclin-Cdk complexes, displayed activity a-S-fold higher than of MyoD(Ala200) alone in transactivation of muscle-specific genes myosin heavy chain, creatine kinase, and myosin light chain 1, Furthermore, p57(Kip2) increases the levels of MyoD(Ala200) in cotransfected cells. This result implies that p57(Kip2) may regulate MyoD through a process distinct from its function as a cyclin-dependent kinase inhibitors. We report that overexpression of p57(Kip2) increased the half-life of MyoD(Ala200). This increased half-life of MyoD involves a physical interaction between MyoD and p57(Kip2) but not with p16(Ink4a), as shown by cross immunoprecipitation not only on overexpressed proteins from transfected cells, but also on endogenous MyoD and p57(Kip2) from C2C12 myogenic cells. Mutational and functional analyses of the two proteins show that the NH2 domain of p57(Kip2) associates with basic region in the basic helix-loop-helix domain of MyoD, Competition/association assays and site-directed mutagenesis of the NH2 terminus of p57(Kip2) identified the intermediate alpha-helix domain, located between the Cdk and the cyclin binding sites, as essential for MyoD interaction. These data show that the alpha-helix domain of p57(Kip2), which is conserved in the Cip/Kip proteins, is implicated in protein-protein interaction and confers a specific regulatory mechanism, outside of their Cdk-inhibitory activity, by which the p57(Kip2) family members positively act on myogenic differentiation.	Inst Gustave Roussy, CNRS, UMR 1599, Lab Genet Oncol, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Leibovitch, SA (corresponding author), Inst Gustave Roussy, CNRS, UMR 1599, Lab Genet Oncol, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	leibovit@igr.fr	Reynaud, Emamnuel/H-2928-2019	Reynaud, Emamnuel/0000-0003-1502-661X; Tintignac, Lionel/0000-0001-5902-1138				Abu Hatoum O, 1998, MOL CELL BIOL, V18, P5670, DOI 10.1128/MCB.18.10.5670; Benayoun B, 1998, FEBS LETT, V437, P39, DOI 10.1016/S0014-5793(98)01192-2; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; Chen IT, 1996, ONCOGENE, V12, P595; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Guo K, 1997, J BIOL CHEM, V272, P791, DOI 10.1074/jbc.272.2.791; GUO K, 1995, MOL CELL BIOL, V15, P3823; Haber DA, 1997, CELL, V91, P555, DOI 10.1016/S0092-8674(00)80441-9; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARDY S, 1993, MOL CELL BIOL, V13, P5943, DOI 10.1128/MCB.13.10.5943; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Kitzmann M, 1999, MOL CELL BIOL, V19, P3167; Kitzmann M, 1998, J CELL BIOL, V142, P1447, DOI 10.1083/jcb.142.6.1447; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lee MH, 1996, P NATL ACAD SCI USA, V93, P3259, DOI 10.1073/pnas.93.8.3259; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEIBOVITCH SA, 1991, ONCOGENE, V6, P1617; Lenormand JL, 1997, MOL CELL BIOL, V17, P584, DOI 10.1128/MCB.17.2.584; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LI L, 1992, MOL CELL BIOL, V12, P4478, DOI 10.1128/MCB.12.10.4478; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MUNOZ V, 1994, NAT STRUCT BIOL, V1, P399, DOI 10.1038/nsb0694-399; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; Reynaud EG, 1999, MOL CELL BIOL, V19, P7621; Reynaud EG, 2000, ONCOGENE, V19, P1147, DOI 10.1038/sj.onc.1203403; REYSNIDOTTIR I, 1995, GENE DEV, V9, P1831; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; TAPSCOTT SJ, 1989, SCIENCE, V245, P532, DOI 10.1126/science.2547249; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Xiong Y, 1996, Biochim Biophys Acta, V1288, P01; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Zhang JM, 1999, EMBO J, V18, P926, DOI 10.1093/emboj/18.4.926; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213	61	86	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18767	18776		10.1074/jbc.M907412199	http://dx.doi.org/10.1074/jbc.M907412199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10764802	hybrid			2022-12-27	WOS:000087815900023
J	Zheng, JH; Khalil, M; Cannon, JF				Zheng, JH; Khalil, M; Cannon, JF			Glc7p protein phosphatase inhibits expression of glutamine-fructose-6-phosphate transaminase from GFA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; RABBIT SKELETAL-MUSCLE; CELL-CYCLE PROGRESSION; GLYCOGEN-METABOLISM; CATALYTIC SUBUNIT; KINASE-C; SERINE/THREONINE PHOSPHATASES; CHROMOSOME SEGREGATION; TRANSCRIPTION FACTOR; REGULATORY SUBUNIT	Inhibitor-1 (I-1) is a specific inhibitor of protein phosphatase-l (PP1). We assayed the ability of I-1 to inhibit Saccharomyces cerevisiae PP1, Glc7p, in vivo. Glc7p hire other PP1 catalytic subunits associates with a variety of noncatalytic subunits, and Glc7p holoenzymes perform distinct physiological roles. Our results show that I-1 inhibits Glc7p holoenzymes that regulate transcription and mitosis, but holoenzymes responsible for meiosis and glycogen metabolism were unaffected. Additionally, we exploited a genetic screen for mutants that were dependent on I-1 to grow. This scheme can identify processes that are negatively regulated by Glc7p-catalyzed dephosphorylation. In this paper I-I-dependent gfa1 mutations were analyzed in detail. GFA1 encodes glutamine-fructose-6-phosphate transaminase. One or more phosphorylated proteins activate GFA1 transcription because the pheromone response and Pkc1p/mitogen-activated protein kinase pathways positively regulate GFA1 transcription Our findings show that an I-1-sensitive Glc7p holoenzyme reduces GFA1 transcription. Therefore, GFA1 is a member of a growing list of genes that are negatively regulated by Glc7p dephosphorylation.	Univ Missouri, Dept Mol Microbiol & Immunol, Columbia, MO 65212 USA	University of Missouri System; University of Missouri Columbia	Cannon, JF (corresponding author), Univ Missouri, Dept Mol Microbiol & Immunol, M607 Med Sci Bldg, Columbia, MO 65212 USA.	CannonJ@missouri.edu		Cannon, John/0000-0001-6698-176X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040326, R29GM040326] Funding Source: NIH RePORTER; NIAID NIH HHS [AI07276] Funding Source: Medline; NIGMS NIH HHS [GM40326] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1982, FEBS LETT, V147, P54, DOI 10.1016/0014-5793(82)81010-7; ALTHOEFER H, 1995, MOL CELL BIOL, V15, P5917; Baker SH, 1997, GENETICS, V145, P615; Beullens M, 1996, EUR J BIOCHEM, V239, P183, DOI 10.1111/j.1432-1033.1996.0183u.x; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; BLACK S, 1995, YEAST, V11, P747, DOI 10.1002/yea.320110806; Bortvin A, 1996, SCIENCE, V272, P1473, DOI 10.1126/science.272.5267.1473; BRUHN L, 1994, MOL CELL BIOL, V14, P2534, DOI 10.1128/MCB.14.4.2534; CAMERON S, 1988, CELL, V53, P555, DOI 10.1016/0092-8674(88)90572-7; CANNON JF, 1994, GENETICS, V136, P485; CANNON JF, 1995, ADV PROTEIN PHOSPHAT, V9, P215; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CID VJ, 1995, MICROBIOL REV, V59, P345, DOI 10.1128/MMBR.59.3.345-386.1995; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, FEBS LETT, V250, P601, DOI 10.1016/0014-5793(89)80804-X; Connor JH, 1998, J BIOL CHEM, V273, P27716, DOI 10.1074/jbc.273.42.27716; Dodou E, 1997, MOL CELL BIOL, V17, P1848, DOI 10.1128/MCB.17.4.1848; Dombek KM, 1999, MOL CELL BIOL, V19, P6029; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; Endo S, 1997, BIOCHEMISTRY-US, V36, P6986, DOI 10.1021/bi970418i; Fassler JS, 1997, J BIOL CHEM, V272, P13365, DOI 10.1074/jbc.272.20.13365; FENG ZH, 1991, J BIOL CHEM, V266, P23796; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; FRANCOIS JM, 1992, EMBO J, V11, P87, DOI 10.1002/j.1460-2075.1992.tb05031.x; Frederick DL, 1996, MOL CELL BIOL, V16, P2922; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; GHOSH S, 1962, METHOD ENZYMOL, V5, P414, DOI 10.1016/S0076-6879(62)05251-9; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; HEMMINGS HC, 1990, J BIOL CHEM, V265, P20369; HISAMOTO N, 1994, MOL CELL BIOL, V14, P3158, DOI 10.1128/MCB.14.5.3158; HISAMOTO N, 1995, MOL CELL BIOL, V15, P3767; HUANG FL, 1976, EUR J BIOCHEM, V70, P419, DOI 10.1111/j.1432-1033.1976.tb11032.x; Hung W, 1997, EUR J BIOCHEM, V245, P241, DOI 10.1111/j.1432-1033.1997.00241.x; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; KRANZ JE, 1990, P NATL ACAD SCI USA, V87, P6629, DOI 10.1073/pnas.87.17.6629; Kuo MH, 1997, MOL CELL BIOL, V17, P819, DOI 10.1128/MCB.17.2.819; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P3536, DOI 10.1073/pnas.94.8.3536; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LILLIE SH, 1980, J BACTERIOL, V143, P1384, DOI 10.1128/JB.143.3.1384-1394.1980; Lin JT, 1999, MOL CELL BIOL, V19, P3237; LIU HP, 1992, GENETICS, V132, P665; MACKELVIE SH, 1995, MOL CELL BIOL, V15, P3777; McInerny CJ, 1997, GENE DEV, V11, P1277, DOI 10.1101/gad.11.10.1277; Milewski S, 1999, J BIOL CHEM, V274, P4000, DOI 10.1074/jbc.274.7.4000; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; NASMYTH KA, 1980, P NATL ACAD SCI-BIOL, V77, P2119, DOI 10.1073/pnas.77.4.2119; NEHLIN JO, 1990, EMBO J, V9, P2891, DOI 10.1002/j.1460-2075.1990.tb07479.x; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; NIMMO GA, 1978, EUR J BIOCHEM, V87, P341, DOI 10.1111/j.1432-1033.1978.tb12383.x; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; Orlean P., 1997, MOL CELLULAR BIOL YE, V21, P229; OZCAN S, 1995, MOL CELL BIOL, V15, P1564; PARK IK, 1994, J BIOL CHEM, V269, P28919; POSAS F, 1995, J BIOL CHEM, V270, P13036, DOI 10.1074/jbc.270.22.13036; Qian OY, 1999, GENETICS, V152, P89; Ramaswamy NT, 1998, GENETICS, V149, P57; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; Sassoon I, 1999, GENE DEV, V13, P545, DOI 10.1101/gad.13.5.545; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Sherman F, 1986, LAB COURSE MANUAL ME; Shirra MK, 1999, GENETICS, V152, P73; SIKORSKI RS, 1989, GENETICS, V122, P19; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Stark MJR, 1996, YEAST, V12, P1647, DOI 10.1002/(SICI)1097-0061(199612)12:16<1647::AID-YEA71>3.0.CO;2-Q; STUART JS, 1994, MOL CELL BIOL, V14, P896, DOI 10.1128/MCB.14.2.896; SUTTON A, 1991, COLD SPRING HARB SYM, V56, P75; Thevelein JM, 1999, MOL MICROBIOL, V33, P904, DOI 10.1046/j.1365-2958.1999.01538.x; Tu JL, 1996, MOL CELL BIOL, V16, P4199; TU JL, 1995, EMBO J, V14, P5939, DOI 10.1002/j.1460-2075.1995.tb00282.x; TUNG HYL, 1995, MOL CELL BIOL, V15, P6064; Van Eynde A, 1995, J BIOL CHEM, V270, P28068, DOI 10.1074/jbc.270.47.28068; WALSH RB, 1983, J BACTERIOL, V154, P1002, DOI 10.1128/JB.154.2.1002-1004.1983; WATZELE G, 1989, J BIOL CHEM, V264, P8753; WEK RC, 1992, MOL CELL BIOL, V12, P5700, DOI 10.1128/MCB.12.12.5700; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985; YU GY, 1995, J BIOL CHEM, V270, P8739, DOI 10.1074/jbc.270.15.8739; ZHANG SR, 1995, MOL CELL BIOL, V15, P2037; Zhao C, 1998, MOL CELL BIOL, V18, P1013, DOI 10.1128/MCB.18.2.1013; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368	85	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18070	18078		10.1074/jbc.M000918200	http://dx.doi.org/10.1074/jbc.M000918200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10764753	hybrid			2022-12-27	WOS:000087659400024
J	Beck, L; Markovich, D				Beck, L; Markovich, D			The mouse Na+-sulfate cotransporter gene Nas1 - Cloning, tissue distribution, gene structure, chromosomal assignment, and transcriptional regulation by vitamin D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-ANALYSIS; TRANSPORTER GENE; RENAL TRANSPORT; 1,25-DIHYDROXYVITAMIN-D3 RECEPTOR; STRUCTURE PREDICTION; GENOMIC STRUCTURE; DIETARY SULFATE; RAT-KIDNEY; EXPRESSION; DNA	NaSi-1 is a Na+-sulfate cotransporter expressed on the apical membrane of the renal proximal tubule and plays an important role in sulfate reabsorption. To understand the molecular mechanisms that mediate the regulation of NaSi-1, we have isolated and characterized the mouse NaSi-1 cDNA (mNaSi-1), gene (Nas1), and promoter region and determined Nas1 chromosomal localization, The mNaSi-1 cDNA encodes a protein of 594 amino acids with 13 putative transmembrane segments, inducing high affinity Na+-dependent transport of sulfate in Xenopus oocytes. Three different mNaSi-1 transcripts derived from alternative polyadenylation and splicing were identified in kidney and intestine. The Nas1 gene is a single copy gene comprising 15 exons spread over 75 kilobase pairs that maps to mouse chromosome 6. Transcription initiation occurs from a single site, 29 base pairs downstream to a TATA box-like sequence. The promoter is AT-rich (61%), contains a number of well characterized cis-acting elements, and can drive basal transcriptional activity in opossum kidney cells but not in COS-1 or NIH3T3 cells. We demonstrated that 1,25-dihydroxyvitamin D-3 stimulated the transcriptional activity of the Nas1 promoter in transiently transfected opossum kidney cells. This study represents the first characterization of the genomic organization of a Na+-sulfate cotransporter gene. It also provides the basis for a detailed analysis of Nas1 gene regulation and the tools required for assessing Nas1 role in sulfate homeostasis using targeted gene manipulation in mice.	Univ Queensland, Dept Physiol & Pharmacol, Brisbane, Qld 4072, Australia	University of Queensland	Markovich, D (corresponding author), Univ Queensland, Dept Physiol & Pharmacol, Brisbane, Qld 4072, Australia.	danielm@plpk.uq.edu.au	Markovich, Daniel/F-7884-2012; BECK, Laurent/P-2952-2014	BECK, Laurent/0000-0002-6730-2762				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARUGA S, 1999, J AM SOC NEPHROL, V10, P50; Beck L, 1997, J CLIN INVEST, V99, P1200, DOI 10.1172/JCI119276; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BESSEGHIR K, 1987, RENAL PHYSIOL BIOCH, V10, P221; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Carlberg C, 1998, CRIT REV EUKAR GENE, V8, P19, DOI 10.1615/CritRevEukarGeneExpr.v8.i1.20; Cederberg A, 1999, J BIOL CHEM, V274, P165, DOI 10.1074/jbc.274.1.165; Chen Z, 1996, TRENDS GENET, V12, P87, DOI 10.1016/0168-9525(96)81412-0; CHENG S, 1994, P NATL ACAD SCI USA, V91, P5695, DOI 10.1073/pnas.91.12.5695; DARWISH HM, 1992, P NATL ACAD SCI USA, V89, P603, DOI 10.1073/pnas.89.2.603; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; Ernstsson S, 1996, J BIOL CHEM, V271, P21094, DOI 10.1074/jbc.271.35.21094; Everett LA, 1997, NAT GENET, V17, P411, DOI 10.1038/ng1297-411; Fernandes I, 1997, J CLIN INVEST, V100, P2196, DOI 10.1172/JCI119756; FRICK A, 1986, PFLUG ARCH EUR J PHY, V407, P541, DOI 10.1007/BF00657513; Girard JP, 1999, P NATL ACAD SCI USA, V96, P12772, DOI 10.1073/pnas.96.22.12772; Haila S, 1998, GENE, V214, P87, DOI 10.1016/S0378-1119(98)00261-3; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; Hastbacka J, 1996, AM J HUM GENET, V58, P255; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; KOPITO RR, 1987, J BIOL CHEM, V262, P8035; LARDELLI M, 1994, BIOTECHNIQUES, V16, P420; Lotscher M, 1996, PFLUG ARCH EUR J PHY, V432, P373, DOI 10.1007/s004240050147; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; LUCKE H, 1979, BIOCHEM J, V182, P223; Markovich D, 1998, J AM SOC NEPHROL, V9, P1568; Markovich D, 1999, KIDNEY INT, V55, P244, DOI 10.1046/j.1523-1755.1999.00255.x; Markovich D, 1998, AM J PHYSIOL-RENAL, V274, pF283, DOI 10.1152/ajprenal.1998.274.2.F283; MARKOVICH D, 1994, J BIOL CHEM, V269, P3022; MARKOVICH D, 1993, P NATL ACAD SCI USA, V90, P8073, DOI 10.1073/pnas.90.17.8073; MCCLATCHEY AI, 1992, HUM MOL GENET, V1, P521; MURER H, 1992, HDB PHYSL 8, V2, P2165; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; NORBIS F, 1994, PFLUG ARCH EUR J PHY, V428, P217, DOI 10.1007/BF00724500; Pajor AM, 1996, AM J PHYSIOL-CELL PH, V271, pC1808, DOI 10.1152/ajpcell.1996.271.6.C1808; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Puttaparthi K, 1999, AM J PHYSIOL-CELL PH, V276, pC1398, DOI 10.1152/ajpcell.1999.276.6.C1398; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RENFRO JL, 1989, AM J PHYSIOL, V256, pR1176, DOI 10.1152/ajpregu.1989.256.6.R1176; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; Sagawa K, 1998, J PHARMACOL EXP THER, V287, P1056; Sagawa K, 1998, J PHARMACOL EXP THER, V287, P1092; Sagawa K, 1999, J PHARMACOL EXP THER, V290, P1182; Sagawa K, 1999, AM J PHYSIOL-RENAL, V276, pF164, DOI 10.1152/ajprenal.1999.276.1.F164; Satoh H, 1998, J BIOL CHEM, V273, P12307, DOI 10.1074/jbc.273.20.12307; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SupertiFurga A, 1996, NAT GENET, V12, P100, DOI 10.1038/ng0196-100; Taketani Y, 1997, BIOCHEM J, V324, P927, DOI 10.1042/bj3240927; Tallgren L G, 1980, Acta Med Scand Suppl, V640, P1; TURK E, 1994, J BIOL CHEM, V269, P15204; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VonHeijne G, 1996, PROG BIOPHYS MOL BIO, V66, P113, DOI 10.1016/S0079-6107(97)85627-1; Wright EM, 1998, ACTA PHYSIOL SCAND, V163, P257	57	61	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11880	11890		10.1074/jbc.275.16.11880	http://dx.doi.org/10.1074/jbc.275.16.11880			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766815	hybrid			2022-12-27	WOS:000086695500050
J	He, LH; Poblenz, AT; Medrano, CJ; Fox, DA				He, LH; Poblenz, AT; Medrano, CJ; Fox, DA			Lead and calcium produce rod photoreceptor cell apoptosis by opening the mitochondrial permeability transition pore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; HUMAN T-LYMPHOCYTES; PC12 CELLS; CEREBELLAR NEURONS; INDUCE APOPTOSIS; OUTER SEGMENTS; CASPASE FAMILY; BIPOLAR CELLS; IN-VITRO; EXPOSURE	Calcium overload is suggested to play a fundamental role in the process of rod apoptosis in chemical-induced and inherited retinal degenerations, However, this hypothesis has not been tested directly. We developed an in vitro model utilizing isolated rat retinas to determine the mechanisms underlying Ca2+- and/or Pb2+-induced retinal degeneration. Confocal microscopy, histological, and biochemical studies established that the elevated [Ca2+] and/or [Pb2+] were localized to photoreceptors and produced rod-selective apoptosis. Ca2+ and/or Pb2+ induced mitochondrial depolarization, swelling, and cytochrome c release. Subsequently caspase-9 and caspase-3 were sequentially activated. Caspase-7 and caspase-8 were not activated. The effects of Ca2+ and Pb2+ were additive and blocked completely by the mitochondrial permeability transition pore (PTP) inhibitor cyclosporin A, whereas the calcineurin inhibitor FK506 had no effect. The caspase inhibitors carbobenzoxy-Leu-Glu-His-Asp-CH2F and carbobenzoxy-Asp-Glu-Val-AspCH(2)F, but not carbobenzoxy-Ile-Glu-Thr-Asp-CH2F, differentially blocked post-mitochondrial events. The levels of reduced and oxidized glutathione and pyridine nucleotides in rods were unchanged. Our results demonstrate that rod mitochondria are the target site for Ca2+ and Pb2+. Moreover, they suggest that Ca2+ and Pb2+ bind to the internal metal (Me2+) binding site of the PTP and subsequently open the PTP, which initiates the cytochrome c-caspase cascade of apoptosis in rods.	Univ Houston, Coll Optometry, Houston, TX 77204 USA; Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA	University of Houston System; University of Houston; University of Houston System; University of Houston	Fox, DA (corresponding author), Univ Houston, Coll Optometry, 4901 Calhoun Blvd, Houston, TX 77204 USA.				NEI NIH HHS [EY07024] Funding Source: Medline; NIEHS NIH HHS [ES03183] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003183] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adamus G, 1998, J AUTOIMMUN, V11, P523, DOI 10.1006/jaut.1998.0221; Andreyev AY, 1998, FEBS LETT, V439, P373, DOI 10.1016/S0014-5793(98)01394-5; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BROWN DG, 1993, J BIOL CHEM, V268, P3037; Burkitt MJ, 1996, BIOCHEM J, V313, P163, DOI 10.1042/bj3130163; Chakraborti T, 1999, CELL SIGNAL, V11, P77, DOI 10.1016/S0898-6568(98)00025-4; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; Chauhan D, 1997, J BIOL CHEM, V272, P29995, DOI 10.1074/jbc.272.48.29995; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; CROSSON CE, 1990, J OCUL PHARMACOL, V6, P293, DOI 10.1089/jop.1990.6.293; Desole MS, 1996, NEUROSCI LETT, V209, P193, DOI 10.1016/0304-3940(96)12645-8; Dyatlov VA, 1998, NEUROTOXICOLOGY, V19, P293; EDWARD DP, 1991, ARCH OPHTHALMOL-CHIC, V109, P554, DOI 10.1001/archopht.1991.01080040122042; Fox DA, 1999, ANN NY ACAD SCI, V893, P282, DOI 10.1111/j.1749-6632.1999.tb07837.x; FOX DA, 1988, EXP EYE RES, V46, P613, DOI 10.1016/S0014-4835(88)80017-4; FOX DA, 1992, VISION RES, V32, P249, DOI 10.1016/0042-6989(92)90134-5; Fox DA, 1997, NEUROTOXICOLOGY, V18, P645; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gotzes S, 1998, VISUAL NEUROSCI, V15, P945, DOI 10.1017/S0952523898155141; GRAYMORE CLIVE N., 1965, VISION RES, V5, P379, DOI 10.1016/0042-6989(65)90011-8; Guo TL, 1998, TOXICOL APPL PHARM, V153, P250, DOI 10.1006/taap.1998.8549; Guo TL, 1998, TOXICOL APPL PHARM, V152, P397, DOI 10.1006/taap.1998.8526; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Huang B, 1996, VISUAL NEUROSCI, V13, P441, DOI 10.1017/S0952523800008117; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; JONES DP, 1981, J CHROMATOGR, V225, P446, DOI 10.1016/S0378-4347(00)80293-5; JULLIARD AK, 1993, HISTOL HISTOPATHOL, V8, P655; KAY JE, 1990, TRANSPLANT P, V22, P96; Marty MS, 1998, TOXICOL APPL PHARM, V150, P98, DOI 10.1006/taap.1998.8383; MATSCHINSKY FM, 1968, J NEUROCHEM, V15, P643, DOI 10.1111/j.1471-4159.1968.tb08963.x; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; MEDRANO CJ, 1994, TOXICOL APPL PHARM, V125, P309, DOI 10.1006/taap.1994.1077; MINTA A, 1989, J BIOL CHEM, V264, P8171; MOKRASCH LC, 1984, ANAL BIOCHEM, V140, P506, DOI 10.1016/0003-2697(84)90201-X; Monnet-Tschudi F, 1998, J NEUROSCI RES, V53, P361, DOI 10.1002/(SICI)1097-4547(19980801)53:3<361::AID-JNR10>3.0.CO;2-8; Nagashima K, 1996, ACTA NEUROPATHOL, V91, P72; Nicotera P, 1998, CELL CALCIUM, V23, P173, DOI 10.1016/S0143-4160(98)90116-6; Oberto A, 1996, J PHARMACOL EXP THER, V279, P435; POUNDS JG, 1984, NEUROTOXICOLOGY, V5, P295; RATTO GM, 1988, J NEUROSCI, V8, P3240; ROSSI AD, 1993, FASEB J, V7, P1507, DOI 10.1096/fasebj.7.15.8262335; Scortegagna M, 1997, NEUROTOXICOLOGY, V18, P331; SHAH GM, 1995, ANAL BIOCHEM, V227, P1, DOI 10.1006/abio.1995.1245; SHIELLS RA, 1992, P ROY SOC B-BIOL SCI, V247, P21, DOI 10.1098/rspb.1992.0004; Shulman LM, 1996, P NATL ACAD SCI USA, V93, P8034, DOI 10.1073/pnas.93.15.8034; SIMONS TJB, 1993, NEUROTOXICOLOGY, V14, P77; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; SZABO I, 1992, J BIOL CHEM, V267, P2940; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Tang DG, 1998, BIOCHEM BIOPH RES CO, V242, P380, DOI 10.1006/bbrc.1997.7969; THIRKILL CE, 1987, ARCH OPHTHALMOL-CHIC, V105, P372; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Van Soest S, 1999, SURV OPHTHALMOL, V43, P321, DOI 10.1016/S0039-6257(98)00046-0; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; VIVIANI B, 1995, NEUROTOXICOLOGY, V16, P19; WIEGAND RD, 1986, INVEST OPHTH VIS SCI, V27, P727; WINKLER BS, 1981, BIOCH PHYSL EYE, P227; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	66	182	200	4	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12175	12184		10.1074/jbc.275.16.12175	http://dx.doi.org/10.1074/jbc.275.16.12175			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766853	hybrid			2022-12-27	WOS:000086695500088
J	McGinty, A; Chang, YWE; Sorokin, A; Bokemeyer, D; Dunn, MJ				McGinty, A; Chang, YWE; Sorokin, A; Bokemeyer, D; Dunn, MJ			Cyclooxygenase-2 expression inhibits trophic withdrawal apoptosis in nerve growth factor-differentiated PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON-CANCER CELLS; ACTIVATED CASPASE-3; PROTEIN-SYNTHESIS; EPITHELIAL-CELLS; MESSENGER-RNA; INDUCTION; GENE; SYNTHASE-2; INCREASES; BUTYRATE	Cyclooxygenase-2 (Cox-2), an enzyme responsible for catalyzing the committed step in prostanoid biosynthesis, is the product of an immediate early gene capable of being up-regulated by diverse stimuli. Significantly Cox-2 mRNA is absent from rat pheochromocytoma (PC12) cells, both basally and following stimulation with a range of agonists, Using PC12 cells engineered to stably express isopropyl-1-thio-beta-D-galactopyranoside-inducible Cox-2 (PCXII-4), we have investigated the putative effects of Cox-2 expression on differentiation, proliferation, and trophic withdrawal apoptosis, Cox-2 bioactivity had no effect on nerve growth factor-induced differentiation, epidermal growth factor-induced proliferation, or aromatic L-amino acid decarboxylase expression, However, trophic withdrawal apoptosis, induced by the removal of nerve growth factor following differentiation, was markedly reduced in the PCXII-4 when compared with control cells, as assessed by annexin V staining, DNA laddering, and Hoechst 33258 staining. The specificity of this effect was confirmed using two pharmacologically distinct nonsteroidal antiinflammatory drugs, indomethacin and NS398. Investigations showed that the activity of the pro-apoptotic protease caspase-3 was reduced in PCXII cells. This study demonstrates that Cox-2-derived prostaglandins exert cytoprotective effects in trophic factor withdrawal apoptosis and provides evidence that this is, at least in part, due to suppression of caspase-3 activity.	Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Cardiovasc Res Ctr, Milwaukee, WI 53226 USA; Univ Bonn, Med Poliklin, D-53111 Bonn, Germany	Medical College of Wisconsin; Medical College of Wisconsin; University of Bonn	Dunn, MJ (corresponding author), Med Coll Wisconsin, Dept Med, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	mdunn@mcw.edu		Sorokin, Andrey/0000-0002-5660-0190	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022563, R37HL022563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041684] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-22563] Funding Source: Medline; NIDDK NIH HHS [DK-41684] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGERMANSTEWART JA, 1995, ARCH BIOCHEM BIOPHYS, V318, P378, DOI 10.1006/abbi.1995.1243; ARENANDER AT, 1989, J NEUROSCI RES, V23, P247, DOI 10.1002/jnr.490230302; Bokemeyer D, 1997, J CLIN INVEST, V100, P582, DOI 10.1172/JCI119568; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; DEGEORGE JJ, 1988, J NEUROSCI RES, V21, P323, DOI 10.1002/jnr.490210225; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HARRIS RC, 1994, J CLIN INVEST, V94, P2504, DOI 10.1172/JCI117620; Kaplan MD, 1997, J BIOL CHEM, V272, P18534, DOI 10.1074/jbc.272.30.18534; KESTER M, 1994, J BIOL CHEM, V269, P22574; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LI XM, 1994, NEUROCHEM RES, V19, P591, DOI 10.1007/BF00971335; LIM RW, 1987, ONCOGENE, V1, P263; Loftin CD, 1996, ARCH BIOCHEM BIOPHYS, V330, P419, DOI 10.1006/abbi.1996.0271; Mandal M, 1999, BIOCHEM BIOPH RES CO, V260, P775, DOI 10.1006/bbrc.1999.0966; Medina V, 1997, CANCER RES, V57, P3697; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Ruemmele FM, 1999, CELL DEATH DIFFER, V6, P729, DOI 10.1038/sj.cdd.4400545; RYSECK RP, 1992, CELL GROWTH DIFFER, V3, P443; Schulz JB, 1997, J NEUROCHEM, V69, P2075; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Sheng HM, 1997, CELL GROWTH DIFFER, V8, P463; Simmons D.L., 1991, PROSTAGLANDINS LEUKO, P67; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; TENB KK, 1994, CELL BIOL LAB HDB, P218; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315	34	78	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12095	12101		10.1074/jbc.275.16.12095	http://dx.doi.org/10.1074/jbc.275.16.12095			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766843	hybrid, Green Published			2022-12-27	WOS:000086695500078
J	Tong, HY; Chen, WN; London, RE; Murphy, E; Steenbergen, C				Tong, HY; Chen, WN; London, RE; Murphy, E; Steenbergen, C			Preconditioning enhanced glucose uptake is mediated by p38 MAP kinase not by phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; 3T3-L1 ADIPOCYTES; GLUT4 TRANSLOCATION; NITRIC-OXIDE; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; TRANSPORTER TRANSLOCATION; INSULIN ACTION; PROTEIN; STIMULATION; ACTIVATION	Ischemia is reported to stimulate glucose uptake, but the signaling pathways involved are poorly understood. Modulation of glucose transport could be important for the cardioprotective effects of brief intermittent periods of ischemia and reperfusion, termed ischemic preconditioning, Previous work indicates that preconditioning reduces production of acid and lactate during subsequent sustained ischemia, consistent with decreased glucose utilization, However, there are also data that preconditioning enhances glucose uptake. The present study examines whether preconditioning alters glucose transport and whether this is mediated by either phosphatidylinositol 3-kinase (PI3K) or p38 MAP kinase, Langendorff-perfused rat hearts were preconditioned with 4 cycles of 5 min of ischemia and 5 min of reperfusion, with glucose as substrate. During the last reflow, glucose was replaced with 5 mM acetate and 5 mM 2-deoxyglucose (2DG), and hexose transport was measured from the rate of production of 2-deoxyglucose 6-phosphate (2DG6P), using P-31 nuclear magnetic resonance. Preconditioning stimulated 2DG uptake; after 15 min of perfusion with 2DG, 2DG6P levels were 165% of initial ATP in preconditioned hearts compared with 96% in control hearts (p < 0.05). Wortmannin, an inhibitor of PI3K, did not block the preconditioning induced stimulation of 2DG6P production, but perfusion with SB202190, an inhibitor of p38 MAP kinase, did attenuate 2DG6P accumulation (111% of initial ATP, p < 0.05 compared with preconditioned hearts), SB202190 had no effect on 2DG6P accumulation in nonpreconditioned hearts. Preconditioning stimulation of translocation of GLUT I: to the plasma membrane was not inhibited by wortmannin, The data demonstrate that ischemic preconditioning increases hexose transport and that this is mediated by p38 MAP kinase and is PI3K-independent.	Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA	Duke University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Steenbergen, C (corresponding author), Duke Univ, Med Ctr, Dept Pathol, Box 3712, Durham, NC 27710 USA.		London, Robert E/F-7990-2019	London, Robert E/0000-0001-9108-8463	NHLBI NIH HHS [R01 HL039752] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES010004] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Barros LF, 1997, J PHYSIOL-LONDON, V504, P517, DOI 10.1111/j.1469-7793.1997.517bd.x; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; Brozinick JT, 1998, J BIOL CHEM, V273, P14679, DOI 10.1074/jbc.273.24.14679; CARTEE GD, 1991, J APPL PHYSIOL, V70, P1593, DOI 10.1152/jappl.1991.70.4.1593; Charron MJ, 1999, J BIOL CHEM, V274, P3253, DOI 10.1074/jbc.274.6.3253; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Coffer PJ, 1998, BIOCHEM J, V335, P1; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Cortright RN, 1997, CAN J APPL PHYSIOL, V22, P519, DOI 10.1139/h97-033; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Doenst T, 1999, CIRC RES, V84, P467, DOI 10.1161/01.RES.84.4.467; Egert S, 1997, CARDIOVASC RES, V35, P283, DOI 10.1016/S0008-6363(97)00133-8; Etgen GJ, 1997, DIABETES, V46, P1915, DOI 10.2337/diabetes.46.11.1915; EWAWA K, 1999, J BIOL CHEM, V274, P14306; Fischer Y, 1996, AM J PHYSIOL-CELL PH, V270, pC1211, DOI 10.1152/ajpcell.1996.270.4.C1211; Frevert EU, 1998, J BIOL CHEM, V273, P25480, DOI 10.1074/jbc.273.39.25480; GOODYEAR LJ, 1995, AM J PHYSIOL-ENDOC M, V268, pE987, DOI 10.1152/ajpendo.1995.268.5.E987; GOULD GW, 1995, BIOCHEM J, V311, P735, DOI 10.1042/bj3110735; Graness A, 1998, J BIOL CHEM, V273, P32016, DOI 10.1074/jbc.273.48.32016; Han XX, 1998, AM J PHYSIOL-ENDOC M, V274, pE700, DOI 10.1152/ajpendo.1998.274.4.E700; Hansen PA, 1997, AM J PHYSIOL-ENDOC M, V273, pE28, DOI 10.1152/ajpendo.1997.273.1.E28; HENRIKSEN EJ, 1989, AM J PHYSIOL, V256, pE662, DOI 10.1152/ajpendo.1989.256.5.E662; JANIER MF, 1994, AM J PHYSIOL-HEART C, V267, pH1353, DOI 10.1152/ajpheart.1994.267.4.H1353; Jiang T, 1998, J BIOL CHEM, V273, P11017, DOI 10.1074/jbc.273.18.11017; Kapur S, 1997, DIABETES, V46, P1691, DOI 10.2337/diabetes.46.11.1691; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; LASLEY RD, 1993, CARDIOVASC RES, V27, P565, DOI 10.1093/cvr/27.4.565; LEE AD, 1995, FEBS LETT, V361, P51, DOI 10.1016/0014-5793(95)00147-2; LIU YG, 1992, AM J PHYSIOL, V263, pH1107, DOI 10.1152/ajpheart.1992.263.4.H1107; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; MURPHY E, 1993, AM J PHYSIOL, V265, pC1146, DOI 10.1152/ajpcell.1993.265.4.C1146; MURRY CE, 1990, CIRC RES, V66, P913, DOI 10.1161/01.RES.66.4.913; *NIH, 1985, GUID CAR US LAB AN; OKADA T, 1994, J BIOL CHEM, V269, P3598; OmatsuKanbe M, 1996, BIOCHEM J, V315, P25, DOI 10.1042/bj3150025; Rett K, 1996, DIABETES, V45, pS66, DOI 10.2337/diab.45.1.S66; Roberts CK, 1997, AM J PHYSIOL-ENDOC M, V273, pE220, DOI 10.1152/ajpendo.1997.273.1.E220; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Shimizu Y, 1998, BIOCHEM J, V330, P397, DOI 10.1042/bj3300397; STEENBERGEN C, 1993, CIRC RES, V72, P112, DOI 10.1161/01.RES.72.1.112; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; Tanaka K, 1997, EUR J BIOCHEM, V245, P512, DOI 10.1111/j.1432-1033.1997.00512.x; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Todaka M, 1996, BIOCHEM J, V315, P875, DOI 10.1042/bj3150875; Tsiani E, 1998, DIABETES, V47, P1676, DOI 10.2337/diabetes.47.11.1676; Weinbrenner C, 1997, J MOL CELL CARDIOL, V29, P2383, DOI 10.1006/jmcc.1997.0473; Weiss RG, 1996, CIRC RES, V79, P435, DOI 10.1161/01.RES.79.3.435; YELLON DM, 1993, LANCET, V342, P276, DOI 10.1016/0140-6736(93)91819-8; Young LH, 1997, CIRCULATION, V95, P415; Young ME, 1997, BIOCHEM J, V322, P223, DOI 10.1042/bj3220223	53	76	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11981	11986		10.1074/jbc.275.16.11981	http://dx.doi.org/10.1074/jbc.275.16.11981			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766828	hybrid			2022-12-27	WOS:000086695500063
J	van Dalen, CJ; Winterbourn, CC; Senthilmohan, R; Kettle, AJ				van Dalen, CJ; Winterbourn, CC; Senthilmohan, R; Kettle, AJ			Nitrite as a substrate and inhibitor of myeloperoxidase - Implications for nitration and hypochlorous acid production at sites of inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; ANTIINFLAMMATORY DRUGS; HORSERADISH-PEROXIDASE; OXIDATIVE MODIFICATION; CATALYZED OXIDATION; TYROSINE NITRATION; BIOLOGICAL-FLUIDS; MASS-SPECTROMETRY; AMINO-ACIDS; SUPEROXIDE	Myeloperoxidase is a heme enzyme of neutrophils that uses hydrogen peroxide to oxidize chloride to hypochlorous acid. Recently, it has been shown to catalyze nitration of tyrosine. In this study we have investigated the mechanism by which it oxidizes nitrite and promotes nitration of tyrosyl residues. Nitrite was found to be a poor substrate for myeloperoxidase but an excellent inhibitor of its chlorination activity. Nitrite slowed chlorination by univalently reducing the enzyme to an inactive form and as a consequence was oxidized to nitrogen dioxide. In the presence of physiological concentrations of nitrite and chloride, myeloperoxidase catalyzed little nitration of tyrosyl residues in a heptapeptide. However, the efficiency of nitration was enhanced at least 4-fold by free tyrosine. Our data are consistent with a mechanism in which myeloperoxidase oxidizes free tyrosine to tyrosyl radicals that exchange with tyrosyl residues in peptides, These peptide radicals then couple with nitrogen dioxide to form 3-nitrotyrosyl residues. With neutrophils, myeloperoxidase-dependent nitration required a high concentration of nitrite (1 mM), was doubled by tyrosine, and increased 4-fold by superoxide dismutase, Superoxide is likely to inhibit nitration by reacting with nitrogen dioxide and/or tyrosyl radicals. We propose that at sites of inflammation myeloperoxidase will nitrate proteins, even though nitrite is a poor substrate, because the co-substrate tyrosine will be available to facilitate the reaction. Also, production of 3-nitrotyrosine will be most favorable when the concentration of superoxide is low.	Christchurch Sch Med, Dept Pathol, Biomed Res Unit, Free Rad Res Grp, Christchurch, New Zealand	University of Otago	van Dalen, CJ (corresponding author), Christchurch Sch Med, Dept Pathol, Biomed Res Unit, Free Rad Res Grp, POB 4345, Christchurch, New Zealand.		Kettle, Anthony J/A-8520-2008	Kettle, Anthony J/0000-0002-8218-7766				BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; DOMIGAN NM, 1995, J BIOL CHEM, V270, P16542, DOI 10.1074/jbc.270.28.16542; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Eiserich JP, 1996, J BIOL CHEM, V271, P19199, DOI 10.1074/jbc.271.32.19199; FOLKES LK, 1995, ARCH BIOCHEM BIOPHYS, V323, P120, DOI 10.1006/abbi.1995.0017; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HADDAD IY, 1993, AM J PHYSIOL, V265, pL555, DOI 10.1152/ajplung.1993.265.6.L555; HADDAD IY, 1994, J CLIN INVEST, V94, P2407, DOI 10.1172/JCI117607; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; Heinecke JW, 1999, METHOD ENZYMOL, V300, P124; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5299, DOI 10.1021/bi00695a011; HOOGLAND H, 1987, BIOCHIM BIOPHYS ACTA, V916, P76, DOI 10.1016/0167-4838(87)90212-3; Hule R.E., 1993, FREE RADICAL RES COM, V18, P195; JARRETT HW, 1986, ANAL BIOCHEM, V153, P189, DOI 10.1016/0003-2697(86)90079-5; Jiang Q, 1997, J BIOL CHEM, V272, P32767, DOI 10.1074/jbc.272.52.32767; JIN FM, 1993, J CHEM SOC PERK T 2, P1583, DOI 10.1039/p29930001583; Kettle AJ, 1999, METHOD ENZYMOL, V300, P111; KETTLE AJ, 1991, BIOCHEM PHARMACOL, V41, P1485, DOI 10.1016/0006-2952(91)90565-M; Kettle AJ, 1996, FEBS LETT, V379, P103, DOI 10.1016/0014-5793(95)01494-2; KETTLE AJ, 1988, BIOCHEM J, V252, P529, DOI 10.1042/bj2520529; Kettle AJ, 1997, REDOX REP, V3, P3, DOI 10.1080/13510002.1997.11747085; KETTLE AJ, 1994, METHOD ENZYMOL, V233, P502; KETTLE AJ, 1993, BIOCHEM PHARMACOL, V45, P2003, DOI 10.1016/0006-2952(93)90010-T; Klebanoff S.J., 1999, INFLAMMATION BASIC P, P721; KOBAYASHI K, 1995, J CHEM SOC DALTON, P2885, DOI 10.1039/dt9950002885; Koppenol WH, 1998, FREE RADICAL BIO MED, V25, P385, DOI 10.1016/S0891-5849(98)00093-8; LEONE AM, 1994, BIOCHEM BIOPH RES CO, V200, P951, DOI 10.1006/bbrc.1994.1542; McCormick ML, 1998, J BIOL CHEM, V273, P32030, DOI 10.1074/jbc.273.48.32030; ODAJIMA T, 1970, BIOCHIM BIOPHYS ACTA, V206, P71, DOI 10.1016/0005-2744(70)90083-5; Panasenko OM, 1997, ARCH BIOCHEM BIOPHYS, V343, P254, DOI 10.1006/abbi.1997.0171; Pfeiffer S, 1998, J BIOL CHEM, V273, P27280, DOI 10.1074/jbc.273.42.27280; Podrez EA, 1999, J CLIN INVEST, V103, P1547, DOI 10.1172/JCI5549; PRUTZ WA, 1985, ARCH BIOCHEM BIOPHYS, V243, P125, DOI 10.1016/0003-9861(85)90780-5; Sampson JB, 1998, ARCH BIOCHEM BIOPHYS, V356, P207, DOI 10.1006/abbi.1998.0772; THOMAS MJ, 1992, J LEUKOCYTE BIOL, V51, P591, DOI 10.1002/jlb.51.6.591; Tien M, 1999, ARCH BIOCHEM BIOPHYS, V367, P61, DOI 10.1006/abbi.1999.1226; Tsikas D, 1997, ANAL BIOCHEM, V244, P208, DOI 10.1006/abio.1996.9880; vanDalen CJ, 1997, BIOCHEM J, V327, P487; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617	41	123	125	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11638	11644		10.1074/jbc.275.16.11638	http://dx.doi.org/10.1074/jbc.275.16.11638			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766781	hybrid			2022-12-27	WOS:000086695500016
J	Badorff, C; Berkely, N; Mehrotra, S; Talhouk, JW; Rhoads, RE; Knowlton, KU				Badorff, C; Berkely, N; Mehrotra, S; Talhouk, JW; Rhoads, RE; Knowlton, KU			Enteroviral protease 2A directly cleaves dystrophin and is inhibited by a dystrophin-based substrate analogue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED DILATED CARDIOMYOPATHY; DUCHENNE MUSCULAR-DYSTROPHY; HEART-FAILURE; ROD DOMAIN; POLIOVIRUS; RHINOVIRUS; MICE; SITE; IMMUNODEFICIENCY; INFECTION	Enteroviruses such as Coxsackievirus B3 can cause dilated cardiomyopathy through unknown pathological mechanism(s). Dystrophin is a large extrasarcomeric cytoskeletal protein whose genetic deficiency causes hereditary dilated cardiomyopathy, In addition, we have recently shown that dystrophin is proteolytically cleaved by the Coxsackievirus protease 2A leading to functional impairment and morphological disruption. However, the mechanism of dystrophin cleavage and the exact cleavage site remained to be identified. Antibody epitope mapping of endogenous dystrophin indicated protease 2A-mediated cleavage at the site in the hinge 3 region predicted by a neural network algorithm (human, amino acid 2434; mouse, amino acid 2427). Using site-directed mutagenesis, peptide sequencing, and fluorescence resonance energy transfer assays with recombinant dystrophin, we demonstrate that this putative site in mouse and human dystrophin is a direct substrate for the Coxsackieviral protease 2A both in vitro and in vivo. The substrate analogue protease inhibitor z-LSTT-fmk was designed based on the dystrophin sequence that interacts with the protease 2A and was found to have an IC50 of 550 nM in vitro, Dystrophin is the first cellular substrate of the enteroviral protease 2A that was identified using by a bioinformatic approach and for which the cleavage site was molecularly mapped within living cells.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Enzyme Syst Prod, Livermore, CA 94550 USA	University of California System; University of California San Diego; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Knowlton, KU (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NHLBI NIH HHS [R01 HL57365-01] Funding Source: Medline; NIGMS NIH HHS [GM20818] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057365] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amann KJ, 1998, J BIOL CHEM, V273, P28419, DOI 10.1074/jbc.273.43.28419; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Baboonian C, 1997, CURR TOP MICROBIOL, V223, P31; Badorff C, 1999, NAT MED, V5, P320, DOI 10.1038/6543; Beggs AH, 1997, CIRCULATION, V95, P2344, DOI 10.1161/01.CIR.95.10.2344; Blom N, 1996, PROTEIN SCI, V5, P2203, DOI 10.1002/pro.5560051107; Bovee ML, 1998, VIROLOGY, V245, P229, DOI 10.1006/viro.1998.9171; Chen J, 1999, J CLIN INVEST, V103, P1483, DOI 10.1172/JCI7297; Chou KC, 1996, ANAL BIOCHEM, V233, P1, DOI 10.1006/abio.1996.0001; CHOW LH, 1992, LAB INVEST, V66, P24; Gradi A, 1998, P NATL ACAD SCI USA, V95, P11089, DOI 10.1073/pnas.95.19.11089; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; JUNG D, 1995, J BIOL CHEM, V270, P27305, DOI 10.1074/jbc.270.45.27305; KAHANA E, 1995, BIOCHEMISTRY-US, V34, P8110, DOI 10.1021/bi00025a017; KASPER EK, 1994, J AM COLL CARDIOL, V23, P586, DOI 10.1016/0735-1097(94)90740-4; Kerekatte V, 1999, J VIROL, V73, P709, DOI 10.1128/JVI.73.1.709-717.1999; KOENIG M, 1990, J BIOL CHEM, V265, P4560; Lamphear BJ, 1996, BIOCHEMISTRY-US, V35, P15726, DOI 10.1021/bi961864t; LAMPHEAR BJ, 1993, J BIOL CHEM, V268, P19200; MALHOTRA SB, 1988, SCIENCE, V242, P755, DOI 10.1126/science.3055295; Melacini P, 1996, CIRCULATION, V94, P3168, DOI 10.1161/01.CIR.94.12.3168; MOLLA A, 1993, J VIROL, V67, P4688, DOI 10.1128/JVI.67.8.4688-4695.1993; Morris GE, 1998, BIOCHEMISTRY-US, V37, P11117, DOI 10.1021/bi9805137; MUNTONI F, 1993, NEW ENGL J MED, V329, P921, DOI 10.1056/NEJM199309233291304; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Rueckert Roland R., 1996, P477; Sagot I, 1999, FEBS LETT, V447, P53, DOI 10.1016/S0014-5793(99)00258-6; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOCKEN DD, 1992, J AM COLL CARDIOL, V20, P301, DOI 10.1016/0735-1097(92)90094-4; Sole MJ, 1993, J AM COLL CARDIOL, V22, P99; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; TOWBIN JA, 1993, CIRCULATION, V87, P1854, DOI 10.1161/01.CIR.87.6.1854; Towbin JA, 1998, CURR OPIN CELL BIOL, V10, P131, DOI 10.1016/S0955-0674(98)80096-3; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Ventoso I, 1999, J VIROL, V73, P814, DOI 10.1128/JVI.73.1.814-818.1999; Wang QM, 1998, ARCH BIOCHEM BIOPHYS, V356, P12, DOI 10.1006/abbi.1998.0746; Wang QM, 1998, ANTIMICROB AGENTS CH, V42, P916, DOI 10.1128/AAC.42.4.916; Wessely R, 1998, J CLIN INVEST, V102, P1444, DOI 10.1172/JCI1972; Xu X, 1998, NUCLEIC ACIDS RES, V26, P2034, DOI 10.1093/nar/26.8.2034	40	67	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11191	11197		10.1074/jbc.275.15.11191	http://dx.doi.org/10.1074/jbc.275.15.11191			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753926	hybrid			2022-12-27	WOS:000086466600068
J	Toru, S; Murakoshi, T; Ishikawa, K; Saegusa, H; Fujigasaki, H; Uchihara, T; Nagayama, S; Osanai, M; Mizusawa, H; Tanabe, T				Toru, S; Murakoshi, T; Ishikawa, K; Saegusa, H; Fujigasaki, H; Uchihara, T; Nagayama, S; Osanai, M; Mizusawa, H; Tanabe, T			Spinocerebellar ataxia type 6 mutation alters P-type calcium channel function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HEMIPLEGIC MIGRAINE; PURE CEREBELLAR-ATAXIA; LEANER MUTANT MICE; PURKINJE-CELLS; CAG REPEAT; EXPANSION; GENE; ATROPHY; TRINUCLEOTIDE; IDENTIFICATION	Abnormal CAG repeat expansion in the alpha 1A voltage-dependent calcium channel gene is associated with spinocerebellar ataxia type 6, an autosomal dominant cerebellar ataxia with a predominant loss of the Purkinje cell. A reverse transcriptase-polymerase chain reaction analysis of mRNA from mouse Purkinje cells revealed a predominant expression of the alpha 1A channel lacking an asparagine-proline (NP) stretch in the domain TV (alpha 1A(-NP)). Human alpha 1A channels carrying various polyglutamine length with or without NP were expressed in HEK293 cells, and channel properties were compared using a whole-cell voltage clamp technique. alpha 1A(-NP), corresponding to P-type channel, with 24 and 28 polyglutamines found in patients showed the voltage dependence of inactivation shifting negatively by 6 and 11 mV, respectively, from the 13 polyglutamine control. Contrarily, the alpha 1A channel with NP (alpha 1A(+NP)), corresponding to Q-type channel, with 28 polyglutamines exhibited a positive shift of 5 mV. These results suggest that altered function of alpha 1A(-NP) may contribute to degeneration of Purkinje cells, which express predominantly alpha 1A(-NP), due to the reduced Ca2+ influx resulting from the negative shift of voltage-dependent inactivation. On the other hand, other types of neurons, expressing both alpha 1A(-NP) and alpha 1A(+NP), may survive because the positive shift of voltage-dependent inactivation of alpha 1A(+NP) compensates Ca2+ influx.	Tokyo Med & Dent Univ, Grad Sch Med, Dept Pharmacol & Neurobiol, Bunkyo Ku, Tokyo 1138519, Japan; Tokyo Med & Dent Univ, Grad Sch Med, Dept Neurol & Neurol Sci, Bunkyo Ku, Tokyo 1138519, Japan; Tokyo Metropolitan Neurol Hosp, Dept Neurol, Fuchu, Tokyo 1830042, Japan; Tokyo Metropolitan Inst Neurosci, Dept Neuropathol, Fuchu, Tokyo 1838526, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; Japan Science & Technology Agency (JST)	Tanabe, T (corresponding author), Tokyo Med & Dent Univ, Grad Sch Med, Dept Pharmacol & Neurobiol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	t-tanabe.mphm@med.tmd.ac.jp	Osanai, Makoto/B-7048-2009	Osanai, Makoto/0000-0002-3572-8195				Bourinet E, 1999, NAT NEUROSCI, V2, P407, DOI 10.1038/8070; David G, 1997, NAT GENET, V17, P65, DOI 10.1038/ng0997-65; Dove LS, 1998, J NEUROSCI, V18, P7687; FRETCHER CF, 1996, CELL, V87, P607; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hans M, 1999, J NEUROSCI, V19, P1610; HECKROTH JA, 1994, BRAIN RES, V658, P93, DOI 10.1016/S0006-8993(09)90014-2; HERRUP K, 1982, NEUROSCIENCE, V7, P2185, DOI 10.1016/0306-4522(82)90129-4; HUNTER AGW, 1993, HUMAN MALFORMATIONS, V2, P1; Imbert G, 1996, NAT GENET, V14, P285, DOI 10.1038/ng1196-285; Ishikawa K, 1999, HUM MOL GENET, V8, P1185, DOI 10.1093/hmg/8.7.1185; Ishikawa K, 1997, AM J HUM GENET, V61, P336, DOI 10.1086/514867; Ishikawa K, 1999, J NEUROL NEUROSUR PS, V67, P86, DOI 10.1136/jnnp.67.1.86; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; Kraus RL, 1998, J BIOL CHEM, V273, P5586, DOI 10.1074/jbc.273.10.5586; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LLINAS R, 1992, TRENDS NEUROSCI, V15, P351, DOI 10.1016/0166-2236(92)90053-B; Lorenzon NM, 1998, J NEUROSCI, V18, P4482; Matsuyama Z, 1999, J Neurosci, V19, pRC14; MEIER H, 1971, J HERED, V62, P297, DOI 10.1093/oxfordjournals.jhered.a108176; MINTZ IM, 1995, NEURON, V15, P675, DOI 10.1016/0896-6273(95)90155-8; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269; Sanpei K, 1996, NAT GENET, V14, P277, DOI 10.1038/ng1196-277; Subramony SH, 1996, MOVEMENT DISORD, V11, P174, DOI 10.1002/mds.870110210; Wakamori M, 1998, J BIOL CHEM, V273, P34857, DOI 10.1074/jbc.273.52.34857; WESTENBROEK RE, 1995, J NEUROSCI, V15, P6403; Yabe I, 1998, J NEUROL SCI, V156, P89, DOI 10.1016/S0022-510X(98)00009-4; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62; ZONG ZQ, 1994, BIOCHEM BIOPH RES CO, V201, P1117, DOI 10.1006/bbrc.1994.1821	34	83	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10893	10898		10.1074/jbc.275.15.10893	http://dx.doi.org/10.1074/jbc.275.15.10893			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753886	hybrid			2022-12-27	WOS:000086466600028
J	Yee, J; Mowatt, MR; Dennis, PP; Nash, TE				Yee, J; Mowatt, MR; Dennis, PP; Nash, TE			Transcriptional analysis of the glutamate dehydrogenase gene in the primitive eukaryote, Giardia lamblia - Identification of a primordial gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ARCHAEBACTERIUM HALOBACTERIUM-CUTIRUBRUM; UNUSUAL RIBOSOMAL-RNA; PROTEIN-CODING GENES; BOX-BINDING-PROTEIN; CYST WALL PROTEIN; TRYPANOSOMA-BRUCEI; MESSENGER-RNA; POLYMERASE-I; SEQUENCES	We studied gene expression in the ancient eukaryote, Giardia lamblia, by taking advantage of assays developed recently in our laboratory, which allow new genetic analyses of this organism. We examined the transcription of a 2.2-kilobase segment of the Giardia genome that contains the glutamate dehydrogenase (GDH) gene and a portion of a second open reading frame encoding an uncharacterized gene. Nuclear firn-on analyses showed that the genes are transcribed as two separate units spaced less than 200 base pairs apart, and transcription of the GDH gene initiates just 3-6 nucleotides upstream of its translation start codon, We characterized the GDH promoter by transfecting Giardia with DNA constructs that used the GDH upstream sequence to drive the expression of a luciferase reporter gene. By deletion and mutational analyses, we localized promoter function to three motifs within a 50-base pair region of the GDH upstream sequence. Using band shift assays and UV cross-linking, we demonstrated specific binding of a 68-kDa protein from Giardia nuclear extracts to short poly(T) tracts contained within two of the sequence motifs on single-stranded DNA from the promoter region, This report describes one of the first functional gene promoter and its cognate DNA-binding protein in this primitive eukaryote.	NIAID, Parasit Dis Lab, Bethesda, MD 20892 USA; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V5Z 1M9, Canada	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of British Columbia	Yee, J (corresponding author), Trent Univ, Dept Biol, 1600 W Bank Dr, Peterborough, ON K9J 7B8, Canada.							ADAM RD, 1991, MICROBIOL REV, V55, P706, DOI 10.1128/MMBR.55.4.706-732.1991; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; BOOTHROYD JC, 1987, NUCLEIC ACIDS RES, V15, P4065, DOI 10.1093/nar/15.10.4065; Dennis PP, 1997, CELL, V89, P1007, DOI 10.1016/S0092-8674(00)80288-3; EDLIND TD, 1987, NUCLEIC ACIDS RES, V15, P7889, DOI 10.1093/nar/15.19.7889; HASHIMOTO T, 1995, MOL BIOL EVOL, V12, P782; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HORIKOSHI M, 1989, P NATL ACAD SCI USA, V86, P4843, DOI 10.1073/pnas.86.13.4843; HUANG J, 1991, MOL CELL BIOL, V11, P3180, DOI 10.1128/MCB.11.6.3180; KLENK HP, 1995, ARCH PROTISTENKD, V145, P221, DOI 10.1016/S0003-9365(11)80317-9; LANZENDORFER M, 1992, NUCLEIC ACIDS RES, V20, P1145, DOI 10.1093/nar/20.5.1145; LATHANGUE NB, 1988, TRANSCRIPTION SPLICI, P1; Lee MGS, 1997, ANNU REV MICROBIOL, V51, P463, DOI 10.1146/annurev.micro.51.1.463; LUJAN HD, 1995, J BIOL CHEM, V270, P29307, DOI 10.1074/jbc.270.49.29307; Lujan HD, 1997, MICROBIOL MOL BIOL R, V61, P294; MAY BP, 1989, J BIOL CHEM, V264, P12253; MORRISON HG, 1999, MOL PAR M SEPT 12 16, V10, pC262; MOWATT MR, 1995, MOL MICROBIOL, V15, P955, DOI 10.1111/j.1365-2958.1995.tb02364.x; NASH T, 1992, PARASITOL TODAY, V8, P229, DOI 10.1016/0169-4758(92)90119-M; Nash TE, 1997, PHILOS T R SOC B, V352, P1369, DOI 10.1098/rstb.1997.0122; NEWMAN A, 1987, EMBO J, V6, P3833, DOI 10.1002/j.1460-2075.1987.tb02720.x; NIU XH, 1994, MOL BIOCHEM PARASIT, V66, P49, DOI 10.1016/0166-6851(94)90035-3; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; QUON DVK, 1994, P NATL ACAD SCI USA, V91, P4579, DOI 10.1073/pnas.91.10.4579; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; RUDENKO G, 1989, EMBO J, V8, P4259, DOI 10.1002/j.1460-2075.1989.tb08611.x; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; SHEA C, 1987, CELL, V50, P603, DOI 10.1016/0092-8674(87)90033-X; SHIMMIN LC, 1989, EMBO J, V8, P1225, DOI 10.1002/j.1460-2075.1989.tb03496.x; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; Sun CH, 1999, J BIOL CHEM, V274, P19699, DOI 10.1074/jbc.274.28.19699; Tomonaga T, 1996, P NATL ACAD SCI USA, V93, P5830, DOI 10.1073/pnas.93.12.5830; ULLU E, 1990, NUCLEIC ACIDS RES, V18, P3319, DOI 10.1093/nar/18.11.3319; YEE J, 1995, P NATL ACAD SCI USA, V92, P5615, DOI 10.1073/pnas.92.12.5615; YEE J, 1992, J BIOL CHEM, V267, P7539; ZOMERDIJK JCBM, 1991, NATURE, V353, P772, DOI 10.1038/353772a0	39	69	71	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11432	11439		10.1074/jbc.275.15.11432	http://dx.doi.org/10.1074/jbc.275.15.11432			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753960	hybrid			2022-12-27	WOS:000086466600102
J	Hansen, PA; Marshall, BA; Chen, M; Holloszy, JO; Mueckler, M				Hansen, PA; Marshall, BA; Chen, M; Holloszy, JO; Mueckler, M			Transgenic overexpression of hexokinase II in skeletal muscle does not increase glucose disposal in wild-type or Glut1-overexpressing mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHESIS; TRANSPORT ACTIVITY; INSULIN; GLUT4; DISSOCIATION; HOMEOSTASIS	Glut1 transgenic mice were bred with transgenic mice that overexpress hexokinase II in skeletal muscle in order to determine whether whole-body glucose disposal could be further augmented in mice overexpressing glucose transporters. Overexpression of hexokinase alone in skeletal muscle had no effect on glucose transport or metabolism in isolated muscles, nor did it alter blood glucose levels or the rate of whole-body glucose disposal, Expression of the hexokinase transgene in the context of the Glut1 transgenic background did not alter glucose transport in isolated muscles but did cause additional increases in steady-state glucose 6-phosphate (3.2-fold) and glycogen (7.5-fold) levels compared with muscles that overexpress the Glut1 transporter alone. Surprisingly, however, these increases were not accompanied by a change in basal or insulin-stimulated whole-body glucose disposal in the doubly transgenic mice compared with Glut1 transgenic mice, probably due to an inhibition of de novo glycogen synthesis as a result of the high levels of steady-state glycogen in the muscles of doubly transgenic mice (430 mu mol/g versus 10 mu mol/g in wild-type mice). We conclude that the hexokinase gene may not be a good target for therapies designed to counteract insulin resistance or hyperglycemia.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Mueckler, M (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Box 8228,660 S Euclid Ave, St Louis, MO 63110 USA.		Mueckler, Mike M/F-6115-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038495, R01DK018986] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18986, DK38495] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chang PY, 1996, J BIOL CHEM, V271, P14834, DOI 10.1074/jbc.271.25.14834; Cline GW, 1999, NEW ENGL J MED, V341, P240, DOI 10.1056/NEJM199907223410404; CRANE RK, 1954, J BIOL CHEM, V210, P597; FURLER SM, 1991, AM J PHYSIOL, V261, pE337, DOI 10.1152/ajpendo.1991.261.3.E337; GULVE EA, 1994, J BIOL CHEM, V269, P18366; HANSEN PA, 1994, J APPL PHYSIOL, V76, P979, DOI 10.1152/jappl.1994.76.2.979; HANSEN PA, 1995, J BIOL CHEM, V270, P1679; Hansen PA, 1998, J BIOL CHEM, V273, P18173, DOI 10.1074/jbc.273.29.18173; Laurent D, 2000, AM J PHYSIOL-ENDOC M, V278, pE663, DOI 10.1152/ajpendo.2000.278.4.E663; Lombardi AM, 1997, FASEB J, V11, P1137, DOI 10.1096/fasebj.11.13.9367348; Marshall BA, 1999, AM J PHYSIOL-ENDOC M, V276, pE390, DOI 10.1152/ajpendo.1999.276.2.E390; MARSHALL BA, 1993, J BIOL CHEM, V268, P18442; MARSHALL BA, 1994, AM J PHYSIOL-ENDOC M, V267, pE738, DOI 10.1152/ajpendo.1994.267.5.E738; MUECKLER MM, 1995, NEWS PHYSIOL SCI, V10, P22; NESHER R, 1985, AM J PHYSIOL, V249, pC226, DOI 10.1152/ajpcell.1985.249.3.C226; Passonneau J.V., 1972, FLEXIBLE SYSTEM ENZY; PASSONNEAU JV, 1974, ANAL BIOCHEM, V60, P405, DOI 10.1016/0003-2697(74)90248-6; REN JM, 1993, J BIOL CHEM, V268, P16113; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; STAUFFACHER W, 1969, AM J PHYSIOL, V216, P98, DOI 10.1152/ajplegacy.1969.216.1.98; Wang WC, 1996, J CELL BIOL, V135, P415, DOI 10.1083/jcb.135.2.415; ZAWALICH WS, 1977, ENDOCRINOLOGY, V100, P1	22	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22381	22386		10.1074/jbc.M001946200	http://dx.doi.org/10.1074/jbc.M001946200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10764781	hybrid			2022-12-27	WOS:000088363800085
J	Van Oene, M; Lukacs, GL; Rommens, JM				Van Oene, M; Lukacs, GL; Rommens, JM			Cystic fibrosis mutations lead to carboxyl-terminal fragments that highlight an early biogenesis step of the cystic fibrosis transmembrane conductance regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; DISEASE-ASSOCIATED MUTATIONS; ENDOPLASMIC-RETICULUM; SECRETORY PROTEIN; CYTOPLASMIC LOOP; MOLECULAR-BASIS; WILD-TYPE; DEGRADATION; PROTEASOME; DELTA-F508	Inefficient delivery of the cystic fibrosis transmembrane conductance regulator (CFTR) to the surface of cells contributes to disease in the majority of cystic fibrosis patients. Analysis of cystic fibrosis-associated missense mutations in the first nucleotide binding domain (NBD1), including A455E, S549R, Y563N, and P574H, revealed reduced levels of mature CFTR with elevated levels of carboxyl-terminal polypeptide fragments of 105 and 90 kDa, These fragments appear early in biogenesis and degrade rapidly in four distinct cell types tested including the bronchial epithelial IB3-1 cell Line. They were detected at highest levels with CFTRA455E where the 105-kDa fragment accounted for 40% of newly synthesized polypeptide but for only 20 and 7% of nascent wild type and mutant Delta F508 proteins, respectively. The bands represent core- and unglycosylated forms of the same CFTR fragment supporting that precursor forms are correctly inserted into the membrane of the endoplasmic reticulum, Proteolytic cleavage would be predicted to occur on the cytosolic face of the endoplasmic reticulum within the NBD1-R domain segment, but pharmacological testing did not support involvement of the 26 S proteasome. The examined missense mutations in NBD1 manifest differently than the major mutant, Delta F508, and highlight a critical conformational aspect of biogenesis of CFTR.	Univ Toronto, Hosp Sick Children, Dept Mol & Med Genet, Program Genet & Genom Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Lab Med & Pathobiol, Program Cell Biol & Lung Gene therapy, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Rommens, JM (corresponding author), Univ Toronto, Hosp Sick Children, Dept Mol & Med Genet, Program Genet & Genom Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.			Lukacs, Gergely/0000-0003-0900-0675	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK049096] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49096] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; Bebok Z, 1998, J BIOL CHEM, V273, P29873, DOI 10.1074/jbc.273.45.29873; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Devidas S, 1998, J BIOL CHEM, V273, P29373, DOI 10.1074/jbc.273.45.29373; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; EGAN M, 1992, NATURE, V358, P781; FULLER W, 1998, PEDIATR PULM, V17, P196; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; Haardt M, 1999, J BIOL CHEM, V274, P21873, DOI 10.1074/jbc.274.31.21873; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; Kartner N, 1998, METHOD ENZYMOL, V292, P629; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KRISTIDIS P, 1992, AM J HUM GENET, V50, P1178; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; LUKACS GL, 1993, J BIOL CHEM, V268, P21592; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Ostedgaard LS, 1999, J CELL SCI, V112, P2091; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; PIND S, 1994, J BIOL CHEM, V269, P12784; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Plemper RK, 1998, J BIOL CHEM, V273, P32848, DOI 10.1074/jbc.273.49.32848; Ramjeesingh M, 1997, BIOCHEM J, V327, P17, DOI 10.1042/bj3270017; ROMMENS JM, 1991, P NATL ACAD SCI USA, V88, P7500, DOI 10.1073/pnas.88.17.7500; Rozmahel R, 1996, NAT GENET, V12, P280, DOI 10.1038/ng0396-280; Sato S, 1998, J BIOL CHEM, V273, P7189, DOI 10.1074/jbc.273.13.7189; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; Seibert FS, 1996, J BIOL CHEM, V271, P27493, DOI 10.1074/jbc.271.44.27493; Seibert FS, 1997, BIOCHEMISTRY-US, V36, P11966, DOI 10.1021/bi9712652; Seibert FS, 1996, J BIOL CHEM, V271, P15139, DOI 10.1074/jbc.271.25.15139; SHEPPARD DN, 1995, EMBO J, V14, P876, DOI 10.1002/j.1460-2075.1995.tb07069.x; Spector D. L., 1998, CELLS LAB MANUAL; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; Vankeerberghen A, 1998, HUM MOL GENET, V7, P1761, DOI 10.1093/hmg/7.11.1761; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; *WORLD CYST FIBR G, CYST FIBR MUT DAT BA; YANG YP, 1993, HUM MOL GENET, V2, P1253, DOI 10.1093/hmg/2.8.1253; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649; Zielenski J, 1999, NAT GENET, V22, P128, DOI 10.1038/9635; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	55	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19577	19584		10.1074/jbc.M002186200	http://dx.doi.org/10.1074/jbc.M002186200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10764788	hybrid			2022-12-27	WOS:000087941300021
J	Byrd, JC; MacDonald, RG				Byrd, JC; MacDonald, RG			Mechanisms for high affinity mannose 6-phosphate ligand binding to the insulin-like growth factor II/mannose 6-phosphate receptor - Negative cooperactivity and receptor oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II RECEPTOR; BREAST-CANCER CELLS; LYSOSOMAL-ENZYMES; CATHEPSIN-D; IGF-II; DEFICIENT FIBROBLASTS; UROKINASE RECEPTOR; COOPERATIVITY; ACTIVATION; TRANSPORT	The two mannose 6-phosphate (Man-6-P) binding domains of the insulin-like growth factor II/mannose 6-phosphate receptor (Man-6-P/IGF2R), located in extracytoplasmic repeats 1-3 and 7-9, are capable of binding Man-6-P with low affinity and glycoproteins that contain more than one Man-6-P residue with high affinity. High affinity multivalent ligand binding sites could be formed through two possible mechanisms: the interaction of two Man-6-P binding domains within one Man-6-P/IGF2R molecule or by receptor oligomerization. To discriminate between these mechanisms, truncated FLAG epitope tagged Man-6-P/IGF2R constructs, containing one or both of the Man-6-P binding domains, were expressed in 293T cells, and characterized for binding of pentamannose phosphate-bovine serum albumin (PMP-BSA), a pseudoglycoprotein bearing multiple Man-6-P residues. A construct containing all 15 repeats of the Man-6-P/IGF2R extracytoplasmic domain bound PMP-BSA with the same affinity as the full-length receptor (K-d = 0.54 nM) with a curvilinear Scatchard plot. The presence of excess unlabeled PMP-BSA increased the dissociation rate of pre-formed I-125-PMP-BSA/receptor complexes, suggesting negative cooperativity in multivalent ligand binding and affirming the role of multiple Man-6-P/IGF2R binding domains in forming high affinity binding sites. Truncated receptors containing only one Man-6-P binding domain and mutant receptor constructs, containing an Arg(1325) --> Ala mutation that eliminates binding to the repeats 7-9 binding domain, formed high affinity PMP-BSA binding, but with reduced stoichiometries, Collectively, these observations suggest that alignment of Man-6-P binding domains of separate Man-6-P/IGF2R molecules is responsible for the formation of high affinity Man-6-P binding sites and provide functional evidence for Man-6-P/IGF2R oligomerization.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	MacDonald, RG (corresponding author), 984525 Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.				NIDDK NIH HHS [DK44212] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044212] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AULETTA M, 1992, J NEUROSCI RES, V31, P14, DOI 10.1002/jnr.490310103; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; BRAULKE T, 1988, BIOCHEM BIOPH RES CO, V150, P1287, DOI 10.1016/0006-291X(88)90769-3; Byrd JC, 1999, J BIOL CHEM, V274, P24408, DOI 10.1074/jbc.274.34.24408; Byrd JC, 2000, J BIOL CHEM, V275, P18647, DOI 10.1074/jbc.M001273200; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; DELEAN A, 1979, RECEPTORS, V1, P143; DEMEYTS P, 1975, BIOCHEM BIOPH RES CO, V66, P1118, DOI 10.1016/0006-291X(75)90473-8; DEMEYTS P, 1978, NATURE, V273, P504; DEMEYTS P, 1976, J BIOL CHEM, V251, P1877; DEMEYTS P, 1973, BIOCHEM BIOPH RES CO, V55, P154, DOI 10.1016/S0006-291X(73)80072-5; Garmroudi F, 1996, MOL ENDOCRINOL, V10, P642, DOI 10.1210/me.10.6.642; Gleizes PE, 1997, STEM CELLS, V15, P190, DOI 10.1002/stem.150190; Godar S, 1999, EUR J IMMUNOL, V29, P1004, DOI 10.1002/(SICI)1521-4141(199903)29:03<1004::AID-IMMU1004>3.0.CO;2-Q; Kasper D, 1996, J CELL BIOL, V134, P615, DOI 10.1083/jcb.134.3.615; KORNFELD S, 1982, CIBA F SYMP, V92, P138; LEMANSKY P, 1985, J BIOL CHEM, V260, P9023; LOBEL P, 1988, J BIOL CHEM, V263, P2563; LUDWIG T, 1993, EMBO J, V12, P5225, DOI 10.1002/j.1460-2075.1993.tb06218.x; LUDWIG T, 1994, EMBO J, V13, P3430, DOI 10.1002/j.1460-2075.1994.tb06648.x; Luo RZT, 1999, SCIENCE, V285, P1077, DOI 10.1126/science.285.5430.1077; Marron-Terada PG, 1998, J BIOL CHEM, V273, P22358, DOI 10.1074/jbc.273.35.22358; MATHIEU M, 1991, MOL ENDOCRINOL, V5, P815, DOI 10.1210/mend-5-6-815; MATHIEU M, 1990, MOL ENDOCRINOL, V4, P1327, DOI 10.1210/mend-4-9-1327; MunierLehmann H, 1996, J BIOL CHEM, V271, P15166, DOI 10.1074/jbc.271.25.15166; MURRAY GJ, 1980, J BIOL CHEM, V255, P1942; NIELSEN FC, 1991, J NEUROCHEM, V56, P12, DOI 10.1111/j.1471-4159.1991.tb02556.x; Nykjaer A, 1998, J CELL BIOL, V141, P815, DOI 10.1083/jcb.141.3.815; OKA Y, 1986, J BIOL CHEM, V261, P9090; OKA Y, 1985, J BIOL CHEM, V260, P9435; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PERDUE JF, 1983, J BIOL CHEM, V258, P7800; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; POHLMANN R, 1995, J BIOL CHEM, V270, P27311, DOI 10.1074/jbc.270.45.27311; REITMAN ML, 1981, J CLIN INVEST, V67, P1574, DOI 10.1172/JCI110189; Roberts DL, 1998, CELL, V93, P639, DOI 10.1016/S0092-8674(00)81192-7; ROSS JS, 1995, AM J CLIN PATHOL, V104, P36, DOI 10.1093/ajcp/104.1.36; SLEAT DE, 1995, CANCER RES, V55, P3424; Sohar I, 1998, BIOCHEM J, V330, P903, DOI 10.1042/bj3300903; STEIN M, 1987, BIOL CHEM H-S, V368, P927, DOI 10.1515/bchm3.1987.368.2.927; STEIN M, 1987, BIOL CHEM H-S, V368, P937, DOI 10.1515/bchm3.1987.368.2.937; STEIN M, 1987, EMBO J, V6, P2677, DOI 10.1002/j.1460-2075.1987.tb02559.x; TONG PY, 1989, J BIOL CHEM, V264, P7962; TONG PY, 1989, J BIOL CHEM, V264, P7970; WESTLUND B, 1991, J BIOL CHEM, V266, P23233; York SJ, 1999, J BIOL CHEM, V274, P1164, DOI 10.1074/jbc.274.2.1164	49	37	38	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18638	18646		10.1074/jbc.M000010200	http://dx.doi.org/10.1074/jbc.M000010200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10764735	hybrid			2022-12-27	WOS:000087815900005
J	Sohn, HY; Keller, M; Gloe, T; Morawietz, H; Rueckschloss, U; Pohl, U				Sohn, HY; Keller, M; Gloe, T; Morawietz, H; Rueckschloss, U; Pohl, U			The small G-protein Rac mediates depolarization-induced superoxide formation in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; SMOOTH-MUSCLE CELLS; MEMBRANE-POTENTIAL CHANGES; MESSENGER-RNA EXPRESSION; NADPH OXIDASE; TYROSINE PHOSPHORYLATION; HUMAN-NEUTROPHILS; KINASE-C; HYPERTENSIVE RATS; HYDROGEN-PEROXIDE	Superoxide anions impair nitric oxide-mediated responses and are involved in the development of hypertensive vascular hypertrophy, The regulation of their production in the vascular system is, however, poorly understood. We investigated whether changes in membrane potential that occur in hypertensive vessels modulate endothelial superoxide production, In cultured human umbilical vein endothelial cells, changes in membrane potential were induced by high potassium buffer, the non-selective potassium channel blocker tetrabutylammonium chloride (1 mM), and the non-selective cat ion ionophore gramicidin (1 mu M). Superoxide formation was significantly elevated to a similar degree by all three treatments (by similar to 60%, n = 23, p < 0.01), whereas hyperpolarization by the K-ATP channel activator Hoe234 (1 mu M) significantly decreased superoxide formation. Depolarization also induced an increased tyrosine phosphorylation of several not yet identified proteins (90-110 kDa) and resulted in a significant increase in membrane association of the small G-protein Rac. Accordingly, the Rac inhibitor Clostridium difficile toxin B blocked the effects of depolarization on superoxide formation. The tyrosine kinase inhibitor genistein (30 mu M, n = 15) abolished depolarization-induced superoxide formation and also prevented depolarization-induced Rac translocation associated with it. It is concluded that depolarization is an important stimulus of endothelial superoxide production, which involves a tyrosine phosphorylation-dependent translocation of the small G-protein Rac.	Univ Munich, Inst Physiol, D-80336 Munich, Germany; Univ Halle, Inst Pathophysiol, D-06097 Halle, Germany	University of Munich; Martin Luther University Halle Wittenberg	Sohn, HY (corresponding author), Univ Munich, Inst Physiol, Schillerstr 44, D-80336 Munich, Germany.							Al-Mehdi AB, 1998, CIRC RES, V83, P730, DOI 10.1161/01.RES.83.7.730; Bauersachs J, 1999, CIRCULATION, V100, P292, DOI 10.1161/01.CIR.100.3.292; Bayraktutan U, 1998, CARDIOVASC RES, V38, P256, DOI 10.1016/S0008-6363(98)00003-0; BENY JL, 1994, AM J PHYSIOL, V266, pH1465, DOI 10.1152/ajpheart.1994.266.4.H1465; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; Cross AR, 1999, BIOCHEM J, V341, P251, DOI 10.1042/0264-6021:3410251; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DORSEUIL O, 1995, J LEUKOCYTE BIOL, V58, P108, DOI 10.1002/jlb.58.1.108; Dusi S, 1996, J IMMUNOL, V157, P4615; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; Fukui T, 1997, CIRC RES, V80, P45, DOI 10.1161/01.RES.80.1.45; Gamaley IA, 1998, FREE RADICAL BIO MED, V24, P168, DOI 10.1016/S0891-5849(97)00212-8; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; GRUNFELD S, 1995, HYPERTENSION, V26, P854, DOI 10.1161/01.HYP.26.6.854; HE P, 1995, MICROVASC RES, V50, P183, DOI 10.1006/mvre.1995.1052; HENDERSON LM, 1987, BIOCHEM J, V246, P325, DOI 10.1042/bj2460325; Huang A, 1998, CIRC RES, V83, P960; Irani K, 1998, BIOCHEM PHARMACOL, V55, P1339; Jones SA, 1996, AM J PHYSIOL-HEART C, V271, pH1626, DOI 10.1152/ajpheart.1996.271.4.H1626; Kawakami N, 1998, ARCH BIOCHEM BIOPHYS, V349, P89, DOI 10.1006/abbi.1997.0446; Kim KS, 1998, J CLIN INVEST, V101, P1821, DOI 10.1172/JCI1830; Kreck ML, 1996, BIOCHEMISTRY-US, V35, P15683, DOI 10.1021/bi962064l; Langheinrich U, 1997, J PHYSIOL-LONDON, V502, P397, DOI 10.1111/j.1469-7793.1997.397bk.x; Li PF, 1997, CIRCULATION, V96, P3602; LUCKHOFF A, 1990, N-S ARCH PHARMACOL, V342, P94; LUKACS GL, 1993, AM J PHYSIOL, V265, pC3, DOI 10.1152/ajpcell.1993.265.1.C3; MARCHENKO SM, 1994, AM J PHYSIOL, V267, pH804, DOI 10.1152/ajpheart.1994.267.2.H804; Martens JR, 1996, CIRC RES, V79, P295, DOI 10.1161/01.RES.79.2.295; MEHRKE G, 1991, J PHYSIOL-LONDON, V439, P277, DOI 10.1113/jphysiol.1991.sp018667; MITSUYAMA T, 1993, FEBS LETT, V322, P280, DOI 10.1016/0014-5793(93)81586-O; MohazzabH KM, 1997, CIRCULATION, V96, P614; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; Pagano PJ, 1998, HYPERTENSION, V32, P331, DOI 10.1161/01.HYP.32.2.331; PIEPER GM, 1992, IMMUNOPHARMACOLOGY, V23, P191, DOI 10.1016/0162-3109(92)90025-8; QUINN MT, 1993, J BIOL CHEM, V268, P20983; RuizLarrea MB, 1997, FREE RADICAL RES, V26, P63, DOI 10.3109/10715769709097785; Schmid E, 1999, FASEB J, V13, P1491, DOI 10.1096/fasebj.13.12.1491; Sohn HY, 1999, J VASC RES, V36, P456, DOI 10.1159/000025688; Thannickal VJ, 1998, J BIOL CHEM, V273, P23611, DOI 10.1074/jbc.273.36.23611; WHITIN JC, 1980, J BIOL CHEM, V255, P1874; Wolin Michael S., 1996, Microcirculation (Philadelphia), V3, P1, DOI 10.3109/10739689609146778; Yaname H, 1999, ARCH BIOCHEM BIOPHYS, V361, P1, DOI 10.1006/abbi.1998.0947; Yeh LH, 1999, AM J PHYSIOL-CELL PH, V276, pC838, DOI 10.1152/ajpcell.1999.276.4.C838	45	106	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18745	18750		10.1074/jbc.M000026200	http://dx.doi.org/10.1074/jbc.M000026200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10764736	hybrid			2022-12-27	WOS:000087815900020
J	Pinz, KG; Bogenhagen, DF				Pinz, KG; Bogenhagen, DF			Characterization of a catalytically slow AP lyase activity in DNA polymerase gamma and other family A DNA polymerases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; 5'-TERMINAL DEOXYRIBOSE-PHOSPHATE; ESCHERICHIA-COLI; XENOPUS-LAEVIS; ABASIC SITES; FPG PROTEIN; BETA; GLYCOSYLASE; MECHANISM; CLONING	Mitochondrial DNA polymerase gamma (pol gamma) is active in base excision repair of AP (apurinic/apyrimidinic) sites in DNA. Usually AP site repair involves cleavage on the 5' side of the deoxyribose phosphate by AP endonuclease. Previous experiments suggested that DNA pol gamma acts to catalyze the removal of a S'-deoxyribose phosphate (dRP) group in addition to playing the conventional role of a DNA polymerase. We confirm that DNA pol gamma is an active dRP lyase and show that other members of the family A of DNA polymerases including Escherichia coli DNA pol I also possess this activity. The dRP lyase reaction proceeds by formation of a covalent enzyme-DNA intermediate that is converted to an enzyme-dRP intermediate following elimination of the DNA. Both intermediates can be cross-linked with NaBH4. For both DNA pol gamma and the Klenow fragment of pol I, the enzyme-dRP intermediate is extremely stable. This limits the overall catalytic rate of the dRP lyase, so that family A DNA polymerases, unlike pol beta, may only be able to act as dRP lyases in repair of AP sites when they occur at low frequency in DNA.	SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Bogenhagen, DF (corresponding author), SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA.				NIEHS NIH HHS [P01-ES04068] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES004068] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARZILAY G, 1995, BIOESSAYS, V17, P713, DOI 10.1002/bies.950170808; Bogenhagen DF, 1998, J BIOL CHEM, V273, P7888, DOI 10.1074/jbc.273.14.7888; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DIANOV G, 1994, NUCLEIC ACIDS RES, V22, P993, DOI 10.1093/nar/22.6.993; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; DODSON ML, 1994, J BIOL CHEM, V269, P32709; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; GRAVES RJ, 1992, J BIOL CHEM, V267, P14429; INSDORF NF, 1989, J BIOL CHEM, V264, P21491; ITO J, 1990, NUCLEIC ACIDS RES, V18, P6716, DOI 10.1093/nar/18.22.6716; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LOEB LA, 1985, CELL, V40, P483, DOI 10.1016/0092-8674(85)90191-6; Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; Mikhailov VS, 1996, J BIOL CHEM, V271, P18939, DOI 10.1074/jbc.271.31.18939; MOSBAUGH DW, 1982, J BIOL CHEM, V257, P575; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Pinz KG, 1998, MOL CELL BIOL, V18, P1257, DOI 10.1128/MCB.18.3.1257; Prasad R, 1998, J BIOL CHEM, V273, P11121, DOI 10.1074/jbc.273.18.11121; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Stierum RH, 1999, NUCLEIC ACIDS RES, V27, P3712, DOI 10.1093/nar/27.18.3712; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; TCHOU J, 1995, J BIOL CHEM, V270, P11671, DOI 10.1074/jbc.270.19.11671; Ye F, 1996, NUCLEIC ACIDS RES, V24, P1481, DOI 10.1093/nar/24.8.1481; Zharkov DO, 1998, BIOCHEMISTRY-US, V37, P12384, DOI 10.1021/bi981066y; Zharkov DO, 1997, J BIOL CHEM, V272, P5335, DOI 10.1074/jbc.272.8.5335	30	61	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12509	12514		10.1074/jbc.275.17.12509	http://dx.doi.org/10.1074/jbc.275.17.12509			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777538	hybrid			2022-12-27	WOS:000086762300022
J	Shimizu, S; Ide, T; Yanagida, T; Tsujimoto, Y				Shimizu, S; Ide, T; Yanagida, T; Tsujimoto, Y			Electrophysiological study of a novel large pore formed by Bax and the voltage-dependent anion channel that is permeable to cytochrome c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BCL2 PROTEIN; TRANSITION PORE; MITOCHONDRIAL CHANNEL; CONSERVED DOMAINS; SKELETAL-MUSCLE; RELEASE; APOPTOSIS; MEMBRANE; VDAC; INHIBITION	The Bcl-2 family of proteins, consisting of anti-apoptotic and pro-apoptotic members, regulates cell death by controlling mitochondrial membrane permeability that is crucial for apoptotic signal transduction, We have recently shown that some of these proteins, such as Bcl-x(L), Bax, and Bak, directly modulate the mitochondrial voltage-dependent anion channel (VDAC) and thus regulate apoptogenic cytochrome c release and potential loss. To elucidate the molecular mechanisms of VDAC regulation by Bcl-2 family proteins, an electrophysiological study was carried out. It was found that VDAC and pro-apoptotic Pax created a large pore, with conductance levels 4- and 10-fold greater than those of the VDAC and Bax channels, respectively. Although the VDAC and Bax channels both show ion selectivity and voltage-dependent modulation of their activity, the VDAC-Bax channel had neither of their properties. Anti-apoptotic Bcl-x(L) and its BH4 oligopeptide completely closed the VDAC, in contrast to the Bax. Cytochrome c passed through a single VDAC-Bax channel but not through the VDAC or Bax channel in a planar lipid bilayer. These data provide direct evidence that VDAC forms a novel large pore together with Bax.	Osaka Univ, Grad Sch Med, Japan Sci & Technol Corp, CREST,Dept Med Genet,Biomed Res Ctr, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Physiol, Osaka 5650871, Japan; Japan Sci & Technol Corp, Int Cooperat Res Project, Single Mol Proc Project, Osaka 5620035, Japan	Japan Science & Technology Agency (JST); Osaka University; Osaka University; Japan Science & Technology Agency (JST)	Tsujimoto, Y (corresponding author), Osaka Univ, Grad Sch Med, Japan Sci & Technol Corp, CREST,Dept Med Genet,Biomed Res Ctr, 2-2 Yamadaoka, Osaka 5650871, Japan.		Ide, Toru/L-7110-2015; Yanagida, Toshio/D-1919-2009					Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Bathori G, 1998, BIOCHEM BIOPH RES CO, V243, P258, DOI 10.1006/bbrc.1997.7926; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BLACHLYDYSON E, 1993, J BIOL CHEM, V268, P1835; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; COLOMBINI M, 1989, J MEMBRANE BIOL, V111, P103, DOI 10.1007/BF01871775; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Lee LC, 1996, J BIOL CHEM, V271, P23284, DOI 10.1074/jbc.271.38.23284; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MANNELLA CA, 1992, J BIOENERG BIOMEMBR, V24, P55, DOI 10.1007/BF00769531; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Priault M, 1999, EUR J BIOCHEM, V260, P684, DOI 10.1046/j.1432-1327.1999.00198.x; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; SHIMIZU S, 2000, IN PRESS P NATL ACAD; ShoshanBarmatz V, 1996, FEBS LETT, V386, P205, DOI 10.1016/0014-5793(96)00442-5; SZABO I, 1993, FEBS LETT, V330, P206, DOI 10.1016/0014-5793(93)80274-X; THINNES FP, 1994, BIOL CHEM H-S, V375, P315, DOI 10.1515/bchm3.1994.375.5.315; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Yuto J, 1997, BIOPHYS J, V72, P720, DOI 10.1016/S0006-3495(97)78708-3; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	31	292	302	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12321	12325		10.1074/jbc.275.16.12321	http://dx.doi.org/10.1074/jbc.275.16.12321			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766872	hybrid			2022-12-27	WOS:000086695500107
J	Soutourina, J; Blanquet, S; Plateau, P				Soutourina, J; Blanquet, S; Plateau, P			D-Tyrosyl-tRNA(Tyr) metabolism in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID PERMEASE; YEAST ASCOSPORE WALL; ESCHERICHIA-COLI; RHODOTORULA-GRACILIS; L-TYROSINE; GENE; TRANSFORMATION; DEHYDROGENASE; DITYROSINE; OXIDASE	The Saccharomyces cerevisiae YDL219w (DTD1) gene, which codes for an amino acid sequence sharing 34% identity with the Escherichia coli D-Tyr-tRNA(Tyr) deacylase, was cloned, and its product was functionally characterized. Overexpression in the yeast of the DTD1 gene from a multicopy plasmid increased D-Tyr-tRNA(Tyr) deacylase activity in crude extracts by two orders of magnitude. Upon disruption of the chromosomal gene, deacylase activity was decreased by more than 90%, and the sensitivity to D-tyrosine of the growth of S. cerevisiae was exacerbated. The toxicity of D-tyrosine was also enhanced under conditions of nitrogen starvation, which stimulate the uptake of D-amino acids. In relation with these behaviors, the capacity of purified S. cerevisiae tyrosyl-tRNA synthetase to produce D-Tyr-tRNA(Tyr) could be shown. Finally, the phylogenetic distribution of genes homologous to DTD1 was examined in connection with L-tyrosine prototrophy or auxotrophy. In the auxotrophs, DTD1-like genes are systematically absent. In the prototrophs, the putative occurrence of a deacylase is variable. It possibly depends on the L-tyrosine anabolic pathway adopted by the cell.	Ecole Polytech, CNRS, Biochim Lab, Unite Mixte Rech 7654, F-91128 Palaiseau, France	Centre National de la Recherche Scientifique (CNRS); Institut Polytechnique de Paris	Plateau, P (corresponding author), Ecole Polytech, CNRS, Biochim Lab, Unite Mixte Rech 7654, F-91128 Palaiseau, France.	plateau@coli.polytechnique.fr	Soutourina, Julie/F-8305-2014	Soutourina, Julie/0000-0001-5218-2350				ADAMS AEM, 1989, GENETICS, V121, P675; Briza P, 1996, EUR J BIOCHEM, V239, P124, DOI 10.1111/j.1432-1033.1996.0124u.x; BRIZA P, 1986, J BIOL CHEM, V261, P4288; BRIZA P, 1990, J BIOL CHEM, V265, P15118; CALENDAR R, 1966, BIOCHEMISTRY-US, V5, P1690, DOI 10.1021/bi00869a034; CALENDAR R, 1966, BIOCHEMISTRY-US, V5, P1681, DOI 10.1021/bi00869a033; CALENDAR R, 1967, J MOL BIOL, V26, P39, DOI 10.1016/0022-2836(67)90259-8; COSLOY SD, 1973, J BACTERIOL, V114, P685, DOI 10.1128/JB.114.2.685-694.1973; Curti B., 1991, CHEM BIOCH FLAVOENZY, V3, P69; FAZEL AM, 1979, J BACTERIOL, V138, P805, DOI 10.1128/JB.138.3.805-815.1979; Fischer L, 1996, ANN NY ACAD SCI, V799, P683, DOI 10.1111/j.1749-6632.1996.tb33274.x; FRANKLIN FCH, 1976, MOL GEN GENET, V149, P229, DOI 10.1007/BF00332894; GIMENO CJ, 1992, SCIENCE, V257, P626, DOI 10.1126/science.1496375; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; GRENSON M, 1983, EUR J BIOCHEM, V133, P141, DOI 10.1111/j.1432-1033.1983.tb07439.x; GRENSON M, 1983, EUR J BIOCHEM, V133, P135, DOI 10.1111/j.1432-1033.1983.tb07438.x; HALL GC, 1982, J BACTERIOL, V149, P65, DOI 10.1128/JB.149.1.65-78.1982; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; INGLEDEW WJ, 1984, MICROBIOL REV, V48, P222, DOI 10.1128/MMBR.48.3.222-271.1984; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAUNIAUX JC, 1990, EUR J BIOCHEM, V190, P39, DOI 10.1111/j.1432-1033.1990.tb15542.x; JENSEN R, 1987, METHOD ENZYMOL, V142, P472; JENSEN RA, 1975, NATURE, V254, P667, DOI 10.1038/254667a0; KUBICEKPRANZ EM, 1985, BIOTECHNOL LETT, V7, P9, DOI 10.1007/BF01032412; LINGENS F, 1983, NATURWISSENSCHAFTEN, V70, P115, DOI 10.1007/BF00401594; MCFALL E, 1987, ESCHERICHIA COLI SAL, V2, P1520; OHNISHI E, 1962, J BIOL CHEM, V237, P138; OLSIEWSKI PJ, 1980, J BIOL CHEM, V255, P4487; PLATEAU P, 1990, J BACTERIOL, V172, P6892, DOI 10.1128/jb.172.12.6892-6899.1990; POLLEGIONI L, 1992, BIOCHIM BIOPHYS ACTA, V1120, P11, DOI 10.1016/0167-4838(92)90418-D; RYTKA J, 1975, J BACTERIOL, V121, P562, DOI 10.1128/JB.121.2.562-570.1975; Sherman F., 1986, METHODS YEAST GENETI, P163; SIMONETTA MP, 1982, FEMS MICROBIOL LETT, V15, P27, DOI 10.1016/0378-1097(82)90006-4; Soutourina J, 1999, J BIOL CHEM, V274, P19109, DOI 10.1074/jbc.274.27.19109; STENMARK SL, 1974, NATURE, V247, P290, DOI 10.1038/247290a0; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WEBSTER TD, 1983, GENE, V26, P243, DOI 10.1016/0378-1119(83)90194-4; WILD J, 1974, MOL GEN GENET, V128, P131, DOI 10.1007/BF02654486; WILD J, 1981, MOL GEN GENET, V181, P373, DOI 10.1007/BF00425614; WOODWARD JR, 1980, BIOCHEM J, V192, P659, DOI 10.1042/bj1920659; XIA TH, 1990, J BIOL CHEM, V265, P20033; YAMANE T, 1981, BIOCHEMISTRY-US, V20, P7059, DOI 10.1021/bi00528a001; ZENK MH, 1965, BIOCHEM Z, V342, P54; ZWART KB, 1983, FEMS MICROBIOL LETT, V19, P225, DOI 10.1111/j.1574-6968.1983.tb00547.x	44	40	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11626	11630		10.1074/jbc.275.16.11626	http://dx.doi.org/10.1074/jbc.275.16.11626			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766779	hybrid			2022-12-27	WOS:000086695500014
J	Ijuin, T; Mochizuki, Y; Fukami, K; Funaki, M; Asano, T; Takenawa, T				Ijuin, T; Mochizuki, Y; Fukami, K; Funaki, M; Asano, T; Takenawa, T			Identification and characterization of a novel inositol polyphosphate 5-phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE 5-PHOSPHATASE; SIGNAL-TRANSDUCTION; HUMAN-PLATELETS; ALPHA-ACTININ; CLONING; POLYPHOSPHATE-5-PHOSPHATASE; 4,5-BISPHOSPHATE; SYNAPTOJANIN; EXPRESSION; 1,4,5-TRISPHOSPHATE	We have identified a cDNA encoding a novel inositol polyphosphate 5-phosphatase. It contains two highly conserved catalytic motifs for 5-phosphatase, has a molecular mass of 51 kDa, and is ubiquitously expressed and especially abundant in skeletal muscle, heart, and kidney. We designated this 5-phosphatase as SKIP (Skeletal muscle and Kidney enriched Inositol Phosphatase), SKIP is a simple 5-phosphatase with no other motifs. Baculovirus-expressed recombinant SKIP protein exhibited 5-phosphatase activities toward inositol 1,4,5-trisphosphate, inositol 1,3,4,5-tetrakisphosphate, phosphatidylinositol (PtdIns) 4,5-bisphosphate, and PtdIns 3,4,5-trisphosphate but has 6-fold more substrate specificity for PtdIns 4,5-bisphosphate (K-m = 180 mu M) than for inositol 1,4,5-trisphosphate (K-m = 1.15 mM), The ectopic expression of SKIP protein in COS-7 cells and immunostaining of neuroblastoma N1E-115 cells revealed that SKIP is expressed in cytosol and that loss of actin stress fibers occurs where the SKIP protein is concentrated. These results imply that SKIP plays a negative role in regulating the actin cytoskeleton through hydrolyzing PtdIns 1,4-bisphosphate.	Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 1088639, Japan; Asahi Life Fdn, Inst Adult Dis, Shinjuku Ku, Tokyo 160, Japan; Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, Tokyo 113, Japan	University of Tokyo; Asahi Life Foundation; University of Tokyo	Takenawa, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 1088639, Japan.	takenawa@ims.u-tokyo.ac.jp	Ijuin, Takeshi/H-7016-2017	Ijuin, Takeshi/0000-0002-0618-1776				ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CONNOLLY TM, 1985, J BIOL CHEM, V260, P7868; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; Fukami K, 1996, J BIOL CHEM, V271, P2646, DOI 10.1074/jbc.271.5.2646; Funaki M, 1999, J BIOL CHEM, V274, P22019, DOI 10.1074/jbc.274.31.22019; Guo SL, 1999, J BIOL CHEM, V274, P12990, DOI 10.1074/jbc.274.19.12990; Haffner C, 1997, FEBS LETT, V419, P175, DOI 10.1016/S0014-5793(97)01451-8; HEJNA JA, 1995, GENOMICS, V29, P285, DOI 10.1006/geno.1995.1247; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Khvotchev M, 1998, J BIOL CHEM, V273, P2306, DOI 10.1074/jbc.273.4.2306; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Majerus PW, 1999, J BIOL CHEM, V274, P10669, DOI 10.1074/jbc.274.16.10669; Matzaris M, 1998, J BIOL CHEM, V273, P8256, DOI 10.1074/jbc.273.14.8256; MATZARIS M, 1994, J BIOL CHEM, V269, P3397; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Mochizuki Y, 1999, J BIOL CHEM, V274, P36790, DOI 10.1074/jbc.274.51.36790; Nemoto Y, 1997, J BIOL CHEM, V272, P30817, DOI 10.1074/jbc.272.49.30817; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; ROSS TS, 1991, J BIOL CHEM, V266, P20283; Sakisaka T, 1997, MOL CELL BIOL, V17, P3841, DOI 10.1128/MCB.17.7.3841; Seet LF, 1998, BIOCHEM BIOPH RES CO, V247, P116, DOI 10.1006/bbrc.1998.8564; VERJANS B, 1994, BIOCHEM J, V300, P85, DOI 10.1042/bj3000085; Woscholski R, 1995, J BIOL CHEM, V270, P31001, DOI 10.1074/jbc.270.52.31001; Woscholski R, 1998, FEBS LETT, V432, P5, DOI 10.1016/S0014-5793(98)00820-5; Woscholski R, 1997, J BIOL CHEM, V272, P9625; Zhang L, 1998, Methods Mol Biol, V105, P47; Zhang XL, 1998, J BIOL CHEM, V273, P1574, DOI 10.1074/jbc.273.3.1574; ZHANG XL, 1995, P NATL ACAD SCI USA, V92, P4853, DOI 10.1073/pnas.92.11.4853	34	74	80	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10870	10875		10.1074/jbc.275.15.10870	http://dx.doi.org/10.1074/jbc.275.15.10870			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753883	hybrid			2022-12-27	WOS:000086466600025
J	Li, YH; Zhuang, SB; Guo, HQ; Mabuchi, K; Lu, RC; Wang, CLA				Li, YH; Zhuang, SB; Guo, HQ; Mabuchi, K; Lu, RC; Wang, CLA			The major myosin-binding site of caldesmon resides near its N-terminal extreme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CALDESMON; HEAVY-MEROMYOSIN; ATPASE ACTIVITY; ACTIN; TROPOMYOSIN; CALMODULIN; FILAMENTS; CONTRACTION; FRAGMENTS; LOCATION	The primary myosin-binding site of caldesmon was thought to be in the N-terminal region of the molecule, but the exact nature of the caldesmon-myosin interaction has not been well characterized. A caldesmon fragment that encompasses residues 1-240 (N240) was found to bind full-length smooth muscle myosin on the basis of co-sedimentation experiments. The interaction between myosin and N240 was not affected by phosphorylation of myosin, but it was weakened by the presence of Ca2+/ calmodulin. To locate the myosin-binding site, we have designed several synthetic peptides based on the N-terminal caldesmon sequence. We found that a peptide stretch corresponding to the first 27 residues (Met-1 to Tyr-27), but not that of the first 22 residues (Met-1 to Ala-22), exhibited a moderate affinity toward myosin, We also found that a peptide containing the segment from Ile/Leu-25 to Lys-53 bound both myosin and heavy meromyosin more strongly aria was capable of displacing caldesmon from myosin, Our results demonstrate that the sequence near the N-terminal extreme of caldesmon harbors a major myosin-binding site of caldesmon, in which both the nonpolar residues and clusters of positively and negatively charged residues confer the specificity and affinity of the caldesmon-myosin interaction.	Boston Biomed Res Inst, Muscle & Motil Grp, Watertown, MA 02472 USA	Boston Biomedical Research Institute	Wang, CLA (corresponding author), 64 Grove St, Watertown, MA 02472 USA.				NIAMS NIH HHS [P01-AR41637] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041637] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		DRAEGER A, 1990, J CELL BIOL, V111, P2463, DOI 10.1083/jcb.111.6.2463; HAEBERLE JR, 1992, J BIOL CHEM, V267, P23001; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; HEMRIC ME, 1993, J BIOL CHEM, V268, P15305; HUBER PAJ, 1995, BIOCHEM J, V312, P617, DOI 10.1042/bj3120617; IKEBE M, 1978, J BIOCHEM, V83, P1643, DOI 10.1093/oxfordjournals.jbchem.a132077; IKEBE M, 1988, J BIOL CHEM, V263, P3055; KATAYAMA E, 1995, J BIOL CHEM, V270, P3919, DOI 10.1074/jbc.270.8.3919; KATAYAMA E, 1989, BIOCHEM BIOPH RES CO, V160, P1316, DOI 10.1016/S0006-291X(89)80147-0; LIN JJC, 1991, CELL MOTIL CYTOSKEL, V20, P95, DOI 10.1002/cm.970200203; Mabuchi K, 1996, J MUSCLE RES CELL M, V17, P243, DOI 10.1007/BF00124246; MABUCHI K, 1991, J STRUCT BIOL, V107, P22, DOI 10.1016/1047-8477(91)90027-T; MARSTON SB, 1989, BIOCHEM J, V259, P303, DOI 10.1042/bj2590303; MARSTON SB, 1989, J MUSCLE RES CELL M, V10, P97, DOI 10.1007/BF01739965; MARSTON SB, 1996, BIOCH SMOOTH MUSCLE, P77; MORRIS EP, 1984, BIOCHEMISTRY-US, V23, P2214, DOI 10.1021/bi00305a018; NORTH AJ, 1994, J CELL SCI, V107, P437; SEIDEL JC, 1980, J BIOL CHEM, V255, P4355; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUTHERLAND C, 1989, J BIOL CHEM, V264, P578; VELAZ L, 1990, J BIOL CHEM, V265, P2929; Vorotnikov AV, 1997, BIOCHEM J, V328, P211; WANG CLA, 1989, BIOCHEM BIOPH RES CO, V162, P746, DOI 10.1016/0006-291X(89)92373-5; WANG CLA, 1988, BIOCHEM BIOPH RES CO, V156, P1033, DOI 10.1016/S0006-291X(88)80948-3; WANG CLA, 1990, BIOPHYS J, V57, P162; Wang EZ, 1996, ARCH BIOCHEM BIOPHYS, V329, P156, DOI 10.1006/abbi.1996.0204; Wang Z, 1997, P NATL ACAD SCI USA, V94, P11899, DOI 10.1073/pnas.94.22.11899; ZHUANG SB, 1995, J BIOL CHEM, V270, P19964, DOI 10.1074/jbc.270.34.19964; Zhuang SB, 1996, J BIOL CHEM, V271, P30242, DOI 10.1074/jbc.271.47.30242	29	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10989	10994		10.1074/jbc.275.15.10989	http://dx.doi.org/10.1074/jbc.275.15.10989			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753900	hybrid			2022-12-27	WOS:000086466600042
J	Plotz, BM; Lindner, B; Stetter, KO; Holst, O				Plotz, BM; Lindner, B; Stetter, KO; Holst, O			Characterization of a novel lipid A containing D-galacturonic acid that replaces phosphate residues - The structure of the lipid A of the lipopolysaccharide from the hyperthermophilic bacterium Aquifex pyrophilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP-NOV REPRESENTS; ESCHERICHIA-COLI; RHIZOBIUM-LEGUMINOSARUM; THERMOTOGA-MARITIMA; LASER-DESORPTION; A BIOSYNTHESIS; FATTY-ACIDS; CORE; GENOME; STRAIN	According to the 16 S rRNA phylogenetic tree, the hyperthermophilic bacterium Aquifex pyrophilus represents the deepest and shortest branching species of the kingdom Bacteria, We show for the first time that an organism, which is phylogenetically ancient on the basis of its 16 S rRNA and that exists at extreme conditions, may contain lipopolysaccharide (LPS), The LPS was extracted from dried bacteria using a modified phenol/water method. SDS-polyacrylamide gel electrophoresis and silver stain displayed a ladder-like pattern, which is typical for smooth-form LPS (possessing an O-specific polysaccharide), The molecular masses of the LPS populations were determined by matrix-assisted laser-desorption ionization mass spectrometry, Lipid A was precipitated after mild acid hydrolysis of LPS, Its complete structure was determined by chemical analyses, combined gas-liquid chromatography-mass spectrometry, matrix-assisted laser-desorption ionization mass spectrometry, and one- and two-dimensional NMR spectroscopy. The lipid A consists of a beta-(1-->6)-linked 2,3-diamino-2,3-dideoxy-D-glucopyranose (DAG) disaccharide carrying two residues each of (R)-3-hydroxytetradecanoic acid and (R)-3-hydroxyhexadecanoic acid in amide linkage and one residue of octadecanoic acid in ester linkage. Each DAG moiety carries one residue of each 3-hydroxytetradecanoic and 3-hydroxyhexadecanoic acid. In the nonreducing DAG, the octadecanoic acid is attached to the 3-hydroxy group of S-hydroxytetradecanoic acid. Each DAG is substituted by one D-galacturonic acid residue, which is linked to O-1 of the reducing and to O-4 of the nonreducing end, This structure represents a novel type of lipid A.	Res Ctr Borstel, Ctr Med & Biosci, Div Med & Biochem Microbiol, D-23845 Borstel, Germany; Univ Regensburg, Dept Microbiol, D-93053 Regensburg, Germany; Res Ctr Borstel, Ctr Med & Biosci, Div Biophys, D-23845 Borstel, Germany	Forschungszentrum Borstel; University of Regensburg; Forschungszentrum Borstel	Holst, O (corresponding author), Res Ctr Borstel, Ctr Med & Biosci, Div Med & Biochem Microbiol, Pk Allee 22, D-23845 Borstel, Germany.	oholst@fz-borstel.de	Lindner, Buko/G-9731-2014					BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; BOCK K, 1983, ADV CARBOHYD CHEM BI, V41, P27, DOI 10.1016/S0065-2318(08)60055-4; Brade H., 1999, ENDOTOXIN HLTH DIS; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brozek KA, 1996, J BIOL CHEM, V271, P32112, DOI 10.1074/jbc.271.50.32119; BURGGRAF S, 1992, SYST APPL MICROBIOL, V15, P352, DOI 10.1016/S0723-2020(11)80207-9; CAROFF M, 1994, J BACTERIOL, V176, P5156, DOI 10.1128/jb.176.16.5156-5159.1994; Carty SM, 1999, J BIOL CHEM, V274, P9677, DOI 10.1074/jbc.274.14.9677; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; Fukuoka S, 1997, EUR J BIOCHEM, V250, P55, DOI 10.1111/j.1432-1033.1997.00055.x; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; GALANOS C, 1985, EUR J BIOCHEM, V148, P1, DOI 10.1111/j.1432-1033.1985.tb08798.x; GERWIG GJ, 1979, CARBOHYD RES, V77, P1, DOI 10.1016/S0008-6215(00)83788-X; Gibson BW, 1997, J AM SOC MASS SPECTR, V8, P645, DOI 10.1016/S1044-0305(97)00042-1; HAISHIMA Y, 1992, EUR J BIOCHEM, V203, P127, DOI 10.1111/j.1432-1033.1992.tb19837.x; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HOLST O, 1993, EUR J BIOCHEM, V214, P703, DOI 10.1111/j.1432-1033.1993.tb17971.x; Holst O, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P115; HUBER R, 1992, SYST APPL MICROBIOL, V15, P340, DOI 10.1016/S0723-2020(11)80206-7; HUBER R, 1986, ARCH MICROBIOL, V144, P324, DOI 10.1007/BF00409880; Jansson PE, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P155; KACA W, 1988, CARBOHYD RES, V179, P289, DOI 10.1016/0008-6215(88)84125-9; Kadrmas JL, 1998, J BIOL CHEM, V273, P26432, DOI 10.1074/jbc.273.41.26432; Kadrmas JL, 1996, J BIOL CHEM, V271, P32119, DOI 10.1074/jbc.271.50.32112; KNIREL YA, 1994, BIOCHEMISTRY-MOSCOW+, V59, P1325; KULSHIN VA, 1991, EUR J BIOCHEM, V198, P697, DOI 10.1111/j.1432-1033.1991.tb16069.x; Lindner B, 2000, METH MOL B, V145, P311; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; PRICE NPJ, 1995, P NATL ACAD SCI USA, V92, P7352, DOI 10.1073/pnas.92.16.7352; QURESHI N, 1983, J BIOL CHEM, V258, P2947; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RIETSCHEL ET, 1976, EUR J BIOCHEM, V64, P423, DOI 10.1111/j.1432-1033.1976.tb10318.x; Rund S, 1999, J BIOL CHEM, V274, P16819, DOI 10.1074/jbc.274.24.16819; Stetter KO, 1996, FEMS MICROBIOL REV, V18, P149, DOI 10.1111/j.1574-6976.1996.tb00233.x; Susskind M, 1998, J BIOL CHEM, V273, P7006, DOI 10.1074/jbc.273.12.7006; TAKAYAMA K, 1986, J BIOL CHEM, V261, P624; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; Vinogradov EV, 1996, EUR J BIOCHEM, V239, P602, DOI 10.1111/j.1432-1033.1996.0602u.x; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; WOLLENWEBER HW, 1990, J MICROBIOL METH, V11, P195, DOI 10.1016/0167-7012(90)90056-C; ZAHRINGER U, 1994, ADV CARBOHYD CHEM BI, V50, P211, DOI 10.1016/S0065-2318(08)60152-3; Zahringer U, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P93	42	77	80	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11222	11228		10.1074/jbc.275.15.11222	http://dx.doi.org/10.1074/jbc.275.15.11222			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753930	hybrid			2022-12-27	WOS:000086466600072
J	Yao, N; Leu, FP; Anjelkovic, J; Turner, J; O'Donnell, M				Yao, N; Leu, FP; Anjelkovic, J; Turner, J; O'Donnell, M			DNA structure requirements for the Escherichia coli gamma complex clamp loader and DNA polymerase III holoenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL REPLICATION MACHINE; PRIMER-TEMPLATE JUNCTION; ORIGIN-BINDING PROTEIN; EPSTEIN-BARR-VIRUS; ACCESSORY PROTEINS; SLIDING CLAMPS; LAGGING-STRAND; ATP-BINDING; SUBUNIT; PARTICLE	The Escherichia coli chromosomal replicase, DNA polymerase III holoenzyme, is highly processive during DNA synthesis. Underlying high processivity is a ring-shaped protein, the beta clamp, that encircles DNA and slides along it, thereby tethering the enzyme to the template. The beta clamp is assembled onto DNA by the multiprotein gamma complex clamp loader that opens and closes the beta ring around DNA in an ATP-dependent manner. This study examines the DNA structure required for clamp loading action. We found that the gamma complex assembles beta onto supercoiled DNA (replicative form I), but only at very low ionic strength, where regions of unwound DNA may exist in the duplex, Consistent with this, the gamma complex does not assemble beta onto relaxed closed circular DNA even at low ionic strength. Hence, a 3'-end is not required for clamp loading, but a single-stranded DNA (ssDNA)/double-stranded DNA (dsDNA) junction can be utilized as a substrate, a result confirmed using synthetic oligonucleotides that form forked ssDNA/dsDNA junctions on M13 ssDNA On a flush primed template, the gamma complex exhibits polarity; it acts specifically at the 3'-ssDNA/dsDNA junction to assemble beta onto the DNA, The gamma complex can assemble beta onto a primed site as short as 10 nucleotides, corresponding to the width of the beta ring. However, a protein block placed closer than 14 base pairs (bp) upstream from the primer 3' terminus prevents the clamp loading reaction, indicating that the gamma complex and its associated beta clamp interact with similar to 14-16 bp at a ssDNA/dsDNA junction during the clamp loading operation. A protein block positioned closer than 20-22 bp from the 3' terminus prevents use of the clamp by the polymerase in chain elongation, indicating that the polymerase has an even greater spatial requirement than the gamma complex on the duplex portion of the primed site for function with beta. Interestingly, DNA secondary structure elements placed near the 3' terminus impose similar steric limits on the gamma complex and polymerase action with beta. The possible biological significance of these structural constraints is discussed.	Rockefeller Univ, Lab DNA Replicat, New York, NY 10021 USA; Cornell Univ, Joan & Sanford I Weill Grad Sch Med Sci, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA	Rockefeller University; Cornell University; Howard Hughes Medical Institute	O'Donnell, M (corresponding author), Rockefeller Univ, Lab DNA Replicat, POB 228,1230 York Ave, New York, NY 10021 USA.				NIGMS NIH HHS [GM38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R37GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; BOCHKAREV A, 1995, CELL, V83, P39, DOI 10.1016/0092-8674(95)90232-5; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1468; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FAY PJ, 1981, J BIOL CHEM, V256, P976; Fijalkowska IJ, 1996, P NATL ACAD SCI USA, V93, P2856, DOI 10.1073/pnas.93.7.2856; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; FRADKIN LG, 1992, J BIOL CHEM, V267, P10318; Fu TJ, 1996, EMBO J, V15, P4414, DOI 10.1002/j.1460-2075.1996.tb00814.x; Hingorani MM, 1999, EMBO J, V18, P5131, DOI 10.1093/emboj/18.18.5131; Hingorani MM, 1998, J BIOL CHEM, V273, P24550, DOI 10.1074/jbc.273.38.24550; Kelman Z, 1998, EMBO J, V17, P2436, DOI 10.1093/emboj/17.8.2436; Kelman Z, 1995, METHOD ENZYMOL, V262, P430; KHIDHIR MA, 1985, MOL GEN GENET, V199, P133, DOI 10.1007/BF00327522; KITANI T, 1985, J MOL BIOL, V184, P45, DOI 10.1016/0022-2836(85)90042-7; KODAIRA M, 1983, MOL GEN GENET, V192, P80, DOI 10.1007/BF00327650; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KORNBERG A, 1992, DNA REPLICATION, P169; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; MAKI S, 1988, J BIOL CHEM, V263, P6555; Maniatis T., 1982, MOL CLONING LAB MANU; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Mozzherin DJ, 1999, J BIOL CHEM, V274, P19862, DOI 10.1074/jbc.274.28.19862; MUNN MM, 1991, J BIOL CHEM, V266, P20034; MUNN MM, 1991, J BIOL CHEM, V266, P20024; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; REEMS JA, 1995, J BIOL CHEM, V270, P5606, DOI 10.1074/jbc.270.10.5606; REEMS JA, 1994, J BIOL CHEM, V269, P33091; ROWEN L, 1978, J BIOL CHEM, V253, P758; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; SUCK D, 1986, NATURE, V321, P620, DOI 10.1038/321620a0; TINKER RL, 1994, EMBO J, V13, P5330, DOI 10.1002/j.1460-2075.1994.tb06867.x; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Turner J, 1995, METHOD ENZYMOL, V262, P442; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; WITKIN EM, 1987, P NATL ACAD SCI USA, V84, P6805, DOI 10.1073/pnas.84.19.6805; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; XIAO H, 1995, J BIOL CHEM, V270, P13378, DOI 10.1074/jbc.270.22.13378; XIAO H, 1993, J BIOL CHEM, V268, P11773; Yao N, 2000, J BIOL CHEM, V275, P1421, DOI 10.1074/jbc.275.2.1421; Yuzhakov A, 1999, EMBO J, V18, P6189, DOI 10.1093/emboj/18.21.6189; Zhang D, 1998, NUCLEIC ACIDS RES, V26, P631, DOI 10.1093/nar/26.2.631	53	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11440	11450		10.1074/jbc.275.15.11440	http://dx.doi.org/10.1074/jbc.275.15.11440			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753961	hybrid			2022-12-27	WOS:000086466600103
J	Li, KKC; Lee, KAW				Li, KKC; Lee, KAW			Transcriptional activation by the Ewing's sarcoma (EWS) oncogene can be cis-repressed by the EWS RNA-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMITIVE NEUROECTODERMAL TUMOR; POLYMERASE-II ELONGATION; EWS/FLI-1 FUSION GENE; ROUND-CELL TUMORS; CHROMOSOME-TRANSLOCATION; MALIGNANT-MELANOMA; PROTEIN-KINASE; SOFT PARTS; EWS/ATF1 ONCOGENE; CHIMERIC PROTEIN	The Ewing's sarcoma (EWS) oncogene contains an N-terminal transcriptional activation domain (EWS activation domain, EAD) and a C-terminal RNA-binding domain (RBD). Although it has been established that the EAD is a potent trans-activation domain that is required for the oncogenic activity of several EWS fusion proteins (EFPs), the precise function of the RBD and the normal role of intact EWS are poorly characterized, Here we show that a cis-linked RBD can strongly and specifically repress trans-activation by the EAD, Fusion proteins containing the RBD are expressed at normal levels, are nuclear-localized, and can bind to DNA both in vitro and in vivo, demonstrating that the RBD represses transactivation directly at the promoter. The RNA recognition motif within the RBD is not required for repression, whereas regions of the RBD containing multiple RGG motifs play a critical role. The finding that the RBD can antagonize transcriptional activation by EWS provides the first direct evidence of a role for the RBD in transcription. Further studies of the repression phenomenon should illuminate key molecular interactions that distinguish EWS from EFPs and provide insights into the normal cellular function of EW.	Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Lee, KAW (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China.							Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bertolotti A, 1999, ONCOGENE, V18, P8000, DOI 10.1038/sj.onc.1203207; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; BROWN AD, 1995, ONCOGENE, V10, P1749; Brown V, 1998, J BIOL CHEM, V273, P15521, DOI 10.1074/jbc.273.25.15521; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Deloulme JC, 1997, J BIOL CHEM, V272, P27369, DOI 10.1074/jbc.272.43.27369; Dempsey LA, 1998, J BIOL CHEM, V273, P29224, DOI 10.1074/jbc.273.44.29224; EMAMI KH, 1992, EMBO J, V11, P5005, DOI 10.1002/j.1460-2075.1992.tb05607.x; Felsch JS, 1999, CURR BIOL, V9, P485, DOI 10.1016/S0960-9822(99)80214-0; Fujimura Y, 1996, ONCOGENE, V12, P159; Hackl W, 1996, J MOL BIOL, V264, P843, DOI 10.1006/jmbi.1996.0681; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; HAYNES SR, 1992, NEW BIOL, V4, P421; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; Kim J, 1998, ONCOGENE, V16, P1021, DOI 10.1038/sj.onc.1201616; Kim J, 1998, ONCOGENE, V16, P1973, DOI 10.1038/sj.onc.1201716; Kim MK, 1999, MOL CELL BIOL, V19, P6833; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; Lee MH, 1996, J BIOL CHEM, V271, P3420; LESSNICK SL, 1995, ONCOGENE, V10, P423; Li KKC, 1998, ONCOGENE, V16, P1325, DOI 10.1038/sj.onc.1201649; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MASSON N, 1993, NUCLEIC ACIDS RES, V21, P4166, DOI 10.1093/nar/21.18.4166; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; May WA, 1997, CURR TOP MICROBIOL, V220, P143; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; OUCHIDA M, 1995, ONCOGENE, V11, P1049; Pan S, 1998, ONCOGENE, V16, P1625, DOI 10.1038/sj.onc.1201671; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; PLOUGASTEL B, 1993, GENOMICS, V18, P609, DOI 10.1016/S0888-7543(05)80363-5; Powers CA, 1998, MOL ENDOCRINOL, V12, P4, DOI 10.1210/mend.12.1.0043; PRASAD DDK, 1994, ONCOGENE, V9, P3717; Rauscher FJ, 1997, CURR TOP MICROBIOL, V220, P151; RIBEIRO A, 1994, J BIOL CHEM, V269, P31124; Ron D, 1997, CURR TOP MICROBIOL, V220, P131; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SEIPEL K, 1993, NUCLEIC ACIDS RES, V21, P5609, DOI 10.1093/nar/21.24.5609; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; Steinmetz EJ, 1998, P NATL ACAD SCI USA, V95, P6699, DOI 10.1073/pnas.95.12.6699; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; TILEY LS, 1992, GENE DEV, V6, P2077, DOI 10.1101/gad.6.11.2077; Tolnay M, 1999, BIOCHEM J, V338, P417, DOI 10.1042/0264-6021:3380417; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099; Zhang D, 1998, J BIOL CHEM, V273, P18086, DOI 10.1074/jbc.273.29.18086; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; Zinszner H, 1997, ONCOGENE, V14, P451, DOI 10.1038/sj.onc.1200854; Zinszner H, 1997, J CELL SCI, V110, P1741; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	57	37	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23053	23058		10.1074/jbc.M002961200	http://dx.doi.org/10.1074/jbc.M002961200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10767297	hybrid			2022-12-27	WOS:000088419400061
J	Meng, F; Wei, Q; Hoversten, MT; Taylor, LP; Akil, H				Meng, F; Wei, Q; Hoversten, MT; Taylor, LP; Akil, H			Switching agonist/antagonist properties of opiate alkaloids at the delta opioid receptor using mutations based on the structure of the orphanin FQ receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PROTEIN-COUPLED RECEPTORS; TRANSMEMBRANE DOMAIN; CONSTITUTIVE ACTIVATION; MOLECULAR MECHANISM; INTRINSIC ACTIVITY; BINDING; AGONIST; SELECTIVITY; ANTAGONISTS	In an earlier study, we have demonstrated that by mutating five amino acid residues to those conserved in the opioid receptors, the OFQ receptor could be converted to a functional receptor that bound many opioid alkaloids with nanomolar affinities. Surprisingly, when the reciprocal mutations, Lys-214 --> Ala (TM5), Ile-277 --> Val/His-278 --> Gln/Ile-279 --> Val (TM6), and Ile-304 --> Thr (TM7), are introduced in the 6 receptor, neither the individual mutations nor their various combinations significantly reduce the binding affinities of opioid alkaloids tested. However, these mutations cause profound alterations in the functional characteristics of the mutant receptors as measured in guanosine 5'-3-O-(thio)triphosphate binding assays, Some agonists become antagonists at some constructs as they lose their ability to activate them. Some alkaloid antagonists are transformed into agonists at other constructs, but their agonistic effects can still be blocked by the peptide antagonist TIPP, Even the 6 inverse agonist 7-benzylidenenaltrexone becomes an agonist at the mutant containing both the Ile-277 --> Val/His-278 --> Gln/Ile-279 --> Val and Ile-304 --> Thr mutations. Thus, although the mutated residues are thought to be part of the binding pocket, they are critically involved in the control of the 6 receptor activation process. These findings shed light on some of the structural bases of ligand efficacy. They are also compatible with the hypothesis that a ligand may achieve high affinity binding in several different ways, each having different effects on receptor activation.	Univ Michigan, Mental Hlth Res Inst, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Meng, F (corresponding author), Univ Michigan, Mental Hlth Res Inst, Ann Arbor, MI 48109 USA.				NIADDK NIH HHS [P30-AM34933] Funding Source: Medline; NIDA NIH HHS [R01 DA02265] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [P30AM034933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002265] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Befort K, 1999, J BIOL CHEM, V274, P18574, DOI 10.1074/jbc.274.26.18574; Bot G, 1998, J PHARMACOL EXP THER, V284, P283; Cavalli A, 1999, NEUROSCIENCE, V93, P1025, DOI 10.1016/S0306-4522(99)00280-8; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Claude PA, 1996, P NATL ACAD SCI USA, V93, P5715, DOI 10.1073/pnas.93.12.5715; Fanelli F, 1998, METHODS, V14, P302, DOI 10.1006/meth.1998.0586; Fong TM, 1996, CELL SIGNAL, V8, P217; GOLDSTEIN P, 1989, BRIT J OBSTET GYNAEC, V96, P265, DOI 10.1111/j.1471-0528.1989.tb02385.x; HUGGENVIK JI, 1991, MOL ENDOCRINOL, V5, P921, DOI 10.1210/mend-5-7-921; Knapp RJ, 1996, J PHARMACOL EXP THER, V277, P1284; Kobilka B, 1999, J RECEPT SIGNAL TR R, V19, P293, DOI 10.3109/10799899909036652; KONG HY, 1994, P NATL ACAD SCI USA, V91, P8042, DOI 10.1073/pnas.91.17.8042; KONG HY, 1993, J BIOL CHEM, V268, P23055; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; MANSOUR A, 1992, EUR J PHARM-MOLEC PH, V227, P205, DOI 10.1016/0922-4106(92)90129-J; Meng F, 1996, EUR J PHARMACOL, V311, P285, DOI 10.1016/0014-2999(96)00431-1; Meng F, 1998, MOL PHARMACOL, V53, P772, DOI 10.1124/mol.53.4.772; METZGER TG, 1995, FEBS LETT, V375, P1, DOI 10.1016/0014-5793(95)01185-H; Mollereau C, 1996, FEBS LETT, V395, P17, DOI 10.1016/0014-5793(96)00993-3; Nickoloff J A, 1996, Methods Mol Biol, V58, P455; Pardo L, 1997, EUR J PHARMACOL, V335, P73, DOI 10.1016/S0014-2999(97)01170-9; Paterlini G, 1997, J MED CHEM, V40, P3254; Pauwels PJ, 1998, MOL NEUROBIOL, V17, P109, DOI 10.1007/BF02802027; Pogozheva ID, 1998, BIOPHYS J, V75, P612, DOI 10.1016/S0006-3495(98)77552-6; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Schwartz T. W., 1998, Trends in Pharmacological Sciences, V19, P433, DOI 10.1016/S0165-6147(98)01262-0; SCHWYZER R, 1986, BIOCHEMISTRY-US, V25, P6335, DOI 10.1021/bi00368a075; Seifert R, 1999, MOL PHARMACOL, V56, P348, DOI 10.1124/mol.56.2.348; Seki T, 1998, JPN J PHARMACOL, V77, P301, DOI 10.1254/jjp.77.301; Strahs D, 1997, PROTEIN ENG, V10, P1019, DOI 10.1093/protein/10.9.1019; SURRATT CK, 1994, J BIOL CHEM, V269, P20548; Szekeres PG, 1997, J PHARMACOL EXP THER, V283, P1276; Tang Y, 1996, ACTA PHARM SINIC, V17, P156; TIAN WN, 1994, MOL PHARMACOL, V45, P524; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Wheatley M, 1998, ESSAYS BIOCHEM, V33, P15, DOI 10.1042/bse0330015	36	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21939	21945		10.1074/jbc.M002864200	http://dx.doi.org/10.1074/jbc.M002864200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10777506	hybrid			2022-12-27	WOS:000088363800027
J	Kotti, TJ; Savolainen, K; Helander, HM; Yagi, A; Novikov, DK; Kalkkinen, N; Conzelmann, E; Hiltunen, JK; Schmitz, W				Kotti, TJ; Savolainen, K; Helander, HM; Yagi, A; Novikov, DK; Kalkkinen, N; Conzelmann, E; Hiltunen, JK; Schmitz, W			In mouse alpha-methylacyl-CoA racemase, the same gene product is simultaneously located in mitochondria and peroxisomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIFUNCTIONAL PROTEIN-DEFICIENCY; RAT-LIVER; CHENODEOXYCHOLIC ACID; BETA-OXIDATION; PRISTANIC ACID; PHYTANIC ACID; DEHYDROGENASE; PURIFICATION; SEQUENCE; QUANTITIES	alpha-Methylacyl-CoA racemase, an enzyme of the bile acid biosynthesis and branched chain fatty acid degradation pathway, was studied at the protein, cDNA, and genomic levels in mouse liver. Immunoelectron microscopy and subcellular fractionation located racemase to mitochondria and peroxisomes. The enzymes were purified from both organelles with immunoaffinity chromatography, The isolated proteins mere of the same size, with identical N-terminal amino acid sequences, and the existence of additional proteins with alpha-methylacyl-CoA racemase activity was excluded. A racemase gene of about 15 kilobases was isolated. Southern blot analysis and chromosomal localization showed that only one racemase gene is present, on chromosome 15, region 15B1. The putative initial ATG in the racemase gene was preceded by a functional promotor as shown with the luciferase reporter gene assay. The corresponding cDNAs were isolated from rat and mouse liver. The recombinant rat protein was overexpressed in active form in Pichia pastoris. The presented data suggest that the polypeptide encoded by the racemase gene can alternatively be targeted to peroxisomes or mitochondria without modifications. It is concluded that the noncleavable N-terminal sequence of the polypeptide acts as a weak mitochondrial and that the C-terminal sequence acts as a peroxisomal targeting signal.	Univ Wurzburg, Biozentrum, Theodor Boveri Inst Biowissensch, D-97074 Wurzburg, Germany; Oulu Univ, Bioctr Oulu, FIN-90014 Oulu, Finland; Oulu Univ, Dept Biochem, FIN-90014 Oulu, Finland; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland	University of Wurzburg; University of Oulu; Finland National Institute for Health & Welfare; University of Oulu; University of Helsinki	Schmitz, W (corresponding author), Univ Wurzburg, Biozentrum, Theodor Boveri Inst Biowissensch, Hubland, D-97074 Wurzburg, Germany.	wschmitz@biozentrum.uni-wuerzburg.de	Kalkkinen, Nisse EJ/B-3923-2010	Helander, Heli/0000-0002-7319-3531; Savolainen, Kalle/0000-0002-1244-7200				ACKMAN RG, 1967, LIPIDS, V2, P357, DOI 10.1007/BF02531848; ALBERS C, 1999, THESIS U WURZBURG; BANERJEE A, 1984, H-S Z PHYSIOL CHEM, V365, P347, DOI 10.1515/bchm2.1984.365.1.347; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLEMALM E, 1985, J MICROSC-OXFORD, V140, P55, DOI 10.1111/j.1365-2818.1985.tb02660.x; DANPURE CJ, 1995, TRENDS CELL BIOL, V5, P230, DOI 10.1016/S0962-8924(00)89016-9; Filppula SA, 1998, J BIOL CHEM, V273, P349, DOI 10.1074/jbc.273.1.349; GIOVANNA P, 1991, MOL CELL BIOL, V11, P4796; HAKKOLA EH, 1989, J HISTOCHEM CYTOCHEM, V37, P1863, DOI 10.1177/37.12.2584694; HUBL P, 1964, H-S Z PHYSIOL CHEM, V335, P146, DOI 10.1515/bchm2.1964.335.1.146; KOIKE K, 1988, P NATL ACAD SCI USA, V85, P41, DOI 10.1073/pnas.85.1.41; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Pedersen JI, 1996, BIOCHEM BIOPH RES CO, V224, P37, DOI 10.1006/bbrc.1996.0981; PRYDZ K, 1986, J LIPID RES, V27, P622; Purdue PE, 1996, J CELL BIOL, V134, P849, DOI 10.1083/jcb.134.4.849; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; Sambrook J., 1989, MOL CLONING, V2.9, P14; SCHMITZ W, 1994, EUR J BIOCHEM, V222, P313, DOI 10.1111/j.1432-1033.1994.tb18870.x; Schmitz W, 1997, EUR J BIOCHEM, V244, P434, DOI 10.1111/j.1432-1033.1997.00434.x; Schmitz W, 1997, BIOCHEM J, V326, P883, DOI 10.1042/bj3260883; SCHMITZ W, 1995, EUR J BIOCHEM, V231, P815, DOI 10.1111/j.1432-1033.1995.0815d.x; SHEFER S, 1978, J BIOL CHEM, V253, P6386; SHIEH WR, 1993, J BIOL CHEM, V268, P3487; Soltys BJ, 1999, TRENDS BIOCHEM SCI, V24, P174, DOI 10.1016/S0968-0004(99)01390-0; Steinberg D., 1995, METABOLIC MOL BASES, P2351; Suzuki Y, 1997, AM J HUM GENET, V61, P1153, DOI 10.1086/301599; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; van Grunsven EG, 1998, P NATL ACAD SCI USA, V95, P2128, DOI 10.1073/pnas.95.5.2128; VanVeldhoven PP, 1996, FEBS LETT, V388, P80, DOI 10.1016/0014-5793(96)00508-X; Verhoeven NM, 1998, J INHERIT METAB DIS, V21, P697, DOI 10.1023/A:1005476631419; Verhoeven NM, 1998, J LIPID RES, V39, P66	34	51	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20887	20895		10.1074/jbc.M002067200	http://dx.doi.org/10.1074/jbc.M002067200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10770938	hybrid			2022-12-27	WOS:000088084500094
J	Koipally, J; Georgopoulos, K				Koipally, J; Georgopoulos, K			Ikaros interactions with CtBP reveal a repression mechanism that is independent of histone deacetylase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL BINDING-PROTEIN; MEDIATES TRANSCRIPTIONAL REPRESSION; ADENOVIRUS E1A; CO-REPRESSOR; CELLULAR PHOSPHOPROTEIN; LYMPHOCYTE DEVELOPMENT; NEGATIVE MODULATION; DROSOPHILA CTBP; N-COR; COREPRESSOR	We have previously shown that Ikaros can repress transcription through the recruitment of histone deacetylase complexes. Here we provide evidence that Ikaros can also repress transcription through its interactions with the co-repressor, C-terminal binding protein (CtBP). CtBP interacts with Ikaros isoforms through a PEDLS motif present at the N terminus of these proteins but not with homologues like Aiolos which lack this motif. Mutations in Ikaros that prevent CtBP interactions reduce its ability to repress transcription, CtBP interacts with Sin3A but not with the Mi-2 co-repressor and it represses transcription in a manner that is independent of histone deacetylase activity. These data strongly suggest that CtBP contributes to a histone deacetylase activity independent mechanism of repression by Ikaros. Finally, we show that the viral oncoprotein E1A, which binds to CtBP, also shows a strong association with Ikaros. This Ikaros-E1A interaction may underlie Ikaros's decreased ability to repress transcription in E1A transformed cells.	Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University	Georgopoulos, K (corresponding author), Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Bldg 149,13th St, Charlestown, MA 02129 USA.	katia.georgopoulos@cbrc2.mgh.harvard.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033062] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI33062] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Avitahl N, 1999, IMMUNITY, V10, P333, DOI 10.1016/S1074-7613(00)80033-3; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Brannon M, 1999, DEVELOPMENT, V126, P3159; Cortes M, 1999, CURR OPIN IMMUNOL, V11, P167, DOI 10.1016/S0952-7915(99)80028-4; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Fox AH, 1999, EMBO J, V18, P2812, DOI 10.1093/emboj/18.10.2812; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; Ghosh AK, 1999, BIOCHEM BIOPH RES CO, V260, P405, DOI 10.1006/bbrc.1999.0921; Hahm K, 1998, GENE DEV, V12, P782, DOI 10.1101/gad.12.6.782; HAHM KM, 1994, MOL CELL BIOL, V14, P7111, DOI 10.1128/MCB.14.11.7111; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Katsanis N, 1998, GENOMICS, V47, P294, DOI 10.1006/geno.1997.5115; Kelley CM, 1998, CURR BIOL, V8, P508, DOI 10.1016/S0960-9822(98)70202-7; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Koipally J, 1999, EMBO J, V18, P3090, DOI 10.1093/emboj/18.11.3090; Kolle D, 1998, METHODS, V15, P323, DOI 10.1006/meth.1998.0636; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Laj A, 1999, MOL CELL BIOL, V19, P6632; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; Look DC, 1998, IMMUNITY, V9, P871, DOI 10.1016/S1074-7613(00)80652-4; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; Morgan B, 1997, EMBO J, V16, P2004, DOI 10.1093/emboj/16.8.2004; Muscat GEO, 1998, NUCLEIC ACIDS RES, V26, P2899, DOI 10.1093/nar/26.12.2899; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Nibu Y, 1998, EMBO J, V17, P7009, DOI 10.1093/emboj/17.23.7009; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Sollerbrant K, 1996, NUCLEIC ACIDS RES, V24, P2578, DOI 10.1093/nar/24.13.2578; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Strouboulis J, 1999, MOL CELL BIOL, V19, P3958; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; Sundqvist A, 1998, FEBS LETT, V429, P183, DOI 10.1016/S0014-5793(98)00588-2; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wang JH, 1996, IMMUNITY, V5, P537, DOI 10.1016/S1074-7613(00)80269-1; Wang JH, 1998, IMMUNITY, V9, P543, DOI 10.1016/S1074-7613(00)80637-8; Wargnier A, 1998, J BIOL CHEM, V273, P35326, DOI 10.1074/jbc.273.52.35326; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1; Winandy S, 1999, J EXP MED, V190, P1039, DOI 10.1084/jem.190.8.1039; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1	50	156	160	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19594	19602		10.1074/jbc.M000254200	http://dx.doi.org/10.1074/jbc.M000254200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10766745	hybrid			2022-12-27	WOS:000087941300023
J	Yu, JH; Deuel, TF; Kim, HRC				Yu, JH; Deuel, TF; Kim, HRC			Platelet-derived growth factor (PDGF) receptor-alpha activates c-Jun NH2-terminal kinase-1 and antagonizes PDGF receptor-beta-induced phenotypic transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN SARCOMA-VIRUS; N-TERMINAL KINASE; NIH 3T3 CELLS; PROTEIN-KINASE; MAP KINASES; PHOSPHATIDYLINOSITOL-3 KINASE; DIFFERENTIAL ACTIVATION; SIGNAL-TRANSDUCTION; MURINE FIBROBLASTS; DNA-SYNTHESIS	Platelet-derived growth factor (PDGF) is a potent mitogen for mesenchymal cells. The PDGF B-chain (c-sis proto-oncogene) homodimer (PDGF BE) and v-sis, its viral counterpart, activate both alpha- and beta-receptor subunits (alpha-PDGFR and beta-PDGFR) and mediate anchorage-independent growth in NIH3T3 cells. In contrast, the PDGF A chain homodimer (PDGF AA) activates alpha-PDGFR only and fails to induce phenotypic transformation. In the present study, we investigated alpha- and beta-PDGFR specific signaling pathways that are responsible for the differences between the transforming ability of PDGF AA and BE. To study PDGF BE activation of beta-PDGFR, we established NIH3T3 clones in which alpha-PDGFR signaling is inhibited by a dominant-negative alpha-PDGFR, or an antisense construct of alpha-PDGFR. Here, we demonstrate that beta-PDGFR activation alone is sufficient for PDGF BE-mediated anchorage-independent cell growth. More importantly, inhibition of alpha-PDGFR signaling enhanced PDGF BB-mediated phenotypic transformation, suggesting that alpha-PDGFR antagonizes beta-PDGFR-induced transformation. While both alpha- and beta-receptors effectively activate ERKs, alpha-PDGFR, but not beta-PDGFR, activates stress-activated protein kinase-1/c-Jun NH2-terminal kinase-1 (JNK-1), Inhibition of JNK-1 activity using a dominant-negative JNK-1 mutant markedly enhanced PDGF BB-mediated anchorage-independent cell growth, demonstrating an antagonistic role for JNK-1 in PDGF-induced transformation. Consistently, overexpression of wild-type JNK-1 reduced PDGF BB-mediated transformation. Taken together, the present study showed that alpha- and beta-PDGFRs differentially regulate Ras-mitogen-activated protein kinase pathways critical for regulation of cell transformation, and transformation suppressing activity of alpha-PDGFR involves JNK-1 activation.	Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Growth Regulat, Boston, MA 02215 USA	Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Kim, HRC (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, 540 E Canfield, Detroit, MI 48201 USA.				NATIONAL CANCER INSTITUTE [R01CA064139, R29CA064139] Funding Source: NIH RePORTER; NCI NIH HHS [CA64139] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; ARMSTRONG DK, 1994, CANCER RES, V54, P5280; BAZENET CE, 1994, ONCOGENE, V9, P517; BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BEJCEK BE, 1993, BIOCHEM BIOPH RES CO, V196, P69, DOI 10.1006/bbrc.1993.2217; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; Birkenkamp KU, 1999, LEUKEMIA, V13, P1037, DOI 10.1038/sj.leu.2401447; Bost F, 1999, MOL CELL BIOL, V19, P1938; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; ClaessonWelsh L, 1996, INT J BIOCHEM CELL B, V28, P373, DOI 10.1016/1357-2725(95)00156-5; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CLARKE MF, 1984, NATURE, V308, P464, DOI 10.1038/308464a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; Davis W, 1999, BIOCHEM J, V338, P387, DOI 10.1042/0264-6021:3380387; DeMali KA, 1997, J BIOL CHEM, V272, P9011; DEUEL TF, 1983, SCIENCE, V221, P1348, DOI 10.1126/science.6310754; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; EASTMAN A, 1995, SEMIN CANCER BIOL, V6, P45, DOI 10.1006/scbi.1995.0006; ESCOBEDO JA, 1988, J BIOL CHEM, V263, P1482; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; Fritz G, 1999, MOL CELL BIOL, V19, P1768; Fruttiger M, 1999, DEVELOPMENT, V126, P457; Galley Y, 1997, P NATL ACAD SCI USA, V94, P5119, DOI 10.1073/pnas.94.10.5119; Gibson S, 1999, J BIOL CHEM, V274, P10916, DOI 10.1074/jbc.274.16.10916; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HEIDARAN MA, 1993, J BIOL CHEM, V268, P9287; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Huang CS, 1999, J BIOL CHEM, V274, P14595, DOI 10.1074/jbc.274.21.14595; KIM HRC, 1994, J BIOL CHEM, V269, P30604; KIM HRC, 1995, P NATL ACAD SCI USA, V92, P9500, DOI 10.1073/pnas.92.21.9500; Kottke TJ, 1999, J BIOL CHEM, V274, P15927, DOI 10.1074/jbc.274.22.15927; Lallemand D, 1998, EMBO J, V17, P5615, DOI 10.1093/emboj/17.19.5615; Lindahl P, 1997, DEVELOPMENT, V124, P3943; Lindahl P, 1998, DEVELOPMENT, V125, P3313; LopezIlasaca M, 1997, BIOCHEM BIOPH RES CO, V232, P273, DOI 10.1006/bbrc.1997.6289; Mallat A, 1998, J BIOL CHEM, V273, P27300, DOI 10.1074/jbc.273.42.27300; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matsuda N, 1998, BIOCHEM BIOPH RES CO, V249, P350, DOI 10.1006/bbrc.1998.9151; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; OLIVER BL, 1995, P SOC EXP BIOL MED, V210, P162; Page K, 1999, AM J RESP CELL MOL, V20, P1294, DOI 10.1165/ajrcmb.20.6.3597; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; Qi JH, 1999, J BIOL CHEM, V274, P14455, DOI 10.1074/jbc.274.20.14455; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Rosenkranz S, 1999, GROWTH FACTORS, V16, P201, DOI 10.3109/08977199909002130; Rosenkranz S, 1999, J BIOL CHEM, V274, P28335, DOI 10.1074/jbc.274.40.28335; Rusch Valerie, 1996, Cytokine and Growth Factor Reviews, V7, P133, DOI 10.1016/1359-6101(96)00016-0; SEGER R, 1994, J BIOL CHEM, V269, P25699; Soriano P, 1997, DEVELOPMENT, V124, P2691; Spiegel S, 1998, BIOCHEMISTRY-MOSCOW+, V63, P69; Spiegel S, 1998, ANN NY ACAD SCI, V845, P11, DOI 10.1111/j.1749-6632.1998.tb09658.x; Unlu Shebnem, 1998, Biochemical Society Transactions, V26, pS325; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yokote K, 1996, J BIOL CHEM, V271, P5101; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	65	58	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19076	19082		10.1074/jbc.M910329199	http://dx.doi.org/10.1074/jbc.M910329199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10777515	hybrid			2022-12-27	WOS:000087815900061
J	Angata, K; Suzuki, M; McAuliffe, J; Ding, YL; Hindsgaul, O; Fukuda, M				Angata, K; Suzuki, M; McAuliffe, J; Ding, YL; Hindsgaul, O; Fukuda, M			Differential biosynthesis of polysialic acid on neural cell adhesion molecule (NCAM) and oligosaccharide accepters by three distinct alpha 2,8-sialyltransferases, ST8Sia IV (PST), ST8Sia II (STX), and ST8Sia III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTALLY-REGULATED MEMBER; EXPRESSION CLONING; N-CAM; HUMAN POLYSIALYLTRANSFERASE; SYNAPTIC PLASTICITY; NEURITE OUTGROWTH; OLFACTORY-BULB; G(D3) SYNTHASE; NERVOUS-SYSTEM; SINGLE ENZYME	Polysialylated neural cell adhesion molecule (NCAM) is thought to play a critical role in neural development. Polysialylation of NCAM was shown to be achieved by two alpha 2,8-polysialyltransferases, ST8Sia TV (PST) and ST8Sia II (STX), which are moderately related to another alpha 2,8-sialyltransferase, ST8Sia III. Here we describe that all three alpha 2,8-sialyltransferases can utilize oligosaccharides as accepters but differ in the efficiency of adding polysialic acid on NCAM. First, we found that ST8Sia III can form polysialic acid on the enzyme itself (autopolysialylation) but not on NCAM. These discoveries prompted us to determine if ST8Sia IV and ST8Sia II share the property of ST8Sia III in utilizing low molecular weight oligosaccharides as accepters. By using a newly established method, we found that ST8Sia IV, ST8Sia II, and ST8Sia III all add oligosialic and polysialic acid on various sialylated N-acetyllactosaminyl oligosaccharides, including NCAM N-glycans, fetuin N-glycans, synthetic sialylated N-acetyllactosamines, and on a,alpha(2)-HS-glycoprotein, Our results also showed that monosialyl and disialyl N-acetyllactosamines can serve equally as an acceptor, suggesting that no initial addition of alpha 2,8-sialic acid is necessary for the action of polysialyltransferases. Polysialylation of NCAM by ST8Sia IV and ST8Sia II is much more efficient than polysialylation of N-glycans isolated from NCAM. Moreover, ST8Sia. IV and ST8Sia II catalyze polysialylation of NCAM much more efficiently than ST8Sia III. These results suggest that no specific acceptor recognition is involved in polysialylation of low molecular weight sialylated oligosaccharides, whereas the enzymes exhibit pronounced acceptor specificities if glycoproteins are used as accepters.	Burnham Inst, Ctr Canc Res, Glycobiol Program, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Fukuda, M (corresponding author), Burnham Inst, Ctr Canc Res, Glycobiol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	minoru@burnham-inst.org	Angata, Kiyohiko/M-2749-2018	Angata, Kiyohiko/0000-0001-5561-1368	NATIONAL CANCER INSTITUTE [P01CA071932] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA71932, R01 CA33595] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; Angata K, 1997, J BIOL CHEM, V272, P7182, DOI 10.1074/jbc.272.11.7182; CHUNG WW, 1991, J COMP NEUROL, V314, P290, DOI 10.1002/cne.903140207; Close BE, 1998, J BIOL CHEM, V273, P34586, DOI 10.1074/jbc.273.51.34586; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; Ding YL, 1998, BIOORG MED CHEM LETT, V8, P1903, DOI 10.1016/S0960-894X(98)00332-1; DOHERTY P, 1990, NEURON, V5, P209, DOI 10.1016/0896-6273(90)90310-C; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; Fambrough D, 1996, CELL, V87, P1049, DOI 10.1016/S0092-8674(00)81799-7; FINNE J, 1982, J BIOL CHEM, V257, P1966; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; HIRABAYASHI Y, 1988, J BIOCHEM, V104, P973, DOI 10.1093/oxfordjournals.jbchem.a122593; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; ITO M, 1989, J BIOL CHEM, V264, P9510; JAMES WM, 1987, BIOCHEM BIOPH RES CO, V148, P817, DOI 10.1016/0006-291X(87)90949-1; Kim YJ, 1997, BIOCHEM BIOPH RES CO, V235, P327, DOI 10.1006/bbrc.1997.6725; Kiss JZ, 1997, CURR OPIN NEUROBIOL, V7, P640, DOI 10.1016/S0959-4388(97)80083-9; KITAZUME S, 1994, J BIOL CHEM, V269, P10330; Kojima N, 1996, J BIOL CHEM, V271, P19457, DOI 10.1074/jbc.271.32.19457; KOJIMA N, 1995, FEBS LETT, V373, P119, DOI 10.1016/0014-5793(95)01024-9; Kono M, 1996, J BIOL CHEM, V271, P29366, DOI 10.1074/jbc.271.46.29366; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; LIVINGSTON BD, 1988, J BIOL CHEM, V263, P9443; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; McAuliffe JC, 1999, BIOORG MED CHEM LETT, V9, P2855, DOI 10.1016/S0960-894X(99)00485-0; MCCOY RD, 1985, J BIOL CHEM, V260, P2695; Muhlenhoff M, 1996, EMBO J, V15, P6943, DOI 10.1002/j.1460-2075.1996.tb01086.x; Muhlenhoff M, 1996, CURR BIOL, V6, P1188, DOI 10.1016/S0960-9822(02)70687-8; Muller D, 1996, NEURON, V17, P413, DOI 10.1016/S0896-6273(00)80174-9; Nakayama J, 1996, J BIOL CHEM, V271, P3684; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; Nakayama J, 1996, J BIOL CHEM, V271, P1829, DOI 10.1074/jbc.271.4.1829; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; NELSON RW, 1995, J BIOL CHEM, V270, P17171, DOI 10.1074/jbc.270.29.17171; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; ONO K, 1994, NEURON, V13, P595, DOI 10.1016/0896-6273(94)90028-0; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; SADOUL R, 1983, NATURE, V304, P347, DOI 10.1038/304347a0; SASAKI K, 1994, J BIOL CHEM, V269, P15950; Sato C, 2000, J BIOL CHEM, V275, P15422, DOI 10.1074/jbc.275.20.15422; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; SIMMONS DL, 1993, CELLULAR INTERACTION, P93; TANG JC, 1994, NEURON, V13, P405, DOI 10.1016/0896-6273(94)90356-5; Toikka J, 1998, J BIOL CHEM, V273, P28557, DOI 10.1074/jbc.273.44.28557; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; Ujita M, 1998, J BIOL CHEM, V273, P34843, DOI 10.1074/jbc.273.52.34843; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; YOSHIDA Y, 1995, J BIOL CHEM, V270, P14628, DOI 10.1074/jbc.270.24.14628; YOSHIOKA Y, 1986, J BIOL CHEM, V261, P1665; ZUBER C, 1992, J BIOL CHEM, V267, P9965	52	92	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18594	18601		10.1074/jbc.M910204199	http://dx.doi.org/10.1074/jbc.M910204199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10766765	hybrid			2022-12-27	WOS:000087659400093
J	Morishima, Y; Murphy, PJM; Li, DP; Sanchez, ER; Pratt, WB				Morishima, Y; Murphy, PJM; Li, DP; Sanchez, ER; Pratt, WB			Stepwise assembly of a glucocorticoid receptor center dot hsp90 heterocomplex resolves two sequential ATP-dependent events involving first hsp70 and then hsp90 in opening of the steroid binding pocket	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; PROGESTERONE-RECEPTOR; FUNCTIONAL HETEROCOMPLEX; CHAPERONE MACHINERY; COMPLEX; RECONSTITUTION; CONFORMATION; DOMAIN; SUFFICIENT; FOLDOSOME	A system of five purified proteins that assembles stable glucocorticoid receptor (GR)-hsp90 heterocomplexes has been reconstituted from reticulocyte lysate. Two proteins, hsp90 and hsp70, are required for the activation of steroid binding activity that occurs with heterocomplex assembly, and three proteins, Hop, hsp40, p23, act as co-chaperones that enhance activation and assembly (Morishima, Y., Kanelakis, K. C., Silverstein, it RI., Dittmar, IL D., Estrada, L., and Pratt, W. B. (2000) J. Biol, Chem. 275, 6894-6900). Here we demonstrate that the first step in assembly is the ATP-dependent and hsp40 (YDJ-1)-dependent binding of hsp70 to the GR After elimination of free hsp70, these preformed GR.hsp70 complexes can be activated to the steroid binding state by the hsp70 free assembly system in a second ATP-dependent step. hsp90 is required for opening of the steroid binding pocket and is converted to its ATP-dependent conformation during this second step. We predict that hsp70 in its ATP-dependent conformation binds initially to the folded receptor and is then converted to the ADP-dependent form with high affinity for hydrophobic substrate. This conversion initiates the opening of the hydrophobic steroid binding pocket such that it can now accept the hydrophobic binding form of hsp90, which in turn must be converted to its ATP-dependent conformation for the pocket to be accessible by steroid.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Med Coll Ohio, Dept Pharmacol, Toledo, OH 43699 USA	University of Michigan System; University of Michigan	Pratt, WB (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1301 MSRB 3,, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031573, R29DK043867, R01DK043867, R01DK031573] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43867, DK31573, R01 DK043867] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; Dittmar KD, 1997, J BIOL CHEM, V272, P13047, DOI 10.1074/jbc.272.20.13047; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; Giannoukos G, 1999, J BIOL CHEM, V274, P36527, DOI 10.1074/jbc.274.51.36527; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HUTCHISON KA, 1994, J BIOL CHEM, V269, P27894; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; Kosano H, 1998, J BIOL CHEM, V273, P32973, DOI 10.1074/jbc.273.49.32973; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; Morishima Y, 2000, J BIOL CHEM, V275, P6894, DOI 10.1074/jbc.275.10.6894; Prapapanich V, 1996, MOL ENDOCRINOL, V10, P420, DOI 10.1210/me.10.4.420; Pratt WB, 1998, TRENDS ENDOCRIN MET, V9, P244, DOI 10.1016/S1043-2760(98)00059-9; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; Silverstein AM, 1999, J BIOL CHEM, V274, P36980, DOI 10.1074/jbc.274.52.36980; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; Srinivasan G, 1997, J STEROID BIOCHEM, V60, P1, DOI 10.1016/S0960-0760(96)00182-3; SRINIVASAN G, 1994, MOL ENDOCRINOL, V8, P189, DOI 10.1210/me.8.2.189; Stancato LF, 1996, BIOCHEMISTRY-US, V35, P554, DOI 10.1021/bi9511649; Stancato LF, 1996, J BIOL CHEM, V271, P8831, DOI 10.1074/jbc.271.15.8831; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Toft DO, 1998, TRENDS ENDOCRIN MET, V9, P238, DOI 10.1016/S1043-2760(98)00060-5; Xu M, 1998, J BIOL CHEM, V273, P13918, DOI 10.1074/jbc.273.22.13918	32	136	141	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18054	18060		10.1074/jbc.M000434200	http://dx.doi.org/10.1074/jbc.M000434200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10764743	hybrid			2022-12-27	WOS:000087659400022
J	Laage, R; Rohde, J; Brosig, B; Langosch, D				Laage, R; Rohde, J; Brosig, B; Langosch, D			A conserved membrane-spanning amino acid motif drives homomeric and supports heteromeric assembly of presynaptic SNARE proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE; TRANSMEMBRANE SEGMENT; COMPLEX-FORMATION; FUSION COMPLEX; T-SNARES; SYNAPTOBREVIN; SYNTAXIN; SNAP-25; SYNAPTOPHYSIN; DIMERIZATION	Assembly of the SNARE proteins synaptobrevin/VAMP, syntaxin, and SNAP-25 to binary and ternary complexes is important for docking and/or fusion of presynaptic vesicles to the neuronal plasma membrane prior to regulated neurotransmitter release. Despite the well characterized structure of their cytoplasmic assembly domains, little is known about the role of the transmembrane segments in SNARE protein assembly and function, Here, we identified conserved amino acid motifs within the transmembrane segments that are required for homodimerization of synaptobrevin II and syntaxin 1A Minimal motifs of 6-8 residues grafted onto an otherwise monomeric oligoalanine host sequence were sufficient for self-interaction of both transmembrane segments in detergent solution or membranes, These motifs constitute contiguous areas of interfacial residues assuming alpha-helical secondary structures. Since the motifs are conserved, they also contributed to heterodimerization of synaptobrevin II and syntaxin 1A and therefore appear to constitute interaction domains independent of the cytoplasmic coiled coil regions, Interactions between the transmembrane segments may stabilize the SNARE complex, cause its multimerization to previously observed multimeric superstructures, and/or be required for the fusogenic activity of SNARE proteins.	Heidelberg Univ, Inst Neurobiol, Dept Neurobiol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Langosch, D (corresponding author), Heidelberg Univ, Inst Neurobiol, Dept Neurobiol, Neuenheimer Feld 364, D-69120 Heidelberg, Germany.	Langosch@sun0.urz.uni-heidelberg.de						Albillos A, 1997, NATURE, V389, P509, DOI 10.1038/39081; BEDOUELLE H, 1988, EUR J BIOCHEM, V171, P541, DOI 10.1111/j.1432-1033.1988.tb13823.x; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; Brosig B, 1998, PROTEIN SCI, V7, P1052; BRUNS D, 1995, NATURE, V377, P62, DOI 10.1038/377062a0; CALAKOS N, 1994, J BIOL CHEM, V269, P24534; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Danieli T, 1996, J CELL BIOL, V133, P559, DOI 10.1083/jcb.133.3.559; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; Fiebig KM, 1999, NAT STRUCT BIOL, V6, P117; GRASBERGER B, 1986, P NATL ACAD SCI USA, V83, P6258, DOI 10.1073/pnas.83.17.6258; Gurezka R, 1999, J BIOL CHEM, V274, P9265, DOI 10.1074/jbc.274.14.9265; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Hohl TM, 1998, MOL CELL, V2, P539, DOI 10.1016/S1097-2765(00)80153-7; IBARAKI K, 1995, BIOCHEM BIOPH RES CO, V211, P997, DOI 10.1006/bbrc.1995.1910; Isenmann S, 1998, MOL BIOL CELL, V9, P1649, DOI 10.1091/mbc.9.7.1649; Jahn R, 1998, NATURE, V393, P14, DOI 10.1038/29871; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; KOLMAR H, 1995, EMBO J, V14, P3895, DOI 10.1002/j.1460-2075.1995.tb00061.x; Kretzschmar S, 1996, NEUROSCI RES, V26, P141, DOI 10.1016/S0168-0102(96)01086-3; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Laage R, 1997, EUR J BIOCHEM, V249, P540, DOI 10.1111/j.1432-1033.1997.00540.x; Langosch D, 1996, J MOL BIOL, V263, P525, DOI 10.1006/jmbi.1996.0595; LEMMON MA, 1994, Q REV BIOPHYS, V27, P157, DOI 10.1017/S0033583500004522; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; Linial M, 1997, J NEUROCHEM, V69, P1781; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; Margittai M, 1999, FEBS LETT, V446, P40, DOI 10.1016/S0014-5793(99)00028-9; Markovic I, 1998, J CELL BIOL, V143, P1155, DOI 10.1083/jcb.143.5.1155; McNew JA, 1999, MOL CELL, V4, P415, DOI 10.1016/S1097-2765(00)80343-3; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Nonet ML, 1998, J NEUROSCI, V18, P70; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; Poirier MA, 1998, J BIOL CHEM, V273, P11370, DOI 10.1074/jbc.273.18.11370; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Rizo J, 1998, NAT STRUCT BIOL, V5, P839, DOI 10.1038/2280; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Saifee O, 1998, MOL BIOL CELL, V9, P1235, DOI 10.1091/mbc.9.6.1235; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Taubenblatt P, 1999, J CELL SCI, V112, P3559; Ungermann C, 1999, J CELL BIOL, V145, P1435, DOI 10.1083/jcb.145.7.1435; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; WASHBOURNE P, 1995, BIOCHEM J, V305, P721, DOI 10.1042/bj3050721; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; White JM, 1996, SOC GEN PHY, V51, P223; Whitley P, 1996, J BIOL CHEM, V271, P7583, DOI 10.1074/jbc.271.13.7583	56	110	111	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17481	17487		10.1074/jbc.M910092199	http://dx.doi.org/10.1074/jbc.M910092199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10764817	hybrid			2022-12-27	WOS:000087485000039
J	Hausner, W; Lange, U; Musfeldt, M				Hausner, W; Lange, U; Musfeldt, M			Transcription factor S, a cleavage induction factor of the archaeal RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; ELONGATION-FACTOR TFIIS; CELL-FREE TRANSCRIPTION; TATA-BINDING PROTEIN; II SUBUNIT RPB9; METHANOCOCCUS-VANNIELII; TERNARY COMPLEXES; ESCHERICHIA-COLI; INITIATION; SITE	We have analyzed the function of an archaeal protein (now called transcription factor S (TFS)) that shows sequence similarity to eukaryotic transcription factor IIS (TFIIS) as well as to small subunits of eukaryotic RNA polymerases I (A12.6), II (B12.2), and III (C11). Western blot analysis with antibodies against recombinant TFS demonstrated that this protein is not a subunit of the RNA polymerase. bz vitro transcription experiments with paused elongation complexes at position +25 showed that TFS is able to induce cleavage activity in the archaeal RNA polymerase in a similar manner to TFIIS. In the presence of TFS, the cleavage activity of the RNA polymerase truncates the RNA back to position +15 by releasing mainly dinucleotides from the 3'-end of the nascent RNA. Furthermore, TFS reduces the amount of non-chaseable elongation complexes at position +25 as well as position +45, These findings clearly demonstrate that this protein has a similar function to eukaryotic TFIIS.	Univ Kiel, Inst Allgemeine Mikrobiol, D-24118 Kiel, Germany	University of Kiel	Hausner, W (corresponding author), Univ Kiel, Inst Allgemeine Mikrobiol, Bot Garten 1-9, D-24118 Kiel, Germany.	whausner@ifam.uni-kiel.de						Awrey DE, 1997, J BIOL CHEM, V272, P14747, DOI 10.1074/jbc.272.23.14747; Awrey DE, 1998, J BIOL CHEM, V273, P22595, DOI 10.1074/jbc.273.35.22595; Bell SD, 1998, TRENDS MICROBIOL, V6, P222, DOI 10.1016/S0966-842X(98)01281-5; Bobkova EV, 1997, J BIOL CHEM, V272, P22832, DOI 10.1074/jbc.272.36.22832; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Chedin S, 1998, GENE DEV, V12, P3857, DOI 10.1101/gad.12.24.3857; FREY G, 1990, NUCLEIC ACIDS RES, V18, P1361, DOI 10.1093/nar/18.6.1361; FURTERGRAVES EM, 1994, NUCLEIC ACIDS RES, V22, P4932, DOI 10.1093/nar/22.23.4932; HAUSNER W, 1991, J MOL BIOL, V222, P495, DOI 10.1016/0022-2836(91)90492-O; HAUSNER W, 1993, J BIOL CHEM, V268, P24047; HAUSNER W, 1995, J BIOL CHEM, V270, P17649, DOI 10.1074/jbc.270.30.17649; Hausner W, 1996, J BIOL CHEM, V271, P30144, DOI 10.1074/jbc.271.47.30144; HULL MW, 1995, GENE DEV, V9, P481, DOI 10.1101/gad.9.4.481; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; JEON CJ, 1994, P NATL ACAD SCI USA, V91, P9106, DOI 10.1073/pnas.91.19.9106; KAINE BP, 1994, P NATL ACAD SCI USA, V91, P3854, DOI 10.1073/pnas.91.9.3854; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Labhart P, 1997, J BIOL CHEM, V272, P9055; LANGER D, 1993, NUCLEIC ACIDS RES, V21, P2251, DOI 10.1093/nar/21.9.2251; LANGER D, 1995, P NATL ACAD SCI USA, V92, P5768, DOI 10.1073/pnas.92.13.5768; Morin PE, 1996, P NATL ACAD SCI USA, V93, P10604, DOI 10.1073/pnas.93.20.10604; NAKANISHI T, 1995, J BIOL CHEM, V270, P8991, DOI 10.1074/jbc.270.15.8991; ORLOVA M, 1995, P NATL ACAD SCI USA, V92, P4596, DOI 10.1073/pnas.92.10.4596; Qureshi SA, 1997, EMBO J, V16, P2927, DOI 10.1093/emboj/16.10.2927; Reeve JN, 1997, CELL, V89, P999, DOI 10.1016/S0092-8674(00)80286-X; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Soppa J, 1999, MOL MICROBIOL, V31, P1295, DOI 10.1046/j.1365-2958.1999.01273.x; Thomas MJ, 1998, CELL, V93, P627, DOI 10.1016/S0092-8674(00)81191-5; Thomm M, 1996, FEMS MICROBIOL REV, V18, P159; Tschochner H, 1996, P NATL ACAD SCI USA, V93, P12914, DOI 10.1073/pnas.93.23.12914; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; WHITEHALL SK, 1994, J BIOL CHEM, V269, P2299	39	70	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12393	12399		10.1074/jbc.275.17.12393	http://dx.doi.org/10.1074/jbc.275.17.12393			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777522	hybrid			2022-12-27	WOS:000086762300006
J	Klingenberg, O; Wiedlocha, A; Citores, L; Olsnes, S				Klingenberg, O; Wiedlocha, A; Citores, L; Olsnes, S			Requirement of phosphatidylinositol 3-kinase activity for translocation of exogenous aFGF to the cytosol and nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							FIBROBLAST-GROWTH-FACTOR; PROTEIN-KINASE-B; ATHEROSCLEROTIC HUMAN ARTERIES; TOXIN A-FRAGMENT; DIPHTHERIA-TOXIN; FACTOR-I; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; FACTOR RECEPTOR; 3T3 CELLS	Acidic fibroblast growth factor (aFGF) is a potent mitogen for many cells. Exogenous aFGF is able to enter the cytosol and nucleus of sensitive cells. There are indications that both activation of the receptor tyrosine kinase and translocation of aFGF to the nucleus are of importance for mitogenesis. However, the mechanism of transport of aFGF hom the cell surface to the nucleus is poorly understood. In this work we demonstrate that inhibition of phosphatidylinositol (PI) 3-kinase by chemical inhibitors and by expression of a dominant negative mutant of PI 3-kinase blocks translocation of aFGF to the cytosol and nucleus. Translocation to the cytosol and nucleus was monitored by cell fractionation, by farnesylation of aFGF modified to contain a farnesylation signal, and by phosphorylation by protein kinase C of aFGF added externally to cells. If aFGF is fused to diphtheria toxin A-fragment, it can be artificially translocated from the cell surface to the cytoplasm by the diphtheria toxin pathway, Upon further incubation, the fusion protein enters the nucleus due to a nuclear localization sequence in aFGF. We demonstrate here that upon inhibition of PI 3-kinase the fusion protein remains in the cytosol. We also provide evidence that the phosphorylation status of the fusion protein does not regulate its nucleocytoplasmic distribution.	Norwegian Radium Hosp, Inst Canc Res, Dept Biochem, N-0310 Oslo, Norway	University of Oslo	Olsnes, S (corresponding author), Norwegian Radium Hosp, Inst Canc Res, Dept Biochem, N-0310 Oslo, Norway.		CITORES, LUCIA/G-7273-2017; CITORES, LUCIA/AAD-9770-2022	CITORES, LUCIA/0000-0003-3784-5042; CITORES, LUCIA/0000-0003-3784-5042				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Ananyeva NM, 1997, ARTERIOSCL THROM VAS, V17, P445, DOI 10.1161/01.ATV.17.3.445; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; BURGESS WH, 1990, J CELL BIOL, V111, P2129, DOI 10.1083/jcb.111.5.2129; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Carreira CM, 1998, J BIOL CHEM, V273, P22224, DOI 10.1074/jbc.273.35.22224; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; Citores L, 1999, MOL BIOL CELL, V10, P3835, DOI 10.1091/mbc.10.11.3835; CLEVES AE, 1997, CURR BIOL, V7, P318; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GOULD GW, 1994, J BIOL CHEM, V269, P26622; HANSEN SH, 1995, J BIOL CHEM, V270, P28425; HUGHES SE, 1993, CARDIOVASC RES, V27, P1214, DOI 10.1093/cvr/27.7.1214; Hughes SE, 1996, CARDIOVASC RES, V32, P557, DOI 10.1016/S0008-6363(96)00102-2; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JACKSON TR, 1992, J BIOL CHEM, V267, P16627; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; Kanda S, 1997, J BIOL CHEM, V272, P23347, DOI 10.1074/jbc.272.37.23347; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Klingenberg O, 1998, J BIOL CHEM, V273, P11164, DOI 10.1074/jbc.273.18.11164; Klingenberg O, 1999, J BIOL CHEM, V274, P18081, DOI 10.1074/jbc.274.25.18081; Klingenberg O, 1996, BIOCHEM J, V313, P647, DOI 10.1042/bj3130647; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LaVallee TM, 1998, J BIOL CHEM, V273, P22217, DOI 10.1074/jbc.273.35.22217; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; LIAU G, 1993, J VASC RES, V30, P327, DOI 10.1159/000159014; LONDON E, 1992, BIOCHIM BIOPHYS ACTA, V1113, P25, DOI 10.1016/0304-4157(92)90033-7; LUTZ RJ, 1992, P NATL ACAD SCI USA, V89, P3000, DOI 10.1073/pnas.89.7.3000; MADSHUS IH, 1992, INFECT IMMUN, V60, P3296, DOI 10.1128/IAI.60.8.3296-3302.1992; Martys JL, 1996, J BIOL CHEM, V271, P10953, DOI 10.1074/jbc.271.18.10953; MASCARELLI F, 1989, EMBO J, V8, P2265, DOI 10.1002/j.1460-2075.1989.tb08351.x; Mehta VB, 1998, J BIOL CHEM, V273, P4197, DOI 10.1074/jbc.273.7.4197; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Mizukami Y, 1997, FEBS LETT, V401, P247, DOI 10.1016/S0014-5793(96)01481-0; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MOSKAUG JO, 1988, J BIOL CHEM, V263, P2518; Munoz R, 1997, ONCOGENE, V15, P525, DOI 10.1038/sj.onc.1201226; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; NERI LM, 1994, CELL MOL BIOL, V40, P619; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; OKADA T, 1994, J BIOL CHEM, V269, P3568; Paine Philip L., 1993, Trends in Cell Biology, V3, P325, DOI 10.1016/0962-8924(93)90096-J; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Prochiantz A, 1996, CURR OPIN NEUROBIOL, V6, P629, DOI 10.1016/S0959-4388(96)80095-X; Prudovsky IA, 1996, J BIOL CHEM, V271, P14198, DOI 10.1074/jbc.271.24.14198; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; Rapak A, 1997, P NATL ACAD SCI USA, V94, P3783, DOI 10.1073/pnas.94.8.3783; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P627; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; ROGEL A, 1992, J BIOL CHEM, V267, P22599; Ryan PJ, 1998, BIOCHEM BIOPH RES CO, V244, P763, DOI 10.1006/bbrc.1998.8326; SANDVIG K, 1981, J BIOL CHEM, V256, P9068; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; Schlenstedt G, 1996, FEBS LETT, V389, P75, DOI 10.1016/0014-5793(96)00583-2; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; Shepherd PR, 1996, TRENDS CELL BIOL, V6, P92, DOI 10.1016/0962-8924(96)80998-6; Shpetner H, 1996, J CELL BIOL, V132, P595, DOI 10.1083/jcb.132.4.595; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; SINENSKY M, 1994, J CELL SCI, V107, P61; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; STENMARK H, 1992, BIOCHEM J, V281, P619, DOI 10.1042/bj2810619; TAGAWA T, 1995, J CELL BIOL, V130, P255, DOI 10.1083/jcb.130.2.255; Tarantini F, 1998, J BIOL CHEM, V273, P22209, DOI 10.1074/jbc.273.35.22209; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; URICH M, 1995, J BIOL CHEM, V270, P29286, DOI 10.1074/jbc.270.49.29286; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; Ward SG, 1996, IMMUNOL TODAY, V17, P187, DOI 10.1016/0167-5699(96)80618-9; WENNSTROM S, 1992, J BIOL CHEM, V267, P13749; WENNSTROM S, 1994, ONCOGENE, V9, P651; Wiedlocha A, 1995, J BIOL CHEM, V270, P30680, DOI 10.1074/jbc.270.51.30680; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; Wiedlocha A, 1996, MOL CELL BIOL, V16, P270; WIEDLOCHA A, 1992, EMBO J, V11, P4835, DOI 10.1002/j.1460-2075.1992.tb05589.x; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N; ZHAN X, 1993, J BIOL CHEM, V268, P9611; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	102	35	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11972	11980		10.1074/jbc.275.16.11972	http://dx.doi.org/10.1074/jbc.275.16.11972			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766827	hybrid			2022-12-27	WOS:000086695500062
J	Marcel, V; Estrada-Mondaca, S; Magne, F; Stojan, J; Klaebe, A; Fournier, D				Marcel, V; Estrada-Mondaca, S; Magne, F; Stojan, J; Klaebe, A; Fournier, D			Exploration of the Drosophila acetylcholinesterase substrate activation site using a reversible inhibitor (Triton X-100) and mutated enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL-SITE; MUSCA-DOMESTICA; BUTYRYLCHOLINESTERASE; MELANOGASTER; MUTAGENESIS; PROTEIN; LIGANDS; DOMAIN; ANCHOR; BRAIN	Cholinesterases are activated at low substrate concentration, and this is followed by inhibition as the level of substrate increases. However, one of these two components is sometimes lacking. In Drosophila acetylcholinesterase, the two phases are present, allowing both phenomena to be studied. Several kinetic schemes can explain this complex kinetic behavior. Among them, one model assumes that activation results from the binding of a substrate molecule to a non-productive site affecting the entrance of a substrate molecule into the active site. To test this hypothesis, we looked for an inhibitor competitive for activation and we found Triton X-100. Using organophosphates or carbamates as hemisubstrates, we showed that Triton X-100 inhibits or increases phosphorylation or carbamoylation of the enzyme. In vitro mutagenesis of the residues lining the active site gorge allowed us to locate the Triton X-100 binding site at the rim of the gorge with glutamate 107 playing the major role. These results led to the hypothesis that substrate binding at this site affects the entrance of another substrate molecule into the active site cleft.	Univ Toulouse 3, Lab Synth & Physicochim Mol Interet Biol, ESA 5068, Grp Biochim Prot, F-31062 Toulouse, France; Univ Ljubljana, Fac Med, Inst Biochem, Ljubljana 1000, Slovenia	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); University of Ljubljana	Fournier, D (corresponding author), Univ Toulouse 3, Lab Synth & Physicochim Mol Interet Biol, ESA 5068, Grp Biochim Prot, Bat 4 R3, F-31062 Toulouse, France.							ALDRIDGE WN, 1950, BIOCHEM J, V46, P451, DOI 10.1042/bj0460451; BARAK D, 1994, J BIOL CHEM, V269, P6296; BERMAN HA, 1981, BIOCHEMISTRY-US, V20, P4803, DOI 10.1021/bi00519a043; CAUET G, 1987, BIOCHEM CELL BIOL, V65, P529, DOI 10.1139/o87-068; CHAABIHI H, 1994, BIOCHEM BIOPH RES CO, V203, P734, DOI 10.1006/bbrc.1994.2243; CHANGEUX JP, 1966, MOL PHARMACOL, V2, P369; Cousin X, 1996, J BIOL CHEM, V271, P15099, DOI 10.1074/jbc.271.25.15099; DEVONSHIRE AL, 1975, BIOCHEM J, V149, P463, DOI 10.1042/bj1490463; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Estrada-Mondaca S, 1998, PROTEIN EXPRES PURIF, V12, P166, DOI 10.1006/prep.1997.0831; FOURNIER D, 1988, J NEUROCHEM, V50, P1158, DOI 10.1111/j.1471-4159.1988.tb10587.x; FRAENKEL Y, 1994, BIOCHEMISTRY-US, V33, P644, DOI 10.1021/bi00169a004; HAAS R, 1988, BIOCHEMISTRY-US, V27, P6453, DOI 10.1021/bi00417a038; HALL LMC, 1986, EMBO J, V5, P2949, DOI 10.1002/j.1460-2075.1986.tb04591.x; HAREL M, 1992, P NATL ACAD SCI USA, V89, P10827, DOI 10.1073/pnas.89.22.10827; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; JOHNSON CD, 1983, J NEUROCHEM, V41, P30, DOI 10.1111/j.1471-4159.1983.tb11811.x; KAMARIC L, 1982, PERIOD BIOL, V84, P143; LEVY D, 1986, BIOCHEM PHARMACOL, V35, P1079, DOI 10.1016/0006-2952(86)90142-5; LoewensteinLichtenstein Y, 1996, MOL PHARMACOL, V50, P1423; Marcel V, 1998, BIOCHEM J, V329, P329, DOI 10.1042/bj3290329; MILLAR DB, 1979, BIOPHYS CHEM, V10, P147, DOI 10.1016/0301-4622(79)85034-6; NACHMANSOHN D, 1951, ADV ENZYMOL REL S BI, V12, P259; ORDENTLICH A, 1995, J BIOL CHEM, V270, P2082, DOI 10.1074/jbc.270.5.2082; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; RADIC Z, 1993, BIOCHEMISTRY-US, V32, P12074, DOI 10.1021/bi00096a018; ROSENBERRY TL, 1971, BIOCHEMISTRY-US, V10, P4114, DOI 10.1021/bi00798a016; ROSS S, 1959, J PHYS CHEM-US, V63, P1671, DOI 10.1021/j150580a025; ROUFOGALIS BD, 1972, MOL PHARMACOL, V8, P41; SHAFFERMAN A, 1992, EMBO J, V11, P3561, DOI 10.1002/j.1460-2075.1992.tb05439.x; Stojan J, 1999, J ENZYM INHIB, V14, P193, DOI 10.3109/14756369909030316; Stojan J, 1999, CHEM-BIOL INTERACT, V119, P137, DOI 10.1016/S0009-2797(99)00022-8; Stojan J, 1998, FEBS LETT, V440, P85, DOI 10.1016/S0014-5793(98)01434-3; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; SZDEGLETES T, 1999, BIOCHEMISTRY-US, V38, P122; Szegletes T, 1998, BIOCHEMISTRY-US, V37, P4206, DOI 10.1021/bi972158a; WILSON IB, 1956, J AM CHEM SOC, V78, P202, DOI 10.1021/ja01582a056	37	36	36	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11603	11609		10.1074/jbc.275.16.11603	http://dx.doi.org/10.1074/jbc.275.16.11603			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766776	hybrid			2022-12-27	WOS:000086695500011
J	Sorci-Thomas, MG; Thomas, M; Curtiss, L; Landrum, M				Sorci-Thomas, MG; Thomas, M; Curtiss, L; Landrum, M			Single repeat deletion in ApoA-I blocks cholesterol esterification and results in rapid catabolism of Delta 6 and wild-type ApoA-I in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; HIGH-DENSITY-LIPOPROTEIN; CORONARY-ARTERY DISEASE; ACYLTRANSFERASE ACTIVATION; CELLULAR CHOLESTEROL; PLASMA-LEVELS; FATTY-ACIDS; LIPID-FREE; PRE-BETA; LPA-I	The deletion mutation Delta 6 apolipoprotein A-I lacks residues 143-164 or repeat 6 in the mature apoA-I protein. In vitro studies show this mutation dramatically reduces the rate of lecithin:cholesterol acyltransferase (LCAT) catalyzed cholesterol esterification. The present study was initiated to investigate the effect of this mutation on in vivo high density lipoprotein (HDL) cholesterol esterification and metabolism. Transgenic mice ex pressing human Delta 6 apoA-I (Tg Delta 6 +/+) were created and then crossed with apoA-I knockout mice (-/-) to generate mice expressing only human Delta 6 apoA-I (Tg Delta 6 -/-). Human Delta 6 apoA-I was associated with homogeneous sized alpha-HDL, when wild-type mouse apoA-I was present (in Tg Delta 6 +/+ and +/- mice). However, in the absence of endogenous mouse apoA-I, Delta 6 apoA-I was found exclusively in cholesterol ester-poor HDL, and lipid-free HDL fractions. This observation coincides with the 2-fold lower cholesterol ester mass in Tg Delta 6 -/- mouse plasma compared with control, Structural studies show that despite the structural perturbation of a domain extending from repeat 5 to repeat 8 (137-178), Delta 6 apoA-I binds to spherical unilamellar vesicles with only 2-fold less binding affinity. In summary, these data show a domain corresponding to apoA-I repeat 6 is responsible for providing an essential conformation for LCAT catalyzed generation of cholesterol esters. Deletion of apoA-I repeat 6 not only blocks normal levels of cholesterol esterification but also exerts a dominant inhibition on the ability of mild-type apoA-I to activate LCAT in vivo.	Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27157 USA; Scripps Res Inst, Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Scripps Research Institute; Scripps Research Institute	Sorci-Thomas, MG (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol Comparat Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.	msthomas@wfubmc.edu		Sorci-Thomas, Mary/0000-0002-6464-5006	NCI NIH HHS [CAA13148] Funding Source: Medline; NHLBI NIH HHS [HL-43815, HL-49373] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043815, P01HL049373] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; AIELLO DB, 1995, CIRCULATION S1, V92, P494; ASSMANN G, 1993, CIRCULATION, V87, P28; AUERBACH BJ, 1989, J BIOL CHEM, V264, P10264; BOOTH DR, 1995, QJM-INT J MED, V88, P695; BRESLOW JL, 1989, METABOLIC BASIS INHE, P1251; Bruckert E, 1997, ATHEROSCLEROSIS, V128, P121, DOI 10.1016/S0021-9150(96)05982-5; Curtiss LK, 1996, J LIPID RES, V37, P884; CZARNECKA H, 1995, BIOCHEMISTRY-US, V34, P4385, DOI 10.1021/bi00013a030; de Backer G, 1998, ATHEROSCLEROSIS, V137, pS1, DOI 10.1016/S0021-9150(97)00310-9; DEEB SS, 1991, J BIOL CHEM, V266, P13654; Dhoest A, 1997, J BIOL CHEM, V272, P15967, DOI 10.1074/jbc.272.25.15967; FIELDING CJ, 1995, J LIPID RES, V36, P211; Fiske CH, 1925, J BIOL CHEM, V66, P375; Frank PG, 1998, BIOCHEMISTRY-US, V37, P13902, DOI 10.1021/bi981205b; Funke H, 1997, CURR OPIN LIPIDOL, V8, P189, DOI 10.1097/00041433-199706000-00010; GLASS CK, 1983, J BIOL CHEM, V258, P7161; GLOMSET JA, 1968, J LIPID RES, V9, P155; GLOMSET JA, 1973, ADV LIPID RES, V1, P1; GOLDBERG IJ, 1990, J CLIN INVEST, V86, P463, DOI 10.1172/JCI114732; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; Hogan B, 1994, MANIPULATING MOUSE E; HOLVOET P, 1995, BIOCHEMISTRY-US, V34, P13334, DOI 10.1021/bi00041a009; HUANG CH, 1969, BIOCHEMISTRY-US, V8, P344, DOI 10.1021/bi00829a048; Huang W, 1998, ARTERIOSCL THROM VAS, V18, P389, DOI 10.1161/01.ATV.18.3.389; Hughes SD, 1997, ARTERIOSCL THROM VAS, V17, P1725, DOI 10.1161/01.ATV.17.9.1725; JOHNSON WJ, 1988, J BIOL CHEM, V263, P14099; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; Jonas A, 1998, PROG LIPID RES, V37, P209, DOI 10.1016/S0163-7827(98)00007-1; KAWANO M, 1993, BIOCHEMISTRY-US, V32, P5025, DOI 10.1021/bi00070a008; KORITNIK DL, 1983, J LIPID RES, V24, P1639; Leren TP, 1997, J LIPID RES, V38, P121; LI H, 1993, ARTERIOSCLER THROMB, V13, P1814, DOI 10.1161/01.ATV.13.12.1814; Lindholm EM, 1998, BIOCHEMISTRY-US, V37, P4863, DOI 10.1021/bi972888i; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANIATIS T, 1982, MOL CLONING LABORATO, P187; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; Miettinen HE, 1997, ARTERIOSCL THROM VAS, V17, P3021, DOI 10.1161/01.ATV.17.11.3021; Miettinen HE, 1997, ARTERIOSCL THROM VAS, V17, P83, DOI 10.1161/01.ATV.17.1.83; MINNICH A, 1992, J BIOL CHEM, V267, P16553; Mishra VK, 1998, BIOCHEMISTRY-US, V37, P10313, DOI 10.1021/bi980042o; NG DS, 1995, ARTERIOSCL THROM VAS, V15, P2157, DOI 10.1161/01.ATV.15.12.2157; NORUM RA, 1982, NEW ENGL J MED, V306, P1513, DOI 10.1056/NEJM198206243062503; Oram JF, 1996, J LIPID RES, V37, P2473; Palgunachari MN, 1996, ARTERIOSCL THROM VAS, V16, P328, DOI 10.1161/01.ATV.16.2.328; PARKS JS, 1979, J BIOL CHEM, V254, P6716; Parks JS, 1997, J LIPID RES, V38, P266; PARKS JS, 1995, J LIPID RES, V36, P349; PASZTY C, 1994, J CLIN INVEST, V94, P899, DOI 10.1172/JCI117412; Phillips MC, 1998, ATHEROSCLEROSIS, V137, pS13, DOI 10.1016/S0021-9150(97)00312-2; Polites H. Greg, 1994, P15; RAINWATER DL, 1992, J LIPID RES, V33, P1876; Rogers DP, 1998, BIOCHEMISTRY-US, V37, P11714, DOI 10.1021/bi973112k; ROSSENEU M, 1995, FASEB J, V9, P768, DOI 10.1096/fasebj.9.9.7601341; Rothblat GH, 1999, J LIPID RES, V40, P781; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; Rudel LL, 1998, ARTERIOSCL THROM VAS, V18, P1818, DOI 10.1161/01.ATV.18.11.1818; SCHAEFER EJ, 1985, J LIPID RES, V26, P1089; SCHWENKE DC, 1988, CIRC RES, V62, P699, DOI 10.1161/01.RES.62.4.699; Segel IH, 1976, BIOCH CALCULATIONS; Sorci-Thomas MG, 1998, J BIOL CHEM, V273, P11776, DOI 10.1074/jbc.273.19.11776; SORCITHOMAS M, 1993, J BIOL CHEM, V268, P21403; SorciThomas MG, 1996, J LIPID RES, V37, P673; SorciThomas MG, 1997, J BIOL CHEM, V272, P7278, DOI 10.1074/jbc.272.11.7278; Sparks DL, 1999, BIOCHEMISTRY-US, V38, P1727, DOI 10.1021/bi981945k; UTERMANN G, 1984, EUR J BIOCHEM, V144, P325, DOI 10.1111/j.1432-1033.1984.tb08467.x; VANDRIEL IR, 1987, J BIOL CHEM, V262, P16127; VONECKARDSTEIN A, 1989, J CLIN INVEST, V84, P1722, DOI 10.1172/JCI114355; VONECKARDSTEIN A, 1990, J BIOL CHEM, V265, P8610; Voyiaziakis E, 1998, J LIPID RES, V39, P313; WALSH A, 1989, J BIOL CHEM, V264, P6488; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WEISGRABER KH, 1980, J CLIN INVEST, V66, P901, DOI 10.1172/JCI109957; WILLIAMSON R, 1992, P NATL ACAD SCI USA, V89, P7134, DOI 10.1073/pnas.89.15.7134; WISH L, 1950, P SOC EXP BIOL MED, V74, P644; YOKOYAMA S, 1980, J BIOL CHEM, V255, P7333; Yokoyama S, 1998, BBA-LIPID LIPID MET, V1392, P1, DOI 10.1016/S0005-2760(98)00032-0	78	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12156	12163		10.1074/jbc.275.16.12156	http://dx.doi.org/10.1074/jbc.275.16.12156			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766851	hybrid			2022-12-27	WOS:000086695500086
J	Galan, A; Garcia-Bermejo, ML; Troyano, A; Vilaboa, NE; de Blas, E; Kazanietz, MG; Aller, P				Galan, A; Garcia-Bermejo, ML; Troyano, A; Vilaboa, NE; de Blas, E; Kazanietz, MG; Aller, P			Stimulation of p38 mitogen-activated protein kinase is an early regulatory event for the cadmium-induced apoptosis in human promonocytic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK; SIGNALING PATHWAYS; HL-60 CELLS; DEATH; EXPRESSION; MITOCHONDRIA; INDUCTION; NECROSIS; CHLORIDE; STRESS	Pulse treatment of U-937 promonocytic cells with cadmium chloride (2 h at 200 mu M) provoked apoptosis and induced a rapid phosphorylation of p38 mitogen-activated protein kinase (p38(MAPK)) as Well as a late phosphorylation of extracellular signal-regulated protein kinases (ERK1/2). However, although the p38(MAPK)-specific inhibitor SB203580 attenuated apoptosis, the process was not affected by the ERK-specific inhibitor PD98059. The attenuation of the cadmium-provoked apoptosis by SB203580 was a highly specific effect. In fact, the kinase inhibitor did not prevent the generation of apoptosis by heat shock and camptothecin, nor the generation of necrosis by cadmium treatment of glutathione-depleted cells, nor the cadmium-provoked activation of the stress response. The generation of apoptosis was preceded by intracellular H2O2 accumulation and was accompanied by the disruption of mitochondrial transmembrane potential, both of which were inhibited by SB203580, On the other hand, the antioxidant agent butylated hydroxyanisole-inhibited apoptosis but did not prevent p38(MAPK) phosphorylation. In a similar manner, p38(MAPK) phosphorylation was not affected by the caspase inhibitors Z-VAD and DEVD-CHO, which nevertheless prevented apoptosis. These results indicate that p38(MAPK) activation is an early and specific regulatory event for the cadmium-provoked apoptosis in promonocytic cells.	CSIC, Ctr Invest Biol, E-28006 Madrid, Spain; Univ Penn, Sch Med, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); University of Pennsylvania; University of Pennsylvania	Aller, P (corresponding author), CSIC, Ctr Invest Biol, Velazquez 144, E-28006 Madrid, Spain.		Vilaboa, Nuria/S-2794-2019; Vilaboa, Nuria/L-1727-2014; García-Bermejo, María Laura/E-1542-2015	Vilaboa, Nuria/0000-0003-4473-4498; García-Bermejo, María Laura/0000-0002-8167-2276				BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; Bhat NR, 1999, J NEUROCHEM, V72, P112, DOI 10.1046/j.1471-4159.1999.0720112.x; Birkenkamp KU, 1999, LEUKEMIA, V13, P1037, DOI 10.1038/sj.leu.2401447; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; BUJA LM, 1993, ARCH PATHOL LAB MED, V117, P1208; Callsen D, 1999, BIOCHEMISTRY-US, V38, P2279, DOI 10.1021/bi982292a; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; FERNANDES RS, 1994, BIOCHEM PHARMACOL, V48, P675, DOI 10.1016/0006-2952(94)90044-2; Franklin CC, 1998, P NATL ACAD SCI USA, V95, P3014, DOI 10.1073/pnas.95.6.3014; Frantz B, 1998, BIOCHEMISTRY-US, V37, P13846, DOI 10.1021/bi980832y; GEBHART E, 1991, METALS THEIR COMPOUN, P617; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; Gorman AM, 1999, FEBS LETT, V445, P98, DOI 10.1016/S0014-5793(99)00094-0; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hung JJ, 1998, J BIOL CHEM, V273, P31924, DOI 10.1074/jbc.273.48.31924; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Lal AS, 1999, BIOCHEM BIOPH RES CO, V259, P465, DOI 10.1006/bbrc.1999.0759; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Mackay K, 1999, J BIOL CHEM, V274, P6272, DOI 10.1074/jbc.274.10.6272; MAJNO G, 1995, AM J PATHOL, V146, P3; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; McGowan AJ, 1996, FEBS LETT, V392, P299, DOI 10.1016/0014-5793(96)00838-1; NOSSERI C, 1994, EXP CELL RES, V212, P367, DOI 10.1006/excr.1994.1156; OCHI T, 1987, MUTAT RES, V180, P257, DOI 10.1016/0027-5107(87)90222-3; ORMEROD MG, 1992, J IMMUNOL METHODS, V153, P57, DOI 10.1016/0022-1759(92)90305-D; Parameswaran N, 1999, EUR J PHARMACOL, V371, P75, DOI 10.1016/S0014-2999(99)00146-6; PEREZ C, 1994, CELL GROWTH DIFFER, V6, P337; Polverino AJ, 1997, J BIOL CHEM, V272, P7013, DOI 10.1074/jbc.272.11.7013; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAMET J, 1998, AM J PHYSIOL, V275, P6551; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Slater AFG, 1995, TOXICOL LETT, V82-3, P149, DOI 10.1016/0378-4274(95)03474-9; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; VAYSSIER M, 1998, AM J PHYSIOL, V275, P6771; VILABOA NE, 1995, J CELL SCI, V108, P2877; Vilaboa NE, 1997, J CELL SCI, V110, P201; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Watabe M, 1996, J BIOL CHEM, V271, P14067, DOI 10.1074/jbc.271.24.14067; Watson RWG, 1997, FEBS LETT, V412, P603, DOI 10.1016/S0014-5793(97)00779-5; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	55	160	163	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11418	11424		10.1074/jbc.275.15.11418	http://dx.doi.org/10.1074/jbc.275.15.11418			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753958	hybrid, Green Published			2022-12-27	WOS:000086466600100
J	Petersen, CE; Ha, CE; Harohalli, K; Feix, JB; Bhagavan, NV				Petersen, CE; Ha, CE; Harohalli, K; Feix, JB; Bhagavan, NV			A dynamic model for bilirubin binding to human serum albumin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM; QUANTUM YIELD; CHEMICAL MODIFICATION; THYROXINE-BINDING; BOUND BILIRUBIN; LYSINE RESIDUES; COMPLEXES; AFFINITY; CONFORMATION; WAVELENGTH	Site-directed mutagenesis of human serum albumin was used to study the role of various amino acid residues in bilirubin binding. A comparison of thermodynamic, proteolytic, and x-ray crystallographic data from previous studies allowed a small number of amino acid residues in subdomain 2A to be selected as targets for substitution. The following recombinant human serum albumin species were synthesized in the yeast species Pichia pastoris: K195M, K199M, F211V, W214L, R218M, R222M, H242V, R257M, and wild type human serum albumin. The affinity of bilirubin was measured by two independent methods and found to be similar for all human serum albumin species. Examination of the absorption and circular dichroism spectra of bilirubin bound to its high affinity site revealed dramatic differences between the conformations of bilirubin bound to the above human serum albumin species. The absorption and circular dichroism spectra of bilirubin bound to the above human serum albumin species in aqueous solutions saturated with chloroform were also examined. The effect of certain amino acid substitutions on the conformation of bound bilirubin was altered by the addition of chloroform. In total, the present study suggests a dynamic, unusually flexible high affinity binding site for bilirubin on human serum albumin.	Univ Hawaii, John A Burns Sch Med, Dept Biochem & Biophys, Honolulu, HI 96822 USA; Med Coll Wisconsin, Biophys Res Inst, Milwaukee, WI 53226 USA	University of Hawaii System; Medical College of Wisconsin	Bhagavan, NV (corresponding author), Univ Hawaii, John A Burns Sch Med, Dept Biochem & Biophys, 1960 EW Rd, Honolulu, HI 96822 USA.	bhagavan@jabsom.biomed.hawaii.edu						AGATI G, 1992, PHOTOCHEM PHOTOBIOL, V55, P185, DOI 10.1111/j.1751-1097.1992.tb04226.x; BERNSTEIN RB, 1969, J CLIN INVEST, V48, P1678, DOI 10.1172/JCI106133; BLAUER G, 1972, BIOCHIM BIOPHYS ACTA, V278, P68, DOI 10.1016/0005-2795(72)90108-0; Boiadjiev SE, 1997, CHIRALITY, V9, P604, DOI 10.1002/(SICI)1520-636X(1997)9:5/6<604::AID-CHIR31>3.0.CO;2-Q; BRODERSEN R, 1974, J CLIN INVEST, V54, P1353, DOI 10.1172/JCI107882; BRODERSEN R, 1979, CRC CR REV CL LAB SC, V11, P305; CARTER DC, 1994, ADV PROTEIN CHEM, V45, P153; CASHORE WJ, 1982, PEDIATRICS, V69, P481; GEISOW MJ, 1977, BIOCHEM J, V163, P477, DOI 10.1042/bj1630477; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; HONORE B, 1987, J BIOL CHEM, V262, P14939; ITOH S, 1987, BIOL NEONATE, V51, P10; JACOBSEN C, 1972, EUR J BIOCHEM, V27, P513, DOI 10.1111/j.1432-1033.1972.tb01867.x; JACOBSEN C, 1978, BIOCHEM J, V171, P453, DOI 10.1042/bj1710453; JACOBSEN J, 1983, J BIOL CHEM, V258, P6319; JACOBSEN J, 1969, FEBS LETT, V5, P112, DOI 10.1016/0014-5793(69)80307-8; JACOBSEN J, 1977, INT J PEPT PROT RES, V9, P235; Johansson JS, 1997, J BIOL CHEM, V272, P17961, DOI 10.1074/jbc.272.29.17961; KUENZLE CC, 1976, J BIOL CHEM, V251, P801; LABRUNE P, 1990, CLIN CHIM ACTA, V192, P29, DOI 10.1016/0009-8981(90)90268-W; LEVINE RL, 1977, CLIN CHEM, V23, P2292; LIGHTNER DA, 1988, J BIOL CHEM, V263, P16669; LIGHTNER DA, 1984, PEDIATR RES, V18, P696, DOI 10.1203/00006450-198408000-00003; LIGHTNER DA, 1987, TETRAHEDRON, V43, P4287, DOI 10.1016/S0040-4020(01)90304-7; LIGHTNER DA, 1986, J BIOL CHEM, V261, P6034; LIGHTNER DA, 1988, ARCH BIOCHEM BIOPHYS, V262, P543, DOI 10.1016/0003-9861(88)90406-7; MALHOTRA V, 1987, PEDIATR RES, V21, P530, DOI 10.1203/00006450-198706000-00003; MCDONAGH AF, 1988, SEMIN LIVER DIS, V8, P272, DOI 10.1055/s-2008-1040549; MCDONAGH AF, 1989, PHOTOCHEM PHOTOBIOL, V50, P305, DOI 10.1111/j.1751-1097.1989.tb04164.x; MCDONAGH AF, 1992, EXPERIENTIA, V48, P246, DOI 10.1007/BF01930465; MINCHIOTTI L, 1993, EUR J BIOCHEM, V214, P437, DOI 10.1111/j.1432-1033.1993.tb17939.x; MIR MM, 1992, BIOCHIM BIOPHYS ACTA, V1119, P261, DOI 10.1016/0167-4838(92)90212-V; NOGALES D, 1995, J BIOL CHEM, V270, P73, DOI 10.1074/jbc.270.1.73; ONISHI S, 1985, BIOCHEM J, V230, P561, DOI 10.1042/bj2300561; Patra SK, 1997, EUR J BIOCHEM, V246, P658, DOI 10.1111/j.1432-1033.1997.t01-1-00658.x; Petersen CE, 1996, J BIOL CHEM, V271, P19110, DOI 10.1074/jbc.271.32.19110; Petersen CE, 1997, BIOCHEMISTRY-US, V36, P7012, DOI 10.1021/bi970225v; PETERSEN CE, 1995, BIOCHEM BIOPH RES CO, V202, P781; PETERSEN CE, 1999, CLIN CHEM, V1248; REED RG, 1975, BIOCHEMISTRY-US, V14, P4578, DOI 10.1021/bi00692a004; SCHEIDT PC, 1977, J PEDIATR-US, V91, P292, DOI 10.1016/S0022-3476(77)80835-4; SCHENKER S, 1964, J CLIN INVEST, V43, P32, DOI 10.1172/JCI104891; SJODIN T, 1977, BIOCHIM BIOPHYS ACTA, V494, P61, DOI 10.1016/0005-2795(77)90135-0; TAYYAB S, 1989, BIOCHEM INT, V18, P343; ZUCKER SD, 1995, J BIOL CHEM, V270, P1074, DOI 10.1074/jbc.270.3.1074	45	79	83	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					20985	20995		10.1074/jbc.M001038200	http://dx.doi.org/10.1074/jbc.M001038200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10764755	hybrid			2022-12-27	WOS:000088230600005
J	Nakajima, K; Yamauchi, K; Shigematsu, S; Ikeo, S; Komatsu, M; Aizawa, T; Hashizume, K				Nakajima, K; Yamauchi, K; Shigematsu, S; Ikeo, S; Komatsu, M; Aizawa, T; Hashizume, K			Selective attenuation of metabolic branch of insulin receptor down-signaling by high glucose in a hepatoma cell line, HepG2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GLYCOGEN-SYNTHASE KINASE-3; INDUCED TYROSINE PHOSPHORYLATION; GLUTAMINE-FRUCTOSE-6-PHOSPHATE AMIDOTRANSFERASE; 3T3-L1 ADIPOCYTES; INHIBITION; SUBSTRATE-1; RESISTANCE; LOCALIZATION; ACTIVATION	The effects of a high concentration of glucose on the insulin receptor-down signaling were investigated in human hepatoma (HepG2) cells in vitro to delineate the molecular mechanism of insulin resistance under glucose toxicity. Treatment of the cells with high concentrations of glucose (15-33 mM) caused phosphorylation of serine residues of the insulin receptor substrate 1 (IRS-1), leading to reduced electrophoretic mobility of it. The phosphorylation of IRS-1 with high glucose treatment was blocked only by protein kinase C (PKC) inhibitors. The high glucose treatment attenuated insulin-induced association of IRS-1 and phosphatidylinositol 3-kinase and insulin stimulated phosphorylation of Akt. A metabolic effect of insulin, stimulation of glycogen synthesis, was also inhibited by the treatment. In contrast, insulin-induced association of Shc and Grb2 was not inhibited. Treatment of the cells with high glucose promoted the translocation of PKC epsilon and PKC delta from the cytosol to the plasma membrane but not that of other PKC isoforms. Finally, PKC epsilon and PKC delta directly phosphorylated IRS-1 under cell-free conditions. We conclude that a high concentration of glucose causes phosphorylation of IRS-1, leading to selective attenuation of metabolic signaling of insulin. PKC epsilon and PKC delta are involved in the down-regulation of insulin signaling, and they may lie in a pathway regulating the phosphorylation of IRS-1.	Shinshu Univ, Sch Med, Dept Aging Med & Geriatr, Matsumoto, Nagano 3908621, Japan	Shinshu University	Yamauchi, K (corresponding author), Shinshu Univ, Sch Med, Dept Aging Med & Geriatr, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	keishi@hsp.md.shinshu-u.ac.jp						Asada A, 1998, J BIOL CHEM, V273, P28392, DOI 10.1074/jbc.273.43.28392; BARSKI OA, 1995, BIOCHEMISTRY-US, V34, P11264, DOI 10.1021/bi00035a036; Bergman RN, 1997, RECENT PROG HORM RES, V52, P359; Brady MJ, 1998, J BIOL CHEM, V273, P14063, DOI 10.1074/jbc.273.23.14063; Chen MG, 1997, MOL CELL ENDOCRINOL, V135, P67, DOI 10.1016/S0303-7207(97)00191-3; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DeVente JE, 1996, J BIOL CHEM, V271, P32276, DOI 10.1074/jbc.271.50.32276; DIMITRIJEVIC SM, 1995, MOL PHARMACOL, V48, P259; Douglas DN, 1999, BBA-MOL CELL RES, V1448, P439, DOI 10.1016/S0167-4889(98)00161-X; Frevert EU, 1996, BIOCHEM J, V316, P865, DOI 10.1042/bj3160865; FUKUMOTO H, 1988, P NATL ACAD SCI USA, V85, P5434, DOI 10.1073/pnas.85.15.5434; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; Hresko RC, 1998, J BIOL CHEM, V273, P20658, DOI 10.1074/jbc.273.32.20658; JOHANNES FJ, 1995, EUR J BIOCHEM, V227, P303, DOI 10.1111/j.1432-1033.1995.tb20389.x; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; Kanety H, 1996, J BIOL CHEM, V271, P9895, DOI 10.1074/jbc.271.17.9895; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; MAGNUSON NS, 1994, SEMIN CANCER BIOL, V5, P247; MARSHALL S, 1991, J BIOL CHEM, V266, P10155; Matsuoka T, 1997, J CLIN INVEST, V99, P144, DOI 10.1172/JCI119126; Oakes ND, 1997, DIABETES, V46, P1768, DOI 10.2337/diabetes.46.11.1768; OUWENS DM, 1994, J BIOL CHEM, V269, P33116; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911; ROSSETTI L, 1995, CLIN INVEST MED, V18, P255; ROTHENBERG PL, 1995, DIABETES, V44, P802, DOI 10.2337/diabetes.44.7.802; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; THORENS B, 1990, DIABETES CARE, V13, P209, DOI 10.2337/diacare.13.3.209; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; YALOW RS, 1965, ANN NY ACAD SCI, V131, P357, DOI 10.1111/j.1749-6632.1965.tb34803.x; YAMAUCHI K, 1995, J BIOL CHEM, V270, P17716, DOI 10.1074/jbc.270.30.17716; YAMAUCHI K, 1991, ENDOCRINOL JAPON, V38, P175	34	87	90	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20880	20886		10.1074/jbc.M905410199	http://dx.doi.org/10.1074/jbc.M905410199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10764799	hybrid			2022-12-27	WOS:000088084500093
J	Chung, N; Jenkins, G; Hannun, YA; Heitman, J; Obeid, LM				Chung, N; Jenkins, G; Hannun, YA; Heitman, J; Obeid, LM			Sphingolipids signal heat stress-induced ubiquitin-dependent proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE PROTEIN; YEAST URACIL PERMEASE; SACCHAROMYCES-CEREVISIAE; DEGRADATION; GENE; RESISTANCE; MUTANT; MULTIUBIQUITINATION; ENDOCYTOSIS; INHIBITION	Sphingolipids are essential eukaryotic membrane lipids that are structurally and metabolically conserved through evolution. Sphingolipids have also been proposed to regulate eukaryotic stress responses as novel second messengers. Here we show that, in Saccharomyces cerevisiae, phytosphingosine, a putative sphingolipid second messenger, mediates heat stress signaling and activates ubiquitin-dependent proteolysis via the endocytosis vacuolar degradation and 26 S proteasome pathways. Inactivation of serine palmitoyltransferase, a key enzyme in generating endogenous phytosphingosine, prevents proteolysis during heat stress. Addition of phytosphingosine bypasses the requirement for serine palmitoyltransferase and restores proteolysis, Phytosphingosine-induced proteolysis requires multiubiquitin chain formation through the stress-responsive lysine 63 residue of ubiquitin, We propose that heat stress increases phytosphingosine and activates ubiquitin-dependent proteolysis.	Med Univ S Carolina, Ralph H Johnson Vet Adm, Charleston, SC 29403 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29403 USA; Med Univ S Carolina, Dept Biochem, Charleston, SC 29403 USA; Duke Univ, Dept Pharmacol & Canc Biol, Program Mol Canc Biol, Med Ctr, Durham, NC 27710 USA; Duke Univ, Dept Cell Biol, Med Ctr, Durham, NC 27710 USA; Duke Univ, Dept Genet, Med Ctr, Durham, NC 27710 USA; Duke Univ, Dept Microbiol, Med Ctr, Durham, NC 27710 USA; Duke Univ, Dept Med, Med Ctr, Durham, NC 27710 USA; Duke Univ, Dept Med, Howard Hughes Med Inst, Med Ctr, Durham, NC 27710 USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Medical University of South Carolina; Medical University of South Carolina; Duke University; Duke University; Duke University; Duke University; Duke University; Duke University; Howard Hughes Medical Institute	Obeid, LM (corresponding author), Med Univ S Carolina, Ralph H Johnson Vet Adm, Charleston, SC 29403 USA.		Heitman, Joseph/ABC-6006-2021	obeid, lina/0000-0002-0734-0847	NIAID NIH HHS [AI41937] Funding Source: Medline; NIA NIH HHS [AG12467] Funding Source: Medline; NIGMS NIH HHS [GM43825] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM043825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R55AG012467, R29AG012467] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Ballou L.R, 1997, SPHINGOLIPID MEDIATE, P35; BUEDE R, 1991, J BACTERIOL, V173, P4325, DOI 10.1128/JB.173.14.4325-4332.1991; CARDENAS ME, 1995, J BIOL CHEM, V270, P20997, DOI 10.1074/jbc.270.36.20997; CHEVALLIER MR, 1982, MOL CELL BIOL, V2, P977, DOI 10.1128/MCB.2.8.977; Chung N, 2000, METHOD ENZYMOL, V311, P319; Dickson RC, 1998, ANNU REV BIOCHEM, V67, P27, DOI 10.1146/annurev.biochem.67.1.27; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Galan JM, 1998, FASEB J, V12, P315, DOI 10.1096/fasebj.12.3.315; Galan JM, 1996, J BIOL CHEM, V271, P10946, DOI 10.1074/jbc.271.18.10946; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Guthrie C., 1991, METHODS ENZYMOLOGY G, V194; HAKOMORI S, 1983, HDB LIPID RES, V3, P1; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; Harlow E., 1988, ANTIBODIES LAB MANUA; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; NAGIEC MM, 1994, P NATL ACAD SCI USA, V91, P7899, DOI 10.1073/pnas.91.17.7899; ROMANOS MA, 1995, DNA CLONING, V2, P123; Sambrook J., 2002, MOL CLONING LAB MANU; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Sutterlin C, 1997, J CELL SCI, V110, P2703; VOLLAND C, 1994, J BIOL CHEM, V269, P9833; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WELLS GB, 1983, J BIOL CHEM, V258, P200	40	96	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17229	17232		10.1074/jbc.C000229200	http://dx.doi.org/10.1074/jbc.C000229200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10764732	hybrid			2022-12-27	WOS:000087485000003
J	Fortea, MI; Soler, F; Fernandez-Belda, F				Fortea, MI; Soler, F; Fernandez-Belda, F			Insight into the uncoupling mechanism of sarcoplasmic reticulum ATPase using the phosphorylating substrate UTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOPIAZONIC ACID; CALCIUM-PUMP; STEADY-STATE; PHOSPHOENZYME INTERMEDIATE; RAPID-FILTRATION; CA2+; TRANSPORT; RELEASE; CA2+-ATPASE; MEMBRANES	Ca2+ transport and UTP hydrolysis catalyzed by sarcoplasmic reticulum Ca2+-ATPase from skeletal muscle was studied. A passive Ca2+ load inside microsomal vesicles clearly decreased the net uptake rate and the final accumulation of Ca2+ but not the UTP hydrolysis rate, causing energy uncoupling. In the absence of passive leak, the Ca2+/P-i coupling ratio was 0.7-0.8. UTP hydrolysis did not maintain a rapid component of Ca2+ exchange between the cytoplasmic and lumenal compartments as occurs with ATP. The uncoupling process in the presence of UTP is associated with: (i) the absence of a steady state accumulation of ADP-insensitive phosphoenzyme; (ii) the cytoplasmic dissociation of Ca2+ bound to the ADP-sensitive phosphoenzyme; and (iii) the absence of enzyme inhibition by cyclopiazonic acid. All these characteristics confirm the lack of enzyme conformations with low Ca2+ affinity and point to the existence of an uncoupling mechanism mediated by a phosphorylated form of the enzyme. Suboptimal coupling values can be explained in molecular terms by the proposed functional model.	Univ Murcia, Edificio Vet, Dept Bioquim & Biol Mol A, E-30071 Murcia, Spain	University of Murcia	Fernandez-Belda, F (corresponding author), Univ Murcia, Edificio Vet, Dept Bioquim & Biol Mol A, Campus Espinardo, E-30071 Murcia, Spain.	fbelda@fcu.um.es						ANDERSEN JP, 1985, P NATL ACAD SCI USA, V82, P4573, DOI 10.1073/pnas.82.14.4573; BLINKS JR, 1982, PROG BIOPHYS MOL BIO, V40, P1, DOI 10.1016/0079-6107(82)90011-6; CHAMPEIL P, 1986, BIOCHEMISTRY-US, V25, P7623, DOI 10.1021/bi00371a053; de Meis L, 1973, J Biol Chem, V248, P3691; DEMEIS L, 1991, J BIOL CHEM, V266, P5736; DUGGAN PF, 1970, J GEN PHYSIOL, V56, P147, DOI 10.1085/jgp.56.2.147; DUPONT Y, 1984, ANAL BIOCHEM, V142, P504, DOI 10.1016/0003-2697(84)90496-2; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; HANSTEIN WG, 1976, BIOCHIM BIOPHYS ACTA, V456, P129, DOI 10.1016/0304-4173(76)90010-0; HASSELBACH W, 1978, BIOCHIM BIOPHYS ACTA, V515, P23, DOI 10.1016/0304-4157(78)90007-2; INESI G, 1989, J BIOL CHEM, V264, P5929; INESI G, 1988, METHOD ENZYMOL, V157, P154; Inesi G, 1978, Ann N Y Acad Sci, V307, P224, DOI 10.1111/j.1749-6632.1978.tb41947.x; INESI G, 1974, BIOCHEMISTRY-US, V13, P3298, DOI 10.1021/bi00713a019; KESSLER RJ, 1976, P NATL ACAD SCI USA, V73, P3141, DOI 10.1073/pnas.73.9.3141; LIN TI, 1977, ANAL BIOCHEM, V77, P10, DOI 10.1016/0003-2697(77)90284-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAKINOSE M, 1965, BIOCHEM Z, V343, P383; MCINTOSH DB, 1991, P NATL ACAD SCI USA, V88, P6437, DOI 10.1073/pnas.88.15.6437; MELTZER S, 1984, J BIOL CHEM, V259, P4244; NAKAMURA Y, 1991, J BIOCHEM-TOKYO, V91, P449; ORR I, 1991, BIOCHEM J, V276, P89, DOI 10.1042/bj2760089; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; PlengeTellechea F, 1997, J BIOL CHEM, V272, P2794, DOI 10.1074/jbc.272.5.2794; PUCELL A, 1971, J BIOL CHEM, V246, P3389; ROSSI B, 1979, J BIOL CHEM, V254, P2302; SCARPA A, 1972, J GEN PHYSIOL, V60, P735, DOI 10.1085/jgp.60.6.735; SCHWARTZENBACH G, 1982, HELV CHIM ACTA, V40, P1886; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1451; Soler F, 1998, BIOCHEMISTRY-US, V37, P4266, DOI 10.1021/bi971455c; SOLER F, 1990, EUR J BIOCHEM, V192, P347, DOI 10.1111/j.1432-1033.1990.tb19233.x; TAKAKUWA Y, 1981, J BIOL CHEM, V256, P2696; WAKABAYASHI S, 1986, J BIOL CHEM, V261, P9762; WAKABAYASHI S, 1987, J BIOL CHEM, V262, P11524; WEBER K, 1969, J BIOL CHEM, V244, P4406; WOLOSKER H, 1994, AM J PHYSIOL, V266, pC1376, DOI 10.1152/ajpcell.1994.266.5.C1376; YU X, 1995, J BIOL CHEM, V270, P4361, DOI 10.1074/jbc.270.9.4361	39	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12521	12529		10.1074/jbc.275.17.12521	http://dx.doi.org/10.1074/jbc.275.17.12521			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777540	hybrid			2022-12-27	WOS:000086762300024
J	Hazan-Halevy, I; Seger, R; Levy, R				Hazan-Halevy, I; Seger, R; Levy, R			The requirement of both extracellular regulated kinase and p38 mitogen-activated protein kinase for stimulation of cytosolic phospholipase A(2) activity by either Fc gamma RIIA or Fc gamma RIIIB in human neutrophils - A possible role for Pyk2 but not for the Grb2-Sos-Shc complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR CROSS-LINKING; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; RESPIRATORY BURST; NADPH OXIDASE; COUPLED RECEPTORS; MAP KINASE; DEPENDENT ACTIVATION; MURINE MACROPHAGES; TNF-ALPHA	The signal transduction pathways initiated by opsonized zymosan (OZ) leading to activation of cytosolic phospholipase A(2) (cPLA(2)) in human neutrophils remain obscure. In a previous study, we showed that the activation of cPLA(2) by OZ is tyrosine kinase-dependent. The present study demonstrates that the signals initiated by OZ involve activation of tyrosine kinase Pyk2 but not the formation of the adhesion protein complex, Shc-Grb2-Sos. Stimulation of cPLA(2) activity by OZ is mediated by Fc gamma receptors (Fc gamma Rs) and not by complement receptors for the C3b protein. Cross-linking of Fc gamma RILA or Fc gamma RIIIB induces p38 mitogen-activated protein (MAP) kinase and extracellular regulated kinase (ERK) phosphorylation. The kinetics of cPLA(2) activity stimulated by either of the Fc gamma Rs or by both is similar to that of p38 MAP kinase and was detected as early as 15 s after stimulation, maintained a plateau for 10 min, and decreased thereafter. ERK activation was detected also within 15 s but decreased significantly 5 min after stimulation. The MEK inhibitor, PD-098059, or the p38 MAP kinase inhibitor, SB-203580, caused a partial inhibition during the time course of cPLA(2) activity, whereas their combination caused a total inhibition. Thus, although ERK activation is significantly shorter than that of p38 MAP kinase, it is equally required for activation and maintenance of cPLA(2) activity by occupancy of a single receptor, Fc gamma RILA or Fc gamma RIIIB.	Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Biochem, Infect Dis Lab, IL-84105 Beer Sheva, Israel; Soroka Med Ctr, IL-84105 Beer Sheva, Israel; Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	Ben Gurion University; Ben Gurion University; Soroka Medical Center; Weizmann Institute of Science	Levy, R (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Biochem, Infect Dis Lab, IL-84105 Beer Sheva, Israel.	ral@bgumail.bgu.ac.i1						ANDERSON CL, 1990, J EXP MED, V171, P1333, DOI 10.1084/jem.171.4.1333; Borsch-Haubold AG, 1998, BIOCHEM SOC T, V26, P350; BorschHaubold AG, 1997, EUR J BIOCHEM, V245, P751, DOI 10.1111/j.1432-1033.1997.t01-1-00751.x; BOYUM A, 1976, SCAND J IMMUNOL, P9, DOI 10.1111/j.1365-3083.1976.tb03851.x; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; Dana R, 1998, J BIOL CHEM, V273, P441, DOI 10.1074/jbc.273.1.441; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; EDBERG JC, 1994, J IMMUNOL, V152, P5826; EDBERG JC, 1992, IMMUNOL RES, V11, P239, DOI 10.1007/BF02919130; ERNST JD, 1995, BIOCHEM BIOPH RES CO, V209, P1032, DOI 10.1006/bbrc.1995.1601; FEARON DT, 1980, J EXP MED, V152, P20, DOI 10.1084/jem.152.1.20; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; Fuortes M, 1999, J CLIN INVEST, V104, P327, DOI 10.1172/JCI6018; Galandrini R, 1997, J IMMUNOL, V159, P3767; GHAZIZADEH S, 1994, J IMMUNOL, V152, P30; GHAZIZADEH S, 1995, BIOCHEM J, V305, P669, DOI 10.1042/bj3050669; Green JM, 1997, J CELL BIOL, V139, P1209, DOI 10.1083/jcb.139.5.1209; HAMADA F, 1993, P NATL ACAD SCI USA, V90, P6305, DOI 10.1073/pnas.90.13.6305; Hazan I, 1997, BIOCHEM J, V326, P867, DOI 10.1042/bj3260867; HUIZINGA TWJ, 1989, J IMMUNOL, V142, P2365; HUIZINGA TWJ, 1990, J IMMUNOL, V144, P1432; HUNDT M, 1992, EUR J IMMUNOL, V22, P811, DOI 10.1002/eji.1830220327; Kiefer F, 1998, MOL CELL BIOL, V18, P4209, DOI 10.1128/MCB.18.7.4209; KIENER PA, 1993, J BIOL CHEM, V268, P24442; KIMBERLY RP, 1990, J EXP MED, V171, P1239, DOI 10.1084/jem.171.4.1239; Lang ML, 1997, BIOCHEM SOC T, V25, pS333, DOI 10.1042/bst025333s; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVY R, 1991, J IMMUNOL, V147, P3066; LIANG L, 1995, BIOCHEM J, V306, P489, DOI 10.1042/bj3060489; LIAO F, 1992, P NATL ACAD SCI USA, V89, P3659, DOI 10.1073/pnas.89.8.3659; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MACKENZIE SJ, 1995, BIOCHEM J, V306, P519, DOI 10.1042/bj3060519; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; Miyazaki T, 1998, GENE DEV, V12, P770, DOI 10.1101/gad.12.6.770; Neet K, 1996, GENES CELLS, V1, P147, DOI 10.1046/j.1365-2443.1996.d01-234.x; Nick JA, 1997, J CLIN INVEST, V99, P975, DOI 10.1172/JCI119263; ODIN JA, 1991, SCIENCE, V254, P1785, DOI 10.1126/science.1837175; Okazaki H, 1997, J BIOL CHEM, V272, P32443, DOI 10.1074/jbc.272.51.32443; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; Park RK, 1996, J BIOL CHEM, V271, P13342, DOI 10.1074/jbc.271.23.13342; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; Rane MJ, 1997, J IMMUNOL, V159, P5070; RANKIN BM, 1993, J IMMUNOL, V150, P605; Rose DM, 1997, J IMMUNOL, V158, P3433; ROSS GD, 1982, J EXP MED, V155, P96, DOI 10.1084/jem.155.1.96; SALMON JE, 1991, J IMMUNOL, V146, P997; Sanghera JS, 1996, J IMMUNOL, V156, P4457; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SMITH JA, 1994, J LEUKOCYTE BIOL, V56, P672, DOI 10.1002/jlb.56.6.672; Sylvestre D, 1996, J EXP MED, V184, P2385, DOI 10.1084/jem.184.6.2385; Syrbu SI, 1999, J IMMUNOL, V162, P2334; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Torres M, 1999, ARCH BIOCHEM BIOPHYS, V366, P231, DOI 10.1006/abbi.1999.1225; Trotta R, 1996, J EXP MED, V184, P1027, DOI 10.1084/jem.184.3.1027; Tsuchida M, 1999, J BIOL CHEM, V274, P6735, DOI 10.1074/jbc.274.10.6735; Vossebeld PJM, 1997, INT J BIOCHEM CELL B, V29, P465, DOI 10.1016/S1357-2725(96)00160-4; Vossebeld PJM, 1997, BIOCHEM J, V323, P87, DOI 10.1042/bj3230087; VOSSEBELD PJM, 1995, J BIOL CHEM, V270, P10671, DOI 10.1074/jbc.270.18.10671; WALKER BAM, 1991, J IMMUNOL, V146, P735; Waterman WH, 1996, BIOCHEM J, V319, P17, DOI 10.1042/bj3190017; WIJKANDER J, 1995, J BIOL CHEM, V270, P26543, DOI 10.1074/jbc.270.44.26543; Yagisawa M, 1999, EXP HEMATOL, V27, P1063, DOI 10.1016/S0301-472X(99)00040-5; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; ZHOU BP, 1995, J BIOL CHEM, V270, P23653, DOI 10.1074/jbc.270.40.23653; ZHOU MJ, 1994, J CELL BIOL, V125, P1407, DOI 10.1083/jcb.125.6.1407	68	59	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12416	12423		10.1074/jbc.275.17.12416	http://dx.doi.org/10.1074/jbc.275.17.12416			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777525	hybrid			2022-12-27	WOS:000086762300009
J	Sato, R; Okamoto, A; Inoue, J; Miyamoto, W; Sakai, Y; Emoto, N; Shimano, H; Maeda, M				Sato, R; Okamoto, A; Inoue, J; Miyamoto, W; Sakai, Y; Emoto, N; Shimano, H; Maeda, M			Transcriptional regulation of the ATP citrate-lyase gene by sterol regulatory element-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID BIOSYNTHESIS; TRANSGENIC MICE; CULTURED-CELLS; EXPRESSION; CHOLESTEROL; ACTIVATION; SYNTHASE; SREBP-1; REGION; LIVER	In an attempt to identify unknown target genes for SREBP-1, total RNA from a stable Chinese hamster ovary cell line (CHO-487) expressing a mature form of human SREBP-1a (amino acids 1-487) with a LacSwitch Inducible Mammalian Expression System was subjected to a polymerase chain reaction subtraction method. One of the fragments was found to have 90 and 86% homology with rat and human ATP citrate-lyase (ACL) cDNA, respectively. When Hep G2 cells are cultured under either sterol-loaded or -depleted conditions, expression of the gene is induced approximately 2-3-fold by sterol depletion. To investigate the direct effect of SREBP-1a on transcription, luciferase assays using the promoter of the human ACL gene were performed. These deletion studies indicated that a minimum 160-base pair segment contains the information required for the transcriptional regulation brought about by enforced expression of SREBP-1a. Luciferase assays using mutant reporter genes revealed that SREBP-dependent transcriptional regulation is mediated by two nearby motifs, the SREBP-binding site (a TCAGGCTAG sequence) and the NF-Y-binding site (a CCAAT box). It was confirmed by gel mobility shift assays that recombint SREBP-1a binds to the sequence. Data from studies with transgenic mice and reporter assays show that the ACL gene promoter is activated by SREBP-1a more strongly than SREBP-2 in contrast to the HMG CoA synthase and LDL receptor gene promoters, which exhibit the same preference for the two factors. Therefore, SREBPs transcriptionally regulates ACL enzyme activity, which generates the cytosolic acetyl CoA required for both cholesterol and fatty acid synthesis.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo 1138657, Japan; Osaka Univ, Grad Sch Pharmaceut Sci, Biochem & Mol Biol Lab, Suita, Osaka 5650871, Japan; Kobe Univ, Sch Med, Int Ctr Med Res, Kobe, Hyogo 6500017, Japan; Univ Tokyo, Fac Med, Dept Metab Dis, Tokyo 1138655, Japan	University of Tokyo; Osaka University; Kobe University; University of Tokyo	Sato, R (corresponding author), 1-1-1 Yayoi,Bunkyo Ku, Tokyo 1138657, Japan.	aroysato@mail.ccc.u-tokyo.ac.jp	INOUE, Jun/O-7352-2016; Shimano, Hitoshi/V-1761-2019; Shimano, Hitoshi/AAI-5648-2020	INOUE, Jun/0000-0003-4145-3754; Shimano, Hitoshi/0000-0002-5562-5572; Emoto, Noriaki/0000-0001-6673-2616				Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CHEN IT, 1986, P NATL ACAD SCI USA, V83, P6907, DOI 10.1073/pnas.83.18.6907; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Fukuda H, 1996, FEBS LETT, V380, P204, DOI 10.1016/0014-5793(96)00031-2; Fukuda H, 1997, EUR J BIOCHEM, V247, P497, DOI 10.1111/j.1432-1033.1997.00497.x; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; Inoue J, 1998, J BIOCHEM-TOKYO, V123, P1191; KIM KS, 1994, BIOCHEM J, V302, P759, DOI 10.1042/bj3020759; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; Park SW, 1997, BBA-GENE STRUCT EXPR, V1353, P236, DOI 10.1016/S0167-4781(97)00094-8; RUSS AP, 1992, BIOCHIM BIOPHYS ACTA, V1132, P329, DOI 10.1016/0167-4781(92)90172-V; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sato R, 1999, J BIOL CHEM, V274, P24714, DOI 10.1074/jbc.274.35.24714; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; SATO R, 1994, J BIOL CHEM, V269, P17267; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WANG Z, 1991, P NATL ACAD SCI USA, V88, P11505, DOI 10.1073/pnas.88.24.11505; Yahagi N, 1999, J BIOL CHEM, V274, P35840, DOI 10.1074/jbc.274.50.35840; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	28	107	109	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12497	12502		10.1074/jbc.275.17.12497	http://dx.doi.org/10.1074/jbc.275.17.12497			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777536	hybrid			2022-12-27	WOS:000086762300020
J	Dionne, MA; Sanchez, A; Compton, DA				Dionne, MA; Sanchez, A; Compton, DA			ch-TOGp is required for microtubule aster formation in a mammalian mitotic extract	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINESIN-RELATED PROTEIN; XENOPUS EGG EXTRACTS; SPINDLE POLE BODY; PLUS-END; CYTOPLASMIC DYNEIN; SELF-ORGANIZATION; CELL-CYCLE; CENTROSOMES; MITOSIS; DROSOPHILA	Microtubules induced to polymerize with taxol in a mammalian mitotic extract organize into aster-like arrays in a centrosome-independent process that is driven by microtubule motors and structural proteins. These microtubule asters accurately reflect the noncentrosomal aspects of mitotic spindle pole formation. We show here that colonic-hepatic tumor-overexpressed gene (ch-TOGp) is an abundant component of these asters. We have prepared ch-TOGp-specific antibodies and show by immunodepletion that ch-TOGp is required for microtubule aster assembly. Microtubule polymerization is severely inhibited in the absence of ch-TOGp, and silver stain analysis of the ch-TOGp immunoprecipitate indicates that it is not present in a preformed complex and is the only protein removed from the extract during immunodepletion. Furthermore, the reduction in microtubule polymerization efficiency in the absence of ch-TOGp is dependent on ATP. These results demonstrate that ch-TOGp is a major constituent of microtubule asters assembled in a mammalian mitotic extract and that it is required for robust microtubule polymerization in an ATP-dependent manner in this system even though taxol is present. These data, coupled with biochemical and genetic data derived from analysis of ch-TOGp-related proteins in other organisms, indicate that ch-TOGp is a key factor regulating microtubule dynamics during mitosis.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Compton, DA (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA.				NIGMS NIH HHS [GM51542] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM051542, R01GM051542] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLANGY A, 1995, CELL, V84, P49; Charrasse S, 1996, NEUROSCI LETT, V212, P119, DOI 10.1016/0304-3940(96)12789-0; Charrasse S, 1998, J CELL SCI, V111, P1371; CHARRASSE S, 1995, EUR J BIOCHEM, V234, P406, DOI 10.1111/j.1432-1033.1995.406_b.x; Compton DA, 1998, J CELL SCI, V111, P1477; Cullen CF, 1999, J CELL BIOL, V146, P1005, DOI 10.1083/jcb.146.5.1005; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Dionne MA, 1999, CELL MOTIL CYTOSKEL, V42, P189, DOI 10.1002/(SICI)1097-0169(1999)42:3<189::AID-CM3>3.0.CO;2-X; Endow SA, 1997, J CELL BIOL, V137, P1321, DOI 10.1083/jcb.137.6.1321; GAGLIO T, 1995, J CELL BIOL, V131, P693, DOI 10.1083/jcb.131.3.693; Gaglio T, 1997, J CELL BIOL, V138, P1055, DOI 10.1083/jcb.138.5.1055; Gaglio T, 1996, J CELL BIOL, V135, P399, DOI 10.1083/jcb.135.2.399; GARD DL, 1987, J CELL BIOL, V105, P2203, DOI 10.1083/jcb.105.5.2203; Heald R, 1997, J CELL BIOL, V138, P615, DOI 10.1083/jcb.138.3.615; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; INOUE S, 1995, MOL BIOL CELL, V6, P1619, DOI 10.1091/mbc.6.12.1619; Matthews LR, 1998, J CELL BIOL, V141, P1159, DOI 10.1083/jcb.141.5.1159; Matthies HJG, 1996, J CELL BIOL, V134, P455, DOI 10.1083/jcb.134.2.455; MAZIA D, 1984, EXP CELL RES, V153, P1, DOI 10.1016/0014-4827(84)90442-7; McIntosh J.R., 1983, Modern Cell Biology, V2, P115; MCINTOSH JR, 1989, SCIENCE, V246, P622; McNally FJ, 1996, CURR OPIN CELL BIOL, V8, P23, DOI 10.1016/S0955-0674(96)80044-5; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; Mountain V, 1999, J CELL BIOL, V147, P351, DOI 10.1083/jcb.147.2.351; NABESHIMA K, 1995, GENE DEV, V9, P1572, DOI 10.1101/gad.9.13.1572; OLMSTED JB, 1986, ANNU REV CELL BIOL, V2, P421, DOI 10.1146/annurev.cb.02.110186.002225; Palazzo RE, 1999, J CELL SCI, V112, P1291; SLUDER G, 1985, J CELL BIOL, V100, P897, DOI 10.1083/jcb.100.3.897; VASQUEZ RJ, 1994, J CELL BIOL, V127, P985, DOI 10.1083/jcb.127.4.985; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; Walczak CE, 1997, J CELL BIOL, V136, P859, DOI 10.1083/jcb.136.4.859; Wang PJJ, 1997, J CELL BIOL, V139, P1271, DOI 10.1083/jcb.139.5.1271; Wang XM, 1996, J CELL BIOL, V132, P345, DOI 10.1083/jcb.132.3.345; Whitehead CM, 1998, J CELL SCI, V111, P2551; WORDEMAN L, 1995, J CELL BIOL, V128, P95, DOI 10.1083/jcb.128.1.95	38	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12346	12352		10.1074/jbc.275.16.12346	http://dx.doi.org/10.1074/jbc.275.16.12346			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766876	hybrid			2022-12-27	WOS:000086695500111
J	Learn, CA; Mizel, SB; McCall, CE				Learn, CA; Mizel, SB; McCall, CE			mRNA and protein stability regulate the differential expression of pro- and anti-inflammatory genes in endotoxin-tolerant THP-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1 RECEPTOR ANTAGONIST; TUMOR-NECROSIS-FACTOR; MESSENGER-RNA DEGRADATION; HUMAN MONOCYTES; NUCLEAR FACTOR; LIPOPOLYSACCHARIDE; SEPSIS; BLOOD; INDUCTION; SITE	The products of proinflammatory genes such as interleukin-1 beta (IL-1 beta) and cyclooxygenase 2 (COX-2) initiate many of the events associated with sepsis. Transcription of these genes is subsequently down-regulated, whereas expression of anti-inflammatory genes such as secretory interleukin-1 receptor antagonist (sIL-1 RA) is maintained. Differential expression is associated with endotoxin tolerance, a cellular phenomenon common to sepsis and characterized by reduced proinflammatory gene expression after repeated exposure to lipopolysaccharide. As a model for endotoxin tolerance, we examined the expression of COX-2 and sIL-1 RA in a human promonocyte cell line, THP-1. We observed a 5-fold decrease in COX-2 protein in endotoxin-tolerant cells relative to control cells. In contrast, sIL-1 RA protein in creased 5-fold in control and tolerant cells and remained elevated. Decreased COX-2 production is due to repressed transcription and not enhanced mRNA degradation. In addition, COX-2 protein is turned over rapidly. Transcription of sIL-1 RA is also repressed during tolerance. However, sIL-1 RA mRNA is degraded more slowly than COX-2 mRNA, allowing continued synthesis of sIL-1 RA protein that is very stable. These results indicate that differential expression during endotoxin tolerance occurs by transcriptional repression of COX-2 and by protein and mRNA stabilization of sIL-1 RA.	Wake Forest Univ, Bowman Gray Sch Med, Dept Med, Infect Dis Sect, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	McCall, CE (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Med, Infect Dis Sect, Med Ctr Blvd, Winston Salem, NC 27157 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL050395, R01HL029293] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI009169, R01AI009169] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-50395, HL-29293] Funding Source: Medline; NIAID NIH HHS [AI-09169] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AREND WP, 1991, J IMMUNOL, V147, P1530; BEESON PB, 1947, J EXP MED, V86, P29, DOI 10.1084/jem.86.1.29; BEUTLER B, 1991, J CLIN INVEST, V87, P1336, DOI 10.1172/JCI115137; BONE RC, 1991, INFECT DIS CLIN AM, V5, P739; BROOKS JW, 1995, MOL IMMUNOL, V32, P779, DOI 10.1016/0161-5890(95)00055-J; CASSATELLA MA, 1994, J EXP MED, V179, P1695, DOI 10.1084/jem.179.5.1695; Colotta F, 1996, J IMMUNOL, V156, P2534; DEBONT ESJM, 1995, PEDIATR RES, V37, P626, DOI 10.1203/00006450-199505000-00012; Durando M, 1998, SHOCK, V9, P359, DOI 10.1097/00024382-199805000-00008; FISHER CJ, 1994, CIRC SHOCK, V44, P1; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Kastelic T, 1996, CYTOKINE, V8, P751, DOI 10.1006/cyto.1996.0100; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARUE KEA, 1994, J EXP MED, V180, P2269, DOI 10.1084/jem.180.6.2269; Lopez S, 1997, J BIOL CHEM, V272, P22788, DOI 10.1074/jbc.272.36.22788; MALYAK M, 1994, J CLIN IMMUNOL, V14, P20, DOI 10.1007/BF01541172; MCCALL CE, 1993, J CLIN INVEST, V91, P853, DOI 10.1172/JCI116306; Ogura S, 1999, SHOCK, V12, P105, DOI 10.1097/00024382-199908000-00003; Olszyna DP, 1998, INFECT IMMUN, V66, P3527, DOI 10.1128/IAI.66.8.3527-3534.1998; Porreca E, 1996, IMMUNOLOGY, V89, P424, DOI 10.1046/j.1365-2567.1996.d01-753.x; ROGY MA, 1994, J AM COLL SURGEONS, V178, P132; Sciorra VA, 1996, J BIOL CHEM, V271, P14226, DOI 10.1074/jbc.271.24.14226; SHIRAKAWA F, 1993, MOL CELL BIOL, V13, P1332, DOI 10.1128/MCB.13.3.1332; Shoup M, 1998, J TRAUMA, V45, P215, DOI 10.1097/00005373-199808000-00003; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SMITH MF, 1994, J IMMUNOL, V153, P3584; vanderPoll T, 1996, J INFECT DIS, V174, P1356, DOI 10.1093/infdis/174.6.1356; Yoza BK, 1998, CLIN DIAGN LAB IMMUN, V5, P281, DOI 10.1128/CDLI.5.3.281-287.1998; ZIEGLERHEITBROCK HWL, 1992, IMMUNOLOGY, V75, P264; ZIEGLERHEITBROCK HWL, 1994, J BIOL CHEM, V269, P17001; ZUCKERMAN SH, 1991, INFECT IMMUN, V59, P2774, DOI 10.1128/IAI.59.8.2774-2780.1991	31	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12185	12193		10.1074/jbc.275.16.12185	http://dx.doi.org/10.1074/jbc.275.16.12185			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766854	hybrid			2022-12-27	WOS:000086695500089
J	Rivas, G; Lopez, A; Mingorance, J; Ferrandiz, MJ; Zorrilla, S; Minton, AP; Vicente, M; Andreu, JM				Rivas, G; Lopez, A; Mingorance, J; Ferrandiz, MJ; Zorrilla, S; Minton, AP; Vicente, M; Andreu, JM			Magnesium-induced linear self-association of the FtsZ bacterial cell division protein monomer - The primary steps for FtsZ assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-BINDING; TUBULIN DOUBLE RINGS; CALF BRAIN TUBULIN; ESCHERICHIA-COLI; GTP HYDROLYSIS; GDP-TUBULIN; ACTIN POLYMERIZATION; INORGANIC-PHOSPHATE; CIRCULAR-DICHROISM; GENOME SEQUENCE	The bacterial cell division protein FtsZ from Escherichia coli has been purified with a new calcium precipitation method. The protein contains one GDP and one Mg2+ bound, it shows GTPase activity, and requires GTP and Mg2+ to polymerize into long thin filaments at pH 6.5. FtsZ, with moderate ionic strength and low Mg2+ concentrations, at pH 7.5, is a compact and globular monomer, Mg2+ induces FtsZ self-association into oligomers, which has been studied by sedimentation equilibrium over a wide range of Mg2+ and FtsZ concentrations, The oligomer formation mechanism is best described as an indefinite self-association, with binding of an additional Mg2+ for each FtsZ monomer added to the growing oligomer, and a slight gradual decrease of the affinity of addition of a protomer with increasing oligomer size. The sedimentation velocity of FtsZ oligomer populations is compatible with a linear single-stranded arrangement of FtsZ monomers and a spacing of 4 nm. It is proposed that these FtsZ oligomers and the polymers formed under assembly conditions share a similar axial interaction between monomers (like in the case of tubulin, the eukaryotic homolog of FtsZ). Similar mechanisms may apply to FtsZ assembly in vivo, but additional factors, such as macromolecular crowding, nucleoid occlusion, or specific interactions with other cellular components active in septation have to be invoked to explain FtsZ assembly into a division ring.	CSIC, Ctr Invest Biol, E-28006 Madrid, Spain; CSIC, Ctr Nacl Biotecnol, E-28006 Madrid, Spain; NIDDKD, NIH, Bethesda, MD 20892 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Rivas, G (corresponding author), CSIC, Ctr Invest Biol, Velazquez 144, E-28006 Madrid, Spain.	grivas@cib.csic.es	Mingorance, Jesus/B-7562-2009; Rivas, German/AFL-7528-2022; Ferrandiz, Maria-Jose/K-2820-2014; Rivas, German/AAG-7458-2022; Zorrilla, Silvia/J-9771-2014	Mingorance, Jesus/0000-0001-6173-5711; Rivas, German/0000-0003-3450-7478; Ferrandiz, Maria-Jose/0000-0003-1428-9506; Rivas, German/0000-0003-3450-7478; Andreu, Jose M/0000-0001-8064-6933; Minton, Allen/0000-0001-8459-1247; Zorrilla, Silvia/0000-0002-6309-9058				ANDREU JM, 1986, METHOD ENZYMOL, V130, P47; BI E, 1991, NATURE, V354, P161, DOI 10.1038/354161a0; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BLOOMFIE.V, 1967, BIOPOLYMERS, V5, P135, DOI 10.1002/bip.1967.360050202; Bramhill D, 1997, ANNU REV CELL DEV BI, V13, P395, DOI 10.1146/annurev.cellbio.13.1.395; CANTOR CR, 1980, BIOPHYSICAL CHEM, V2, P539; Carlier MF, 1991, CURR OPIN CELL BIOL, V3, P12, DOI 10.1016/0955-0674(91)90160-Z; CHANG CF, 1986, J BACTERIOL, V167, P935, DOI 10.1128/jb.167.3.935-939.1986; Charles B., 1997, PERKIN ELMER CORP, V3, P2; CHATELIER RC, 1987, BIOPHYS CHEM, V28, P121, DOI 10.1016/0301-4622(87)80081-9; COOPER JA, 1982, METHOD ENZYMOL, V85, P182; CORREIA JJ, 1988, J BIOL CHEM, V263, P10681; CORREIA JJ, 1987, J BIOL CHEM, V262, P17278; DEBOER P, 1992, NATURE, V359, P254, DOI 10.1038/359254a0; Den Blaauwen T, 1999, J BACTERIOL, V181, P5167, DOI 10.1128/JB.181.17.5167-5175.1999; dePereda JM, 1996, BIOCHEMISTRY-US, V35, P14203, DOI 10.1021/bi961357b; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Diaz JF, 1996, BIOPHYS J, V70, P2408, DOI 10.1016/S0006-3495(96)79809-0; DIAZ JF, 1994, J MOL BIOL, V238, P214, DOI 10.1006/jmbi.1994.1282; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P2747, DOI 10.1021/bi00062a003; DRECHSEL DN, 1994, CURR BIOL, V4, P1053, DOI 10.1016/S0960-9822(00)00243-8; Erickson HP, 1996, P NATL ACAD SCI USA, V93, P519, DOI 10.1073/pnas.93.1.519; Erickson HP, 1996, J CELL BIOL, V135, P5, DOI 10.1083/jcb.135.1.5; ERICKSON HP, 1995, CELL, V80, P367, DOI 10.1016/0092-8674(95)90486-7; Erickson HP, 1997, TRENDS CELL BIOL, V7, P362, DOI 10.1016/S0962-8924(97)01108-2; FASMAN GD, 1992, PRACTICAL HDB BIOCH, P81; FRIGON RP, 1975, BIOCHEMISTRY-US, V14, P4567, DOI 10.1021/bi00692a002; FRIGON RP, 1975, BIOCHEMISTRY-US, V14, P4559, DOI 10.1021/bi00692a001; Hale CA, 1997, CELL, V88, P175, DOI 10.1016/S0092-8674(00)81838-3; HOENIG M, 1989, J BIOCHEM BIOPH METH, V19, P249, DOI 10.1016/0165-022X(89)90031-6; HOWARD WD, 1986, BIOCHEMISTRY-US, V25, P8292, DOI 10.1021/bi00373a025; JONES CA, 1984, EMBO J, V3, P1181, DOI 10.1002/j.1460-2075.1984.tb01948.x; Kalman S, 1999, NAT GENET, V21, P385, DOI 10.1038/7716; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LEE JC, 1977, BIOCHEMISTRY-US, V16, P1754, DOI 10.1021/bi00627a037; Levin PA, 1999, P NATL ACAD SCI USA, V96, P9642, DOI 10.1073/pnas.96.17.9642; LOBERT S, 1995, BIOCHEMISTRY-US, V34, P8050, DOI 10.1021/bi00025a011; Lowe J, 1998, NATURE, V391, P203, DOI 10.1038/34472; Lowe J, 1999, EMBO J, V18, P2364, DOI 10.1093/emboj/18.9.2364; Lu CL, 1998, CELL MOTIL CYTOSKEL, V40, P71, DOI 10.1002/(SICI)1097-0169(1998)40:1<71::AID-CM7>3.3.CO;2-Z; Lu CL, 1998, METHOD ENZYMOL, V298, P305, DOI 10.1016/S0076-6879(98)98027-2; Lutkenhaus J, 1997, ANNU REV BIOCHEM, V66, P93, DOI 10.1146/annurev.biochem.66.1.93; Margolin W, 1998, TRENDS MICROBIOL, V6, P233, DOI 10.1016/S0966-842X(98)01280-3; MARTIN MT, 1988, METHOD ENZYMOL, V158, P365, DOI 10.1016/0076-6879(88)58068-0; MELKI R, 1989, BIOCHEMISTRY-US, V28, P9143, DOI 10.1021/bi00449a028; Menendez M, 1998, J BIOL CHEM, V273, P167, DOI 10.1074/jbc.273.1.167; Minton A.P., 1994, MODERN ANAL ULTRACEN, P81; Minton AP, 1997, CURR OPIN BIOTECH, V8, P65, DOI 10.1016/S0958-1669(97)80159-0; Mukherjee A, 1999, J BACTERIOL, V181, P823, DOI 10.1128/JB.181.3.823-832.1999; MUKHERJEE A, 1994, J BACTERIOL, V176, P2754, DOI 10.1128/JB.176.9.2754-2758.1994; MUKHERJEE A, 1993, P NATL ACAD SCI USA, V90, P1053, DOI 10.1073/pnas.90.3.1053; Mukherjee A, 1998, P NATL ACAD SCI USA, V95, P2885, DOI 10.1073/pnas.95.6.2885; Mukherjee A, 1998, METHOD ENZYMOL, V298, P296, DOI 10.1016/S0076-6879(98)98026-0; Mukherjee A, 1998, EMBO J, V17, P462, DOI 10.1093/emboj/17.2.462; Muller-Reichert T, 1998, P NATL ACAD SCI USA, V95, P3661, DOI 10.1073/pnas.95.7.3661; Muramatsu N, 1989, J Mol Recognit, V1, P166, DOI 10.1002/jmr.300010404; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; OLMSTED JB, 1973, BIOCHEMISTRY-US, V12, P4282, DOI 10.1021/bi00745a037; OZOLS J, 1990, METHOD ENZYMOL, V182, P587; Pace C. N., 1997, PROTEIN STRUCTURE PR, P253; PADAN E, 1987, J MEMBRANE BIOL, V95, P189, DOI 10.1007/BF01869481; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; PETERMAN BF, 1979, ANAL BIOCHEM, V93, P442, DOI 10.1016/S0003-2697(79)80176-1; Philo JS, 1997, BIOPHYS J, V72, P435, DOI 10.1016/S0006-3495(97)78684-3; PIA J, 1991, MOL MICROBIOL, V5, P1681; RayChaudhuri D, 1999, EMBO J, V18, P2372, DOI 10.1093/emboj/18.9.2372; RAYCHAUDHURI D, 1992, NATURE, V359, P251, DOI 10.1038/359251a0; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; Record MT, 1998, TRENDS BIOCHEM SCI, V23, P190, DOI 10.1016/S0968-0004(98)01207-9; Rothfield LI, 1996, CELL, V84, P183, DOI 10.1016/S0092-8674(00)80971-X; Rothfield LI, 1997, CELL, V88, P581, DOI 10.1016/S0092-8674(00)81899-1; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHEARWIN KE, 1992, BIOCHEMISTRY-US, V33, P885; Sossong TM, 1999, BIOCHEMISTRY-US, V38, P14843, DOI 10.1021/bi990917e; STAFFORD WF, 1994, METHOD ENZYMOL, V240, P478; Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754; Tanford C, 1970, Adv Protein Chem, V24, P1, DOI 10.1016/S0065-3233(08)60241-7; Vicente M, 1996, MOL MICROBIOL, V20, P1, DOI 10.1111/j.1365-2958.1996.tb02482.x; WAGGONER A, 1995, METHOD ENZYMOL, V246, P362; Wang X, 1996, MOL MICROBIOL, V21, P313, DOI 10.1046/j.1365-2958.1996.6421360.x; Wang XD, 1997, J BACTERIOL, V179, P5551, DOI 10.1128/jb.179.17.5551-5559.1997; WILLIAMS RC, 1982, METHOD ENZYMOL, V85, P376; WOLDRINGH CL, 1991, RES MICROBIOL, V142, P309, DOI 10.1016/0923-2508(91)90046-D; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Yu XC, 1997, EMBO J, V16, P5455, DOI 10.1093/emboj/16.17.5455; ZIMMERMAN SB, 1991, J MOL BIOL, V222, P599, DOI 10.1016/0022-2836(91)90499-V; ZIMMERMAN SB, 1993, ANNU REV BIOPH BIOM, V22, P27, DOI 10.1146/annurev.bb.22.060193.000331	92	150	151	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11740	11749		10.1074/jbc.275.16.11740	http://dx.doi.org/10.1074/jbc.275.16.11740			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766796	Green Submitted, hybrid			2022-12-27	WOS:000086695500031
J	Romero, PA; Vallee, F; Howell, PL; Herscovics, A				Romero, PA; Vallee, F; Howell, PL; Herscovics, A			Mutation of Arg(273) to Leu alters the specificity of the yeast N-glycan processing class I alpha 1,2-mannosidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; SACCHAROMYCES-CEREVISIAE; ALPHA-MANNOSIDASE; BIOSYNTHESIS; PURIFICATION; EXPRESSION; MURINE	Class I alpha 1,2-mannosidases (glycosyl hydrolase family 47) involved in the processing of N-glycans during glycoprotein maturation have different specificities, Enzymes in the endoplasmic reticulum of yeast and mammalian cells remove a single mannose from Man(9)GlcNAc(2) to form Man(8)GlcNAc(2) isomer B (lacking the alpha 1, 2-mannose residue of the middle alpha 1, 3-arm), whereas other alpha 1,2-mannosidases, including Golgi alpha 1,2-mannosidases IA and IB, can convert Man(9)GlcNAc(2) to Man(5)GlcNAc(2). In the present work, it is demonstrated that with a single mutation in its catalytic domain (Arg(273) --> Leu) the yeast endoplasmic reticulum alpha 1,2-mannosidase acquires the ability to transform Man(9)GlcNAc to Man(5)GlcNAc. High resolution proton nuclear magnetic resonance analysis of the products shows that the order of removal of mannose from Man(9)GlcNAc is different from that of other alpha 1,2-mannosidases that remove four mannose from Man(9)GlcNAc. These results demonstrate that Arg(273) is in part responsible for the specificity of the endoplasmic reticulum alpha 1,2-mannosidase and that small differences in non-conserved amino acids interacting with the oligosaccharide substrate in the active site of class I alpha 1,2-mannosidases are responsible for the different specificities of these enzymes.	McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Fac Med, Dept Biochem, Toronto, ON M5S 1A8, Canada	McGill University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Herscovics, A (corresponding author), McGill Univ, McGill Canc Ctr, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.				NIGMS NIH HHS [GM31265] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUSE E, 1992, EUR J BIOCHEM, V208, P451, DOI 10.1111/j.1432-1033.1992.tb17207.x; BRISSON JR, 1983, BIOCHEMISTRY-US, V22, P3680, DOI 10.1021/bi00284a022; BYRD JC, 1982, J BIOL CHEM, V257, P4657; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Gonzalez DS, 1999, J BIOL CHEM, V274, P21375, DOI 10.1074/jbc.274.30.21375; GREMBLAY LO, 1999, GLYCOBIOLOGY, V9, P1073; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; Herscovics A, 1999, BBA-GEN SUBJECTS, V1473, P96, DOI 10.1016/S0304-4165(99)00171-3; Herscovics A, 1999, BBA-GEN SUBJECTS, V1426, P275, DOI 10.1016/S0304-4165(98)00129-9; HOMANS SW, 1987, BIOCHEMISTRY-US, V26, P6649, DOI 10.1021/bi00395a014; Ichishima E, 1999, BIOCHEM J, V339, P589, DOI 10.1042/0264-6021:3390589; JELINEKKELLY S, 1985, J BIOL CHEM, V260, P2253; KAWAR Z, 2000, IN PRESS GLYCOBIOLOG; LAL A, 1994, J BIOL CHEM, V269, P9872; Lal A, 1998, GLYCOBIOLOGY, V8, P981, DOI 10.1093/glycob/8.10.981; LIPARI F, 1995, BIOCHEM BIOPH RES CO, V209, P322, DOI 10.1006/bbrc.1995.1506; Lipari F, 1999, BIOCHEMISTRY-US, V38, P1111, DOI 10.1021/bi981643i; LIPARI F, 1994, GLYCOBIOLOGY, V4, P697, DOI 10.1093/glycob/4.5.697; Lipari F, 1996, J BIOL CHEM, V271, P27615, DOI 10.1074/jbc.271.44.27615; Moran DG, 1998, J FERMENT BIOENG, V86, P277, DOI 10.1016/S0922-338X(98)80130-X; ROMERO PA, 1985, BIOCHEM J, V226, P733, DOI 10.1042/bj2260733; ROMERO PA, 1994, GLYCOBIOLOGY, V4, P135, DOI 10.1093/glycob/4.2.135; SCHNEIKERT J, 1994, GLYCOBIOLOGY, V4, P445, DOI 10.1093/glycob/4.4.445; Tremblay LO, 1998, GLYCOBIOLOGY, V8, P585, DOI 10.1093/glycob/8.6.585; Vallee F, 2000, EMBO J, V19, P581, DOI 10.1093/emboj/19.4.581; Yoshida T, 1998, BIOSCI BIOTECH BIOCH, V62, P309, DOI 10.1271/bbb.62.309	26	27	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11071	11074		10.1074/jbc.275.15.11071	http://dx.doi.org/10.1074/jbc.275.15.11071			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753911	hybrid			2022-12-27	WOS:000086466600053
J	Sen, R; Nagai, H; Shimamoto, N				Sen, R; Nagai, H; Shimamoto, N			Polymerase arrest at the lambda P-R promoter during transcription initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; TERNARY COMPLEXES; STRUCTURAL-ANALYSIS; MECHANISM; CLEAVAGE; REGION-3; SUBUNIT; GREA; DNA	During transcription initiation by Escherichia coli RNA polymerase, a fraction of the homogeneous enzyme population has been kinetically shown to form two types of nonproductive complexes at some promoters: moribund complexes, which produce only abortive transcripts, and fully inactive ternary complexes (Kubori, T., and Shimamoto, N, (1996) J, Mol Biol, 256, 449-457), Here we report biochemical isolation of the complexes arrested at the lambda P-R promoter and an analysis of their structure by DNA and protein footprintings, We found that the isolated promoter-arrested complexes retain a stoichiometric amount of sigma(70) subunit, Exonuclease III footprints of the arrested complexes are backtracked compared with that of the binary complex, and KMnO4 footprinting reveals a decrease in the melting of DNA id the promoter region. Protein footprints of the retained sigma(70) have shown a more exposed conformation in region 3, compared with binary complexes. This feature is similar to that of the complexes arrested in inactive state during transcription elongation, indicating the existence of a common inactivating mechanism during transcription initiation and elongation. The possible involvement of the promoter arrest in transcriptional regulation is discussed.	Natl Inst Genet, Struct Biol Ctr, Mishima, Shizuoka 4118540, Japan	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Shimamoto, N (corresponding author), Natl Inst Genet, Struct Biol Ctr, Mishima, Shizuoka 4118540, Japan.		Nagai, Hiroki/G-4113-2015; Shimamoto, Nobuo/AAJ-4999-2020; Nagai, Hiroki/GXZ-7815-2022	Nagai, Hiroki/0000-0003-1659-2197; Shimamoto, Nobuo/0000-0001-7579-0084; 				ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; BURUKHOV S, 1993, CELL, V72, P459; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; DeHaseth PL, 1998, J BACTERIOL, V180, P3019, DOI 10.1128/JB.180.12.3019-3025.1998; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; FENG GH, 1994, J BIOL CHEM, V269, P22282; HSU LM, 1995, P NATL ACAD SCI USA, V92, P11588, DOI 10.1073/pnas.92.25.11588; Johnston D. E., 1976, RNA POLYMERASE, P413; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; Kubori T, 1996, J MOL BIOL, V256, P449, DOI 10.1006/jmbi.1996.0100; Kubori T, 1996, NUCLEIC ACIDS RES, V24, P1380, DOI 10.1093/nar/24.7.1380; Kubori T, 1997, NUCLEIC ACIDS RES, V25, P2640, DOI 10.1093/nar/25.13.2640; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MCCLURE WR, 1978, J BIOL CHEM, V253, P8949; MUNSON LM, 1981, BIOCHEMISTRY-US, V20, P2081, DOI 10.1021/bi00511a003; Nagai H, 1997, GENES CELLS, V2, P725, DOI 10.1046/j.1365-2443.1997.1600357.x; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Sen R, 1998, J BIOL CHEM, V273, P9872, DOI 10.1074/jbc.273.16.9872; SEVERINOV K, 1994, J BIOL CHEM, V269, P20826; Tagami H, 1998, EMBO J, V17, P1759, DOI 10.1093/emboj/17.6.1759; Tagami H, 1999, P NATL ACAD SCI USA, V96, P7202, DOI 10.1073/pnas.96.13.7202; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133	25	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10899	10904		10.1074/jbc.275.15.10899	http://dx.doi.org/10.1074/jbc.275.15.10899			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753887	hybrid			2022-12-27	WOS:000086466600029
J	Zhang, H; Cowan-Jacob, SW; Simonen, M; Greenhalf, W; Heim, J; Meyhack, B				Zhang, H; Cowan-Jacob, SW; Simonen, M; Greenhalf, W; Heim, J; Meyhack, B			Structural basis of BFL-1 for its interaction with BAX and its anti-apoptotic action in mammalian and yeast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 PROTEIN FAMILY; FUNCTIONAL DISSECTION; VIRAL HOMOLOG; BH3 DOMAIN; DEATH; SEQUENCE; VIRUS; GENE; HETERODIMERIZATION; INHIBITION	BFL-1 is the smallest member of the BCL-2 family and has been shown to retard apoptosis in various cell lines. However, the structural basis for its function remains unclear. Molecular modeling showed that BFL-1 could have a similar core structure as BCL-xL, consisting of seven ru helices, although both proteins share only the conserved BCL-2 homology domains (BH1 and BH2 domains), but otherwise have very limited sequence homology, particularly in the N-terminal region. We demonstrated in the yeast two-hybrid system that Bn-l interacts strongly with human BAX but is not able to form homodimers nor to interact with human BCL-2 or BCL-xL, Overexpression experiments in REF52 rat fibroblasts showed that BFL-1 conferred increased resistance to apoptosis induced by serum deprivation. BFL-1 had also the ability to neutralize BAX lethality in yeast. BAX requires the BH3 domain for interaction with BFL-1. However, the minimal region of BFL-1 for the interaction with BAX in coimmunoprecipitation experiments was not sufficient to protect cells from apoptosis. Further examination of BFL-1 and several other anti-apoptotic proteins suggests a more general type of structure based on structural motifs, i.e. a hydrophobic pocket for the binding of proapoptotic proteins, rather than extended sequence homologies.	Novartis Pharma AG, Oncol, Mol Genet, CH-4002 Basel, Switzerland; Novartis Pharma AG, Core Technol Area, Analyt & Biomol Struct, CH-4002 Basel, Switzerland	Novartis; Novartis	Meyhack, B (corresponding author), Novartis Pharma AG, Oncol, Mol Genet, WKL-125-12-58, CH-4002 Basel, Switzerland.	bernd.meyhack@pharma.novartis.com	Greenhalf, William/A-2680-2013					Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Aritomi M, 1997, J BIOL CHEM, V272, P27886, DOI 10.1074/jbc.272.44.27886; BODRUG SE, 1995, CELL DEATH DIFFER, V2, P173; BOYD JM, 1995, ONCOGENE, V11, P1921; Cheng EHY, 1997, P NATL ACAD SCI USA, V94, P690, DOI 10.1073/pnas.94.2.690; CHOI SS, 1995, ONCOGENE, V11, P1693; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; D'Sa-Eipper C, 1998, ONCOGENE, V16, P3105, DOI 10.1038/sj.onc.1201851; DSaEipper C, 1996, CANCER RES, V56, P3879; GILLET G, 1995, EMBO J, V14, P1372, DOI 10.1002/j.1460-2075.1995.tb07123.x; Greenhalf W, 1996, FEBS LETT, V380, P169, DOI 10.1016/0014-5793(96)00044-0; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Ink B, 1997, MOL CELL BIOL, V17, P2468, DOI 10.1128/MCB.17.5.2468; Inohara N, 1998, J BIOL CHEM, V273, P8705, DOI 10.1074/jbc.273.15.8705; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Laskowski R. A., 1993, J APPL CRYSTALLOGR, V26, P282; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Mangeney M, 1996, ONCOGENE, V13, P1441; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; MILLER JC, 1986, STATISTICS ANAL CHEM, P33; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nava VE, 1997, J VIROL, V71, P4118, DOI 10.1128/JVI.71.5.4118-4122.1997; NEILAN JG, 1993, J VIROL, V67, P4391, DOI 10.1128/JVI.67.7.4391-4394.1993; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Perry G, 1998, SCIENCE, V282, P1268; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALI A, 1994, PROTEIN SCI, V3, P1582, DOI 10.1002/pro.5560030923; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Simonen M, 1997, EUR J BIOCHEM, V249, P85, DOI 10.1111/j.1432-1033.1997.t01-1-00085.x; SMITH CA, 1995, TRENDS CELL BIOL, V5, P344, DOI 10.1016/S0962-8924(00)89061-3; TAKAYAMA S, 1994, DNA CELL BIOL, V13, P679, DOI 10.1089/dna.1994.13.679; Tao WK, 1997, J BIOL CHEM, V272, P15547, DOI 10.1074/jbc.272.24.15547; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Yao R, 1996, ONCOGENE, V13, P343; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, MOL CELL BIOL, V16, P6494; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	49	60	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11092	11099		10.1074/jbc.275.15.11092	http://dx.doi.org/10.1074/jbc.275.15.11092			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753914	hybrid			2022-12-27	WOS:000086466600056
J	Andrews, SR; Charnock, SJ; Lakey, JH; Davies, GJ; Claeyssens, M; Nerinckx, W; Underwood, M; Sinnott, ML; Warren, RAJ; Gilbert, HJ				Andrews, SR; Charnock, SJ; Lakey, JH; Davies, GJ; Claeyssens, M; Nerinckx, W; Underwood, M; Sinnott, ML; Warren, RAJ; Gilbert, HJ			Substrate specificity in glycoside hydrolase family 10 - Tyrosine 87 and Leucine 314 play a pivotal, role in discriminating between glucose and xylose binding in the proximal active site of pseudomonas cellulosa xylanase 10A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENS SUBSPECIES CELLULOSA; BETA-1,4-GLYCANASE CEX; DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; SEQUENCE; ENZYME; FIMI; INTERMEDIATE; EXPRESSION; PROTEIN	The Pseudomonas family 10 xylanase, Xyl10A, hydrolyzes beta 1,4-linked xylans but exhibits very low activity against aryl-beta-cellobiosides. The family 10 enzyme, Cex, from Cellulomonas fimi, hydrolyzes aryl-beta-cellobiosides more efficiently than does Xyl10A, and the movements of two residues in the -1 and -2 subsites are implicated in this relaxed substrate specificity (Notenboom, V., Birsan, C., Warren, R. A. J., Withers, S. G., and Rose, D. R. (1998) Biochemistry 37, 4751-4758). The three-dimensional structure of Xyl10A suggests that Tyr-87 reduces the affinity of the enzyme for glucose-derived substrates by steric hindrance with the C6-OH in the -2 subsite of the enzyme. Furthermore, Leu-314 impedes the movement of Trp-313 that is necessary to accommodate glucose-derived substrates in the -1 subsite. We have evaluated the catalytic activities of the mutants Y87A, Y87F, L314A, L314A/Y87F, and W313A of Xyl10A. Mutations to Tyr-87 increased and decreased the catalytic efficiency against 4-nitrophenyl-beta-cellobioside and 4-nitrophenyl-beta-xylobioside, respectively The L314A mutation caused a 200-fold decrease in 4-nitrophenyl-beta-xylobioside activity but did not significantly reduce 4-nitrophenyl-beta-cellobioside hydrolysis. The mutation L314A/Y87A gave a 6500-fold improvement in the hydrolysis of glucose-derived substrates compared with xylose-derived equivalents. These data show that substantial improvements in the ability of Xyl10A to accommodate the C6-OH of glucose-derived substrates are achieved when steric hindrance is removed.	Newcastle Univ, Dept Biol & Nutr Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Newcastle Univ, Dept Biochem & Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ York, Dept Chem, Struct Biol Lab, York YO10 5DD, N Yorkshire, England; Univ Ghent, Dept Biochem, B-9000 Ghent, Belgium; Univ Manchester, Inst Sci & Technol, Dept Paper Sci, Manchester M60 1QD, Lancs, England; Univ British Columbia, Dept Microbiol, Vancouver, BC V6T 1Z1, Canada	Newcastle University - UK; Newcastle University - UK; University of York - UK; Ghent University; University of Manchester; University of British Columbia	Gilbert, HJ (corresponding author), Newcastle Univ, Dept Biol & Nutr Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	H.J.Gilbert@newcastle.ac.ub	Davies, Gideon J/A-9042-2011	Davies, Gideon J/0000-0002-7343-776X				ARCAND N, 1993, BIOCHEM J, V290, P857, DOI 10.1042/bj2900857; ATKIN EDA, 1991, XYLAN XYLANASES, P39; Bolam DN, 1998, BIOCHEM J, V331, P775, DOI 10.1042/bj3310775; Brumer H, 1999, BIOCHEM J, V339, P43, DOI 10.1042/0264-6021:3390043; Charnock SJ, 1998, J BIOL CHEM, V273, P32187, DOI 10.1074/jbc.273.48.32187; Charnock SJ, 1997, J BIOL CHEM, V272, P2942, DOI 10.1074/jbc.272.5.2942; Christakopoulos P, 1997, CARBOHYD RES, V302, P191, DOI 10.1016/S0008-6215(97)00075-X; Coutinho PM, 1999, ROY SOC CH, P3; CUTIELD SM, 1999, J MOL BIOL, V294, P771; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Davies GJ, 1998, BIOCHEMISTRY-US, V37, P11707, DOI 10.1021/bi981315i; DEREWENDA U, 1994, J BIOL CHEM, V269, P20811; Ducros V, 2000, J BIOL CHEM, V275, P23020, DOI 10.1074/jbc.275.30.23020; GILKES NR, 1991, EUR J BIOCHEM, V202, P367, DOI 10.1111/j.1432-1033.1991.tb16384.x; HALL J, 1995, BIOCHEM J, V309, P749, DOI 10.1042/bj3090749; HALL J, 1989, MOL MICROBIOL, V3, P1211, DOI 10.1111/j.1365-2958.1989.tb00271.x; HARRIS GW, 1994, STRUCTURE, V2, P1107, DOI 10.1016/S0969-2126(94)00112-X; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; Kaneko S, 1999, FEBS LETT, V460, P61, DOI 10.1016/S0014-5793(99)01318-6; KITAOKA M, 1993, BIOSCI BIOTECH BIOCH, V57, P1987, DOI 10.1271/bbb.57.1987; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; McKie VA, 1997, BIOCHEM J, V323, P547, DOI 10.1042/bj3230547; MILLER GL, 1959, ANAL CHEM, V31, P426, DOI 10.1021/ac60147a030; MORIYAMA H, 1987, EUR J BIOCHEM, V166, P539, DOI 10.1111/j.1432-1033.1987.tb13547.x; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; Notenboom V, 1998, BIOCHEMISTRY-US, V37, P4751, DOI 10.1021/bi9729211; Sidhu G, 1999, BIOCHEMISTRY-US, V38, P5346, DOI 10.1021/bi982946f; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VANTILBEURGH H, 1982, FEBS LETT, V149, P152, DOI 10.1016/0014-5793(82)81092-2; WHITE A, 1994, BIOCHEMISTRY-US, V33, P12546, DOI 10.1021/bi00208a003; White A, 1996, NAT STRUCT BIOL, V3, P149, DOI 10.1038/nsb0296-149; WITHERS SG, 1986, BIOCHEM BIOPH RES CO, V139, P487, DOI 10.1016/S0006-291X(86)80017-1; WOOD TM, 1991, XYLANS XYLANASES, P187	36	42	45	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23027	23033		10.1074/jbc.M000128200	http://dx.doi.org/10.1074/jbc.M000128200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10767281	hybrid			2022-12-27	WOS:000088419400058
J	Carmical, JR; Kowalczyk, A; Zou, Y; Van Houten, B; Nechev, LV; Harris, CM; Harris, TM; Lloyd, RS				Carmical, JR; Kowalczyk, A; Zou, Y; Van Houten, B; Nechev, LV; Harris, CM; Harris, TM; Lloyd, RS			Butadiene-induced intrastrand DNA cross-links: A possible role in deletion mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; BONE-MARROW; IN-VITRO; INHALATION EXPOSURE; 1,3-BUTADIENE; ADDUCTS; MUTAGENICITY; REPLICATION; FREQUENCY; MUTATIONS	To initiate studies designed to identify the mutagenic spectrum associated with butadiene diepoxide-induced N-2-N-2 guanine intrastrand cross-links, site specifically adducted oligodeoxynucleotides were synthesized in which the adducted bases were centrally located within the context of the human ras 12 codon, The two stereospecifically modified DNAs and the corresponding unmodified DNA were ligated into a single-stranded M13mp7L2 vector and transfected into Escherichia coli, Both stereoisomeric forms (R,R and S,S) of the DNA cross-links resulted in very severely decreased plaque-forming ability, along with an increased mutagenic frequency for both single base substitutions and deletions compared with unadducted DNAs, with the S,S stereoisomer being the most mutagenic. Consistent with decreased plaque formation, in vitro replication of DNA templates containing the cross-links by the three major E. coli polymerases revealed replication blockage by both stereoisomeric forms of the cross-links. The same DNAs that were used for replication studies were also assembled into duplex DNAs and tested as substrates for the initiation of nucleotide excision repair by the E, coli UvrABC complex. UvrABC incised linear substrates containing these intrastrand cross-links with low efficiency, suggesting that these lesions may be inefficiently repaired by the nucleotide excision repair system.	Univ Texas, Med Branch, Dept Prevent Med & Community Hlth, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37235 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Vanderbilt University	Lloyd, RS (corresponding author), Phase 1 Mol Toxicol Inc, Santa Fe, NM 87505 USA.	rslloyd@utmb.edu	Van Houten, Bennett/K-2284-2019	Lloyd, R. Stephen/0000-0001-7273-372X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007781, P01ES005355, P30ES006676] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05355, P30-ES06676, ES07781] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Carmical JR, 2000, ENVIRON MOL MUTAGEN, V35, P48, DOI 10.1002/(SICI)1098-2280(2000)35:1<48::AID-EM7>3.3.CO;2-3; Carmical JR, 2000, CHEM RES TOXICOL, V13, P18, DOI 10.1021/tx9901332; CHARY P, 1995, J BIOL CHEM, V270, P4990, DOI 10.1074/jbc.270.10.4990; COCHRANE JE, 1994, CARCINOGENESIS, V15, P713, DOI 10.1093/carcin/15.4.713; DeCorte BL, 1996, CHEM RES TOXICOL, V9, P630, DOI 10.1021/tx9501795; DEMEESTER C, 1988, MUTAT RES, V195, P273, DOI 10.1016/0165-1110(88)90005-X; FAIT PW, 1970, J MED CHEM, V13, P447; GAY P, 1993, MOL GEN GENET, V239, P361, DOI 10.1007/BF00276934; HARRIS CM, 1991, J AM CHEM SOC, V113, P4328, DOI 10.1021/ja00011a044; Henderson RF, 1996, TOXICOLOGY, V113, P17, DOI 10.1016/0300-483X(96)03422-1; Jelitto B, 1989, Arch Toxicol Suppl, V13, P246; Kligerman AD, 1999, MUTAT RES-GEN TOX EN, V439, P13, DOI 10.1016/S1383-5718(98)00170-3; LATHAM GJ, 1993, J BIOL CHEM, V268, P23427; LAWLEY PD, 1965, NATURE, V206, P480, DOI 10.1038/206480a0; LAWLEY PD, 1967, J MOL BIOL, V25, P143, DOI 10.1016/0022-2836(67)90285-9; McNees AG, 1997, J BIOL CHEM, V272, P33211, DOI 10.1074/jbc.272.52.33211; MILLARD JT, 1993, BIOCHEMISTRY-US, V32, P2120, DOI 10.1021/bi00059a034; RECIO L, 1992, TOXICOL APPL PHARM, V117, P58, DOI 10.1016/0041-008X(92)90217-G; RECIO L, 1995, ENVIRON MOL MUTAGEN, V26, P1, DOI 10.1002/em.2850260102; Recio L, 1995, TOXICOL LETT, V82-3, P607, DOI 10.1016/0378-4274(95)03504-4; Recio L, 1996, TOXICOLOGY, V113, P106, DOI 10.1016/0300-483X(96)03434-8; Recio L, 1996, ENVIRON MOL MUTAGEN, V28, P424; Roberts J J, 1979, Prog Nucleic Acid Res Mol Biol, V22, P71, DOI 10.1016/S0079-6603(08)60799-0; Sambrook J., 2002, MOL CLONING LAB MANU; SISK SC, 1994, CARCINOGENESIS, V15, P471, DOI 10.1093/carcin/15.3.471; SKLADANOWSKI A, 1994, BIOCHEM PHARMACOL, V47, P2269, DOI 10.1016/0006-2952(94)90265-8; Steen AM, 1997, MUTAGENESIS, V12, P359, DOI 10.1093/mutage/12.5.359; TSAROUHTSIS D, 1995, J AM CHEM SOC, V117, P11013, DOI 10.1021/ja00149a027; VANGALA RR, 1993, ARCH TOXICOL, V67, P34, DOI 10.1007/BF02072032; VERLY WG, 1969, BIOCHIM BIOPHYS ACTA, V174, P674, DOI 10.1016/0005-2787(69)90296-2; VERLY WG, 1971, BIOCHIM BIOPHYS ACTA, V228, P400, DOI 10.1016/0005-2787(71)90046-3; YAREMA KJ, 1995, NUCLEIC ACIDS RES, V23, P4066, DOI 10.1093/nar/23.20.4066	32	41	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19482	19489		10.1074/jbc.M002037200	http://dx.doi.org/10.1074/jbc.M002037200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10766753	hybrid			2022-12-27	WOS:000087941300009
J	Park, SY; Avraham, H; Avraham, S				Park, SY; Avraham, H; Avraham, S			Characterization of the tyrosine kinases RAFTK/Pyk2 and FAK in nerve growth factor-induced neuronal differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PC12 CELLS; SIGNAL-TRANSDUCTION; RAPID REDISTRIBUTION; IN-VITRO; F-ACTIN; PAXILLIN; PHOSPHORYLATION; CALCIUM; IDENTIFICATION	The related adhesion focal tyrosine kinase (RAFTK), a member of the focal adhesion kinase (FAK) family and highly expressed in brain, is a key mediator of various extracellular signals that elevate intracellular Ca2+ concentration. We investigated RAFTK and FAK signaling upon nerve growth factor (NGF) stimulation of PC12 cells. NGF induced the tyrosine phosphorylation of RAFTK in a time- and dose-dependent manner, whereas no change in the tyrosine phosphorylation of FAK was observed Chemical inhibition showed that RAFTK phosphorylation was inhibited by blocking phospholipase Cy activity or intracellular Ca2+. Blocking of extracellular Ca2+ or phosphatidylinositol 3-kinase activity partially reduced the phosphorylation of RAFTK. In addition, disruption of actin polymerization abolished RAFTK phosphorylation, indicating that an intact actin-based cytoskeletal organization is required for RAFTK phosphorylation. The focal adhesion molecule paxillin was co-immunoprecipitated with RAFTK, and its tyrosine phosphorylation was increased in a Ca2+-dependent manner upon NGF stimulation. Confocal microscopic analysis demonstrated that RAFTK translocated from the cytoplasm to potential neurite initiation sites at the cell periphery, where RAFTK co-localized with paxillin and bundled actin in the early phase (within 5 min) of NGF stimulation, whereas FAK co-localized with paxillin at "point contacts," which are the primary cell adhesion sites in neuronal cells. Significant distribution of RAFTK was observed in the neurites and growth cones of differentiated PC12 cells. Furthermore, potassium depolarization induced the tyrosine phosphorylation of both RAFTK and paxillin in an intracellular Ca2+ dependent manner in the differentiated PC12 cells. Taken together, these results demonstrate that RAFTK is involved in NGF-induced cytoskeletal organization and may play a role in neurite and growth cone function(s).	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Harvard Inst Med,Div Expt Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Avraham, S (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Harvard Inst Med,Div Expt Med, 4 Blackfan Circle, Boston, MA 02115 USA.			Avraham, Hava/0000-0002-7545-3640; Park, Shin-Young/0000-0001-6385-4132	NCI NIH HHS [CA76226] Funding Source: Medline; NHLBI NIH HHS [HL55445, HL51456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076226] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051456, R01HL055445] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andreev J, 1999, MOL CELL BIOL, V19, P2338; ARREGUI CO, 1994, J NEUROSCI, V14, P6967; Astier A, 1997, J BIOL CHEM, V272, P228; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Combs CK, 1999, J NEUROSCI, V19, P928; Ganju RK, 1997, J EXP MED, V185, P1055, DOI 10.1084/jem.185.6.1055; Goldberg DJ, 1999, NEURON, V22, P423, DOI 10.1016/S0896-6273(00)80697-2; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hatch WC, 1998, BLOOD, V91, P3967, DOI 10.1182/blood.V91.10.3967.3967_3967_3973; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; Khan MA, 1996, EUR J BIOCHEM, V235, P579, DOI 10.1111/j.1432-1033.1996.00579.x; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Leventhal PS, 1996, J BIOL CHEM, V271, P5957, DOI 10.1074/jbc.271.11.5957; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; LOEB DM, 1992, NEURON, V9, P1053, DOI 10.1016/0896-6273(92)90065-L; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matsuya M, 1998, J BIOL CHEM, V273, P1003, DOI 10.1074/jbc.273.2.1003; MELAMED I, 1995, J EXP MED, V181, P1071, DOI 10.1084/jem.181.3.1071; Mitaka T, 1997, AM J PATHOL, V150, P267; NIKODIJEVIC B, 1991, J NEUROSCI RES, V28, P192, DOI 10.1002/jnr.490280206; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; PANDIELLAALONSO A, 1986, FEBS LETT, V208, P48, DOI 10.1016/0014-5793(86)81529-0; PAVES H, 1988, FEBS LETT, V235, P141, DOI 10.1016/0014-5793(88)81250-X; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SANO M, 1992, CELL STRUCT FUNCT, V17, P341, DOI 10.1247/csf.17.341; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; Schindelholz B, 1997, J NEUROSCI, V17, P8391; SCHLAEPFER DD, 1994, NATURE, V372, P786; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; TOLEDOARAL JJ, 1995, NEURON, V14, P607, DOI 10.1016/0896-6273(95)90317-8; TURNER CE, 1994, J CELL SCI, V107, P1583; Turner CE, 1998, INT J BIOCHEM CELL B, V30, P955, DOI 10.1016/S1357-2725(98)00062-4; Yamashita H, 1999, J BIOL CHEM, V274, P15059, DOI 10.1074/jbc.274.21.15059; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Zwick E, 1999, J BIOL CHEM, V274, P20989, DOI 10.1074/jbc.274.30.20989	43	46	46	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19768	19777		10.1074/jbc.M909932199	http://dx.doi.org/10.1074/jbc.M909932199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10764815	hybrid			2022-12-27	WOS:000087941300047
J	Hang, J; Shi, HF; Li, DY; Liao, YL; Lian, DJ; Xiao, YZ; Xue, H				Hang, J; Shi, HF; Li, DY; Liao, YL; Lian, DJ; Xiao, YZ; Xue, H			Ligand binding and structural properties of segments of GABA(A) receptor alpha(1) subunit overexpressed in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; AMINOBUTYRIC ACID(A) RECEPTORS; BENZODIAZEPINE BINDING; A RECEPTORS; FLUORESCENCE POLARIZATION; FUNCTIONAL EXPRESSION; EXTRACELLULAR DOMAIN; CIRCULAR-DICHROISM; GAMMA(2) SUBUNIT; POINT MUTATION	The gamma-aminobutyric acid, type A (GABA(A)), receptor is the target for numerous therapeutic compounds. In the present study, the Gln(28)-Leu(296), Gln(28)-Arg(276), Gln(28)-Arg(248), and Gln(28)-Glu(165) (numbering of bovine precursor protein) segments of its alpha(1) subunit were overexpressed in Escherichia coli, along with Cys(166)-Leu(296) produced previously, for structural analysis by circular dichroism and ligand binding studies by fluorescence spectroscopy, Results showed that the protein segments were rich in beta-sheet structures. Binding of the fluorescent benzodiazepine Bodipy-FL Ro-1986 was evident from fluorescence resonance energy transfer and fluorescence anisotropy measurements. The binding affinity was in the micromolar range. The binding was attributable more to Cys(166)-Leu(296) than 60 Gln(28)-Glu(165) and was inhibited by known central benzodiazepine site ligands, Three point mutations, Y187A, T234A, and Y237A, were found to perturb protein secondary structures. Studies with the single Trp mutants W198Y and W273Y indicated that Trp(273) was closer to the binding site than Trp(198).	Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Xue, H (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Hong Kong, Peoples R China.		Shi, Haifeng/AAT-4640-2020	Shi, Haifeng/0000-0001-9050-2140				Amin J, 1997, MOL PHARMACOL, V51, P833, DOI 10.1124/mol.51.5.833; Buhr A, 1997, MOL PHARMACOL, V52, P676, DOI 10.1124/mol.52.4.676; Buhr A, 1997, P NATL ACAD SCI USA, V94, P8824, DOI 10.1073/pnas.94.16.8824; Buhr A, 1997, J BIOL CHEM, V272, P11799, DOI 10.1074/jbc.272.18.11799; Buhr A, 1996, MOL PHARMACOL, V49, P1080; CARTER DB, 1992, BIO-TECHNOL, V10, P679, DOI 10.1038/nbt0692-679; CHECOVICH WJ, 1995, NATURE, V375, P254, DOI 10.1038/375254a0; Costa E, 1996, TRENDS PHARMACOL SCI, V17, P192, DOI 10.1016/0165-6147(96)10015-8; FRASER DD, 1995, J NEUROSCI, V15, P2720; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GUNTHER U, 1995, P NATL ACAD SCI USA, V92, P7749, DOI 10.1073/pnas.92.17.7749; Gupta S P, 1995, Prog Drug Res, V45, P67; HADINGHAM KL, 1992, P NATL ACAD SCI USA, V89, P6378, DOI 10.1073/pnas.89.14.6378; Hemmila I, 1997, DRUG DISCOV TODAY, V2, P373, DOI 10.1016/S1359-6446(97)01080-5; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KRANTIS A, 1994, NEUROSCI LETT, V176, P32, DOI 10.1016/0304-3940(94)90864-8; Lehrer S S, 1978, Methods Enzymol, V49, P222; LEVITAN ES, 1988, NATURE, V335, P76, DOI 10.1038/335076a0; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; MCCABE RT, 1990, FASEB J, V4, P2934, DOI 10.1096/fasebj.4.11.2165950; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; Mehta AK, 1999, BRAIN RES REV, V29, P196, DOI 10.1016/S0165-0173(98)00052-6; MILLER LG, 1992, PHARMACOL BIOCHEM BE, V43, P413, DOI 10.1016/0091-3057(92)90170-K; NAYEEM N, 1994, J NEUROCHEM, V62, P815; PRITCHETT DB, 1989, SCIENCE, V245, P1389, DOI 10.1126/science.2551039; PRITCHETT DB, 1991, P NATL ACAD SCI USA, V88, P1421, DOI 10.1073/pnas.88.4.1421; Renard S, 1999, J BIOL CHEM, V274, P13370, DOI 10.1074/jbc.274.19.13370; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; Schrattenholz A, 1998, J BIOL CHEM, V273, P32393, DOI 10.1074/jbc.273.49.32393; SIEGHART W, 1995, PHARMACOL REV, V47, P181; Sigel E, 1997, TRENDS PHARMACOL SCI, V18, P425, DOI 10.1016/S0165-6147(97)90675-1; SREERAMA N, 1994, J MOL BIOL, V242, P497, DOI 10.1006/jmbi.1994.1597; STEPHENSON FA, 1995, BIOCHEM J, V310, P1; STEPHENSON FA, 1990, J BIOL CHEM, V265, P21160; WEI AP, 1993, ANAL CHEM, V65, P3372, DOI 10.1021/ac00071a007; West AP, 1997, J BIOL CHEM, V272, P25468, DOI 10.1074/jbc.272.41.25468; WIELAND HA, 1994, J MED CHEM, V37, P4576, DOI 10.1021/jm00052a019; WIELAND HA, 1992, J BIOL CHEM, V267, P1426; Xue H, 1998, PROTEIN SCI, V7, P216, DOI 10.1002/pro.5560070124; Xue H, 1999, J MOL BIOL, V285, P55, DOI 10.1006/jmbi.1998.2317; Xue H, 2000, J MOL BIOL, V296, P739, DOI 10.1006/jmbi.2000.3502	41	10	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18818	18823		10.1074/jbc.M000193200	http://dx.doi.org/10.1074/jbc.M000193200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10764739	hybrid			2022-12-27	WOS:000087815900029
J	Hu, YK; Kaplan, JH				Hu, YK; Kaplan, JH			Site-directed chemical labeling of extracellular loops in a membrane protein - The topology of the Na,K-ATPase alpha-subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTED INSECT CELLS; C-TERMINAL DOMAIN; CATALYTIC SUBUNIT; BETA-SUBUNIT; NA/K-ATPASE; MUTAGENESIS; NA+,K+-ATPASE; EXPRESSION; CHAIN; IDENTIFICATION	We have mapped the membrane topology of the renal Na,K-ATPase alpha-subunit by using a combination of introduced cysteine mutants and surface labeling with a membrane impermeable Cys-directed reagent, N-biotinylaminoethyl methanethiosulfonate. To bean our investigation, two cysteine residues (Cys(911) and Cys(964)) in the wild-type alpha-subunit were substituted to create a background mutant devoid of exposed cysteines (Lutsenko, S., Daoud, S., and Kaplan, J. H. (1997) J. Biol, Chem. 272, 5249-5255). Into this background construct were then introduced single cysteines in each of the five putative extracellular loops (P118C, T309C, L793C, L876C, and M973C) and the resulting alpha-subunit mutants were co-expressed with the beta-subunit in baculovirus-infected insect cells. All of our expressed Na,K-ATPase mutants were functionally active. Their ATPase, phosphorylation, and ouabain binding activities were measured, and the turnover of the phosphoenzyme intermediate was close to the wild-type enzyme, suggesting that they are folded properly in the infected cells. Incubation of the insect cells with the cysteine-selective reagent revealed essentially no labeling of the alpha-subunit of the background construct and labeling of all five mutants with single cysteine residues in putative extracellular loops. Two additional mutants, V969C and L976C, were created to further define the M9M10 loop. The lack of labeling for these two mutants showed that although Met(973) is apparently exposed, Val(969) and Leu(976) are not, demonstrating that this method may also be utilized to define membrane aqueous boundaries of membrane proteins. Our labeling studies are consistent with a specific 10-transmembrane segment model of the Na,K-ATPase alpha-subunit. This strategy utilized only functional Na,K-ATPase mutants to establish the membrane topology of the entire alpha-subunit, in contrast to most previously applied methods.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University	Kaplan, JH (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, L224,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	kaplanj@ohsu.edu		Kaplan, Jack/0000-0002-7048-6574	NHLBI NIH HHS [HL30315] Funding Source: Medline; NIGMS NIH HHS [GM39500] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030315] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039500] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bar Shimon M, 1998, J BIOL CHEM, V273, P34190, DOI 10.1074/jbc.273.51.34190; Besancon M, 1997, J BIOL CHEM, V272, P22438, DOI 10.1074/jbc.272.36.22438; BLANCO G, 1994, J BIOL CHEM, V269, P23420; BROTHERUS JR, 1981, BIOCHEM BIOPH RES CO, V100, P146, DOI 10.1016/S0006-291X(81)80075-7; CANESSA CM, 1992, EMBO J, V11, P1681, DOI 10.1002/j.1460-2075.1992.tb05218.x; Canfield VA, 1996, BIOCHEMISTRY-US, V35, P14165, DOI 10.1021/bi961851f; DETOMASO AW, 1993, J BIOL CHEM, V268, P1470; Fiedler B, 1996, J BIOL CHEM, V271, P29312, DOI 10.1074/jbc.271.46.29312; Gatto C, 1999, J BIOL CHEM, V274, P13737, DOI 10.1074/jbc.274.20.13737; Gatto C, 1998, J BIOL CHEM, V273, P10578, DOI 10.1074/jbc.273.17.10578; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; Hu YK, 1999, BIOPHYS J, V76, pA387; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KYTE J, 1982, J MOL BIOL, V265, P4189; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee K, 1998, BIOCHEM BIOPH RES CO, V251, P693, DOI 10.1006/bbrc.1998.9534; LEMAS MV, 1994, J BIOL CHEM, V269, P8255; LIANG SM, 1976, BIOCHIM BIOPHYS ACTA, V452, P552, DOI 10.1016/0005-2744(76)90207-2; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lutsenko S, 1997, J BIOL CHEM, V272, P5249, DOI 10.1074/jbc.272.8.5249; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; LUTSENKO S, 1994, J BIOL CHEM, V269, P4555; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MOHRAZ M, 1994, J BIOL CHEM, V269, P2929; Moller JV, 1997, J BIOL CHEM, V272, P29015, DOI 10.1074/jbc.272.46.29015; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; OVCHINNIKOV YA, 1988, FEBS LETT, V227, P230, DOI 10.1016/0014-5793(88)80904-9; PEDEMONTE CH, 1986, J BIOL CHEM, V261, P6660; Pedersen PA, 1996, J BIOL CHEM, V271, P2514, DOI 10.1074/jbc.271.5.2514; PRICE EM, 1989, J BIOL CHEM, V264, P21902; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; PRICE EM, 1990, J BIOL CHEM, V265, P6638; Xie YH, 1996, J BIOL CHEM, V271, P2563, DOI 10.1074/jbc.271.5.2563; Yang BX, 1997, BIOCHEMISTRY-US, V36, P7625, DOI 10.1021/bi970231r; YOON KL, 1994, J BIOL CHEM, V269, P28249	40	84	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19185	19191		10.1074/jbc.M000641200	http://dx.doi.org/10.1074/jbc.M000641200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10764750	hybrid			2022-12-27	WOS:000087815900075
J	Terstegen, L; Gatsios, P; Bode, JG; Schaper, F; Heinrich, PC; Graeve, L				Terstegen, L; Gatsios, P; Bode, JG; Schaper, F; Heinrich, PC; Graeve, L			The inhibition of interleukin-6-dependent STAT activation by mitogen-activated protein kinases depends on tyrosine 759 in the cytoplasmic tail of glycoprotein 130	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCER GP130; GENE-EXPRESSION; T-LYMPHOCYTES; ONCOSTATIN-M; SH2 DOMAIN; RECEPTOR; BINDING; CELLS; PATHWAY; COMPLEX	Mitogen-activated protein (MAP) kinases stimulated by phorbol 13-myristate 12-acetate (PMA) have been shown to inhibit interleukin-6-induced activation of STAT3 (Sengupta, T. K., Talbot, E. S., Scherle, P. A., and Ivashkiv, L, B. (1998) Proc. Natl. Acad. Sci. U.S.A. 95, 11107-11112). In the present study we demonstrate that in addition to STAT3, also tyrosine phosphorylation of STAT1, signal transducer gp130, and phosphotyrosine-phosphatase SHP2 underlies negative regulation by MAP kinases. Stimulation of Erks by basic fibroblast growth factor or a constitutively active mutant of Raf also led to down-regulation of STAT activity. Using chimeric receptor mutants we show that tyrosine 759 of glycoprotein 130 is crucial for the inhibitory effect of MAP kinases, Inhibition is also dependent on gene transcription and translation indicating that newly synthesized proteins are involved. Both PMA and basic fibroblast growth factor rapidly stimulate mRNA expression of the suppressor of cytokine signaling-3 (SOCS-3) and this induction is strongly reduced by an inhibitor of MAP kinase activation, Together with recent results demonstrating that SOCS-3 can bind in vitro to a phosphorylated tyrosine 759 peptide of glycoprotein 130 these data suggest SOCS-3 to be instrumental in the inhibition of the Janus kinase/STAT pathway by MAP kinases.	Rhein Westfal TH Aachen, Inst Biochem, D-52074 Aachen, Germany; Rhein Westfal TH Aachen, Interdisziplinares Zentrum Klin Forsch Biomat, D-52074 Aachen, Germany	RWTH Aachen University; RWTH Aachen University	Gatsios, P (corresponding author), Rhein Westfal TH Klinikum, Inst Biochem, Pauwelsstr 30, D-52057 Aachen, Germany.		Schaper, Fred/F-1403-2013	Schaper, Fred/0000-0002-8899-5414				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; Bhat GJ, 1996, J BIOL CHEM, V271, P22447, DOI 10.1074/jbc.271.37.22447; Bode JG, 1999, FEBS LETT, V463, P365, DOI 10.1016/S0014-5793(99)01662-2; Bode JG, 1999, J BIOL CHEM, V274, P30222, DOI 10.1074/jbc.274.42.30222; Bright JJ, 1998, J IMMUNOL, V161, P1772; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gatsios P, 1996, EUR J BIOCHEM, V241, P56, DOI 10.1111/j.1432-1033.1996.0056t.x; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hoffmeyer A, 1999, J BIOL CHEM, V274, P4319, DOI 10.1074/jbc.274.7.4319; Kim HK, 1998, MOL CELL BIOL, V18, P1525, DOI 10.1128/MCB.18.3.1525; Kordula T, 1998, J BIOL CHEM, V273, P4112, DOI 10.1074/jbc.273.7.4112; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; MACKIEWICZ A, 1992, J IMMUNOL, V149, P2021; Mao YL, 1999, ENDOCRINOLOGY, V140, P5505, DOI 10.1210/en.140.12.5505; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; MULLBERG J, 1993, EUR J IMMUNOL, V23, P473, DOI 10.1002/eji.1830230226; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; Schaper F, 1998, BIOCHEM J, V335, P557, DOI 10.1042/bj3350557; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; Sengupta TK, 1996, P NATL ACAD SCI USA, V93, P9499, DOI 10.1073/pnas.93.18.9499; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Stoiber D, 1999, J IMMUNOL, V163, P2640; Symes A, 1997, CURR BIOL, V7, P697, DOI 10.1016/S0960-9822(06)00298-3; VONDERGEER P, 1994, ANN REV CELL BIOL, V10, P251; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEIERGRABER O, 1995, EUR J BIOCHEM, V234, P661, DOI 10.1111/j.1432-1033.1995.661_b.x; Wijdenes J, 1995, EUR J IMMUNOL, V25, P3474, DOI 10.1002/eji.1830251240; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309	41	60	63	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18810	18817		10.1074/jbc.M904148199	http://dx.doi.org/10.1074/jbc.M904148199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10764798	hybrid			2022-12-27	WOS:000087815900028
J	Oh, SK; Han, KH; Ryu, SB; Kang, H				Oh, SK; Han, KH; Ryu, SB; Kang, H			Molecular cloning, expression, and functional analysis of a cis-prenyltransferase from Arabidopsis thaliana - Implications in rubber biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FARNESYL DIPHOSPHATE SYNTHASE; CHAIN-LENGTH DETERMINATION; ESCHERICHIA-COLI; PYROPHOSPHATE SYNTHETASE; SACCHAROMYCES-CEREVISIAE; HEVEA-BRASILIENSIS; DOLICHOL SYNTHESIS; YEAST RER2; KEY ENZYME; GENE	cis-Prenyltransferase catalyzes the sequential condensation of isopentenyl diphosphate with allylic diphosphate to synthesize polyprenyl diphosphates that play vital roles in cellular activity. Despite potential significance of cis-prenyltransferase in plant growth and development, no gene of the enzyme has been cloned from higher plants. Using sequence information of the conserved region of cis-prenyltransferase cloned recently from Escherichia coli, Micrococcus luteus, and yeast, we have isolated and characterized the first plant cis-prenyltransferase from Arabidopsis thaliana. Sequence analysis revealed that the protein is highly homologous in several conserved regions to cis-prenyltransferases from M. luteus, E. coli, and yeast. In vitro analyses using the recombinant protein overexpressed in E. coli revealed that the enzyme catalyzed the formation of polyprenyl diphosphates ranging in carbon number from 100 to 130 with a predominance of C-120. The enzyme exhibited a higher affinity for farnesyl diphosphate than for geranylgeranyl diphosphate, with the K-m values being 0.13 and 3.62 mu M, respectively, but a lower affinity for isopentenyl diphosphate, with a K-m value of 23 mu M. In vitro rubber biosynthesis analysis indicated that the Arabidopsis cis-prenyltransferase itself could not catalyze the formation of higher molecular weight polyprenyl diphosphates similar to natural rubber. A reverse transcriptase-polymerase chain reaction analysis showed that the gene was expressed at low levels in Arabidopsis plant, in which expression of the cis-prenyltransferase in leaf and root was higher than that in stem, flower, and silique. These results indicate the tissue-specific expression of cis-prenyltransferase and suggest a potential role and significance of the enzyme in the polyisoprenoid biosynthesis in plants.	Kumho Life & Environm Sci Lab, Puk Gu, Kwangju 500712, South Korea		Kang, H (corresponding author), Kumho Life & Environm Sci Lab, Puk Gu, 1 Oryong Dong, Kwangju 500712, South Korea.		Han, Kyung-Hwan/G-6141-2012	Han, Kyung-Hwan/0000-0001-9481-4643				Adiwilaga K, 1996, PLANT MOL BIOL, V30, P935, DOI 10.1007/BF00020805; ANDERSON MS, 1989, J BIOL CHEM, V264, P19176; Apfel CM, 1999, J BACTERIOL, V181, P483, DOI 10.1128/JB.181.2.483-492.1999; ASAI K, 1994, BIOCHEM BIOPH RES CO, V202, P340, DOI 10.1006/bbrc.1994.1933; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; CARATTOLI A, 1991, J BIOL CHEM, V266, P5854; CHEN AJ, 1994, ARCH BIOCHEM BIOPHYS, V314, P399, DOI 10.1006/abbi.1994.1459; ERICSSON J, 1992, J BIOL CHEM, V267, P19730; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; FUJISAKI S, 1990, J BIOCHEM-TOKYO, V108, P995, DOI 10.1093/oxfordjournals.jbchem.a123327; Kato JI, 1999, J BACTERIOL, V181, P2733, DOI 10.1128/JB.181.9.2733-2738.1999; KOIKETAKESHITA A, 1995, J BIOL CHEM, V270, P18396, DOI 10.1074/jbc.270.31.18396; KOYAMA T, 1993, J BIOCHEM-TOKYO, V113, P355, DOI 10.1093/oxfordjournals.jbchem.a124051; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATH SK, 1992, P NATL ACAD SCI USA, V89, P6761, DOI 10.1073/pnas.89.15.6761; MISAWA N, 1990, J BACTERIOL, V172, P6704, DOI 10.1128/jb.172.12.6704-6712.1990; Oh SK, 1999, J BIOL CHEM, V274, P17132, DOI 10.1074/jbc.274.24.17132; Ohnuma S, 1996, J BIOL CHEM, V271, P18831, DOI 10.1074/jbc.271.31.18831; Ohnuma S, 1996, J BIOL CHEM, V271, P30748, DOI 10.1074/jbc.271.48.30748; OHNUMA S, 1994, J BIOL CHEM, V269, P14792; Ohnuma S, 1998, J BIOL CHEM, V273, P26705, DOI 10.1074/jbc.273.41.26705; Ohnuma SI, 1996, J BIOL CHEM, V271, P10087, DOI 10.1074/jbc.271.17.10087; Okada K, 1997, J BACTERIOL, V179, P5992, DOI 10.1128/jb.179.19.5992-5998.1997; Pan ZQ, 1996, ARCH BIOCHEM BIOPHYS, V332, P196, DOI 10.1006/abbi.1996.0333; Sambrook J., 2002, MOL CLONING LAB MANU; Sato M, 1999, MOL CELL BIOL, V19, P471; Shimizu N, 1998, J BIOL CHEM, V273, P19476, DOI 10.1074/jbc.273.31.19476; Suzuki K, 1997, J BIOCHEM, V121, P496; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; WILKIN DJ, 1990, J BIOL CHEM, V265, P4607; YANG SF, 1969, PLANT PHYSIOL, V44, P1203, DOI 10.1104/pp.44.8.1203; Zhu XF, 1997, PLANT CELL PHYSIOL, V38, P357, DOI 10.1093/oxfordjournals.pcp.a029174; Zhu XF, 1997, PLANT MOL BIOL, V35, P331, DOI 10.1023/A:1005898805326	33	88	101	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18482	18488		10.1074/jbc.M002000200	http://dx.doi.org/10.1074/jbc.M002000200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10764783	hybrid			2022-12-27	WOS:000087659400078
J	Xu, MJ; Zhao, RX; Zhao, ZZJ				Xu, MJ; Zhao, RX; Zhao, ZZJ			Identification and characterization of leukocyte-associated Ig-like receptor-1 as a major anchor protein of tyrosine phosphatase SHP-1 in hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC HOMOLOGY-2 DOMAINS; GROWTH-FACTOR RECEPTOR; INHIBITORY RECEPTOR; SH2 DOMAINS; SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; PHOSPHOTYROSINE PHOSPHATASES; MOTH-EATEN; PHOSPHORYLATION; PURIFICATION	SHP-1, an SH2 domain-containing tyrosine phosphatase, has a crucial role in hematopoiesis, Here we report that SHP-1 is associated with two major tyrosine-phosphorylated proteins in hematopoietic cells treated with the tyrosine phosphatase inhibitor, pervanadate. One of the proteins corresponds to leukocyte-associated Ig-like receptor-1 (LAIR-1), a recently cloned transmembrane protein. Molecular cloning revealed four isoforms of the protein. LAIR-1 is hyper-phosphorylated on tyrosyl residues in cells overexpressing a catalytically inactive mutant form of SHP-1 as well as in pervanadate-treated cells. An antibody against the extracellular domain of the protein also induced its tyrosine phosphorylation. Tyrosine-phosphorylated LAIR-1 specifically interacts with SHP-1 but not with SHP-2, a structurally related tyrosine phosphatase. Using site-specific mutagenesis, we demonstrated that Tyr(233) and Tyr(263), each embedded in an immunoreceptor tyrosine-based inhibitory motif, are responsible for tyrosine phosphorylation of LAIR-1 and recruitment of SHP-1, Both tyrosyl residues are required for SHP-1 binding. Protein kinases responsible for tyrosine phosphorylation of LAIR-1 may belong to the Src family since PP1, a Src family kinase inhibitor, significantly inhibited its phosphorylation, As a major binding protein of SHP-1 on the plasma membrane, LAIR-1 may play an important role in hematopoietic cell signaling.	Vanderbilt Univ, Dept Med, Vanderbilt Ingram Canc Ctr, Div Hematol Oncol, Nashville, TN 37232 USA	Vanderbilt University	Zhao, ZZJ (corresponding author), Vanderbilt Univ, Dept Med, Vanderbilt Ingram Canc Ctr, Div Hematol Oncol, 547,MRB 2,2220 Pierce Ave, Nashville, TN 37232 USA.				NCI NIH HHS [CA75218, CA-68485] Funding Source: Medline; NHLBI NIH HHS [HL-57393] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485, R01CA075218] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057393] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adachi M, 1996, CELL, V85, P15; Adachi T, 1998, J IMMUNOL, V160, P4662; Burshtyn DN, 1997, TRENDS CELL BIOL, V7, P473, DOI 10.1016/S0962-8924(97)01167-7; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DAVID M, 1995, MOL CELL BIOL, V15, P7050; de Vries ARV, 1999, EUR J IMMUNOL, V29, P3160; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; Frearson JA, 1997, BIOESSAYS, V19, P417, DOI 10.1002/bies.950190509; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Isakov N, 1997, IMMUNOL RES, V16, P85, DOI 10.1007/BF02786325; Izzi L, 1999, ONCOGENE, V18, P5563, DOI 10.1038/sj.onc.1202935; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Law CL, 1996, J EXP MED, V183, P547, DOI 10.1084/jem.183.2.547; Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875; Lorenz U, 1996, J EXP MED, V184, P1111, DOI 10.1084/jem.184.3.1111; Meyaard L, 1997, IMMUNITY, V7, P283, DOI 10.1016/S1074-7613(00)80530-0; Meyaard L, 1999, J IMMUNOL, V162, P5800; MICHEL S, 1996, CURR OPIN CELL BIOL, V183, P182; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; Newton-Nash DK, 1999, J IMMUNOL, V163, P682; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; Pani G, 1996, J EXP MED, V184, P839, DOI 10.1084/jem.184.3.839; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; Sui XW, 1997, BLOOD, V90, P651, DOI 10.1182/blood.V90.2.651.651_651_657; Taylor VC, 1999, J BIOL CHEM, V274, P11505, DOI 10.1074/jbc.274.17.11505; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; Ulyanova T, 1999, EUR J IMMUNOL, V29, P3440, DOI 10.1002/(SICI)1521-4141(199911)29:11<3440::AID-IMMU3440>3.3.CO;2-3; Unkeless JC, 1997, CURR OPIN IMMUNOL, V9, P338, DOI 10.1016/S0952-7915(97)80079-9; Vely F, 1997, J IMMUNOL, V159, P2075; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; Zhao RX, 2000, J BIOL CHEM, V275, P5453, DOI 10.1074/jbc.275.8.5453; Zhao RX, 1999, BIOCHEM J, V338, P35, DOI 10.1042/0264-6021:3380035; ZHAO Z, 1995, ADV PROT PHOSPHATASE, V9, P297; ZHAO ZH, 1993, P NATL ACAD SCI USA, V90, P4251, DOI 10.1073/pnas.90.9.4251; ZHAO ZH, 1994, P NATL ACAD SCI USA, V91, P5007, DOI 10.1073/pnas.91.11.5007; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780; ZHAO ZZ, 1993, J BIOL CHEM, V268, P2816; Zhao ZZ, 1996, J BIOL CHEM, V271, P22251, DOI 10.1074/jbc.271.36.22251	45	46	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17440	17446		10.1074/jbc.M001313200	http://dx.doi.org/10.1074/jbc.M001313200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10764762	hybrid			2022-12-27	WOS:000087485000033
J	Flynn, P; Mellor, H; Casamassima, A; Parker, PJ				Flynn, P; Mellor, H; Casamassima, A; Parker, PJ			Rho GTPase control of protein kinase C-related protein kinase activation by 3-phosphoinositide-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL REGION; ZIPPER-LIKE SEQUENCES; PHOSPHATIDYLINOSITOL 3-KINASE; POTENTIAL EFFECTOR; PLASMA-MEMBRANE; RAT-LIVER; PKN; PHOSPHORYLATION; PDK1; DOMAIN	The protein kinase C-related protein kinases (PRKs) have been shown to be under the control of the Rho GTPases and influenced by autophosphorylation. In analyzing the relationship between these inputs, it is shown that activation in vitro and in vivo involves the activation loop phosphorylation of PRK1/2 by 3-phosphoinositide-dependent protein kinase-1 (PDK1). Rho overexpression in cultured cells is shown to increase the activation loop phosphorylation of endogenous PRKs and is demonstrated to influence this process by controlling the ability of PRKs to bind to PDK1. The interaction of PRK1/2 with PDK1 is shown to be dependent upon Rho. Direct demonstration of ternary (Rho . PRK . PDK1) complex formation in situ is provided by the observation that PDK1 is recruited to RhoB-containing endosomes only if PRK is coexpressed. Furthermore, this in vivo complex is maintained after phosphoinositide 3-kinase inhibition. The control of PRKs by PDK1 thus evidences a novel strategy of substrate-directed control involving GTPases.	Imperial Canc Res Fund, Prot Phosphorylat Lab, London WC2A 3PX, England; Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	Cancer Research UK; University of Bristol	Parker, PJ (corresponding author), Imperial Canc Res Fund, Prot Phosphorylat Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Parker, Peter j/D-5192-2013	parker, peter/0000-0002-6218-2933; Mellor, Harry/0000-0003-3894-0623				ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Flynn P, 1998, J BIOL CHEM, V273, P2698, DOI 10.1074/jbc.273.5.2698; Kitagawa M, 1996, BIOCHEM BIOPH RES CO, V220, P963, DOI 10.1006/bbrc.1996.0515; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lebowitz PF, 1997, J BIOL CHEM, V272, P16093, DOI 10.1074/jbc.272.26.16093; Matsuzawa K, 1997, BIOCHEM BIOPH RES CO, V234, P621, DOI 10.1006/bbrc.1997.6669; Mellor H, 1998, J BIOL CHEM, V273, P4811, DOI 10.1074/jbc.273.9.4811; MORRICE NA, 1994, FEBS LETT, V351, P171, DOI 10.1016/0014-5793(94)00854-X; MORRICE NA, 1994, J BIOL CHEM, V269, P20040; Mukai H, 1996, J BIOL CHEM, V271, P9816, DOI 10.1074/jbc.271.16.9816; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V204, P348, DOI 10.1006/bbrc.1994.2466; Nishida K, 1999, ONCOGENE, V18, P407, DOI 10.1038/sj.onc.1202301; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; PALMER RH, 1994, FEBS LETT, V356, P5, DOI 10.1016/0014-5793(94)01202-4; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; PALMER RH, 1995, BIOCHEM J, V309, P315, DOI 10.1042/bj3090315; Parekh D, 1999, J BIOL CHEM, V274, P34758, DOI 10.1074/jbc.274.49.34758; Peng B, 1996, J BIOL CHEM, V271, P32233, DOI 10.1074/jbc.271.50.32233; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; SCHAFFHAUSEN B, 1982, J BIOL CHEM, V257, P2467; Shibata H, 1996, FEBS LETT, V385, P221, DOI 10.1016/0014-5793(96)00385-7; Standaert M, 1998, J BIOL CHEM, V273, P7470, DOI 10.1074/jbc.273.13.7470; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Welch H, 1998, J BIOL CHEM, V273, P11248, DOI 10.1074/jbc.273.18.11248; Ziegler WH, 1999, CURR BIOL, V9, P522, DOI 10.1016/S0960-9822(99)80236-X	43	99	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11064	11070		10.1074/jbc.275.15.11064	http://dx.doi.org/10.1074/jbc.275.15.11064			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753910	hybrid			2022-12-27	WOS:000086466600052
J	Tsao, PI; von Zastrow, M				Tsao, PI; von Zastrow, M			Type-specific sorting of G protein-coupled receptors after endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; DELTA-OPIOID RECEPTOR; HUMAN BETA-2-ADRENERGIC RECEPTOR; DYNAMIN-DEPENDENT ENDOCYTOSIS; CLATHRIN-MEDIATED ENDOCYTOSIS; NG108-15 HYBRID-CELLS; DOWN-REGULATION; BETA(2)-ADRENERGIC RECEPTOR; ACTIVATED RECEPTOR-1; AGONIST EXPOSURE	The beta-adrenergic receptor (B2AR) and delta-opioid receptor (DOR) are structurally distinct G protein-coupled receptors (GPCRs) that undergo rapid, agonist-induced internalization by clathrin-coated pits. We have observed that these receptors differ substantially in their membrane trafficking after endocytosis, B2AR expressed in stably transfected HEK293 cells exhibits negligible (<10%) down-regulation after continuous incubation of cells with agonist for 3 h, as assessed both by radioligand binding (to detect functional receptors) and immunoblotting (to detect total receptor protein), In contrast, DOR exhibits substantial (greater than or equal to 50%) agonist-induced down-regulation when examined by similar means. Degradation of internalized DOR is sensitive to inhibitors of lysosomal proteolysis. Flow cytometric and surface biotinylation assays indicate that differential sorting of B2AR and DOR between distinct recycling and non-recycling pathways (respectively) can be detected within similar to 10 min after endocytosis, significantly before the onset of detectable proteolytic degradation of receptors (similar to 60 min after endocytosis), Studies using pulsatile application of agonist suggest that after this sorting event occurs, later steps of membrane transport leading to lysosomal degradation of receptors do not require the continued presence of agonist in the culture medium. These observations establish that distinct GPCRs differ significantly in endocytic membrane trafficking after internalization by the same membrane mechanism, and they suggest a mechanism by which brief application of agonist can induce substantial down-regulation of receptors.	Univ Calif San Francisco, Dept Biochem & Biophys, Cell Biol Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	von Zastrow, M (corresponding author), 401 Parnassus Ave,Box 0984, San Francisco, CA 94143 USA.	zastrow@itsa.ucsf.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008120] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32GM08120] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARAK LS, 1994, J BIOL CHEM, V269, P2790; Bohm SK, 1996, J BIOL CHEM, V271, P22003; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Cao TT, 1998, J BIOL CHEM, V273, P24592, DOI 10.1074/jbc.273.38.24592; Chu P, 1997, J BIOL CHEM, V272, P27124, DOI 10.1074/jbc.272.43.27124; COLLINS S, 1989, P NATL ACAD SCI USA, V86, P4853, DOI 10.1073/pnas.86.13.4853; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; EBNER R, 1991, CELL REGUL, V2, P599, DOI 10.1091/mbc.2.8.599; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Gaudriault G, 1997, J BIOL CHEM, V272, P2880, DOI 10.1074/jbc.272.5.2880; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; GUAN XM, 1992, J BIOL CHEM, V267, P21995; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; HADCOCK JR, 1993, J NEUROCHEM, V60, P1, DOI 10.1111/j.1471-4159.1993.tb05816.x; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HERTEL C, 1983, J CELL BIOL, V97, P1538, DOI 10.1083/jcb.97.5.1538; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; Innamorati G, 1998, P NATL ACAD SCI USA, V95, P2222, DOI 10.1073/pnas.95.5.2222; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kallal L, 1998, J BIOL CHEM, V273, P322, DOI 10.1074/jbc.273.1.322; Keith DE, 1998, MOL PHARMACOL, V53, P377, DOI 10.1124/mol.53.3.377; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Ko JL, 1999, MOL BRAIN RES, V69, P171, DOI 10.1016/S0169-328X(99)00094-7; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; KURZ JB, 1992, MOL PHARMACOL, V41, P375; LAW PY, 1982, MOL PHARMACOL, V22, P1; LAW PY, 1984, J BIOL CHEM, V259, P4096; LAW PY, 1983, MOL PHARMACOL, V24, P413; Lee KB, 1998, J BIOL CHEM, V273, P12967, DOI 10.1074/jbc.273.21.12967; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; Moore RH, 1999, J CELL SCI, V112, P329; Morrison KJ, 1996, MOL PHARMACOL, V50, P692; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; TAO PL, 1988, BRAIN RES, V462, P313, DOI 10.1016/0006-8993(88)90559-8; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; Trejo J, 1999, J BIOL CHEM, V274, P2216, DOI 10.1074/jbc.274.4.2216; Trejo J, 1998, P NATL ACAD SCI USA, V95, P13698, DOI 10.1073/pnas.95.23.13698; Vickery RG, 1999, J CELL BIOL, V144, P31, DOI 10.1083/jcb.144.1.31; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; Zhang J, 1999, J RECEPT SIGNAL TR R, V19, P301, DOI 10.3109/10799899909036653; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	60	186	191	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11130	11140		10.1074/jbc.275.15.11130	http://dx.doi.org/10.1074/jbc.275.15.11130			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753919	hybrid			2022-12-27	WOS:000086466600061
J	van Ree, R; Cabanes-Macheteau, M; Akkerdaas, J; Milazzo, JP; Loutelier-Bourhis, C; Rayon, C; Villalba, M; Koppelman, S; Aalberse, R; Rodriguez, R; Faye, L; Lerouge, P				van Ree, R; Cabanes-Macheteau, M; Akkerdaas, J; Milazzo, JP; Loutelier-Bourhis, C; Rayon, C; Villalba, M; Koppelman, S; Aalberse, R; Rodriguez, R; Faye, L; Lerouge, P			beta(1,2)-xylose and alpha(1,3)-fucose residues have a strong contribution in IgE binding to plant glycoallergens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED CARBOHYDRATE; HONEYBEE VENOM PHOSPHOLIPASE-A2; ASCORBIC-ACID OXIDASE; GRASS-POLLEN ALLERGEN; CROSS-REACTIVE IGE; BIRCH POLLEN; HORSERADISH-PEROXIDASE; MAJOR ALLERGEN; MONOCLONAL-ANTIBODY; GLYCOSYLATION SITE	Primary structures of the N-glycans of two major pollen allergens (Lol p 11 and Ole e 1) and a major peanut allergen (Ara h 1) were determined. Ole e 1 and Ara h 1 carried high mannose and complex N-glycans, whereas Lol p 11 carried only the complex. The complex structures all had a beta(1,2)-xylose linked to the core mannose, Substitution of the proximal N-acetylglucosamine with an alpha(1,3)-fucose was observed on Lol p 11 and a minor fraction of Ole e 1 but not on Ara h 1, To elucidate the structural basis for IgE recognition of plant N-glycans, radioallergosorbent test analysis with protease digests of the three allergens and a panel of glycoproteins with known N-glycan structures was performed. It was demonstrated that both alpha(1,3)-fucose and beta(1,2)-xylose are involved in IgE binding. Surprisingly, xylose-specific IgE antibodies that bound to Lol p 11 and bromelain did not recognize closely related xylose-containing structures on horseradish peroxidase, phytohemeagglutinin, Ole e 1, and Ara h 1, On Lol p 11 and bromelain, the core beta-mannose is substituted with just an alpha(1,6)-mannose. On the other xylose-containing N-glycans, an additional alpha(1,3)-mannose is present. These observations indicate that IgE binding to xylose is sterically hampered by the presence of an alpha(1,3)-antenna.	Netherlands Red Cross, Blood Transfus Serv, Cent Lab, Dept Allergy, NL-1066 CX Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Expt & Clin Immunol Lab, NL-1066 CX Amsterdam, Netherlands; Univ Rouen, Transports Intracellulaires Lab, CNRS, ESA 6037, F-76821 Mt St Aignan, France; Univ Rouen, Inst Federatif Rech Multidisciplinaire Peptides 2, Ctr Reg Univ Spect, F-76821 Mt St Aignan, France; Univ Complutense, Fac Quim, Dept Bioquim & Biol Mol 1, E-28040 Madrid, Spain; Toegepast Nat Wetenschappelijk Onderzoek, Nutr & Food Res Inst, NL-3700 AJ Zeist, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Centre National de la Recherche Scientifique (CNRS); Universite de Rouen Normandie; Universite de Rouen Normandie; Complutense University of Madrid	van Ree, R (corresponding author), Netherlands Red Cross, Blood Transfus Serv, Cent Lab, Dept Allergy, Plesmanlaan 125, NL-1066 CX Amsterdam, Netherlands.		Loutelier, Corinne/L-6899-2015; Villalba, Mayte/K-5365-2014; RODRIGUEZ, ROSALIA/K-4993-2014; Villalba, María Teresa/AAW-1067-2020	RODRIGUEZ, ROSALIA/0000-0002-4280-3691; Villalba, María Teresa/0000-0002-0042-9953; Loutelier-Bourhis, Corinne/0000-0002-3361-1532				AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; AALBERSE RC, 1981, INT ARCH ALLER A IMM, V66, P259, DOI 10.1159/000232913; Aalberse RC, 1997, CLIN REV ALLERG IMMU, V15, P375, DOI 10.1007/BF02737733; AALBERSE RC, 1999, HIGHLIGHTS FOOD ALLE, P78; AALBERSE RC, 1983, RECENT DEV RAST OTHE; Altmann F, 1998, GLYCOCONJUGATE J, V15, P79, DOI 10.1023/A:1006947701714; ALTMANN F, 1995, GLYCOCONJUGATE J, V12, P84, DOI 10.1007/BF00731873; Batanero E, 1999, J ALLERGY CLIN IMMUN, V103, P147, DOI 10.1016/S0091-6749(99)70538-5; BATANERO E, 1994, MOL IMMUNOL, V31, P31, DOI 10.1016/0161-5890(94)90135-X; Batanero E, 1996, J ALLERGY CLIN IMMUN, V97, P1264, DOI 10.1016/S0091-6749(96)70194-X; Bonin CP, 1997, P NATL ACAD SCI USA, V94, P2085, DOI 10.1073/pnas.94.5.2085; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; BROICHMANN PW, 1992, ALLERGOLOGIE, V15, P295; CALKHOVEN PG, 1987, ALLERGY, V42, P382, DOI 10.1111/j.1398-9995.1987.tb02225.x; DANDREA G, 1988, GLYCOCONJUGATE J, V5, P151, DOI 10.1007/BF01061204; De Jong EC, 1998, CLIN EXP ALLERGY, V28, P743, DOI 10.1046/j.1365-2222.1998.00301.x; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; FAYE L, 1993, ANAL BIOCHEM, V209, P104, DOI 10.1006/abio.1993.1088; FAYE L, 1988, GLYCOCONJUGATE J, V5, P245, DOI 10.1007/BF01049085; FAYE L, 1985, ANAL BIOCHEM, V149, P218, DOI 10.1016/0003-2697(85)90498-1; Fitchette-Laine AC, 1997, PLANT J, V12, P1411, DOI 10.1046/j.1365-313x.1997.12061411.x; Fotisch K, 1998, ALLERGY, V53, P1043, DOI 10.1111/j.1398-9995.1998.tb03813.x; GarciaCasado G, 1996, GLYCOBIOLOGY, V6, P471, DOI 10.1093/glycob/6.4.471; Gray JSS, 1998, CARBOHYD RES, V311, P61, DOI 10.1016/S0008-6215(98)00209-2; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; Heiss S, 1996, J ALLERGY CLIN IMMUN, V98, P938, DOI 10.1016/S0091-6749(96)80010-8; JANKIEWICZ A, 1998, ALLERGO J, V7, P87; KUBELKA V, 1993, EUR J BIOCHEM, V213, P1193, DOI 10.1111/j.1432-1033.1993.tb17870.x; KUROSAKA A, 1991, J BIOL CHEM, V266, P4168; LAURIERE M, 1989, PLANT PHYSIOL, V90, P1182, DOI 10.1104/pp.90.3.1182; Lerouge P, 1998, PLANT MOL BIOL, V38, P31, DOI 10.1023/A:1006012005654; LOMMERSE JPM, 1995, BIOCHEMISTRY-US, V34, P8196, DOI 10.1021/bi00025a027; MCMANUS MT, 1988, PLANTA, V175, P506, DOI 10.1007/BF00393072; Melo NS, 1997, FEBS LETT, V415, P186, DOI 10.1016/S0014-5793(97)01121-6; Montreuil J, 1986, CARBOHYDRATE ANAL PR, P143; Ogawa H, 1996, GLYCOCONJUGATE J, V13, P555, DOI 10.1007/BF00731443; Ohsuga H, 1996, J BIOL CHEM, V271, P26653, DOI 10.1074/jbc.271.43.26653; OHTA M, 1989, ARCH BIOCHEM BIOPHYS, V275, P151, DOI 10.1016/0003-9861(89)90359-7; Oxley D, 1996, GLYCOBIOLOGY, V6, P611, DOI 10.1093/glycob/6.6.611; Petersen A, 1996, J ALLERGY CLIN IMMUN, V98, P805, DOI 10.1016/S0091-6749(96)70130-6; PETERSEN A, 1995, ELECTROPHORESIS, V16, P869, DOI 10.1002/elps.11501601144; PRENNER C, 1992, BIOCHEM J, V284, P377, DOI 10.1042/bj2840377; Rayon C, 1999, PLANT PHYSIOL, V119, P725, DOI 10.1104/pp.119.2.725; RAYON C, 1996, PLANT PHYSIOL BIOCH, V34, P281; SANCHEZMONGE R, 1992, BIOCHEM J, V281, P401, DOI 10.1042/bj2810401; Schuurman J, 1997, J ALLERGY CLIN IMMUN, V99, P545, DOI 10.1016/S0091-6749(97)70083-6; STAUDACHER E, 1992, GLYCOCONJUGATE J, V9, P82, DOI 10.1007/BF00731703; STURM A, 1992, EUR J BIOCHEM, V204, P313, DOI 10.1111/j.1432-1033.1992.tb16639.x; Takahashi N, 1998, ANAL BIOCHEM, V255, P183, DOI 10.1006/abio.1997.2463; TOMIYA N, 1987, ANAL BIOCHEM, V163, P489, DOI 10.1016/0003-2697(87)90253-3; TRETTER V, 1993, INT ARCH ALLERGY IMM, V102, P259, DOI 10.1159/000236534; TRETTER V, 1991, EUR J BIOCHEM, V199, P647, DOI 10.1111/j.1432-1033.1991.tb16166.x; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 1996, J ALLERGY CLIN IMMUN, V97, P893, DOI 10.1016/S0091-6749(96)80062-5; van Ree R, 1998, J ALLERGY CLIN IMMUN, V102, P184, DOI 10.1016/S0091-6749(98)70084-3; vanderVeen MJ, 1997, J ALLERGY CLIN IMMUN, V100, P327, DOI 10.1016/S0091-6749(97)70245-8; VANKUIK JA, 1986, GLYCOCONJUGATE J, V3, P27, DOI 10.1007/BF01108609; VANREE R, 1993, J CLIN IMMUNOASSAY, V16, P124; VANREE R, 1989, J ALLERGY CLIN IMMUN, V83, P144, DOI 10.1016/0091-6749(89)90489-2; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P970, DOI 10.1016/S0091-6749(95)70097-8; Vieths S, 1997, ENVIRON TOXICOL PHAR, V4, P61, DOI 10.1016/S1382-6689(97)10043-6; Vieths S., 1994, Food and Agricultural Immunology, V6, P453, DOI 10.1080/09540109409354857; VITALE A, 1984, J CELL BIOL, V99, P133, DOI 10.1083/jcb.99.1.133; VONSCHAEWEN A, 1993, PLANT PHYSIOL, V102, P1109, DOI 10.1104/pp.102.4.1109; WEBER A, 1987, ALLERGY, V42, P464, DOI 10.1111/j.1398-9995.1987.tb00364.x; Wilson IBH, 1998, GLYCOBIOLOGY, V8, P651, DOI 10.1093/glycob/8.7.651; Wilson IBH, 1998, GLYCOCONJUGATE J, V15, P1055, DOI 10.1023/A:1006960401562	69	291	308	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11451	11458		10.1074/jbc.275.15.11451	http://dx.doi.org/10.1074/jbc.275.15.11451			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753962	hybrid			2022-12-27	WOS:000086466600104
J	Humphries, JD; Askari, JA; Zhang, XP; Takada, Y; Humphries, MJ; Mould, AP				Humphries, JD; Askari, JA; Zhang, XP; Takada, Y; Humphries, MJ; Mould, AP			Molecular basis of ligand recognition by integrin alpha(5)beta(1) - II. Specificity of Arg-Gly-Asp binding is determined by Trp(157) of the alpha subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOAFFINITY CROSS-LINKING; DEPENDENT ADHESION SITE; PHAGE DISPLAY LIBRARY; AMINO-ACID-RESIDUES; CELL-ADHESION; BETA-SUBUNIT; ALPHA-5-BETA-1-FIBRONECTIN INTERACTIONS; MONOCLONAL-ANTIBODIES; A-DOMAIN; FIBRONECTIN	Different beta(1) integrins bind Arg-Gly-Asp (RGD) peptides with differing specificities, suggesting a role for residues in the a subunit in determining ligand specificity, Integrin alpha(5)beta(1) has been shown to bind with high affinity to peptides containing an Arg-Gly-Asp-Gly-Trp (RGDGW) sequence but with relatively low affinity to other RGD peptides, The residues within the ligand-binding pocket that determine this specificity are currently unknown, A cyclic peptide containing the RGDGW sequence was found to strongly perturb the binding of the anti-a, monoclonal antibody (mAb) 16 to alpha(5)beta(1) In contrast, RGD peptides lacking the tryptophan residue acted as weak inhibitors of mAb 16 binding. The epitope of mAb 16 has previously been localized to a region of the alpha(5) subunit that contains Ser(156)-Trp(157). Mutation of Trp(157) (but not of Ser(156) or surrounding residues) to alanine blocked recognition of mAb 16 and perturbed the high affinity binding of RGDGW-containing peptides to alpha(5)beta(1). The same mutation also abrogated recognition of the alpha(5)beta(1)-specific ligand peptide Arg-Arg-Glu-Thr-Ala-Trp-Ala (RRETAWA). Based on these findings, we propose that Trp(167) of alpha(5) participates in a hydrophobic interaction with the tryptophan residue in RGDGW, and that this interaction determines the specificity of alpha(5)beta(1) for RGDGW-containing peptides, Since the RGD sequence is recognized predominantly by amino acid residues on the beta(1) subunit, our results suggest that Trp167 Of alpha(5) must lie very close to these residues. Our findings therefore provide new insights into the structure of the ligand-binding pocket of alpha(5)beta(1).	Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; Scripps Res Inst, Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	University of Manchester; Scripps Research Institute	Mould, AP (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.		Humphries, Jonathan D./AAE-7760-2022	Humphries, Jonathan D./0000-0002-8953-7079; takada, yoshikazu/0000-0001-5481-9589; Mould, Paul/0000-0003-0076-6228; Humphries, Martin/0000-0002-4331-6967	NIGMS NIH HHS [GM47157] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047157] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOTA S, 1994, J BIOL CHEM, V269, P24756; BAJT ML, 1994, J BIOL CHEM, V269, P20913; Bitan G, 1999, BIOCHEMISTRY-US, V38, P3414, DOI 10.1021/bi981946c; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; Burrows L, 1999, BIOCHEM J, V344, P527, DOI 10.1042/0264-6021:3440527; Cierniewski CS, 1999, J BIOL CHEM, V274, P16923, DOI 10.1074/jbc.274.24.16923; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Curley GP, 1999, CELL MOL LIFE SCI, V56, P427, DOI 10.1007/s000180050443; DANEN EHJ, 1995, J BIOL CHEM, V270, P21612, DOI 10.1074/jbc.270.37.21612; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; FERNANDEZ C, 1998, FRONT BIOSCI, V3, P684; Goodman TG, 1996, J BIOL CHEM, V271, P23729, DOI 10.1074/jbc.271.39.23729; Honda S, 1998, J CLIN INVEST, V102, P1183, DOI 10.1172/JCI3206; Humphries MJ, 1998, TRENDS CELL BIOL, V8, P78, DOI 10.1016/S0962-8924(98)80016-0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Irie A, 1997, P NATL ACAD SCI USA, V94, P7198, DOI 10.1073/pnas.94.14.7198; IRIE A, 1995, EMBO J, V14, P5550, DOI 10.1002/j.1460-2075.1995.tb00242.x; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; KOIVUNEN E, 1995, BIO-TECHNOL, V13, P265, DOI 10.1038/nbt0395-265; Kraft S, 1999, J BIOL CHEM, V274, P1979, DOI 10.1074/jbc.274.4.1979; Krukonis ES, 1998, J BIOL CHEM, V273, P31837, DOI 10.1074/jbc.273.48.31837; KUIJPERS TW, 1993, J EXP MED, V178, P279, DOI 10.1084/jem.178.1.279; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lin ECK, 1997, J BIOL CHEM, V272, P14236, DOI 10.1074/jbc.272.22.14236; Lin ECK, 1997, J BIOL CHEM, V272, P23912, DOI 10.1074/jbc.272.38.23912; Loftus JC, 1997, J CLIN INVEST, V99, P2302, DOI 10.1172/JCI119408; MAHLER HR, 1966, BIOL CHEM, P250; McGaughey GB, 1998, J BIOL CHEM, V273, P15458, DOI 10.1074/jbc.273.25.15458; Mould AP, 2000, J BIOL CHEM, V275, P20324, DOI 10.1074/jbc.M000572200; Mould AP, 1998, J BIOL CHEM, V273, P25664, DOI 10.1074/jbc.273.40.25664; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Mould AP, 1997, J BIOL CHEM, V272, P17283, DOI 10.1074/jbc.272.28.17283; Mould AP, 1996, J BIOL CHEM, V271, P20365, DOI 10.1074/jbc.271.34.20365; Mould AP, 1998, BIOCHEM J, V331, P821, DOI 10.1042/bj3310821; MULLER B, 1993, J BIOL CHEM, V268, P6800; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P20438, DOI 10.1074/jbc.271.34.20438; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; SCHREINER CL, 1989, J CELL BIOL, V109, P3157, DOI 10.1083/jcb.109.6.3157; Shih DT, 1997, J CELL SCI, V110, P2619; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; Takada Y, 1997, MATRIX BIOL, V16, P143, DOI 10.1016/S0945-053X(97)90002-0; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Takagi J, 1997, J BIOL CHEM, V272, P19794, DOI 10.1074/jbc.272.32.19794; TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044; Tan K, 1998, STRUCTURE, V6, P793, DOI 10.1016/S0969-2126(98)00080-X; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; TUCKWELL DS, 1992, BIOCHEM J, V285, P325, DOI 10.1042/bj2850325; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; Zhang XP, 1999, BIOCHEMISTRY-US, V38, P14424, DOI 10.1021/bi990323b	54	53	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20337	20345		10.1074/jbc.M000568200	http://dx.doi.org/10.1074/jbc.M000568200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10764747	hybrid			2022-12-27	WOS:000088084500018
J	Jono, S; Peinado, C; Giachelli, CM				Jono, S; Peinado, C; Giachelli, CM			Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC PLAQUES; HORMONE-RELATED PEPTIDE; IN-VITRO; POSTTRANSLATIONAL MODIFICATIONS; HYDROXYAPATITE FORMATION; BOVINE OSTEOPONTIN; BINDING-PROPERTIES; BONE SIALOPROTEIN; MESSENGER-RNA; IDENTIFICATION	Osteopontin (OPN) is a non-collagenous, glycosylated phosphoprotein associated with biomineralization in osseous tissues, as well as ectopic calcification. We previously reported that osteopontin was co-localized with calcified deposits in atherosclerotic lesions, and that osteopontin potently inhibits calcium deposition in a human smooth muscle cell (HSMC) culture model of vascular calcification. In this report, the role of phosphorylation in osteopontin's mineralization inhibitory function was examined, The ability of OPN to inhibit calcification completely depended on post-translational modifications, since bacteria-derived recombinant OPN did not inhibit HSMC mineralization, Following casein kinase II treatment, phosphorylated OPN (P-OPN) dose-dependently inhibited calcification of HSMC cultured in vitro about as effectively as native OPN. The inhibitory effect of osteopontin depended on the extent of phosphorylation. To determine the specific structural domains of OPN important for inhibition of calcification, we compared OPN fragments (N-terminal, C-terminal, and full-length), and compared the inhibitory effect of both phosphorylated and non-phosphorylated fragments. While none of the non-phosphorylated OPN fragments effected calcification, P-OPN caused dose dependent inhibition of HSMC calcification. P-OPN was treated with alkaline phosphatase to create dephosphorylated OPN. Dephosphorylated OPN did not have an inhibitory effect on calcification. The expression of OPN mRNA and P-OPN secretion by HSMC were decreased in a time-dependent manner during culture calcification. These results indicate that phosphorylation is required for the inhibitory effect of OPN on HSMC calcification, and that regulation of OPN phosphorylation represents one way in which mineralization may be controlled by cells.	Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; Osaka City Univ, Sch Med, Dept Internal Med 2, Osaka 545, Japan	University of Washington; University of Washington Seattle; Osaka Metropolitan University	Giachelli, CM (corresponding author), Univ Washington, Dept Bioengn, Box 351720,Bagley Hall Rm 479, Seattle, WA 98195 USA.	ceci@u.washington.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062329] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK047659] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL062329, R01HL62329-01] Funding Source: Medline; NIDDK NIH HHS [P50 DK047659] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENINATI S, 1994, J BIOCHEM-TOKYO, V115, P675, DOI 10.1093/oxfordjournals.jbchem.a124395; Blumenthal Herman T., 1944, AMER JOUR PATH, V20, P665; BOSKEY AL, 1993, BONE MINER, V22, P147, DOI 10.1016/S0169-6009(08)80225-5; BOSTROM K, 1993, J CLIN INVEST, V91, P1800, DOI 10.1172/JCI116391; CHANG PL, 1991, CANCER RES, V51, P2144; CHEN Y, 1992, J BIOL CHEM, V267, P24871; EKRYLANDER B, 1994, J BIOL CHEM, V269, P14853; FITZGERALD PJ, 1992, CIRCULATION, V86, P64, DOI 10.1161/01.CIR.86.1.64; FRINK RJ, 1970, AM J CARDIOL, V26, P241, DOI 10.1016/0002-9149(70)90790-3; GERSTENFELD LC, 1989, CONNECT TISSUE RES, V21, P545; GIACHELLI CM, 1993, J CLIN INVEST, V92, P1686, DOI 10.1172/JCI116755; GIACHELLI CM, 1995, ANN NY ACAD SCI, V760, P109, DOI 10.1111/j.1749-6632.1995.tb44624.x; GOTOH Y, 1990, EUR J BIOCHEM, V187, P49, DOI 10.1111/j.1432-1033.1990.tb15276.x; HIROTA S, 1993, AM J PATHOL, V143, P1003; Hunter GK, 1996, BIOCHEM J, V317, P59, DOI 10.1042/bj3170059; HUNTER GK, 1994, BIOCHEM J, V300, P723, DOI 10.1042/bj3000723; HUNTER GK, 1994, BIOCHEM J, V302, P175, DOI 10.1042/bj3020175; Jono S, 1998, CIRCULATION, V98, P1302, DOI 10.1161/01.CIR.98.13.1302; Jono S, 1997, ARTERIOSCL THROM VAS, V17, P1135, DOI 10.1161/01.ATV.17.6.1135; Katayama Y, 1998, J CELL PHYSIOL, V176, P179, DOI 10.1002/(SICI)1097-4652(199807)176:1<179::AID-JCP19>3.3.CO;2-M; KIEFER MC, 1989, NUCLEIC ACIDS RES, V17, P3306, DOI 10.1093/nar/17.8.3306; Lasa M, 1997, BIOCHEM BIOPH RES CO, V240, P602, DOI 10.1006/bbrc.1997.7702; LIAW L, 1994, CIRC RES, V74, P214, DOI 10.1161/01.RES.74.2.214; LOECKER TH, 1992, J AM COLL CARDIOL, V19, P1167, DOI 10.1016/0735-1097(92)90319-I; NAGATA T, 1989, BIOCHEM BIOPH RES CO, V165, P234, DOI 10.1016/0006-291X(89)91059-0; Parhami F, 1997, ARTERIOSCL THROM VAS, V17, P680, DOI 10.1161/01.ATV.17.4.680; PRINCE CW, 1987, J BIOL CHEM, V262, P2900; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; Salih E, 1997, J BIOL CHEM, V272, P13966, DOI 10.1074/jbc.272.21.13966; Salih E, 1996, J BONE MINER RES, V11, P1461; Salih E, 1996, CONNECT TISSUE RES, V35, P207, DOI 10.3109/03008209609029193; SHANAHAN CM, 1994, J CLIN INVEST, V93, P2393, DOI 10.1172/JCI117246; SINGH K, 1990, J BIOL CHEM, V265, P18696; SINGH K, 1993, J BIOCHEM-TOKYO, V114, P702, DOI 10.1093/oxfordjournals.jbchem.a124240; Smith LL, 1996, J BIOL CHEM, V271, P28485, DOI 10.1074/jbc.271.45.28485; SORENSEN ES, 1995, PROTEIN SCI, V4, P2040, DOI 10.1002/pro.5560041009; SORENSEN ES, 1994, BIOCHEM BIOPH RES CO, V198, P200, DOI 10.1006/bbrc.1994.1028; TANIMURA A, 1986, Journal of Experimental Pathology (New York), V2, P261; Wada T, 1999, CIRC RES, V84, P166, DOI 10.1161/01.RES.84.2.166; YOUNG MF, 1990, GENOMICS, V7, P491, DOI 10.1016/0888-7543(90)90191-V	40	268	280	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					20197	20203		10.1074/jbc.M909174199	http://dx.doi.org/10.1074/jbc.M909174199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10766759	hybrid			2022-12-27	WOS:000087941300101
J	Kisseleva, MV; Wilson, MP; Majerus, PW				Kisseleva, MV; Wilson, MP; Majerus, PW			The isolation and characterization of a cDNA encoding phospholipid-specific inositol polyphosphate 5-phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-GAMMA; SYNAPTOJANIN; DOMAINS; IDENTIFICATION; PHOSPHATASES; ACTIVATION; SEQUENCES; MEMBRANE; BETAINE; FORMS	We report the cDNA cloning and characterization of a novel human inositol polyphosphate 5-phosphatase (5-phosphatase) that has substrate specificity unlike previously described members of this large gene family. All previously described members hydrolyze water soluble inositol phosphates. This enzyme hydrolyzes only lipid substrates, phosphatidylinositol 3,4,5-trisphosphate and phosphatidylinositol 4,5-bisphosphate. The cDNA isolated comprises 3110 base pairs and predicts a protein product of 644 amino acids and M-r 70,023. We designate this 5-phosphatase as type IV. It is a highly basic protein (pI = 8.8) and has the greatest affinity toward phosphatidylinositol 3,4,5-trisphosphate of known 5-phosphatases. The K-m is 0.65 mu M, 1/10 that of SHIP (5.95 mu M), another 5-phosphatase that hydrolyzes phosphatidylinositol 3,4,5-trisphosphate. The activity of Ei-phosphatase type TV is sensitive to the presence of detergents in the in vitro assay. Thus the enzyme hydrolyzes lipid substrates in the absence of detergents or in the presence of n-octyl beta-glucopyranoside or Triton X-100, but not in the presence of cetyltriethylammonium bromide, the detergent that has been used in other studies of the hydrolysis of phosphatidylinositol 4,5-bisphosphate. Remarkably SHIP, a 5-phosphatase previously characterized as hydrolyzing only substrates with D-3 phosphates, also readily hydrolyzed phosphatidylinositol 4,5-bisphosphate in the presence of n-octyl P-glucopyranoside but not cetyltriethylammonium bromide. We used antibodies prepared against a peptide predicted by the cDNA to identify the B-phosphatase type IV enzyme in human tissues and find that it is highly expressed in the brain as determined by Western blotting. We also performed Western blotting of mouse tissues and found high levels of expression in the brain, testes, and heart with lower levels of expression in other tissues. mRNA was detected in many tissues and cell lines as determined by Northern blotting.	Washington Univ, Sch Med, Dept Internal Med, Div Hematol, St Louis, MO 63110 USA	Washington University (WUSTL)	Majerus, PW (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Hematol, Campus Box 8125,660 S Euclid Ave, St Louis, MO 63110 USA.	phil@im.wustl.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016634, R01HL016634] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 16634, HL55772] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson RA, 1999, J BIOL CHEM, V274, P9907, DOI 10.1074/jbc.274.15.9907; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; DeSmedt F, 1996, J BIOL CHEM, V271, P10419, DOI 10.1074/jbc.271.17.10419; Erneux C, 1998, BBA-MOL CELL BIOL L, V1436, P185, DOI 10.1016/S0005-2760(98)00132-5; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Guo SL, 1999, J BIOL CHEM, V274, P12990, DOI 10.1074/jbc.274.19.12990; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Hengen PN, 1997, TRENDS BIOCHEM SCI, V22, P225, DOI 10.1016/S0968-0004(97)01069-4; Henke W, 1997, NUCLEIC ACIDS RES, V25, P3957, DOI 10.1093/nar/25.19.3957; Janne PA, 1998, J CLIN INVEST, V101, P2042, DOI 10.1172/JCI2414; JEFFERSON AB, 1995, J BIOL CHEM, V270, P9370, DOI 10.1074/jbc.270.16.9370; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Khvotchev M, 1998, J BIOL CHEM, V273, P2306, DOI 10.1074/jbc.273.4.2306; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LIPS DL, 1989, J BIOL CHEM, V264, P19911; Majerus PW, 1999, J BIOL CHEM, V274, P10669, DOI 10.1074/jbc.274.16.10669; Matzaris M, 1998, J BIOL CHEM, V273, P8256, DOI 10.1074/jbc.273.14.8256; MATZARIS M, 1994, J BIOL CHEM, V269, P3397; NORRIS FA, 1994, J BIOL CHEM, V269, P8716; Rameh LE, 1998, J BIOL CHEM, V273, P23750, DOI 10.1074/jbc.273.37.23750; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Ramjaun AR, 1996, J BIOL CHEM, V271, P24856, DOI 10.1074/jbc.271.40.24856; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; Tridandapani S, 1997, MOL CELL BIOL, V17, P4305, DOI 10.1128/MCB.17.8.4305; Woscholski R, 1998, FEBS LETT, V432, P5, DOI 10.1016/S0014-5793(98)00820-5; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756	29	110	112	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					20110	20116		10.1074/jbc.M910119199	http://dx.doi.org/10.1074/jbc.M910119199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10764818	hybrid			2022-12-27	WOS:000087941300092
J	Coqueret, O; Gascan, H				Coqueret, O; Gascan, H			Functional interaction of STAT3 transcription factor with the cell cycle inhibitor p21(WAF1/CIP1/SD11)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; CILIARY NEUROTROPHIC FACTOR; DEPENDENT KINASES; INDUCED-DIFFERENTIATION; SIGNAL-TRANSDUCTION; CDK INHIBITORS; TGF-BETA; ACTIVATION; P21; CBP	Signal transducers and activators of transcription (STAT) factors are cytoplasmic proteins that induce gene activation in response to cytokine receptor stimulation, Following tyrosine phosphorylation, STAT proteins dimerize, translocate into the nucleus, and activate specific target genes. Activation is transient, and down-regulation of STAT signaling occurs within a few hours. In the present study, we show that the cyclin-dependent kinase inhibitor p21(WAF1/CIP1/SD11) inhibits STAT3 transcriptional activation. Following leukemia inhibitory factor stimulation, p21(WAF1/CIP1/SD11) was found to associate with STAT3 proteins in coimmunoprecipitation and pull down assays. In vivo, overexpression of p21(WAF1/CIP1/SD11) reduced transcriptional activation by STAT3 proteins but did not modify DNA binding activity. Interestingly, pull down experiments showed that p21(WAF1/CIP1/SD11) could interact with the CREB-binding coactivator protein, and inhibition of STAT3 activity by p21(WAF1/CIP1/SD11) did not occur when CREB-binding protein was overexpressed, These results suggest a model by which p21(WAF1/CIP1/SD11) functions as an inhibitor of STAT3 signaling and highlight a new activity for this cyclin-dependent kinase inhibitor.	CHU Angers, INSERM, F-49033 Angers, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Centre Hospitalier Universitaire d'Angers	Coqueret, O (corresponding author), CHU Angers, INSERM, E-9928,4 Rue Larrey, F-49033 Angers, France.	olivier.coqueret@univ-angers.fr	Coqueret, Olivier/K-9660-2015	Coqueret, Olivier/0000-0002-2843-7867				Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; CONOVER JC, 1993, DEVELOPMENT, V119, P559; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Dynlacht BD, 1997, NATURE, V389, P149, DOI 10.1038/38225; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Fritsche M, 1998, MOL CELL ENDOCRINOL, V143, P143, DOI 10.1016/S0303-7207(98)00140-3; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARPER JW, 1993, CELL, V75, P805; Haspel RL, 1999, P NATL ACAD SCI USA, V96, P10188, DOI 10.1073/pnas.96.18.10188; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; Hirano T, 1998, Int Rev Immunol, V16, P249; Hoey T, 1998, CURR OPIN GENET DEV, V8, P582, DOI 10.1016/S0959-437X(98)80015-4; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kim HK, 1998, MOL CELL BIOL, V18, P1525, DOI 10.1128/MCB.18.3.1525; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Robledo O, 1996, J NEUROCHEM, V66, P1391; Schaefer TS, 1997, MOL CELL BIOL, V17, P5307, DOI 10.1128/MCB.17.9.5307; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Shuai K, 1996, MOL CELL BIOL, V16, P4932; Solvason N, 1996, J EXP MED, V184, P407, DOI 10.1084/jem.184.2.407; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Sudarshan C, 1999, J IMMUNOL, V162, P2974; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4	63	130	137	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18794	18800		10.1074/jbc.M001601200	http://dx.doi.org/10.1074/jbc.M001601200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10764767	hybrid			2022-12-27	WOS:000087815900026
J	Desai, U; Swanson, R; Bock, SC; Bjork, I; Olson, ST				Desai, U; Swanson, R; Bock, SC; Bjork, I; Olson, ST			Role of arginine 129 in heparin binding and activation of antithrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY HEPARIN; SERPIN-PROTEINASE COMPLEX; REACTIVE CENTER LOOP; FACTOR-XA; RECOMBINANT ANTITHROMBIN; PLASMINOGEN-ACTIVATOR; CONFORMATIONAL CHANGE; BETA-ANTITHROMBIN; ANTI-THROMBIN; MECHANISM	The contribution of Arg(129) of the serpin, antithrombin, to the mechanism of allosteric activation of the protein by heparin was determined from the effect of mutating this residue to either His or Gln. R129H and R129Q antithrombins bound pentasaccharide and full-length heparins containing the antithrombin recognition sequence with similar large reductions in affinity ranging from 400- to 2500-fold relative to the control serpin, corresponding to a loss of 28-35% of the binding free energy. The salt dependence of pentasaccharide binding showed that the binding defect of the mutant serpin resulted from the loss of similar to 2 ionic interactions, suggesting that Arg(129) binds the pentasaccharide cooperatively with other residues. Rapid kinetic studies showed that the mutation minimally affected the initial low affinity binding of heparin to antithrombin, but greatly affected the subsequent conformational activation of the serpin leading to high affinity heparin binding, although not enough to disfavor activation. Consistent with these findings, the mutant antithrombin was normally activated by heparin for accelerated inhibition of factor Xa and thrombin. These results support an important role for Arg(129) in an induced-fit mechanism of heparin activation of antithrombin wherein conformational activation of the serpin positions Arg(129) and other residues for cooperative interactions with the heparin pentasaccharide so as to lock the serpin in the activated state.	Univ Illinois, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA; Virginia Commonwealth Univ, Dept Med Chem, Richmond, VA 23298 USA; Univ Utah, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Dept Bioengn, Salt Lake City, UT 84132 USA; Swedish Univ Agr Sci, Uppsala Biomed Ctr, Dept Vet Med Chem, SE-75123 Uppsala, Sweden	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Virginia Commonwealth University; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Swedish University of Agricultural Sciences	Olson, ST (corresponding author), Univ Illinois, Ctr Mol Biol Oral Dis, Rm 530E,Dent M-C 860,801 S Paulina St, Chicago, IL 60612 USA.		Desai, Umesh/D-3741-2013	Desai, Umesh/0000-0002-1976-6597	NHLBI NIH HHS [HL 39888, HL 30712] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039888, R01HL030712, R29HL039888, R37HL039888] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arocas V, 1999, BIOCHEMISTRY-US, V38, P10196, DOI 10.1021/bi990686b; ATHA DH, 1984, P NATL ACAD SCI-BIOL, V81, P1030, DOI 10.1073/pnas.81.4.1030; Bjork I, 1997, ADV EXP MED BIOL, V425, P17; BJORK I, 1992, BIOCHEM J, V286, P793; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; BRENNAN SO, 1987, FEBS LETT, V219, P431, DOI 10.1016/0014-5793(87)80266-1; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; DEMOERLOOSE PA, 1987, THROMB HAEMOSTASIS, V57, P154; Desai UR, 1998, J BIOL CHEM, V273, P7478, DOI 10.1074/jbc.273.13.7478; Egelund R, 1998, BIOCHEMISTRY-US, V37, P6375, DOI 10.1021/bi973043+; ErsdalBadju E, 1997, J BIOL CHEM, V272, P19393, DOI 10.1074/jbc.272.31.19393; ERSDALBADJU E, 1995, BIOCHEM J, V310, P323, DOI 10.1042/bj3100323; FAN BQ, 1994, BIOCHEMISTRY-US, V33, P14156, DOI 10.1021/bi00251a026; GANDRILLE S, 1990, J BIOL CHEM, V265, P18997; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; Kvassman JO, 1998, BIOCHEMISTRY-US, V37, P15491, DOI 10.1021/bi9814787; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LINDAHL U, 1983, J BIOL CHEM, V258, P9826; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; Meagher JL, 2000, J BIOL CHEM, V275, P2698, DOI 10.1074/jbc.275.4.2698; NAJJAM S, 1994, BBA-MOL BASIS DIS, V1225, P135, DOI 10.1016/0925-4439(94)90070-1; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; NORDENMAN B, 1978, EUR J BIOCHEM, V90, P1, DOI 10.1111/j.1432-1033.1978.tb12567.x; OLSON ST, 1995, J BIOL CHEM, V270, P30007; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1981, J BIOL CHEM, V256, P1073; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1981, J BIOL CHEM, V256, P1065; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; Olson ST, 1997, ARCH BIOCHEM BIOPHYS, V341, P212, DOI 10.1006/abbi.1997.9973; PETITOU M, 1992, PROGR CHEM ORGANIC N, P143; PICARD V, 1995, BIOCHEMISTRY-US, V34, P8433, DOI 10.1021/bi00026a026; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; Rezaie AR, 1998, J BIOL CHEM, V273, P16824, DOI 10.1074/jbc.273.27.16824; SCHRAGGER H, 1987, ANAL BIOCHEM, V166, P368; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; SUN XJ, 1990, BIOCHEMISTRY-US, V29, P8957, DOI 10.1021/bi00490a011; Turk B, 1997, BIOCHEMISTRY-US, V36, P6682, DOI 10.1021/bi9702492; TURKO IV, 1993, FEBS LETT, V335, P9, DOI 10.1016/0014-5793(93)80429-X; VANBOECKEL CAA, 1994, NAT STRUCT BIOL, V1, P423, DOI 10.1038/nsb0794-423; Wardell MR, 1997, BIOCHEMISTRY-US, V36, P13133, DOI 10.1021/bi970664u	47	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18976	18984		10.1074/jbc.M001340200	http://dx.doi.org/10.1074/jbc.M001340200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10764763	hybrid			2022-12-27	WOS:000087815900049
J	Wu, SW; Moore, TM; Brough, GH; Whitt, SR; Chinkers, M; Li, M; Stevens, T				Wu, SW; Moore, TM; Brough, GH; Whitt, SR; Chinkers, M; Li, M; Stevens, T			Cyclic nucleotide-gated channels mediate membrane depolarization following activation of store-operated calcium entry in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLFACTORY RECEPTOR NEURONS; NITRIC-OXIDE SYNTHASE; SMOOTH-MUSCLE CELLS; FUNCTIONAL EXPRESSION; ION CHANNELS; MICROVESSEL PERMEABILITY; MONOVALENT CATIONS; BARRIER FUNCTION; PLASMA-MEMBRANE; CA2+ INFLUX	Calcium agonists induce membrane depolarization in endothelial cells through an unknown mechanism. Present studies tested the hypothesis that pulmonary artery endothelial cells express a cyclic nucleotide-gated (CNG) cation channel activated by store-operated calcium entry to produce membrane depolarization. In the whole-cell configuration, voltage-clamped cells revealed a large non-inactivating, outwardly rectifying cationic current in the absence of extra- or intracellular Ca2+ that was reduced upon replenishment of Ca2+. The inward current was non-selective for K+, Na+, Cs+, and Rb+ and was not inhibited by high tetraethylammonium concentrations. cAMP and cGMP stimulated the current and changed the cation permeability to favor Na+. Moreover, 8-bromo-cAMP stimulated the current in voltage-clamped cells in the perforated patch mode. The cationic current was inhibited by the CNG channel blocker LY83,583, and reverse transcriptase-polymerase chain reaction cloning identified expression of a CNG channel resembling that seen in olfactory neurons. Activation of store-operated calcium entry using thapsigargin increased a current through the CNG channel. Stimulation of the current paralleled pulmonary artery endothelial cell membrane depolarization, and both the current and membrane depolarization were abolished using LY83,583, Taken together, these data demonstrate activation of store-operated calcium entry stimulates a CNG channel producing membrane depolarization. Such membrane depolarization may contribute to slow feedback inhibition of store-operated calcium entry.	Univ S Alabama, Coll Med, Dept Pharmacol, Mobile, AL 36688 USA	University of South Alabama	Stevens, T (corresponding author), Univ S Alabama, Coll Med, Dept Pharmacol, MSB 3130, Mobile, AL 36688 USA.				NHLBI NIH HHS [HL47063] Funding Source: Medline; NIDDK NIH HHS [DK50151, DK55877] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055877, R29DK050151] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berridge M, 1999, CURR BIOL, V9, pR157, DOI 10.1016/S0960-9822(99)80101-8; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; BIEL M, 1994, P NATL ACAD SCI USA, V91, P3505, DOI 10.1073/pnas.91.9.3505; Bradley J, 1997, J NEUROSCI, V17, P1993; Broillet MC, 1997, NEURON, V18, P951, DOI 10.1016/S0896-6273(00)80334-7; BUCKLEY BJ, 1995, AM J PHYSIOL-CELL PH, V269, pC757, DOI 10.1152/ajpcell.1995.269.3.C757; CHINKERS M, 1992, J BIOL CHEM, V267, P18589; Demura Y, 1998, FREE RADICAL BIO MED, V25, P314, DOI 10.1016/S0891-5849(98)00056-2; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; Ding CL, 1997, AM J PHYSIOL-CELL PH, V272, pC1335, DOI 10.1152/ajpcell.1997.272.4.C1335; EISMANN E, 1994, P NATL ACAD SCI USA, V91, P1109, DOI 10.1073/pnas.91.3.1109; Feng L, 1996, FEBS LETT, V395, P77, DOI 10.1016/0014-5793(96)01011-3; Finn JT, 1996, ANNU REV PHYSIOL, V58, P395, DOI 10.1146/annurev.ph.58.030196.002143; FIRESTEIN S, 1991, J NEUROSCI, V11, P3565; FIRESTEIN S, 1991, NEURON, V6, P825, DOI 10.1016/0896-6273(91)90178-3; FRINGS S, 1995, NEURON, V15, P169, DOI 10.1016/0896-6273(95)90074-8; FRINGS S, 1992, J GEN PHYSIOL, V100, P45, DOI 10.1085/jgp.100.1.45; FURMAN RE, 1990, J GEN PHYSIOL, V96, P57, DOI 10.1085/jgp.96.1.57; GUY HR, 1991, SCIENCE, V254, P730, DOI 10.1126/science.1658932; HE P, 1991, AM J PHYSIOL, V261, pH1246, DOI 10.1152/ajpheart.1991.261.4.H1246; HE P, 1994, J APPL PHYSIOL, V76, P2288, DOI 10.1152/jappl.1994.76.6.2288; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; Kingston PA, 1999, SYNAPSE, V32, P1, DOI 10.1002/(SICI)1098-2396(199904)32:1<1::AID-SYN1>3.0.CO;2-M; Kingston PA, 1996, P NATL ACAD SCI USA, V93, P10440, DOI 10.1073/pnas.93.19.10440; KOLESNIKOV SS, 1990, FEBS LETT, V266, P96, DOI 10.1016/0014-5793(90)81515-P; KURAHASHI T, 1993, J PHYSIOL-LONDON, V466, P287; KURAHASHI T, 1990, J PHYSIOL-LONDON, V430, P355, DOI 10.1113/jphysiol.1990.sp018295; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LeindersZufall T, 1997, J NEUROSCI, V17, P4136; LeindersZufall T, 1995, J NEUROPHYSIOL, V74, P2759, DOI 10.1152/jn.1995.74.6.2759; MENINI A, 1990, J PHYSIOL-LONDON, V424, P167, DOI 10.1113/jphysiol.1990.sp018061; MISTRY DK, 1990, BRAIN RES, V535, P318, DOI 10.1016/0006-8993(90)91616-O; MOORE T, 2000, IN PRESS AM J PHYSL; Moore TM, 1998, AM J PHYSIOL-LUNG C, V275, pL574, DOI 10.1152/ajplung.1998.275.3.L574; Moore TM, 1998, AM J PHYSIOL-LUNG C, V275, pL203, DOI 10.1152/ajplung.1998.275.2.L203; Muramatsu M, 1996, J APPL PHYSIOL, V80, P1336, DOI 10.1152/jappl.1996.80.4.1336; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; Nilius B, 1998, Verh K Acad Geneeskd Belg, V60, P215; Paltauf-Doburzynska J, 1998, J PHYSIOL-LONDON, V513, P369, DOI 10.1111/j.1469-7793.1998.369bb.x; Papapetropoulos A, 1996, J CELL PHYSIOL, V167, P213, DOI 10.1002/(SICI)1097-4652(199605)167:2<213::AID-JCP4>3.0.CO;2-S; PICONES A, 1992, J GEN PHYSIOL, V100, P647, DOI 10.1085/jgp.100.4.647; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; Putney JW, 1999, BIOESSAYS, V21, P38; PUTNEY JW, 1993, SCIENCE, V262, P676, DOI 10.1126/science.8235587; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; REED RR, 1992, NEURON, V8, P205, DOI 10.1016/0896-6273(92)90287-N; Ruiz ML, 1996, J MOL CELL CARDIOL, V28, P1453, DOI 10.1006/jmcc.1996.0136; Santana LF, 1998, SCIENCE, V279, P1027, DOI 10.1126/science.279.5353.1027; SESTI F, 1994, J PHYSIOL-LONDON, V474, P203, DOI 10.1113/jphysiol.1994.sp020014; STEVENS T, 1995, P NATL ACAD SCI USA, V92, P2696, DOI 10.1073/pnas.92.7.2696; STEVENS T, 1994, AM J PHYSIOL, V266, pH1416, DOI 10.1152/ajpheart.1994.266.4.H1416; Stevens T, 1999, AM J PHYSIOL-LUNG C, V277, pL119, DOI 10.1152/ajplung.1999.277.1.L119; Stevens T, 1997, AM J PHYSIOL-LUNG C, V272, pL51, DOI 10.1152/ajplung.1997.272.1.L51; Vaca L, 1996, AM J PHYSIOL-CELL PH, V270, pC819, DOI 10.1152/ajpcell.1996.270.3.C819; VARNUM M, 1977, SCIENCE, V278, P110; Wang YP, 1996, J BIOL CHEM, V271, P5647, DOI 10.1074/jbc.271.10.5647; Watanabe H, 1998, FASEB J, V12, P341, DOI 10.1096/fasebj.12.3.341; Wells GB, 1997, BIOPHYS J, V72, P127, DOI 10.1016/S0006-3495(97)78652-1; WEYAND I, 1994, NATURE, V368, P859, DOI 10.1038/368859a0; XU X, 1994, J BIOL CHEM, V269, P12645; Yao XQ, 1999, CARDIOVASC RES, V41, P282, DOI 10.1016/S0008-6363(98)00158-8; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315; Zharikov SI, 1998, BBA-BIOMEMBRANES, V1369, P173, DOI 10.1016/S0005-2736(97)00191-0; Zharikov SI, 1997, AM J PHYSIOL-LUNG C, V272, pL78, DOI 10.1152/ajplung.1997.272.1.L78; ZUFALL F, 1994, ANNU REV BIOPH BIOM, V23, P577, DOI 10.1146/annurev.bb.23.060194.003045	66	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18887	18896		10.1074/jbc.M002795200	http://dx.doi.org/10.1074/jbc.M002795200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10764797	hybrid			2022-12-27	WOS:000087815900038
J	Brown, DA; London, E				Brown, DA; London, E			Structure and function of sphingolipid- and cholesterol-rich membrane rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							DETERGENT-RESISTANT MEMBRANES; T-CELL ACTIVATION; GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED PROTEINS; FC-EPSILON-RI; LIPID RAFTS; TYROSINE PHOSPHORYLATION; BIOLOGICAL-MEMBRANES; TRANSMEMBRANE DOMAIN; MASS-SPECTROMETRY; ANTIGEN RECEPTOR		SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Brown, DA (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	deborah.brown@sunysb.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047897] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 47897, GM 48596] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Arni S, 1998, J BIOL CHEM, V273, P28478, DOI 10.1074/jbc.273.43.28478; Bagatolli LA, 2000, BIOPHYS J, V78, P290, DOI 10.1016/S0006-3495(00)76592-1; Benting JH, 1999, J CELL BIOL, V146, P313, DOI 10.1083/jcb.146.2.313; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Bruckner K, 1999, NEURON, V22, P511, DOI 10.1016/S0896-6273(00)80706-0; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Chuang FYS, 2000, J IMMUNOL, V164, P350, DOI 10.4049/jimmunol.164.1.350; Field KA, 1999, J BIOL CHEM, V274, P1753, DOI 10.1074/jbc.274.3.1753; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; Fivaz M, 1999, TRENDS CELL BIOL, V9, P212, DOI 10.1016/S0962-8924(99)01567-6; Fridriksson EK, 1999, BIOCHEMISTRY-US, V38, P8056, DOI 10.1021/bi9828324; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Ge MT, 1999, BIOPHYS J, V77, P925, DOI 10.1016/S0006-3495(99)76943-2; Green JM, 1999, J CELL BIOL, V146, P673, DOI 10.1083/jcb.146.3.673; Green JM, 1997, J CELL BIOL, V139, P1209, DOI 10.1083/jcb.139.5.1209; HAGMANN J, 1982, BIOCHIM BIOPHYS ACTA, V720, P181, DOI 10.1016/0167-4889(82)90010-6; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; Ilangumaran S, 2000, IMMUNOL TODAY, V21, P2, DOI 10.1016/S0167-5699(99)01494-2; Jacobson K, 1999, TRENDS CELL BIOL, V9, P87, DOI 10.1016/S0962-8924(98)01495-0; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Kenworthy AK, 2000, MOL BIOL CELL, V11, P1645, DOI 10.1091/mbc.11.5.1645; Korlach J, 1999, P NATL ACAD SCI USA, V96, P8461, DOI 10.1073/pnas.96.15.8461; Krauss K, 1999, J BIOL CHEM, V274, P36921, DOI 10.1074/jbc.274.52.36921; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Lang ML, 1999, J IMMUNOL, V163, P5391; Lin J, 1999, J BIOL CHEM, V274, P28861, DOI 10.1074/jbc.274.41.28861; Lou ZK, 2000, J EXP MED, V191, P347, DOI 10.1084/jem.191.2.347; MABREY S, 1976, P NATL ACAD SCI USA, V73, P3862, DOI 10.1073/pnas.73.11.3862; Machleidt T, 2000, J CELL BIOL, V148, P17, DOI 10.1083/jcb.148.1.17; Manes S, 1999, EMBO J, V18, P6211, DOI 10.1093/emboj/18.22.6211; Martens JR, 2000, J BIOL CHEM, V275, P7443, DOI 10.1074/jbc.275.11.7443; MATEO CR, 1995, BIOPHYS J, V68, P978, DOI 10.1016/S0006-3495(95)80273-0; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; Montanari GC, 1998, IEEE T DIELECT EL IN, V5, P148, DOI 10.1109/94.660821; Moran M, 1998, IMMUNITY, V9, P787, DOI 10.1016/S1074-7613(00)80644-5; Mukherjee S, 1999, J CELL BIOL, V144, P1271, DOI 10.1083/jcb.144.6.1271; Ostermeyer AG, 1999, J BIOL CHEM, V274, P34459, DOI 10.1074/jbc.274.48.34459; PERSCHL A, 1995, J CELL SCI, V108, P1033; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Polyak MJ, 1998, J IMMUNOL, V161, P3242; Puertollano R, 1998, J BIOL CHEM, V273, P12740, DOI 10.1074/jbc.273.21.12740; Ravetch JV, 1998, ANNU REV IMMUNOL, V16, P421, DOI 10.1146/annurev.immunol.16.1.421; Ren JH, 1997, BIOCHEMISTRY-US, V36, P10213, DOI 10.1021/bi9709295; Ren JH, 1999, BIOCHEMISTRY-US, V38, P5905, DOI 10.1021/bi982942a; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; SCHMIDT CF, 1978, NATURE, V271, P775, DOI 10.1038/271775a0; Schneiter R, 1999, J CELL BIOL, V146, P741, DOI 10.1083/jcb.146.4.741; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Schutz GJ, 2000, EMBO J, V19, P892, DOI 10.1093/emboj/19.5.892; Sheets ED, 1999, J CELL BIOL, V145, P877, DOI 10.1083/jcb.145.4.877; Silvius JR, 1996, BIOCHEMISTRY-US, V35, P15198, DOI 10.1021/bi9615506; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; Weimbs T, 1997, TRENDS CELL BIOL, V7, P393, DOI 10.1016/S0962-8924(97)01130-6; Xavier R, 1999, CURR OPIN IMMUNOL, V11, P265, DOI 10.1016/S0952-7915(99)80043-0; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Xu XL, 2000, BIOCHEMISTRY-US, V39, P843, DOI 10.1021/bi992543v; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	68	1968	2026	3	257	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17221	17224		10.1074/jbc.R000005200	http://dx.doi.org/10.1074/jbc.R000005200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10770957	hybrid			2022-12-27	WOS:000087485000001
J	Gu, JM; Fukudome, K; Esmon, CT				Gu, JM; Fukudome, K; Esmon, CT			Characterization and regulation of the 5 '-flanking region of the murine endothelial protein C receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE BLOOD-VESSELS; RNA POLYMERASE-II; PURPURA FULMINANS; NUCLEOTIDE STRUCTURE; ESCHERICHIA-COLI; CYTOCHROME-C; THROMBOMODULIN; TRANSCRIPTION; IDENTIFICATION; CONCENTRATE	The protein C pathway plays a critical role in the negative regulation of blood coagulation The nucleotide sequence of the murine endothelial protein C receptor (mEPCR) gene was determined for 8.8 kilobase pairs of the genomic structure and 3.4 kilobase pairs of the 5'-flanking region. RNase protection assay revealed six major transcription start sites clustered at -100 to - 109 upstream of the translation initiation site. A series of 5'-promoter deletion fragments were fused to a luciferase reporter gene and transiently transfected into bovine aortic endothelium. Deletion of the sequence from -220 to -180 dramatically reduced luciferase expression in bovine aortic endothelial cells. This region of the murine endothelial protein C receptor gene contains one AP4 site and one SP1 site. Mutations in the core sequence of the AP4 and SP1 sites impaired both nuclear protein binding and luciferase expression. These results suggest important roles for AP4 and SP1 in the constitutive expression of mEPCR. A thrombin response element (CCCACCCC) was found to mediate the induction of mEPCR by thrombin in cell culture. Transgenic mice were developed expressing green fluorescent protein driven by the -350 to -1 or - 1080 to -1 promoter. Thrombin up-regulated mEPCR and the transgene in vivo.	Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Saga Med Sch, Dept Immunol, Saga 849, Japan; Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Howard Hughes Med Inst, Oklahoma City, OK 73104 USA	Oklahoma Medical Research Foundation; Saga University; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Howard Hughes Medical Institute	Esmon, CT (corresponding author), Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.	charles-esmon@omrf.ouhsc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054804] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL 54804] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CONWAY EM, 1988, MOL CELL BIOL, V8, P5588, DOI 10.1128/MCB.8.12.5588; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUS M, 1991, NEW ENGL J MED, V325, P1565, DOI 10.1056/NEJM199111283252207; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; ESMON CT, 1995, TRENDS CARDIOVAS MED, V5, P141, DOI 10.1016/1050-1738(95)00054-D; ESMON CT, 1989, J BIOL CHEM, V264, P4743; Fukudome K, 1998, J EXP MED, V187, P1029, DOI 10.1084/jem.187.7.1029; Fukudome K, 1996, J BIOL CHEM, V271, P17491, DOI 10.1074/jbc.271.29.17491; FUKUDOME K, 1995, J BIOL CHEM, V270, P5571, DOI 10.1074/jbc.270.10.5571; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; Hartman DL, 1998, INTENS CARE MED, V24, pS77; HEALY AM, 1995, P NATL ACAD SCI USA, V92, P850, DOI 10.1073/pnas.92.3.850; Jalbert LR, 1998, THROMB HAEMOSTASIS, V79, P310, DOI 10.1055/s-0037-1615006; Jalbert LR, 1998, J CLIN INVEST, V102, P1481, DOI 10.1172/JCI3011; Kurosawa S, 1997, J CLIN INVEST, V100, P411, DOI 10.1172/JCI119548; Laszik Z, 1997, CIRCULATION, V96, P3633; Liang Z, 1999, THROMB HAEMOSTASIS, V81, P585; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; MARIN M, 1997, CURR OPIN CELL BIOL, V9, P240; Merati G, 1999, THROMB HAEMOSTASIS, P507; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PRODY CA, 1991, J BIOL CHEM, V266, P22588; Regan LM, 1996, J BIOL CHEM, V271, P17499, DOI 10.1074/jbc.271.29.17499; RIVARD GE, 1995, J PEDIATR-US, V126, P646, DOI 10.1016/S0022-3476(95)70369-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Scarpati EM, 1996, J BIOL CHEM, V271, P3025, DOI 10.1074/jbc.271.6.3025; Simmonds RE, 1999, BLOOD, V94, P632, DOI 10.1182/blood.V94.2.632.414k24_632_641; SMITH EO, 1993, BIOCHIM BIOPHYS ACTA, V1174, P63, DOI 10.1016/0167-4781(93)90092-R; Smith OP, 1997, LANCET, V350, P1590, DOI 10.1016/S0140-6736(97)06356-3; StearnsKurosawa DJ, 1996, P NATL ACAD SCI USA, V93, P10212, DOI 10.1073/pnas.93.19.10212; TAYLOR F, 1991, BLOOD, V78, P357, DOI 10.1182/blood.V78.2.357.357; Taylor FB, 2000, BLOOD, V95, P1680, DOI 10.1182/blood.V95.5.1680.005k33_1680_1686; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; VIRBASIUS JV, 1988, J BIOL CHEM, V263, P6791; VONDERAHE D, 1993, NUCLEIC ACIDS RES, V21, P5636, DOI 10.1093/nar/21.24.5636; Xu J, 1999, J BIOL CHEM, V274, P6704, DOI 10.1074/jbc.274.10.6704; ZENTELLA A, 1991, PROG CLIN BIOL RES, V367, P9	39	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12481	12488		10.1074/jbc.275.17.12481	http://dx.doi.org/10.1074/jbc.275.17.12481			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777534	hybrid			2022-12-27	WOS:000086762300018
J	Ariizumi, K; Shen, GL; Shikano, S; Ritter, R; Zukas, P; Edelbaum, D; Morita, A; Takashima, A				Ariizumi, K; Shen, GL; Shikano, S; Ritter, R; Zukas, P; Edelbaum, D; Morita, A; Takashima, A			Cloning of a second dendritic cell-associated C-type lectin (Dectin-2) and its alternatively spliced isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL LANGERHANS CELLS; EARLY ACTIVATION ANTIGEN; RECEPTOR CDNA SEQUENCE; STIMULATING FACTOR-I; ASIALOGLYCOPROTEIN RECEPTOR; MURINE EPIDERMIS; T-CELLS; MANNOSE RECEPTOR; LIGAND-BINDING; GAMMA-CHAIN	Using a subtractive cDNA cloning strategy, we isolated previously five novel genes that were expressed abundantly by the murine dendritic cell (DC) line XS52, but not by the J774 macrophage line. One of these genes encoded a unique, DC-associated C-type lectin, termed "dectin-1." Here we report the characterization of a second novel gene that was also expressed in a DC-specific manner. Clone 1B12 encoded a type II membrane-integrated polypeptide of 209 amino acids containing a single carbohydrate recognition domain motif in the COOH terminus. The expression pattern of this molecule, termed "dectin-2," was almost indistinguishable from that for dectin-1; that is, both were expressed abundantly at mRNA and protein levels by the XS52 DC line, but not by non-DC lines, and both were detected in spleen and thymus, as well as in skin resident DC (i.e. Langerhans cells). Interestingly, reverse transcriptase-polymerase chain reaction and immunoblotting revealed multiple bands of dectin-2 transcripts and proteins suggesting molecular heterogeneity. In fact, we isolated additional cDNA clones encoding two distinct, truncated dectin-2 isoforms. Genomic analyses indicated that a full-length dectin-2 (alpha isoform) is encoded by 6 exons, whereas truncated isoforms (beta and gamma) are produced by alternative splicing. We propose that dectin-2 and its isoforms, together with dectin-1, represent a unique subfamily of DC-associated C-type lectins.	Univ Texas, SW Med Ctr, Dept Dermatol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Takashima, A (corresponding author), Univ Texas, SW Med Ctr, Dept Dermatol, Dallas, TX 75235 USA.	atakas@mednet.swmed.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044189, R01AR043777, R01AR035068] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01-AR35068, R01-AR43777, R01-AR44189] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARIIZUMI K, 1995, J IMMUNOL, V154, P6031; ARIIZUMI K, 1995, EUR J IMMUNOL, V25, P2137, DOI 10.1002/eji.1830250803; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bates EEM, 1999, J IMMUNOL, V163, P1973; BEZOUSKA K, 1995, BIOCHEM BIOPH RES CO, V208, P68, DOI 10.1006/bbrc.1995.1306; BIEBER T, 1989, J EXP MED, V170, P309, DOI 10.1084/jem.170.1.309; BIEBER T, 1992, J INVEST DERMATOL, V98, P771, DOI 10.1111/1523-1747.ep12499948; Brown MG, 1997, IMMUNOL REV, V155, P53, DOI 10.1111/j.1600-065X.1997.tb00939.x; Furukawa H, 1998, IMMUNOGENETICS, V48, P87, DOI 10.1007/s002510050407; GOLLNICK SO, 1990, J IMMUNOL, V144, P1974; Hart DNJ, 1997, BLOOD, V90, P3245, DOI 10.1182/blood.V90.9.3245; Houchins JP, 1997, J IMMUNOL, V158, P3603; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; Kitajima T, 1996, J IMMUNOL, V157, P3312; KITAJIMA T, 1995, J IMMUNOL, V155, P3794; KITAJIMA T, 1995, J IMMUNOL, V155, P5190; Kitajima T, 1996, J CLIN INVEST, V98, P142, DOI 10.1172/JCI118759; KUZIEL WA, 1987, NATURE, V328, P263, DOI 10.1038/328263a0; LOEB JA, 1988, J BIOL CHEM, V263, P9752; Matsue H, 1999, J IMMUNOL, V162, P5287; Mohamadzadeh M, 1996, J IMMUNOL, V156, P3102; Mohamadzadeh M, 1996, EUR J IMMUNOL, V26, P156, DOI 10.1002/eji.1830260124; NUNEZ R, 1995, IMMUNOL LETT, V44, P169, DOI 10.1016/0165-2478(95)00210-V; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RICE KG, 1990, J BIOL CHEM, V265, P18429; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SANFORD JP, 1990, BIOCHIM BIOPHYS ACTA, V1087, P259, DOI 10.1016/0167-4781(90)90216-O; SATO M, 1992, J BIOCHEM-TOKYO, V111, P331, DOI 10.1093/oxfordjournals.jbchem.a123758; SCHUHMACHERS G, 1995, J INVEST DERMATOL, V105, P225, DOI 10.1111/1523-1747.ep12317512; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; TAKASHIMA A, 1995, J IMMUNOL, V154, P5128; TAKEZAWA R, 1993, BIOCHIM BIOPHYS ACTA, V1172, P220, DOI 10.1016/0167-4781(93)90300-3; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; VERCELLI D, 1989, NATURE, V338, P649, DOI 10.1038/338649a0; Vivier E, 1997, IMMUNOL TODAY, V18, P286, DOI 10.1016/S0167-5699(97)80025-4; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; XU S, 1995, EUR J IMMUNOL, V25, P1018, DOI 10.1002/eji.1830250424; XU S, 1995, J IMMUNOL, V154, P2697; YING H, 1995, J IMMUNOL, V154, P2743; Yokota K, 1996, J IMMUNOL, V157, P1529; YOKOYAMA WM, 1995, CURRENT PROTOCOLS IM; YUSPA SH, 1980, CANCER RES, V40, P4694; ZIEGLER SF, 1993, EUR J IMMUNOL, V23, P1643, DOI 10.1002/eji.1830230737	44	130	138	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11957	11963		10.1074/jbc.275.16.11957	http://dx.doi.org/10.1074/jbc.275.16.11957			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766825	hybrid			2022-12-27	WOS:000086695500060
J	Bordji, K; Grillasca, JP; Gouze, JN; Magdalou, J; Schohn, H; Keller, JM; Bianchi, A; Dauca, M; Netter, P; Terlain, B				Bordji, K; Grillasca, JP; Gouze, JN; Magdalou, J; Schohn, H; Keller, JM; Bianchi, A; Dauca, M; Netter, P; Terlain, B			Evidence for the presence of peroxisome proliferator-activated receptor (PPAR) alpha and gamma and retinoid Z receptor in cartilage - PPAR gamma activation modulates the effects of interleukin-1 beta on rat chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; NUCLEAR RECEPTOR; GENE-EXPRESSION; KAPPA-B; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); DIFFERENTIAL EXPRESSION; ARTICULAR CHONDROCYTES; RHEUMATOID-ARTHRITIS; RESPONSE ELEMENTS; INHIBITION	Peroxisome proliferator-activated receptor (PPAR) alpha, PPAR gamma, and retinoid acid receptor-related orphan receptor (ROR) alpha are members of the nuclear receptor superfamily of ligand-activated transcription factors. Although they play a key role in adipocyte differentiation, lipid metabolism, or glucose homeostasis regulation, recent studies suggested that they might be involved in the inflammation control and especially in the modulation of the cytokine production. This strongly suggests that these transcriptional factors could modulate the deleterious effects of interleukin-1 (IL-1) on cartilage. However, to date, their presence in cartilage has never been investigated. By quantitative reverse transcription-polymerase chain reaction, Western blot, and immunocytochemistry analysis, we demonstrated, for the first time, the presence of PPAR alpha, PPAR gamma, and ROR alpha in rat cartilage, at both mRNA and protein levels. Comparatively, the PPAR alpha mRNA content in cartilage was much lower than in the liver but not significantly different to that of the adipose tissue. PPAR gamma mRNA expression in cartilage was weak, when compared with adipose tissue, but similar to that found in the liver. ROR alpha mRNA levels were similar in the three tissues. mRNA expression of the three nuclear receptors was very differently modulated by IL-1 or mono-iodoacetate treatments. This indicates that they should be unequally involved in the effects of IL-1 on chondrocyte, which is in accordance with results obtained in other cell types. Indeed, we showed that 15d-PGJ2 mainly, but also the drug troglitazone, that are ligands of PPAR gamma could significantly counteract the decrease in proteoglycan synthesis and NO production induced by IL-1. By contrast, PPAR alpha ligands such as Wy-14,643 or clofibrate had no effect on this process. Therefore, the presence of PPAR gamma in chondrocytes opens up new perspectives to modulate the effects of cytokines on cartilage by the use of specific ligands. The function of the two other transcription factors, PPAR alpha and ROR alpha identified in chondrocytes remains to be explored.	Univ Nancy 1, Fac Med, Pharmacol Lab, CNRS,UHP,UMR 7561, F-54505 Vandoeuvre Les Nancy, France; Univ Nancy 1, Fac Sci, Lab Biol Cellulaire Dev, Unite Propre Rech Enseignement Super 2402, F-54500 Vandoeuvre Les Nancy, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; Universite de Lorraine	Netter, P (corresponding author), Univ Nancy 1, Fac Med, Pharmacol Lab, CNRS,UHP,UMR 7561, Ave Foret de Haye,BP 184, F-54505 Vandoeuvre Les Nancy, France.	netter@facmed.u-nancy.fr	bianchi, arnaud/AAY-7059-2021	bianchi, arnaud/0000-0003-4925-5269				Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; AREND WP, 1990, ARTHRITIS RHEUM-US, V33, P305, DOI 10.1002/art.1780330302; AREND WP, 1995, ARTHRITIS RHEUM, V38, P151, DOI 10.1002/art.1780380202; Barnes PJ, 1998, CLIN SCI, V94, P557, DOI 10.1042/cs0940557; BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; Braissant O, 1998, ENDOCRINOLOGY, V139, P2748, DOI 10.1210/en.139.6.2748; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Camp HS, 1999, ENDOCRINOLOGY, V140, P392, DOI 10.1210/en.140.1.392; CARLBERG C, 1995, J PINEAL RES, V18, P171, DOI 10.1111/j.1600-079X.1995.tb00157.x; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; Cipolletta C, 1998, BRIT J PHARMACOL, V124, P1719, DOI 10.1038/sj.bjp.0702005; Colville-Nash PR, 1998, J IMMUNOL, V161, P978; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DINGLE JT, 1991, J RHEUMATOL, V18, P30; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gonzalez FJ, 1997, BIOCHIMIE, V79, P139, DOI 10.1016/S0300-9084(97)81506-4; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Guingamp C, 1997, ARTHRITIS RHEUM, V40, P1670, DOI 10.1002/art.1780400917; Hagiwara H, 1996, BIOCHEM BIOPH RES CO, V222, P220, DOI 10.1006/bbrc.1996.0725; HAUSELMANN HJ, 1992, MATRIX, V12, P116; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; Khiri H, 1996, MOL CELL PROBE, V10, P201, DOI 10.1006/mcpr.1996.0028; Koibuchi N, 1998, ENDOCRINOLOGY, V139, P2335, DOI 10.1210/en.139.5.2335; KUETTNER KE, 1982, J CELL BIOL, V93, P743, DOI 10.1083/jcb.93.3.743; LOTZ M, 1995, J RHEUMATOL, V22, P104; Missbach M, 1996, J BIOL CHEM, V271, P13515, DOI 10.1074/jbc.271.23.13515; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; Petrova TV, 1999, P NATL ACAD SCI USA, V96, P4668, DOI 10.1073/pnas.96.8.4668; POOLE AR, 1993, ARTHRITIS ALLIED CON, P279; Poynter ME, 1998, J BIOL CHEM, V273, P32833, DOI 10.1074/jbc.273.49.32833; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Saladin R, 1999, CELL GROWTH DIFFER, V10, P43; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Schrader M, 1996, J BIOL CHEM, V271, P19732, DOI 10.1074/jbc.271.33.19732; Shalom-Barak T, 1998, J BIOL CHEM, V273, P27467, DOI 10.1074/jbc.273.42.27467; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Spiegelman BM, 1998, CELL, V93, P153, DOI 10.1016/S0092-8674(00)81567-6; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Torra IP, 1999, CURR OPIN LIPIDOL, V10, P151, DOI 10.1097/00041433-199904000-00009; VidalPuig AJ, 1997, J CLIN INVEST, V99, P2416, DOI 10.1172/JCI119424; Vincenti MP, 1998, ARTHRITIS RHEUM, V41, P1987, DOI 10.1002/1529-0131(199811)41:11<1987::AID-ART14>3.3.CO;2-#; Wiesenberg I, 1998, MOL PHARMACOL, V53, P1131	46	120	137	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12243	12250		10.1074/jbc.275.16.12243	http://dx.doi.org/10.1074/jbc.275.16.12243			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766862	hybrid			2022-12-27	WOS:000086695500097
J	De Freitas, JM; Liba, A; Meneghini, R; Valentine, JS; Gralla, EB				De Freitas, JM; Liba, A; Meneghini, R; Valentine, JS; Gralla, EB			Yeast lacking Cu-Zn superoxide dismutase show altered iron homeostasis - Role of oxidative stress in iron metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE ENCODES; OXYGEN-TOXICITY; ESCHERICHIA-COLI; SULFUR PROTEINS; ABC TRANSPORTER; DNA-DAMAGE; FET3 GENE; IN-VIVO; MITOCHONDRIAL; CELLS	Saccharomyces cerervisiae lacking copper-zinc superoxide dismutase (sod1) shows a series of defects, including reduced rates of aerobic growth in synthetic glucose medium and reduced ability to grow by respiration in glycerol-rich medium. In this work, we observed that addition of iron improved the respiratory growth of the sod1 mutant and in glucose medium total intracellular iron content was higher in the sod1 mutant than in wild type cells. Transcription of the high affinity iron transporter gene, FET3, was enhanced in the sod1 mutant, suggesting that iron transport systems were up-regulated. An sod1/fet3 double mutant showed increased sensitivity to oxygen and increased transcription of FET4, an alternative, low affinity, iron transporter. We propose that this increased iron demand in the sod1 mutant may be a reflection of the cells' efforts to reconstitute iron-sulfur cluster-containing enzymes that are continuously inactivated in conditions of excess superoxide.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05599970 Sao Paulo, Brazil	University of California System; University of California Los Angeles; Universidade de Sao Paulo	Gralla, EB (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 405 Hilgard Ave, Los Angeles, CA 90095 USA.	egralla@chem.ucla.edu	Meneghini, Rogério/I-2961-2015; Valentine, Joan S/B-6665-2008	Valentine, Joan S/0000-0002-7174-925X	NIDDK NIH HHS [DK46828] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046828] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Benov L, 1998, J BIOL CHEM, V273, P10313, DOI 10.1074/jbc.273.17.10313; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Corson LB, 1999, J BIOL CHEM, V274, P27590, DOI 10.1074/jbc.274.39.27590; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; deSilva D, 1997, J BIOL CHEM, V272, P14208, DOI 10.1074/jbc.272.22.14208; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; DeSilva DM, 1996, PHYSIOL REV, V76, P31, DOI 10.1152/physrev.1996.76.1.31; Dix D, 1997, J BIOL CHEM, V272, P11770, DOI 10.1074/jbc.272.18.11770; Do TQ, 1996, P NATL ACAD SCI USA, V93, P7534, DOI 10.1073/pnas.93.15.7534; Flint DH, 1996, CHEM REV, V96, P2315, DOI 10.1021/cr950041r; Fridovich I, 1998, J EXP BIOL, V201, P1203; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GRALLA EB, 1991, J BACTERIOL, V173, P5918, DOI 10.1128/jb.173.18.5918-5920.1991; GRALLA EB, 1997, OXIDATIVE STRESS MOL, P495; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; Hassett RF, 1998, J BIOL CHEM, V273, P7628, DOI 10.1074/jbc.273.13.7628; Iyer V, 1996, P NATL ACAD SCI USA, V93, P5208, DOI 10.1073/pnas.93.11.5208; Kaiser C., 1994, METHODS YEAST GENETI; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; Kispal G, 1997, FEBS LETT, V418, P346, DOI 10.1016/S0014-5793(97)01414-2; KSENZENKO M, 1983, FEBS LETT, V155, P19, DOI 10.1016/0014-5793(83)80200-2; LAPINSKAS PJ, 1995, MOL CELL BIOL, V15, P1382; LEIGHTON J, 1995, EMBO J, V14, P188, DOI 10.1002/j.1460-2075.1995.tb06989.x; Li LT, 1998, J BIOL CHEM, V273, P22181, DOI 10.1074/jbc.273.35.22181; LIAO ZR, 1994, J INORG BIOCHEM, V55, P165, DOI 10.1016/0162-0134(94)85017-8; Lill R, 1999, BIOL CHEM, V380, P1157, DOI 10.1515/BC.1999.147; Lin SJ, 1996, MOL CELL BIOL, V16, P6303; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; LIOCHEV SI, 1994, FREE RADICAL BIO MED, V16, P29, DOI 10.1016/0891-5849(94)90239-9; LIU XF, 1992, J BIOL CHEM, V267, P18298; LIU XF, 1994, MOL CELL BIOL, V14, P7037, DOI 10.1128/MCB.14.11.7037; Longo VD, 1996, J BIOL CHEM, V271, P12275, DOI 10.1074/jbc.271.21.12275; MARBOIS BN, 1994, ARCH BIOCHEM BIOPHYS, V313, P83, DOI 10.1006/abbi.1994.1362; Maringanti S, 1999, J BACTERIOL, V181, P3792, DOI 10.1128/JB.181.12.3792-3802.1999; Meneghini R, 1997, FREE RADICAL BIO MED, V23, P783, DOI 10.1016/S0891-5849(97)00016-6; Murakami K, 1997, BIOCHEM MOL BIOL INT, V41, P481; Radisky DC, 1999, J BIOL CHEM, V274, P4497, DOI 10.1074/jbc.274.8.4497; ROSE M, 1983, METHOD ENZYMOL, V101, P167; Rouault TA, 1996, J BIOL INORG CHEM, V1, P494, DOI 10.1007/s007750050083; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; TAMAI KT, 1993, P NATL ACAD SCI USA, V90, P8013, DOI 10.1073/pnas.90.17.8013; Valentine JS, 1998, CURR OPIN CHEM BIOL, V2, P253, DOI 10.1016/S1367-5931(98)80067-7; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x	48	69	70	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11645	11649		10.1074/jbc.275.16.11645	http://dx.doi.org/10.1074/jbc.275.16.11645			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766782	hybrid			2022-12-27	WOS:000086695500017
J	Ferrandez, A; Garcia, JL; Diaz, E				Ferrandez, A; Garcia, JL; Diaz, E			Transcriptional regulation of the divergent paa catabolic operons for phenylacetic acid degradation in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; MOLECULAR CHARACTERIZATION; POSITIVE REGULATOR; PROMOTER ACTIVITY; COA CATABOLON; LAC REPRESSOR; FACTOR FADR; PATHWAY; DNA; PROTEIN	The expression of the divergently transcribed paaZ and paaABCDEFGHIJK: catabolic operons, which are responsible for phenylacetic acid (PA) degradation in Escherichia coli, is driven by the Pt and Pa promoters, respectively. To study the transcriptional regulation of the inducible paa catabolic genes, genetic and biochemical approaches were used. Gel retardation assays showing that the PaaX regulator binds specifically to the Pa and Pt promoters were complemented with in vivo experiments that indicated a PaaX-mediated repression effect on the expression of Pa-lacZ and Pz-lacZ reporter fusions. The region within the Pa and Pt promoters that is protected by the PaaX repressor in DNase I footprinting assays contains a conserved 15-base pair imperfect palindromic sequence motif that was shown, through mutational analysis, to be indispensable for PaaX binding and repression. PA-coenzyme A (PA-CoA), but not PA, specifically inhibited binding of PaaX to the target sequences, thus confirming the first intermediate of the pathway as the true inducer and PaaX as the only bacterial regulatory protein described so far that responds to an aryl-CoA compound. Superimposed in the specific PaaX-mediated regulation is transcriptional activation by the cAMP receptor protein and the integration host factor protein. These global regulators may adjust the transcriptional output from Pa and Pt promoters to the overall growth status of the cell.	CSIC, Ctr Invest Biol, Dept Mol Microbiol, E-28006 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Diaz, E (corresponding author), CSIC, Ctr Invest Biol, Dept Mol Microbiol, Velazquez 144, E-28006 Madrid, Spain.		Diaz, Eduardo/F-8605-2016; Garcia Lopez, Jose Luis/G-9139-2015	Diaz, Eduardo/0000-0002-9731-6524; Garcia Lopez, Jose Luis/0000-0002-9238-2485				[Anonymous], 1996, ESCHERICHIA COLI SAL, P1325; Arai H, 1999, MOL MICROBIOL, V33, P1132, DOI 10.1046/j.1365-2958.1999.01554.x; Azizan A, 1999, ARCH BIOCHEM BIOPHYS, V365, P299, DOI 10.1006/abbi.1999.1171; BIEK DP, 1989, J BACTERIOL, V171, P2056, DOI 10.1128/jb.171.4.2056-2065.1989; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; Cases I, 1998, CURR OPIN MICROBIOL, V1, P303, DOI 10.1016/S1369-5274(98)80034-9; DELORENZO V, 1994, METHOD ENZYMOL, V235, P386; DiRusso CC, 1998, J BIOL CHEM, V273, P33652, DOI 10.1074/jbc.273.50.33652; Eaton RW, 1997, J BACTERIOL, V179, P3171, DOI 10.1128/jb.179.10.3171-3180.1997; Ferrandez A, 1997, FEBS LETT, V406, P23, DOI 10.1016/S0014-5793(97)00228-7; Ferrandez A, 1998, J BIOL CHEM, V273, P25974, DOI 10.1074/jbc.273.40.25974; FUJITA Y, 1989, J BIOL CHEM, V264, P4201; Garcia B, 1999, J BIOL CHEM, V274, P29228, DOI 10.1074/jbc.274.41.29228; GOOSEN N, 1995, MOL MICROBIOL, V16, P1, DOI 10.1111/j.1365-2958.1995.tb02386.x; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; MACGREGOR CH, 1992, PSEUDOMONAS : MOLECULAR BIOLOGY AND BIOTECHNOLOGY, P198; Maxam A M, 1980, Methods Enzymol, V65, P499; Miller JH., 1972, EXPT MOL GENETICS; Olivera ER, 1998, P NATL ACAD SCI USA, V95, P6419, DOI 10.1073/pnas.95.11.6419; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Prieto MA, 1996, J BACTERIOL, V178, P111, DOI 10.1128/jb.178.1.111-120.1996; Prieto MA, 1997, BIOCHEM BIOPH RES CO, V232, P759, DOI 10.1006/bbrc.1997.6368; QUAIL MA, 1995, MOL MICROBIOL, V15, P519, DOI 10.1111/j.1365-2958.1995.tb02265.x; Raman N, 1997, J BIOL CHEM, V272, P30645, DOI 10.1074/jbc.272.49.30645; RASTINEJAD F, 1993, J MOL BIOL, V233, P389, DOI 10.1006/jmbi.1993.1519; ROPER DI, 1993, MOL GEN GENET, V237, P241, DOI 10.1007/BF00282806; SADLER JR, 1983, P NATL ACAD SCI-BIOL, V80, P6785, DOI 10.1073/pnas.80.22.6785; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMITZ A, 1992, APPL ENVIRON MICROB, V58, P4068, DOI 10.1128/AEM.58.12.4068-4071.1992; SCHWEIZER H, 1983, MOL GEN GENET, V192, P293, DOI 10.1007/BF00327683; USHIDA C, 1990, NUCLEIC ACIDS RES, V18, P6325, DOI 10.1093/nar/18.21.6325; Vicente M, 1999, MOL MICROBIOL, V33, P8, DOI 10.1046/j.1365-2958.1999.01445.x; Yamashita M, 1996, J BACTERIOL, V178, P2941, DOI 10.1128/jb.178.10.2941-2947.1996; Yoshida KI, 1999, J MOL BIOL, V285, P917, DOI 10.1006/jmbi.1998.2398	36	74	90	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12214	12222		10.1074/jbc.275.16.12214	http://dx.doi.org/10.1074/jbc.275.16.12214			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766858	Green Published, hybrid			2022-12-27	WOS:000086695500093
J	Plastaras, JP; Guengerich, FP; Nebert, DW; Marnett, LJ				Plastaras, JP; Guengerich, FP; Nebert, DW; Marnett, LJ			Xenobiotic-metabolizing cytochromes P450 convert prostaglandin endoperoxide to hydroxyheptadecatrienoic acid and the mutagen, malondialdehyde	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBOXANE SYNTHASE; COLORECTAL-CANCER; ESCHERICHIA-COLI; CYCLOOXYGENASE-2 EXPRESSION; SUBSTRATE-SPECIFICITY; COLONIC-CARCINOMA; GENE-EXPRESSION; HUMAN-PLATELETS; NUCLEIC-ACID; LARGE-BOWEL	Cyclooxygenases catalyze the oxygenation of arachidonic acid to prostaglandin endoperoxides. Cyclooxygenase-2- and the xenobiotic-metabolizing cytochrome P450s 1A and 3A are all aberrantly expressed during colorectal carcinogenesis. To probe for a role of P450s in prostaglandin endoperoxide metabolism, we studied the 12-hydroxyheptadecatrienoate (HHT)/malondialdehyde (MDA) synthase activity of human liver microsomes and purified P450s. We found that human liver microsomes have HHT/MDA synthase activity that is concentration-dependent and inhibited by the P450 inhibitors, ketoconazole and clotrimazole with IC50 values of 1 and 0.4 mu M, respectively. This activity does not require P450 reductase, HHT/MDA synthase activity was present in purified P450s but not in heme alone or other heme proteins. The catalytic activities of various purified P450s were determined by measuring rates of MDA production from prostaglandin endoperoxide, At 50 mu M substrate, the catalytic activities of purified human P450s varied from 10 +/- 1 to 0.62 +/- 0.02 min(-1), 3A4 >> 2E1 > 1A2, Oxabicycloheptane analogs of prostaglandin endoperoxide, U-44069 and U-46619, induced spectral changes in human P450 3A4 with K-s values of 240 +/- 20 and 130 +/- 10 mu M, respectively. These results suggest that co-expression of cyclooxygenase-a and P450s in developing cancers may contribute to genomic instability due to production of the endogenous mutagen, MDA.	Vanderbilt Univ, Sch Med, Dept Biochem, Ctr Mol Toxicol,AB Hancock Jr Mem Lab Canc Res, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH 45267 USA; Univ Cincinnati, Ctr Environm Genet, Cincinnati, OH 45267 USA	Vanderbilt University; Vanderbilt University; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Marnett, LJ (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, Ctr Mol Toxicol,AB Hancock Jr Mem Lab Canc Res, 221 Kirkland Hall, Nashville, TN 37232 USA.	marnett@toxicology.mc.vanderbilt.edu	Plastaras, John P./A-5315-2010	Plastaras, John/0000-0002-4916-9857	NATIONAL CANCER INSTITUTE [R35CA047479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALTERMAN MA, 1990, BIOMED CHROMATOGR, V4, P221, DOI 10.1002/bmc.1130040510; ANDERSON MW, 1978, PROSTAGLANDINS, V16, P563, DOI 10.1016/0090-6980(78)90186-7; BARON JA, 1991, NEW ENGL J MED, V325, P1644, DOI 10.1056/NEJM199112053252309; BASU AK, 1988, CHEM RES TOXICOL, V1, P53, DOI 10.1021/tx00001a010; BASU AK, 1983, CARCINOGENESIS, V4, P331, DOI 10.1093/carcin/4.3.331; BENNETT A, 1975, GUT, V16, P409; BENNETT A, 1977, BRIT J CANCER, V35, P881, DOI 10.1038/bjc.1977.132; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; DICZFALUSY U, 1977, FEBS LETT, V84, P271, DOI 10.1016/0014-5793(77)80704-7; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; FALK JE, 1964, PORPHYRINS METALLOPO; FOSTER JR, 1993, J PATHOL, V169, P457, DOI 10.1002/path.1711690412; Gibbs MA, 1999, DRUG METAB DISPOS, V27, P596; GILLAM EMJ, 1994, ARCH BIOCHEM BIOPHYS, V312, P59, DOI 10.1006/abbi.1994.1280; GILLAM EMJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P123, DOI 10.1006/abbi.1993.1401; Guengerich F. Peter, 1994, P1259; GUENGERICH FP, 1982, BIOCHEMISTRY-US, V21, P6019, DOI 10.1021/bi00266a045; Hakkak R, 1996, BIOCHEM PHARMACOL, V51, P61, DOI 10.1016/0006-2952(95)02154-X; HAMBERG M, 1973, P NATL ACAD SCI USA, V70, P899, DOI 10.1073/pnas.70.3.899; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P345, DOI 10.1073/pnas.71.2.345; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P3400, DOI 10.1073/pnas.71.9.3400; HECKER M, 1987, ARCH BIOCHEM BIOPHYS, V254, P124, DOI 10.1016/0003-9861(87)90088-9; HECKER M, 1989, J BIOL CHEM, V264, P141; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kim PM, 1997, FREE RADICAL BIO MED, V23, P579, DOI 10.1016/S0891-5849(97)00012-9; Kune GA, 2007, INT J EPIDEMIOL, V36, P951, DOI 10.1093/ije/dym193; Lewis DFV, 1998, CHEM-BIOL INTERACT, V115, P175, DOI 10.1016/S0009-2797(98)00068-4; MARNETT LJ, 1985, MUTAT RES, V148, P25; MAXWELL WJ, 1990, DIGESTION, V47, P160, DOI 10.1159/000200492; McFadyen MCE, 1997, BIOCHEM SOC T, V25, pS577, DOI 10.1042/bst025s577; MCKAY JA, 1995, FEBS LETT, V374, P270, DOI 10.1016/0014-5793(95)01126-Y; MCKAY JA, 1993, GUT, V34, P1234, DOI 10.1136/gut.34.9.1234; MCKAY JA, 1996, BIOCH SOC T S, V24, P327; MCLEMORE TL, 1990, J NATL CANCER I, V82, P1333, DOI 10.1093/jnci/82.16.1333; MURRAY GI, 1995, INT J EXP PATHOL, V76, P271; MURRAY GI, 1994, GUT, V35, P599, DOI 10.1136/gut.35.5.599; MURRAY GI, 1993, J PATHOL, V171, P49, DOI 10.1002/path.1711710110; MURRAY GI, 1995, J PATHOL, V177, P147, DOI 10.1002/path.1711770208; Murray GI, 1997, CANCER RES, V57, P3026; NAIR V, 1984, J AM CHEM SOC, V106, P3370, DOI 10.1021/ja00323a061; NARISAWA T, 1990, DIS COLON RECTUM, V33, P840, DOI 10.1007/BF02051919; NUSING R, 1994, VIRCHOWS ARCH, V424, P69; OMURA T, 1964, J BIOL CHEM, V239, P2370; Puga A, 1997, BIOCHEM PHARMACOL, V54, P1287, DOI 10.1016/S0006-2952(97)00417-6; ROSENBERG L, 1991, J NATL CANCER I, V83, P355, DOI 10.1093/jnci/83.5.355; SANDHU P, 1994, ARCH BIOCHEM BIOPHYS, V309, P168, DOI 10.1006/abbi.1994.1099; SETO H, 1983, B CHEM SOC JPN, V56, P1799, DOI 10.1246/bcsj.56.1799; Sheehan KM, 1999, JAMA-J AM MED ASSOC, V282, P1254, DOI 10.1001/jama.282.13.1254; SHEN RF, 1986, J BIOL CHEM, V261, P1585; SHIMADA T, 1986, J BIOL CHEM, V261, P909; Spalding J. W., 1988, NATL TOXICOL PROGRAM, V331, P5; STONE K, 1990, CHEM RES TOXICOL, V3, P33, DOI 10.1021/tx00013a006; TAYLOR MC, 1996, BIOCH SOC T S, V24, P328; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; Wang LH, 1996, J BIOL CHEM, V271, P19970, DOI 10.1074/jbc.271.33.19970; Yamamoto S, 1980, Adv Prostaglandin Thromboxane Res, V6, P27; YAU TM, 1979, MECH AGEING DEV, V11, P137, DOI 10.1016/0047-6374(79)90031-9	58	64	65	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11784	11790		10.1074/jbc.275.16.11784	http://dx.doi.org/10.1074/jbc.275.16.11784			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766802	hybrid			2022-12-27	WOS:000086695500037
J	Siddhanta, A; Backer, JM; Shields, D				Siddhanta, A; Backer, JM; Shields, D			Inhibition of phosphatidic acid synthesis alters the structure of the Golgi apparatus and inhibits secretion in endocrine cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PHOSPHATIDYLINOSITOL TRANSFER PROTEIN; PHOSPHOLIPASE-D ACTIVITY; VESICLE FORMATION; COATED VESICLES; ENDOPLASMIC-RETICULUM; ORGANELLE STRUCTURE; EXCHANGE FACTOR; BREFELDIN-A; FREE SYSTEM	In mammalian cells, activation of a Golgi-associated phospholipase D by ADP ribosylation factor results in the hydrolysis of phosphatidylcholine to form phosphatidic acid (PA), This reaction stimulates the release of nascent secretory vesicles from the trans-Golgi network of endocrine cells. To understand the role of PA in mediating secretion, me have exploited the transphosphatidylation activity of phospholipase D. Rat anterior pituitary GH3 cells, which secrete growth hormone and prolactin, were treated with 1-butanol resulting in the synthesis of phosphatidylbutanol rather than PA. Under these conditions transport from the ER through the Golgi apparatus and secretion of polypeptide hormones were inhibited quantitatively, Furthermore, the in vitro synthesis of phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P-2) by Golgi membranes was inhibited quantitatively, Most significantly, in the presence of 1-butanol the architecture of the Golgi apparatus was disrupted, resulting in its disassembly and fragmentation. Removal of the alcohol resulted in the rapid restoration of Golgi structure and secretion of growth hormone and prolactin. Our results suggest that PA stimulation of PtdIns(4,5)P-2 synthesis is required for maintaining the structural integrity and function of the Golgi apparatus.	Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Shields, D (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021860, R37DK021860] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK21860] Funding Source: Medline; NIGMS NIH HHS [GM55692] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alonso M, 1998, EUR J CELL BIOL, V76, P93, DOI 10.1016/S0171-9335(98)80021-6; Arneson LS, 1999, J BIOL CHEM, V274, P17794, DOI 10.1074/jbc.274.25.17794; Austin CD, 1996, J CELL BIOL, V135, P1471, DOI 10.1083/jcb.135.6.1471; Bi K, 1997, CURR BIOL, V7, P301, DOI 10.1016/S0960-9822(06)00153-9; BRESMER M, 1999, CELL, V96, P495; Brown FD, 1998, CURR BIOL, V8, P835, DOI 10.1016/S0960-9822(98)70326-4; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; BURKE B, 1984, CELL, V36, P847, DOI 10.1016/0092-8674(84)90034-5; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; DANOFF A, 1991, J BIOL CHEM, V266, P10004; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; de Figueiredo P, 1998, P NATL ACAD SCI USA, V95, P8642, DOI 10.1073/pnas.95.15.8642; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; Franco M, 1998, P NATL ACAD SCI USA, V95, P9926, DOI 10.1073/pnas.95.17.9926; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Godi A, 1998, P NATL ACAD SCI USA, V95, P8607, DOI 10.1073/pnas.95.15.8607; Gonatas NK, 1998, HISTOCHEM CELL BIOL, V109, P591, DOI 10.1007/s004180050257; GREEN R, 1984, J CELL BIOL, V99, P97, DOI 10.1083/jcb.99.1.97; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Herman Paul K., 1992, Trends in Cell Biology, V2, P363, DOI 10.1016/0962-8924(92)90048-R; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Kearns BG, 1998, TRENDS CELL BIOL, V8, P276, DOI 10.1016/S0962-8924(98)01281-1; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Martys JL, 1996, J BIOL CHEM, V271, P10953, DOI 10.1074/jbc.271.18.10953; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MISTELI T, 1994, J CELL BIOL, V125, P269, DOI 10.1083/jcb.125.2.269; Monier S, 1998, J CELL SCI, V111, P3427; OHASHI M, 1995, NATURE, V377, P544, DOI 10.1038/377544a0; PAGANO RE, 1983, J BIOL CHEM, V258, P2034; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; PERTILE P, 1995, J BIOL CHEM, V270, P5130, DOI 10.1074/jbc.270.10.5130; RABOUILLE C, 1995, J CELL BIOL, V129, P605, DOI 10.1083/jcb.129.3.605; Randazzo PA, 1997, J BIOL CHEM, V272, P7688; Rose K, 1995, P NATL ACAD SCI USA, V92, P12151, DOI 10.1073/pnas.92.26.12151; Roth MG, 1999, TRENDS CELL BIOL, V9, P174, DOI 10.1016/S0962-8924(99)01535-4; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Shields D, 1999, CURR OPIN CELL BIOL, V11, P489, DOI 10.1016/S0955-0674(99)80070-2; Siddhanta A, 1998, J BIOL CHEM, V273, P17995, DOI 10.1074/jbc.273.29.17995; Siddhanta U, 1998, J CELL BIOL, V143, P1647, DOI 10.1083/jcb.143.6.1647; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; Spang A, 1998, P NATL ACAD SCI USA, V95, P11199, DOI 10.1073/pnas.95.19.11199; Sreenivas A, 1998, J BIOL CHEM, V273, P16635, DOI 10.1074/jbc.273.27.16635; Stamnes M, 1998, P NATL ACAD SCI USA, V95, P13676, DOI 10.1073/pnas.95.23.13676; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; TAKIZAWA PA, 1993, CELL, V73, P1079, DOI 10.1016/0092-8674(93)90638-7; TOCKER A, 1997, NATURE, V387, P673; Tolias KF, 1998, J BIOL CHEM, V273, P18040, DOI 10.1074/jbc.273.29.18040; Tuscher O, 1997, FEBS LETT, V419, P271, DOI 10.1016/S0014-5793(97)01471-3; WAKELAM MJO, 1995, SIGNAL TRANSDUCTION, P271; Warren G, 1998, CURR OPIN CELL BIOL, V10, P493, DOI 10.1016/S0955-0674(98)80064-1; Xie ZG, 1998, P NATL ACAD SCI USA, V95, P12346, DOI 10.1073/pnas.95.21.12346; XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169	72	92	95	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12023	12031		10.1074/jbc.275.16.12023	http://dx.doi.org/10.1074/jbc.275.16.12023			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766834	hybrid			2022-12-27	WOS:000086695500069
J	Yan, SF; Lu, JS; Zou, YS; Kisiel, W; Mackman, N; Leitges, M; Steinberg, S; Pinsky, D; Stern, D				Yan, SF; Lu, JS; Zou, YS; Kisiel, W; Mackman, N; Leitges, M; Steinberg, S; Pinsky, D; Stern, D			Protein kinase C-beta and oxygen deprivation - A novel Egr-1-dependent pathway for fibrin deposition in hypoxemic vasculature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR-1; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; GLUCOSE-TRANSPORT; ENDOTHELIAL-CELLS; PKC-BETA; INDUCTION; MICE; RAT; DEATH	Fibrin deposition is a salient feature of hypoxemic vasculature and results from induction of tissue factor. Such tissue factor expression in an oxygen deficient environment is driven by the transcription factor Early Growth Response (Egr)-1. Using homozygous null mice for the protein kinase C beta-isoform gene (PKC beta null), PKC beta is shown to be upstream of Egr-1 in this oxygen deprivation-mediated pathway for triggering procoagulant events. Whereas wild-type mice exposed to hypoxia (6%) displayed a robust increase in tissue factor transcripts and antigen, and vascular fibrin deposition, PKC beta null animals showed a markedly blunted response. Consistent with a central role for Egr-1 in hypoxia-induced expression of tissue factor, PKC beta null mice subjected to oxygen deprivation displayed at most a minor elevation in Egr-1 transcripts, antigen, and intensity of the gel shift band by electrophoretic mobility shift assay, compared with normoxic animals. These data firmly establish PKC beta as a trigger for events leading to induction of Egr-1 and tissue factor under hypoxic conditions, and provide insight into a biologic cascade whereby oxygen deprivation recruits targets of PKC beta and Egr-1, thereby amplifying the cellular response.	Columbia Univ Coll Phys & Surg, Dept Surg, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Physiol & Cellular Biophys, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med & Pharmacol, New York, NY 10032 USA; Univ New Mexico, Sch Med, Dept Pathol, Albuquerque, NM 87131 USA; Scripps Res Inst, Dept Immunol & Vasc Biol, La Jolla, CA 92037 USA; Max Planck Inst Immunbiol, Mol Embryol Unit, D-79108 Freiburg, Germany	Columbia University; Columbia University; Columbia University; University of New Mexico; Scripps Research Institute; Max Planck Society	Yan, SF (corresponding author), Columbia Univ Coll Phys & Surg, Dept Surg, P&S 11-420,630 W 168th St, New York, NY 10032 USA.		Leitges, Michael/AAN-1953-2021		NHLBI NIH HHS [HL63967, HL48872, HL42507] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048872, R01HL042507, R37HL063967, R01HL063967] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; Bandyopadhyay G, 1997, ENDOCRINOLOGY, V138, P4721, DOI 10.1210/en.138.11.4721; Bowman JC, 1997, J CLIN INVEST, V100, P2189, DOI 10.1172/JCI119755; Braiman L, 1999, DIABETES, V48, P1922, DOI 10.2337/diabetes.48.10.1922; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Cain BS, 1999, J SURG RES, V81, P249, DOI 10.1006/jsre.1998.5508; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; Danis RP, 1998, INVEST OPHTH VIS SCI, V39, P171; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DiSanto E, 1997, CYTOKINE, V9, P300, DOI 10.1006/cyto.1996.0169; Efendiev R, 1999, FEBS LETT, V456, P45, DOI 10.1016/S0014-5793(99)00925-4; FATTORI E, 1994, J EXP MED, V180, P1243, DOI 10.1084/jem.180.4.1243; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FRANCIS CW, 1980, BLOOD, V56, P456; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Goekjian PG, 1999, CURR MED CHEM, V6, P877; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Hata Y, 1999, DIABETES, V48, P1145, DOI 10.2337/diabetes.48.5.1145; HEACOCK CS, 1986, INT J RADIAT ONCOL, V12, P1287, DOI 10.1016/0360-3016(86)90155-0; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; Kanashiro CA, 1998, CLIN EXP PHARMACOL P, V25, P974, DOI 10.1111/j.1440-1681.1998.tb02170.x; Kotch LE, 1999, DEV BIOL, V209, P254, DOI 10.1006/dbio.1999.9253; Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859; Kuwabara K, 1996, J BIOL CHEM, V271, P5025; Ladilov YV, 1998, CIRC RES, V82, P451, DOI 10.1161/01.RES.82.4.451; LAHIRI B, 1981, THROMB RES, V23, P103, DOI 10.1016/0049-3848(81)90243-7; Lasley RD, 1997, J MOL CELL CARDIOL, V29, P3345, DOI 10.1006/jmcc.1997.0559; Lawson CA, 1997, J CLIN INVEST, V99, P1729, DOI 10.1172/JCI119337; Leitges M, 1996, SCIENCE, V273, P788, DOI 10.1126/science.273.5276.788; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; Li JF, 1998, J BIOL CHEM, V273, P30870, DOI 10.1074/jbc.273.47.30870; LI YW, 1995, AM J PHYSIOL-HEART C, V268, pH426, DOI 10.1152/ajpheart.1995.268.1.H426; LOIKE JD, 1992, AM J PHYSIOL, V263, pC326, DOI 10.1152/ajpcell.1992.263.2.C326; MCCARRON RM, 1984, METHOD ENZYMOL, V108, P274; MICHELS C, 1993, AM J PHYSIOL, V264, pC866, DOI 10.1152/ajpcell.1993.264.4.C866; Morgan KG, 1998, ACTA PHYSIOL SCAND, V164, P495; Muller JN, 1997, J BIOL CHEM, V272, P23435, DOI 10.1074/jbc.272.37.23435; Nakamura J, 1999, DIABETES, V48, P2090, DOI 10.2337/diabetes.48.10.2090; Numaguchi K, 1996, AM J PHYSIOL-HEART C, V270, pH1634, DOI 10.1152/ajpheart.1996.270.5.H1634; Ozawa K, 1999, J BIOL CHEM, V274, P6397, DOI 10.1074/jbc.274.10.6397; Pinsky DJ, 1996, J CLIN INVEST, V97, P493, DOI 10.1172/JCI118440; Qiu YM, 1998, J CLIN INVEST, V101, P2182, DOI 10.1172/JCI1258; Rabbi MF, 1998, VIROLOGY, V245, P257, DOI 10.1006/viro.1998.9158; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Semenza GL, 1996, TRENDS CARDIOVAS MED, V6, P151, DOI 10.1016/1050-1738(96)00039-4; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Simkhovich BZ, 1998, CARDIOVASC RES, V40, P9, DOI 10.1016/S0008-6363(98)00142-4; SPEECHLYDICK ME, 1994, CIRC RES, V75, P586, DOI 10.1161/01.RES.75.3.586; Wakasaki H, 1997, P NATL ACAD SCI USA, V94, P9320, DOI 10.1073/pnas.94.17.9320; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; WYNN RM, 1994, J LAB CLIN MED, V124, P31; Yan SF, 1998, P NATL ACAD SCI USA, V95, P8298, DOI 10.1073/pnas.95.14.8298; YAN SF, 1995, J BIOL CHEM, V270, P11463, DOI 10.1074/jbc.270.19.11463; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030; Zhu H, 1999, RESP PHYSIOL, V115, P239, DOI 10.1016/S0034-5687(99)00024-9	60	45	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11921	11928		10.1074/jbc.275.16.11921	http://dx.doi.org/10.1074/jbc.275.16.11921			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766820	hybrid			2022-12-27	WOS:000086695500055
J	Brendza, KM; Sontag, CA; Saxton, WM; Gilbert, SP				Brendza, KM; Sontag, CA; Saxton, WM; Gilbert, SP			A kinesin mutation that uncouples motor domains and desensitizes the gamma-phosphate sensor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURE; CRYSTAL-STRUCTURE; ATP HYDROLYSIS; NUCLEOTIDE-BINDING; DIMERIC KINESIN; G-PROTEINS; MICROTUBULE; MECHANISM; MOTILITY; SEDIMENTATION	Conventional kinesin is a processive, microtubule-based motor protein that drives movements of membranous organelles in neurons. Amino acid Thr(291) Of Drosophila kinesin heavy chain is identical in all superfamily members and is located in alpha-helix 5 on the microtubule-binding surface of the catalytic motor domain. Substitution of methionine at Thr(291) results in complete loss of function in vivo. In vitro, the T291M mutation disrupts the ATPase cross-bridge cycle of a kinesin motor/neck construct, K401-4 (Brendza, K. M., Rose, D, J,, Gilbert, S. P,, and Saxton, W, M, (1999) J, Biol. Chem, 274, 31506-31514), The pre-steady-state kinetic analysis presented here shows that ATP binding is weakened significantly, and the rate ofATP hydrolysis is increased. The mutant motor also fails to distinguish ATP from ADP, suggesting that the contacts important for sensing the gamma-phosphate have been altered. The resuits indicate that there is a signaling defect between the motor domains of the T291M dimer, The ATPase cycles of the two motor domains appear to become kinetically uncoupled, causing them to work more independently rather than in the strict, coordinated fashion that is typical of kinesin.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA; Univ Pittsburgh, Dept Sci Biol, Pittsburgh, PA 15260 USA	Indiana University System; Indiana University Bloomington; University of Mississippi; University of Mississippi Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Gilbert, SP (corresponding author), Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046295, R37GM054141, R01GM054141] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM046295-09, R37 GM054141, GM-54141, R01 GM046295, GM-46295, R01 GM054141] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Block SM, 1998, J CELL BIOL, V140, P1281, DOI 10.1083/jcb.140.6.1281; Brendza KM, 1999, J BIOL CHEM, V274, P31506, DOI 10.1074/jbc.274.44.31506; CORREIA JJ, 1995, BIOCHEMISTRY-US, V34, P4898, DOI 10.1021/bi00014a047; Furch M, 1999, J MOL BIOL, V290, P797, DOI 10.1006/jmbi.1999.2921; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GILBERT SP, 1994, BIOCHEMISTRY-US, V33, P1951, DOI 10.1021/bi00173a044; Gilbert SP, 1998, BIOCHEMISTRY-US, V37, P792, DOI 10.1021/bi971117b; Gulick AM, 1998, BIOCHEMISTRY-US, V37, P1769, DOI 10.1021/bi972504o; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; Hoenger A, 1998, J CELL BIOL, V141, P419, DOI 10.1083/jcb.141.2.419; Hurd DD, 1996, GENETICS, V144, P1075; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Kull FJ, 1998, J MUSCLE RES CELL M, V19, P877, DOI 10.1023/A:1005489907021; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; Ma YZ, 1997, J BIOL CHEM, V272, P717, DOI 10.1074/jbc.272.2.717; Mandelkow E, 1998, TRENDS BIOCHEM SCI, V23, P429, DOI 10.1016/S0968-0004(98)01278-X; Moore JD, 1996, EMBO J, V15, P3306, DOI 10.1002/j.1460-2075.1996.tb00695.x; Moyer ML, 1996, BIOCHEMISTRY-US, V35, P6321, DOI 10.1021/bi960017n; Moyer ML, 1998, BIOCHEMISTRY-US, V37, P800, DOI 10.1021/bi9711184; Muller J, 1999, BIOL CHEM, V380, P981, DOI 10.1515/BC.1999.122; Philo JS, 2000, ANAL BIOCHEM, V279, P151, DOI 10.1006/abio.2000.4480; Philo JS, 1997, BIOPHYS J, V72, P435, DOI 10.1016/S0006-3495(97)78684-3; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Romberg L, 1998, J CELL BIOL, V140, P1407, DOI 10.1083/jcb.140.6.1407; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Sablin EP, 1998, NATURE, V395, P813, DOI 10.1038/27463; Sack S, 1997, BIOCHEMISTRY-US, V36, P16155, DOI 10.1021/bi9722498; SADHU A, 1992, J BIOL CHEM, V267, P11352; SAXTON WM, 1991, CELL, V64, P1093, DOI 10.1016/0092-8674(91)90264-Y; Song HB, 1998, NATURE, V396, P587, DOI 10.1038/25153; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3	35	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22187	22195		10.1074/jbc.M001124200	http://dx.doi.org/10.1074/jbc.M001124200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10767290	Green Accepted, hybrid			2022-12-27	WOS:000088363800061
J	Winstall, E; Sadowski, M; Kuhn, U; Wahle, E; Sachs, AB				Winstall, E; Sadowski, M; Kuhn, U; Wahle, E; Sachs, AB			The Saccharomyces cerevisiae RNA-binding protein Rbp29 functions in cytoplasmic mRNA metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST POLY(A)-BINDING PROTEIN; TRANSLATION INITIATION-FACTORS; MESSENGER-RNA; IN-VITRO; DEPENDENT TRANSLATION; POLY(A) POLYMERASE; CRYSTAL-STRUCTURE; 3'-END FORMATION; CELL VIABILITY; RECOGNITION	Here we report that the Saccharomyces cerevisiae RBP29 (SGN1, YIR001C) gene encodes a 29-kDa cytoplasmic protein that binds to mRNA in vivo. Rbp29p can be co-immunoprecipitated with the poly(A) tail-binding protein Pab1p from crude yeast extracts in a dosage-and RNA-dependent manner. In addition, recombinant Rbp29p binds preferentially to poly(A) with nanomolar binding affinity in vitro, Although RBP29 is not essential for cell viability, its deletion exacerbates the slow growth phenotype of yeast strains harboring mutations in the eIF4G genes TIP4631 and TIF4632, Furthermore, overexpression of RBP29 suppresses the temperature-sensitive growth phenotype of specific tif4631, tif4632, and pab1 alleles, These data suggest that Rbp29p is an mRNA-binding protein that plays a role in modulating the expression of cytoplasmic mRNA.	Univ Calif Berkeley, Dept Cell & Mol Biol, Berkeley, CA 94720 USA; Univ Giessen, Inst Biochem, D-35392 Giessen, Germany	University of California System; University of California Berkeley; Justus Liebig University Giessen	Sachs, AB (corresponding author), Univ Calif Berkeley, Dept Cell & Mol Biol, 401 Barker Hall, Berkeley, CA 94720 USA.	asachs@uclink4.berkeley.edu		Wahle, Elmar/0000-0003-2504-0677	NIGMS NIH HHS [GM50308] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050308] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; Allain FHT, 1997, EMBO J, V16, P5764, DOI 10.1093/emboj/16.18.5764; ALTMANN M, 1989, NUCLEIC ACIDS RES, V17, P5923, DOI 10.1093/nar/17.15.5923; Amrani N, 1997, MOL CELL BIOL, V17, P3694, DOI 10.1128/MCB.17.7.3694; ANDERSON JT, 1993, MOL CELL BIOL, V13, P2730, DOI 10.1128/MCB.13.5.2730; ANDERSON JT, 1993, MOL CELL BIOL, V13, P6102, DOI 10.1128/MCB.13.10.6102; Benoit B, 1999, NUCLEIC ACIDS RES, V27, P3771, DOI 10.1093/nar/27.19.3771; Boeck R, 1996, J BIOL CHEM, V271, P432, DOI 10.1074/jbc.271.1.432; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER C, 1988, MOL CELL BIOL, V8, P3556, DOI 10.1128/MCB.8.8.3556; Brown CE, 1998, MOL CELL BIOL, V18, P6548, DOI 10.1128/MCB.18.11.6548; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Calado A, 2000, RNA, V6, P245, DOI 10.1017/S1355838200991908; Chen ZY, 1999, EMBO J, V18, P2273, DOI 10.1093/emboj/18.8.2273; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; Entian KD, 1999, MOL GEN GENET, V262, P683, DOI 10.1007/PL00013817; FABRIZIO P, 1994, SCIENCE, V264, P261, DOI 10.1126/science.8146658; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; GOYER C, 1993, MOL CELL BIOL, V13, P4860, DOI 10.1128/MCB.13.8.4860; GRONER B, 1975, J BIOL CHEM, V250, P5640; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; Hershey PEC, 1999, J BIOL CHEM, V274, P21297, DOI 10.1074/jbc.274.30.21297; Kessler MM, 1997, GENE DEV, V11, P2545, DOI 10.1101/gad.11.19.2545; Kessler SH, 1998, MOL CELL BIOL, V18, P51, DOI 10.1128/MCB.18.1.51; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; KRAUSE S, 1994, EXP CELL RES, V214, P75, DOI 10.1006/excr.1994.1235; Martin G, 1996, EMBO J, V15, P2593, DOI 10.1002/j.1460-2075.1996.tb00617.x; MINVIELLESEBASTIA L, 1991, MOL CELL BIOL, V11, P3075, DOI 10.1128/MCB.11.6.3075; MinvielleSebastia L, 1997, P NATL ACAD SCI USA, V94, P7897, DOI 10.1073/pnas.94.15.7897; Neff CL, 1999, MOL CELL BIOL, V19, P5557; NEMETH A, 1995, NUCLEIC ACIDS RES, V23, P4034, DOI 10.1093/nar/23.20.4034; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; Otero LJ, 1999, EMBO J, V18, P3153, DOI 10.1093/emboj/18.11.3153; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PATEL D, 1992, MOL CELL BIOL, V12, P3297, DOI 10.1128/MCB.12.7.3297; PREKER PJ, 1995, CELL, V81, P379, DOI 10.1016/0092-8674(95)90391-7; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; SACHS AB, 1985, MOL CELL BIOL, V5, P1993, DOI 10.1128/MCB.5.8.1993; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SACHS AB, 1987, MOL CELL BIOL, V7, P3268, DOI 10.1128/MCB.7.9.3268; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHMID SR, 1991, MOL CELL BIOL, V11, P3463, DOI 10.1128/MCB.11.7.3463; Siomi H, 1997, CURR OPIN GENET DEV, V7, P345, DOI 10.1016/S0959-437X(97)80148-7; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; Tarun SZ, 1997, MOL CELL BIOL, V17, P6876, DOI 10.1128/MCB.17.12.6876; Tarun SZ, 1997, P NATL ACAD SCI USA, V94, P9046, DOI 10.1073/pnas.94.17.9046; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; WAHLE E, 1991, CELL, V66, P759, DOI 10.1016/0092-8674(91)90119-J; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7; WILSON SM, 1994, J CELL BIOL, V127, P1173, DOI 10.1083/jcb.127.5.1173	57	28	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21817	21826		10.1074/jbc.M002412200	http://dx.doi.org/10.1074/jbc.M002412200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10764794	hybrid			2022-12-27	WOS:000088363800011
J	Gu, CH; Ma, YC; Benjamin, J; Littman, D; Chao, MV; Huang, XY				Gu, CH; Ma, YC; Benjamin, J; Littman, D; Chao, MV; Huang, XY			Apoptotic signaling through the beta-adrenergic receptor - A new G(s) effector pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; MOUSE LYMPHOMA-CELLS; TYROSINE-KINASE; ADENYLATE-CYCLASE; ALPHA-SUBUNIT; CYCLIC-AMP; GS-ALPHA; DNA FRAGMENTATION; TRANSGENIC MICE; T-CELLS	Stimulation of beta-adrenergic receptor normally results in signaling by the heterotrimeric G protein G(s), leading to the activation of adenylyl cyclase, production of cAMP, and activation of cAMP-dependent protein kinase (PKA), Here we report that cell death of thymocytes can be induced after stimulation of beta-adrenergic receptor, or by addition of exogenous cAMP. Apoptotic cell death in both cases was observed with the appearance of terminal deoxynucleotidyl transferase-mediated UTP end labeling reactivity and the activation of caspase-3 in S49 T cells. Using thymocytes deficient in either G alpha(s) or PKA, we find that engagement of beta-adrenergic receptors initiated a G alpha(s)-dependent, PKA-independent pathway leading to apoptosis, This alternative pathway involves Src family tyrosine kinase Lck. Furthermore, we show that Lck protein kinase activity can be directly stimulated by purified G alpha(s). Our data reveal a new signaling pathway for G alpha(s), distinct from the classical PKA pathway, that accounts for the apoptotic action of beta-adrenergic receptors.	NYU, Med Ctr, Skirball Inst, New York, NY 10016 USA; Cornell Univ, Coll Med, Grad Program Cell Biol & Genet, New York, NY 10021 USA; Cornell Univ, Coll Med, Grad Program Physiol Biophys & Mol Med, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Physiol, New York, NY 10021 USA	New York University; Cornell University; Cornell University; Cornell University	Chao, MV (corresponding author), NYU, Med Ctr, Skirball Inst, New York, NY 10016 USA.			Chao, Moses/0000-0002-6969-3744; Benjamin, Jonathan/0000-0002-6078-616X; Ma, Yongchao/0000-0002-2469-4356				ABRAMSON SN, 1988, BIOCHEM PHARMACOL, V37, P4289, DOI 10.1016/0006-2952(88)90609-0; Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; Amsterdam A, 1996, STEROIDS, V61, P252, DOI 10.1016/0039-128X(96)00031-1; Amsterdam A, 1998, STEROIDS, V63, P314, DOI 10.1016/S0039-128X(98)00016-6; BARBER DL, 1992, J BIOL CHEM, V267, P20607; Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; Berestetskaya YV, 1998, J BIOL CHEM, V273, P27816, DOI 10.1074/jbc.273.43.27816; BOURNE HR, 1975, SCIENCE, V187, P750, DOI 10.1126/science.163487; BOURNE HR, 1975, J CELL PHYSIOL, V85, P611, DOI 10.1002/jcp.1040850313; COFFINO P, 1975, J CELL PHYSIOL, V85, P603, DOI 10.1002/jcp.1040850312; Colucci WS, 1998, CLIN CARDIOL, V21, P20, DOI 10.1002/clc.4960211305; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Donovan FM, 1997, J NEUROSCI, V17, P5316; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Geng YJ, 1999, CIRC RES, V84, P34; GENG YJ, 1997, CIRCULATION S1, V96, P116; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GonzalezGarcia A, 1997, J IMMUNOL, V158, P4104; Gu CH, 1999, J NEUROSCI, V19, P3043; HAGA T, 1977, P NATL ACAD SCI USA, V74, P2016, DOI 10.1073/pnas.74.5.2016; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HERRON LR, 1993, J IMMUNOL, V151, P3450; INSEL PA, 1975, SCIENCE, V190, P896, DOI 10.1126/science.171770; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; Kleuss C, 1997, P NATL ACAD SCI USA, V94, P6116, DOI 10.1073/pnas.94.12.6116; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; LANOTTE M, 1991, J CELL PHYSIOL, V146, P73, DOI 10.1002/jcp.1041460110; LEE E, 1994, METHOD ENZYMOL, V237, P146; Liu XX, 1998, J BIOL CHEM, V273, P11685, DOI 10.1074/jbc.273.19.11685; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MAGUIRE ME, 1980, J BIOL CHEM, V255, P1030; MCCONKEY DJ, 1990, J IMMUNOL, V145, P1227; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NORTHUP JK, 1980, P NATL ACAD SCI-BIOL, V77, P6516, DOI 10.1073/pnas.77.11.6516; OYAIZU N, 1995, BIOCHEM BIOPH RES CO, V213, P994, DOI 10.1006/bbrc.1995.2227; Penninger JM, 1996, J IMMUNOL, V157, P5359; ROSS EM, 1977, P NATL ACAD SCI USA, V74, P3715, DOI 10.1073/pnas.74.9.3715; Schlottmann KE, 1996, J LEUKOCYTE BIOL, V60, P546, DOI 10.1002/jlb.60.4.546; SHIZUKUDA Y, 1997, CIRCULATION S1, V96, P745; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; Skov S, 1997, J IMMUNOL, V158, P3189; Sondhi D, 1998, BIOCHEMISTRY-US, V37, P165, DOI 10.1021/bi9722960; STEINBERG RA, 1978, CELL, V15, P1351, DOI 10.1016/0092-8674(78)90060-0; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wan Y, 1998, J BIOL CHEM, V273, P14533, DOI 10.1074/jbc.273.23.14533; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; Wang HY, 1999, J BIOL CHEM, V274, P32159, DOI 10.1074/jbc.274.45.32159; Wang HY, 1996, J BIOL CHEM, V271, P22022, DOI 10.1074/jbc.271.36.22022; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; Wolfgang WJ, 1996, P NATL ACAD SCI USA, V93, P14542, DOI 10.1073/pnas.93.25.14542; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamatsuji T, 1996, SCIENCE, V272, P1349, DOI 10.1126/science.272.5266.1349	59	95	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20726	20733		10.1074/jbc.M000152200	http://dx.doi.org/10.1074/jbc.M000152200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10767282	hybrid			2022-12-27	WOS:000088084500071
J	Pabst, S; Hazzard, JW; Antonin, W; Sudhof, TC; Jahn, R; Rizo, J; Fasshauer, D				Pabst, S; Hazzard, JW; Antonin, W; Sudhof, TC; Jahn, R; Rizo, J; Fasshauer, D			Selective interaction of complexin with the neuronal SNARE complex - Determination of the binding regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-FUSION; NEUROTRANSMITTER RELEASE; PROTEIN; SYNTAXIN; SYNAPTOBREVIN; EXOCYTOSIS; SYNAPSES; IDENTIFICATION; TRANSPORT; MECHANISM	Complexins are evolutionarily conserved proteins that specifically bind to soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complexes and thus may regulate SNARE function. Using purified proteins, we have performed a detailed analysis of the structure of complexin and of its interaction with SNARE proteins. NMR spectroscopy revealed that isolated complexins have no tertiary structure but contain an unusual alpha-helical middle domain of approximately 58 amino acids that overlaps with the most highly conserved region of the molecules. Complexins form a stable stoichiometric complex with the central domain of the ternary SNARE complex, whereas no binding was observed to monomeric SNAREs. Using a combination of limited proteolysis, deletion mutagenesis, and NMR spectroscopy, we found that the helical middle region of complexin is responsible for binding to the SNARE complex. Binding was highly sensitive to substitution of syntaxin 1 or synaptobrevin 2 with other SNARE homologs but less sensitive to substitution of SNAP-25. In addition, a stretch of 12 amino acids in the middle of the SNARE motif of syntaxin 1A was able to confer binding activity to the non-binding relative syntaxin 4, Furthermore, disassembly of ternary complexes is not affected by complexins. We conclude that complexins are specific ligands of the neuronal core complex that bind with a central alpha-helical domain, probably to the middle of the surface groove formed by synaptobrevin and syntaxin, Complexins may regulate the function of ternary complexes and control membrane fusion through this interaction.	Max Planck Inst Biophys Chem, Dept Neurobiol, D-37077 Gottingen, Germany; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dept Mol Genet, Dallas, TX 75235 USA	Max Planck Society; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Fasshauer, D (corresponding author), Max Planck Inst Biophys Chem, Dept Neurobiol, D-37077 Gottingen, Germany.		Antonin, Wolfram/P-3648-2019; Antonin, Wolfram/A-8656-2014; Fasshauer, Dirk/B-1563-2013	Antonin, Wolfram/0000-0003-4669-379X; Antonin, Wolfram/0000-0003-4669-379X; Fasshauer, Dirk/0000-0002-1040-4282; Jahn, Reinhard/0000-0003-1542-3498	NINDS NIH HHS [NS37200] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037200] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruns D, 1997, J NEUROSCI, V17, P1898; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Hazzard J, 1999, J BIOMOL NMR, V14, P203, DOI 10.1023/A:1008382027065; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; ISHIZUKA T, 1995, BIOCHEM BIOPH RES CO, V213, P1107, DOI 10.1006/bbrc.1995.2241; Itakura M, 1999, BIOCHEM BIOPH RES CO, V265, P691, DOI 10.1006/bbrc.1999.1756; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145; KAY LE, 1993, J AM CHEM SOC, V115, P2055, DOI 10.1021/ja00058a072; Lacroix E, 1998, J MOL BIOL, V284, P173, DOI 10.1006/jmbi.1998.2145; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Margittai M, 1999, FEBS LETT, V446, P40, DOI 10.1016/S0014-5793(99)00028-9; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; Montecucco C, 1996, EXPERIENTIA, V52, P1026, DOI 10.1007/BF01952098; Morgans CW, 1996, J NEUROSCI, V16, P6713; Ono S, 1998, EUR J NEUROSCI, V10, P2143, DOI 10.1046/j.1460-9568.1998.00225.x; Poirier MA, 1998, J BIOL CHEM, V273, P11370, DOI 10.1074/jbc.273.18.11370; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Shao XG, 1997, NEURON, V18, P133, DOI 10.1016/S0896-6273(01)80052-0; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Takahashi S, 1999, EUR J NEUROSCI, V11, P2359, DOI 10.1046/j.1460-9568.1999.00652.x; TAKAHASHI S, 1995, FEBS LETT, V368, P455, DOI 10.1016/0014-5793(95)00713-J; TAKUMARU H, 1999, ABSTR SOC NEUROSCI, V25, P1748; Weimbs T, 1998, TRENDS CELL BIOL, V8, P260, DOI 10.1016/S0962-8924(98)01285-9; Wong SH, 1999, MOL BIOL CELL, V10, P119, DOI 10.1091/mbc.10.1.119; Xu T, 1999, CELL, V99, P713, DOI 10.1016/S0092-8674(00)81669-4; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	43	140	150	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19808	19818		10.1074/jbc.M002571200	http://dx.doi.org/10.1074/jbc.M002571200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10777504	hybrid			2022-12-27	WOS:000087941300052
J	Fucini, RV; Navarrete, A; Vadakkan, C; Lacomis, L; Erdjument-Bromage, H; Tempst, P; Stamnes, M				Fucini, RV; Navarrete, A; Vadakkan, C; Lacomis, L; Erdjument-Bromage, H; Tempst, P; Stamnes, M			Activated ADP-ribosylation factor assembles distinct pools of actin on Gel membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COP-COATED VESICLES; GTP-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; TRANSPORT VESICLES; ENDOSOME FUNCTION; MAMMALIAN-CELLS; COMPLEX; SPECTRIN; BETA; ARF6	The small GTP-binding protein ADP-ribosylation factor (ARF) has been shown to regulate the interaction of actin and actin-binding proteins with the Golgis apparatus. Here we report that ARF activation stimulates the assembly of distinct pools of actin on Golgi membranes. One pool of actin cofractionates with coatomer (COPI)-coated vesicles and is sensitive to salt extraction and the plus end actin-binding toxin cytochalasin D. A second ARF-dependent actin pool remains on the Golgi membranes following vesicle extraction and is insensitive to cytochalasin D. Isolation of the salt-extractable ARF-dependent actin from the Golgi reveals that it is bound to a distinct repertoire of actin-binding proteins. The two abundant actin-binding proteins of the ARF-dependent actin complex are identified as spectrin and drebrin. We show that drebrin is a specific component of the cytochalasin D-sensitive, ARF-dependent actin pool on the Golgi. Finally, we show that depolymerization of this actin pool with cytochalasin D increases the extent of the salt-dependent release of COPI-coated vesicles from the Golgi following cell-free budding reactions. Together these data suggest that regulation of the actin-based cytoskeleton may play an important role during ARF-mediated transport vesicle assembly or release on the Golgi.	Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	University of Iowa; Memorial Sloan Kettering Cancer Center	Stamnes, M (corresponding author), Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA.			Stamnes, Mark/0000-0002-5869-7985; Tempst, Paul/0000-0002-6680-3987; Erdjument-Bromage, Hediye/0000-0003-0224-3594				ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; Beck KA, 1997, J CELL SCI, V110, P1239; Blader IJ, 1999, MOL BIOL CELL, V10, P581, DOI 10.1091/mbc.10.3.581; Bremser M, 1999, CELL, V96, P495, DOI 10.1016/S0092-8674(00)80654-6; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; Daro E, 1997, J CELL BIOL, V139, P1747, DOI 10.1083/jcb.139.7.1747; Devarajan P, 1996, J CELL BIOL, V133, P819, DOI 10.1083/jcb.133.4.819; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; Franco M, 1999, EMBO J, V18, P1480, DOI 10.1093/emboj/18.6.1480; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Godi A, 1998, P NATL ACAD SCI USA, V95, P8607, DOI 10.1073/pnas.95.15.8607; GRIFFITHS G, 1994, J CELL BIOL, V127, P1557, DOI 10.1083/jcb.127.6.1557; Gu F, 1997, J CELL BIOL, V139, P1183, DOI 10.1083/jcb.139.5.1183; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; Heimann K, 1999, J BIOL CHEM, V274, P10743, DOI 10.1074/jbc.274.16.10743; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; Holleran EA, 1998, TRENDS CELL BIOL, V8, P26, DOI 10.1016/S0962-8924(97)01195-1; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Keon BH, 2000, J CELL SCI, V113, P325; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MANN M, 1993, BIOL MASS SPECTROM, V22, P338, DOI 10.1002/bms.1200220605; Meacci E, 1999, J BIOL CHEM, V274, P18605, DOI 10.1074/jbc.274.26.18605; Orci L, 1998, P NATL ACAD SCI USA, V95, P2279, DOI 10.1073/pnas.95.5.2279; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; Peitsch WK, 1999, EUR J CELL BIOL, V78, P767, DOI 10.1016/S0171-9335(99)80027-2; Radhakrishna H, 1999, J CELL SCI, V112, P855; Roth MG, 1999, TRENDS CELL BIOL, V9, P174, DOI 10.1016/S0962-8924(99)01535-4; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; Shimohama S, 1998, BIOCHEM BIOPH RES CO, V251, P394, DOI 10.1006/bbrc.1998.9480; Shorter J, 1999, J CELL BIOL, V146, P57, DOI 10.1083/jcb.146.1.57; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; Spang A, 1998, P NATL ACAD SCI USA, V95, P11199, DOI 10.1073/pnas.95.19.11199; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; Stankewich MC, 1998, P NATL ACAD SCI USA, V95, P14158, DOI 10.1073/pnas.95.24.14158; Stow JL, 1998, BBA-MOL CELL RES, V1404, P161, DOI 10.1016/S0167-4889(98)00055-X; Toda M, 1999, DEV BRAIN RES, V114, P193, DOI 10.1016/S0165-3806(99)00030-9; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; Valderrama F, 1998, EUR J CELL BIOL, V76, P9, DOI 10.1016/S0171-9335(98)80012-5; Valderrama F, 2000, P NATL ACAD SCI USA, V97, P1560, DOI 10.1073/pnas.97.4.1560; Wesp A, 1997, MOL BIOL CELL, V8, P2291, DOI 10.1091/mbc.8.11.2291; WHITNEY JA, 1995, CELL, V83, P703	45	80	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18824	18829		10.1074/jbc.M000024200	http://dx.doi.org/10.1074/jbc.M000024200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10777475	hybrid			2022-12-27	WOS:000087815900030
J	Smits, VAJ; van Peer, MA; Essers, MAG; Klompmaker, R; Rijksen, G; Medema, RH				Smits, VAJ; van Peer, MA; Essers, MAG; Klompmaker, R; Rijksen, G; Medema, RH			Negative growth regulation of SK-N-MC cells by bFGF defines a growth factor-sensitive point in G(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; DNA-DAMAGE; NUCLEAR-LOCALIZATION; GENE-EXPRESSION; M-PHASE; IONIZING-RADIATION; ENDOTHELIAL-CELLS; MAMMALIAN-CELLS; TYROSINE KINASE; G2 PHASE	Basic fibroblast growth factor (bFGF) has been shown to induce growth inhibition of the neuroepithelioma cell line SK-N-MC, Here we show that this growth inhibition occurs in G(2). We show that bFGF is active on these cells during S and early G(2) phase. Therefore, this constitutes a rather unusual mechanism of growth inhibition, because it is generally believed that cells become refractory to extracellular signals after passage through the restriction point. We show that bFGF treatment inhibits Tyr-15 dephosphorylation of cdc2 and prevents activation of Cdc25C, similar to what is seen upon activation of the G(2) DNA damage checkpoint. Interestingly, both DNA damage- and bFGF-induced effects on cdc2 phosphorylation are reverted by caffeine. To confirm the involvement of similar pathways induced by bFGF and DNA damage, we generated tetracycline-regulatable SK-N-MC clones expressing Cdc25C-S216A. Expression of this Cdc25C mutant can revert the bFGF-induced effects on cdc2 phosphorylation and can rescue cells from the block in G(2) imposed by bFGF. Taken together, these data define a growth factor-sensitive point in G(2) that most likely involves regulation of Cdc25C phosphorylation.	Univ Med Ctr Utrecht, Dept Hematol, Jordan Lab, NL-3508 GA Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Medema, RH (corresponding author), Univ Med Ctr Utrecht, Dept Hematol, Jordan Lab, G03-647,POB 85500, NL-3508 GA Utrecht, Netherlands.		Essers, Marieke A.G./B-7758-2017; Smits, Veronique A.J./R-2302-2019; Medema, Rene H/G-5415-2011; Medema, Rene H/E-2981-2013	Essers, Marieke A.G./0000-0003-3117-1809; Smits, Veronique A.J./0000-0002-9160-4525; Medema, Rene/0000-0002-6754-0381				Abrieu A, 1997, EMBO J, V16, P6407, DOI 10.1093/emboj/16.21.6407; ALBERS MW, 1993, J BIOL CHEM, V268, P22825; BARTH H, 1994, EXP CELL RES, V212, P383, DOI 10.1006/excr.1994.1158; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; FUKS Z, 1994, CANCER RES, V54, P2582; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GOSPODAROWICZ D, 1974, NATURE, V249, P123, DOI 10.1038/249123a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HAIMOVITZFRIEDMAN A, 1991, CANCER RES, V51, P2552; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFMANN J, 1994, BIOCHEM BIOPH RES CO, V199, P937, DOI 10.1006/bbrc.1994.1319; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; JUNG M, 1994, CANCER RES, V54, P5194; KHARBANDA S, 1994, CANCER RES, V54, P1412; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KINZEL V, 1990, CANCER RES, V50, P7932; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Moll UM, 1996, MOL CELL BIOL, V16, P1126; Nishijima H, 1997, J CELL BIOL, V138, P1105, DOI 10.1083/jcb.138.5.1105; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; TAMEMOTO H, 1992, J BIOL CHEM, V267, P20293; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; vanPuijenbroek AAFL, 1997, ONCOGENE, V14, P1147, DOI 10.1038/sj.onc.1200911	43	19	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19375	19381		10.1074/jbc.M001764200	http://dx.doi.org/10.1074/jbc.M001764200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10770932	hybrid			2022-12-27	WOS:000087815900098
J	Boyer, LA; Shao, X; Ebright, RH; Peterson, CL				Boyer, LA; Shao, X; Ebright, RH; Peterson, CL			Roles of the histone H2A-H2B dimers and the (H3-H4)(2) tetramer in nucleosome remodeling by the SWI-SNF complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SWI/SNF COMPLEX; ACTIVE DNA-SEQUENCES; CORE PARTICLE; TRANSCRIPTIONAL ACTIVATORS; TRANSCRIBING CHROMATIN; RNA GENE; BINDING; ARRAYS; OCTAMER; RECRUITMENT	SWI-SNF is an ATP-dependent chromatin remodeling complex required for expression of a number of yeast genes. Previous studies have suggested that SWI-SNF action may remove or rearrange the histone H2A-H2B dimers or induce a novel alteration in the histone octamer. Here, we have directly tested these and other models by quantifying the remodeling activity of SWI-SNF on arrays of (H3-H4)(2) tetramers, on nucleosomal arrays reconstituted with disulfide-linked histone H3, and on arrays reconstituted with histone H3 derivatives site-specifically modified at residue 110 with the fluorescent probe acetylethylenediamine-(1,5)-naphthol sulfonate, We find that SWI-SNF can remodel (H3-H4)(2) tetramers, although tetramers are poor substrates for SWI-SNF remodeling compared with nucleosomal arrays. SWI-SNF can also remodel nucleosomal arrays that harbor disulfide-linked (H3-H4)(2) tetramers, indicating that SWI-SNF action does not involve an obligatory disruption of the tetramer, Finally, we find that although the fluorescence emission intensity of acetylethylenediamine-(1,5)-naphthol sulfonate-modified histone H3 is sensitive to octamer structure, SWI-SNF action does not alter fluorescence emission intensity. These data suggest that perturbation of the histone octamer is not a requirement or a consequence of ATP-dependent nucleosome remodeling by SWI-SNF.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Worcester, MA 01605 USA; Rutgers State Univ, Waksman Inst, Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Chem, Piscataway, NJ 08854 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Peterson, CL (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St,Biotech 2,Suite 301, Worcester, MA 01605 USA.	craig.peterson@umassmed.edu	Ebright, Richard/O-3321-2019	Ebright, Richard/0000-0001-8915-7140	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049056, R37GM049650, R01GM049650] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM049650, R01 GM049650, GM49056-07] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEGRA P, 1987, J MOL BIOL, V196, P379, DOI 10.1016/0022-2836(87)90698-X; Auble DT, 1999, MOL CELL BIOL, V19, P412; AUSIO J, 1984, J MOL BIOL, V176, P77, DOI 10.1016/0022-2836(84)90383-8; Bazett-Jones DP, 1999, MOL CELL BIOL, V19, P1470; BazettJones DP, 1996, NUCLEIC ACIDS RES, V24, P321, DOI 10.1093/nar/24.2.321; Burns LG, 1997, BBA-GENE STRUCT EXPR, V1350, P159; Burns LG, 1997, MOL CELL BIOL, V17, P4811, DOI 10.1128/MCB.17.8.4811; CAMERINIOTERO RD, 1977, P NATL ACAD SCI USA, V74, P5519, DOI 10.1073/pnas.74.12.5519; Cantor C R, 1981, Ann N Y Acad Sci, V366, P246, DOI 10.1111/j.1749-6632.1981.tb20758.x; CHEN TA, 1991, J BIOL CHEM, V266, P6489; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Cote J, 1998, P NATL ACAD SCI USA, V95, P4947, DOI 10.1073/pnas.95.9.4947; Czarnota GJ, 1997, MICRON, V28, P419, DOI 10.1016/S0968-4328(97)00050-4; Czarnota GJ, 1996, J BIOL CHEM, V271, P3677; DABAN JR, 1989, METHOD ENZYMOL, V170, P192; DIETERICH AE, 1977, COLD SPRING HARB SYM, V42, P199; DIETERICH AE, 1979, J MOL BIOL, V129, P587, DOI 10.1016/0022-2836(79)90470-4; DONG F, 1991, P NATL ACAD SCI USA, V88, P10596, DOI 10.1073/pnas.88.23.10596; DONG F, 1990, P NATL ACAD SCI USA, V87, P5724, DOI 10.1073/pnas.87.15.5724; ESHAGHPOUR H, 1980, BIOCHEMISTRY-US, V19, P1797, DOI 10.1021/bi00550a011; FEINSTEIN DL, 1986, BIOCHEMISTRY-US, V25, P8409, DOI 10.1021/bi00374a013; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; HANSEN JC, 1992, TRENDS BIOCHEM SCI, V17, P187, DOI 10.1016/0968-0004(92)90264-A; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; HANSEN JC, 1993, J BIOL CHEM, V268, P5840; HANSEN JC, 1994, P NATL ACAD SCI USA, V91, P2339, DOI 10.1073/pnas.91.6.2339; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; HAYES JJ, 1992, P NATL ACAD SCI USA, V89, P1229, DOI 10.1073/pnas.89.4.1229; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; JASKELIOFF M, 2000, IN PRESS MOL CELL BI; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; Lee KM, 1999, BIOCHEMISTRY-US, V38, P8423, DOI 10.1021/bi990090o; Logie C, 1999, METHOD ENZYMOL, V304, P726; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Logie C, 1999, BIOCHEMISTRY-US, V38, P2514, DOI 10.1021/bi982109d; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; Lorch Y, 1998, CELL, V94, P29, DOI 10.1016/S0092-8674(00)81218-0; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Natarajan K, 1999, MOL CELL, V4, P657, DOI 10.1016/S1097-2765(00)80217-8; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; PENNINGS S, 1991, J MOL BIOL, V220, P101, DOI 10.1016/0022-2836(91)90384-I; Peterson CL, 1998, COLD SPRING HARB SYM, V63, P545, DOI 10.1101/sqb.1998.63.545; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; Pollard KJ, 1998, BIOESSAYS, V20, P771, DOI 10.1002/(SICI)1521-1878(199809)20:9<771::AID-BIES10>3.0.CO;2-V; PRIOR CP, 1983, CELL, V34, P1033, DOI 10.1016/0092-8674(83)90561-5; Protacio RU, 1996, J MOL BIOL, V256, P458, DOI 10.1006/jmbi.1996.0101; Quinn J, 1996, NATURE, V379, P844, DOI 10.1038/379844a0; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; Spangenberg C, 1998, J MOL BIOL, V278, P725, DOI 10.1006/jmbi.1998.1718; STEIN A, 1979, J MOL BIOL, V130, P103, DOI 10.1016/0022-2836(79)90421-2; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; Tse C, 1998, P NATL ACAD SCI USA, V95, P12169, DOI 10.1073/pnas.95.21.12169; Utley RT, 1997, J BIOL CHEM, V272, P12642, DOI 10.1074/jbc.272.19.12642; VARGAWEISZ PD, 1995, FEBS LETT, V369, P118, DOI 10.1016/0014-5793(95)00549-O; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; YAGER TD, 1984, J BIOL CHEM, V259, P4212; Yudkovsky N, 1999, GENE DEV, V13, P2369, DOI 10.1101/gad.13.18.2369	64	37	40	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11545	11552		10.1074/jbc.275.16.11545	http://dx.doi.org/10.1074/jbc.275.16.11545			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766768	hybrid			2022-12-27	WOS:000086695500003
J	Coughlin, BC; Teixeira, SMR; Kirchhoff, LV; Donelson, JE				Coughlin, BC; Teixeira, SMR; Kirchhoff, LV; Donelson, JE			Amastin mRNA abundance in Trypanosoma cruzi is controlled by a 3 '-untranslated region position-dependent cis-element and an untranslated region-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; GENE-EXPRESSION; DIFFERENTIAL EXPRESSION; CHAGASI PROMASTIGOTES; TARGETED INSERTION; LEISHMANIA-CHAGASI; GP63 RNAS; SITE; POLYADENYLATION; BRUCEI	The genome of Trypanosoma cruzi contains tandem arrays of alternating genes encoding amastin and tuzin. Amastin is a surface glycoprotein abundantly expressed on the intracellular mammalian amastigote form of the protozoan parasite, and tuzin is a G-like protein. We demonstrated previously that the amastin-tuzin gene cluster is polycistronically transcribed to an equal extent in all parasite life cycle stages. The steady state level of amastin mRNA, however, is 68-fold more abundant in amastigotes than in epimastigotes. Here we show that the half-life of amastin mRNA is 7 times longer in amastigotes than in epimastigotes. Linker replacement experiments demonstrate that the middle one-third of the 630-nucleotide 3'-untranslated region (UTR) is responsible for the amastin mRNA up-regulation. This positive effect is dependent on the distance of the 3'-UTR segment from the stop codon and the polyadenylation site as well as on its orientation. A protein or protein complex more abundant in amastigotes than in epimastigotes binds to this minimally defined 3'-UTR segment and may be involved in its regulatory function.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; Dept Vet Affairs Med Ctr, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Donelson, JE (corresponding author), Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA.		Donelson, John E/F-5795-2010; TEIXEIRA, SANTUZA MR/I-8137-2013		FIC NIH HHS [TW00958] Funding Source: Medline; NIAID NIH HHS [AI40591] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW000958] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040591] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abuin G, 1999, J BIOL CHEM, V274, P13041, DOI 10.1074/jbc.274.19.13041; ALY R, 1994, NUCLEIC ACIDS RES, V22, P2922, DOI 10.1093/nar/22.15.2922; GRAHAM SV, 1995, PARASITOL TODAY, V11, P217, DOI 10.1016/0169-4758(95)80081-6; Graveley BR, 1996, MOL CELL BIOL, V16, P4942; HEHL A, 1994, P NATL ACAD SCI USA, V91, P370, DOI 10.1073/pnas.91.1.370; Higgins CF, 1992, CURR OPIN GENET DEV, V2, P739, DOI 10.1016/S0959-437X(05)80134-0; Hines JC, 1997, MOL BIOCHEM PARASIT, V89, P41, DOI 10.1016/S0166-6851(97)00099-6; Holcik M, 1997, P NATL ACAD SCI USA, V94, P2410, DOI 10.1073/pnas.94.6.2410; Hotz HR, 1995, MOL BIOCHEM PARASIT, V75, P1, DOI 10.1016/0166-6851(95)02503-0; Hotz HR, 1998, MOL BIOCHEM PARASIT, V91, P131, DOI 10.1016/S0166-6851(97)00196-5; HUG M, 1994, MOL CELL BIOL, V14, P7428, DOI 10.1128/MCB.14.11.7428; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; KIRCHHOFF LV, 1984, J IMMUNOL, V133, P2731; LEBOWITZ JH, 1993, GENE DEV, V7, P996, DOI 10.1101/gad.7.6.996; McGary EC, 1997, J BIOL CHEM, V272, P8628, DOI 10.1074/jbc.272.13.8628; Otsu K, 1995, EXP PARASITOL, V81, P529, DOI 10.1006/expr.1995.1146; OTSU K, 1993, MOL BIOCHEM PARASIT, V57, P317, DOI 10.1016/0166-6851(93)90207-E; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; Peltz Stuart W., 1992, Current Opinion in Cell Biology, V4, P979, DOI 10.1016/0955-0674(92)90129-Z; Pham VP, 1997, MOL BIOCHEM PARASIT, V89, P11, DOI 10.1016/S0166-6851(97)00094-7; PIZZI T, 1957, THESIS U CHILE SANTI; RAMAMOORTHY R, 1992, J BIOL CHEM, V267, P1888; RAMAMOORTHY R, 1995, J BIOL CHEM, V270, P12133, DOI 10.1074/jbc.270.20.12133; Ramamoorthy R, 1996, MOL BIOCHEM PARASIT, V77, P65, DOI 10.1016/0166-6851(96)02581-9; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; TEIXEIRA SMR, 1994, J BIOL CHEM, V269, P20509; Teixeira SMR, 1999, EXP PARASITOL, V93, P143, DOI 10.1006/expr.1999.4446; Teixeira SMR, 1999, MOL BIOCHEM PARASIT, V98, P265, DOI 10.1016/S0166-6851(98)00158-3; TEIXEIRA SMR, 1995, J BIOL CHEM, V270, P22586, DOI 10.1074/jbc.270.38.22586; ULLU E, 1993, MOL CELL BIOL, V13, P720, DOI 10.1128/MCB.13.1.720; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; VASSELLA E, 1994, NUCLEIC ACIDS RES, V22, P1359, DOI 10.1093/nar/22.8.1359; WILLIAMS RD, 1976, IN VITRO CELL DEV B, V12, P623; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133; Zuker M, 1994, Methods Mol Biol, V25, P267	35	66	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12051	12060		10.1074/jbc.275.16.12051	http://dx.doi.org/10.1074/jbc.275.16.12051			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766837	hybrid			2022-12-27	WOS:000086695500072
J	Jhee, KH; McPhie, P; Miles, EW				Jhee, KH; McPhie, P; Miles, EW			Yeast cystathionine beta-synthase is a pyridoxal phosphate enzyme but, unlike the human enzyme, is not a heme protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	4th Meeting on PQQ and Quinoproteins	OCT 31-NOV 05, 1999	SANTA FE, NEW MEXICO				O-ACETYLSERINE SULFHYDRYLASE; TRYPTOPHAN SYNTHASE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; SALMONELLA-TYPHIMURIUM; L-SERINE; 3-DIMENSIONAL STRUCTURE; MECHANISM; IDENTIFICATION; PURIFICATION	Our studies of cystathionine beta-synthase from Saccharomyces cerevisiae (yeast) are aimed at (1) clarifying the cofactor dependence and catalytic mechanism and (2) obtaining a system for future investigations of the effects of mutations that cause human disease (homocystinuria or coronary heart disease). We report methods that yielded high expression of the yeast gene in Escherichia coli and of purified yeast cystathionine beta-synthase. The absorption and circular dichroism spectra of the homogeneous enzyme were characteristic of a pyridoxal phosphate enzyme and showed the absence of heme, which is found in human and rat cystathionine beta-synthase. The absence of heme in the yeast enzyme facilitates spectroscopic studies to probe the catalytic mechanism. The reaction of the enzyme with L-serine in the absence of L-homocysteine produced the aldimine of aminoacrylate, which absorbed at 460 nm and had a strong negative circular dichroism band at 460 nm. The formation of this intermediate from the product, L-cystathionine, demonstrates the partial reversibility of the reaction. Our results establish the overall catalytic mechanism of yeast cystathionine beta-synthase and provide a useful system for future studies of structure and function. The absence of heme in the functional yeast enzyme suggests that heme does not play an essential catalytic role in the rat and human enzymes. The results are consistent with the absence of heme in the closely related enzymes O-acetylserine sulfhydrylase, threonine deaminase, and tryptophan synthase.	NIDDK, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Miles, EW (corresponding author), NIDDK, Lab Biochem & Genet, NIH, Bldg 8,Rm 225,MSC 0830,8 Ctr Dr, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK034002, Z01DK034002, Z01DK024942, Z01DK024140, ZIHDK034002] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BORCSOK E, 1982, ARCH BIOCHEM BIOPHYS, V213, P695, DOI 10.1016/0003-9861(82)90600-2; BRAUNSTEIN AE, 1984, ADV ENZYMOL RAMB, V56, P1; BUKOVSKA G, 1994, PROTEIN EXPRES PURIF, V5, P442, DOI 10.1006/prep.1994.1063; Burkhard P, 1998, J MOL BIOL, V283, P121, DOI 10.1006/jmbi.1998.2037; Chen P, 1999, ADV ENZYME REGUL, V39, P93, DOI 10.1016/S0065-2571(98)00029-6; CHEREST H, 1993, J BACTERIOL, V175, P5366, DOI 10.1128/JB.175.17.5366-5374.1993; CHEREST H, 1992, GENETICS, V130, P51; COOK PF, 1992, BIOCHEMISTRY-US, V31, P2298, DOI 10.1021/bi00123a013; COOK PF, 1976, J BIOL CHEM, V251, P2023; DREWE WF, 1985, BIOCHEMISTRY-US, V24, P3977, DOI 10.1021/bi00336a027; DRUMMOND JT, 1995, ANAL BIOCHEM, V228, P323, DOI 10.1006/abio.1995.1358; Gallagher DT, 1998, STRUCTURE, V6, P465, DOI 10.1016/S0969-2126(98)00048-3; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; HASAN N, 1986, GENE, V50, P55, DOI 10.1016/0378-1119(86)90309-4; HYDE CC, 1988, J BIOL CHEM, V263, P17857; ISHIHARA S, 1990, J BIOCHEM-TOKYO, V108, P899, DOI 10.1093/oxfordjournals.jbchem.a123310; KAYASTHA AM, 1991, J BIOL CHEM, V266, P7618; Kery V, 1999, BIOCHEMISTRY-US, V38, P2716, DOI 10.1021/bi981808n; KERY V, 1995, ARCH BIOCHEM BIOPHYS, V316, P24, DOI 10.1006/abbi.1995.1005; Kery V, 1998, ARCH BIOCHEM BIOPHYS, V355, P222, DOI 10.1006/abbi.1998.0723; KERY V, 1994, J BIOL CHEM, V269, P25283; KRAUS J, 1978, J BIOL CHEM, V253, P6523; KRAUS JP, 1993, HUM MOL GENET, V2, P1633, DOI 10.1093/hmg/2.10.1633; KRUGER WD, 1994, P NATL ACAD SCI USA, V91, P6614, DOI 10.1073/pnas.91.14.6614; LANE AN, 1983, EUR J BIOCHEM, V129, P571; Miles E.W., 1986, PYRIDOXAL PHOSPHAT B, V1, P253; MILES EW, 1977, J BIOL CHEM, V252, P6594; MUDD SH, 1995, METABOLIC BASIS INHE, P1272; ONO B, 1992, CURR GENET, V21, P285, DOI 10.1007/BF00351684; ONO BI, 1994, YEAST, V10, P333, DOI 10.1002/yea.320100306; SCHNACKERZ KD, 1995, BIOCHEMISTRY-US, V34, P12152, DOI 10.1021/bi00038a008; SCHNACKERZ KD, 1979, BIOCHEMISTRY-US, V18, P3557, DOI 10.1021/bi00583a019; SUDA M, 1973, METHOD ENZYMOL, V17, P454; SWAROOP M, 1992, J BIOL CHEM, V267, P11455; Taoka S, 1999, BIOCHEMISTRY-US, V38, P2738, DOI 10.1021/bi9826052; Taoka S, 1998, J BIOL CHEM, V273, P25179, DOI 10.1074/jbc.273.39.25179; Taoka S, 1999, BIOCHEMISTRY-US, V38, P13155, DOI 10.1021/bi990865t; Taylor LM, 1999, J VASC SURG, V29, P8, DOI 10.1016/S0741-5214(99)70345-9; TUNAC JB, 1989, J FERMENT BIOENG, V68, P157, DOI 10.1016/0922-338X(89)90068-8; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; Woehl EU, 1996, BIOCHEMISTRY-US, V35, P4776, DOI 10.1021/bi952938o	41	72	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11541	11544		10.1074/jbc.C000056200	http://dx.doi.org/10.1074/jbc.C000056200			4	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766767	hybrid			2022-12-27	WOS:000086695500002
J	Muto, T; Feese, MD; Shimada, Y; Kudou, Y; Okamoto, T; Ozawa, T; Tahara, T; Ohashi, H; Ogami, K; Kato, T; Miyazaki, H; Kuroki, R				Muto, T; Feese, MD; Shimada, Y; Kudou, Y; Okamoto, T; Ozawa, T; Tahara, T; Ohashi, H; Ogami, K; Kato, T; Miyazaki, H; Kuroki, R			Functional analysis of the C-terminal region of recombinant human thrombopoietin - C-terminal region of thrombopoietin is a "shuttle" peptide to help secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROPOIETIN; N-GLYCOSYLATION; MPL LIGAND; CHROMOSOMAL LOCALIZATION; TYROSINE-PHOSPHORYLATION; MEGAKARYOCYTE GROWTH; BIOLOGICAL-ACTIVITY; PLATELET PRODUCTION; RECEPTOR; CLONING	Thrombopoietin (TPO) is a cytokine that primarily stimulates megakaryocytopoiesis and thrombopoiesis. TPO has a unique C-terminal tail peptide of about 160 amino acids that consists mostly of hydrophilic residues and contains six N-linked sugar chains. In order to investigate the biological function of the C-terminal. domain, two series of mutations were performed. One is systematic truncation from the C terminus. Another is elimination of N-glycosylation sites in the C-terminal domain by Asn to Gln mutations. After the mutant proteins were expressed by mammalian cells, it was found that the elimination of the N-linked sugar sites did not affect the biological activity, whereas truncation of the C-terminal domain resulted in elevation of in vitro activity up to 4-fold. The C-terminal peptide itself was found to inhibit the in vitro activity. Moreover, both the C-terminal truncation and the elimination of the N-glycosylation sites decreased the secretion level progressively down to 1/10 that of wild type, and the amount of the mutant left in the cell increased. The N-glycosylation in the C-terminal region was found to be important for secretion of TPO. Among six N-glycosylation sites in the C-terminal region, two locations, Asn-213 and Asn-234, were found to be critical for secretion, and two other locations, Asn-319 and Asn-327, did not affect the secretion.	Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanazawa Ku, Yokohama, Kanagawa 236, Japan; Kirin Brewery Co Ltd, Pharmaceut Res Lab, Takasaki, Gumma 37012, Japan	Kirin Brewery Company Limited; Kirin Brewery Company Limited	Kuroki, R (corresponding author), Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanazawa Ku, 1-13-5 Fukuura, Yokohama, Kanagawa 236, Japan.		Kato, Takashi/AFO-2557-2022	Kato, Takashi/0000-0003-0384-7971				BARTLEY TD, 1994, CELL, V77, P1117, DOI 10.1016/0092-8674(94)90450-2; CEBON J, 1990, J BIOL CHEM, V265, P4483; DELORME E, 1992, BIOCHEMISTRY-US, V31, P9871, DOI 10.1021/bi00156a003; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; Elliott S, 1996, BLOOD, V87, P2714, DOI 10.1182/blood.V87.7.2714.bloodjournal8772714; FIBI MR, 1995, BLOOD, V85, P1229, DOI 10.1182/blood.V85.5.1229.bloodjournal8551229; GURNEY AL, 1995, BLOOD, V85, P981, DOI 10.1182/blood.V85.4.981.bloodjournal854981; Hirayama Y, 1998, BLOOD, V92, P46, DOI 10.1182/blood.V92.1.46.413k44_46_52; Hoffman RC, 1996, BIOCHEMISTRY-US, V35, P14849, DOI 10.1021/bi961075b; Kato T., 1995, Blood, V86, p365A; Kato T, 1997, P NATL ACAD SCI USA, V94, P4669, DOI 10.1073/pnas.94.9.4669; KATO T, 1995, J BIOCHEM-TOKYO, V118, P229, DOI 10.1093/oxfordjournals.jbchem.a124883; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; KAWASAKI ES, 1990, COLONY STIMULATING F, P155; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUTER DJ, 1994, P NATL ACAD SCI USA, V91, P11104, DOI 10.1073/pnas.91.23.11104; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Miyakawa Y, 1996, BLOOD, V87, P439, DOI 10.1182/blood.V87.2.439.bloodjournal872439; Morita H, 1996, FEBS LETT, V395, P228, DOI 10.1016/0014-5793(96)01047-2; OGAMI K, 1995, GENE, V158, P309, DOI 10.1016/0378-1119(95)00125-P; SARENEVA T, 1994, BIOCHEM J, V303, P831, DOI 10.1042/bj3030831; SOHMA Y, 1994, FEBS LETT, V353, P57, DOI 10.1016/0014-5793(94)01008-0; Tahara T, 1996, BRIT J HAEMATOL, V93, P783, DOI 10.1046/j.1365-2141.1996.d01-1741.x; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WADA T, 1995, BIOCHEM BIOPH RES CO, V213, P1091, DOI 10.1006/bbrc.1995.2239; WENDLING F, 1994, NATURE, V369, P571, DOI 10.1038/369571a0; YAMAGUCHI K, 1991, J BIOL CHEM, V266, P20434	31	24	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12090	12094		10.1074/jbc.275.16.12090	http://dx.doi.org/10.1074/jbc.275.16.12090			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766842	hybrid			2022-12-27	WOS:000086695500077
J	Verrijdt, G; Schoenmakers, E; Haelens, A; Peeters, B; Verhoeven, G; Rombauts, W; Claessens, F				Verrijdt, G; Schoenmakers, E; Haelens, A; Peeters, B; Verhoeven, G; Rombauts, W; Claessens, F			Change of specificity mutations in androgen-selective enhancers - Evidence for a role of differential DNA binding by the androgen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID RESPONSE ELEMENT; AMINO-TERMINAL DOMAIN; MAMMARY-TUMOR VIRUS; GENE ACTIVATION; TRANSCRIPTIONAL REGULATION; STRUCTURAL DETERMINANTS; PROBASIN GENE; SLP GENE; REGION; COACTIVATOR	The androgen and glucocorticoid receptors recognize identical DNA motifs, leaving unanswered the question of how steroid specificity of transcriptional regulation is established in cells containing both receptors, Here, we protide evidence that subtle differences in low affinity DNA recognition might be a crucial element in the generation of steroid-specific responses. Here we identify simple hormone response elements in the mouse sex-limited protein enhancer and the human secretory component androgen response unit to be essential for the androgen specificity of both enhancers. We describe specific in vitro binding to these motifs by the DNA-binding domain of the androgen but not the glucocorticoid receptor. Both elements can be considered partial direct repeats of the 5'-TGTTCT-3' core binding motif. In addition, we show that specific point mutations in their left half-sites, essentially changing the nature of the repeats, strongly enhance the glucocorticoid sensitivity of the respective enhancers, whereas they have no effect on their androgen responsiveness. Accordingly, these mutations allow specific binding of the glucocorticoid receptor DNA-binding domain to both elements in, vitro. With these experiments, we demonstrate that differential recognition by the androgen receptor of nonconventional steroid response elements is, at least in some cases, an important mechanism in androgen-specific transcriptional regulation.	Katholieke Univ Leuven, Fac Med, Div Biochem, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Fac Med, Lab Expt Med & Endocrinol, B-3000 Louvain, Belgium	KU Leuven; KU Leuven	Claessens, F (corresponding author), Katholieke Univ Leuven, Fac Med, Div Biochem, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.		Claessens, Frank/M-8565-2016	Claessens, Frank/0000-0002-8676-7709				ADLER AJ, 1993, MOL CELL BIOL, V13, P6326, DOI 10.1128/MCB.13.10.6326; ADLER AJ, 1992, P NATL ACAD SCI USA, V89, P11660, DOI 10.1073/pnas.89.24.11660; Alen P, 1999, MOL CELL BIOL, V19, P6085; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; Claessens F, 1996, J BIOL CHEM, V271, P19013, DOI 10.1074/jbc.271.32.19013; CLAESSENS F, 1993, BIOCHEM BIOPH RES CO, V191, P688, DOI 10.1006/bbrc.1993.1272; CLAESSENS F, 1989, THESIS CATHOLIC U LE; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; DAHLMANWRIGHT K, 1990, J BIOL CHEM, V265, P14030; FUNDER JW, 1993, SCIENCE, V259, P1132, DOI 10.1126/science.8382375; Haelens A, 1999, MOL CELL ENDOCRINOL, V153, P91, DOI 10.1016/S0303-7207(99)00079-9; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; Huang WB, 1999, J BIOL CHEM, V274, P25756, DOI 10.1074/jbc.274.36.25756; Kasper S, 1999, J MOL ENDOCRINOL, V22, P313, DOI 10.1677/jme.0.0220313; KASPER S, 1994, J BIOL CHEM, V269, P31763; LI Q, 1995, MOL CELL BIOL, V15, P4375; LORENI F, 1988, MOL CELL BIOL, V8, P2350, DOI 10.1128/MCB.8.6.2350; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Ning YM, 1999, J BIOL CHEM, V274, P30624, DOI 10.1074/jbc.274.43.30624; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1866, DOI 10.1210/mend-4-12-1866; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; RUNDLETT SE, 1995, MOL CELL ENDOCRINOL, V109, P1, DOI 10.1016/0303-7207(95)03477-O; RUNDLETT SE, 1990, MOL ENDOCRINOL, V4, P708, DOI 10.1210/mend-4-5-708; Scarlett CO, 1997, DNA CELL BIOL, V16, P45, DOI 10.1089/dna.1997.16.45; Scheller A, 1998, J BIOL CHEM, V273, P24216, DOI 10.1074/jbc.273.37.24216; Scheller A, 1996, MOL CELL ENDOCRINOL, V121, P75, DOI 10.1016/0303-7207(96)03854-3; Schoenmakers E, 1999, BIOCHEM J, V341, P515, DOI 10.1042/0264-6021:3410515; Schoenmakers E, 2000, J BIOL CHEM, V275, P12290, DOI 10.1074/jbc.275.16.12290; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; Sui XM, 1999, J BIOL CHEM, V274, P9449, DOI 10.1074/jbc.274.14.9449; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; Verrijdt G, 1999, MOL ENDOCRINOL, V13, P1558, DOI 10.1210/me.13.9.1558; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	38	87	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12298	12305		10.1074/jbc.275.16.12298	http://dx.doi.org/10.1074/jbc.275.16.12298			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766869	hybrid			2022-12-27	WOS:000086695500104
J	Olson, NE; Kozlowski, J; Reidy, MA				Olson, NE; Kozlowski, J; Reidy, MA			Proliferation of intimal smooth muscle cells - Attenuation of basic fibroblast growth factor 2-stimulated proliferation is associated with increased expression of cell cycle inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; SWISS 3T3 CELLS; ARTERIAL INJURY; TGF-BETA; SIGNALING CASCADES; RESTRICTION POINT; LESION FORMATION; CDK INHIBITORS; DNA-SYNTHESIS; G(1) PHASE	Basic fibroblast growth factor (FGF2) is a potent mitogen for medial smooth muscle cells and is necessary for their proliferation after balloon catheter injury; however, intimal smooth muscle cells do not require FGF2 for their proliferation, and they respond only weakly to exogenous FGF2 The present study examined the activation of extracellular signal-regulated kinase (ERK) signaling as well as the expression and activity of cell cycle proteins in FGF2-stimulated intimal smooth muscle cells. FGF2 activates ERKs 1 and 2, and Western blot analysis showed that cyclin D, cyclin E, and cyclin-dependent kinase (CDKs) 2 and 4 were expressed in intimal smooth muscle cells after FGF2 infusion, FGF2 stimulation, however, did not lead to phosphorylation of the retinoblastoma protein (Rb), CDK 2 activation, or expression of cyclin A. Western blot analysis showed that intimal smooth muscle cells express elevated levels of the cell cycle inhibitors p15(INK4b) and p27(Kipl), compared with medial smooth muscle cells, and that FGF2 stimulation does not reduce the level of these inhibitors. These studies suggest that despite activation of ERKs 1 and 2 and expression of the cell cycle activators, cyclin D and cyclin E, high levels of cell cycle inhibitors may inhibit cell cycle transit in FGF2-stimulated intimal smooth muscle cells.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Olson, NE (corresponding author), Univ Washington, Dept Pathol, Box 357335, Seattle, WA 98195 USA.				NHLBI NIH HHS [HL03174, HL07312, HL41103] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041103, T32HL007312] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bouchard C, 1997, J IMMUNOL, V159, P4155; Carnero A, 1998, CURR TOP MICROBIOL, V227, P43; Chen DH, 1997, J CLIN INVEST, V99, P2334, DOI 10.1172/JCI119414; CLOWES AW, 1983, LAB INVEST, V49, P208; Coffer PJ, 1998, BIOCHEM J, V335, P1; FINGERLE J, 1990, ARTERIOSCLEROSIS, V10, P1082, DOI 10.1161/01.ATV.10.6.1082; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Greulich H, 1998, J BIOL CHEM, V273, P13280, DOI 10.1074/jbc.273.21.13280; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; Iavarone A, 1997, NATURE, V387, P417; JACKSON TR, 1992, J BIOL CHEM, V267, P16627; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; Koyama H, 1997, CIRC RES, V80, P408, DOI 10.1161/01.res.0000435857.23307.bd; Koyama H, 1998, CIRC RES, V82, P713, DOI 10.1161/01.RES.82.6.713; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; LUBINUS M, 1994, J BIOL CHEM, V269, P9822; Lukas J, 1996, MOL CELL BIOL, V16, P6917; MAJESKY MW, 1991, J CLIN INVEST, V88, P904, DOI 10.1172/JCI115393; Mann DJ, 1997, ONCOGENE, V14, P1759, DOI 10.1038/sj.onc.1201134; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Murgia C, 1998, EMBO J, V17, P3940, DOI 10.1093/emboj/17.14.3940; NIKKARI ST, 1994, AM J PATHOL, V144, P1348; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OLSON NE, 1992, AM J PATHOL, V140, P1017; OWENS GK, 1988, J CELL BIOL, V107, P771, DOI 10.1083/jcb.107.2.771; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Peeper DS, 1997, FEBS LETT, V410, P11, DOI 10.1016/S0014-5793(97)00319-0; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Scott PH, 1996, BIOCHEM J, V318, P965, DOI 10.1042/bj3180965; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Shankland SJ, 1997, KIDNEY INT, V51, P1088, DOI 10.1038/ki.1997.151; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Tanner FC, 1998, CIRC RES, V82, P396, DOI 10.1161/01.RES.82.3.396; Tombes RM, 1998, BIOCHEM J, V330, P1451; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; WEIS SRH, 1996, AM J PHYSIOL, V270, pC619; WOLF YG, 1994, J CLIN INVEST, V93, P1172, DOI 10.1172/JCI117070; Yang ZY, 1996, P NATL ACAD SCI USA, V93, P7905, DOI 10.1073/pnas.93.15.7905; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	59	36	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11270	11277		10.1074/jbc.275.15.11270	http://dx.doi.org/10.1074/jbc.275.15.11270			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753937	hybrid			2022-12-27	WOS:000086466600079
J	Peng, RW; De Antoni, A; Gallwitz, D				Peng, RW; De Antoni, A; Gallwitz, D			Evidence for overlapping and distinct functions in protein transport of coat protein Sec24p family members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; YEAST-CELLS; GENE; MEMBRANE; BINDING; MUTANT; COPII; YPT1; SUPPRESSORS	Budding of transport vesicles from the endoplasmic reticulum in yeast requires the formation, at the budding site, of a coat protein complex (COPII) that consists of two heterodimeric subcomplexes (Sec23p/Sec24p and Sec13p/Sec31p) and the Sari GTPase. Sec24p is an essential protein and involved in cargo selection. In addition to Sec24p, the yeast Saccharomyces cerevisiae expresses two non-essential Sec24p-related proteins, termed Sfb2p (product of YNL049c) and Sfb3p/Lst1p (product of YHR098c). We here show that Sfb2p and, less efficiently, Sfb3p/Lst1p are able to bind, like Sec24p, the integral membrane cargo protein Sed5p. We also demonstrate that Sfb2p, like Sec24p and Sfb3p/Lst1p, forms a complex with Sec23p in vivo, Whereas the deletion of SFB2 did not affect transport kinetics of various proteins, the maturation of the glycolipid-anchored plasma membrane protein Gas1p was differentially impaired in sfb3 knock-out cells. We generated several conditional-lethal sec24 mutants that, combined with null alleles of SFB2 and SFB3/LST1, led to a complete block of transport between the endoplasmic reticulum and the Golgi (sec24-11/Delta sfb2) or to cell death (sec24-11/Delta sfb3). Of the Sec24p family members, Sfb2p is the least abundant at steady state, but high intracellular concentrations of Sfb2p can rescue sec24 mutants under restrictive conditions. The data presented strongly suggest that the Sec24p-related proteins function as COPII components.	Max Planck Inst Biophys Chem, Dept Mol Genet, D-37070 Gottingen, Germany	Max Planck Society	Gallwitz, D (corresponding author), Max Planck Inst Biophys Chem, Dept Mol Genet, D-37070 Gottingen, Germany.	dgallwi1@gwdg.de	Peng, Ren-Wang/AAM-8542-2021	Peng, Ren-Wang/0000-0003-1199-6520; De Antoni, Anna/0000-0003-4908-1684				BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; Doering TL, 1996, EMBO J, V15, P182, DOI 10.1002/j.1460-2075.1996.tb00346.x; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gimeno RE, 1996, MOL BIOL CELL, V7, P1815, DOI 10.1091/mbc.7.11.1815; Grabowski R, 1997, FEBS LETT, V411, P169, DOI 10.1016/S0014-5793(97)00720-5; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; Harlow E., 1988, ANTIBODIES LAB MANUA; HICKE L, 1992, MOL BIOL CELL, V3, P667, DOI 10.1091/mbc.3.6.667; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; OSSIG R, 1991, MOL CELL BIOL, V11, P2980, DOI 10.1128/MCB.11.6.2980; Pagano A, 1999, J BIOL CHEM, V274, P7833, DOI 10.1074/jbc.274.12.7833; Peng RW, 1999, P NATL ACAD SCI USA, V96, P3751, DOI 10.1073/pnas.96.7.3751; Roberg KJ, 1999, J CELL BIOL, V145, P659, DOI 10.1083/jcb.145.4.659; Rowe T, 1998, SCIENCE, V279, P696, DOI 10.1126/science.279.5351.696; SCHATZ PJ, 1986, MOL CELL BIOL, V6, P3722, DOI 10.1128/MCB.6.11.3722; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SIKORSKI RS, 1989, GENETICS, V122, P19; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; Tsukada M, 1996, J CELL SCI, V109, P2471; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Wooding S, 1998, MOL BIOL CELL, V9, P2667, DOI 10.1091/mbc.9.9.2667; Yang XP, 1998, EMBO J, V17, P4954, DOI 10.1093/emboj/17.17.4954	29	80	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11521	11528		10.1074/jbc.275.15.11521	http://dx.doi.org/10.1074/jbc.275.15.11521			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753972	Green Published, hybrid			2022-12-27	WOS:000086466600114
J	Thomas, G; Bertrand, F; Saunier, B				Thomas, G; Bertrand, F; Saunier, B			The differential regulation of group IIA and group V low molecular weight phospholipases A(2) in cultured rat astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FACTOR-KAPPA-B; NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; ARACHIDONIC-ACID RELEASE; PRIMARY GLIAL CULTURES; N-TERMINAL KINASE; GENE-EXPRESSION; THYROID-HORMONE; GROWTH-FACTORS	In astrocytes, cytokines stimulate the release of secretory phospholipase A(2) (sPLA(2)) activity and group IIA sPLA(2), expression. This paper reports that two sPLA(2) isoforms, group IIA and group V, are in fact expressed by astrocytes, Our studies showed that tumor necrosis factor alpha (TNF alpha) enhanced the mRNA of both isoforms, but the time courses of enhancement differed; group V was induced much faster than group IIA. Moreover, TNF alpha stimulated both the NF-kappa B and mitogen-activated protein (MAP) kinase (extracellular signal-regulated kinase, c-Jun NH2-terminal kinase, and p38 MAP kinase) signaling pathways in astrocytes, Interestingly, PI 3-kinase activity also was enhanced by TNF alpha, and NF-kappa B pathway was involved in mediating its effect. Specific inhibitors were used to show that both extracellular signal-regulated kinase and p38 MAP kinase may contribute to the effect of TNF alpha and that blocking phosphatidylinositol 3-kinase activity fully reversed the effect of TNF alpha. Furthermore, in astrocytes, TNF alpha-induced release of sPLA(2) activity was partially reversed by thyroid hormone and almost abolished by growth factors. This phenomenon was accompanied by a less marked increase in both group IIA and group V sPLA(2) mRNA. In the presence of growth factors, the increase in group V mRNA was inhibited early and transiently, in contrast to what was observed with group IIA, which was more persistently inhibited. Although a transcriptional effect of thyroid hormone or growth factors in astrocytes cannot be definitively excluded, both types of factor interfered with sPLA(2) expression in a manner suggesting the existence of regulation of post-transcriptional events.	INSERM, Unite Rech Glande Thyroide & Regulat Hormonale, F-94276 Le Kremlin Bicetre, France; CHU St Antoine, CNRS, UPRES A, F-75012 Paris, France; CHU St Antoine, INSERM, U402, F-75012 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Saunier, B (corresponding author), INSERM, Unite Rech Glande Thyroide & Regulat Hormonale, F-94276 Le Kremlin Bicetre, France.			Saunier, Bertrand/0000-0002-0700-3082				Auclair M, 1999, J CLIN ENDOCR METAB, V84, P3197, DOI 10.1210/jc.84.9.3197; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; BERENBAUM F, 1994, FEBS LETT, V340, P51, DOI 10.1016/0014-5793(94)80171-1; Bhat NR, 1998, J NEUROSCI, V18, P1633; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Bonventre JV, 1997, J LIPID MEDIAT CELL, V17, P71, DOI 10.1016/S0929-7855(97)00021-7; Borge L, 1997, IN VITRO CELL DEV-AN, V33, P703; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN J, 1994, J BIOL CHEM, V269, P2365; CHEN J, 1994, BBA-LIPID LIPID MET, V1215, P115, DOI 10.1016/0005-2760(94)90099-X; Chen YJ, 1998, BBA-LIPID LIPID MET, V1394, P57, DOI 10.1016/S0005-2760(98)00098-8; Cheng JD, 1998, J EXP MED, V188, P1055, DOI 10.1084/jem.188.6.1055; DaSilva J, 1997, J BIOL CHEM, V272, P28373, DOI 10.1074/jbc.272.45.28373; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Farooqui AA, 1997, NEUROCHEM INT, V30, P517; Farooqui AA, 1997, J NEUROCHEM, V69, P889; FEUILLARD J, 1991, CYTOKINE, V3, P257, DOI 10.1016/1043-4666(91)90025-9; GAVARET JM, 1991, DEV BRAIN RES, V58, P43, DOI 10.1016/0165-3806(91)90235-B; Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308; Han SK, 1998, BIOCHEM J, V331, P353, DOI 10.1042/bj3310353; Hernandez M, 1998, J BIOL CHEM, V273, P606, DOI 10.1074/jbc.273.1.606; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Koike K, 1997, PROG SURG, V24, P94, DOI 10.1159/000075456; Kolko M, 1996, J BIOL CHEM, V271, P32722, DOI 10.1074/jbc.271.51.32722; KOMADA M, 1989, J BIOCHEM-TOKYO, V106, P545, DOI 10.1093/oxfordjournals.jbchem.a122890; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; Kwon J, 1996, J BIOL CHEM, V271, P22383, DOI 10.1074/jbc.271.37.22383; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; Lee NH, 1998, J BIOL CHEM, V273, P22317, DOI 10.1074/jbc.273.35.22317; LEINGARTNER A, 1994, J BIOL CHEM, V269, P828; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Matsuzawa A, 1996, BIOCHEM J, V318, P701, DOI 10.1042/bj3180701; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; Molloy GY, 1998, NEUROSCI LETT, V258, P139, DOI 10.1016/S0304-3940(98)00838-6; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; OHARA O, 1990, NUCLEIC ACIDS RES, V18, P6997, DOI 10.1093/nar/18.23.6997; OKA S, 1991, J BIOL CHEM, V266, P9956; Oppenheimer JH, 1997, ENDOCR REV, V18, P462, DOI 10.1210/er.18.4.462; Pahan K, 1999, J BIOL CHEM, V274, P7528, DOI 10.1074/jbc.274.11.7528; Pfeilschifter J, 1997, PROG SURG, V24, P31, DOI 10.1159/000075465; PIERRE M, 1988, FEBS LETT, V228, P219, DOI 10.1016/0014-5793(88)80002-4; POMERANCE M, 1995, J NEUROSCI RES, V40, P737, DOI 10.1002/jnr.490400605; Pruzanski W, 1998, BBA-MOL CELL RES, V1403, P47, DOI 10.1016/S0167-4889(98)00029-9; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RADANY EH, 1992, P NATL ACAD SCI USA, V89, P6467, DOI 10.1073/pnas.89.14.6467; Raju U, 1997, J BIOL CHEM, V272, P24624, DOI 10.1074/jbc.272.39.24624; Raju U, 1998, INT J RADIAT BIOL, V74, P617, DOI 10.1080/095530098141195; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROGHANI A, 1988, BIOCHEMISTRY-US, V27, P7428, DOI 10.1021/bi00419a038; Savolainen KM, 1998, TOXICOL LETT, V103, P363, DOI 10.1016/S0378-4274(98)00233-1; Sun GY, 1995, PROG BRAIN RES, V105, P231; Taylor AH, 1997, MOL PHARMACOL, V52, P542, DOI 10.1124/mol.52.3.542; TEJADABERGES T, 1994, BRAIN RES, V653, P297, DOI 10.1016/0006-8993(94)90404-9; THELEN MHM, 1994, BIOCHEM J, V303, P467, DOI 10.1042/bj3030467; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Togashi H, 1997, P NATL ACAD SCI USA, V94, P2676, DOI 10.1073/pnas.94.6.2676; TONG W, 1995, MOL CHEM NEUROPATHOL, V25, P1, DOI 10.1007/BF02815083; TOURNIER C, 1994, GLIA, V10, P81, DOI 10.1002/glia.440100202; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Zhang PS, 1996, J NEUROSCI RES, V46, P114, DOI 10.1002/(SICI)1097-4547(19961001)46:1<114::AID-JNR14>3.0.CO;2-5	65	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10876	10886		10.1074/jbc.275.15.10876	http://dx.doi.org/10.1074/jbc.275.15.10876			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753884	hybrid			2022-12-27	WOS:000086466600026
J	Chatterji, M; Unniraman, S; Maxwell, A; Nagaraja, V				Chatterji, M; Unniraman, S; Maxwell, A; Nagaraja, V			The additional 165 amino acids in the B protein of Escherichia coli DNA gyrase have an important role in DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAKAGE-REUNION DOMAIN; N-TERMINAL FRAGMENT; CATALYTIC PROPERTIES; CRYSTAL-STRUCTURE; A-PROTEIN; TOPOISOMERASE; SUBUNIT; GENES; ATP; ALIGNMENT	DNA gyrase is the only enzyme known to negatively supercoli DNA. The enzyme is a heterotetramer of A(2)B(2) subunit composition. Alignment of the primary sequence of gyrase B (GyrB) from various species shows that they can be grouped into two classes. The GyrB of Gram-negative eubacteria has a stretch of about 165 amino acids in the C-terminal half, which is lacking in other GyrB subunits and type II topoisomerases. In Escherichia coli, no function has so far been attributed to this stretch. In this study, we have tried to assess the function of this region both in vivo and in vitro. A deletant (GyrB Delta 160) lacking this region is non-functional in vivo. The holoenzyme reconstituted from gyrase A (GyrA) and GyrB Delta 160 shows reduced but detectable supercoliing and quinolone-induced cleavage activity in vitro. GyrB Delta 160 retains its ability to bind to GyrA and novobiocin. However, when reconstituted with GyrA, the deletant shows greatly impaired DNA binding. The intrinsic ATPase activity of the GyrB Delta 160 is comparable to that of wild type GyrB, but this activity is not stimulated by DNA. These studies indicate that the additional stretch present in GyrB is essential for the DNA binding ability off. coli gyrase.	Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India; Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	Indian Institute of Science (IISC) - Bangalore; University of Leicester	Nagaraja, V (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.	vraj@mcbl.iisc.ernet.in		Maxwell, Anthony/0000-0002-5756-6430				ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; BROWN PO, 1979, P NATL ACAD SCI USA, V76, P6110, DOI 10.1073/pnas.76.12.6110; Cabral JHM, 1997, NATURE, V388, P903, DOI 10.1038/42294; Caron P R, 1994, Adv Pharmacol, V29B, P271; FISHER LM, 1981, P NATL ACAD SCI-BIOL, V78, P4165, DOI 10.1073/pnas.78.7.4165; GELLERT M, 1979, P NATL ACAD SCI USA, V76, P6289, DOI 10.1073/pnas.76.12.6289; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; HADI SM, 1975, J BIOL CHEM, V250, P4159; HALLETT P, 1990, GENE, V93, P139, DOI 10.1016/0378-1119(90)90148-K; Huang WM, 1996, ANNU REV GENET, V30, P79; JACKSON AP, 1993, P NATL ACAD SCI USA, V90, P11232, DOI 10.1073/pnas.90.23.11232; Kampranis SC, 1998, J BIOL CHEM, V273, P26305, DOI 10.1074/jbc.273.41.26305; Lewis RJ, 1996, BIOESSAYS, V18, P661, DOI 10.1002/bies.950180810; Liu QY, 1999, P NATL ACAD SCI USA, V96, P881, DOI 10.1073/pnas.96.3.881; LYNN RM, 1989, PROTEINS, V6, P231, DOI 10.1002/prot.340060305; Madhusudan K, 1996, J BIOSCIENCE, V21, P613, DOI 10.1007/BF02703140; Maxwell A, 1997, TRENDS MICROBIOL, V5, P102, DOI 10.1016/S0966-842X(96)10085-8; MAXWELL A, 1984, J BIOL CHEM, V259, P4472; MAXWELL A, 1999, PROTOCOLS DNA TOPOIS, P135; MENZEL R, 1983, CELL, V34, P105, DOI 10.1016/0092-8674(83)90140-X; MIZZUUCHI K, 1978, P NATL ACAD SCI USA, V75, P5960; ODea MH, 1996, J BIOL CHEM, V271, P9723, DOI 10.1074/jbc.271.16.9723; REECE RJ, 1989, J BIOL CHEM, V264, P19648; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; REECE RJ, 1991, NUCLEIC ACIDS RES, V19, P1399, DOI 10.1093/nar/19.7.1399; REECE RJ, 1991, J BIOL CHEM, V266, P3540; Sambrook J., 2002, MOL CLONING LAB MANU; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; STAUDENBAUER WL, 1981, NUCLEIC ACIDS RES, V9, P3589, DOI 10.1093/nar/9.15.3589; TINGEY AP, 1996, NUCLEIC ACIDS RES, V24, P4686; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0	35	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22888	22894		10.1074/jbc.M001047200	http://dx.doi.org/10.1074/jbc.M001047200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10764756	hybrid, Green Published			2022-12-27	WOS:000088419400041
J	Emerson, M; Travis, AR; Bathgate, R; Stojanov, T; Cook, DI; Harding, E; Lu, DP; O'Neill, C				Emerson, M; Travis, AR; Bathgate, R; Stojanov, T; Cook, DI; Harding, E; Lu, DP; O'Neill, C			Characterization and functional significance of calcium transients in the 2-cell mouse embryo induced by an autocrine growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; PREIMPLANTATION EMBRYOS; IN-VITRO; RECEPTOR; ALBUMIN; RELEASE; FERTILIZATION; OOCYTES; INFLUX; ENTRY	Growth of preimplantation embryos is influenced by autocrine trophic factors that need to act by the 2-cell stage, but their mode of action is not yet described, This report shows that late zygote and 2-cell stage mouse embryos responded to embryo derived platelet-activating factor (PAF) with transient increases in intracellular calcium concentration ([Ca2+](i)). [Ca2+](i) transients were single global events and were specifically induced by embryo-derived PAF. They were blocked by inhibition of phospholipase C (U 73122) and an inositol trisphosphate (IP3) receptor antagonist (xestospongin C), indicating the release of calcium from IP3-sensitive intracellular stores. Transients were also inhibited by the absence of calcium from extracellular medium and partially inhibited by treatment with dihydropyridine (nifedipine, 10 mu M), but not pimozide (an inhibitor of an embryonic T-type calcium channel). (+/-)BAY K8644 (an L-type channel agonist) induced [Ca2+](i) transients, yet these were completely inhibited by nifedipine (10 mu M). The complete inhibition of BAY K8644, but only partial inhibition of PAF by nifedipine shows that L-type channels were only partly responsible for the calcium influx. Depolarization of 2-cell embryos by 50 mM K+ did not inhibit PAF-induced calcium transients, showing that the influx channels were not voltage-dependent. Depletion of intracellular calcium stores by thapsigargin revealed the presence of store-operated channels. The interdependent requirement for IP3-sensitive internal calcium stores and extracellular calcium in the generation of PAF-induced transients may be explained by a requirement for capacitative calcium entry via store-operated channels. A functionally important role for the PAF-induced transients is supported by the observation that inhibition of [Ca2+](i) transients by a PAF-antagonist (WEB 2086) or an intracellular calcium chelator (1,2-bis (2-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid tetrakis-acetoxymethyl ester; BAPTA-AM) caused marked inhibition of early embryo development. Growth inhibition by BAPTA-AM was relieved by addition of exogenous PAF.	Univ Sydney, Royal N Shore Hosp, Human Reprod Unit, St Leonards, NSW 2065, Australia; Univ Sydney, Royal N Shore Hosp, Dept Physiol, St Leonards, NSW 2065, Australia	Royal North Shore Hospital; University of Sydney; Royal North Shore Hospital; University of Sydney	O'Neill, C (corresponding author), Univ Sydney, Royal N Shore Hosp, Human Reprod Unit, St Leonards, NSW 2065, Australia.	chriso@med.usyd.edu.au		O'Neill, Christopher/0000-0003-4003-8727; Bathgate, Roslyn/0000-0002-7922-5610				Ammit AJ, 1997, J REPROD FERTIL, V109, P309, DOI 10.1530/jrf.0.1090309; Ammit AJ, 1997, J BIOL CHEM, V272, P18772, DOI 10.1074/jbc.272.30.18772; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; CHEEK TR, 1993, DEVELOPMENT, V119, P179; CLAY KL, 1990, BIOCHIM BIOPHYS ACTA, V1046, P309, DOI 10.1016/0005-2760(90)90246-T; Day ML, 1998, PFLUG ARCH EUR J PHY, V436, P834, DOI 10.1007/s004240050712; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; Golovina VA, 1999, AM J PHYSIOL-CELL PH, V277, pC343, DOI 10.1152/ajpcell.1999.277.2.C343; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3450; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kono T, 1996, J CELL BIOL, V132, P915, DOI 10.1083/jcb.132.5.915; KORTH R, 1989, BRIT J PHARMACOL, V98, P653, DOI 10.1111/j.1476-5381.1989.tb12640.x; LUDWIG JC, 1985, ARCH BIOCHEM BIOPHYS, V241, P337, DOI 10.1016/0003-9861(85)90555-7; O'Neill C, 1998, BIOL REPROD, V58, P1303, DOI 10.1095/biolreprod58.5.1303; ONEILL C, 1985, J REPROD FERTIL, V75, P375; ONeill C, 1997, BIOL REPROD, V56, P229, DOI 10.1095/biolreprod56.1.229; Pantaleon M, 1997, P NATL ACAD SCI USA, V94, P5125, DOI 10.1073/pnas.94.10.5125; Pantaleon M, 1996, MOL REPROD DEV, V44, P71, DOI 10.1002/(SICI)1098-2795(199605)44:1&lt;71::AID-MRD8&gt;3.0.CO;2-Q; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PARIA BC, 1990, P NATL ACAD SCI USA, V87, P4756, DOI 10.1073/pnas.87.12.4756; Parrington J, 1996, NATURE, V379, P364, DOI 10.1038/379364a0; Petersen CCH, 1996, PFLUG ARCH EUR J PHY, V432, P286, DOI 10.1007/s004240050135; POUEYMIROU WT, 1990, MOL REPROD DEV, V26, P211, DOI 10.1002/mrd.1080260303; Putney JW, 1999, P NATL ACAD SCI USA, V96, P14669, DOI 10.1073/pnas.96.26.14669; RAPPOLEE DA, 1990, UCLA SYM BI, V117, P11; RAPPOLEE DA, 1988, SCIENCE, V241, P1823, DOI 10.1126/science.3175624; Roudebush WE, 1997, BIOL REPROD, V57, P575, DOI 10.1095/biolreprod57.3.575; STACHECKI JJ, 1994, BIOL REPROD, V50, P1, DOI 10.1095/biolreprod50.1.1; Stachecki JJ, 1996, DEVELOPMENT, V122, P2485; Stojanov T, 1999, BIOL REPROD, V60, P674, DOI 10.1095/biolreprod60.3.674; SWANN K, 1990, DEVELOPMENT, V110, P1295; SWANN K, 1992, BIOCHEM J, V287, P79, DOI 10.1042/bj2870079; Thomas D, 1998, VITAM HORM, V54, P97, DOI 10.1016/S0083-6729(08)60923-1; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; WELLS XE, 1992, J REPROD FERTIL, V96, P61; WELLS XE, 1994, J REPROD FERTIL, V101, P385, DOI 10.1530/jrf.0.1010385; WHITAKER M, 1990, DEVELOPMENT, V108, P525	37	42	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21905	21913		10.1074/jbc.M001719200	http://dx.doi.org/10.1074/jbc.M001719200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10764773	hybrid			2022-12-27	WOS:000088363800023
J	Chen, PF; Flory, E; Avots, A; Jordan, BWM; Kirchhoff, F; Ludwig, S; Rapp, UR				Chen, PF; Flory, E; Avots, A; Jordan, BWM; Kirchhoff, F; Ludwig, S; Rapp, UR			Transactivation of naturally occurring HIV-1 long terminal repeats by the JNK signaling pathway - The most frequent naturally occurring length polymorphism sequence introduces a novel binding site for AP-1 factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVATED PROTEIN-KINASE; T-CELL ACTIVATION; P38 MAP KINASE; SERUM RESPONSE ELEMENT; NF-KAPPA-B; C-JUN; TRANSCRIPTION FACTOR; GENE-EXPRESSION; TRANSDUCTION PATHWAY	To study the role of MAPK cascades in the regulation of naturally occurring human immunodeficiency virus type I long terminal repeats (HIV-1 LTRs), we analyzed several HIV-1 LTRs from patients at different stages of disease progression. One of these naturally occurring HIV-1 LTRs contains an insertion termed the most frequent naturally occurring length polymorphism (MFNLP) and exhibited high inducibility upon T cell activation. We found that the protein kinase mixed lineage kinase 3/src-homology 3 domain-containing proline-rich kinase, a specific activator of the stress-activated protein kinase (SAPK)/JNK signaling pathway in T lymphocytes, induces high transcriptional activation of this promoter. Promoter inducibility is inhibited by the SAPK/JNK inhibitor, the JNK binding domain of the JNK interacting protein 1, and Tam-67 (N-terminal deletion mutant of c-Jun). In electrophoretic mobility shift assay, several protein complexes were found to bind to the MFNLP sequence in T cells. me identified AP-1 factors c-Fos and JunB as MFNLP-binding proteins, whose binding: is abolished by introducing point mutations in the 3'-half of the MFNLP sequence. Introduction of these point mutations into the MFNLP containing HIV-1 LTR reduced src-homology 3 domain-containing proline-rich kinase -mediated transactivation. These data indicate that the AP-1-like binding site in the MFNLP sequence gives rise to a higher inducibility of natural HIV-LTRs by the SAPK/JNR. signaling pathway.	Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany; Univ Erlangen Nurnberg, Inst Klin & Mol Virol, D-91054 Erlangen, Germany; Univ Wurzburg, Inst Pathol, D-97078 Wurzburg, Germany	University of Wurzburg; University of Erlangen Nuremberg; University of Wurzburg	Flory, E (corresponding author), Paul Ehrlich Inst, Abt Med Biotechnol, Paul Ehrlich Str 95, D-63225 Langen, Germany.		Kirchhoff, Frank/O-8367-2018	Kirchhoff, Frank/0000-0002-7052-2360; Ludwig, Stephan/0000-0003-4490-3052				ALLEGRETTO EA, 1990, J CELL BIOCHEM, V42, P193, DOI 10.1002/jcb.240420403; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BROWN PH, 1994, ONCOGENE, V9, P791; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Cohen PS, 1997, MOL MED, V3, P339, DOI 10.1007/BF03401812; CONNOR RI, 1994, AIDS RES HUM RETROV, V10, P321, DOI 10.1089/aid.1994.10.321; CONNOR RI, 1994, J VIROL, V68, P4400, DOI 10.1128/JVI.68.7.4400-4408.1994; DASGUPTA P, 1990, P NATL ACAD SCI USA, V87, P8090, DOI 10.1073/pnas.87.20.8090; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; DORN P, 1990, J VIROL, V64, P1616, DOI 10.1128/JVI.64.4.1616-1624.1990; Estable MC, 1996, J VIROL, V70, P4053, DOI 10.1128/JVI.70.6.4053-4062.1996; Estable MC, 1998, J VIROL, V72, P6465, DOI 10.1128/JVI.72.8.6465-6474.1998; EZOE K, 1994, ONCOGENE, V9, P935; Flory E, 1996, J VIROL, V70, P2260, DOI 10.1128/JVI.70.4.2260-2268.1996; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GalchevaGargova Z, 1996, SCIENCE, V272, P1797, DOI 10.1126/science.272.5269.1797; GALLO KA, 1994, J BIOL CHEM, V269, P15092; GARCIA JA, 1989, EMBO J, V8, P765, DOI 10.1002/j.1460-2075.1989.tb03437.x; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GOLUB EI, 1990, J VIROL, V64, P3654, DOI 10.1128/JVI.64.8.3654-3660.1990; GOWDA SD, 1989, J IMMUNOL, V142, P773; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HARRICH D, 1989, J VIROL, V63, P2585, DOI 10.1128/JVI.63.6.2585-2591.1989; HAUBER J, 1988, J VIROL, V62, P673, DOI 10.1128/JVI.62.3.673-679.1988; Hoffmeyer A, 1998, J BIOL CHEM, V273, P10112, DOI 10.1074/jbc.273.17.10112; Huang XC, 1998, ENDOCRINOLOGY, V139, P245, DOI 10.1210/en.139.1.245; ING YL, 1994, ONCOGENE, V9, P1745; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Janknecht R, 1997, J BIOL CHEM, V272, P4219, DOI 10.1074/jbc.272.7.4219; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kirchhoff F, 1997, VIROLOGY, V232, P319, DOI 10.1006/viro.1997.8586; KLAVER B, 1994, J VIROL, V68, P3830, DOI 10.1128/JVI.68.6.3830-3840.1994; KOKEN SEC, 1992, VIROLOGY, V191, P968, DOI 10.1016/0042-6822(92)90274-S; Kumar R, 1996, J BIOL CHEM, V271, P29612, DOI 10.1074/jbc.271.47.29612; Kumar S, 1996, J BIOL CHEM, V271, P30864, DOI 10.1074/jbc.271.48.30451; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE J, 1994, GENE, V138, P247, DOI 10.1016/0378-1119(94)90817-6; MICHAEL NL, 1994, J VIROL, V68, P3163, DOI 10.1128/JVI.68.5.3163-3174.1994; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; OKAMOTO T, 1990, VIROLOGY, V177, P606, DOI 10.1016/0042-6822(90)90526-W; POMBO CM, 1994, J BIOL CHEM, V269, P26546; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; RAPP UR, 1994, ONCOGENE, V9, P3493; REDDY EP, 1992, PATHOBIOLOGY, V60, P219; Reunanen N, 1998, J BIOL CHEM, V273, P5137, DOI 10.1074/jbc.273.9.5137; Rosenberger SF, 1999, ONCOGENE, V18, P3626, DOI 10.1038/sj.onc.1202695; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sambrook J., 2002, MOL CLONING LAB MANU; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shapiro L, 1998, P NATL ACAD SCI USA, V95, P7422, DOI 10.1073/pnas.95.13.7422; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; Taher MM, 1999, BIOCHEMISTRY-US, V38, P13055, DOI 10.1021/bi9902900; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; TONGSTARKSEN SE, 1987, P NATL ACAD SCI USA, V84, P6845, DOI 10.1073/pnas.84.19.6845; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; YAN MH, 1994, NATURE, V372, P798; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1999, MOL CELL BIOL, V19, P4547	76	13	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20382	20390		10.1074/jbc.M001149200	http://dx.doi.org/10.1074/jbc.M001149200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10764760	hybrid			2022-12-27	WOS:000088084500024
J	Spittle, C; Charrasse, S; Larroque, C; Cassimeris, L				Spittle, C; Charrasse, S; Larroque, C; Cassimeris, L			The interaction of TOGp with microtubules and tubulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SLOWLY HYDROLYZABLE ANALOG; SPINDLE POLE BODY; DYNAMIC INSTABILITY; MITOTIC SPINDLE; BINDING PROTEIN; GTP HYDROLYSIS; ALPHA-TUBULIN; XENOPUS EGGS; TAU-PROTEIN; CELL-CYCLE	TOGp is the human homolog of XMAP215, a Xenopus microtubule-associated protein that promotes rapid microtubule assembly at plus ends. These proteins are thought to be critical for microtubule assembly and/or mitotic spindle formation. To understand how TOGp interacts with the microtubule lattice, we cloned full-length TOGp and various truncations for expression in a reticulocyte assays, the microtubule binding domain is contained within a basic 600-amino acid region near the N terminus, with critical domains flanking a region homologous to the microtubule binding domain found in the related proteins Stu2p (S. cerevisiae) and Dis1 (S. pombe). Both full-length TOGp and the N-terminal fragment show enhanced binding to microtubule ends. Full-length TOGp also binds altered polymer lattice structures including parallel protofilament sheets, antiparallel protofilament sheets induced with zinc ions, and protofilament rings, suggesting that TOGp binds along the length of individual protofilaments. The C-terminal region of TOGp has a low affinity for microtubule polymer but binds tubulin dimer. We propose a model to explain the microtubule-stabilizing and/or assembly-promoting XMAP215/TOGp of microtubule-associated proteins based on the binding properties we have identified.	Lehigh Univ, Dept Biol Sci, Bethlehem, PA 18015 USA; INSERM Unite 128, F-34293 Montpellier, France; Novartis Pharma Ag, CH-4002 Basel, Switzerland	Lehigh University; Institut National de la Sante et de la Recherche Medicale (Inserm); Novartis	Spittle, C (corresponding author), Lehigh Univ, Dept Biol Sci, 111 Res Dr, Bethlehem, PA 18015 USA.	css3@lehigh.edu			NIGMS NIH HHS [GM 58025] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOS LA, 1979, NATURE, V279, P607, DOI 10.1038/279607a0; Andersen SSL, 1999, BIOESSAYS, V21, P53, DOI 10.1002/(SICI)1521-1878(199901)21:1<53::AID-BIES7>3.0.CO;2-L; ARNAL I, 1995, CURR BIOL, V5, P900, DOI 10.1016/S0960-9822(95)00180-1; BAKER TS, 1978, J MOL BIOL, V123, P89, DOI 10.1016/0022-2836(78)90378-9; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CARLIER MF, 1984, BIOCHEMISTRY-US, V23, P1582, DOI 10.1021/bi00302a037; Cassimeris L, 1999, CURR OPIN CELL BIOL, V11, P134, DOI 10.1016/S0955-0674(99)80017-9; CHAPIN SJ, 1992, CELL MOTIL CYTOSKEL, V23, P236, DOI 10.1002/cm.970230403; Charrasse S, 1998, J CELL SCI, V111, P1371; CHARRASSE S, 1995, EUR J BIOCHEM, V234, P406, DOI 10.1111/j.1432-1033.1995.406_b.x; Chau MF, 1998, BIOCHEMISTRY-US, V37, P17692, DOI 10.1021/bi9812118; CHRETIEN D, 1995, J CELL BIOL, V129, P1311, DOI 10.1083/jcb.129.5.1311; Cullen CF, 1999, J CELL BIOL, V146, P1005, DOI 10.1083/jcb.146.5.1005; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Diamantopoulos GS, 1999, J CELL BIOL, V144, P99, DOI 10.1083/jcb.144.1.99; DIAZ JF, 1994, J MOL BIOL, V238, P214, DOI 10.1006/jmbi.1994.1282; Dionne MA, 2000, J BIOL CHEM, V275, P12346, DOI 10.1074/jbc.275.16.12346; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; DURSO NA, 1994, PLANT CELL, V6, P893, DOI 10.1105/tpc.6.6.893; Erickson HP, 1996, J CELL BIOL, V135, P5, DOI 10.1083/jcb.135.1.5; FAIRE K, 1993, DEV BIOL, V159, P581, DOI 10.1006/dbio.1993.1266; Felgner H, 1997, J CELL BIOL, V138, P1067, DOI 10.1083/jcb.138.5.1067; GARD DL, 1987, J CELL BIOL, V105, P2203, DOI 10.1083/jcb.105.5.2203; GARD DL, 1999, MOL BIOL CELL S, V10, P24; GASKIN F, 1977, J BIOL CHEM, V252, P6918; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; HYMAN AA, 1992, MOL BIOL CELL, V3, P1155, DOI 10.1091/mbc.3.10.1155; Illenberger S, 1996, J BIOL CHEM, V271, P10834, DOI 10.1074/jbc.271.18.10834; Jain SK, 1997, MOL BIOL CELL, V8, P276; KAMIMURA S, 1992, J CELL BIOL, V118, P865, DOI 10.1083/jcb.118.4.865; KOWALSKI RJ, 1993, J BIOL CHEM, V268, P9847; Larcher JC, 1996, J BIOL CHEM, V271, P22117, DOI 10.1074/jbc.271.36.22117; LITTAUER UZ, 1986, P NATL ACAD SCI USA, V83, P7162, DOI 10.1073/pnas.83.19.7162; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; Matthews LR, 1998, J CELL BIOL, V141, P1159, DOI 10.1083/jcb.141.5.1159; Mimori-Kiyosue Y, 2000, J CELL BIOL, V148, P505, DOI 10.1083/jcb.148.3.505; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Muller-Reichert T, 1998, P NATL ACAD SCI USA, V95, P3661, DOI 10.1073/pnas.95.7.3661; NABESHIMA K, 1995, GENE DEV, V9, P1572, DOI 10.1101/gad.9.13.1572; Nakaseko Y, 1996, GENES CELLS, V1, P633, DOI 10.1046/j.1365-2443.1996.00253.x; Odde DJ, 1997, BIOPHYS J, V73, P88, DOI 10.1016/S0006-3495(97)78050-0; PEDROTTI B, 1994, BIOCHEMISTRY-US, V33, P12463, DOI 10.1021/bi00207a013; PEYROT V, 1990, ARCH BIOCHEM BIOPHYS, V279, P328, DOI 10.1016/0003-9861(90)90499-O; Preuss U, 1997, J CELL SCI, V110, P789; PRYER NK, 1992, J CELL SCI, V103, P965; RICKARD JE, 1990, J CELL BIOL, V110, P1623, DOI 10.1083/jcb.110.5.1623; RODIONOV VI, 1990, J BIOL CHEM, V265, P5702; SERRANO L, 1985, EUR J BIOCHEM, V153, P595, DOI 10.1111/j.1432-1033.1985.tb09342.x; SERRANO L, 1984, P NATL ACAD SCI-BIOL, V81, P5989, DOI 10.1073/pnas.81.19.5989; SERRANO L, 1984, BIOCHEMISTRY-US, V23, P4675, DOI 10.1021/bi00315a024; SIMON JR, 1990, J CELL SCI, V96, P571; Tournebize R, 2000, NAT CELL BIOL, V2, P13, DOI 10.1038/71330; VALLEE RB, 1985, BIOCHEM BIOPH RES CO, V133, P128, DOI 10.1016/0006-291X(85)91850-9; VASQUEZ RJ, 1994, J CELL BIOL, V127, P985, DOI 10.1083/jcb.127.4.985; Wang PJJ, 1997, J CELL BIOL, V139, P1271, DOI 10.1083/jcb.139.5.1271; Wilde A, 1999, SCIENCE, V284, P1359, DOI 10.1126/science.284.5418.1359	59	86	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20748	20753		10.1074/jbc.M002597200	http://dx.doi.org/10.1074/jbc.M002597200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10770946	hybrid			2022-12-27	WOS:000088084500074
J	Ziegler, J; Stenzel, I; Hause, B; Maucher, H; Hamberg, M; Grimm, R; Ganal, M; Wasternack, C				Ziegler, J; Stenzel, I; Hause, B; Maucher, H; Hamberg, M; Grimm, R; Ganal, M; Wasternack, C			Molecular cloning of allene oxide cyclase - The enzyme establishing the stereochemistry of octadecanoids and jasmonates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID HYDROPEROXIDES; PLANT-CELL CULTURES; VULGARE CV SALOME; ARABIDOPSIS-THALIANA; METHYL JASMONATE; GENE-EXPRESSION; 12-OXO-PHYTODIENOIC ACID; SIGNALING PATHWAY; TOMATO LEAVES; LIPOXYGENASE	Allene oxide cyclase (EC 5.3.99.6) catalyzes the stereospecific cyclization of an unstable allene oxide to (9S,13S)-12 oxo-(10,15Z)-phytodienoic acid, the ultimate precursor of jasmonic acid. This dimeric enzyme has previously been purified, and two almost identical N-terminal peptides were found, suggesting allene oxide cyclase to be a homodimeric protein. Furthermore, the native protein was N-terminally processed. Using degenerate primers, a polymerase chain reaction fragment could be generated from tomato, which was further used to isolate a full-length cDNA clone of 1 kilobase pair coding for a protein of 245 amino acids with a molecular mass of 26 kDa. Whereas expression of the whole coding region failed to detect allene oxide cyclase activity, a 5'-truncated protein showed high activity, suggesting that additional amino acids impair the enzymatic function. Steric analysis of the 12-oxophytodienoic acid formed by the recombinant enzyme revealed exclusive (>99%) formation of the 9S,13S enantiomer. Exclusive formation of this enantiomer was also found in wounded tomato leaves. Southern analysis and genetic mapping revealed the existence of a single gene for allene oxide cyclase located on chromosome 2 of tomato. Inspection of the N terminus revealed the presence of a chloroplastic transit peptide, and the location of allene oxide cyclase protein in that compartment could be shown by immunohistochemical methods. Concomitant with the jasmonate levels, the accumulation of aliene oxide cyclase mRNA was transiently induced after wounding of tomato leaves.	Leibniz Inst Plant Biochem, Dept Nat Prod Biotechnol, D-06120 Halle, Germany; Karolinska Inst, Dept Med Biochem & Biophys, Div Physiol Chem 2, S-17177 Stockholm, Sweden; Hewlett Packard GmbH, D-76337 Waldbronn, Germany; Inst Plant Genet & Crop Plant Res, D-06466 Gatersleben, Germany	Leibniz Institut fur Pflanzenbiochemie; Karolinska Institutet; Hewlett-Packard; Leibniz Institut fur Pflanzengenetik und Kulturpflanzenforschung	Wasternack, C (corresponding author), Leibniz Inst Plant Biochem, Dept Nat Prod Biotechnol, Weinberg 3, D-06120 Halle, Germany.	cwastern@ipb.uni-halle.de	Ziegler, Jörg/W-7645-2019	Hamberg, Mats/0000-0002-8910-7810				ALDRIDGE DC, 1971, J CHEM SOC C, P1623, DOI 10.1039/j39710001623; Baldwin IT, 1997, PLANTA, V201, P397, DOI 10.1007/s004250050082; BELL E, 1995, P NATL ACAD SCI USA, V92, P8675, DOI 10.1073/pnas.92.19.8675; Biesgen C, 1999, PLANTA, V208, P155, DOI 10.1007/s004250050545; Blechert S, 1999, PLANTA, V207, P470, DOI 10.1007/s004250050506; BLECHERT S, 1995, P NATL ACAD SCI USA, V92, P4099, DOI 10.1073/pnas.92.10.4099; Blee E, 1996, PLANT PHYSIOL, V110, P445, DOI 10.1104/pp.110.2.445; Blee E, 1998, PROG LIPID RES, V37, P33, DOI 10.1016/S0163-7827(98)00004-6; Bohlmann H, 1998, FEBS LETT, V437, P281, DOI 10.1016/S0014-5793(98)01251-4; CLOS J, 1994, PROTEIN EXPRES PURIF, V5, P133, DOI 10.1006/prep.1994.1020; Conconi A, 1996, PLANT PHYSIOL, V111, P797, DOI 10.1104/pp.111.3.797; Creelman RA, 1997, ANNU REV PLANT PHYS, V48, P355, DOI 10.1146/annurev.arplant.48.1.355; FARMER EE, 1990, P NATL ACAD SCI USA, V87, P7713, DOI 10.1073/pnas.87.19.7713; FEUSSNER I, 1995, PLANT J, V7, P949, DOI 10.1046/j.1365-313X.1995.07060949.x; FEYS BJF, 1994, PLANT CELL, V6, P751, DOI 10.1105/tpc.6.5.751; GUNDLACH H, 1992, P NATL ACAD SCI USA, V89, P2389, DOI 10.1073/pnas.89.6.2389; HAMBERG M, 1988, BIOCHEM BIOPH RES CO, V156, P543, DOI 10.1016/S0006-291X(88)80876-3; HAMBERG M, 1992, BIOCHIM BIOPHYS ACTA, V1165, P1, DOI 10.1016/0005-2760(92)90069-8; Hause B, 1996, PLANT CELL PHYSIOL, V37, P641, DOI 10.1093/oxfordjournals.pcp.a028993; Heitz T, 1997, PLANT PHYSIOL, V114, P1085, DOI 10.1104/pp.114.3.1085; Howe GA, 1996, PLANT CELL, V8, P2067, DOI 10.1105/tpc.8.11.2067; KNOFEL HD, 1984, BIOCHEM PHYSIOL PFL, V179, P317; Koch T, 1999, PLANT PHYSIOL, V121, P153, DOI 10.1104/pp.121.1.153; Koda Y, 1997, PHYSIOL PLANTARUM, V100, P639, DOI 10.1034/j.1399-3054.1997.1000327.x; Kramell R, 1997, FEBS LETT, V414, P197, DOI 10.1016/S0014-5793(97)01005-3; Kubigsteltig I, 1999, PLANTA, V208, P463, DOI 10.1007/s004250050583; Laudert D, 1997, ANAL BIOCHEM, V246, P211, DOI 10.1006/abio.1997.2012; Laudert D, 1998, PLANT J, V15, P675, DOI 10.1046/j.1365-313x.1998.00245.x; Laudert D, 1996, PLANT MOL BIOL, V31, P323, DOI 10.1007/BF00021793; LEHMANN J, 1995, PLANTA, V197, P156, DOI 10.1007/BF00239952; Maucher H, 2000, PLANT J, V21, P199, DOI 10.1046/j.1365-313x.2000.00669.x; McConn M, 1996, PLANT CELL, V8, P403, DOI 10.1105/tpc.8.3.403; MILLIGAN SB, 1995, PLANT MOL BIOL, V28, P691, DOI 10.1007/BF00021194; ODonnell PJ, 1996, SCIENCE, V274, P1914, DOI 10.1126/science.274.5294.1914; Parchmann S, 1997, PLANT PHYSIOL, V115, P1057, DOI 10.1104/pp.115.3.1057; PENACORTES H, 1995, P NATL ACAD SCI USA, V92, P4106, DOI 10.1073/pnas.92.10.4106; Rosahl S, 1996, Z NATURFORSCH C, V51, P123; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schaller F, 1998, PLANT PHYSIOL, V118, P1345, DOI 10.1104/pp.118.4.1345; Schaller F, 1997, J BIOL CHEM, V272, P28066, DOI 10.1074/jbc.272.44.28066; SONG WC, 1991, SCIENCE, V253, P781, DOI 10.1126/science.1876834; SONG WC, 1993, P NATL ACAD SCI USA, V90, P8519, DOI 10.1073/pnas.90.18.8519; TANKSLEY SD, 1992, GENETICS, V132, P1141; Thomma BPHJ, 1998, P NATL ACAD SCI USA, V95, P15107, DOI 10.1073/pnas.95.25.15107; VICK BA, 1983, BIOCHEM BIOPH RES CO, V111, P470, DOI 10.1016/0006-291X(83)90330-3; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; Voros K, 1998, EUR J BIOCHEM, V251, P36, DOI 10.1046/j.1432-1327.1998.2510036.x; Wasternack C, 1997, TRENDS PLANT SCI, V2, P302, DOI 10.1016/S1360-1385(97)89952-9; Ziegler J, 1999, LIPIDS, V34, P1005, DOI 10.1007/s11745-999-0451-z; Ziegler J, 1997, PLANT PHYSIOL, V114, P565, DOI 10.1104/pp.114.2.565	50	180	205	4	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19132	19138		10.1074/jbc.M002133200	http://dx.doi.org/10.1074/jbc.M002133200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10764787	hybrid			2022-12-27	WOS:000087815900068
J	Tucker, SJ; Imbrici, P; Salvatore, L; D'Adamo, MC; Pessia, M				Tucker, SJ; Imbrici, P; Salvatore, L; D'Adamo, MC; Pessia, M			pH dependence of the inwardly rectifying potassium channel, Kir5.1, and localization in renal tubular epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFIER K+ CHANNEL; EXPRESSION; MEMBRANE; CLONING; FAMILY; KIR4.1	The physiological role of the inwardly rectifying potassium channel, Kir5.1, is poorly understood, as is the molecular identity of many renal potassium channels. In this study we have used Kir5.1-specific antibodies to reveal abundant expression of Kir5.1 in renal tubular epithelial cells, where Kir4.1 is also expressed. Moreover, we also show that Kir5.1/Kir4.1 heteromeric channel activity is extremely sensitive to inhibition by intracellular acidification and that this novel property is conferred predominantly by the Kir5.1 subunit. These findings suggest that Kir5.1/Kir4.1 heteromeric channels are likely to exist in vivo and implicate an important and novel functional role for the Kir5.1, subunit.	Univ Oxford, Physiol Lab, Oxford OX1 3PT, England; Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Vasc Med & Pharmacol, I-66030 Santa Maria Imbaro, Chieti, Italy; Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Mol Pharmacol & Pathol, I-66030 Santa Maria Imbaro, Chieti, Italy	University of Oxford; Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Tucker, SJ (corresponding author), Univ Oxford, Physiol Lab, Parks Rd, Oxford OX1 3PT, England.		D'Adamo, Maria Cristina/AAD-3701-2022; imbrici, paola/J-6855-2018; Tucker, Stephen J./ABE-6741-2020; Tucker, Stephen J./ABE-7468-2020	D'Adamo, Maria Cristina/0000-0002-6758-6064; imbrici, paola/0000-0001-9140-5350; Tucker, Stephen J./0000-0001-8996-2000; Tucker, Stephen J./0000-0001-8996-2000; Pessia, Mauro/0000-0002-2857-6795	Telethon [1083] Funding Source: Medline	Telethon(Fondazione Telethon)		BOND CT, 1994, RECEPTOR CHANNEL, V2, P183; Choe H, 1997, AM J PHYSIOL-RENAL, V273, pF516, DOI 10.1152/ajprenal.1997.273.4.F516; Fakler B, 1996, EMBO J, V15, P4093, DOI 10.1002/j.1460-2075.1996.tb00784.x; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Ito M, 1996, FEBS LETT, V388, P11, DOI 10.1016/0014-5793(96)00502-9; Kawahara K, 1997, JPN J PHYSIOL, V47, P1, DOI 10.2170/jjphysiol.47.1; Mouri T, 1998, GENOMICS, V54, P181, DOI 10.1006/geno.1998.5572; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Pearson WL, 1999, J PHYSIOL-LONDON, V514, P639, DOI 10.1111/j.1469-7793.1999.639ad.x; Pessia M, 1996, EMBO J, V15, P2980, DOI 10.1002/j.1460-2075.1996.tb00661.x; Reimann F, 1999, CURR OPIN CELL BIOL, V11, P503, DOI 10.1016/S0955-0674(99)80073-8; Salvatore L, 1999, FEBS LETT, V449, P146, DOI 10.1016/S0014-5793(99)00420-2; Schulte U, 1999, P NATL ACAD SCI USA, V96, P15298, DOI 10.1073/pnas.96.26.15298; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Wang WH, 1997, ANNU REV PHYSIOL, V59, P413, DOI 10.1146/annurev.physiol.59.1.413; Xu JZ, 1997, AM J PHYSIOL-RENAL, V273, pF739, DOI 10.1152/ajprenal.1997.273.5.F739; Yang ZJ, 1999, J PHYSIOL-LONDON, V520, P921, DOI 10.1111/j.1469-7793.1999.00921.x; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	18	99	103	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16404	16407		10.1074/jbc.C000127200	http://dx.doi.org/10.1074/jbc.C000127200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10764726	hybrid, Green Published			2022-12-27	WOS:000087392200002
J	Adachi, K; Zhao, Y; Yamaguchi, T; Surrey, S				Adachi, K; Zhao, Y; Yamaguchi, T; Surrey, S			Assembly of gamma- with alpha-globin chains to form human fetal hemoglobin in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; AMINO-ACIDS; KINETICS; ADULT	Soluble gamma-globin chains were expressed in bacteria and purified to assess the mechanism of gamma- and alpha-chain assembly to form Hb F. Formation of Hb F in vitro following incubation of equimolar mixtures of gamma and alpha chains was about 4 x 10(5)-fold slower than assembly of alpha and beta chains to form Hb A in vitro. Results of assembly for gamma(116Ile-->His) and gamma(112Thr-->Asp) chains with alpha chains were similar to that of beta chains, whereas assembly of gamma(112Thr-->Cys) and alpha chains was similar to wild type gamma chains, indicating that amino acid differences at alpha 1 beta 1 and alpha 1 gamma 1 interaction sites between gamma 116 Ile and beta 116 His are responsible for the different assembly rates in vitro in the formation of Hb F and Hb A. Homoassembly in vitro of individual gamma chains as assessed by size exclusion chromatography shows that gamma and gamma(112Thr-->Cys) chains form stable dimers like alpha beta and alpha gamma that do not dissociate readily into monomers like beta chains. In contrast, gamma(116Ile-->His) chains form monomers and dimers upon dilution. These results are consistent with the slower assembly rate in vitro of gamma and gamma(112Thr-->Cys) with a chains, whereas the faster rate of assembly of gamma(116Ile-->His) and gamma(112Thr-->Asp) chains with a chains, like beta chains, may be caused by dissociation to monomers. These results suggest that dissociation of gamma(2) dimers to monomers limits formation of Hb F in vitro. However, yields of soluble Hb F expressed in bacteria were similar to Hb A, and no unassembled a and gamma chains were detected. These results indicate that gamma chains assemble in vivo with a chains prior to forming stable gamma(2) dimers, possibly binding to alpha chains as partially folded nascent gamma-globin chains prior to release from polyribosomes.	Childrens Hosp Philadelphia, Div Hematol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Jefferson Med Coll, Dept Pediat, Philadelphia, PA 19104 USA; AI duPont Hosp Children, Wilmington, DE 19803 USA	University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania; Jefferson University; Nemours Alfred I. duPont Hospital for Children	Adachi, K (corresponding author), Childrens Hosp Philadelphia, Div Hematol, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058879] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58879] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI K, 1993, J BIOL CHEM, V268, P21650; Adachi K, 1997, BLOOD, V90, P2916, DOI 10.1182/blood.V90.8.2916; ADACHI K, 1996, BLOOD, V15, P1617; ANTONINI E, 1966, J MOL BIOL, V17, P29, DOI 10.1016/S0022-2836(66)80092-X; ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, V21, P9; Ascoli F, 1981, Methods Enzymol, V76, P72; BORGSTAHL GEO, 1994, J MOL BIOL, V236, P817, DOI 10.1006/jmbi.1994.1191; BUCCI E, 1965, J MOL BIOL, V12, P183, DOI 10.1016/S0022-2836(65)80292-3; BUNN HF, 1987, BLOOD, V69, P1; BUNN HF, 1986, HEMOGLOBIN MOL GENET, P13; DANCE N, 1983, BIOCHEM J, V87, P240; FEDOROV AN, 1995, P NATL ACAD SCI USA, V92, P1227, DOI 10.1073/pnas.92.4.1227; Fedorov AN, 1997, J BIOL CHEM, V272, P32715, DOI 10.1074/jbc.272.52.32715; GARLICK RL, 1981, J BIOL CHEM, V256, P1727; HUEENS E, 1964, BIOCHEM J, V92, P444; HUEHNS ER, 1965, J MOL BIOL, V12, P215, DOI 10.1016/S0022-2836(65)80295-9; JOSHI AA, 1994, J BIOL CHEM, V269, P8549; KASTENJOLLY J, 1987, BIOCHIM BIOPHYS ACTA, V913, P89, DOI 10.1016/0167-4838(87)90236-6; KAWAMURA Y, 1983, J BIOCHEM-TOKYO, V94, P1851, DOI 10.1093/oxfordjournals.jbchem.a134538; KAWAMURAKONISHI Y, 1989, BIOCHEM INT, V19, P469; Komar AA, 1997, J BIOL CHEM, V272, P10646; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCDONALD MJ, 1981, J BIOL CHEM, V256, P6487; MCDONALD MJ, 1987, J BIOL CHEM, V262, P5951; MCGOVERN P, 1978, J BIOL CHEM, V251, P7871; MRABET NT, 1986, J BIOL CHEM, V261, P5222; Shackleton CHL, 1994, MASS SPECTROMETRY CL, V2, P135; SHEN TJ, 1993, P NATL ACAD SCI USA, V90, P8108, DOI 10.1073/pnas.90.17.8108; Shen TJ, 1997, PROTEIN ENG, V10, P1085, DOI 10.1093/protein/10.9.1085; STALLINGS M, 1983, BLOOD, V62, P75; VALDES R, 1977, J BIOL CHEM, V252, P74; Yamaguchi T, 1998, J BIOL CHEM, V273, P14179, DOI 10.1074/jbc.273.23.14179; Yamaguchi T, 1996, J BIOL CHEM, V271, P26677, DOI 10.1074/jbc.271.43.26677; YIP YK, 1977, P NATL ACAD SCI USA, V74, P64, DOI 10.1073/pnas.74.1.64	34	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12424	12429		10.1074/jbc.C000137200	http://dx.doi.org/10.1074/jbc.C000137200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777526	hybrid			2022-12-27	WOS:000086762300010
J	D'Silva, PR; Lala, AK				D'Silva, PR; Lala, AK			Organization of diphtheria toxin in membranes - A hydrophobic photolabeling study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLTEN GLOBULE STATE; ALTERED FRAGMENT-B; T-DOMAIN; LOW PH; IMMUNOCHEMICAL ANALYSIS; TRANSMEMBRANE DOMAIN; LIPID INTERACTION; MODEL MEMBRANES; PLASMA-MEMBRANE; HIGH-YIELD	Diphtheria toxin (DT) is a disulfide linked AB-toxin consisting of a catalytic domain (C), a membrane-inserting domain (T), and a receptor-binding domain (R). It gains entry into cells by receptor-mediated endocytosis. The low pH (similar to 5.5) inside the endosomes induces a conformational change in the toxin leading to insertion of the toxin in the membrane and subsequent translocation of the C domain into the cell, where it inactivates protein synthesis ultimately leading to cell death. We have used a highly reactive hydrophobic photoactivable reagent, DAF, to identify the segments of DT that interact with the membrane at pH 5.2. This reagent readily partitions into membranes and, on photolysis, indiscriminately inserts into lipids and membrane-inserted domains of proteins. Subsequent chemical and/or enzymatic fragmentation followed by peptide sequencing allows for identification of the modified residues. Using this approach it was observed that T domain helices, TH1, TH8, and TH9 insert into the membrane. Furthermore, the disulfide link was found on the trans side leaving part of the C domain on the trans side. This domain then comes out to the cis side via a highly hydrophobic patch corresponding to residues 134-141, originally corresponding to a beta-strand in the solution structure of DT. It appears that the three helices of the T domain could participate in the formation of a channel from a DT-oligomer, thus providing the transport route to the C domain after the disulfide reductase separates the two chains.	Indian Inst Technol, Dept Chem, Biomembrane Lab, Bombay 400076, Maharashtra, India; Indian Inst Technol, Ctr Biotechnol, Bombay 400076, Maharashtra, India	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Bombay; Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Bombay	Lala, AK (corresponding author), Indian Inst Technol, Dept Chem, Biomembrane Lab, Bombay 400076, Maharashtra, India.	anillala@chem.iitb.ernet.in	D'Silva, Patrick/L-6653-2019					AMES BN, 1960, J BIOL CHEM, V235, P769; Asuncion-Punzalan E, 1998, BIOCHEMISTRY-US, V37, P4603, DOI 10.1021/bi9726234; BENNETT MJ, 1994, PROTEIN SCI, V3, P1464, DOI 10.1002/pro.5560030912; BYCHKOVA VE, 1988, FEBS LETT, V238, P231, DOI 10.1016/0014-5793(88)80485-X; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; COLLIER RJ, 1975, BACTERIOL REV, V39, P54, DOI 10.1128/MMBR.39.1.54-85.1975; D'Silva PR, 1998, J BIOL CHEM, V273, P16216, DOI 10.1074/jbc.273.26.16216; D'Silva PR, 1999, PROTEIN SCI, V8, P1099, DOI 10.1110/ps.8.5.1099; EIBL H, 1983, METHOD ENZYMOL, V98, P623; GONZALEZ JE, 1988, J BIOL CHEM, V263, P15257; HONJO T, 1968, J BIOL CHEM, V243, P3553; HU VW, 1984, J BIOL CHEM, V259, P2226; Huynh PD, 1997, J GEN PHYSIOL, V110, P229, DOI 10.1085/jgp.110.3.229; Kachel K, 1998, J BIOL CHEM, V273, P22950, DOI 10.1074/jbc.273.36.22950; KALLURY RK, 1987, J ORG CHEM, V52, P5478, DOI 10.1021/jo00233a037; Kaul P, 1996, PROTEIN SCI, V5, P687; Lacy DB, 1998, CURR OPIN STRUC BIOL, V8, P778; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALA AK, 1995, J BIOL CHEM, V270, P11348, DOI 10.1074/jbc.270.19.11348; LALA AK, 1990, BIOTECHNOL APPL BIOC, V12, P586; LALA AK, 1990, PURE APPL CHEM, V62, P1453, DOI 10.1351/pac199062071453; LALA AK, 1992, J BIOL CHEM, V267, P19914; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADSHUS IH, 1994, J BIOL CHEM, V269, P4648; MAHONEY WC, 1979, BIOCHEMISTRY-US, V18, P3810, DOI 10.1021/bi00584a026; Malenbaum SE, 1998, BIOCHEMISTRY-US, V37, P17915, DOI 10.1021/bi981230h; Marciano DK, 1999, SCIENCE, V284, P1516, DOI 10.1126/science.284.5419.1516; MINDELL JA, 1994, J MEMBRANE BIOL, V137, P45; MINDELL JA, 1994, J MEMBRANE BIOL, V137, P29; MINDELL JA, 1994, P NATL ACAD SCI USA, V91, P5272, DOI 10.1073/pnas.91.12.5272; MOSKAUG JO, 1991, J BIOL CHEM, V266, P2652; MOZDZANOWSKI J, 1992, ANAL BIOCHEM, V207, P11, DOI 10.1016/0003-2697(92)90492-P; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; Oh KJ, 1999, BIOCHEMISTRY-US, V38, P10336, DOI 10.1021/bi990520a; Oh KJ, 1999, P NATL ACAD SCI USA, V96, P8467, DOI 10.1073/pnas.96.15.8467; Oh KJ, 1996, SCIENCE, V273, P810, DOI 10.1126/science.273.5276.810; OKEEFE DO, 1992, P NATL ACAD SCI USA, V89, P6202, DOI 10.1073/pnas.89.13.6202; PAPINI E, 1987, EUR J BIOCHEM, V169, P629, DOI 10.1111/j.1432-1033.1987.tb13654.x; PAPINI E, 1987, EUR J BIOCHEM, V169, P637, DOI 10.1111/j.1432-1033.1987.tb13655.x; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P64; PRADHAN D, 1987, J BIOL CHEM, V262, P8242; PTITSYN OB, 1995, CURR OPIN STRUC BIOL, V5, P74, DOI 10.1016/0959-440X(95)80011-O; Quertenmont P, 1999, BIOCHEMISTRY-US, V38, P660, DOI 10.1021/bi9818624; Quertenmont P, 1996, MOL MICROBIOL, V21, P1283, DOI 10.1046/j.1365-2958.1996.851446.x; Ren JH, 1999, BIOCHEMISTRY-US, V38, P976, DOI 10.1021/bi981576s; Ren JH, 1999, SCIENCE, V284, P955, DOI 10.1126/science.284.5416.955; Retamal CA, 1999, ANAL BIOCHEM, V268, P15, DOI 10.1006/abio.1998.2977; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Senzel L, 1998, J GEN PHYSIOL, V112, P317, DOI 10.1085/jgp.112.3.317; Sharpe JC, 1999, J MEMBRANE BIOL, V171, P209, DOI 10.1007/s002329900572; SILVERMAN JA, 1994, J BIOL CHEM, V269, P22524; TORTORELLA D, 1995, J BIOL CHEM, V270, P27439, DOI 10.1074/jbc.270.46.27439; TORTORELLA D, 1995, J BIOL CHEM, V270, P27446, DOI 10.1074/jbc.270.46.27446; Umata T, 1998, J BIOL CHEM, V273, P8351, DOI 10.1074/jbc.273.14.8351; ZHAN HJ, 1994, BIOCHEMISTRY-US, V33, P11254, DOI 10.1021/bi00203a022; ZHAO JM, 1988, J BIOL CHEM, V263, P15369	58	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11771	11777		10.1074/jbc.275.16.11771	http://dx.doi.org/10.1074/jbc.275.16.11771			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766800	hybrid			2022-12-27	WOS:000086695500035
J	Fedosov, SN; Fedosova, NU; Nexo, E; Petersen, TE				Fedosov, SN; Fedosova, NU; Nexo, E; Petersen, TE			Conformational changes of transcobalamin induced by aquocobalamin binding - Mechanism of substitution of the cobalt-coordinated group in the bound ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRINSIC-FACTOR; SEQUENCE; PROTEIN; PURIFICATION; VITAMIN-B-12; HAPTOCORRIN; MILK	Binding of aquo-, cyano-, or azidocobalamin (Cbl . OH2, Cbl . CN, and Cbl . N-3, respectively) to the recombinant human transcobalamin (TC) and haptocorrin from human plasma was investigated via stopped-flow spectroscopy, Association of cobalamins with haptocorrin always proceeded in one step. TC, however, displayed a certain selectivity for the ligands: Cbl . CN or Cbl . N-3 bound in one step with k(+1) = 1 x 10(8) M-1 s(-1) (20 degrees C), whereas binding of Cbl . OH, under the same conditions occurred in two steps with k(+1) = 3 x 10(7) M-1 s(-1) (E-a = 30 kJ/mol) and k(+2) = 0.02 s(-1) (E-a = 120 kJ/mol). The second step of Cbl . OH2 binding was interpreted as a transformation of the initial "open" intermediate TC . Cbl . OH, to the "closed" conformation TC(Cbl) with displaced water. The backward transition from the closed to the open conformation was the reason for the identical rate-limiting steps during substitution of H2O in TC . Cbl . OH2 for cyanide or azide according to the reaction TC(Cbl) --> TC . Cbl . OH2 + CN-/N-3(-). The cyano and azido forms of holo-TC which were produced behaved as the open proteins. Different conformations of holo-TC, determined by the nature of the active group in the bound Cbl, may direct transportation of cobalamins in the organism.	Aarhus Univ, Dept Biol Mol & Struct, Prot Chem Lab, DK-8000 Aarhus C, Denmark; Aarhus Univ, Dept Biophys, DK-8000 Aarhus, Denmark; AKH Aarhus Univ Hosp, Dept Clin Biochem, DK-8000 Aarhus C, Denmark	Aarhus University; Aarhus University; Aarhus University	Fedosov, SN (corresponding author), Aarhus Univ, Dept Biol Mol & Struct, Prot Chem Lab, Sci Pk,Gustav Wieds Vej 10, DK-8000 Aarhus C, Denmark.		Fedosov, Sergey N./J-2340-2019	Fedosov, Sergey N./0000-0002-7016-2959; Nexo, Ebba/0000-0001-9406-9081; Fedosova, Natalya U./0000-0002-1706-6108				ALLEN RH, 1972, J BIOL CHEM, V247, P7702; Esmann M, 1997, ANN NY ACAD SCI, V834, P310, DOI 10.1111/j.1749-6632.1997.tb52261.x; Fedosov SN, 1999, J BIOL CHEM, V274, P26015, DOI 10.1074/jbc.274.37.26015; Fedosov SN, 1995, BIOCHEMISTRY-US, V34, P16082, DOI 10.1021/bi00049a023; Fedosov SN, 1996, BBA-PROTEIN STRUCT M, V1292, P113, DOI 10.1016/0167-4838(95)00173-5; FIRTH RA, 1967, BIOCHEMISTRY-US, V6, P2178, DOI 10.1021/bi00859a040; GIMSING P, 1983, COBALAMINS, P7; GOTTLIEB C, 1965, BLOOD-J HEMATOL, V25, P875, DOI 10.1182/blood.V25.6.875.875; GRUBER K, 1998, VITAMIN B12 B12 PROT, P335; HERBERT V, 1964, ANN NY ACAD SCI, V112, P855, DOI 10.1111/j.1749-6632.1964.tb45063.x; HIPPE E, 1970, BIOCHIM BIOPHYS ACTA, V208, P337, DOI 10.1016/0304-4165(70)90255-2; KOLHOUSE JF, 1977, J CLIN INVEST, V60, P1381, DOI 10.1172/JCI108899; Konrat R., 1998, VITAMIN B12 B12 PROT, P349; KRAUTLER B, 1998, VITAMIN B12 B12 PROT, P3; LI N, 1993, BIOCHIM BIOPHYS ACTA, V1172, P21, DOI 10.1016/0167-4781(93)90264-E; MARCHAJ A, 1995, J AM CHEM SOC, V117, P11640, DOI 10.1021/ja00152a003; Mendes P, 1997, TRENDS BIOCHEM SCI, V22, P361, DOI 10.1016/S0968-0004(97)01103-1; MOESTRUP SK, 1998, VITAMIN B12 B12 PROT, P477; NEXO E, 1975, BIOCHIM BIOPHYS ACTA, V379, P189, DOI 10.1016/0005-2795(75)90021-5; NEXO E, 1976, BIOCHIM BIOPHYS ACTA, V446, P143, DOI 10.1016/0005-2795(76)90106-9; NEXO E, 1985, BIOCHIM BIOPHYS ACTA, V838, P264, DOI 10.1016/0304-4165(85)90088-1; NEXO E, 1975, SCAND J HAEMATOL, V14, P320; NEXO E, 1998, VITAMIN B12 B12 PROT, P461, DOI DOI 10.1002/9783527612192.CH30; NEXO E, 1982, B12 BIOCH MED, V2, P87; Nilsson-Ehle H, 1998, DRUG AGING, V12, P277, DOI 10.2165/00002512-199812040-00003; PLATICA O, 1991, J BIOL CHEM, V266, P7860; QUADROS EV, 1986, J BIOL CHEM, V261, P5455; ROTHENBERG SP, 1995, BAILLIERE CLIN HAEM, V8, P499, DOI 10.1016/S0950-3536(05)80218-5	28	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11791	11798		10.1074/jbc.275.16.11791	http://dx.doi.org/10.1074/jbc.275.16.11791			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766803	hybrid			2022-12-27	WOS:000086695500038
J	Huang, S; New, L; Pan, ZX; Han, JH; Nemerow, GR				Huang, S; New, L; Pan, ZX; Han, JH; Nemerow, GR			Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38 alpha mitogen-activated protein kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; N-TERMINAL KINASE; MESSENGER-RNA; POSTTRANSCRIPTIONAL REGULATION; EXTRACELLULAR-MATRIX; SIGNALING PATHWAY; GENE-EXPRESSION; TUMOR; P38; PROMOTER	Overexpression of urokinase plasminogen activator (uPA) and its receptor (uPAR) has been well documented in a wide variety of tumor cells. In breast cancer, expression of uPA/uPAR is essential for tumor cell invasion and metastasis. However, the mechanism responsible for uPA/uPAR expression in cancer cells remains unclear. In the studies reported here, we show that endogenous p38 MAPK activity correlates web with breast carcinoma cell invasiveness. Treatment of highly invasive BT549 cells with a specific p38 MAPK inhibitor SB203580 diminished both uPA/uPAR mRNA and protein expression and abrogated the ability of these cells to invade matrigel, suggesting that p38 MAPK signaling pathway is involved in the regulation of uPA/uPAR expression and breast cancer cell invasion. We also demonstrated that SB203580-induced reduction in uPA/uPAR mRNA expression resulted from the destabilization of uPA and uPAR mRNA. Finally, by selectively inhibiting p38 alpha or p38 beta MAPK isoforms, we demonstrate that p38 alpha, rather than paspl p38 beta, MAPK activity is essential for uPA/uPAR expression. These studies suggest that p38 alpha MAPK signaling pathway is important for the maintenance of breast cancer invasive phenotype by promoting the stabilities of uPA and uPAR mRNA.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Huang, S (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	shuang@scripps.edu	Han, J/G-4671-2010		NEI NIH HHS [R01 EY11431] Funding Source: Medline; NHLBI NIH HHS [HL54352] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011431] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054352] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AZNAVOORIAN S, 1993, CANCER-AM CANCER SOC, V71, P1368, DOI 10.1002/1097-0142(19930215)71:4<1368::AID-CNCR2820710432>3.0.CO;2-L; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Besser D, 1997, ONCOGENE, V14, P705, DOI 10.1038/sj.onc.1200879; Blasi F, 1997, IMMUNOL TODAY, V18, P415, DOI 10.1016/S0167-5699(97)01121-3; Bouchet C, 1998, BRIT J CANCER, V77, P1495, DOI 10.1038/bjc.1998.246; Camussi G, 1997, J IMMUNOL, V158, P1302; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Dano K, 1999, APMIS, V107, P120, DOI 10.1111/j.1699-0463.1999.tb01534.x; DECLERCK YA, 1999, CANCER RES, V52, P701; Ghiso JAA, 1999, EUR J BIOCHEM, V263, P295, DOI 10.1046/j.1432-1327.1999.00507.x; Guerra FK, 1996, INT J CANCER, V65, P812, DOI 10.1002/(SICI)1097-0215(19960315)65:6<812::AID-IJC18>3.3.CO;2-5; Henke CA, 1996, J CLIN INVEST, V97, P2541, DOI 10.1172/JCI118702; HolstHansen C, 1996, CLIN EXP METASTAS, V14, P297; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; HUANG SA, 1994, J BIOL CHEM, V269, P28764; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; LAIHO M, 1989, CANCER RES, V49, P2533; Lee JC, 1999, PHARMACOL THERAPEUT, V82, P389, DOI 10.1016/S0163-7258(99)00008-X; LEIRISALOREPO M, 1994, PHARMACOL TOXICOL, V75, P1, DOI 10.1111/j.1600-0773.1994.tb01988.x; Lengyel E, 1996, J BIOL CHEM, V271, P23176, DOI 10.1074/jbc.271.38.23176; LENGYEL E, 1995, J BIOL CHEM, V270, P23007, DOI 10.1074/jbc.270.39.23007; Lim M, 1998, FEBS LETT, V441, P88, DOI 10.1016/S0014-5793(98)01474-4; LIOTTA LA, 1979, P NATL ACAD SCI USA, V76, P2268, DOI 10.1073/pnas.76.5.2268; Lisnock JM, 1998, BIOCHEMISTRY-US, V37, P16573, DOI 10.1021/bi981591x; LUND LR, 1995, BIOCHEM J, V310, P345, DOI 10.1042/bj3100345; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; Miralles F, 1998, J BIOL CHEM, V273, P2052, DOI 10.1074/jbc.273.4.2052; Miyazawa K, 1998, J BIOL CHEM, V273, P24832, DOI 10.1074/jbc.273.38.24832; Mustjoki S, 1999, APMIS, V107, P144, DOI 10.1111/j.1699-0463.1999.tb01537.x; Nanbu R, 1997, EUR J BIOCHEM, V247, P169, DOI 10.1111/j.1432-1033.1997.00169.x; NANBU R, 1994, MOL CELL BIOL, V14, P4920, DOI 10.1128/MCB.14.7.4920; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; New LG, 1998, TRENDS CARDIOVAS MED, V8, P220, DOI 10.1016/S1050-1738(98)00012-7; NIP J, 1995, J CLIN INVEST, V95, P2096, DOI 10.1172/JCI117897; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Reuning U, 1998, INT J ONCOL, V13, P893; RICCIO A, 1985, NUCLEIC ACIDS RES, V13, P2759, DOI 10.1093/nar/13.8.2759; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Simon C, 1998, CANCER RES, V58, P1135; Smicun Y, 1998, EUR J BIOCHEM, V251, P704, DOI 10.1046/j.1432-1327.1998.2510704.x; SORAVIA E, 1995, BLOOD, V86, P624, DOI 10.1182/blood.V86.2.624.bloodjournal862624; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Symes K, 1996, P NATL ACAD SCI USA, V93, P9641, DOI 10.1073/pnas.93.18.9641; VASSALLI JD, 1994, NATURE, V370, P14, DOI 10.1038/370014a0; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; Wang GJ, 1998, P NATL ACAD SCI USA, V95, P6296, DOI 10.1073/pnas.95.11.6296; Wang ZL, 1998, STRUCTURE, V6, P1117, DOI 10.1016/S0969-2126(98)00113-0; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; Westermarck J, 1998, MATRIX BIOL, V17, P547, DOI 10.1016/S0945-053X(98)90107-X; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Xing RH, 1996, INT J CANCER, V67, P423, DOI 10.1002/(SICI)1097-0215(19960729)67:3<423::AID-IJC18>3.0.CO;2-8; YU DH, 1994, CANCER RES, V54, P3260	55	92	116	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12266	12272		10.1074/jbc.275.16.12266	http://dx.doi.org/10.1074/jbc.275.16.12266			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766865	hybrid			2022-12-27	WOS:000086695500100
J	Enriquez, JA; Cabezas-Herrera, J; Bayona-Bafaluy, MP; Attardi, G				Enriquez, JA; Cabezas-Herrera, J; Bayona-Bafaluy, MP; Attardi, G			Very rare complementation between mitochondria carrying different mitochondrial DNA mutations points to intrinsic genetic autonomy of the organelles in cultured human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY NADH DEHYDROGENASE; TRANSFER RNALEU(UUR) GENE; INTERGENOMIC RECOMBINATION; DISTINCT ORGANELLES; PROTEIN-SYNTHESIS; ENCODED SUBUNITS; HUMAN BRAIN; WILD-TYPE; MTDNA; DEFECTS	In the present work, a large scale investigation was done regarding the capacity of cultured human, cell lines (carrying in homoplasmic form either the mitochondrial tRNA(Lys) A8344G mutation associated with the myoclonic epilepsy and ragged red fiber (MERRF) encephalomyopathy or a frameshift mutation, isolated in vitro, in the gene for the ND4 subunit of NADH dehydrogenase) to undergo transcomplementation of their recessive mitochondrial DNA (mtDNA) mutations after cell fusion. The presence of appropriate nuclear drug resistance markers in the two cell lines allowed measurements of the frequency of cell fusion in glucose-containing medium, non-selective for respiratory capacity, whereas the frequency of transcomplementation of the two mtDNA mutations was determined by growing the same cell fusion mixture in galactose-containing medium, selective for respiratory competence. Transcomplementation of the two mutations was revealed by the re-establishment of normal mitochondrial protein synthesis and respiratory activity and by the relative rates synthesis of two isoforms of the ND3 subunit of NADH dehydrogenase. The results of several experiments showed a cell fusion frequency between 1.4 and 3.4% and an absolute transcomplementation frequency that varied between 1.2 x 10(-5) and 5.5 x 10(-4). Thus, only 0.3-1.6% of the fusion products exhibited transcomplementation of the two mutations. These rare transcomplementing clones were very sluggish in developing, grew very slowly thereafter, and showed a substantial rate of cell death (22-28%). The present results strongly support the conclusion that the capacity of mitochondria to fuse and mix their contents is not a general intrinsic property of these organelles in mammalian cells, although it may become activated in some developmental or physiological situations.	CALTECH, Div Biol, Pasadena, CA 91125 USA; Univ Zaragoza, Dept Bioquim & Biol Mol & Celular, E-50013 Zaragoza, Spain	California Institute of Technology; University of Zaragoza	Attardi, G (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.		Enríquez, J.A./M-8468-2016; CABEZAS-HERRERA, JUAN/J-9434-2015; Cabezas-Herrera, Juan/F-3850-2016	Enríquez, J.A./0000-0002-3671-2961; CABEZAS-HERRERA, JUAN/0000-0001-9053-5380; Cabezas-Herrera, Juan/0000-0002-6833-4977	NIGMS NIH HHS [GM-11726] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai YD, 1998, EMBO J, V17, P4848, DOI 10.1093/emboj/17.16.4848; Bai YD, 2000, MOL CELL BIOL, V20, P805, DOI 10.1128/MCB.20.3.805-815.2000; BAKEEVA LE, 1981, EUR J CELL BIOL, V25, P175; BAKEEVA LE, 1983, J MOL CELL CARDIOL, V15, P413, DOI 10.1016/0022-2828(83)90261-4; BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303; BOYNTON JE, 1987, P NATL ACAD SCI USA, V84, P2391, DOI 10.1073/pnas.84.8.2391; BRANDT JT, 1974, BIOCHEM BIOPH RES CO, V59, P1097, DOI 10.1016/S0006-291X(74)80091-4; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; CLARKWALKER GD, 1975, P NATL ACAD SCI USA, V72, P372, DOI 10.1073/pnas.72.1.372; CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324; DESJARDINS P, 1985, MOL CELL BIOL, V5, P1163, DOI 10.1128/MCB.5.5.1163; DITTA G, 1976, SOMAT CELL GENET, V2, P331, DOI 10.1007/BF01538838; Dujon B., 1981, MOL BIOL YEAST SACCH, P505; Enriquez J A, 1996, Methods Enzymol, V264, P183, DOI 10.1016/S0076-6879(96)64019-1; ENRIQUEZ JA, 1995, NAT GENET, V10, P47, DOI 10.1038/ng0595-47; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; Guan MX, 1996, HUM MOL GENET, V5, P963, DOI 10.1093/hmg/5.7.963; Hales KG, 1997, CELL, V90, P121, DOI 10.1016/S0092-8674(00)80319-0; HAYAKAWA M, 1993, MOL CELL BIOCHEM, V119, P95, DOI 10.1007/BF00926859; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HAYASHI JI, 1994, J CELL BIOL, V125, P43, DOI 10.1083/jcb.125.1.43; Hermann GJ, 1998, J CELL BIOL, V143, P359, DOI 10.1083/jcb.143.2.359; Hofhaus G, 1996, Methods Enzymol, V264, P476, DOI 10.1016/S0076-6879(96)64043-9; Hofhaus G, 1996, J BIOL CHEM, V271, P13155, DOI 10.1074/jbc.271.22.13155; HOFHAUS G, 1995, MOL CELL BIOL, V15, P964; HOFHAUS G, 1993, EMBO J, V12, P3043, DOI 10.1002/j.1460-2075.1993.tb05973.x; KAWANO S, 1991, PROTOPLASMA, V160, P167, DOI 10.1007/BF01539968; Kawasaki E.S., 1990, PCR PROTOCOLS GUIDE, P146; King M P, 1996, Methods Enzymol, V264, P313, DOI 10.1016/S0076-6879(96)64030-0; KING MP, 1988, CELL, V52, P811, DOI 10.1016/0092-8674(88)90423-0; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5; Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774; MITCHELL CH, 1978, SOMAT CELL GENET, V4, P737, DOI 10.1007/BF01543161; OLIVER NA, 1983, J BIOL CHEM, V258, P5834; OLSON GE, 1992, MOL REPROD DEV, V33, P89, DOI 10.1002/mrd.1080330113; PREISS T, 1995, TRENDS GENET, V11, P211, DOI 10.1016/S0168-9525(00)89048-4; RANCOURT MW, 1975, J ULTRA MOL STRUCT R, V51, P418, DOI 10.1016/S0022-5320(75)80105-5; Rapaport D, 1998, J BIOL CHEM, V273, P20150, DOI 10.1074/jbc.273.32.20150; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; ROBINSON BH, 1992, BIOCHEM MED METAB B, V48, P122, DOI 10.1016/0885-4505(92)90056-5; ROTHENBERG M, 1985, CURR GENET, V9, P615, DOI 10.1007/BF00381175; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; SOONG NW, 1992, NAT GENET, V2, P318; Stevens B., 1981, MOL BIOL YEAST SACCH, V11, P471; Takai D, 1999, J BIOL CHEM, V274, P11199, DOI 10.1074/jbc.274.16.11199; Takai D, 1997, J BIOL CHEM, V272, P6028, DOI 10.1074/jbc.272.9.6028; VEDEL F, 1986, CURR GENET, V11, P17, DOI 10.1007/BF00389421; Villani G, 1997, P NATL ACAD SCI USA, V94, P1166, DOI 10.1073/pnas.94.4.1166; WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739; YONEDA M, 1992, P NATL ACAD SCI USA, V89, P11164, DOI 10.1073/pnas.89.23.11164; YONEDA M, 1994, MOL CELL BIOL, V14, P2699, DOI 10.1128/MCB.14.4.2699; ZHANG C, 1992, FEBS LETT, V297, P34, DOI 10.1016/0014-5793(92)80321-7	55	75	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11207	11215		10.1074/jbc.275.15.11207	http://dx.doi.org/10.1074/jbc.275.15.11207			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753928	hybrid, Green Submitted, Green Accepted			2022-12-27	WOS:000086466600070
J	Matsui, H; Kimura, A; Yamashiki, N; Moriyama, A; Kaya, M; Yoshida, I; Takagi, N; Takahashi, T				Matsui, H; Kimura, A; Yamashiki, N; Moriyama, A; Kaya, M; Yoshida, I; Takagi, N; Takahashi, T			Molecular and biochemical characterization of a serine proteinase predominantly expressed in the medulla oblongata and cerebellar white matter of mouse brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; MESSENGER-RNA; PROTEOLYTIC ACTIVATION; POLYACRYLAMIDE GELS; GENE; PROTEASE; ORGANIZATION; NEUROPSIN; CLEAVAGE; CANCER	A full-length cDNA clone of a serine proteinase, mouse brain serine proteinase (mBSP), was isolated from a mouse brain cDNA library. mBSP, which has been recently reported to be expressed in the hair follicles of nude mice, is most similar (88% identical) in sequence to rat myelencephalon-specific protease, The mBSP mRNA was steadily expressed in the brain of adult mice with a transient expression in the early fetal stage during development. The genomic structure of the mouse gene for mBSP was determined. The gene, which is mapped to chromosome 7B4-B5, is about 7.4 kilobases in size and contains 7 exons, Interestingly, the 5'-untranslated region of the mBSP gene was interrupted by two introns, In situ hybridization analyses revealed that mBSP is expressed in the white matter of the cerebellum, medulla oblongata, and capsula interna and capsula interna pars retrolenticularis of mouse brain. Further, mBSP was immunolocalized to the neuroglial cells in the white matter of the cerebellum. Recombinant mBSP was produced in the bacterial expression system and activated by lysyl endopeptidase digestion, and the activated enzyme was purified for characterization. The enzyme showed amidolytic activities preferentially cleaving Arg-X bonds when 4-methylcoumaryl-7-amide-containing peptide substrates were used. Typical serine proteinase inhibitors, such as diisopropyl fluorophosphates, phenylmethanesulfonyl fluoride, soybean trypsin inhibitor, aprotinin, leupeptin, antipain, and benzamidine, strongly inhibited the enzyme activity, The recombinant mBSP effectively hydrolyzed fibronectin and gelatin, but not laminin, collagens I and IV, or elastin. These results suggest that mBSP plays an important role in association with the function of the adult mouse brain.	Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan; Hokkaido Univ, Res Ctr Mol Genet, Sapporo, Hokkaido 0600810, Japan; Hokkaido Univ, Grad Sch Environm Earth Sci, Div Biosci, Sapporo, Hokkaido 0600810, Japan; Rakuno Gakuen Univ, Biol Lab, Ebetsu, Hokkaido 0698501, Japan; Nagoya City Univ, Inst Nat Sci, Div Biomol Sci, Nagoya, Aichi 4678501, Japan	Hokkaido University; Hokkaido University; Hokkaido University; Rakuno Gakuen University; Nagoya City University	Takahashi, T (corresponding author), Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan.	ttakaha@sci.hokudai.ac.jp						Anisowicz A, 1996, MOL MED, V2, P624, DOI 10.1007/BF03401646; APPLE W, 1974, METHOD ENZYMAT AN, V2, P1041; BARRETT AJ, 1980, BIOCHEM J, V187, P909, DOI 10.1042/bj1870909; BERNIER F, 1994, J BIOL CHEM, V269, P28200; CHEN ZL, 1995, J NEUROSCI, V15, P5088; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; HADDAD P, 1990, GENE, V87, P265, DOI 10.1016/0378-1119(90)90311-E; HARADA N, 1992, BIOCHEM BIOPH RES CO, V189, P1001, DOI 10.1016/0006-291X(92)92303-F; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; HOHN PA, 1989, J BIOL CHEM, V264, P13412; ICHINOSE A, 1984, FEBS LETT, V175, P412, DOI 10.1016/0014-5793(84)80779-6; KHOKHA R, 1989, INVAS METAST, V9, P391; Kimura A, 1999, J BIOL CHEM, V274, P24047, DOI 10.1074/jbc.274.34.24047; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Little SP, 1997, J BIOL CHEM, V272, P25135, DOI 10.1074/jbc.272.40.25135; Mareel MM, 1991, MECHANISMS INVASION, P73; Matsui H, 1998, ZOOL SCI, V15, P499, DOI 10.2108/0289-0003(1998)15[499:PAOTPA]2.0.CO;2; Meier N, 1999, BIOCHEM BIOPH RES CO, V258, P374, DOI 10.1006/bbrc.1999.0600; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; RAUVALA H, 1989, BIOSCIENCE REP, V9, P1, DOI 10.1007/BF01117507; RICKLES RJ, 1988, FEBS LETT, V229, P100, DOI 10.1016/0014-5793(88)80806-8; Scarisbrick IA, 1997, J NEUROSCI, V17, P8156; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Shimizu C, 1998, J BIOL CHEM, V273, P11189, DOI 10.1074/jbc.273.18.11189; SHIROTA M, 1990, MOL ENDOCRINOL, V4, P1136, DOI 10.1210/mend-4-8-1136; STEVENSON BJ, 1986, NUCLEIC ACIDS RES, V14, P8307, DOI 10.1093/nar/14.21.8307; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; Yamashiro K, 1997, BBA-GENE STRUCT EXPR, V1350, P11, DOI 10.1016/S0167-4781(96)00187-X; Yoshida S, 1998, GENE, V213, P9, DOI 10.1016/S0378-1119(98)00232-7	31	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11050	11057		10.1074/jbc.275.15.11050	http://dx.doi.org/10.1074/jbc.275.15.11050			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753908	hybrid			2022-12-27	WOS:000086466600050
J	Frasch, SC; Henson, PM; Kailey, JM; Richter, DA; Janes, MS; Fadok, VA; Bratton, DL				Frasch, SC; Henson, PM; Kailey, JM; Richter, DA; Janes, MS; Fadok, VA; Bratton, DL			Regulation of phospholipid scramblase activity during apoptosis and cell activation by protein kinase C delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE PHOSPHOLIPIDS; TRANSBILAYER MOVEMENT; AMINOPHOSPHOLIPID TRANSLOCASE; PROTEOLYTIC ACTIVATION; EXTRACELLULAR RELEASE; PHOSPHATIDYLSERINE; CLEAVAGE; MACROPHAGES; LYMPHOCYTES; PAF	Phospholipid scramblase induces nonspecific bidirectional movement of phospholipids across the membrane during cell activation and has been proposed to mediate the appearance of phosphatidylserine (PS) in the plasma membrane outer leaflet during apoptosis, a cell surface change that is critical for apoptotic cell removal. We report here that protein kinase C (PKC) delta plays an important role in activated transbilayer movement of phospholipids and surface PS exposure by directly enhancing the activity of phospholipid scrambIase, Specific inhibition of PKC delta by rottlerin prevented both apoptosis- and activation-induced scrambIase activity. PKC delta was either selectively cleaved and activated in a caspase 3-dependent manner (during apoptosis) or translocated to the plasma membrane (in stimulated cells) and could directly phosphorylate scramblase immunoprecipitated from Jurkat cells. Furthermore, reconstitution of PKC delta and scramblase, but not scramblase or PKC delta alone in Chinese hamster ovary cells demonstrated enhanced scramblase activity.	Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA	National Jewish Health	Frasch, SC (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048211] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL34303] Funding Source: Medline; NIGMS NIH HHS [GM48211] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An B, 1996, CANCER RES, V56, P438; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; BRATTON DL, 1991, BIOCHIM BIOPHYS ACTA, V1062, P24, DOI 10.1016/0005-2736(91)90330-B; BRATTON DL, 1994, J BIOL CHEM, V269, P22517; Bratton DL, 1997, J BIOL CHEM, V272, P26159, DOI 10.1074/jbc.272.42.26159; BRATTON DL, 1994, J LIPID MEDIAT CELL, V10, P43; BRATTON DL, 1993, J BIOL CHEM, V268, P3364; BRATTON DL, 1992, J IMMUNOL, V148, P514; BRETSCHER MS, 1972, NATURE-NEW BIOL, V236, P11, DOI 10.1038/newbio236011a0; COMFURIUS P, 1990, BIOCHIM BIOPHYS ACTA, V1026, P153, DOI 10.1016/0005-2736(90)90058-V; COMFURIUS P, 1996, BOICHEMISTRY, V36, P7631; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fadok VA, 1998, CELL DEATH DIFFER, V5, P551, DOI 10.1038/sj.cdd.4400404; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Fadok VA, 1998, J IMMUNOL, V161, P6250; Frutos S, 1999, J BIOL CHEM, V274, P10765, DOI 10.1074/jbc.274.16.10765; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; HASLETT C, 1985, AM J PATHOL, V119, P101; HEMKER HC, 1983, BLOOD CELLS, V9, P303; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; ISEKI R, 1991, J IMMUNOL, V147, P4286; Khwaja A, 1999, BLOOD, V94, P291, DOI 10.1182/blood.V94.1.291.413k10_291_301; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Marguet D, 1999, NAT CELL BIOL, V1, P454, DOI 10.1038/15690; MCEVOY L, 1986, FASEB J, V130, P504; MIDDELKOOP E, 1988, BIOCHIM BIOPHYS ACTA, V937, P281, DOI 10.1016/0005-2736(88)90250-7; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Pongracz J, 1999, J BIOL CHEM, V274, P37329, DOI 10.1074/jbc.274.52.37329; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; RODRIGUEZTARDUCHY G, 1989, BIOCHEM BIOPH RES CO, V164, P1069, DOI 10.1016/0006-291X(89)91778-6; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SCHLEGEL RA, 1987, J CELL PHYSIOL, V132, P381, DOI 10.1002/jcp.1041320229; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; Verhoven B, 1999, CELL DEATH DIFFER, V6, P262, DOI 10.1038/sj.cdd.4400491; ZACHOWSKI A, 1986, BIOCHEMISTRY-US, V25, P2585, DOI 10.1021/bi00357a046; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240	45	190	198	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23065	23073		10.1074/jbc.M003116200	http://dx.doi.org/10.1074/jbc.M003116200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10770950	hybrid			2022-12-27	WOS:000088419400063
J	Matsumura, T; Otera, H; Fujiki, Y				Matsumura, T; Otera, H; Fujiki, Y			Disruption of the interaction of the longer isoform of Pex5p, Pex5pL, with Pex7p abolishes peroxisome targeting signal type 2 - Study with a novel PEX5-impaired Chinese hamster ovary cell mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHIZOMELIC CHONDRODYSPLASIA PUNCTATA; ASSEMBLY FACTOR-II; FUNCTIONAL COMPLEMENTATION; ZELLWEGER-SYNDROME; BIOGENESIS DISORDERS; PTS1 RECEPTOR; CDNA CLONING; SACCHAROMYCES-CEREVISIAE; MUTATION ANALYSIS; MEMBRANE-PROTEIN	We isolated peroxisome biogenesis-defective Chinese hamster ovary cell mutants from TKaG2 cells, wild-type CHO-K1 cells transformed with two cDNAs encoding rat Pex2p and peroxisome targeting signal (PTS) type 2-tagged green fluorescent protein, by the 9-(1'-pyrene)nonanol/UV selection method. Ten mutant clones showed cytosolic PTS2-green fluorescent protein, indicative of a defect in PTS2 import, and were classified in five complementation groups, i.e. pex1, pex2, pex5, pex14, and group A. One PEX5-deficient mutant, ZPG231, showed a novel phenotype: PTS2 proteins in the cytosol, but PTS1 proteins and catalase in peroxisomes. In ZPG231, two isoforms of the PTS1 receptor Pex5p, a shorter Pex5pS and a longer Pex5pL, were expressed as in wild-type cells, but possessed the missense point mutation S214F in both Pex5p isoforms, termed Pex5pS-S214F and Pex5pL-S214F, respectively. The S214F mutation was located only one amino acid upstream of the Pex5pL-specific 37-amino acid insertion site. Pex5pS-S214F and Pex5pL-S214F interacted with peroxisomal proteins, including PTS1 protein, catalase, and Pex14p, as efficiently as normal Pex5p. In contrast, the S214F mutation severely affected the binding of Pex5pL to the PTS2 receptor Pex7p. Expression of Pex5pL-S214F in pex5 cell mutants defective in PTS1 and PTS2 transport restored peroxisomal import of PTS1, but not PTS2. Together, the results indicate that ZPG231 is the first cell mutant providing evidence that disruption of the Pex5pL-Pex7p interaction completely abolishes PTS2 import in mammals.	Kyushu Univ, Grad Sch Sci, Dept Biol, Fukuoka 8128581, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Tokyo 1070013, Japan	Kyushu University; Japan Science & Technology Agency (JST)	Fujiki, Y (corresponding author), Kyushu Univ, Grad Sch Sci, Dept Biol, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.							Braverman N, 1997, NAT GENET, V15, P369, DOI 10.1038/ng0497-369; Braverman N, 1998, HUM MOL GENET, V7, P1195, DOI 10.1093/hmg/7.8.1195; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; FUJIKI Y, 1985, BIOCHEM J, V226, P697, DOI 10.1042/bj2260697; Fujiki Y, 1997, BBA-MOL BASIS DIS, V1361, P235, DOI 10.1016/S0925-4439(97)00051-3; Fukuda S, 1996, AM J HUM GENET, V59, P1210; FURUTA S, 1986, P NATL ACAD SCI USA, V83, P313, DOI 10.1073/pnas.83.2.313; Ghaedi K, 1999, EXP CELL RES, V248, P482, DOI 10.1006/excr.1999.4412; Ghaedi K, 1999, EXP CELL RES, V248, P489, DOI 10.1006/excr.1999.4413; Kinoshita N, 1998, J BIOL CHEM, V273, P24122, DOI 10.1074/jbc.273.37.24122; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; MIYAZAWA S, 1989, MOL CELL BIOL, V9, P83, DOI 10.1128/MCB.9.1.83; MORAND OH, 1990, BIOCHIM BIOPHYS ACTA, V1034, P132, DOI 10.1016/0304-4165(90)90066-6; Motley AM, 1997, NAT GENET, V15, P377, DOI 10.1038/ng0497-377; Okumoto K, 1997, EXP CELL RES, V233, P11, DOI 10.1006/excr.1997.3552; Okumoto K, 1997, NAT GENET, V17, P265, DOI 10.1038/ng1197-265; Okumoto K, 1998, MOL CELL BIOL, V18, P4324, DOI 10.1128/MCB.18.7.4324; Otera H, 2000, J BIOL CHEM, V275, P21703, DOI 10.1074/jbc.M000720200; Otera H, 1998, MOL CELL BIOL, V18, P388, DOI 10.1128/MCB.18.1.388; Purdue PE, 1997, NAT GENET, V15, P381, DOI 10.1038/ng0497-381; Purdue PE, 1996, J CELL BIOL, V134, P849, DOI 10.1083/jcb.134.4.849; Rehling P, 1996, EMBO J, V15, P2901, DOI 10.1002/j.1460-2075.1996.tb00653.x; Shimizu N, 1999, J BIOL CHEM, V274, P12593, DOI 10.1074/jbc.274.18.12593; Shimozawa N, 1999, HUM MOL GENET, V8, P1077, DOI 10.1093/hmg/8.6.1077; SHIMOZAWA N, 1992, J CLIN INVEST, V90, P1864, DOI 10.1172/JCI116063; SHIMOZAWA N, 1992, SCIENCE, V255, P1132, DOI 10.1126/science.1546315; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; Subramani S, 1997, NAT GENET, V15, P331, DOI 10.1038/ng0497-331; Tamura S, 1998, P NATL ACAD SCI USA, V95, P4350, DOI 10.1073/pnas.95.8.4350; Tateishi K, 1997, EUR J CELL BIOL, V73, P352; Toyama R, 1999, HUM MOL GENET, V8, P1673, DOI 10.1093/hmg/8.9.1673; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; TSUKAMOTO T, 1995, NAT GENET, V11, P395, DOI 10.1038/ng1295-395; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; ZHANG JW, 1995, J CELL BIOL, V129, P65, DOI 10.1083/jcb.129.1.65; ZOELLER RA, 1986, P NATL ACAD SCI USA, V83, P5170, DOI 10.1073/pnas.83.14.5170; ZOELLER RA, 1988, J BIOL CHEM, V263, P11590	37	93	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21715	21721		10.1074/jbc.M000721200	http://dx.doi.org/10.1074/jbc.M000721200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10767287	hybrid			2022-12-27	WOS:000088230600099
J	Subbaiah, CC; Sachs, MM				Subbaiah, CC; Sachs, MM			Maize cap1 encodes a novel SERCA-type calcium-ATPase with a calmodulin-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUSPENSION-CULTURED CELLS; ENDOPLASMIC-RETICULUM; STIMULATED ATPASE; PHOSPHORYLATED INTERMEDIATE; INTRACELLULAR CALCIUM; GENE-EXPRESSION; ALEURONE CELLS; MESSENGER-RNA; CA2+-ATPASE; CA2+	A cDNA (CAP1) isolated from maize roots shares sequence identity with genes encoding P-type Ca2+-ATPases and restores the growth phenotype of yeast mutants defective in Ca2+-pumps. CAP1 was transcribed and translated in the yeast mutant. Furthermore, the membrane-integrated product formed a Ca2+-dependent phosphorylated intermediate and supported Ca2+ transport. Although CAP1 shares greater sequence identity with mammalian "endoplasmic reticulum-type" Ca2+-pumps, it differs from these genes by having features of calmodulin (CaM)-regulated Ca2+-pumps. CAP1 from yeast microsomes bound CaM, and the CAP1-dependent Ca2+ transport in yeast was stimulated by CaM. Peptides from the C terminus of CAP1 bound CaM. Anti-CAP1 antibodies specifically recognized a maize microsomal polypeptide that also bound CaM. A similar polypeptide also formed a Ca2+-dependent phosphoenzyme. Our results suggest that cap1 encodes a novel form of CaM-regulated Ca2+-ATPase in maize. CAP1 appears to be encoded by one or two genes in maize. CAP1 RNA is induced only during early anoxia, indicating that the Ca2+-pump may play an important role in O-2-deprived maize cells.	Univ Illinois, Dept Crop Sci, Urbana, IL 61801 USA; ARS, USDA, Soybean Maize Germplasm Pathol & Genet Unit, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; United States Department of Agriculture (USDA)	Subbaiah, CC (corresponding author), Univ Illinois, Dept Crop Sci, Urbana, IL 61801 USA.							Askerlund P, 1997, PLANT PHYSIOL, V114, P999, DOI 10.1104/pp.114.3.999; BERS DM, 1994, METHOD CELL BIOL, V40, P3; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRAUER D, 1990, PHYSIOL PLANTARUM, V78, P335, DOI 10.1034/j.1399-3054.1990.780304.x; BRIARS SA, 1988, PLANTA, V176, P283, DOI 10.1007/BF00392457; BRIARS SA, 1989, BIOCHEM BIOPH RES CO, V159, P185, DOI 10.1016/0006-291X(89)92421-2; BRISKIN DP, 1986, PHYSIOL PLANTARUM, V68, P159, DOI 10.1111/j.1399-3054.1986.tb06612.x; BUSH DS, 1995, PLANTA, V197, P19, DOI 10.1007/BF00239935; BUSH DS, 1995, ANNU REV PLANT PHYS, V46, P95, DOI 10.1146/annurev.pp.46.060195.000523; CAMACHO P, 1993, SCIENCE, V260, P226, DOI 10.1126/science.8385800; CHEISI M, 1980, BIOCHEMISTRY-US, V19, P2912; CHEN FH, 1993, PLANT PHYSIOL, V102, P651, DOI 10.1104/pp.102.2.651; Chen XF, 1997, PLANT J, V11, P363, DOI 10.1046/j.1365-313X.1997.11030363.x; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; Durr G, 1998, MOL BIOL CELL, V9, P1149, DOI 10.1091/mbc.9.5.1149; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; EVANS DE, 1994, PHYSIOL PLANTARUM, V90, P420, DOI 10.1111/j.1399-3054.1994.tb00408.x; Ferrol N, 1996, PLANT CELL, V8, P1159, DOI 10.2307/3870359; GAVIN O, 1993, PLANT SCI, V92, P143, DOI 10.1016/0168-9452(93)90200-J; GEITZ RD, 1995, YEAST, V11, P355; GILROY S, 1993, PLANTA, V190, P289, DOI 10.1007/BF00196956; GRIESS EA, 1994, PLANT PHYSIOL, V104, P1467, DOI 10.1104/pp.104.4.1467; Harper JF, 1998, J BIOL CHEM, V273, P1099, DOI 10.1074/jbc.273.2.1099; HUANG B, 1988, J CELL BIOL, V107, P121, DOI 10.1083/jcb.107.1.121; KAKIUCHI S, 1981, FEBS LETT, V126, P203, DOI 10.1016/0014-5793(81)80242-6; LAL SK, 1995, PLANT PHYSIOL, V108, P1295, DOI 10.1104/pp.108.3.1295; Liang F, 1997, P NATL ACAD SCI USA, V94, P8579, DOI 10.1073/pnas.94.16.8579; Liang F, 1998, PLANT PHYSIOL, V118, P817, DOI 10.1104/pp.118.3.817; Liao BR, 1995, METHOD CELL BIOL, V49, P487, DOI 10.1016/S0091-679X(08)61475-2; LOGAN DC, 1995, J PLANT PHYSIOL, V145, P702, DOI 10.1016/S0176-1617(11)81284-8; Malmstrom S, 1997, FEBS LETT, V400, P324, DOI 10.1016/S0014-5793(96)01448-2; MOORE PB, 1984, J CELL SCI, V72, P121; PEREZPRAT E, 1992, PLANT PHYSIOL, V100, P1471, DOI 10.1104/pp.100.3.1471; RASICALDOGNO F, 1992, PLANT PHYSIOL, V98, P1202, DOI 10.1104/pp.98.3.1202; ROBINSON C, 1988, PHYSIOL PLANTARUM, V72, P177, DOI 10.1111/j.1399-3054.1988.tb06640.x; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 2002, MOL CLONING LAB MANU; SARKADI B, 1986, J BIOL CHEM, V261, P9552; Sorin A, 1997, J BIOL CHEM, V272, P9895; SUBBAIAH CC, 1994, PLANT PHYSIOL, V105, P369, DOI 10.1104/pp.105.1.369; Subbaiah CC, 1998, PLANT PHYSIOL, V118, P759, DOI 10.1104/pp.118.3.759; SUBBAIAH CC, 1994, PLANT CELL, V6, P1747, DOI 10.1105/tpc.6.12.1747; SUBBAIAH CCC, 1993, EUR J BIOCHEM, V211, P171, DOI 10.1111/j.1432-1033.1993.tb19884.x; THEODOULOU FL, 1994, J EXP BOT, V45, P1553, DOI 10.1093/jxb/45.11.1553; WIMMERS LE, 1992, P NATL ACAD SCI USA, V89, P9205, DOI 10.1073/pnas.89.19.9205; Zielinski RE, 1998, ANNU REV PLANT PHYS, V49, P697, DOI 10.1146/annurev.arplant.49.1.697	48	30	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21678	21687		10.1074/jbc.M001484200	http://dx.doi.org/10.1074/jbc.M001484200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10770930	hybrid			2022-12-27	WOS:000088230600095
J	Wellington, CL; Singaraja, R; Ellerby, L; Savill, J; Roy, S; Leavitt, B; Cattaneo, E; Hackam, A; Sharp, A; Thornberry, N; Nicholson, DW; Bredesen, DE; Hayden, MR				Wellington, CL; Singaraja, R; Ellerby, L; Savill, J; Roy, S; Leavitt, B; Cattaneo, E; Hackam, A; Sharp, A; Thornberry, N; Nicholson, DW; Bredesen, DE; Hayden, MR			Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRANUCLEAR INCLUSIONS; POLYGLUTAMINE TRACT; COMBINATORIAL APPROACH; PRECURSOR PROTEIN; MOUSE MODEL; IN-VITRO; DISEASE; APOPTOSIS; LENGTH; BRAIN	Huntington's disease is a neurodegenerative disorder caused by CAG expansion that results in expansion of a polyglutamine tract at the extreme N terminus of huntingtin (htt). htt with polyglutamine expansion is proapoptotic in different cell types. Here, we show that caspase inhibitors diminish the toxicity of htt, Additionally, we define htt itself as an important caspase substrate by generating a site-directed htt mutant that is resistant to caspase-3 cleavage at positions 513 and 530 and to caspase-6 cleavage at position 586, In contrast to cleavable htt, caspase-resistant htt with an expanded polyglutamine tract has reduced toxicity in apoptotically stressed neuronal and nonneuronal cells and forms aggregates at a much reduced frequency. These results suggest that inhibiting caspase cleavage of htt may therefore be of potential therapeutic benefit in Huntington's disease.	Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada; Buck Ctr Res Aging, Novato, CA 94945 USA; Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada; Univ Milan, Inst Pharmacol Sci, I-20133 Milan, Italy; Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21287 USA; Merck Res Labs, Dept Enzymol, Rahway, NJ 07065 USA	University of British Columbia; Buck Institute for Research on Aging; Merck & Company; University of Milan; Johns Hopkins University; Merck & Company	Hayden, MR (corresponding author), Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada.	mrh@cmmt.ubc.ca; mrh@cmmt.ubc.ca	Hayden, Michael R/D-8581-2011; Leavitt, Blair R/G-1934-2012	Hayden, Michael R/0000-0001-5159-1419; CATTANEO, ELENA/0000-0002-0755-4917; Singaraja, Roshni/0000-0002-3418-3867	NCI NIH HHS [CA69381] Funding Source: Medline; NIA NIH HHS [AG12282] Funding Source: Medline; NINDS NIH HHS [NS40251A] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040251] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012282] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Becher MW, 1998, NEUROBIOL DIS, V4, P387, DOI 10.1006/nbdi.1998.0168; Chen NS, 1999, J NEUROCHEM, V72, P1890, DOI 10.1046/j.1471-4159.1999.0721890.x; Cooper JK, 1998, HUM MOL GENET, V7, P783, DOI 10.1093/hmg/7.5.783; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DIFIGLIA M, 1990, TRENDS NEUROSCI, V13, P286, DOI 10.1016/0166-2236(90)90111-M; DRAGUNOW M, 1995, NEUROREPORT, V6, P1053, DOI 10.1097/00001756-199505090-00026; Ellerby LM, 1999, J NEUROCHEM, V72, P185, DOI 10.1046/j.1471-4159.1999.0720185.x; Ellerby LM, 1999, J BIOL CHEM, V274, P8730, DOI 10.1074/jbc.274.13.8730; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Goldberg YP, 1996, HUM MOL GENET, V5, P177, DOI 10.1093/hmg/5.2.177; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Hackam AS, 1999, HUM MOL GENET, V8, P25, DOI 10.1093/hmg/8.1.25; Hackam AS, 1998, J CELL BIOL, V141, P1097, DOI 10.1083/jcb.141.5.1097; Hayden MR., 1981, HUNTINGTONS CHOREA, P45; HEDREEN JC, 1995, J NEUROPATH EXP NEUR, V54, P105, DOI 10.1097/00005072-199501000-00013; HEDREEN JC, 1991, NEUROSCI LETT, V133, P257, DOI 10.1016/0304-3940(91)90583-F; Hodgson JG, 1999, NEURON, V23, P181, DOI 10.1016/S0896-6273(00)80764-3; Kalchman MA, 1996, J BIOL CHEM, V271, P19385, DOI 10.1074/jbc.271.32.19385; Kalchman MA, 1997, NAT GENET, V16, P44, DOI 10.1038/ng0597-44; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; Lunkes A, 1998, HUM MOL GENET, V7, P1355, DOI 10.1093/hmg/7.9.1355; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; Nasir J, 1996, HUM MOL GENET, V5, P1431, DOI 10.1093/hmg/5.Supplement_1.1431; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; Rano TA, 1997, CHEM BIOL, V4, P149, DOI 10.1016/S1074-5521(97)90258-1; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; THOMAS LB, 1995, EXP NEUROL, V133, P265, DOI 10.1006/exnr.1995.1029; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Walter J, 1999, P NATL ACAD SCI USA, V96, P1391, DOI 10.1073/pnas.96.4.1391; Wanker EE, 1997, HUM MOL GENET, V6, P487, DOI 10.1093/hmg/6.3.487; Weidemann A, 1999, J BIOL CHEM, V274, P5823, DOI 10.1074/jbc.274.9.5823; Wellington CL, 1998, J BIOL CHEM, V273, P9158, DOI 10.1074/jbc.273.15.9158; Wellington CL, 1997, CURR OPIN NEUROL, V10, P291, DOI 10.1097/00019052-199708000-00003	41	270	280	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19831	19838		10.1074/jbc.M001475200	http://dx.doi.org/10.1074/jbc.M001475200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10770929	hybrid			2022-12-27	WOS:000087941300055
J	Shiraha, H; Gupta, K; Drabik, K; Wells, A				Shiraha, H; Gupta, K; Drabik, K; Wells, A			Aging fibroblasts present reduced epidermal growth factor (EGF) responsiveness due to preferential loss of EGF receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE ACTIVITY; AGE-RELATED DECLINE; TYROSINE PHOSPHORYLATION; SKIN FIBROBLASTS; PHOSPHOLIPASE-C; RAT HEPATOCYTES; CELL MOTILITY; ENDOTHELIAL-CELLS; SIGNALING PATHWAY; LIFE-SPAN	Wound healing is compromised in aging adults in part due to decreased responsiveness of fibroblasts to extracellular signals. However, the cellular mechanisms underlying this phenomenon are not known. Aged dermal fibroblasts with reduced remaining replicative capacities demonstrated decreased epidermal growth factor (EGF)-induced cell migrative and cell proliferative capacities, as reported previously. Thus, as cells approach senescence, programmed in vivo or in vitro, EGF responsiveness is preferentially lost. To define the rate-limiting signaling event, we found that the activity of two different EGF receptor (EGFR)-signaling pathways to cell migration (phospholipase-C gamma) and/or mitogenesis (extracellular signal/regulated-mitogen-activated kinases) were decreased in near senescent cells despite unchanged levels of effector molecules. Aged cells presented decreased levels of EGFR, although insulin receptor and transferrin receptor levels were relatively unchanged. EGFR, mRNA levels and production of new transcripts decreased during aging, suggesting that this preferential loss of EGFR was due to diminished production, which more than counteracts the reduced ligand-induced receptor loss. Since these data suggested that the decrement in EGF was rate-limiting, higher levels of EGFR were established in near senescent cells by electroporation of EGFR cDNA. These cells presented higher levels of EGFR and recovered their EGF-induced migration and proliferation responsiveness. Thus, the defect in EGF responsiveness of aged dermal fibroblasts is secondary to reduced EGFR message transcription. Our experimental model suggests that EGFR gene delivery might be an effective future therapy for compromised wound healing.	Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Alabama System; University of Alabama Birmingham	Wells, A (corresponding author), Univ Pittsburgh, Dept Pathol, S713 Scaife,Terrace St, Pittsburgh, PA 15261 USA.	wellsa@msx.upmc.edu		Wells, Alan/0000-0002-1637-8150	NIGMS NIH HHS [GM54739] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054739] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOYAGI M, 1995, J CELL PHYSIOL, V164, P376, DOI 10.1002/jcp.1041640218; Ashcroft GS, 1997, J ANAT, V190, P351, DOI 10.1046/j.1469-7580.1997.19030351.x; ASHCROFT GS, 1995, J ANAT, V187, P1; BARRANDON Y, 1987, CELL, V50, P1131, DOI 10.1016/0092-8674(87)90179-6; BECK LS, 1993, J CLIN INVEST, V92, P2841, DOI 10.1172/JCI116904; Benn SI, 1996, J CLIN INVEST, V98, P2894, DOI 10.1172/JCI119118; BENNETT NT, 1993, AM J SURG, V165, P728, DOI 10.1016/S0002-9610(05)80797-4; BLAY J, 1985, J CELL PHYSIOL, V124, P107, DOI 10.1002/jcp.1041240117; BLOTNICK S, 1994, P NATL ACAD SCI USA, V91, P2890, DOI 10.1073/pnas.91.8.2890; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BROWN GL, 1989, NEW ENGL J MED, V321, P76, DOI 10.1056/NEJM198907133210203; BURNS AL, 1979, MECH AGEING DEV, V11, P153; CARLIN CR, 1983, NATURE, V306, P617, DOI 10.1038/306617a0; CARPENTER G, 1978, NATL CANCER I MONOGR, V48, P149; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; Clark RA, 1996, MOL CELLULAR BIOL WO, P22; COLIGE A, 1990, J CELL PHYSIOL, V145, P450, DOI 10.1002/jcp.1041450309; Cristofalo VJ, 1998, P NATL ACAD SCI USA, V95, P10614, DOI 10.1073/pnas.95.18.10614; Cristofalo VJ, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 1, P321; Garfinkel S, 1996, BBA-MOL CELL RES, V1314, P109, DOI 10.1016/S0167-4889(96)00105-X; Garfinkel S, 1996, J CELL BIOL, V134, P783, DOI 10.1083/jcb.134.3.783; GERSTEIN AD, 1993, DERMATOL CLIN, V11, P749, DOI 10.1016/S0733-8635(18)30227-4; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GOSPODAROWICZ D, 1977, J CELL PHYSIOL, V93, P117, DOI 10.1002/jcp.1040930115; Haugh JM, 1999, J BIOL CHEM, V274, P8958, DOI 10.1074/jbc.274.13.8958; Hay ED, 1993, CURR OPIN CELL BIOL, V5, P1029, DOI 10.1016/0955-0674(93)90088-8; HENNESSEY PJ, 1991, J PEDIATR SURG, V26, P362, DOI 10.1016/0022-3468(91)90980-8; HOLLENBERG MD, 1979, MECH AGEING DEV, V11, P37, DOI 10.1016/0047-6374(79)90062-9; ISHIGAMI A, 1993, BIOCHEM BIOPH RES CO, V196, P181, DOI 10.1006/bbrc.1993.2232; Ji GS, 1998, MOL BIOL CELL, V9, P749, DOI 10.1091/mbc.9.4.749; KAWAMOTO T, 1984, J BIOL CHEM, V259, P7761; Kiritsy Christopher P., 1993, Critical Reviews in Oral Biology and Medicine, V4, P729; KONDO H, 1992, MECH AGEING DEV, V63, P223, DOI 10.1016/0047-6374(92)90001-T; Kondo H, 1996, MECH AGEING DEV, V87, P141, DOI 10.1016/0047-6374(95)01699-6; LAWRENCE WT, 1994, CLIN DERMATOL, V12, P157, DOI 10.1016/0738-081X(94)90266-6; Liu YS, 1996, J BIOL CHEM, V271, P3604; LOBER CW, 1991, SOUTHERN MED J, V84, P1444, DOI 10.1097/00007611-199112000-00008; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MEERSON FZ, 1978, J MOL CELL CARDIOL, V10, P145, DOI 10.1016/0022-2828(78)90039-1; NEWMAN RA, 1975, CONNECT TISSUE RES, V3, P231, DOI 10.3109/03008207509152183; NICOLLE LE, 1992, J CLIN EPIDEMIOL, V45, P357, DOI 10.1016/0895-4356(92)90036-M; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Palmer HJ, 1999, J BIOL CHEM, V274, P11424, DOI 10.1074/jbc.274.16.11424; PHILLIPS GD, 1994, MECH AGEING DEV, V73, P189, DOI 10.1016/0047-6374(94)90051-5; PIENTA KJ, 1990, MECH AGEING DEV, V56, P99, DOI 10.1016/0047-6374(90)90001-V; Reenstra WR, 1996, EXP CELL RES, V227, P252, DOI 10.1006/excr.1996.0274; REFF M, 1981, MOL CELL BIOCHEM, V36, P169, DOI 10.1007/BF02357034; SCHNEIDER EL, 1979, J INVEST DERMATOL, V73, P15, DOI 10.1111/1523-1747.ep12532753; SCHULTZ G, 1994, EYE, V8, P184, DOI 10.1038/eye.1994.43; Shiraha H, 1999, J CELL BIOL, V146, P243; STEENFOS HH, 1994, SCAND J PLAST RECONS, V28, P95, DOI 10.3109/02844319409071186; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; VISKUP RW, 1979, EXP AGING RES, V5, P487, DOI 10.1080/03610737908257223; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WILEY HS, 1989, J BIOL CHEM, V264, P18912; WILEY HS, 1981, CELL, V25, P433, DOI 10.1016/0092-8674(81)90061-1; Xie H, 1998, J CELL SCI, V111, P615	59	96	97	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19343	19351		10.1074/jbc.M000008200	http://dx.doi.org/10.1074/jbc.M000008200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10764734	hybrid			2022-12-27	WOS:000087815900094
J	Siniossoglou, S; Hurt, EC; Pelham, HRB				Siniossoglou, S; Hurt, EC; Pelham, HRB			Psr1p/Psr2p, two plasma membrane phosphatases with an essential DXDX(T/V) motif required for sodium stress response in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; TRANSCRIPTION FACTOR; SALT TOLERANCE; NA+/H+ ANTIPORTER; ION HOMEOSTASIS; GENE; CALCINEURIN; PATHWAY; EXPRESSION	Regulation of intracellular ion concentration is an essential function of all cells. In this study, we report the identification of two previously uncharacterized genes, PSR1 and PSR2, that perform an essential function under conditions of sodium ion stress in the yeast Saccharomyces cerevisiae. Psr1p and Psr2p are highly homologous and were identified through their homology with the endoplasmic reticulum membrane protein Nem1p, Localization and biochemical fractionation studies show that Psr1p is associated with the plasma membrane via a short amino-terminal sequence also present in Psr2p. Growth of the psr1psr2 mutant is severely inhibited under conditions of sodium but not potassium ion or sorbitol stress. This growth defect is due to the inability of the psr1psr2 mutant to properly induce transcription of ENA1/PMR2, the major sodium extrusion pump of yeast cells. We provide genetic evidence that this regulation is independent of the phosphatase calcineurin, previously implicated in the sodium stress response in yeast. We show that Psr1p contains a DXDX(T/V) phosphatase motif essential for its function in vivo and that a Psr1p-PtA fusion purified from yeast extracts exhibits phosphatase activity. Based on these data, we suggest that Psr1p/Psr2p, members of an emerging class of eukaryotic phosphatases, are novel regulators of salt stress response in yeast.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Biochem Zentrum Heidelberg, Heidelberg, Germany	MRC Laboratory Molecular Biology; Ruprecht Karls University Heidelberg	Pelham, HRB (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.		Ed Hurt, Dr./AAE-8874-2019	Ed Hurt, Dr./0000-0002-4535-8255				ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; Alepuz PM, 1997, MOL MICROBIOL, V26, P91, DOI 10.1046/j.1365-2958.1997.5531917.x; Archambault J, 1997, P NATL ACAD SCI USA, V94, P14300, DOI 10.1073/pnas.94.26.14300; Benito B, 1997, BBA-BIOMEMBRANES, V1328, P214, DOI 10.1016/S0005-2736(97)00098-9; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Clotet J, 1996, J BIOL CHEM, V271, P26349, DOI 10.1074/jbc.271.42.26349; Collet JF, 1998, J BIOL CHEM, V273, P14107, DOI 10.1074/jbc.273.23.14107; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; FERRANDO A, 1995, MOL CELL BIOL, V15, P5470; FOOR F, 1992, NATURE, V360, P682; GARCIADEBLAS B, 1993, MOL GEN GENET, V236, P363, DOI 10.1007/BF00277134; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; Kobor MS, 1999, MOL CELL, V4, P55, DOI 10.1016/S1097-2765(00)80187-2; Marquez JA, 1996, FEBS LETT, V382, P89, DOI 10.1016/0014-5793(96)00157-3; McCabe JB, 1999, MOL BIOL CELL, V10, P3771, DOI 10.1091/mbc.10.11.3771; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; Mulet JM, 1999, MOL CELL BIOL, V19, P3328; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PINNER E, 1992, J BIOL CHEM, V267, P11064; POSAS F, 1995, J BIOL CHEM, V270, P13036, DOI 10.1074/jbc.270.22.13036; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; RAHAVMANOR O, 1992, J BIOL CHEM, V267, P10433; REYNOLDS A, 1997, CURRENT PROTOCOLS MO, V2; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; Sambrook J., 2002, MOL CLONING LAB MANU; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; Sherman F., 1986, METHODS YEAST GENETI; Siniossoglou S, 1998, EMBO J, V17, P6449, DOI 10.1093/emboj/17.22.6449; Stark MJR, 1996, YEAST, V12, P1647, DOI 10.1002/(SICI)1097-0061(199612)12:16<1647::AID-YEA71>3.0.CO;2-Q; Stathopoulos AM, 1997, GENE DEV, V11, P3432, DOI 10.1101/gad.11.24.3432; Stathopoulos-Gerontides A, 1999, GENE DEV, V13, P798, DOI 10.1101/gad.13.7.798; VARELA JCS, 1995, MOL CELL BIOL, V15, P6232; WIELAND J, 1995, EMBO J, V14, P3870, DOI 10.1002/j.1460-2075.1995.tb00059.x; Withee JL, 1998, GENETICS, V149, P865	38	48	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19352	19360		10.1074/jbc.M001314200	http://dx.doi.org/10.1074/jbc.M001314200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10777497	hybrid			2022-12-27	WOS:000087815900095
J	Pype, S; Declercq, W; Ibrahimi, A; Michiels, C; Van Rietschoten, JGI; Dewulf, N; de Boer, M; Vandenabeele, P; Huylebroeck, D; Remacle, JE				Pype, S; Declercq, W; Ibrahimi, A; Michiels, C; Van Rietschoten, JGI; Dewulf, N; de Boer, M; Vandenabeele, P; Huylebroeck, D; Remacle, JE			TTRAP, a novel protein that associates with CD40, tumor necrosis factor (TNF) receptor-75 and TNF receptor-associated factors (TRAFs), and that inhibits nuclear factor-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING CD40; GENE-EXPRESSION; CONTAINS 2; TRANSCRIPTION FACTOR; INTERACTING PROTEIN; SIGNALING PATHWAY; IMMUNE-RESPONSES; BINDING-SITES; FACTOR FAMILY; KINASE	CD40 belongs to the tumor necrosis factor (TNF) receptor family. CD40 signaling involves the recruitment of TNF receptor-associated factors (TRAFs) to its cytoplasmic domain. We have identified a novel intracellular CD40-binding protein termed (T) under bar RAF and (T) under bar NF (r) under bar eceptor-associated (p) under bar rotein (TTRAP) that also interacts with TNF-R75 and CD30. The region of the CD40 cytoplasmic domain that is required for TTRAP association overlaps with the TRAF6 recognition motif. Association of TTRAP with CD40 increases profoundly in response to treatment of cells with CD40L. Interestingly, TTRAP also associates with TRAFs, with the highest affinity for TRAF6. In transfected cells, TTRAP inhibits in a dose-dependent manner the transcriptional activation of a nuclear factor-kappa B (NF-kappa B) dependent reporter mediated by CD40, TNF-R75 or Phorbol 12-myristate 13-acetate (PMA) and to a lesser extent by TRAF2, TRAF6, TNF-alpha, or interleukin-1 beta (IL-1 beta). TTRAP does not affect stimulation of NF-KB induced by overexpression of the NF-kappa B-inducing kinase (NIK), the I kappa B kinase alpha (IKK alpha), or the NF-KB subunit P65/RelA suggesting it acts upstream of the latter proteins. Our results indicate that we have isolated a novel regulatory factor that is involved in signal transduction by distinct members of the TNF receptor family.	Catholic Univ Louvain VIB, Dept Cell Growth Differentiat & Dev, B-3000 Louvain, Belgium; Catholic Univ Louvain, Lab Mol Biol Celgen, B-3000 Louvain, Belgium; State Univ Ghent VIB, Dept Biol Mol, B-9000 Ghent, Belgium; Tanox Pharma BV, NL-1098 SM Amsterdam, Netherlands	Flanders Institute for Biotechnology (VIB); Universite Catholique Louvain; Flanders Institute for Biotechnology (VIB); Ghent University	Huylebroeck, D (corresponding author), Catholic Univ Louvain VIB, Dept Cell Growth Differentiat & Dev, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	dhu@sgi.celgen.kuleuven.ac.be	Vandenabeele, Peter/C-8597-2009; Vandenabeele, Peter/AAD-5793-2022	Vandenabeele, Peter/0000-0002-6669-8822; Huylebroeck, Danny/0000-0003-4862-1079				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; BERBERICH I, 1994, J IMMUNOL, V153, P4357; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chang MP, 1999, MOL CELL BIOL, V19, P1056; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; Devergne O, 1996, MOL CELL BIOL, V16, P7098; DEWULF N, 1995, ENDOCRINOLOGY, V136, P2652, DOI 10.1210/en.136.6.2652; DRAPER MP, 1994, MOL CELL BIOL, V14, P4522, DOI 10.1128/MCB.14.7.4522; Dupressoir A, 1999, J BIOL CHEM, V274, P31068, DOI 10.1074/jbc.274.43.31068; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Franken M, 1996, J VIROL, V70, P7819, DOI 10.1128/JVI.70.11.7819-7826.1996; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; Gedrich RW, 1996, J BIOL CHEM, V271, P12852, DOI 10.1074/jbc.271.22.12852; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Green CB, 1996, P NATL ACAD SCI USA, V93, P14884, DOI 10.1073/pnas.93.25.14884; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hanissian SH, 1997, IMMUNITY, V6, P379, DOI 10.1016/S1074-7613(00)80281-2; Heyninck K, 1999, J CELL BIOL, V145, P1471, DOI 10.1083/jcb.145.7.1471; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Kuhne MR, 1997, J EXP MED, V186, P337, DOI 10.1084/jem.186.2.337; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Lupas A, 1997, CURR OPIN STRUC BIOL, V7, P388, DOI 10.1016/S0959-440X(97)80056-5; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MALVAR T, 1992, GENETICS, V132, P951; McWhirter SM, 1999, P NATL ACAD SCI USA, V96, P8408, DOI 10.1073/pnas.96.15.8408; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Nguyen LT, 1999, IMMUNITY, V11, P379, DOI 10.1016/S1074-7613(00)80113-2; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Park YC, 1999, NATURE, V398, P533, DOI 10.1038/19110; Pradier O, 1996, EUR J IMMUNOL, V26, P3048, DOI 10.1002/eji.1830261234; Pullen SS, 1999, J BIOL CHEM, V274, P14246, DOI 10.1074/jbc.274.20.14246; RENSHAW BR, 1994, J EXP MED, V180, P1889, DOI 10.1084/jem.180.5.1889; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Tsukamoto N, 1999, P NATL ACAD SCI USA, V96, P1234, DOI 10.1073/pnas.96.4.1234; VANDENABEELE P, 1995, J IMMUNOL, V154, P2904; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2	57	113	125	1	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18586	18593		10.1074/jbc.M000531200	http://dx.doi.org/10.1074/jbc.M000531200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10764746	hybrid			2022-12-27	WOS:000087659400092
J	Ueyama, T; Zhu, CX; Valenzuela, YM; Suzow, JG; Stewart, AFR				Ueyama, T; Zhu, CX; Valenzuela, YM; Suzow, JG; Stewart, AFR			Identification of the functional domain in the transcription factor RTEF-1 that mediates alpha(1)-adrenergic signaling in hypertrophied cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN HEAVY-CHAIN; PROTEIN-KINASE-C; ENHANCER FACTOR-I; FAILING HUMAN-HEART; M-CAT ELEMENTS; GENE-EXPRESSION; STIMULATED HYPERTROPHY; PROMOTER; MUSCLE; INDUCTION	Cardiac myocytes respond to alpha(1)-adrenergic receptor stimulation by a progressive hypertrophy accompanied by the activation of many fetal genes, including skeletal muscle alpha-actin. The skeletal muscle alpha-actin gene is activated by signaling through an MCAT element, the binding site of the transcription enhancer factor-1 (TEF-1) family of transcription factors, Previously, we showed that overexpression of the TEF-1-related factor (RTEF-1) increased the alpha(1)-adrenergic response of the skeletal muscle ru-actin promoter, whereas TEF-1 overexpression did not. Here, we identified the functional domains and specific sequences in RTEF-1 that mediate the alpha(1)-adrenergic response. Chimeric TEF-1 and RTEF-1 expression constructs localized the region responsible for the alpha(1)-adrenergic response to the carboxyl-terminal domain of RTEF-1, Site-directed mutagenesis was used to inactivate eight serine residues of RTEF-1, not present in TEF-1, that are putative targets of alpha(1)-adrenergic-dependent kinases, Mutation of a single serine residue, Ser-322, reduced the alpha(1)-adrenergic activation of RTEF-1 by 70% without affecting protein stability, suggesting that phosphorylation at this serine residue accounts for most of the alpha(1)-adrenergic response. Thus, these results demonstrate that RTEF-1 is a direct target of alpha(1)-adrenergic signaling in hypertrophied cardiac myocytes.	Univ Pittsburgh, Sch Med, Cardiovasc Inst, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Stewart, AFR (corresponding author), Univ Pittsburgh, Sch Med, Cardiovasc Inst, BST 1704-3,200 Lothrop St, Pittsburgh, PA 15213 USA.	stewartaf@msx.upmc.edu	Stewart, Alexandre F.R./A-5677-2011	Stewart, Alexandre/0000-0003-2673-9164	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL057211] Funding Source: NIH RePORTER; NHLBI NIH HHS [R29 HL57211] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRISTOW MR, 1988, J PHARMACOL EXP THER, V247, P1039; BRISTOW MR, 1993, J CLIN INVEST, V92, P2737, DOI 10.1172/JCI116891; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Esler M, 1997, AM J CARDIOL, V80, pL7, DOI 10.1016/S0002-9149(97)00844-8; Farrance IKG, 1996, J BIOL CHEM, V271, P8266, DOI 10.1074/jbc.271.14.8266; Fentzke RC, 1998, J CLIN INVEST, V101, P2415, DOI 10.1172/JCI2950; GILLESPIEBROWN J, 1995, J BIOL CHEM, V270, P28092; GUPTA MP, 1991, BIOCHEM BIOPH RES CO, V174, P1196, DOI 10.1016/0006-291X(91)91548-Q; Gupta MP, 1997, MOL CELL BIOL, V17, P3924, DOI 10.1128/MCB.17.7.3924; GUPTA MP, 1994, J BIOL CHEM, V269, P29677; Jacquemin P, 1997, J BIOL CHEM, V272, P12928, DOI 10.1074/jbc.272.20.12928; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KARIYA K, 1994, J BIOL CHEM, V269, P3775; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; KNOWLTON KU, 1993, J BIOL CHEM, V268, P15374; Larkin SB, 1996, MOL CELL BIOL, V16, P3742; LONG CS, 1989, J CLIN INVEST, V83, P1078, DOI 10.1172/JCI113951; Lowes BD, 1997, J CLIN INVEST, V100, P2315, DOI 10.1172/JCI119770; Nakao K, 1997, J CLIN INVEST, V100, P2362, DOI 10.1172/JCI119776; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Rokosh DG, 1996, J BIOL CHEM, V271, P5839, DOI 10.1074/jbc.271.10.5839; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; Stewart AFR, 1996, GENOMICS, V37, P68, DOI 10.1006/geno.1996.0522; Stewart AFR, 1998, CIRC RES, V83, P43, DOI 10.1161/01.RES.83.1.43; Thuerauf DJ, 1997, J BIOL CHEM, V272, P7464, DOI 10.1074/jbc.272.11.7464; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; WASPE LE, 1990, J CLIN INVEST, V85, P1206, DOI 10.1172/JCI114554; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YASUNAMI M, 1995, J BIOL CHEM, V270, P18649, DOI 10.1074/jbc.270.31.18649; Yockey CE, 1996, J BIOL CHEM, V271, P3727, DOI 10.1074/jbc.271.7.3727	34	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17476	17480		10.1074/jbc.M001970200	http://dx.doi.org/10.1074/jbc.M001970200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10764782	hybrid			2022-12-27	WOS:000087485000038
J	Jonassen, T; Clarke, CF				Jonassen, T; Clarke, CF			Isolation and functional expression of human COQ3, a gene encoding a methyltransferase required for ubiquinone biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATECHOL O-METHYLTRANSFERASE; POLYUNSATURATED FATTY-ACIDS; COENZYME Q(10) DEFICIENCY; SACCHAROMYCES-CEREVISIAE; CAENORHABDITIS-ELEGANS; MITOCHONDRIAL ENCEPHALOMYOPATHY; ALPHA-TOCOPHEROL; PLASMA-MEMBRANE; YEAST; CLK-1	The COQ3 gene in Saccharomyces cerevisiae encodes an O-methyltransferase required for two steps in the biosynthetic pathway of ubiquinone (coenzyme Q, or Q). This enzyme methylates an early Q intermediate, 3,4-dihydroxy-6-polyprenylbenzoic acid, as well as the final intermediate in the pathway, converting demethyl-Q to Q, This enzyme is also capable of methylating the distinct prokaryotic early intermediate 2-hydroxy-6-polyprenyl phenol. A full-length cDNA encoding the human homologue of COQ3 was isolated from a human heart cDNA library by sequence homology to rat Coq3. The clone contained a 933-base pair open reading frame that encoded a polypeptide with a great deal of sequence identity to a variety of eukaryotic and prokaryotic Coq3 homologues, In the region between amino acids 89 and 255 in the human sequence, the rat and human homologues are 87% identical, whereas human and yeast are 35% identical. When expressed in multicopy, the human construct rescued the growth of a yeast coq3 null mutant on a nonfermentable carbon source and restored coenzyme Q biosynthesis, although at lower levels than that of wild type yeast. In vitro methyltransferase assays using farnesylated analogues of intermediates in the coenzyme Q biosynthetic pathway as substrates showed that the human enzyme is active with all three substrates tested.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Clarke, CF (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 607 Charles E Young Dr E, Los Angeles, CA 90095 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045952] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45952, GM07185] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asaumi S, 1999, GENOMICS, V58, P293, DOI 10.1006/geno.1999.5838; Avelange-Macherel MH, 1998, PLANT J, V14, P203, DOI 10.1046/j.1365-313X.1998.00109.x; Beal MF, 1998, BRAIN RES, V783, P109, DOI 10.1016/S0006-8993(97)01192-X; Boitier E, 1998, J NEUROL SCI, V156, P41, DOI 10.1016/S0022-510X(98)00006-9; BOWRY VW, 1995, J BIOL CHEM, V270, P5756, DOI 10.1074/jbc.270.11.5756; CLARKE CF, 1991, J BIOL CHEM, V266, P16636; Do TQ, 1996, P NATL ACAD SCI USA, V93, P7534, DOI 10.1073/pnas.93.15.7534; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Ernster L., 1993, CLIN INVESTIGATOR, V71, P60; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; Felkai S, 1999, EMBO J, V18, P1783, DOI 10.1093/emboj/18.7.1783; Finckh B, 1995, ANAL BIOCHEM, V232, P210, DOI 10.1006/abio.1995.0009; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HATEFI Y, 1963, ADV ENZYMOL REL S BI, V25, P275; Hsu AY, 1996, BIOCHEMISTRY-US, V35, P9797, DOI 10.1021/bi9602932; Jonassen T, 1996, ARCH BIOCHEM BIOPHYS, V330, P285, DOI 10.1006/abbi.1996.0255; Jonassen T, 1998, J BIOL CHEM, V273, P3351, DOI 10.1074/jbc.273.6.3351; JONASSEN T, 2000, COENZYME Q MOL MECHA; KAAKKOLA S, 1994, GEN PHARMACOL-VASC S, V25, P813, DOI 10.1016/0306-3623(94)90082-5; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; KAGAN V, 1990, BIOCHEM BIOPH RES CO, V169, P851, DOI 10.1016/0006-291X(90)91971-T; KAGAN VE, 1996, HDB ANTIOXIDANTS, P157; Lass A, 1999, FREE RADICAL BIO MED, V26, P1375, DOI 10.1016/S0891-5849(98)00330-X; Lonnrot K, 1998, BRIT J PHARMACOL, V124, P1500, DOI 10.1038/sj.bjp.0701970; LOTTA T, 1995, BIOCHEMISTRY-US, V34, P4202, DOI 10.1021/bi00013a008; Mannisto P T, 1992, Prog Drug Res, V39, P291; MARBOIS BN, 1994, GENE, V138, P213; Matthews RT, 1998, P NATL ACAD SCI USA, V95, P8892, DOI 10.1073/pnas.95.15.8892; Meganathan R., 1996, ESCHERICHIA COLI SAL, P642; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Murakami S, 1996, GENETICS, V143, P1207; OGASAHARA S, 1989, P NATL ACAD SCI USA, V86, P2379, DOI 10.1073/pnas.86.7.2379; OLSON RE, 1983, VITAM HORM, V40, P1, DOI 10.1016/S0083-6729(08)60431-8; Poon WW, 1999, J BIOL CHEM, V274, P21665, DOI 10.1074/jbc.274.31.21665; Poon WW, 1997, MOL ASPECTS MED, V18, pS121; Rowland MA, 1998, CARDIOVASC RES, V40, P165, DOI 10.1016/S0008-6363(98)00132-1; Santos-Ocana C, 1998, J BIOENERG BIOMEMBR, V30, P465, DOI 10.1023/A:1020542230308; Santos-Ocana C, 1998, J BIOL CHEM, V273, P8099, DOI 10.1074/jbc.273.14.8099; Schultz JR, 1996, BIOCHEMISTRY-US, V35, P6595, DOI 10.1021/bi960245h; Schultz JR, 1999, BIOFACTORS, V9, P121, DOI 10.1002/biof.5520090206; Shepherd JA, 1996, TETRAHEDRON LETT, V37, P2395, DOI 10.1016/0040-4039(96)00324-3; Shults CW, 1999, BIOFACTORS, V9, P267, DOI 10.1002/biof.5520090223; Shults CW, 1997, ANN NEUROL, V42, P261, DOI 10.1002/ana.410420221; Sobreira C, 1997, NEUROLOGY, V48, P1238, DOI 10.1212/WNL.48.5.1238; Suzuki K, 1997, J BIOCHEM, V121, P496; TRUMPOWER BL, 1981, J BIOENERG BIOMEMBR, V13, P1, DOI 10.1007/BF00744743; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; Vajo Z, 1999, MAMM GENOME, V10, P1000, DOI 10.1007/s003359901147; VIDGREN J, 1994, NATURE, V368, P354, DOI 10.1038/368354a0; Walker G A, 1998, J Investig Dermatol Symp Proc, V3, P6; WIDGREN J, 1999, S ADENOSYLMETHIONINE, P55; Wood WB, 1998, CELL, V95, P147, DOI 10.1016/S0092-8674(00)81744-4; Zhang YY, 1996, J NUTR, V126, P2089, DOI 10.1093/jn/126.9.2089; [No title captured]	55	61	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12381	12387		10.1074/jbc.275.17.12381	http://dx.doi.org/10.1074/jbc.275.17.12381			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777520	hybrid			2022-12-27	WOS:000086762300004
J	Milne, KG; Ferguson, MAJ				Milne, KG; Ferguson, MAJ			Cloning, expression, and characterization of the acyl-CoA-binding protein in African trypanosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; GLYCOSYL PHOSPHATIDYLINOSITOL MYRISTOYLATION; TITRATION CALORIMETRY; MYRISTATE EXCHANGE; MEMBRANE ANCHOR; LIGAND-BINDING; BRUCEI; ACID; GLYCOSYLPHOSPHATIDYLINOSITOL; BIOSYNTHESIS	African trypanosomes are shielded from their hosts' defenses by a coat of variant surface glycoprotein molecules, each of which is attached to the plasma membrane by a glycosylphosphatidylinositol anchor. During the later stages of glycosylphosphatidylinositol biosynthesis, myristic acid is incorporated into the anchor from the donor myristoyl-CoA by a series of unique fatty acid remodeling and exchange reactions. We have cloned and expressed a recombinant trypanosome acyl-CoA-binding protein that has a preference for binding relatively short chain acyl-CoAs and that has a high affinity for binding myristoyl-CoA (K-d = 3.5 x 10(-10) M). This protein enhances fatty acid remodeling of glycosylphosphatidylinositol precursors in the trypanosome cell-free system. We speculate that the trypanosome acyl-CoA-binding protein plays an active role in supplying myristoyl-CoA to the fatty acid remodeling machinery in the parasite.	Univ Dundee, Dept Biochem, Div Mol Parasitol & Biol Chem, Dundee DD1 5EH, Scotland	University of Dundee	Milne, KG (corresponding author), Univ Dundee, Dept Biochem, Div Mol Parasitol & Biol Chem, Wellcome Trust Bldg, Dundee DD1 5EH, Scotland.		Ferguson, Michael A. J./F-7829-2010	Ferguson, Michael A. J./0000-0003-1321-8714				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3207, DOI 10.1073/pnas.82.10.3207; BOWES AE, 1993, J BIOL CHEM, V268, P13885; Buxbaum LU, 1996, P NATL ACAD SCI USA, V93, P1178, DOI 10.1073/pnas.93.3.1178; BUXBAUM LU, 1994, J BIOL CHEM, V269, P30212; CROSS GAM, 1990, ANNU REV IMMUNOL, V8, P83, DOI 10.1146/annurev.iy.08.040190.000503; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DOERING TL, 1994, P NATL ACAD SCI USA, V91, P9735, DOI 10.1073/pnas.91.21.9735; DOERING TL, 1994, BIOCHEM J, V299, P741, DOI 10.1042/bj2990741; DOERING TL, 1991, SCIENCE, V252, P1851, DOI 10.1126/science.1829548; Faergeman NJ, 1997, BIOCHEM J, V323, P1; Faergeman NJ, 1996, BIOCHEMISTRY-US, V35, P14118, DOI 10.1021/bi960545z; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; GUTHER MLS, 1995, EMBO J, V14, P3080, DOI 10.1002/j.1460-2075.1995.tb07311.x; KNUDSEN J, 1994, BIOCHEM J, V302, P479, DOI 10.1042/bj3020479; KRAGELUND BB, 1993, J MOL BIOL, V230, P1260, DOI 10.1006/jmbi.1993.1240; KRAKOW JL, 1989, MOL BIOCHEM PARASIT, V36, P263, DOI 10.1016/0166-6851(89)90174-6; MANDRUP S, 1993, BIOCHEM J, V290, P369, DOI 10.1042/bj2900369; Maniatis T., 1982, MOL CLONING LAB MANU; MARQUARDT H, 1986, J BIOL CHEM, V261, P9727; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V59, P327, DOI 10.1016/0166-6851(93)90231-L; MENON AK, 1990, J BIOL CHEM, V265, P9033; MIKKELSEN J, 1987, BIOCHEM J, V245, P857, DOI 10.1042/bj2450857; Milne KG, 1999, J BIOL CHEM, V274, P1465, DOI 10.1074/jbc.274.3.1465; RASMUSSEN JT, 1994, BIOCHEM J, V299, P165, DOI 10.1042/bj2990165; RASMUSSEN JT, 1993, BIOCHEM J, V292, P907, DOI 10.1042/bj2920907; ROSENDAL J, 1993, BIOCHEM J, V290, P321, DOI 10.1042/bj2900321; SAMAD A, 1988, PARASITOL TODAY, V5, P239; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schjerling CK, 1996, J BIOL CHEM, V271, P22514, DOI 10.1074/jbc.271.37.22514; Sharma DK, 1999, J BIOL CHEM, V274, P16479, DOI 10.1074/jbc.274.23.16479; SIGURSKJOLD BW, 1994, BIOCHEMISTRY-US, V33, P10191, DOI 10.1021/bi00199a048; Werbovetz KA, 1996, MOL BIOCHEM PARASIT, V81, P115, DOI 10.1016/0166-6851(96)02708-9; Werbovetz KA, 1997, MOL BIOCHEM PARASIT, V85, P1, DOI 10.1016/S0166-6851(96)02820-4; Yu JL, 1997, P NATL ACAD SCI USA, V94, P12580, DOI 10.1073/pnas.94.23.12580	38	21	21	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12503	12508		10.1074/jbc.275.17.12503	http://dx.doi.org/10.1074/jbc.275.17.12503			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777537	hybrid			2022-12-27	WOS:000086762300021
J	Muralidhara, BK; Hirose, M				Muralidhara, BK; Hirose, M			Anion-mediated iron release from transferrins - The kinetic and mechanistic model for N-lobe of ovotransferrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SERUM TRANSFERRIN; TERMINAL MONOFERRIC TRANSFERRIN; ACETOHYDROXAMIC ACID; HEN OVOTRANSFERRIN; BINDING; REMOVAL; RECOMBINANT; PYROPHOSPHATE; SITE; COMPLEX	Iron release process of ovotransferrin N-lobe (N-oTf) to anion/chelators has been resolved using kinetic and mechanistic approach. The iron release kinetics of N-oTf were measured at the endosomal pH of 5.6 with three different anions such as nitrilotriacetate, pyrophosphate, and sulfate using stopped flow spectrofluorimetric method, all yielding clear biphasic progress curves. The two observed rate constants and the corresponding amplitudes obtained from the double exponential curve fit to the biphasic curves varied depending on the type and concentration of anions. Several possible models for the iron release kinetic mechanism were examined on the basis of a newly introduced quantitative equation. Results from the curve fitting analyses were consistent with a dual pathway mechanism that includes the competitive iron release from two different protein states, namely, X and Y, with the respective first order rate constants of K-1 and K-2 (X, domain closed holo N-oTf; Y, anion induced different conformer of holo N-oTf). The reversible interconversions of X to Y and Y to X are driven by the second order rate constant k(3) and the first order rate constant K-4, respectively. The obtained rate constants were greatly variable for the three anions depending on the synergistic or nonsynergistic nature. In the light of the anion-binding sites of N-oTf located crystallographically, the compatible mechanistic model that includes competitive anion binding to the iron coordination sites and to a specific anion site is suggested for the dual pathway iron release mechanism.	Kyoto Univ, Food Sci Res Inst, Kyoto 6110011, Japan	Kyoto University	Hirose, M (corresponding author), Kyoto Univ, Food Sci Res Inst, Kyoto 6110011, Japan.			Hirose, Masaaki/0000-0003-2672-4384				Abdallah FB, 1999, EUR J BIOCHEM, V263, P912, DOI 10.1046/j.1432-1327.1999.00596.x; AISEN P, 1980, ANNU REV BIOCHEM, V49, P357, DOI 10.1146/annurev.bi.49.070180.002041; AISEN P, 1978, J BIOL CHEM, V253, P1930; Baker E., 1994, ADV INORG CHEM, P389, DOI [10.1016/S0898-8838(08)60176-2, DOI 10.1016/S0898-8838(08)60176-2]; BALDWIN DA, 1981, BIOCHEM BIOPH RES CO, V99, P1101, DOI 10.1016/0006-291X(81)90732-4; BALI PK, 1989, J AM CHEM SOC, V111, P4457, DOI 10.1021/ja00194a047; BALI PK, 1991, INORG CHEM, V30, P502, DOI 10.1021/ic00003a030; CHAHINE JME, 1994, EUR J BIOCHEM, V223, P581; CHENG YG, 1995, BIOCHEMISTRY-US, V34, P14879, DOI 10.1021/bi00045a032; COWART RE, 1982, J BIOL CHEM, V257, P7560; COWART RE, 1986, J BIOL CHEM, V261, P4607; DEWAN JC, 1993, BIOCHEMISTRY-US, V32, P11963, DOI 10.1021/bi00096a004; EGAN TJ, 1993, BIOCHEMISTRY-US, V32, P8162, DOI 10.1021/bi00083a016; EGAN TJ, 1992, INORG CHEM, V31, P1994, DOI 10.1021/ic00037a005; HARRIS WR, 1991, BIOCHEMISTRY-US, V30, P6930, DOI 10.1021/bi00242a017; Harris WR, 1998, BBA-PROTEIN STRUCT M, V1383, P197, DOI 10.1016/S0167-4838(97)00152-0; HARRIS WR, 1999, BIOCHIM BIOPHYS ACTA, V1430, P267; He QY, 1999, BIOCHEMISTRY-US, V38, P9704, DOI 10.1021/bi990134t; He QY, 1997, BIOCHEM J, V328, P439, DOI 10.1042/bj3280439; He QY, 1997, BIOCHEMISTRY-US, V36, P14853, DOI 10.1021/bi9719556; He QY, 1997, BIOCHEMISTRY-US, V36, P5522, DOI 10.1021/bi963028p; KRETCHMAR SA, 1986, J AM CHEM SOC, V108, P6212, DOI 10.1021/ja00280a017; KRETCHMAR SA, 1988, INORG CHEM, V27, P1436, DOI 10.1021/ic00281a028; KUROKAWA H, 1994, J BIOL CHEM, V269, P6671; LEHRER SS, 1969, J BIOL CHEM, V244, P3613; Li YJ, 1998, BBA-PROTEIN STRUCT M, V1387, P89, DOI 10.1016/S0167-4838(98)00109-5; Li YJ, 1998, BIOCHEMISTRY-US, V37, P14157, DOI 10.1021/bi9810454; LIN LN, 1994, BIOCHEMISTRY-US, V33, P1881, DOI 10.1021/bi00173a035; LIN LN, 1993, BIOCHEM J, V293, P517, DOI 10.1042/bj2930517; MARQUES HM, 1991, INORG CHEM, V30, P3758, DOI 10.1021/ic00019a037; MARQUES HM, 1995, J INORG BIOCHEM, V57, P11, DOI 10.1016/0162-0134(94)00009-Y; Mason AB, 1998, BIOCHEM J, V330, P35; Mizutani K, 1999, J BIOL CHEM, V274, P10190, DOI 10.1074/jbc.274.15.10190; MIZUTANI K, 2000, IN PRESS BIOCHEMISTR, V39; NGUYEN SAK, 1993, J AM CHEM SOC, V115, P6758; OE H, 1989, J BIOCHEM-TOKYO, V106, P858, DOI 10.1093/oxfordjournals.jbchem.a122942; OE H, 1988, J BIOCHEM-TOKYO, V103, P1066, DOI 10.1093/oxfordjournals.jbchem.a122381; SHEN ZM, 1992, PROTEIN SCI, V1, P1477, DOI 10.1002/pro.5560011109; Steinlein LM, 1998, BIOCHEMISTRY-US, V37, P13696, DOI 10.1021/bi980318s; WILLIAMS J, 1982, EUR J BIOCHEM, V122, P297, DOI 10.1111/j.1432-1033.1982.tb05880.x; Zak O, 1997, BIOCHEMISTRY-US, V36, P11036, DOI 10.1021/bi970628v; ZAK O, 1995, BIOCHEMISTRY-US, V34, P14428, DOI 10.1021/bi00044a020	42	28	29	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12463	12469		10.1074/jbc.275.17.12463	http://dx.doi.org/10.1074/jbc.275.17.12463			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777531	hybrid			2022-12-27	WOS:000086762300015
J	Brittsan, AG; Carr, AN; Schmidt, AG; Kranias, EG				Brittsan, AG; Carr, AN; Schmidt, AG; Kranias, EG			Maximal inhibition of SERCA2 Ca2+ affinity by phospholamban in transgenic hearts overexpressing a non-phosphorylatable form of phospholamban	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; 3'-5'-MONOPHOSPHATE-DEPENDENT PROTEIN-KINASE; BETA-ADRENERGIC STIMULATION; HORMONE-INDUCED ALTERATIONS; CALCIUM-TRANSPORT; GENE-EXPRESSION; PUMP; CA2+-ATPASE; MECHANISM; MUSCLE	Phospholamban is a phosphoprotein in the cardiac sarcoplasmic reticulum (SR) which regulates the apparent Ca2+ affinity of the SR Ca2+-ATPase (SERCA2). To determine the levels of phospholamban which are associated with maximal inhibition of SERCA2, several lines of transgenic mice were generated which expressed increasing levels of a non-phosphorylatable form of phospholamban (S16A,T17A) specifically in the heart. This mutant form of phospholamban was chosen to prevent phosphorylation as a compensatory mechanism in vivo. Quantitative immunoblotting revealed increased phospholamban protein levels of 1.8-, 2.6-, 3.7-, and 4.7-fold in transgenic hearts compared with wild types. There were no changes in the expression levels of SERCA2, calsequestrin, calreticulin, and ryanodine receptor. Assessment of SR Ca2+ uptake in hearts of transgenic mice indicated increases in the inhibition of the affinity of SERCA2 for Ca2+ with increased phospholamban expression. Maximal inhibition was obtained at phospholamban expression levels of 2.6-fold or higher. Transgenic hearts with functional saturation in phospholamban:SERCA2 (greater than or equal to 2.6:1) exhibited increases in beta-myosin heavy chain expression, associated with cardiac hypertrophy. These findings demonstrate that overexpression of a non-phosphorylatable form of phospholamban in transgenic mouse hearts resulted in saturation of the functional phospholamban:SERCA2 ratio at 2.6:1 and suggest that approximately 40% of the SR Ca2+ pumps are functionally regulated by phospholamban in vivo.	Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Kranias, EG (corresponding author), Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, 231 Bethesda Ave,POB 670575, Cincinnati, OH 45267 USA.				NHLBI NIH HHS [HL52318, HL26057, HL07382] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052318, R37HL026057, R01HL026057, T32HL007382] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD Z, 1989, J BIOL CHEM, V264, P3859; BOWMAN S, 1990, Technique (Philadelphia), V2, P254; BRIGGS FN, 1992, J BIOL CHEM, V267, P26056; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLYER J, 1991, J BIOL CHEM, V266, P17486; Cornea RL, 1997, BIOCHEMISTRY-US, V36, P2960, DOI 10.1021/bi961955q; GANIM JR, 1992, CIRC RES, V71, P1021, DOI 10.1161/01.RES.71.5.1021; Hajjar RJ, 1997, CIRC RES, V81, P145, DOI 10.1161/01.RES.81.2.145; Harrer JM, 1997, AM J PHYSIOL-HEART C, V272, pH57, DOI 10.1152/ajpheart.1997.272.1.H57; HARRER JM, 1995, BIOTECHNIQUES, V18, P995; HGAN B, 1986, MANIPULATING MOUSE E; HICKS MJ, 1979, CIRC RES, V44, P384, DOI 10.1161/01.RES.44.3.384; JONES LR, 1985, J BIOL CHEM, V260, P7721; Kadambi VJ, 1996, J CLIN INVEST, V97, P533, DOI 10.1172/JCI118446; Kim SJ, 1999, J CLIN INVEST, V103, P1089, DOI 10.1172/JCI4848; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; KIRCHBERGER MA, 1976, J BIOL CHEM, V251, P725; Kiss E, 1998, CIRC RES, V83, P608, DOI 10.1161/01.RES.83.6.608; KISS E, 1994, CIRC RES, V75, P245, DOI 10.1161/01.RES.75.2.245; KOSS KL, 1995, CIRC RES, V77, P342, DOI 10.1161/01.RES.77.2.342; KRANIAS EG, 1985, BIOCHIM BIOPHYS ACTA, V844, P193, DOI 10.1016/0167-4889(85)90090-4; KRANIAS EG, 1985, J BIOL CHEM, V260, P1006; KRANIAS EG, 1986, J BIOL CHEM, V261, P29; KRANIAS EG, 1985, BIOCHEM J, V226, P113, DOI 10.1042/bj2260113; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LINDEMANN JP, 1983, J BIOL CHEM, V258, P464; LOUIS CF, 1987, NEUROCHEM RES, V12, P937, DOI 10.1007/BF00966316; Luo WS, 1996, CIRC RES, V78, P839, DOI 10.1161/01.RES.78.5.839; Luo WS, 1998, J BIOL CHEM, V273, P4734, DOI 10.1074/jbc.273.8.4734; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; MEYER M, 1995, CIRCULATION, V92, P778, DOI 10.1161/01.CIR.92.4.778; Neumann J, 1997, J MOL CELL CARDIOL, V29, P265, DOI 10.1006/jmcc.1996.0271; RAEYMAEKERS L, 1990, CELL CALCIUM, V11, P261, DOI 10.1016/0143-4160(90)90002-C; Reddy LG, 1999, BIOCHEMISTRY-US, V38, P3954, DOI 10.1021/bi981795d; Reddy LG, 1999, J BIOL CHEM, V274, P7649, DOI 10.1074/jbc.274.12.7649; Schwinger RHG, 1999, J MOL CELL CARDIOL, V31, P479, DOI 10.1006/jmcc.1998.0897; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; SOLARO RJ, 1974, CIRC RES, V34, P531, DOI 10.1161/01.RES.34.4.531; Sutliff RL, 1999, CIRC RES, V84, P360, DOI 10.1161/01.RES.84.3.360; TADA M, 1983, J MOL CELL CARDIOL, V15, P335, DOI 10.1016/0022-2828(83)91345-7; TADA M, 1974, J BIOL CHEM, V249, P6174; TADA M, 1982, ANNU REV PHYSIOL, V44, P401, DOI 10.1146/annurev.ph.44.030182.002153; TALOSI L, 1993, AM J PHYSIOL, V264, pH791; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; Vikstrom KL, 1998, CIRC RES, V82, P773, DOI 10.1161/01.RES.82.7.773; VOSS J, 1994, BIOPHYS J, V67, P190, DOI 10.1016/S0006-3495(94)80469-2; Walter C A, 1989, Biotechniques, V7, P1065; WEGENER AD, 1984, J BIOL CHEM, V259, P1834; WEGENER AD, 1989, J BIOL CHEM, V264, P11468	50	69	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12129	12135		10.1074/jbc.275.16.12129	http://dx.doi.org/10.1074/jbc.275.16.12129			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766848	hybrid			2022-12-27	WOS:000086695500083
J	David-Cordonnier, MH; Laval, J; O'Neill, P				David-Cordonnier, MH; Laval, J; O'Neill, P			Clustered DNA damage, influence on damage excision by XRS5 nuclear extracts and Escherichia coli Nth and Fpg proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC SITES; HUMAN CELL-EXTRACTS; ENDONUCLEASE-III; SUBSTRATE-SPECIFICITY; IONIZING-RADIATION; BETA-ELIMINATION; OXIDATIVE DAMAGE; STRAND BREAKS; IN-VITRO; REPAIR	Ionizing radiation and radiomimetic anticancer agents induce clustered DNA damage, which are thought to reflect the biological severity. Escherichia coli Nth and Fpg and nuclear extracts from XRS5, a Chinese hamster ovary Ku-deficient cell line, have been used to study the influence on their substrate recognition by the presence of a neighboring damage or an abasic site on the opposite strand, as models of clustered DNA damage. These proteins were tested for their efficiency to induce a single-strand break on a P-32-labeled oligonucleotide containing either an abasic (AP) site, dihydrothymine (DHT), 7,8-dihydro-8-oxo-2-'deoxyguanine, or 7,8-dihydro-8-oxo-2'deoxyadenine at positions 1, 3, or 5 base pairs 5' or 3' to either an AP site or DHT on the labeled strand. DHT excision is much more affected than cleavage of an AP site by the presence of other damage. The effect on DHT excision is greatest with a neighboring AP site, with the effect being asymmetric with Nth and Fpg, Therefore, this large inhibition of the excision of DHT by the presence of an opposite AP site may minimize the formation of double strand breaks in the processing of DNA clustered damages.	MRC, Radiat & Genome Stabil Unit, Didcot OX11 0RD, Oxon, England; Inst Gustave Roussy, CNRS, UMR 8532, F-94805 Villejuif, France	MRC Harwell; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	David-Cordonnier, MH (corresponding author), MRC, Radiat & Genome Stabil Unit, Didcot OX11 0RD, Oxon, England.		DAVID-CORDONNIER, Marie-Helene/P-9909-2019; David-Cordonnier, Marie-Helene/M-3725-2018	DAVID-CORDONNIER, Marie-Helene/0000-0001-9831-5577; David-Cordonnier, Marie-Helene/0000-0001-9831-5577				ASAHARA H, 1989, BIOCHEMISTRY-US, V28, P4444, DOI 10.1021/bi00436a048; BAILLY V, 1987, BIOCHEM J, V242, P565, DOI 10.1042/bj2420565; BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; Bhagwat M, 1996, BIOCHEMISTRY-US, V35, P659, DOI 10.1021/bi9522662; BLOCHER D, 1988, INT J RADIAT BIOL, V54, P761, DOI 10.1080/09553008814552201; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; BOITEUX S, 1993, J PHOTOCH PHOTOBIO B, V19, P87, DOI 10.1016/1011-1344(93)87101-R; Bourdat AG, 1999, NUCLEIC ACIDS RES, V27, P1015, DOI 10.1093/nar/27.4.1015; BREIMER LH, 1984, J BIOL CHEM, V259, P5543; Calsou P, 1996, J BIOL CHEM, V271, P27601, DOI 10.1074/jbc.271.44.27601; Castaing B, 1999, NUCLEIC ACIDS RES, V27, P608, DOI 10.1093/nar/27.2.608; Chaudhry MA, 1997, J BIOL CHEM, V272, P15650, DOI 10.1074/jbc.272.25.15650; CHETSANGA CJ, 1979, NUCLEIC ACIDS RES, V6, P3673, DOI 10.1093/nar/6.11.3673; Cunniffe S, 1999, RADIAT RES, V152, P421, DOI 10.2307/3580227; D'Ham C, 1999, BIOCHEMISTRY-US, V38, P3335, DOI 10.1021/bi981982b; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DEMPLE B, 1980, NATURE, V287, P203, DOI 10.1038/287203a0; DIZDAROGLU M, 1993, BIOCHEMISTRY-US, V32, P12105, DOI 10.1021/bi00096a022; FUCIARELLI AF, 1990, INT J RADIAT BIOL, V58, P397, DOI 10.1080/09553009014551761; GETTS RC, 1994, J BIOL CHEM, V269, P15981; Girard PM, 1997, NUCLEIC ACIDS RES, V25, P3204, DOI 10.1093/nar/25.16.3204; GOODHEAD DT, 1993, INT J RADIAT BIOL, V63, P543, DOI 10.1080/09553009314450721; Harrison L, 1999, J MOL BIOL, V290, P667, DOI 10.1006/jmbi.1999.2892; Harrison L, 1998, NUCLEIC ACIDS RES, V26, P932, DOI 10.1093/nar/26.4.932; HATAHET Z, 1994, J BIOL CHEM, V269, P18814; Hodgkins PS, 1996, RADIAT RES, V146, P660, DOI 10.2307/3579382; Hodgkins PS, 1996, RADIAT RES, V145, P24, DOI 10.2307/3579191; JENNER TJ, 1993, INT J RADIAT BIOL, V64, P264; Laval J, 1998, MUTAT RES-FUND MOL M, V402, P93, DOI 10.1016/S0027-5107(97)00286-8; Nikjoo H, 1999, RADIAT ENVIRON BIOPH, V38, P31, DOI 10.1007/s004110050135; OCONNOR TR, 1989, P NATL ACAD SCI USA, V86, P5222, DOI 10.1073/pnas.86.14.5222; OHANDLEY S, 1995, BIOCHEMISTRY-US, V34, P2528, DOI 10.1021/bi00008a017; SATOH MS, 1993, J BIOL CHEM, V268, P5480; SHADLEY JD, 1991, MUTAT RES, V248, P73, DOI 10.1016/0027-5107(91)90089-7; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TCHOU J, 1993, J BIOL CHEM, V268, P26738; THACKER J, 1985, MUTAT RES, V146, P99, DOI 10.1016/0167-8817(85)90060-4; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X	39	155	156	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11865	11873		10.1074/jbc.275.16.11865	http://dx.doi.org/10.1074/jbc.275.16.11865			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766813	hybrid			2022-12-27	WOS:000086695500048
J	Feng, JH; Smith, DL; Smith, JB				Feng, JH; Smith, DL; Smith, JB			Human lens beta-crystallin solubility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGE-RELATED-CHANGES; ALPHA-CRYSTALLINS; POSTTRANSLATIONAL MODIFICATIONS; MOLECULAR CHAPERONE; MASS-SPECTROMETRY; SEQUENCE; PEPTIDES; PROTEINS; CDNA	The human lens is composed primarily of water and proteins called crystallins. Insolubility of these crystallins is correlated with aging and cataractogenesis. The alpha-crystallins have chaperone-like activity in maintaining the solubility of denatured beta- and gamma-crystallins. One established test of this chaperone activity is the ability of alpha-crystallin to prevent thermal destabilization of beta-crystallins. Several studies have addressed the effects of structural modifications of alpha-crystallin on chaperone activity, but little is known about the solubilities of the various beta-crystallins or the effects of post translational modifications. Understanding the solubilities of different forms of beta-crystallins is important to elucidating the mechanism of chaperone activity. In this study, the solubilities of beta-crystallins were examined. The beta-crystallins included the gene products of beta B2, beta A1/A3, beta A4, and beta B1 as well as forms modified in vivo. Analysis of the beta-crystallins by high performance liquid chromatography and mass spectrometry before and after heating revealed large differences in the relative solubilities of the beta-crystallins. These results demonstrate a decreased solubility of specific beta-crystallins and post-translational modifications that may play a role in the crystallin insolubility associated with aging and cataract.	Univ Nebraska, Dept Chem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Smith, JB (corresponding author), Univ Nebraska, Dept Chem, Lincoln, NE 68588 USA.				NEI NIH HHS [EY RO1 07609] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007609] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ajaz MS, 1997, J BIOL CHEM, V272, P11250; ALCALA J, 1988, CURR EYE RES, V7, P353, DOI 10.3109/02713688809031784; BIEMANN K, 1990, METHOD ENZYMOL, V193, P455, DOI 10.1016/0076-6879(90)93433-L; BLOEMENDAL H, 1990, EXP EYE RES, V50, P711, DOI 10.1016/0014-4835(90)90118-E; BULL HB, 1974, ARCH BIOCHEM BIOPHYS, V161, P665, DOI 10.1016/0003-9861(74)90352-X; CHAMBERS C, 1993, GENE, V133, P295, DOI 10.1016/0378-1119(93)90655-M; CHERIAN M, 1995, BIOCHEM BIOPH RES CO, V208, P675, DOI 10.1006/bbrc.1995.1391; David LL, 1996, J BIOL CHEM, V271, P4273; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; Hanson SRA, 1998, EXP EYE RES, V67, P301, DOI 10.1006/exer.1998.0530; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; KAMEI A, 1993, BIOL PHARM BULL, V16, P870; Lampi KJ, 1997, J BIOL CHEM, V272, P2268; Lou MF, 1997, ADVANCES IN OCULAR TOXICOLOGY, P27; Lund AL, 1996, EXP EYE RES, V63, P661, DOI 10.1006/exer.1996.0160; Ma ZX, 1998, EXP EYE RES, V67, P21, DOI 10.1006/exer.1998.0482; MAITI M, 1988, FEBS LETT, V236, P109, DOI 10.1016/0014-5793(88)80295-3; MCFALNGAI M, 1986, CURR EYE RES, V5, P387, DOI 10.3109/02713688609025178; MIESBAUER LR, 1993, PROTEIN SCI, V2, P290; MIESBAUER LR, 1994, J BIOL CHEM, V269, P12494; MOSTAFAPOUR MK, 1982, CURR EYE RES, V1, P517, DOI 10.3109/02713688208996359; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SMITH JB, 1995, J PROTEIN CHEM, V14, P179, DOI 10.1007/BF01980330; Smulders RHPH, 1996, J BIOL CHEM, V271, P29060, DOI 10.1074/jbc.271.46.29060; Takemoto LJ, 1997, EXP EYE RES, V64, P609, DOI 10.1006/exer.1996.0247; ZIGLER JS, 1980, EXP EYE RES, V31, P41, DOI 10.1016/0014-4835(80)90089-5	26	38	40	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11585	11590		10.1074/jbc.275.16.11585	http://dx.doi.org/10.1074/jbc.275.16.11585			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766773	hybrid			2022-12-27	WOS:000086695500008
J	Faure, E; Equils, O; Sieling, PA; Thomas, L; Zhang, FX; Kirschning, CJ; Polentarutti, N; Muzio, M; Arditi, M				Faure, E; Equils, O; Sieling, PA; Thomas, L; Zhang, FX; Kirschning, CJ; Polentarutti, N; Muzio, M; Arditi, M			Bacterial lipopolysaccharide activates NF-kappa B through Toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells - Differential expression of TLR-4 and TLR-2 in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNATE IMMUNITY; CUTTING EDGE; DROSOPHILA TOLL; MICE; ENDOTOXIN; GENE; RESPONSIVENESS; LIPOPROTEINS; RECOGNITION; MUTATIONS	A missense mutation in the cytoplasmic domain of the Toll-like receptor-4 (TLR-4) has been identified as the defect responsible for lipopolysaccharide (LPS) hyporesponsiveness in C3H/HeJ mice, TLR-4 and TLR-2 have recently been implicated in LPS signaling in studies where these receptors were overexpressed in LPS nonresponsive 293 human embryonic kidney cells. However, the signaling role of TLR-4 or TLR-2 in human cells with natural LPS response remains largely undefined. Here we show that human dermal microvessel endothelial cells (HMEC) and human umbilical vein endothelial cells express predominantly TLR-4 but very weak TLR-2 and respond vigorously to LPS but not to Mycobacterium tuberculosis 19-kDa lipoprotein, Transient transfection of non-signaling mutant forms of TLR-4 and anti-TLR-4 monoclonal antibody inhibited LPS-induced NF-KB activation in HMEC, while a monoclonal antibody against TLR-2 was ineffective. In contrast to LPS responsiveness, the ability of HMEC to respond to 19-kDa lipoprotein correlated with the expression of TLR-2. Transfection of TLR-2 into HMEC conferred responsiveness to 19-kDa lipoprotein, These data indicate that TLR-4 is the LPS signaling receptor in HMEC and that human endothelial cells (EC) express predominantly TLR-4 and weak TLR-2, which may explain why they do not respond to 19-kDa lipoprotein. The differential expression of TLRs on human EC may have important implications in the participation of vascular EC in innate immune defense mechanisms against various infectious pathogens, which may use different TLRs to signal.	Cedars Sinai Med Ctr, Steven Spielberg Pediat Res Ctr, Ahmanson Dept Pediat, Div Pediat Infect Dis, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Div Dermatol, Los Angeles, CA 90095 USA; Tech Univ Munich, Inst Med Microbiol & Immunol, D-81675 Munich, Germany; Mario Negri Inst Pharmacol Res, Dept Immunol & Cell Biol, I-20157 Milan, Italy	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Technical University of Munich; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Arditi, M (corresponding author), Cedars Sinai Med Ctr, Dept Pediat, 8700 Beverly Blvd,Rm 4400, Los Angeles, CA 90048 USA.	moshe.arditi@cshs.org	Muzio, Marta/J-9360-2018	Muzio, Marta/0000-0002-7761-759X	NIAID NIH HHS [AI40275] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI040275] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; ARDITI M, 1993, INFECT IMMUN, V61, P3149, DOI 10.1128/IAI.61.8.3149-3156.1993; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; CROSTON GE, 1995, J BIOL CHEM, V270, P16514, DOI 10.1074/jbc.270.28.16514; DIRIENZO JM, 1978, ANNU REV BIOCHEM, V47, P481, DOI 10.1146/annurev.bi.47.070178.002405; Heine H, 1999, J IMMUNOL, V162, P6971; Heumann D, 1998, CURR OPIN MICROBIOL, V1, P49, DOI 10.1016/S1369-5274(98)80142-2; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hoshino K, 1999, J IMMUNOL, V162, P3749; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Means TK, 1999, J IMMUNOL, V163, P3920; Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Opal SM, 1999, CRIT CARE MED, V27, P1608, DOI 10.1097/00003246-199908000-00039; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi N, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P687; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; RIETSCHEL ET, 1996, CURR TOP MICROBIOL I, V216, P40; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; ROSENSTREICH DL, 1985, HDB ENDOTOXIN, V3, P82; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; SIRONI M, 1989, J IMMUNOL, V142, P549; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Vogel SN, 1999, J IMMUNOL, V162, P5666; Wenzel RP, 1996, CLIN INFECT DIS, V22, P407, DOI 10.1093/clinids/22.3.407; Wright SD, 1999, J EXP MED, V189, P605, DOI 10.1084/jem.189.4.605; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Zahringer U, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P93; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611; Zhang HW, 1997, J IMMUNOL, V159, P4868	37	476	506	0	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11058	11063		10.1074/jbc.275.15.11058	http://dx.doi.org/10.1074/jbc.275.15.11058			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753909	hybrid, Green Submitted			2022-12-27	WOS:000086466600051
J	Laronga, C; Yang, HY; Neal, C; Lee, MH				Laronga, C; Yang, HY; Neal, C; Lee, MH			Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; PROTEIN-KINASE; POTENTIAL MEDIATOR; EXPRESSION CLONING; BREAST-CANCER; INHIBITOR; 14-3-3-PROTEINS; CHECKPOINT; P27(KIP1); CDC25	14-3-3 sigma, implicated in cell cycle arrest by p53, was cloned by expression cloning through cyclin-dependent kinase 2 (CDK2) association. 14-3-3 sigma shares cyclin-CDR2 binding motifs with different cell cycle regulators, including p107, p130, p21(CIP1), p27(KIP1), and p57(KIP2), and is associated with cyclin.CDK complexes in vitro and in vivo. Overexpression of 14-3-3 sigma obstructs cell cycle entry by inhibiting cyclin-CDK activity in many breast cancer cell lines. Overexpression of 14-3-3 sigma can also inhibit cell proliferation and prevent anchorage-independent growth of these cell lines. These findings define 14-3-3 sigma as a negative regulator of the cell cycle progression and suggest that it has an important function in preventing breast tumor cell growth.	Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Breast Canc Res Program, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Lee, MH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, 1515 Holcombe Blvd,Box 18, Houston, TX 77030 USA.			Lee, Mong-Hong/0000-0001-8675-8215				AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chen L, 1999, GENE DEV, V13, P675, DOI 10.1101/gad.13.6.675; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; DELLAMBRA E, 1995, J CELL SCI, V108, P3569; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hilgers W, 1999, GENE CHROMOSOME CANC, V24, P351, DOI 10.1002/(SICI)1098-2264(199904)24:4<351::AID-GCC9>3.3.CO;2-P; Honda R, 1997, BIOCHEM BIOPH RES CO, V230, P262, DOI 10.1006/bbrc.1996.5933; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Pines J, 1999, NATURE, V397, P104, DOI 10.1038/16344; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Ragnarsson G, 1999, BRIT J CANCER, V79, P1468, DOI 10.1038/sj.bjc.6690234; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sladeczek F, 1997, MOL GEN GENET, V254, P571, DOI 10.1007/s004380050453; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vellucci VF, 1995, GENE, V166, P213, DOI 10.1016/0378-1119(95)00543-9; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766	45	262	278	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23106	23112		10.1074/jbc.M905616199	http://dx.doi.org/10.1074/jbc.M905616199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10767298	hybrid			2022-12-27	WOS:000088419400068
J	Boll, M; Laempe, D; Eisenreich, W; Bacher, A; Mittelberger, T; Heinze, J; Fuchs, G				Boll, M; Laempe, D; Eisenreich, W; Bacher, A; Mittelberger, T; Heinze, J; Fuchs, G			Nonaromatic products from anoxic conversion of benzoyl-CoA with benzoyl-CoA reductase and cyclohexa-1,5-diene-1-carbonyl-CoA hydratase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAEROBIC AROMATIC METABOLISM; BACTERIUM THAUERA-AROMATICA; KEY ENZYME; DEGRADATION; PROTEINS; STRAIN; GENES	The enzymes benzoyl-CoA reductase and cyclohex-1,5-diene-1-carbonyl-CoA hydratase catalyzing the first steps of benzoyl-CoA conversion under anoxic conditions were purified from the denitrifying bacterium, Thauera aromatica. Reaction products obtained with [ring-C-13(6)]benzoyl-CoA and [ring-C-14]benzoyl-CoA as substrates were analyzed by high pressure liquid chromatography and by NMR spectroscopy. The main product obtained with titanium(III) citrate or with reduced [8Fe-8S]-ferredoxin from T. aromatica as electron donors was identified as cyclohexa-1,5-diene-1-carbonyl-CoA The cyclic diene was converted into 6-hydroxycyclohex-1-ene1-carbonyl-CoA by the hydratase, Assay mixtures containing reductase, hydratase, and sodium dithionite or a mixture of sulfite and titanium(III) citrate as reducing agent afforded cyclohex-2-ene-1-carbonyl-CoA and 6-hydroxycylohex-2-ene-1-carbonyl-CoA The potential required for the first electron transfer to the model compound S-ethyl-thiobenzoate yielding a radical anion was determined by cyclic voltammetry as -1.9 V versus a standard hydrogen electrode. The energetics of enzymatic ring reduction of benzoyl-CoA are discussed.	Univ Freiburg, Inst Biol 2, D-79104 Freiburg, Germany; Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany; Inst Chem Phys, D-79104 Freiburg, Germany	University of Freiburg; Technical University of Munich	Fuchs, G (corresponding author), Univ Freiburg, Inst Biol 2, Schanzlestr 1, D-79104 Freiburg, Germany.	fuchsgeo@uni-freiburg.de	Eisenreich, Wolfgang/A-1258-2013	Eisenreich, Wolfgang/0000-0002-9832-8279				ANDERS HJ, 1995, INT J SYST BACTERIOL, V45, P327, DOI 10.1099/00207713-45-2-327; Birch A. J., 1972, ADV ORG CHEM, V8, P1; BIRCH AJ, 1980, J AM CHEM SOC, V102, P3370, DOI 10.1021/ja00530a012; Boll M, 1995, EUR J BIOCHEM, V234, P921, DOI 10.1111/j.1432-1033.1995.921_a.x; Boll M, 1997, EUR J BIOCHEM, V244, P840, DOI 10.1111/j.1432-1033.1997.00840.x; Boll M, 1998, EUR J BIOCHEM, V251, P946, DOI 10.1046/j.1432-1327.1998.2510946.x; BRACKMANN R, 1993, EUR J BIOCHEM, V213, P563, DOI 10.1111/j.1432-1033.1993.tb17795.x; Breese K, 1998, EUR J BIOCHEM, V256, P148, DOI 10.1046/j.1432-1327.1998.2560148.x; Buckel W., 1995, ANGEW CHEM, V107, P1595; Egland PG, 1997, P NATL ACAD SCI USA, V94, P6484, DOI 10.1073/pnas.94.12.6484; GIBSON KJ, 1992, APPL ENVIRON MICROB, V58, P696, DOI 10.1128/AEM.58.2.696-698.1992; GROSS GG, 1966, Z NATURFORSCH PT B, VB 21, P683; Harwood CS, 1997, J BACTERIOL, V179, P301, DOI 10.1128/jb.179.2.301-309.1997; Harwood CS, 1998, FEMS MICROBIOL REV, V22, P439, DOI 10.1016/S0168-6445(98)00026-6; Heider J, 1997, ANAEROBE, V3, P1, DOI 10.1006/anae.1997.0073; Heider J, 1997, EUR J BIOCHEM, V243, P577, DOI 10.1111/j.1432-1033.1997.00577.x; KOCH J, 1993, EUR J BIOCHEM, V211, P649, DOI 10.1111/j.1432-1033.1993.tb17593.x; KRAPCHO AP, 1959, J AM CHEM SOC, V81, P3658, DOI 10.1021/ja01523a042; Laempe D, 1998, EUR J BIOCHEM, V255, P618, DOI 10.1046/j.1432-1327.1998.2550618.x; LAMBETH DO, 1973, J BIOL CHEM, V248, P6095; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mortensen J., 1984, ANGEW CHEM-GER EDIT, V96, P64; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEIFERT A, 1885, J PRAKT CHEM, V31, P471; TSCHECH A, 1987, ARCH MICROBIOL, V148, P213, DOI 10.1007/BF00414814; ZEHR BD, 1989, ANAL BIOCHEM, V182, P157, DOI 10.1016/0003-2697(89)90734-3; ZIEGLER K, 1987, ARCH MICROBIOL, V149, P62, DOI 10.1007/BF00423138	27	48	49	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21889	21895		10.1074/jbc.M001833200	http://dx.doi.org/10.1074/jbc.M001833200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10766750	hybrid			2022-12-27	WOS:000088363800021
J	Easton, RL; Patankar, MS; Clark, GF; Morris, HR; Dell, A				Easton, RL; Patankar, MS; Clark, GF; Morris, HR; Dell, A			Pregnancy-associated changes in the glycosylation of Tamm-Horsfall glycoprotein - Expression of sialyl Lewis sequences on core 2 type O-glycans derived from uromodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; LEUKOCYTE ADHESION MOLECULE-1; P-SELECTIN; LINKED OLIGOSACCHARIDES; URINARY GLYCOPROTEIN; CARBOHYDRATE LIGAND; TYROSINE SULFATION; ESCHERICHIA-COLI; CELL-ADHESION; PROTEIN	Tamm-Horsfall glycoprotein (THP) is a major glycoprotein associated with human urine that binds proinflammatory cytokines and also inhibits in vitro T cell proliferation induced by specific antigens, THP derived from human pregnancy urine (designated uromodulin) has previously been shown to be 13-fold more effective as an inhibitor of antigen-induced T cell proliferation than THP obtained from other sources. Structural analysis of human THP and uromodulin has for the first time revealed that these glycoproteins are O-glycosylated. THP from nonpregnant females and males expresses primarily core 1 type O-glycans terminated with either sialic acid or fucose but not the sialyl Lewis(X) epitope, By contrast, the O-glycans linked to uromodulin include unusual core 2 type glycans terminated with one, two, or three sialyl Lewis(X) sequences, The specific association of these unusual carbohydrate sequences with uromodulin could explain its enhanced immunomodulatory effects compared with THP obtained from males and nonpregnant females. Analysis of THP from one of the pregnant females 2 months postpartum showed a reversion of the O-glycan profile to that found for a nonpregnant female. These data suggest that the glycosylation state of uromodulin could be under the regulation of steroidal hormones produced during pregnancy. The significant physiological implications of these observations are discussed.	Eastern Virginia Med Sch, Dept Physiol Sci, Norfolk, VA 23501 USA; Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England	Eastern Virginia Medical School; Imperial College London	Dell, A (corresponding author), Eastern Virginia Med Sch, Dept Physiol Sci, Norfolk, VA 23501 USA.				NICHD NIH HHS [HD35652] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD035652] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADCOCK EW, 1973, SCIENCE, V181, P845, DOI 10.1126/science.181.4102.845; AFONSO AMM, 1981, CARBOHYD RES, V89, P309, DOI 10.1016/S0008-6215(00)85256-8; ALBERSHEIM PETER, 1967, CARBOHYD RES, V5, P340, DOI 10.1016/S0008-6215(00)80510-8; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; CALDWELL JL, 1975, J IMMUNOL, V115, P1249; CONCOLINO G, 1976, J STEROID BIOCHEM, V7, P831, DOI 10.1016/0022-4731(76)90186-2; CONTRACTOR SF, 1973, NATURE-NEW BIOL, V243, P284, DOI 10.1038/newbio243284a0; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1235; DELL A, 1995, J BIOL CHEM, V270, P24116, DOI 10.1074/jbc.270.41.24116; DELL A, 1993, GLYCOBIOLOGY PRACTIC, P187; DONALD ASR, 1983, BIOCHEM BIOPH RES CO, V115, P625, DOI 10.1016/S0006-291X(83)80190-9; Ellies LG, 1998, IMMUNITY, V9, P881, DOI 10.1016/S1074-7613(00)80653-6; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; FUKUDA M, 1984, J BIOL CHEM, V259, P925; HARD K, 1992, EUR J BIOCHEM, V209, P895, DOI 10.1111/j.1432-1033.1992.tb17362.x; HESSION C, 1987, SCIENCE, V237, P1479, DOI 10.1126/science.3498215; HOYER JR, 1979, KIDNEY INT, V16, P279, DOI 10.1038/ki.1979.130; IMAI Y, 1993, NATURE, V361, P555; Kumar S, 1998, EUR J CLIN INVEST, V28, P483; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; MATTEY M, 1992, EXPERIENTIA, V48, P975, DOI 10.1007/BF01919145; MIZOGUCHI A, 1984, J BIOL CHEM, V259, P1949; MOONEN P, 1988, FEBS LETT, V226, P314, DOI 10.1016/0014-5793(88)81446-7; Morris HR, 1996, J BIOL CHEM, V271, P32159, DOI 10.1074/jbc.271.50.32159; MUCHMORE AV, 1977, J IMMUNOL, V118, P881; MUCHMORE AV, 1985, SCIENCE, V229, P479, DOI 10.1126/science.2409603; MUCHMORE AV, 1987, J IMMUNOL, V138, P2541; ORSKOV I, 1980, INFECT IMMUN, V27, P657, DOI 10.1128/IAI.27.2.657-666.1980; ORSKOV I, 1980, LANCET, V1, P887; PENNICA D, 1987, SCIENCE, V236, P83, DOI 10.1126/science.3453112; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; SHERBLOM AP, 1989, J IMMUNOL, V143, P939; SHERBLOM AP, 1988, J BIOL CHEM, V263, P5418; SMAGULA RM, 1990, GLYCOCONJUGATE J, V7, P609, DOI 10.1007/BF01189081; TAMM I, 1952, J EXP MED, V95, P71, DOI 10.1084/jem.95.1.71; TAMM I, 1950, P SOC EXP BIOL MED, V74, P108, DOI 10.3181/00379727-74-17825; Tandai-Hiruma M, 1999, J BIOL CHEM, V274, P4459, DOI 10.1074/jbc.274.7.4459; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; TOMA G, 1994, BIOCHEM BIOPH RES CO, V200, P275, DOI 10.1006/bbrc.1994.1445; TULCHINSKY D, 1972, AM J OBSTET GYNECOL, V112, P1095, DOI 10.1016/0002-9378(72)90185-8; TULCHINSKY D, 1973, AM J OBSTET GYNECOL, V117, P884, DOI 10.1016/0002-9378(73)90057-4; van Rooijen JJM, 1999, GLYCOBIOLOGY, V9, P21, DOI 10.1093/glycob/9.1.21; Van Rooijen JJM, 1998, EUR J BIOCHEM, V256, P471, DOI 10.1046/j.1432-1327.1998.2560471.x; van Rooijen JJM, 1998, GLYCOBIOLOGY, V8, P1065, DOI 10.1093/glycob/8.11.1065; WEAKER FJ, 1984, J UROLOGY, V132, P792, DOI 10.1016/S0022-5347(17)49875-2; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; YU CL, 1992, IMMUNOPHARMACOLOGY, V24, P181, DOI 10.1016/0162-3109(92)90074-M	50	64	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21928	21938		10.1074/jbc.M001534200	http://dx.doi.org/10.1074/jbc.M001534200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10770931	hybrid			2022-12-27	WOS:000088363800026
J	Jiang, F; Ryan, MT; Schlame, M; Zhao, M; Gu, ZM; Klingenberg, M; Pfanner, N; Greenberg, ML				Jiang, F; Ryan, MT; Schlame, M; Zhao, M; Gu, ZM; Klingenberg, M; Pfanner, N; Greenberg, ML			Absence of cardiolipin in the crd1 null mutant results in decreased mitochondrial membrane potential and reduced mitochondrial function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; NUCLEAR-MAGNETIC-RESONANCE; 6 ARGININE MUTATIONS; SACCHAROMYCES-CEREVISIAE; ADP/ATP CARRIER; ESCHERICHIA-COLI; PHOSPHATIDYLGLYCEROLPHOSPHATE SYNTHASE; YEAST MITOCHONDRIAL; INTERMEMBRANE SPACE; CYTOPLASMIC MUTANTS	Cardiolipin (CL) is a unique phospholipid which is present throughout the eukaryotic kingdom and is localized in mitochondrial membranes. Saccharomyces cerevisiae cells containing a disruption of CRD1, the structural gene encoding CL synthase, have no CL in mitochondrial membranes. To elucidate the physiological role of CL, we compared mitochondrial functions in the crd1 Delta mutant and isogenic wild type. The crd1 Delta mutant loses viability at elevated temperature, and prolonged culture at 37 degrees C leads to loss of the mitochondrial genome. Mutant membranes have increased phosphatidylglycerol (PG) when grown in a nonfermentable carbon source but have almost no detectable PG; in medium containing glucose. In glucose-grown cells, maximum respiratory rate, ATPase and cytochrome oxidase activities, and protein import are deficient in the mutant. The ADP/ATP carrier is defective even during growth in a nonfermentable carbon source. The mitochondrial membrane potential is decreased in mutant cells. The decrease is more pronounced in glucose-grown cells, which lack PG;, but is also apparent in membranes containing PC: (i.e. in nonfermentable carbon sources). We propose that CL is required for maintaining the mitochondrial membrane potential and that reduced membrane potential in the absence of CL leads to defects in protein import and other mitochondrial functions.	Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA; Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; Hosp Special Surg, Dept Anesthesiol, New York, NY 10021 USA; Univ Munich, inst Phys Biochem, D-80336 Munich, Germany	Wayne State University; University of Freiburg; University of Munich	Greenberg, ML (corresponding author), Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA.	MLGREEN@sun.science.wayne.edu	Pfanner, Nikolaus/AAV-7878-2021; Ryan, Michael T/C-6673-2011; Ryan, Michael/X-2152-2019	Ryan, Michael T/0000-0003-2586-8829; Ryan, Michael/0000-0003-2586-8829	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062263] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62263] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AWASTHI YC, 1969, BIOCHIM BIOPHYS ACTA, V189, P457, DOI 10.1016/0005-2728(69)90179-0; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BEYER K, 1985, BIOCHEMISTRY-US, V24, P3821, DOI 10.1021/bi00336a001; BLOM J, 1995, EUR J BIOCHEM, V232, P309, DOI 10.1111/j.1432-1033.1995.tb20813.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chang SC, 1998, J BIOL CHEM, V273, P9829, DOI 10.1074/jbc.273.16.9829; Chang SC, 1998, J BIOL CHEM, V273, P14933, DOI 10.1074/jbc.273.24.14933; CHRISTIANSEN K, 1972, BIOCHIM BIOPHYS ACTA, V260, P449, DOI 10.1016/0005-2760(72)90060-4; COBON GS, 1974, BIOCHEM J, V144, P265, DOI 10.1042/bj1440265; DAUM G, 1982, J BIOL CHEM, V257, P3028; Dekker PJT, 1997, EMBO J, V16, P5408, DOI 10.1093/emboj/16.17.5408; DREES M, 1988, BIOCHEMISTRY-US, V27, P8584, DOI 10.1021/bi00423a012; EBLE KS, 1990, J BIOL CHEM, V265, P19434; EILERS M, 1989, J BIOL CHEM, V264, P2945; ENDO T, 1989, J BIOL CHEM, V264, P2951; FRY M, 1981, J BIOL CHEM, V256, P1874; GARTNER F, 1995, J BIOL CHEM, V270, P3788; GOLDRING ES, 1970, J MOL BIOL, V52, P323, DOI 10.1016/0022-2836(70)90033-1; GOORMAGHTIGH E, 1982, BIOCHEM BIOPH RES CO, V104, P314, DOI 10.1016/0006-291X(82)91976-3; GREENBERG ML, 1988, MOL CELL BIOL, V8, P4773, DOI 10.1128/MCB.8.11.4773; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HAYERHARTL M, 1992, EUR J BIOCHEM, V209, P423, DOI 10.1111/j.1432-1033.1992.tb17305.x; HEACOCK PN, 1989, J BIOL CHEM, V264, P14972; Heidkamper D, 1996, BIOCHEMISTRY-US, V35, P16144, DOI 10.1021/bi960668j; HIRSCHBERG CB, 1972, P NATL ACAD SCI USA, V69, P648, DOI 10.1073/pnas.69.3.648; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; HOFFMANN B, 1994, J BIOL CHEM, V269, P1940; HOSTETLER KY, 1972, BIOCHIM BIOPHYS ACTA, V260, P507, DOI 10.1016/0005-2760(72)90065-3; Jiang F, 1997, MOL MICROBIOL, V26, P481, DOI 10.1046/j.1365-2958.1997.5841950.x; Jiang F, 1999, MOL MICROBIOL, V31, P373, DOI 10.1046/j.1365-2958.1999.01181.x; Jiang F, 1998, J BIOL CHEM, V273, P4681, DOI 10.1074/jbc.273.8.4681; KADENBACH B, 1982, FEBS LETT, V139, P109, DOI 10.1016/0014-5793(82)80498-5; KLINGENBERG M, 1975, EUR J BIOCHEM, V52, P351, DOI 10.1111/j.1432-1033.1975.tb04003.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JE, 1988, J BIOL CHEM, V263, P14812; MARTIN J, 1991, J BIOL CHEM, V266, P18051; Muller V, 1996, BIOCHEMISTRY-US, V35, P16132, DOI 10.1021/bi960667r; NISHIJIMA S, 1988, J BACTERIOL, V170, P775, DOI 10.1128/jb.170.2.775-780.1988; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; ROBINSON NC, 1993, J BIOENERG BIOMEMBR, V25, P153, DOI 10.1007/BF00762857; Ryan MT, 1999, J BIOL CHEM, V274, P20619, DOI 10.1074/jbc.274.29.20619; Sambrook F., 1989, MOL CLONING LAB MANU; Schlame M, 1997, BBA-LIPID LIPID MET, V1348, P201, DOI 10.1016/S0005-2760(97)00117-3; SCHLAME M, 1993, EUR J BIOCHEM, V212, P727, DOI 10.1111/j.1432-1033.1993.tb17711.x; Schlame M, 1999, J LIPID RES, V40, P1585; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; STEINER MR, 1972, BIOCHIM BIOPHYS ACTA, V260, P222, DOI 10.1016/0005-2760(72)90035-5; SUBIK J, 1974, FEBS LETT, V42, P309, DOI 10.1016/0014-5793(74)80753-2; TAMAI KT, 1990, BIOCHIM BIOPHYS ACTA, V1046, P214, DOI 10.1016/0005-2760(90)90192-Z; TRIVEDI A, 1988, INTEGRATION MITOCHON, P87; Tuller G, 1998, FEBS LETT, V421, P15, DOI 10.1016/S0014-5793(97)01525-1; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8236; TZAGOLOFF A, 1975, J BACTERIOL, V122, P826, DOI 10.1128/JB.122.3.826-831.1975; VANDENBOSCH H, 1972, REV PHYSL BIOCH PHAR, V66, P13; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627	56	319	324	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22387	22394		10.1074/jbc.M909868199	http://dx.doi.org/10.1074/jbc.M909868199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10777514	hybrid			2022-12-27	WOS:000088363800086
J	Bisse, E; Zorn, N; Heinrichs, I; Eigel, A; Van Dorsselaer, A; Wieland, H; Kister, J; Marden, MC				Bisse, E; Zorn, N; Heinrichs, I; Eigel, A; Van Dorsselaer, A; Wieland, H; Kister, J; Marden, MC			Characterization of a new electrophoretically silent hemoglobin variant - Hb Saale OR alpha(2)beta(2) 84(EF8)Thr -> ala	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEPARATION; CHAINS	A new abnormal hemoglobin was detected in a young German anemic patient by cation-exchange high performance liquid chromatography (HPLC), Using a combination of electrospray mass spectrometry, HPLC, direct sequencing, and family screening with polymerase chain reaction/restriction digestion approach, we have characterized this hemoglobin variant as resulting from a Thr --> Ala replacement at beta 84(EF8). It could be separated neither by electrophoresis nor by isoelectric focusing. Hb Saale is slightly unstable, exhibiting a moderate tendency to auto-oxidize. Functional properties and the heterotropic interactions are similar to those of Hb A.	Univ Hosp, Dept Clin Chem, D-79106 Freiburg, Germany; Univ Strasbourg 1, Fac Chim, Lab Spectrometrie Masse Bioorgan, CNRS,URA 31, F-67008 Strasbourg, France; Univ Munster, Inst Humangenet, D-48149 Munster, Germany; INSERM, U473, F-94276 Le Kremlin Bicetre, France; Univ Halle Wittenberg, Div Pediat, D-06097 Halle, Germany	University of Freiburg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Munster; Institut National de la Sante et de la Recherche Medicale (Inserm); Martin Luther University Halle Wittenberg	Bisse, E (corresponding author), Univ Hosp, Dept Clin Chem, Hugstetterstr 55, D-79106 Freiburg, Germany.		Marden, Michael C/G-3139-2012; Marden, Michael/AAA-5923-2020	Marden, Michael C/0000-0002-5254-6385; 				ALTAY C, 1988, HEMOGLOBIN, V12, P87, DOI 10.3109/03630268808996888; Beutler E, 1982, GLUTATHIONE RED CELL, V3 rd; BISSE E, 1991, ACTA HAEMATOL-BASEL, V85, P212; Bisse E, 1998, CLIN CHEM, V44, P2172; BISSE E, 1988, J CHROMATOGR-BIOMED, V434, P95, DOI 10.1016/0378-4347(88)80065-3; Bunn HF, 1986, HEMOGLOBIN MOL GENET; Dacie J. V, 1988, HAEMOLYTIC ANAEMIAS, V2; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; FESSAS P, 1966, BIOCHIM BIOPHYS ACTA, V124, P430, DOI 10.1016/0304-4165(66)90216-9; HARANO T, 1986, HEMOGLOBIN, V10, P417, DOI 10.3109/03630268608996871; HEDIWOLF A, 1983, BLUT, V46, P271; HUISMAN THJ, 1987, J CHROMATOGR-BIOMED, V418, P277, DOI 10.1016/0378-4347(87)80012-9; HUISMAN THJ, 1988, SYLLABUS HUMAN HEMOG; Jonxis, 1977, CLIN BIOCH ANAL, V6; KISTER J, 1987, J BIOL CHEM, V262, P12085; MANSOURI A, 1973, BIOCHEMISTRY-US, V12, P4946, DOI 10.1021/bi00748a020; MARDEN MC, 1988, BIOCHEMISTRY-US, V27, P1659, DOI 10.1021/bi00405a041; MORIMOTO H, 1971, NATURE, V232, P408, DOI 10.1038/232408a0; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; WAJCMAN H, 1995, HEMOGLOBIN, V19, P281, DOI 10.3109/03630269509005815	21	2	2	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21380	21384		10.1074/jbc.M001827200	http://dx.doi.org/10.1074/jbc.M001827200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10770934	hybrid, Green Published			2022-12-27	WOS:000088230600057
J	Yagyu, H; Kitamine, T; Osuga, J; Tozawa, R; Chen, Z; Kaji, Y; Oka, T; Perrey, S; Tamura, Y; Ohashi, K; Okazaki, H; Yahagi, N; Shionoiri, F; Iizuka, Y; Harada, K; Shimano, H; Yamashita, H; Gotoda, T; Yamada, N; Ishibashi, S				Yagyu, H; Kitamine, T; Osuga, J; Tozawa, R; Chen, Z; Kaji, Y; Oka, T; Perrey, S; Tamura, Y; Ohashi, K; Okazaki, H; Yahagi, N; Shionoiri, F; Iizuka, Y; Harada, K; Shimano, H; Yamashita, H; Gotoda, T; Yamada, N; Ishibashi, S			Absence of ACAT-1 attenuates atherosclerosis but causes dry eye and cutaneous xanthomatosis in mice with congenital hyperlipidemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COENZYME-A; COA-CHOLESTEROL ACYLTRANSFERASE; RECEPTOR KNOCKOUT MICE; ESTERIFICATION ENZYMES; LIPOPROTEIN-LIPASE; MOLECULAR-CLONING; APOLIPOPROTEIN-E; MESSENGER-RNA; EXPRESSION; LESIONS	Acyl-CoA:cholesterol acyltransferase (ACAT) catalyzes esterification of cellular cholesterol. To investigate the role of ACAT-1 in atherosclerosis, we have generated ACAT-1 null (ACAT-1-/-) mice. ACAT activities were present in the liver and intestine but were completely absent in adrenal, testes, ovaries, and peritoneal macrophages in our ACAT-1-/- mice. The ACAT-1-/- mice had decreased openings of the eyes because of atrophy of the meibomian glands, a modified form of sebaceous glands normally expressing high ACAT activities. This phenotype is similar to dry eye syndrome in humans. To determine the role of ACAT-1 in atherogenesis, we crossed the ACAT-1-/- mice with mice lacking apolipoprotein (apo) E or the low density lipoprotein receptor (LDLR), hyperlipidemic models susceptible to atherosclerosis. High fat feeding resulted in extensive cutaneous xanthomatosis with loss of hair in both ACAT-1-/-:apo E-/- and ACAT-1-/-:LDLR-/- mice. Free cholesterol content was significantly increased in their skin. Aortic fatty streak lesion size as well as cholesteryl ester content were moderately reduced in both double mutant mice compared with their respective controls. These results indicate that the local inhibition of ACAT activity in tissue macrophages is protective against cholesteryl ester accumulation but causes cutaneous xanthomatosis in mice that lack apo E or LDLR.	Univ Tokyo, Fac Med, Dept Metab Dis, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Fac Med, Dept Ophthalmol, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Fac Med, Dept Pathol, Bunkyo Ku, Tokyo 1138655, Japan	University of Tokyo; University of Tokyo; University of Tokyo	Ishibashi, S (corresponding author), Univ Tokyo, Fac Med, Dept Metab Dis, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.		Shimano, Hitoshi/V-1761-2019; Shimano, Hitoshi/AAI-5648-2020; Yahagi, Naoya/D-2360-2014; perrey, stephane/B-7483-2008	Shimano, Hitoshi/0000-0002-5562-5572; Yahagi, Naoya/0000-0002-1823-1865; perrey, stephane/0000-0002-8741-629X				Accad M, 2000, J CLIN INVEST, V105, P711, DOI 10.1172/JCI9021; Anderson RA, 1998, J BIOL CHEM, V273, P26747, DOI 10.1074/jbc.273.41.26747; BECKER A, 1994, ARTERIOSCLER THROMB, V14, P1346, DOI 10.1161/01.ATV.14.8.1346; BILLHEIMER JT, 1981, ANAL BIOCHEM, V111, P331, DOI 10.1016/0003-2697(81)90570-4; BOCAN TMA, 1991, ARTERIOSCLER THROMB, V11, P1830, DOI 10.1161/01.ATV.11.6.1830; BURGDORF WHC, 1998, LEVERS HISTOPATHOLOG, P591; Cases S, 1998, J BIOL CHEM, V273, P26755, DOI 10.1074/jbc.273.41.26755; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fujimura K, 1997, J CLIN LAB ANAL, V11, P315; GATES AH, 1965, SCIENCE, V148, P1471, DOI 10.1126/science.148.3676.1471; GOODMAN DS, 1965, PHYSIOL REV, V45, P747, DOI 10.1152/physrev.1965.45.4.747; Harlow E., 1988, ANTIBODIES LAB MANUA; Hart, 1992, ADLERS PHYSL EYE, P18; HEIDER JG, 1978, J LIPID RES, V19, P514; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; ISHIBASHI S, 1994, J CLIN INVEST, V93, P1885, DOI 10.1172/JCI117179; Jong MC, 1998, J CLIN INVEST, V101, P145, DOI 10.1172/JCI791; Joyce C, 1999, CURR OPIN LIPIDOL, V10, P89, DOI 10.1097/00041433-199904000-00002; KRAUSE BR, 1995, ACAT INHIBITORS PHSL; Lee O, 1998, J LIPID RES, V39, P1722; Li BL, 1999, J BIOL CHEM, V274, P11060, DOI 10.1074/jbc.274.16.11060; Lin S, 1999, J BIOL CHEM, V274, P23276, DOI 10.1074/jbc.274.33.23276; MCCULLEY JP, 1977, AM J OPHTHALMOL, V84, P788, DOI 10.1016/0002-9394(77)90497-4; Meiner V, 1997, J LIPID RES, V38, P1928; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; Miyazaki A, 1998, ARTERIOSCL THROM VAS, V18, P1568, DOI 10.1161/01.ATV.18.10.1568; Oelkers P, 1998, J BIOL CHEM, V273, P26765, DOI 10.1074/jbc.273.41.26765; OSUGA J, 1995, BIOCHEM BIOPH RES CO, V214, P653, DOI 10.1006/bbrc.1995.2336; PAIGEN B, 1985, ATHEROSCLEROSIS, V57, P65, DOI 10.1016/0021-9150(85)90138-8; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; REINDEL JF, 1994, TOXICOL PATHOL, V22, P510, DOI 10.1177/019262339402200505; Sambrook J., 2002, MOL CLONING LAB MANU; Shimada M, 1996, P NATL ACAD SCI USA, V93, P7242, DOI 10.1073/pnas.93.14.7242; SUCKLING KE, 1985, J LIPID RES, V26, P647; Tabas I, 1997, TRENDS CARDIOVAS MED, V7, P256, DOI 10.1016/S1050-1738(97)00086-8; Tozawa R, 1999, J BIOL CHEM, V274, P30843, DOI 10.1074/jbc.274.43.30843; UELMEN PJ, 1995, J BIOL CHEM, V270, P26192, DOI 10.1074/jbc.270.44.26192; Yagyu H, 1999, J LIPID RES, V40, P1677; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; Zheng Y, 1999, NAT GENET, V23, P268, DOI 10.1038/15446	42	143	155	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21324	21330		10.1074/jbc.M002541200	http://dx.doi.org/10.1074/jbc.M002541200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10777503	hybrid			2022-12-27	WOS:000088230600050
J	Kanai, Y; Fukasawa, Y; Cha, SH; Segawa, H; Chairoungdua, A; Kim, DK; Matsuo, H; Kim, JY; Miyamoto, K; Takeda, E; Endou, H				Kanai, Y; Fukasawa, Y; Cha, SH; Segawa, H; Chairoungdua, A; Kim, DK; Matsuo, H; Kim, JY; Miyamoto, K; Takeda, E; Endou, H			Transport properties of a system y(+)L neutral and basic amino acid transporter - Insights into the mechanisms of substrate recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY GLUTAMATE TRANSPORTER; HUMAN ERYTHROCYTES; FUNCTIONAL-CHARACTERIZATION; HEAVY-CHAIN; MOLECULAR-BIOLOGY; MEMBRANE-PROTEIN; IDENTIFICATION; GLYCOPROTEIN; SPECIFICITY; EXPRESSION	The properties of system y(+)L-mediated transport were investigated on rat system y(+)L transporter, ry(+)LAT1, coexpressed with the heavy chain of cell surface antigen 4F2 in Xenopus oocytes, ry(+)LAT1-mediated transport of basic amino acids was Na+-independent, whereas that of neutral amino acids, although not completely, was dependent on Na+, as is typical of system y(+)L-mediated transport. In the absence of Na+, lowering of pH increased leucine transport, without affecting lysine transport. Therefore, it is proposed that H+, besides Na+ and Li+, is capable of supporting neutral amino acid transport. Na+ and H+ augmented leucine transport by decreasing the apparent Ii, values, without affecting the V-max values. We demonstrate that although ry(+)LAT1-mediated transport of [C-14]L-leucine was accompanied by the cotransport of Na-22(+), that of [C-14]L-lysine was not. The Na+ to leucine coupling ratio was determined to be 1:1 in the presence of high concentrations of Na+. ry(+)LAT1-mediated leucine transport, but not lysine transport, induced intracellular acidification in Chinese hamster ovary cells coexpressing ry(+)LAT1 and 4F2 heavy chain in the absence of Na+, but not in the presence of physiological concentrations of Na+, indicating that cotransport of HC with leucine occurred in the absence of Na+. Therefore, for the substrate recognition by ry(+)LAT1, the positive charge on basic amino acid side chains or that conferred by inorganic monovalent cations such as Na+ and H+, which are cotransported with neutral amino acids, is presumed to be required. We further demonstrate that ry(+)LAT1, due to its peculiar cation dependence, mediates a heteroexchange, wherein the influx of substrate amino acids is accompanied by the efflux of basic amino acids.	Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, Mitaka, Tokyo 1818611, Japan; Univ Tokushima, Sch Med, Dept Clin Nutr, Tokushima 7708503, Japan; Univ Tokushima, Sch Med, Dept Nutr Chem, Tokushima 7708503, Japan; Natl Def Med Coll, Dept Physiol 1, Tokorozawa, Saitama 3598513, Japan	Kyorin University; Tokushima University; Tokushima University; National Defense Medical College - Japan	Kanai, Y (corresponding author), Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, 6-20-2 Shinkawa, Mitaka, Tokyo 1818611, Japan.			Matsuo, Hirotaka/0000-0003-4302-8719				AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; ANGELO S, 1994, J MEMBRANE BIOL, V141, P183; Angelo S, 1996, J MEMBRANE BIOL, V153, P37, DOI 10.1007/s002329900107; Chairoungdua A, 1999, J BIOL CHEM, V274, P28845, DOI 10.1074/jbc.274.41.28845; Chaudhry FA, 1999, CELL, V99, P769, DOI 10.1016/S0092-8674(00)81674-8; Chillaron J, 1996, J BIOL CHEM, V271, P17761, DOI 10.1074/jbc.271.30.17761; DEVES R, 1993, J PHYSIOL-LONDON, V468, P753, DOI 10.1113/jphysiol.1993.sp019799; DEVES R, 1992, J PHYSIOL-LONDON, V454, P491, DOI 10.1113/jphysiol.1992.sp019275; Deves R, 1998, PHYSIOL REV, V78, P487, DOI 10.1152/physrev.1998.78.2.487; Feliubadalo L, 1999, NAT GENET, V23, P52, DOI 10.1038/12652; Fukasawa Y, 2000, J BIOL CHEM, V275, P9690, DOI 10.1074/jbc.275.13.9690; GRUNEWALD M, 1995, J BIOL CHEM, V270, P17017, DOI 10.1074/jbc.270.28.17017; HIRAYAMA BA, 1994, J BIOL CHEM, V269, P21407; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; KANAI Y, 1995, J BIOL CHEM, V270, P16561, DOI 10.1074/jbc.270.28.16561; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; Kanai Y, 1997, CURR OPIN CELL BIOL, V9, P565, DOI 10.1016/S0955-0674(97)80035-X; MACLEOD CL, 1994, J EXP BIOL, V196, P109; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; Nakamura E, 1999, J BIOL CHEM, V274, P3009, DOI 10.1074/jbc.274.5.3009; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Pfeiffer R, 1999, EMBO J, V18, P49, DOI 10.1093/emboj/18.1.49; Pineda M, 1999, J BIOL CHEM, V274, P19738, DOI 10.1074/jbc.274.28.19738; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Segawa H, 1999, J BIOL CHEM, V274, P19745, DOI 10.1074/jbc.274.28.19745; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437; UtsunomiyaTate N, 1997, FEBS LETT, V416, P312, DOI 10.1016/S0014-5793(97)01232-5; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; Varoqui H, 2000, J BIOL CHEM, V275, P4049, DOI 10.1074/jbc.275.6.4049; Verrey F, 1999, J MEMBRANE BIOL, V172, P181, DOI 10.1007/s002329900595; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; Weinlich M, 1997, Z GASTROENTEROL, V35, P263; Weinlich M, 1998, J EXP BIOL, V201, P57	33	79	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20787	20793		10.1074/jbc.M000634200	http://dx.doi.org/10.1074/jbc.M000634200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10777485	hybrid			2022-12-27	WOS:000088084500080
J	Maschberger, P; Bauer, M; Baumann-Siemons, J; Zangl, KJ; Negrescu, EV; Reininger, AJ; Siess, W				Maschberger, P; Bauer, M; Baumann-Siemons, J; Zangl, KJ; Negrescu, EV; Reininger, AJ; Siess, W			Mildly oxidized low density lipoprotein rapidly stimulates via activation of the lysophosphatidic acid receptor Src family and Syk tyrosine kinases and Ca2+ influx in human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-PALMITOYL-SERINE; SHAPE CHANGE; INTEGRIN ALPHA(IIB)BETA(3); SPHINGOSINE 1-PHOSPHATE; ATHEROSCLEROTIC LESIONS; PHOSPHOLIPASE A(2); PHOSPHATIDIC-ACID; ENDOTHELIAL-CELLS; PHOSPHORIC-ACIDS; C ACTIVATION	In contrast to native low density lipoprotein (LDL), mildly oxidized LDL (mox-LDL) induced platelet shape change and stimulated during shape change the tyrosine phosphorylation of specific proteins including Syk; the translocation of Src, Fyn, and Syk to the cytoskeleton; and the increase of cytosolic Ca2+ due to mainly Ca2+ entry. The stimulation of these early signal pathways by mox-LDL was inhibited by desensitization of the lysophosphatidic acid (LPA) receptor and specific LPA receptor antagonists, was independent of the alpha(IIb)beta(3)-integrin, and was mimicked by LPA. Stimulation of tyrosine phosphorylation and Syk activation were independent of the increase of cytosolic Ca2+ and were suppressed by genistein and two specific inhibitors of the Src family tyrosine kinases, PP1 and PD173956. In contrast to PP1 and PD 173956, genistein prevented shape change by mox-LDL. The results indicate that mox-LDL, through activation of the LPA receptor, stimulates two separate early signal pathways, (a) Src family and Syk tyrosine kinases, and (b) Ca2+ entry. The activation of these early signaling pathways by mox-LDL probably plays a role in platelet responses subsequent to shape change. The inhibition of mox-LDL-induced platelet activation by LPA receptor antagonists or dietary isoflavonoids such as genistein could have implications in the prevention and therapy of cardiovascular diseases.	Univ Munich, Klinikum Innenstadt, Inst Prophylaxe & Epidemiol Kreislaufkrankheiten, D-80336 Munich, Germany; Tech Univ Munich, Inst Anat, D-80802 Munich, Germany	University of Munich; Technical University of Munich	Siess, W (corresponding author), Univ Munich, Klinikum Innenstadt, Inst Prophylaxe & Epidemiol Kreislaufkrankheiten, Pettenkoferstr 9, D-80336 Munich, Germany.		Siess, Wolfgang/A-6430-2009	Siess, Wolfgang/0000-0003-0698-6416				Bauer M, 1999, BLOOD, V94, P1665, DOI 10.1182/blood.V94.5.1665.417k33_1665_1672; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; BILLAH MM, 1981, J BIOL CHEM, V256, P5399; Bittman R, 1996, J LIPID RES, V37, P391; Borsch-Haubold AG, 1998, BIOCHEM SOC T, V26, P350; CLARK EA, 1994, J BIOL CHEM, V269, P28859; COFFEY MD, 1995, J CLIN INVEST, V96, P1866, DOI 10.1172/JCI118232; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; FALK E, 1995, CIRCULATION, V92, P657, DOI 10.1161/01.CIR.92.3.657; FERNANDEZORTIZ A, 1994, J AM COLL CARDIOL, V23, P1562, DOI 10.1016/0735-1097(94)90657-2; GERRARD JM, 1984, BIOCHIM BIOPHYS ACTA, V795, P487, DOI 10.1016/0005-2760(84)90177-2; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Gooderham MJ, 1996, J NUTR, V126, P2000; GUYTON JR, 1994, ARTERIOSCLER THROMB, V14, P1305, DOI 10.1161/01.ATV.14.8.1305; Hackeng CM, 1999, ARTERIOSCL THROM VAS, V19, P239, DOI 10.1161/01.ATV.19.2.239; Hers I, 1998, ARTERIOSCL THROM VAS, V18, P404, DOI 10.1161/01.ATV.18.3.404; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HUGHES H, 1994, ARTERIOSCLER THROMB, V14, P1177, DOI 10.1161/01.ATV.14.7.1177; JENNINGS LK, 1981, J BIOL CHEM, V256, P6927; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; KOLLER E, 1989, J BIOL CHEM, V264, P12412; Law DA, 1999, BLOOD, V93, P2645, DOI 10.1182/blood.V93.8.2645.408k13_2645_2652; Liliom K, 1996, MOL PHARMACOL, V50, P616; Meraji S, 1992, Platelets, V3, P155, DOI 10.3109/09537109209013176; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Negrescu EV, 1996, J BIOL CHEM, V271, P26547, DOI 10.1074/jbc.271.43.26547; NEGRESCU EV, 1995, J BIOL CHEM, V270, P1057, DOI 10.1074/jbc.270.3.1057; PARHAMI F, 1993, J CLIN INVEST, V92, P471, DOI 10.1172/JCI116590; PEDRENO J, 1992, ARTERIOSCLER THROMB, V12, P1353, DOI 10.1161/01.ATV.12.11.1353; PEDRENO J, 1994, ARTERIOSCLER THROMB, V14, P401, DOI 10.1161/01.ATV.14.3.401; Pedreno J, 1997, ARTERIOSCL THROM VAS, V17, P156, DOI 10.1161/01.ATV.17.1.156; RASMUSSEN UB, 1993, J BIOL CHEM, V268, P14322; Sevanian A, 1997, J LIPID RES, V38, P419; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; SIESS W, 1989, BIOCHEM J, V263, P377, DOI 10.1042/bj2630377; Siess W, 1999, P NATL ACAD SCI USA, V96, P6931, DOI 10.1073/pnas.96.12.6931; SIESS W, 1984, J BIOL CHEM, V259, P8286; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; SLYPER AH, 1994, JAMA-J AM MED ASSOC, V272, P305, DOI 10.1001/jama.272.4.305; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; THOMPSON NT, 1986, EUR J BIOCHEM, V161, P399, DOI 10.1111/j.1432-1033.1986.tb10459.x; Torti M, 1996, BLOOD COAGUL FIBRIN, V7, P253, DOI 10.1097/00001721-199603000-00036; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WATSON SP, 1985, BIOCHEM BIOPH RES CO, V132, P555, DOI 10.1016/0006-291X(85)91169-6; WEIDTMANN A, 1995, ARTERIOSCL THROM VAS, V15, P1131, DOI 10.1161/01.ATV.15.8.1131; Yang LB, 1996, BIOCHEM BIOPH RES CO, V229, P440, DOI 10.1006/bbrc.1996.1822	46	72	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19159	19166		10.1074/jbc.M910257199	http://dx.doi.org/10.1074/jbc.M910257199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10764819	hybrid			2022-12-27	WOS:000087815900072
J	Phee, H; Jacob, A; Coggeshall, KM				Phee, H; Jacob, A; Coggeshall, KM			Enzymatic activity of the Src homology 2 domain-containing inositol phosphatase is regulated by a plasma membrane location	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-GAMMA-RIIB; CELL ANTIGEN-RECEPTOR; IMMUNORECEPTOR SIGNALING MOTIFS; PROTEIN-TYROSINE KINASES; B-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; POLYPHOSPHATE 5-PHOSPHATASE; PH DOMAIN; SHIP; ACTIVATION	The negative regulatory role of the Src homology 2 domain-containing inositol B-phosphatase (SHIP) has been invoked in a variety of receptor-mediated signaling pathways. In B lymphocytes, co-clustering of antigen receptor surface immunoglobulin with Fc gamma RIIb promotes the negative effects of SHIP, but how SHIP activity is regulated is unknown. To explore this issue, we investigated the effect of SHIP phosphorylation, receptor tyrosine engagement by its Src homology 2 domain, and membrane recruitment of SHIP on its enzymatic activity. We examined two SHIP phosphorylation kinase candidates, Lyn and Syk, and observed that the Src protein-tyrosine kinase, Lyn is far superior to Syk in its ability to phosphorylate SHIP both in vitro and in vivo. However, we found a minimal effect of phosphorylation or receptor tyrosine engagement of SHIP on its enzymatic activity, whereas membrane localization of SHIP significantly reduced cellular phosphatidylinositol 3,4,5-triphosphate levels. Based on our results, we propose that a membrane localization of SHIP is the crucial event in the induction of its phosphatase effects.	Oklahoma Med Res Fdn, Immunobiol & Canc Program, Oklahoma City, OK 73104 USA; Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA; Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA	Oklahoma Medical Research Foundation; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Coggeshall, KM (corresponding author), Oklahoma Med Res Fdn, Immunobiol & Canc Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.			Phee, Hyewon/0000-0002-1942-0414	NATIONAL CANCER INSTITUTE [R29CA064268, R01CA064268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041447] Funding Source: NIH RePORTER; NCI NIH HHS [CA64268] Funding Source: Medline; NIAID NIH HHS [AI41447] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; Astoul E, 1999, J CELL BIOL, V145, P1511, DOI 10.1083/jcb.145.7.1511; Bewarder N, 1996, MOL CELL BIOL, V16, P4735; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; BURG DL, 1994, J BIOL CHEM, V269, P28136; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; Campbell KS, 1999, CURR OPIN IMMUNOL, V11, P256, DOI 10.1016/S0952-7915(99)80042-9; Chacko GW, 1996, J IMMUNOL, V157, P2234; Coggeshall KM, 2000, CURR TOP MICROBIOL, V245, P213; Coggeshall KM, 1999, IMMUNOL RES, V19, P47, DOI 10.1007/BF02786476; Coggeshall KM, 1998, CURR OPIN IMMUNOL, V10, P306, DOI 10.1016/S0952-7915(98)80169-6; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DeuterReinhard M, 1997, MOL CELL BIOL, V17, P2559, DOI 10.1128/MCB.17.5.2559; Edmunds C, 1999, EUR J IMMUNOL, V29, P3507, DOI 10.1002/(SICI)1521-4141(199911)29:11<3507::AID-IMMU3507>3.0.CO;2-9; Gupta N, 1999, J BIOL CHEM, V274, P7489, DOI 10.1074/jbc.274.11.7489; Gupta N, 1997, J EXP MED, V186, P473, DOI 10.1084/jem.186.3.473; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hawkins PT, 1997, BIOCHEM SOC T, V25, P1147, DOI 10.1042/bst0251147; Hippen KL, 1997, IMMUNITY, V7, P49, DOI 10.1016/S1074-7613(00)80509-9; Huber M, 1999, PROG BIOPHYS MOL BIO, V71, P423, DOI 10.1016/S0079-6107(98)00049-2; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; Hyvonen M, 1997, EMBO J, V16, P3396, DOI 10.1093/emboj/16.12.3396; Isakov N, 1997, J LEUKOCYTE BIOL, V61, P6, DOI 10.1002/jlb.61.1.6; Jacob A, 1999, J BIOL CHEM, V274, P13704, DOI 10.1074/jbc.274.19.13704; JOHNSON SA, 1995, J IMMUNOL, V155, P4596; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu L, 1997, LEUKEMIA, V11, P181, DOI 10.1038/sj.leu.2400559; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; Nishizumi H, 1998, J EXP MED, V187, P1343, DOI 10.1084/jem.187.8.1343; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; PHILLIPS NE, 1985, J IMMUNOL, V134, P2835; PHILLIPS NE, 1984, J IMMUNOL, V132, P627; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Sarkar S, 1996, J BIOL CHEM, V271, P20182, DOI 10.1074/jbc.271.33.20182; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; SINCLAIR NR, 1970, IMMUNOLOGY, V19, P105; SINCLAIR NRS, 1971, ADV EXP MED BIOL, V12, P609; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; Tridandapani S, 1998, MOL IMMUNOL, V35, P1135, DOI 10.1016/S0161-5890(98)00097-2; Tridandapani S, 1999, J IMMUNOL, V162, P1408; Tridandapani S, 1997, J IMMUNOL, V158, P1125; Tridandapani S, 1997, MOL CELL BIOL, V17, P4305, DOI 10.1128/MCB.17.8.4305; Vely F, 1997, J IMMUNOL, V159, P2075	55	82	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19090	19097		10.1074/jbc.M001093200	http://dx.doi.org/10.1074/jbc.M001093200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10764758	hybrid			2022-12-27	WOS:000087815900063
J	Ricupero, DA; Romero, JR; Rishikof, DC; Goldstein, RH				Ricupero, DA; Romero, JR; Rishikof, DC; Goldstein, RH			Des-Arg(10)-kallidin engagement of the B1 receptor stimulates type I collagen synthesis via stabilization of connective tissue growth factor mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-1 BRADYKININ RECEPTOR; 3' UNTRANSLATED REGION; PROTEIN-KINASE-C; MESSENGER-RNA; MESANGIAL CELLS; EXPRESSION CLONING; GENE-EXPRESSION; RESPONSES; KININS; MOUSE	Expression of the kinin B1 receptor is up-regulated in chronic inflammatory and fibrotic disorders; however, little is known about its role in fibrogenesis. We examined human embryonic lung fibroblasts that constitutively express the B1 receptor and report that engagement of the B1 receptor by des-Arg(10)-kallidin stabilized connective tissue growth factor (CTGF) mRNA, stimulated an increase in al(I) collagen mRNA, and stimulated type I collagen production. These events were not observed in B2 receptor activated fibroblasts. In addition, B1 receptor activation by des-Arg(10)-kallidin induced a rise in cytosolic Ca2+ that is consistent with B1 receptor pharmacology. Our results show that the des-Arg(10)-kallidin-stimulated increase in alpha 1(I) collagen mRNA was time- and dose-dependent, with a peak response observed at: 20 h with 100 nM des-Arg(10)-kallidin. The increase in CTGF mRNA was also time- and dose-dependent, with a peak response observed at 4 h with 100 nM des-Arg(10)-kallidin. The increase in CTGF mRNA was blocked by the B1 receptor antagonist des-Arg(10),Leu(9)-kallidin. Inhibition of protein synthesis by cycloheximide did not block the des-Arg(10)-kallidin-induced increase in CTGF mRNA. These results suggest that engagement of the kinin B1 receptor contributes to fibrogenesis through increased expression of CTGF.	Boston Univ, Sch Med, Dept Med, Ctr Pulm, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Vet Affairs Med Ctr, Boston, MA 02118 USA; Harvard Univ, Sch Med, Dept Med, Div Endocrine Hypertens, Boston, MA 02118 USA	Boston University; Boston University; Harvard University; Harvard Medical School	Ricupero, DA (corresponding author), Boston Univ, Sch Med, Dept Med, Ctr Pulm, 715 Albany St,R3, Boston, MA 02118 USA.	ricupero@bu.edu		Romero, Jose Ricardo/0000-0001-8225-0772	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK053538] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50HL56386] Funding Source: Medline; NIDDK NIH HHS [R03DK53538] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKASHI M, 1991, BLOOD, V78, P2005; Allogho SN, 1995, CAN J PHYSIOL PHARM, V73, P1759, DOI 10.1139/y95-240; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; BASCANDS JL, 1993, AM J PHYSIOL, V264, pF548, DOI 10.1152/ajprenal.1993.264.3.F548; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; CAHILL M, 1988, AGENTS ACTIONS, V24, P224, DOI 10.1007/BF02028275; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cuthbert AW, 1997, IMMUNOPHARMACOLOGY, V36, P149, DOI 10.1016/S0162-3109(97)00014-3; DANIELPOUR D, 1989, J CELL PHYSIOL, V138, P79, DOI 10.1002/jcp.1041380112; DAVIS AJ, 1994, NEUROPHARMACOLOGY, V33, P127, DOI 10.1016/0028-3908(94)90107-4; DEWITT BJ, 1994, CIRC RES, V75, P1064, DOI 10.1161/01.RES.75.6.1064; FAJTOVA VT, 1991, AM J PHYSIOL, V261, pE151, DOI 10.1152/ajpendo.1991.261.1.E151; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; GIBBONS GH, 1992, J CLIN INVEST, V90, P456, DOI 10.1172/JCI115881; GOLDSTEIN RH, 1984, J BIOL CHEM, V259, P9263; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; HERXHEIMER H, 1961, J PHYSIOL-LONDON, V158, pP38; Hess JF, 1996, IMMUNOPHARMACOLOGY, V33, P1, DOI 10.1016/0162-3109(96)00074-4; IGARASHI A, 1995, J INVEST DERMATOL, V105, P280, DOI 10.1111/1523-1747.ep12318465; ISSANDOU M, 1991, J BIOL CHEM, V266, P21037; Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1046/j.1523-1755.1998.00820.x; JOHNSON AR, 1973, P SOC EXP BIOL MED, V142, P1252; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; Kumar S, 1999, J BIOL CHEM, V274, P17123, DOI 10.1074/jbc.274.24.17123; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; Lasky JA, 1998, AM J PHYSIOL-LUNG C, V275, pL365, DOI 10.1152/ajplung.1998.275.2.L365; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LORTIE M, 1992, AM J PHYSIOL, V262, pR72, DOI 10.1152/ajpregu.1992.262.1.R72; Ma JX, 1996, EXP EYE RES, V63, P19, DOI 10.1006/exer.1996.0087; Marceau F, 1998, PHARMACOL REV, V50, P357; Mathis SA, 1996, MOL PHARMACOL, V50, P128; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MENKE JG, 1994, J BIOL CHEM, V269, P21583; Nadar R, 1996, IMMUNOPHARMACOLOGY, V33, P317, DOI 10.1016/0162-3109(96)00053-7; Pan ZK, 1996, J CLIN INVEST, V98, P2042, DOI 10.1172/JCI119009; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49, DOI 10.1146/annurev.iy.06.040188.000405; REGOLI D, 1980, PHARMACOL REV, V32, P1; Reynolds CJ, 1999, AM J RESP CRIT CARE, V159, P431, DOI 10.1164/ajrccm.159.2.9804132; Ricupero DA, 1999, AM J PHYSIOL-LUNG C, V277, pL1165, DOI 10.1152/ajplung.1999.277.6.L1165; Roberts R A, 1989, Prog Growth Factor Res, V1, P237, DOI 10.1016/0955-2235(89)90013-6; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; SARIA A, 1988, AM REV RESPIR DIS, V137, P1330, DOI 10.1164/ajrccm/137.6.1330; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STUDER RK, 1995, KIDNEY INT, V48, P422, DOI 10.1038/ki.1995.310; VILLANUEVA AG, 1991, CIRC RES, V69, P134, DOI 10.1161/01.RES.69.1.134; WEISS IM, 1994, MOL CELL BIOL, V14, P8123, DOI 10.1128/MCB.14.12.8123; WHALLEY ET, 1987, N-S ARCH PHARMACOL, V336, P652, DOI 10.1007/BF00165756; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YEN TJ, 1988, MOL CELL BIOL, V8, P1224, DOI 10.1128/MCB.8.3.1224; Ying ZT, 1996, GENE, V171, P243, DOI 10.1016/0378-1119(95)00891-8; Zuzack JS, 1996, J PHARMACOL EXP THER, V277, P1337	55	42	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12475	12480		10.1074/jbc.275.17.12475	http://dx.doi.org/10.1074/jbc.275.17.12475			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777533	hybrid			2022-12-27	WOS:000086762300017
J	Bigler, D; Takahashi, Y; Chen, MS; Almeida, EAC; Osbourne, L; White, JM				Bigler, D; Takahashi, Y; Chen, MS; Almeida, EAC; Osbourne, L; White, JM			Sequence-specific interaction between the disintegrin domain of mouse ADAM 2 (Fertilin beta) and murine eggs - Role of the alpha(6) integrin subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO FERTILIZATION; POTENTIAL ROLE; SPERM; PROTEIN; BINDING; FUSION; MEMBRANE; ALPHA-6-BETA-1; RECEPTOR; PEPTIDES	Little is set known about the biological and biochemical properties of the disintegrin-like domains of ADAM ((a) under bar (d) under bar isintegrin (a) under bar nd (m) under bar etalloprotease) proteins. Mouse ADAM 2 2 (mADAM 2; fertilin beta) is a sperm surface protein involved in murine fertilization. We produced recombinant proteins containing the disintegrin-like domain of mADAM 2 in both insect cells and in bacteria. The protein produced in insect cells (baculo D+C) contained a signal sequence followed by the disintegrin-like and cysteine-rich domains; it was purified from the medium of recombinant baculovirus-infected cells. A bacterial construct containing the disintegrin-like domain was produced in Escherichia coli as a glutathione S-transferase chimera. Baculo D+C, as well as the D domain of the bacterial construct (released with thrombin), bound to the microvillar surface of murine eggs. Using concentrations in the range of 1 to 5 mu m, both recombinant proteins strongly inhibited sperm-egg binding and fusion; the baculovirus-produced protein exhibited a somewhat greater extent of inhibition (similar to 75 versus similar to 55% maximal inhibition). Substitution of alanine for each of the five charged residues within the disintegrin loop of mADAM 2 revealed a critical importance for the aspartic acid at position nine. Binding of both recombinant proteins to the egg was inhibited by the function blocking anti-alpha(6) monoclonal antibody, GoH3, but not by a nonfunction-blocking anti-alpha(6) monoclonal antibody. Binding was also inhibited by a peptide analogue of, and with an antibody against, the disintegrin loop of mADAM 2.	Univ Virginia, Dept Cell Biol, Charlottesville, VA 22908 USA; Biogen Inc, Cambridge, MA 02142 USA	University of Virginia; Biogen	White, JM (corresponding author), UVA Hlth Syst, Sch Med, Dept Cell Biol, POB 800732, Charlottesville, VA 22908 USA.	jw7g@virginia.edu			NIGMS NIH HHS [GM48739] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048739] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; Balliet JW, 1999, J VIROL, V73, P3054, DOI 10.1128/JVI.73.4.3054-3061.1999; BERGELSON JM, 1995, CURR BIOL, V5, P615, DOI 10.1016/S0960-9822(95)00124-2; Bigler D, 1997, TRENDS CELL BIOL, V7, P220, DOI 10.1016/S0962-8924(97)01058-1; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Blobel Carl P., 1992, Current Opinion in Cell Biology, V4, P760; BLOBEL CP, 1990, J CELL BIOL, V111, P69, DOI 10.1083/jcb.111.1.69; Bronson RA, 1999, MOL HUM REPROD, V5, P433, DOI 10.1093/molehr/5.5.433; Chen H, 1999, CHEM BIOL, V6, P1, DOI 10.1016/S1074-5521(99)80015-5; Chen LL, 1997, AM J PHYSIOL-LUNG C, V272, pL494, DOI 10.1152/ajplung.1997.272.3.L494; Chen MS, 1999, P NATL ACAD SCI USA, V96, P11830, DOI 10.1073/pnas.96.21.11830; Chen MS, 1999, J CELL BIOL, V144, P549, DOI 10.1083/jcb.144.3.549; Cho CH, 1998, SCIENCE, V281, P1857, DOI 10.1126/science.281.5384.1857; Coonrod SA, 1999, DEV BIOL, V207, P334, DOI 10.1006/dbio.1998.9161; DELWEL GO, 1995, CELL ADHES COMMUN, V3, P143, DOI 10.3109/15419069509081283; Evans JP, 1997, DEV BIOL, V187, P79, DOI 10.1006/dbio.1997.8611; EVANS JP, 1995, J CELL SCI, V108, P3267; Evans JP, 1998, BIOL REPROD, V59, P145, DOI 10.1095/biolreprod59.1.145; EVANS JP, 1999, FRONT BIOSCI, V4, P114; Gichuhi PM, 1997, INT J ANDROL, V20, P165, DOI 10.1046/j.1365-2605.1997.00058.x; GILBERT JM, 1993, J VIROL, V67, P6889, DOI 10.1128/JVI.67.11.6889-6892.1993; Hunnicutt GR, 1997, DEV BIOL, V191, P146, DOI 10.1006/dbio.1997.8700; Jia LG, 1997, J BIOL CHEM, V272, P13094, DOI 10.1074/jbc.272.20.13094; LEWIS V, 1985, J CELL BIOL, V100, P1839, DOI 10.1083/jcb.100.6.1839; Linder B, 1997, DEV GROWTH DIFFER, V39, P243; Lum L, 1997, DEV BIOL, V191, P131, DOI 10.1006/dbio.1997.8609; McLane MA, 1998, P SOC EXP BIOL MED, V219, P109, DOI 10.3181/00379727-219-44322; Myles DG, 1997, BIOL REPROD, V56, P320, DOI 10.1095/biolreprod56.2.320; MYLES DG, 1994, P NATL ACAD SCI USA, V91, P4195, DOI 10.1073/pnas.91.10.4195; Nath D, 1999, J CELL SCI, V112, P579; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; PHELPS BM, 1990, J CELL BIOL, V111, P1839, DOI 10.1083/jcb.111.5.1839; Pyluck A, 1997, BIOORG MED CHEM LETT, V7, P1053, DOI 10.1016/S0960-894X(97)00160-1; Schlondorff J, 1999, J CELL SCI, V112, P3603; Shilling FM, 1997, DEV BIOL, V186, P155, DOI 10.1006/dbio.1997.8586; TESSIER DC, 1991, GENE, V98, P177, DOI 10.1016/0378-1119(91)90171-7; Wassarman PM, 1999, CELL, V96, P175, DOI 10.1016/S0092-8674(00)80558-9; Wilson NF, 1998, TRENDS CELL BIOL, V8, P93, DOI 10.1016/S0962-8924(98)01234-3; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; Yuan RY, 1997, J CELL BIOL, V137, P105, DOI 10.1083/jcb.137.1.105; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345	42	92	103	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11576	11584		10.1074/jbc.275.16.11576	http://dx.doi.org/10.1074/jbc.275.16.11576			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766772	hybrid			2022-12-27	WOS:000086695500007
J	Iwase, K; Miyanaka, K; Shimizu, A; Nagasaki, A; Gotoh, T; Mori, M; Takiguchi, M				Iwase, K; Miyanaka, K; Shimizu, A; Nagasaki, A; Gotoh, T; Mori, M; Takiguchi, M			Induction of endothelial nitric-oxide synthase in rat brain astrocytes by systemic lipopolysaccharide treatment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING; MESSENGER-RNA; IN-VIVO; NEUROTRANSMITTER RELEASE; INDUCIBLE FORM; SMOOTH-MUSCLE; L-ARGININE; EXPRESSION; GENE; LOCALIZATION	In the brain, three isoforms of nitric oxide (NO) synthase (NOS), namely neuronal NOS (nNOS, NOS1), inducible NOS (iNOS, NOS2), and endothelial NOS (eNOS, NOS3), have been implicated in biological roles such as neurotransmission, neurotoxicity, immune function, and blood vessel regulation, each isoform exhibiting in part overlapping roles. Previous studies showed that iNOS is induced in the brain by systemic treatment with lipopolysaccharide (LPS), a Gram-negative bacteria-derived stimulant of the innate immune system. Here we found that eNOS mRNA is induced in the rat brain by intraperitoneal injection of LPS of a smaller amount than that required for induction of iNOS mRNA. The induction of eNOS mRNA was followed by an increase in eNOS protein. Immunohistochemical analysis revealed that eNOS is located in astrocytes of both gray and white matters as well as in blood vessels. Induction of eNOS in response to a low dose of LPS, together with its localization in major components of the blood brain barrier, suggests that brain eNOS is involved in early pathophysiologic response against systemic infection before iNOS is induced with progression of the infection.	Chiba Univ, Sch Med, Dept Biochem, Chiba 2608670, Japan; Kumamoto Univ, Sch Med, Dept Mol Genet, Kumamoto 8620976, Japan	Chiba University; Kumamoto University	Takiguchi, M (corresponding author), Chiba Univ, Sch Med, Dept Biochem, Inohana 1-8-1, Chiba 2608670, Japan.							Adamson DC, 1996, SCIENCE, V274, P1917, DOI 10.1126/science.274.5294.1917; Bagasra O, 1995, P NATL ACAD SCI USA, V92, P12041, DOI 10.1073/pnas.92.26.12041; Barna M, 1996, VIROLOGY, V223, P331, DOI 10.1006/viro.1996.0484; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; DINERMAN JL, 1994, P NATL ACAD SCI USA, V91, P4214, DOI 10.1073/pnas.91.10.4214; Doyle CA, 1997, NEUROSCIENCE, V76, P387, DOI 10.1016/S0306-4522(96)00297-7; ENDOH M, 1994, BRAIN RES, V651, P92, DOI 10.1016/0006-8993(94)90683-1; Gabbott PLA, 1996, BRAIN RES, V714, P135, DOI 10.1016/0006-8993(95)01509-4; GENG YJ, 1994, BBA-GENE STRUCT EXPR, V1218, P421, DOI 10.1016/0167-4781(94)90196-1; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; HANDY RLC, 1995, BRIT J PHARMACOL, V116, P2349, DOI 10.1111/j.1476-5381.1995.tb15078.x; Hara E, 1996, BIOCHEM BIOPH RES CO, V224, P153, DOI 10.1006/bbrc.1996.0999; HEVEL JM, 1994, METHOD ENZYMOL, V233, P250; HOM GJ, 1995, J PHARMACOL EXP THER, V272, P452; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; Hunot S, 1996, NEUROSCIENCE, V72, P355, DOI 10.1016/0306-4522(95)00578-1; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P378, DOI 10.1038/jcbfm.1995.47; Iadecola C, 1997, J NEUROSCI, V17, P9157; ISOBE Y, 1977, ACTA HISTOCHEM CYTOC, V10, P161, DOI 10.1267/ahc.10.161; Iwase K, 1998, MOL BRAIN RES, V53, P1, DOI 10.1016/S0169-328X(97)00139-3; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; Kano T, 1998, NEUROSCIENCE, V86, P695, DOI 10.1016/S0306-4522(98)00179-1; KOPROWSKI H, 1993, P NATL ACAD SCI USA, V90, P3024, DOI 10.1073/pnas.90.7.3024; Liu SF, 1996, CRIT CARE MED, V24, P1219, DOI 10.1097/00003246-199607000-00026; Mayer B, 1997, TRENDS BIOCHEM SCI, V22, P477, DOI 10.1016/S0968-0004(97)01147-X; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; MITROVIC B, 1994, NEUROSCIENCE, V61, P575, DOI 10.1016/0306-4522(94)90435-9; Nagasaki A, 1996, J BIOL CHEM, V271, P2658, DOI 10.1074/jbc.271.5.2658; NELSON RJ, 1995, NATURE, V378, P383, DOI 10.1038/378383a0; ODELL TJ, 1994, SCIENCE, V265, P542, DOI 10.1126/science.7518615; RODRIGO J, 1994, PHILOS T R SOC B, V345, P175, DOI 10.1098/rstb.1994.0096; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; Shimizu-Sasamata M, 1998, J NEUROSCI, V18, P9564; Son H, 1996, CELL, V87, P1015, DOI 10.1016/S0092-8674(00)81796-1; Sonoki T, 1997, J BIOL CHEM, V272, P3689, DOI 10.1074/jbc.272.6.3689; Vodovotz Y, 1996, J EXP MED, V184, P1425, DOI 10.1084/jem.184.4.1425; Wong ML, 1996, NAT MED, V2, P581, DOI 10.1038/nm0596-581; Zhang HQ, 1997, J MED CHEM, V40, P3869, DOI 10.1021/jm970550g	44	90	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11929	11933		10.1074/jbc.275.16.11929	http://dx.doi.org/10.1074/jbc.275.16.11929			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766821	hybrid			2022-12-27	WOS:000086695500056
J	Li, DQ; Takimoto, K; Levitan, ES				Li, DQ; Takimoto, K; Levitan, ES			Surface expression of Kv1 channels is governed by a C-terminal motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG QT SYNDROME; POTASSIUM CHANNEL; GENE-EXPRESSION; CARDIAC-ARRHYTHMIA; RAT-HEART; TRAFFICKING; INDUCTION; SUBUNITS; CURRENTS; PROTEIN	Voltage-gated K+ channel subunits must reach the plasma membrane to repolarize action potentials. Yet the efficiency of cell surface targeting varies among Kv subunits with some requiring auxiliary subunits for optimal expression. Here we identify a conserved motif located in the variable C-terminal region of Kv1 channels that controls the efficiency of functional channel expression. Variations among wild type channels in the optimal sequence VXYSL produce differences in distribution and the requirement for auxiliary subunits. Furthermore, deletion of this motif decreases subunit glycosylation and surface localization but does not prohibit subunit multimerization. Finally, the action of the essential sequence is shown to be independent of the chaperone effect of Kv beta subunits. Thus, the newly identified C-terminal motif governs processing and cell surface expression of Kv1 voltage-gated K+ channels.	Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Levitan, ES (corresponding author), Univ Pittsburgh, Dept Pharmacol, E1351 Biomed Sci Tower, Pittsburgh, PA 15261 USA.	Levitan@server.pharm.pitt.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055312, R01HL063123] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL63123, HL55312] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; Burke NA, 1999, J GEN PHYSIOL, V113, P71, DOI 10.1085/jgp.113.1.71; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; DEAL KK, 1994, J NEUROSCI, V14, P1666, DOI 10.1523/JNEUROSCI.14-03-01666.1994; Furutani M, 1999, CIRCULATION, V99, P2290, DOI 10.1161/01.CIR.99.17.2290; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kullmann DM, 1999, NEUROLOGY, V52, pA553; Kupershmidt S, 1998, J BIOL CHEM, V273, P27231, DOI 10.1074/jbc.273.42.27231; Levitan E S, 1999, Methods Enzymol, V294, P47; Levitan ES, 1998, J NEUROBIOL, V37, P60, DOI 10.1002/(SICI)1097-4695(199810)37:1<60::AID-NEU5>3.0.CO;2-6; MCKINNON D, 1989, J BIOL CHEM, V264, P8230; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; ROBERDS SL, 1991, P NATL ACAD SCI USA, V88, P1798, DOI 10.1073/pnas.88.5.1798; SANTACRUZTOLOZA L, 1994, BIOCHEMISTRY-US, V33, P5607, DOI 10.1021/bi00184a033; Sharma N, 1999, J BIOL CHEM, V274, P20628, DOI 10.1074/jbc.274.29.20628; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; TAKIMOTO K, 1994, CIRC RES, V75, P1006, DOI 10.1161/01.RES.75.6.1006; Takimoto K, 1996, BIOCHEMISTRY-US, V35, P14149, DOI 10.1021/bi961290s; Tu LW, 1999, BIOPHYS J, V76, P2004, DOI 10.1016/S0006-3495(99)77358-3; UEBELE VN, 1994, FEBS LETT, V340, P104, DOI 10.1016/0014-5793(94)80181-9; Uebele VN, 1996, J BIOL CHEM, V271, P2406, DOI 10.1074/jbc.271.5.2406; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061	24	92	121	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11597	11602		10.1074/jbc.275.16.11597	http://dx.doi.org/10.1074/jbc.275.16.11597			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766775	hybrid			2022-12-27	WOS:000086695500010
J	Prinetti, A; Chigorno, V; Tettamanti, G; Sonnino, S				Prinetti, A; Chigorno, V; Tettamanti, G; Sonnino, S			Sphingolipid-enriched membrane domains from rat cerebellar granule cells differentiated in culture - A compositional study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXOGENOUS GANGLIOSIDE GM1; CHAIN BASE COMPOSITION; GPI-ANCHORED PROTEINS; MELANOMA B16 CELLS; THERMOTROPIC PROPERTIES; SIGNAL-TRANSDUCTION; CAVEOLAE MEMBRANE; SPHINGOSINE; LOCALIZATION; GLYCOSPHINGOLIPIDS	Sphingolipid-enriched membrane domains, characterized by a particular protein and lipid composition, have been detected in a variety of cells. However, limited data are available concerning these domains in neuronal cells. We analyzed the lipid and protein composition of a sphingolipid-enriched membrane fraction prepared from primary rat cerebellar granule cells differentiated in culture. Although the protein content of this fraction was only 1.4% of total cellular protein, 60% of the gangliosides, 67% of the sphingomyelin, 50% of the ceramide, and 40% of the cholesterol were located in this fraction. The protein pattern of the sphingolipid-enriched domain fraction was dramatically different from that associated with the cell homogenate, This fraction contained 25% of the tyrosine-phosphorylated proteins and was enriched in two proteins with apparent molecular masses of 135 and 15 kDa. 12% of cellular glycerophospholipids were located in the fraction, with phosphatidylcholine having the highest enrichment. The molar ratio between proteins, glycerophospholipids, cholesterol, sphingomyelin,ceramide and gangliosides in cerebellar granule cells was 1.6:41.6:6.1:1.3:0.3:1 in the cell homogenate and 0.04:8.3:4.0:1.4:0.2:1 in the sphingolipid-enriched membrane fraction. These data indicate that selected proteins segregate with sphingolipids in specialized domains in the membrane of cultured neurons.	Univ Milan, Sch Med, LITA Segrate,Dept Med Chem & Biochem, Study Ctr Funct Biochem Brain Lipids, I-20090 Milan, Italy	University of Milan	Sonnino, S (corresponding author), Univ Milan, Sch Med, LITA Segrate,Dept Med Chem & Biochem, Study Ctr Funct Biochem Brain Lipids, Via Fratelli Cervi 93, I-20090 Milan, Italy.	Sandro.Sonnino@unimi.it	Prinetti, Alessandro/R-4206-2017; Sonnino, Sandro/R-4154-2017	Prinetti, Alessandro/0000-0003-0252-2593; Sonnino, Sandro/0000-0001-8180-5908				BALAZS R, 1980, TISSUE CULTURE NEURO, P155; BERTOLI E, 1981, BIOCHIM BIOPHYS ACTA, V647, P196, DOI 10.1016/0005-2736(81)90246-7; Bilderback TR, 1997, J BIOL CHEM, V272, P10922; Bilderback TR, 1999, J BIOL CHEM, V274, P257, DOI 10.1074/jbc.274.1.257; Bordi F, 1999, COLLOID SURFACE B, V13, P135, DOI 10.1016/S0927-7765(99)00009-0; Brocca P, 1997, TRENDS GLYCOSCI GLYC, V9, P433, DOI 10.4052/tigg.9.433; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CANTU L, 1990, CHEM PHYS LIPIDS, V55, P223, DOI 10.1016/0009-3084(90)90160-S; CARTER HE, 1961, J LIPID RES, V2, P228; Chester MA, 1997, PURE APPL CHEM, V69, P2475, DOI 10.1351/pac199769122475; Chigorno V, 1997, EUR J BIOCHEM, V250, P661, DOI 10.1111/j.1432-1033.1997.00661.x; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; CINEK T, 1992, J IMMUNOL, V149, P2262; Cornish-Bowden A, 1998, CARBOHYD RES, V312, P167; Ferraretto A, 1997, BIOCHEMISTRY-US, V36, P9232, DOI 10.1021/bi970428j; FRA AM, 1994, J BIOL CHEM, V269, P30745; FRIES E, 1988, BIOCHEM INT, V16, P737; GALLO V, 1982, P NATL ACAD SCI-BIOL, V79, P7919, DOI 10.1073/pnas.79.24.7919; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; Iwabuchi K, 1998, J BIOL CHEM, V273, P33766, DOI 10.1074/jbc.273.50.33766; JOLLES J, 1981, BIOCHIM BIOPHYS ACTA, V666, P90, DOI 10.1016/0005-2760(81)90094-1; Kasahara K, 1999, MOL BIOL CELL, V10, p306A; Kasahara K, 1997, J BIOL CHEM, V272, P29947, DOI 10.1074/jbc.272.47.29947; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASSERINI M, 1988, BIOCHEMISTRY-US, V27, P7973, DOI 10.1021/bi00420a057; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; OLIVE S, 1995, J NEUROCHEM, V65, P2307; PALMER FBSC, 1981, J LIPID RES, V22, P1296; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; PASCHER I, 1976, BIOCHIM BIOPHYS ACTA, V455, P433, DOI 10.1016/0005-2736(76)90316-3; Prinetti A, 1999, J BIOL CHEM, V274, P20916, DOI 10.1074/jbc.274.30.20916; RIBONI L, 1992, FEBS LETT, V300, P188, DOI 10.1016/0014-5793(92)80193-K; RIBONI L, 1990, NEUROCHEM RES, V15, P1175, DOI 10.1007/BF01208577; Riboni L, 1999, BIOCHEM J, V338, P147, DOI 10.1042/0264-6021:3380147; RIBONI L, 1993, FEBS LETT, V322, P257, DOI 10.1016/0014-5793(93)81582-K; ROCK P, 1990, BIOCHEMISTRY-US, V29, P8484, DOI 10.1021/bi00488a040; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; SARAFIAN T, 1990, J NEUROCHEM, V55, P913, DOI 10.1111/j.1471-4159.1990.tb04578.x; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; SHAROM FJ, 1978, BIOCHIM BIOPHYS ACTA, V507, P280, DOI 10.1016/0005-2736(78)90423-6; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Sorice M, 1997, J LIPID RES, V38, P969; Svennerholm L, 1980, Adv Exp Med Biol, V125, P11; TAKI T, 1994, ANAL BIOCHEM, V223, P232, DOI 10.1006/abio.1994.1579; TERZAGHI A, 1994, EUR J CELL BIOL, V65, P172; TERZAGHI A, 1993, BIOCHEMISTRY-US, V32, P9722, DOI 10.1021/bi00088a026; TETTAMAN.G, 1973, BIOCHIM BIOPHYS ACTA, V296, P160, DOI 10.1016/0005-2760(73)90055-6; Tettamanti G, 1996, J LIPID MEDIAT CELL, V14, P263, DOI 10.1016/0929-7855(96)00535-4; TOYOKUNI T, 1991, J LABELLED COMPD RAD, V29, P567, DOI 10.1002/jlcr.2580290508; VALSECCHI M, 1993, J NEUROCHEM, V60, P193, DOI 10.1111/j.1471-4159.1993.tb05837.x; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554	59	133	134	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11658	11665		10.1074/jbc.275.16.11658	http://dx.doi.org/10.1074/jbc.275.16.11658			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766784	hybrid			2022-12-27	WOS:000086695500019
J	Renirie, R; Hemrika, W; Wever, R				Renirie, R; Hemrika, W; Wever, R			Peroxidase and phosphatase activity of active-site mutants of vanadium chloroperoxidase from the fungus Curvularia inaequalis - Implications for the catalytic mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURE; HUMAN GLUCOSE-6-PHOSPHATASE; ASCOPHYLLUM-NODOSUM; CONTAINING ENZYME; BROMOPEROXIDASE; HALOPEROXIDASE; REACTIVITY; HISTIDINE; TOPOLOGY; VANADATE	Mutation studies were performed on active site residues of vanadium chloroperoxidase from the fungus Curvularia inaequalis, an enzyme which exhibits both haloperoxidase and phosphatase activity and is related to glucose-6 phosphatase. The effects of mutation to alanine on haloperoxidase activity were studied for the proposed catalytic residue His-404 and for residue Asp-292, which is located close to the vanadate cofactor. The mutants were strongly impaired in their ability to oxidize chloride but still oxidized bromide, although they inactivate during turnover. The effects on the optical absorption spectrum of vanadium chloroperoxidase indicate that mutant H404A has a reduced affinity for the cofactor, whereas this affinity is unchanged in mutant D292A. The effect on the phosphatase activity of the apoenzyme was investigated for six mutants of putative catalytic residues, Effects of mutation of His-496, Arg-490, Arg-360, Lys-353, and His-404 to alanine are in line with their proposed roles in nucleophilic attack, transition-state stabilization, and leaving-group protonation, Asp-292 is excluded as the group that protonates the leaving group. A model based on the mutagenesis studies is presented and may serve as a template for glucose-6-phosphatase and other related phosphatases. Hydrolysis of a phospho-histidine intermediate is the rate-determining step in the phosphatase activity of apochloroperoxidase, as shown by burst kinetics.	Univ Amsterdam, Biocentrum Amsterdam, EC Slater Inst, NL-1018 TV Amsterdam, Netherlands	University of Amsterdam	Wever, R (corresponding author), Univ Amsterdam, Biocentrum Amsterdam, EC Slater Inst, Plantage Muidergracht 12, NL-1018 TV Amsterdam, Netherlands.		Wever, Ron/AAM-4520-2020					ARBER JM, 1989, BIOCHEMISTRY-US, V28, P7968, DOI 10.1021/bi00445a062; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Colpas GJ, 1996, J AM CHEM SOC, V118, P3469, DOI 10.1021/ja953791r; CORNISHBOWDEN A, 1995, FUNDAMENTALS ENZYME, P274; COUNTAWAY JL, 1988, J BIOL CHEM, V263, P2673; Crans, 1998, VANADIUM COMPOUNDS C, P216; CRANS DC, 1994, COMMENT INORG CHEM, V16, P1; DEBOER E, 1988, J BIOL CHEM, V263, P12326; FELDMAN F, 1972, BIOCHIM BIOPHYS ACTA, V268, P698, DOI 10.1016/0005-2744(72)90274-4; Hamstra BJ, 1998, INORG CHEM, V37, P949, DOI 10.1021/ic9711776; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Hemrika W, 1999, J BIOL CHEM, V274, P23820, DOI 10.1074/jbc.274.34.23820; Hemrika W, 1997, FEBS LETT, V409, P317, DOI 10.1016/S0014-5793(97)00530-9; Hemrika W, 1997, P NATL ACAD SCI USA, V94, P2145, DOI 10.1073/pnas.94.6.2145; LEI KJ, 1995, J BIOL CHEM, V270, P11882, DOI 10.1074/jbc.270.20.11882; Macedo-Ribeiro S, 1999, J BIOL INORG CHEM, V4, P209, DOI 10.1007/s007750050306; Messerschmidt A, 1997, BIOL CHEM, V378, P309, DOI 10.1515/bchm.1997.378.3-4.309; Messerschmidt A, 1996, P NATL ACAD SCI USA, V93, P392, DOI 10.1073/pnas.93.1.392; Neuwald AF, 1997, PROTEIN SCI, V6, P1764, DOI 10.1002/pro.5560060817; Pan CJ, 1998, J BIOL CHEM, V273, P21658, DOI 10.1074/jbc.273.34.21658; Pan CJ, 1998, J BIOL CHEM, V273, P6144, DOI 10.1074/jbc.273.11.6144; Renirie R, 2000, BIOCHEMISTRY-US, V39, P1133, DOI 10.1021/bi9921790; SINGH J, 1981, BIOCHIM BIOPHYS ACTA, V678, P477, DOI 10.1016/0304-4165(81)90129-X; Stukey J, 1997, PROTEIN SCI, V6, P469; VANSCHIJNDEL JWPM, 1993, FEBS LETT, V336, P239, DOI 10.1016/0014-5793(93)80811-8; Weyand M, 1999, J MOL BIOL, V293, P595, DOI 10.1006/jmbi.1999.3179; Winter GEM, 1996, BIOCHEMISTRY-US, V35, P11805, DOI 10.1021/bi960381m	27	63	63	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11650	11657		10.1074/jbc.275.16.11650	http://dx.doi.org/10.1074/jbc.275.16.11650			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766783	hybrid			2022-12-27	WOS:000086695500018
J	Stanciu, M; Wang, Y; Kentor, R; Burke, N; Watkins, S; Kress, G; Reynolds, I; Klann, E; Angiolieri, MR; Johnson, JW; DeFranco, DB				Stanciu, M; Wang, Y; Kentor, R; Burke, N; Watkins, S; Kress, G; Reynolds, I; Klann, E; Angiolieri, MR; Johnson, JW; DeFranco, DB			Persistent activation of ERK contributes to glutamate-induced oxidative toxicity in a neuronal cell line and primary cortical neuron cultures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; ARACHIDONIC-ACID RELEASE; SMOOTH-MUSCLE CELLS; PROTEIN-KINASE; C-JUN; GLUTATHIONE DEPLETION; LIPID-PEROXIDATION; CEREBRAL-ISCHEMIA; INDUCED APOPTOSIS; CARDIAC-ARREST	Oxidative stress can trigger neuronal cell death and has been implicated in several chronic neurological diseases and in acute neurological injury. Oxidative toxicity can be induced by glutamate treatment in cells that lack ionotrophic glutamate receptors, such as the immortalized HT22 hippocampal cell line and immature primary cortical neurons. Previously, we found that neuroprotective effects of geldanamycin, a benzoquinone ansamycin, in HT22 cells were associated with a down-regulation of c-Raf-1, an upstream activator of the extracellular signal-regulated protein kinases (ERKs). ERK activation, although often attributed strictly to neuronal cell survival and proliferation, can also be associated with neuronal cell death that occurs in response to specific insults. in this report we show that delayed and persistent activation of ERKs is associated with glutamate-induced oxidative toxicity in HT22 cells and immature primary cortical neuron cultures. Furthermore, me find that U0126, a specific inhibitor of the ERK-activating kinase, MEK-1/2, protects both HT22 cells and immature primary cortical neuron cultures from glutamate toxicity. Glutamate-induced ERK activation requires the production of specific arachidonic acid metabolites and appears to be downstream of a burst of reactive oxygen species (ROS) accumulation characteristic of oxidative stress in HT22 cells. However, inhibition of ERK activation reduces glutamate-induced intracellular Ca2+ accumulation. We hypothesize that the precise kinetics and duration of ERR activation may determine whether downstream targets are mobilized to enhance neuronal cell survival or ensure cellular demise.	Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	DeFranco, DB (corresponding author), Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA.		Reynolds, Ian/C-4358-2008; Reynolds, Ian Jeffery/ABH-3197-2020; Watkins, Simon/ABG-2590-2021	Watkins, Simon/0000-0003-4092-1552; Reynolds, Ian/0000-0003-3028-5070; Kress, Geraldine/0000-0001-9442-8734	NATIONAL CANCER INSTITUTE [R01CA043037] Funding Source: NIH RePORTER; NCI NIH HHS [CA43037] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; BENDANI MK, 1995, NEUROSCI LETT, V189, P159, DOI 10.1016/0304-3940(95)11482-C; Bhat NR, 1999, J NEUROCHEM, V72, P112, DOI 10.1046/j.1471-4159.1999.0720112.x; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Capodici C, 1998, J CLIN INVEST, V102, P165, DOI 10.1172/JCI592; CHEN QL, 1995, J BIOL CHEM, V270, P28499, DOI 10.1074/jbc.270.48.28499; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cook SJ, 1999, MOL CELL BIOL, V19, P330; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Creedon DJ, 1996, J BIOL CHEM, V271, P20713, DOI 10.1074/jbc.271.34.20713; DAVIS JB, 1994, BRAIN RES, V652, P169, DOI 10.1016/0006-8993(94)90334-4; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; Derkinderen P, 1999, NEUROREPORT, V10, pR24; Dulin NO, 1998, P NATL ACAD SCI USA, V95, P8098, DOI 10.1073/pnas.95.14.8098; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; Gijon MA, 1999, J LEUKOCYTE BIOL, V65, P330, DOI 10.1002/jlb.65.3.330; GREENAMYRE JT, 1985, SCIENCE, V227, P1496, DOI 10.1126/science.2858129; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hayashi T, 1999, BRAIN RES, V832, P159, DOI 10.1016/S0006-8993(99)01409-2; Herdegen T, 1998, J NEUROSCI, V18, P5124, DOI 10.1523/JNEUROSCI.18-14-05124.1998; Ho PD, 1998, J BIOL CHEM, V273, P21730, DOI 10.1074/jbc.273.34.21730; Horstmann S, 1998, J NEUROSCI RES, V52, P483, DOI 10.1002/(SICI)1097-4547(19980515)52:4<483::AID-JNR12>3.3.CO;2-Y; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; KOMARA JS, 1986, ANN EMERG MED, V15, P384, DOI 10.1016/S0196-0644(86)80171-8; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; LAZZARINO G, 1992, FREE RADICAL BIO MED, V13, P489, DOI 10.1016/0891-5849(92)90143-5; LEI BP, 1994, STROKE, V25, P147, DOI 10.1161/01.STR.25.1.147; Lezoualc'h F, 1998, J NEUROSCI, V18, P3224; LI Y, 1997, P NATL ACAD SCI USA, V95, P7748; Li YH, 1997, NEURON, V19, P453, DOI 10.1016/S0896-6273(00)80953-8; Li YH, 1997, J CELL BIOL, V139, P1317, DOI 10.1083/jcb.139.5.1317; LiSmerin YY, 1996, J PHYSIOL-LONDON, V491, P121, DOI 10.1113/jphysiol.1996.sp021201; Love S, 1999, BRAIN PATHOL, V9, P119; Luo YQ, 1998, J BIOL CHEM, V273, P3756, DOI 10.1074/jbc.273.6.3756; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McGahon B, 1999, NEUROSCIENCE, V90, P1167, DOI 10.1016/S0306-4522(98)00528-4; MORIMOTO BH, 1990, NEURON, V5, P875, DOI 10.1016/0896-6273(90)90347-I; MURPHY TH, 1990, FASEB J, V4, P1624, DOI 10.1096/fasebj.4.6.2180770; MURPHY TH, 1989, NEURON, V2, P1547, DOI 10.1016/0896-6273(89)90043-3; Murray B, 1998, P NATL ACAD SCI USA, V95, P11975, DOI 10.1073/pnas.95.20.11975; Muthalif MM, 1998, P NATL ACAD SCI USA, V95, P12701, DOI 10.1073/pnas.95.21.12701; Park DS, 1998, J NEUROSCI, V18, P830; PAVLOVICSURJANCEV B, 1992, J NEUROCHEM, V59, P2134; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; RAO GN, 1994, J BIOL CHEM, V269, P32586; RATAN RR, 1994, J NEUROSCI, V14, P4385; Runden E, 1998, J NEUROSCI, V18, P7296; Sagara Y, 1998, J NEUROSCI, V18, P6662; Samanta S, 1998, J NEUROCHEM, V70, P2082; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; Tan SL, 1998, J NEUROCHEM, V71, P95; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; Tournier C, 1997, EUR J BIOCHEM, V244, P587, DOI 10.1111/j.1432-1033.1997.00587.x; WATANABE T, 1993, EUR J BIOCHEM, V212, P605, DOI 10.1111/j.1432-1033.1993.tb17699.x; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiao NQ, 1999, J NEUROCHEM, V72, P95, DOI 10.1046/j.1471-4159.1999.0720095.x; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zhang C, 1997, J BIOL CHEM, V272, P13397, DOI 10.1074/jbc.272.20.13397	68	469	488	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12200	12206		10.1074/jbc.275.16.12200	http://dx.doi.org/10.1074/jbc.275.16.12200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766856	hybrid			2022-12-27	WOS:000086695500091
J	Boone, AN; Chan, A; Kulpa, JE; Brownsey, RW				Boone, AN; Chan, A; Kulpa, JE; Brownsey, RW			Bimodal activation of acetyl-CoA carboxylase by glutamate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; DEPENDENT PROTEIN-KINASE; FATTY-ACID OXIDATION; RAT-LIVER; ADIPOSE-TISSUE; MALONYL-COA; MOLECULAR-CLONING; INSULIN-SECRETION; AMINO-ACIDS; 2 ISOFORMS	Acetyl-CoA carboxylase (ACC) catalyzes the formation of malonyl-CoA, an essential substrate for fatty acid biosynthesis and a potent inhibitor of fatty acid oxidation, Here, we provide evidence that glutamate may be a physiologically relevant activator of ACC, Glutamate induced the activation of both major isoforms of ACC, prepared from rat liver, heart, or white adipose tissue. In agreement with previous studies, a type 2A protein phosphatase contributed to the effects of glutamate on ACC. However, the protein phosphatase inhibitor microcystin LR did not abolish the effects of glutamate on ACC activity. Moreover, glutamate directly activated purified preparations of ACC when protein phosphatase activity was excluded. Phosphatase-independent ACC activation by glutamate was also reflected by polymerization of the enzyme as judged by size-exclusion chromatography, The sensitivity of ACC to direct activation by glutamate was diminished by treatment in vitro with AMP-activated protein kinase or cAMP-dependent protein kinase or by beta-adrenergic stimulation of intact adipose tissue. We conclude that glutamate, an abundant intracellular amino acid, induces ACC activation through complementary actions as a phosphatase activator and as a direct allosteric ligand for dephosphorylated ACC. This study supports the general hypothesis that amino acids fulfill important roles as signal molecules as well as intermediates in carbon and nitrogen metabolism.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Brownsey, RW (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, Rm 4027,Med Blok A,2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	rogerb@interchange.ubc.ca						ABUELHEIGA L, 1995, P NATL ACAD SCI USA, V92, P4011, DOI 10.1073/pnas.92.9.4011; AbuElheiga L, 1997, J BIOL CHEM, V272, P10669; ALLRED JB, 1980, J LIPID RES, V21, P488; Antinozzi PA, 1998, J BIOL CHEM, V273, P16146, DOI 10.1074/jbc.273.26.16146; AWAN MM, 1993, BIOCHEM J, V295, P61, DOI 10.1042/bj2950061; BAQUET A, 1993, EUR J BIOCHEM, V217, P1083, DOI 10.1111/j.1432-1033.1993.tb18340.x; Barber MC, 1998, BIOCHEM J, V333, P17, DOI 10.1042/bj3330017; Boone AN, 1999, BIOCHEM J, V341, P347, DOI 10.1042/0264-6021:3410347; BORTHWICK AC, 1987, BIOCHEM J, V241, P773, DOI 10.1042/bj2410773; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNSEY RW, 1977, BIOCHEM J, V168, P441, DOI 10.1042/bj1680441; BROWNSEY RW, 1979, BIOCHEM J, V184, P23, DOI 10.1042/bj1840023; Brownsey RW, 1997, BIOCHEM SOC T, V25, P1232, DOI 10.1042/bst0251232; BROWNSEY RW, 1999, CAN J DIABETES CARE, V23, pS7; BROWNSEY RW, 1987, ENZYMES B, V18, P123, DOI DOI 10.1016/S1874-6047(08)60256-5; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; CERSOSIMO E, 1986, AM J PHYSIOL, V250, pE248, DOI 10.1152/ajpendo.1986.250.3.E248; COHEN P, 1991, BIOCHIM BIOPHYS ACTA, V1094, P292, DOI 10.1016/0167-4889(91)90089-G; COX HL, 1998, AM J PHYSIOL, V274, pC206; DAVIES SP, 1992, EUR J BIOCHEM, V203, P615, DOI 10.1111/j.1432-1033.1992.tb16591.x; DAVIS EJ, 1973, EUR J BIOCHEM, V38, P86, DOI 10.1111/j.1432-1033.1973.tb03037.x; Dyck JRB, 1999, EUR J BIOCHEM, V262, P184, DOI 10.1046/j.1432-1327.1999.00371.x; FELLER DD, 1965, HDB PHYSL 5, P239; Fox Heather L., 1998, American Journal of Physiology, V275, pC1232; Gaussin V, 1996, BIOCHEM J, V316, P217, DOI 10.1042/bj3160217; GREENBAUM AL, 1971, ARCH BIOCHEM BIOPHYS, V143, P617, DOI 10.1016/0003-9861(71)90247-5; HA J, 1994, J BIOL CHEM, V269, P22162; HALESTRA.AP, 1973, BIOCHEM J, V132, P509, DOI 10.1042/bj1320509; HALESTRAP AP, 1974, BIOCHEM J, V142, P365, DOI 10.1042/bj1420365; Hardie DG, 1999, BIOCHEM J, V338, P717, DOI 10.1042/0264-6021:3380717; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; HERS HG, 1983, ANNU REV BIOCHEM, V52, P617, DOI 10.1146/annurev.bi.52.070183.003153; Kantor PF, 1999, AM J MED SCI, V318, P3, DOI 10.1097/00000441-199907000-00002; Khogali SEO, 1998, J MOL CELL CARDIOL, V30, P819, DOI 10.1006/jmcc.1998.0647; Kim KH, 1997, ANNU REV NUTR, V17, P77, DOI 10.1146/annurev.nutr.17.1.77; KOHANSKI RA, 1990, METHOD ENZYMOL, V184, P194; Krause U, 1996, J BIOL CHEM, V271, P16668, DOI 10.1074/jbc.271.28.16668; Lane M D, 1974, Curr Top Cell Regul, V8, P139; LOPASCHUK GD, 1994, CAN J PHYSIOL PHARM, V72, P1101, DOI 10.1139/y94-156; LOPEZCASILLAS F, 1988, P NATL ACAD SCI USA, V85, P5784, DOI 10.1073/pnas.85.16.5784; MATHIAS MM, 1981, LIPIDS, V16, P739, DOI 10.1007/BF02535341; MCGARRY JD, 1977, J CLIN INVEST, V60, P265, DOI 10.1172/JCI108764; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; MIEKLE AW, 1972, AM J PHYSIOL, V222, P1246; MOULE SK, 1992, BIOCHEM J, V283, P35, DOI 10.1042/bj2830035; OGIWARA H, 1978, EUR J BIOCHEM, V89, P33, DOI 10.1111/j.1432-1033.1978.tb20893.x; Patti ME, 1998, J CLIN INVEST, V101, P1519, DOI 10.1172/JCI1326; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; QUAYLE KA, 1993, BIOCHEM J, V292, P75, DOI 10.1042/bj2920075; RANDLE PJ, 1963, LANCET, V1, P785; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; SAHA AK, 1995, AM J PHYSIOL-ENDOC M, V269, pE283, DOI 10.1152/ajpendo.1995.269.2.E283; SONG CS, 1981, J BIOL CHEM, V256, P7786; Stumvoll M, 1999, KIDNEY INT, V55, P778, DOI 10.1046/j.1523-1755.1999.055003778.x; TAKAI T, 1988, J BIOL CHEM, V263, P2651; VOLPE JJ, 1976, PHYSIOL REV, V56, P339, DOI 10.1152/physrev.1976.56.2.339; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; Wang XM, 1998, BIOCHEM J, V334, P261, DOI 10.1042/bj3340261; Widmer J, 1996, BIOCHEM J, V316, P915, DOI 10.1042/bj3160915; Williamson J R, 1979, Methods Enzymol, V55, P200; Winder WW, 1997, J APPL PHYSIOL, V82, P219, DOI 10.1152/jappl.1997.82.1.219; Winder WW, 1998, ADV EXP MED BIOL, V441, P239; WINZ R, 1994, J BIOL CHEM, V269, P14438	64	24	26	1	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10819	10825		10.1074/jbc.275.15.10819	http://dx.doi.org/10.1074/jbc.275.15.10819			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753875	hybrid			2022-12-27	WOS:000086466600017
J	Korvatska, E; Henry, H; Mashima, Y; Yamada, M; Bachmann, C; Munier, FL; Schorderet, DF				Korvatska, E; Henry, H; Mashima, Y; Yamada, M; Bachmann, C; Munier, FL; Schorderet, DF			Amyloid and non-amyloid forms of 5q31-linked corneal dystrophy resulting from kerato-epithelin mutations at Arg-124 are associated with abnormal turnover of the protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; BETA-IG-H3; SEQUENCE; CDNA	Mutations in kerato-epithelin are responsible for a group of hereditary cornea-specific deposition diseases, 5q31-linked corneal dystrophies, These conditions are characterized by progressive accumulation of protein deposits of different ultrastructure, Herein, we studied the corneas with mutations at kerato-epithelin residue Arg-124 resulting in amyloid (R124C), non-amyloid (R124L), and a mixed pattern of deposition (R124H), We found that aggregated kerato-epithelin comprised all types of pathological deposits. Each mutation was associated with characteristic changes of protein turnover in corneal tissue. Amyloidogenesis in R124C corneas was accompanied by the accumulation of N-terminal kerato-epithelin fragments, whereby species of 44 kDa were the major constituents of amyloid fibrils, R124H corneas with prevailing non-amyloid inclusions showed accumulation of a new 66-kDa species altogether with the full-size 68-kDa form, Finally, in R124L cornea with non amyloid deposits, we found only the accumulation of the 68-kDa form. Two-dimensional gels revealed mutation-specific changes in the processing of the full-size protein in all affected corneas, It appears that substitutions at the same residue (Arg-124) result in cornea-specific deposition of kerato-epithelin via distinct aggregation pathways each involving altered turnover of the protein in corneal tissue.	CHU Vaudois, Div Med Genet, CH-1011 Lausanne, Switzerland; CHU Vaudois, Clin Chem Lab, CH-1011 Lausanne, Switzerland; Keio Univ, Sch Med, Dept Ophthalmol, Shinjuku Ku, Tokyo 1608582, Japan; Jules Gonin Ophthalm Hosp, Dept Ophthalmol, CH-1004 Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Keio University	Korvatska, E (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Stanley Hall SM03, Berkeley, CA 94720 USA.							Benson MD, 1996, CIBA F SYMP, V199, P104; BJELLQVIST B, 1994, ELECTROPHORESIS, V15, P529, DOI 10.1002/elps.1150150171; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; ESCRIBANO J, 1994, J CELL PHYSIOL, V160, P511, DOI 10.1002/jcp.1041600314; Hashimoto K, 1997, BBA-MOL CELL RES, V1355, P303, DOI 10.1016/S0167-4889(96)00147-4; Henry H, 1997, J LAB CLIN MED, V129, P412, DOI 10.1016/S0022-2143(97)90074-3; Henry H, 1999, CLIN CHEM, V45, P1408; Klintworth GK, 1998, AM J PATHOL, V152, P743; Konishi M, 1997, CORNEA, V16, P635; Konishi M, 1999, CORNEA, V18, P424, DOI 10.1097/00003226-199907000-00006; Korvatska E, 1999, INVEST OPHTH VIS SCI, V40, P2213; Korvatska E, 1998, AM J HUM GENET, V62, P320, DOI 10.1086/301720; LAURIERE M, 1993, ANAL BIOCHEM, V212, P206, DOI 10.1006/abio.1993.1313; Mashima Y, 1999, ARCH OPHTHALMOL-CHIC, V117, P90; Munier FL, 1997, NAT GENET, V15, P247, DOI 10.1038/ng0397-247; ROSENWASSER GOD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1546, DOI 10.1001/archopht.1993.01090110112035; SIPE JD, 1994, CRIT REV CL LAB SCI, V31, P325, DOI 10.3109/10408369409084679; SKONIER J, 1994, DNA CELL BIOL, V13, P571, DOI 10.1089/dna.1994.13.571; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; Streeten BW, 1999, ARCH OPHTHALMOL-CHIC, V117, P67; Takacs L, 1998, EXP EYE RES, V66, P739, DOI 10.1006/exer.1998.0471	21	106	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11465	11469		10.1074/jbc.275.15.11465	http://dx.doi.org/10.1074/jbc.275.15.11465			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753964	hybrid			2022-12-27	WOS:000086466600106
J	Ohtani, K; Iwanaga, R; Arai, M; Huang, YP; Matsumura, Y; Nakamura, M				Ohtani, K; Iwanaga, R; Arai, M; Huang, YP; Matsumura, Y; Nakamura, M			Cell type-specific E2F activation and cell cycle progression induced by the oncogene product Tax of human T-cell leukemia virus type I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; ACTING TRANSCRIPTIONAL ACTIVATOR; DEPENDENT KINASE-ACTIVITY; RECEPTOR GENE-EXPRESSION; HTLV-I; INTERLEUKIN-2 RECEPTOR; KAPPA-B; 21-BASE-PAIR ENHANCER; FUNCTIONAL-ANALYSIS; HUMAN-LYMPHOCYTES	The transactivator protein Tax of human T-cell leukemia virus type I plays an important role in the development of adult T-cell leukemia probably through modulation of growth regulatory molecules including p16(INK4a). The molecular mechanism of leukemogenesis induced by Tax has yet to be elucidated. We analyzed Tax function in the cell cycle using an interleukin-2 (IL-2)-dependent human T-cell line (Kit 225) that can undergo cell cycle arrest at G(0)/G(1) phase by deprivation of IL-2. Tax activated endogenous E2F activity in EL-2-starved Kit 225 cells, resulting in activation of E2F site-carrying promoters of genes involved in G(1) to S phase transition in a cell type-dependent and p16(INK4a)-independent manner, The ability of Tax mutants to activate E2F coincided with that to activate nuclear factors KB and AT, sole expression of which, however, did not activate E2F, suggesting involvement of another pathway in activation of E2F, Introduction of Tax by a recombinant adenovirus induced cell cycle progression to G(2)/M phase in resting Kit 225 cells accompanied by endogenous cyclin D2 gene expression, Similarly, Tax-induced cell cycle progression was seen with peripheral blood lymphocytes prestimulated with phytohemagglutinin, Analyses with Tax mutants did not allow Tax-induced cell cycle progression to be differentiated from Tax-dependent activation of E2F, suggesting that Tax induces cell cycle progression presumably through activation of E2F. Nevertheless, infection with an E2F1-expressing virus, which is sufficient for induction of S phase in serum-starved fibroblasts, was not sufficient for either E2F activation or cell cycle progression in IL-2-starved Kit 225 cells, implying differential regulation of E2F activation and cell cycle progression in T-cells that is activated by Tax.	Tokyo Med & Dent Univ, Sch Med, Human Gene Sci Ctr, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Sch Med, Dept Microbiol, Bunkyo Ku, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Nakamura, M (corresponding author), Tokyo Med & Dent Univ, Sch Med, Human Gene Sci Ctr, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	naka.gene@cmn.tmd.ac.jp						Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; AKAGI T, 1995, BLOOD, V86, P4243, DOI 10.1182/blood.V86.11.4243.bloodjournal86114243; Akagi T, 1996, ONCOGENE, V12, P1645; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DURO D, 1995, ONCOGENE, V11, P21; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GESSAIN A, 1985, LANCET, V2, P407; Good L, 1997, J BIOL CHEM, V272, P1425, DOI 10.1074/jbc.272.3.1425; Good LF, 1996, EMBO J, V15, P3744, DOI 10.1002/j.1460-2075.1996.tb00744.x; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; Higashimura N, 1996, JPN J CANCER RES, V87, P227, DOI 10.1111/j.1349-7006.1996.tb00210.x; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; HIRAI H, 1992, ONCOGENE, V7, P1737; HORI T, 1987, BLOOD, V70, P1069; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; ISRAEL DI, 1989, NUCLEIC ACIDS RES, V17, P4589, DOI 10.1093/nar/17.12.4589; Iwanaga Y, 1999, J VIROL, V73, P1271, DOI 10.1128/JVI.73.2.1271-1277.1999; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; LEE B, 1989, TOHOKU J EXP MED, V157, P1, DOI 10.1620/tjem.157.1; Lemasson I, 1998, J BIOL CHEM, V273, P23598, DOI 10.1074/jbc.273.36.23598; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LI M, 1993, MOL CELL BIOL, V13, P6490, DOI 10.1128/MCB.13.10.6490; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; MAO L, 1995, CANCER RES, V55, P2995; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; Matsumoto K, 1997, J VIROL, V71, P4445, DOI 10.1128/JVI.71.6.4445-4451.1997; MCGUIRE KL, 1993, J VIROL, V67, P1590, DOI 10.1128/JVI.67.3.1590-1599.1993; MINOWADA J, 1972, J NATL CANCER I, V49, P891; MIURA S, 1991, MOL CELL BIOL, V11, P1313, DOI 10.1128/MCB.11.3.1313; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; MORI N, 1995, J RHEUMATOL, V22, P2049; Mori N, 1997, EUR J HAEMATOL, V58, P114; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NAKAMURA M, 1989, NUCLEIC ACIDS RES, V17, P5207, DOI 10.1093/nar/17.13.5207; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OHBO K, 1995, J BIOL CHEM, V270, P7479, DOI 10.1074/jbc.270.13.7479; OHTANI K, 1987, EMBO J, V6, P389, DOI 10.1002/j.1460-2075.1987.tb04767.x; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ohtani K, 1998, J BIOL CHEM, V273, P14119, DOI 10.1074/jbc.273.23.14119; Ohtani K, 1998, ONCOGENE, V17, P1777, DOI 10.1038/sj.onc.1202105; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; Ohtani K, 1999, ONCOGENE, V18, P2299, DOI 10.1038/sj.onc.1202544; OSAME M, 1986, LANCET, V1, P1031; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POTEAT HT, 1990, J VIROL, V64, P1264, DOI 10.1128/JVI.64.3.1264-1270.1990; QUELLE DE, 1995, CELL, V83, P993; Rivera I, 1998, J BIOL CHEM, V273, P22382, DOI 10.1074/jbc.273.35.22382; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; Schmitt I, 1998, J VIROL, V72, P633, DOI 10.1128/JVI.72.1.633-640.1998; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TAN TH, 1989, MOL CELL BIOL, V9, P1733, DOI 10.1128/MCB.9.4.1733; Tanaka N, 1997, EUR J IMMUNOL, V27, P834; Tanaka Y, 1996, J VIROL, V70, P8508, DOI 10.1128/JVI.70.12.8508-8517.1996; UCHIUMI F, 1992, MOL CELL BIOL, V12, P3784, DOI 10.1128/MCB.12.9.3784; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	88	58	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11154	11163		10.1074/jbc.275.15.11154	http://dx.doi.org/10.1074/jbc.275.15.11154			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753922	hybrid			2022-12-27	WOS:000086466600064
J	Zhao, AZ; Shinohara, MM; Huang, DM; Shimizu, M; Eldar-Finkelman, H; Krebs, EG; Beavo, JA; Bornfeldt, KE				Zhao, AZ; Shinohara, MM; Huang, DM; Shimizu, M; Eldar-Finkelman, H; Krebs, EG; Beavo, JA; Bornfeldt, KE			Leptin induces insulin-like signaling that antagonizes cAMP elevation by glucagon in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; RAT HEPATOCYTES; OBESE GENE; PHOSPHODIESTERASE 3B; GLYCOGEN-SYNTHESIS; C2C12 MYOTUBES; DIABETIC MICE; BODY-WEIGHT; FOOD-INTAKE; OB PROTEIN	Although many effects of leptin are mediated through the central nervous system, leptin can regulate metabolism through a direct action on peripheral tissues, such as fat and liver. We show here that leptin, at physiological concentrations, acts through an intracellular signaling pathway similar to that activated by insulin in isolated primary rat hepatocytes, This pathway involves stimulation of phosphatidylinositol 3-kinase (PI3K) binding to insulin receptor substrate-1 and insulin receptor substrate-a, activation of PI3K and protein kinase B (AKT), and PI3K-dependent activation of cyclic nucleotide phosphodiesterase 3B, a cAMP-degrading enzyme. One important function of this signaling pathway is to reduce levels of cAMP, because leptin-mediated activation of both protein kinase B and phosphodiesterase 3B is most marked following elevation of cAMP by glucagon, and because leptin suppresses glucagon-induced cAMP elevation in a PI3K-dependent manner. There is little or no expression of the long form leptin receptor in primary rat hepatocytes, and these signaling events are probably mediated through the short forms of the leptin receptor. Thus, leptin, like insulin, induces an intracellular signaling pathway in hepatocytes that culminates in cAMP degradation and an antagonism of the actions of glucagon.	Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Bornfeldt, KE (corresponding author), Univ Washington, Sch Med, Dept Pathol, Box 357470, Seattle, WA 98195 USA.	bornf@u.washington.edu	Eldar-Finkelman, Hagit/AAF-8329-2019; Bornfeldt, Karin/AAI-2241-2019	Eldar-Finkelman, Hagit/0000-0002-8460-9686; Bornfeldt, Karin/0000-0001-9208-6523; Shinohara, Michi/0000-0003-1388-5330	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021723, P30DK017047, R01DK042528] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-42528, P30 DK17047, DK-21723] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aiston S, 1999, DIABETES, V48, P15, DOI 10.2337/diabetes.48.1.15; Barroso I, 1999, J BIOL CHEM, V274, P17997, DOI 10.1074/jbc.274.25.17997; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Bennett BD, 1996, CURR BIOL, V6, P1170, DOI 10.1016/S0960-9822(02)70684-2; Berti L, 1997, DIABETOLOGIA, V40, P606, DOI 10.1007/s001250050722; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; Bouloumie A, 1998, CIRC RES, V83, P1059, DOI 10.1161/01.RES.83.10.1059; BOYLAN JM, 1994, AM J PHYSIOL-GASTR L, V267, pG1078, DOI 10.1152/ajpgi.1994.267.6.G1078; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Cherrington AD, 1999, DIABETES, V48, P1198, DOI 10.2337/diabetes.48.5.1198; Chinookoswong N, 1999, DIABETES, V48, P1487, DOI 10.2337/diabetes.48.7.1487; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; Cohen SM, 1998, P NATL ACAD SCI USA, V95, P7385, DOI 10.1073/pnas.95.13.7385; Coleman RA, 1999, DIABETOLOGIA, V42, P639, DOI 10.1007/s001250051210; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Degerman E, 1997, J BIOL CHEM, V272, P6823, DOI 10.1074/jbc.272.11.6823; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; Giacca A, 1997, ENDOCRINOLOGY, V138, P999, DOI 10.1210/en.138.3.999; GLINSMANN WH, 1968, AM J PHYSIOL, V215, P553, DOI 10.1152/ajplegacy.1968.215.3.553; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hoggard N, 1997, BIOCHEM BIOPH RES CO, V232, P383, DOI 10.1006/bbrc.1997.6245; Ito Y, 1997, BIOCHEM J, V324, P379, DOI 10.1042/bj3240379; Kamohara S, 1997, NATURE, V389, P374, DOI 10.1038/38717; Kellerer M, 1997, DIABETOLOGIA, V40, P1358, DOI 10.1007/s001250050832; Kim YB, 1998, DIABETES, V47, pA317; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; KRODER G, 1996, EXP CLIN ENDOCR S2, V104, P66; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Levin N, 1996, P NATL ACAD SCI USA, V93, P1726, DOI 10.1073/pnas.93.4.1726; LEWIS GF, 1997, AM J PHYSIOL, V272, pE372; Liu LS, 1998, J BIOL CHEM, V273, P31160, DOI 10.1074/jbc.273.47.31160; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; LOTEN EG, 1970, BIOCHEM J, V120, P187, DOI 10.1042/bj1200187; Manganiello VC, 1996, CURR TOP CELL REGUL, V34, P63, DOI 10.1016/S0070-2137(96)80003-3; Mantzoros CS, 1998, CLIN ENDOCRINOL, V49, P551, DOI 10.1046/j.1365-2265.1998.00571.x; Muller G, 1997, J BIOL CHEM, V272, P10585, DOI 10.1074/jbc.272.16.10585; Nemecz M, 1999, HEPATOLOGY, V29, P166, DOI 10.1002/hep.510290110; O'Doherty RM, 1999, AM J PHYSIOL-ENDOC M, V277, pE544, DOI 10.1152/ajpendo.1999.277.3.E544; Peak M, 1998, DIABETOLOGIA, V41, P16, DOI 10.1007/s001250050861; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Rossetti L, 1997, J BIOL CHEM, V272, P27758, DOI 10.1074/jbc.272.44.27758; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SIDHU JS, 1993, ARCH BIOCHEM BIOPHYS, V301, P103, DOI 10.1006/abbi.1993.1121; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Stehling O, 1996, AM J PHYSIOL-REG I, V271, pR1770, DOI 10.1152/ajpregu.1996.271.6.R1770; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; STRICKLAND WG, 1980, DIABETES, V29, P617, DOI 10.2337/diabetes.29.8.617; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Turner SM, 1998, DIABETES, V47, pA279; UNGER RH, 1992, WILLIAMS TXB ENDOCRI, P1255; Wang MY, 1996, FEBS LETT, V392, P87, DOI 10.1016/0014-5793(96)00790-9; Wang YP, 1997, J BIOL CHEM, V272, P16216, DOI 10.1074/jbc.272.26.16216; White David W., 1996, Cytokine and Growth Factor Reviews, V7, P303, DOI 10.1016/S1359-6101(96)00040-8; Wijkander J, 1998, ENDOCRINOLOGY, V139, P219, DOI 10.1210/en.139.1.219; Woods SC, 1998, SCIENCE, V280, P1378, DOI 10.1126/science.280.5368.1378; YAN C, 1995, P NATL ACAD SCI USA, V92, P9677, DOI 10.1073/pnas.92.21.9677; Yaspelkis BB, 1999, METABOLISM, V48, P671, DOI 10.1016/S0026-0495(99)90070-7; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhao AZ, 1998, J CLIN INVEST, V102, P869, DOI 10.1172/JCI3920	63	201	210	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11348	11354		10.1074/jbc.275.15.11348	http://dx.doi.org/10.1074/jbc.275.15.11348			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753948	hybrid			2022-12-27	WOS:000086466600090
J	Lindquist, JM; Fredriksson, JM; Rehnmark, S; Cannon, B; Nedergaard, J				Lindquist, JM; Fredriksson, JM; Rehnmark, S; Cannon, B; Nedergaard, J			beta(3)- and alpha(1)-adrenergic Erk1/2 activation is Src- but not G(i)-mediated in brown adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; KINASE PATHWAY; MAP KINASE; FAT-CELLS; ADRENERGIC-RECEPTOR; SIGNALING PATHWAY; PHOSPHATIDYLINOSITOL 3-KINASE; BETA(2)-ADRENERGIC RECEPTOR; BETA-3-ADRENERGIC RECEPTOR; MOLECULAR CHARACTERIZATION	novel signaling pathway for mediation of beta(3)-adrenergic activation of the mitogen-activated protein kinases Erk1/2 (associated with proliferation, differentiation, and apoptosis) has recently been proposed, which implies mediation via constitutively coupled G(i)-proteins and C beta gamma-subunits, distinct from the classical cAMP pathway of p-adrenergic stimulation. To verify the significance of this pathway in cells in primary cultures that entopically express beta(3)-adrenoreceptors, we examined the functionality of this pathway in cultured brown adipocytes. Norepinephrine activated Erk1/2 via both beta(3) receptors and a, receptors but not via ct, receptors. Forskolin induced Erk1/2 activation similarly to beta(3) activation, indicating cAMP-mediation; this induction could be inhibited with H89, implying protein kinase A mediation. The G(i)-pathway was functional in these cells, as pertussis toxin increased agonist-induced cAMP accumulation. However, pertussis toxin was unable to affect adrenergically induced Erk1/2 activation. Also, wortmannin was without effect, implying that G beta gamma activation of the phosphatidylinositol 3-kinase pathway was not involved. PP1/2, which inhibits Src, abolished both beta(3)- and alpha(1)-induced Erk1/2 activation. Thus, the proposed novel G(i) pathway for beta(3) mediation is not universal, because it is not functional in the untransformed primary cell culture system with entopically expressed beta(3) receptors examined here. Here, the beta(3) signal is mediated classically via cAMP/protein kinase A. beta(3) and alpha(1) signals converge at Src, which thus mediates Erk1/2 activation in both pathways.	Univ Stockholm, Arrhenius Labs F3, Wenner Gren Inst, SE-10691 Stockholm, Sweden	Stockholm University	Lindquist, JM (corresponding author), Univ Stockholm, Arrhenius Labs F3, Wenner Gren Inst, SE-10691 Stockholm, Sweden.		Nedergaard, Jan/A-1706-2010; Nedergaard, Jan/Q-8286-2019; Cannon, Barbara/B-3089-2016	Cannon, Barbara/0000-0001-6594-2363; Nedergaard, Jan/0000-0003-2070-1587				Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; ALBLAS J, 1993, J BIOL CHEM, V268, P22235; Bengtsson T, 2000, BIOCHEM J, V347, P643, DOI 10.1042/0264-6021:3470643; Bengtsson T, 1996, J BIOL CHEM, V271, P33366, DOI 10.1074/jbc.271.52.33366; Betuing S, 1997, BIOCHEM BIOPH RES CO, V235, P765, DOI 10.1006/bbrc.1997.6887; BHAT NR, 1995, J CELL PHYSIOL, V165, P417, DOI 10.1002/jcp.1041650223; Bogoyevitch MA, 1996, BIOCHEM J, V314, P115, DOI 10.1042/bj3140115; BOULOUMIE A, 1994, J BIOL CHEM, V269, P30254; Bronnikov G, 1999, ENDOCRINOLOGY, V140, P4185, DOI 10.1210/en.140.9.4185; BRONNIKOV G, 1992, J BIOL CHEM, V267, P2006; Budd DC, 1999, J BIOL CHEM, V274, P12355, DOI 10.1074/jbc.274.18.12355; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHAUDHRY A, 1994, CELL SIGNAL, V6, P457, DOI 10.1016/0898-6568(94)90093-0; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DAngelo G, 1997, J CELL BIOCHEM, V67, P353, DOI 10.1002/(SICI)1097-4644(19971201)67:3<353::AID-JCB7>3.3.CO;2-2; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; FAURE M, 1995, MOL BIOL CELL, V6, P1025, DOI 10.1091/mbc.6.8.1025; Fredriksson JM, 2000, J BIOL CHEM, V275, P13802, DOI 10.1074/jbc.275.18.13802; Gerhardt CC, 1999, MOL PHARMACOL, V55, P255, DOI 10.1124/mol.55.2.255; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOPECKY J, 1990, J BIOL CHEM, V265, P22204; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Lindquist JM, 1998, J BIOL CHEM, V273, P30147, DOI 10.1074/jbc.273.46.30147; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Melien O, 1998, J CELL PHYSIOL, V175, P348, DOI 10.1002/(SICI)1097-4652(199806)175:3<348::AID-JCP13>3.0.CO;2-1; MOHELL N, 1989, BIOCHEM J, V261, P401, DOI 10.1042/bj2610401; Muthalif MM, 1996, J BIOL CHEM, V271, P30149, DOI 10.1074/jbc.271.47.30149; NAHMIAS C, 1991, EMBO J, V10, P3721, DOI 10.1002/j.1460-2075.1991.tb04940.x; NECHAD M, 1987, AM J PHYSIOL, V253, pC889, DOI 10.1152/ajpcell.1987.253.6.C889; NECHAD M, 1983, EXP CELL RES, V149, P105, DOI 10.1016/0014-4827(83)90384-1; Nisoli E, 1996, MOL PHARMACOL, V49, P7; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; Penn RB, 1999, J PHARMACOL EXP THER, V288, P428; REHNMARK S, 1990, J BIOL CHEM, V265, P16464; Romanelli A, 1997, METABOLISM, V46, P548, DOI 10.1016/S0026-0495(97)90193-1; Sawada T, 1997, ENDOCRINOLOGY, V138, P5275, DOI 10.1210/en.138.12.5275; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; Shimizu Y, 1997, ENDOCRINOLOGY, V138, P248, DOI 10.1210/en.138.1.248; Soeder KJ, 1999, J BIOL CHEM, V274, P12017, DOI 10.1074/jbc.274.17.12017; Spector MS, 1997, MOL CELL BIOL, V17, P3556, DOI 10.1128/MCB.17.7.3556; STANDAERT ML, 1995, BIOCHEM BIOPH RES CO, V209, P1082, DOI 10.1006/bbrc.1995.1608; Sugden PH, 1997, CELL SIGNAL, V9, P337, DOI 10.1016/S0898-6568(96)00191-X; UEHARA T, 1995, BIOCHEM BIOPH RES CO, V210, P574, DOI 10.1006/bbrc.1995.1698; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wan Y, 1998, J BIOL CHEM, V273, P14533, DOI 10.1074/jbc.273.23.14533; Williams NG, 1998, J BIOL CHEM, V273, P24624, DOI 10.1074/jbc.273.38.24624; Yarwood SJ, 1996, BIOCHEM BIOPH RES CO, V224, P734, DOI 10.1006/bbrc.1996.1092; Zhao J, 1998, AM J PHYSIOL-REG I, V275, pR2002, DOI 10.1152/ajpregu.1998.275.6.R2002; Zhao J, 1997, J BIOL CHEM, V272, P32847, DOI 10.1074/jbc.272.52.32847; Zhong HY, 1999, J NEUROCHEM, V72, P2388, DOI 10.1046/j.1471-4159.1999.0722388.x; Zou YZ, 1999, J BIOL CHEM, V274, P9760, DOI 10.1074/jbc.274.14.9760	61	65	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22670	22677		10.1074/jbc.M909093199	http://dx.doi.org/10.1074/jbc.M909093199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10770951	hybrid			2022-12-27	WOS:000088419400013
J	Cervellera, M; Raschella, G; Santilli, G; Tanno, B; Ventura, A; Mancini, C; Sevignani, C; Calabretta, B; Sala, A				Cervellera, M; Raschella, G; Santilli, G; Tanno, B; Ventura, A; Mancini, C; Sevignani, C; Calabretta, B; Sala, A			Direct transactivation of the anti-apoptotic gene apolipoprotein J (Clusterin) by B-MYB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATION; NECROSIS-FACTOR-ALPHA; V-MYB; SULFATED GLYCOPROTEIN-2; NEUROBLASTOMA-CELLS; SGP-2 CLUSTERIN; S-PHASE; C-MYB; EXPRESSION; TRANSCRIPTION	B-MYB is a ubiquitously expressed transcription factor involved in the regulation of cell survival, proliferation, and differentiation. In an attempt to isolate B-MYB-regulated genes that may explain the role of B-MYB in cellular processes, representational difference analysis was performed in neuroblastoma cell lines with different levels of B-MYB expression. One of the genes, the mRNA levels of which were enhanced in B-MYB expressing cells, was ApoJ/Clusterin(SGP-2/TRMP-2) (ApoJ/Clusterin), previously implicated in regulation of apoptosis and tumor progression. Here we show that the human ApoJ/Clusterin gene contains a Myb binding site in its 5' flanking region, which interacts with bacterially synthesized B-MYB protein and mediates B-MYB-dependent transactivation of the ApoJ/Clusterin promoter in transient transfection assays. Endogenous ApoJ/Clusterin expression is induced in mammalian cell lines following transient transfection of a B-MYB cDNA, Blockage of secreted clusterin by a monoclonal antibody results in increased apoptosis of neuroblastoma cells exposed to the chemotherapeutic drug doxorubicin. Thus, activation of ApoJ/Clusterin by B-MYB may be an important step in the regulation of apoptosis in normal and diseased cells.	Consorzio Mario Negri Sud, Lab Mol Pharmacol & Pathol, I-66030 Santa Maria Imbaro, Italy; ENEA, Sect Toxicol & Biomed Sci, I-00060 Rome, Italy; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Immunol Microbiol, Philadelphia, PA 19107 USA	Consorzio Mario Negri Sud; Italian National Agency New Technical Energy & Sustainable Economics Development; Jefferson University	Sala, A (corresponding author), Consorzio Mario Negri Sud, Lab Mol Pharmacol & Pathol, I-66030 Santa Maria Imbaro, Italy.		sala, arturo/C-4959-2008	Sala, Arturo/0000-0002-2841-7866; Ventura, Andrea/0000-0003-4320-9907				Ansieau S, 1997, J MOL MED-JMM, V75, P815, DOI 10.1007/s001090050170; ARSURA M, 1992, BLOOD, V79, P2708; Bailey R, 1999, MOL CELL ENDOCRINOL, V151, P17, DOI 10.1016/S0303-7207(99)00016-7; Bies J, 1996, ONCOGENE, V12, P355; Burk O, 1997, EMBO J, V16, P1371, DOI 10.1093/emboj/16.6.1371; Claas C, 1998, J CELL BIOL, V141, P267, DOI 10.1083/jcb.141.1.267; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; Fulda S, 1997, CANCER RES, V57, P3823; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; Grassilli E, 1999, CANCER RES, V59, P2451; Hibi K, 1998, CANCER RES, V58, P5690; Ho SM, 1998, AM J PATHOL, V153, P131, DOI 10.1016/S0002-9440(10)65553-8; Humphreys D, 1997, BIOCHEMISTRY-US, V36, P15233, DOI 10.1021/bi9703507; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; KADOMATSU K, 1993, CANCER RES, V53, P1480; Koch-Brandt C, 1996, Prog Mol Subcell Biol, V16, P130; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; ONeill MJ, 1997, NUCLEIC ACIDS RES, V25, P2681, DOI 10.1093/nar/25.13.2681; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; Raschella G, 1999, CANCER RES, V59, P3365; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; Robinson C, 1996, ONCOGENE, V12, P1855; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sala A, 1999, J CELL PHYSIOL, V179, P245; Salomoni P, 1997, P NATL ACAD SCI USA, V94, P3296, DOI 10.1073/pnas.94.7.3296; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; Saville MK, 1998, ADV CANCER RES, V72, P109; SENSIBAR JA, 1995, CANCER RES, V55, P2431; Sintich SM, 1999, PROSTATE, V39, P87; Sitzmann J, 1996, ONCOGENE, V12, P1889; Steinberg J, 1997, CLIN CANCER RES, V3, P1707; SZALA S, 1990, P NATL ACAD SCI USA, V87, P6833, DOI 10.1073/pnas.87.17.6833; TASHIRO S, 1995, ONCOGENE, V10, P1699; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; Viard I, 1999, J INVEST DERMATOL, V112, P290, DOI 10.1046/j.1523-1747.1999.00531.x; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WONG P, 1994, EUR J BIOCHEM, V221, P917, DOI 10.1111/j.1432-1033.1994.tb18807.x; Yang CR, 1999, NUCLEIC ACIDS RES, V27, P2165, DOI 10.1093/nar/27.10.2165; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	47	94	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21055	21060		10.1074/jbc.M002055200	http://dx.doi.org/10.1074/jbc.M002055200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10770937	Green Published, hybrid			2022-12-27	WOS:000088230600014
J	Feltzer, RE; Gray, RD; Dean, WL; Pierce, WM				Feltzer, RE; Gray, RD; Dean, WL; Pierce, WM			Alkaline proteinase inhibitor of Pseudomonas aeruginosa - Interaction of native and N-terminally truncated inhibitor proteins with Pseudomonas metalloproteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERRATIA-MARCESCENS METALLOPROTEASE; ERWINIA-CHRYSANTHEMI; COMPUTER-SIMULATION; CRYSTAL-STRUCTURE; PROTEASE; ASSOCIATION; ELASTASE; KINETICS; BINDING; COMPLEX	The apr locus of Pseudomonas aeruginosa encodes alkaline proteinase (APR), a member of the metzincin metalloendopeptidase superfamily, and an 11.4-kDa alkaline proteinase inhibitor (APRin), We describe here the expression in Escherichia coli and characterization of full-length and N-terminally truncated APRin proteins. Fluorescence and circular dichroism spectra indicated that the recombinant proteins were folded into native-like structures. Analytical ultracentrifugation showed that APRin was monomeric and formed a 1:1 complex with APR. Binding of wild-type APRin to APR occurred with association (k(on)) and dissociation (k(off)) rate constants of 0.29 +/- 0.06 x 10(6) M-1 s(-1) and 1.15 +/- 0.08 x 10(-6) s(-1) to give an equilibrium dissociation constant (K-D) of similar to 4 x 10(-12) M (25 degrees C, pH 7.0, ionic strength 2.4 M). The association rate decreased by similar to 2-fold in 20% glycerol and increased by similar to 3-fold in 0.1 M NaCl. The glycerol effect suggests a diffusion-limited reaction, and the small salt effect indicates that electrostatic interactions contribute little to binding. Deletion of residues 1-10, 1-6, or 6-10 abolished inhibition, and deletion of residues 1-2, 1-3, 1-4, and 1-5 resulted in a progressively decreased affinity of APRin for APR (K-D = 0.12 mu M for the Delta(1-5) mutant). Substitution of APRin residues 6-10 with a (Gly)(5) or (Pro)(5) linker restored inhibitory activity of the Delta(6-10) mutant but with a 100- and 50-fold reduction in K-D. Log k(on) for the full-length and truncated inhibitors correlated with the solvent-accessible surface area of their N-terminal regions, suggesting that increased interactions and/or desolvation of these residues in the transition state for binding contribute to the enhanced association rate. Treatment of APRin with pseudolysin, also secreted by P. aeruginosa, resulted in removal of residues 1-5. APRin was neither an inhibitor nor a substrate of other metzincins, including collagenase or gelatinases A or B.	Univ Louisville, Sch Med, Dept Biochem & Mol Biol, Louisville, KY 40292 USA; Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA; Univ Louisville, Sch Med, Dept Ophthalmol & Visual Sci, Louisville, KY 40292 USA	University of Louisville; University of Louisville; University of Louisville	Gray, RD (corresponding author), Univ Louisville, Sch Med, Dept Biochem & Mol Biol, Louisville, KY 40292 USA.				NCRR NIH HHS [1 S10 RR11368-01A1] Funding Source: Medline; NEI NIH HHS [EY09722] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR011368] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY009722] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Bae KH, 1998, ARCH BIOCHEM BIOPHYS, V352, P37, DOI 10.1006/abbi.1997.0561; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BAUMANN U, 1994, J MOL BIOL, V242, P244, DOI 10.1006/jmbi.1994.1576; BAUMANN U, 1995, J MOL BIOL, V248, P653, DOI 10.1006/jmbi.1995.0249; BURNS FR, 1990, ANTIMICROB AGENTS CH, V34, P2065, DOI 10.1128/AAC.34.11.2065; CREIGHTON TE, 1993, PROTEINS STRUCTURE M, P142; DUONG F, 1992, GENE, V121, P47, DOI 10.1016/0378-1119(92)90160-Q; Elcock AH, 1999, J MOL BIOL, V291, P149, DOI 10.1006/jmbi.1999.2919; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; Gabdoulline RR, 1997, BIOPHYS J, V72, P1917, DOI 10.1016/S0006-3495(97)78838-6; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRAY RD, 1992, EXP EYE RES S1, V55, P74; GROBELNY D, 1992, BIOCHEMISTRY-US, V31, P7152, DOI 10.1021/bi00146a017; GUTFREUND H, 1995, KINETICS LIFE SCI, P270; GUZZO J, 1991, J BACTERIOL, V173, P5290, DOI 10.1128/jb.173.17.5290-5297.1991; HECK LW, 1986, INFECT IMMUN, V54, P149, DOI 10.1128/IAI.54.1.149-153.1986; Homma J. Y., 1985, BACTERIAL ENZYMES VI, P41; HORVAT RT, 1988, INFECT IMMUN, V56, P2925, DOI 10.1128/IAI.56.11.2925-2932.1988; HOWE TR, 1984, INFECT IMMUN, V43, P1058, DOI 10.1128/IAI.43.3.1058-1063.1984; HUNG T, 1990, NUCLEIC ACIDS RES, V18, P4953, DOI 10.1093/nar/18.16.4953; JOCELYN PC, 1987, METHOD ENZYMOL, V143, P44; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; KERNACKI KA, 1995, INVEST OPHTH VIS SCI, V36, P1371; KOKLITIS PA, 1991, BIOCHEM J, V276, P217, DOI 10.1042/bj2760217; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P208; LETOFFE S, 1989, MOL MICROBIOL, V3, P79, DOI 10.1111/j.1365-2958.1989.tb00106.x; MAEDA H, 1995, METHOD ENZYMOL, V248, P395; Maniatis T., 1989, MOL CLONING LABORATO, P21; MOLLA A, 1989, J BIOL CHEM, V264, P10589; MORIHARA K, 1963, BIOCHIM BIOPHYS ACTA, V73, P113; MORIHARA K, 1965, J BIOL CHEM, V240, P3295; MORIHARA K, 1967, ADV ENZYMOL RELAT AR, V35, P179; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; NORTHRUP SH, 1993, BIOCHEMISTRY-US, V32, P6613, DOI 10.1021/bi00077a014; NORTHRUP SH, 1992, P NATL ACAD SCI USA, V89, P3338, DOI 10.1073/pnas.89.8.3338; Pollack M, 1998, INFECT DIS, P1824; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; Schreiber G, 1996, NAT STRUCT BIOL, V3, P427, DOI 10.1038/nsb0596-427; SHAGGER H, 1987, ANAL BIOCHEM, V166, P368; SHIBUYA Y, 1991, BIOCHIM BIOPHYS ACTA, V1077, P316, DOI 10.1016/0167-4838(91)90546-C; STOCKER W, 1995, PROTEIN SCI, V4, P823; STONE SR, 1989, BIOCHEMISTRY-US, V28, P6857, DOI 10.1021/bi00443a012; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TWINING SS, 1993, INVEST OPHTH VIS SCI, V34, P2699; WEINGARTEN H, 1986, BIOCHEM BIOPH RES CO, V139, P1184, DOI 10.1016/S0006-291X(86)80302-3; Winzor DJ, 1998, BIOCHEMISTRY-US, V37, P2226, DOI 10.1021/bi972211v	47	30	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21002	21009		10.1074/jbc.M002088200	http://dx.doi.org/10.1074/jbc.M002088200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10770939	hybrid			2022-12-27	WOS:000088230600007
J	Kojima, T; Morikawa, Y; Copeland, NG; Gilbert, DJ; Jenkins, NA; Senba, E; Kitamura, Y				Kojima, T; Morikawa, Y; Copeland, NG; Gilbert, DJ; Jenkins, NA; Senba, E; Kitamura, Y			TROY, a newly identified member of the tumor necrosis factor receptor superfamily, exhibits a homology with edar and is expressed in embryonic skin and hair follicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOTOXIC LIGAND TRAIL; P55 TNF RECEPTOR; NF-KAPPA-B; MOLECULAR-CLONING; SURFACE-ANTIGEN; VIRAL-PROTEINS; FAMILY; CD40; DOMAIN; ACTIVATION	In a signal sequence trap screening of the murine brain, we identified a new member of the tumor necrosis factor receptor superfamily designated TROY. TROY is a type I membrane protein of 416 amino acids with characteristic cysteine-rich motifs in the extracellular domain and a tumor necrosis factor receptor-associated factor (TRAF) 2 binding sequence in the cytoplasmic domain of 223 amino acids. In fact, activation of nuclear factor kappa B was induced by the overexpression of TROY and inhibited by dominant negative forms of TRAF2, TRAF5, and TRAF6, indicating that TRAFs and nuclear factor kappa B are involved in the signal transduction of TROY. We also cloned a cDNA for a human counterpart, which showed a 75% homology with mouse TROY at the amino acid level. The extracellular domain of TROY exhibits an extensive homology with that of Edar, a receptor that specifies hair follicle fate. TROY mRNA is strongly expressed in brain and embryo and moderately expressed in the heart, lung, and liver but not the spleen. In the embryo, the expression level is particularly strong in the skin. Interestingly, in situ hybridization analysis of the embryo showed that TROY mRNA was exclusively expressed in the epithelium of many tissues. On the other hand, in neonatal mice, TROY is expressed in hair follicles Like Edar as well as in the cerebrum, suggesting pleiotropic functions of TROY in development as well as in the adult mice. The Troy gene is located near the waved coat (Wc) locus, a mutant related to abnormalities in skin and hair.	Univ Tokyo, Inst Med Sci, Dept Hematopoiet Factors, Minato Ku, Tokyo 1088639, Japan; Chugai Res Inst Mol Med Inc, Cytokine Res Program, Ibaraki, Osaka 3004101, Japan; Wakayama Med Coll, Dept Anat & Neurobiol, Wakayama 6408509, Japan; NCI, Frederick Canc Res & Dev Ctr, Mouse Canc Genet Program, Frederick, MD 21702 USA	University of Tokyo; Wakayama Medical University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Kitamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Dept Hematopoiet Factors, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.							Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Arch RH, 1998, MOL CELL BIOL, V18, P558, DOI 10.1128/MCB.18.1.558; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; Bajorath J, 1997, PROTEINS, V27, P59; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Braissant O, 1998, ENDOCRINOLOGY, V139, P2748, DOI 10.1210/en.139.6.2748; Braissant O, 1998, BIOCHEMICA, V1, P10; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; DIWAN S, 1974, MOUSE NEWS LETT, V51, P24; FUJISAWA J, 1988, JPN J CANCER RES, V79, P800, DOI 10.1111/j.1349-7006.1988.tb00038.x; GREEN MC, 1972, MOUSE NEWS LETT, V47, P36; GREEN MC, 1973, MOUSE NEWS LETT, V49, P32; GRUSS HJ, 1995, BLOOD, V85, P3378, DOI 10.1182/blood.V85.12.3378.bloodjournal85123378; Headon DJ, 1999, NAT GENET, V22, P370, DOI 10.1038/11943; HEUSEL JW, 1993, BLOOD, V81, P1614; HONIGBERG SM, 1986, P NATL ACAD SCI USA, V83, P9586, DOI 10.1073/pnas.83.24.9586; Hu SM, 1999, GENOMICS, V62, P103, DOI 10.1006/geno.1999.5979; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; Kashiwada M, 1998, J EXP MED, V187, P237, DOI 10.1084/jem.187.2.237; Kojima T, 1999, NAT BIOTECHNOL, V17, P487, DOI 10.1038/8666; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; MARSTERS SA, 1992, J BIOL CHEM, V267, P5747; MASON PJ, 1986, CELL, V46, P263, DOI 10.1016/0092-8674(86)90743-9; MIYAJIMA A, 1987, GENE, V58, P273, DOI 10.1016/0378-1119(87)90382-9; Monreal AW, 1999, NAT GENET, V22, P366, DOI 10.1038/11937; NAKANO H, 1996, J BIOL CHEM, V271, P14664; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; RIGAS B, 1986, P NATL ACAD SCI USA, V83, P9591, DOI 10.1073/pnas.83.24.9591; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEINTZE M, 1995, BIOCHEM BIOPH RES CO, V211, P804, DOI 10.1006/bbrc.1995.1883; Wang YS, 1996, J BIOL CHEM, V271, P4468; WONG GHW, 1994, J IMMUNOL, V152, P1751; Ye H, 1999, MOL CELL, V4, P321, DOI 10.1016/S1097-2765(00)80334-2	54	99	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20742	20747		10.1074/jbc.M002691200	http://dx.doi.org/10.1074/jbc.M002691200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10764796	hybrid			2022-12-27	WOS:000088084500073
J	Grootjans, JJ; Reekmans, G; Ceulemans, H; David, G				Grootjans, JJ; Reekmans, G; Ceulemans, H; David, G			Syntenin-syndecan binding requires syndecan-synteny and the co-operation of both PDZ domains of syntenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; NITRIC-OXIDE SYNTHASE; CRYSTAL-STRUCTURE; PROTEIN; MEMBRANE; RECOGNITION; CASK/LIN-2; RECEPTORS; PEPTIDE	Syntenin is an adaptor-like molecule that binds to the cytoplasmic domains of all four vertebrate syndecans, Syntenin-syndecan binding involves the C-terminal part of syntenin that contains a tandem of PDZ domains. Here we provide evidence that each PDZ domain of syntenin can interact with a syndecan, Isolated or combined mutations of the carboxylate binding lysines in the inter-beta A beta B loops and of the alpha B1 residues in either one or both the PDZ domains of syntenin all reduce syntenin-syndecan binding in yeast two-hybrid, blot-overlay, and surface plasmon resonance assays. PDZ2 mutations have more pronounced effects on binding: than PDZ1 mutations, but complete abrogation of syntenin-syndecan binding requires the combination of both the lysine and the alpha B1 mutations in both the PDZ domains of syntenin, Isothermal calorimetric titration of syntenin with syndecan peptide reveals the presence of two binding sites in syntenin, Yet, unlike a tandem of two PDZ2 domains and a reconstituted PDZ1 + PDZ2 tandem, a tandem of two PDZ1 domains and isolated PDZ1 or PDZ2 domains do not interact with syndecan bait. We conclude to a co-operative binding mode whereby neither of these two PDZ domains is sufficient by itself but where PDZ2 functions as a "major" or "high affinity" syndecan binding domain, and PDZ1 functions as an "accessory" or "low affinity" syndecan binding domain. The paired, but not the isolated PDZ domains of syntenin bind also strongly to the immobilized cytoplasmic domains of neurexin and B-class ephrins, By inference, these data suggest a model whereby recruitment of syntenin to membrane surfaces requires two compatible types of bait that are in "synteny" (occurring together in location) and engages both PDZ domains of syntenin, The synteny of compatible bait may result from the assemblies and co-assemblies of syndecans and other similarly suited partners in larger supramolecular complexes, In general, an intramolecular combination of PDZ domains that are weak, taken individually, would appear to be designed to detect rather than drive the formation of specific molecular assemblies.	Katholieke Univ Leuven, Ctr Human Genet, Lab Glycobiol & Dev Genet, B-3000 Leuven, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Leuven, Belgium	KU Leuven	David, G (corresponding author), Katholieke Univ Leuven, Ctr Human Genet, Lab Glycobiol & Dev Genet, Campus Gasthuisberg,O&N,Herestr 49, B-3000 Leuven, Belgium.							Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; Hata Y, 1996, J NEUROSCI, V16, P2488; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hsueh YP, 1999, J NEUROSCI, V19, P7415, DOI 10.1523/JNEUROSCI.19-17-07415.1999; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Lin D, 1999, J BIOL CHEM, V274, P3726, DOI 10.1074/jbc.274.6.3726; Lue RA, 1996, J CELL BIOL, V135, P1125, DOI 10.1083/jcb.135.4.1125; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Tochio H, 1999, NAT STRUCT BIOL, V6, P417; Tochio H, 2000, J MOL BIOL, V295, P225, DOI 10.1006/jmbi.1999.3350; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7	20	135	140	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19933	19941		10.1074/jbc.M002459200	http://dx.doi.org/10.1074/jbc.M002459200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10770943	hybrid			2022-12-27	WOS:000087941300069
J	Nelson, KL; Buckley, JT				Nelson, KL; Buckley, JT			Channel formation by the glycosylphosphatidylinositol-anchored protein binding toxin aerolysin is not promoted by lipid rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL ALKALINE-PHOSPHATASE; PLASMA-MEMBRANE; BIOLOGICAL-MEMBRANES; CELL-SURFACE; RECEPTOR; MICRODOMAINS; PURIFICATION; CYCLODEXTRIN; AGGREGATION; RESISTANCE	Glycosylphosphatidylinositol-anchored proteins may be concentrated in membrane microdomains (lipid rafts) that are also enriched in cholesterol and sphingolipids. The glycosyl anchor of these proteins is a specific, high affinity receptor for the channel-forming protein aerolysin. We wished to determine if the presence of rafts promotes the activity of aerolysin, Treatment of T lymphocytes with methyl-beta-cyclodextrin, which destroys lipid rafts by sequestering cholesterol, had no measurable effect on the sensitivity of the cells to aerolysin; nor did similar treatment of erythrocytes decrease the rate at which they were lysed by the toxin. We also studied the rate of aerolysin-induced channel formation in liposomes containing glycosylphosphatidylinositol-anchored placental alkaline phosphatase, which we show is a receptor for aerolysin. In liposomes containing sphingolipids as well as glycerophospholipids and cholesterol, most of the enzyme was Triton X-100-insoluble, indicating that it was localized in rafts, whereas in liposomes prepared without sphingolipids, all of the enzyme was soluble. Aerolysin was no more active against liposomes containing rafts than against those that did not. We conclude that lipid rafts do not promote channel formation by aerolysin.	Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada	University of Victoria	Buckley, JT (corresponding author), Univ Victoria, Dept Biochem & Microbiol, POB 3055, Victoria, BC V8W 3P6, Canada.	tbuckley@uvic.ca						Abrami L, 1998, J BIOL CHEM, V273, P32656, DOI 10.1074/jbc.273.49.32656; Abrami L, 1999, J CELL BIOL, V147, P175, DOI 10.1083/jcb.147.1.175; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Benting J, 1999, FEBS LETT, V462, P47, DOI 10.1016/S0014-5793(99)01501-X; Brodsky RA, 1999, BLOOD, V93, P1749, DOI 10.1182/blood.V93.5.1749.405k09_1749_1756; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; CHANG TC, 1992, EUR J BIOCHEM, V209, P241, DOI 10.1111/j.1432-1033.1992.tb17282.x; Cowell S, 1997, MOL MICROBIOL, V25, P343, DOI 10.1046/j.1365-2958.1997.4691828.x; Diep DB, 1999, MOL MICROBIOL, V31, P785, DOI 10.1046/j.1365-2958.1999.01217.x; Diep DB, 1998, J BIOL CHEM, V273, P2355, DOI 10.1074/jbc.273.4.2355; Ferguson MR, 1997, INFECT IMMUN, V65, P4299, DOI 10.1128/IAI.65.10.4299-4308.1997; FRA AM, 1994, J BIOL CHEM, V269, P30745; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; GARLAND WJ, 1988, INFECT IMMUN, V56, P1249, DOI 10.1128/IAI.56.5.1249-1253.1988; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; HOWARD SP, 1982, BIOCHEMISTRY-US, V21, P1662, DOI 10.1021/bi00536a029; Ilangumaran S, 1998, BIOCHEM J, V335, P433, DOI 10.1042/bj3350433; Jacobson K, 1999, TRENDS CELL BIOL, V9, P87, DOI 10.1016/S0962-8924(98)01495-0; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; MacKenzie CR, 1999, J BIOL CHEM, V274, P22604, DOI 10.1074/jbc.274.32.22604; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; Nelson KL, 1997, J BIOL CHEM, V272, P12170, DOI 10.1074/jbc.272.18.12170; Nelson KL, 1999, CELL MICROBIOL, V1, P69, DOI 10.1046/j.1462-5822.1999.00009.x; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; Nosjean O, 1999, EUR J BIOCHEM, V263, P865, DOI 10.1046/j.1432-1327.1999.00573.x; Ostermeyer AG, 1999, J BIOL CHEM, V274, P34459, DOI 10.1074/jbc.274.48.34459; REDMAN CA, 1994, BIOCHEM J, V302, P861, DOI 10.1042/bj3020861; ROBERTS WL, 1987, P NATL ACAD SCI USA, V84, P7817, DOI 10.1073/pnas.84.22.7817; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Sheets ED, 1997, BIOCHEMISTRY-US, V36, P12449, DOI 10.1021/bi9710939; VANDERGOOT FG, 1993, BIOCHEMISTRY-US, V32, P2636, DOI 10.1021/bi00061a023; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563	35	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19839	19843		10.1074/jbc.M002785200	http://dx.doi.org/10.1074/jbc.M002785200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10770947	hybrid			2022-12-27	WOS:000087941300056
J	Paolucci, C; Rovere, P; De Nadai, C; Manfredi, AA; Clementi, E				Paolucci, C; Rovere, P; De Nadai, C; Manfredi, AA; Clementi, E			Nitric oxide inhibits the tumor necrosis factor alpha-regulated endocytosis of human dendritic cells in a cyclic GMP-dependent way	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA T-CELLS; PERIPHERAL-BLOOD; DOWN-REGULATION; APOPTOSIS; SYNTHASE; ANTIGEN; GAMMA; MECHANISMS; CERAMIDE; MACROPHAGES	Tumor necrosis factor-alpha (TNF alpha)-induced maturation of dendritic cells (DC), with down-regulation of their endocytic ability, has been reported to be mediated by the accumulation of the lipid messenger ceramide. We have now studied the effects and mechanisms of action of NO on endocytosis, investigated with fluorescein isothiocyanate-labeled dextran using human monocyte-derived DC, both immature and after treatment with TNF alpha. Exposure of DC to NO, released by either bystander phagocytes or NO donors, reversed the inhibition of endocytosis induced by TNF alpha. The intracellular accumulation of ceramide induced by TNF alpha was also inhibited by NO. In addition, NO was found to exert an inhibitory effect downstream of the TNF alpha-triggered ceramide accumulation, because NO donors reversed the inhibition of endocytosis induced by the cell-permeant C-2-ceramide. These effects of NO were mimicked by the membrane-permeant cyclic GMP analogue, 8-Br cyclic GMP, and prevented by inhibition of the soluble guanylyl cyclase. At variance with rodents, the inducible isoform of the NO synthase was expressed neither in immature human DC nor after cell treatment with TNF alpha, interferon-gamma, and lipopolysaccharide, suggesting that regulation of these cells depends on exogenous NO, NO, working through cyclic GMP, might therefore prolong the ability of human DC to internalize antigens at the site of inflammation and thus modulate the initial steps leading to antigen-specific immune responses.	Ist Sci San Raffaele, DIBIT, Dept Neurosci, I-20132 Milan, Italy; Ist Sci San Raffaele, Lab Tumour Immunol, Gene Therapy Programme, I-20132 Milan, Italy; CNR, Ctr Cellular & Mol Pharmacol, I-20129 Milan, Italy; Univ Calabria, Dept Pharmacobiol, I-87036 Arcavacata Di Rende, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR); University of Calabria	Clementi, E (corresponding author), Ist Sci San Raffaele, DIBIT, Dept Neurosci, Via Olgettina 58, I-20132 Milan, Italy.	clementi.emilio@hsr.it	Manfredi, Angelo A./C-7018-2014; Rovere-Querini, Patrizia/J-2340-2012	Manfredi, Angelo A./0000-0001-8370-6970; 				Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BETZCORRADIN S, 1993, GLIA, V7, P255; Bonham CA, 1997, TRANSPL P, V29, P1116, DOI 10.1016/S0041-1345(96)00458-7; Chen BG, 1998, BLOOD, V91, P4652, DOI 10.1182/blood.V91.12.4652.412a03_4652_4661; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; Clancy RM, 1998, ARTHRITIS RHEUM-US, V41, P1141, DOI 10.1002/1529-0131(199807)41:7<1141::AID-ART2>3.0.CO;2-S; Downing JEG, 1998, IMMUNOLOGY, V95, P148; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; HOLT PG, 1993, J EXP MED, V177, P397, DOI 10.1084/jem.177.2.397; Huang FP, 1998, EUR J IMMUNOL, V28, P4062, DOI 10.1002/(SICI)1521-4141(199812)28:12<4062::AID-IMMU4062>3.0.CO;2-K; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; LIEW FY, 1995, CURR OPIN IMMUNOL, V7, P396, DOI 10.1016/0952-7915(95)80116-2; Lu LN, 1996, J IMMUNOL, V157, P3577; Lutz MB, 1997, J IMMUNOL, V159, P3707; MacLean A, 1998, J GEN VIROL, V79, P825, DOI 10.1099/0022-1317-79-4-825; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; McInnes LB, 1996, J EXP MED, V184, P1519, DOI 10.1084/jem.184.4.1519; MONCADA S, 1995, FASEB J, V9, P1319, DOI 10.1096/fasebj.9.13.7557022; Nelson EL, 1999, FASEB J, V13, P2021, DOI 10.1096/fasebj.13.14.2021; Ninomiya T, 1999, J HEPATOL, V31, P323, DOI 10.1016/S0168-8278(99)80231-1; Perry DK, 1999, TRENDS BIOCHEM SCI, V24, P226, DOI 10.1016/S0968-0004(99)01407-3; Perry DK, 1998, BBA-MOL CELL BIOL L, V1436, P233, DOI 10.1016/S0005-2760(98)00145-3; Reiling N, 1996, EUR J IMMUNOL, V26, P511, DOI 10.1002/eji.1830260302; Rovere P, 1996, J IMMUNOL, V156, P4631; Sallusto F, 1996, J EXP MED, V184, P2411, DOI 10.1084/jem.184.6.2411; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Sciorati C, 1999, J IMMUNOL, V163, P1570; Sciorati C, 1997, J BIOL CHEM, V272, P23211, DOI 10.1074/jbc.272.37.23211; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; Xiao BG, 1999, J NEUROIMMUNOL, V97, P25, DOI 10.1016/S0165-5728(99)00041-7; Yamamoto K, 1998, CLIN EXP IMMUNOL, V114, P94	33	49	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19638	19644		10.1074/jbc.M000511200	http://dx.doi.org/10.1074/jbc.M000511200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10777484	hybrid			2022-12-27	WOS:000087941300028
J	Thomson, LM; Bates, S; Yamazaki, S; Arisawa, M; Aoki, Y; Gow, NAR				Thomson, LM; Bates, S; Yamazaki, S; Arisawa, M; Aoki, Y; Gow, NAR			Functional characterization of the Candida albicans MNT1 mannosyltransferase expressed heterologously in Pichia pastoris	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE FAMILY; PROTEIN GLYCOSYLATION; GLYCOPROTEIN-BIOSYNTHESIS; O-GLYCOSYLATION; YEAST; GLYCOSYLTRANSFERASES; CELLS; ALPHA-1,2-MANNOSYLTRANSFERASE; IDENTIFICATION	The alpha 1,2-mannosyltransferase gene MNT1 of the human fungal pathogen Candida albicans has been shown to be important for its adherence to various human surfaces and for virulence (Buurman, E. T., Westwater, C., Hube, B., Brown, A. P. J., Odds, F. C., and Gow, N. A. R. (1998) Proc. Natl, Acad. Sci. U. S, A. 95, 7670-7675). The CaMnt1p is a type II membrane protein, which is part of a family of proteins that are important for both O- and N-linked mannosylation in fungi and which represent a distinct subclass of glycosyltransferase enzymes. Here we use heterologous expression of CaMNT1 in the methylotrophic yeast Pichia pastoris to characterize the properties of the CaMnt1p enzyme as an example of this family of enzymes and to identify key amino acid residues required for coordination of the metal co-factor and for the retaining nucleophilic mechanism of the transferase reaction. We show that the enzyme can use both Mn2+ and Zn2+ as metal ion co-factors and that the reaction catalyzed is specific for alpha-methyl mannoside and alpha 1,2-mannobiose accepters. The N-terminal cytoplasmic tail, transmembrane domains, and stem regions were shown to be dispensable for activity, whereas truncations to the C-terminal catalytic domain destroyed activity without markedly affecting transcription of the truncated gene.	Univ Aberdeen, Inst Med Sci, Dept Mol & Cell Biol, Aberdeen AB25 2ZD, Scotland; Nippon Roche Res Ctr, Dept Mycol, Kamakura, Kanagawa 247, Japan	University of Aberdeen; Roche Holding	Gow, NAR (corresponding author), Univ Aberdeen, Inst Med Sci, Dept Mol & Cell Biol, Aberdeen AB25 2ZD, Scotland.	n.gow@abdn.ac.uk	GOW, Neil/AAS-5323-2021	GOW, Neil/0000-0002-2776-5850; Bates, Steven/0000-0003-0489-5705; Yamazaki, Soh/0000-0001-5038-1567				ARNOLD E, 1982, FEBS LETT, V148, P49, DOI 10.1016/0014-5793(82)81240-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRETON C, 1996, J BIOCH, V123, P1000; Buurman ET, 1998, P NATL ACAD SCI USA, V95, P7670, DOI 10.1073/pnas.95.13.7670; CALDERONE RA, 1991, MICROBIOL REV, V55, P1; Calderone Richard A., 1993, Trends in Microbiology, V1, P55, DOI 10.1016/0966-842X(93)90033-N; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; CASANOVA M, 1992, INFECT IMMUN, V60, P4221, DOI 10.1128/IAI.60.10.4221-4229.1992; CUTLER JE, 1991, ANNU REV MICROBIOL, V45, P187, DOI 10.1146/annurev.mi.45.100191.001155; Drickamer K, 1998, TRENDS BIOCHEM SCI, V23, P321, DOI 10.1016/S0968-0004(98)01246-8; Fukazawa Y, 1997, J MED VET MYCOL, V35, P87; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Gentzsch M, 1996, EMBO J, V15, P5752, DOI 10.1002/j.1460-2075.1996.tb00961.x; Gow NAR, 1999, BIOCHEM SOC T, V27, P512, DOI 10.1042/bst0270512; HAUSLER A, 1992, GLYCOBIOLOGY, V2, P77, DOI 10.1093/glycob/2.1.77; HAUSLER A, 1992, P NATL ACAD SCI USA, V89, P6846, DOI 10.1073/pnas.89.15.6846; HAYETTE MP, 1992, J CLIN MICROBIOL, V30, P411, DOI 10.1128/JCM.30.2.411-417.1992; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HENRICKSON TL, 1995, BIOCHEMISTRY-US, V29, P9444; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HILL K, 1992, GENETICS, V130, P273; Kapitonov D, 1999, GLYCOBIOLOGY, V9, P961, DOI 10.1093/glycob/9.10.961; Kapteyn JC, 1999, BBA-GEN SUBJECTS, V1426, P373, DOI 10.1016/S0304-4165(98)00137-8; Karlin S, 1997, P NATL ACAD SCI USA, V94, P14225, DOI 10.1073/pnas.94.26.14225; KLIS FM, 1994, YEAST, V10, P851, DOI 10.1002/yea.320100702; KOSSACZKA Z, 1995, CAN J MICROBIOL, V41, P971, DOI 10.1139/m95-135; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI RK, 1993, J BIOL CHEM, V268, P18293; LIS H, 1993, EUR J BIOCHEM, V218, P1, DOI 10.1111/j.1432-1033.1993.tb18347.x; LOWARY TL, 1994, CARBOHYD RES, V251, P33, DOI 10.1016/0008-6215(94)84275-2; Lussier M, 1997, YEAST, V13, P267, DOI 10.1002/(SICI)1097-0061(19970315)13:3<267::AID-YEA72>3.0.CO;2-K; Lussier M, 1997, J BIOL CHEM, V272, P15527, DOI 10.1074/jbc.272.24.15527; Lussier M, 1996, J BIOL CHEM, V271, P11001, DOI 10.1074/jbc.271.18.11001; Lussier M, 1999, BBA-GEN SUBJECTS, V1426, P323, DOI 10.1016/S0304-4165(98)00133-0; Mackenzie LF, 1998, BIOCHEM J, V335, P409, DOI 10.1042/bj3350409; MIYAKAWA Y, 1992, INFECT IMMUN, V60, P2493, DOI 10.1128/IAI.60.6.2493-2499.1992; Murray BW, 1996, BIOCHEMISTRY-US, V35, P11183, DOI 10.1021/bi961065a; NAKAJIMA T, 1975, P NATL ACAD SCI USA, V72, P3912, DOI 10.1073/pnas.72.10.3912; NELSON RD, 1991, CLIN MICROBIOL REV, V4, P1; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PAULSON JC, 1987, METHOD ENZYMOL, V138, P162; Romero PA, 1999, GLYCOBIOLOGY, V9, P1045, DOI 10.1093/glycob/9.10.1045; Romero PA, 1997, BIOCHEM J, V321, P289, DOI 10.1042/bj3210289; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SEXANA A, 1989, INFECT IMMUN, V57, P413; SHIBATA N, 1993, EUR J BIOCHEM, V217, P1, DOI 10.1111/j.1432-1033.1993.tb18211.x; Sundstrom P, 1999, CURR OPIN MICROBIOL, V2, P353, DOI 10.1016/S1369-5274(99)80062-9; Suzuki A, 1997, J BIOL CHEM, V272, P16822, DOI 10.1074/jbc.272.27.16822; Tanner W, 1995, ACTA BIOCHIM POL, V42, P505; Timpel C, 1998, J BIOL CHEM, V273, P20837, DOI 10.1074/jbc.273.33.20837; van West P, 1998, FUNGAL GENET BIOL, V23, P126, DOI 10.1006/fgbi.1998.1036; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; ZVELEBIL MJJM, 1988, PROTEIN ENG, V2, P127, DOI 10.1093/protein/2.2.127	55	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18933	18938		10.1074/jbc.M909699199	http://dx.doi.org/10.1074/jbc.M909699199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10766761	hybrid			2022-12-27	WOS:000087815900044
J	Yamamoto, T; El-Hayek, R; Ikemoto, N				Yamamoto, T; El-Hayek, R; Ikemoto, N			Postulated role of interdomain interaction within the ryanodine receptor in Ca2+ channel regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; CALCIUM-RELEASE CHANNEL; CENTRAL CORE DISEASE; II-III-LOOP; SKELETAL-MUSCLE; MALIGNANT HYPERTHERMIA; DIHYDROPYRIDINE RECEPTOR; FOOT PROTEIN; GENE; IDENTIFICATION	Localized distribution of malignant hyperthermia (MH) and central core disease (CCD) mutations in N-terminal and central domains of the ryanodine receptor suggests that the interaction between these domains may be involved in Ca2+ channel regulation. To test this hypothesis, we investigated the effects of a new synthetic domain peptide DP4 corresponding to the Leu(2442)-Pro(2477) region of the central domain. DP4 enhanced ryanodine binding and induced a rapid Ca2+ release. The concentration for half-maximal activation by agonists was considerably reduced in the presence of DP4. These effects of DP4 are analogous to the functional modifications of the ryanodine receptor caused by MH/CCD mutations (viz. hyperactivation of the channel and hypersensitization of the channel to agonists). Replacement of Arg of DP4 with Cys, mimic-king the in vivo Arg(2458)-to-Cys(2458) mutation, abolished the activating effects of DP4, An N-terminal domain peptide DP1 (El-Hayek, R., Saiki, Y., Yamamoto, T., and Ikemoto, N. (1999) J. Biol. Chem. 274, 33341-33347) shows similar activation/sensitization effects. The addition of both DP4 and DP1 produced mutual interference of their activating functions. We tentatively propose that contact between the two (N-terminal and central) domains closes the channel, whereas removal of the contact by these domain peptides or by MH/CCD mutations deblocks the channel, resulting in hyperactivation/hypersensitization effects.	Boston Biomed Res Inst, Watertown, MA 02472 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA	Boston Biomedical Research Institute; Harvard University; Harvard Medical School	Ikemoto, N (corresponding author), Boston Biomed Res Inst, 64 Grove St, Watertown, MA 02472 USA.	ikemoto@bbri.org			NIAMS NIH HHS [AR16922] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR016922] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aghdasi B, 1997, J BIOL CHEM, V272, P3739, DOI 10.1074/jbc.272.6.3739; ASHLEY CC, 1991, Q REV BIOPHYS, V24, P1, DOI 10.1017/S0033583500003267; Cameron AM, 1997, J BIOL CHEM, V272, P27582, DOI 10.1074/jbc.272.44.27582; CHEN SRW, 1993, J BIOL CHEM, V268, P13414; CHEN SRW, 1994, J BIOL CHEM, V269, P22698; CHEN ZD, 1991, J BIOL CHEM, V266, P12386; CIFUENTES ME, 1989, ARCH BIOCHEM BIOPHYS, V273, P554, DOI 10.1016/0003-9861(89)90515-8; CORONADO A, 1994, AM J PHYSIOL, V35, pC1485; El-Hayek R, 1999, J BIOL CHEM, V274, P33341, DOI 10.1074/jbc.274.47.33341; El-Hayek R, 1998, BIOCHEMISTRY-US, V37, P7015, DOI 10.1021/bi972907o; ELHAYEK R, 1995, J BIOL CHEM, V270, P15634, DOI 10.1074/jbc.270.26.15634; ELHAYEK R, 1995, J BIOL CHEM, V270, P28696, DOI 10.1074/jbc.270.48.28696; ELHAYEK R, 1995, J BIOL CHEM, V270, P22116, DOI 10.1074/jbc.270.38.22116; ENDO M, 1983, BIOMED RES-TOKYO, V4, P83, DOI 10.2220/biomedres.4.83; FILL M, 1991, BIOPHYS J, V59, P1085, DOI 10.1016/S0006-3495(91)82323-2; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FUJII J, 1991, SCIENCE, V253, P448, DOI 10.1126/science.1862346; GALLANT EM, 1982, NEUROSCI LETT, V28, P181, DOI 10.1016/0304-3940(82)90149-5; GILLARD EF, 1991, GENOMICS, V11, P751, DOI 10.1016/0888-7543(91)90084-R; GILLARD EF, 1992, GENOMICS, V13, P1247, DOI 10.1016/0888-7543(92)90042-Q; IKEMOTO N, 1988, METHOD ENZYMOL, V157, P469; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; MACLENNAN DH, 1995, RYANODINE RECEPTORS, P155; MACLENNAN DH, 1994, CALCIUM CELL SIGNAL, P141; Manning BM, 1998, HUM MUTAT, V11, P45, DOI 10.1002/(SICI)1098-1004(1998)11:1<45::AID-HUMU7>3.0.CO;2-K; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MELZER W, 1995, BBA-REV BIOMEMBRANES, V1241, P59, DOI 10.1016/0304-4157(94)00014-5; Mickelson JR, 1996, PHYSIOL REV, V76, P537, DOI 10.1152/physrev.1996.76.2.537; MICKELSON JR, 1988, J BIOL CHEM, V263, P9310; OHTA T, 1989, AM J PHYSIOL, V256, pC358, DOI 10.1152/ajpcell.1989.256.2.C358; PHILLIPS MS, 1994, HUM MOL GENET, V3, P2181, DOI 10.1093/hmg/3.12.2181; QUANE KA, 1993, NAT GENET, V5, P51, DOI 10.1038/ng0993-51; QUANE KA, 1994, HUM MOL GENET, V3, P471, DOI 10.1093/hmg/3.3.471; RIOS E, 1991, J MUSCLE RES CELL M, V12, P127, DOI 10.1007/BF01774031; RIOS E, 1992, ANNU REV PHYSIOL, V54, P109, DOI 10.1146/annurev.ph.54.030192.000545; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; Saiki Y, 1999, J BIOL CHEM, V274, P7825, DOI 10.1074/jbc.274.12.7825; SCHNEIDER MF, 1994, ANNU REV PHYSIOL, V56, P463, DOI 10.1146/annurev.ph.56.030194.002335; SEILER S, 1984, J BIOL CHEM, V259, P8550; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; VALDIVIA HH, 1992, P NATL ACAD SCI USA, V89, P12185, DOI 10.1073/pnas.89.24.12185; Wu YL, 1997, J BIOL CHEM, V272, P25051, DOI 10.1074/jbc.272.40.25051; YAMADA S, 1980, J BIOL CHEM, V255, P3108; ZHANG YL, 1993, NAT GENET, V5, P46, DOI 10.1038/ng0993-46; Zorzato F, 1996, J BIOL CHEM, V271, P22759, DOI 10.1074/jbc.271.37.22759	46	102	106	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11618	11625		10.1074/jbc.275.16.11618	http://dx.doi.org/10.1074/jbc.275.16.11618			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766778	hybrid			2022-12-27	WOS:000086695500013
J	Burcelin, R; Munoz, MD; Guillam, MT; Thorens, B				Burcelin, R; Munoz, MD; Guillam, MT; Thorens, B			Liver hyperplasia and paradoxical regulation of glycogen metabolism and glucose-sensitive gene expression in GLUT2-null hepatocytes - Further evidence for the existence of a membrane-based glucose release pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-KINASE GENE; CARBOHYDRATE REGULATION; PANCREATIC-ISLETS; HEXOKINASE-I; S14 GENE; GLUCOKINASE; SYNTHASE; PROTEIN; INSULIN; GLUT-2	We investigated the impact of GLUT2 gene inactivation on the regulation of hepatic glucose metabolism during the fed to fast transition. In control and GLUT2-null mice, fasting was accompanied by a similar to 10-fold increase in plasma glucagon to insulin ratio, a similar activation of liver glycogen phosphorylase and inhibition of glycogen synthase and the same elevation in phosphoenolpyruvate carboxykinase and glucose-6-phosphatase mRNAs, In GLUT2-null mice, mobilization of glycogen stores was, however, strongly impaired. This was correlated with glucose-6-phosphate (G6P) levels, which remained at the fed values, indicating an important allosteric stimulation of glycogen synthase by G6P, These G6P levels were also accompanied by a paradoxical elevation of the mRNAs for L-pyruvate kinase, Reexpression of GLUT2 in liver corrected the abnormal regulation of glycogen and L-pyruvate kinase gene expression. Interestingly, GLUT2-null livers were hyperplasic, as revealed by a 40% increase in liver mass and 30% increase in liver DNA content, Together, these data indicate that in the absence of GLUTS, the G6P levels cannot decrease during a fasting period. This may be due to neosynthesized glucose entering the cytosol, being unable to diffuse into the extracellular space, and being phosphorylated back to G6P, Because hepatic glucose production is nevertheless quantitatively normal, glucose produced in the endoplasmic reticulum may also be exported out of the cell through an alternative, membrane traffic-based pathway, as previously reported (Guillam, M,-T,, Burcelin, R., and Thorens, B, (1998) Proc. Natl, Acad Sci. U.S.A. 95, 12317-12321), Therefore, in fasting, GLUT2 is not required for quantitative normal glucose output but is necessary to equilibrate cytosolic glucose with the extracellular space. In the absence of this equilibration, the control of hepatic glucose metabolism by G6P is dominant over that by plasma hormone concentrations.	Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland; Univ Barcelona, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain	University of Lausanne; University of Barcelona	Thorens, B (corresponding author), Univ Lausanne, Inst Pharmacol & Toxicol, 27 Rue Bugnon, CH-1005 Lausanne, Switzerland.	Bernard.Thorens@ipharm.unil.ch						AGIUS L, 1995, BIOCHEM J, V309, P711, DOI 10.1042/bj3090711; Antoine B, 1997, J BIOL CHEM, V272, P17937, DOI 10.1074/jbc.272.29.17937; Bollen M, 1998, BIOCHEM J, V336, P19, DOI 10.1042/bj3360019; Brown KS, 1997, DIABETES, V46, P179, DOI 10.2337/diabetes.46.2.179; BURCELIN R, 1995, DIABETOLOGIA, V38, P283, DOI 10.1007/s001250050283; Burcelin R, 1998, J BIOL CHEM, V273, P8088, DOI 10.1074/jbc.273.14.8088; CARABAZA A, 1992, FEBS LETT, V296, P211, DOI 10.1016/0014-5793(92)80381-P; Chatelain F, 1998, DIABETES, V47, P882, DOI 10.2337/diabetes.47.6.882; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GILBOE DP, 1972, ANAL BIOCHEM, V47, P20, DOI 10.1016/0003-2697(72)90274-6; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; GIRARD J, 1994, FASEB J, V8, P36, DOI 10.1096/fasebj.8.1.7905448; Gremlich S, 1997, J BIOL CHEM, V272, P30261, DOI 10.1074/jbc.272.48.30261; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; Guillam MT, 1998, P NATL ACAD SCI USA, V95, P12317, DOI 10.1073/pnas.95.21.12317; Guillam MT, 1997, NAT GENET, V17, P327, DOI 10.1038/ng1197-327; HOPCROFT DW, 1985, HORM METAB RES, V17, P559, DOI 10.1055/s-2007-1013606; MARIE S, 1993, J BIOL CHEM, V268, P23881; Mithieux G, 1997, EUR J ENDOCRINOL, V136, P137, DOI 10.1530/eje.0.1360137; ODoherty RM, 1996, J BIOL CHEM, V271, P20524, DOI 10.1074/jbc.271.34.20524; Ota Y, 1997, MOL CELL ENDOCRINOL, V126, P75, DOI 10.1016/S0303-7207(96)03971-8; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; PRIPBUUS C, 1995, EUR J BIOCHEM, V230, P309, DOI 10.1111/j.1432-1033.1995.tb20564.x; Seoane J, 1996, J BIOL CHEM, V271, P23756, DOI 10.1074/jbc.271.39.23756; SHIH HM, 1995, J BIOL CHEM, V270, P21991, DOI 10.1074/jbc.270.37.21991; SHIH HM, 1992, J BIOL CHEM, V267, P13222; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; THORENS B, 1990, AM J PHYSIOL, V259, P279; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888	29	61	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10930	10936		10.1074/jbc.275.15.10930	http://dx.doi.org/10.1074/jbc.275.15.10930			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753892	hybrid			2022-12-27	WOS:000086466600034
J	Chambers, JK; Macdonald, LE; Sarau, HM; Ames, RS; Freeman, K; Foley, JJ; Zhu, Y; McLaughlin, MM; Murdock, P; McMillan, L; Trill, J; Swift, A; Aiyar, N; Taylor, P; Vawter, L; Naheed, S; Szekeres, P; Hervieu, G; Scott, C; Watson, JM; Murphy, AJ; Duzic, E; Klein, C; Bergsma, DJ; Wilson, S; Livi, GP				Chambers, JK; Macdonald, LE; Sarau, HM; Ames, RS; Freeman, K; Foley, JJ; Zhu, Y; McLaughlin, MM; Murdock, P; McMillan, L; Trill, J; Swift, A; Aiyar, N; Taylor, P; Vawter, L; Naheed, S; Szekeres, P; Hervieu, G; Scott, C; Watson, JM; Murphy, AJ; Duzic, E; Klein, C; Bergsma, DJ; Wilson, S; Livi, GP			A G protein-coupled receptor for UDP-glucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARTIAL AGONIST; LIGAND; GENE; IDENTIFICATION; SELECTION; P2Y(1); CELLS; YEAST	Uridine 5'-diphosphoglucose (UDP-glucose) has a well established biochemical role as a glycosyl donor in the enzymatic biosynthesis of carbohydrates. It is less well known that UDP-glucose may possess pharmacological activity, suggesting that a receptor for this molecule may exist, Here, we show that UDP-glucose, and some closely related molecules, potently activate the orphan G protein-coupled receptor KIAA0001 heterologously expressed in yeast or mammalian cells. Nucleotides known to activate P2Y receptors were inactive, indicating the distinctly novel pharmacology of this receptor. The receptor is expressed in a wide variety of human tissues, including many regions of the brain. These data suggest that some sugar-nucleotides may serve important physiological roles as extracellular signaling molecules in addition to their familiar role in intermediary metabolism.	SmithKline Beecham Pharmaceut, Dept Vasc Biol, Harlow CM19 5AW, Essex, England; SmithKline Beecham Pharmaceut, Dept Gene Express Sci, Harlow CM19 5AW, Essex, England; SmithKline Beecham Pharmaceut, Dept Neurosci, Harlow CM19 5AW, Essex, England; Cadus Pharmaceut Corp, Tarrytown, NY 10591 USA; SmithKline Beecham Pharmaceut, Dept Pulm Pharmacol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Mol Biol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Comparat Genet, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Gene Express Sci, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Cardiovasc Biol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Screening Sci, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Bioinformat, King Of Prussia, PA 19406 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Chambers, JK (corresponding author), SmithKline Beecham Pharmaceut, Dept Vasc Biol, New Frontiers Sci Pk,So Way, Harlow CM19 5AW, Essex, England.							AIYAR N, 1994, MOL CELL BIOCHEM, V131, P75, DOI 10.1007/BF01075727; Ames RS, 1999, NATURE, V401, P282, DOI 10.1038/45809; BIRKENBACH M, 1993, J VIROL, V67, P2209, DOI 10.1128/JVI.67.4.2209-2220.1993; BLUMER KJ, 1988, J BIOL CHEM, V263, P10836; Burnstock G, 1997, NEUROPHARMACOLOGY, V36, P1127, DOI 10.1016/S0028-3908(97)00125-1; Chambers J, 1999, NATURE, V400, P261, DOI 10.1038/22313; Charlton ME, 1997, BRAIN RES, V764, P141, DOI 10.1016/S0006-8993(97)00438-1; CONNOLLY GP, 1995, BRIT J PHARMACOL, V116, P2764, DOI 10.1111/j.1476-5381.1995.tb17239.x; Feighner SD, 1999, SCIENCE, V284, P2184, DOI 10.1126/science.284.5423.2184; GIROTTO T, 1981, Clinica Terapeutica, V96, P593; HARTMAN SC, 1988, P NATL ACAD SCI USA, V85, P8047, DOI 10.1073/pnas.85.21.8047; Herzog H, 1996, GENOME RES, V6, P858, DOI 10.1101/gr.6.9.858; Jacobs KA, 1997, GENE, V198, P289, DOI 10.1016/S0378-1119(97)00330-2; Klein C, 1998, NAT BIOTECHNOL, V16, P1334, DOI 10.1038/4310; Lazarowski ER, 1997, J BIOL CHEM, V272, P24348, DOI 10.1074/jbc.272.39.24348; Manfredi JP, 1996, MOL CELL BIOL, V16, P4700; Marchese A, 1999, GENOMICS, V56, P12, DOI 10.1006/geno.1998.5655; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; PASTORIS O, 1979, FARMACO-ED SCI, V34, P211; PASTORIS O, 1981, FARMACO-ED SCI, V36, P721; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; Schachter JB, 1997, BRIT J PHARMACOL, V121, P338, DOI 10.1038/sj.bjp.0701136; Schachter JB, 1997, NEUROPHARMACOLOGY, V36, P1181, DOI 10.1016/S0028-3908(97)00138-X; SWOFFORD DL, 1999, PAUP PHYLOGENETIC AN; VANHOUTTE B, 1995, BIOTECHNOL BIOENG, V48, P1, DOI 10.1002/bit.260480103; Watson JM, 1996, EUR J PHARMACOL, V314, P365, DOI 10.1016/S0014-2999(96)00579-1; YIP LC, 1987, BIOCHEM PHARMACOL, V36, P633, DOI 10.1016/0006-2952(87)90713-1	28	257	269	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10767	10771		10.1074/jbc.275.15.10767	http://dx.doi.org/10.1074/jbc.275.15.10767			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753868	hybrid			2022-12-27	WOS:000086466600010
J	Homma, H; Kurachi, H; Nishio, Y; Takeda, T; Yamamoto, T; Adachi, K; Morishige, K; Ohmichi, M; Matsuzawa, Y; Murata, Y				Homma, H; Kurachi, H; Nishio, Y; Takeda, T; Yamamoto, T; Adachi, K; Morishige, K; Ohmichi, M; Matsuzawa, Y; Murata, Y			Estrogen suppresses transcription of lipoprotein lipase gene - Existence of a unique estrogen response element on the lipoprotein lipase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE-TISSUE; REPLACEMENT THERAPY; NUCLEAR RECEPTORS; 3T3-L1 ADIPOCYTES; BINDING-PROTEIN; RAT ADIPOCYTES; FOOD-INTAKE; BODY-FAT; C-JUN; DIFFERENTIATION	Estrogen exerts a variety of effects not only on female reproductive organs but also on nonreproductive organs, including adipose tissue. Estrogen inhibits obesity triggered by ovariectomy in rodents. We studied the mechanism underlying this estrogen-dependent inhibition of obesity. Estrogen markedly decreased the amounts of fat accumulation and lipoprotein lipase (LPL) mRNA as well as triglyceride accumulation in genetically manipulated 3T3-L1 adipocytes stably expressing the estrogen receptor (ER), A pLPL(1980)-CAT construct, along with an ER expression vector, was introduced into differentiated 3T3-L1 cells, and CAT activities were determined, ER, mostly ligand-dependently, inhibited the basal LPL promoter activity by 7-fold. We searched the LPL promoter for an estrogen-responsive suppressive element by employing a set of 5'-deletion mutants of the pLPL-CAT reporter. Although there was no classical estrogen response element, it was demonstrated that an AP-1-like TGAATTC sequence located at (-1856/-1850) was responsible for the suppression of the LPL gene transcription by estrogen, An electrophoretic mobility shift assay probed with the TGAATTC sequence demonstrated formation of a specific DNA-nuclear protein complex. Interestingly, this complex was not affected by the addition of any antibodies against ER, c-Jun, c-Fos, JunB, or JunD, Because this TGAATTC element responded to phorbol ester and overexpression of CREB-binding protein abrogated the suppressive effect of estrogen on the LPL promoter, we conclude that a unique protein that is related to the AP-1 transcription factor families may be involved in the complex that binds to the TGAATTC element.	Osaka Univ, Fac Med, Dept Obstet & Gynecol E5, Suita, Osaka 5650871, Japan; Osaka Univ, Fac Med, Dept Internal Med 2, Suita, Osaka 5650871, Japan	Osaka University; Osaka University	Nishio, Y (corresponding author), Osaka Univ, Fac Med, Dept Obstet & Gynecol E5, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ynishio@gyne.med.osaba-u.ac.jp						Akira S, 1997, INT J BIOCHEM CELL B, V29, P1401, DOI 10.1016/S1357-2725(97)00063-0; BARCELLINICOUGET S, 1993, ENDOCRINOLOGY, V132, P53, DOI 10.1210/en.132.1.53; CIOCCA DR, 1995, ENDOCR REV, V16, P35, DOI 10.1210/er.16.1.35; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRYDEN GL, 1977, SCIENCE, V197, P782, DOI 10.1126/science.887921; ENERBACK S, 1992, MOL CELL BIOL, V12, P4622, DOI 10.1128/MCB.12.10.4622; ENERBACK S, 1993, BIOCHIM BIOPHYS ACTA, V1169, P107, DOI 10.1016/0005-2760(93)90196-G; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GREEN S, 1986, J STEROID BIOCHEM, V24, P77, DOI 10.1016/0022-4731(86)90035-X; GULLER S, 1989, ENDOCRINOLOGY, V125, P2360, DOI 10.1210/endo-125-5-2360; GURA T, 1995, SCIENCE, V269, P771, DOI 10.1126/science.7543696; HAARBO J, 1991, METABOLISM, V40, P1323, DOI 10.1016/0026-0495(91)90037-W; HAMOSH M, 1975, J CLIN INVEST, V55, P1132, DOI 10.1172/JCI108015; HUA XX, 1991, GENE, V107, P247, DOI 10.1016/0378-1119(91)90325-6; IVERIUS PH, 1988, J CLIN INVEST, V82, P1106, DOI 10.1172/JCI113667; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KIM HJ, 1975, J CLIN INVEST, V56, P888, DOI 10.1172/JCI108168; LAZZARINI SJ, 1991, AM J PHYSIOL, V260, pR47, DOI 10.1152/ajpregu.1991.260.1.R47; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MIYASHITA Y, 1990, J STEROID BIOCHEM, V35, P561, DOI 10.1016/0022-4731(90)90199-3; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; PEDERSEN SB, 1992, MOL CELL ENDOCRINOL, V85, P13, DOI 10.1016/0303-7207(92)90120-U; PEDERSEN SB, 1991, BIOCHIM BIOPHYS ACTA, V1093, P80, DOI 10.1016/0167-4889(91)90141-J; PEINADOONSURBE J, 1993, HORM RES, V40, P184, DOI 10.1159/000183792; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PHILIPS A, 1993, J BIOL CHEM, V268, P14103; PREVIATO L, 1991, J BIOL CHEM, V266, P18958; Price TM, 1998, AM J OBSTET GYNECOL, V178, P101, DOI 10.1016/S0002-9378(98)70634-9; RAMIREZZACARIAS JL, 1992, HISTOCHEMISTRY, V97, P493, DOI 10.1007/BF00316069; Ranganathan G, 1997, J BIOL CHEM, V272, P2515; Ranganathan G, 1999, J BIOL CHEM, V274, P9122, DOI 10.1074/jbc.274.13.9122; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sartippour MR, 1998, DIABETES, V47, P431, DOI 10.2337/diabetes.47.3.431; SCHMITT M, 1995, J NEUROSCI RES, V40, P152, DOI 10.1002/jnr.490400203; SEMENKOVICH CF, 1989, J BIOL CHEM, V264, P9030; SHIMOMURA Y, 1990, PHYSIOL BEHAV, V47, P155, DOI 10.1016/0031-9384(90)90055-9; Shoham Z, 1996, FERTIL STERIL, V65, P687; Somjen D, 1997, J STEROID BIOCHEM, V62, P401, DOI 10.1016/S0960-0760(97)00059-9; SPIEGELMAN BM, 1980, J BIOL CHEM, V255, P8811; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STEFFEN F, 1992, NUCLEIC ACIDS RES, V20, P3; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; TANUMA Y, 1995, MOL CELL BIOL, V15, P517, DOI 10.1128/MCB.15.1.517; Uht RM, 1997, ENDOCRINOLOGY, V138, P2900, DOI 10.1210/en.138.7.2900; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Urabe M, 1996, ENDOCR J, V43, P737, DOI 10.1507/endocrj.43.737; WADE GN, 1978, ENDOCRINOLOGY, V103, P1695, DOI 10.1210/endo-103-5-1695; WADE GN, 1975, J COMP PHYSIOL PSYCH, V88, P183, DOI 10.1037/h0076186; WADE GN, 1979, PHYSIOL BEHAV, V22, P583, DOI 10.1016/0031-9384(79)90028-3; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443	52	150	158	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11404	11411		10.1074/jbc.275.15.11404	http://dx.doi.org/10.1074/jbc.275.15.11404			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753956	hybrid			2022-12-27	WOS:000086466600098
J	Kagan, A; Yu, ZH; Fishman, GI; McDonald, TV				Kagan, A; Yu, ZH; Fishman, GI; McDonald, TV			The dominant negative LQT2 mutation A561V reduces wild-type HERG expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-QT SYNDROME; TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS; POTASSIUM CHANNEL; INTRACELLULAR-TRANSPORT; CARDIAC-ARRHYTHMIA; XENOPUS OOCYTES; MOLECULAR-BASIS; PROTEASOME; DEGRADATION	HERG(1) K+ channel mutations are responsible for one form of dominantly inherited Long QT syndrome (LQT), Some LQT mutations exert a dominant negative effect on wild-type current expression. To investigate mechanisms of dominant-negative behavior, we co-expressed wild-type HERG with the A561V mutant in mammalian cells. Transfection with various cDNA ratios produced HERG K+ current densities that approached a predicted binomial distribution where mutant and wild-type subunits co-assemble in a tetramer with nearly complete dominance. Using C terminus myc-tagged wild-type HERG we specifically followed the mutant's effect on full-length wild-type HERG protein expression. Co-expression with A561V reduced the abundance of full-length wild-type HERG protein comparable to the current reduction. Reduction of wild-type protein was due to decreased synthesis and increased turnover. Conditions facilitating protein folding (growth at 30 degrees C, or in 10% glycerol) resulted in partial rescue from the dominant effect, as did the 26 S proteosome inhibitor ALLN. Thus, for A561V, dominant negative effects result from assembly of wild-type subunits with mutant very early in production leading to rapid recognition of mutant channels and targeting for proteolysis. These results establish protein misfolding, cellular proofreading, and bystander involvement as contributing mechanisms for dominant effects in LQT2.	Albert Einstein Coll Med, Dept Med, Sect Mol Cardiol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Mol Pharmacol, Sect Mol Cardiol, Bronx, NY 10461 USA; CUNY Mt Sinai Sch Med, Dept Med, Zena & Michael A Wiener Cardiovasc Inst, Sect Myocardial Biol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, Zena & Michael A Wiener Cardiovasc Inst, Sect Myocardial Biol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Biochem & Mol Biol, Zena & Michael A Wiener Cardiovasc Inst, Sect Myocardial Biol, New York, NY 10029 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	McDonald, TV (corresponding author), Albert Einstein Coll Med, Dept Med, Sect Mol Cardiol, Bronx, NY 10461 USA.			Fishman, Glenn/0000-0002-2366-8527	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057388] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 57388] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ackerman MJ, 1998, MAYO CLIN PROC, V73, P250, DOI 10.4065/73.3.250; Chen J, 1999, J BIOL CHEM, V274, P10113, DOI 10.1074/jbc.274.15.10113; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CREIGHTON TE, 1980, J MOL BIOL, V144, P521, DOI 10.1016/0022-2836(80)90335-6; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Dausse E, 1996, J MOL CELL CARDIOL, V28, P1609, DOI 10.1006/jmcc.1996.0151; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; Flagg TP, 1999, J GEN PHYSIOL, V114, P685, DOI 10.1085/jgp.114.5.685; Furutani M, 1999, CIRCULATION, V99, P2290, DOI 10.1161/01.CIR.99.17.2290; HAMMILL OP, 1981, PFLUGERS ARCH, V391, P85; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Itoh T, 1998, HUM GENET, V102, P435, DOI 10.1007/s004390050717; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Keating MT, 1996, CURR OPIN GENET DEV, V6, P326, DOI 10.1016/S0959-437X(96)80010-4; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Li XD, 1997, J BIOL CHEM, V272, P705, DOI 10.1074/jbc.272.2.705; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Roden DM, 1996, CIRCULATION, V94, P1996, DOI 10.1161/01.CIR.94.8.1996; Sanguinetti MC, 1996, P NATL ACAD SCI USA, V93, P2208, DOI 10.1073/pnas.93.5.2208; Satler CA, 1996, AM J MED GENET, V65, P27, DOI 10.1002/(SICI)1096-8628(19961002)65:1<27::AID-AJMG4>3.3.CO;2-J; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; SAWANO H, 1992, FEBS LETT, V303, P11, DOI 10.1016/0014-5793(92)80466-T; Tanaka T, 1997, CIRCULATION, V95, P565, DOI 10.1161/01.CIR.95.3.565; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wigley WC, 1999, J CELL BIOL, V145, P481; Zhou ZF, 1999, J BIOL CHEM, V274, P31123, DOI 10.1074/jbc.274.44.31123; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061; Zou AR, 1998, J PHYSIOL-LONDON, V509, P129, DOI 10.1111/j.1469-7793.1998.129bo.x	38	76	87	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11241	11248		10.1074/jbc.275.15.11241	http://dx.doi.org/10.1074/jbc.275.15.11241			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753933	hybrid			2022-12-27	WOS:000086466600075
J	Kawamoto, Y; Nakamura, Y; Naito, Y; Torii, Y; Kumagai, T; Osawa, T; Ohigashi, H; Satoh, K; Imagawa, M; Uchida, K				Kawamoto, Y; Nakamura, Y; Naito, Y; Torii, Y; Kumagai, T; Osawa, T; Ohigashi, H; Satoh, K; Imagawa, M; Uchida, K			Cyclopentenone prostaglandins as potential inducers of phase II detoxification enzymes - 15-deoxy-Delta(12,14)-prostaglandin J2-induced expression of glutathione S-transferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT CHEMICAL HEPATOCARCINOGENESIS; ANTIOXIDANT RESPONSE ELEMENT; YA-SUBUNIT GENE; P-GENE; ANTIPROLIFERATIVE ACTIVITY; INDUCIBLE EXPRESSION; GROWTH-INHIBITION; HEPATIC-NECROSIS; MAMMALIAN-CELLS; PLACENTAL FORM	Exposure of cells to a wide variety of chemoprotective compounds confers resistance to a broad set of carcinogens. For a subset of the chemoprotective compounds, protection is generated by an increase in the abundance of protective enzymes, such as glutathione S-transferases (GSTs), In the present study, we developed a cell culture system that potently responds to phenolic antioxidants and found that antitumor prostaglandins (PGs) are potential inducers of GSTs, We screened primary hepatocytes and multiple cell lines for inducing GST activity upon incubation with the phenolic antioxidant (tert-butylhydroquinone) and found that rat liver epithelial RL34 cells most potently responded. Based on an extensive screening of diverse chemical agents on the induction of GST activity in RL34 cells, the J2 series of PGs, 15-deoxy-Delta(12,14)-prostaglandin J2 (15-deoxy-Delta(12,14)- PGJ2) in particular, were found to be potential inducers of GST, Enhanced gene expression of Class rr GST isozyme (GSTP1) by 15-deoxy-Delta(12,14)-PGJ2 was evident as a drastic elevation of the mRNA level, Hence, we examined the molecular mechanism underlying the 15-deoxy-Delta(12,14)-PGJ2-induced GSTP1 gene expression, From functional analysis of various deletion mutant genes, we found that the 15-deoxy-Delta(12,14)-PGJ2 reponse element was localized in a region containing a GSTP1 enhancer I (GPEI) that consists of two imperfect phorbol 12-O-tetradecanoylphorbol-13-acetate response elements. When the GPEI was combined with the minimum GSTP1 promoter, the element indeed showed an enhancer activity in response to 15-deoxy-Delta(12,14)-PGJ2. Point mutations of either of the two imperfect 12-O-tetradecanoylphorbol-13-acetate response elements in GPEI completely abolished the enhancer activity. Gel mobility shift assays demonstrated that 15-deoxy-Delta(12,14)-PGJ2 specifically stimulated the binding of nuclear proteins including the transcription factor c-Jun, but not Nrf2, to GPEI, These results suggest that 15-deoxy-Delta(12,14)-PGJ2 induces the expression of the rat GSTP1 gene through binding of proteins, including c-Jun, to a specific GPEI.	Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan; Kyoto Univ, Grad Sch Agr, Div Appl Sci, Lab Organ Chem Life Sci, Kyoto 606, Japan; Hirosaki Univ, Sch Med, Dept Biochem 2, Hirosaki, Aomori 036, Japan; Osaka Univ, Grad Sch Pharmaceut Sci, Suita, Osaka 5650871, Japan	Nagoya University; Kyoto University; Hirosaki University; Osaka University	Uchida, K (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan.	uchidak@agr.nagoya-u.ac.jp	Torii, Yasuyoshi/G-7800-2016	Uchida, Koji/0000-0003-3894-5299				AINBINDER E, 1995, EUR J BIOCHEM, V243, P49; ALP MH, 1987, J HEPATOL, V4, P99, DOI 10.1016/S0168-8278(87)80016-8; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARAKI H, 1980, AM J PHYSIOL, V238, pH176, DOI 10.1152/ajpheart.1980.238.2.H176; ATSMON J, 1990, CANCER RES, V50, P1879; ATSMON J, 1990, BIOCHEMISTRY-US, V29, P3760, DOI 10.1021/bi00467a023; BERHANE K, 1994, P NATL ACAD SCI USA, V91, P1480, DOI 10.1073/pnas.91.4.1480; Breyer MD, 1996, J AM SOC NEPHROL, V7, P8; CAGEN LM, 1976, J BIOL CHEM, V251, P6550; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOI AMK, 1992, EXP CELL RES, V199, P85, DOI 10.1016/0014-4827(92)90464-J; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS DC, 1974, LIFE SCI, V14, P2099, DOI 10.1016/0024-3205(74)90092-7; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DICCIANNI MB, 1992, NUCLEIC ACIDS RES, V20, P5153, DOI 10.1093/nar/20.19.5153; DIILIO C, 1987, CARCINOGENESIS, V8, P861, DOI 10.1093/carcin/8.6.861; FITZPATRICK FA, 1983, J BIOL CHEM, V258, P1713; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; FUKUSHIMA M, 1990, EICOSANOIDS, V3, P189; FUKUSHIMA M, 1992, PROSTAG LEUKOTR ESS, V47, P1, DOI 10.1016/0952-3278(92)90178-L; GILES H, 1988, PROSTAGLANDINS, V35, P277, DOI 10.1016/0090-6980(88)90093-7; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Henderson CJ, 1998, P NATL ACAD SCI USA, V95, P5275, DOI 10.1073/pnas.95.9.5275; HIRATA M, 1994, P NATL ACAD SCI USA, V91, P11192, DOI 10.1073/pnas.91.23.11192; HIRATA Y, 1988, J BIOL CHEM, V263, P16619; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P5, DOI 10.1093/nar/19.1.5; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; JAISWAL AK, 1994, BIOCHEM PHARMACOL, V48, P439, DOI 10.1016/0006-2952(94)90272-0; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KARASAKI S, 1976, CANCER RES, V36, P4491; KHAN SH, 1990, P NATL ACAD SCI USA, V87, P9401, DOI 10.1073/pnas.87.23.9401; KIKAWA Y, 1984, P NATL ACAD SCI-BIOL, V81, P1317, DOI 10.1073/pnas.81.5.1317; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KODATE C, 1986, GANN, V77, P226; KOIZUMI T, 1995, J BIOL CHEM, V270, P21779, DOI 10.1074/jbc.270.37.21779; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; Matsumoto M, 1999, BIOCHEM J, V338, P599, DOI 10.1042/0264-6021:3380599; MIZOGUCHI Y, 1987, HEPATOLOGY, V7, P1184, DOI 10.1002/hep.1840070603; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MORIMURA S, 1993, P NATL ACAD SCI USA, V90, P2065, DOI 10.1073/pnas.90.5.2065; NARUMIYA S, 1987, J PHARMACOL EXP THER, V242, P306; NODA Y, 1986, J HEPATOL, V2, P53, DOI 10.1016/S0168-8278(86)80008-3; NOWAK J, 1979, ACTA PHYSIOL SCAND, V106, P307, DOI 10.1111/j.1748-1716.1979.tb06403.x; NOYORI R, 1993, SCIENCE, V259, P44, DOI 10.1126/science.8418493; OGAWA M, 1988, GASTROENTEROLOGY, V94, P1024, DOI 10.1016/0016-5085(88)90562-8; OHNO K, 1988, J BIOL CHEM, V263, P19764; OHNO K, 1990, CHEM-BIOL INTERACT, V76, P77, DOI 10.1016/0009-2797(90)90035-L; Ohtani-Fujita N, 1998, BIOCHEM BIOPH RES CO, V251, P648, DOI 10.1006/bbrc.1998.9511; OKIGAKI T, 1976, P JPN ACAD, V52, P312, DOI 10.2183/pjab1945.52.312; OKIGAKI T, 1977, TCA (Tissue Culture Association) Manual, V3, P565, DOI 10.1007/BF00918382; OKUDA A, 1990, EMBO J, V9, P1131, DOI 10.1002/j.1460-2075.1990.tb08219.x; OKUDA A, 1989, J BIOL CHEM, V264, P16919; OKUDA A, 1987, J BIOL CHEM, V262, P3858; Osada S, 1995, J BIOL CHEM, V270, P31288, DOI 10.1074/jbc.270.52.31288; PARKER J, 1992, BIOCHEM PHARMACOL, V43, P1053, DOI 10.1016/0006-2952(92)90612-M; PRESTERA T, 1993, P NATL ACAD SCI USA, V90, P2965, DOI 10.1073/pnas.90.7.2965; PRESTERA T, 1993, ADV ENZYME REGUL, V33, P281; PROCHASKA HJ, 1985, P NATL ACAD SCI USA, V82, P8232, DOI 10.1073/pnas.82.23.8232; RUSH B, 1986, PROSTAGLANDINS, V32, P439, DOI 10.1016/0090-6980(86)90011-0; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; SANTORO MG, 1989, P NATL ACAD SCI USA, V86, P8407, DOI 10.1073/pnas.86.21.8407; SATO K, 1989, ADV CANCER RES, V52, P205; SATO K, 1984, GANN, V75, P199; SATOH K, 1985, P NATL ACAD SCI USA, V82, P3964, DOI 10.1073/pnas.82.12.3964; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SHEA TC, 1988, CANCER RES, V48, P527; SPENCER SR, 1991, BIOCHEM J, V273, P711, DOI 10.1042/bj2730711; SUGUOKA Y, 1985, NUCLEIC ACIDS RES, V13, P6049, DOI 10.1093/nar/13.17.6049; TALALAY P, 1989, ADV ENZYME REGUL, V28, P237, DOI 10.1016/0065-2571(89)90074-5; TALALAY P, 1988, P NATL ACAD SCI USA, V85, P8261, DOI 10.1073/pnas.85.21.8261; TALALAY P, 1987, CANCER BIOL THERAPEU, P197; TASAKI Y, 1991, PROSTAGLANDINS, V41, P303, DOI 10.1016/0090-6980(91)90001-V; TATEMATSU M, 1985, CARCINOGENESIS, V6, P1621, DOI 10.1093/carcin/6.11.1621; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Yu R, 1999, J BIOL CHEM, V274, P27545, DOI 10.1074/jbc.274.39.27545	83	92	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11291	11299		10.1074/jbc.275.15.11291	http://dx.doi.org/10.1074/jbc.275.15.11291			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753940	hybrid			2022-12-27	WOS:000086466600082
J	Matsushita, T; Meyer, D; Sadler, JE				Matsushita, T; Meyer, D; Sadler, JE			Localization of von Willebrand factor-binding sites for platelet glycoprotein Ib and botrocetin by charged-to-alanine scanning mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR-BINDING; FACTOR A1 DOMAIN; MONOCLONAL-ANTIBODY; BOTHROPS-JARARACA; CRYSTAL-STRUCTURE; HEMOPHILIA-A; ALPHA-CHAIN; RISTOCETIN; DISEASE; MUTATION	At sites of vascular injury, von Willebrand factor (VWF) mediates platelet adhesion through binding to platelet glycoprotein lb (GPIb). Previous studies identified clusters of charged residues within VWF domain Al that were involved in binding GPIb or botrocetin, The contribution of 28 specific residues within these clusters was analyzed by mutating single amino acids to alanine, Binding to a panel of six conformation-dependent monoclonal antibodies was decreased by mutations at Asp(514) Asp(520) Arg(552), and Arg(611) (numbered from the N-terminal Ser of the mature processed VWF), suggesting that these residues are necessary for domain Al folding. Binding of I-125-botrocetin was decreased by mutations at Arg(629), Arg(632), Arg(636), and Lys(667). Ristocetin-induced and botrocetin-induced binding to GPIb both were decreased by mutations at Lys(599), Arg(629), and Arg(632); among this group the K599A mutant was unique because I-125-botrocetin binding was normal, suggesting that Lys(599) interacts directly with GPIb. Ristocetin and botrocetin actions on VWF were dissociated readily by mutagenesis, Ristocetin-induced binding to GPIb was reduced selectively by substitutions at positions Lys(534), Arg(571), Lys(572), Glu(596), Glu(613) Arg(616), Glu(626), and Lys(642), whereas botrocetin-induced binding to GPIb, was decreased selectively by mutations at Arg(636) and Lys(667) The binding of monoclonal antibody B724 involved Lys(660) and Arg(663), and this antibody inhibits I-125-botrocetin binding to VWF, The crystal structure of the Al domain suggests that the botrocetin-binding site overlaps the monoclonal antibody B724 epitope on helix 5 and spans helices 4 and 5, The binding of botrocetin also activates the nearby VWF-binding site for GPIb that involves Lys(599) on helix 3.	Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Hop Bicetre, INSERM, U143, F-94275 Le Kremlin Bicetre, France	Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Sadler, JE (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Med, 660 S Euclid Ave,Box 8022, St Louis, MO 63110 USA.		Sadler, Evan/D-8556-2011; Matsushita, Tadadshi/I-7349-2014					ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8326, DOI 10.1021/bi00447a010; ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8317, DOI 10.1021/bi00447a009; Celikel R, 1998, NAT STRUCT BIOL, V5, P189, DOI 10.1038/nsb0398-189; CHRISTOPHE O, 1995, BRIT J HAEMATOL, V90, P195, DOI 10.1111/j.1365-2141.1995.tb03400.x; COLLER BS, 1983, BLOOD, V61, P99; DONG ZG, 1994, J BIOL CHEM, V269, P6753; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Emsley J, 1998, J BIOL CHEM, V273, P10396, DOI 10.1074/jbc.273.17.10396; FUJIMURA Y, 1991, BLOOD, V77, P113; FUJIMURA Y, 1991, BIOCHEMISTRY-US, V30, P1957, DOI 10.1021/bi00221a032; GINSBURG D, 1993, THROMB HAEMOSTASIS, V69, P177; GIRMA JP, 1990, THROMB HAEMOSTASIS, V64, P326; HANDA M, 1986, J BIOL CHEM, V261, P2579; Hillery CA, 1998, BLOOD, V91, P1572, DOI 10.1182/blood.V91.5.1572.1572_1572_1581; HOLMBERG L, 1993, J CLIN INVEST, V91, P2169, DOI 10.1172/JCI116443; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JORIEUX S, 1987, THROMB HAEMOSTASIS, V57, P278; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; MATSUSHITA T, 1995, J BIOL CHEM, V270, P13406, DOI 10.1074/jbc.270.22.13406; MAZURIER C, 1990, BRIT J HAEMATOL, V76, P372, DOI 10.1111/j.1365-2141.1990.tb06371.x; Meyer D, 1997, THROMB HAEMOSTASIS, V78, P451; MOHRI H, 1988, J BIOL CHEM, V263, P17901; MURATA M, 1991, J BIOL CHEM, V266, P15474; RABINOWITZ I, 1993, J BIOL CHEM, V268, P20497; RABINOWITZ I, 1992, P NATL ACAD SCI USA, V89, P9846, DOI 10.1073/pnas.89.20.9846; RAINES G, 1990, THROMB RES, V60, P201, DOI 10.1016/0049-3848(90)90181-B; RANDI AM, 1992, J BIOL CHEM, V267, P21187; RIBBA AS, 1994, BLOOD, V83, P833; Ruggeri ZM, 1997, J CLIN INVEST, V99, P559, DOI 10.1172/JCI119195; SCHULLEK J, 1984, J CLIN INVEST, V73, P421, DOI 10.1172/JCI111228; SCOTT JP, 1991, J BIOL CHEM, V266, P8149; SOBEL M, 1992, J BIOL CHEM, V267, P8857; STEL HV, 1984, BLOOD, V63, P1408; TULEY EA, 1991, P NATL ACAD SCI USA, V88, P6377, DOI 10.1073/pnas.88.14.6377; VICENTE V, 1990, J BIOL CHEM, V265, P274; Wood N, 1996, THROMB HAEMOSTASIS, V75, P363	37	66	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11044	11049		10.1074/jbc.275.15.11044	http://dx.doi.org/10.1074/jbc.275.15.11044			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753907	hybrid			2022-12-27	WOS:000086466600049
J	Wertz, IE; Dixit, VM				Wertz, IE; Dixit, VM			Characterization of calcium release-activated apoptosis of LNCaP prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-X-L; DEATH; PROLIFERATION; THAPSIGARGIN; CASPASE-9; SUPPRESSION; INDICATORS; INHIBITOR; DEPLETION; PROTEASE	Apoptosis inhibition rather than enhanced cellular proliferation occurs in prostate cancer (CaP), the most commonly diagnosed malignancy in American men. Therefore, it is important to characterize residual apoptotic pathways in CaP cells. When intracellular Ca2+ stores are released and plasma membrane "store-operated" Ca2+ entry channels subsequently open, cytosolic [Ca2+] increases and is thought to induce apoptosis, However, cells incapable of releasing Ca2+ stores are resistant to apoptotic stimuli, indicating that Ca2+ store release is also important. We investigated whether release of intracellular Ca2+ stores is sufficient to induce apoptosis of the CaP cell line LNCaP. We developed a method to release stored Ca2+ without elevating cytosolic [Ca2+]; this stimulus induced LNCaP cell apoptosis, We compared the apoptotic pathways activated by intracellular Ca2+ store release with the dual insults of store release and cytosolic [Ca2+] elevation. Earlier processing of caspases-3 and -7 occurred when intracellular store release was the sole Ca2+ perturbation. Apoptosis was attenuated in both conditions in stable transfected cells expressing antiapoptotic proteins Bclx(L) and catalytically inactive caspase-9, and in both scenarios inactive caspase-9 became complexed with caspase-7. Thus, intracellular Ca2+ store release initiates an apoptotic pathway similar to that elicited by the dual stimuli of cytosolic [Ca2+] elevation and intracellular store release.	Genentech Inc, Dept Mol Oncol, S San Francisco, CA 94080 USA; Univ Calif Davis, Sch Med, Dept Human Physiol, Davis, CA 95616 USA; Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA	Roche Holding; Genentech; University of California System; University of California Davis; University of California System; University of California Davis	Dixit, VM (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way, S San Francisco, CA 94080 USA.		dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326				Berridge MJ, 1995, ANN NY ACAD SCI, V766, P31, DOI 10.1111/j.1749-6632.1995.tb26646.x; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; COLOMBEL MC, 1995, METHOD CELL BIOL, V46, P369; Darzynkiewicz Z, 1997, CYTOMETRY, V27, P1; DAY ML, 1994, CELL GROWTH DIFFER, V5, P735; Denmeade S R, 1996, Adv Pharmacol, V35, P281, DOI 10.1016/S1054-3589(08)60278-1; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FURUYA Y, 1994, CANCER RES, V54, P6167; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gumerlock P. H., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P47; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HARPER JW, 1993, CELL, V75, P805; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Huang A, 1998, UROLOGY, V51, P346, DOI 10.1016/S0090-4295(97)00636-5; KAO JPY, 1994, METHOD CELL BIOL, V40, P155; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KYPRIANOU N, 1988, PROSTATE, V13, P103, DOI 10.1002/pros.2990130203; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Lotem J, 1998, P NATL ACAD SCI USA, V95, P4601, DOI 10.1073/pnas.95.8.4601; LYTTON J, 1991, J BIOL CHEM, V266, P17067; Marin MC, 1996, ONCOGENE, V12, P2259; Marks AR, 1997, AM J PHYSIOL-HEART C, V272, pH597, DOI 10.1152/ajpheart.1997.272.2.H597; MUENZER JT, 1997, P AM ASS CLIN ONCOL, V16, pA245; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Prosperi E, 1997, Prog Cell Cycle Res, V3, P193; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Skryma RN, 1997, PROSTATE, V33, P112, DOI 10.1002/(SICI)1097-0045(19971001)33:2<112::AID-PROS5>3.0.CO;2-M; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Thomas D, 1998, VITAM HORM, V54, P97, DOI 10.1016/S0083-6729(08)60923-1; THOMAS D, 1994, METHOD CELL BIOL, V40, P65; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; Tu HC, 1996, INT J CANCER, V69, P357, DOI 10.1002/(SICI)1097-0215(19961021)69:5<357::AID-IJC1>3.0.CO;2-4; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wertz IE, 1996, TRENDS BIOCHEM SCI, V21, P359, DOI 10.1016/0968-0004(96)40002-0; WYLLIE AH, 1982, AM J PATHOL, V109, P78; Yao Y, 1997, J GEN PHYSIOL, V109, P703, DOI 10.1085/jgp.109.6.703; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	46	110	114	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11470	11477		10.1074/jbc.275.15.11470	http://dx.doi.org/10.1074/jbc.275.15.11470			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753965				2022-12-27	WOS:000086466600107
J	Chou, CC; Sun, YJ; Meng, MS; Hsiao, CD				Chou, CC; Sun, YJ; Meng, MS; Hsiao, CD			The crystal structure of phosphoglucose isomerase/autocrine motility factor/neuroleukin complexed with its carbohydrate phosphate inhibitors suggests its substrate/receptor recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-BROMOACETYLETHANOLAMINE PHOSPHATE; GLUCOSE-6-PHOSPHATE ISOMERASE; PHOSPHOHEXOSE ISOMERASE; FACTOR NEUROLEUKIN; PROTEIN STRUCTURES; ELECTRON-DENSITY; CELLS; PROGRAM; PURIFICATION; EXPRESSION	Phosphoglucose isomerase catalyzes the reversible isomerization of glucose 6-phosphate to fructose B-phosphate. In addition, phosphoglucose isomerase has been shown to have functions equivalent to neuroleukin, autocrine motility factor, and maturation factor. Here we present the crystal structures of phosphoglucose isomerase complexed with 5-phospho-D-arabinonate and N-bromoacetylethanolamine phosphate at 2.5- and 2.3-Angstrom resolution, respectively. The inhibitors bind to a region within the domains' interface and interact with a histidine residue (His(306)) from the other subunit. We also demonstrated that the inhibitors not only affect the enzymatic activity of phosphoglucose isomerase, but can also inhibit the autocrine motility factor-induced cell motility of CT-26 mouse colon tumor cells. These results indicate that the substrate and the receptor binding sites of phosphoglucose isomerase and autocrine motility factor are located within close proximity to each other. Based on these two complex structures, together with biological and biochemical results, we propose a possible isomerization mechanism for phosphoglucose isomerase.	Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; Taipei Med Coll, Inst Cell & Mol Biol, Taipei, Taiwan; Natl Chung Hsing Univ, Grad Inst Agr Biotechnol, Taichung 40227, Taiwan	Academia Sinica - Taiwan; National Defense Medical Center; Taipei Medical University; National Chung Hsing University	Hsiao, CD (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan.	mbhsiao@ccvax.sinica.edu.tw	Hsiao, Chwan-Deng/AAZ-8869-2021; Hsiao, Chwan-Deng/D-7327-2013	Hsiao, Chwan-Deng/0000-0002-7012-1532; 				ACHARI A, 1981, PHILOS T ROY SOC B, V293, P145, DOI 10.1098/rstb.1981.0068; BAUMANN M, 1990, CANCER INVEST, V8, P351, DOI 10.3109/07357909009012053; Baumgart E, 1996, J BIOL CHEM, V271, P3846; BRUNGER AT, 1992, EXPLOR 3 1 SYSTEM CR; CHAPUT M, 1988, NATURE, V332, P454, DOI 10.1038/332454a0; CHIRGWIN JM, 1975, J BIOL CHEM, V250, P7272; DYSON JED, 1968, J BIOL CHEM, V243, P1401; FAIK P, 1988, NATURE, V332, P455, DOI 10.1038/332455a0; GIBSON DR, 1980, J BIOL CHEM, V255, P9369; Gracy R W, 1975, Methods Enzymol, V41, P392; GURNEY ME, 1986, SCIENCE, V234, P574, DOI 10.1126/science.3020690; Hardre R, 1998, BIOORG MED CHEM LETT, V8, P3435, DOI 10.1016/S0960-894X(98)00621-0; HARTMAN FC, 1973, J BIOL CHEM, V248, P8233; Hsiao CD, 1997, J STRUCT BIOL, V120, P196, DOI 10.1006/jsbi.1997.3913; Jeffery CJ, 2000, BIOCHEMISTRY-US, V39, P955, DOI 10.1021/bi991604m; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kugler W, 1998, HUM GENET, V103, P450, DOI 10.1007/s004390050849; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LIN MT, 1992, MOL CELL ENDOCRINOL, V84, P47, DOI 10.1016/0303-7207(92)90070-M; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; MALAISSE WJ, 1990, MOL CELL BIOCHEM, V93, P153; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Meng MS, 1999, PROTEIN SCI, V8, P2438; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MIZRACHI Y, 1989, J NEUROSCI RES, V23, P217, DOI 10.1002/jnr.490230212; NABI IR, 1990, CANCER RES, V50, P409; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Niinaka Y, 1998, CANCER RES, V58, P2667; OCONNELL EL, 1973, J BIOL CHEM, V248, P2225; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; SALAS M, 1965, J BIOL CHEM, V240, P561; SCHRAY KJ, 1973, J BIOL CHEM, V248, P2219; SHAW PJ, 1977, J MOL BIOL, V109, P475, DOI 10.1016/S0022-2836(77)80025-9; Sun YJ, 1999, P NATL ACAD SCI USA, V96, P5412, DOI 10.1073/pnas.96.10.5412; TOR J, 1981, MED CLIN-BARCELONA, V77, P236; TOR J, 1982, REV CLIN ESP, V164, P15; Watanabe H, 1996, CANCER RES, V56, P2960; WATANABE H, 1991, J BIOL CHEM, V266, P13442; WELCH SG, 1971, HUM HERED, V21, P467, DOI 10.1159/000152439; Xu W, 1996, BLOOD, V87, P4502, DOI 10.1182/blood.V87.11.4502.bloodjournal87114502	41	48	48	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23154	23160		10.1074/jbc.M002017200	http://dx.doi.org/10.1074/jbc.M002017200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10770936	hybrid			2022-12-27	WOS:000088419400075
J	Song, JL; Wynn, RM; Chuang, DT				Song, JL; Wynn, RM; Chuang, DT			Interactions of GroEL/GroES with a heterodimeric intermediate during alpha(2)beta(2) assembly of mitochondrial branched-chain alpha-ketoacid dehydrogenase - cis capping of the native-like 86-kDa intermediate by GroES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONIN GROEL; SUBSTRATE-BINDING; CRYSTAL-STRUCTURE; CO-CHAPERONIN; PROTEIN; LACTALBUMIN; POLYPEPTIDE; ATP; IDENTIFICATION; DECARBOXYLASE	We showed previously that the interaction of an alpha beta heterodimeric intermediate with GroEL/GroES is essential for efficient alpha(2)beta(2) assembly of human mitochondrial branched chain alpha-ketoacid dehydrogenase. In the present study, we further characterized the mode of interaction between the chaperonins and the native-like alpha beta heterodimer, The alpha beta heterodimer, as an intact entity, was found to bind to GroEL at a 1:1 stoichiometry with a K-D of 1.1 x 10(-7) M, The 1:1 molar ratio of the GroEL-alpha beta complex was confirmed by the ability of the complex to bind a stoichiometric amount of denatured lysozyme in the trans cavity, Surprisingly, in the presence of Mg-ADP, GroES was able to cap the GroEL-alpha beta complex in cis, despite the size of 86 kDa of the heterodimer (with a His(6) tag and a linker). Incubation of the GroEL-alpha beta complex with Mg-ATP, but not AMP-PNP, resulted in the release of alpha monomers, In the presence of Mg-ATP, the beta subunit was also released but was unable to assemble with the alpha subunit, and rebound to GroEL, The apparent differential subunit release from GroEL is explained, in part, by the significantly higher binding affinity of the beta subunit (K-D < 4.15 x 10(-9) M) than the alpha (K-D = 1.6 x 10(-8) M) for GroEL, Incubation of the GroEL-alpha beta complex with Mg-ATP and GroES resulted in dissociation and discharge of both the alpha and beta subunits from GroEL. The beta subunit upon binding to GroEL underwent further folding in the cis cavity sequestered by GroES. This step rendered the beta subunit competent for reassociation with the soluble alpha subunit to produce a new heterodimer, We propose that this mechanism is responsible for the iterative annealing of the kinetically trapped heterodimeric intermediate, leading to an efficient alpha(2)beta(2) assembly of human branched-chain alpha-ketoacid dehydrogenase.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chuang, DT (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Wynn, Richard/0000-0002-1879-2136	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026758] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-26758] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEvarsson A, 2000, STRUCTURE, V8, P277, DOI 10.1016/S0969-2126(00)00105-2; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; Chatellier J, 1999, J MOL BIOL, V292, P163, DOI 10.1006/jmbi.1999.3040; Chen LL, 1999, CELL, V99, P757, DOI 10.1016/S0092-8674(00)81673-6; CHUANG DT, 1995, METABOLIC MOL BASES, P1239; Chuang JL, 1999, J BIOL CHEM, V274, P10395, DOI 10.1074/jbc.274.15.10395; Esnouf R. M., 1997, J MOL GRAPHICS, V15, P133; Fedorov AN, 1997, J MOL BIOL, V268, P712, DOI 10.1006/jmbi.1997.1007; Feltham JL, 2000, CELL, V100, P193, DOI 10.1016/S0092-8674(00)81557-3; Fenton WA, 1997, PROTEIN SCI, V6, P743; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; GUNST RF, 1980, REGRESSION ANAL ITS, P232; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; Houry WA, 1999, NATURE, V402, P147, DOI 10.1038/45977; Huang YS, 1999, J BIOL CHEM, V274, P10405, DOI 10.1074/jbc.274.15.10405; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; Kawata Y, 1999, BIOCHEMISTRY-US, V38, P15731, DOI 10.1021/bi9909750; Kobayashi N, 1999, J MOL BIOL, V292, P181, DOI 10.1006/jmbi.1999.3042; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Li J, 1999, J BIOL CHEM, V274, P10790, DOI 10.1074/jbc.274.16.10790; Lorimer G, 1997, NATURE, V388, P720, DOI 10.1038/41892; Makio T, 1999, J MOL BIOL, V293, P125, DOI 10.1006/jmbi.1999.3142; Mande SC, 1996, SCIENCE, V271, P203, DOI 10.1126/science.271.5246.203; MURAI N, 1995, J BIOL CHEM, V270, P19957, DOI 10.1074/jbc.270.34.19957; PUIG A, 1994, J BIOL CHEM, V269, P7764; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Rye HS, 1999, CELL, V97, P325, DOI 10.1016/S0092-8674(00)80742-4; SAIKAWA C, 1999, J BIOL CHEM, V274, P21251; Shtilerman M, 1999, SCIENCE, V284, P822, DOI 10.1126/science.284.5415.822; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; Tanaka N, 1999, J MOL BIOL, V292, P173, DOI 10.1006/jmbi.1999.3041; Wang ZL, 1999, BIOCHEMISTRY-US, V38, P12537, DOI 10.1021/bi991070p; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Wynn RM, 1998, J BIOL CHEM, V273, P13110, DOI 10.1074/jbc.273.21.13110; Wynn RM, 2000, J BIOL CHEM, V275, P2786, DOI 10.1074/jbc.275.4.2786; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Xu ZH, 1998, J STRUCT BIOL, V124, P129, DOI 10.1006/jsbi.1998.4060; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	43	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22305	22312		10.1074/jbc.M002038200	http://dx.doi.org/10.1074/jbc.M002038200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10764784	hybrid			2022-12-27	WOS:000088363800076
J	Bodas, E; Aleu, J; Pujol, G; Martin-Satue, M; Marsal, J; Solsona, C				Bodas, E; Aleu, J; Pujol, G; Martin-Satue, M; Marsal, J; Solsona, C			ATP crossing the cell plasma membrane generates an ionic current in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CFTR CL CHANNEL; ADENINE-NUCLEOTIDES; INDUCED RELEASE; EPITHELIA; MUSCLE; MECHANISMS; SECRETION; RECEPTORS; ANALOGS	The presence of ATP within cells is well established However, ATP also operates as an intercellular signal cia specific purinoceptors, Furthermore, nonsecretory cells can release ATP under certain experimental conditions. To measure ATP release and membrane currents from a single cell simultaneously, we used Xenopus oocytes, We simultaneously recorded membrane currents and luminescence, Here, we show that ATP release can be triggered in Xenopus oocytes by hyperpolarizing pulses. ATP release (3.2 +/- 0.3 pmol/oocyte) generated a slow inward current (2.3 +/- 0.1 mu A). During hyperpolarizing pulses, the permeability for ATP(4-) was more than 4000 times higher than that for Cl-. The sensitivity to GdCl3 (0.2 mM) of hyperpolarization-induced ionic current, ATP release and E-ATPase activity suggests their dependence on stretch-activated ion channels. The pharmacological profile of the current inhibition coincides with the inhibition of ecto-ATPase activity. This enzyme is highly conserved among species, and in humans, it has been cloned and characterized as CD39, The translation, in Xenopus oocytes, of human CD39 mRNA encoding enhances the ATP-supported current, indicating that CD39 is directly or indirectly responsible for the electrodiffusion of ATP.	Univ Barcelona, Bellvitge Hosp, Sch Med,Dept Cell Biol & Pathol, Mol & Cellular Neurobiol Lab, E-08907 Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona	Solsona, C (corresponding author), Univ Barcelona, Bellvitge Hosp, Sch Med,Dept Cell Biol & Pathol, Mol & Cellular Neurobiol Lab, Campus Bellvitge,Feixa Llarga S-N,Hosp Llobregat, E-08907 Barcelona, Spain.		Aleu, Jordi/B-8768-2008	Aleu, Jordi/0000-0002-1882-3756				ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; Abraham EH, 1997, SCIENCE, V275, P1324, DOI 10.1126/science.275.5304.1324; Ackerman MJ, 1997, NEW ENGL J MED, V336, P1575, DOI 10.1056/NEJM199705293362207; Aleksandrov AA, 1998, FEBS LETT, V431, P97, DOI 10.1016/S0014-5793(98)00713-3; Arellano RO, 1998, AM J PHYSIOL-CELL PH, V274, pC333, DOI 10.1152/ajpcell.1998.274.2.C333; BEELER TJ, 1983, BIOCHIM BIOPHYS ACTA, V734, P221, DOI 10.1016/0005-2736(83)90120-7; Beigi R, 1999, AM J PHYSIOL-CELL PH, V276, pC267, DOI 10.1152/ajpcell.1999.276.1.C267; BERGFELD GR, 1992, CARDIOVASC RES, V26, P40, DOI 10.1093/cvr/26.1.40; Bosch I, 1996, AM J PHYSIOL-CELL PH, V271, pC1527, DOI 10.1152/ajpcell.1996.271.5.C1527; CANTIELLO HF, 1994, J BIOL CHEM, V269, P11224; Cantiello HF, 1997, BIOSCIENCE REP, V17, P147, DOI 10.1023/A:1027381412574; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; Devidas S, 1997, CURR OPIN CELL BIOL, V9, P547, DOI 10.1016/S0955-0674(97)80032-4; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FORRESTER T, 1977, J PHYSIOL-LONDON, V272, pP44; FORRESTER T, 1966, J PHYSIOL-LONDON, V186, pP107; FRANCO A, 1991, BIOPHYS J, V59, P1164, DOI 10.1016/S0006-3495(91)82332-3; GRUBB BR, 1994, AM J PHYSIOL, V266, pC1478, DOI 10.1152/ajpcell.1994.266.5.C1478; Grygorczyk R, 1997, AM J PHYSIOL-CELL PH, V272, pC1058; Grygorczyk R, 1996, J MEMBRANE BIOL, V151, P139, DOI 10.1007/s002329900065; ISRAEL M, 1977, J NEUROCHEM, V28, P1259, DOI 10.1111/j.1471-4159.1977.tb12319.x; Ivorra I, 1997, PFLUG ARCH EUR J PHY, V434, P413, DOI 10.1007/s004240050415; Jiang QS, 1998, J CELL BIOL, V143, P645, DOI 10.1083/jcb.143.3.645; KADO RT, 1993, METHOD ENZYMOL, V221, P273, DOI 10.1016/0076-6879(93)21024-3; Ko YH, 1997, BIOCHEMISTRY-US, V36, P5053, DOI 10.1021/bi9630265; KOWDLEY GC, 1994, J GEN PHYSIOL, V103, P217, DOI 10.1085/jgp.103.2.217; Marti E, 1996, BRIT J PHARMACOL, V118, P1232, DOI 10.1111/j.1476-5381.1996.tb15528.x; MEUNIER FM, 1975, NATURE, V257, P407, DOI 10.1038/257407a0; MILEDI R, 1982, EMBO J, V1, P1307, DOI 10.1002/j.1460-2075.1982.tb01315.x; Pasyk EA, 1997, J BIOL CHEM, V272, P7746, DOI 10.1074/jbc.272.12.7746; PEARSON JD, 1979, NATURE, V281, P384, DOI 10.1038/281384a0; Prat AG, 1996, AM J PHYSIOL-CELL PH, V270, pC538, DOI 10.1152/ajpcell.1996.270.2.C538; Queiroz G, 1997, NEUROSCIENCE, V78, P1203, DOI 10.1016/S0306-4522(96)00637-9; Reddy MM, 1996, SCIENCE, V271, P1876, DOI 10.1126/science.271.5257.1876; REISIN IL, 1994, J BIOL CHEM, V269, P20584; ROJAS E, 1985, FEBS LETT, V185, P323, DOI 10.1016/0014-5793(85)80931-5; Roman RM, 1999, AM J PHYSIOL-GASTR L, V277, pG1222, DOI 10.1152/ajpgi.1999.277.6.G1222; Schneider SW, 1999, P NATL ACAD SCI USA, V96, P12180, DOI 10.1073/pnas.96.21.12180; SCHULTZ BD, 1995, J GEN PHYSIOL, V105, P329, DOI 10.1085/jgp.105.3.329; SILINSKY EM, 1975, J PHYSIOL-LONDON, V247, P145, DOI 10.1113/jphysiol.1975.sp010925; SILINSKY EM, 1992, BRIT J PHARMACOL, V106, P762, DOI 10.1111/j.1476-5381.1992.tb14408.x; Sugita M, 1998, EMBO J, V17, P898, DOI 10.1093/emboj/17.4.898; Taylor AL, 1998, AM J PHYSIOL-CELL PH, V275, pC1391, DOI 10.1152/ajpcell.1998.275.5.C1391; Wang TF, 1998, J BIOL CHEM, V273, P24814, DOI 10.1074/jbc.273.38.24814; Wang TF, 1996, J BIOL CHEM, V271, P9898, DOI 10.1074/jbc.271.17.9898; Watt WC, 1998, J BIOL CHEM, V273, P14053, DOI 10.1074/jbc.273.22.14053; WHITE TD, 1977, NATURE, V267, P67, DOI 10.1038/267067a0; YAO Y, 1992, J PHYSIOL-LONDON, V458, P319, DOI 10.1113/jphysiol.1992.sp019420; Zhang Y, 2000, J PHYSIOL-LONDON, V523, P83, DOI 10.1111/j.1469-7793.2000.t01-2-00083.x; ZIGANSHIN AU, 1995, PFLUG ARCH EUR J PHY, V429, P412, DOI 10.1007/BF00374157	50	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20268	20273		10.1074/jbc.M000894200	http://dx.doi.org/10.1074/jbc.M000894200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10764752	Green Published, hybrid			2022-12-27	WOS:000088084500009
J	Cruz, MA; Diacovo, TG; Emsley, J; Liddington, R; Handin, RI				Cruz, MA; Diacovo, TG; Emsley, J; Liddington, R; Handin, RI			Mapping the glycoprotein Ib-binding site in the von Willebrand factor A1 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN VONWILLEBRAND-FACTOR; ALANINE-SCANNING MUTAGENESIS; PLATELET-AGGREGATION; FIBRINOGEN BINDING; THROMBUS FORMATION; CRYSTAL-STRUCTURE; IIB/IIIA COMPLEX; ESCHERICHIA-COLI; COLLAGEN; DISEASE	The von Willebrand factor (vWF) mediates platelet adhesion to exposed subendothelium at sites of vascular injury. It does this by forming a bridge between subendothelial collagen and the platelet glycoprotein Ib-IX-V complex (GPIb), The GPIb-binding site within VWF has been localized to the vWF-A1 domain. Based on the crystal structure of the vWF-A1 domain (Emsley, J., Cruz, M., Handin, R., and Liddington, R. (1998) J. Biol. Chem. 273, 10396-10401), we introduced point mutations into 16 candidate residues that might form all or part of the GPIb interaction site. We also introduced two mutations previously reported to impair vWF function yielding a total of 18 mutations. The recombinant vWF-A1 mutant proteins were then expressed in Escherichia coli, and the activity of the purified proteins was assessed by their ability to support flow-dependent platelet adhesion and their ability to inhibit ristocetin-induced platelet agglutination. Six mutations located on the front and upper anterior face of the folded VWF-A1 domain, R524S, G561S, H563T, T594S/E596A, Q604R, and S607R, showed reduced activity in all the assays, and we suggest that these residues form part of the GPIb interaction site. One mutation, G561S, with impaired activity occurs in the naturally occurring variant form of von Willebrand's disease-type 2M underscoring the physiologic relevance of the mutations described here.	Brigham & Womens Hosp, Dept Med, Div Hematol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Leicester	Handin, RI (corresponding author), Brigham & Womens Hosp, Dept Med, Div Hematol, 75 Francis St, Boston, MA 02115 USA.		emsley, jonas/A-8509-2016	emsley, jonas/0000-0002-8949-8030	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054876] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL54876] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AZUMA H, 1991, J BIOL CHEM, V266, P12342; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BUTTRUM SM, 1993, BLOOD, V82, P1165; Celikel R, 1998, NAT STRUCT BIOL, V5, P189, DOI 10.1038/nsb0398-189; CRUZ MA, 1993, J BIOL CHEM, V268, P21238; DEMARCO L, 1985, P NATL ACAD SCI USA, V82, P7424; DEMARCO L, 1985, J CLIN INVEST, V75, P1198, DOI 10.1172/JCI111816; Emsley J, 1998, J BIOL CHEM, V273, P10396, DOI 10.1074/jbc.273.17.10396; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Fischer BE, 1996, THROMB RES, V84, P55, DOI 10.1016/0049-3848(96)00161-2; FOWLER WE, 1985, J CLIN INVEST, V76, P1491, DOI 10.1172/JCI112129; GIRMA JP, 1987, BLOOD, V70, P605; Hillery CA, 1998, BLOOD, V91, P1572, DOI 10.1182/blood.V91.5.1572.1572_1572_1581; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kroner PA, 1996, BIOCHEMISTRY-US, V35, P13460, DOI 10.1021/bi9610313; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUSHITA T, 1995, J BIOL CHEM, V270, P13406, DOI 10.1074/jbc.270.22.13406; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOHRI H, 1989, J BIOL CHEM, V264, P17361; MOHRI H, 1988, J BIOL CHEM, V263, P17901; PIETU G, 1989, BIOCHEM BIOPH RES CO, V164, P1339; RABINOWITZ I, 1992, P NATL ACAD SCI USA, V89, P9846, DOI 10.1073/pnas.89.20.9846; Siedlecki CA, 1996, BLOOD, V88, P2939, DOI 10.1182/blood.V88.8.2939.bloodjournal8882939; SIXMA JJ, 1991, EUR J BIOCHEM, V196, P369, DOI 10.1111/j.1432-1033.1991.tb15826.x; SLAYTER H, 1985, J BIOL CHEM, V260, P8559; Smith C, 2000, J BIOL CHEM, V275, P4205, DOI 10.1074/jbc.275.6.4205; SOBEL M, 1992, J BIOL CHEM, V267, P8857; SUGIMOTO M, 1991, BIOCHEMISTRY-US, V30, P5202, DOI 10.1021/bi00235a013; TURITTO VT, 1984, J CLIN INVEST, V74, P1730, DOI 10.1172/JCI111591; WEISS HJ, 1978, J LAB CLIN MED, V92, P750	31	88	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19098	19105		10.1074/jbc.M002292200	http://dx.doi.org/10.1074/jbc.M002292200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10764791	hybrid			2022-12-27	WOS:000087815900064
J	Yu, X; Baer, R				Yu, X; Baer, R			Nuclear localization and cell cycle-specific expression of CtIP, a protein that associates with the BRCA1 tumor suppressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-II HOLOENZYME; MAMMARY EPITHELIAL-CELLS; OVARIAN-CANCER CELLS; C-TERMINAL REGION; INTERACT IN-VIVO; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVATION; MOLECULAR-CLONING; NEGATIVE MODULATION; BINDING-PROTEIN	The BRCA1 tumor suppressor has been implicated in a diverse spectrum of cellular processes, including transcriptional regulation, DNA repair, and cell cycle checkpoint control. CtIP was recently identified as a protein that associates with BRCA1 and two other nuclear factors, CtBP1 and Rb1. To understand the functions of CtIP, we have evaluated its biological properties with respect to those of BRCA1, Our results show that CtIP, like its associated factors, is predominantly a nuclear protein. A subset of the endogenous pool of CtIP polypeptides exists in a protein complex that includes both ERCA1 and the BRCA1-associated RING domain protein (BARD1), At the protein level, CtIP expression varies with cell cycle progression in a pattern identical to that of BRCA1. Thus, the steady-state levels of CtIP polypeptides, which remain low in resting cells and G(1) cycling cells, increase dramatically as dividing cells traverse the G(1)/S boundary. In contrast to BRCA1, however, the G(1)/S induction of CtIP expression is mediated primarily by post transcriptional mechanisms. Finally, the interaction between CtIP and BRCA1 is shown to be stable in the face of genotoxic stress elicited by treatment with UV light, adriamycin, or hydrogen peroxide, Together, these results indicate that CtIP can potentially modulate the functions ascribed to BRCA1 in transcriptional regulation, DNA repair, and/or cell cycle checkpoint control.	Univ Texas, SW Med Ctr, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Baer, R (corresponding author), Rockefeller Univ, Biochem & Mol Biol Lab, 1230 York Ave, New York, NY 10021 USA.				NCI NIH HHS [CA76334] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076334] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen YM, 1996, CANCER RES, V56, P3168; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DEFROMENTEL CC, 1985, EXP CELL RES, V160, P83, DOI 10.1016/0014-4827(85)90238-1; Fan SJ, 1998, INT J CANCER, V77, P600, DOI 10.1002/(SICI)1097-0215(19980812)77:4<600::AID-IJC21>3.0.CO;2-8; Fox AH, 1999, EMBO J, V18, P2812, DOI 10.1093/emboj/18.10.2812; Fusco C, 1998, GENOMICS, V51, P351, DOI 10.1006/geno.1998.5368; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Larson JS, 1997, CANCER RES, V57, P3351; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Sollerbrant K, 1996, NUCLEIC ACIDS RES, V24, P2578, DOI 10.1093/nar/24.13.2578; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Spanfo S, 1999, J BIOL CHEM, V274, P17705, DOI 10.1074/jbc.274.25.17705; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; TSAN JT, 1997, YEAST 2 HYBRID SYSTE, P217; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhang HB, 1998, CELL, V92, P433, DOI 10.1016/S0092-8674(00)80936-8	53	131	133	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18541	18549		10.1074/jbc.M909494199	http://dx.doi.org/10.1074/jbc.M909494199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10764811	hybrid			2022-12-27	WOS:000087659400086
J	Inaba, K; Ishimori, K; Imai, K; Morishima, I				Inaba, K; Ishimori, K; Imai, K; Morishima, I			Substitution of the heme binding module in hemoglobin alpha- and beta-subunits - Implication for different regulation mechanisms of the heme proximal structure between hemoglobin and myoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; NUCLEAR-MAGNETIC-RESONANCE; HUMAN MUTANT HEMOGLOBINS; LIGAND-BINDING; ALPHA-1-BETA-2 INTERFACE; QUATERNARY STRUCTURES; PROTON RESONANCES; FUNCTIONAL ROLES; ESCHERICHIA-COLI; HYDROGEN-BONDS	In our previous work, we demonstrated that the replacement of the "heme binding module," a segment from F1 to G5 site, in myoglobin with that of hemoglobin alpha-subunit converted the heme proximal structure of myoglobin into the alpha-subunit type (Inaba, K., Ishimori, K. and Morishima, I. (1998) J. Mel. Biol. 283, 311-327). To further examine the structural regulation by the heme binding module in hemoglobin, we synthesized the beta alpha(HBM)-subunit, in which the heme binding module (HBM) of hemoglobin beta-subunit was replaced by that of hemoglobin a-subunit. Based on the gel chromatography, the beta alpha(HBM)-subunit was preferentially associated with the alpha-subunit to form a heterotetramer, alpha(2)[beta alpha(HBM)(2)], just as is native beta-subunit. Deoxy-alpha(2)[beta alpha(HBM)(2)] tetramer exhibited the hyperfine-shifted NMR resonance from the proximal histidyl NdeltaH proton and the resonance Raman band from the Fe-His vibrational mode at the same positions as native hemoglobin. Also, NMR spectra of carbonmonoxy and cyanomet alpha(2)[beta alpha(HBM)(2)] tetramer were quite similar to those of native hemoglobin. Consequently, the heme environmental structure of the beta alpha(HBM)-subunit in tetrameric alpha(2)[beta alpha(HBM)(2)] was similar to that of the beta-subunit in native tetrameric Hb A, and the structural conversion by the module substitution was not clear in the hemoglobin subunits, The contrastive structural effects of the module substitution on myoglobin and hemoglobin subunits strongly suggest different regulation mechanisms of the heme proximal structure between these two globins, Whereas the heme proximal structure of monomeric myoglobin is simply determined by the amino acid sequence of the heme binding module, that of tetrameric hemoglobin appears to be closely coupled to the subunit interactions.	Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6068501, Japan; Osaka Univ, Sch Med, Dept Physicochem Physiol, Suita, Osaka 5650871, Japan	Kyoto University; Osaka University	Morishima, I (corresponding author), Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6068501, Japan.		Ishimori, Koichiro/AAQ-4434-2021; Ishimori, Koichiro/S-1247-2016	Ishimori, Koichiro/0000-0002-5868-0462; Ishimori, Koichiro/0000-0002-5868-0462; Inaba, Kenji/0000-0001-8229-0467				ADACHI K, 1984, BIOCHIM BIOPHYS ACTA, V790, P132, DOI 10.1016/0167-4838(84)90216-4; ADACHI S, 1993, BIOCHEMISTRY-US, V32, P241, DOI 10.1021/bi00052a031; ADACHI S, 1991, BIOCHEM BIOPH RES CO, V180, P138, DOI 10.1016/S0006-291X(05)81266-5; ADACHI S, 1992, J BIOL CHEM, V267, P12614; ASAKURA T, 1976, J MOL BIOL, V104, P185, DOI 10.1016/0022-2836(76)90008-5; Barrick D, 1997, NAT STRUCT BIOL, V4, P78, DOI 10.1038/nsb0197-78; BORGSTAHL GEO, 1994, J MOL BIOL, V236, P831, DOI 10.1006/jmbi.1994.1192; CRAESCU CT, 1988, EUR J BIOCHEM, V176, P171, DOI 10.1111/j.1432-1033.1988.tb14265.x; DALVIT C, 1985, BIOCHEMISTRY-US, V24, P3398, DOI 10.1021/bi00335a003; DAYHOFF MO, 1972, ATLAS PROTEIN SEQUEN, V0005; EATON WA, 1980, NATURE, V284, P183, DOI 10.1038/284183a0; Eliezer D, 1996, J MOL BIOL, V263, P531, DOI 10.1006/jmbi.1996.0596; FUNG LWM, 1975, BIOCHEMISTRY-US, V14, P2526, DOI 10.1021/bi00682a036; Go M, 1995, TRACING BIOLOGICAL EVOLUTION IN PROTEIN AND GENE STRUCTURES, P229; GO M, 1981, NATURE, V291, P90, DOI 10.1038/291090a0; HASHIMOTO M, 1993, BIOCHEMISTRY-US, V32, P13688, DOI 10.1021/bi00212a038; HAYASHI A, 1973, BIOCHIM BIOPHYS ACTA, V310, P309, DOI 10.1016/0005-2795(73)90110-4; HILDEBRAND DP, 1995, BIOCHEMISTRY-US, V34, P1997, DOI 10.1021/bi00006a021; HO C, 1992, ADV PROTEIN CHEM, V43, P153, DOI 10.1016/S0065-3233(08)60555-0; IMAI K, 1994, METHOD ENZYMOL, V232, P559; IMAI K, 1970, Biochimica et Biophysica Acta, V200, P189, DOI 10.1016/0005-2795(70)90163-7; IMAI K, 1991, J MOL BIOL, V218, P769, DOI 10.1016/0022-2836(91)90265-8; Imai K, 1981, Methods Enzymol, V76, P438; Imai K., 1982, ALLOSTERIC EFFECT HA; Inaba K, 1998, J MOL BIOL, V283, P311, DOI 10.1006/jmbi.1998.2073; Inaba K, 1998, J BIOL CHEM, V273, P8080, DOI 10.1074/jbc.273.14.8080; Inaba K, 1997, J BIOL CHEM, V272, P30054, DOI 10.1074/jbc.272.48.30054; ISHIMORI K, 1988, BIOCHEMISTRY-US, V27, P4747, DOI 10.1021/bi00413a025; ISHIMORI K, 1994, BIOCHEMISTRY-US, V33, P2546, DOI 10.1021/bi00175a025; ISHIMORI K, 1992, BIOCHEMISTRY-US, V31, P3256, DOI 10.1021/bi00127a030; Jellie AM, 1996, J MOL EVOL, V42, P641, DOI 10.1007/BF02338797; LAMAR, 1979, BIOL APPL MAGNETIC R, P305; LAMAR GN, 1988, BIOCHIM BIOPHYS ACTA, V952, P131, DOI 10.1016/0167-4838(88)90108-2; LAMAR GN, 1985, BIOCHEMISTRY-US, V24, P3826, DOI 10.1021/bi00336a002; LEUTZINGER Y, 1981, P NATL ACAD SCI-BIOL, V78, P780, DOI 10.1073/pnas.78.2.780; LIM VI, 1977, FEBS LETT, V78, P279, DOI 10.1016/0014-5793(77)80323-2; LINDSTROM TR, 1972, BIOCHEMISTRY-US, V11, P1677, DOI 10.1021/bi00759a023; LYNCH RE, 1976, J BIOL CHEM, V251, P1015; Matsui T, 1999, J BIOL CHEM, V274, P2838, DOI 10.1074/jbc.274.5.2838; Matsui T, 1996, BIOCHEMISTRY-US, V35, P13118, DOI 10.1021/bi960459z; NAGAI K, 1980, J MOL BIOL, V136, P271, DOI 10.1016/0022-2836(80)90374-5; NAGAI K, 1980, P NATL ACAD SCI-BIOL, V77, P2033, DOI 10.1073/pnas.77.4.2033; NAGAI K, 1982, BIOCHEMISTRY-US, V21, P842, DOI 10.1021/bi00534a005; NAGAI K, 1985, P NATL ACAD SCI USA, V82, P7252, DOI 10.1073/pnas.82.21.7252; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; NOGUTI T, 1993, PROTEINS, V16, P357, DOI 10.1002/prot.340160405; OLDFIELD TJ, 1992, BIOCHEMISTRY-US, V31, P8732, DOI 10.1021/bi00152a008; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Poulos TL, 1996, J BIOL INORG CHEM, V1, P356, DOI 10.1007/s007750050064; POULOS TL, 1980, J BIOL CHEM, V255, P575; RYRIE DR, 1977, FEBS LETT, V83, P260, DOI 10.1016/0014-5793(77)81018-1; SASAKI J, 1978, J BIOL CHEM, V253, P87; SCHAEFFER C, 1988, EUR J BIOCHEM, V173, P317, DOI 10.1111/j.1432-1033.1988.tb14001.x; SHIH DTB, 1985, J BIOL CHEM, V260, P5919; SHULMAN RG, 1970, J MOL BIOL, V53, P143, DOI 10.1016/0022-2836(70)90050-1; SMERDON SJ, 1993, BIOCHEMISTRY-US, V32, P5132, DOI 10.1021/bi00070a023; SMITH LL, 1972, J BIOL CHEM, V247, P1433; TAKAHASHI S, 1980, BIOCHEMISTRY-US, V19, P5196, DOI 10.1021/bi00564a007; Tanaka M, 1999, BIOCHEMISTRY-US, V38, P10463, DOI 10.1021/bi9907328; Uchida T, 1997, J BIOL CHEM, V272, P30108, DOI 10.1074/jbc.272.48.30108; VALDES R, 1977, J BIOL CHEM, V252, P74; WADA Y, 1989, BIOMED ENVIRON MASS, V18, P563, DOI 10.1002/bms.1200180809; Wakasugi K, 1997, BIOPHYS CHEM, V68, P265, DOI 10.1016/S0301-4622(97)80556-X; WAKASUGI K, 1994, J BIOL CHEM, V269, P18750; WILLIAMSON D, 1994, BRIT J HAEMATOL, V86, P890, DOI 10.1111/j.1365-2141.1994.tb04852.x; WINTERBOURN CC, 1976, BIOCHEM J, V155, P493, DOI 10.1042/bj1550493; YAMAMOTO Y, 1986, BIOCHEMISTRY-US, V25, P5288, DOI 10.1021/bi00366a045	69	10	10	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12438	12445		10.1074/jbc.275.17.12438	http://dx.doi.org/10.1074/jbc.275.17.12438			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777528	hybrid			2022-12-27	WOS:000086762300012
J	Liu, JY; Qiao, XG; Du, DY; Lee, MGS				Liu, JY; Qiao, XG; Du, DY; Lee, MGS			Receptor-mediated endocytosis in the procyclic form of Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY LIPOPROTEIN RECEPTOR; VARIANT SURFACE GLYCOPROTEIN; TRANSFERRIN-BINDING PROTEIN; BLOOD-STREAM FORM; AFRICAN TRYPANOSOMES; FLAGELLAR POCKET; ANTIGENIC VARIATION; EXPRESSION SITE; CULTURE FORMS; COAT PROTEINS	In Trypanosomatids, endocytosis and exocytosis occur exclusively at the flagellar pocket, a deep invagination of the plasma membrane where the flagellum extends from the cell. Both bloodstream and procyclic trypanosomes are capable of internalizing macromolecules, However, structures resembling coated vesicles were only identified in bloodstream form and not in procyclic form trypanosomes. Due to the apparent absence of coated vesicles in procyclics, the significance of receptor-mediated endocytosis in procyclic trypanosomes has been considered of minimal importance. We show that the flagellar pocket associated cysteine-rich acidic transmembrane protein (CRAM) may function as an high density lipoprotein receptor in the procyclic form trypanosome. Using anti-CRAM IgG we have characterized the process of CRAM-mediated endocytosis in procyclic form trypanosomes, The wild type procyclic trypanosome binds and internalizes anti-CRAM IgG but not the non-immune IgG in a saturable and time-dependent manner; the binding and uptake of I-125-labeled anti-CRAM IgG are inhibited by excess unlabeled anti-CRAM IgG. Uptake and degradation of anti-CRAM IgG do not occur at 4 degrees C, At 28 degrees C, the internalized anti-CRAM IgG were efficiently degraded through a process that is inhibited by incubation at 4 degrees C and sensitive to the presence of chloroquine. The uptake and degradation of anti-CRAM IgG does not occur in the CRAM null mutant cell line, These results suggested that the uptake of anti-CRAM IgG in the wild type procyclics occurs via receptor-mediated endocytosis of the CRAM protein. Deletion of the cytoplasmic extension of CRAM drastically reduced the degradation but not the binding of anti-CRAM IgG, This result indicated that potential internalization signals may be present in the cytoplasmic extension of CRAM. This is the first time that the importance of receptor-mediated endocytosis in procyclic form trypanosomes has been demonstrated.	NYU, Sch Med, Dept Pathol, New York, NY 10016 USA	New York University	Lee, MGS (corresponding author), NYU, Sch Med, Dept Pathol, New York, NY 10016 USA.	leeg02@med.nyu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI031117, R01AI031117] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31117] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALBER AE, 1990, CRIT REV IMMUNOL, V10, P177; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; Borst P, 1998, ANNU REV MICROBIOL, V52, P745, DOI 10.1146/annurev.micro.52.1.745; BORST P, 1991, IMMUNOPARASITOL TOD, pA29, DOI 10.1016/S0167-5699(05)80009-X; BRUN R, 1979, ACTA TROP, V36, P289; COPPENS I, 1988, P NATL ACAD SCI USA, V85, P6753, DOI 10.1073/pnas.85.18.6753; COPPENS I, 1987, J PROTOZOOL, V34, P465, DOI 10.1111/j.1550-7408.1987.tb03216.x; CROSS GAM, 1990, ANNU REV IMMUNOL, V8, P83, DOI 10.1146/annurev.iy.08.040190.000503; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DIXON H, 1972, COMP BIOCHEM PHYSIOL, V41, P1, DOI 10.1016/0305-0491(72)90002-8; DIXON H, 1971, COMP BIOCHEM PHYSIOL, V39, P247, DOI 10.1016/0305-0491(71)90168-4; GILLETT MPT, 1992, BIOCHIM BIOPHYS ACTA, V1123, P239, DOI 10.1016/0005-2760(92)90002-D; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GRAB DJ, 1993, EUR J CELL BIOL, V62, P114; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Kelley RJ, 1999, MOL BIOCHEM PARASIT, V98, P17, DOI 10.1016/S0166-6851(98)00155-8; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; LANGRETH SG, 1975, J PROTOZOOL, V22, P40, DOI 10.1111/j.1550-7408.1975.tb00943.x; Lee MGS, 1999, MOL BIOCHEM PARASIT, V100, P153, DOI 10.1016/S0166-6851(99)00009-2; LEE MGS, 1990, MOL CELL BIOL, V10, P4506, DOI 10.1128/MCB.10.9.4506; LIGTENBERG MJL, 1994, EMBO J, V13, P2565, DOI 10.1002/j.1460-2075.1994.tb06546.x; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Markwell M A, 1981, Methods Enzymol, V72, P296; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MELLORS A, 1989, PARASITOL TODAY, V5, P239, DOI 10.1016/0169-4758(89)90255-X; Overath P, 1997, TRENDS CELL BIOL, V7, P27, DOI 10.1016/S0962-8924(97)10046-0; PAYS E, 1992, EUKARYOTIC GENOME OR; PLEY U, 1993, CRIT REV BIOCHEM MOL, V28, P431, DOI 10.3109/10409239309078441; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; SALMON D, 1994, CELL, V78, P75, DOI 10.1016/0092-8674(94)90574-6; SAMAD A, 1988, MOL BIOCHEM PARASIT, V29, P159, DOI 10.1016/0166-6851(88)90071-0; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHELL D, 1991, EMBO J, V10, P1061, DOI 10.1002/j.1460-2075.1991.tb08045.x; SHAPIRO SZ, 1989, J PROTOZOOL, V36, P344, DOI 10.1111/j.1550-7408.1989.tb05524.x; STEVERDING D, 1994, EUR J CELL BIOL, V64, P78; VICKERMAN K, 1969, J PROTOZOOL, V16, P54, DOI 10.1111/j.1550-7408.1969.tb02233.x; VICKERMAN K, 1969, J CELL SCI, V5, P163; WEBSTER P, 1990, EXP PARASITOL, V70, P154, DOI 10.1016/0014-4894(90)90096-U; WEBSTER P, 1989, EUR J CELL BIOL, V49, P295; WEBSTER P, 1988, J CELL BIOL, V106, P279, DOI 10.1083/jcb.106.2.279; WEBSTER P, 1993, PARASITOL TODAY, V9, P201, DOI 10.1016/0169-4758(93)90008-4; WEBSTER P, 1989, EUR J CELL BIOL, V49, P303; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; Zheng BJ, 1999, MOL BIOCHEM PARASIT, V100, P235, DOI 10.1016/S0166-6851(99)00048-1	45	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12032	12040		10.1074/jbc.275.16.12032	http://dx.doi.org/10.1074/jbc.275.16.12032			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766835	hybrid			2022-12-27	WOS:000086695500070
J	Paturiaux-Hanocq, F; Hanocq-Quertier, J; de Almeida, MLC; Nolan, DP; Pays, A; Vanhamme, L; Van den Abbeele, J; Wasunna, CL; Carrington, M; Pays, E				Paturiaux-Hanocq, F; Hanocq-Quertier, J; de Almeida, MLC; Nolan, DP; Pays, A; Vanhamme, L; Van den Abbeele, J; Wasunna, CL; Carrington, M; Pays, E			A role for the dynamic acylation of a cluster of cysteine residues in regulating the activity of the glycosylphosphatidylinositol-specific phospholipase C of Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; BLOOD-STREAM FORMS; MEMBRANE ANCHOR; ALPHA-SUBUNITS; EXPRESSION; PALMITOYLATION; PURIFICATION; PROTEINS; IDENTIFICATION; LOCALIZATION	The glycosylphosphatidylinositol-specific phospholipase C or VSG lipase is the enzyme responsible for the cleavage of the glycosylphosphatidylinositol anchor of the variant surface glycoprotein (VSG) and concommitant release of the surface coat in Trypanosoma brucei during osmotic shock or extracellular acidic stress. In Xenopus laevis oocytes the VSG lipase was expressed as a nonacylated and a thioacylated form. This thioacylation occurred within a cluster of three cysteine residues but was not essential for catalytic activity per se. These two forms were also detected in trypanosomes and appeared to be present at roughly equivalent amounts. A reversible shift to the acylated form occurred when cells were triggered to release the VSG by either nonlytic acid stress or osmotic lysis, A wild type VSG lipase or a gene mutated in the three codons for the acylated cysteines were reinserted in the genome of a trypanosome null mutant for this gene. A comparative analysis of these revertant trypanosomes indicated that thioacylation might be involved in regulating enzyme access to the VSG substrate.	Free Univ Brussels, Dept Mol Biol, B-6041 Gosselies, Belgium; Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England	Institute of Tropical Medicine (ITM); University of Cambridge	Pays, E (corresponding author), Free Univ Brussels, Dept Mol Biol, 12 Rue Profs Jeener & Brachet, B-6041 Gosselies, Belgium.		Carrington, Mark/N-4892-2018; Carrington, Mark/N-3653-2019	Carrington, Mark/0000-0002-6435-7266; Carrington, Mark/0000-0002-6435-7266; Nolan, Derek/0000-0002-3742-4304; Van Den Abbeele, Jan/0000-0002-4533-4480				Armah DA, 1999, J BIOL CHEM, V274, P5931, DOI 10.1074/jbc.274.9.5931; BIZZOZERO OA, 1995, METHOD ENZYMOL, V250, P361; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRINGAUD F, 1993, MOL CELL BIOL, V13, P1146, DOI 10.1128/MCB.13.2.1146; BULOW R, 1989, J CELL SCI, V93, P233; BULOW R, 1986, J BIOL CHEM, V261, P1918; Carnall N, 1997, MOL BIOCHEM PARASIT, V90, P423, DOI 10.1016/S0166-6851(97)00177-1; Carrington M, 1998, MOL BIOCHEM PARASIT, V91, P153, DOI 10.1016/S0166-6851(97)00190-4; CARRINGTON M, 1989, MOL BIOCHEM PARASIT, V33, P289, DOI 10.1016/0166-6851(89)90091-1; CARRINGTON M, 1991, CELL BIOL INT REP, V15, P1101, DOI 10.1016/0309-1651(91)90058-Q; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; DEALMEIDA MLC, 1983, NATURE, V302, P349, DOI 10.1038/302349a0; Duncan JA, 1996, J BIOL CHEM, V271, P23594, DOI 10.1074/jbc.271.38.23594; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; Field M. C., 1992, LIPID MODIFICATION P, P155; FIELD MC, 1991, J BIOL CHEM, V266, P8392; FOX JA, 1986, J BIOL CHEM, V261, P5767; HERELD D, 1986, J BIOL CHEM, V261, P3813; JACKSON DG, 1993, J BIOL CHEM, V268, P8085; JEFFERIES D, 1993, NUCLEIC ACIDS RES, V21, P191, DOI 10.1093/nar/21.2.191; LANHAM SM, 1968, NATURE, V218, P1273, DOI 10.1038/2181273a0; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LONSDALEECCLES JD, 1987, J PROTOZOOL, V34, P405, DOI 10.1111/j.1550-7408.1987.tb03201.x; MCIHLINNEY RAJ, 1992, LIPID MODIFICATION P, P15; MENSAWILMOT K, 1992, MOL BIOCHEM PARASIT, V56, P311, DOI 10.1016/0166-6851(92)90180-R; MENSAWILMOT K, 1990, MOL CELL BIOL, V10, P720, DOI 10.1128/MCB.10.2.720; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; Morello JP, 1996, BIOCHEM CELL BIOL, V74, P449, DOI 10.1139/o96-049; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; PAINDAVOINE P, 1992, MOL CELL BIOL, V12, P1218, DOI 10.1128/MCB.12.3.1218; PaturiauxHanocq F, 1997, BIOCHEM J, V324, P885, DOI 10.1042/bj3240885; Pays E, 1998, MOL BIOCHEM PARASIT, V91, P3, DOI 10.1016/S0166-6851(97)00183-7; QUESNEL S, 1994, BIOCHEMISTRY-US, V33, P13340, DOI 10.1021/bi00249a021; Rolin S, 1996, J BIOL CHEM, V271, P10844, DOI 10.1074/jbc.271.18.10844; Rolin S, 1998, MOL BIOCHEM PARASIT, V93, P251, DOI 10.1016/S0166-6851(98)00046-2; SALMON D, 1994, CELL, V78, P75, DOI 10.1016/0092-8674(94)90574-6; Webb H, 1997, J CELL BIOL, V139, P103, DOI 10.1083/jcb.139.1.103; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; ZAMZE SE, 1988, EUR J BIOCHEM, V176, P527, DOI 10.1111/j.1432-1033.1988.tb14310.x	39	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12147	12155		10.1074/jbc.275.16.12147	http://dx.doi.org/10.1074/jbc.275.16.12147			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766850	hybrid			2022-12-27	WOS:000086695500085
J	Schoenmakers, E; Verrijdt, G; Peeters, B; Verhoeven, G; Rombauts, W; Claessens, F				Schoenmakers, E; Verrijdt, G; Peeters, B; Verhoeven, G; Rombauts, W; Claessens, F			Differences in DNA binding characteristics of the androgen and glucocorticoid receptors can determine hormone-specific responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL DETERMINANTS; ESTROGEN-RECEPTOR; GENE-REGULATION; PROBASIN GENE; DOMAIN; ELEMENT; COACTIVATOR; ACTIVATION; TRANSCRIPTION; IDENTIFICATION	The basis for specificity of gene regulation by steroid hormone receptors remains an important problem in the study of steroid hormone action. One possible mechanism for steroid specificity is the difference in DNA binding characteristics of the receptors, although they share a high homology in their DNA-binding domains. Indeed, the androgen-specific expression of, for example, the probasin (PB) gene can be explained by the presence of an androgen response element (ARE) in its promoter (PB-ARE-2), specifically recognized by the androgen and not by the glucocorticoid receptor. Three residues in the DNA-binding domain of the AR were identified as main determinants for its high affinity for the PB-ARE-2, In addition, the direct repeat nature of this ARE seems to prohibit high affinity binding by the glucocorticoid receptor. This is confirmed by the fact that several imperfect direct repeats of the 5'-TGT-TCT-3' core recognition sequence are recognized by the androgen receptor and not by the glucocorticoid receptor. Up to now, only differences between the androgen and glucocorticoid receptor in the transcription activation functions were invoked to explain the specificity of their genomic actions. In the present study, we describe the influence of the DNA-binding domain on the specificity of androgen action. The novelty of our working hypothesis resides in the demonstration of the capacity of the AR-DNA-binding domain to recognize elements with a direct repeat structure.	Katholieke Univ Leuven, Fac Med, Div Biochem, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Fac Med, Lab Expt Med & Endocrinol, B-3000 Louvain, Belgium	KU Leuven; KU Leuven	Claessens, F (corresponding author), Katholieke Univ Leuven, Fac Med, Div Biochem, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.		Claessens, Frank/M-8565-2016	Claessens, Frank/0000-0002-8676-7709				Alen P, 1999, MOL CELL BIOL, V19, P6085; Alen P, 1999, MOL ENDOCRINOL, V13, P117, DOI 10.1210/me.13.1.117; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; Claessens F, 1996, J BIOL CHEM, V271, P19013, DOI 10.1074/jbc.271.32.19013; DAHLMANWRIGHT K, 1990, J BIOL CHEM, V265, P14030; Doesburg P, 1997, BIOCHEMISTRY-US, V36, P1052, DOI 10.1021/bi961775g; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FREEDMAN LP, 1992, ENDOCR REV, V13, P129, DOI 10.1210/er.13.2.129; FUNDER JW, 1993, SCIENCE, V259, P1132, DOI 10.1126/science.8382375; GUSTAFSSON JA, 1989, J STEROID BIOCHEM, V34, P1; Haelens A, 1999, MOL CELL ENDOCRINOL, V153, P91, DOI 10.1016/S0303-7207(99)00079-9; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; JENSTER G, 1993, BIOCHEM J, V293, P761, DOI 10.1042/bj2930761; KASPER S, 1994, J BIOL CHEM, V269, P31763; LEE MS, 1993, SCIENCE, V260, P1117, DOI 10.1126/science.8388124; Lobaccaro JM, 1996, MOL CELL ENDOCRINOL, V116, P137, DOI 10.1016/0303-7207(95)03709-8; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; Ma H, 1999, MOL CELL BIOL, V19, P6164; MARIVOET S, 1990, J STEROID BIOCHEM, V37, P39, DOI 10.1016/0960-0760(90)90370-Z; Moilanen A, 1997, FEBS LETT, V412, P355, DOI 10.1016/S0014-5793(97)00791-6; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1866, DOI 10.1210/mend-4-12-1866; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; REMEROWSKI ML, 1991, BIOCHEMISTRY-US, V30, P11620, DOI 10.1021/bi00114a003; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; RUNDLETT SE, 1995, MOL CELL ENDOCRINOL, V109, P1, DOI 10.1016/0303-7207(95)03477-O; Scheller A, 1998, J BIOL CHEM, V273, P24216, DOI 10.1074/jbc.273.37.24216; Schoenmakers E, 1999, BIOCHEM J, V341, P515, DOI 10.1042/0264-6021:3410515; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SPENCE AM, 1989, P NATL ACAD SCI USA, V86, P7843, DOI 10.1073/pnas.86.20.7843; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; Sui XM, 1999, J BIOL CHEM, V274, P9449, DOI 10.1074/jbc.274.14.9449; Tilley WD, 1996, CLIN CANCER RES, V2, P277; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TRUSS M, 1991, MOL CELL BIOL, V11, P3247, DOI 10.1128/MCB.11.6.3247; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; Verrijdt G, 2000, J BIOL CHEM, V275, P12298, DOI 10.1074/jbc.275.16.12298; Verrijdt G, 1999, MOL ENDOCRINOL, V13, P1558, DOI 10.1210/me.13.9.1558; WANG C, 1997, JPN J UROL, V88, P550; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Zhou ZF, 1997, J BIOL CHEM, V272, P8227, DOI 10.1074/jbc.272.13.8227; ZILLIACUS J, 1991, J BIOL CHEM, V266, P3101	50	86	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12290	12297		10.1074/jbc.275.16.12290	http://dx.doi.org/10.1074/jbc.275.16.12290			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766868	hybrid			2022-12-27	WOS:000086695500103
J	Hakimelahi, S; Parker, HR; Gilchrist, AJ; Barry, M; Li, Z; Bleackley, RC; Pasdar, M				Hakimelahi, S; Parker, HR; Gilchrist, AJ; Barry, M; Li, Z; Bleackley, RC; Pasdar, M			Plakoglobin regulates the expression of the anti-apoptotic protein BCL-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR LEF-1; SQUAMOUS CARCINOMA-CELLS; BETA-CATENIN; ADHERENS JUNCTIONS; CADHERIN FUNCTION; N-CADHERIN; IN-VIVO; DEATH; FAMILY; APC	Plakoglobin is a cytoplasmic protein and a homologue of beta-catenin and Armadillo of Drosophila with similar adhesive and signaling functions, These proteins interact with cadherins to mediate cell-cell adhesion and associate with transcription factors to induce changes in the expression of genes involved in cell fate determination and proliferation. Unlike the relatively well characterized role of beta-catenin in cell proliferation via activation of c-MYC and cyclin D1 gene expression, the signaling function of plakoglobin in regulation of cell growth is undefined. Here, we show that high levels of plakoglobin expression in plakoglobin-deficient human SCC9 cells leads to uncontrolled growth and foci formation. Concurrent with the change in growth characteristics we observe a pronounced inhibition of apoptosis, This correlates with an induction of expression of BCL-2, a prototypic member of apoptosis-regulating proteins. The BCL-2 expression coincides with decreased proteolytic processing and activation of caspase-3, an executor of programmed cell death. Our data suggest that the growth regulatory function of plakoglobin is independent of its role in mediating cell-cell adhesion, These observations clearly implicate plakoglobin in pathways regulating cell growth and provide initial evidence of its role as a pivotal molecular link between pathways regulating cell adherence and cell death.	Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	University of Alberta; University of Alberta	Pasdar, M (corresponding author), Univ Alberta, Dept Cell Biol, 6-24 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	mpasdar@ualberta.ca						Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ahmed Y, 1998, CELL, V93, P1171, DOI 10.1016/S0092-8674(00)81461-0; Aoshiba K, 1997, AM J PHYSIOL-LUNG C, V272, pL28, DOI 10.1152/ajplung.1997.272.1.L28; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BEHRENS J, 1994, INVAS METAST, V14, P61; Brancolini C, 1998, CELL DEATH DIFFER, V5, P1042, DOI 10.1038/sj.cdd.4400443; Bullions Linda C., 1998, Current Opinion in Oncology, V10, P81, DOI 10.1097/00001622-199801000-00013; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Domen J, 1998, BLOOD, V91, P2272, DOI 10.1182/blood.V91.7.2272.2272_2272_2282; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Kodama S, 1999, J BIOL CHEM, V274, P27682, DOI 10.1074/jbc.274.39.27682; Lewis JE, 1997, J CELL BIOL, V136, P919, DOI 10.1083/jcb.136.4.919; Li Z, 1998, J CELL SCI, V111, P1005; Lu QL, 1996, HUM PATHOL, V27, P102, DOI 10.1016/S0046-8177(96)90362-7; MERIO GR, 1997, CELL GROWTH DIFFER, V8, P251; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Parker HR, 1998, CELL MOTIL CYTOSKEL, V40, P87, DOI 10.1002/(SICI)1097-0169(1998)40:1<87::AID-CM8>3.0.CO;2-C; PASDAR M, 1995, CELL MOTIL CYTOSKEL, V32, P258, DOI 10.1002/cm.970320403; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; Potter E, 1999, ENDOCR REV, V20, P207, DOI 10.1210/er.20.2.207; Rubenstein A, 1997, DEV GENET, V20, P91, DOI 10.1002/(SICI)1520-6408(1997)20:2<91::AID-DVG2>3.0.CO;2-3; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Salomon D, 1997, J CELL BIOL, V139, P1325, DOI 10.1083/jcb.139.5.1325; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; STRATER J, 1995, GUT, V37, P819, DOI 10.1136/gut.37.6.819; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; [No title captured]	42	77	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10905	10911		10.1074/jbc.275.15.10905	http://dx.doi.org/10.1074/jbc.275.15.10905			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753888	hybrid			2022-12-27	WOS:000086466600030
J	Nishizawa, T; Nagao, T; Iwatsubo, T; Forte, JG; Urushidani, T				Nishizawa, T; Nagao, T; Iwatsubo, T; Forte, JG; Urushidani, T			Molecular cloning and characterization of a novel chloride intracellular channel-related protein, parchorin, expressed in water-secreting cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-DIMENSIONAL GEL-ELECTROPHORESIS; SEQUENCE-ANALYSIS; GASTRIC GLANDS; ACTIVATION; ERYTHROCYTES; STIMULATION; MECHANISMS; DIGESTION; KIDNEY; GENE	We previously reported a 120-kDa phosphoprotein that translocated from cytosol to the apical membrane of gastric parietal cells in association with stimulation of HCl secretion. To determine the molecular identity of the protein, we performed molecular cloning and expression of the protein. Immunoblot analysis showed that this protein was highly enriched in tissues that secrete water, such as parietal cell, choroid plexus, salivary duct, lacrimal gland, kidney, airway epithelia, and chorioretinal epithelia, We named this protein "parchorin" based on its highest enrichment in parietal cells and choroid plexus, We obtained cDNA for parchorin from rabbit choroid plexus coding a protein consisting of 637 amino acids with a predicted molecular mass of 65 kDa, The discrepancy in size on 6% SDS-polyacrylamide gel electrophoresis is considered to be due to its highly acidic nature (pI = 4.18), because COS-7 cells transfected with parchorin cDNA produced a protein with apparent molecular mass of 120 kDa on 6% SDS-polyacrylamide gel electrophoresis. Parchorin is a novel protein that has significant homology to the family of chloride intracellular channels (CLIC), especially the chloride channel from bovine kidney, p64, in the C-terminal 235 amino acids. When expressed as a fusion protein with green fluorescent protein (GFP) in the LLCPK1 kidney cell line, GFP-parchorin, unlike other CLIC family members, existed mainly in the cytosol, Furthermore, when C1(-) efflux from the cell was elicited, GFP-parchorin translocated to the plasma membrane. These results suggest that parchorin generally plays a critical role in water-secreting cells, possibly through the regulation of chloride ion transport.	Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Pharmacol & Toxicol, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Tokyo 1130033, Japan; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of Tokyo; University of Tokyo; University of California System; University of California Berkeley	Urushidani, T (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Pharmacol & Toxicol, Tokyo 1130033, Japan.				NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR008282, P41RR001614] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01614, RR08282] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Akagi K, 1999, AM J PHYSIOL-GASTR L, V277, pG736, DOI 10.1152/ajpgi.1999.277.3.G736; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BAQUET A, 1991, FEBS LETT, V278, P103, DOI 10.1016/0014-5793(91)80094-J; BERGLINDH T, 1990, METHOD ENZYMOL, V192, P93; CHAO AC, 1989, BIOPHYS J, V56, P1071, DOI 10.1016/S0006-3495(89)82755-9; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; Duman JG, 1999, AM J PHYSIOL-CELL PH, V277, pC361, DOI 10.1152/ajpcell.1999.277.3.C361; Duncan RR, 1997, J BIOL CHEM, V272, P23880, DOI 10.1074/jbc.272.38.23880; Edwards JC, 1999, AM J PHYSIOL-RENAL, V276, pF398, DOI 10.1152/ajprenal.1999.276.3.F398; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; GIBSON JS, 1995, PFLUG ARCH EUR J PHY, V429, P446, DOI 10.1007/BF00374163; GSCHWENTNER M, 1995, PFLUG ARCH EUR J PHY, V430, P464, DOI 10.1007/BF00373882; Heiss NS, 1997, GENOMICS, V45, P224, DOI 10.1006/geno.1997.4922; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Krapivinsky G, 1998, J BIOL CHEM, V273, P10811, DOI 10.1074/jbc.273.18.10811; KRAPIVINSKY GB, 1994, CELL, V76, P439, DOI 10.1016/0092-8674(94)90109-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY D, 1993, J BIOL CHEM, V268, P14948; LANDRY DW, 1989, SCIENCE, V244, P1469, DOI 10.1126/science.2472007; LANDRY DW, 1987, J GEN PHYSIOL, V90, P791; MALINOWSKA DH, 1995, AM J PHYSIOL-CELL PH, V268, pC191, DOI 10.1152/ajpcell.1995.268.1.C191; MCCONNELL FM, 1988, AM J PHYSIOL, V255, pR982, DOI 10.1152/ajpregu.1988.255.6.R982; NILSSON C, 1992, BRAIN RES REV, V17, P109, DOI 10.1016/0165-0173(92)90011-A; Okamoto CT, 1998, AM J PHYSIOL-CELL PH, V274, pC1017, DOI 10.1152/ajpcell.1998.274.4.C1017; Qian ZJ, 1999, J BIOL CHEM, V274, P1621, DOI 10.1074/jbc.274.3.1621; Qiu YC, 1998, J BIOL CHEM, V273, P17940, DOI 10.1074/jbc.273.28.17940; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Sheppard David N., 1999, Physiological Reviews, V79, pS23; Sorota S, 1995, PFLUG ARCH EUR J PHY, V431, P178, DOI 10.1007/BF00410189; URUSHIDANI T, 1987, BIOCHIM BIOPHYS ACTA, V930, P209, DOI 10.1016/0167-4889(87)90033-4; Urushidani T, 1999, J MEMBRANE BIOL, V168, P209; Urushidani T, 1997, J MEMBRANE BIOL, V159, P99, DOI 10.1007/s002329900274; Valenzuela SM, 1997, J BIOL CHEM, V272, P12575, DOI 10.1074/jbc.272.19.12575; Ward DT, 1999, ANNU REV PHYSIOL, V61, P683, DOI 10.1146/annurev.physiol.61.1.683	34	72	73	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11164	11173		10.1074/jbc.275.15.11164	http://dx.doi.org/10.1074/jbc.275.15.11164			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753923	hybrid			2022-12-27	WOS:000086466600065
J	Mayanil, CSK; George, D; Mania-Farnell, B; Bremer, CL; McLone, DG; Bremer, EG				Mayanil, CSK; George, D; Mania-Farnell, B; Bremer, CL; McLone, DG; Bremer, EG			Overexpression of murine Pax3 increases NCAM polysialylation in a human medulloblastoma cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR ALVEOLAR RHABDOMYOSARCOMA; ADHESION MOLECULE; POLYSIALIC ACID; N-CAM; TRANSCRIPTION ACTIVATION; NEUROECTODERMAL TUMORS; HOMOPHILIC BINDING; GENE-EXPRESSION; PAIRED DOMAIN; WILMS TUMOR	Polysialic acid (PSA) is a developmentally regulated carbohydrate found primarily on neural cell adhesion molecules (NCAM) in embryonic tissues. The majority of NCAM in adult tissues lacks this unique carbohydrate, but polysialylated NCAM (PSA-NCAM) is present in adult brain regions where neural regeneration persists and in some pediatric brain tumors such as medulloblastoma, which show greater propensity for leptomeningeal spread. Pax3, a developmentally regulated paired homeodomain transcription factor, is thought to be involved in the regulation of neural cell adhesion molecules. Overexpression of murine Pax3 into a human medulloblastoma cell line (DAOY) resulted in an increase in NCAM polysialylation and a 2-4-fold increase in alpha 2,8-polysialyltransferase type II mRNA levels. No difference was observed in alpha 2,8-polysialyltransferase type n7 message. The addition of PSA to NCAM changed the adhesive behavior of these Pax3 transfectants. Transfectants expressing high PSA-NCAM show much less NCAM-dependent aggregation than those with less PSA-NCAM. In addition, Pax3 transfectants having high PSA-NCAM show heterophilic adhesion involving polysialic acid to heparan sulfate proteoglycan and agrin. These observations suggest that a developmentally regulated transcription factor, Pax3, could affect NCAM polysialylation and subsequently cell cell and cell-substratum interaction.	Childrens Mem Inst Educ & Res, Dept Neurosurg, Pediat Brain Tumor Res Program, Chicago, IL 60614 USA; Purdue Univ Calumet, Dept Biol, Hammond, IN 46323 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Sch Med, Chicago, IL 60614 USA	Purdue University System; Purdue University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Bremer, EG (corresponding author), Childrens Mem Med Ctr, Brain Tumor Res Program, 2300 Childrens Pl,M-C 226, Chicago, IL 60614 USA.	egbremer@nwu.edu			NINDS NIH HHS [NS33383] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033383] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; Bennett GD, 1998, TERATOLOGY, V57, P17, DOI 10.1002/(SICI)1096-9926(199801)57:1<17::AID-TERA4>3.0.CO;2-4; Bennicelli JL, 1996, P NATL ACAD SCI USA, V93, P5455, DOI 10.1073/pnas.93.11.5455; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cai J, 1998, DIABETES, V47, P1803, DOI 10.2337/diabetes.47.11.1803; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; DOHERTY P, 1990, NATURE, V343, P464, DOI 10.1038/343464a0; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; FIGARELLABRANGER DF, 1990, CANCER RES, V50, P6364; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Ginsberg JP, 1998, CANCER RES, V58, P3542; Gluer S, 1998, PEDIATR RES, V43, P145, DOI 10.1203/00006450-199801000-00022; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HIGUCHI R, 1993, BIO-TECHNOL, V11, P1026, DOI 10.1038/nbt0993-1026; Hill AL, 1998, DEV GENES EVOL, V208, P128, DOI 10.1007/s004270050163; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; KIOUSSI C, 1995, NEURON, V15, P553, DOI 10.1016/0896-6273(95)90144-2; Kojima N, 1997, J BIOCHEM-TOKYO, V122, P1265; LIVINGSTON BD, 1988, J BIOL CHEM, V263, P9443; Maroto M, 1997, CELL, V89, P139, DOI 10.1016/S0092-8674(00)80190-7; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; MOLENAAR WM, 1991, ACTA NEUROPATHOL, V83, P46, DOI 10.1007/BF00294429; NEALE SA, 1994, TERATOLOGY, V50, P118, DOI 10.1002/tera.1420500206; Phelan SA, 1998, J BIOL CHEM, V273, P19153, DOI 10.1074/jbc.273.30.19153; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; ROTH J, 1990, LAB INVEST, V62, P55; ROTH J, 1988, P NATL ACAD SCI USA, V85, P2999, DOI 10.1073/pnas.85.9.2999; ROUGON G, 1992, CANCER J - FRANCE, V5, P137; RUTISHAUSER U, 1985, J CELL BIOL, V101, P1842, DOI 10.1083/jcb.101.5.1842; SCHEIDEGGER EP, 1994, LAB INVEST, V70, P95; Sevigny MB, 1998, GLYCOBIOLOGY, V8, P857, DOI 10.1093/glycob/8.9.857; SOLER AP, 1993, EXP CELL RES, V208, P84, DOI 10.1006/excr.1993.1225; Storms SD, 1998, J BIOL CHEM, V273, P27124, DOI 10.1074/jbc.273.42.27124; STUART ET, 1995, HUM MOL GENET, V4, P1717, DOI 10.1093/hmg/4.suppl_1.1717; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; TROY FA, 1995, SIALIC ACID MOL REGU, P95; Tsuji S, 1996, J BIOCHEM-TOKYO, V120, P1; Walsh FS, 1997, ANNU REV CELL DEV BI, V13, P425, DOI 10.1146/annurev.cellbio.13.1.425; WIKSTRAND CJ, 1991, INVAS METAST, V11, P310; YE J, 1994, METHOD ENZYMOL, V230, P460; Yoshida Y, 1996, J BIOL CHEM, V271, P30167, DOI 10.1074/jbc.271.47.30167	44	41	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23259	23266		10.1074/jbc.M002975200	http://dx.doi.org/10.1074/jbc.M002975200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10770948	hybrid			2022-12-27	WOS:000088419400091
J	Liu, W; Nichols, AF; Graham, JA; Dualan, R; Abbas, A; Linn, S				Liu, W; Nichols, AF; Graham, JA; Dualan, R; Abbas, A; Linn, S			Nuclear transport of human DDB protein induced by ultraviolet light	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; PIGMENTOSUM GROUP-E; COMPLEMENTATION GROUP-E; DAMAGED DNA; REPAIR PROTEIN; CELLS; INTERACTS; IMPORT; SYSTEM; FAMILY	Human damage-specific DNA-binding (DDB) protein can be purified as a heterodimer (p48 and p127) that binds to DNA damaged by ultraviolet light. We report here the effects of UV irradiation on the cellular localization of each DDB subunit as a function of time using green fluorescent fusion proteins in three diploid fibroblast strains: repair-proficient IMR-90 and two repair-deficient xeroderma pigmentosum group E strains (XP95TO and XP3RO). Although p48 remained in the nucleus after UV irradiation, a dynamic nuclear accumulation of p127 from the cytoplasm was found after 24 h. In IMR-90 cells, the nuclear localization of p127 corresponded to the up-regulation of p48 mRNA and protein levels and of DDB activity. XP3RO cells showed delayed but similar kinetics with less transport, whereas XP95TO cells appeared to have different kinetics, suggesting that these cells exhibit different defects in p127 translocation. We propose that p48 might act as the transporter for nuclear entry of p127 but that a third factor might be necessary for efficient transportation.	Univ Calif Berkeley, Div Biochem & Mol Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Linn, S (corresponding author), Univ Calif Berkeley, Div Biochem & Mol Biol, 401 Barker Hall, Berkeley, CA 94720 USA.		Graham, Jay A/A-4896-2014; Graham, Jay/AAL-5732-2020	Graham, Jay A/0000-0003-2054-1253; Graham, Jay/0000-0003-2054-1253	NIEHS NIH HHS [P30ES08196] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; CAREW JA, 1985, NUCLEIC ACIDS RES, V13, P303, DOI 10.1093/nar/13.1.303; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; FELDBERG RS, 1980, NUCLEIC ACIDS RES, V8, P1133, DOI 10.1093/nar/8.5.1133; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; Hayes S, 1998, MOL CELL BIOL, V18, P240, DOI 10.1128/MCB.18.1.240; HIRSCHFELD S, 1990, MOL CELL BIOL, V10, P2041, DOI 10.1128/MCB.10.5.2041; Jullien D, 1999, EMBO J, V18, P4348, DOI 10.1093/emboj/18.15.4348; KATAOKA H, 1991, BIOCHEM BIOPH RES CO, V175, P1139, DOI 10.1016/0006-291X(91)91684-5; Kazantsev A, 1996, P NATL ACAD SCI USA, V93, P5014, DOI 10.1073/pnas.93.10.5014; KEENEY S, 1994, P NATL ACAD SCI USA, V91, P4053, DOI 10.1073/pnas.91.9.4053; KEENEY S, 1993, J BIOL CHEM, V268, P21293; KEENEY S, 1992, MUTAT RES, V273, P49, DOI 10.1016/0921-8777(92)90049-9; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Krishnamoorthy RR, 1997, BIOCHEMISTRY-US, V36, P960, DOI 10.1021/bi961407c; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Li S, 1998, J BIOL CHEM, V273, P6183, DOI 10.1074/jbc.273.11.6183; Lin GY, 1998, VIROLOGY, V249, P189, DOI 10.1006/viro.1998.9317; Mathias N, 1996, MOL CELL BIOL, V16, P6634; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nichols AF, 2000, J BIOL CHEM, V275, P21422, DOI 10.1074/jbc.M000960200; Nichols AF, 1996, J BIOL CHEM, V271, P24317, DOI 10.1074/jbc.271.40.24317; Otrin VR, 1997, J CELL SCI, V110, P1159; PAYNE A, 1994, MUTAT RES-FUND MOL M, V310, P89, DOI 10.1016/0027-5107(94)90012-4; Protic M, 1989, Mol Toxicol, V2, P255; SAMPLE J, 1986, P NATL ACAD SCI USA, V83, P5096, DOI 10.1073/pnas.83.14.5096; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Shiyanov P, 1999, MOL CELL BIOL, V19, P4935; Shiyanov P, 1999, J BIOL CHEM, V274, P35309, DOI 10.1074/jbc.274.50.35309; VAISMAN A, 1995, BIOCHEMISTRY-US, V34, P105, DOI 10.1021/bi00001a013; Watanabe T, 1999, J NEUROCHEM, V72, P549, DOI 10.1046/j.1471-4159.1999.0720549.x	32	67	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21429	21434		10.1074/jbc.M000961200	http://dx.doi.org/10.1074/jbc.M000961200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10777491	hybrid			2022-12-27	WOS:000088230600064
J	Mukhopadhyay, CK; Mazumder, B; Fox, PL				Mukhopadhyay, CK; Mazumder, B; Fox, PL			Role of hypoxia-inducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROPOIETIN GENE; GROWTH-FACTOR GENE; FACTOR-I; FERROXIDASE ACTIVITY; RAT CERULOPLASMIN; O-2 HOMEOSTASIS; EXPRESSION; CELLS; TRANSFERRIN; BINDING	A role of the copper protein ceruloplasmin (Cp) in iron metabolism is suggested by its ferroxidase activity and by the tissue iron overload in hereditary Cp deficiency patients. In addition, plasma Cp increases markedly in several conditions of anemia, e.g. iron deficiency, hemorrhage, renal failure, sickle cell disease, pregnancy, and inflammation. However, little is known about the cellular and molecular mechanism(s) involved. We have reported that iron chelators increase Cp mRNA expression and protein synthesis in human hepatocarcinoma HepG2 cells. Furthermore, we have shown that the increase in Cp mRNA is due to increased rate of transcription. We here report the results of new studies designed to elucidate the molecular mechanism underlying transcriptional activation of Cp by iron deficiency. The 5'-flanking region of the Cp gene was cloned from a human genomic library. A 4774-base pair segment of the Cp promoter/enhancer driving a luciferase reporter was transfected into HepG2 or Hep3B cells. Iron deficiency or hypoxia increased luciferase activity by 5-10-fold compared with untreated cells. Examination of the sequence showed three pairs of consensus hypoxia-responsive elements (HREs). Deletion and mutation analysis showed that a single HRE was necessary and sufficient for gene activation. The involvement of hypoxia-inducible factor-1 (HIF-1) was shown by gel-shift and supershift experiments that showed HIF-1 alpha and HIF-1 beta binding to a radiolabeled oligonucleotide containing the Cp promoter HRE. Furthermore, iron deficiency (and hypoxia) did not activate Cp gene expression in Hepa c4 hepatoma cells deficient in HIF-1 beta, as shown functionally by the inactivity of a transfected Cp promoter-luciferase construct and by the failure of HIF-1 to bind the Cp HRE in nuclear extracts from these cells. These results are consistent with in vivo findings that iron deficiency increases plasma Cp and provides a molecular mechanism that may help to understand these observations.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Fox, PL (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029582] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29582] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Attieh ZK, 1999, J BIOL CHEM, V274, P1116, DOI 10.1074/jbc.274.2.1116; Barik S, 1993, Methods Mol Biol, V15, P277, DOI 10.1385/0-89603-244-2:277; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BEAUMIER DL, 1984, INFECT IMMUN, V46, P489, DOI 10.1128/IAI.46.2.489-494.1984; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; CARTWRIGHT GE, 1948, BLOOD, V3, P501, DOI 10.1182/blood.V3.5.501.501; CARTWRIGHT GE, 1946, J CLIN INVEST, V25, P65, DOI 10.1172/JCI101690; CHEN HM, 1993, MOL CELL BIOL, V13, P6766, DOI 10.1128/MCB.13.11.6766; DAIMON M, 1995, BIOCHEM BIOPH RES CO, V208, P1028, DOI 10.1006/bbrc.1995.1437; Damert A, 1997, BIOCHEM J, V327, P419, DOI 10.1042/bj3270419; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; Erel O, 1998, CLIN CHEM, V44, P2313; FAY J, 1949, J CLIN INVEST, V28, P487, DOI 10.1172/JCI102095; FLEMING RE, 1992, J BIOL CHEM, V267, P479; FLEMING RE, 1990, J BIOL CHEM, V265, P7701; GUBLER CJ, 1953, J CLIN INVEST, V32, P405, DOI 10.1172/JCI102752; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Harris ZL, 1999, P NATL ACAD SCI USA, V96, P10812, DOI 10.1073/pnas.96.19.10812; HART E. B., 1928, JOUR BIOL CHEM, V77, P797; IWANSKA S, 1978, Acta Physiologica Polonica, V29, P465; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; JOHNSON DA, 1967, CLIN CHEM, V13, P142; KALRA R, 1989, Indian Journal of Pathology and Microbiology, V32, P28; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Kotch LE, 1999, DEV BIOL, V209, P254, DOI 10.1006/dbio.1999.9253; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LINDER MC, 1981, JNCI-J NATL CANCER I, V67, P263; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; Lok CN, 1999, J BIOL CHEM, V274, P24147, DOI 10.1074/jbc.274.34.24147; MARKOWITZ H, 1955, J CLIN INVEST, V34, P1498, DOI 10.1172/JCI103201; Mazumder B, 1997, J IMMUNOL, V159, P1938; Mazumder B, 1999, MOL CELL BIOL, V19, P6898; McHargue JS, 1928, J BIOL CHEM, V78, P637; Melillo G, 1997, J BIOL CHEM, V272, P12236, DOI 10.1074/jbc.272.18.12236; MIYAJIMA H, 1987, NEUROLOGY, V37, P761, DOI 10.1212/WNL.37.5.761; MORIMOTO A, 1987, J PHYSIOL-LONDON, V391, P209, DOI 10.1113/jphysiol.1987.sp016734; Morita H, 1992, Rinsho Shinkeigaku, V32, P483; Mukhopadhyay CK, 1998, SCIENCE, V279, P714, DOI 10.1126/science.279.5351.714; Okamoto N, 1996, HUM GENET, V97, P755; OSAKI S, 1969, J BIOL CHEM, V244, P5757; OSAKI S, 1966, J BIOL CHEM, V241, P2746; PEDERSEN JZ, 1987, EUR J RESPIR DIS, V70, P140; PETERSON CM, 1975, BLOOD, V46, P583; RAGAN HA, 1969, AM J PHYSIOL, V217, P1320, DOI 10.1152/ajplegacy.1969.217.5.1320; Rolfs A, 1997, J BIOL CHEM, V272, P20055, DOI 10.1074/jbc.272.32.20055; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Ryden L., 1984, COPP PROTEINS COPP E, V3, P37; SACHS ADOLPH, 1938, AMER JOUR DIGEST DIS AND NUTRITION, V4, P803; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; SHIMIZU M, 1982, ACTA HAEMATOL JAPON, V45, P1183; SHIMIZU M, 1979, TRANSFUSION, V19, P742, DOI 10.1046/j.1537-2995.1979.19680104101.x; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; SURKS MI, 1966, J APPL PHYSIOL, V21, P1185; Tacchini L, 1999, J BIOL CHEM, V274, P24142, DOI 10.1074/jbc.274.34.24142; TAYLOR JE, 1994, CLIN NEPHROL, V41, P297; Venakteshwara Rao M, 1975, J ASSOC PHYSICIAN I, V23, P571; Vulpe CD, 1999, NAT GENET, V21, P195, DOI 10.1038/5979; Warburg O, 1927, BIOCHEM Z, V190, P143; WEISSMAN SM, 1966, AM J PHYSIOL, V210, P128, DOI 10.1152/ajplegacy.1966.210.1.128; WENGER RH, 1995, J BIOL CHEM, V270, P27865, DOI 10.1074/jbc.270.46.27865; Wenger RH, 1997, BIOL CHEM, V378, P609; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; YANG F, 1986, P NATL ACAD SCI USA, V83, P3257, DOI 10.1073/pnas.83.10.3257	71	208	217	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21048	21054		10.1074/jbc.M000636200	http://dx.doi.org/10.1074/jbc.M000636200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10777486	hybrid			2022-12-27	WOS:000088230600013
J	Nichols, AF; Itoh, T; Graham, JA; Liu, W; Yamaizumi, M; Linn, S				Nichols, AF; Itoh, T; Graham, JA; Liu, W; Yamaizumi, M; Linn, S			Human damage-specific DNA-binding protein p48 - Characterization of XPE mutations and regulation following UV irradiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENTOSUM GROUP-E; COMPLEMENTATION GROUP-E; XERODERMA-PIGMENTOSUM; RECOGNITION PROTEIN; REPAIR DEFECT; CELLS; DDB; PHOTOPRODUCTS; LOCALIZATION; PHENOTYPE	Damage-specific DNA binding (DDB) activity purifies from HeLa cells as a heterodimer (p127 and p48) and is absent from cells of a subset (Ddb(-)) of xeroderma pigmentosum Group E (XPE) patients. Each subunit was overexpressed in insect cells and purified. Both must be present for the damaged DNA band shift characteristic of the HeLa heterodimer. However, overexpressed p48 peptides containing the mutations found in three Ddb(-) XPE strains are inactive, and wild type p48 restores DDB activity to extracts from a fourth XPE Ddb(-) strain, GM01389, in which compound heterozygous mutations in DDB2 (p48) lead to a L350P change from one allele and a Asn-349 deletion from the other. Although these results indicate that these mutations are each responsible for the loss of DDB activity, they do not affect nuclear localization of p48. In normal fibroblasts, a 4-fold increase in p48 mRNA amount was observed 38 h after UV irradiation, preceding a similar elevation in p48 protein and DDB activity at 48 h, implying that p48 limits DDB activity in vivo. Because DNA repair is virtually complete before 48 h, a role for DDB other than DNA repair is suggested.	Univ Calif Berkeley, Div Biochem & Mol Biol, Berkeley, CA 94720 USA; Kumamoto Univ, Sch Med, Inst Mol Embryol & Genet, Dept Cell Genet, Kumamoto 860, Japan	University of California System; University of California Berkeley; Kumamoto University	Linn, S (corresponding author), Univ Calif Berkeley, Div Biochem & Mol Biol, 401 Barker Hall, Berkeley, CA 94720 USA.		Graham, Jay A/A-4896-2014; Graham, Jay/AAL-5732-2020	Graham, Jay A/0000-0003-2054-1253; Graham, Jay/0000-0003-2054-1253	NIEHS NIH HHS [P30ES08196] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; Borson ND, 1998, BIOTECHNIQUES, V25, P130, DOI 10.2144/98251rr01; CAREW JA, 1985, NUCLEIC ACIDS RES, V13, P303, DOI 10.1093/nar/13.1.303; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; Cleaver JE, 1999, HUM MUTAT, V14, P9, DOI 10.1002/(SICI)1098-1004(1999)14:1<9::AID-HUMU2>3.3.CO;2-Y; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; DUALAN R, 1995, GENOMICS, V29, P62, DOI 10.1006/geno.1995.1215; FELDBERG RS, 1980, NUCLEIC ACIDS RES, V8, P1133, DOI 10.1093/nar/8.5.1133; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P285; HIRSCHFELD S, 1990, MOL CELL BIOL, V10, P2041, DOI 10.1128/MCB.10.5.2041; Hwang BJ, 1998, MOL CELL BIOL, V18, P4391, DOI 10.1128/MCB.18.7.4391; Itoh T, 1999, J INVEST DERMATOL, V113, P251, DOI 10.1046/j.1523-1747.1999.00652.x; JOHNSON RT, 1989, HUM GENET, V81, P203; KATAOKA H, 1991, BIOCHEM BIOPH RES CO, V175, P1139, DOI 10.1016/0006-291X(91)91684-5; Kazantsev A, 1996, P NATL ACAD SCI USA, V93, P5014, DOI 10.1073/pnas.93.10.5014; KEENEY S, 1994, P NATL ACAD SCI USA, V91, P4053, DOI 10.1073/pnas.91.9.4053; KEENEY S, 1993, J BIOL CHEM, V268, P21293; KEENEY S, 1992, MUTAT RES, V273, P49, DOI 10.1016/0921-8777(92)90049-9; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lin GY, 1998, VIROLOGY, V249, P189, DOI 10.1006/viro.1998.9317; Liu W, 2000, J BIOL CHEM, V275, P21429, DOI 10.1074/jbc.M000961200; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nichols AF, 1996, J BIOL CHEM, V271, P24317, DOI 10.1074/jbc.271.40.24317; Otrin VR, 1998, MOL CELL BIOL, V18, P3182, DOI 10.1128/MCB.18.6.3182; PAYNE A, 1994, MUTAT RES-FUND MOL M, V310, P89, DOI 10.1016/0027-5107(94)90012-4; Protic M, 1989, Mol Toxicol, V2, P255; REARDON JT, 1993, J BIOL CHEM, V268, P21301; Shiyanov P, 1999, MOL CELL BIOL, V19, P4935; Urban A, 1997, NUCLEIC ACIDS RES, V25, P2227, DOI 10.1093/nar/25.11.2227; VAISMAN A, 1995, BIOCHEMISTRY-US, V34, P105, DOI 10.1021/bi00001a013; VAISMAN A, 1996, ONCOL RES, V9, P7; Watanabe T, 1999, J NEUROCHEM, V72, P549, DOI 10.1046/j.1471-4159.1999.0720549.x	34	113	118	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21422	21428		10.1074/jbc.M000960200	http://dx.doi.org/10.1074/jbc.M000960200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10777490	hybrid			2022-12-27	WOS:000088230600063
J	Burakov, D; Wong, CW; Rachez, C; Cheskis, BJ; Freedman, LP				Burakov, D; Wong, CW; Rachez, C; Cheskis, BJ; Freedman, LP			Functional interactions between the estrogen receptor and DRIP205, a subunit of the heteromeric DRIP coactivator complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; NUCLEAR-RECEPTOR; HISTONE DEACETYLASE; TRANSCRIPTIONAL COACTIVATOR; N-COR; PROTEIN; REPRESSION; BINDING; ACETYLTRANSFERASE; GENE	Nuclear receptors regulate transcription in direct response to their cognate hormonal ligands. Ligand binding leads to the dissociation of corepressors and the recruitment of coactivators. Many of these factors, acting in large complexes, have emerged as potential chromatin remodelers through intrinsic histone modifying activities. In addition, other ligand-recruited complexes appear to act more directly on the transcriptional apparatus. The DRIP complex is a 15-subunit complex required for nuclear receptor transcriptional activation in vitro. It is recruited to the receptor in response to ligand through specific interactions of one subunit, DRIP205. Ne present evidence that DRIP205 interacts with another member of the steroid receptor subfamily, estrogen receptor (ER). This interaction occurs in an agonist-stimulated fashion which in turn is inhibited by several ER antagonists. In vivo, a fragment of DRIP205 containing only its receptor interacting region acts to selectively inhibit ER's ability to activate transcription in response to estradiol. These observations suggest a key role for the DRIP coactivator complex in estrogen-ER signaling.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, Sloan Kettering Div, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, New York, NY 10021 USA; Wyeth Ayerst Res, Nucl Receptors Dept, Radnor, PA 19087 USA	Memorial Sloan Kettering Cancer Center; Cornell University; Pfizer	Freedman, LP (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, Sloan Kettering Div, 1275 York Ave,Box 470, New York, NY 10021 USA.		Rachez, Christophe/GLR-0102-2022	Rachez, Christophe/0000-0001-8502-4738	NIDDK NIH HHS [DK45460] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK045460, R01DK045460] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Cheskis B, 1996, BIOCHEMISTRY-US, V35, P3309, DOI 10.1021/bi952283r; CHESKIS BJ, 1999, NUCL RECEPTORS PRACT, P95; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Hampsey M, 1999, CURR OPIN GENET DEV, V9, P132, DOI 10.1016/S0959-437X(99)80020-3; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Huang EY, 2000, GENE DEV, V14, P45; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Kao HY, 2000, GENE DEV, V14, P55; Lemon BD, 1999, CURR OPIN GENET DEV, V9, P499, DOI 10.1016/S0959-437X(99)00010-6; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rachez C, 2000, MOL CELL BIOL, V20, P2718, DOI 10.1128/MCB.20.8.2718-2726.2000; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500; Zhu YJ, 1999, P NATL ACAD SCI USA, V96, P10848, DOI 10.1073/pnas.96.19.10848	37	84	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20928	20934		10.1074/jbc.M002013200	http://dx.doi.org/10.1074/jbc.M002013200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10770935	hybrid			2022-12-27	WOS:000088084500099
J	Mould, AP; Askari, JA; Humphries, MJ				Mould, AP; Askari, JA; Humphries, MJ			Molecular basis of ligand recognition by integrin alpha(5)beta(1) - I. Specificity of ligand binding is determined by amino acid sequences in the second and third NH2-terminal repeats of the alpha subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; FUNCTION-ASSOCIATED ANTIGEN-1; PHOTOAFFINITY CROSS-LINKING; BETA-PROPELLER DOMAIN; CELL-ADHESION; CRYSTAL-STRUCTURE; ALPHA-5-BETA-1-FIBRONECTIN INTERACTIONS; VITRONECTIN RECEPTOR; CRITICAL RESIDUES; A-DOMAIN	The NH2-terminal portion (putative ligand-binding domain) of a subunits contains 7 homologous repeats, the last 3 or 4 of which possess divalent cation binding sequences. These repeats are predicted to form a seven-bladed beta-propeller structure. To map ligand recognition sites on the alpha(5) subunit we have taken the approach of constructing and expressing alpha(V)/alpha(5) chimeras. Although the NH2-terminal repeats of alpha(5) and alpha(V) are >50% identical at the amino acid level, alpha(5)beta(1) and alpha(V)beta(1) show marked differences in their ligand binding specificities, Thus: (i) although both integrins recognize the Arg-Gly-Asp (RGD) sequence in fibronectin, the interaction of alpha(5)beta(1) but not of alpha(V)beta(1) with fibronectin is strongly dependent on the "synergy" sequence Pra-His-Ser-Arg-Asn; (ii) alpha(5)beta(1) binds preferentially to RGD peptides in which RGD is followed by Gly-TrP (GW) whereas alpha(V)beta(1) has a broader specificity; (iii) only alpha(5)beta(1) recognizes peptides containing the sequence Arg-Arg-Glu-Thr-Ala-Trp-Ala (RRETAWA). Therefore, amino acid residues involved in ligand recognition by alpha(5)beta(1) can potentially be identified in gain-of-function experiments by their ability to switch the ligand binding properties of alpha(V)beta(1) to those of alpha(5)beta(1). By introducing appropriate restriction enzyme sites, or using site-directed mutagenesis, parts of the NH2-terminal repeats of a, were replaced with the corresponding regions of the a, subunit. Chimeric subunits were expressed on the surface of Chinese hamster ovary-B2 cells (which lack endogenous alpha(5)) as heterodimers with hamster beta(1). Stable cell lines were generated and tested for their ability to attach to alpha(5)beta(1)-selective ligands. Our results demonstrate that: (a) the first three NH2-terminal repeats contain the amino acid sequences that determine ligand binding specificity and the same repeats include the epitopes of function blocking anti-a subunit mAbs; (b) the divalent cation-binding sites (in repeats 4-7) do not confer alpha(5)beta(1)- or alpha(V)beta(1)-specific ligand recognition; (c) amino acid residues Ala(107)-Tyr(226) of alpha(5) (corresponding approximately to repeats 2 and 3) are sufficient to change all the ligand binding properties of alpha(V)beta(1) to these of alpha(5)beta(1); (d) swapping a small part of a predicted loop region of alpha(5) with the corresponding region of alpha(5) (Asp(154)-Ala(159)) is sufficient to confer selectivity for RGDGW and the ability to recognize RRETAWA.	Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Mould, AP (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.			Humphries, Martin/0000-0002-4331-6967; Mould, Paul/0000-0003-0076-6228				AKIYAMA SK, 1995, CELL ADHES COMMUN, V3, P13, DOI 10.3109/15419069509081275; AOTA S, 1994, J BIOL CHEM, V269, P24756; BAIT ML, 1994, J BIOL CHEM, V269, P20913; Baneres JL, 1998, J BIOL CHEM, V273, P24744, DOI 10.1074/jbc.273.38.24744; BARBAS CF, 1993, P NATL ACAD SCI USA, V90, P10003, DOI 10.1073/pnas.90.21.10003; Bitan G, 1999, BIOCHEMISTRY-US, V38, P3414, DOI 10.1021/bi981946c; Burrows L, 1999, BIOCHEM J, V344, P527, DOI 10.1042/0264-6021:3440527; Cao ZJ, 1998, J BIOL CHEM, V273, P31670, DOI 10.1074/jbc.273.48.31670; Chen J, 1996, CELL ADHES COMMUN, V4, P237, DOI 10.3109/15419069609010769; Cierniewski CS, 1999, J BIOL CHEM, V274, P16923, DOI 10.1074/jbc.274.24.16923; Copie V, 1998, J MOL BIOL, V277, P663; DANEN EHJ, 1995, J BIOL CHEM, V270, P21612, DOI 10.1074/jbc.270.37.21612; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; Dickeson SK, 1998, CELL MOL LIFE SCI, V54, P556, DOI 10.1007/s000180050184; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; Edwards CP, 1998, J BIOL CHEM, V273, P28937, DOI 10.1074/jbc.273.44.28937; Goodman TG, 1996, J BIOL CHEM, V271, P23729, DOI 10.1074/jbc.271.39.23729; GUILINO D, 1992, J BIOL CHEM, V267, P1001; Honda S, 1998, J CLIN INVEST, V102, P1183, DOI 10.1172/JCI3206; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; Humphries JD, 2000, J BIOL CHEM, V275, P20337, DOI 10.1074/jbc.M000568200; Humphries MJ, 1999, BIOCHEM SOC SYMP, V65, P63; Humphries MJ, 1998, TRENDS CELL BIOL, V8, P78, DOI 10.1016/S0962-8924(98)80016-0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Irie A, 1997, P NATL ACAD SCI USA, V94, P7198, DOI 10.1073/pnas.94.14.7198; IRIE A, 1995, EMBO J, V14, P5550, DOI 10.1002/j.1460-2075.1995.tb00242.x; Kamata T, 1999, J BIOL CHEM, V274, P32108, DOI 10.1074/jbc.274.45.32108; KAMATA T, 1995, BIOCHEM J, V305, P945, DOI 10.1042/bj3050945; Kamata T, 1996, J BIOL CHEM, V271, P18610, DOI 10.1074/jbc.271.31.18610; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; KOIVUNEN E, 1995, BIO-TECHNOL, V13, P265, DOI 10.1038/nbt0395-265; Krukonis ES, 1998, J BIOL CHEM, V273, P31837, DOI 10.1074/jbc.273.48.31837; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lin ECK, 1997, J BIOL CHEM, V272, P14236, DOI 10.1074/jbc.272.22.14236; Loftus JC, 1996, J BIOL CHEM, V271, P2033, DOI 10.1074/jbc.271.4.2033; Loftus JC, 1997, J CLIN INVEST, V99, P2302, DOI 10.1172/JCI119408; Mould AP, 1998, J BIOL CHEM, V273, P25664, DOI 10.1074/jbc.273.40.25664; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Mould AP, 1997, J BIOL CHEM, V272, P17283, DOI 10.1074/jbc.272.28.17283; Mould AP, 1996, J BIOL CHEM, V271, P20365, DOI 10.1074/jbc.271.34.20365; Munoz M, 1997, BIOCHEM J, V327, P727, DOI 10.1042/bj3270727; Oxvig C, 1998, P NATL ACAD SCI USA, V95, P4870, DOI 10.1073/pnas.95.9.4870; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; Pujades C, 1997, MOL BIOL CELL, V8, P2647, DOI 10.1091/mbc.8.12.2647; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P20438, DOI 10.1074/jbc.271.34.20438; RANDI AM, 1994, J BIOL CHEM, V269, P12395; SCHIFFER SG, 1995, J BIOL CHEM, V270, P14270, DOI 10.1074/jbc.270.24.14270; SCHREINER CL, 1989, J CELL BIOL, V109, P3157, DOI 10.1083/jcb.109.6.3157; SMITH JW, 1990, J BIOL CHEM, V265, P2168; SMITH JW, 1988, J BIOL CHEM, V263, P18726; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; Takada Y, 1997, MATRIX BIOL, V16, P143, DOI 10.1016/S0945-053X(97)90002-0; Takagi J, 1997, J BIOL CHEM, V272, P19794, DOI 10.1074/jbc.272.32.19794; TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044; Tan K, 1998, STRUCTURE, V6, P793, DOI 10.1016/S0969-2126(98)00080-X; Tozer EC, 1999, BLOOD, V93, P918, DOI 10.1182/blood.V93.3.918.403k26_918_924; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; TUCKWELL DS, 1992, BIOCHEM J, V285, P325, DOI 10.1042/bj2850325; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; TUCKWELL DS, 1994, CELL ADHES COMMUN, V2, P385, DOI 10.3109/15419069409004450; YAMADA KM, 1984, J CELL BIOL, V99, P29, DOI 10.1083/jcb.99.1.29; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223; Zhang L, 1997, J BIOL CHEM, V272, P17558, DOI 10.1074/jbc.272.28.17558; Zhang XP, 1999, BIOCHEMISTRY-US, V38, P14424, DOI 10.1021/bi990323b	66	93	94	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20324	20336		10.1074/jbc.M000572200	http://dx.doi.org/10.1074/jbc.M000572200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10764748	hybrid			2022-12-27	WOS:000088084500017
J	Du, GC; Khanna, VK; MacLennan, DH				Du, GC; Khanna, VK; MacLennan, DH			Mutation of divergent region 1 alters caffeine and Ca2+ sensitivity of the skeletal muscle Ca2+ release channel (ryanodine receptor)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL CORE DISEASE; SARCOPLASMIC-RETICULUM; MOLECULAR-IDENTIFICATION; MALIGNANT HYPERTHERMIA; FUNCTIONAL EXPRESSION; FK506-BINDING PROTEIN; BINDING; ANTIBODIES; SITES; CDNA	Replacement of amino acids 4187-4628 in the skeletal muscle Ca2+ release channel (skeletal ryanodine receptor (RyR1)), including nearly all of divergent region 1 (amino acids 4254-4631), with the corresponding cardiac ryanodine receptor (RyR2) sequence leads to increased sensitivity of channel activation by caffeine and Ca2+ and to decreased sensitivity of channel inactivation by elevated Ca2+ (Du, G. G., and MacLennan, D. H. (1999) J. Biol. Chem. 274, 26120-26126). In further investigations, this region was subdivided by the construction of new chimeras, and alterations in channel function were detected by measurement of the caffeine dependence of in vivo Ca2+ release and the Ca2+ dependence of [H-3]ryanodine binding. Chimera RF10a (amino acids 4187-4381) had a lower EC50 value for activation by caffeine, and RF10c (4557-4628) had a higher EC50 value, whereas the EC50 value for chimera RF10b (4382-4556) was unchanged. Chimeras RF10b and RF10c were more sensitive to activation by Ca2+, whereas RF10a was less sensitive to inactivation by Ca2+, implicating RF10b and RF10c in Ca2+ activation and RF10a in Ca2+ inactivation. Deletion of much of divergent region 1 sequence to create mutant Delta 4274-4535 led to higher caffeine and Ca2+ sensitivity of channel activation and to lower Ca2+ sensitivity for inactivation. Thus, deletion results demonstrate that caffeine, Ca2+, and ryanodine binding sites are not located in amino acids 4274-4535, Nevertheless, the properties of the deletion and chimeric mutants demonstrate that amino acids 4274-4535 and three shorter sequences in this region (F10a, amino acids 4187-4381; F10b, 4382-4556; and F10c, 4557-4628) in RyR1 modulate Ca2+ and caffeine sensitivity of the Ca2+ release channel.	Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada	University of Toronto	MacLennan, DH (corresponding author), Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.	david.maclennan@utoronto.ca						AIREY JA, 1990, J BIOL CHEM, V265, P14187; Bhat MB, 1997, BIOPHYS J, V73, P1329, DOI 10.1016/S0006-3495(97)78166-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN SRW, 1993, BIOCHEMISTRY-US, V32, P3743, DOI 10.1021/bi00065a029; CHEN SRW, 1993, J BIOL CHEM, V268, P13414; CHEN SRW, 1992, J BIOL CHEM, V267, P23318; Chen SRW, 1997, BIOPHYS J, V73, P1904, DOI 10.1016/S0006-3495(97)78221-3; Chen SRW, 1998, J BIOL CHEM, V273, P14675, DOI 10.1074/jbc.273.24.14675; CHEN SRW, 1994, J BIOL CHEM, V269, P22698; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; Du GG, 1998, J BIOL CHEM, V273, P31867, DOI 10.1074/jbc.273.48.31867; Du GG, 1999, J BIOL CHEM, V274, P26120, DOI 10.1074/jbc.274.37.26120; Du GG, 1998, J BIOL CHEM, V273, P33259, DOI 10.1074/jbc.273.50.33259; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; Feng W, 1996, MOL MEMBR BIOL, V13, P85, DOI 10.3109/09687689609160581; FILL M, 1991, BIOCHEM J, V273, P449, DOI 10.1042/bj2730449; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; Gao L, 1997, FEBS LETT, V412, P223, DOI 10.1016/S0014-5793(97)00781-3; INUI M, 1987, J BIOL CHEM, V262, P1740; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Loke J, 1998, AM J MED, V104, P470, DOI 10.1016/S0002-9343(98)00108-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lynch PJ, 1999, P NATL ACAD SCI USA, V96, P4164, DOI 10.1073/pnas.96.7.4164; MARKS AR, 1990, J BIOL CHEM, V265, P13143; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MENEGAZZI P, 1994, BIOCHEMISTRY-US, V33, P9078, DOI 10.1021/bi00197a008; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; Nakai J, 1999, FEBS LETT, V459, P154, DOI 10.1016/S0014-5793(99)01232-6; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; OTSU K, 1990, J BIOL CHEM, V265, P13472; Samso M, 1999, J CELL BIOL, V146, P493, DOI 10.1083/jcb.146.2.493; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; Tong JF, 1999, J BIOL CHEM, V274, P693, DOI 10.1074/jbc.274.2.693; Tong JF, 1997, J BIOL CHEM, V272, P26332, DOI 10.1074/jbc.272.42.26332; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREVES S, 1993, BIOCHEM J, V291, P757, DOI 10.1042/bj2910757; Wagenknecht T, 1997, J BIOL CHEM, V272, P32463, DOI 10.1074/jbc.272.51.32463; Wagenknecht T, 1996, BIOPHYS J, V70, P1709, DOI 10.1016/S0006-3495(96)79733-3; Yamazawa T, 1997, J BIOL CHEM, V272, P8161, DOI 10.1074/jbc.272.13.8161; Zhao MC, 1999, J BIOL CHEM, V274, P25971, DOI 10.1074/jbc.274.37.25971; ZORZATO F, 1989, BIOCHEM J, V261, P863, DOI 10.1042/bj2610863; ZORZATO F, 1990, J BIOL CHEM, V265, P2244; Zucchi R, 1997, PHARMACOL REV, V49, P1	45	47	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11778	11783		10.1074/jbc.275.16.11778	http://dx.doi.org/10.1074/jbc.275.16.11778			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766801	hybrid			2022-12-27	WOS:000086695500036
J	Quiros, LM; Carbajo, RJ; Brana, AF; Salas, JA				Quiros, LM; Carbajo, RJ; Brana, AF; Salas, JA			Glycosylation of macrolide antibiotics - Purification and kinetic studies of a macrolide glycosyltransferase from Streptomyces antibioticus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRODUCER ORGANISM; 2 GENES; OLEANDOMYCIN; BIOSYNTHESIS; RESISTANCE	The oleD gene has been identified in the oleandomycin producer Streptomyces antibioticus and it codes a macrolide glycosyltransferase that is able to transfer a glucose moiety from UDP-glucose (UDP-Glc) to many macrolides. The glycosyltransferase coded by the oleD gene has been purified 371-fold from a Streptomyces lividans clone expressing this protein. The reaction product was isolated, and its structure determined by NMR spectroscopy. The kinetic mechanism of the reaction was analyzed using the macrolide antibiotic lankamycin (LK) as substrate. The reaction operates via a compulsory order mechanism. This has been shown by steady-state kinetic studies and by isotopic exchange reactions at equilibrium. LK binds first to the enzyme, followed by UDP-glucose. A ternary complex is thus formed prior to transfer of glucose. UDP is then released, followed by the glycosylated lankamycin (GS-LK). A pH study of the reaction was performed to determine values for the molecular pK values, suggesting possible amino acid residues involved in the catalytic process.	Univ Oviedo, Dept Biol Func, E-33006 Oviedo, Spain; Univ Oviedo, Dept Quim Organ & Inorgan, E-33006 Oviedo, Spain	University of Oviedo; University of Oviedo	Salas, JA (corresponding author), Univ Oviedo, Dept Biol Func, E-33006 Oviedo, Spain.		Quirós, Luis/T-3822-2017; Fernandez-Brana, Alfredo/O-1488-2019; Brana, Alfredo/M-1836-2014	Quirós, Luis/0000-0003-3505-3762; Fernandez-Brana, Alfredo/0000-0002-3277-9085; Brana, Alfredo/0000-0002-3277-9085				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; Dixon M., 1979, ENZYMES, Vthird; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; Fernandez E, 1998, J BACTERIOL, V180, P4929; FIERRO JF, 1987, J GEN MICROBIOL, V133, P1931; Fromm H J, 1979, Methods Enzymol, V63, P467; HERNANDEZ C, 1993, GENE, V134, P139, DOI 10.1016/0378-1119(93)90189-A; JENKINS G, 1991, GENE, V108, P55, DOI 10.1016/0378-1119(91)90487-V; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PURICH DL, 1980, METHOD ENZYMOL, V64, P3; QUIROS LM, 1995, J BIOL CHEM, V270, P18234, DOI 10.1074/jbc.270.31.18234; Quiros LM, 1998, MOL MICROBIOL, V28, P1177, DOI 10.1046/j.1365-2958.1998.00880.x; QUIROS LM, 1993, EUR J BIOCHEM, V222, P129; Rudolph F B, 1979, Methods Enzymol, V63, P411; Sasaki J, 1996, J ANTIBIOT, V49, P1110, DOI 10.7164/antibiotics.49.1110; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; Segel I.H, 1993, ENZYME KINETICS; Tipton K F, 1979, Methods Enzymol, V63, P183; VILCHES C, 1992, J BACTERIOL, V174, P161, DOI 10.1128/jb.174.1.161-165.1992; Windholz M., 1983, MERCK INDEX	21	66	70	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11713	11720		10.1074/jbc.275.16.11713	http://dx.doi.org/10.1074/jbc.275.16.11713			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766792	hybrid			2022-12-27	WOS:000086695500027
J	Sala-Newby, GB; Freeman, NVE; Skladanowski, AC; Newby, AC				Sala-Newby, GB; Freeman, NVE; Skladanowski, AC; Newby, AC			Distinct roles for recombinant cytosolic 5 '-nucleotidase-I and -II in AMP and IMP catabolism in COS-7 and H9c2 rat myoblast cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE FORMATION; POLYMORPHONUCLEAR LEUKOCYTES; SOLUBLE 5'-NUCLEOTIDASE; RABBIT HEART; PIGEON HEART; NUCLEOTIDES; EXPRESSION; INHIBITOR; MECHANISM; CLONING	Catabolism of AMP during ATP breakdown produces adenosine, which restores energy balance. Catabolism of IMP may be a key step regulating purine nucleotide pools. Two, cloned cytosolic 5'-nucleotidases (cN-I and cN-II) have been implicated in AMP and IMP breakdown. To evaluate their roles directly, we expressed recombinant pigeon cN-I or human cN-II at similar activities in COS-7 or H9c2 cells. During rapid (more than 90% in 10 min) or slower (30-40% in 10 min) ATP catabolism, cN-I-transfected COS-7 and H9c2 cells produced significantly more adenosine than cN-II-transfected cells, which were similar to control-transfected cells, Inosine and hypoxanthine concentrations increased only during slower ATP catabolism. In COS-7 cells, 5'-nucleotidase activity was not rate-limiting for inosine and hypoxanthine production, which was therefore unaffected by cN-II- and actually reduced by cN-I- overexpression. In H9c2 cells, in which 5'-nucleotidase activity was rate-limiting, only cN-II overexpression accelerated inosine and hypoxanthine formation. Guanosine formation from GMP was also increased by cN-II, Our results imply distinct roles for cN-I and cN-II, Under the conditions tested in these cells, only cN-I plays a significant role in AMP breakdown to adenosine, whereas only cN-II breaks down IMP to inosine and GMP to guanosine.	Univ Bristol, Bristol Heart Inst, Bristol BS2 8HW, Avon, England; Med Acad Gdansk, Dept Biochem, PL-80211 Gdansk, Poland	University of Bristol; Fahrenheit Universities; Medical University Gdansk	Sala-Newby, GB (corresponding author), Univ Bristol, Bristol Heart Inst, Bristol BS2 8HW, Avon, England.		Skladanowski, Andrzej C. C/B-4687-2010	Skladanowski, Andrzej C. C/0000-0003-3408-1147				Allegrini S, 1997, BIOCHEM J, V328, P483, DOI 10.1042/bj3280483; Baker AH, 1996, MATRIX BIOL, V15, P383, DOI 10.1016/S0945-053X(96)90158-4; BERNE RM, 1964, PHYSIOL REV, V44, P1, DOI 10.1152/physrev.1964.44.1.1; FISHBEIN WN, 1993, BIOCHIM BIOPHYS ACTA, V1163, P97, DOI 10.1016/0167-4838(93)90284-X; Garvey EP, 1999, ARCH BIOCHEM BIOPHYS, V364, P235, DOI 10.1006/abbi.1999.1133; Gustafson LA, 1998, AM J PHYSIOL-HEART C, V274, pH529, DOI 10.1152/ajpheart.1998.274.2.H529; HESCHELER J, 1991, CIRC RES, V69, P1476, DOI 10.1161/01.RES.69.6.1476; ITOH R, 1981, BIOCHIM BIOPHYS ACTA, V659, P31, DOI 10.1016/0005-2744(81)90268-0; ITOH R, 1991, INT J BIOCHEM, V23, P461; JENKINS JR, 1988, CIRC RES, V63, P97, DOI 10.1161/01.RES.63.1.97; KHAN MT, 1980, BRIT J PHARMACOL, V68, P551, DOI 10.1111/j.1476-5381.1980.tb14571.x; LAGERQVIST B, 1990, CARDIOVASC RES, V24, P609, DOI 10.1093/cvr/24.8.609; LOWENSTEIN JM, 1990, INT J SPORTS MED, V11, pS37, DOI 10.1055/s-2007-1024853; MULLANE K, 1995, J MOL CELL CARDIOL, V27, P1041, DOI 10.1016/0022-2828(95)90073-X; NEWBY AC, 1988, BIOCHEM J, V253, P123, DOI 10.1042/bj2530123; NEWBY AC, 1990, NEWS PHYSIOL SCI, V5, P67; NEWBY AC, 1984, TRENDS BIOCHEM SCI, V9, P42, DOI 10.1016/0968-0004(84)90176-2; NEWBY AC, 1981, BIOCHEM PHARMACOL, V30, P2611, DOI 10.1016/0006-2952(81)90589-X; OKA J, 1994, BIOCHEM BIOPH RES CO, V205, P917, DOI 10.1006/bbrc.1994.2752; Rampazzo C, 1999, EUR J BIOCHEM, V261, P689, DOI 10.1046/j.1432-1327.1999.00320.x; Sala-Newby GB, 1999, J BIOL CHEM, V274, P17789, DOI 10.1074/jbc.274.25.17789; SCHRADER J, 1977, PFLUG ARCH EUR J PHY, V372, P29, DOI 10.1007/BF00582203; SIPIDO KR, 1991, CIRC RES, V69, P1487, DOI 10.1161/01.RES.69.6.1487; Skladanowski AC, 1996, AM J PHYSIOL-HEART C, V270, pH1493, DOI 10.1152/ajpheart.1996.270.4.H1493; SKLADANOWSKI AC, 1989, BIOCHEM J, V262, P203, DOI 10.1042/bj2620203; SKLADANOWSKI AC, 1990, BIOCHEM J, V268, P117, DOI 10.1042/bj2680117; SKLADANOWSKI AC, 1991, ROLE ADENOSINE ADENI, P289; SMOLENSKI RT, 1990, J CHROMATOGR-BIOMED, V527, P414, DOI 10.1016/S0378-4347(00)82125-8; Spychala J, 1996, FASEB J, V10, P601; SPYCHALA J, 1988, J BIOL CHEM, V263, P18759; WORKU Y, 1983, BIOCHEM J, V214, P325, DOI 10.1042/bj2140325; YAMAZAKI Y, 1991, BIOCHEMISTRY-US, V30, P1503, DOI 10.1021/bi00220a009; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345	33	35	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11666	11671		10.1074/jbc.275.16.11666	http://dx.doi.org/10.1074/jbc.275.16.11666			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766785	hybrid			2022-12-27	WOS:000086695500020
J	Singh, V; Merz, WE				Singh, V; Merz, WE			Disulfide bond formation is not required for human chorionic gonadotropin subunit association - Studies with dithiothreitol in JEG-3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; N-LINKED OLIGOSACCHARIDES; ALPHA-BETA-DIMER; VIRUS-G-PROTEIN; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; TUMOR-MARKERS; ISOMERASE; KINETICS; CHORIOCARCINOMA	To study the influence of disulfide bridge formation on the assembly of the subunits of human chorionic gonadotropin in JEG-3 choriocarcinoma cells, dithiothreitol (DTT) was used to create a reducing milieu in the endoplasmic reticulum (ER) in vivo. In the presence of 5 mM DTT during pulse-chase experiments all of the beta-subunit precursors observed in unperturbed cells (p beta(0), p beta(1), p beta(2), and beta*) collapsed into the p beta(0) form. The reducing milieu of the ER was reoxidized in less than 5 min after removal of DTT from the medium. DTT markedly increased the half-life of the p beta(0) precursor from 8.8 to 65.2 min. Under reoxidation conditions, the beta-subunit precursors folded back from p beta(0) in less than 5 min. In unperturbed JEG-3 cells, the alpha-subunit was present in both fully glycosylated and monoglycosylated precursor (pre-alpha) forms. The attachment of the second N-linked glycan residue of the alpha-subunit was accelerated in the presence of DTT, and consequently pre-alpha-subunit was missing from the DTT-treated cultures. The formation of alpha beta-dimers appeared to be at least partially independent of the oxidation state in the ER. The alpha beta-dimer was present under conditions in which disulfide bridge formation was prevented by exposure to 5 mM DTT before and during the pulse period. This clearly suggests that the human chorionic gonadotropin subunits may acquire association-competent conformations even when no disulfide bridge formation has taken place.	Univ Heidelberg, Biochem Zentrum Heidelberg, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Merz, WE (corresponding author), Univ Heidelberg, Biochem Zentrum Heidelberg, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.							BAGSHAWE KD, 1992, ACTA ONCOL, V31, P99, DOI 10.3109/02841869209088275; BEASTALL GH, 1991, ANN CLIN BIOCHEM, V28, P5, DOI 10.1177/000456329102800102; BEDOWS E, 1992, J BIOL CHEM, V267, P8880; BEDOWS E, 1994, J BIOL CHEM, V269, P10574; BEDOWS E, 1993, J BIOL CHEM, V268, P11655; BEEBE JS, 1989, ENDOCRINOLOGY, V124, P1613, DOI 10.1210/endo-124-4-1613; BEEBE JS, 1990, J BIOL CHEM, V265, P312; BEWLEY TA, 1974, ARCH BIOCHEM BIOPHYS, V163, P625, DOI 10.1016/0003-9861(74)90523-2; BIELINSKA M, 1989, J BIOL CHEM, V264, P17113; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BRAUNSTEIN GD, 1972, J CLIN ENDOCR METAB, V35, P857, DOI 10.1210/jcem-35-6-857; BRAUNSTEIN GD, 1973, ANN INTERN MED, V78, P39, DOI 10.7326/0003-4819-78-1-39; Canfield R E, 1971, Recent Prog Horm Res, V27, P121; CHANAT E, 1993, EMBO J, V12, P2159, DOI 10.1002/j.1460-2075.1993.tb05864.x; COSGROVE DE, 1989, BIOCHIM BIOPHYS ACTA, V1007, P44, DOI 10.1016/0167-4781(89)90128-0; Creighton TE, 1996, FASEB J, V10, P110, DOI 10.1096/fasebj.10.1.8566531; DESILVA A, 1993, J CELL BIOL, V120, P647, DOI 10.1083/jcb.120.3.647; FENG W, 1995, J BIOL CHEM, V270, P11851, DOI 10.1074/jbc.270.20.11851; Feng WJ, 1996, J BIOL CHEM, V271, P18543, DOI 10.1074/jbc.271.31.18543; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HILF G, 1989, BIOCHEM BIOPH RES CO, V159, P26, DOI 10.1016/0006-291X(89)92399-1; HOERMANN R, 1994, CLIN CHEM, V40, P2306; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Hussa R O, 1980, Endocr Rev, V1, P268; HUTH JR, 1992, J BIOL CHEM, V267, P21396; HUTH JR, 1992, J BIOL CHEM, V267, P8870; HUTH JR, 1993, J BIOL CHEM, V268, P16472; IBRAHIMI I, 1987, J CELL BIOL, V105, P1555, DOI 10.1083/jcb.105.4.1555; INGHAM KC, 1974, ARCH BIOCHEM BIOPHYS, V163, P589, DOI 10.1016/0003-9861(74)90518-9; INGHAM KC, 1976, BIOCHEMISTRY-US, V15, P1720, DOI 10.1021/bi00653a020; ISAACS NW, 1995, CURR OPIN STRUC BIOL, V5, P391, DOI 10.1016/0959-440X(95)80102-2; KLAUSNER R D, 1989, New Biologist, V1, P3; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LEITZGEN K, 1998, CHEMTRACTS BIOCH MOL, V11, P423; LODISH HF, 1993, J BIOL CHEM, V268, P20598; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MARTELL RE, 1990, ENDOCRINOLOGY, V126, P2757, DOI 10.1210/endo-126-5-2757; MERZ WE, 1973, EUR J BIOCHEM, V35, P297, DOI 10.1111/j.1432-1033.1973.tb02838.x; MERZ WE, 1991, J CLIN ENDOCR METAB, V73, P84, DOI 10.1210/jcem-73-1-84; MERZ WE, 1984, ACTION GONADOTROPINS, P59; MORGAN FJ, 1974, ENDOCRINOLOGY, V94, P1601, DOI 10.1210/endo-94-6-1601; NOIVA R, 1992, J BIOL CHEM, V267, P3553; OPSTELTEN DJE, 1993, J VIROL, V67, P7394, DOI 10.1128/JVI.67.12.7394-7401.1993; PATTILLO RA, 1968, CANCER RES, V28, P1231; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; Ruddon RW, 1997, J BIOL CHEM, V272, P3125, DOI 10.1074/jbc.272.6.3125; SEGAL MS, 1992, J CELL BIOL, V118, P227, DOI 10.1083/jcb.118.2.227; STORY MT, 1980, J CLIN ENDOCR METAB, V50, P1057, DOI 10.1210/jcem-50-6-1057; SVENSSON L, 1994, J VIROL, V68, P5204, DOI 10.1128/JVI.68.8.5204-5215.1994; SWAMINATHAN N, 1970, BIOCHEM BIOPH RES CO, V40, P422, DOI 10.1016/0006-291X(70)91026-0; TATU U, 1993, EMBO J, V12, P2151, DOI 10.1002/j.1460-2075.1993.tb05863.x; VAITUKAITIS JL, 1973, J CLIN ENDOCR METAB, V37, P505, DOI 10.1210/jcem-37-4-505; VAITUKAITIS JL, 1974, ANN CLIN LAB SCI, V4, P276; VOORBERG J, 1991, J CELL BIOL, V113, P195, DOI 10.1083/jcb.113.1.195; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X	61	7	7	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11765	11770		10.1074/jbc.275.16.11765	http://dx.doi.org/10.1074/jbc.275.16.11765			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766799	hybrid			2022-12-27	WOS:000086695500034
J	Denny, PW; Gokool, S; Russell, DG; Field, MC; Smith, DF				Denny, PW; Gokool, S; Russell, DG; Field, MC; Smith, DF			Acylation-dependent protein export in Leishmania	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE B-PROTEIN; ELECTRON-MICROSCOPY; ANCHOR ATTACHMENT; MAMMALIAN-CELLS; SURFACE; SIGNAL; SECRETION; LIPOPHOSPHOGLYCAN; GLYCOPROTEIN; EXPRESSION	The surface of the protozoan parasite Leishmania is unusual in that it consists predominantly of glycosylphosphatidylinositol-anchored glycoconjugates and proteins. Additionally, a family of hydrophilic acylated surface proteins (HASPs) has been localized to the extracellular face of the plasma membrane in infective parasite stages. These surface polypeptides lack a recognizable endoplasmic reticulum secretory signal sequence, transmembrane spanning domain, or glycosylphosphatidylinositol-anchor consensus sequence, indicating that novel mechanisms are involved in their transport and localization, Here, we show that the N-terminal domain of HASPB contains primary structural information that directs both N-myristoylation and palmitoylation and is essential for correct localization of the protein to the plasma membrane, Furthermore, the N-terminal 18 amino acids of HASPB, encoding the dual acylation site, are sufficient to target the heterologous Aequorea victoria green fluorescent protein to the cell surface of Leishmania. Mutagenesis of the predicted acylated residues confirms that modification by both myristate and palmitate is required for correct trafficking. These data suggest that HASPB is a representative of a novel class of proteins whose translocation onto the surface of eukaryotic cells is dependent upon a "nonclassical" pathway involving N-myristoylation/palmitoylation. Significantly, HASPB is also translocated on to the extracellular face of the plasma membrane of transfected mammalian cells, indicating that the export signal for HASPB is recognized by a higher eukaryotic export mechanism.	Univ London Imperial Coll Sci Technol & Med, Dept Biochem, Wellcome Trust Labs Mol Parasitol, London SW7 2AZ, England; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA	Imperial College London; Washington University (WUSTL)	Smith, DF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biochem, Wellcome Trust Labs Mol Parasitol, London SW7 2AZ, England.		Russell, David G/N-5280-2019; Denny, Paul/B-8431-2013; Russell, David G/D-4533-2009; Field, Mark/AAD-6455-2021	Russell, David G/0000-0002-9748-750X; Denny, Paul/0000-0002-5051-1613; Russell, David G/0000-0002-9748-750X; Field, Mark/0000-0002-4866-2885	NIAID NIH HHS [AI 37977] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI037977] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Al-Qahtani A, 1998, BIOCHEM J, V331, P521, DOI 10.1042/bj3310521; BALBER AE, 1988, J PROTOZOOL, V35, P214, DOI 10.1111/j.1550-7408.1988.tb04326.x; Bhatnagar RS, 1997, TRENDS CELL BIOL, V7, P14, DOI 10.1016/S0962-8924(97)10044-7; Bijlmakers MJJE, 1997, J CELL BIOL, V137, P1029, DOI 10.1083/jcb.137.5.1029; BOKMAN SH, 1981, BIOCHEM BIOPH RES CO, V101, P1372, DOI 10.1016/0006-291X(81)91599-0; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; CLAYTON C, 1995, MICROBIOL REV, V59, P325, DOI 10.1128/MMBR.59.3.325-344.1995; Cleves AE, 1997, CURR BIOL, V7, pR318, DOI 10.1016/S0960-9822(06)00148-5; Cleves AE, 1996, J CELL BIOL, V133, P1017, DOI 10.1083/jcb.133.5.1017; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; FERGUSON MAJ, 1994, PARASITOLOGY, V108, pS45, DOI 10.1017/S0031182000075715; Field M. C., 1992, LIPID MODIFICATION P, P155; FIELD MC, 1994, J BIOL CHEM, V269, P10830; FLINN HM, 1994, MOL BIOCHEM PARASIT, V65, P259, DOI 10.1016/0166-6851(94)90077-9; Fraser IDC, 1998, EMBO J, V17, P2261, DOI 10.1093/emboj/17.8.2261; FROMMEL TO, 1990, MOL BIOCHEM PARASIT, V38, P25, DOI 10.1016/0166-6851(90)90201-V; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; Kuchler Karl, 1993, Trends in Cell Biology, V3, P421, DOI 10.1016/0962-8924(93)90030-5; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; Mehul B, 1997, J CELL SCI, V110, P1169; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; MOLYNEUX D, 1987, LEISHMANIASES BIOL M, V1, P122; Morales J, 1998, MOL BIOL CELL, V9, P1, DOI 10.1091/mbc.9.1.1; MORAN P, 1992, J CELL BIOL, V119, P763, DOI 10.1083/jcb.119.4.763; Overath P, 1997, TRENDS CELL BIOL, V7, P27, DOI 10.1016/S0962-8924(97)10046-0; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; PIMENTA PFP, 1994, EXP PARASITOL, V79, P468, DOI 10.1006/expr.1994.1108; RANGARAJAN D, 1995, J CELL SCI, V108, P3359; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; TOBIN JF, 1993, MOL BIOCHEM PARASIT, V62, P243, DOI 10.1016/0166-6851(93)90113-C; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; Wainwright LJ, 1997, BIOCHEM J, V321, P655, DOI 10.1042/bj3210655; WEBSTER P, 1993, PARASITOL TODAY, V9, P201, DOI 10.1016/0169-4758(93)90008-4	38	137	140	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11017	11025		10.1074/jbc.275.15.11017	http://dx.doi.org/10.1074/jbc.275.15.11017			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753904	hybrid			2022-12-27	WOS:000086466600046
J	Hanley, K; Komuves, LG; Ng, DC; Schoonjans, K; He, SS; Lau, P; Bikle, DD; Williams, ML; Elias, PM; Auwerx, J; Feingold, KR				Hanley, K; Komuves, LG; Ng, DC; Schoonjans, K; He, SS; Lau, P; Bikle, DD; Williams, ML; Elias, PM; Auwerx, J; Feingold, KR			Farnesol stimulates differentiation in epidermal keratinocytes via PPAR alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN-2; CORNIFIED CELL-ENVELOPE; FATTY-ACID SYNTHESIS; PERMEABILITY BARRIER; VITAMIN-D; TERMINAL DIFFERENTIATION; INTERMEDIATE FILAMENTS; EXTRACELLULAR CALCIUM; SKIN DEVELOPMENT; RECEPTOR PPAR	The isoprenoids farnesol and juvenile hormone III (JH), metabolites of the cholesterol biosynthetic pathway, have been shown to stimulate fetal epidermal development in rodents. In this study we determined whether this effect might be attributed to a direct induction of keratinocytes differentiation and examined the mechanisms responsible for these effects. Rates of cornified envelope formation, a marker of keratinocyte terminal differentiation, as well as protein and mRNA levels of two proteins required for cornified envelope formation, involucrin (INV) and transglutaminase, increased 2- to 3-fold in normal human keratinocytes (NHK) treated with either farnesol or JH, even at low calcium concentrations (0.03 mM), which otherwise inhibit differentiation. In contrast, neither cholesterol nor mevalonate affected INV or transglutaminase mRNA levels, Effects of farnesol and JH on INV and transglutaminase mRNA levels were additive with high calcium concentrations (1.2 mM) that independently stimulate keratinocyte differentiation. In contrast, keratinocyte DNA synthesis was inhibited by these compounds. Both farnesol and JH stimulated INV and transglutaminase promoter activity, suggesting regulation at the transcriptional level. A series of truncation and deletion experiments revealed a farnesol-responsive region (-2452 to -1880 base pairs (bp)) in the INV gene. This region contained an AP-1 site. A single base pair mutation of the AP-1 site at -2116 to -2110 bp abolished farnesol responsiveness, identical to effects by peroxisome proliferator-activated receptor (PPAR alpha) activators. Farnesoid X-activated receptor mRNA was not detected in NHK, but farnesol treatment increased activities of both a PPAR response element and PPAR alpha mRNA levels in NHK, Furthermore, the increase in PPRE activity by farnesol was dependent upon PPAR alpha in CV-1 cells. Finally, topical applications of farnesol increased mRNA and protein levels of the differentiation-specific genes, profilaggrin and loricrin, determined by immunohistochemistry and in situ hybridization, in wild-type but not in PPAR alpha-/- murine epidermis, These findings suggest a novel role for selected isoprenoid cholesterol intermediates in the regulation of differentiation-specific gene transcription and a convergence of PPAR alpha with the cholesterol synthetic pathway.	Vet Affairs Med Ctr, Dermatol Serv, San Francisco, CA 94121 USA; Vet Affairs Med Ctr, Med Serv, San Francisco, CA 94121 USA; Univ Calif San Francisco, Sch Med, Dept Dermatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Physiol, San Francisco, CA 94143 USA; Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Hanley, K (corresponding author), Vet Affairs Med Ctr, Dermatol Serv 190, 4150 Clement St, San Francisco, CA 94121 USA.	kh1111@hotmail.com		Schoonjans, Kristina/0000-0003-1247-4265; Auwerx, Johan/0000-0002-5065-5393	NIAMS NIH HHS [AR39639, AR29706] Funding Source: Medline; NICHD NIH HHS [HD29706] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029706] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039639] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Banks EB, 1998, BIOCHEM J, V331, P61, DOI 10.1042/bj3310061; BERTHJONES J, 1992, BRIT J DERMATOL, V127, P71, DOI 10.1111/j.1365-2133.1992.tb08035.x; BIKLE DD, 1993, ENDOCR REV, V14, P3, DOI 10.1210/er.14.1.3; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; CRICK DC, 1995, BIOCHEM BIOPH RES CO, V211, P590, DOI 10.1006/bbrc.1995.1854; DOWNING DT, 1992, J LIPID RES, V33, P301; Eichner R, 1996, BRIT J DERMATOL, V135, P687; ELIAS PM, 1991, ADV LIPID RES, V24, P1; FEINGOLD KR, 1991, ADV LIPID RES, V24, P57; Fisher GJ, 1996, FASEB J, V10, P1002, DOI 10.1096/fasebj.10.9.8801161; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; Gibson DFC, 1996, J INVEST DERMATOL, V106, P154, DOI 10.1111/1523-1747.ep12329856; Hanley K, 1997, J CLIN INVEST, V100, P705, DOI 10.1172/JCI119583; Hanley K, 1998, J INVEST DERMATOL, V110, P368, DOI 10.1046/j.1523-1747.1998.00139.x; Hanley K, 1999, J INVEST DERMATOL, V113, P788, DOI 10.1046/j.1523-1747.1999.00743.x; Harris IR, 1998, J LIPID RES, V39, P412; HENNINGS H, 1989, CARCINOGENESIS, V10, P777, DOI 10.1093/carcin/10.4.777; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; IMAKADO S, 1995, GENE DEV, V9, P317, DOI 10.1101/gad.9.3.317; ITIN PH, 1994, ENDOCRINOLOGY, V135, P1793, DOI 10.1210/en.135.5.1793; Kang SW, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 1, APRIL 1996, V1, P15; Komuves LG, 1998, J INVEST DERMATOL, V111, P429, DOI 10.1046/j.1523-1747.1998.00296.x; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MAOQIANG M, 1993, ARCH DERMATOL, V129, P728; MING ME, 1994, J INVEST DERMATOL, V103, P780, DOI 10.1111/1523-1747.ep12413024; Ng D.C., 1996, FRONT BIOSCI-LANDMRK, V1, P16, DOI [10.2741/A101/PDF, DOI 10.2741/A101/PDF, DOI 10.2741/A101]; OBrien ML, 1996, CARCINOGENESIS, V17, P185, DOI 10.1093/carcin/17.2.185; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; PILLAI S, 1991, J CELL PHYSIOL, V146, P94, DOI 10.1002/jcp.1041460113; Reichert Uwe, 1993, P107; RIAZULHAQ, 1991, P NATL ACAD SCI USA, V88, P8272, DOI 10.1073/pnas.88.18.8272; Rivier M, 1998, J INVEST DERMATOL, V111, P1116, DOI 10.1046/j.1523-1747.1998.00439.x; Robinson NA, 1996, J INVEST DERMATOL, V107, P101, DOI 10.1111/1523-1747.ep12298323; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; SAITOU M, 1995, NATURE, V374, P159, DOI 10.1038/374159a0; STEINEGER HH, 1994, EUR J BIOCHEM, V225, P967, DOI 10.1111/j.1432-1033.1994.0967b.x; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; Steinert PM, 1997, J BIOL CHEM, V272, P2021, DOI 10.1074/jbc.272.3.2021; Sterchele PF, 1996, ARCH BIOCHEM BIOPHYS, V326, P281, DOI 10.1006/abbi.1996.0077; THACHER SM, 1989, J INVEST DERMATOL, V92, P578; VOZIYAN PA, 1995, BIOCHEM BIOPH RES CO, V212, P479, DOI 10.1006/bbrc.1995.1995; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Welter JF, 1995, ONCOGENE, V11, P2681; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; Zhou XF, 1999, MOL ENDOCRINOL, V13, P276, DOI 10.1210/me.13.2.276	50	90	90	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11484	11491		10.1074/jbc.275.15.11484	http://dx.doi.org/10.1074/jbc.275.15.11484			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753967	hybrid			2022-12-27	WOS:000086466600109
J	Takano, E; Nihira, T; Hara, Y; Jones, JJ; Gershater, CJL; Yamada, Y; Bibb, M				Takano, E; Nihira, T; Hara, Y; Jones, JJ; Gershater, CJL; Yamada, Y; Bibb, M			Purification and structural determination of SCB1, a gamma-butyrolactone that elicits antibiotic production in Streptomyces coelicolor A3(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP FRI-5; VIRGINIAMYCIN PRODUCTION; A-FACTOR; AUTOREGULATOR; BIOSYNTHESIS; GRISEUS; INDUCER; GENE; IM-2	Early stationary phase culture supernatants of Streptomyces coelicolor A3(2) contained at least four small diffusible signaling molecules that could elicit precocious antibiotic synthesis in the producing strain. The compounds were not detected in exponentially growing cultures. One of these compounds, SCB1, was purified to homogeneity and shown to be a gamma-butyrolactone of structure (2R,3R,1'R)-2-(1'-hydroxy-6-methylheptyl)-3- hydroxymethylbutanolide. Bioassays of chemically synthesized SCB1, and of its purified stereoisomers, suggest that SCB1 acts in a highly specific manner to elicit the production of both actinorhodin and undecylprodigiosin, the two pigmented antibiotics made by S, coelicolor.	John Innes Ctr Plant Sci Res, Dept Genet, Norwich NR4 7UH, Norfolk, England; Osaka Univ, Dept Biotechnol, Suita, Osaka 5650871, Japan; SmithKline Beecham, Harlow CM19 5AW, Essex, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Osaka University; GlaxoSmithKline	Bibb, M (corresponding author), John Innes Ctr Plant Sci Res, Dept Genet, Norwich NR4 7UH, Norfolk, England.	mawyn.bibb@bbsrc.ac.uk		Takano, Eriko/0000-0002-6791-3256				ANISOVA LN, 1984, IZV AN SSSR BIOL+, P98; CHATER KF, 1997, BIOTECHNOLOGY, V7, P57; EFREMENKOVA OV, 1985, ANTIBIOT MED BIOTEK, V30, P687; ENGLAND RR, 1999, MICROBIAL SIGNALLING; Floriano B, 1996, MOL MICROBIOL, V21, P385, DOI 10.1046/j.1365-2958.1996.6491364.x; GRAFE U, 1983, BIOTECHNOL LETT, V5, P591, DOI 10.1007/BF00130838; GRAMAJO HC, 1993, MOL MICROBIOL, V7, P837, DOI 10.1111/j.1365-2958.1993.tb01174.x; HARA O, 1982, J ANTIBIOT, V35, P349, DOI 10.7164/antibiotics.35.349; HASHIMOTO K, 1992, J FERMENT BIOENG, V73, P449, DOI 10.1016/0922-338X(92)90136-I; Hopwood D.A., 1985, GENETIC MANIPULATION; HOPWOOD DA, 1995, GENETICS BIOCH ANTIB, P65; Horinouchi S., 1994, GENETICS BIOCH ANTIB, P103; Kawabuchi M, 1997, FEMS MICROBIOL LETT, V157, P81, DOI 10.1111/j.1574-6968.1997.tb12756.x; KONDO K, 1989, J ANTIBIOT, V42, P1873, DOI 10.7164/antibiotics.42.1873; MIZUNO K, 1994, TETRAHEDRON, V50, P10849, DOI 10.1016/S0040-4020(01)85697-0; MORI K, 1983, TETRAHEDRON, V39, P3107, DOI 10.1016/S0040-4020(01)91552-2; Neumann T, 1996, MICROBIOL-UK, V142, P1953, DOI 10.1099/13500872-142-8-1953; NIHIRA T, 1988, J ANTIBIOT, V41, P1828, DOI 10.7164/antibiotics.41.1828; Ohnishi Y, 1999, MOL MICROBIOL, V34, P102, DOI 10.1046/j.1365-2958.1999.01579.x; SAKUDA S, 1991, TETRAHEDRON LETT, V32, P1817, DOI 10.1016/S0040-4039(00)74338-3; SATO K, 1989, J FERMENT BIOENG, V68, P170, DOI 10.1016/0922-338X(89)90131-1; TAKANO E, 1992, MOL MICROBIOL, V6, P2797, DOI 10.1111/j.1365-2958.1992.tb01459.x; YAMADA Y, 1987, J ANTIBIOT, V40, P496, DOI 10.7164/antibiotics.40.496; Yamada Y, 1999, SYMP SOC GEN MICROBI, V57, P177; Yamada Y, 1995, ACTINOMYCETOLOGICA, V9, P57; Yamada Y., 1997, BIOTECHNOLOGY ANTIBI, P63	26	130	138	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11010	11016		10.1074/jbc.275.15.11010	http://dx.doi.org/10.1074/jbc.275.15.11010			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753903	Green Published, hybrid			2022-12-27	WOS:000086466600045
J	Wang, GZ; Rudland, PS; White, MR; Barraclough, R				Wang, GZ; Rudland, PS; White, MR; Barraclough, R			Interaction in vivo and in vitro of the metastasis-inducing S100 protein, S100A4 (p9Ka) with S100A1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; NONMUSCLE MYOSIN; PEL98 PROTEIN; HEAVY-CHAIN; MTS1 GENE; CELL LINE; EXPRESSION; DIFFERENTIATION; LOCALIZATION; FIBROBLASTS	The calcium-binding protein S100A4 (p9Ka) has been shown to cause a metastatic phenotype in rodent mammary tumor cells and in transgenic mouse model systems. mRNA for S100A4 (p9Ka) is present at a generally higher level in breast carcinoma than in benign breast tumor specimens, and the presence of immunocytochemically detected S100A4 correlates strongly with a poor prognosis for breast cancer patients. Recombinant S100A4 (p9Ka) has been reported to interact in vitro with cytoskeletal components and to form oligomers, particularly homodimers in vitro, Using the yeast two-hybrid system, a strong interaction between S100A4 (p9Ka) and another S100 protein, S100A1, was detected. Site-directed mutagenesis of conserved amino acid residues involved in the dimerization of S100 proteins abolished the interactions. The interaction between S100A4 and S100A1 was also observed in vitro using affinity column chromatography and gel overlay techniques. Both S100A1 and S100A4 can. occur in the same cultured mammary cells, suggesting that in cells containing both proteins, S100A1 might modulate the metastasis-inducing capability of S100A4.	Univ Liverpool, Sch Biol Sci, Canc & Polio Res Fund Labs, Liverpool L69 7ZB, Merseyside, England; Univ Liverpool, Sch Biol Sci, Ctr Cell Imaging, Liverpool L69 7ZB, Merseyside, England	University of Liverpool; University of Liverpool	Barraclough, R (corresponding author), Univ Liverpool, Sch Biol Sci, Canc & Polio Res Fund Labs, Life Sci Bldg,POB 147, Liverpool L69 7ZB, Merseyside, England.		Barraclough, Roger/AAH-6516-2020	Barraclough, Roger/0000-0002-7203-1194; White, Michael/0000-0002-3617-3232				Ambartsumian NS, 1996, ONCOGENE, V13, P1621; BARRACLOUGH R, 1987, J CELL PHYSIOL, V131, P393, DOI 10.1002/jcp.1041310311; BAUDIER J, 1995, BIOCHEMISTRY-US, V34, P7834, DOI 10.1021/bi00024a007; BECKER D, 1993, GENE TRANSCRIPTION P, P295; BENNETT DC, 1978, CELL, V15, P283, DOI 10.1016/0092-8674(78)90104-6; BHARDWAJ RS, 1992, EUR J IMMUNOL, V22, P1891, DOI 10.1002/eji.1830220732; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIES BR, 1993, ONCOGENE, V8, P999; Davies MPA, 1996, ONCOGENE, V13, P1631; DUNNINGTON DJ, 1984, THESIS U LONDON; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; ENGEL LW, 1978, CANCER RES, V38, P4327; ENGELKAMP D, 1992, BIOCHEMISTRY-US, V31, P10258, DOI 10.1021/bi00157a012; Ford HL, 1997, BIOCHEMISTRY-US, V36, P16321, DOI 10.1021/bi971182l; FORD HL, 1995, ONCOGENE, V10, P1597; GIBBS FEM, 1994, J BIOL CHEM, V269, P18992; GIBBS FEM, 1995, J HISTOCHEM CYTOCHEM, V43, P169, DOI 10.1177/43.2.7822773; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; Heierhorst J, 1996, NATURE, V380, P636, DOI 10.1038/380636a0; HILT DC, 1991, NOVEL CALCIUM BINDIN, P65; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Ilg EC, 1996, INT J CANCER, V68, P325, DOI 10.1002/(SICI)1097-0215(19961104)68:3<325::AID-IJC10>3.0.CO;2-7; ISOBE T, 1983, BIOCHEM INT, V6, P419; Ivanenkov VV, 1996, BIOCHEM BIOPH RES CO, V221, P46, DOI 10.1006/bbrc.1996.0542; KATO K, 1985, BIOCHIM BIOPHYS ACTA, V842, P146, DOI 10.1016/0304-4165(85)90196-5; Kilby PM, 1996, STRUCTURE, V4, P1041, DOI 10.1016/S0969-2126(96)00111-6; Kriajevska M, 1998, J BIOL CHEM, V273, P9852, DOI 10.1074/jbc.273.16.9852; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lloyd BH, 1998, ONCOGENE, V17, P465, DOI 10.1038/sj.onc.1201948; Mandinova A, 1998, J CELL SCI, V111, P2043; MOORE BW, 1965, J BIOL CHEM, V240, P1647; NIKITENKO L, 2000, IN PRESS INT J CANC, V86; PEDROCCHI M, 1994, BIOCHEMISTRY-US, V33, P6732, DOI 10.1021/bi00187a045; POTTS BCM, 1995, NAT STRUCT BIOL, V2, P790, DOI 10.1038/nsb0995-790; Takenaga K, 1997, CLIN CANCER RES, V3, P2309; TAKENAGA K, 1994, CELL STRUCT FUNCT, V19, P133, DOI 10.1247/csf.19.133; TAKENAGA K, 1994, BIOCHEM BIOPH RES CO, V202, P94, DOI 10.1006/bbrc.1994.1898; TAKENAGA K, 1994, J CELL BIOL, V124, P757, DOI 10.1083/jcb.124.5.757; TEIGELKAMP S, 1991, J BIOL CHEM, V266, P13462; Treves S, 1997, BIOCHEMISTRY-US, V36, P11496, DOI 10.1021/bi970160w; TULCHINSKY E, 1995, BBA-GENE STRUCT EXPR, V1261, P243, DOI 10.1016/0167-4781(95)00013-7; WATANABE Y, 1993, FEBS LETT, V324, P51, DOI 10.1016/0014-5793(93)81530-D; Yang Q, 1999, EXP CELL RES, V246, P501, DOI 10.1006/excr.1998.4314; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2; ZIMMER DB, 1986, J BIOL CHEM, V261, P1424	46	63	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11141	11146		10.1074/jbc.275.15.11141	http://dx.doi.org/10.1074/jbc.275.15.11141			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753920	hybrid			2022-12-27	WOS:000086466600062
J	Yoneda, T; Imaizumi, K; Maeda, M; Yui, DS; Manabe, T; Katayama, T; Sato, N; Gomi, F; Morihara, T; Mori, Y; Miyoshi, K; Hitomi, J; Ugawa, S; Yamada, S; Okabe, M; Tohyama, M				Yoneda, T; Imaizumi, K; Maeda, M; Yui, DS; Manabe, T; Katayama, T; Sato, N; Gomi, F; Morihara, T; Mori, Y; Miyoshi, K; Hitomi, J; Ugawa, S; Yamada, S; Okabe, M; Tohyama, M			Regulatory mechanisms of TRAF2-mediated signal transduction by Bcl10, a MALT lymphoma-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CELL-DEATH; ACTIVATION; CASPASES; IDENTIFICATION; RECEPTORS; INHIBITOR; KINASE; MICE	To elucidate the function of Bcl10, recently cloned as an apoptosis-associated gene mutated in MALT lymphoma, we identified its binding partner TRAF2, which mediates signaling via tumor necrosis factor receptors, In mammalian cells, low levels of Bcl10 expression promoted the binding of TRAF2 and c-IAPs, Conversely, excessive expression inhibited complex formation. Overexpressed Bcl10 reduced c-Jun N-terminal kinase activation and induced nuclear factor kappa B activation downstream of TRAF2, To determine whether overexpression of Bcl10 could perturb the regulation of apoptosis in vivo, we generated Bcl10 transgenic mice. In these transgenic mice, atrophy of the thymus and spleen was observed at postnatal stages. The morphological changes in these tissues were caused by acceleration of apoptosis in T cells and B cells. The phenotype of Bcl10 transgenic mice was similar to that of TRAF2-deficient mice reported previously, indicating that excessive expression of Bcl10 might deplete the TRAF2 function. in contrast, in the other organs such as the brain, where Bcl10 was expressed at high levels, no apoptosis was detected, The altered sensitivities to overexpressed Bcl10 may have been due to differences in signal responses to Bcl10 among cell types. Thus, Bcl10 was suggested to play crucial roles in the modulation of apoptosis associated with TRAF2.	Osaka Univ, Sch Med, Dept Anat & Neurosci, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Ophthalmol, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Neuropsychiat, Suita, Osaka 5650871, Japan; Japan Sci & Technol, CREST, Abeno Ku, Osaka 5458585, Japan; Tanabe Seiyaku Co Ltd, Abeno Ku, Osaka 5458585, Japan; Osaka City Univ, Sch Med, Dept Anat 1, Abeno Ku, Osaka 5458585, Japan; Osaka Univ, Genome Informat Res Ctr, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University; Japan Science & Technology Agency (JST); Mitsubishi Tanabe Pharma Corporation; Osaka Metropolitan University; Osaka University	Yoneda, T (corresponding author), Osaka Univ, Sch Med, Dept Anat & Neurosci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Morihara, Takashi/AAK-2709-2021; Okabe, Masaru/B-6917-2015	Okabe, Masaru/0000-0002-0803-9044; Gomi, Fumi/0000-0003-0807-8817				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Borchelt DR, 1996, GENET ANAL-BIOMOL E, V13, P159, DOI 10.1016/S1050-3862(96)00167-2; Costanzo A, 1999, J BIOL CHEM, V274, P20127, DOI 10.1074/jbc.274.29.20127; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Koseki T, 1998, P NATL ACAD SCI USA, V95, P5156, DOI 10.1073/pnas.95.9.5156; Koseki T, 1999, J BIOL CHEM, V274, P9955, DOI 10.1074/jbc.274.15.9955; Maeda M, 1998, NEUROSCI LETT, V240, P69, DOI 10.1016/S0304-3940(97)00901-4; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; Thome M, 1999, J BIOL CHEM, V274, P9962, DOI 10.1074/jbc.274.15.9962; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Yan MH, 1999, J BIOL CHEM, V274, P10287, DOI 10.1074/jbc.274.15.10287; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yoneda T, 1998, MOL BRAIN RES, V62, P187, DOI 10.1016/S0169-328X(98)00249-6; Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	21	60	64	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11114	11120		10.1074/jbc.275.15.11114	http://dx.doi.org/10.1074/jbc.275.15.11114			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753917	hybrid			2022-12-27	WOS:000086466600059
J	Friedler, A; Friedler, D; Luedtke, NW; Tor, Y; Loyter, A; Gilon, C				Friedler, A; Friedler, D; Luedtke, NW; Tor, Y; Loyter, A; Gilon, C			Development of a functional backbone cyclic mimetic of the HTV-1 Tat arginine-rich motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REV PROTEIN; RNA-BINDING; BIOLOGICAL-ACTIVITY; NUCLEAR IMPORT; BASIC DOMAIN; CELL-NUCLEUS; SUBSTANCE-P; LOCALIZATION; PEPTIDES; RECOGNITION	We have used the backbone cyclic proteinomimetics approach to develop peptides that functionally mimic the arginine-rich motif (ARM) of the HIV-1 Tat protein. This consensus sequence serves both as a nuclear localization signal (NLS) and as an RNA binding domain. Based on the NMR structure of Tat, we have designed and synthesized a backbone cyclic ARM mimetic peptide library. The peptides were screened for their ability to mediate nuclear import of the corresponding BSA conjugates in permeabilized cells. One peptide, designated "Tat11," displayed active NLS properties. Nuclear import of Tat11-BSA was found to proceed by the same distinct pathway used by the Tat-NLS and not by the common importin alpha pathway, which is used by the SV40 NLS. Most of the Tat-derived backbone cyclic peptides display selective inhibitory activity as demonstrated by the inhibition of the nuclear import mediated by the Tat-NLS and not by the SV40-NLS. The Tat-ARM-derived peptides, including Tat-11, also inhibited binding of the HIV-1 Rev-ARM to its corresponding RNA element (Rev response element) with inhibition constants of 5 nM. Hero we have shown for the first time (alpha) a functional mimetic of a protein sequence, which activates a nuclear import receptor and (b) a mimetic of a protein sequence with a dual functionality. Tat11 is a lead compound which can potentially inhibit the HIV-1 life cycle by a dual mechanism: inhibition of nuclear import and of RNA binding.	Hebrew Univ Jerusalem, Inst Chem, Dept Organ Chem, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	Hebrew University of Jerusalem; Hebrew University of Jerusalem; University of California System; University of California San Diego	Gilon, C (corresponding author), Hebrew Univ Jerusalem, Inst Chem, Dept Organ Chem, IL-91904 Jerusalem, Israel.	gilon@vms.huji.ac.il	Luedtke, Nathan/F-5276-2010		NIAID NIH HHS [AI 40315] Funding Source: Medline; NIGMS NIH HHS [GM 08326] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI040315] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABDOULELA F, 1995, J MOL BIOL, V253, P313; Altstein M, 1999, J BIOL CHEM, V274, P17573, DOI 10.1074/jbc.274.25.17573; BAYER P, 1995, J MOL BIOL, V247, P529, DOI 10.1016/S0022-2836(05)80133-0; Bitan G, 1997, J PEPT RES, V49, P421; Bitan G, 1996, J PEPT SCI, V2, P261, DOI 10.1002/psc.76; Braisted AC, 1996, P NATL ACAD SCI USA, V93, P5688, DOI 10.1073/pnas.93.12.5688; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Byk G, 1996, J MED CHEM, V39, P3174, DOI 10.1021/jm960154i; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; Choudhury I, 1998, J ACQ IMMUN DEF SYND, V17, P104, DOI 10.1097/00042560-199802010-00002; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; DECLERCQ E, 1994, BIOCHEM PHARMACOL, V47, P155, DOI 10.1016/0006-2952(94)90001-9; Efthymiadis A, 1998, J BIOL CHEM, V273, P1623, DOI 10.1074/jbc.273.3.1623; Emerman M, 1998, SCIENCE, V280, P1880, DOI 10.1126/science.280.5371.1880; Erickson JW, 1996, ANNU REV PHARMACOL, V36, P545, DOI 10.1146/annurev.pa.36.040196.002553; Friedler A, 1999, J MOL BIOL, V289, P431, DOI 10.1006/jmbi.1999.2785; Friedler A, 1998, BIOCHEMISTRY-US, V37, P5616, DOI 10.1021/bi972878h; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; Gilon C, 1998, J MED CHEM, V41, P919, DOI 10.1021/jm970633x; GILON C, 1991, BIOPOLYMERS, V31, P745, DOI 10.1002/bip.360310619; GILON C, 1996, PEPTIDES 1996, P423; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Hamy F, 1997, P NATL ACAD SCI USA, V94, P3548, DOI 10.1073/pnas.94.8.3548; HEYDUK T, 1990, P NATL ACAD SCI USA, V87, P1744, DOI 10.1073/pnas.87.5.1744; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HSU MC, 1991, SCIENCE, V254, P1799, DOI 10.1126/science.1763331; Kasher R, 1999, J MOL BIOL, V292, P421, DOI 10.1006/jmbi.1999.3053; KASHER R, 1998, LETT PEPT RES, V5, P1; Kirk SR, 2000, J AM CHEM SOC, V122, P980, DOI 10.1021/ja993387i; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; Mei HY, 1998, BIOCHEMISTRY-US, V37, P14204, DOI 10.1021/bi981308u; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MICHNE WF, 1995, J MED CHEM, V38, P3197, DOI 10.1021/jm00017a003; Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491; Sevenich FW, 1998, NUCLEIC ACIDS RES, V26, P1373, DOI 10.1093/nar/26.6.1373; SIOMI H, 1990, J VIROL, V64, P1803, DOI 10.1128/JVI.64.4.1803-1807.1990; Truant R, 1999, MOL CELL BIOL, V19, P1210; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Westhof E, 1999, CURR OPIN STRUC BIOL, V9, P293, DOI 10.1016/S0959-440X(99)80039-6; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; Yanofsky SD, 1996, P NATL ACAD SCI USA, V93, P7381, DOI 10.1073/pnas.93.14.7381; ZAPP ML, 1993, CELL, V74, P969, DOI 10.1016/0092-8674(93)90720-B	42	54	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23783	23789		10.1074/jbc.M002200200	http://dx.doi.org/10.1074/jbc.M002200200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10764789	hybrid			2022-12-27	WOS:000088564200053
J	Shimizu, M; Potts, JT; Gardella, TJ				Shimizu, M; Potts, JT; Gardella, TJ			Minimization of parathyroid hormone - Novel amino-terminal parathyroid hormone fragments with enhanced potency in activating the type-1 parathyroid hormone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(PTH)/PTH-RELATED PEPTIDE RECEPTOR; PTH-RELATED PEPTIDE; RAT OSTEO-SARCOMA; ADENYLYL-CYCLASE; BIOLOGICAL-ACTIVITY; EXTRACELLULAR LOOP; PHOSPHOLIPASE-C; CROSS-LINKING; BINDING; REGION	The amino-terminal and carboxyl-terminal portions of the 1-34 fragment of parathyroid hormone (PTH) contain the major determinants of receptor activation and receptor binding, respectively. We investigated how the amino-terminal signaling portion of PTH interacts with the receptor by utilizing analogs of the weakly active fragment, rat (r) PTH(1-14)NH2, and cells transfected with the wild-type human PTH-1 receptor (hP1R-WT) or a truncated PTH-1 receptor which lacked most of the amino-terminal extracellular domain (hP1R-delNt). Of 132 mono-substituted PTH(1-14) analogs, most having substitutions in the (1-9) region were inactive in assays of cAMP formation in LLC-PK1 cells stably expressing hP1R-WT, whereas most having substitutions in the (10-14) region were active, Several substitutions (e.g. Ser(3) --> Ala, Asn(10) --> Ala or Gin, Leu(11) --> Arg, Gly(12) --> Ala, Kis(14) --> Trp) enhanced activity 2-10-fold. These effects were additive, as [Ala(3,10,12),Arg(11),Trp(14)] rPTH(1-14)NH2 was 220-fold more potent than rPTH(1-14)NH2 (EC50 = 0.6 +/- 0.1 and 133 +/- 16 mu m respectively). Native rPTH(1-11) was inactive, but [Ala(3,10),Arg(11)]rPTH(1-11)NH2 achieved maximal cAMP stimulation (EC50 = 17 mu M). The modified PTH fragments induced cAMP formation with hP1R-delNt in COS-7 cells as potently as they did with hP1R-WT; PTH(1-34) was 6,000-fold weaker with hP1R-delNt than with hP1R-WT. The most potent analog, [Ala(3,10,12),Arg(11),Trp(14)]rPTH(1-14)NH2, stimulated inositol phosphate production with hP1R-WT, The results show that short NH2-terminal peptides of PTH can be optimized for considerable gains in signaling potency through modification of interactions involving the regions of the receptor containing the transmembrane domains and extracellular loops.	Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Gardella, TJ (corresponding author), Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.	gardella@helix.mgh.harvard.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK011794] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-11794] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abell A, 1996, J BIOL CHEM, V271, P4518; Adams AE, 1998, MOL ENDOCRINOL, V12, P1673, DOI 10.1210/me.12.11.1673; BARDEN JA, 1993, BIOCHEMISTRY-US, V32, P7126, DOI 10.1021/bi00079a008; Behar V, 2000, J BIOL CHEM, V275, P9, DOI 10.1074/jbc.275.1.9; Bergwitz C, 1997, J BIOL CHEM, V272, P28861, DOI 10.1074/jbc.272.46.28861; Bergwitz C, 1996, J BIOL CHEM, V271, P26469, DOI 10.1074/jbc.271.43.26469; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; Bowen WP, 1995, TRENDS PHARMACOL SCI, V16, P413, DOI 10.1016/S0165-6147(00)89091-4; Carter PH, 1999, J BIOL CHEM, V274, P31955, DOI 10.1074/jbc.274.45.31955; Carter PH, 1999, ENDOCRINOLOGY, V140, P4972, DOI 10.1210/en.140.11.4972; COHEN FE, 1991, J BIOL CHEM, V266, P1997; DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690; FRELINGER AL, 1984, J BIOL CHEM, V259, P5507; GARDELLA TJ, 1994, ENDOCRINOLOGY, V135, P1186, DOI 10.1210/en.135.3.1186; GARDELLA TJ, 1991, J BIOL CHEM, V266, P13141; GOLTZMANN D, 1975, J BIOL CHEM, V250, P3199; GOMBERT F, 1996, PEPTIDES CHEM STRUCT, P661; IIDAKLEIN A, 1995, J BIOL CHEM, V270, P8458, DOI 10.1074/jbc.270.15.8458; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KOLAKOWSKI LF, 1994, RECEPTOR CHANNEL, V2, P1; KRONENBERG H, 1997, GENETICS ENDOCRINE M, P389; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE CW, 1995, MOL ENDOCRINOL, V9, P1269, DOI 10.1210/me.9.10.1269; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; Luck MD, 1999, MOL ENDOCRINOL, V13, P670, DOI 10.1210/me.13.5.670; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo-107-5-1494; Mannstadt M, 1998, J BIOL CHEM, V273, P16890, DOI 10.1074/jbc.273.27.16890; MARX UC, 1995, J BIOL CHEM, V270, P15194, DOI 10.1074/jbc.270.25.15194; NEUGEBAUER W, 1995, BIOCHEMISTRY-US, V34, P8835, DOI 10.1021/bi00027a035; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NUSSBAUM SR, 1980, J BIOL CHEM, V255, P183; NUTT RF, 1990, ENDOCRINOLOGY, V127, P491, DOI 10.1210/endo-127-1-491; Oldenburg KR, 1996, J BIOL CHEM, V271, P17582; Pellegrini M, 1998, J BIOL CHEM, V273, P10420, DOI 10.1074/jbc.273.17.10420; Roe EB, 1999, J BONE MINER RES, V14, pS137; Rolz C, 1999, BIOCHEMISTRY-US, V38, P6397, DOI 10.1021/bi9829276; SCHIPANI E, 1993, ENDOCRINOLOGY, V132, P2157, DOI 10.1210/en.132.5.2157; STROOP SD, 1995, BIOCHEMISTRY-US, V34, P1050, DOI 10.1021/bi00003a040; Takasu H, 1999, BIOCHEMISTRY-US, V38, P13453, DOI 10.1021/bi990437n; Takasu H, 1999, J BONE MINER RES, V14, P11, DOI 10.1359/jbmr.1999.14.1.11; TREGEAR GW, 1973, ENDOCRINOLOGY, V93, P1349, DOI 10.1210/endo-93-6-1349; YAMAMOTO I, 1988, ENDOCRINOLOGY, V122, P1208, DOI 10.1210/endo-122-4-1208	43	91	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21836	21843		10.1074/jbc.M909861199	http://dx.doi.org/10.1074/jbc.M909861199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10777513	hybrid			2022-12-27	WOS:000088363800013
J	Walker, AK; See, R; Batchelder, C; Kophengnavong, T; Gronniger, JT; Shi, Y; Blackwell, TK				Walker, AK; See, R; Batchelder, C; Kophengnavong, T; Gronniger, JT; Shi, Y; Blackwell, TK			A conserved transcription motif suggesting functional parallels between Caenorhabditis elegans SKN-1 and Cap'n'Collar-related basic leucine zipper proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; GATA-FACTOR; BZIP; NRF2; GENE; E1A; ACTIVATION; INDUCTION; ELEMENTS; P300	In Caenorhabditis elegans, the predicted transcription factor SKN-1 is required for embryonic endodermal and mesodermal specification and for maintaining differentiated intestinal cells post-embryonically. The SKN-1 DNA-binding region is related to the Cap'n'Collar (CNC) family of basic leucine zipper proteins, but uniquely, SKN-1 binds DNA as a monomer. CNC proteins are absent in C, elegans, however; and their involvement in the endoderm and mesoderm suggests some functional parallels to SKN-1, Using a cell culture assay, we show that SKN-1 induces transcription and contains three potent activation domains. The functional core of one domain is a short motif, the DIDLID element, which is highly conserved in a subgroup of vertebrate CNC proteins. The DIDLID element is important for SKN-1-driven transcription, suggesting a likely significance in other CNC proteins. SKN-1 binds to and activates transcription through the p300/cAMP-rrespossvv element-binding protein-binding protein (CBP) coactivator, supporting the genetic prediction that SKN-1 recruits the C, elegans p300/CBP ortholog, CBP-1, The DIDLID element appears to act independently of p300/CBP, however, suggesting a distinct conserved target. The evolutionarily preservation of the DIDLID transcriptional element supports the model that SKN-1 and some CNC proteins interact with analogous cofactors and may have preserved some similar functions despite having divergent DNA-binding domains.	Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School	Blackwell, TK (corresponding author), Harvard Univ, Sch Med, Ctr Blood Res, 200 Longwood Ave, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009416] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09416] Funding Source: Medline; NIGMS NIH HHS [GM58012, GM50900] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Batchelder C, 1999, GENE DEV, V13, P202, DOI 10.1101/gad.13.2.202; BLACKWELL TK, 1994, SCIENCE, V266, P621, DOI 10.1126/science.7939715; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; Carroll AS, 1997, GENE DEV, V11, P2227, DOI 10.1101/gad.11.17.2227; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chan JY, 1998, EMBO J, V17, P1779, DOI 10.1093/emboj/17.6.1779; Cheng XB, 1997, MOL CELL BIOL, V17, P1407, DOI 10.1128/MCB.17.3.1407; Farmer SC, 1997, GENE DEV, V11, P786, DOI 10.1101/gad.11.6.786; Fukushige T, 1998, DEV BIOL, V198, P286, DOI 10.1016/S0012-1606(98)80006-7; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Kophengnavong T, 1999, MOL CELL BIOL, V19, P3039; Kwong M, 1999, J BIOL CHEM, V274, P37491, DOI 10.1074/jbc.274.52.37491; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Lo MC, 1998, P NATL ACAD SCI USA, V95, P8455, DOI 10.1073/pnas.95.15.8455; Massari ME, 1999, MOL CELL, V4, P63, DOI 10.1016/S1097-2765(00)80188-4; MOHLER J, 1995, DEVELOPMENT, V121, P237; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Rupert PB, 1998, NAT STRUCT BIOL, V5, P484, DOI 10.1038/nsb0698-484; Shi Y, 1998, GENE DEV, V12, P943, DOI 10.1101/gad.12.7.943; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WONG HK, 1994, J VIROL, V68, P4910, DOI 10.1128/JVI.68.8.4910-4920.1994; Zhu JW, 1998, GENE DEV, V12, P3809, DOI 10.1101/gad.12.24.3809; Zhu JW, 1997, GENE DEV, V11, P2883, DOI 10.1101/gad.11.21.2883	38	56	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22166	22171		10.1074/jbc.M001746200	http://dx.doi.org/10.1074/jbc.M001746200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10764775	hybrid			2022-12-27	WOS:000088363800058
J	Orellana, SA; Marfella-Scivittaro, C				Orellana, SA; Marfella-Scivittaro, C			Distinctive cyclic AMP-dependent protein kinase subunit localization is associated with cyst formation and loss of tubulogenic capacity in Madin-Darby canine kidney cell clones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; SERUM-FREE MEDIUM; CATALYTIC SUBUNIT; EPITHELIAL-CELLS; FLUID SECRETION; FACTOR RECEPTOR; SIGNAL-TRANSDUCTION; INHIBITOR PKI; MDCK CELLS; CAMP	Polycystic kidney disease is characterized by abnormal morphological development. Mechanisms that regulate cyst development may involve multiple signaling pathways. Cyst formation by Madin-Darby canine kidney (MDCK) cells in three-dimensional culture is assumed to be cyclic AMP-dependent and due to cyclic AMP-dependent protein kinase (cAPK) activation based on pharmacological responsiveness. To determine if different cyclic AMP (cAMP) pathways are associated with morphological development, the role of cAMP in regulating morphological change was examined in MDCK clones that form tumor-like or tubular structures under basal conditions. Pharmacological cAMP pathway activators induce cyst formation and diminish formation of other structures in three clones, whereas one clone is unaffected. Tyrosine kinase-mediated morphogens have little effect. Although all clones have intact cAMP signaling pathways, each has a unique subcellular distribution of cAPK regulatory subunits. This may reflect distinct mechanisms for cAPK anchoring, allowing cAPK subtype regulation of the unique phenotypic character of each clone through preferential access to substrates. These observations suggest a molecular basis for differential cAMP responsiveness in cells that develop distinct morphological phenotypes. This evidence establishes these MDCK clones as models for understanding the mechanism and functional significance of cAPK subunit localization and may have broader implications for cystogenesis in polycystic kidney disease.	Case Western Reserve Univ, Sch Med, Dept Pediat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Rainbow Babies & Childrens Hosp, Rainbow Ctr Childhood PKD, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital	Orellana, SA (corresponding author), Mail Stop 6003,11100 Euclid Ave, Cleveland, OH 44106 USA.	sao3@po.cwru.edu			NIDDK NIH HHS [DK50707] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK050707] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIYAMA T, 1991, METHOD ENZYMOL, V201, P362; Balkovetz DF, 1999, INT REV CYTOL, V186, P225; Balkovetz DF, 1999, LIFE SCI, V64, P1393, DOI 10.1016/S0024-3205(99)00073-9; BARROS EJG, 1995, P NATL ACAD SCI USA, V92, P4412, DOI 10.1073/pnas.92.10.4412; BAUDE EJ, 1994, J BIOL CHEM, V269, P2316; CANTLEY LG, 1995, J AM SOC NEPHROL, V5, P1872; CANTLEY LG, 1994, AM J PHYSIOL, V267, pF271, DOI 10.1152/ajprenal.1994.267.2.F271; Cao F, 1997, BIOCHEM BIOPH RES CO, V234, P719, DOI 10.1006/bbrc.1997.6703; Carr DW, 1999, BIOCHEM J, V344, P613, DOI 10.1042/0264-6021:3440613; Ciardiello F, 1998, CLIN CANCER RES, V4, P821; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Davies JA, 1999, PEDIATR NEPHROL, V13, P535, DOI 10.1007/s004670050653; DAY RN, 1989, J BIOL CHEM, V264, P431; DEVIS PE, 1985, J CELL PHYSIOL, V125, P23, DOI 10.1002/jcp.1041250105; Emmons SW, 1999, NATURE, V401, P339, DOI 10.1038/43810; FANTOZZI DA, 1992, J BIOL CHEM, V267, P16824; GRANTHAM JJ, 1989, KIDNEY INT, V35, P1379, DOI 10.1038/ki.1989.137; GRANTHAM JJ, 1993, J AM SOC NEPHROL, V3, P1843; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; Hauer JA, 1999, PROTEIN SCI, V8, P545; Hobert ME, 1997, J BIOL CHEM, V272, P32901, DOI 10.1074/jbc.272.52.32901; Li HP, 1999, BIOCHEM BIOPH RES CO, V259, P356, DOI 10.1006/bbrc.1999.0780; MADIN SH, 1992, CATALOGUE CELL LINES, P21; MANGOOKARIM R, 1989, P NATL ACAD SCI USA, V86, P6007, DOI 10.1073/pnas.86.15.6007; MANGOOKARIM R, 1989, FASEB J, V3, P2629, DOI 10.1096/fasebj.3.14.2480260; MCATEER JA, 1987, ANAT REC, V217, P229, DOI 10.1002/ar.1092170303; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; Murcia NS, 1999, KIDNEY INT, V55, P1187, DOI 10.1046/j.1523-1755.1999.00370.x; NEUFELD TK, 1992, KIDNEY INT, V41, P1222, DOI 10.1038/ki.1992.184; Orellana SA, 1996, IN VITRO CELL DEV-AN, V32, P329; Orellana SA, 1998, SEMIN NEPHROL, V18, P233; ORELLANA SA, 1993, J BIOL CHEM, V268, P6843; Parnell SC, 1999, BIOCHEM BIOPH RES CO, V259, P539, DOI 10.1006/bbrc.1999.0810; Pollack AL, 1997, J CELL BIOL, V137, P1651, DOI 10.1083/jcb.137.7.1651; PUGH JL, 1995, KIDNEY INT, V47, P774, DOI 10.1038/ki.1995.118; RICHARDSON JCW, 1981, BIOCHIM BIOPHYS ACTA, V673, P26, DOI 10.1016/0304-4165(81)90307-X; Rothen-Rutishauser B, 1998, PHARMACEUT RES, V15, P964, DOI 10.1023/A:1011953405272; SANTOS OFP, 1993, DEV BIOL, V159, P535, DOI 10.1006/dbio.1993.1262; Sullivan LP, 1998, PHYSIOL REV, V78, P1165, DOI 10.1152/physrev.1998.78.4.1165; Sweeney WE, 1999, KIDNEY INT, V56, P406, DOI 10.1046/j.1523-1755.1999.00577.x; Sweeney WE, 2000, KIDNEY INT, V57, P33, DOI 10.1046/j.1523-1755.2000.00829.x; Tasken K, 1997, ADV SEC MESS PHOSPH, V31, P191; TAUB M, 1983, J CELL PHYSIOL, V114, P153, DOI 10.1002/jcp.1041140203; TAUB M, 1984, J CELL PHYSIOL, V120, P19, DOI 10.1002/jcp.1041200104; TAUB M, 1979, P NATL ACAD SCI USA, V76, P3338, DOI 10.1073/pnas.76.7.3338; TAUB ML, 1992, J CELL PHYSIOL, V151, P337, DOI 10.1002/jcp.1041510215; Torgersen KM, 1997, J BIOL CHEM, V272, P5495, DOI 10.1074/jbc.272.9.5495; Valentich J D, 1981, Ann N Y Acad Sci, V372, P384, DOI 10.1111/j.1749-6632.1981.tb15490.x; VANPATTEN SM, 1992, MOL ENDOCRINOL, V6, P2114, DOI 10.1210/me.6.12.2114; WEN W, 1995, J BIOL CHEM, V270, P2041, DOI 10.1074/jbc.270.5.2041; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93; Wiley JC, 1999, J BIOL CHEM, V274, P6381, DOI 10.1074/jbc.274.10.6381; WOOLF AS, 1998, PEDIAT NEPHROLOGY, P1; Yang JC, 1998, J CELL BIOL, V142, P511, DOI 10.1083/jcb.142.2.511	56	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21233	21240		10.1074/jbc.M001964200	http://dx.doi.org/10.1074/jbc.M001964200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10767293	hybrid			2022-12-27	WOS:000088230600038
J	Chen, LX; Benner, J; Perler, FB				Chen, LX; Benner, J; Perler, FB			Protein splicing in the absence of an intein penultimate histidine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; HOMING ENDONUCLEASES; IDENTIFICATION; SEQUENCE; HEDGEHOG; MODULATION; EVOLUTION; PEPTIDES; INTRONS; ATPASE	Protein splicing is a self-catalytic process in which an intervening sequence, termed an intein, is excised from a protein precursor, and the flanking polypeptides are religated. The conserved intein penultimate His facilitates this reaction by assisting in Asn cyclization, which results in C-terminal splice junction cleavage. However, many inteins do not have a penultimate His. Previous splicing studies with 2 such inteins yielded contradictory results. To resolve this issue, the splicing capacity of 2 more inteins without penultimate His residues was examined. Both the Methanococcus jannaschii phosphoenolpyruvate synthase and RNA polymerase subunit A' inteins spliced. Splicing of the phosphoenolpyruvate synthase intein improved when its penultimate Phe was changed to His, but splicing of the RNA polymerase subunit A' intein was inhibited when its penultimate Gly was changed to His. We propose that inteins lacking a penultimate His (i) arose by mutation from ancestors in which a penultimate His facilitated splicing, (ii) that loss of this His inhibited, but may not have blocked, splicing, and (iii) that selective pressure for efficient expression of the RNA polymerase yielded an intein that utilizes another residue to assist Asn cyclization, changing the intein active site so that a penultimate His now inhibits splicing.	New England Biolabs Inc, Beverly, MA 01915 USA		Perler, FB (corresponding author), New England Biolabs Inc, 32 Tozer Rd, Beverly, MA 01915 USA.		Wood, David W/B-2992-2012					Belfort M, 1997, NUCLEIC ACIDS RES, V25, P3379, DOI 10.1093/nar/25.17.3379; Chong SR, 1998, J BIOL CHEM, V273, P10567, DOI 10.1074/jbc.273.17.10567; Chong SR, 1996, J BIOL CHEM, V271, P22159, DOI 10.1074/jbc.271.36.22159; COOPER AA, 1993, EMBO J, V12, P2575, DOI 10.1002/j.1460-2075.1993.tb05913.x; Dalgaard JZ, 1997, J COMPUT BIOL, V4, P193, DOI 10.1089/cmb.1997.4.193; DAVIS EO, 1994, EMBO J, V13, P699, DOI 10.1002/j.1460-2075.1994.tb06309.x; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; Hall TMT, 1997, CELL, V91, P85, DOI 10.1016/S0092-8674(01)80011-8; HIRATA R, 1992, BIOCHEM BIOPH RES CO, V188, P40, DOI 10.1016/0006-291X(92)92347-Z; Jurica MS, 1999, CELL MOL LIFE SCI, V55, P1304, DOI 10.1007/s000180050372; Kawasaki M, 1997, J BIOL CHEM, V272, P15668, DOI 10.1074/jbc.272.25.15668; Klabunde T, 1998, NAT STRUCT BIOL, V5, P31, DOI 10.1038/nsb0198-31; Kornberg A., 1992, DNA REPLICATION, P165; Noren CJ, 2000, ANGEW CHEM INT EDIT, V39, P450; PERLER FB, 1994, NUCLEIC ACIDS RES, V22, P1125, DOI 10.1093/nar/22.7.1125; Perler FB, 2000, NUCLEIC ACIDS RES, V28, P344, DOI 10.1093/nar/28.1.344; Perler FB, 1997, NUCLEIC ACIDS RES, V25, P1087, DOI 10.1093/nar/25.6.1087; Perler FB, 1998, CELL, V92, P1, DOI 10.1016/S0092-8674(00)80892-2; Pietrokovski S, 1998, CURR BIOL, V8, pR634, DOI 10.1016/S0960-9822(07)00409-5; Pietrokovski S, 1998, PROTEIN SCI, V7, P64, DOI 10.1002/pro.5560070106; PIETROKOVSKI S, 1994, PROTEIN SCI, V3, P2340, DOI 10.1002/pro.5560031218; Scott CP, 1999, P NATL ACAD SCI USA, V96, P13638, DOI 10.1073/pnas.96.24.13638; Southworth MW, 1999, BIOTECHNIQUES, V27, P110, DOI 10.2144/99271st04; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; Telenti A, 1997, J BACTERIOL, V179, P6378, DOI 10.1128/jb.179.20.6378-6382.1997; Wang SL, 1997, J BIOL CHEM, V272, P11869, DOI 10.1074/jbc.272.18.11869; Wu H, 1998, P NATL ACAD SCI USA, V95, P9226, DOI 10.1073/pnas.95.16.9226; XU MQ, 1993, CELL, V75, P1371, DOI 10.1016/0092-8674(93)90623-X; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x	29	40	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20431	20435		10.1074/jbc.M000178200	http://dx.doi.org/10.1074/jbc.M000178200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10770923	hybrid			2022-12-27	WOS:000088084500030
J	Chow, KM; Csuhai, E; Juliano, MA; St Pyrek, J; Juliano, L; Hersh, LB				Chow, KM; Csuhai, E; Juliano, MA; St Pyrek, J; Juliano, L; Hersh, LB			Studies on the subsite specificity of rat nardilysin (N-arginine dibasic convertase)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-DEGRADING ENZYME; PROTEASE-III; RESIDUES; CLONING; BINDING; TISSUE	The subsite specificity of rat nardilysin was investigated using fluorogenic substrates of the type 2-amino-benzoyl-GGX(1)X(2)RKX(3)GQ-ethylenediamine-2,4-dinitrophenyl, where P-2, P-2', and P-3 residues were varied. (The nomenclature of Schechter and Berger (Schechter, L, and Berger, A. (1967) Biochem, Biophys, Res. Commun, 27, 157-162) is used where cleavage of a peptide occurs between the P-1 and P-1' residues, and adjacent residues are designated P-2, P-3, P-2', P-3', etc.) There was little effect on II, among different residues at any of these positions, In contrast, residues at each position affected k(cat), with P-2 residues having the greatest effect, The S-3, S-2, and S-2' subsites differed in their amino acid preference, Tryptophan and serine, which produced poor substrates at the P-2 position, were among the best P-2' residues, The specificity at P-3 was generally opposite that of P-2. Residues at P-2, and to a lesser extent at P-3, influenced the cleavage site. At the P-2 position, His, Phe, Tyr,Asn, or Trp produced cleavage at the amino side of the first basic residue. In contrast, a P-2 Ile or Val produced cleavage between the dibasic pair, Other residues produced intermediate effects, The pH dependence for substrate binding showed that the enzyme prefers to bind a protonated histidine, A comparison of the effect of arginine or lysine at the P-1' or P-1 position showed that there is a tendency to cleave on the amino side of arginine and that this cleavage produces the highest k(cat) values.	Univ Kentucky, Dept Biochem, Lexington, KY 40563 USA; Univ Kentucky, Mass Spectrometry Facil, Lexington, KY 40563 USA; Escola Paulista Med, Dept Biophys, BR-04034 Sao Paulo, Brazil; Transylvania Univ, Dept Chem, Lexington, KY 40508 USA	University of Kentucky; University of Kentucky; Universidade Federal de Sao Paulo (UNIFESP)	Hersh, LB (corresponding author), Univ Kentucky, Dept Biochem, 800 Rose St, Lexington, KY 40563 USA.		Juliano, Luiz/D-7204-2012	Juliano, Luiz/0000-0002-5589-2822	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002243, R03DA011987] Funding Source: NIH RePORTER; NIDA NIH HHS [DA11987, DA02243] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AFFHOLTER JA, 1988, SCIENCE, V242, P1415, DOI 10.1126/science.3059494; BAUMEISTER H, 1993, FEBS LETT, V317, P250, DOI 10.1016/0014-5793(93)81286-9; BOSCHCOV P, 1983, BIOORG CHEM, V12, P34, DOI 10.1016/0045-2068(83)90005-6; Camargo ACM, 1997, BIOCHEM J, V324, P517, DOI 10.1042/bj3240517; CHAGAS JR, 1991, ANAL BIOCHEM, V192, P419, DOI 10.1016/0003-2697(91)90558-B; CHESNEAU V, 1994, J BIOL CHEM, V269, P2056; Cleland W W, 1979, Methods Enzymol, V63, P103; COHEN P, 1995, METHOD ENZYMOL, V248, P703; Csuhai E, 1999, ARCH BIOCHEM BIOPHYS, V362, P291, DOI 10.1006/abbi.1998.1029; Csuhai E, 1998, BIOCHEMISTRY-US, V37, P3787, DOI 10.1021/bi971969b; Csuhai E, 1999, ANAL BIOCHEM, V269, P149, DOI 10.1006/abio.1999.4033; CSUHAI E, 1995, BIOCHEMISTRY-US, V34, P12411, DOI 10.1021/bi00038a039; FINCH PW, 1986, NUCLEIC ACIDS RES, V14, P7695, DOI 10.1093/nar/14.19.7695; Foulon T, 1996, ANN NY ACAD SCI, V780, P106, DOI 10.1111/j.1749-6632.1996.tb15115.x; HOOPER NM, 1994, FEBS LETT, V345, P1; Mzhavia N, 1999, DNA CELL BIOL, V18, P369, DOI 10.1089/104454999315268; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X	17	18	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19545	19551		10.1074/jbc.M909020199	http://dx.doi.org/10.1074/jbc.M909020199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10764809	hybrid			2022-12-27	WOS:000087941300017
J	Inaba, T; Nagano, Y; Reid, JB; Sasaki, Y				Inaba, T; Nagano, Y; Reid, JB; Sasaki, Y			DE1, a 12-base pair cis-regulatory element sufficient to confer dark-inducible and light down-regulated expression to a minimal promoter in pea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; BILIVERDIN IX-ALPHA; PHYTOCHROME-A; SEEDLING DEVELOPMENT; BETA-GLUCURONIDASE; GENE-EXPRESSION; ARABIDOPSIS; REPRESSION; DEFICIENT; IDENTIFICATION	We found a cis-regulatory element of 12 base pairs (bp) (GGATTTTACAGT) capable of conferring light responsiveness to a minimal promoter, CaMV 35S46, in pea. The 12-bp sequence is located in the 5' upstream region of the light down-regulated gene pra2, which encodes a small GTPase belonging to the YPT/rab family. Here we examined gain-of-function analyses using synthetic promoter-luciferase constructs in a transient assay and found that the 12-bp element alone was sufficient to confer dark induction, as well as light down-regulation on the minimal promoter. We named this dark inducible element DE1. Effects of various Light conditions on the reporter gene activity showed that DEI received signals from phytochrome A, phytochrome B, and blue light photoreceptors, Using phytochrome-deficient mutants, we showed that the pra2 protein level in seedlings was also regulated by these photoreceptors. The changes in the immunoblotting pattern of the pra2 protein in these mutants were correlated with the changes in epicotyl elongation. Results from transient assays using these mutants showed that the DE1 received signals from phytochromes A and B, demonstrating that this element is indeed a light-responsive element. To our knowledge, this is the first cis-element that by itself confers light responsiveness to a minimal promoter.	Nagoya Univ, Grad Sch Agr Sci, Plant Mol Biol Lab, Nagoya, Aichi 4648601, Japan; Univ Tasmania, Sch Plant Sci, Hobart, Tas 7001, Australia	Nagoya University; University of Tasmania	Sasaki, Y (corresponding author), Nagoya Univ, Grad Sch Agr Sci, Plant Mol Biol Lab, Nagoya, Aichi 4648601, Japan.		Nagano, Yukio/H-8734-2019; Reid, James B/C-9269-2013	Nagano, Yukio/0000-0001-5030-676X; Inaba, Takehito/0000-0003-1750-454X				Briggs WR, 1999, ANNU REV CELL DEV BI, V15, P33, DOI 10.1146/annurev.cellbio.15.1.33; BRUCE WB, 1991, EMBO J, V10, P3015, DOI 10.1002/j.1460-2075.1991.tb07852.x; Carabelli M, 1996, P NATL ACAD SCI USA, V93, P3530, DOI 10.1073/pnas.93.8.3530; Chattopadhyay S, 1998, PLANT J, V15, P69, DOI 10.1046/j.1365-313X.1998.00180.x; CHORY J, 1992, DEVELOPMENT, V115, P337; Chory J, 1997, PLANT CELL, V9, P1225, DOI 10.1105/tpc.9.7.1225; Inaba T, 1999, PLANT PHYSIOL, V120, P491, DOI 10.1104/pp.120.2.491; JEFFERSON RA, 1987, EMBO J, V6, P3901; KOSUGI S, 1990, PLANT SCI, V70, P133, DOI 10.1016/0168-9452(90)90042-M; Leu WM, 1995, PLANT CELL, V7, P2187, DOI 10.1105/tpc.7.12.2187; Millar AJ, 1992, PLANT MOL BIOL REP, V10, P324, DOI 10.1007/BF02668909; NAGANO Y, 1995, P NATL ACAD SCI USA, V92, P6314, DOI 10.1073/pnas.92.14.6314; NAGANO Y, 1993, PLANT CELL PHYSIOL, V34, P447; Neuhaus G, 1997, EMBO J, V16, P2554, DOI 10.1093/emboj/16.10.2554; Ngai N, 1997, PLANT J, V12, P1021, DOI 10.1046/j.1365-313X.1997.12051021.x; OKUBARA PA, 1991, PLANT PHYSIOL, V96, P1237, DOI 10.1104/pp.96.4.1237; Puente P, 1996, EMBO J, V15, P3732, DOI 10.1002/j.1460-2075.1996.tb00743.x; REED JW, 1994, PLANT PHYSIOL, V104, P1139, DOI 10.1104/pp.104.4.1139; SMITH H, 1995, ANNU REV PLANT PHYS, V46, P289, DOI 10.1146/annurev.pp.46.060195.001445; TERZAGHI WB, 1995, ANNU REV PLANT PHYS, V46, P445, DOI 10.1146/annurev.pp.46.060195.002305; vonArnim A, 1996, ANNU REV PLANT PHYS, V47, P215, DOI 10.1146/annurev.arplant.47.1.215; WEISSHAAR B, 1991, EMBO J, V10, P1777, DOI 10.1002/j.1460-2075.1991.tb07702.x; Weller JL, 1997, PLANT J, V11, P1177, DOI 10.1046/j.1365-313X.1997.11061177.x; Weller JL, 1996, PLANT CELL, V8, P55; WELLER JL, 1995, PLANT PHYSIOL, V108, P525, DOI 10.1104/pp.108.2.525; Weller JL, 1997, PLANT PHYSIOL, V114, P1225, DOI 10.1104/pp.114.4.1225; YOSHIDA K, 1993, P NATL ACAD SCI USA, V90, P6636, DOI 10.1073/pnas.90.14.6636	27	24	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19723	19727		10.1074/jbc.M001337200	http://dx.doi.org/10.1074/jbc.M001337200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10777499	hybrid			2022-12-27	WOS:000087941300040
J	Podor, TJ; Peterson, CB; Lawrence, DA; Stefansson, S; Shaughnessy, SG; Foulon, DM; Butcher, M; Weitz, JI				Podor, TJ; Peterson, CB; Lawrence, DA; Stefansson, S; Shaughnessy, SG; Foulon, DM; Butcher, M; Weitz, JI			Type 1 plasminogen activator inhibitor binds to fibrin via vitronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOMATOMEDIN-B DOMAIN; TISSUE-TYPE; DEGRADATION PRODUCTS; STRUCTURAL REQUIREMENTS; PLASMA VITRONECTIN; ENDOTHELIAL-CELLS; UROKINASE-TYPE; IN-VIVO; U-PA; PAI-1	Type 1 plasminogen activator inhibitor (PAI-1), the primary inhibitor of tissue-type plasminogen activator (t-PA), circulates as a complex with the abundant plasma glycoprotein, vitronectin. This interaction stabilizes the inhibitor in its active conformation In this report, the effects of vitronectin on the interactions of PAI-1 with fibrin clots were studied. Confocal microscopic imaging of platelet-poor plasma clots reveals that essentially all fibrin-associated PAI-1 colocalizes with fibrin-bound vitronectin. Moreover, formation of platelet-poor plasma clots in the presence of polyclonal antibodies specific for vitronectin attenuated the inhibitory effects of PAI-1 on t-PA-mediated fibrinolysis. Addition of vitronectin during clot formation markedly potentiates PAI-1-mediated inhibition of lysis of I-125-labeled fibrin clots by t-PA. This effect is dependent on direct binding interactions of vitronectin with fibrin. There is no significant effect of fibrin-associated vitronectin on fibrinolysis in the absence of PAI-1. The binding of PAI-1 to fibrin clots formed in the absence of vitronectin was characterized by a low affinity (K-d similar to 3.5 mu M) and rapid loss of PAT-1 inhibitory activity over time. In contrast, a high affinity and stabilization of PAI-1 activity characterized the cooperative binding of PAI-1 to fibrin formed in the presence of vitronectin. These findings indicate that plasma PAI-1 vitronectin complexes can be localized to the surface of fibrin clots; by this localization, they may modulate fibrinolysis and clot reorganization.	Hamilton Civ Hosp, Res Ctr, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8V 1C3, Canada; Amer Red Cross, JH Holland Labs, Rockville, MD 20855 USA; Univ Tennessee, Dept Biochem & Cellular & Mol Biol, Knoxville, TN 37996 USA	McMaster University; McMaster University; American Red Cross; University of Tennessee System; University of Tennessee Knoxville	Podor, TJ (corresponding author), Hamilton Civ Hosp, Res Ctr, 711 Concess St, Hamilton, ON L8V 1C3, Canada.	podort@fhs.csu.mcmaster.ca	Weitz, Jeffrey/AAD-1929-2019	Weitz, Jeffrey/0000-0002-1092-7550; Lawrence, Daniel/0000-0003-3126-1935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL050676, R01HL050676] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50676] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOOTH NA, 1992, ANN NY ACAD SCI, V667, P70, DOI 10.1111/j.1749-6632.1992.tb51599.x; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; FAY WP, 1994, BLOOD, V83, P351; FRANCIS CW, 1994, HEMOSTASIS THROMBOSI, P1076; HANDT S, 1994, FIBRINOLYSIS, V8, P104, DOI 10.1016/S0268-9499(05)80027-X; Hill SA, 1996, BLOOD, V87, P5061, DOI 10.1182/blood.V87.12.5061.bloodjournal87125061; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; JANG IK, 1989, CIRCULATION, V79, P920, DOI 10.1161/01.CIR.79.4.920; KEIJER J, 1991, BLOOD, V78, P401; KEIJER J, 1991, BLOOD, V78, P1254; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN GR, 1988, J BIOL CHEM, V263, P1023; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; Lawrence DA, 1997, J BIOL CHEM, V272, P7676, DOI 10.1074/jbc.272.12.7676; LEVI M, 1992, CIRCULATION, V85, P305, DOI 10.1161/01.CIR.85.1.305; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; MIMURO J, 1989, J BIOL CHEM, V264, P5058; PADRO T, 1995, ARTERIOSCL THROM VAS, V15, P893, DOI 10.1161/01.ATV.15.7.893; POLLANEN J, 1991, ADV CANCER RES, V57, P273; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; PREISSNER KT, 1989, BLOOD, V74, P1989; REILLY CF, 1992, J BIOL CHEM, V267, P17128; RIJKEN DC, 1988, TISSUE TYPE PLASMINO, P101; Ritchie H, 1999, THROMB HAEMOSTASIS, V81, P96; Robbie LA, 1996, THROMB HAEMOSTASIS, V75, P127; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; Seiffert D, 1996, BLOOD, V88, P552, DOI 10.1182/blood.V88.2.552.bloodjournal882552; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SEIFFERT D, 1994, J BIOL CHEM, V269, P2659; Seiffert D, 1996, J BIOL CHEM, V271, P29644, DOI 10.1074/jbc.271.47.29644; SEIFFERT D, 1995, J IMMUNOL, V155, P3180; Seiffert D, 1997, J BIOL CHEM, V272, P13705, DOI 10.1074/jbc.272.21.13705; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 1998, J BIOL CHEM, V273, P6358, DOI 10.1074/jbc.273.11.6358; STRINGER HAR, 1995, J BIOL CHEM, V270, P11205, DOI 10.1074/jbc.270.19.11205; TORRBROWN SR, 1993, THROMB RES, V72, P413, DOI 10.1016/0049-3848(93)90241-F; VANLOON BJP, 1992, THROMB HAEMOSTASIS, V67, P101; VANMEIJER M, 1994, FEBS LETT, V352, P342, DOI 10.1016/0014-5793(94)00990-2; VANMEIJER M, 1995, FIBRINOLYSIS, V9, P263, DOI 10.1016/S0268-9499(95)80015-8; WAGNER OF, 1989, J CLIN INVEST, V84, P647, DOI 10.1172/JCI114211; Walker JB, 1999, J BIOL CHEM, V274, P5201, DOI 10.1074/jbc.274.8.5201; WEITZ JI, 1991, J CLIN INVEST, V87, P1082, DOI 10.1172/JCI115069; Weitz JI, 1998, CIRCULATION, V97, P544; WIMAN B, 1988, FEBS LETT, V242, P125, DOI 10.1016/0014-5793(88)80999-2; Wohn KD, 1999, BRIT J HAEMATOL, V104, P901, DOI 10.1046/j.1365-2141.1999.01242.x; Zhuang P, 1997, J BIOL CHEM, V272, P6858, DOI 10.1074/jbc.272.11.6858	46	62	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19788	19794		10.1074/jbc.M908079199	http://dx.doi.org/10.1074/jbc.M908079199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10764803	Green Published, hybrid			2022-12-27	WOS:000087941300049
J	Tokumitsu, H; Muramatsu, M; Ikura, M; Kobayashi, R				Tokumitsu, H; Muramatsu, M; Ikura, M; Kobayashi, R			Regulatory mechanism of Ca2+/calmodulin-dependent protein kinase kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN KINASE; MOLECULAR-CLONING; GENE-EXPRESSION; MUTATIONAL ANALYSIS; PEPTIDE COMPLEX; RAT-BRAIN; IV KINASE; CALMODULIN; ACTIVATION; CALCIUM	Ca2+/calmodulin-dependent protein kinase kinase (CaM-KK) is a novel member of the CaM kinase family, which specifically phosphorylates and activates CaM kinase I and IV. In this study, we characterized the CaM-binding peptide of alpha CaM-KK (residues 438-463), which suppressed the activity of constitutively active CaM-KK (84-434) in the absence of Ca2+/CaM but competitively with ATP, Truncation and site-directed mutagenesis of the CaM-binding region in CaM-KK reveal that Ile(441) is essential for autoinhibition of CaM-KK. Furthermore, CaM-KK chimera mutants containing the CaM-binding sequence of either myosin light chain kinases or CaM kinase II located C-terminal of Leu(440) exhibited enhanced Ca2+/CaM-independent activity (60% of total activity). Although the CaM-binding domains of myosin light chain kinases and CaM kinase II bind to the N- and C-terminal domains of CaM in the opposite orientation to CaM-KK (Osawa, M., Tokumitsu, H., Swindells, IM. B., Kurihara, H., Orita, M., Shibanuma, T., Furuya, T., and Ikura, M. (1999) Nat. Struct. Biol. 6, 819-824), the chimeric CaM-KKs containing Ile(441) remained Ca2+/CaM-dependent. This result demonstrates that the orientation of the CaM binding is not critical for relief of CaM-KK autoinhibition. However, the requirement of Ile(441) for autoinhibition, which is located at the -3 position from the N-terminal anchoring residue (Trp(444)) to CaM, accounts for the opposite orientation of CaM binding of CaM-KK compared with other CaM kinases.	Kagawa Med Univ, Dept Chem, Miki, Kagawa 76193, Japan; Helix Res Inst Inc, Kisarazu, Chiba 2920812, Japan; Ontario Canc Inst, Div Mol & Struct Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	Kagawa University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Tokumitsu, H (corresponding author), Kagawa Med Univ, Dept Chem, 1750-1 Miki Cho, Miki, Kagawa 76193, Japan.		Tokumitsu, Hiroshi/M-3978-2015	Tokumitsu, Hiroshi/0000-0002-2193-6794; Ikura, Mitsuhiko/0000-0002-9524-1303				ALLETA JM, 1996, J BIOL CHEM, V271, P20930; Anderson KA, 1998, J BIOL CHEM, V273, P31880, DOI 10.1074/jbc.273.48.31880; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRICKEY DA, 1994, J BIOL CHEM, V269, P29047; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; Edelman AM, 1996, J BIOL CHEM, V271, P10806, DOI 10.1074/jbc.271.18.10806; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; Eto K, 1999, J BIOL CHEM, V274, P22556, DOI 10.1074/jbc.274.32.22556; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; HANLEY RM, 1987, SCIENCE, V237, P293, DOI 10.1126/science.3037704; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; Hayashi N, 1998, PROTEIN EXPRES PURIF, V12, P25, DOI 10.1006/prep.1997.0807; HERRING BP, 1991, J BIOL CHEM, V266, P11838; HERRING BP, 1990, J BIOL CHEM, V265, P1724; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Kitani T, 1997, J BIOCHEM-TOKYO, V122, P243; LEACHMAN SA, 1992, J BIOL CHEM, V267, P4930; LEE JSC, 1994, J BIOL CHEM, V269, P2158; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; Matsushita M, 1998, J BIOL CHEM, V273, P21473, DOI 10.1074/jbc.273.34.21473; Matsushita M, 1999, J BIOL CHEM, V274, P10086, DOI 10.1074/jbc.274.15.10086; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MUKHERJI S, 1995, J BIOL CHEM, V270, P14062, DOI 10.1074/jbc.270.23.14062; OKUNO S, 1994, J BIOCHEM, V116, P923, DOI 10.1093/oxfordjournals.jbchem.a124617; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; Osawa M, 1999, NAT STRUCT BIOL, V6, P819; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; ROSKOSKI R, 1985, METHOD ENZYMOL, V99, P3; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Tokumitsu H, 1999, J BIOL CHEM, V274, P15803, DOI 10.1074/jbc.274.22.15803; Tokumitsu H, 1996, J BIOL CHEM, V271, P5617, DOI 10.1074/jbc.271.10.5617; Tokumitsu H, 1997, BIOCHEMISTRY-US, V36, P12823, DOI 10.1021/bi971348i; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147	42	42	42	5	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					20090	20095		10.1074/jbc.M002193200	http://dx.doi.org/10.1074/jbc.M002193200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10770941	hybrid			2022-12-27	WOS:000087941300089
J	Barbirz, S; Jakob, U; Glocker, MO				Barbirz, S; Jakob, U; Glocker, MO			Mass spectrometry unravels disulfide bond formation as the mechanism that activates a molecular chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASSISTED LASER-DESORPTION; COLONY-STIMULATING FACTOR; OXYR TRANSCRIPTION FACTOR; CYSTEINE RESIDUES; PROTEIN; ASSIGNMENT; LINKAGES; STABILIZATION; PEPTIDES; STRESS	The heat shock protein Hsp33 is a very potent molecular chaperone with a distinctive mode of functional regulation; its activity is redox-regulated. In its reduced form all six cysteinyl residues of Hsp33 are present as thiols, and Hsp33 displays no folding helper activity. Exposure of Hsp33 to oxidizing conditions like H2O2, however, rapidly converts Hsp33 into an efficient molecular chaperone. Activated Hsp33 binds tightly to refolding intermediates of chemically denatured luciferase and suppresses efficiently their aggregation in vitro, Matrix-assisted laser desorption/ionization-mass spectrometry peptide mapping in combination with in vitro and on target protein chemical modification showed that this activation process of Hsp33 is accompanied by the formation of two intramolecular disulfide bonds within Hsp33: Cys(252)-S-S-Cys(234) and Cys(265)-S-S-Cys(268). Cys(141), although not involved in disulfide bond formation, was found highly reactive toward chemical modifications. In contrast, Cys(239) is readily accessible under reducing conditions but becomes poorly accessible though still reduced when Hsp33 is in its active state. This indicates a significant conformational change during the activation process of Hsp33. Mass spectrometry, thus, unraveled a novel molecular mechanism by which alteration of the disulfide bond structure, as a result of changes in the cellular redox potential, results in the activation of a molecular chaperone.	Univ Konstanz, Fac Chem, D-78457 Constance, Germany; Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA	University of Konstanz; University of Michigan System; University of Michigan	Glocker, MO (corresponding author), Univ Rostock, Fac Med, Proteome Ctr Rostock, Joachim Jungius Str 9, D-18059 Rostock, Germany.	Michael.Glocker@med.uni-rostock.de	Barbirz, Stefanie/S-9158-2019	Barbirz, Stefanie/0000-0001-6101-9862				Aslund F, 1999, P NATL ACAD SCI USA, V96, P6161, DOI 10.1073/pnas.96.11.6161; Aslund F, 1999, CELL, V96, P751, DOI 10.1016/S0092-8674(00)80584-X; Benaroudj N, 1996, J BIOL CHEM, V271, P18471, DOI 10.1074/jbc.271.31.18471; CLAIBORNE A, 1993, FASEB J, V7, P1483, DOI 10.1096/fasebj.7.15.8262333; Creighton T. E., 1993, PROTEIN STRUCTURE PR; CREIGHTON TE, 1975, J MOL BIOL, V96, P777, DOI 10.1016/0022-2836(75)90152-7; CRIMMINS DL, 1995, ANAL BIOCHEM, V226, P355, DOI 10.1006/abio.1995.1236; DAVIS FA, 1986, J ORG CHEM, V51, P1033, DOI 10.1021/jo00357a017; EGOROV TA, 1994, EUR J BIOCHEM, V224, P631, DOI 10.1111/j.1432-1033.1994.00631.x; Gehrig PM, 1996, PEPTIDE RES, V9, P308; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; GLOCKER MO, 1995, J AM SOC MASS SPECTR, V6, P638, DOI 10.1016/1044-0305(95)00250-H; GLOCKER MO, 1993, BIOCHEMISTRY-US, V32, P482, DOI 10.1021/bi00053a012; GLOCKER O, 1994, P NATL ACAD SCI USA, V91, P5868; Gostick DO, 1998, MICROBIOL-SGM, V144, P705, DOI 10.1099/00221287-144-3-705; Happersberger HP, 1998, ANAL BIOCHEM, V264, P237, DOI 10.1006/abio.1998.2836; Happersberger HP, 1998, PROTEINS, P50; Happersberger HP, 1998, EUR MASS SPECTROM, V4, P209; HAPPERSBERGER HP, 2000, IN PRESS METHODS MOL; Herbst R, 1998, BIOCHEMISTRY-US, V37, P6586, DOI 10.1021/bi972928i; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Kang JG, 1999, EMBO J, V18, P4292, DOI 10.1093/emboj/18.15.4292; PATTERSON SD, 1994, ANAL CHEM, V66, P3727, DOI 10.1021/ac00093a030; Ruddock LW, 1999, CURR BIOL, V9, pR400, DOI 10.1016/S0960-9822(99)80253-X; Spiess C, 1997, J BIOL CHEM, V272, P22125, DOI 10.1074/jbc.272.35.22125; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; Sun Y, 1996, Methods Mol Biol, V61, P185; SVOBODA M, 1995, J MASS SPECTROM, V30, P1562, DOI 10.1002/jms.1190301107; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718; ZHOU J, 1993, INT J MASS SPECTROM, V126, P115, DOI 10.1016/0168-1176(93)80076-Q	30	86	88	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18759	18766		10.1074/jbc.M001089200	http://dx.doi.org/10.1074/jbc.M001089200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10764757	hybrid			2022-12-27	WOS:000087815900022
J	Lee, JK; Hurwitz, J				Lee, JK; Hurwitz, J			Isolation and characterization of various complexes of the minichromosome maintenance proteins of Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; MCM HETEROHEXAMERIC COMPLEXES; CONSTITUTIVE NUCLEAR PROTEINS; REPLICATION LICENSING SYSTEM; CHROMOSOMAL DNA-REPLICATION; FISSION YEAST; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; S-PHASE; CHROMATIN BINDING	Minichromosome maintenance (Mcm) proteins 2-7 are highly conserved in eukaryotes and play an essential role in DNA replication. Here, we describe the reconstitution of the various complexes of the Mcm proteins of Schizosaccharomyces pombe using the baculovirus expression system. The simultaneous expression of all six of the Mcm proteins, as well as different combinations of these proteins, yielded several stable complexes that included the heterohexamer of Mcm2/3/4/5/6/7, the Mcm2/4/6/7 heterotetramer, the dimer of the Mcm4/6/7 heterotrimer, and the Mcm3/5 heterodimer, The purification and characterization of the biochemical properties of these complexes showed that only the dimeric complex of the Mcm4/6/7 heterotrimer possessed single stranded DNA-dependent ATPase, ATP-dependent single stranded DNA binding, and 3' to 5' DNA helicase activities. Consistent with these results, the interaction of either Mcm2 or Mcm3/5 with the Mcm4/6/7 complex resulted in the disassembly of the dimeric complex of Mcm4/6/7 and the loss of DNA helicase activity. These results suggest that the Mcm4/6/7 complex is a catalytic core of the Mcm complex and that Mcm2 and Mcm3/5 may be involved in the regulation of the activity of this complex.	Mem Sloan Kettering Canc Ctr, Grad Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Hurwitz, J (corresponding author), Mem Sloan Kettering Canc Ctr, Grad Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.	j-hurwitz@ski.mskcc.org			NIGMS NIH HHS [GM 58559] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi Y, 1997, GENES CELLS, V2, P467, DOI 10.1046/j.1365-2443.1997.1350333.x; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; Brown GW, 1998, J BIOL CHEM, V273, P22083, DOI 10.1074/jbc.273.34.22083; BURKHART R, 1995, EUR J BIOCHEM, V228, P431; Chong JPJ, 1996, TRENDS BIOCHEM SCI, V21, P102, DOI 10.1016/0968-0004(96)10013-X; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Coue M, 1996, EMBO J, V15, P1085, DOI 10.1002/j.1460-2075.1996.tb00446.x; Dalton S, 1997, MOL CELL BIOL, V17, P5867, DOI 10.1128/MCB.17.10.5867; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; Fujita M, 1998, J BIOL CHEM, V273, P17095, DOI 10.1074/jbc.273.27.17095; Fujita M, 1997, J BIOL CHEM, V272, P10928; Hardy CFJ, 1997, GENE, V187, P239, DOI 10.1016/S0378-1119(96)00761-5; Hardy CFJ, 1997, P NATL ACAD SCI USA, V94, P3151, DOI 10.1073/pnas.94.7.3151; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; Hopwood B, 1996, P NATL ACAD SCI USA, V93, P12309, DOI 10.1073/pnas.93.22.12309; Ishiai M, 1996, J BIOL CHEM, V271, P20868, DOI 10.1074/jbc.271.34.20868; Ishimi Y, 1996, J BIOL CHEM, V271, P24115, DOI 10.1074/jbc.271.39.24115; Ishimi Y, 1998, J BIOL CHEM, V273, P8369, DOI 10.1074/jbc.273.14.8369; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; Kearsey SE, 1996, BIOESSAYS, V18, P183, DOI 10.1002/bies.950180305; Kearsey SE, 1998, BBA-GENE STRUCT EXPR, V1398, P113, DOI 10.1016/S0167-4781(98)00033-5; Kelman Z, 1999, P NATL ACAD SCI USA, V96, P14783, DOI 10.1073/pnas.96.26.14783; Kimura H, 1996, GENES CELLS, V1, P977, DOI 10.1046/j.1365-2443.1996.840284.x; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; Kubota Y, 1997, EMBO J, V16, P3320, DOI 10.1093/emboj/16.11.3320; Leatherwood J, 1998, CURR OPIN CELL BIOL, V10, P742, DOI 10.1016/S0955-0674(98)80117-8; Lei M, 1996, MOL CELL BIOL, V16, P5081; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MADINE MA, 1995, CURR BIOL, V5, P1270, DOI 10.1016/S0960-9822(95)00253-3; MAINE GT, 1984, GENETICS, V106, P365; Maiorano D, 1996, EMBO J, V15, P861, DOI 10.1002/j.1460-2075.1996.tb00421.x; MCENTEE K, 1980, P NATL ACAD SCI-BIOL, V77, P857, DOI 10.1073/pnas.77.2.857; Okishio N, 1996, J CELL SCI, V109, P319; Perkins G, 1998, MOL CELL, V2, P23, DOI 10.1016/S1097-2765(00)80110-0; Richter A, 1998, BIOL CHEM, V379, P1181; Richter A, 1997, EUR J BIOCHEM, V247, P136, DOI 10.1111/j.1432-1033.1997.00136.x; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Romanowski P, 1996, P NATL ACAD SCI USA, V93, P10189, DOI 10.1073/pnas.93.19.10189; Sato N, 1997, EMBO J, V16, P4340, DOI 10.1093/emboj/16.14.4340; Sherman DA, 1998, NUCLEIC ACIDS RES, V26, P3955, DOI 10.1093/nar/26.17.3955; Sherman DA, 1998, MOL BIOL CELL, V9, P1833, DOI 10.1091/mbc.9.7.1833; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STILLMAN B, 1994, J BIOL CHEM, V269, P7047; Su TT, 1996, MOL BIOL CELL, V7, P319, DOI 10.1091/mbc.7.2.319; TAKAHASHI K, 1994, MOL BIOL CELL, V5, P1145, DOI 10.1091/mbc.5.10.1145; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Thommes P, 1997, EMBO J, V16, P3312, DOI 10.1093/emboj/16.11.3312; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; You ZY, 1999, MOL CELL BIOL, V19, P8003; Young MR, 1997, MOL BIOL CELL, V8, P1587, DOI 10.1091/mbc.8.8.1587; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593; Zou L, 1997, MOL CELL BIOL, V17, P553, DOI 10.1128/MCB.17.2.553	60	151	154	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18871	18878		10.1074/jbc.M001118200	http://dx.doi.org/10.1074/jbc.M001118200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10770926	hybrid			2022-12-27	WOS:000087815900036
J	Nguyen, DHD; Webb, DJ; Catling, AD; Song, Q; Dhakephalkar, A; Weber, MJ; Ravichandran, KS; Gonias, SL				Nguyen, DHD; Webb, DJ; Catling, AD; Song, Q; Dhakephalkar, A; Weber, MJ; Ravichandran, KS; Gonias, SL			Urokinase-type plasminogen activator stimulates the Ras/extracellular signal-regulated kinase (ERK) signaling pathway and MCF-7 cell migration by a mechanism that requires focal adhesion kinase, Src, and Shc - Rapid dissociation of GRB2/SOS-SHC complex is associated with the transient phosphorylation of ERK in urokinase-treated cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; C-SRC; TYROSINE PHOSPHORYLATION; HUMAN MONOCYTES; MAP KINASE; IN-VITRO; RECEPTOR; INTEGRIN; BINDING; TRANSDUCTION	Urokinase-type plasminogen activator (uPA) stimulates MCF-7 cell migration by binding to the UPA receptor and activating the Ras-extracellular signal-regulated kinase (Ras-ERK) signaling pathway. Studies presented here show that soluble uPA receptor and a peptide derived from the Linker region between domains 1 and 2 of the uPA receptor also stimulate cellular migration via a mitogen-activated protein kinase/ERK kinase (MEK)-dependent pathway. Signaling proteins that function upstream of Res in uPA-stimulated cells remain undefined. To address this problem, we transfected MCF-7 cells to express the noncatalytic carboxylterminal domain of focal adhesion kinase (FAK), FAK(Y397F), kinase-defective c-Src, or Shc FFF, all of which express dominant-negative activity. In each case, ERK phosphorylation and cellular migration in response to uPA were blocked. Both activities were rescued by co-transfecting the cells to express constitutively active MEK1, indicating that FAK, c-Src, and Shc are upstream of MEK. Shc was tyrosine phosphorylated in uPA-treated cells. The level of phosphorylated Shc was increased within 1 min and remained increased for at least 30 min. Sos co-immunoprecipitated with Shc in cells that were treated with uPA for 1-2.5 min, probably reflecting the formation of Shc-Grb2/Sos complex; however, by 10 min, co-immunoprecipitation of Sos with Shc was no longer observed. Rapid dissociation of Sos from Shc represents a possible mechanism for the transient phosphorylation of ERK in uPA-treated MCF-7 cells.	Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Biochem & Mol Biol, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Microbiol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Gonias, SL (corresponding author), Univ Virginia, Sch Med, Dept Pathol, Box 800214, Charlottesville, VA 22908 USA.				NHLBI NIH HHS [HL60551] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060551] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Besser D, 1996, FIBRINOLYSIS, V10, P215, DOI 10.1016/S0268-9499(96)80018-X; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; CAREY LA, 1996, J CELL SCI, V109, P1787; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; CLARKE PR, 1994, CURR BIOL, V4, P647, DOI 10.1016/S0960-9822(00)00144-5; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; Degryse B, 1999, BLOOD, V94, P649, DOI 10.1182/blood.V94.2.649.414k34_649_662; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; Fazioli F, 1997, EMBO J, V16, P7279, DOI 10.1093/emboj/16.24.7279; Felsenfeld DP, 1999, NAT CELL BIOL, V1, P200, DOI 10.1038/12021; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; Kanse SM, 1997, ARTERIOSCL THROM VAS, V17, P2848, DOI 10.1161/01.ATV.17.11.2848; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KOLSHELNICK Y, 1997, J BIOL CHEM, V272, P28563; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LI H, 1994, J BIOL CHEM, V269, P8153; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; MARINO N, 1995, J BIOL CHEM, V270, P269; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; PLOUG M, 1991, J BIOL CHEM, V266, P1926; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHLAEPFER DD, 1996, MOL CELL BIOL, V16, P623; Simon DI, 1996, BLOOD, V88, P3185, DOI 10.1182/blood.V88.8.3185.bloodjournal8883185; Sitrin RG, 1996, J CLIN INVEST, V97, P1942, DOI 10.1172/JCI118626; STAHL A, 1995, J CELL BIOL, V129, P335, DOI 10.1083/jcb.129.2.335; Tang H, 1998, J BIOL CHEM, V273, P18268, DOI 10.1074/jbc.273.29.18268; Walk SF, 1998, EUR J IMMUNOL, V28, P2265, DOI 10.1002/(SICI)1521-4141(199808)28:08<2265::AID-IMMU2265>3.0.CO;2-P; Wartmann M, 1997, J BIOL CHEM, V272, P3915, DOI 10.1074/jbc.272.7.3915; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Webb DJ, 2000, J CELL SCI, V113, P123; Webb DJ, 1999, J BIOL CHEM, V274, P7412, DOI 10.1074/jbc.274.11.7412; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Xie H, 1998, J CELL SCI, V111, P615; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Xue W, 1997, CANCER RES, V57, P1682; XUE W, 1994, J IMMUNOL, V152, P4630; Yebra M, 1999, EXP CELL RES, V250, P231, DOI 10.1006/excr.1999.4510	58	137	142	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19382	19388		10.1074/jbc.M909575199	http://dx.doi.org/10.1074/jbc.M909575199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10777511	hybrid			2022-12-27	WOS:000087815900099
J	Sandigursky, M; Franklin, WA				Sandigursky, M; Franklin, WA			Uracil-DNA glycosylase in the extreme thermophile Archaeoglobus fulgidus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; ESCHERICHIA-COLI; STRUCTURAL BASIS; GENERATION; SEQUENCE; SITES	Uracil-DNA glycosylase (UDG) is an essential enzyme for maintaining genomic integrity. Here we describe a UDG from the extreme thermophile Archaeoglobus fulgidus. The enzyme is a member of a new class of enzymes found in prokaryotes that is distinct from the UDG enzyme found in Escherichia coli, eukaryotes, and DNA-containing viruses. The A. fulgidus UDG: is extremely thermostable, maintaining full activity after heating for 1.5 h at 95 degrees C. The protein is capable of removing uracil from double-stranded DNA containing either a U/A or U/G base pair as well as from single-stranded DNA. This enzyme is product-inhibited by both uracil and apurinic/apyrimidinic sites. The A. fulgidus UDG has a high degree of similarity at the primary amino acid sequence level to the enzyme found in Thermotoga maritima, a thermophilic eubacteria, and suggests a conserved mechanism of UDG-initiated base excision repair in archaea and thermophilic eubacteria.	Albert Einstein Coll Med, Dept Radiol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Radiat Oncol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Franklin, WA (corresponding author), Albert Einstein Coll Med, Dept Radiol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NCI NIH HHS [CA52025] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA052025, R01CA052025] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Bharati S, 1998, NUCLEIC ACIDS RES, V26, P4953, DOI 10.1093/nar/26.21.4953; Cunningham RP, 1997, MUTAT RES-DNA REPAIR, V383, P189, DOI 10.1016/S0921-8777(97)00008-6; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DOMENA JD, 1988, BIOCHEMISTRY-US, V27, P6742, DOI 10.1021/bi00418a015; EFTEDAL I, 1993, NUCLEIC ACIDS RES, V21, P2095, DOI 10.1093/nar/21.9.2095; GLASSBERG J, 1977, J VIROL, V21, P147, DOI 10.1128/JVI.21.1.147-152.1977; GLASSBERG J, 1977, J VIROL, V21, P54, DOI 10.1128/JVI.21.1.54-60.1977; Greagg MA, 1999, P NATL ACAD SCI USA, V96, P9045, DOI 10.1073/pnas.96.16.9045; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; KABOEV OK, 1981, FEBS LETT, V132, P337, DOI 10.1016/0014-5793(81)81192-1; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Koulis A, 1996, FEMS MICROBIOL LETT, V143, P267; Krokan HE, 1997, BIOCHEM J, V325, P1; LINDAHL T, 1977, J BIOL CHEM, V252, P3286; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P1119, DOI 10.1021/bi00218a033; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MOSBAUGH DW, 1994, PROG NUCLEIC ACID RE, V48, P315, DOI 10.1016/S0079-6603(08)60859-4; OLSEN LC, 1989, EMBO J, V8, P3121, DOI 10.1002/j.1460-2075.1989.tb08464.x; Ravishankar R, 1998, NUCLEIC ACIDS RES, V26, P4880, DOI 10.1093/nar/26.21.4880; Sandigursky M, 1999, CURR BIOL, V9, P531, DOI 10.1016/S0960-9822(99)80237-1; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SCARLATO V, 1992, GENE, V118, P109, DOI 10.1016/0378-1119(92)90256-O; TYE BK, 1977, P NATL ACAD SCI USA, V74, P154, DOI 10.1073/pnas.74.1.154; VARSHNEY U, 1991, BIOCHEMISTRY-US, V30, P4055, DOI 10.1021/bi00230a033; WARNER HR, 1983, J BACTERIOL, V154, P1451, DOI 10.1128/JB.154.3.1451-1454.1983	28	53	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19146	19149		10.1074/jbc.M001995200	http://dx.doi.org/10.1074/jbc.M001995200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10777501	hybrid			2022-12-27	WOS:000087815900070
J	Miyako, K; Takamatsu, C; Umeda, S; Tajiri, T; Furuichi, M; Nakabeppu, Y; Sekiguchi, M; Hamasaki, N; Takeshige, K; Kang, D				Miyako, K; Takamatsu, C; Umeda, S; Tajiri, T; Furuichi, M; Nakabeppu, Y; Sekiguchi, M; Hamasaki, N; Takeshige, K; Kang, D			Accumulation of adenine DNA glycosylase-sensitive sites in human mitochondrial DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI MUTY; OXIDATIVE DAMAGE; INTRACELLULAR-LOCALIZATION; MUTAGENIC SUBSTRATE; HUMAN HOMOLOG; HUMAN-CELLS; REPAIR; PROTEIN; CLONING; REPLICATION	The mitochondrial respiratory chain inevitably produces reactive oxygen species as byproducts of aerobic ATP synthesis. Mitochondrial DNA (mtDNA), which is located close to the respiratory chain, is reported to contain much more 8-oxoguanine (8-oxoG), an oxidatively modified guanine base, than nuclear DNA. Despite such a high amount of 8-oxoG in mt DNA (1-2 8-oxoG/10(4) G), mtDNA is barely cleaved by an 8-oxoG DNA glycosylase or MutM, which specifically excises 8-oxoG from a C:8-oxoG pair. We find here that about half of human mtDNA molecules are cleaved by another 8-oxoG-recognizing enzyme, an adenine DNA glycosylase or MutY, which excises adenine from an A:8-oxoG pair. The cleavage sites are mapped to adenines. The calculated number of MutY-sensitive sites in mtDNA is approximately 1.4/10(4) G. This value roughly corresponds with the electrochemically measured amount of 8-oxoG in mtDNA (2.2/10(4) G), raising the possibility that 8-oxoG mainly accumulates as an A:8-oxoG pair.	Kyushu Univ, Grad Sch Med Sci, Dept Clin Chem & Lab Med, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Biochem, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Biochem, Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol Corp, Core Res Evolutional Sci & Technol, Fukuoka 8128582, Japan; Fukuoka Dent Coll, Dept Biol, Fukuoka 8140193, Japan	Kyushu University; Kyushu University; Kyushu University; Japan Science & Technology Agency (JST); Fukuoka Dental College (FDC)	Kang, D (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Clin Chem & Lab Med, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.		Nakabeppu, Yusaku/A-8902-2011	Nakabeppu, Yusaku/0000-0002-6739-242X				AKIYAMA M, 1989, P NATL ACAD SCI USA, V86, P3949, DOI 10.1073/pnas.86.11.3949; AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Beckman K B, 1996, Methods Enzymol, V264, P442, DOI 10.1016/S0076-6879(96)64040-3; Berdal KG, 1998, EMBO J, V17, P363, DOI 10.1093/emboj/17.2.363; BESTWICK RK, 1982, J BIOL CHEM, V257, P9305; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; Croteau DL, 1997, J BIOL CHEM, V272, P27338, DOI 10.1074/jbc.272.43.27338; DRIGGERS WJ, 1993, J BIOL CHEM, V268, P22042; HAYAKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P979, DOI 10.1016/0006-291X(92)92300-M; HEGLER J, 1993, CARCINOGENESIS, V14, P2309, DOI 10.1093/carcin/14.11.2309; Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288; JANSSEN YMW, 1993, LAB INVEST, V69, P261; KANG D, 1995, J BIOL CHEM, V270, P14659, DOI 10.1074/jbc.270.24.14659; Kang D., 1998, MITOCHONDRIAL DNA MU, P1; Kang DC, 1997, J BIOL CHEM, V272, P15275, DOI 10.1074/jbc.272.24.15275; Khrapko K, 1997, P NATL ACAD SCI USA, V94, P13798, DOI 10.1073/pnas.94.25.13798; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; LU AL, 1995, J BIOL CHEM, V270, P23582, DOI 10.1074/jbc.270.40.23582; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; Miyako K, 1997, J BIOL CHEM, V272, P9605; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; Nishioka K, 1999, MOL BIOL CELL, V10, P1637, DOI 10.1091/mbc.10.5.1637; OGDEN RC, 1987, METHOD ENZYMOL, V152, P61; Papa S, 1996, BBA-BIOENERGETICS, V1276, P87, DOI 10.1016/0005-2728(96)00077-1; PAVLOV YI, 1994, BIOCHEMISTRY-US, V33, P4695, DOI 10.1021/bi00181a029; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; Sekiguchi M, 1996, GENES CELLS, V1, P139, DOI 10.1046/j.1365-2443.1996.d01-232.x; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Slupska MM, 1996, J BACTERIOL, V178, P3885, DOI 10.1128/jb.178.13.3885-3892.1996; Suter M, 1999, BIOCHEMISTRY-US, V38, P459, DOI 10.1021/bi9811922; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; Takao M, 1998, NUCLEIC ACIDS RES, V26, P2917, DOI 10.1093/nar/26.12.2917; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TSAI SL, 1992, J CLIN INVEST, V89, P87, DOI 10.1172/JCI115590	38	8	10	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12326	12330		10.1074/jbc.275.16.12326	http://dx.doi.org/10.1074/jbc.275.16.12326			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766873	hybrid			2022-12-27	WOS:000086695500108
J	Osapay, K; Tran, D; Ladokhin, AS; White, SH; Henschen, AH; Selsted, ME				Osapay, K; Tran, D; Ladokhin, AS; White, SH; Henschen, AH; Selsted, ME			Formation and characterization of a single Trp-Trp cross-link in indolicidin that confers protease stability without altering antimicrobial activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE INDOLICIDIN; NEUTROPHILS; DITYROSINE; TRYPTOPHAN; ANTIBIOTICS; ACID; RICH	Indolicidin is a 13-residue cationic, antimicrobial peptide-amide isolated from the cytoplasmic granules of bovine neutrophils. The unique composition of indolicidin distinguishes it from alpha-helical and P-structured cationic peptides, because five of indolicidin's 13 residues are tryptophans: H-Ile-Leu-Pro-Trp-Lys-Trp-Pro-Trp-Trp-Pro-Trp-Arg-Arg-NH2. Solid phase synthesis of indolicidin gave rise to a minor byproduct that possessed unusual fluorescence and UV absorbance properties compared with authentic indolicidin, The byproduct was purified by combined ion exchange and reversed phase high pressure liquid chromatography steps and was shown be identical to authentic indolicidin in its microbicidal activity against Staphylococcus aureus, Escherichia coli, Candida albicans, and Cryptococcus neoformans. Mass analysis of the byproduct revealed a a-atomic mass unit reduction compared with indolicidin, suggesting the deprotonation of two indole side chains to form an intrachain delta(1),delta(1)'-ditryptophan derivative. We confirmed the nature of the cross-linked byproduct, termed X-indolicidin, by absorbance and fluorescence spectroscopy, peptide mapping, and sequence analysis. Edman degradation revealed that Trp-g and Trp-9 were covalently cross-linked. Compared with indolicidin, X-indolicidin was partially resistant to digestion with trypsin and chymotrypsin, suggesting that the ditryptophan stabilizes a subset of molecular conformations that are protease resistant but that are absent in the native structure.	Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Selsted, ME (corresponding author), Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA.		White, Stephen/N-1507-2019; White, Stephen H/B-1053-2009	White, Stephen H/0000-0001-8540-7907	NIAID NIH HHS [AI22931] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022931, R01AI022931] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHMAD I, 1995, BBA-BIOMEMBRANES, V1237, P109, DOI 10.1016/0005-2736(95)00087-J; ALEY SB, 1994, INFECT IMMUN, V62, P5397, DOI 10.1128/IAI.62.12.5397-5403.1994; AMADO R, 1984, METHOD ENZYMOL, V107, P377; BERGMAN J, 1995, TETRAHEDRON LETT, V36, P3945, DOI 10.1016/0040-4039(95)00648-V; BERTI G, 1960, TETRAHEDRON LETT, V26, P13; BODANSZKY M, 1983, PEPTIDES, P112; BODANSZKY M, 1984, PRINCIPLES PEPTIDES, P188; BOMAN HG, 1994, CIBA FDN S, V186; Carter DS, 1996, TETRAHEDRON LETT, V37, P5629, DOI 10.1016/0040-4039(96)01220-8; Falla TJ, 1996, J BIOL CHEM, V271, P19298, DOI 10.1074/jbc.271.32.19298; GIULIVI C, 1994, METHOD ENZYMOL, V233, P363; Hancock REW, 1998, TRENDS BIOTECHNOL, V16, P82, DOI 10.1016/S0167-7799(97)01156-6; Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7; HASHIZUME K, 1981, B CHEM SOC JPN, V54, P3806, DOI 10.1246/bcsj.54.3806; Ladokhin AS, 1997, BIOPHYS J, V72, P794, DOI 10.1016/S0006-3495(97)78713-7; Ladokhin AS, 1999, BIOCHEMISTRY-US, V38, P12313, DOI 10.1021/bi9907936; LEHRER RI, 1991, J IMMUNOL METHODS, V137, P167, DOI 10.1016/0022-1759(91)90021-7; Malencik DA, 1996, ANAL BIOCHEM, V242, P202, DOI 10.1006/abio.1996.0454; NICOLAS P, 1995, ANNU REV MICROBIOL, V49, P277, DOI 10.1146/annurev.mi.49.100195.001425; OMORI Y, 1976, CHEM LETT, P805, DOI 10.1246/cl.1976.805; Robinson WE, 1998, J LEUKOCYTE BIOL, V63, P94, DOI 10.1002/jlb.63.1.94; SCHLUESENER HJ, 1993, J NEUROIMMUNOL, V47, P199, DOI 10.1016/0165-5728(93)90030-3; Selsted M E, 1993, Genet Eng (N Y), V15, P131; SELSTED ME, 1992, J BIOL CHEM, V267, P4292; Stachel SJ, 1996, J AM CHEM SOC, V118, P1225, DOI 10.1021/ja9533297; STRYDOM DJ, 1994, ANAL BIOCHEM, V222, P19, DOI 10.1006/abio.1994.1448; VANABEL RJ, 1995, INT J PEPT PROT RES, V45, P401; ZANETTI M, 1995, FEBS LETT, V374, P1, DOI 10.1016/0014-5793(95)01050-O	28	33	38	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12017	12022		10.1074/jbc.275.16.12017	http://dx.doi.org/10.1074/jbc.275.16.12017			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766833	hybrid			2022-12-27	WOS:000086695500068
J	von Lintig, J; Vogt, K				von Lintig, J; Vogt, K			Filling the gap in vitamin A research - Molecular identification of an enzyme cleaving beta-carotene to retinal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VISUAL PIGMENT CHROMOPHORE; IN-VITRO; RPE65; EXPRESSION; MUTATIONS; PROTEIN; CLONING; ACID	Vitamin A and its derivatives (retinoids) are essential components in vision; they contribute to pattern formation during development and exert multiple effects on cell differentiation with important clinical implications. It has been known for 50 years that the key step in the formation of vitamin A is the oxidative cleavage of beta-carotene; however, this enzymatic step has resisted molecular analysis. A novel approach enabled us to clone and identify a beta-carotene dioxygenase from Drosophila melanogaster, expressing it into the background of a beta-carotene (provitamin A)-synthesizing and -accumulating Escherichia coli strain. The carotene-cleaving enzyme, identified here for the first time on the molecular level, is the basis of the numerous branches of vitamin A action and links plant and animal carotene metabolism.	Univ Freiburg, Inst Biol Neurobiol & Tierphysiol 1, D-79104 Freiburg, Germany	University of Freiburg	Vogt, K (corresponding author), Univ Freiburg, Inst Biol Neurobiol & Tierphysiol 1, Hauptstr 1, D-79104 Freiburg, Germany.			von Lintig, Johannes/0000-0002-2079-2143				BAVIK CO, 1993, J BIOL CHEM, V268, P20540; Choo DW, 1998, FEBS LETT, V440, P195, DOI 10.1016/S0014-5793(98)01459-8; Chytil F., 1994, Retinoids: from basic science to clinical applications., P11; DOWLING JE, 1960, P NATL ACAD SCI USA, V46, P587, DOI 10.1073/pnas.46.5.587; GOODMAN DS, 1965, SCIENCE, V149, P879, DOI 10.1126/science.149.3686.879; Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194; HAMEL CP, 1993, J BIOL CHEM, V268, P15751; HARDIE R, 1989, J INSECT PHYSIOL, V35, P423, DOI 10.1016/0022-1910(89)90117-0; HUANG TY, 1994, GRAPH COMBINATOR, V10, P235, DOI 10.1007/BF02986671; HUNDLE B, 1994, MOL GEN GENET, V245, P406, DOI 10.1007/BF00302252; Krinsky N. I., 1994, Retinoids: from basic science to clinical applications., P21; Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139; Moore T, 1930, BIOCHEM J, V24, P692, DOI 10.1042/bj0240692; NAPOLI JL, 1988, J BIOL CHEM, V263, P17372; OLSON JA, 1965, P NATL ACAD SCI USA, V54, P1364, DOI 10.1073/pnas.54.5.1364; OLSON JA, 1969, AM J CLIN NUTR, V22, P953; PAK WL, 1970, NEUROGENETICS GENETI, P67; Picking WL, 1996, EXP EYE RES, V63, P493, DOI 10.1006/exer.1996.0139; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Schwartz SH, 1997, SCIENCE, V276, P1872, DOI 10.1126/science.276.5320.1872; Seki T, 1998, EUR J BIOCHEM, V257, P522, DOI 10.1046/j.1432-1327.1998.2570522.x; SEKI T, 1994, EUR J BIOCHEM, V226, P691, DOI 10.1111/j.1432-1033.1994.tb20097.x; Seki T, 1998, COMP BIOCHEM PHYS B, V119, P53, DOI 10.1016/S0305-0491(97)00322-2; STEPHENSON RS, 1983, BIOL PHOTORECEPTION, P477; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; VOGT K, 1984, NATURWISSENSCHAFTEN, V71, P211, DOI 10.1007/BF00490436; VOGT K, 1983, Z NATURFORSCH C, V38, P329; VOGT K, 1984, Z NATURFORSCH C, V39, P196; vonLintig J, 1997, PLANT J, V12, P625, DOI 10.1046/j.1365-313X.1997.00625.x; WALD G, 1968, NATURE, V219, P800, DOI 10.1038/219800a0	30	367	381	0	40	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11915	11920		10.1074/jbc.275.16.11915	http://dx.doi.org/10.1074/jbc.275.16.11915			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766819	hybrid			2022-12-27	WOS:000086695500054
J	Chiang, JYL; Kimmel, R; Weinberger, C; Stroup, D				Chiang, JYL; Kimmel, R; Weinberger, C; Stroup, D			Farnesoid X receptor responds to bile acids and represses cholesterol 7 alpha-hydroxylase gene (CYP7A1) transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN NUCLEAR RECEPTOR; HEPG2 CELLS; IDENTIFICATION; PROMOTER; ELEMENT; METABOLITES; ACTIVATION; EXPRESSION; PATHWAY; LIGANDS	Cholesterol 7 alpha-hydroxylase gene (CYP7A1) transcription is repressed by bile acids. The goal of this study is to elucidate the mechanism of CYP7A1 transcription by bile acid-activated farnesoid X receptor (FXR) in its native promoter and cellular context and to identify FXR response elements in the gene. In Chinese hamster ovary cells transfected with retinoid X receptor alpha (RXR alpha)/FXR, only chenodeoxycholic acid (CDCA) and deoxycholic acid (DCA) were able to stimulate a heterologous promoter/reporter containing an ecdysone response element. In HepG2 cells, all bile acids (25 mu M) were able to repress CYP7A1/luciferase reporter activity, and only CDCA and DCA further repressed reporter activity when cotransfected with RXR alpha/FXR, The concentration of CDCA required to inhibit 50% of reporter activity (IC(50)) was determined to be approximately 25 mu M without FXR and 10 mu M with FXR. Deletion analysis revealed that the bile acid response element located between nucleotides -148 and -128 was the FXR response element, but RXR alpha/FXR did not bind to this sequence. These results suggest that bile acid-activated FXR exerts its inhibitory effect on CYP7A1 transcription by an indirect mechanism, in contrast to the stimulation and binding of FXR to intestinal bile acid-binding protein gene promoter. Results also reveal that bile acid receptors other than FXR are present in HepG2 cells.	NE Ohio Univ, Coll Med, Dept Biochem & Mol Pathol, Rootstown, OH 44272 USA; NIEHS, NIH, Res Triangle Pk, NC 27709 USA	Northeast Ohio Medical University (NEOMED); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Chiang, JYL (corresponding author), NE Ohio Univ, Coll Med, Dept Biochem & Mol Pathol, POB 95, Rootstown, OH 44272 USA.	jchiang@neoucom.edu	Chiang, John Y. L./G-2658-2011	Chiang, John Y. L./0000-0001-9360-7650	NIDDK NIH HHS [DK44442, R01 DK044442, R01 DK058379] Funding Source: Medline; NIGMS NIH HHS [GM31584] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058379, R01DK044442, R56DK044442] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031584] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chen J, 1999, BIOCHEM BIOPH RES CO, V260, P829, DOI 10.1006/bbrc.1999.0980; CHIANG JYL, 1994, J BIOL CHEM, V269, P17502; Chiang JYL, 1999, FALK SYMP, V108, P51; CHIANG JYL, 1998, FRONT BIOSCI, V3, P176; CRESTANI M, 1994, BIOCHEM BIOPH RES CO, V198, P546, DOI 10.1006/bbrc.1994.1080; CRESTANI M, 1993, ARCH BIOCHEM BIOPHYS, V306, P451, DOI 10.1006/abbi.1993.1537; CRESTANI M, 1995, J LIPID RES, V36, P2419; Crestani M, 1998, J LIPID RES, V39, P2192; DeFabiani E, 1996, BIOCHEM BIOPH RES CO, V226, P663, DOI 10.1006/bbrc.1996.1412; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; Foti D, 1998, BIOCHEM BIOPH RES CO, V253, P109, DOI 10.1006/bbrc.1998.9759; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; HEUMAN DM, 1989, J LIPID RES, V30, P1160; Kitareewan S, 1996, MOL BIOL CELL, V7, P1153, DOI 10.1091/mbc.7.8.1153; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARRAPODI M, 2000, IN PRESS J LIPID RES, V41; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; Nitta M, 1999, P NATL ACAD SCI USA, V96, P6660, DOI 10.1073/pnas.96.12.6660; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Peet DJ, 1998, CURR OPIN GENET DEV, V8, P571, DOI 10.1016/S0959-437X(98)80013-0; Princen HMG, 1997, CURR PHARM DESIGN, V3, P59; Russell DW, 1999, CELL, V97, P539, DOI 10.1016/S0092-8674(00)80763-1; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; STRAVITZ RT, 1995, BILE ACIDS CHOLESTAS, P39; Stroup D, 1997, AM J PHYSIOL-GASTR L, V273, pG508, DOI 10.1152/ajpgi.1997.273.2.G508; Stroup D, 1997, J BIOL CHEM, V272, P9833; Wang DP, 1996, J LIPID RES, V37, P1831; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Weinberger C, 1996, TRENDS ENDOCRIN MET, V7, P1, DOI 10.1016/1043-2760(95)00180-8	31	233	247	4	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10918	10924		10.1074/jbc.275.15.10918	http://dx.doi.org/10.1074/jbc.275.15.10918			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753890	hybrid			2022-12-27	WOS:000086466600032
J	Garcia, JJ; Ogilvie, I; Robinson, BH; Capaldi, RA				Garcia, JJ; Ogilvie, I; Robinson, BH; Capaldi, RA			Structure, functioning, and assembly of the ATP synthase in cells from patients with the T8993G mitochondrial DNA mutation - Comparison with the enzyme in Rho(0) cells completely lacking mtDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE HEART-MITOCHONDRIA; SACCHAROMYCES-CEREVISIAE; CROSS-LINKING; H+-ATPASE; OXIDATIVE-PHOSPHORYLATION; ADENOSINE-TRIPHOSPHATASE; SUBUNIT PROTEINS; MEMBRANE SYSTEM; MIT-MUTANTS; F-0 SECTOR	The structure and functioning of the ATP synthase of human fibroblast cell lines with 91 and 100%, respectively, of the T8993G mutation have been studied, with MRC5 human fibroblasts and Rho(0) cells derived from this cell line as controls. ATP hydrolysis was normal but ATP synthesis was reduced by 60% in the 100% mutants. Both activities were highly oligomycin-sensitive. The levels of F1F0 were close to normal, and the enzyme was stable. It is concluded that the loss of ATP synthesis is because of disruption of the proton translocation step within the F-0 part. This is supported by membrane potential measurements using the dye JC-1. Cells with a 91% mutation load grew well and showed only a 25% loss in ATP synthesis. This much reduced effect for only a 9% difference in mutation load mirrors the reduced pathogenicity in patients. F1F0 has been purified for the first time from human cell lines. A partial complex was obtained from Rho(0) cells containing the F-1 subunits associated with several stalk, as well as F-0 subunits, including oligomycin sensitivity conferring protein, b, and c subunits, This partial complex no longer binds inhibitor protein.	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; Hosp Sick Children, Metab Res Inst, Toronto, ON M5G 1X8, Canada	University of Oregon; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Capaldi, RA (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.							ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aggeler R, 1997, J BIOL CHEM, V272, P19621, DOI 10.1074/jbc.272.31.19621; Appleby RD, 1999, EUR J BIOCHEM, V262, P108, DOI 10.1046/j.1432-1327.1999.00350.x; Buchet K, 1998, J BIOL CHEM, V273, P22983, DOI 10.1074/jbc.273.36.22983; Chen XJ, 1998, MOL GEN GENET, V259, P457, DOI 10.1007/s004380050836; CHOO WM, 1985, BIOCHIM BIOPHYS ACTA, V806, P290, DOI 10.1016/0005-2728(85)90108-2; COLLINSON IR, 1994, J MOL BIOL, V242, P408; COLLINSON IR, 1994, BIOCHEMISTRY-US, V33, P7971, DOI 10.1021/bi00191a026; Darley-Usmar V.M., 1987, MITOCHONDRIA PRACTIC, P4; DEGOMEZPUYOU MT, 1977, ARCH BIOCHEM BIOPHYS, V182, P82; DU ZY, 1990, BIOCHEMISTRY-US, V29, P402, DOI 10.1021/bi00454a014; Engelbrecht S, 1997, FEBS LETT, V414, P485, DOI 10.1016/S0014-5793(97)00997-6; Fillingame RH, 1998, ACTA PHYSIOL SCAND, V163, P163; Fillingame RH, 1998, BBA-BIOENERGETICS, V1365, P135, DOI 10.1016/S0005-2728(98)00053-X; Fornells LAMG, 1998, ARCH BIOCHEM BIOPHYS, V349, P304, DOI 10.1006/abbi.1997.0454; Gardner JL, 1999, ARCH BIOCHEM BIOPHYS, V361, P302, DOI 10.1006/abbi.1998.0995; GLASER E, 1981, EUR J BIOCHEM, V115, P189; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; HADIKUSUMO RG, 1988, BIOCHIM BIOPHYS ACTA, V933, P212, DOI 10.1016/0005-2728(88)90072-2; HERMOLIN J, 1995, J BIOL CHEM, V270, P2815, DOI 10.1074/jbc.270.6.2815; HOUSTEK J, 1995, BBA-MOL BASIS DIS, V1271, P349, DOI 10.1016/0925-4439(95)00063-A; Jager H, 1998, EUR J BIOCHEM, V251, P122, DOI 10.1046/j.1432-1327.1998.2510122.x; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBOWITZ MS, 1993, ARCH BIOCHEM BIOPHYS, V301, P64, DOI 10.1006/abbi.1993.1115; Lill H, 1996, J BIOL CHEM, V271, P32737, DOI 10.1074/jbc.271.51.32737; Long JC, 1998, J BIOL CHEM, V273, P16235, DOI 10.1074/jbc.273.26.16235; Majander A, 1997, FEBS LETT, V412, P351, DOI 10.1016/S0014-5793(97)00757-6; Manfred G, 1999, J BIOL CHEM, V274, P9386, DOI 10.1074/jbc.274.14.9386; MARTINS OB, 1988, BIOPHYS CHEM, V29, P111, DOI 10.1016/0301-4622(88)87030-3; Marusich MF, 1997, BBA-MOL BASIS DIS, V1362, P145, DOI 10.1016/S0925-4439(97)00061-6; MARZUKI S, 1989, BIOCHIM BIOPHYS ACTA, V975, P222, DOI 10.1016/S0005-2728(89)80252-X; Nijtmans LGJ, 1995, BBA-MOL BASIS DIS, V1272, P190, DOI 10.1016/0925-4439(95)00087-9; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Ogilvie I, 1998, ACTA PHYSIOL SCAND, V163, P169; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; ORIAN JM, 1984, J BIOENERG BIOMEMBR, V16, P561, DOI 10.1007/BF00743246; PAUL MF, 1992, EUR J BIOCHEM, V205, P163, DOI 10.1111/j.1432-1033.1992.tb16764.x; PAUL MF, 1989, EUR J BIOCHEM, V185, P163, DOI 10.1111/j.1432-1033.1989.tb15098.x; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PULLMAN ME, 1960, J BIOL CHEM, V235, P3322; Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076-6879(95)60154-6; ROBINSON BH, 1994, J BIOENERG BIOMEMBR, V26, P311, DOI 10.1007/BF00763102; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SIERRA MF, 1973, P NATL ACAD SCI USA, V70, P3155, DOI 10.1073/pnas.70.11.3155; TATUCH Y, 1992, AM J HUM GENET, V50, P852; TZAGOLOFF A, 1972, J BIOL CHEM, V247, P594; Valiyaveetil FI, 1998, J BIOL CHEM, V273, P16241, DOI 10.1074/jbc.273.26.16241; Vazquez-Memije ME, 1998, J INHERIT METAB DIS, V21, P829, DOI 10.1023/A:1005418718299; VAZQUEZCONTRERAS E, 1995, J BIOENERG BIOMEMBR, V27, P109, DOI 10.1007/BF02110338; VazquezMemije ME, 1996, J INHERIT METAB DIS, V19, P43, DOI 10.1007/BF01799347; Watts SD, 1996, J BIOL CHEM, V271, P28341, DOI 10.1074/jbc.271.45.28341; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P10583, DOI 10.1073/pnas.94.20.10583	54	93	95	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11075	11081		10.1074/jbc.275.15.11075	http://dx.doi.org/10.1074/jbc.275.15.11075			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753912	hybrid			2022-12-27	WOS:000086466600054
J	Johnson, LL; Pavlovsky, AG; Johnson, AR; Janowicz, JA; Man, CF; Ortwine, DF; Purchase, CF; White, AD; Hupe, DJ				Johnson, LL; Pavlovsky, AG; Johnson, AR; Janowicz, JA; Man, CF; Ortwine, DF; Purchase, CF; White, AD; Hupe, DJ			A rationalization of the acidic pH dependence for stromelysin-1 (matrix metalloproteinase-3) catalysis and inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; HUMAN MATRILYSIN; ZINC-PEPTIDASES; DOMAIN; THERMOLYSIN; OSTEOARTHRITIS; COLLAGENASES; DEGRADATION; SUPERFAMILY; TEMPERATURE	The pH dependence of matrix metalloproteinase (MMP) catalysis is described by a broad bell-shaped curve, indicating the involvement of two unspecified ionizable groups in proteolysis, Stromelysin-1 has a third pK(a) near 6, resulting in a uniquely sharp acidic catalytic optimum, which has recently been attributed to His(224). This suggests the presence of a critical, but unidentified, S1' substructure. Integrating biochemical characterizations of inhibitor-enzyme interactions with active site topography from corresponding crystal structures, we isolated contributions to the pH dependence of catalysis and inhibition of active site residues Glu(202) and His(224). The acidic pK(a) 5.6 is attributed to the Glu(202). zinc . H2O complex, consistent with a role for the invariant active site Glu as a general base in MMP catalysis, The His(224)-dependent substructure is identified as a tripeptide (Pro(221)-Leu(222)-Tyr(223)) that forms the substrate cleft lower wall. Substrate binding induces a beta-conformation in this sequence, which extends and anchors the larger beta-sheet of the enzyme . substrate complex and appears to be essential for productive substrate binding. Because the PXY tripeptide is strictly conserved among MMPs, this "beta-anchor" may represent a common motif required for macromolecular substrate hydrolysis. The striking acidic profile of stromelysin-1 defined by the combined ionization of Glu(202) and His(224) allows the design of highly selective inhibitors.	Parke Davis Pharmaceut Res, Dept Canc Res, Ann Arbor, MI 48105 USA; Parke Davis Pharmaceut Res, Dept Chem, Ann Arbor, MI 48105 USA; Parke Davis Pharmaceut Res, Dept Biochem, Ann Arbor, MI 48105 USA	Pfizer; Pfizer; Pfizer	Johnson, LL (corresponding author), Parke Davis Pharmaceut Res, Dept Canc Res, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.							Beckett RP, 1998, EXPERT OPIN THER PAT, V8, P259, DOI 10.1517/13543776.8.3.259; BLUNDELL TL, 1994, NAT STRUCT BIOL, V1, P73, DOI 10.1038/nsb0294-73; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; Borkakoti N, 1998, PROG BIOPHYS MOL BIO, V70, P73, DOI 10.1016/S0079-6107(98)00003-0; BROWNER MF, 1995, BIOCHEMISTRY-US, V34, P6602, DOI 10.1021/bi00020a004; BROWNER MF, 1994, PERSPECT DRUG DISCOV, V2, P343; CAPUTO CB, 1987, BIOCHEM PHARMACOL, V36, P995, DOI 10.1016/0006-2952(87)90405-9; Cawston TE, 1996, PHARMACOL THERAPEUT, V70, P163, DOI 10.1016/0163-7258(96)00015-0; Cha J, 1997, BIOCHEMISTRY-US, V36, P16019, DOI 10.1021/bi972223g; Cha JH, 1996, BIOCHEMISTRY-US, V35, P15831, DOI 10.1021/bi962085f; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COPELAND RA, 1995, BIOORG MED CHEM LETT, V17, P1947; Dhanaraj V, 1996, STRUCTURE, V4, P375, DOI 10.1016/S0969-2126(96)00043-3; DOLLERY CM, 1995, CIRC RES, V77, P863, DOI 10.1161/01.RES.77.5.863; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; Fersht A., 1985, ENZYME STRUCTURE MEC; Finzel BC, 1998, PROTEIN SCI, V7, P2118, DOI 10.1002/pro.5560071008; GomisRuth FX, 1996, J MOL BIOL, V264, P556, DOI 10.1006/jmbi.1996.0661; GUNJASMITH Z, 1993, AGENTS ACTIONS, V40, P228, DOI 10.1007/BF01984067; HARRISON RK, 1992, BIOCHEMISTRY-US, V31, P10757, DOI 10.1021/bi00159a016; Holman CM, 1999, BIOCHEMISTRY-US, V38, P677, DOI 10.1021/bi9822170; Johnson LL, 1998, CURR OPIN CHEM BIOL, V2, P466, DOI 10.1016/S1367-5931(98)80122-1; Johnson LL, 1999, J BIOL CHEM, V274, P24881, DOI 10.1074/jbc.274.35.24881; KUNUGI S, 1982, EUR J BIOCHEM, V124, P157, DOI 10.1111/j.1432-1033.1982.tb05919.x; MartinezZaguilan R, 1996, CLIN EXP METASTAS, V14, P176, DOI 10.1007/BF00121214; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; Mock WL, 1996, BIOCHEMISTRY-US, V35, P7369, DOI 10.1021/bi952827p; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; Murphy G, 1997, MATRIX BIOL, V15, P511, DOI 10.1016/S0945-053X(97)90025-1; Pavlovsky AG, 1999, PROTEIN SCI, V8, P1455, DOI 10.1110/ps.8.7.1455; PURCHASE CF, 1997, 214 ACS NAT M LAS VE; REINEMER P, 1994, FEBS LETT, V338, P227, DOI 10.1016/0014-5793(94)80370-6; Reynolds JJ, 1997, J ROY COLL SURG EDIN, V42, P154; Sang QXA, 1996, J PROTEIN CHEM, V15, P137, DOI 10.1007/BF01887395; STACK MS, 1990, ARCH BIOCHEM BIOPHYS, V281, P257, DOI 10.1016/0003-9861(90)90441-Z; STEIN RL, 1994, ARCH BIOCHEM BIOPHYS, V308, P274, DOI 10.1006/abbi.1994.1038; StetlerStevenson WG, 1996, AM J PATHOL, V148, P1345; STOCKER W, 1995, PROTEIN SCI, V4, P823; TANFORD C, 1962, ADV PROTEIN CHEM, V17, P69; WHITE AD, 1997, 214 ACS NAT M LAS VE; WILHELM SM, 1993, J BIOL CHEM, V268, P21906; WOESSNER JF, 1991, J RHEUMATOL, V18, P99; WOOLLEY P, 1975, NATURE, V258, P677, DOI 10.1038/258677a0; YE QZ, 1995, BIOCHEMISTRY-US, V34, P4702, DOI 10.1021/bi00014a026; YE QZ, 1992, BIOCHEMISTRY-US, V31, P11231, DOI 10.1021/bi00160a038; Yong VW, 1998, TRENDS NEUROSCI, V21, P75	46	72	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11026	11033		10.1074/jbc.275.15.11026	http://dx.doi.org/10.1074/jbc.275.15.11026			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753905	hybrid			2022-12-27	WOS:000086466600047
J	Jones, PC; Hermolin, J; Fillingame, RH				Jones, PC; Hermolin, J; Fillingame, RH			Mutations in single hairpin units of genetically fused subunit c provide support for a rotary catalytic mechanism in F0F1 ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1F0; COUPLING H+ TRANSPORT; POLAR LOOP REGION; EPSILON-SUBUNIT; CROSS-LINKING; PROTON TRANSLOCATION; GAMMA-SUBUNIT; MOLECULAR MACHINE; F-0 COMPLEX; ROTATION	Previously, we generated genetically fused dimers and trimers of subunit c of the Escherichia coli ATP synthase based upon the precedent of naturally occurring dimers in V-type H+-transporting ATPases, The c(2) and c, oligomers have proven useful in testing hypothesis regarding the mechanism of energy coupling. In the first part of this paper, the uncoupling Q42E substitution has been introduced into the second loop of the c(2) dimer or the third loop of the c(3) trimer, Both mutant proteins proved to be as functional as the wild type c(2) dimer or wild type c(3) trimer, The results argue against an obligatory movement of the epsilon subunit between loops of monomeric subunit c in the c(12), oligomer during rotary catalysis, Rather, the results support the hypothesis that the c-epsilon connection remains fixed as the c-oligomer rotates. In the second section of this paper, we report on the effect of substitution of the proton translocating Asp(61) in every second helical hairpin of the c(2) dimer, or in every third hairpin of the c(3) trimer, Based upon the precedent of V-type ATPases, where the c(2) dimer occurs naturally with a single proton translocating carboxyl in every second hairpin, these modified versions of the E, coli c(2) and c(3) fused proteins were predicted to have a functional H+-transporting ATPase activity, with a reduced H+/ATP stoichiometry, but to be inactive as ATP synthases, A variety of Asp(61)-substituted proteins proved to lack either activity indicating that the switch in function in V-type ATPases is a consequence of more than a single substitution.	Univ Wisconsin, Sch Med, Dept Biomol Chem, Madison, WI 53706 USA; MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England	University of Wisconsin System; University of Wisconsin Madison; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Fillingame, RH (corresponding author), Univ Wisconsin, Sch Med, Dept Biomol Chem, 587 Med Sci Bldg, Madison, WI 53706 USA.				NIGMS NIH HHS [GM23105] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023105, R37GM023105] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aggeler R, 1997, J BIOL CHEM, V272, P19621, DOI 10.1074/jbc.272.31.19621; BIRKENHAGER R, 1995, EUR J BIOCHEM, V230, P58, DOI 10.1111/j.1432-1033.1995.tb20534.x; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Bulygin VV, 1998, J BIOL CHEM, V273, P31765, DOI 10.1074/jbc.273.48.31765; CROSS RL, 1990, FEBS LETT, V259, P227, DOI 10.1016/0014-5793(90)80014-A; DMITRIEV OY, 1995, EUR J BIOCHEM, V233, P478, DOI 10.1111/j.1432-1033.1995.478_2.x; Dmitriev OY, 1999, P NATL ACAD SCI USA, V96, P7785, DOI 10.1073/pnas.96.14.7785; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DUNN SD, 1990, BIOCHEMISTRY-US, V29, P4335, DOI 10.1021/bi00470a011; DUNN SD, 1982, J BIOL CHEM, V257, P7354; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; Engelbrecht S, 1997, FEBS LETT, V414, P485, DOI 10.1016/S0014-5793(97)00997-6; FILLINGAME RH, 1984, J BACTERIOL, V158, P1078, DOI 10.1128/JB.158.3.1078-1083.1984; Fillingame RH, 1997, J EXP BIOL, V200, P217; Fillingame RH, 1998, BBA-BIOENERGETICS, V1365, P135, DOI 10.1016/S0005-2728(98)00053-X; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; FRAGA D, 1989, J BIOL CHEM, V264, P6797; GIRVIN ME, 1989, BIOCHEMISTRY-US, V28, P4340, DOI 10.1021/bi00436a032; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; HERMOLIN J, 1989, J BIOL CHEM, V264, P3896; Hermolin J, 1999, J BIOL CHEM, V274, P17011, DOI 10.1074/jbc.274.24.17011; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; Jones PC, 1995, BIOCHEM J, V312, P739, DOI 10.1042/bj3120739; Jones PC, 1998, J BIOL CHEM, V273, P29701, DOI 10.1074/jbc.273.45.29701; Jones PC, 1998, J BIOL CHEM, V273, P17178, DOI 10.1074/jbc.273.27.17178; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; Ketchum CJ, 1998, J BIOL CHEM, V273, P22292, DOI 10.1074/jbc.273.35.22292; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MOSHER ME, 1985, J BIOL CHEM, V260, P4807; MOSHER ME, 1983, J BACTERIOL, V156, P1078, DOI 10.1128/JB.156.3.1078-1092.1983; Nakamoto RK, 1999, ANNU REV BIOPH BIOM, V28, P205, DOI 10.1146/annurev.biophys.28.1.205; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schulenberg B, 1999, J BIOL CHEM, V274, P34233, DOI 10.1074/jbc.274.48.34233; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; Singh S, 1996, FEBS LETT, V397, P30, DOI 10.1016/S0014-5793(96)01127-1; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Takeyasu K, 1996, FEBS LETT, V392, P110, DOI 10.1016/0014-5793(96)00796-X; Tang CL, 1996, J BIOL CHEM, V271, P3018, DOI 10.1074/jbc.271.6.3018; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Valiyaveetil FI, 1997, J BIOL CHEM, V272, P32635, DOI 10.1074/jbc.272.51.32635; VIK SB, 1994, J BIOL CHEM, V269, P30364; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; Watts SD, 1997, J BIOL CHEM, V272, P15065, DOI 10.1074/jbc.272.24.15065; Watts SD, 1996, J BIOL CHEM, V271, P28341, DOI 10.1074/jbc.271.45.28341; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609; ZHANG Y, 1994, J BIOL CHEM, V269, P10221	52	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11355	11360		10.1074/jbc.275.15.11355	http://dx.doi.org/10.1074/jbc.275.15.11355			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753949	hybrid			2022-12-27	WOS:000086466600091
J	Law, BK; Norgaard, P; Moses, HL				Law, BK; Norgaard, P; Moses, HL			Farnesyltransferase inhibitor induces rapid growth arrest and blocks p70s6k activation by multiple stimuli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; S6 KINASE; TRANSGENIC MICE; P70(S6K) PHOSPHORYLATION; RAF COMPLEXES; N-RAS; FARNESYL; CELLS; TRANSLATION; REQUIREMENT	We have previously shown that the peptidomimetic farnesyltransferase inhibitor L-744,832 (FTI) inhibits p70s6k activation and cell growth in a mouse keratinocyte cell line but only at concentrations of FTI significantly higher than those required for the inhibition of Ras farnesylation, Here we show that the rapid kinetics of FTI inhibition of DNA synthesis (within 1.5 h) in both normal and v-K-Ras transformed keratinocytes matches the rapid kinetics of p70s6k inhibition observed previously. It is further shown that FTI inhibits p70s6k activation in response to serum, phorbol myristate acetate, and increased amino acid levels. The phosphatase inhibitor calyculin A partially reverses the FTI-induced dephosphorylation of p70s6k, suggesting that FTI may act upstream of a protein phosphatase. A rapamycin-resistant mutant of p70s6k is shown to be resistant to FTI-induced dephosphorylation of the major rapamycin-sensitive phosphorylation site of p70s6k, Thr(389). Together, these data demonstrate that FTI rapidly inhibits DNA synthesis irrespective of the presence of v-K-Ras and that FTI inhibits p70s6k activation in response to multiple stimuli. Because the FTI L-744,832 mimics many of the effects of rapamycin, this FTI may prove effective against tumors that exhibit inappropriate activation of the mTOR/p70s6k pathway.	Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Cell Biol, Nashville, TN 37232 USA; Glostrup Univ Hosp, Inst Pathol Anat, DK-2600 Glostrup, Denmark	Vanderbilt University; Vanderbilt University; University of Copenhagen	Moses, HL (corresponding author), Vanderbilt Ingram Canc Ctr, 649 Med Res Bldg 2, Nashville, TN 37232 USA.		Law, Brian/L-6043-2019		NATIONAL CANCER INSTITUTE [R35CA042572] Funding Source: NIH RePORTER; NCI NIH HHS [CA-42572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akimoto K, 1998, BIOCHEM J, V335, P417, DOI 10.1042/bj3350417; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Barinaga M, 1997, SCIENCE, V278, P1036, DOI 10.1126/science.278.5340.1036; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; Chiloeches A, 1999, J BIOL CHEM, V274, P19762, DOI 10.1074/jbc.274.28.19762; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Conus NM, 1998, J BIOL CHEM, V273, P4776, DOI 10.1074/jbc.273.8.4776; Cruz MC, 1999, MOL CELL BIOL, V19, P4101; DEGROOT RP, 1995, ONCOGENE, V10, P543; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Du W, 1999, MOL CELL BIOL, V19, P1831; Grewe M, 1999, CANCER RES, V59, P3581; Hall-Jackson CA, 1999, ONCOGENE, V18, P2047, DOI 10.1038/sj.onc.1202603; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Iiboshi Y, 1999, J BIOL CHEM, V274, P1092, DOI 10.1074/jbc.274.2.1092; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Law BK, 1999, J BIOL CHEM, V274, P4743, DOI 10.1074/jbc.274.8.4743; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; Louro ID, 1999, CELL GROWTH DIFFER, V10, P503; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Mahalingam M, 1996, MOL CELL BIOL, V16, P405; Mangues R, 1998, CANCER RES, V58, P1253; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; McIlroy J, 1997, MOL CELL BIOL, V17, P248, DOI 10.1128/MCB.17.1.248; Norgaard P, 1999, CLIN CANCER RES, V5, P35; Oliff A, 1999, BBA-REV CANCER, V1423, pC19, DOI 10.1016/S0304-419X(99)00007-4; Parrott LA, 1999, J BIOL CHEM, V274, P24731, DOI 10.1074/jbc.274.35.24731; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; Seufferlein T, 1996, CANCER RES, V56, P3895; Singh RP, 1999, J BIOL CHEM, V274, P19593, DOI 10.1074/jbc.274.28.19593; SOZERI O, 1992, ONCOGENE, V7, P2259; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Vilella-Bach M, 1999, J BIOL CHEM, V274, P4266, DOI 10.1074/jbc.274.7.4266; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; WENG QP, 1995, MOL CELL BIOL, V15, P2333; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Xu G, 1998, J BIOL CHEM, V273, P28178, DOI 10.1074/jbc.273.43.28178	49	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10796	10801		10.1074/jbc.275.15.10796	http://dx.doi.org/10.1074/jbc.275.15.10796			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753872	hybrid			2022-12-27	WOS:000086466600014
J	Maddox, BK; Mokashi, A; Keene, DR; Bachinger, HP				Maddox, BK; Mokashi, A; Keene, DR; Bachinger, HP			A cartilage oligomeric matrix protein mutation associated with pseudoachondroplasia changes the structural and functional properties of the type 3 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM; PLATELET THROMBOSPONDIN; MULTIPLE EPIPHYSEAL; CALCIUM; BINDING; COMP; COLLAGEN; RESIDUES; EGF; FIBRILLIN-1	Cartilage oligomeric matrix protein (COMP) is a member of the thrombospondin family of extracellular matrix glycoproteins. All members of the family contain a highly conserved region of thrombospondin type 3 sequence repeats that bind calcium. A mutation in COMP previously identified in a patient with pseudoachondroplasia resulted in abnormal sequestration of COMP in distinctive rER vesicles. The mutation, Asp-446 --> Asn, is located in the type 3 repeats of the molecule. This region was expressed in a mammalian culture with and without the mutation to study the structural or functional properties associated with the mutation. The biophysical parameters of the mutant peptide were compared with those of the wild type and revealed the following difference: secondary structural analysis by circular dichroism showed more alpha-helix content in the wild-type peptides. The calcium binding properties of the two peptides were significantly different; there were 17 calcium ions bound/wild-type COMP3 peptide compared with 8/mutant peptide. In addition, wild-type COMP3 had a higher affinity for calcium and bound calcium more cooperatively. Calcium bound by the wild-type peptide was reflected in a structural change as indicted by velocity sedimentation, Thus, the effect of the COMP mutation appears to profoundly alter the calcium binding properties and may account for the difference observed in the structure of the type 3 domain. Furthermore, the highly cooperative binding of calcium to COMP3 suggests that these type 3 sequence repeats form a single protein domain, the thrombospondin type 3 domain.	Shriners Hosp Crippled Childrens, Res Dept, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Oral & Mol Biol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Bachinger, HP (corresponding author), Shriners Hosp Crippled Childrens, Res Dept, Portland, OR 97201 USA.	hpb@shcc.org			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045582] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR45582] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARON M, 1992, PROTEIN SCI, V1, P81; BORNSTEIN P, 1994, METHOD ENZYMOL, V245, P62; Cohn DH, 1996, ANN NY ACAD SCI, V785, P188, DOI 10.1111/j.1749-6632.1996.tb56258.x; COMPTON LA, 1987, J BIOL CHEM, V262, P13039; COMPTON LA, 1986, ANAL BIOCHEM, V155, P155, DOI 10.1016/0003-2697(86)90241-1; Deere M, 1999, AM J MED GENET, V85, P486, DOI 10.1002/(SICI)1096-8628(19990827)85:5<486::AID-AJMG10>3.0.CO;2-O; Deere M, 1998, AM J MED GENET, V80, P510, DOI 10.1002/(SICI)1096-8628(19981228)80:5<510::AID-AJMG14>3.0.CO;2-F; DICESARE P, 1994, FEBS LETT, V354, P237, DOI 10.1016/0014-5793(94)01134-6; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; FESSLER LI, 1974, J BIOL CHEM, V249, P7637; FIFE RS, 1984, BIOCHIM BIOPHYS ACTA, V802, P506, DOI 10.1016/0304-4165(84)90370-2; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HEDBOM E, 1992, J BIOL CHEM, V267, P6132; Ikegawa S, 1998, HUM GENET, V103, P633, DOI 10.1007/s004390050883; LAWLER J, 1985, J BIOL CHEM, V260, P3762; LAWLER J, 1995, J BIOL CHEM, V270, P2809, DOI 10.1074/jbc.270.6.2809; LAWLER J, 1982, J BIOL CHEM, V257, P2257; LAWLER J, 1983, J BIOL CHEM, V258, P2098; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; Loughlin J, 1998, HUM MUTAT, pS10; Maddox BK, 1997, J BIOL CHEM, V272, P30993, DOI 10.1074/jbc.272.49.30993; Malashkevich VN, 1996, SCIENCE, V274, P761, DOI 10.1126/science.274.5288.761; MAYER U, 1995, FEBS LETT, V365, P129, DOI 10.1016/0014-5793(95)00438-F; MISENHEIMER TM, 1995, J BIOL CHEM, V270, P1729, DOI 10.1074/jbc.270.4.1729; MORGELIN M, 1992, J BIOL CHEM, V267, P6137; Muragaki Y, 1996, NAT GENET, V12, P103, DOI 10.1038/ng0196-103; OLDBERG A, 1992, J BIOL CHEM, V267, P22346; Paassilta P, 1999, AM J HUM GENET, V64, P1036, DOI 10.1086/302328; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; QABAR A, 1995, J BIOL CHEM, V270, P12725, DOI 10.1074/jbc.270.21.12725; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; Reinhardt DP, 1997, J BIOL CHEM, V272, P1231, DOI 10.1074/jbc.272.2.1231; Reinhardt DP, 1997, J BIOL CHEM, V272, P7368, DOI 10.1074/jbc.272.11.7368; Rosenberg K, 1998, J BIOL CHEM, V273, P20397, DOI 10.1074/jbc.273.32.20397; STANESCU V, 1984, J BONE JOINT SURG AM, V66A, P817, DOI 10.2106/00004623-198466060-00002; STANESCU V, 1982, EUR J PEDIATR, V138, P221, DOI 10.1007/BF00441206; TUCKER RP, 1995, DEV DYNAM, V203, P477, DOI 10.1002/aja.1002030410; VERTEL BM, 1989, J CELL BIOL, V109, P1827, DOI 10.1083/jcb.109.4.1827; Zeng BF, 1998, BIOCHEM J, V330, P109, DOI 10.1042/bj3300109	39	58	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11412	11417		10.1074/jbc.275.15.11412	http://dx.doi.org/10.1074/jbc.275.15.11412			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753957	hybrid			2022-12-27	WOS:000086466600099
J	Tani, M; Okino, N; Mori, K; Tanigawa, T; Izu, H; Ito, M				Tani, M; Okino, N; Mori, K; Tanigawa, T; Izu, H; Ito, M			Molecular cloning of the full-length cDNA encoding mouse neutral ceramidase - A novel but highly conserved gene family of neutral/alkaline ceramidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ACID CERAMIDASE; TUMOR-NECROSIS-FACTOR; SPHINGOSINE; PROTEIN; SPHINGOSINE-1-PHOSPHATE; PROLIFERATION; PURIFICATION; METABOLISM; KINASE; ROLES	We report here the molecular cloning, sequencing, and expression of the gene encoding the mouse neutral ceramidase, which has been proposed to function in sphingolipid signaling. A full-length cDNA encoding the neutral ceramidase was cloned from a cDNA library of mouse liver using the partial amino acid sequences of the purified mouse liver ceramidase, The open reading frame of 2,268 nucleotides encoded a polypeptide of 756 amino acids having nine putative N-glycosylation sites. Northern blot analysis revealed that the mRNA of the ceramidase was expressed widely in mouse tissues, with especially strong signals found in the liver and kidney, The ceramidase activity of lysates of CHOP cells increased more than 900-fold when the cells were transformed with a plasmid containing the cDNA encoding ceramidase, We also cloned the ceramidase homologue from the cDNA library of mouse brain and found that the sequence of the open reading frame, but not the 5'-noncoding region, was identical to that of the liver. Interestingly, phylogenetic analysis of various ceramidases clearly indicated that neutral/alkaline ceramidases form a novel but highly conserved gene family that is evolutionarily different from lysosomal acid ceramidases.	Kyushu Univ, Grad Sch, Div Bioresource & Bioenvironm Sci, Dept Biosci & Biotechnol,Higashi Ku, Fukuoka 8128581, Japan; Takara Shuzo Co Ltd, Biotechnol Res Labs, Shiga 5202134, Japan	Kyushu University; Takara Holdings Inc.	Ito, M (corresponding author), Kyushu Univ, Grad Sch, Div Bioresource & Bioenvironm Sci, Dept Biosci & Biotechnol,Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.		Okino, Nozomu/AAY-2635-2021; Ito, Makoto/Q-6164-2019; Tanigawa, Tetsuya/J-6131-2019	Tanigawa, Tetsuya/0000-0002-9305-1637; Tani, Motohiro/0000-0003-4316-8260; ito, Makoto/0000-0003-3159-7818				BERNARDO K, 1995, J BIOL CHEM, V270, P11098, DOI 10.1074/jbc.270.19.11098; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; CHEN WW, 1981, ARCH BIOCHEM BIOPHYS, V208, P444, DOI 10.1016/0003-9861(81)90531-2; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; CURVILLER O, 1996, NATURE, V381, P800; El Bawab S, 1999, J BIOL CHEM, V274, P27948, DOI 10.1074/jbc.274.39.27948; GATT S, 1963, J BIOL CHEM, V238, P3131; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HASSLER DF, 1993, ADV LIPID RES, V26, P49; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Igarashi Y, 1997, J BIOCHEM-TOKYO, V122, P1080; JEFFERSON AB, 1988, J BIOL CHEM, V263, P15241; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Li CM, 1998, GENOMICS, V50, P267, DOI 10.1006/geno.1998.5334; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; Mitsutake S, 1997, ANAL BIOCHEM, V247, P52, DOI 10.1006/abio.1997.2022; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Ohnishi Y, 1999, CLIN DIAGN LAB IMMUN, V6, P101, DOI 10.1128/CDLI.6.1.101-104.1999; OHTA H, 1994, FEBS LETT, V355, P267, DOI 10.1016/0014-5793(94)01218-0; Okino N, 1998, J BIOL CHEM, V273, P14368, DOI 10.1074/jbc.273.23.14368; Okino N, 1999, J BIOL CHEM, V274, P36616, DOI 10.1074/jbc.274.51.36616; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Sambrook H., 1989, MOL CLONING LAB MANU; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Tani M, 1999, J BIOCHEM-TOKYO, V125, P746; Tani M, 2000, J BIOL CHEM, V275, P3462, DOI 10.1074/jbc.275.5.3462; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	35	89	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11229	11234		10.1074/jbc.275.15.11229	http://dx.doi.org/10.1074/jbc.275.15.11229			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753931	hybrid			2022-12-27	WOS:000086466600073
J	Strack, S; McNeill, RB; Colbran, RJ				Strack, S; McNeill, RB; Colbran, RJ			Mechanism and regulation of calcium/calmodulin-dependent protein kinase II targeting to the NR2B subunit of the N-methyl-D-aspartate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; POSTSYNAPTIC DENSITY; GLUTAMATE RECEPTORS; MUTATIONAL ANALYSIS; NMDA RECEPTOR; ALPHA; AUTOPHOSPHORYLATION; PHOSPHORYLATION; TRANSLOCATION; IDENTIFICATION	Calcium influx through the N-methyl-D-aspartate (NMDA)-type glutamate receptor and activation of calcium/calmodulin-dependent kinase II (CaMKII) are critical events in certain forms of synaptic plasticity. We have previously shown that autophosphorylation of CaMKII induces high-affinity binding to the NR2B subunit of the NMDA receptor (Strack, S,, and Colbran, R, J, (1998) J, Biol, Chem. 273, 20689-20692), Here, we show that residues 1290-1309 in the cytosolic tail of NR2B are critical for CaMKII binding and identify by site directed mutagenesis several key residues (Lys(1292), Leu(1298), Arg(1299), Arg(1300), Gln(1301), and Ser(1303)). Phosphorylation of NR2B at Ser1303 by CaMKII inhibits binding and promotes slow dissociation of preformed CaMKII NR2B complexes, Peptide competition studies imply a role for the CaMKII catalytic domain, but not the substrate-binding pocket, in the association with NR2B. However, analysis of monomeric CaMKII mutants indicates that the holoenzyme structure may also be important for stable association with NR2B, Residues 1260-1316 of NR2B are sufficient to direct the subcellular localization of CaMKII in intact cells and to confer dynamic regulation by calcium influx, Furthermore, mutation of residues in the CaMKII-binding domain in full-length NR2B bidirectionally modulates colocalization with CaMKII after NMDA receptor activation, suggesting a dynamic model for the translocation of CaMKII to postsynaptic targets.	Vanderbilt Univ, Med Ctr, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Ctr Mol Neurosci, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Colbran, RJ (corresponding author), Vanderbilt Univ, Med Ctr, Dept Physiol & Mol Biophys, Rm 762,MRB-I,23rd Ave S & Pierce Ave, Nashville, TN 37232 USA.		Colbran, Roger/AAU-7708-2021	Colbran, Roger/0000-0001-7401-8244; Strack, Stefan/0000-0002-6175-7280	NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037508] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline; NINDS NIH HHS [NS37508] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Cho YH, 1998, SCIENCE, V279, P867, DOI 10.1126/science.279.5352.867; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Derkach V, 1999, P NATL ACAD SCI USA, V96, P3269, DOI 10.1073/pnas.96.6.3269; ERONDU NE, 1985, J NEUROSCI, V5, P3270; FONG YL, 1989, J BIOL CHEM, V264, P16759; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; FUKUNAGA K, 1995, J BIOL CHEM, V270, P6119, DOI 10.1074/jbc.270.11.6119; Gardoni F, 1999, FEBS LETT, V456, P394, DOI 10.1016/S0014-5793(99)00985-0; Gardoni F, 1998, J NEUROCHEM, V71, P1733; GELB BD, 1992, P NATL ACAD SCI USA, V89, P202, DOI 10.1073/pnas.89.1.202; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; HU BR, 1995, J NEUROCHEM, V64, P1361; ISHIDA A, 1995, J BIOL CHEM, V270, P2163, DOI 10.1074/jbc.270.5.2163; Kolb SJ, 1998, J BIOL CHEM, V273, P31555, DOI 10.1074/jbc.273.47.31555; Leonard AS, 1999, P NATL ACAD SCI USA, V96, P3239, DOI 10.1073/pnas.96.6.3239; LISMAN JE, 1988, P NATL ACAD SCI USA, V85, P5320, DOI 10.1073/pnas.85.14.5320; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; MCNEILL RB, 1995, J BIOL CHEM, V270, P10043, DOI 10.1074/jbc.270.17.10043; MUKHERJI S, 1994, J BIOL CHEM, V269, P13744; MUKHERJI S, 1995, J BIOL CHEM, V270, P14062, DOI 10.1074/jbc.270.23.14062; Omkumar RV, 1996, J BIOL CHEM, V271, P31670, DOI 10.1074/jbc.271.49.31670; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; Shen K, 1998, J NEUROCHEM, V70, P96; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Strack S, 1999, J COMP NEUROL, V413, P373; Strack S, 1997, J BIOL CHEM, V272, P13467, DOI 10.1074/jbc.272.21.13467; Strack S, 1997, J NEUROCHEM, V68, P2119; Strack S, 1998, J BIOL CHEM, V273, P20689, DOI 10.1074/jbc.273.33.20689; SUZUKI T, 1994, J NEUROCHEM, V63, P1529, DOI 10.1046/j.1471-4159.1994.63041529.x; White RR, 1998, J BIOL CHEM, V273, P3166, DOI 10.1074/jbc.273.6.3166; Yang EY, 1999, J BIOL CHEM, V274, P26199, DOI 10.1074/jbc.274.37.26199	35	254	262	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23798	23806		10.1074/jbc.M001471200	http://dx.doi.org/10.1074/jbc.M001471200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10764765	hybrid			2022-12-27	WOS:000088564200055
J	Chatterjee-Kishore, M; van den Akker, F; Stark, GR				Chatterjee-Kishore, M; van den Akker, F; Stark, GR			Adenovirus E1A down-regulates LMP2 transcription by interfering with the binding of Stat1 to IRF1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONCOGENIC ADENOVIRUS-12; SIGNAL TRANSDUCER; TRANSFORMED-CELLS; GENE-EXPRESSION; AD12 E1A; COMPLEX; PROMOTER; PROTEINS; DOMAINS; IDENTIFICATION	The LMP2 gene, which encodes a protein required for efficient presentation of viral antigens, requires both unphosphorylated Stat1 and IRF1 for basal expression. LMP2 expression is down-regulated by the adenovirus protein E1A, which binds to Stat1 and CBP/p300, and by the mutant E1A protein RG2, which binds to Stat1 but not to CBP/p300, but not by the mutant protein Delta 2-36, which does not bind to either Stat1 or CBP/p300, Stat1 and IRF1 associate in untreated cells and bind as a complex to the overlapping ICS-2/GAS element of the LMP2 promoter. E1A interferes with the formation of this complex by occupying domains of Stat1 that bind to IRF1. These results reveal how adenovirus infection attenuates LMP2 expression, thereby interfering with the presentation of viral antigens.	Cleveland Clin Fdn, Lerner Res Inst, Dept Biol Mol, Cleveland, OH 44145 USA	Cleveland Clinic Foundation	Stark, GR (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Biol Mol, 9500 Euclid Ave, Cleveland, OH 44145 USA.				NIGMS NIH HHS [F32 GM019665-02, F32 GM019665] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019665] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BECK S, 1992, J MOL BIOL, V228, P433, DOI 10.1016/0022-2836(92)90832-5; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Brockmann D, 1996, ONCOGENE, V12, P1715; Chatterjee-Kishore M, 1998, J BIOL CHEM, V273, P16177, DOI 10.1074/jbc.273.26.16177; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; HARROCH S, 1995, NUCLEIC ACIDS RES, V23, P3539, DOI 10.1093/nar/23.17.3539; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Horvath CM, 1996, MOL CELL BIOL, V16, P6957; Huvent I, 1997, CANCER DETECT PREV, V21, P12; KALVAKOLANU DVR, 1991, P NATL ACAD SCI USA, V88, P7459, DOI 10.1073/pnas.88.17.7459; Kirchhoff S, 1998, BIOCHIMIE, V80, P659, DOI 10.1016/S0300-9084(99)80019-4; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Kushner DB, 1996, ONCOGENE, V12, P143; Lin RT, 1999, MOL CELL BIOCHEM, V191, P169, DOI 10.1023/A:1006850009017; Look DC, 1998, IMMUNITY, V9, P871, DOI 10.1016/S1074-7613(00)80652-4; MeyTal SV, 1997, J BIOL CHEM, V272, P353, DOI 10.1074/jbc.272.1.353; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; Proffitt JA, 1997, FEBS LETT, V400, P141, DOI 10.1016/S0014-5793(96)01375-0; PROFFITT JL, 1994, NUCLEIC ACIDS RES, V22, P4779, DOI 10.1093/nar/22.22.4779; REIS LFL, 1994, EMBO J, V13, P4798, DOI 10.1002/j.1460-2075.1994.tb06805.x; RotemYehudar R, 1996, J EXP MED, V183, P499, DOI 10.1084/jem.183.2.499; Schaper F, 1998, BIOCHEM J, V335, P147, DOI 10.1042/bj3350147; Strehlow I, 1998, J BIOL CHEM, V273, P28049, DOI 10.1074/jbc.273.43.28049; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; White LC, 1996, IMMUNITY, V5, P365, DOI 10.1016/S1074-7613(00)80262-9; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	28	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20406	20411		10.1074/jbc.M001861200	http://dx.doi.org/10.1074/jbc.M001861200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10764778	hybrid			2022-12-27	WOS:000088084500027
J	Kishida, K; Kuriyama, H; Funahashi, T; Shimomura, I; Kihara, S; Ouchi, N; Nishida, M; Nishizawa, H; Matsuda, M; Takahashi, M; Hotta, K; Nakamura, T; Yamashita, S; Tochino, Y; Matsuzawa, Y				Kishida, K; Kuriyama, H; Funahashi, T; Shimomura, I; Kihara, S; Ouchi, N; Nishida, M; Nishizawa, H; Matsuda, M; Takahashi, M; Hotta, K; Nakamura, T; Yamashita, S; Tochino, Y; Matsuzawa, Y			Aquaporin adipose, a putative glycerol channel in adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; DEPENDENT DIABETES-MELLITUS; KIDNEY COLLECTING DUCT; FATTY-ACID TRANSPORT; CD WATER CHANNELS; MOLECULAR-CLONING; RAT-KIDNEY; FUNCTIONAL EXPRESSION; GLUCOSE TRANSPORTER; PROTEIN-KINASE	Adipose tissue is a major site of glycerol production in response to energy balance, However, molecular basis of glycerol release from adipocytes has not yet been elucidated. We recently cloned a novel member of the aquaporin family, aquaporin adipose (AQPap), which has glycerol permeability, The current study was designed to examine the hypothesis that AQPap serves as a glycerol channel in adipocytes. Adipose tissue expressed AQPap mRNA in high abundance, but not the mRNAs for the other aquaglyceroporins, AQP3 and AQP9, indicating that AQPap is the only known aquaglyceroporin expressed in adipose tissue. Glycerol release from 3T3-L1 cells was increased during differentiation in parallel with AQPap mRNA levels and suppressed by mercury ion, which inhibits the function of AQPs, supporting AQPap functions as a glycerol channel in adipocytes. Fasting increased and refeeding suppressed adipose AQPap mRNA levels in accordance with plasma glycerol levels and oppositely to plasma insulin levels in mice. Insulin dose-dependently suppressed AQPap mRNA expression in 3T3-L1 cells. AQPap mRNA levels and adipose glycerol concentrations measured by the microdialysis technique were increased in obese mice with insulin resistance. Accordingly, negative regulation of AQPap expression by insulin was impaired in the insulin-resistant state. Exposure of epinephrine translocated AQPap protein from perinuclear cytoplasm to the plasma membrane in 3T3-L1 adipocytes, These results strongly suggest that AQPap plays an important role in glycerol release from adipocytes.	Osaka Univ, Grad Sch Med, Dept Internal Med & Mol Sci, Suita, Osaka 5650871, Japan	Osaka University	Funahashi, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Internal Med & Mol Sci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		OUCHI, Noriyuki/I-7306-2014	Hotta, Kikuko/0000-0003-2427-6354; Nisihida, Makoto/0000-0002-0309-7106				Anthonsen MW, 1998, J BIOL CHEM, V273, P215, DOI 10.1074/jbc.273.1.215; ARNER P, 1988, AM J PHYSIOL, V255, pE737, DOI 10.1152/ajpendo.1988.255.5.E737; ARNER P, 1991, J INTERN MED, V230, P381, DOI 10.1111/j.1365-2796.1991.tb00461.x; BABA H, 1995, NUTRITION, V11, P149; Bergman Richard N., 1998, Journal of Basic and Clinical Physiology and Pharmacology, V9, P205; Botion LM, 1999, DIABETES, V48, P1691, DOI 10.2337/diabetes.48.9.1691; CHERNICK SS, 1986, J LIPID RES, V27, P286; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; ECHEVARRIA M, 1994, P NATL ACAD SCI USA, V91, P10997, DOI 10.1073/pnas.91.23.10997; Froger A, 1998, PROTEIN SCI, V7, P1458, DOI 10.1002/pro.5560070623; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; HONNOR RC, 1985, J BIOL CHEM, V260, P5130; Ibrahimi A, 1996, P NATL ACAD SCI USA, V93, P2646, DOI 10.1073/pnas.93.7.2646; Ishibashi K, 1997, J BIOL CHEM, V272, P20782, DOI 10.1074/jbc.272.33.20782; Ishibashi K, 1997, BIOCHEM BIOPH RES CO, V237, P714, DOI 10.1006/bbrc.1997.7219; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; JANSSON PA, 1992, J CLIN INVEST, V89, P1610, DOI 10.1172/JCI115756; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; Kihara S, 1998, ATHEROSCLEROSIS, V136, P163, DOI 10.1016/S0021-9150(97)00207-4; KLEIN S, 1990, AM J PHYSIOL, V258, pE32, DOI 10.1152/ajpendo.1990.258.1.E32; KNEPPER MA, 1994, P NATL ACAD SCI USA, V91, P6255, DOI 10.1073/pnas.91.14.6255; Koyama Y, 1997, J BIOL CHEM, V272, P30329, DOI 10.1074/jbc.272.48.30329; Kuriyama H, 1997, BIOCHEM BIOPH RES CO, V241, P53, DOI 10.1006/bbrc.1997.7769; KUWAHARA M, 1995, J BIOL CHEM, V270, P10384, DOI 10.1074/jbc.270.18.10384; MA TH, 1993, BIOCHEM BIOPH RES CO, V197, P654, DOI 10.1006/bbrc.1993.2529; Man MZ, 1996, MOL ENDOCRINOL, V10, P1021, DOI 10.1210/me.10.8.1021; Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; NURJHAN N, 1992, J CLIN INVEST, V89, P169, DOI 10.1172/JCI115558; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; OKA Y, 1992, GERONTOLOGY, V38, P3; OKA Y, 1988, J BIOL CHEM, V263, P13432; PRESTON GM, 1993, J BIOL CHEM, V268, P17; PUHAKAINEN I, 1992, J CLIN ENDOCR METAB, V75, P789, DOI 10.1210/jc.75.3.789; RAINA S, 1995, J BIOL CHEM, V270, P1908, DOI 10.1074/jbc.270.4.1908; Ramsay TG, 1996, ENDOCRIN METAB CLIN, V25, P847, DOI 10.1016/S0889-8529(05)70358-3; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; Shimomura I, 1996, NAT MED, V2, P800, DOI 10.1038/nm0796-800; SLAVIN BG, 1994, J LIPID RES, V35, P1535; STREMMEL W, 1985, P NATL ACAD SCI USA, V82, P4, DOI 10.1073/pnas.82.1.4; SZTALRYD C, 1994, AM J PHYSIOL, V266, pE179, DOI 10.1152/ajpendo.1994.266.2.E179; Tsukaguchi H, 1998, J BIOL CHEM, V273, P24737, DOI 10.1074/jbc.273.38.24737; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; WINARTASAPUTRA H, 1980, CLIN CHEM, V26, P613	47	173	194	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20896	20902		10.1074/jbc.M001119200	http://dx.doi.org/10.1074/jbc.M001119200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10777495	hybrid			2022-12-27	WOS:000088084500095
J	Baker, DM; Wang, SL; Bell, DJ; Drevon, CA; Davis, RA				Baker, DM; Wang, SL; Bell, DJ; Drevon, CA; Davis, RA			One or more labile proteins regulate the stability of chimeric mRNA containing the 3 '-untranslated region of cholesterol-7 alpha-hydroxylase mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL 7-ALPHA-HYDROXYLASE GENE; MESSENGER-RNA LEVELS; BILE-ACID BIOSYNTHESIS; AU-RICH ELEMENTS; TRANSCRIPTIONAL ACTIVITY; NUCLEAR RECEPTOR; C-FOS; POSTTRANSCRIPTIONAL REGULATION; RAT HEPATOCYTES; HEPATOMA-CELLS	Multiple AUUUA elements similar to those that regulate the degradation of several different mRNAs are conserved in the 3'-untranslated region (3'-UTR) of cholesterol-7 alpha-hydroxylase (CYP7A1) mRNAs from several species. We examined if stabilization of mRNA decay could account for the >20-fold increase in the expression of CYP7A1 mRNA without a detectable change in transcription following dexamethasone treatment of rat hepatoma cells (L35 cells). Following RNA polymerase II-dependent transcription block or protein synthesis block, the decay of CYP7A1 mRNA displayed a short half-life (similar to 30 min). Control experiments showed that in cells pre-treated with a RNA polymerase II inhibitor, dexamethasone had no detectable effect on CYP7A1 mRNA decay, Stable expression of luciferase reporter mRNAs in L35 cells showed that the CYP7A1 3'-UTR was required to observe a dexamethasone induction. To examine the hypothesis that a labile protein is required for dexamethasone-induced mRNA stabilization, cells were stably transfected with a tetracycline-repressible promoter that drives the expression of a green fluorescent protein analogue (ECFP) with or without the 3'-UTR of CYP7A1, Cells expressing ECFP with the 5'-UTR of CYP7A1 displayed a 3-fold dexamethasone induction of ECFP mRNA, whereas cells expressing ECFP without the 3'-UTR did not. Moreover, specific block of the transcription of ECFP containing the 3'-UTR by adding the tetracycline analogue doxycycline clearly displayed dexamethasone-induced stabilization of mRNA decay, These data provide compelling evidence that a putative labile protein and the 3'-UTR of CYP7A1 act together to decrease the rate of CYP7A1 mRNA degradation.	San Diego State Univ, Dept Biol, Mammalian Cell & Mol Biol Lab, San Diego, CA 92182 USA	California State University System; San Diego State University	Davis, RA (corresponding author), San Diego State Univ, Dept Biol, Mammalian Cell & Mol Biol Lab, 307 Life Sci Bldg,5500 Campanile Dr, San Diego, CA 92182 USA.		Drevon, Christian A/F-6012-2010		NHLBI NIH HHS [HL51648, HL57974] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057974, R01HL051648] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agellon LB, 1997, BIOCHEM J, V328, P393; Andreou ER, 1998, ARCH BIOCHEM BIOPHYS, V357, P137, DOI 10.1006/abbi.1998.0792; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; CHEN CYA, 1992, MOL CELL BIOL, V12, P5748, DOI 10.1128/MCB.12.12.5748; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRESTANI M, 1993, ARCH BIOCHEM BIOPHYS, V306, P451, DOI 10.1006/abbi.1993.1537; EDWARDS PA, 1996, N COMP BIOC, V31, P341; Feingold KR, 1996, J LIPID RES, V37, P223; Foti D, 1998, BIOCHEM BIOPH RES CO, V253, P109, DOI 10.1006/bbrc.1998.9759; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HERRICK DJ, 1994, MOL CELL BIOL, V14, P2119, DOI 10.1128/MCB.14.3.2119; HOEKMAN MFM, 1993, GENE, V130, P217, DOI 10.1016/0378-1119(93)90422-Y; HYLEMON PB, 1992, J BIOL CHEM, V267, P16866; JELINEK DF, 1990, BIOCHEMISTRY-US, V29, P7781, DOI 10.1021/bi00486a001; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; KAI MH, 1995, J LIPID RES, V36, P367; Kren BT, 1996, FASEB J, V10, P559, DOI 10.1096/fasebj.10.5.8621056; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; LEE YH, 1994, J BIOL CHEM, V269, P14681; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LEIGHTON JK, 1991, MOL CELL BIOL, V11, P2049, DOI 10.1128/MCB.11.4.2049; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Massimi M, 1998, HEPATOLOGY, V28, P1064, DOI 10.1002/hep.510280422; MYANT NB, 1977, J LIPID RES, V18, P135; Nitta M, 1999, P NATL ACAD SCI USA, V96, P6660, DOI 10.1073/pnas.96.12.6660; NOSHIRO M, 1990, FEBS LETT, V268, P137, DOI 10.1016/0014-5793(90)80992-R; NOSHIRO M, 1990, J BIOL CHEM, V265, P10036; PANDAK WM, 1991, J BIOL CHEM, V266, P3416; Pandak WM, 1996, AM J PHYSIOL-GASTR L, V270, pG401, DOI 10.1152/ajpgi.1996.270.3.G401; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEHGAL PB, 1976, CELL, V9, P473, DOI 10.1016/0092-8674(76)90092-1; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEFER S, 1992, J LIPID RES, V33, P1193; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SUNDSETH SS, 1990, J BIOL CHEM, V265, P15090; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; Trawick JD, 1997, J BIOL CHEM, V272, P3099, DOI 10.1074/jbc.272.5.3099; TRAWICK JD, 1996, J LIPID RES, V37, P24169; TWISK J, 1993, BIOCHEM J, V290, P685, DOI 10.1042/bj2900685; TWISK J, 1995, HEPATOLOGY, V21, P501, DOI 10.1016/0270-9139(95)90113-2; TWISK J, 1995, J CLIN INVEST, V95, P1235, DOI 10.1172/JCI117773; TZUNG KW, 1994, GENOMICS, V21, P244, DOI 10.1006/geno.1994.1250; VLAHCEVIC ZR, 1992, SEMIN LIVER DIS, V12, P403, DOI 10.1055/s-2008-1040410; WAXMAN DJ, 1992, J STEROID BIOCHEM, V43, P1055, DOI 10.1016/0960-0760(92)90333-E; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	49	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19985	19991		10.1074/jbc.M002351200	http://dx.doi.org/10.1074/jbc.M002351200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10764793	hybrid			2022-12-27	WOS:000087941300076
J	Li, PX; Wong, J; Ayed, A; Ngo, D; Brade, AM; Arrowsmith, C; Austin, RC; Klamut, HJ				Li, PX; Wong, J; Ayed, A; Ngo, D; Brade, AM; Arrowsmith, C; Austin, RC; Klamut, HJ			Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; BREAST-CANCER CELLS; GENE-EXPRESSION; SUPPRESSOR P53; MORPHOGENETIC PROTEIN; P53-INDUCIBLE GENE; ANTICANCER AGENTS; SMAD PROTEINS; CYTOCHROME-C; IN-VITRO	The p53 tumor suppressor gene and members of the transforming growth factor-beta (TGF-beta) superfamily play central roles in signaling cell cycle arrest and apoptosis (programmed cell death) in normal development and differentiation, as well as in carcinogenesis. Here we describe a distantly related member of the TGF-beta superfamily, designated placental TGF-beta (PTGF-beta), that is upregulated in response to both p53-dependent and -independent apoptotic signaling events arising from DNA damage in human breast cancer cells. PTGF-beta is normally expressed in placenta and at lower levels in kidney, lung, pancreas, and muscle but could not be detected in any tumor cell line studied. The PTGF-beta promoter is activated by p53 and contains two p53 binding site motifs, Functional studies demonstrated that one of these p53 binding sites is essential for p53-mediated PTGF-beta promoter induction and specifically binds recombinant p53 in gel mobility shift assays. PTGF-beta overexpression from a recombinant adenoviral vector (AdPTGF-beta) Led to an 80% reduction in MDA-MB-468 breast cancer cell viability and a 50-60% reduction in other human breast cancer cell lines studied, including MCF-7 cells, which are resistant to growth inhibition by recombinant wild-type p53. Like p53, PTGF-beta overexpression was seen to induce both G(1) cell cycle arrest and apoptosis in breast tumor cells. These results provide the first evidence for a direct functional link between p53 and the TGF-beta superfamily and implicate PTGF-beta as an important intercellular mediator of p53 function and the cytostatic effects of radiation and chemotherapeutic cancer agents.	Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Radiat Oncol, Toronto, ON M5G 2M9, Canada; Univ Hlth Network, Princess Margaret Hosp, Ontario Canc Inst, Div Expt Therapeut, Toronto, ON M5G 2M9, Canada; Univ Hlth Network, Princess Margaret Hosp, Ontario Canc Inst, Dept Biol Mol & Struct, Toronto, ON M5G 2M9, Canada; McMaster Univ, Hamilton, ON L8V 1C3, Canada; Hamilton Civ Hosp, Res Ctr, Hamilton, ON L8V 1C3, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; McMaster University; McMaster University	Klamut, HJ (corresponding author), Univ Toronto, Dept Med Biophys, Ontario Canc Inst, Princess Margaret Hosp, 610 Univ Ave,Rm 10-721, Toronto, ON M5G 2M9, Canada.			Arrowsmith, Cheryl/0000-0002-4971-3250; Wong, J. Tze-Fei/0000-0001-8539-8537				BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Brancolini C, 1997, J CELL BIOL, V139, P759, DOI 10.1083/jcb.139.3.759; Brown JM, 1999, CANCER RES, V59, P1391; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Chen HM, 1996, J CELL BIOCHEM, V61, P9, DOI 10.1002/(SICI)1097-4644(19960401)61:1<9::AID-JCB2>3.3.CO;2-2; Chiao PJ, 1999, ANN NY ACAD SCI, V880, P31, DOI 10.1111/j.1749-6632.1999.tb09507.x; Choi KS, 1998, HEPATOLOGY, V27, P415, DOI 10.1002/hep.510270215; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; deWinter JP, 1997, ONCOGENE, V14, P1891, DOI 10.1038/sj.onc.1201017; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Frank DK, 1998, CLIN CANCER RES, V4, P2521; Frenkel J, 1999, ONCOGENE, V18, P2901, DOI 10.1038/sj.onc.1202518; FRUMKIN A, 1994, DEVELOPMENT, V120, P253; Fuchs EJ, 1997, CANCER RES, V57, P2550; HAHM KM, 1994, MOL CELL BIOL, V14, P7111, DOI 10.1128/MCB.14.11.7111; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hishikawa K, 1999, J BIOL CHEM, V274, P37461, DOI 10.1074/jbc.274.52.37461; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hoodless PA, 1998, CURR TOP MICROBIOL, V228, P235; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; Hromas R, 1997, BBA-GENE STRUCT EXPR, V1354, P40, DOI 10.1016/S0167-4781(97)00122-X; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; Katayose D, 1995, CLIN CANCER RES, V1, P889; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lawton LN, 1997, GENE, V203, P17, DOI 10.1016/S0378-1119(97)00485-X; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li PX, 1998, BREAST CANCER RES TR, V48, P273, DOI 10.1023/A:1005961705860; Li PX, 1999, CANCER GENE THER, V6, P179, DOI 10.1038/sj.cgt.7700005; LIANG P, 1995, METHOD ENZYMOL, V254, P304; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Massague J, 1996, CANCER SURV, V27, P41; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MILNER J, 1995, NAT MED, V1, P879, DOI 10.1038/nm0995-879; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Nishizaki M, 1999, CLIN CANCER RES, V5, P1015; Outinen PA, 1998, BIOCHEM J, V332, P213, DOI 10.1042/bj3320213; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Paralkar VM, 1998, J BIOL CHEM, V273, P13760, DOI 10.1074/jbc.273.22.13760; Peled A, 1996, CANCER RES, V56, P2148; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rizk NP, 1999, CANCER GENE THER, V6, P291, DOI 10.1038/sj.cgt.7700059; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Sassone-Corsi P, 1998, INT J BIOCHEM CELL B, V30, P27, DOI 10.1016/S1357-2725(97)00093-9; Schutte M, 1996, CANCER RES, V56, P2527; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; TOWATARI M, 1995, J BIOL CHEM, V270, P4101, DOI 10.1074/jbc.270.8.4101; Utrera R, 1998, EMBO J, V17, P5015, DOI 10.1093/emboj/17.17.5015; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WEICHSELBAUM RR, 1992, SEMIN ONCOL, V19, P14; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; Wolkowicz R, 1998, CANCER DETECT PREV, V22, P1, DOI 10.1046/j.1525-1500.1998.00003.x; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; YokoyamaKobayashi M, 1997, J BIOCHEM-TOKYO, V122, P622; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Yount GL, 1999, CANCER RES, V59, P1362; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0	86	230	245	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					20127	20135		10.1074/jbc.M909580199	http://dx.doi.org/10.1074/jbc.M909580199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10777512	hybrid			2022-12-27	WOS:000087941300094
J	Meyer, CK; Bohme, M; Ockenfels, A; Gartner, W; Hofmann, KP; Ernst, OP				Meyer, CK; Bohme, M; Ockenfels, A; Gartner, W; Hofmann, KP; Ernst, OP			Signaling states of rhodopsin - Retinal provides a scaffold for activating proton transfer switches	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVELY ACTIVE MUTANTS; METARHODOPSIN-II EQUILIBRIUM; SCHIFF-BASE COUNTERION; CARBOXYLIC-ACID GROUP; BOVINE RHODOPSIN; METHYL-GROUP; G-PROTEIN; ALPHA(1B)-ADRENERGIC RECEPTOR; STERIC TRIGGER; PH-DEPENDENCE	The G-protein-coupled receptor rhodopsin is activated by photoconversion of its covalently bound ligand Il-cis-retinal to the agonist all-trans-retinal. After light-induced isomerization and early photointermediates, the receptor reaches a G-protein-dependent equilibrium between active and inactive conformations distinguished by the protonation of key opsin residues. In this report, we study the role of the 9-methyl group of retinal, one of the crucial steric determinants of light activation. We find that when this group is removed, the protonation equilibrium is strongly shifted to the inactive conformation. The residually formed active species is very similar to the active form of normal rhodopsin, metarhodopsin II. It has a deprotonated Schiff base, binds to the retinal G-protein transducin, and is favored at acidic pH. Our data show that the normal proton transfer reactions are inhibited in 9-demethyl rhodopsin but are still mandatory for receptor activation, We propose that retinal and its 9-methyl group act as a scaffold for opsin to adjust key proton donor and acceptor side chains for the proton transfer reactions that stabilize the active conformation. The mechanism may also be applicable to related receptors and may thus explain the partial agonism of certain ligands.	Humboldt Univ, Univ Klinikum Charite, Inst Med Phys & Biophys, D-10098 Berlin, Germany; Max Planck Inst Strahlenchem, D-45470 Mulheim, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Max Planck Society	Hofmann, KP (corresponding author), Humboldt Univ, Univ Klinikum Charite, Inst Med Phys & Biophys, Schumannstr 20-21, D-10098 Berlin, Germany.			Gartner, Wolfgang/0000-0002-6898-7011				Abdulaev NG, 1998, P NATL ACAD SCI USA, V95, P12854, DOI 10.1073/pnas.95.22.12854; ARNIS S, 1995, BIOCHEMISTRY-US, V34, P9333, DOI 10.1021/bi00029a008; ARNIS S, 1993, P NATL ACAD SCI USA, V90, P7849, DOI 10.1073/pnas.90.16.7849; ARNIS S, 1994, J BIOL CHEM, V269, P23879; DeLange F, 1998, BIOCHEMISTRY-US, V37, P1411, DOI 10.1021/bi972397y; Dunham TD, 1999, J BIOL CHEM, V274, P1683, DOI 10.1074/jbc.274.3.1683; EMEIS D, 1982, FEBS LETT, V143, P29, DOI 10.1016/0014-5793(82)80266-4; Ernst OP, 2000, METHOD ENZYMOL, V315, P471; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; GANTER UM, 1989, BIOCHEMISTRY-US, V28, P5954, DOI 10.1021/bi00440a036; GANTER UM, 1988, BIOCHEMISTRY-US, V27, P7480, DOI 10.1021/bi00419a046; Han M, 1997, P NATL ACAD SCI USA, V94, P13442, DOI 10.1073/pnas.94.25.13442; Han M, 1998, BIOCHEMISTRY-US, V37, P538, DOI 10.1021/bi972060w; HECK M, 1993, BIOCHEMISTRY-US, V32, P8220, DOI 10.1021/bi00083a024; Helmreich EJM, 1996, BBA-REV BIOMEMBRANES, V1286, P285, DOI 10.1016/S0304-4157(96)00013-5; HOFMANN KP, 1999, RHODOPSINS PHOTOTRAN, V224, P158; HOFMANN KP, IN PRESS HDB BIOL PH, V4; JAGER F, 1994, BIOCHEMISTRY-US, V33, P7389; JAGER F, 1994, BIOCHEMISTRY-US, V33, P10878; KIBELBEK J, 1991, BIOCHEMISTRY-US, V30, P6761, DOI 10.1021/bi00241a019; Kim JM, 1997, P NATL ACAD SCI USA, V94, P14273, DOI 10.1073/pnas.94.26.14273; LONGSTAFF C, 1986, P NATL ACAD SCI USA, V83, P4209, DOI 10.1073/pnas.83.12.4209; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; OPRIAN DD, 1993, METH NEUROSCI, V15, P301; Parkes JH, 1999, BIOCHEMISTRY-US, V38, P6862, DOI 10.1021/bi9827666; PARKES JH, 1984, BIOCHEMISTRY-US, V23, P5054, DOI 10.1021/bi00316a035; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SAKMAR TP, 1991, P NATL ACAD SCI USA, V88, P3079, DOI 10.1073/pnas.88.8.3079; Sakmar TP, 1998, PROG NUCLEIC ACID RE, V59, P1; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Scheer A, 1997, P NATL ACAD SCI USA, V94, P808, DOI 10.1073/pnas.94.3.808; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; Shieh T, 1997, J MOL BIOL, V269, P373, DOI 10.1006/jmbi.1997.1035; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; Szundi I, 1998, BIOCHEMISTRY-US, V37, P14237, DOI 10.1021/bi981249k; VANDENTEMPEL PJ, 1966, TETRAHEDRON, V22, P293; WEITZ CJ, 1993, BIOCHEMISTRY-US, V32, P14176, DOI 10.1021/bi00214a016; YAN B, 1991, P NATL ACAD SCI USA, V88, P9412, DOI 10.1073/pnas.88.21.9412	41	76	76	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19713	19718		10.1074/jbc.M000603200	http://dx.doi.org/10.1074/jbc.M000603200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10770924	hybrid			2022-12-27	WOS:000087941300038
J	O'Rourke, EJ; Chevalier, C; Boiteux, S; Labigne, A; Ielpi, L; Radicella, JP				O'Rourke, EJ; Chevalier, C; Boiteux, S; Labigne, A; Ielpi, L; Radicella, JP			A novel 3-methyladenine DNA glycosylase from Helicobacter pylori defines a new class within the endonuclease III family of base excision repair glycosylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; ESCHERICHIA-COLI; ALKYLATED DNA; SACCHAROMYCES-CEREVISIAE; METHYLATED PURINES; CRYSTAL-STRUCTURE; ENZYME; RESIDUES; SEQUENCE; RELEASE	The cloning, purification, and characterization of MagIII, a 3-methyladenine DNA glycosylase from Helicobacter pylori, is presented in this paper, Sequence analysis of the genome of this pathogen failed to identify open reading frames potentially coding for proteins with a 3-methyladenine DNA glycosylase activity. The putative product of the HP602 open reading frame, reported as an endonuclease III, shares extensive amino acid sequence homology with some bacterial members of this family and has the canonic active site helix-hairpin-helix-GPD motif, Surprisingly, this predicted H. pylori endonuclease III encodes a 25,220-Da protein able to release 3-methyladenine, but not oxidized bases, from modified DNA. MagIII has no abasic site lyase activity and displays the substrate specificity of the 3-methyladenine-DNA glycosylase type I of Escherichia coli (Tag) because it is not able to recognize 7-methylguanine or hypoxanthine as substrates, The expression of the magIII open reading frame in null 3-methyladenine glycosylase E. coli (tag alkA) restores to this mutant partial resistance to alkylating agents. MagIII-deficient N, pylori cells show an alkylation-sensitive phenotype, H. pylori wild type cells exposed to alkylating agents present an adaptive response by inducing the expression of magIII. MagIII is thus a novel bacterial member of the endonuclease III family, which displays biochemical properties not described for any of the members of this group until now.	CEA, Dept Radiobiol & Radiopathol, CNRS, UMR217, F-92265 Fontenay Aux Roses, France; Univ Buenos Aires, Fac Ciencias Exactas & Nat, Fdn Campomar, Inst Invest Bioquim, RA-1405 Buenos Aires, DF, Argentina; Consejo Nacl Invest Cient & Tecn, RA-1405 Buenos Aires, DF, Argentina; Inst Pasteur, Unite Pathogenie Bacterienne Muqueuses, F-75724 Paris, France	CEA; Centre National de la Recherche Scientifique (CNRS); Leloir Institute; University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Radicella, JP (corresponding author), CEA, Dept Radiobiol & Radiopathol, CNRS, UMR217, BP6, F-92265 Fontenay Aux Roses, France.	jpradicella@cea.fr	chevalier, catherine/L-4803-2015; O'Rourke, Eyleen Jorgelina/AAG-2009-2021; Radicella, J. Pablo/AAU-3178-2020	O'Rourke, Eyleen Jorgelina/0000-0003-0503-4181; Radicella, J. Pablo/0000-0002-8807-7226				Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Begley TJ, 1999, CURR BIOL, V9, P653, DOI 10.1016/S0960-9822(99)80288-7; Berdal KG, 1998, EMBO J, V17, P363, DOI 10.1093/emboj/17.2.363; BJELLAND S, 1993, NUCLEIC ACIDS RES, V21, P2045, DOI 10.1093/nar/21.9.2045; BJELLAND S, 1994, J BIOL CHEM, V269, P30489; BOITEUX S, 1984, EMBO J, V3, P2569, DOI 10.1002/j.1460-2075.1984.tb02175.x; BOITEUX S, 1984, NUCLEIC ACIDS RES, V12, P5429, DOI 10.1093/nar/12.13.5429; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; Elder RH, 1998, MOL CELL BIOL, V18, P5828, DOI 10.1128/MCB.18.10.5828; Fischer D, 1999, PROTEINS, P209; FORMAN D, 1994, LANCET, V343, P243, DOI 10.1016/S0140-6736(94)91034-0; Girard PM, 1997, NUCLEIC ACIDS RES, V25, P3204, DOI 10.1093/nar/25.16.3204; Janvier B, 1999, FEMS IMMUNOL MED MIC, V24, P27; KARRAN P, 1980, J MOL BIOL, V140, P101, DOI 10.1016/0022-2836(80)90358-7; KARRAN P, 1982, NATURE, V296, P770, DOI 10.1038/296770a0; KELLEY LA, 1999, RECOMB 99 P 3 ANN C, P218; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Labahn J, 1996, CELL, V86, P321, DOI 10.1016/S0092-8674(00)80103-8; Labigne Agnes, 1997, P153; LARSON K, 1985, MUTAT RES, V150, P77, DOI 10.1016/0027-5107(85)90103-4; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; LAVAL J, 1977, NATURE, V269, P829, DOI 10.1038/269829a0; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Marais A, 1999, MICROBIOL MOL BIOL R, V63, P642, DOI 10.1128/MMBR.63.3.642-674.1999; Marais A, 1999, CURR TOP MICROBIOL, V241, P103; MARSHALL BJ, 1984, LANCET, V1, P1311; Matijasevic Z, 1996, CARCINOGENESIS, V17, P2249, DOI 10.1093/carcin/17.10.2249; MCCARTHY TV, 1984, EMBO J, V3, P545, DOI 10.1002/j.1460-2075.1984.tb01844.x; MEGRAUD F, 1992, DIGEST DIS SCI, V37, P769, DOI 10.1007/BF01296437; Mobley H L, 1996, Am J Med, V100, p2S; Mobley HLT, 1997, GASTROENTEROLOGY, V113, pS21, DOI 10.1016/S0016-5085(97)80006-6; MOROHOSHI F, 1990, NUCLEIC ACIDS RES, V18, P5473, DOI 10.1093/nar/18.18.5473; MURPHY LD, 1990, BIOCHEMISTRY-US, V29, P10351, DOI 10.1021/bi00497a009; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; OCONNOR TR, 1988, NUCLEIC ACIDS RES, V16, P5879, DOI 10.1093/nar/16.13.5879; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; Rashtchian Ayoub, 1995, Current Opinion in Biotechnology, V6, P30, DOI 10.1016/0958-1669(95)80006-9; RIAZUDDIN S, 1978, BIOCHEMISTRY-US, V17, P2110, DOI 10.1021/bi00604a014; RYDBERG B, 1982, EMBO J, V1, P211, DOI 10.1002/j.1460-2075.1982.tb01149.x; SAPARBAEV M, 1995, NUCLEIC ACIDS RES, V23, P3750, DOI 10.1093/nar/23.18.3750; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; Seeberg E., 1997, BASE EXCISION REPAIR, P151; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; THOMAS L, 1982, BIOCHEMISTRY-US, V21, P1162, DOI 10.1021/bi00535a009; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; TRIEUCUOT P, 1985, EMBO J, V4, P3583, DOI 10.1002/j.1460-2075.1985.tb04120.x; WANG Y, 1993, J GEN MICROBIOL, V139, P2485, DOI 10.1099/00221287-139-10-2485; WEI X, 1993, P NATL ACAD SCI USA, V90, P2117, DOI 10.1073/pnas.90.6.2117; Wyatt MD, 1999, BIOESSAYS, V21, P668, DOI 10.1002/(SICI)1521-1878(199908)21:8<668::AID-BIES6>3.3.CO;2-4; Yamagata Y, 1996, CELL, V86, P311, DOI 10.1016/S0092-8674(00)80102-6	52	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					20077	20083		10.1074/jbc.M001071200	http://dx.doi.org/10.1074/jbc.M001071200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10777493	hybrid, Green Published			2022-12-27	WOS:000087941300087
J	Itoh, T; Ishihara, H; Shibasaki, Y; Oka, Y; Takenawa, T				Itoh, T; Ishihara, H; Shibasaki, Y; Oka, Y; Takenawa, T			Autophosphorylation of type I phosphatidylinositol phosphate kinase regulates its lipid kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; HUMAN PLATELETS; 5-KINASE; FAMILY; CLONING; PHOSPHORYLATION; PI-3-KINASE; ISOFORMS; SIGNALS	Phosphatidylinositol phosphate kinases (PIPKs) have important roles in the production of various phosphoinositides. For type I PIP5Ks (PIP5KI), a broad substrate specificity is known. They phosphorylate phosphatidylinositol 4-phosphate most effectively but also phosphorylate phosphatidylinositol (PI), phosphatidylinositol 3-phosphate, and phosphatidylinositol (3,4)-bisphosphate (PI(3, 4)P-2), resulting in the production of phosphatidylinositol (4,5)-bisphosphate (PI(4,5)P-2), phosphatidylinositol S-phosphate, phosphatidylinositol (3,4)bisphosphate (PI(3,4)P-2), phosphatidylinositol (3,5)bisphosphate (PI(3,5)P-2), and phosphatidylinositol (3,4,5)-trisphosphate. We show here that PIP5KIs have also protein kinase activities. When each isozyme of PIP5KI (PIP5KI alpha, -beta, and -gamma) was subjected to in vitro kinase assay, autophosphorylation occurred. The lipid kinase-negative mutant of PIP5KI alpha (K138A) lost the protein kinase activity, suggesting the same catalytic mechanism for the lipid and the protein kinase activities. PIP5KI beta expressed in Escherichia coli also retains this protein kinase activity, thus confirming that no co-immunoprecipitated protein kinase is involved. In addition, the autophosphorylation of PIP5KI is markedly enhanced by the addition of PI. No other phosphoinositides such as phosphatidylinositol phosphate, phosphatidylinositol bisphosphate, or phosphatidylinositol trisphosphate have such an effect. We also found that the PI-dependent autophosphorylation strongly suppresses the lipid kinase activity of PIP5KI, The lipid kinase activity of PIP5KI was decreased to one-tenth upon PI-dependent autophosphorylation, All these results indicate that the lipid kinase activity of PIP5KI that acts predominantly for PI(4,5)P-2 synthesis is regulated by PI-dependent autophosphorylation in vivo.	Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Dept Internal Med 3, Bunkyo Ku, Tokyo 1138655, Japan; Yamaguchi Univ, Sch Med, Dept Internal Med 3, Yamaguchi 7558505, Japan	University of Tokyo; University of Tokyo; Yamaguchi University	Takenawa, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 1088639, Japan.	takenawa@ims.u-tokyo.ac.jp						Anderson RA, 1999, J BIOL CHEM, V274, P9907, DOI 10.1074/jbc.274.15.9907; BAZENET CE, 1990, J BIOL CHEM, V265, P18012; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; Castellino AM, 1997, J BIOL CHEM, V272, P5861, DOI 10.1074/jbc.272.9.5861; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Hinchliffe KA, 1996, EMBO J, V15, P6516, DOI 10.1002/j.1460-2075.1996.tb01042.x; Hinchliffe KA, 1998, BIOCHEM J, V329, P115; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; Itoh T, 1998, J BIOL CHEM, V273, P20292, DOI 10.1074/jbc.273.32.20292; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Majerus PW, 1999, J BIOL CHEM, V274, P10669, DOI 10.1074/jbc.274.16.10669; Nishikawa K, 1998, J BIOL CHEM, V273, P23126, DOI 10.1074/jbc.273.36.23126; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rao VD, 1998, CELL, V94, P829, DOI 10.1016/S0092-8674(00)81741-9; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; SCHACHT J, 1978, J LIPID RES, V19, P1063; Shisheva A, 1999, MOL CELL BIOL, V19, P623; STACK JH, 1994, J BIOL CHEM, V269, P31552; Stoyanova S, 1997, BIOCHEM J, V324, P489, DOI 10.1042/bj3240489; Tolias KF, 1998, J BIOL CHEM, V273, P18040, DOI 10.1074/jbc.273.29.18040; Vanhaesebroeck B, 1999, EMBO J, V18, P1292, DOI 10.1093/emboj/18.5.1292; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525; YOSHIDA S, 1994, MOL GEN GENET, V242, P631, DOI 10.1007/BF00283416; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756	34	34	34	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19389	19394		10.1074/jbc.M000426200	http://dx.doi.org/10.1074/jbc.M000426200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10777481	hybrid			2022-12-27	WOS:000087815900100
J	Klein, ES; Wang, JW; Khalifa, B; Gavigan, SA; Chandraratna, RAS				Klein, ES; Wang, JW; Khalifa, B; Gavigan, SA; Chandraratna, RAS			Recruitment of nuclear receptor corepressor and coactivator to the retinoic acid receptor by retinoid ligands - Influence of DNA-heterodimer interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; DISTINCT CONFORMATIONAL-CHANGES; INVERSE AGONISTS; TRANSCRIPTIONAL COACTIVATOR; TRANSACTIVATION DOMAIN; MAMMALIAN-CELLS; HIGHLY POTENT; ACTIVATION; BINDING; GAMMA	Ligand activation of retinoic acid receptors (RARs) involves coordinated changes in their interaction with coregulatory molecules. Binding of the agonist all-trans-retinoic acid to the RAR results in increased interaction with coactivator molecules as well as a decreased interaction with corepressor molecules. Thus, an all-trans-retinoic acid antagonist might function either by preventing agonist induction of such events or, additionally, by actively increasing repression via corepressor recruitment. We demonstrate that the repression of the transcriptional activity of a constitutively active RAR gamma-VP-16 chimeric receptor by the inverse agonist AGN193109 requires a functional Co-R box and that binding of this ligand to RAR gamma leads to an increased interaction with the corepressor N-CoR both in glutathione S-transferase pull-down and yeast two-hybrid analyses. Detection of nuclear receptor corepressor (N-CoR) association with RAR gamma was greatly facilitated by inclusion of a RARE oligonucleotide in coimmunoprecipitation analyses, a result of an increase in association of the ternary complex consisting of RAR, RXR, and DNA. Similarly, this DNA-dependent increase in heterodimer formation likewise resulted in an increase in agonist-mediated recruitment efficiency of the coactivator SRC-1, Under conditions which favor ternary complex formation, a RAR neutral antagonist is distinguished from an inverse agonist with respect to corepressor recruitment as is a RAR partial agonist distinguished from an agonist with respect to coactivator recruitment. These results indicate that it is possible to design RAR ligands with distinct recruitment capabilities for coregulators, both coactivators as well as corepressors, In addition, using this recruitment assay, we show that SRC-1 and the related coactivator molecule ACTR associate with the ternary complex via utilization of different helical motifs within their conserved receptor interaction domains.	Allergan Pharmaceut Inc, Retinoid Res, Dept Biol, Irvine, CA 92715 USA; Allergan Pharmaceut Inc, Retinoid Res, Dept Chem, Irvine, CA 92715 USA	AbbVie; Allergan; AbbVie; Allergan	Klein, ES (corresponding author), Mail Code RD-3D,2525 Dupont Dr, Irvine, CA 92715 USA.	klein_elliott@allergan.com		Wang, Jenny W/0000-0003-0217-7275				ALLAN GF, 1992, J BIOL CHEM, V267, P19513; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; BRENT G A, 1989, New Biologist, V1, P329; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GRAUPNER G, 1991, BIOCHEM BIOPH RES CO, V179, P1554, DOI 10.1016/0006-291X(91)91750-7; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; Hall DA, 1997, BRIT J PHARMACOL, V121, P731, DOI 10.1038/sj.bjp.0701196; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JOHNSON AT, 1995, J MED CHEM, V38, P4764, DOI 10.1021/jm00024a003; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; Klein ES, 1996, J BIOL CHEM, V271, P22692, DOI 10.1074/jbc.271.37.22692; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Lee MO, 1996, J BIOL CHEM, V271, P11897, DOI 10.1074/jbc.271.20.11897; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Milligan G, 1997, RECEPTOR CHANNEL, V5, P209; Mouchon A, 1999, MOL CELL BIOL, V19, P3073; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Oberfield JL, 1999, P NATL ACAD SCI USA, V96, P6102, DOI 10.1073/pnas.96.11.6102; ONATE SA, 1995, SCIENCE, V270, P1354; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Teng M, 1997, J MED CHEM, V40, P2445, DOI 10.1021/jm9703911; Thacher SM, 1999, CELL GROWTH DIFFER, V10, P255; THOMAS DR, 1995, J RECEPT SIGNAL TR R, V15, P199, DOI 10.3109/10799899509045217; TONE Y, 1994, J BIOL CHEM, V269, P31157; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WOLOSHIN P, 1995, CELL, V82, P611, DOI 10.1016/0092-8674(95)90033-0; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	53	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19401	19408		10.1074/jbc.M002472200	http://dx.doi.org/10.1074/jbc.M002472200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10777502	hybrid			2022-12-27	WOS:000087815900102
J	Maxwell, KL; Davidson, AR; Murialdo, H; Gold, M				Maxwell, KL; Davidson, AR; Murialdo, H; Gold, M			Thermodynamic and functional characterization of protein W from bacteriophage lambda - The three C-terminal residues are critical for activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENE-PRODUCTS; SH3 DOMAIN; STABILITY; IDENTIFICATION; MORPHOGENESIS; INFORMATION; NETWORKS; MUTANTS; INVITRO	Gene product W (gpW), the head-tail joining protein from bacteriophage lambda, provides a fascinating model for studying protein interactions. Composed of only 68 residues, it must interact with at least two other proteins in the phage, and probably with DNA. To study the structural and functional properties of gpW, plasmids were constructed expressing gpW with hexahistidine tag sequences at either the N or C terminus. The purified wild type fusion proteins were found to be stably folded and biologically active. The protein is monomeric as judged by equilibrium ultracentrifugation, and appears to unfold by a cooperative two-state mechanism. Circular dichroism studies indicate that the protein is 47% helical, with a T-m of 71.3 degrees C, and a Delta G(u) of 3.01 kcal/mol at 25 degrees C, Mutagenesis of the three hydrophobic C-terminal residues of gpW showed that they are critical for activity, even though they do not contribute to the thermodynamic stability of the protein. Using secondary structure prediction as a guide, we also designed destabilized gpW mutants. The hydrophobic nature of the gpW C terminus caused these mutants to be degraded by the ClpP-containing proteases in Escherichia coli.	Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Fdn Ciencias Vida, Santiago, Chile	University of Toronto; University of Toronto	Gold, M (corresponding author), Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada.	davidson@hkl.med.utoronto.ca; marvin.gold@utoronto.ca		Maxwell, Karen/0000-0002-0211-5480				ALEXANDER P, 1992, BIOCHEMISTRY-US, V31, P3597, DOI 10.1021/bi00129a007; Bhandari P, 1997, J BACTERIOL, V179, P4403, DOI 10.1128/jb.179.13.4403-4406.1997; Breslauer KJ, 1995, METHOD ENZYMOL, V259, P221; CASJENS S, 1972, J MOL BIOL, V64, P551, DOI 10.1016/0022-2836(72)90082-4; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; IMBER R, 1980, J MOL BIOL, V139, P277, DOI 10.1016/0022-2836(80)90131-X; KATSURA I, 1977, VIROLOGY, V76, P129, DOI 10.1016/0042-6822(77)90290-2; KATSURA I, 1983, J MOL BIOL, V171, P297, DOI 10.1016/0022-2836(83)90095-5; Levchenko I, 1997, CELL, V91, P939, DOI 10.1016/S0092-8674(00)80485-7; LIM WA, 1994, PROTEIN SCI, V3, P1261, DOI 10.1002/pro.5560030812; Maxwell KL, 1998, BIOCHEMISTRY-US, V37, P16172, DOI 10.1021/bi981788p; MCCLURE SCC, 1973, VIROLOGY, V54, P1, DOI 10.1016/0042-6822(73)90109-8; MURIALDO H, 1979, VIROLOGY, V96, P341, DOI 10.1016/0042-6822(79)90094-1; MURIALDO H, 1978, J MOL BIOL, V125, P57, DOI 10.1016/0022-2836(78)90254-1; MURIALDO H, 1987, NUCLEIC ACIDS RES, V15, P119, DOI 10.1093/nar/15.1.119; MURIALDO H, 1972, VIROLOGY, V48, P785, DOI 10.1016/0042-6822(72)90162-6; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; PACE CN, 1989, BIOCHEMISTRY-US, V28, P2520, DOI 10.1021/bi00432a026; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PARSELL DA, 1989, J BIOL CHEM, V264, P7590; PERUCCHETTI R, 1988, VIROLOGY, V165, P103, DOI 10.1016/0042-6822(88)90663-0; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SIEGELE DA, 1983, VIROLOGY, V129, P484, DOI 10.1016/0042-6822(83)90187-3; Towell J.F, 1994, ANAL APPL CIRCULAR D, P175, DOI DOI 10.1016/S0167-9244(08)70179-3; YANOFSKY C, 1966, J MOL BIOL, V21, P313, DOI 10.1016/0022-2836(66)90102-1	28	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18879	18886		10.1074/jbc.M001178200	http://dx.doi.org/10.1074/jbc.M001178200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10770927	hybrid			2022-12-27	WOS:000087815900037
J	Zhong, ZD; Hammani, K; Bae, WS; DeClerck, YA				Zhong, ZD; Hammani, K; Bae, WS; DeClerck, YA			NF-Y and Sp1 cooperate for the transcriptional activation and cAMP response of human tissue inhibitor of metalloproteinases-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; HISTONE ACETYLTRANSFERASES; DEPENDENT REGULATION; BINDING PROTEINS; CCAAT BOX; PROMOTER; ELEMENT; MATRIX; IDENTIFICATION; SUBUNIT	The balance between matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) is a key determinant in the homeostasis of the extracellular matrix. We have identified two cis-acting elements involved in the transcriptional regulation of TIMP-2. The first is an inverted CCAAT box located at position -73 to -69 in the TIMP-2 promoter that binds the transcription factor NF-Y The second is a GAGGAGGGGG motif located at position -107 to -98, that binds the transcription factors Sp1 and Sp3. NF-Y and Sp1 cooperate for the basal transcription activity of the promoter. We then determined that TIMP-2 is transcriptionally up-regulated by cAMP analogs. Up-regulation of TIMP-2 by dibutyryl cAMP is a delayed response that requires de novo protein synthesis and does not affect RNA stability The NF-Y and the Sp1 binding site are both involved in cAMP-dependent up-regulation of TIMP-2. Whereas NF-Y is essential for cAMP mediated regulation, Spl alone is not sufficient but enhances the activity of NF-Y. Dibutyryl cAMP has no effect on the expression of MMP-2 and MMP-9 and switches the MMP-TIMP balance in favor of the inhibitor.	Childrens Hosp Los Angeles, Div Hematol Oncol, Los Angeles, CA 90027 USA; Childrens Hosp Los Angeles, Dept Pediat, Los Angeles, CA 90027 USA; Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles; Children's Hospital Los Angeles; University of Southern California	DeClerck, YA (corresponding author), Childrens Hosp Los Angeles, Div Hematol Oncol, MS 54,4650 Sunset Blvd, Los Angeles, CA 90027 USA.		Hammani, khalil/GSD-7743-2022	DeClerck, Yves/0000-0002-3688-0113; Hammani, Khalil/0000-0002-4005-4244	NATIONAL CANCER INSTITUTE [R01CA042919] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42919] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexander JP, 1998, CURR EYE RES, V17, P276, DOI 10.1076/ceyr.17.3.276.5219; Alonso CR, 1996, J BIOL CHEM, V271, P22271, DOI 10.1074/jbc.271.36.22271; Benbow U, 1997, MATRIX BIOL, V15, P519, DOI 10.1016/S0945-053X(97)90026-3; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; BOULARAND S, 1995, J BIOL CHEM, V270, P3757, DOI 10.1074/jbc.270.8.3757; Bugno M, 1995, NUCLEIC ACIDS RES, V23, P5041, DOI 10.1093/nar/23.24.5041; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAMPBELL CE, 1991, J BIOL CHEM, V266, P7199; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark IM, 1997, BIOCHEM J, V324, P611, DOI 10.1042/bj3240611; CORSI PS, 1995, ANNU REV CELL DEV BI, V11, P355; Currie RA, 1997, J BIOL CHEM, V272, P30880, DOI 10.1074/jbc.272.49.30880; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; Daniel PB, 1998, ANNU REV NUTR, V18, P353, DOI 10.1146/annurev.nutr.18.1.353; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; Faniello MC, 1999, J BIOL CHEM, V274, P7623, DOI 10.1074/jbc.274.12.7623; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; Hammani K, 1996, J BIOL CHEM, V271, P25498, DOI 10.1074/jbc.271.41.25498; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KARSENTY G, 1988, J BIOL CHEM, V263, P13909; KARSENTY G, 1990, J BIOL CHEM, V265, P9934; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; Korzus E, 1997, J BIOL CHEM, V272, P1188, DOI 10.1074/jbc.272.2.1188; LALLI E, 1994, J BIOL CHEM, V269, P17359; Li Q, 1998, EMBO J, V17, P6300, DOI 10.1093/emboj/17.21.6300; Lim YT, 1996, J CELL PHYSIOL, V167, P333, DOI 10.1002/(SICI)1097-4652(199605)167:2<333::AID-JCP18>3.0.CO;2-8; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MURPHY G, 1985, J BIOL CHEM, V260, P3079; Osawa H, 1996, J BIOL CHEM, V271, P17296, DOI 10.1074/jbc.271.29.17296; PITTMAN N, 1995, J BIOL CHEM, V270, P28848, DOI 10.1074/jbc.270.48.28848; REED GE, 1995, BRAIN RES, V682, P1, DOI 10.1016/0006-8993(95)00284-W; Roder K, 1997, GENE, V184, P21, DOI 10.1016/S0378-1119(96)00568-9; Roder K, 1999, GENE, V234, P61, DOI 10.1016/S0378-1119(99)00180-8; Roder K, 1997, J BIOL CHEM, V272, P21616, DOI 10.1074/jbc.272.34.21616; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; Sorensen P, 1999, J BIOL CHEM, V274, P30943, DOI 10.1074/jbc.274.43.30943; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; TANAKA K, 1995, CANCER RES, V55, P2927; URIA JA, 1994, CANCER RES, V54, P2091; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978	48	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18602	18610		10.1074/jbc.M001389200	http://dx.doi.org/10.1074/jbc.M001389200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10764764	hybrid			2022-12-27	WOS:000087659400094
J	Solecki, D; Bernhardt, G; Lipp, M; Wimmer, E				Solecki, D; Bernhardt, G; Lipp, M; Wimmer, E			Identification of a nuclear respiratory factor-1 binding site within the core promoter of the human polio virus receptor/CD155 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC INITIATION FACTOR-2-ALPHA; TRANSCRIPTION FACTOR; IMMUNOGLOBULIN SUPERFAMILY; CELLULAR RECEPTOR; ADHESION MOLECULE; NEURITE-OUTGROWTH; MURINE HOMOLOG; FACTOR-I; PROTEIN; EXPRESSION	In this report we describe a cis-acting element within the core promoter of the CD155 gene specifying the polio virus receptor that is bound by the nuclear respiratory factor-1 (NRF-1) transcription factor. DNase I footprint analysis identified a nuclear protein binding site from -282 to -264 nucleotides upstream of the translation initiation codon of the CD155 gene, which we have called foot print IV (FPIV). Linker scanning mutagenesis revealed that a tandem repeat motif, GCGCAGGCG-CAG, located within FPIV was essential for the basal. activity of the CD155 core promoter. The results of the electrophoretic mobility shift assay experiments suggested that identical FPIV binding activities were present in a variety of nuclear extracts and that the tandem repeat was essential for binding. A one-hybrid screen was then carried out using FPIV as bait to clone the cDNA of the FPIV binding factor. The sequences of the cDNAs that were cloned from the screen were identical to NRF-1, a result that was confirmed by further electrophoretic mobility shift assay experiments. Overexpression of full-length NRF-1 and a dominant-negative form of NRF-1 modulated reporter gene expression driven by the core promoter. Remarkably, CD155 is the first gene shown to be regulated by NRF-1 that possesses an expression profile during embryogenesis correlating with this factor's proposed role in the development of the vertebrate optic system. We propose that NRF-1, which has been shown by others to be expressed during embryogenesis in animal systems, may be involved in regulating the expression of CD155 at specific stages of central nervous system development.	SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Solecki, D (corresponding author), Rockefeller Univ, Dev Neurobiol Lab, 1230 York Ave, New York, NY 10021 USA.	soleckd@rockvax.rockefeller.edu	Bernhardt, Günter/F-6946-2012; Lipp, Martin/G-2235-2010; Solecki, David/N-8080-2018	Bernhardt, Günter/0000-0002-0510-2853; Lipp, Martin/0000-0002-0087-2672	NIAID NIH HHS [AI39485] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI039485, R01AI039485] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aoki J, 1997, EXP CELL RES, V235, P374, DOI 10.1006/excr.1997.3685; Becker TS, 1998, DEVELOPMENT, V125, P4369; BERNHARDT G, 1994, VIROLOGY, V199, P105, DOI 10.1006/viro.1994.1102; BIBB JA, 1994, J VIROL, V68, P6111, DOI 10.1128/JVI.68.9.6111-6115.1994; BURNS FR, 1991, NEURON, V7, P209, DOI 10.1016/0896-6273(91)90259-3; CALZONE FJ, 1991, DEVELOPMENT, V112, P335; Chadeneau C, 1996, MAMM GENOME, V7, P636, DOI 10.1007/s003359900194; CHADENEAU C, 1994, J BIOL CHEM, V269, P15601; CHAU CMA, 1992, J BIOL CHEM, V267, P6999; Chen SH, 1997, NUCLEIC ACIDS RES, V25, P1809, DOI 10.1093/nar/25.9.1809; Cocchi F, 1998, J VIROL, V72, P9992, DOI 10.1128/JVI.72.12.9992-10002.1998; DESIMONE SM, 1993, MOL CELL BIOL, V13, P3641, DOI 10.1128/MCB.13.6.3641; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; EFIOK BJS, 1994, J BIOL CHEM, V269, P18921; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; GOMEZCUADRADO A, 1995, MOL CELL BIOL, V15, P6670; GROMEIER M, 1995, MICROB PATHOGENESIS, V18, P253, DOI 10.1016/S0882-4010(05)80002-6; Gugneja S, 1996, MOL CELL BIOL, V16, P5708; JACOB WF, 1989, J BIOL CHEM, V264, P20372; KOIKE S, 1990, EMBO J, V9, P3217, DOI 10.1002/j.1460-2075.1990.tb07520.x; KOIKE S, 1992, J VIROL, V66, P7059, DOI 10.1128/JVI.66.12.7059-7066.1992; Lopez M, 1998, BLOOD, V92, P4602, DOI 10.1182/blood.V92.12.4602.424k21_4602_4611; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; Mohajeri MH, 1996, EUR J NEUROSCI, V8, P1085, DOI 10.1111/j.1460-9568.1996.tb01276.x; Morales G, 1996, EUR J NEUROSCI, V8, P1098, DOI 10.1111/j.1460-9568.1996.tb01277.x; MORRISON ME, 1992, J VIROL, V66, P2807, DOI 10.1128/JVI.66.5.2807-2813.1992; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shukla D, 1999, J VIROL, V73, P4493, DOI 10.1128/JVI.73.5.4493-4497.1999; Solecki D, 1998, J MOL RECOGNIT, V11, P2, DOI 10.1002/(SICI)1099-1352(199812)11:1/6<2::AID-JMR380>3.0.CO;2-D; Solecki D, 1997, J BIOL CHEM, V272, P5579, DOI 10.1074/jbc.272.9.5579; Solecki D, 1999, J BIOL CHEM, V274, P1791, DOI 10.1074/jbc.274.3.1791; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; TAMURA T, 1996, METHODS ORLANDO, V10, P321; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; Wegner SA, 1998, J BIOL CHEM, V273, P4754, DOI 10.1074/jbc.273.8.4754; West-Mays JA, 1999, DEV BIOL, V206, P46, DOI 10.1006/dbio.1998.9132; WIMMER E, 1994, COLD SPRING HARBOR M, P101; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0; Zhang Z, 1998, NUCLEIC ACIDS RES, V26, P3986, DOI 10.1093/nar/26.17.3986; ZIBERT A, 1991, VIROLOGY, V182, P250, DOI 10.1016/0042-6822(91)90668-2	45	31	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12453	12462		10.1074/jbc.275.17.12453	http://dx.doi.org/10.1074/jbc.275.17.12453			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777530	hybrid			2022-12-27	WOS:000086762300014
J	Liu, J; Shen, XN; Nguyen, VA; Kunos, G; Gao, B				Liu, J; Shen, XN; Nguyen, VA; Kunos, G; Gao, B			alpha(1) adrenergic agonist induction of p21(waf1/cip1) mRNA stability in transfected HepG2 cells correlates with the increased binding of an AU-rich element binding factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOGEN-ACTIVATED PROTEIN; CYCLIN-DEPENDENT KINASES; RNA STABILIZATION; GENE-EXPRESSION; RAT HEPATOCYTES; IN-VITRO; RECEPTOR; INHIBITOR; GROWTH; LIVER	Stimulation of transfected HepG2 cells (TFG2) with the alpha(1)-adrenergic agonist phenylephrine (PE) significantly activated p21(waf1/cip1) gene expression without affecting p53 gene expression. Northern blotting and reporter assay demonstrated that this induction was due to PE stimulation of p21(waf1/cip1) mRNA stability. To further define the underlying mechanism, we prepared a chloramphenicol acetyltransferase (CAT)-p21(waf1/cip1) 3'-untranslated region (3'-UTR) hybrid construct by inserting the 3'-UTR of p21(waf1/cip1) mRNA just downstream from the CAT coding sequence and transfected it into TFG2 cells. PE treatment enhanced the activity of this construct by 6-fold. Deletion analyses indicated that an AU-rich element (AURE) located between 553 to 625 within the p21(waf1/cip1) 3'-UTR was required for this induction. RNA gel shift assays demonstrated that this AURE bound an RNA-binding protein. This protein has been purified 5000-fold from PE-treated TFG2 cells by heparin-Sepharose and RNA affinity chromatography. SDS-polyacrylamide gel electrophoresis, UV cross-linking, and Northwestern analyses indicated the molecular mass of this protein as 24 and 52 kDa. Finally, PE treatment markedly enhanced this RNA-protein binding by a p42/44 mitogen-activated protein kinase-dependent mechanism. These data suggest that the AURE located between 553 and 625 within the p21(waf1/cip1) mRNA 3'-UTR, which binds an RNA-binding protein, is responsible for PE-induced p21(waf1/cip1) mRNA stability.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA	Virginia Commonwealth University	Gao, B (corresponding author), Box 980613, Richmond, VA 23298 USA.	bgao@hsc.vcu.edu			NCI NIH HHS [R29CA72681] Funding Source: Medline; NIAAA NIH HHS [R01AA12637, R03AA11823] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA072681] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R03AA011823, R01AA012637] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; Antic D, 1997, AM J HUM GENET, V61, P273, DOI 10.1086/514866; Auer KL, 1998, FEBS LETT, V436, P131, DOI 10.1016/S0014-5793(98)01074-6; Boluyt MO, 1997, CIRC RES, V81, P176, DOI 10.1161/01.RES.81.2.176; Chen LQ, 1995, J BIOL CHEM, V270, P30980, DOI 10.1074/jbc.270.52.30980; CRUISE JL, 1985, SCIENCE, V227, P749, DOI 10.1126/science.2982212; CRUISE JL, 1987, HEPATOLOGY, V7, P1189, DOI 10.1002/hep.1840070604; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Esposito F, 1997, EUR J BIOCHEM, V245, P730, DOI 10.1111/j.1432-1033.1997.00730.x; Gao B, 1996, MOL CELL BIOL, V16, P5997; GAO B, 1994, J BIOL CHEM, V269, P15762; Gartel A L, 1998, Prog Mol Subcell Biol, V20, P43; Gorospe M, 1998, MOL CELL BIOL, V18, P1400, DOI 10.1128/MCB.18.3.1400; Graham RM, 1996, CIRC RES, V78, P737, DOI 10.1161/01.RES.78.5.737; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HARPER JW, 1993, CELL, V75, P805; Hu ZW, 1996, J BIOL CHEM, V271, P8977, DOI 10.1074/jbc.271.15.8977; Johannessen LE, 1999, BIOCHEM J, V337, P599, DOI 10.1042/0264-6021:3370599; Joseph B, 1998, J BIOL CHEM, V273, P20511, DOI 10.1074/jbc.273.32.20511; KUNOS G, 1995, ANN NY ACAD SCI, V757, P261, DOI 10.1111/j.1749-6632.1995.tb17483.x; LEE WMF, 1988, MOL CELL BIOL, V8, P5521, DOI 10.1128/MCB.8.12.5521; Li XS, 1996, CANCER RES, V56, P5055; MINNEMAN KP, 1994, ANNU REV PHARMACOL, V34, P117; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; NAKAGAWA J, 1995, P NATL ACAD SCI USA, V92, P2051, DOI 10.1073/pnas.92.6.2051; NANBU R, 1993, J BIOCHEM-TOKYO, V114, P432, DOI 10.1093/oxfordjournals.jbchem.a124193; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Ravi RK, 1999, J CELL BIOCHEM, V72, P458, DOI 10.1002/(SICI)1097-4644(19990315)72:4<458::AID-JCB2>3.0.CO;2-C; RAYMOND V, 1989, ONCOGENE RES, V4, P861; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SCHWALLER J, 1995, J CLIN INVEST, V95, P973, DOI 10.1172/JCI117806; Shao ZM, 1998, J CELL BIOCHEM, V69, P44, DOI 10.1002/(SICI)1097-4644(19980401)69:1<44::AID-JCB5>3.3.CO;2-B; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Spector MS, 1997, MOL CELL BIOL, V17, P3556, DOI 10.1128/MCB.17.7.3556; Zeng YX, 1996, ONCOGENE, V12, P1557; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	41	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11846	11851		10.1074/jbc.275.16.11846	http://dx.doi.org/10.1074/jbc.275.16.11846			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766810	hybrid			2022-12-27	WOS:000086695500045
J	Zapata, JM; Matsuzawa, S; Godzik, A; Leo, E; Wasserman, SA; Reed, JC				Zapata, JM; Matsuzawa, S; Godzik, A; Leo, E; Wasserman, SA; Reed, JC			The Drosophila tumor necrosis factor receptor-associated factor-1 (DTRAF1) interacts with Pelle and regulates NF kappa B activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; DORSOVENTRAL POLARITY; JNK/SAPK ACTIVATION; TARGETED DISRUPTION; APOPTOSIS PROTEINS; CYTOPLASMIC DOMAIN; SIGNALING PATHWAY; FAMILY; KINASE; TUBE	A member of the tumor necrosis factor (TNF) receptor-associated factor (TRAF) family was identified in Drosophila. DTRAF1 contains 7 zinc finger domains followed by a TRAF domain, similar to mammalian TRAFs and other members of the family identified in data bases from Caenorhabditis elegans, Arabidopsis, and Dictyostelium. Analysis of DTRAF1 binding to different members of the human TNF receptor family showed that this protein can interact through its TRAF domain with the p75 neurotrophin receptor and weakly with the lymphotoxin-p receptor. DTRAF1 can also self-associate and binds to human TRAF1, TRAF2, and TRAF4. Interestingly, DTRAF1 interacts with human cIAP-1 and cIAP-2 but not with Drosophila DIAP-1 and -2. By itself, DTRAF1 did not induce significant NF kappa B activation when overexpressed in mammalian cells, although it specifically increased NF kappa B induction by TRAF6. In contrast, TRAF2-mediated NF kappa B induction was partially inhibited by DTRAF1. Mutants of DTRAF1 lacking the N-terminal region inhibited NF kappa B induction by either TRAF2 or TRAF6. DTRAF1 specifically associated with the regulatory N-terminal domain of Pelle, a Drosophila homolog of the human kinase interleukin-1 receptor-associated kinase (IRAK). Interestingly, though Pelle and DTRAF1 individually were unable to induce NF kappa B in a human cell line, co-expression of Pelle and DTRAF1 resulted in significant NF kappa B activity. Interactions of DTRAF1 with human TRAF-, TNF receptor-, and IAP-family proteins imply strong evolutionary conservation of TRAF protein structure and function throughout Metazoan evolution.	Burnham Inst, La Jolla, CA 92037 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego	Reed, JC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jreed@burnham-inst.org	Godzik, Adam/A-7279-2009; Godzik, Adam/AAW-1467-2020; Zapata, Juan M/J-6304-2014	Godzik, Adam/0000-0002-2425-852X; Godzik, Adam/0000-0002-2425-852X; Zapata, Juan M/0000-0002-0110-0009	NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050545] Funding Source: NIH RePORTER; NCI NIH HHS [CA-69381] Funding Source: Medline; NIGMS NIH HHS [GM50545] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; GALINDO RL, 1995, DEVELOPMENT, V121, P2209; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Krajewska M, 1998, AM J PATHOL, V152, P1549; Leo E, 1999, J BIOL CHEM, V274, P22414, DOI 10.1074/jbc.274.32.22414; LETSOU A, 1991, P NATL ACAD SCI USA, V88, P810, DOI 10.1073/pnas.88.3.810; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Magnusson C, 1999, IMMUNOL CELL BIOL, V77, P41, DOI 10.1046/j.1440-1711.1999.00800.x; Medzhitov R, 1998, CURR OPIN IMMUNOL, V10, P12, DOI 10.1016/S0952-7915(98)80024-1; MIYASHITA T, 1995, CELL, V80, P293; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Nakano H, 1999, P NATL ACAD SCI USA, V96, P9803, DOI 10.1073/pnas.96.17.9803; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Qiu P, 1998, DEVELOPMENT, V125, P1909; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; Schiffmann DA, 1999, BIOCHEMISTRY-US, V38, P11722, DOI 10.1021/bi9904252; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; Shen BH, 1998, DEVELOPMENT, V125, P4719; SONG HY, 1995, BIOCHEM J, V309, P825, DOI 10.1042/bj3090825; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Xiao T, 1999, CELL, V99, P545, DOI 10.1016/S0092-8674(00)81542-1; Xu Y, 1996, IMMUNITY, V5, P407, DOI 10.1016/S1074-7613(00)80497-5; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	36	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12102	12107		10.1074/jbc.275.16.12102	http://dx.doi.org/10.1074/jbc.275.16.12102			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766844	hybrid			2022-12-27	WOS:000086695500079
J	Koth, CM; Botuyan, MV; Moreland, RJ; Jansma, DB; Conaway, JW; Conaway, RC; Chazin, WJ; Friesen, JD; Arrowsmith, CH; Edwards, AM				Koth, CM; Botuyan, MV; Moreland, RJ; Jansma, DB; Conaway, JW; Conaway, RC; Chazin, WJ; Friesen, JD; Arrowsmith, CH; Edwards, AM			Elongin from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; ELONGATION-FACTOR-SII; TRANSCRIPTION FACTOR-SIII; TUMOR-SUPPRESSOR PROTEIN; F-BOX; GENE; BINDING; PURIFICATION; PROTEOLYSIS; ACTIVATION	Elongin is a transcription elongation factor that was first identified in mammalian systems and is composed of the three subunits, elongin A, B, and C. Sequence homologues of elongin A and elongin C, but not elongin B, were identified in the yeast genome. Neither yeast elongin A nor C sequence homologues was required for cell viability. The two gene products could be purified from yeast as a complex. A recombinant form of the complex, which could only be produced in bacteria if the gene products were co-expressed, was purified over several chromatographic steps. The complex did not stimulate transcription elongation by yeast RNA polymerase II. Using limited proteolysis, the N-terminal 144 residues of yeast elongin A were shown to be sufficient for interaction with yeast elongin C, The purified complex of yeast elongin C/elongin A(1-143) was analyzed using circular dichroism and nuclear magnetic spectroscopy. These studies revealed that yeast elongin A is unfolded but undergoes a dramatic modification of its structure in the presence of elongin C, and that elongin C forms a stable dimer in the absence of elongin A.	Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Oklahoma Med Res Fdn, Howard Hughes Med Res Inst, Oklahoma City, OK 73190 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Scripps Research Institute; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center	Edwards, AM (corresponding author), Univ Toronto, Dept Med Genet & Microbiol, 1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.			Conaway, Joan/0000-0002-2786-0663; Arrowsmith, Cheryl/0000-0002-4971-3250; Koth, Christopher/0000-0003-3939-8856; Edwards, Aled/0000-0002-4782-6016				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Aso T, 1996, EMBO J, V15, P5557, DOI 10.1002/j.1460-2075.1996.tb00940.x; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; Aso T, 1997, BIOCHEM BIOPH RES CO, V241, P334, DOI 10.1006/bbrc.1997.7819; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; Dresser ME, 1997, GENETICS, V147, P533; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; Fujinaga K, 1998, J VIROL, V72, P7154, DOI 10.1128/JVI.72.9.7154-7159.1998; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MOTE J, 1994, J MOL BIOL, V236, P725, DOI 10.1006/jmbi.1994.1185; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Powell W, 1996, J BIOL CHEM, V271, P6866, DOI 10.1074/jbc.271.12.6866; REINES D, 1993, CELL MOL BIOL RES, V39, P331; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; Thompson DA, 1999, GENETICS, V153, P621; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	40	18	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11174	11180		10.1074/jbc.275.15.11174	http://dx.doi.org/10.1074/jbc.275.15.11174			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753924	hybrid			2022-12-27	WOS:000086466600066
J	Carreira, S; Liu, BG; Goding, CR				Carreira, S; Liu, BG; Goding, CR			The gene encoding the T-box factor Tbx2 is a target for the microphthalmia-associated transcription factor in melanocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSERVED PROTEIN MOTIF; WAARDENBURG SYNDROME; TYROSINASE GENE; ZIPPER TRANSCRIPTION; FAMILY GENES; IN-VITRO; MOUSE; PROMOTER; EXPRESSION; MUTATIONS	Commitment to the melanocyte lineage is characterized by the onset of microphthalmia-associated transcription factor (Mitf) expression. Mitf plays a fundamental role in melanocyte development, with mice lacking Mitf being entirely devoid of pigment cells. In the absence of functional Mitf protein, melanoblasts expressing Mitf mRNA disappear around 2 days after their first appearance either by apoptosis or by losing their identity and adopting an alternative cell fate. The role of Mitf must therefore be to regulate genes required for melanoblast survival, proliferation, or the maintenance of melanoblast identity. Yet to date, Mitf has been shown to regulate genes such as Tyrosinase, Tyrp-1, and Dct, which are required for pigmentation, a differentiation-specific process. Because expression of these genes cannot account for the complete absence of pigment cells in Mitf-negative mice, Mitf must regulate the expression of other as yet uncharacterized genes. Here we provide several lines of evidence to suggest that Mitf may regulate the expression of the Tbx2 transcription factor, a member of the T-box family of proteins implicated in the maintenance of cell identity. First, isolation and sequencing of the entire murine Tbx2 gene revealed that the Tbx2 promoter contains a full consensus Mitf recognition element; second, Mitf could bind the promoter in vitro and activate Tbx2 expression in vivo in an E box-dependent fashion; and third, Tbx2 is expressed in melanoma cell lines expressing Mitf, but not in a line in which Mitf expression was not detectable. Taken together, with the fact that Tbx2 is expressed in Mitf-positive melanoblasts and melanocytes, but not in Mitf-negative melanoblast precursor cells, the evidence suggests that the Tbx2 gene may represent one of the first known targets for Mitf that is not a gene involved directly in the manufacture of pigment.	Marie Curie Res Inst, Eukaryot Transcript Lab, Surrey RH8 0TL, England		Goding, CR (corresponding author), Marie Curie Res Inst, Eukaryot Transcript Lab, Surrey RH8 0TL, England.		Carreira, Suzanne/C-8445-2012	Goding, Colin/0000-0002-1614-3909; Carreira, Suzanne/0000-0002-5077-5379				Aksan I, 1998, MOL CELL BIOL, V18, P6930, DOI 10.1128/MCB.18.12.6930; BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; Bamshad M, 1997, NAT GENET, V16, P311, DOI 10.1038/ng0797-311; Bassi MT, 1996, GENOME RES, V6, P880, DOI 10.1101/gr.6.9.880; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; Bertolotto C, 1996, J CELL BIOL, V134, P747, DOI 10.1083/jcb.134.3.747; Bertolotto C, 1998, MOL CELL BIOL, V18, P694, DOI 10.1128/MCB.18.2.694; Bertolotto C, 1998, J CELL BIOL, V142, P827, DOI 10.1083/jcb.142.3.827; BOLLAG RJ, 1994, NAT GENET, V7, P383, DOI 10.1038/ng0794-383; CAMPBELL C, 1995, GENOMICS, V28, P255, DOI 10.1006/geno.1995.1139; Carreira S, 1998, MOL CELL BIOL, V18, P5099, DOI 10.1128/MCB.18.9.5099; Chapman DL, 1996, DEV DYNAM, V206, P379, DOI 10.1002/(SICI)1097-0177(199608)206:4<379::AID-AJA4>3.0.CO;2-F; Chapman DL, 1998, NATURE, V391, P695, DOI 10.1038/35624; Chervitz SA, 1998, SCIENCE, V282, P2022, DOI 10.1126/science.282.5396.2022; EASTY DJ, 1995, CANCER RES, V55, P2528; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FIDLER IJ, 1981, J NATL CANCER I, V67, P947; Galibert MD, 1999, J BIOL CHEM, V274, P26894, DOI 10.1074/jbc.274.38.26894; GALIBERT MD, 1997, J IMMUNOL, V159, P6167; GANSS R, 1994, J BIOL CHEM, V269, P29808; GOSS P, 1977, CANCER RES, V37, P152; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; KISPERT A, 1995, EMBO J, V14, P4763, DOI 10.1002/j.1460-2075.1995.tb00158.x; KISPERT A, 1993, EMBO J, V12, P3211, DOI 10.1002/j.1460-2075.1993.tb05990.x; Li QY, 1997, NAT GENET, V15, P21; LOWINGS P, 1992, MOL CELL BIOL, V12, P3653, DOI 10.1128/MCB.12.8.3653; MOORE KJ, 1995, TRENDS GENET, V11, P442, DOI 10.1016/S0168-9525(00)89143-X; Muller CW, 1997, NATURE, V389, P884, DOI 10.1038/39929; Opdecamp K, 1997, DEVELOPMENT, V124, P2377; Papaioannou VE, 1997, TRENDS GENET, V13, P212, DOI 10.1016/S0168-9525(97)01144-X; Papaioannou VE, 1998, BIOESSAYS, V20, P9, DOI 10.1002/(SICI)1521-1878(199801)20:1<9::AID-BIES4>3.0.CO;2-Q; Rodriguez-Esteban C, 1999, NATURE, V398, P814, DOI 10.1038/19769; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; Smith J, 1997, CURR OPIN GENET DEV, V7, P474, DOI 10.1016/S0959-437X(97)80073-1; Takeuchi JK, 1999, NATURE, V398, P810, DOI 10.1038/19762; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; Vallet VS, 1998, J BIOL CHEM, V273, P20175, DOI 10.1074/jbc.273.32.20175; Watanabe A, 1998, NAT GENET, V18, P283, DOI 10.1038/ng0398-283; Wattler S, 1998, GENOMICS, V48, P24, DOI 10.1006/geno.1997.5150; Wu M, 2000, GENE DEV, V14, P301; Xu WD, 2000, EXP CELL RES, V255, P135, DOI 10.1006/excr.2000.4803; Yasumoto K, 1997, J BIOL CHEM, V272, P503; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058; YAVUZER U, 1994, MOL CELL BIOL, V14, P3494, DOI 10.1128/MCB.14.5.3494; YAVUZER U, 1995, ONCOGENE, V10, P123; Yi CH, 1999, GENOMICS, V55, P10, DOI 10.1006/geno.1998.5632	49	83	87	3	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21920	21927		10.1074/jbc.M000035200	http://dx.doi.org/10.1074/jbc.M000035200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10770922	hybrid			2022-12-27	WOS:000088363800025
J	Lau, OD; Courtney, AD; Vassilev, A; Marzilli, LA; Cotter, RJ; Nakatani, Y; Cole, PA				Lau, OD; Courtney, AD; Vassilev, A; Marzilli, LA; Cotter, RJ; Nakatani, Y; Cole, PA			p300/CBP-associated factor histone acetyltransferase processing of a peptide substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEROTONIN N-ACETYLTRANSFERASE; MELATONIN RHYTHM ENZYME; CATALYTIC MECHANISM; COACTIVATORS P300; CRYSTAL-STRUCTURE; COENZYME-A; DNA-DAMAGE; ACETYLATION; PCAF; BINDING	p300/CBP-associated factor (PCAF) is a histone acetyltransferase that; plays an important role in the remodeling of chromatin and the regulation of gene expression. It has been shown to catalyze preferentially acetylation of the epsilon-amino group of lysine 14 in histone H3, In this study, the kinetic mechanism of PCAF was evaluated with a 20-amino acid peptide substrate derived from the amino terminus of histone H3 (H3-20) and recombinant bacterially expressed PCAF catalytic domain (PCAF(cat)). The enzymologic behavior of full-length PCAF and PCAF(cat) were shown to be similar. PCAF-catalyzed acetylation of the substrate H3-20 was shown to be specific for Lys-14, analogous to its behavior with the full-length histone H3 protein. Two-substrate kinetic analysis displayed an intersecting line pattern, consistent with a ternary complex mechanism for PCAF, The dead-end inhibitor analog desulfo-CoA was competitive versus acetyl-CoA and noncompetitive versus H3-20, The dead-end analog inhibitor H3-20 K14A was competitive versus H3-20 and uncompetitive versus acetylCoA The potent bisubstrate analog inhibitor H3-CoA-20 was competitive versus acetyl-CoA and noncompetitive versus H3-20. Taken together, these inhibition patterns support an ordered BiBi kinetic mechanism for PCAF in which acetyl-CoA binding precedes H3-20 binding. Viscosity experiments suggest that diffusional release of product is not rate-determining for PCAF catalysis, These results provide a mechanistic framework for understanding the detailed catalytic behavior of an important subset of the histone acetyltransferases and have significant implications for molecular regulation of and inhibitor design for these enzymes.	Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; NICHHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Harvard University; Dana-Farber Cancer Institute	Cole, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Rm 316,Hunterian Bldg,725 N Wolfe St, Baltimore, MD 21205 USA.							Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Cleland W W, 1979, Methods Enzymol, V63, P103; Clements A, 1999, EMBO J, V18, P3521, DOI 10.1093/emboj/18.13.3521; COLE PA, 1994, J BIOL CHEM, V269, P30880; COON SL, 1995, SCIENCE, V270, P1681, DOI 10.1126/science.270.5242.1681; De Angelis J, 1998, J BIOL CHEM, V273, P3045, DOI 10.1074/jbc.273.5.3045; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Herrera JE, 1997, J BIOL CHEM, V272, P27253, DOI 10.1074/jbc.272.43.27253; Hickman AB, 1999, CELL, V97, P361, DOI 10.1016/S0092-8674(00)80745-X; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Khalil EM, 1998, J BIOL CHEM, V273, P30321, DOI 10.1074/jbc.273.46.30321; Khalil EM, 1998, J AM CHEM SOC, V120, P6195, DOI 10.1021/ja981365a; Khalil EM, 1999, P NATL ACAD SCI USA, V96, P12418, DOI 10.1073/pnas.96.22.12418; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Lau OD, 2000, MOL CELL, V5, P589, DOI 10.1016/S1097-2765(00)80452-9; Liu L, 1999, MOL CELL BIOL, V19, P1202; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ott M, 1999, CURR BIOL, V9, P1489, DOI 10.1016/S0960-9822(00)80120-7; Rojas JR, 1999, NATURE, V401, P93, DOI 10.1038/43487; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Schiltz RL, 2000, BBA-REV CANCER, V1470, pM37, DOI 10.1016/S0304-419X(99)00037-2; Segel IH, 1975, ENZYME KINETICS BEHA; Tanner KG, 1999, J BIOL CHEM, V274, P18157, DOI 10.1074/jbc.274.26.18157; Wolf E, 1998, CELL, V94, P439, DOI 10.1016/S0092-8674(00)81585-8; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; ZALUZEC EJ, 1995, PROTEIN EXPRES PURIF, V6, P109, DOI 10.1006/prep.1995.1014	35	103	103	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21953	21959		10.1074/jbc.M003219200	http://dx.doi.org/10.1074/jbc.M003219200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10777508	hybrid			2022-12-27	WOS:000088363800029
J	Jones, M; Basran, J; Sutcliffe, MJ; Grossmann, JG; Scrutton, NS				Jones, M; Basran, J; Sutcliffe, MJ; Grossmann, JG; Scrutton, NS			X-ray scattering studies of Methylophilus methylotrophus (sp W(3)A(1)) electron-transferring flavoprotein - Evidence for multiple conformational states and an induced fit mechanism for assembly with trimethylamine dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; BACTERIUM; W3A1; RESOLUTION; KINETICS; PROGRAM; SITE; AMP; FAD	Small angle x-ray solution scattering has been used to generate a low resolution, model-independent molecular envelope structure for electron-transferring flavoprotein (ETF) from Methylophilus methylotrophus (sp. W(3)A(1)). Analysis of both the oxidized and 1-electron-reduced (anionic flavin semiquinone) forms of the protein revealed that the solution structures of the protein are similar in both oxidation states. Comparison of the molecular envelope of ETF from the x-ray scattering data with previously determined structural models of the protein suggests that ETF samples a range of conformations in solution. These conformations correspond to a rotation of domain II with respect to domains I and III about two flexible "hinge" sequences that are unique to M. methylotrophus ETF, The x-ray scattering data are consistent with previous models concerning the interaction of M. methylotrophus ETF with its physiological redox partner, trimethylamine dehydrogenase. Our data reveal that an "induced fit" mechanism accounts for the assembly of the trimethylamine dehydrogenase-ETF electron transfer complex, consistent with spectroscopic and modeling studies of the assembly process.	SERC, Daresbury Lab, Res Council, Cent Lab, Warrington WA4 4AD, Cheshire, England; Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ Leicester, Dept Chem, Leicester LE1 7RH, Leics, England	STFC Daresbury Laboratory; University of Leicester; University of Leicester	Grossmann, JG (corresponding author), SERC, Daresbury Lab, Res Council, Cent Lab, Warrington WA4 4AD, Cheshire, England.			Sutcliffe, Mike/0000-0003-0414-1700				BARBER MJ, 1988, BIOCHEM J, V256, P657, DOI 10.1042/bj2560657; BYRON CM, 1989, BIOCHEMISTRY-US, V28, P8582, DOI 10.1021/bi00447a047; CHEN DW, 1994, J BIOL CHEM, V269, P32120; Chohan KK, 1998, PROTEIN PEPTIDE LETT, V5, P231; DUPLESSIS ER, 1994, BIOCHEM MOL BIOL INT, V32, P195; Feigin L.A., 1987, STRUCTURE ANAL SMALL; Gallagher SC, 1999, BIOCHEMISTRY-US, V38, P6752, DOI 10.1021/bi982991n; Grossmann JG, 1997, J APPL CRYSTALLOGR, V30, P770; Grossmann JG, 1998, J MOL BIOL, V279, P461, DOI 10.1006/jmbi.1998.1787; Jang MH, 2000, J BIOL CHEM, V275, P12546, DOI 10.1074/jbc.275.17.12546; LEWIS R, 1994, J SYNCHROTRON RADIAT, V1, P43, DOI 10.1107/S090904959400693X; LIM LW, 1986, J BIOL CHEM, V261, P5140; POROD G, 1951, KOLLOID Z Z POLYM, V124, P83, DOI 10.1007/BF01512792; Roberts DL, 1999, BIOCHEMISTRY-US, V38, P1977, DOI 10.1021/bi9820917; Roberts DL, 1996, P NATL ACAD SCI USA, V93, P14355, DOI 10.1073/pnas.93.25.14355; SATO K, 1993, J BIOCHEM, V114, P215, DOI 10.1093/oxfordjournals.jbchem.a124157; SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X; STEENKAMP DJ, 1976, BIOCHIM BIOPHYS ACTA, V429, P705, DOI 10.1016/0005-2744(76)90319-3; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P4086; STUHRMAN.HB, 1970, ACTA CRYSTALL A-CRYS, VA 26, P297, DOI 10.1107/S0567739470000748; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 1997, J APPL CRYSTALLOGR, V30, P798, DOI 10.1107/S0021889897001714; Thorpe C, 1991, CHEM BIOCH FLAVOENZY, P471; TOWNSANDREWS E, 1989, REV SCI INSTRUM, V60, P2346, DOI 10.1063/1.1140765; WHITE SA, 1994, J MOL BIOL, V240, P265, DOI 10.1006/jmbi.1994.1440; WHITFIELD CD, 1974, J BIOL CHEM, V249, P2801; Wilson EK, 1997, BIOCHEMISTRY-US, V36, P41, DOI 10.1021/bi961224q	27	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21349	21354		10.1074/jbc.M001564200	http://dx.doi.org/10.1074/jbc.M001564200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10766748	hybrid			2022-12-27	WOS:000088230600053
J	Zheng, L; Krishnamoorthi, R; Zolkiewski, M; Wang, XM				Zheng, L; Krishnamoorthi, R; Zolkiewski, M; Wang, XM			Distinct Ca2+ binding properties of novel C2 domains of plant phospholipase D alpha and beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MOLECULAR HETEROGENEITY; CRYSTAL-STRUCTURE; SYNAPTOTAGMIN-I; CALCIUM-BINDING; SWISS-MODEL; C-2 DOMAIN; PLD-BETA; ACTIVATION; CALMODULIN	Of the isoforms of plant phospholipase D (PLD) that have been cloned and characterized, PLD alpha requires millimolar levels of Ca2+ for optimal activity, whereas PLD beta is most active at micromolar concentrations of Ca2+. Multiple amino acid sequence alignments suggest that PLD alpha and PLD beta both contain a Ca2+-dependent phospholipid-binding Ca domain near their N termini. In the present study, we expressed and characterized the putative C2 domains of PLD alpha and PLD beta, designated PLD alpha C2 and PLD beta C2, by CD spectroscopy, isothermal titration calorimetry, and phospholipid binding assay. Both PLD C2 domains displayed CD spectra consistent with anticipated major beta-sheet structures but underwent spectral changes upon binding Ca2+; the magnitude was larger for PLD beta C2. These conformational changes, not shown by any of the previously characterized C2 domains of animal origin, occurred at micromolar Ca2+ concentrations for PLD beta C2 but at millimolar levels of the cation for PLD alpha C2. PLD beta C2 exhibited three Ca2+-binding sites: one with a dissociation constant (K-d) of 0.8 mu M and the other two with a K-d of 24 mu M. In contrast, isothermal titration calorimetry data of PLD alpha C2 were consistent with 1-3 low affinity Ca2+ binding sites with K-d in the range of 590-470 mu M. The thermodynamics of Ca2+ binding markedly differed for the two C2 domains. Likewise, PLD beta C2 bound phosphatidylcholine (PC), the substrate of PLD, in the presence of submillimolar Ca2+ concentrations, whereas PLD alpha C2 did so only in the presence of millimolar levels of the metal ion. Both C2 domains bound phosphatidylinoistol 4,5-bisphosphate, a regulator of PC hydrolysis by PLD. However, added Ca2+ displaced the bound phosphatidylinoistol 4,5-bisphosphate. Ca2+ and PC binding properties of PLD alpha C2 and PLD beta C2 follow a trend similar to the Ca2+ requirements of the whole enzymes, PLD alpha and PLD beta, for PC hydrolysis. Taken together, the results suggest that the C2 domains of PLD alpha and PLD beta have novel structural features and serve as handles by which Ca2+ differentially regulates the activities of the isoforms.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA	Kansas State University	Krishnamoorthi, R (corresponding author), Kansas State Univ, Dept Biochem, Willard Hall, Manhattan, KS 66506 USA.		Wang, Xuemin/M-2853-2013	wang, xuemin/0000-0002-6251-6745				ACKERS GK, 1970, ADV PROTEIN CHEM, V24, P342; Ames JB, 1995, J BIOL CHEM, V270, P30909, DOI 10.1074/jbc.270.52.30909; CONCHA NO, 1993, SCIENCE, V261, P1321, DOI 10.1126/science.8362244; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; deVrije T, 1997, J EXP BOT, V48, P1631, DOI 10.1093/jexbot/48.314.1631; Essen LO, 1997, BIOCHEMISTRY-US, V36, P2753, DOI 10.1021/bi962466t; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; IMAIZUMI M, 1987, J BIOL CHEM, V262, P7963; Jacob T, 1999, P NATL ACAD SCI USA, V96, P12192, DOI 10.1073/pnas.96.21.12192; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; Jones D, 1999, BBA-MOL CELL BIOL L, V1439, P229, DOI 10.1016/S1388-1981(99)00097-9; Kopka J, 1998, PLANT MOL BIOL, V36, P627, DOI 10.1023/A:1005915020760; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lomasney JW, 1999, J BIOL CHEM, V274, P21995, DOI 10.1074/jbc.274.31.21995; LU F, 1997, PLANT CELL, V9, P2183; Medkova M, 1999, J BIOL CHEM, V274, P19852, DOI 10.1074/jbc.274.28.19852; Mikoshiba K, 1999, CHEM PHYS LIPIDS, V98, P59, DOI 10.1016/S0009-3084(99)00018-3; MILOS M, 1986, BIOCHEMISTRY-US, V25, P6279, DOI 10.1021/bi00368a067; Moore DD, 1995, GLOB MOB SURV; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Pappan K, 1997, J BIOL CHEM, V272, P7055, DOI 10.1074/jbc.272.11.7055; Pappan K, 1997, J BIOL CHEM, V272, P7048, DOI 10.1074/jbc.272.11.7048; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Ponting CP, 1996, PROTEIN SCI, V5, P162; Qin WS, 1997, J BIOL CHEM, V272, P28267, DOI 10.1074/jbc.272.45.28267; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Rose K, 1995, P NATL ACAD SCI USA, V92, P12151, DOI 10.1073/pnas.92.26.12151; ROSS PD, 1981, BIOCHEMISTRY-US, V20, P3096, DOI 10.1021/bi00514a017; SAMMUEL D, 1997, BIOCHEM MOL BIOL INT, V41, P235; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; Shao XG, 1998, BIOCHEMISTRY-US, V37, P16106, DOI 10.1021/bi981789h; Smith SP, 1998, STRUCTURE, V6, P211, DOI 10.1016/S0969-2126(98)00022-7; Sutton RB, 1998, STRUCTURE, V6, P1395, DOI 10.1016/S0969-2126(98)00139-7; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; WADA Y, 1985, BIOCHIM BIOPHYS ACTA, V832, P383, DOI 10.1016/0167-4838(85)90275-4; Waite KA, 1997, J BIOL CHEM, V272, P15569, DOI 10.1074/jbc.272.24.15569; Wang XM, 1999, PLANT PHYSIOL, V120, P645, DOI 10.1104/pp.120.3.645; WANG XM, 1994, J BIOL CHEM, V269, P20312; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Xu GY, 1998, J MOL BIOL, V280, P485, DOI 10.1006/jmbi.1998.1874	45	109	120	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19700	19706		10.1074/jbc.M001945200	http://dx.doi.org/10.1074/jbc.M001945200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10777500	hybrid			2022-12-27	WOS:000087941300036
J	Ziegler, I; McDonaldo, T; Hesslinger, C; Pelletier, I; Boyle, P				Ziegler, I; McDonaldo, T; Hesslinger, C; Pelletier, I; Boyle, P			Development of the pteridine pathway in the zebrafish, Danio rerio	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP CYCLOHYDROLASE-I; CREST CELL FATE; XANTHINE-OXIDASE; NEURAL CREST; SEPIAPTERIN REDUCTASE; NITRIC-OXIDE; MAST-CELLS; DROSOPHILA-MELANOGASTER; SIGNALING PATHWAY; TETRAHYDROBIOPTERIN	In the zebrafish, the peripheral neurons and the pigment cells are derived from the neural crest and share the pteridine pathway, which leads either to the cofactor tetrahydrobiopterin or to xanthophore pigments. The components of the pteridine pattern were identified as tetrahydrobiopterin, sepiapterin, 7-oxobiopterin, isoxanthopterin, and 2,4,7-trioxopteridine. The expression of GTP cyclohydrolase I activity during the first 24-h postfertilization, followed by 6-pyruvoyl-5,6,7,8-tetrahydropterin synthase and sepiapterin reductase, suggest an early supply of tetrahydrobiopterin for neurotransmitter synthesis in the neurons and for tyrosine supply in the melanophores. At 48-h postfertilization, sepiapterin formation branches off the de novo pathway of tetrahydrobiopterin synthesis, Sepiapterin, via 7,8-dihydrobiopterin and biopterin, serves as a precursor for the formation of 7-oxobiopterin, which may be further catabolized to isoxanthopterin and 2,4,7-trioxopteridine, Neither 7,8-dihydrobiopterin nor biopterin is a substrate for xanthine oxidoreductase. In contrast, both of these compounds are oxidized at C-7 by a xanthine oxidase variant form, which is inactivated by KCN, but is insensitive to allopurinol. The oxidase and the dehydrogenase form of xanthine oxidoreductase as well as the xanthine oxidase variant have specific developmental patterns. It follows that GTP cyclohydrolase I, the formation of sepiapterin, and the xanthine oxidoreductase family control the pteridine pathway in the zebrafish.	GSF, Res Ctr, Inst Klin Mol Biol & Tumorgenet, D-81377 Munich, Germany; Univ Dublin Trinity Coll, Univ Chem Lab, Dublin 2, Ireland	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Trinity College Dublin	Ziegler, I (corresponding author), Tech Univ Munich, Inst Anat, Biedersteinerstr 29, D-80802 Munich, Germany.							AMAYA Y, 1990, J BIOL CHEM, V265, P14170; Auerbach G, 1997, EMBO J, V16, P7219, DOI 10.1093/emboj/16.24.7219; BAGNARA JT, 1979, SCIENCE, V203, P410, DOI 10.1126/science.760198; BECKMAN JS, 1989, FREE RADICAL BIO MED, V6, P607, DOI 10.1016/0891-5849(89)90068-3; BURG AW, 1968, J BIOL CHEM, V243, P2349; DAVIS MD, 1984, J BIOL CHEM, V259, P3526; Dorsky RI, 1998, NATURE, V396, P370, DOI 10.1038/24620; DUTCH DS, 1991, J NUTR BIOCH, V2, P411; Eisen JS, 1996, CELL, V87, P969, DOI 10.1016/S0092-8674(00)81792-4; EISEN JS, 1993, DEV BIOL, V159, P50, DOI 10.1006/dbio.1993.1220; FERRE J, 1985, J CHROMATOGR, V350, P389, DOI 10.1016/S0021-9673(01)93544-7; FORREST HS, 1956, SCIENCE, V124, P725, DOI 10.1126/science.124.3225.725; FUKUSHIMA T, 1980, ANAL BIOCHEM, V102, P176, DOI 10.1016/0003-2697(80)90336-X; Gutlich M, 1996, BIOCHEM J, V314, P95; GUTLICH M, 1994, BIOCHEM BIOPH RES CO, V203, P1675, DOI 10.1006/bbrc.1994.2379; HENION PD, 1996, DEV GENET, V18, P18; Hesslinger C, 1998, J BIOL CHEM, V273, P21616, DOI 10.1074/jbc.273.34.21616; Hirayama K, 1998, J NEUROCHEM, V70, P164; HODNETT CN, 1976, J PHARM SCI, V65, P1150, DOI 10.1002/jps.2600650806; HUNT J, 1992, J BIOL CHEM, V267, P21479; Huttel R, 1943, LIEBIGS ANN CHEM, V554, P69; KAPATOS G, 1992, J NEUROCHEM, V59, P2048; KATOH S, 1982, BIOCHEM BIOPH RES CO, V105, P75, DOI 10.1016/S0006-291X(82)80012-0; KATOH S, 1987, J BIOCHEM-TOKYO, V101, P275, DOI 10.1093/oxfordjournals.jbchem.a121901; Kauffmann T, 1959, LIEBIGS ANN CHEM, V625, P133; KAUFMAN S, 1962, OXYGENASES, P285; Kelsh RN, 1996, DEVELOPMENT, V123, P369; KERLER F, 1990, J CELL PHYSIOL, V142, P268, DOI 10.1002/jcp.1041420208; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MASSEY V, 1970, J BIOL CHEM, V245, P6595; MASSEY V, 1970, J BIOL CHEM, V245, P2837; MATSUMOTO J, 1960, GENETICS, V45, P1177; Milstien S, 1996, J BIOL CHEM, V271, P19743, DOI 10.1074/jbc.271.33.19743; MILSTIEN S, 1983, BIOCHEM BIOPH RES CO, P888; NAKAGOSHI M, 1983, EXPERIENTIA, V39, P742, DOI 10.1007/BF01990303; NICHOL CA, 1983, P NATL ACAD SCI-BIOL, V80, P1546, DOI 10.1073/pnas.80.6.1546; Nilsson GE, 1997, COMP BIOCHEM PHYS A, V118, P949, DOI 10.1016/S0300-9629(97)00024-8; Odenthal J, 1996, DEVELOPMENT, V123, P391; PFLEIDERER W, 1979, CHEM BER-RECL, V112, P2750; PFLEIDERER W, 1957, CHEM BER-RECL, V90, P2588, DOI 10.1002/cber.19570901126; PFLEIDERER W, 1963, ANGEW CHEM INT EDIT, V75, P993, DOI 10.1002/ange.19630752102; Pluss C, 1996, BIOCHEM J, V318, P665; RAIBLE DW, 1994, DEVELOPMENT, V120, P495; REMBOLD H, 1985, FOLATES PTERINS, V2, P155; SCHALLREUTER KU, 1994, SCIENCE, V263, P1444, DOI 10.1126/science.8128228; Schier AF, 1997, CURR OPIN NEUROBIOL, V7, P119, DOI 10.1016/S0959-4388(97)80129-8; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; SWITCHENKO AC, 1984, BIOCHEM BIOPH RES CO, V120, P754, DOI 10.1016/S0006-291X(84)80171-0; SWITCHENKO AC, 1985, J BIOL CHEM, V260, P2945; TAKIKAWA S, 1989, CHEM BIOL PTERIDINES, P306; TAKIKAWA SI, 1986, EUR J BIOCHEM, V161, P295, DOI 10.1111/j.1432-1033.1986.tb10446.x; Terao M, 1997, BIOCHEM SOC T, V25, P791, DOI 10.1042/bst0250791; TSCHESCHE R, 1958, CHEM BER-RECL, V91, P2081, DOI 10.1002/cber.19580911012; UNNASCH TR, 1982, J BIOL CHEM, V257, P4211; WALDNER A, 1986, TETRAHEDRON LETT, V27, P6059, DOI 10.1016/S0040-4039(00)85398-8; Yamamoto T, 1996, J CHROMATOGR B, V681, P395, DOI 10.1016/0378-4347(96)00071-0; ZIEGLER I, 1990, J BIOL CHEM, V265, P17026; ZIEGLER I, 1985, J CELL BIOCHEM, V28, P197, DOI 10.1002/jcb.240280303; ZIEGLER I, 1993, J BIOL CHEM, V268, P12544; ZIEGLER I, 1992, FEBS LETT, V307, P147, DOI 10.1016/0014-5793(92)80755-6; ZIEGLER I, 1963, Z NATURFORSCH PT B, VB 18, P551, DOI 10.1515/znb-1963-0710; ZIEGLERGUNDER I, 1956, Z VERGL PHYSIOL, V39, P163, DOI 10.1007/BF00340422	63	37	44	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18926	18932		10.1074/jbc.M910307199	http://dx.doi.org/10.1074/jbc.M910307199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10770954	hybrid			2022-12-27	WOS:000087815900043
J	Xing, HR; Lozano, J; Kolesnick, R				Xing, HR; Lozano, J; Kolesnick, R			Epidermal growth factor treatment enhances the kinase activity of kinase suppressor of Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; KSR-1 GENE ENCODES; C-ELEGANS; SIGNAL-TRANSDUCTION; MAP KINASE; CERAMIDE; BINDING; MEK; PHOSPHORYLATION; APOPTOSIS	In Drosophila melanogaster and Caenorhabditis elegans, kinase suppressor of Ras (KSR) functions as a positive modulator of Has-dependent signaling either upstream of or parallel to Raf, Attempts to characterize the biochemical and biological properties of mammalian KSR, however, have had limited success. Although some studies demonstrated a requirement of KSR kinase activity for its action, others indicated the kinase function of KSR is dispensable and suggested that KSR acts primarily as a scaffold protein. Interpretations of KSR function are further hampered by the lack of a standardized assay for its kinase activity in vitro, To address this issue, we established a two-stage in vitro kinase assay in which KSR never comes in contact with any recombinant kinases other than c-Raf-l, Using this assay, we show that KSR immunoprecipitated from quiescent COS-7 cells overexpressing Flag-tagged KSR was inactive, but its activity was rapidly and markedly induced upon epidermal growth factor treatment. Moreover, KSR-reconstituted mitogen-activated protein kinase activation was detected in KSR immunoprecipitates depleted of all contaminating kinases (c-Raf-l, MEK1, ERK2) by multiple high salt washes. Only full-length kinase-active KSR was capable of signaling c-Raf-1-dependent activity as kinase inactive and C- and N-terminal deletion mutants were without effect. Furthermore, endogenous KSR isolated from A431 cells, which contain high levels of activated EGF receptor, displays constitutively enhanced kinase activity. Hence, KSR kinase activity is not an artifact of overexpression but a property intrinsic to this protein. The recognition of EGF as a potent activator of KSR kinase activity and the availability of a well defined in vitro kinase assay should facilitate the definition of the function of KSR as a Ras-effector molecule.	Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, Sloan Kettering, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Kolesnick, R (corresponding author), Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, Sloan Kettering, 1275 York Ave, New York, NY 10021 USA.		Lozano, José/C-2760-2014	Lozano, José/0000-0002-8187-2833	NCI NIH HHS [CA42385] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Basu S, 1998, J BIOL CHEM, V273, P30419, DOI 10.1074/jbc.273.46.30419; Cacace AM, 1999, MOL CELL BIOL, V19, P229; Denouel-Galy A, 1998, CURR BIOL, V8, P46, DOI 10.1016/S0960-9822(98)70019-3; Joneson T, 1998, J BIOL CHEM, V273, P7743, DOI 10.1074/jbc.273.13.7743; KING ICL, 1986, BIOCHEM BIOPH RES CO, V140, P837, DOI 10.1016/0006-291X(86)90710-2; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; Michaud NR, 1997, P NATL ACAD SCI USA, V94, P12792, DOI 10.1073/pnas.94.24.12792; Payne SG, 1999, J CELL PHYSIOL, V180, P263, DOI 10.1002/(SICI)1097-4652(199908)180:2<263::AID-JCP14>3.0.CO;2-H; Sieburth DS, 1999, GENE DEV, V13, P2562, DOI 10.1101/gad.13.19.2562; Sieburth DS, 1998, CELL, V94, P119, DOI 10.1016/S0092-8674(00)81227-1; Stewart S, 1999, MOL CELL BIOL, V19, P5523; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; Therrien M, 1998, CELL, V95, P343, DOI 10.1016/S0092-8674(00)81766-3; Xing HM, 1997, CURR BIOL, V7, P294, DOI 10.1016/S0960-9822(06)00152-7; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Yu W, 1998, CURR BIOL, V8, P56, DOI 10.1016/S0960-9822(98)70020-X; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	19	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17276	17280		10.1074/jbc.C900989199	http://dx.doi.org/10.1074/jbc.C900989199			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10764733	hybrid			2022-12-27	WOS:000087485000011
J	Berson, JF; Frank, DW; Calvo, PA; Bieler, BM; Marks, MS				Berson, JF; Frank, DW; Calvo, PA; Bieler, BM; Marks, MS			A common temperature-sensitive allelic form of human tyrosinase is retained in the endoplasmic reticulum at the nonpermissive temperature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HLA-DR MOLECULES; OCULOCUTANEOUS ALBINISM; PROTEIN-DEGRADATION; SECRETORY PATHWAY; QUALITY-CONTROL; PARAMYOTONIA-CONGENITA; MISFOLDED PROTEINS; GENE-MUTATIONS; T-CELL; MELANOCYTES	Oculocutaneous albinism type 1TS is caused by mutations that render the melanocyte-specific enzyme tyrosinase temperature-sensitive (ts); the enzyme is inactive in cells grown at 37 degrees C but displays full activity in cells grown at 31 degrees C. To distinguish whether the ts phenotype of the common R402Q variant of human tyrosinase is due to altered enzymatic activity or to misfolding and a defect in intracellular trafficking, we analyzed its localization and processing in transiently transfected HeLa cells. R402Q tyrosinase accumulates in the endoplasmic reticulum (ER) at 37 degrees C but exits the ER and accumulates in endosomal structures in cells grown at 31 degrees C. The inability of the R402Q variant to exit the ER is confirmed by the failure to acquire endoglycosidase H resistance at 37 degrees C and cannot be accounted for solely by enhanced proteasome-mediated degradation. ER retention at 37 degrees C is mediated by the lumenal domain of R402Q tyrosinase, is not dependent on tethering to the membrane, and is irreversible. Finally, a wild-type allelic form of tyrosinase is partially ts in transiently transfected HeLa cells. The data show that human tyrosinase expressed in non-melanogenic cells folds and exits the ER inefficiently and that R402Q tyrosinase exaggerates this defect, resulting in a failure to exit the ER at physiologic temperatures.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Marks, MS (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 277 John Morgan Bldg 6082,36th & Hamilton Walk, Philadelphia, PA 19104 USA.	marksm@mail.med.upenn.edu	Marks, Michael S/Q-7223-2019	Marks, Michael S/0000-0001-7435-7262	NCI NIH HHS [T32 CA 09140] Funding Source: Medline; NEI NIH HHS [T32 EY 07131, R01 EY 12207] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009140] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY012207, T32EY007131] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Bergmann JE, 1989, METHOD CELL BIOL, V32, P85; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; Calvo PA, 1999, J BIOL CHEM, V274, P12780, DOI 10.1074/jbc.274.18.12780; CHEN YT, 1995, P NATL ACAD SCI USA, V92, P8125, DOI 10.1073/pnas.92.18.8125; DAKOUR J, 1993, EXP CELL RES, V209, P288, DOI 10.1006/excr.1993.1313; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; delMarmol V, 1996, FEBS LETT, V381, P165, DOI 10.1016/0014-5793(96)00109-3; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Denzin LK, 1996, J EXP MED, V184, P2153, DOI 10.1084/jem.184.6.2153; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; DONATIEN PD, 1995, EUR J BIOCHEM, V232, P159, DOI 10.1111/j.1432-1033.1995.tb20794.x; Durr G, 1998, MOL BIOL CELL, V9, P1149, DOI 10.1091/mbc.9.5.1149; GIEBEL LB, 1991, J CLIN INVEST, V87, P1119, DOI 10.1172/JCI115075; GIEBEL LB, 1991, AM J HUM GENET, V48, P1159; HALABAN R, 1988, P NATL ACAD SCI USA, V85, P7241, DOI 10.1073/pnas.85.19.7241; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hebert DN, 1997, J CELL BIOL, V139, P613, DOI 10.1083/jcb.139.3.613; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; Hong E, 1996, J CELL BIOL, V135, P623, DOI 10.1083/jcb.135.3.623; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Jimbow K, 1997, PIGM CELL RES, V10, P206, DOI 10.1111/j.1600-0749.1997.tb00486.x; JIMENEZ M, 1991, J BIOL CHEM, V266, P1147; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; King J, 1996, FASEB J, V10, P57, DOI 10.1096/fasebj.10.1.8566549; KING RA, 1991, J CLIN INVEST, V87, P1046, DOI 10.1172/JCI115064; KING RA, 1991, MOL BIOL MED, V8, P19; KING RA, 1995, METABOLIC MOL BASES, V3, P4353; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; Kobayashi T, 1998, J BIOL CHEM, V273, P31801, DOI 10.1074/jbc.273.48.31801; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Kropshofer H, 1997, IMMUNITY, V6, P293, DOI 10.1016/S1074-7613(00)80332-5; KWON BS, 1989, BIOCHEM BIOPH RES CO, V161, P252, DOI 10.1016/0006-291X(89)91588-X; KWON BS, 1987, P NATL ACAD SCI USA, V84, P7473, DOI 10.1073/pnas.84.21.7473; LEONARD WJ, 1983, P NATL ACAD SCI-BIOL, V80, P6957, DOI 10.1073/pnas.80.22.6957; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LOW SH, 1994, J BIOL CHEM, V269, P1985; MARKS MS, 1995, J CELL BIOL, V131, P351, DOI 10.1083/jcb.131.2.351; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; MCCLATCHEY AI, 1992, CELL, V68, P769, DOI 10.1016/0092-8674(92)90151-2; Mosse CA, 1998, J EXP MED, V187, P37, DOI 10.1084/jem.187.1.37; ORLOW SJ, 1995, J INVEST DERMATOL, V105, P3, DOI 10.1111/1523-1747.ep12312291; ORLOW SJ, 1993, J INVEST DERMATOL, V100, P55, DOI 10.1111/1523-1747.ep12354138; Payne AS, 1998, P NATL ACAD SCI USA, V95, P10854, DOI 10.1073/pnas.95.18.10854; Potterf SB, 1998, EXP CELL RES, V244, P319, DOI 10.1006/excr.1998.4173; PTACEK LJ, 1992, NEURON, V8, P891; Santini F, 1998, MOL BIOL CELL, V9, P1177, DOI 10.1091/mbc.9.5.1177; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; TOMITA Y, 1993, J INVEST DERMATOL, V100, pS186, DOI 10.1111/1523-1747.ep12465155; Topalian SL, 1996, J EXP MED, V183, P1965, DOI 10.1084/jem.183.5.1965; TOPALIAN SL, 1994, P NATL ACAD SCI USA, V91, P9461, DOI 10.1073/pnas.91.20.9461; Toyofuku K, 1999, J BIOCHEM, V125, P82, DOI 10.1093/oxfordjournals.jbchem.a022272; TRIPATHI RK, 1992, J BIOL CHEM, V267, P23707; TRIPATHI RK, 1992, AM J MED GENET, V43, P865, DOI 10.1002/ajmg.1320430523; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Zhang JX, 1997, MOL BIOL CELL, V8, P1943, DOI 10.1091/mbc.8.10.1943	61	97	99	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12281	12289		10.1074/jbc.275.16.12281	http://dx.doi.org/10.1074/jbc.275.16.12281			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766867	hybrid			2022-12-27	WOS:000086695500102
J	Gao, BN; Sekido, Y; Maximov, A; Saad, M; Forgacs, E; Latif, F; Wei, MH; Lerman, M; Lee, JH; Perez-Reyes, E; Bezprozvanny, I; Minna, JD				Gao, BN; Sekido, Y; Maximov, A; Saad, M; Forgacs, E; Latif, F; Wei, MH; Lerman, M; Lee, JH; Perez-Reyes, E; Bezprozvanny, I; Minna, JD			Functional properties of a new voltage-dependent calcium channel alpha(2)delta auxiliary subunit gene (CACNA2D2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EATON-MYASTHENIC-SYNDROME; TUMOR-SUPPRESSOR GENE; BETA-SUBUNIT; MOLECULAR DIVERSITY; DNA METHYLATION; SKELETAL-MUSCLE; GAMMA-SUBUNIT; CA2+ CHANNELS; LUNG-CANCER; N-TYPE	We have positionally cloned and characterized a new calcium channel auxiliary subunit, alpha(2)delta-2 (CACNA2D2), which shares 56% amino acid identity with the known alpha(2)delta-1 subunit. The gene maps to the critical human tumor suppressor gene region in chromosome 3p21.3, showing very frequent allele loss and occasional homozygous deletions in lung, breast, and other cancers. The tissue distribution of alpha(2)delta-2 expression is different from alpha(2)delta-1, and alpha(2)delta-2 mRNA is most abundantly expressed in lung and testis and well expressed in brain, heart, and pancreas. In contrast, alpha(2)delta-1 is expressed predominantly in brain, heart, and skeletal muscle. When co-expressed (via cRNA injections) with alpha(1B) and beta(3) subunits in Xenopus oocytes, alpha(2)delta-2 increased peak size of the N-type Ca2+ currents 9-fold, and when co-expressed with alpha(1C) or alpha(1G) subunits in Xenopus oocytes increased peak size of L-type channels 2-fold and T-type channels 1.8-fold, respectively. Anti-peptide antibodies detect the expression of a 129-kDa alpha(2)delta-2 polypeptide in some but not all lung tumor cells, We conclude that the alpha(2)delta-2 gene encodes a functional auxiliary subunit of voltage-gated Ca2+ channels. Because of its chromosomal location and expression patterns, CACNA2D2 needs to be explored as a potential tumor suppressor gene linking Ca2+ signaling and lung, breast, and other cancer pathogenesis. The homologous location on mouse chromosome 9 is also the site of the mouse neurologic mutant ducky (du), and thus, CACNA2D2 is also a candidate gene for this inherited idiopathic generalized epilepsy syndrome.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Univ Birmingham, Birmingham B15 2TT, W Midlands, England; NCI, Frederick Canc Res & Dev Ctr, Immunobiol Lab, Frederick, MD 21702 USA; Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Birmingham; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Virginia	Minna, JD (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Sekido, Yoshitaka/P-9756-2015; Tuluc, Petronel/C-2527-2011	Sekido, Yoshitaka/0000-0002-2428-3848	NCI NIH HHS [P50-CA70907, P50 CA070907, CA71618, R01 CA071618] Funding Source: Medline; NINDS NIH HHS [R01 NS038691, NS38691] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071618, P50CA070907, Z01BC008579] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038691] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Angelotti T, 1996, FEBS LETT, V397, P331, DOI 10.1016/S0014-5793(96)01205-7; Bangalore R, 1996, AM J PHYSIOL-HEART C, V270, pH1521, DOI 10.1152/ajpheart.1996.270.5.H1521; Barclay J, 1999, EPILEPSIA, V40, P137; Baylin SB, 1998, ADV CANCER RES, V72, P141; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; Black JL, 1999, MAYO CLIN PROC, V74, P357, DOI 10.4065/74.4.357; Brown JP, 1998, J BIOL CHEM, V273, P25458, DOI 10.1074/jbc.273.39.25458; BRUST PF, 1993, NEUROPHARMACOLOGY, V32, P1089, DOI 10.1016/0028-3908(93)90004-M; Burgess DL, 1997, CELL, V88, P385, DOI 10.1016/S0092-8674(00)81877-2; CASTELLANO A, 1994, BIOCHEM SOC T, V22, P483, DOI 10.1042/bst0220483; Chuang RSI, 1998, NAT NEUROSCI, V1, P668, DOI 10.1038/3669; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; DEWAARD M, 1995, J PHYSIOL-LONDON, V485, P619, DOI 10.1113/jphysiol.1995.sp020757; Dolphin AC, 1999, J PHYSIOL-LONDON, V519, P35, DOI 10.1111/j.1469-7793.1999.0035o.x; ELLINOR PT, 1994, NATURE, V372, P272, DOI 10.1038/372272a0; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; Estacion M, 1997, CELL SIGNAL, V9, P363, DOI 10.1016/S0898-6568(96)00184-2; Fondon JW, 1998, P NATL ACAD SCI USA, V95, P7514, DOI 10.1073/pnas.95.13.7514; Gurnett CA, 1996, NEURON, V16, P431, DOI 10.1016/S0896-6273(00)80061-6; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Jones LP, 1998, J GEN PHYSIOL, V112, P125, DOI 10.1085/jgp.112.2.125; Klugbauer N, 1999, J NEUROSCI, V19, P684; Lehmann-Horn F, 1999, PHYSIOL REV, V79, P1317, DOI 10.1152/physrev.1999.79.4.1317; LENNON VA, 1995, NEW ENGL J MED, V332, P1467, DOI 10.1056/NEJM199506013322203; Letts VA, 1998, NAT GENET, V19, P340, DOI 10.1038/1228; Lory P, 1997, HUM GENET, V100, P149, DOI 10.1007/s004390050481; MCENERY MW, 1991, P NATL ACAD SCI USA, V88, P11095, DOI 10.1073/pnas.88.24.11095; MEIER H, 1968, ACTA NEUROPATHOL, V11, P15, DOI 10.1007/BF00692792; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; NOEBELS JL, 1995, IDIOPATHIC GEN EPILE, P215; ONEILL JH, 1988, BRAIN, V111, P577, DOI 10.1093/brain/111.3.577; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; PEREZREYES E, 1995, KIDNEY INT, V48, P1111, DOI 10.1038/ki.1995.395; Qin N, 1998, AM J PHYSIOL-CELL PH, V274, pC1324, DOI 10.1152/ajpcell.1998.274.5.C1324; Randall A, 1999, MOL CELL NEUROSCI, V14, P255, DOI 10.1006/mcne.1999.0795; Raymond C, 1999, NEUROSCIENCE, V90, P269, DOI 10.1016/S0306-4522(98)00378-9; RUDY B, 1992, METHOD ENZYMOL, V207, P225; SCHMID A, 1986, BIOCHEMISTRY-US, V25, P3492, DOI 10.1021/bi00360a002; Schmutte C, 1998, BIOL CHEM, V379, P377; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Sekido Y, 1998, BBA-REV CANCER, V1378, pF21, DOI 10.1016/S0304-419X(98)00010-9; SHARP AH, 1989, J BIOL CHEM, V264, P2816; Shirokov R, 1998, J GEN PHYSIOL, V111, P807, DOI 10.1085/jgp.111.6.807; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; Stefani A, 1998, NEUROPHARMACOLOGY, V37, P83, DOI 10.1016/S0028-3908(97)00189-5; SuhKim HY, 1996, RECEPTOR CHANNEL, V4, P217; Takamori M, 1999, INTERNAL MED, V38, P86, DOI 10.2169/internalmedicine.38.86; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; Toyota M, 1999, CANCER RES, V59, P4535; Voltz R, 1999, MUSCLE NERVE, V22, P119, DOI 10.1002/(SICI)1097-4598(199901)22:1<119::AID-MUS19>3.0.CO;2-5; Walker D, 1998, TRENDS NEUROSCI, V21, P148, DOI 10.1016/S0166-2236(97)01200-9; Wei MH, 1996, CANCER RES, V56, P1487; Wei X, 1996, RECEPTOR CHANNEL, V4, P205; WEI XY, 1995, J BIOL CHEM, V270, P27106, DOI 10.1074/jbc.270.45.27106; WELLING A, 1992, AM J PHYSIOL, V262, pL351, DOI 10.1152/ajplung.1992.262.3.L351; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; Wistuba II, 1999, ONCOGENE, V18, P643, DOI 10.1038/sj.onc.1202349	59	129	141	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12237	12242		10.1074/jbc.275.16.12237	http://dx.doi.org/10.1074/jbc.275.16.12237			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766861	hybrid, Green Accepted			2022-12-27	WOS:000086695500096
J	Jordi, JAM; Higgins, CF				Jordi, JAM; Higgins, CF			The downstream regulatory element of the proU operon of Salmonella typhimurium inhibits open complex formation by RNA polymerase at a distance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN H-NS; TRANSCRIPTIONAL SILENCER DOWNSTREAM; ESCHERICHIA-COLI; GENE-EXPRESSION; OSMOTIC REGULATION; POTASSIUM GLUTAMATE; PROLINE TRANSPORT; DNA INTERACTIONS; GLYCINE BETAINE; HIGH-OSMOLALITY	The intracellular concentration of K+-glutamate, chromatin-associated proteins, and a downstream regulatory element (DRE) overlapping with the coding sequence, have been implicated in the regulation of the proU operon of Salmonella typhimurium, The basal expression of the proU operon is low, but it is rapidly induced when the bacteria are grown in media of high osmolarity (e.g. 0.3 M NaCl). It has previously been suggested that increased intracellular concentrations of K+-glutamate activate the proU promoter in response to increased extracellular osmolarity. We show here that the activation of the proU promoter by K+-glutamate in vitro is nonspecific, and the in vivo regulation cannot simply be mimicked in vitro. In vivo specificity requires both the chromatin-associated protein H-NS and the DRE; they are both needed to maintain repression of proU expression at low osmolarity, How H-NS and the DRE repress the proU promoter in vivo has so far been unclear. We show that, in vivo, the DRE acts at a distance to inhibit open complex formation at the proU promoter.	Fac Vet Sci, Inst Infect Dis & Immunol, Dept Bacteriol, NL-3508 TD Utrecht, Netherlands; Hammersmith Hosp, Imperial Coll Sch Med, MRC, Ctr Clin Sci, London W12 0NN, England	Imperial College London	Jordi, JAM (corresponding author), Fac Vet Sci, Inst Infect Dis & Immunol, Dept Bacteriol, Yalelaan 1, NL-3508 TD Utrecht, Netherlands.							AHMAD KA, 1988, BIOCHEM SOC T, V16, P1068, DOI 10.1042/bst0161068; Atlung T, 1997, MOL MICROBIOL, V24, P7, DOI 10.1046/j.1365-2958.1997.3151679.x; BERTANI G, 1951, J BACTERIOL, V62, P293, DOI 10.1128/JB.62.3.293-300.1951; BURNS H, 1994, NUCLEIC ACIDS RES, V22, P3840, DOI 10.1093/nar/22.19.3840; CAIRNEY J, 1985, J BACTERIOL, V164, P1224, DOI 10.1128/JB.164.3.1224-1232.1985; CARTWRIGHT CP, 1992, YEAST, V8, P261, DOI 10.1002/yea.320080404; CSONKA LN, 1994, J BACTERIOL, V176, P6324, DOI 10.1128/jb.176.20.6324-6333.1994; DAYN A, 1991, J BACTERIOL, V173, P2658, DOI 10.1128/jb.173.8.2658-2664.1991; DRUGERLIOTTA J, 1986, J BACTERIOL, V169, P2449; DUNLAP VJ, 1985, J BACTERIOL, V163, P296, DOI 10.1128/JB.163.1.296-304.1985; FLETCHER SA, 1995, J BACTERIOL, V177, P4508, DOI 10.1128/jb.177.15.4508-4513.1995; GOWRISHANKAR J, 1985, J BACTERIOL, V164, P434, DOI 10.1128/JB.164.1.434-445.1985; GRALLA JD, 1993, FOOTPRINTING NUCL AC, V1, P107; HIGGINS CF, 1988, CELL, V52, P569, DOI 10.1016/0092-8674(88)90470-9; HINTON JCD, 1992, MOL MICROBIOL, V6, P2327, DOI 10.1111/j.1365-2958.1992.tb01408.x; HSIEH LS, 1991, J BACTERIOL, V173, P3914, DOI 10.1128/JB.173.12.3914-3917.1991; HULTON CSJ, 1990, CELL, V63, P631, DOI 10.1016/0092-8674(90)90458-Q; Jordi BJAM, 1997, J BIOL CHEM, V272, P12083, DOI 10.1074/jbc.272.18.12083; JORDI BJAM, 1995, EMBO J, V14, P5690, DOI 10.1002/j.1460-2075.1995.tb00256.x; JOVANOVICH SB, 1989, J BIOL CHEM, V264, P7821; JUBETE Y, 1995, J BACTERIOL, V177, P242, DOI 10.1128/jb.177.1.242-246.1995; LEIRMO S, 1987, BIOCHEMISTRY-US, V26, P2095, DOI 10.1021/bi00382a006; LUCHT JM, 1991, J BACTERIOL, V173, P801, DOI 10.1128/jb.173.2.801-809.1991; LUCHT JM, 1994, J BIOL CHEM, V269, P6578; MANNA D, 1994, J BACTERIOL, V176, P5378, DOI 10.1128/JB.176.17.5378-5384.1994; Maxam A M, 1980, Methods Enzymol, V65, P499; MAY G, 1986, MOL GEN GENET, V205, P225, DOI 10.1007/BF00430432; MCCLELLAN JA, 1990, P NATL ACAD SCI USA, V87, P8373, DOI 10.1073/pnas.87.21.8373; Murphree D, 1997, J BACTERIOL, V179, P5736, DOI 10.1128/jb.179.18.5736-5743.1997; OVERDIER DG, 1992, P NATL ACAD SCI USA, V89, P3140, DOI 10.1073/pnas.89.7.3140; OWENHUGHES TA, 1992, CELL, V71, P255, DOI 10.1016/0092-8674(92)90354-F; PRINCE WS, 1990, J BIOL CHEM, V265, P17673; RAMIREZ RM, 1989, P NATL ACAD SCI USA, V86, P1153, DOI 10.1073/pnas.86.4.1153; RICHEY B, 1987, J BIOL CHEM, V262, P7157; ROE JH, 1985, BIOCHEMISTRY-US, V24, P4721, DOI 10.1021/bi00339a002; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNETZ K, 1995, EMBO J, V14, P2545, DOI 10.1002/j.1460-2075.1995.tb07252.x; STIRLING DA, 1989, MOL MICROBIOL, V3, P1025, DOI 10.1111/j.1365-2958.1989.tb00253.x; SUTHERLAND L, 1986, J BACTERIOL, V168, P805, DOI 10.1128/jb.168.2.805-814.1986; Trachman JD, 1998, J BACTERIOL, V180, P3715, DOI 10.1128/JB.180.14.3715-3718.1998; TUPPER AE, 1994, EMBO J, V13, P258, DOI 10.1002/j.1460-2075.1994.tb06256.x; UEGUCHI C, 1993, EMBO J, V12, P1039, DOI 10.1002/j.1460-2075.1993.tb05745.x; USSERY DW, 1994, BIOCHIMIE, V76, P968, DOI 10.1016/0300-9084(94)90022-1	43	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12123	12128		10.1074/jbc.275.16.12123	http://dx.doi.org/10.1074/jbc.275.16.12123			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766847	hybrid			2022-12-27	WOS:000086695500082
J	Bates, ME; Green, VL; Bertics, PJ				Bates, ME; Green, VL; Bertics, PJ			ERK1 and ERK2 activation by chemotactic factors in human eosinophils is interleukin 5-dependent and contributes to leukotriene C-4 biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; COLONY-STIMULATING FACTOR; PROTEIN-KINASE KINASE; TYROSINE KINASE; MAP KINASE; IN-VITRO; GM-CSF; RECEPTOR; IL-5; JAK2	Eosinophils, the major immune effector cells contributing to allergic inflammation and asthma, are profoundly affected by interleukin (IL) 5 with respect to their differentiation, viability, recruitment, and cytotoxic effector functions. IL-5 enhances eosinophil responsiveness to a variety of chemotactic factors via a process called priming, although the molecular mechanism is unknown. In this study, we report that, following IL-5 priming of eosinophils, chemotactic agents including fMet-Leu-Phe, IL-8, and RANTES, promote vigorous transient activation of ERK1 and ERK2. In contrast, these chemotactic factors stimulate weak or indiscernible ERK activation in unprimed eosinophils. Furthermore, this intracellular marker of priming is selective for IL-5-related cytokines, in that it is observed following exposure to IL-5 and granulocyte macrophage-colony stimulating factor but not to interferon-gamma, stem cell factor, tumor necrosis factor alpha, or IL-4, Interestingly, priming of chemoattractant-induced ERK activation is accompanied by an increase in association of tyrosine-phosphorylated proteins with the adapter protein Grb2, The biological relevance of ERK activation to IL-5 priming is supported by the observation that inhibition of ERK activity by treatment with the MEK inhibitors PD98059 or U0126 inhibited the release of leukotriene C-4 stimulated by fMet-Leu-Phe in IL-5-primed eosinophils, These data provide evidence for a previously undescribed fundamental mechanism by which stimulation of IL-5 family receptors induces a rapid phenotypic alteration in the signal transduction pathways of chemotactic receptors, enabling their activation of the ERK1 and ERK2 pathway and contributing to the capacity of these cells to synthesize LTC4.	Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Bertics, PJ (corresponding author), Univ Wisconsin, Dept Biomol Chem, 1300 Univ Ave, Madison, WI 53706 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI034891, U01AI034891] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56396] Funding Source: Medline; NIAID NIH HHS [AI34891] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALAM R, 1995, INT ARCH ALLERGY IMM, V107, P226, DOI 10.1159/000236985; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Aragay AM, 1998, FEBS LETT, V430, P37, DOI 10.1016/S0014-5793(98)00495-5; Bates ME, 1998, AM J RESP CELL MOL, V18, P75, DOI 10.1165/ajrcmb.18.1.2766; Bates ME, 1996, J IMMUNOL, V156, P711; BATES ME, 1998, THESIS U WISCONSIN M; Boehme SA, 1999, J IMMUNOL, V163, P1611; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; BOULTON TG, 1990, J BIOL CHEM, V265, P2713; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; Coffer PJ, 1998, BLOOD, V91, P2547, DOI 10.1182/blood.V91.7.2547.2547_2547_2557; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Duncia JV, 1998, BIOORG MED CHEM LETT, V8, P2839, DOI 10.1016/S0960-894X(98)00522-8; FABIAN I, 1992, BRIT J HAEMATOL, V80, P137, DOI 10.1111/j.1365-2141.1992.tb08890.x; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Giembycz MA, 1999, PHARMACOL REV, V51, P213; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GLEICH GJ, 1993, ANNU REV MED, V44, P85, DOI 10.1146/annurev.me.44.020193.000505; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; Hiraguri M, 1997, J ALLERGY CLIN IMMUN, V100, pS45; Humbert M, 1997, AM J RESP CELL MOL, V16, P1; KERNEN P, 1991, J CLIN INVEST, V87, P2012, DOI 10.1172/JCI115230; KITA H, 1991, J IMMUNOL, V147, P3466; Kodama T, 1999, BIOCHEM J, V337, P201, DOI 10.1042/0264-6021:3370201; Lalani T, 1999, ANN ALLERG ASTHMA IM, V82, P317, DOI 10.1016/S1081-1206(10)63281-4; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; MORITA E, 1989, SCAND J IMMUNOL, V29, P709, DOI 10.1111/j.1365-3083.1989.tb01175.x; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; Ogata N, 1998, BLOOD, V91, P2264, DOI 10.1182/blood.V91.7.2264.2264_2264_2271; PAZDRAK K, 1995, J IMMUNOL, V155, P397; Pazdrak K, 1997, J EXP MED, V186, P561, DOI 10.1084/jem.186.4.561; PAZDRAK K, 1995, J EXP MED, V181, P1827, DOI 10.1084/jem.181.5.1827; Power CA, 1996, TRENDS PHARMACOL SCI, V17, P209, DOI 10.1016/0165-6147(96)10019-5; Rane MJ, 1997, J IMMUNOL, V159, P5070; RAY LB, 1988, J BIOL CHEM, V263, P12721; Saito M, 1996, FASEB J, V10, P792, DOI 10.1096/fasebj.10.7.8635697; Scherle PA, 1998, J IMMUNOL, V161, P5681; SCHWEIZER RC, 1994, BLOOD, V83, P3697; SEDGWICK JB, 1995, J ALLERGY CLIN IMMUN, V96, P375, DOI 10.1016/S0091-6749(95)70057-9; SEHMI R, 1992, BLOOD, V79, P2952; TAKAFUJI S, 1991, J IMMUNOL, V147, P3855; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; VANDERBRUGGEN T, 1995, BLOOD, V85, P1442, DOI 10.1182/blood.V85.6.1442.bloodjournal8561442; VANOOSTERHOUT AJM, 1994, MEDIAT INFLAMM, V3, P53, DOI 10.1155/S0962935194000098; WARRINGA RAJ, 1992, AM J RESP CELL MOL, V7, P631, DOI 10.1165/ajrcmb/7.6.631; Xu SC, 1997, MOL ENDOCRINOL, V11, P1618, DOI 10.1210/me.11.11.1618; Yousefi S, 1996, J EXP MED, V183, P1407, DOI 10.1084/jem.183.4.1407	49	70	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10968	10975		10.1074/jbc.275.15.10968	http://dx.doi.org/10.1074/jbc.275.15.10968			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753897	hybrid			2022-12-27	WOS:000086466600039
J	Matkovich, SJ; Woodcock, EA				Matkovich, SJ; Woodcock, EA			Ca2+-activated but not G protein-mediated inositol phosphate responses in rat neonatal cardiomyocytes involve inositol 1,4,5-trisphosphate generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C ISOZYMES; CARDIAC SARCOPLASMIC-RETICULUM; POLYPHOSPHATE 1-PHOSPHATASE; KINASE-C; VENTRICULAR MYOCYTES; MYOCARDIAL-ISCHEMIA; ALPHA-SUBUNITS; METABOLISM; RELEASE; HEART	Inositol phosphate (InsP) responses to receptor activation are assumed to involve phospholipase C cleavage of phosphatidylinositol 4,5-bisphosphate to generate Ins(1,4,5)P-3. However, in [H-3]inositol-labeled rat neonatal cardiomyocytes (NCM) both initial and sustained [H-3]InsP responses to alpha(1)-adrenergic receptor stimulation with norepinephrine (100 mu M) were insensitive to the phosphatidylinositol 4,5-bisphosphate-binding agent neomycin (5 mM). Introduction of 300 mu M unlabeled Ins(1,4,5)P-3 into guanosine 5'-3-O-(thio)triphosphate (GTP gamma S)-stimulated, permeabilized [H-3]inositol-labeled NCM increased [H-3]Ins(1,4,5)P-3 slightly but did not significantly reduce levels of its metabolites [H-3]Ins(1,4)P-2 and [H-3]Ins(4)P, suggesting that these [H-3]InsPs are not formed principally from [H-3]Ins(1,4,5)P,. in contrast, the calcium ionophore A23187 (10 mu M) provoked [H-3]InsP responses in intact NCM which were sensitive to neomycin, and elevation of free calcium in permeabilized NCM led to [H-3]InsP responses characterized by marked increases in [H-3]Ins(1,4,5)P, (2.9 +/- 0.2% of total [H-3]InsPs after 20 min of high Ca2+ treatment in comparison to 0.21 +/- 0.05% of total [H-3] InsPs accumulated after 20 min of GTP gamma S stimulation). These data provide evidence that Ins(1,4,5)P-3 generation is not a major contributor to G protein-coupled InsP responses in NCM, but that substantial Ins(1,4,5)P-3 generation occurs under conditions of Ca2+ overload. Thus in NCM, Ca2+-induced Ins(1,4,5)P-3 generation has the potential to worsen. Ca2+ overload and thereby aggravate Ca2+-induced electrophysiological perturbations.	Baker Med Res Inst, Cellular Biochem Lab, Melbourne, Vic 8008, Australia	Baker Heart and Diabetes Institute	Woodcock, EA (corresponding author), Baker Med Res Inst, Cellular Biochem Lab, POB 6492,St Kilda Rd Cent, Melbourne, Vic 8008, Australia.		Matkovich, Scot J/AFP-0908-2022; Matkovich, Scot J/B-9077-2009	Matkovich, Scot J/0000-0002-7398-6857; Matkovich, Scot J/0000-0002-7398-6857				Allen V, 1997, BIOCHEM J, V327, P545, DOI 10.1042/bj3270545; ANDERSON KE, 1995, CIRC RES, V76, P261, DOI 10.1161/01.RES.76.2.261; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bian JS, 1998, J MOL CELL CARDIOL, V30, P2103, DOI 10.1006/jmcc.1998.0774; BIDEN TJ, 1992, BIOCHEM J, V285, P541, DOI 10.1042/bj2850541; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; Bowling N, 1999, CIRCULATION, V99, P384, DOI 10.1161/01.CIR.99.3.384; Felzen B, 1998, CIRC RES, V82, P438, DOI 10.1161/01.RES.82.4.438; GABEV E, 1989, BIOCHIM BIOPHYS ACTA, V979, P105, DOI 10.1016/0005-2736(89)90529-4; GILBERT JC, 1991, CIRC RES, V69, P1632, DOI 10.1161/01.RES.69.6.1632; GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901; GU X, 1994, CIRC RES, V75, P926, DOI 10.1161/01.RES.75.5.926; HANSEN CA, 1995, J MOL CELL CARDIOL, V27, P471, DOI 10.1016/S0022-2828(08)80043-0; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; IMAI A, 1986, P NATL ACAD SCI USA, V83, P8540, DOI 10.1073/pnas.83.22.8540; INHORN RC, 1988, J BIOL CHEM, V263, P14559; Jacobsen AN, 1996, CIRCULATION, V93, P23, DOI 10.1161/01.CIR.93.1.23; Jacobsen AN, 1997, AM J PHYSIOL-HEART C, V273, pH1119, DOI 10.1152/ajpheart.1997.273.3.H1119; Jalili T, 1999, CARDIOVASC RES, V44, P5, DOI 10.1016/S0008-6363(99)00211-4; KENTISH JC, 1990, AM J PHYSIOL, V258, pH610, DOI 10.1152/ajpheart.1990.258.2.H610; LAXMINARAYAN KM, 1994, J BIOL CHEM, V269, P17305; Lopez-Coronado JM, 1999, J BIOL CHEM, V274, P16034, DOI 10.1074/jbc.274.23.16034; PHILLIPPE M, 1994, BIOCHEM BIOPH RES CO, V205, P245, DOI 10.1006/bbrc.1994.2656; RHEE SG, 1992, J BIOL CHEM, V267, P12393; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; Schnabel P, 1996, J MOL CELL CARDIOL, V28, P2419, DOI 10.1006/jmcc.1996.0235; SHEARS SB, 1989, BIOCHEM J, V260, P313, DOI 10.1042/bj2600313; SIMPSON P, 1982, CIRC RES, V51, P787, DOI 10.1161/01.RES.51.6.787; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; Spiegelberg BD, 1999, J BIOL CHEM, V274, P13619, DOI 10.1074/jbc.274.19.13619; STEINBERG SF, 1989, J PHARMACOL EXP THER, V250, P1141; SYLVIA V, 1988, CELL, V54, P651, DOI 10.1016/S0092-8674(88)80009-6; Wakasaki H, 1997, P NATL ACAD SCI USA, V94, P9320, DOI 10.1073/pnas.94.17.9320; WILSON DB, 1984, J BIOL CHEM, V259, P1718; WOODCOCK EA, 1992, BIOCHEM J, V281, P683, DOI 10.1042/bj2810683; Woodcock EA, 1996, J MOL CELL CARDIOL, V28, P2129, DOI 10.1006/jmcc.1996.0205; Woodcock EA, 1997, MOL CELL BIOCHEM, V172, P121, DOI 10.1023/A:1006871722652; Woodcock EA, 1998, CARDIOVASC RES, V40, P251, DOI 10.1016/S0008-6363(98)00187-4; Woodcock EA, 1997, J MOL CELL CARDIOL, V29, P3275, DOI 10.1006/jmcc.1997.0553; Woodcock EA, 1999, CIRCULATION, V99, P823, DOI 10.1161/01.CIR.99.6.823; WOODCOCK EA, 1995, CIRC RES, V76, P252, DOI 10.1161/01.RES.76.2.252; WU DQ, 1992, J BIOL CHEM, V267, P25798; YORK JD, 1994, J BIOL CHEM, V269, P19992; YORK JD, 1995, P NATL ACAD SCI USA, V92, P5149, DOI 10.1073/pnas.92.11.5149; ZHU Y, 1991, PFLUG ARCH EUR J PHY, V418, P1, DOI 10.1007/BF00370444	46	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10845	10850		10.1074/jbc.275.15.10845	http://dx.doi.org/10.1074/jbc.275.15.10845			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753879	hybrid			2022-12-27	WOS:000086466600021
J	Furukawa, Y; Iwase, S; Kikuchi, J; Terui, Y; Nakamura, M; Yamada, H; Kano, Y; Matsuda, M				Furukawa, Y; Iwase, S; Kikuchi, J; Terui, Y; Nakamura, M; Yamada, H; Kano, Y; Matsuda, M			Phosphorylation of Bcl-2 protein by CDC2 kinase during G(2)/M phases and its role in cell cycle regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-APOPTOSIS FUNCTION; OKADAIC ACID; X-L; DEATH; ACTIVATION; INHIBITOR; DOMAIN; DIFFERENTIATION; P34(CDC2); SURVIVAL	Although it has been reported that Bcl-2 phosphorylation is associated with certain types of apoptosis, there is much controversy over the functional significance of and the kinases responsible for the phosphorylation. In this study, we examined whether Bcl-2 is phosphorylated by CDC2 kinase, a master regulator of G(2)/M transition in the eukaryotic cell cycle. When CDC2 was activated by okadaic acid in HL-60 cells, Bcl-2 phosphorylation was readily induced. The phosphorylation was correlated with the accumulation of cells in G(2)/M phases, but was not proportional to the level of apoptosis. Furthermore, we found that Bcl-2 was phosphorylated during G(2)/M phases of normal cell cycle. The ability of CDC2 to phosphorylate Bcl-2 was confirmed by in vitro kinase assay with a highly purified CDC2-cyclin B complex. Using synthetic peptides and mutant cell lines, we identified threonine 56, one of two consensus sites for CDC2 within the Bcl-2 sequence, as a residue phosphorylated by CDC2. Mutation at threonine 56 abrogated the cell cycle inhibitory effect of Bcl-2 without affecting anti-apoptotic function. These results suggest that two distinct functions of Bcl-2 (anti-apoptosis and cell cycle inhibition) are differentially regulated by post-translational mechanisms such as phosphorylation. CDC2-mediated phosphorylation of Bcl-2 may play some physiological roles in the negative regulatory events during mitosis.	Jichi Med Sch, Ctr Mol Med, Div Mol Hematopoiesis, Minami Kawachi, Tochigi 3290498, Japan; Jichi Med Sch, Dept Hematol, Minami Kawachi, Tochigi 3290498, Japan; Jikei Univ, Sch Med, Dept Internal Med Aoto, Tokyo 1058461, Japan; Jikei Univ, Sch Med, Dept Mol Genet, Inst DNA Med, Tokyo 1058461, Japan; Tochigi Canc Ctr, Div Med Oncol, Utsunomiya, Tochigi 3200834, Japan	Jichi Medical University; Jichi Medical University; Jikei University; Jikei University; Tochigi Prefectural Cancer Center	Furukawa, Y (corresponding author), Jichi Med Sch, Ctr Mol Med, Div Mol Hematopoiesis, 3311-1 Yakushiji, Minami Kawachi, Tochigi 3290498, Japan.		Furukawa, Yusuke/Y-1342-2018	Furukawa, Yusuke/0000-0002-7249-6418				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; Blagosklonny MV, 1997, CANCER RES, V57, P130; Brady HJM, 1996, EMBO J, V15, P6991, DOI 10.1002/j.1460-2075.1996.tb01091.x; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Furukawa Y, 1996, J BIOL CHEM, V271, P28469, DOI 10.1074/jbc.271.45.28469; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; Haldar S, 1997, CANCER RES, V57, P229; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; ISHIDA Y, 1992, J CELL PHYSIOL, V150, P484, DOI 10.1002/jcp.1041500308; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Kimura K, 1998, SCIENCE, V282, P487, DOI 10.1126/science.282.5388.487; Lee LC, 1996, J BIOL CHEM, V271, P23284, DOI 10.1074/jbc.271.38.23284; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Lowe M, 1998, CELL, V94, P783, DOI 10.1016/S0092-8674(00)81737-7; LU QL, 1994, J CELL SCI, V107, P363; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MAY WS, 1994, J BIOL CHEM, V269, P26865; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Newton K, 1998, CURR OPIN GENET DEV, V8, P68, DOI 10.1016/S0959-437X(98)80064-6; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; RIME H, 1995, EXP CELL RES, V219, P29, DOI 10.1006/excr.1995.1201; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SCHIEVELLA AR, 1993, CELL GROWTH DIFFER, V4, P239; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; Tashiro E, 1998, JPN J CANCER RES, V89, P940, DOI 10.1111/j.1349-7006.1998.tb00652.x; Terui Y, 1998, EXP HEMATOL, V26, P236; TERUI Y, 1995, J BIOCHEM-TOKYO, V117, P77, DOI 10.1093/oxfordjournals.jbchem.a124725; TERUI Y, 1995, J CELL PHYSIOL, V164, P74, DOI 10.1002/jcp.1041640110; Uhlmann EJ, 1996, CANCER RES, V56, P2506; Vairo G, 1996, ONCOGENE, V13, P1511; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x	47	101	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21661	21667		10.1074/jbc.M906893199	http://dx.doi.org/10.1074/jbc.M906893199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10766756	hybrid			2022-12-27	WOS:000088230600093
J	Marin, F; Corstjens, P; de Gaulejac, B; Vrind-De Jong, ED; Westbroek, P				Marin, F; Corstjens, P; de Gaulejac, B; Vrind-De Jong, ED; Westbroek, P			Mucins and molluscan calcification - Molecular characterization of mucoperlin, a novel mucin-like protein from the nacreous shell layer of the fan mussel Pinna nobilis (Bivalvia, Pteriomorphia)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SNAIL BIOMPHALARIA-GLABRATA; CALCIUM-BINDING PROTEIN; CRYSTAL-GROWTH; MATRIX PROTEIN; GEL-ELECTROPHORESIS; CAMBRIAN EXPLOSION; ANIMAL EVOLUTION; INTESTINAL MUCIN; SALIVARY MUCINS; SOLUBLE MATRIX	A cDNA expression library constructed from mantle tissue mRNA of the Mediterranean fan mussel Pinna nobilis was screened with antibodies raised against the acetic acid-soluble shell matrix of the same species. This resulted in the isolation of a 2138-base pair cDNA, containing 13 tandem repeats of 93 base pairs. The deduced protein has a molecular mass of 66.7 kDa and a isoelectric point of 4.8. This protein, which is enriched in serine and proline residues, was overexpressed, purified, and used for producing polyclonal antibodies. Immunological in situ and in vitro tests showed that the protein is localized in the nacreous aragonitic layer of P. nobilis, but not in the calcitic prisms, Because this protein of the nacre of P nobilis exhibits some mucin-like characteristics, we propose the name mucoperlin, This is the first paper reporting the cloning of a molluscan mucin and the first molecular evidence for the involvement of a mucin in molluscan calcification. This finding corroborates our previous hypothesis that some of the proteinaceous constituents of the molluscan shell matrix would derive from mucins, common to many metazoan lineages of the late Precambrian (Marin, F., Smith, M., Isa, Y., Muyzer, G. and Westbroek, P. (1996) Proc. Natl, Acad, Sci, U. S. A. 93, 1554-1559), The adaptation of an ancestral mucin to a new function, the regulation of the mineralization process, may be one of the molecular events, among others, that would explain the simultaneous emergence of organized calcification in many metazoan lineages during the Cambrian explosion.	Leiden Univ, Leiden Inst Chem, Gorlaeus Labs, NL-2300 RA Leiden, Netherlands; Fac Sci & Tech St Jerome, Ctr Etud Ressources Anim Marines, F-13397 Marseille 20, France	Leiden University; Leiden University - Excl LUMC; UDICE-French Research Universities; Aix-Marseille Universite	Marin, F (corresponding author), Leiden Univ, Leiden Inst Chem, Gorlaeus Labs, POB 9502, NL-2300 RA Leiden, Netherlands.	f.marin@chem.leidenuniv.nl	Corstjens, Paul/Y-6310-2018	Corstjens, Paul/0000-0002-0004-0526				ADDADI L, 1992, ANGEW CHEM INT EDIT, V31, P153, DOI 10.1002/anie.199201531; ADDADI L, 1987, P NATL ACAD SCI USA, V84, P2732, DOI 10.1073/pnas.84.9.2732; Adoutte A, 1999, TRENDS GENET, V15, P104, DOI 10.1016/S0168-9525(98)01671-0; AFDHAL NH, 1995, GASTROENTEROLOGY, V109, P1661, DOI 10.1016/0016-5085(95)90656-8; AKBARIEH M, 1991, SCANNING MICROSCOPY, V5, P1019; Albeck S, 1996, CHEM-EUR J, V2, P278, DOI 10.1002/chem.19960020308; ALBONE EF, 1994, J BIOL CHEM, V269, P16845; Amerongen AVN, 1998, BIOL CHEM, V379, P1; AMERONGEN AVN, 1989, J BIOL BUCCALE, V17, P85; AMERONGEN AVN, 1988, ADV BIOMATER, V8, P327; [Anonymous], 1983, SHELL FORMATION MO 1; Atlan G, 1997, CR ACAD SCI III-VIE, V320, P253, DOI 10.1016/S0764-4469(97)86933-8; Axelsson MAB, 1998, J BIOL CHEM, V273, P18864, DOI 10.1074/jbc.273.30.18864; Ayala FJ, 1998, P NATL ACAD SCI USA, V95, P606, DOI 10.1073/pnas.95.2.606; Bengtson S., 1992, P397; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; Bromham L, 1998, P NATL ACAD SCI USA, V95, P12386, DOI 10.1073/pnas.95.21.12386; Carter J.G., 1990, SKELETAL BIOMINERALI; Collins M.J., 1988, Historical Biology, V1, P207; Corstjens PLAM, 1998, J PHYCOL, V34, P622, DOI 10.1046/j.1529-8817.1998.340622.x; Crenshaw M.A., 1972, Biomineralization Res Rep, V6, P6; Crenshaw MA., 1976, MECHANISMS MINERALIZ, P355; Cuif J. P., 1985, SCI REP PORT CROS NA, V11, P95; DAUPHIN Y, 1995, EXPERIENTIA, V51, P278, DOI 10.1007/BF01931112; delaPorte PL, 1996, J HEPATOL, V25, P339, DOI 10.1016/S0168-8278(96)80121-8; Dickman S, 1997, SCIENCE, V276, P1502, DOI 10.1126/science.276.5318.1502; DINOIA JM, 1995, J BIOL CHEM, V270, P24146, DOI 10.1074/jbc.270.41.24146; EDGE ASB, 1981, ANAL BIOCHEM, V118, P131, DOI 10.1016/0003-2697(81)90168-8; GAFFEY SJ, 1993, J SEDIMENT PETROL, V63, P752, DOI 10.1306/D4267BE0-2B26-11D7-8648000102C1865D; Gaunt SJ, 1996, DEV DYNAM, V207, P270, DOI 10.1002/(SICI)1097-0177(199611)207:3<270::AID-AJA4>3.0.CO;2-E; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; Grases F, 1998, MICRON, V29, P105, DOI 10.1016/S0968-4328(98)00006-7; GUM JR, 1991, J BIOL CHEM, V266, P22733; Gum JR, 1995, BIOCHEM SOC T, V23, P795, DOI 10.1042/bst0230795; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; HILKENS J, 1992, TRENDS BIOCHEM SCI, V17, P359, DOI 10.1016/0968-0004(92)90315-Z; HUTTNER WB, 1987, TRENDS BIOCHEM SCI, V12, P361, DOI 10.1016/0968-0004(87)90166-6; JACKSON AP, 1988, PROC R SOC SER B-BIO, V234, P415, DOI 10.1098/rspb.1988.0056; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; Knoll AH, 1999, SCIENCE, V284, P2129, DOI 10.1126/science.284.5423.2129; KNOLL AH, 1993, PALAIOS, V8, P512, DOI 10.2307/3515029; Kono M, 2000, BIOCHEM BIOPH RES CO, V269, P213, DOI 10.1006/bbrc.2000.2274; Kurachi S, 1998, EUR J BIOCHEM, V254, P217, DOI 10.1046/j.1432-1327.1998.2540217.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONG MML, 1986, J HISTOCHEM CYTOCHEM, V34, P1645, DOI 10.1177/34.12.3537113; LOPEZ E, 1992, TISSUE CELL, V24, P667, DOI 10.1016/0040-8166(92)90037-8; LOWENSTAM HA, 1980, BIOSYSTEMS, V12, P27, DOI 10.1016/0303-2647(80)90036-2; Lowenstam HA, 1989, BIOMINERALIZATION; Marin F, 1996, P NATL ACAD SCI USA, V93, P1554, DOI 10.1073/pnas.93.4.1554; MARIN F, 1994, CR ACAD SCI II, V318, P1653; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; Marxen JC, 1997, COMP BIOCHEM PHYS B, V118, P23, DOI 10.1016/S0305-0491(97)00010-2; Marxen JC, 1998, BIOL BULL-US, V194, P231, DOI 10.2307/1543052; MCCALDON P, 1988, PROTEINS, V4, P99, DOI 10.1002/prot.340040204; Miyamoto H, 1996, P NATL ACAD SCI USA, V93, P9657, DOI 10.1073/pnas.93.18.9657; Mutvei H., 1980, P49; MUYZER G, 1989, GEOCHIM COSMOCHIM AC, V53, P1699, DOI 10.1016/0016-7037(89)90255-X; Myers JM, 1996, ANAL BIOCHEM, V240, P300, DOI 10.1006/abio.1996.0361; Nakahara H., 1991, P343; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Perez-Vilar J, 1998, J BIOL CHEM, V273, P14442, DOI 10.1074/jbc.273.23.14442; PEREZVILAR J, 1998, J BIOL CHEM, V271, P9845; Prezant R.S., 1990, P83; Reddi A. Hari, 1997, Cytokine and Growth Factor Reviews, V8, P11, DOI 10.1016/S1359-6101(96)00049-4; Rodan GA, 1997, CELL, V89, P677, DOI 10.1016/S0092-8674(00)80249-4; ROSEN V, 1992, TRENDS GENET, V8, P97, DOI 10.1016/0168-9525(92)90063-A; Samata T, 1999, FEBS LETT, V462, P225, DOI 10.1016/S0014-5793(99)01387-3; Sarashina I, 1998, AM MINERAL, V83, P1510, DOI 10.2138/am-1998-11-1239; Schmidt W. J., 1924, ZOOL JAHRB       AOT, V45, P1; Seregni E, 1997, TUMORI J, V83, P625, DOI 10.1177/030089169708300301; Shen XY, 1997, J BIOL CHEM, V272, P32472, DOI 10.1074/jbc.272.51.32472; Smith BL, 1999, NATURE, V399, P761, DOI 10.1038/21607; Sudo S, 1997, NATURE, V387, P563, DOI 10.1038/42391; TABAK LA, 1995, ANNU REV PHYSIOL, V57, P547, DOI 10.1146/annurev.ph.57.030195.002555; Theopold U, 1996, J BIOL CHEM, V271, P12708, DOI 10.1074/jbc.271.22.12708; TORIBARA NW, 1993, J BIOL CHEM, V268, P5879; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURNER BS, 1995, BIOCHEM J, V308, P89, DOI 10.1042/bj3080089; TYTGAT KMAJ, 1995, BIOCHEM J, V310, P1053, DOI 10.1042/bj3101053; Valentine JW, 1999, DEVELOPMENT, V126, P851; Van Klinken BJW, 1998, ANAL BIOCHEM, V265, P103; Wang P, 1997, J BIOL CHEM, V272, P16663, DOI 10.1074/jbc.272.26.16663; WEINER S, 1984, PHILOS T ROY SOC B, V304, P425, DOI 10.1098/rstb.1984.0036; Weiss IM, 2000, BIOCHEM BIOPH RES CO, V267, P17, DOI 10.1006/bbrc.1999.1907; Westbroek P, 1998, NATURE, V392, P861, DOI 10.1038/31798; WHEELER AP, 1987, COMP BIOCHEM PHYS B, V87, P953, DOI 10.1016/0305-0491(87)90418-4; WHEELER AP, 1981, SCIENCE, V212, P1397, DOI 10.1126/science.212.4501.1397; WHEELER AP, 1988, CHEM ASPECTS REGULAT, P9; Yuasa HJ, 1998, COMP BIOCHEM PHYS B, V119, P479, DOI 10.1016/S0305-0491(98)00008-X; 1992, OFF JEC L, V206	91	144	148	0	48	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20667	20675		10.1074/jbc.M003006200	http://dx.doi.org/10.1074/jbc.M003006200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10770949	hybrid, Green Published			2022-12-27	WOS:000088084500064
J	Mizukami, Y; Kobayashi, S; Uberall, F; Hellbert, K; Kobayashi, N; Yoshida, K				Mizukami, Y; Kobayashi, S; Uberall, F; Hellbert, K; Kobayashi, N; Yoshida, K			Nuclear mitogen-activated protein kinase activation by protein kinase C zeta during reoxygenation after ischemic hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; PKC-EPSILON; RAT-HEART; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; NA+/H+ EXCHANGE; MESSENGER-RNA; EXPORT SIGNAL; REPERFUSION; PHOSPHORYLATION	We examined the upstream kinases for mitogen-activated protein kinase (MAPK) activation during ischemic hypoxia and reoxygenation using H9c2 cells derived from rat cardiomyocytes. Protein kinase C (PKC)zeta, an atypical PKC isoform mainly expressed in rat heart, has been shown to act as an upstream kinase of MAPK during ischemic hypoxia and reoxygenation by analyses with PKC inhibitors, antisense DNA, a dominant negative kinase defective mutant, and constitutively active mutants of PKC zeta. Immunocytochemical observations show PKC zeta staining in the nucleus during ischemic hypoxia and reoxygenation when phosphorylated MAPK is also detected in the nucleus. This nuclear localization of PKC zeta is inhibited by treatment with wortmannin, a phosphoinositide 3-kinase inhibitor that also inhibits MAPK activation in a dose-dependent manner. This is supported by the inhibition of MAPK phosphorylation by another blocker of phosphoinositide 3-kinase, LY294002. An upstream kinase of MAPK, MEK1/2, is significantly phosphorylated 15 min after reoxygenation and observed mainly in the nucleus, whereas it is present in the cytoplasm in serum stimulation. The phosphorylation of MEK is blocked by PKC inhibitors and phosphoinositide 3-kinase inhibitors, as observed in the case of MAPK phosphorylation, These observations indicate that PKC zeta, which is activated by phosphoinositide 3-kinase, induces MAPK activation through MEK in the nucleus during reoxygenation after ischemic hypoxia.	Yamaguchi Univ, Sch Med, Dept Physiol 1, Yamaguchi 7558505, Japan; Yamaguchi Univ, Sch Med, Dept Legal Med, Yamaguchi 7558505, Japan; Univ Innsbruck, Inst Med Chem & Biochem, A-6020 Innsbruck, Austria; Nagasaki Univ, Fac Pharmaceut Sci, Lab Mol Biol Dis, Nagasaki 8528131, Japan	Yamaguchi University; Yamaguchi University; University of Innsbruck; Nagasaki University	Mizukami, Y (corresponding author), Yamaguchi Univ, Sch Med, Dept Physiol 1, 1-1-1 Minamikogushi, Yamaguchi 7558505, Japan.	mizukami@po.cc.yamaguchi-u.ac.jp	Kobayashi, Sei/E-7175-2010	Mizukami, Yoichi/0000-0002-3290-0754				BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; BESTERMAN JM, 1985, J BIOL CHEM, V260, P1155; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; BRAND T, 1992, CIRC RES, V71, P1351, DOI 10.1161/01.RES.71.6.1351; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DARGEMONT C, 1992, J CELL BIOL, V118, P1, DOI 10.1083/jcb.118.1.1; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dean N, 1996, CANCER RES, V56, P3499; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HerreraVelit P, 1997, J BIOL CHEM, V272, P16445, DOI 10.1074/jbc.272.26.16445; IKEDA U, 1988, J MOL CELL CARDIOL, V20, P493, DOI 10.1016/S0022-2828(88)80076-2; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; Joyal JL, 1997, J BIOL CHEM, V272, P28183, DOI 10.1074/jbc.272.45.28183; Kampfer S, 1998, EMBO J, V17, P4046, DOI 10.1093/emboj/17.14.4046; Kawamura S, 1998, AM J PHYSIOL-HEART C, V275, pH2266; Kawata Y, 1998, J BIOL CHEM, V273, P16905, DOI 10.1074/jbc.273.27.16905; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Li YZ, 1998, P NATL ACAD SCI USA, V95, P4864, DOI 10.1073/pnas.95.9.4864; LIANO DF, 1997, J BIOL CHEM, V272, P6146; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MESTRIL R, 1994, J CLIN INVEST, V93, P759, DOI 10.1172/JCI117030; Mizukami Y, 1997, BIOCHEM J, V323, P785, DOI 10.1042/bj3230785; Mizukami Y, 1997, FEBS LETT, V401, P247, DOI 10.1016/S0014-5793(96)01481-0; Mizukami Y, 1997, J BIOL CHEM, V272, P16657, DOI 10.1074/jbc.272.26.16657; MOROOKA H, 1995, J BIOL CHEM, V270, P30084; MUNICIO MM, 1995, J BIOL CHEM, V270, P15884, DOI 10.1074/jbc.270.26.15884; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Onishi I, 1997, FEBS LETT, V420, P201, DOI 10.1016/S0014-5793(97)01517-2; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; PARRATT JR, 1994, TRENDS PHARMACOL SCI, V15, P19, DOI 10.1016/0165-6147(94)90129-5; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; Qiu YM, 1998, J CLIN INVEST, V101, P2182, DOI 10.1172/JCI1258; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; Takeda H, 1999, EMBO J, V18, P386, DOI 10.1093/emboj/18.2.386; Tolwinski NS, 1999, J BIOL CHEM, V274, P6168, DOI 10.1074/jbc.274.10.6168; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Traub O, 1997, J BIOL CHEM, V272, P31251, DOI 10.1074/jbc.272.50.31251; Uberall F, 1997, J BIOL CHEM, V272, P4072, DOI 10.1074/jbc.272.7.4072; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Wang YX, 1999, J BIOL CHEM, V274, P13859, DOI 10.1074/jbc.274.20.13859; WEBSTER KA, 1993, J BIOL CHEM, V268, P16852; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu JH, 1997, J CELL BIOL, V136, P473, DOI 10.1083/jcb.136.2.473; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yoshida K, 1999, BBA-MOL BASIS DIS, V1453, P230, DOI 10.1016/S0925-4439(98)00105-7; YOSHIDA K, 1995, CIRC RES, V77, P603, DOI 10.1161/01.RES.77.3.603; Yoshida K, 1996, BBA-MOL BASIS DIS, V1317, P36, DOI 10.1016/0925-4439(96)00035-X; Yoshida K, 1997, J BIOCHEM, V122, P506; Zhao J, 1998, J BIOL CHEM, V273, P23072, DOI 10.1074/jbc.273.36.23072; Zhou GS, 1997, J BIOL CHEM, V272, P31130, DOI 10.1074/jbc.272.49.31130	69	65	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19921	19927		10.1074/jbc.M907901199	http://dx.doi.org/10.1074/jbc.M907901199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10777509	hybrid			2022-12-27	WOS:000087941300067
J	Lee, C; Kim, SR; Chung, JK; Frohman, MA; Kilimann, MW; Rhee, SG				Lee, C; Kim, SR; Chung, JK; Frohman, MA; Kilimann, MW; Rhee, SG			Inhibition of phospholipase D by amphiphysins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION-FACTOR; PHOSPHATIDYLINOSITOL TRANSFER PROTEIN; CLATHRIN-MEDIATED ENDOCYTOSIS; SECRETORY VESICLE FORMATION; PHOSPHATIDIC-ACID; INOSITIDE PHOSPHORYLATION; LYSOPHOSPHATIDIC ACID; NERVE-TERMINALS; PLASMA-MEMBRANE; BINDING-SITE	Two distinct proteins inhibiting phospholipase D (PLD) activity in rat brain cytosol were previously purified and identified as synaptojanin and AP180, which are specific to nerve terminals and associate with the clathrin coat. Two additional PLD-inhibitory proteins have now been purified and identified as the amphiphysins I and II, which forms a heterodimer that also associates with the clathrin coat. Bacterially expressed recombinant amphiphysins inhibited both PLD1 and PLDS isozymes in vitro with a potency similar to that of brain amphiphysin (median inhibitory concentration of similar to 15 nM). Expressions of either amphiphysin in COS-7 cells reduced activity of endogenous PLD as well as exogenously expressed PLD1 and PLD2, Coprecipitation experiments suggested that the inhibitory effect of amphiphysins results from their direct interaction with PLDs. The NH2 terminus of amphiphysin I was critical for both inhibition of and binding to PLD. Phosphatidic acid formed by signal-induced PLD is thought to be required for the assembly of clathrin-coated vesicles during endocytosis, Thus, the inhibition of PLD by amphiphysins, synaptojanin, and AP180 might play an important role in synaptic vesicle trafficking.	NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA; SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; Ruhr Univ Bochum, Inst Physiol Chem, D-44780 Bochum, Germany	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Ruhr University Bochum	Rhee, SG (corresponding author), NHLBI, Lab Cell Signaling, NIH, Bldg 3,Rm 120,3 Ctr Dr,MSC 0320, Bethesda, MD 20892 USA.	rheesg@nhlbi.nih.gov						Arneson LS, 1999, J BIOL CHEM, V274, P17794, DOI 10.1074/jbc.274.25.17794; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; Bauerfeind R, 1997, J BIOL CHEM, V272, P30984, DOI 10.1074/jbc.272.49.30984; Bi K, 1997, CURR BIOL, V7, P301, DOI 10.1016/S0960-9822(06)00153-9; Brown FD, 1998, CURR BIOL, V8, P835, DOI 10.1016/S0960-9822(98)70326-4; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; Chung JK, 1997, J BIOL CHEM, V272, P15980, DOI 10.1074/jbc.272.25.15980; Colley WC, 1997, BIOCHEM J, V326, P745, DOI 10.1042/bj3260745; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; Guo SL, 1999, J BIOL CHEM, V274, P12990, DOI 10.1074/jbc.274.19.12990; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Han JS, 1996, J BIOL CHEM, V271, P11163, DOI 10.1074/jbc.271.19.11163; Hao WH, 1997, J BIOL CHEM, V272, P6393, DOI 10.1074/jbc.272.10.6393; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Katayama K, 1998, BIOCHEM J, V329, P647, DOI 10.1042/bj3290647; KATTUNEN J, 1991, P NATL ACAD SCI USA, V88, P3972; Kodaki T, 1997, J BIOL CHEM, V272, P11408; Ktistakis NT, 1998, BIOESSAYS, V20, P495; Lee CH, 1997, J BIOL CHEM, V272, P15986, DOI 10.1074/jbc.272.25.15986; Leprince C, 1997, J BIOL CHEM, V272, P15101, DOI 10.1074/jbc.272.24.15101; LICHTE B, 1992, EMBO J, V11, P2521, DOI 10.1002/j.1460-2075.1992.tb05317.x; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Mikoshiba K, 1999, CHEM PHYS LIPIDS, V98, P59, DOI 10.1016/S0009-3084(99)00018-3; MOOLENAAR WH, 1991, ADV CANCER RES, V57, P87; OHASHI M, 1995, NATURE, V377, P544, DOI 10.1038/377544a0; Poulin B, 1998, MOL CELL ENDOCRINOL, V142, P99, DOI 10.1016/S0303-7207(98)00114-2; Profit AA, 1998, ARCH BIOCHEM BIOPHYS, V357, P85, DOI 10.1006/abbi.1998.0796; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Roth MG, 1999, CHEM PHYS LIPIDS, V98, P141, DOI 10.1016/S0009-3084(99)00026-2; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Steed PM, 1998, FASEB J, V12, P1309, DOI 10.1096/fasebj.12.13.1309; Sung TC, 1999, J BIOL CHEM, V274, P494, DOI 10.1074/jbc.274.1.494; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; Tuscher O, 1997, FEBS LETT, V419, P271, DOI 10.1016/S0014-5793(97)01471-3; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; YAMAMOTO R, 1995, HUM MOL GENET, V4, P265, DOI 10.1093/hmg/4.2.265; Zhang XY, 1998, BIOCHEMISTRY-US, V37, P12395, DOI 10.1021/bi9807512; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002	55	54	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18751	18758		10.1074/jbc.M001695200	http://dx.doi.org/10.1074/jbc.M001695200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10764771	hybrid			2022-12-27	WOS:000087815900021
J	Patricelli, MP; Cravatt, BF				Patricelli, MP; Cravatt, BF			Clarifying the catalytic roles of conserved residues in the amidase signature family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SERINE CARBOXYPEPTIDASE-Y; MOLECULAR CHARACTERIZATION; CANNABINOID RECEPTOR; HUMAN ACETYLCHOLINESTERASE; OVERLAP EXTENSION; NITRILE HYDRATASE; CRYSTAL-STRUCTURE; ACID; GENE	Fatty acid amide hydrolase (FAAH) is a mammalian integral membrane enzyme responsible for the hydrolysis of a number of neuromodulatory fatty acid amides, including the endogenous cannabinoid anandamide and the sleep-inducing lipid oleamide, FAAH belongs to a large class of hydrolytic enzymes termed the "amidase signature family," whose members are defined by a conserved stretch of approximately 130 amino acids termed the "amidase signature sequence." Recently, site-directed mutagenesis studies of FAAH have targeted a limited number of conserved residues in the amidase signature sequence of the enzyme, identifying Ser-241 as the catalytic nucleophile and Lys-142 as an acid/base catalyst. The roles of several other conserved residues with potentially important and/or overlapping catalytic functions have not yet been examined. In this study, we have mutated all potentially catalytic residues in FAAH that are conserved among members of the amidase signature family, and have assessed their individual roles in catalysis through chemical labeling and kinetic methods. Several of these residues appear to serve primarily structural roles, as their mutation produced FAAH variants with considerable catalytic activity but reduced expression in prokaryotic and/or eukaryotic systems. In contrast, five mutations, K142A, S217A, S218A, S241A, and R243A, decreased the amidase activity of FAAH greater than 100-fold without detectably impacting the structural integrity of the enzyme, The pH rate profiles, amide/ester selectivities, and fluorophosphonate reactivities of these mutants revealed distinct catalytic roles for each residue, Of particular interest, one mutant, R243A, displayed uncompromised esterase activity but severely reduced amidase activity, indicating that the amidase and esterase efficiencies of FAAH can be functionally uncoupled. Collectively, these studies provide evidence that amidase signature enzymes represent a large class of serine-lysine catalytic dyed hydrolases whose evolutionary distribution rivals that of the catalytic triad superfamily.	Scripps Res Inst, Res Inst, Dept Cell Biol, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Cravatt, BF (corresponding author), Scripps Res Inst, Res Inst, Dept Cell Biol, Skaggs Inst Chem Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NIMH NIH HHS [R01 MH058542-04, MH58542] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH058542] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Basile AS, 1999, NEUROREPORT, V10, P947, DOI 10.1097/00001756-199904060-00010; BENDER ML, 1962, J AM CHEM SOC, V84, P2540, DOI 10.1021/ja00872a018; Boger DL, 1998, CURR PHARM DESIGN, V4, P303; Boshoff HIM, 1998, J BACTERIOL, V180, P5809, DOI 10.1128/JB.180.22.5809-5814.1998; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; CARTER P, 1990, PROTEINS, V7, P335, DOI 10.1002/prot.340070405; CARTER P, 1987, SCIENCE, V237, P394, DOI 10.1126/science.3299704; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; Chebrou H, 1996, BBA-PROTEIN STRUCT M, V1298, P285, DOI 10.1016/S0167-4838(96)00145-8; CRAIK CS, 1987, SCIENCE, V237, P909, DOI 10.1126/science.3303334; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; CRAVATT BF, 1995, SCIENCE, V268, P1506, DOI 10.1126/science.7770779; Curnow AW, 1997, P NATL ACAD SCI USA, V94, P11819, DOI 10.1073/pnas.94.22.11819; Dalbey RE, 1997, PROTEIN SCI, V6, P1129, DOI 10.1002/pro.5560060601; Dessen A, 1999, CELL, V97, P349, DOI 10.1016/S0092-8674(00)80744-8; DEUTSCH DG, 1993, BIOCHEM PHARMACOL, V46, P791, DOI 10.1016/0006-2952(93)90486-G; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 1998, NEUROBIOL DIS, V5, P386, DOI 10.1006/nbdi.1998.0214; Dodson G, 1998, TRENDS BIOCHEM SCI, V23, P347, DOI 10.1016/S0968-0004(98)01254-7; ETTINGER RA, 1995, ARCH BIOCHEM BIOPHYS, V316, P14, DOI 10.1006/abbi.1995.1003; GASSAMADIAGNE A, 1992, J BIOL CHEM, V267, P13418; Giang DK, 1997, P NATL ACAD SCI USA, V94, P2238, DOI 10.1073/pnas.94.6.2238; GOMI K, 1991, GENE, V108, P91, DOI 10.1016/0378-1119(91)90491-S; Goparaju SK, 1999, BBA-MOL CELL BIOL L, V1441, P77, DOI 10.1016/S1388-1981(99)00143-2; HASHIMOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1088, P225, DOI 10.1016/0167-4781(91)90058-T; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HYNES MJ, 1975, AUST J BIOL SCI, V28, P301, DOI 10.1071/BI9750301; Jaggar SI, 1998, PAIN, V76, P189, DOI 10.1016/S0304-3959(98)00041-4; Kobayashi M, 1997, P NATL ACAD SCI USA, V94, P11986, DOI 10.1073/pnas.94.22.11986; KOBAYASHI M, 1993, EUR J BIOCHEM, V217, P327, DOI 10.1111/j.1432-1033.1993.tb18250.x; LERNER RA, 1994, P NATL ACAD SCI USA, V91, P9505, DOI 10.1073/pnas.91.20.9505; Liu YS, 1999, P NATL ACAD SCI USA, V96, P14694, DOI 10.1073/pnas.96.26.14694; MAYAUX JF, 1990, J BACTERIOL, V172, P6764, DOI 10.1128/jb.172.12.6764-6773.1990; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Mendelson WB, 1999, NEUROREPORT, V10, P3237, DOI 10.1097/00001756-199910190-00021; MORTENSEN UH, 1994, BIOCHEMISTRY-US, V33, P508, DOI 10.1021/bi00168a016; Omeir RL, 1999, BIOCHEM BIOPH RES CO, V264, P316, DOI 10.1006/bbrc.1999.1524; Ordentlich A, 1998, J BIOL CHEM, V273, P19509, DOI 10.1074/jbc.273.31.19509; Ordentlich A, 1996, J BIOL CHEM, V271, P11953, DOI 10.1074/jbc.271.20.11953; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; Patricelli MP, 1999, BIOCHEMISTRY-US, V38, P14125, DOI 10.1021/bi991876p; Patricelli MP, 1998, BIOCHEMISTRY-US, V37, P15177, DOI 10.1021/bi981733n; Patricelli MP, 1999, BIOCHEMISTRY-US, V38, P9804, DOI 10.1021/bi990637z; Peat TS, 1996, NATURE, V380, P727, DOI 10.1038/380727a0; Polgar L, 1999, BIOCHEMISTRY-US, V38, P15548, DOI 10.1021/bi991767a; Romero J, 1996, LIFE SCI, V58, P1249, DOI 10.1016/0024-3205(96)00086-0; Sako Y, 1996, INT J SYST BACTERIOL, V46, P1070, DOI 10.1099/00207713-46-4-1070; Simons JWFA, 1999, BIOCHEMISTRY-US, V38, P6346, DOI 10.1021/bi982498b; SMITH PB, 1994, J PHARMACOL EXP THER, V270, P219; Stennicke HR, 1996, BIOCHEMISTRY-US, V35, P7131, DOI 10.1021/bi952758e; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437	53	108	111	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19177	19184		10.1074/jbc.M001607200	http://dx.doi.org/10.1074/jbc.M001607200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10764768	hybrid			2022-12-27	WOS:000087815900074
J	Suetake, T; Tsuda, S; Kawabata, S; Miura, K; Iwanaga, S; Hikichi, K; Nitta, K; Kawano, K				Suetake, T; Tsuda, S; Kawabata, S; Miura, K; Iwanaga, S; Hikichi, K; Nitta, K; Kawano, K			Accelerated Publication - Chitin-binding proteins in invertebrates and plants comprise a common chitin-binding structural motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRAB TACHYPLEUS-TRIDENTATUS; VECTOR ANOPHELES-GAMBIAE; PRAWN PENAEUS-JAPONICUS; HORSESHOE-CRAB; ANTIMICROBIAL PEPTIDES; AMARANTHUS-CAUDATUS; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; HEVEIN; CDNA	Tachycitin, a 73-residue polypeptide having antimicrobial activity is present in the hemocyte of horseshoe crab (Tachypleus tridentatus). The first three-dimensional structure of invertebrate chitin-binding protein was determined for tachycitin using two-dimensional nuclear magnetic resonance spectroscopy. The measurements indicate that the structure of tachycitin is largely divided into N- and C-terminal domains; the former comprises a three-stranded beta-sheet and the latter a two-stranded beta-sheet following a short helical turn. The latter structural. motif shares a significant tertiary structural similarity with the chitin-binding domain of plant chitin-binding protein. This result is thought to provide faithful experimental evidence to the recent hypothesis that chitin-binding proteins of invertebrates and plants are correlated by a convergent evolution process.	Kyushu Univ, Dept Biol, Fukuoka 8128581, Japan; Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan; Hokkaido Natl Ind Res Inst, Biosci & Chem Div, Sapporo, Hokkaido 0628517, Japan; Jap Sci & Technol Corp, Core Res Evolut Sci & Technol, Tokyo 1010062, Japan; Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Biol Struct, Toyama 9300194, Japan	Kyushu University; Hokkaido University; National Institute of Advanced Industrial Science & Technology (AIST); Japan Science & Technology Agency (JST); University of Toyama	Tsuda, S (corresponding author), Kyushu Univ, Dept Biol, Fukuoka 8128581, Japan.		Tsuda, Sakae/M-2756-2018	Tsuda, Sakae/0000-0002-1399-0619				ANDERSEN NH, 1993, BIOCHEMISTRY-US, V32, P1407, DOI 10.1021/bi00057a004; Asensio JL, 1998, GLYCOBIOLOGY, V8, P569, DOI 10.1093/glycob/8.6.569; ASENSIO JL, 1995, EUR J BIOCHEM, V230, P621; BEINTEMA JJ, 1994, FEBS LETT, V350, P159, DOI 10.1016/0014-5793(94)00753-5; Beisel HG, 1999, EMBO J, V18, P2313, DOI 10.1093/emboj/18.9.2313; BROEKAERT WF, 1992, BIOCHEMISTRY-US, V31, P4308, DOI 10.1021/bi00132a023; BRUNGER AT, 1992, X PLOR SYSTEM XRAY C; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dimarcq JL, 1998, BIOPOLYMERS, V47, P465, DOI 10.1002/(SICI)1097-0282(1998)47:6<465::AID-BIP5>3.0.CO;2-#; Elvin CM, 1996, J BIOL CHEM, V271, P8925, DOI 10.1074/jbc.271.15.8925; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Harrison PM, 1996, J MOL BIOL, V264, P603, DOI 10.1006/jmbi.1996.0664; HOESS A, 1993, EMBO J, V12, P3351, DOI 10.1002/j.1460-2075.1993.tb06008.x; Iwanaga S, 1998, J BIOCHEM, V123, P1; Kawabata S, 1996, J BIOCHEM-TOKYO, V120, P1253; KAWANO K, 1990, J BIOL CHEM, V265, P15365; Kondratev KY, 1996, EARTH OBS REMOT SEN+, V14, P51; Koo JC, 1998, BBA-PROTEIN STRUCT M, V1382, P80, DOI 10.1016/S0167-4838(97)00148-9; KRISHNAN A, 1994, J BIOL CHEM, V269, P20971; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Martins JC, 1996, J MOL BIOL, V258, P322, DOI 10.1006/jmbi.1996.0253; Shen ZC, 1999, J MOL EVOL, V48, P341, DOI 10.1007/PL00006478; Shen ZC, 1997, J BIOL CHEM, V272, P28895, DOI 10.1074/jbc.272.46.28895; Shen ZC, 1998, J BIOL CHEM, V273, P17665, DOI 10.1074/jbc.273.28.17665; Wang P, 1997, J BIOL CHEM, V272, P16663, DOI 10.1074/jbc.272.26.16663; Watanabe T, 1998, BBA-PROTEIN STRUCT M, V1382, P181, DOI 10.1016/S0167-4838(97)00184-2; Watanabe T, 1996, MOL MAR BIOL BIOTECH, V5, P299; Weaver JL, 1998, BIOCHEMISTRY-US, V37, P116, DOI 10.1021/bi971619p; WRIGHT CS, 1990, J MOL BIOL, V215, P635, DOI 10.1016/S0022-2836(05)80174-3	29	125	138	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					17929	17932		10.1074/jbc.C000184200	http://dx.doi.org/10.1074/jbc.C000184200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10770921	hybrid			2022-12-27	WOS:000087659400004
J	Sun, XG; Majumder, P; Shioya, H; Wu, F; Kumar, S; Weichselbaum, R; Kharbanda, S; Kufe, D				Sun, XG; Majumder, P; Shioya, H; Wu, F; Kumar, S; Weichselbaum, R; Kharbanda, S; Kufe, D			Activation of the cytoplasmic c-Abl tyrosine kinase by reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DAMAGE-INDUCED APOPTOSIS; DNA-DAMAGE; OXIDATIVE STRESS; PROTEIN-KINASE; CELLULAR-RESPONSE; NUCLEAR; 1-BETA-D-ARABINOFURANOSYLCYTOSINE; ADAPTER; CRK	The ubiquitously expressed c-Abl protein tyrosine kinase localizes to both the nucleus and cytoplasm. The nuclear form of c-Abl is activated in the cellular response to genotoxic stress. Here we show that cytoplasmic c-Abl is activated by oxidative stress, The results also demonstrate that mitochondrial cytochrome c is released in the cellular response to H2O2 and that this effect is mediated by a c-Abl-dependent mechanism. In concert with these results, we show that H2O2-induced apoptosis is attenuated in c-Abl-deficient cells. These findings demonstrate that cytoplasmic c-Abl is involved in the apoptotic response of cells to oxidative stress.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA042802] Funding Source: NIH RePORTER; NCI NIH HHS [CA42802] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Gong JG, 1999, NATURE, V399, P806; GUDAS JM, 1986, J CELL PHYSIOL, V128, P441, DOI 10.1002/jcp.1041280313; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Huang YY, 1997, ONCOGENE, V15, P1947, DOI 10.1038/sj.onc.1201376; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; IMLAY JA, 1988, SCIENCE, V240, P640, DOI 10.1126/science.2834821; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Kharbanda S, 1996, CANCER RES, V56, P3617; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; KIRKEN RA, 1995, PROTEIN EXPRES PURIF, V6, P707, DOI 10.1006/prep.1995.1093; KONISHI H, 1997, P NATL ACAD SCI USA, V94, P11223; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Li TK, 1999, GENE DEV, V13, P1553, DOI 10.1101/gad.13.12.1553; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROEDERER M, 1990, P NATL ACAD SCI USA, V87, P4884, DOI 10.1073/pnas.87.12.4884; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1997, J BIOL CHEM, V272, P23485, DOI 10.1074/jbc.272.38.23485; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704	35	133	140	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17237	17240		10.1074/jbc.C000099200	http://dx.doi.org/10.1074/jbc.C000099200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10770918	hybrid			2022-12-27	WOS:000087485000005
J	Hernandez-Barrantes, S; Toth, M; Bernardo, MM; Yurkova, M; Gervasi, DC; Raz, Y; Sang, QXA; Fridman, R				Hernandez-Barrantes, S; Toth, M; Bernardo, MM; Yurkova, M; Gervasi, DC; Raz, Y; Sang, QXA; Fridman, R			Binding of active (57 kDa) membrane type 1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; HUMAN GELATINASE-A; MATRIX-METALLOPROTEINASE; CELL-SURFACE; PROGELATINASE-A; CATALYTIC DOMAIN; IV COLLAGENASE; EXTRACELLULAR-MATRIX; FIBROSARCOMA CELLS; 72-KDA GELATINASE	Previous studies have shown that membrane type 1-matrix metalloproteinase (MT1-MMP) (MMP-14) initiates pro-MMP-2 activation in a process that is tightly regulated by the level of tissue inhibitor of metalloproteinase (TIMP)-2. However, given the difficulty in modulating TIMP-2 levels, the direct effect of TIMP-2 on MT1-MMP processing and on pro-MMP-2 activation in a cellular system could not be established. Here, recombinant vaccinia viruses encoding full-length MT1-MMP or TIMP-2 were used to express MT1-MMP alone or in combination with various levels of TIMP-2 in mammalian cells. We show that TIMP-2 regulates the amount of active MT1-MMP (57 kDa) on the cell surface whereas in the absence of TIMP-2 MT1-MMP undergoes autocatalysis to a 44-kDa form, which displays a N terminus starting at Gly(285) and hence lacks the entire catalytic domain. Neither pro-MT1-MMP (N terminus Ser(24)) nor the 44-kDa form bound TIMP-2. In contrast, active MT1-MMP (N terminus Tyr(112)) formed a complex with TIMP-2 suggesting that regulation of MT1-MMP processing is mediated by a complex of TIMP-2 with the active enzyme. Consistently, TIMP-2 enhanced the activation of pro-MMP-2 by MT1-MMP. Thus, under controlled conditions, TIMP-2 may act as a positive regulator of MT1-MMP activity by promoting the availability of active MT1-MMP on the cell surface and consequently, may support pericellular proteolysis.	Wayne State Univ, Dept Pathol, Detroit, MI 48201 USA; Wayne State Univ, Karmanos Canc Inst, Detroit, MI 48201 USA; Florida State Univ, Dept Chem, Div Biochem, Tallahassee, FL 32306 USA	Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University; State University System of Florida; Florida State University	Fridman, R (corresponding author), Wayne State Univ, Dept Pathol, 540 E Canfield Ave, Detroit, MI 48201 USA.			Raz, Yuval/0000-0002-2402-0466	NATIONAL CANCER INSTITUTE [R01CA061986, R29CA078646] Funding Source: NIH RePORTER; NCI NIH HHS [CA-78646, CA-61986] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Cao J, 1998, J BIOL CHEM, V273, P34745, DOI 10.1074/jbc.273.52.34745; Cao JA, 1996, J BIOL CHEM, V271, P30174, DOI 10.1074/jbc.271.47.30174; d'Ortho MP, 1998, FEBS LETT, V421, P159, DOI 10.1016/S0014-5793(97)01555-X; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Ellerbroek SM, 1999, CANCER RES, V59, P1635; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; FRIDMAN R, 1993, BIOCHEM J, V289, P411, DOI 10.1042/bj2890411; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; FRIDMAN R, 1995, CANCER RES, V55, P2548; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; Gervasi DC, 1996, BIOCHEM BIOPH RES CO, V228, P530, DOI 10.1006/bbrc.1996.1694; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; HOYHTYA M, 1994, INT J CANCER, V56, P500, DOI 10.1002/ijc.2910560408; Imai K, 1996, CANCER RES, V56, P2707; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; KNIGHT CG, 1995, METHOD ENZYMOL, V248, P18; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Kurschat P, 1999, J BIOL CHEM, V274, P21056, DOI 10.1074/jbc.274.30.21056; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Li H, 1998, MOL CARCINOGEN, V22, P84; Lichte A, 1996, FEBS LETT, V397, P277, DOI 10.1016/S0014-5793(96)01206-9; Mallet WG, 1999, J CELL BIOL, V146, P345, DOI 10.1083/jcb.146.2.345; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Puente XS, 1996, CANCER RES, V56, P944; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; SATO H, 1916, THROMB HAEMOSTASIS, V497, P97; Stanton H, 1998, J CELL SCI, V111, P2789; Steffensen B, 1998, J BIOL CHEM, V273, P20622, DOI 10.1074/jbc.273.32.20622; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Toth M, 1997, CANCER RES, V57, P3159; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	50	272	275	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					12080	12089		10.1074/jbc.275.16.12080	http://dx.doi.org/10.1074/jbc.275.16.12080			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766841	hybrid			2022-12-27	WOS:000086695500076
J	Yousef, GM; Chang, A; Diamandis, EP				Yousef, GM; Chang, A; Diamandis, EP			Identification and characterization of KLK-L4, a new kallikrein-like gene that appears to be down-regulated in breast cancer tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-SPECIFIC ANTIGEN; HUMAN GLANDULAR KALLIKREIN; SERINE-PROTEASE; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; HUMAN NEUROPSIN; EXPRESSION; TRANSCRIPT; DISEASE; BENIGN	Kallikreins are a subgroup of serine proteases and these proteolytic enzymes have diverse physiological functions in many tissues. Growing evidence suggests that many kallikreins are implicated in carcinogenesis. In rodents, kallikreins constitute a large multigene family, but in humans, only three genes were identified. By using the positional candidate gene approach, we were able to identify a new kallikrein-like gene, tentatively named KLK-L4 (for kallikrein-like gene 4), This new gene maps to chromosome 19q13.3-q13.4, is formed of five coding exons and four introns, and shows structural similarity to other kallikreins and kallikrein-like genes. KLK-L4 is expressed in a variety of tissues including prostate, salivary gland, breast, and testis, Our preliminary results show that KLK-L4 is down-regulated, at the mRNA level, in breast cancer tissues and breast cancer cell lines. Its expression is regulated by steroid hormones in the breast cancer cell line BT-474. This gene may be involved in the pathogenesis and/or progression of breast cancer and may find applicability as a novel cancer biomarker.	Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X5, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Diamandis, EP (corresponding author), Mt Sinai Hosp, Dept Pathol & Lab Med, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	ediamandis@mtsinai.onca		Diamandis, Eleftherios/0000-0002-1589-820X				Adams MD, 1996, CURR OPIN CELL BIOL, V8, P331, DOI 10.1016/S0955-0674(96)80006-8; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anisowicz A, 1996, MOL MED, V2, P624, DOI 10.1007/BF03401646; ASHLEY PL, 1985, BIOCHEMISTRY-US, V24, P4520, DOI 10.1021/bi00338a006; Baffa R, 1996, UROLOGY, V47, P795, DOI 10.1016/S0090-4295(96)00060-X; Black MH, 1999, CLIN CHEM, V45, P790; CHEN LM, 1994, BRAZ J MED BIOL RES, V27, P1829; CLEMENTS J, 1997, KININ SYSTEM, P71; Dayhoff M., 1978, ATLAS PROTEIN SEQ ST, V5; Diamandis EP, 1998, TRENDS ENDOCRIN MET, V9, P310, DOI 10.1016/S1043-2760(98)00082-4; Diamandis EP, 2000, TRENDS ENDOCRIN MET, V11, P54, DOI 10.1016/S1043-2760(99)00225-8; EVANS BA, 1988, BIOCHEMISTRY-US, V27, P3124, DOI 10.1021/bi00409a003; EVANS BA, 1987, J BIOL CHEM, V262, P8027; Fortier AH, 1999, J NATL CANCER I, V91, P1635, DOI 10.1093/jnci/91.19.1635; Goyal J, 1998, CANCER RES, V58, P4782; HANSSON L, 1994, J BIOL CHEM, V269, P19420; HENTTU P, 1990, INT J CANCER, V45, P654, DOI 10.1002/ijc.2910450414; Heuze N, 1999, CANCER RES, V59, P2820; IIDA Y, 1990, J THEOR BIOL, V145, P523, DOI 10.1016/S0022-5193(05)80486-2; IRWIN DM, 1988, J MOL BIOL, V200, P31, DOI 10.1016/0022-2836(88)90331-2; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Little SP, 1997, J BIOL CHEM, V272, P25135, DOI 10.1074/jbc.272.40.25135; Liu XL, 1996, CANCER RES, V56, P3371; MASON AJ, 1983, NATURE, V303, P300, DOI 10.1038/303300a0; Mitsui S, 1999, EUR J BIOCHEM, V260, P627, DOI 10.1046/j.1432-1327.1999.00213.x; Nelson PS, 1999, P NATL ACAD SCI USA, V96, P3114, DOI 10.1073/pnas.96.6.3114; REIGMAN PHJ, 1989, BIOCHEM BIOPH RES CO, V159, P95, DOI 10.1016/0006-291X(89)92409-1; RIEGMAN PHJ, 1991, MOL CELL ENDOCRINOL, V76, P181, DOI 10.1016/0303-7207(91)90272-T; RIEGMAN PHJ, 1989, FEBS LETT, V247, P123, DOI 10.1016/0014-5793(89)81253-0; RIEGMAN PHJ, 1988, BIOCHEM BIOPH RES CO, V155, P181, DOI 10.1016/S0006-291X(88)81066-0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHEDLICH LJ, 1987, DNA-J MOLEC CELL BIO, V6, P429, DOI 10.1089/dna.1987.6.429; Simmer JP, 1998, J DENT RES, V77, P377, DOI 10.1177/00220345980770020601; Stenman UH, 1999, CLIN CHEM, V45, P753; Underwood LJ, 1999, CANCER RES, V59, P4435; Yoshida S, 1998, GENE, V213, P9, DOI 10.1016/S0378-1119(98)00232-7; Yousef GM, 1999, CANCER RES, V59, P4252; Yousef GM, 1999, GENOMICS, V62, P251, DOI 10.1006/geno.1999.6012; Yousef GM, 1999, J BIOL CHEM, V274, P37511, DOI 10.1074/jbc.274.53.37511; Yousef GM, 1999, ANTICANCER RES, V19, P2843	40	81	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2000	275	16					11891	11898		10.1074/jbc.275.16.11891	http://dx.doi.org/10.1074/jbc.275.16.11891			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	308DP	10766816	hybrid			2022-12-27	WOS:000086695500051
J	Espey, MG; Miranda, KM; Pluta, RM; Wink, DA				Espey, MG; Miranda, KM; Pluta, RM; Wink, DA			Nitrosative capacity of macrophages is dependent on nitric-oxide synthase induction signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED MACROPHAGES; MOUSE MACROPHAGES; IN-VITRO; OXIDATION; KINETICS; NITRATE; ASSOCIATION; HEPATOCYTES; MECHANISMS; INHIBITION	Nitrosative stress can occur when reactive nitric oxide (NO) species compromise the function of biomolecules via formation of NO adducts on critical amine and thiol residues. The capacity of inducible nitric-oxide synthase (iNOS) to generate nitrosative stress was investigated in the murine macrophage line ANA-1. Sequential activation with the cytokines IFN-gamma and either tumor necrosis factor-alpha or interleukin-1 beta resulted in the induction of iNOS and production of nitrite (20 nM/min) but failed to elicit nitrosation of extracellular 2,3-diaminonapthalene. Stimulation with IFN-gamma and bacterial lipopolysaccharide increased the relative level of iNOS protein and nitrite production of ANA-1 cells S-fold; however, a substantial level of NO in the media was also observed, and nitrosation of 2,3-diaminonapthalene was increased greater than 30-fold. Selective scavenger compounds suggested that the salient nitrosating mechanism was the NO/O-2 reaction leading to N2O3 formation. These data mimicked the pattern observed with a 5 mu M concentration of the synthetic NO donor (Z)-1-[N-ammoniopropyl) -N-(n-propyl) aminoldiazen-1-ium- 1,2-diolate (PAPA/NO), The NO profiles derived from iNOS can be distinct and depend on the inductive signal cascades. The diverse consequences of NO production in macrophages may reside in the cellular mechanisms that control the ability of iNOS to form N2O3 and elicit nitrosative stress.	NCI, Radiat Biol Branch, NIH, Bethesda, MD 20892 USA; NINDS, Surg Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Espey, MG (corresponding author), NCI, Radiat Biol Branch, NIH, Bldg 10,Rm B3-B69, Bethesda, MD 20892 USA.		Miranda, Katrina M/B-7823-2009	Wink, David/0000-0002-5652-7480; Azad, Mahan/0000-0002-8633-3513				BAEK KJ, 1993, J BIOL CHEM, V268, P21120; Bingisser RM, 1998, J IMMUNOL, V160, P5729; BOESE M, 1995, J BIOL CHEM, V270, P29244, DOI 10.1074/jbc.270.49.29244; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Christodoulou D, 1996, METHOD ENZYMOL, V268, P69; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; ESPEY MG, 2000, IN PRESS ANN N Y ACA, V899; Fang FC, 1997, J CLIN INVEST, V99, P2818, DOI 10.1172/JCI119473; Feelisch M., 1996, METHODS NITRIC OXIDE, P455; Fukuto J M, 1995, Adv Pharmacol, V34, P1; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; Geller DA, 1998, CANCER METAST REV, V17, P7, DOI 10.1023/A:1005940202801; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Grisham MB, 1999, AM J PHYSIOL-GASTR L, V276, pG315, DOI 10.1152/ajpgi.1999.276.2.G315; Huang FP, 1998, EUR J IMMUNOL, V28, P4062, DOI 10.1002/(SICI)1521-4141(199812)28:12<4062::AID-IMMU4062>3.0.CO;2-K; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; IYENGAR R, 1987, P NATL ACAD SCI USA, V84, P6369, DOI 10.1073/pnas.84.18.6369; Keefer LK, 1996, METHOD ENZYMOL, V268, P281; KOSAKA H, 1989, CARCINOGENESIS, V10, P563, DOI 10.1093/carcin/10.3.563; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LAVAL F, 1994, CARCINOGENESIS, V15, P443, DOI 10.1093/carcin/15.3.443; LEWIS RS, 1995, J BIOL CHEM, V270, P29350, DOI 10.1074/jbc.270.49.29350; LEWIS RS, 1994, CHEM RES TOXICOL, V7, P568, DOI 10.1021/tx00040a013; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Miles AM, 1996, METHOD ENZYMOL, V268, P105; MIWA M, 1987, CARCINOGENESIS, V8, P955, DOI 10.1093/carcin/8.7.955; Mulero V, 1999, BLOOD, V94, P2383, DOI 10.1182/blood.V94.7.2383.419k20_2383_2389; NUSSLER AK, 1993, BIOCHEM BIOPH RES CO, V194, P826, DOI 10.1006/bbrc.1993.1896; SHIBUKI K, 1990, NEUROSCI RES, V9, P69, DOI 10.1016/0168-0102(90)90048-J; Shingles R, 1997, J BIOENERG BIOMEMBR, V29, P611, DOI 10.1023/A:1022491220299; Simon DI, 1996, P NATL ACAD SCI USA, V93, P4736, DOI 10.1073/pnas.93.10.4736; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; Vanin AF, 1997, NITRIC OXIDE-BIOL CH, V1, P191, DOI 10.1006/niox.1997.0122; VEDIA LM, 1992, J BIOL CHEM, V267, P24929; VODOVOTZ Y, 1995, J IMMUNOL, V154, P2914; Williams D. L. H., 1988, NITROSATION; Wink DA, 1998, FREE RADICAL BIO MED, V25, P434, DOI 10.1016/S0891-5849(98)00092-6; WINK DA, 1994, CARCINOGENESIS, V15, P2125, DOI 10.1093/carcin/15.10.2125; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; WINK DA, 1994, CHEM RES TOXICOL, V7, P519, DOI 10.1021/tx00040a007	43	77	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					11341	11347		10.1074/jbc.275.15.11341	http://dx.doi.org/10.1074/jbc.275.15.11341			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753947	hybrid			2022-12-27	WOS:000086466600089
J	Sato, E; Simpson, KL; Grisham, MB; Koyama, S; Robbins, RA				Sato, E; Simpson, KL; Grisham, MB; Koyama, S; Robbins, RA			Reactive nitrogen and oxygen species attenuate interleukin-8-induced neutrophil chemotactic activity in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED TYROSINE NITRATION; NITRIC-OXIDE DONORS; CYCLIC-GMP; IN-VITRO; PEROXYNITRITE; INHIBITION; SUPEROXIDE; IDENTIFICATION; EXPRESSION; MECHANISM	Peroxynitrite, formed by the reaction between nitric oxide and superoxide, has been shown to induce protein nitration, which compromises protein function. We hypothesized that peroxynitrite may regulate cytokine function during inflammation. To test this hypothesis, the neutrophil chemotactic activity (NCA) of interleukin-8 (IL-8) incubated with peroxynitrite was evaluated. Peroxynitrite attenuated IL-8 NCA in a dose-dependent manner (p < 0.01) but did not significantly reduce NCA induced by leukotriene B-4 or complement-activated serum. The reducing agents, dithionite, deferoxamine, and dithiothreitol, reversed and exogenous L-tyrosine abrogated the peroxynitrite-induced NCA inhibition. Papa-NONOate [N-(3-ammoniopropyl)-N-(n-propyl)amino]diazen-1-ium-1,2-dialase or sodium nitroprusside, NO donors, or a combination of xanthine and xanthine oxidase to generate superoxide did not show an inhibitory effect on NCA induced by IL-8, In contrast, small amounts of SIN-1, a peroxynitrite generator, caused a concentration-dependent inhibition of NCA by IL-8, Consistent with its capacity to reduce NCA, peroxynitrite treatment reduced IL-8 binding to neutrophils. Nitrotyrosine was detected in the IL-8 incubated with peroxynitrite by enzyme-linked immunosorbent assay. These findings are consistent with nitration of tyrosine by peroxynitrite with subsequent inhibition of IL-8 binding to neutrophils and a reduction in NCA and suggest that oxidants may play an important role in regulation of IL-8-induced neutrophil chemotaxis.	So Arizona Vet Hlth Care Syst, Res Hlth Care Grp, Tucson, AZ 85723 USA; Univ Arizona, Dept Med, Tucson, AZ 85723 USA; Louisiana State Univ, Med Ctr, Dept Mol & Cellular Physiol, Shreveport, LA 71130 USA; Shinshu Univ, Sch Med, Dept Internal Med 1, Matsumoto, Nagano 3908621, Japan	US Department of Veterans Affairs; Veterans Health Administration (VHA); Southern Arizona Veterans Affairs Health Care System; University of Arizona; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Shinshu University	Robbins, RA (corresponding author), So Arizona Vet Hlth Care Syst, Res Hlth Care Grp, 3601 S 6th Ave, Tucson, AZ 85723 USA.							Alvarez B, 1996, CHEM RES TOXICOL, V9, P390, DOI 10.1021/tx950133b; ANDREWS WW, 1984, J BIOL CHEM, V259, P8219; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BATH PMW, 1993, EUR J CLIN PHARMACOL, V45, P53, DOI 10.1007/BF00315350; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BELENKY SN, 1993, J LAB CLIN MED, V122, P388; Bolanos JP, 1996, FREE RADICAL BIO MED, V21, P995, DOI 10.1016/S0891-5849(96)00240-7; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRAY MR, 1995, BIOCHEMISTRY-US, V34, P2006, DOI 10.1021/bi00006a022; Burney S, 1997, NITRIC OXIDE-BIOL CH, V1, P130, DOI 10.1006/niox.1996.0114; CLARKLEWIS I, 1994, J BIOL CHEM, V269, P16075; CURRIE DC, 1987, LANCET, V1, P1335; DENICOLA A, 1995, FREE RADICAL BIO MED, V19, P11, DOI 10.1016/0891-5849(94)00239-G; FRIDOVICH I, 1970, J BIOL CHEM, V245, P4053; Gow AJ, 1996, FEBS LETT, V385, P63, DOI 10.1016/0014-5793(96)00347-X; Gow AJ, 1997, J BIOL CHEM, V272, P2841, DOI 10.1074/jbc.272.5.2841; HARVATH L, 1980, J IMMUNOL METHODS, V37, P39, DOI 10.1016/0022-1759(80)90179-9; Holm P, 1998, EUR J PHARMACOL, V346, P97, DOI 10.1016/S0014-2999(98)00009-0; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; KAPLAN SS, 1989, BLOOD, V74, P1885; LIRA SA, 1994, J EXP MED, V180, P2039, DOI 10.1084/jem.180.6.2039; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MCCALL MN, 1989, BIOCHEM J, V257, P845, DOI 10.1042/bj2570845; MOILANEN E, 1993, BRIT J PHARMACOL, V109, P852, DOI 10.1111/j.1476-5381.1993.tb13653.x; MOSER B, 1991, J BIOL CHEM, V266, P10666; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEY P, 1990, EICOSANOIDS, V3, P243; RADI R, 1991, J BIOL CHEM, V266, P4244; Rohn TT, 1998, EUR J PHARMACOL, V353, P329, DOI 10.1016/S0014-2999(98)00399-9; SCHRAUFSTATTER IU, 1995, J BIOL CHEM, V270, P10428, DOI 10.1074/jbc.270.18.10428; SHEN WQ, 1995, CIRCULATION, V92, P3505, DOI 10.1161/01.CIR.92.12.3505; SNYDERMAN R, 1968, J EXP MED, V128, P259, DOI 10.1084/jem.128.2.259; VANDERVORT AL, 1994, J IMMUNOL, V152, P4102; VOGT W, 1995, FREE RADICAL BIO MED, V18, P93, DOI 10.1016/0891-5849(94)00158-G; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; Wink DA, 1997, NITRIC OXIDE-BIOL CH, V1, P88, DOI 10.1006/niox.1996.0108	38	39	42	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10826	10830		10.1074/jbc.275.15.10826	http://dx.doi.org/10.1074/jbc.275.15.10826			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753876	hybrid			2022-12-27	WOS:000086466600018
